[
  {
    "text": "# CERVICAL CANCER GUIDELINES # TABLE OF CONTENTS # 1 Introduction .# 2 Acknowledgements .# 3 Method.3.1 Nomination of multidisciplinary international development group .3.2 Identification of scientific evidence .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "..3.3 Formulation of guidelines 3.4 External evaluation of the guidelines - International review.....8 3.5 Integration of international reviewers comments 4 Management of conflicts of interest ..9 5 Summary of guidelines 10 5.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1 General recommendations.0 5.2 Staging....10 5.3 Management of stage T1a 13 5.4 Management of stages T1b1/T2a1 .........14 5.5 Fertility sparing treatment.16 5.6 Clinically occult cervical cancer diagnosed after simple hysterectomy .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "17 5.7 Management of locally advanced cervical cancer...19 5.8 Distant metastatic disease at presentation ....20 5.9 Recurrent disease...20 5.10 Follow-up.23 5.11 Cervical cancer in pregnancy ...25 6 Principles of radiotherapy 26 6.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1 Definitive chemoradiotherapy and brachytherapy: general aspects ....26 6.2 Definitive chemoradiotherapy ...26 6.3 Definitive brachytherapy ....26 6.4 Adjuvant radiotherapy or chemoradiotherapy based on intensity modulated radiotherapy and image guided radiotherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "..27 6.5 Definitive 3D conformal external beam radiotherapy or chemoradiotherapy and radiography-based brachytherapy.......27 6.6 Comment of the radiation oncology subgroup of the development group..28 7 Principles of pathological evaluation.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "....30 7.1 Requirements for specimen submitted for pathological evaluation ....30 7.2 Specimen grossing and sampling.........31 7.3 Pathological analysis of sentinel lymph node ...32 7.4 Requirements for pathology report.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "...33 7.5 Items to be included on pathology report of carcinomas of the cervix ..34 8 Staging .......35 8.1 Summary of available scientific evidence...35 8.2 Previous initiatives ...42 8.3 Development group comments 42 8.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "4 Guidelines....43 # 9 Management of stage T1a...50 9.1 Summary of available scientific evidence ....50 9.2 Previous initiatives ....53 9.3 Development group comments..53 9.4 Guidelines..54 # 10 Management of stages T1b1/T2a1 59 10.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1 Summary of available scientific evidence....59 10.2 Previous initiatives ...73 10.3 Development group comments...74 10.4 Guidelines..75 # 11 Fertility sparing treatment..83 11.1 Summary of available scientific evidence.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "...83 11.2 Previous initiatives ....94 11.3 Development group comments...94 11.4 Guidelines...95 # 12 Clinically occult carcinoma diagnosed after simple hysterectomy 108 12.1 Summary of available scientific evidence.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "108 12.2 Previous initiatives ..109 12.3 Development group comments...109 12.4 Guidelines...110 # 13 Management of locally advanced cervical cancer..112 13.1 Summary of available scientific evidence ..",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "..112 13.2 Previous initiatives ....128 13.3 Development group comments...128 13.4 Guidelines..129 # 14 Distant metastatic disease at presentation & recurrent disease..140 14.1 Summary of available scientific evidence.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "...140 14.2 Previous initiatives ....147 14.3 Development group comments....148 14.4 Guidelines..148 # 15 Follow-up.159 15.1 Summary of available scientific evidence....159 15.2 Previous initiatives ..",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "..168 15.3 Development group comments...168 15.4 Guidelines...168 # 16 Cervical cancer in pregnancy 173 16.1 Summary of available scientific evidence.173 16.2 Previous initiatives ....177 16.3 Development group comments.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ".177 16.4 Guidelines..178 # 17 Acronyms and abbreviations .184 # 18 References.187 # 19 Appendices.308 19.1 Appendix 1 - People involved in the development of the guidelines..308 19.2 Appendix 2 - List of evidence-based medicine websites consulted .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "...315 19.3 Appendix 3 - Key to evidence statements and grades of recommendations ...316 # 1 Introduction Cervical cancer is uncommon in Europe but still represents a major public health problem1.The estimated number of new cervical cancer cases in Europe in 2012 was 58 348 with 24 397 deaths2.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Five-year relative survival for European women diagnosed with cervical cancer in 2000-2007 was $6 2 \\%$ , ranging from $5 7 \\%$ in Eastern Europe to $67 \\%$ in Northern Europe.Survival was particularly low $( < 5 5 \\% )$ in Bulgaria, Latvia and Poland and highest in Norway $( 7 1 \\% ) ^ { 3 }$ .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The large geographic variation in cervical cancer rates reflects differences in the availability of screening and in human papillomarivus (HPV) infection prevalence.In countries with a low incidence of cervical cancer, the prevalence of chronic HPV is approximately two folds lower than in high-incidence countries.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Other epidemiologic risk factors associated with cervical cancer are notably a history of smoking, parity, oral contraceptive use, early age of onset of coitus, larger number of sexual partners, history of sexually transmitted disease, certain autoimmune diseases, and chronic immunosuppression.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Squamous cell carcinomas account for approximately $8 0 \\%$ of all cervical cancers and adenocarcinoma accounts for approximately $2 0 \\%$ .The objectives of the guidelines are to improve and to homogenize the management of patients with cervical cancer within a multidisciplinary setting.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "These guidelines are intended for use by gynecologic oncologists, general gynaecologists, surgeons, radiation oncologists, pathologists, medical and clinical oncologists, radiologists, general practitioners, palliative care teams, and allied health professionals.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The guidelines aim at covering comprehensively staging, management, and follow-up for patients with cervical cancer.Management includes fertility sparing treatment (FST); stage T1a, T1b1/T2a1, clinically occult cervical cancer diagnosed after simple hysterectomy; early and locally advanced cervical cancer (LACC); primary distant metastatic disease; cervical cancer in pregnancy (CCIP); and recurrent disease.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Algorithms presenting guidelines for the management of patients with cervical cancer are available online at the Web sites of the European Society of Gynaecological Oncology, the European SocieTy for Radiotherapy and Oncology, and the European Society of Pathology.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "These guidelines exclude the management of neuroendocrine carcinomas, sarcomas, and other rare histologic subtypes.They also do not include any economic analysis of the strategies.Any clinician seeking to apply or consult these guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 2 Acknowledgements The European Society of Gynaecological Oncology (ESGO) would like to thank the European SocieTy for Radiotherapy and Oncology (ESTRO), the European Society of Pathology (ESP), and the international development group for their constant availability, work, and for making possible the development of these guidelines for the management of patients with cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "ESGO also wishes to express sincere gratitude to the Institut national du cancer (France) for providing the main funding for this work.# 3 Method The guidelines were developed using a five-step process (see Figure 1).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The strengths of the process include creation of a multidisciplinary international development group, use of scientific evidence and/or international expert consensus to support the guidelines, and use of an international external review process (physicians and patients).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "This development process involved three meetings of the international development group, chaired by Professor David Cibula (Charles University Hospital, Prague, Czech Republic), Professor Richard Poetter (Vienna General Hospital, Vienna, Austria) and Professor Maria Rosaria Raspollini (University Hospital, Careggi - Florence, Italy).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "![](images/ced70f37829fa8a99ca4e013780e76efdd51a22cc2308a6513e5e63a396c1582.jpg) Figure 1.Development process # 3.1 Nomination of multidisciplinary international development group The ESGO/ESTRO/ESP nominated practicing clinicians that are involved in the management of cervical cancer patients and have demonstrated leadership in clinical management of patients through research, administrative responsibilities, and/or committee membership to serve on the expert panel.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The objective was to assemble a multidisciplinary panel.It was therefore essential to include professionals from relevant disciplines (surgery, medical oncology, pathology, radiology, gynaecology, radiation oncology) to contribute to the validity and acceptability of the guidelines.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The list of the development group is available in Appendix 1.# 3.2 Identification of scientific evidence To ensure that the statements were evidence based, the current literature was reviewed and critically appraised.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A systematic literature review of relevant studies published between January 1997 and January 2017 was carried out using the MEDLINE database.This search used indexing terms as follows: 5- fluorouracil (5-FU), abdominal trachelectomy, abdominal radical trachelectomy, advanced cervical cancer, advanced cervical disease, advanced disease, advanced stage, biomarker, bleomycin, cancer antigen 125 (CA 125), cancer antigen 15-3 (CA 15-3), carboplatin, carcinoembryonic antigen (CEA), cervical cancer, cervix cancer, circulating immune complexes (CIC), cisplatin, cis-diamminedichloroplatinum, cis-platinum, clinical staging, clinically occult carcinoma, cold knife conisation (CKC), complications, computed tomography (CT), cone biopsy, cone resection, cone resection margins, conisation, cryopreservation, cytokeratin fragment 21-1 (CYFRA 21-1), destructive techniques, excisional techniques, external beam radiotherapy (EBRT), fertility, fertility outcome, fertility preservation, fertility sparing, fertility sparing management, fertility sparing surgery (FSS), Fédération Internationale de Gynecologie et d’Obstétrique (FIGO), FIGO staging system, follow-up, follow-up protocols, frozen sections, FST, gestation, high sensitivity C-reactive protein (hsCRP), HPV testing, hysterectomy, image guided adaptive brachytherapy (IGABT), image guided radiotherapy (IGRT), imaging, imaging modalities, immunosuppressive acidic protein (IAP), intensity modulated radiotherapy (IMRT), intensive care, intensive care unit, interleukin 6 (IL-6), LACC, laparoscopic staging, laparoscopy, laparotomy, large loop excision of the transformation zone (LLETZ), laser ablation, laser ablation-destruction, laser conisation, laser conisation-excision, laser destruction, length of stay, LACC, locally advanced cervical disease, locally advanced disease, locally advanced stage, loop electrosurgical excision procedure (LEEP), lymphadenectomy, lymph node (LN), LN assessment, LN dissection, LN staging, lymphovascular space involvement (LVSI), magnetic resonance imaging (MRI), metastatic disease, microinvasive cancer, microinvasive cervical cancer, mortality rate, mortality analysis, multivariate analysis, neoadjuvant chemotherapy (NACT), neonatal intensive care unit (NICU) admission, nerve-sparing radical surgery, nerve-sparing robotic radical hysterectomy, nodal involvement, obstetric outcomes, occult carcinoma, occult invasive carcinoma, occult invasive cervical cancer, oncologic outcome, ovarian preservation, ovarian transplantation, ovarian transposition (OT), oxaliplatin, paclitaxel, para-aortic lymphadenectomy, para-aortic lymph node (PALN) assessement, paraaortic lymph node dissection (PALND), pathology, pathology report, pathology report adequacy, pelvic lymph node (PLN) assessement, pelvic lymph node dissection (PLND), pelvic lymphadenectomy, perioperative care, physical examination, platinum, positron emission tomography (PET), positron emission tomography-computed tomography (PET-CT), postoperative care, postoperative complications, postoperative recurrence, pregnancy, preterm spontaneous rupture of membranes (pPROM), preoperative brachytherapy, pregnancy, pregnancy rate, pregnant patient, preoperative care, preoperative workup, prognosis, prognostic factor, quality of health care, quality of life, radical abdominal trachelectomy, radical surgery, radical trachelectomy, radical vaginal trachelectomy, recurrence, recurrent disease, reoperation, reproduction, reproductive techniques, residual disease, residual tumour, restaging, risk factors, robotic radical hysterectomy, sensitivity, sentinel lymph node (SLN), SLN procedure, sentinel node (SN), serum biomarker, serum marker, specificity, simple trachelectomy, squamous cell carcinoma antigen (SCC-Ag), staging, staging procedures, surgery, surgical management, surgical outcome, surgical outcome criteria, surgical procedures, surgical resection, surveillance, survival rate, survival analysis, tissue polypeptide antigen (TPA), TNM classification, total laparoscopic radical trachelectomy, trachelectomy, transplantation, transposition, treatment outcome, tumour-associated trypsin inhibitor (TATI), tumour necrosis factor alpha (TNF- $\\cdot \\alpha ^ { \\cdot }$ ), ultrastaging, ultrasound (US), upstaging, uterine cervix cancer, uterine transplantation, vaginal radical trachelectomy, vaginal trachelectomy, vascular space involvement, vascular endothelial growth factor (VEGF), vincristine.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The literature search was limited to publications in English.Priority was given to high-quality systematic reviews, meta-analyses, and randomized controlled trials (RCTs) but lower levels of evidence were also evaluated.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The search strategy excluded editorials, letters, and in vitro studies.The reference list of each identified article was reviewed for other potentially relevant papers.The bibliography was also supplemented by additional references provided by the international development group.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Another bibliographic search was carried out to identify previous initiatives using a systematic literature search in MEDLINE database (no restriction in the search period, indexing terms: clinical practice guidelines, evidence-based medicine, guidelines, methodology, recommendations, cervical cancer) and a bibliographic search using selected websites (see Appendix 2).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "After the selection and critical appraisal of the articles, a summary of the scientific evidence was developed.# 3.3 Formulation of guidelines The development group developed guidelines for staging, FST, management (stage T1a, T1b1/T2a1, clinically occult cervical cancer diagnosed after simple hysterectomy, LACC, primary distant metastatic disease, CCIP, and recurrent disease), and follow-up for patients with cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The guidelines were retained if they were supported by sufficient high level scientific evidence and/or when a large consensus among experts was obtained.If an approach is judged to be acceptable but is not unanimously recognized as a criterion-standard clinical approach, indication is given that it is still subject to discussion and/or evaluation.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the development group (expert agreement).The reliability and quality of the evidence given throughout this document has been graded following the Scottish intercollegiate guidelines network (SIGN) grading system (see Appendix 3).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Principles of radiotherapy and principles of pathological evaluation were also defined.# 3.4 External evaluation of the guidelines - International review The ESGO/ESTRO/ESP consulted a large panel of practicing clinicians that are involved in the management of cervical cancer patients.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cervical cancer patients were also included.The objective was to assemble a multidisciplinary panel.The 159 international reviewers were independent from the development group.International reviewers were asked to evaluate each guideline according to their relevance and feasibility in clinical practice (only physicians).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Quantitative and qualitative evaluations of the guidelines were performed.Patients were asked to qualitatively evaluate each guideline (according their experience, preferences, feelings, etc.).The list of international reviewers is available in Appendix 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 3.5 Integration of international reviewers comments Responses of the 159 external reviewers were pooled and discussed by the development group to finalize the guidelines.# 4 Management of conflicts of interest The experts of the multidisciplinary international development group were required to complete a declaration of interest form, and to promptly inform the ESGO council if any change in the disclosed information occurred during the course of this work.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 5 Summary of guidelines # 5.1 General recommendations ![](images/6d7018a203d56cd0355f78c7ed9292744c337c4b08f4d3a83ec9f22b93c9a1c6.jpg) Treatment planning should be made on a multidisciplinary basis (generally at a tumor board meeting) and based on the comprehensive and precise knowledge of prognostic and predictive factors for oncological outcome, morbidity, and quality of life.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Patients should be carefully counseled on the suggested treatment plan and potential alternatives, including risks and benefits of all options.Treatment should be undertaken by a dedicated team of specialists in the diagnosis and management of gynecologic cancers.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 5.2 Staging # 5.2.1 TNM classification and FIGO ![](images/9cc35bcd1e2753ed1c056e80540b54219d07a0f54f5fffed110a13a921002b27.jpg) Patients with cervical cancer should be staged according to the TNM classification.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Clinical staging (FIGO) should also be documented (Figure 2).![](images/97e94048520369328f36ecdda3bdaa349cafc51e977b1c4a0fb0cbf1dc2396a5.jpg) TNM should be based on a correlation of various modalities (integrating physical examination, imaging and pathology) after discussion in a multidisciplinary forum.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The method used to determine tumor status (T), lymph node status (N), and systemic status (M), that is, clinical (c), imaging (i), and/or pathological (p) should be recorded.LN metastases should be classified according to the TNM classification (see Principles of pathological evaluation).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 5.2.2 Prognostic factors Proper documentation of the following major tumorrelated prognostic factors is recommended: TNM and FIGO stage, including a maximum tumor size and detailed description of extracervical tumor extension and nodal involvement (number, size, location).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Pathological tumor type.Depth of cervical stromal invasion and a minimum thickness of uninvolved cervical stroma Presence or absence of LVSI. Presence or absence of distant metastases.# 5.2.3 Local clinical and radiological diagnostic workup Pelvic examination and biopsy $+ / -$ colposcopy are mandatory components to diagnose cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# Mandatory initial workup for assessment of pelvic tumor extent and to guide treatment options is pelvic MRI.Endovaginal/transrectal US is an option if performed by a properly trained sonographer.Cystoscopy or rectoscopy may be considered to provide a biopsy if suspicious lesions in the urinary bladder or rectum are documented on MRI or US.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 5.2.4 Nodal/distant diagnostic workup # B In early stage (T1a, T1b1, T2a1), surgical/pathological staging of PLNs is the criterion standard to assess the prognosis and guide treatment (except of T1a1 and no LVSI).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# B In LACC (T1b2 and higher (except T2a1)) or in early-stage disease with suspicious LNs on imaging, PET-CT, or chest/abdomen CT is recommended for assessment of nodal and distant disease.# B PET-CT is the preferred option for treatment planning before chemoradiotherapy with curative intent.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# PALN dissection, at least up to inferior mesenteric artery, may be considered in LACC with negative PALNs on imaging for staging purposes.Equivocal extrauterine disease is to be considered for biopsy to confirm or rule out metastatic disease and to avoid inappropriate treatment.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Tru-Cut (core-cut) biopsy is the preferred option than fine-needle aspiration biopsy because it allows histological assessment of the tissue.Figure 2.FIGO staging and TNM classification <html><body><table><tr><td>T category4</td><td> FIGO stage5-7</td><td>Definition</td></tr><tr><td>TX</td><td></td><td>Primary tumour cannot be assessed</td></tr><tr><td>TO</td><td></td><td>No evidence of primary tumour</td></tr><tr><td>T1</td><td>1</td><td>Cervical carcinoma confined to the uterus (extension to corpus should be disregarded)</td></tr><tr><td>T1a</td><td>IA</td><td>Invasive carcinoma diagnosed only by microscopy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Stromal invasion with a maximum depth of 5.0 mm measured from the base of the epithelium and a horizontal spread of 7.0 mm or less; vascular space involvement, venous or</td></tr><tr><td>T1a1</td><td>IA1</td><td>lymphatic, does not affect classification.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Measured stromal invasion of 3.0 mm or less in depth and 7.0 mm or less in</td></tr><tr><td>T1a2</td><td>IA2</td><td>horizontal spread Measured stromal invasion of more than 3.0 mm and not more than 5.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0</td></tr><tr><td>T1b</td><td>IB</td><td>mm, with a horizontal spread of 7.0 mm or less Clinically visible lesion confined to the cervix or microscopic lesion greater than T1a2/IA2.Includes all macroscopically visible lesions, even those with</td></tr><tr><td>T1b1</td><td>IB1</td><td>superficial invasion.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Clinically visible lesion 4.0 cm or less in greatest dimension</td></tr><tr><td>T1b2</td><td>IB2</td><td>Clinically visible lesion more than 4.0 cm in greatest dimension</td></tr><tr><td>T2</td><td>11</td><td>Cervical carcinoma invading beyond the uterus but not to the pelvic wall or</td></tr><tr><td>T2a</td><td>IIA</td><td>to lower third of the vagina Tumour without parametrial invasion</td></tr><tr><td>T2a1</td><td>IIA1</td><td>Clinically visible lesion 4.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 cm or less in greatest dimension</td></tr><tr><td>T2a2</td><td>IIA2</td><td>Clinically visible lesion more than 4.0 cm in greatest dimension</td></tr><tr><td>T2b</td><td>IIB</td><td>Tumour with parametrial invasion</td></tr><tr><td>T3</td><td>III</td><td>Tumour extending to the pelvic sidewall* and/or involving the lower third of the vagina and/or causing hydronephrosis or nonfunctioning kidney</td></tr><tr><td>T3a</td><td>IIIA</td><td>Tumour involving the lower third of the vagina but not extending to the pelvic wall</td></tr><tr><td>T3b</td><td>IIIB</td><td>Tumour extending to the pelvic wall and/or causing hydronephrosis or nonfunctioning kidney</td></tr><tr><td>T4</td><td>IVA</td><td>Tumour invading the mucosa of the bladder or rectum and/or extending beyond the true pelvis (bullous edema is not sufficient to classify a tumour</td></tr><tr><td></td><td>IVB</td><td>as T4) Tumour invading distant organs</td></tr><tr><td></td><td></td><td>* the pelvic sidewallis defined as the muscle, fascia, neurovascular structures, and skeletal portions of the</td></tr></table></body></html> # 5.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "3 Management of stage T1a # 5.3.1 Diagnosis of stage T1a disease Diagnosis of T1a cancer should be based on a conization (or excision) specimen examined by an expert pathologist.Management must be based on an expert pathology review, with accurate measurement of the maximum horizontal 2 dimensions, depth of invasion, margin status, coexisting pathology, and reliable assessment of LVSI.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Loop or laser conization is preferable to CKC in women desiring fertility preservation.Maximum care should be taken to provide an intact (unfragmented) specimen with minimal thermal artifact.The cone specimen should be oriented for the pathologist.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# Surgical margins of the cone specimen should be clear of both invasive and preinvasive disease (except for preinvasive disease in ectocervix).# 5.3.2 Management of stage T1a1 disease Management of patients with stage T1a1 disease should be individualized depending on the age, the desire for fertility preservation, and the presence or absence of LVSI.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In case of positive margins (except for preinvasive disease in ectocervix), a repeat conization should be performed to rule out more extensive invasive disease.# B LN staging is not indicated in T1a1 LVSI-negative patients but can be considered in T1a1 LVSIpositive patients.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "SLN biopsy (without additional PLN dissection) is an acceptable method of LN staging.Conization can be considered a definitive treatment as hysterectomy does not improve the outcome.# C Radical surgical approaches such as radical hysterectomy or parametrectomy represent overtreatment for patients with T1a1 disease.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 5.3.3 Management of stage T1a2 disease In patients with stage T1a2 disease, conization alone or simple hysterectomy is an adequate treatment.Parametrial resection is not indicated.# B LN staging can be considered in LVSI-negative patients but should be performed in LVSI-positive patients.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "SLN biopsy alone (without additional PLN dissection) appears to be an acceptable method of LN staging.Routine completion of hysterectomy is not recommended after conservative management of stage T1a disease.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 5.4 Management of stages T1b1/T2a1 # 5.4.1 General recommendation # B Treatment strategy should aim for the avoidance of combining radical surgery and radiotherapy because of the highest morbidity after combined treatment.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 5.4.2 Negative lymph nodes on radiological staging # Surgical treatment Radical surgery by a gynecologic oncologist is the preferred treatment modality.Minimally invasive approach is favored.The standard LN staging procedure is systematic pelvic lymphadenectomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "SN biopsy before pelvic lymphadenectomy is strongly recommended.Combination of blue dye with radiocolloid or use of indocyanine green alone is the recommended technique.LN assessment should be performed as the first step of surgical management.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Intraoperative assessment of LN status (frozen section) is recommended.All SNs from both sides of the pelvis and/or any suspicious LNs should be sent for frozen section.If SN is not detected, intraoperative assessment of the PLNs should be considered.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "If intraoperative LN assessment is negative or not done, systematic PLN dissection should be performed.At present, SN biopsy alone cannot be recommended outside prospective clinical trials.Systematic LN dissection should include the removal of lymphatic tissue from regions with the most frequent occurrence of positive LNs (SNs) including obturator fossa, external iliac regions, common iliac regions bilaterally, and presacral region.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Distal external iliac LNs (so-called circumflex iliac LNs) should be spared if they are not macroscopically suspicious.The type of radical hysterectomy (extent of parametrial resection, type A-C2) should be based on the presence of prognostic risk factors identified preoperatively (Figure 3).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Major prognostic factors for oncological outcome as tumor size, maximum stromal invasion, and LVSI are used to categorize patients at high, intermediate, and low risk of treatment failure.Complete description of the template used for radical hysterectomy should be present in the surgical report.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The 2017 modification of the Querleu-Morrow classification is recommended as a tool (Figure 4).Ovarian preservation should be offered to premenopausal patients with squamous cell carcinoma and usual-type (HPV-related) adenocarcinoma.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Bilateral salpingectomy should be considered.If LN involvement is detected intraoperatively including macrometastases or micrometastases, further PLN dissection and radical hysterectomy should be avoided.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Patients should be referred for definitive chemoradiotherapy.PALN dissection, at least up to inferior mesenteric artery, may be considered for staging purposes.If a combination of risk factors is known at diagnosis, which would require an adjuvant treatment, definitive radiochemotherapy and brachytherapy can be considered without previous radical pelvic surgery.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "PLN dissection should be avoided.PALN dissection, at least up to inferiormesenteric artery,may be considered in patients with negative PALN on imaging.Figure 3.Risk groups according to prognostic factors: suggested type(s) of radical hysterectomy <html><body><table><tr><td>Risk group</td><td>Tumour size</td><td>LVSI</td><td>Stromal invasion</td><td>Type of radical hysterectomy*</td></tr><tr><td>Low risk</td><td><2 cm</td><td>Negative</td><td>Inner 1/3</td><td>B1 (A)</td></tr><tr><td>Intermediate risk</td><td>≥2cm</td><td>Negative</td><td>Any</td><td>B2 (C1)</td></tr><tr><td></td><td><2 cm</td><td>Positive</td><td>Any</td><td></td></tr><tr><td>High risk</td><td>≥2 cm</td><td>Positive</td><td>Any</td><td>C1 (C2)</td></tr><tr><td colspan=\"5\">* according to the Querleu-Morrow classification (see Figure 4)</td></tr></table></body></html> Figure 4.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Querleu-Morrow classification8 <html><body><table><tr><td>Type of radical hysterectomy</td><td>Paracervix or lateral parametrium</td><td>Ventral parametrium</td><td>Dorsal parametrium</td></tr><tr><td>Type A</td><td>Halfway between the cervix and Minimal excision ureter (medial to the ureter-ureter identified but not mobilized)</td><td></td><td>Minimal excision</td></tr><tr><td>Type B1</td><td>At the ureter (at the level of the ureteral bed-ureter mobilized from the cervix and lateral parametrium)</td><td>Partial vesicouterine ligament</td><td>excisionof the Partial resection of the rectouterine-rectovaginal ligament and uterosacral peritoneal fold</td></tr><tr><td>Type B2</td><td>Identical to B1 plus paracervical lymphadenectomy without resection of vascular/nerve structures</td><td>vesicouterine ligament</td><td>Partial excision of the Partial resection of the rectouterine-rectovaginal ligament and uterosacral fold</td></tr><tr><td>Type C1</td><td>At the iliac vessels transversally, caudal part is preserved</td><td>Excision of the vesicouterine ligament (cranial to the ureter) at the bladder.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Proximal part of the vesicovaginal ligament (bladder nerves are dissected and spared)</td><td>At the rectum (hypogastric nerve is dissected and spared)</td></tr><tr><td>Type C2</td><td>At the level of the medial aspect of At the bladder (bladder At the sacrum (hypogastric iliac vessels completely (including the caudal part)</td><td>nerves are sacrificed)</td><td>nerve is sacrificed)</td></tr><tr><td>Type D</td><td>Atthe pelvic wall, including Atthe resection of the internal iliac vessels and/or components of the pelvic sidewall</td><td>bladder.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Not applicable if part of exenteration</td><td>At the sacrum.applicable if part exenteration</td></tr></table></body></html> # 5.4.2.2 Alternative treatment options Definitive radiotherapy including brachytherapy represents effective alternative treatment (see Principles of radiotherapy).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It can be considered in particular in case of unfavorable prognostic and predictive factors for oncological and morbidity outcome.For high risk and intermediate risk, preoperative brachytherapy followed by surgery (type A) is used in a limited number of centers.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It is an acceptable alternative option only in teams experienced in this approach.NACT followed by surgery is not recommended.# 5.4.3 Positive pelvic lymph nodes on radiological staging # In patients with unequivocally involved PLNs on imaging, definitive chemoradiotherapy is recommended (see Principles of radiotherapy).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "PALN dissection, at least up to inferior mesenteric artery, may be considered in patients with negative PALNs on imaging.Debulking of suspicious PLNs may be considered.# 5.4.4 Adjuvant treatment # B Adjuvant radiotherapy should be considered in the presence of combination of risk factors at final pathology such as tumor size, LVSI, and depth of stromal invasion.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "When in these situations an adequate type of radical hysterectomy has been performed (Figure 3), observation is an alternative option, especially in teams experienced in this approach.After primary radical surgery, adjuvant chemoradiotherapy is indicated in the following groups of patients (see Principles of radiotherapy): metastatic involvement of PLNs, including the presence of macrometastases pN1 or micrometastases pN1(mi) in either SN or any other PLNs detected by intraoperative or final pathologic assessment $\\Rightarrow$ chemoradiotherapy positive surgical margins (vagina/parametria) $\\Rightarrow$ chemoradiotherapy, brachytherapy boost may be considered parametrial involvement $\\Rightarrow$ chemoradiotherapy # 5.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "4.5 Cervical stump cancer Management of cervical stump cancer follows the recommendations for patients without previous subtotal hysterectomy.Adaptation of radiotherapy may be necessary, in particular for brachytherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 5.5 Fertility sparing treatment Before starting FST, consultation at a fertility center is recommended.FST should exclusively be undertaken in gynecologic-oncological centers with comprehensive expertise in this kind of oncologic therapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "For patients who consider FST, prognostic factors, clinical staging, and preoperative workup do not differ from those who do not consider this (see above).Every woman with a desire to spare fertility and histologically proven squamous cell carcinoma or usual-type (HPV-related) adenocarcinoma equal to or less than $2 \\ \\mathrm { c m }$ of the largest diameter should be counseled about the possibility of FST.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "This consultation should encompass the risk of FST abandonment if there are positive margins or LN involvement and oncologic and obstetric risks related to this type of management.FST should not be recommended for rare histological subtypes of cervical cancer including neuroendocrine carcinomas and non-HPV-related adenocarcinomas (except for adenoid basal carcinoma), which tend to exhibit aggressive behavior.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Expert sonography and/or pelvic MRI are recommended imaging tests to measure remaining (after cone biopsy) cervical length and noninvolved cervical length.However, no imaging system can exactly predict the extent of necessary local resection in order to reach sound margins with adequate safety distance.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Negative PLN status is the precondition for any FST.Therefore, PLN (SLN) staging should always be the first step in each FST procedure.Identification of SLN and its ultrastaging is highly recommended because it increases staging accuracy, namely, the identification of micrometastases and small macrometastases.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The involvement of suspicious LNs should be confirmed by histology.Intraoperative assessment of LN status is highly recommended.All SLNs from both sides of the pelvis or any suspicious LNs should be sent for frozen section.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "If bilateral SLN is not detectable, intraoperative assessment of PLNs should be considered (see Management of stages T1b1/T2a1).LN staging is not indicated in stage T1a1 LVSI negative.In case of intraoperatively proven lymph node involvement, fertility-sparing surgery should be abandoned, and the patient referred to definitive chemoradiotherapy (see above).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The specific aim of fertility-sparing surgery must be the resection of invasive tumor with adequate free margins and preservation of the upper part of the cervix.Intraoperative frozen section is a reliable way of assessing the upper resection margin in trachelectomy specimen and should be considered.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Conization and simple trachelectomy are adequate fertility sparing procedures for stages T1a1 and T1a2, LN-negative, LVSI-negative patients.Radical trachelectomy (type A) can be considered for stages T1a1 and T1a2, LN-negative, LVSIpositive patients.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Conization or simple trachelectomy is an option.Radical trachelectomy (type B) should be performed for patients with cervical cancer stage T1b1 equal to or less than $2 \\mathrm { c m }$ of the largest diameter, LN-negative, $\\mathrm { \\ L V S I \\pm }$ Intraoperative placement of permanent cerclage should be performed during simple or radical trachelectomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "FST in patients with tumors greater than $2 \\mathrm { c m }$ cannot be recommended and is considered as an experimental approach.In more advanced cases, different propositions for fertility preservation should be discussed.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The goal of the fertility preservation should be to offer the most efficient approach related to the legal aspects of the country while not increasing the oncological risk.Any pregnancy following FST should be considered as a high-risk pregnancy, and delivery should be performed in a perinatal center.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Following simple or radical trachelectomy with its inherent placement of a permanent cerclage delivery can be performed only by cesarean section.Routine hysterectomy after finishing fertility plans is not necessary.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 5.6 Clinically occult cervical cancer diagnosed after simple hysterectomy # 5.6.1 General recommendations Management of occult disease should be based on expert pathology review and discussed in a multidisciplinary tumor board.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Prior to making further management decisions, optimal imaging to evaluate the local and regional (nodal) disease status is necessary.Optimal imaging follows the same recommendations as that for nonoccult disease (see above).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# B In general, management of occult disease follows the same principles as that of nonoccult disease.Treatment strategy should aim for the avoidance of combining radical surgery and radiotherapy because of the highest morbidity after combined treatment.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 5.6.2 Management of patients with pT1a1, LVSI $\\pm$ and pT1a2 LVSI-negative, with clear margins In patients with tumor stage pT1a1 regardless of LVSI status and pT1a2 LVSI negative with clear margins in the hysterectomy specimen, no additional treatment is recommended.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "5.6.3 Management of patients with pT1a2 LVSI-positive or pT1b1 or pT2a1, with clear margins In patients with tumor stage pT1a2 LVSI positive or pT1b1 or pT2a1 after simple hysterectomy, potential disease in the parametria and LNs has to be addressed.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Radiotherapy or chemoradiotherapy is recommended as an effective treatment option that avoids further surgery.In absence of residual tumor on imaging (including suspicious LNs), radiotherapy alone is recommended.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In case of residual tumor on imaging, including suspicious LNs, chemoradiotherapy is recommended.PALN dissection, at least up to inferior mesenteric artery, may be considered in patients without suspicious para-aortic nodes on imaging for staging purposes.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "![](images/32e3c6420d49536da5b277ec2b3f992fd0029490f7e0818ec375d98f4520af00.jpg) Debulking of suspicious PLNs may be considered.Radical surgery is an option in patients without LN involvement on imaging and in the absence of an upfront indication for adjuvant radiotherapy (combination of negative prognostic factors.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "PLN dissection should be performed as the first step of the surgery.Intraoperative assessment of PLNs may be considered.If intraoperative LN assessment is negative or is not performed, radical parametrectomy with the resection of the upper vagina should be performed preferably using minimally invasive techniques.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The type of radical parametrectomy (extent of parametrial resection) should be tailored to the presence of prognostic risk factors of the primary tumor as described above (Figure 3).Complete description of the template used for radical parametrectomy should be present in the operative report.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "![](images/1a4e18fdfefe8fbc5a1798e766bbc241a6adedb74bb46e42818ff667daaa0cbc.jpg) The 2017 modification of the Querleu-Morrow classification is recommended as a tool (Figure 4).If LN involvement, including macrometastases or micrometastases, is detected intraoperatively, further surgery (PLN dissection and radical parametrectomy) should be avoided, and chemoradiotherapy is recommended.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "PALN dissection, at least up to inferior mesenteric artery,may be considered for staging purposes.Debulking of suspicious nodes may be considered.# 5.6.4 Management of patients with stage pT1b2 and higher or involved surgical margins or residual tumour including involved lymph node on imaging In patients with stage pT1b2 and higher, involved surgical margins or in those with residual tumor including involved lymph node on imaging, chemoradiotherapy is recommended, and further surgery should be avoided.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# C PALN dissection, at least up to inferior mesenteric artery, may be considered for staging purposes in patients with negative PALNs on imaging.Debulking of suspicious PLNs may be considered.# 5.7 Management of locally advanced cervical cancer # 5.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "7.1 Stage T1b2/T2a2 and negative lymph nodes on radiological staging # Treatment strategy should aim for avoiding the combination of radical surgery and postoperative external radiotherapy because of the significant increase in morbidity and no evident impact on survival.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# A Definitive platinum-based chemoradiotherapy and brachytherapy are the preferred treatment (see Principles of radiotherapy).# C PALN dissection, at least up to inferior mesenteric artery, may be considered before chemoradiotherapy and brachytherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "PLN dissection is not required.Radical surgery is an alternative option, in particular in patients without negative risk factors (combinations of tumor size, LVSI, and/or depth of stromal invasion).Quality of surgery, both parametrectomy and LN dissection, is, however, of key importance in the management of large tumors.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Intraoperative assessment of LN status (frozen section) is recommended as the first step.If LN involvement is detected intraoperatively, including macrometastases or micrometastases, further PLN dissection and radical hysterectomy should be avoided, and patients should be referred for definitive chemoradiotherapy and brachytherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "PALN dissection, at least up to inferior mesenteric artery, may be considered for staging purposes.If intraoperative LN assessment is negative or is not done, systematic PLN dissection should be performed.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Type C2 radical hysterectomy is recommended.# C NACT followed by radical surgery is a controversial alternative.The benefit of tumor downsizing with regard to prognosis has not been proven.# 5.7.2 Stage T1b2/T2a2 and involved lymph nodes on radiological staging !",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "[](images/317a5f20d9e1804bad9879030b5f9661e9b2ceef42b17922de3b4887a52d7190.jpg) Definitive chemoradiotherapy and brachytherapy are recommended in patients with unequivocally involved PLNs on imaging (see Principles of radiotherapy).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "An additional radiation boost to the involved LNs should be applied (see Principles of radiotherapy).PALN dissection, at least up to inferior mesenteric artery, may be considered before treatment for staging purposes in patients with negative PALN on imaging.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Debulking of suspicious PLNs may be considered.# 5.7.3 Stage T2b, T3a/b, T4a # A Definitive platinum-based chemoradiotherapy and brachytherapy are recommended (see Principles of radiotherapy).An additional radiation boost to the involved LNs should be applied (see Principles of radiotherapy).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# PALN dissection, at least up to inferior mesenteric artery, may be considered before treatment in patients with negative PALNs on imaging.Debulking of suspicious PLNs may be considered.Pelvic exenteration is an option in selected cases with stage T4 N0 M0 disease.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 5.7.4 Cervical stump cancer Management of cervical stump cancer follows the recommendations for patients without previous subtotal hysterectomy.Adaptation of radiotherapy may be necessary, in particular for brachytherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 5.8 Distant metastatic disease at presentation Patients with distant metastatic disease at presentation should have a full diagnostic workup (see Staging) to assess extent of disease, suitability for active treatment, and treatment modality including best supportive care.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# B In medically fit patients with widespread distant metastatic disease at presentation (visceral $+ / \\ l$ nodal), combination chemotherapy is recommended.Carboplatin/paclitaxel and cisplatin/paclitaxel are preferred regimens in the first-line treatment.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# Addition of bevacizumab to standard chemotherapy is recommended in patients with good performance status and where the risk of significant gastrointestinal/genitourinary toxicity has been carefully assessed and discussed with the patient.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Patients with limited distant metastatic disease at presentation, confined to the PALN region, should be treated with curative intent with definitive extended field chemoradiotherapy including brachytherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Treatment algorithm may also include surgical debulking of enlarged LN and additional chemotherapy.Patients with supraclavicular LN as the only site of distant disease can be considered for chemoradiotherapy with curative intent.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Treatment algorithm may include additional chemotherapy.Adjuvant chemotherapy may be considered in cases carrying a high risk of recurrence such as positive margins, positive LN, or LVSI-positive tumors.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The role of radiotherapy in palliating symptoms such as bleeding and pain must be considered especially in radiotherapy naive patients.# 5.9 Recurrent disease # 5.9.1 Curative intent treatment Treatment of recurrent disease with curative intent requires centralization and involvement of a broad multidisciplinary team including gynecologic oncologist, radiation oncologist, radiologist, pathologist, medical oncologist, urologist, and plastic surgeon.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A structured program for multidisciplinary diagnostic workup, treatment, and follow-up must be present in centers responsible for the treatment.Each center involved in the primary treatment of cervical cancer should have an established network for discussion of difficult cases and willingness for referring patients with recurrence for treatment to highly specialized units.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Participation in clinical trials is encouraged to improve the clinical evidence for the effect of curative treatment of recurrent disease.The aim of the diagnostic workup is to exclude distant metastases and locoregional tumor extension beyond curative treatment.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The recurrence should be confirmed by histological examination.Patients with multiple nodal/distant metastases or multifocal local disease with extensive pelvic wall involvement are usually not considered candidates for curative treatment.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The prognostic factors should be carefully evaluated and balanced in relation to the major morbidity caused by the treatment.![](images/bb974d8cdd16b25aae4ef27aeebc787100a757165a3b4b25b51b319cdc621683.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "jpg) A full diagnostic package consisting of relevant imaging is recommended to establish the status of the disease locally, regionally, and systemically (see Staging).Patient should be carefully counseled regarding not only treatment options but also the involved risks and consequences.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 5.9.1.2 Central pelvic recurrence after primary surgery Definitive chemoradiotherapy combined with image guided adaptive brachytherapy is the treatment of choice (see Principles of radiotherapy).The use of boost by external beam techniques to replace brachytherapy is not recommended.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "For brachytherapy, small superficial lesions (ie, $< 5 \\mathrm { - m m }$ thickness) in the vagina may be treated using a vaginal cylinder, ovoids, or mold, whereas other lesions usually require combined intracavitary-interstitial techniques.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "5.9.1.3 Pelvic sidewall recurrence after primary surgery Definitive chemoradiotherapy is the preferred option.![](images/85074f43e09bb21c7388a78e963ba8e5457743dc2e0d0aa8d241e0a6f2ed52d3.jpg) Extended pelvic surgery may be considered in highly selected patients provided that the tumor does not invade extensively into the pelvic sidewall.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# D Combined operative-radiotherapy procedures using intraoperative radiotherapy or brachytherapy are an option if free surgical margins are not achievable.Definitive radiotherapy or chemoradiotherapy followed by a stereotactic ablative boost/imageguided interstitial brachytherapy/particle beam therapy is an emerging option.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "5.9.1.4 Central pelvic or pelvic sidewall recurrence after radiotherapy or chemoradiotherapy # D Pelvic exenteration is recommended for central pelvic recurrence where there is no involvement of the pelvic sidewall and extrapelvic nodes.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Laterally extended endopelvic resection may be considered for a recurrence that extends close to or involves the pelvic sidewall.Reirradiation with image guided adaptive brachytherapy for central recurrences is an alternative option especially in patients unfit for or refusing exenteration surgery, which should be restricted to highly specialized centers.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "If further surgery or radiotherapy is considered, no more than 2 to 4 courses of combination chemotherapy should be given to avoid unnecessary long interval before definitive treatment.Locoregional recurrences, which at diagnosis appear incurable, should be reassessed for the possibility of radical treatment if major response is obtained.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Suitable candidates for adjuvant chemotherapy are patients who recover well within 2 months after primary treatment for recurrence.# 5.9.1.6 Nodal and oligometastatic recurrences Localized para-aortic, mediastinal, and/or periclavicular recurrences above previously irradiated fields may be treated by radical EBRT if possible in combination with concomitant chemotherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It is recommended to electively irradiate the immediate regional nodal stations below and upstream.The therapeutic effect of nodal resection/debulking is unclear and should, if possible, always be followed by radiotherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The management of isolated organ metastases (lung, liver, etc) should be discussed in a multidisciplinary team involved in the treatment of the specific organ affected by the metastasis and should be treated according to the preferred method for that organ involving local resection, radiofrequency ablation, interventional brachytherapy, or stereotactic ablative radiotherapy according to size and anatomical position.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 5.9.2 Palliative treatment Recommendations for palliative treatment should be made only after a thorough review of the case by a specialist multidisciplinary team and taking into account the performance status, comorbidities, patient’s symptoms, and wishes of the patient.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The palliative care specialist should be actively involved.Palliative taxane/platinum combination chemotherapy with/without bevacizumab is the preferred option.There is currently no standard second-line chemotherapy, and such patients should be considered for clinical trials.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In symptomatic patients, palliative treatment should be tailored according to clinical situations.In patients with disseminated disease at presentation, radiotherapy (usually a fractionated course) should be considered for effective palliation.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "![](images/5536ab9725ceb4876a42612e0c9d4f67fd47934252de451f7d412f8bde04134b.jpg) Palliative radiotherapy (single fraction/short course) to control bleeding, discharge, and pain due to pelvic disease or bone metastases should be considered.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "For spinal cord compression due to bone metastases, neurosurgical intervention or short-course fractionated radiotherapy schedule should be considered.Surgical interventions including diversion stoma and/or stenting should be considered as appropriate, for example, in case of obstructive symptomatic disease.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 5.10 Follow-up # 1 General recommendations Primary objectives of follow-up for patients with cervical cancer should include the following:  Early detection of recurrent disease. Patient education and support.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": " Cancer rehabilitation with the goal to prevent and reduce psychosocial, physical, social, and existential consequences of cancer and its treatment starts at time of diagnosis.The efforts should optimize the physical abilities and quality of life of women affected by cervical cancer and include family members/care givers.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Several professions for counseling should be available, for example, psychologist, sexual therapist, physiotherapist, and dietitian. Assessment of long-term outcome of novel treatment strategies. Quality control of care.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Each visit should be composed of the following: Patient history (including elicitation of relevant symptoms)  Physical examination (including a speculum examination and bimanual pelvic examination)  Physician assessment of adverse events using validated scales (eg, Common Terminology Criteria for Adverse Events)  Prevention and management of cancer- and treatment-related adverse effects, for example, sexual dysfunction (eg, counseling, vaginal lubricants, local estrogen) In case of the appearance of treatment-related symptoms, a referral to a dedicated specialist (eg, gastroenterologist, urologist/gynecologist) should be considered.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Patients should be educated about symptoms of potential recurrence and potential long-term and late effects of treatment.Patients should also be counseled on sexual health, lifestyle adaptation, nutrition, exercise, obesity, and cessation of smoking.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Follow-up schemes may be individualized, taking into account prognostic factors, treatment modality, and estimated risk and/or occurrence of adverse effects.In general, follow-up intervals of 3 to 4 (6) months for the first 2 years and then 6 to 12 months up to 5 years are recommended.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Prescription of hormonal replacement treatment to cervical cancer survivors with premature menopause is advocated and should be according to regular menopausal recommendation.Combined estrogen and progestin replacement therapy should be prescribed if uterus is in situ (including after definitive radiotherapy).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Monotherapy with estrogen is recommended after hysterectomy.Imaging and laboratory tests should be performed based on symptoms or findings suggestive of recurrence or morbidity.In symptomatic women,MRI or CT should be considered to assess potential clinical recurrence.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "If positive, whole body PET-CT should be performed in patients in whom salvage therapy (surgery or radiotherapy) is being considered.Similarly, for suspected recurrence, PET-CT can be added when other imaging finding is equivocal.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Pathologic confirmation of any persistent or recurrent tumor should be considered.If a lesion is located deeply in the endocervix (in case of conservative treatment or definitive chemoradiotherapy), ultrasound-guided Tru-Cut biopsy is the preferred method.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "For any disease beyond the primary tumor site, ultrasound or CT-guided methods can be used to achieve pathologic confirmation.In case of clinically or radiologically suspicious disease, a negative biopsy may not be conclusive.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 5.10.2 Follow-up after fertility sparing treatment All women remain at risk of tumor recurrence following FST and must be carefully followed up.Follow-up should be carried out by a provider with specific expertise in detection of lower genital tract dysplasia (eg, gynecologic oncologist, colposcopy expert).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "C Follow-up intervals should be 3 to 4 months for the first 2 years postoperatively, and then 6 to 12 months up to 5 years.Thereafter the patient may return to population-based screening.The duration of follow-up, however, may be individualized depending on the risk of recurrence or persistence of treatment-related complications.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# C Follow-up should include HPV testing (with or without cytology).Colposcopy in combination with HPV testing in parallel performed by an experienced colposcopist is an option.The incorporation of high-risk HPV testing at 6, 12, and 24 months after treatment is advocated.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "If HPV testing is negative, then every 3 to 5 years as long as follow-up is indicated.# 5.10.3 Follow-up after simple or radical hysterectomy Follow-up should be carried out by physician experienced with follow-up care after surgery following the general recommendations (see above).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The vaginal vault cytology is not recommended.# 5.10.4 Follow-up after definitive chemoradiotherapy The same imaging method should be used for evaluation of tumor response as was used at baseline.Imaging should be performed not earlier than 3 months following completion of treatment.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In dubious cases, a reevaluation should be performed not before 8 weeks thereafter.# B For re-evaluation purposes, the optimal diagnostic workup for local extent is pelvic MRI, and for distant spread, it is chest/abdomen CT or PET-CT (preferred after definitive chemoradiotherapy or in high-risk patients).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Follow-up should be performed by a physician experienced with follow-up care after radiotherapy.Cytology is not recommended in these patients.Providers should inform and educate on sexual and vaginal health because vaginal stenosis and dryness may occur.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Vaginal dilation should be offered, as well as vaginal lubricants and local estrogen.# 5.11 Cervical cancer in pregnancy Every patient diagnosed with CCIP must be counseled by a multidisciplinary team.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "This team should consist of experts in the fields of gynecologic oncology, neonatology, obstetrics, anesthesiology, radiation oncology, medical oncology, psychooncology, and, if requested, theology or ethics.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Given the large spectrum of described therapeutic options, the multidisciplinary team recommends an individual consensual treatment plan according to patient’s intention, tumor stage, and gestational age of pregnancy at cancer diagnosis.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Primary aims of recommended treatment plan are oncological safety of the pregnant woman, as well as survival without additional morbidity of the fetus.Treatment of patients with CCIP should exclusively be done in gynecologic oncology centers associated with a highest level perinatal center with expertise in all aspects of oncologic therapy in pregnancy and intensive medical care of premature neonates.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Because of the low incidence of CCIP, centralization in a few well-equiped facilities is compulsory.Besides clinical examination and histologic verification of invasive cervical cancer, preferred imaging modalities for clinical staging in patients with CCIP include MRI or expert ultrasound.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Because of limited experience and inherent radioactivity PET-CT (PET-MRI) should be indicated only under very selected circumstances.Tumor involvement of suspicious nodes should be verified histologically because of its prognostic significance and the impact on the management up to $2 4 ^ { \\mathrm { t h } }$ week of gestation (fetal viability), preferably by minimally invasive approach.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Depending on tumor stage and gestational week of pregnancy, the following treatment options have to be discussed with the patient including risks and benefits of individual approaches: Adapted surgery including removal of the tumor: conization, trachelectomy, and lymph node staging (see above) according to the stage of the disease with the intent to preserve the pregnancy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": " Radical surgery or definitive chemoradiation as recommended for the stage of the disease without preservation of the pregnancy, with or without previous pregnancy termination. Delay of oncological treatment until fetal maturity (if possible $> 3 2$ weeks of gestation) and beginning of cancer-specific treatment immediately after delivery by cesarean section.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": " Chemotherapy until fetal maturity and beginning of cancer specific treatment immediately after delivery by cesarean section.Treatment after delivery must consider application of previous chemotherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In patients with locally advanced stage or with residual tumor after conization that cannot be completely excised (risk of premature rupture of membranes (PROM) and/or cervical insufficiency), platinum-based chemotherapy can be considered starting earliest at 14 weeks of gestation.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Spontaneous delivery seems to have negative prognostic impact in patients with CCIP.Thus, cesarean section after the $3 2 ^ { \\mathrm { n d } }$ week of gestation (if possible) is the recommended mode of delivery.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "At the time of or following casarean section, definitive stage-adjusted oncologic therapy has to be performed corresponding to that of nonpregnant women, taking into account therapy that has already been given during pregnancy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 6 Principles of radiotherapy # 6.1 Definitive chemoradiotherapy and brachytherapy: general aspects Definitive management (without tumor related surgery) consists of concomitant pelvic chemoradiotherapy (platinum based) and brachytherapy or pelvic EBRT alone and brachytherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Overall treatment time for the definitive treatment should not exceed 7 to 8 weeks.Delay of treatment and/or treatment interruptions have to be avoided.# 6.2 Definitive chemoradiotherapy EBRT is recommended minimum as 3-dimensional (3D) conformal radiotherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The preferred treatment is IMRT because of the more conformal dose distribution that maximizes sparing of organs at risk9.EBRT can be applied as concomitant chemoradiotherapy with total dose of 45 to 50 Gy (1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "8 Gy per fraction) and single-agent radiosensitizing chemotherapy, preferably cisplatin (weekly $4 0 ~ \\mathrm { m g / m } ^ { 2 \\cdot }$ ) so that definitive radiotherapy is not compromised.If cisplatin is not applicable, alternative treatment options are fluorouracil or carboplatin.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "EBRT may also be applied without concomitant chemotherapy according to treatment selection (ie, patients unfit for any chemotherapy).In such cases, regional hyperthermia may be considered.Tumor and LN-related target volume for IMRT includes the primary cervical tumor and the adjacent tissues such as parametria, uterine corpus, upper vagina, and the PLNs (obturator, internal, external and common iliac, presacral).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In case of PLN involvement indicating an increased risk of PALN spread, EBRT may include the para-aortic region up to the renal vessels (45 Gy).In case of PALN involvement, target volume includes at a minimum the region up to the renal vessels.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A reduced target volume for EBRT resulting in a small pelvic field not including the common iliac nodes may be considered in low- and intermediate-risk T1b1 patients with negative LNs on imaging and no LVSI.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Boost treatment for involved LN(s) may be applied as simultaneous integrated boost within the IMRT treatment or as sequential boost.The total dose including the contribution from brachytherapy should be 55 to 60 Gy (equi-effective dose to 2 Gy per fraction (EQD2)).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "An alternative treatment option is surgical debulking of enlarged nodes.IGRT is recommended for IMRT to ensure safe dose application in the tumor-related targets, to account for motion uncertainties, to reduce margins, and to achieve reduced doses to organs at risk.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Overall treatment time for EBRT should not exceed 5 to 6 weeks.# 6.3 Definitive brachytherapy IGABT is recommended, preferably using MRI at the time of brachytherapy.IGABT is delivered in large tumors toward the end of or after concomitant chemoradiotherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Repeated gynecologic examination is mandatory, and alternative imaging modalities such as CT and ultrasound may be used.The tumor-related targets for brachytherapy include the residual gross tumor volume (GTV- $\\cdot \\mathrm { T } _ { \\mathrm { r e s .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "} } \\cdot$ ) after chemoradiotherapy, the adaptive high-risk clinical target volume (CTV-THR) including the whole cervix and residual adjacent pathologic tissue, and the intermediate-risk clinical target volume (CTV- $\\cdot \\mathrm { T } _ { \\mathrm { I R } }$ )10-12.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Intracavitary and combined intracavitary/interstitial brachytherapy should be performed under anesthesia.The brachytherapy applicator should consist of a uterine tandem and avaginal component (ovoids/ring/mold/combined ring/ovoid).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Combined intracavitary/interstitial brachytherapy for adjusting the application further to the individual target should be considered.The vaginal component carries holes for straight or oblique needle guidance into the parametria.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In case of significant residual disease in the parametrium (as in any extracervical area, eg, vagina, uterine corpus, adjacent organ), this should become part of the CTV- $\\cdot \\mathrm { T } _ { \\mathrm { H R } }$ .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The brachytherapy application should be a combined intracavitary/interstitial approach in order to achieve a sufficiently high radiation dose in the whole CTV- $\\cdot \\mathrm { T } _ { \\mathrm { H R } }$ .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In IGABT, the planning aim should be to deliver a brachytherapy dose of 40 to 45 Gy (EQD2) to reach a total EBRT $^ +$ brachytherapy dose of equal to or greater than 85 to 90 Gy EQD2 (D90) (assuming 45 Gy through EBRT) to the CTV- $\\cdot \\mathrm { T } _ { \\mathrm { H R } } ,$ equal to or greater than 60 Gy (D98) to the CTV- $\\cdot \\mathrm { T } _ { \\mathrm { I R } } ,$ and equal to or greater than 90 Gy (D98) to the GTV- $\\cdot \\mathrm { T } _ { \\mathrm { r e s } }$ .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Three dimensional and 2D dose volume and point constraints for rectum, bladder, vagina, sigmoid, and bowel are recommended, and they have to be based on the published clinical evidence10-12.Point A dose normalization should be used as starting point for stepwise treatment plan optimization, although point A dose reporting and prescription have been extended by the volumetric approach10-12.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Brachytherapy should be delivered in several fractions as high dose rate (usually 3-4) or in 1 to 2 fractions as pulse dose rate brachytherapy.In large tumors, brachytherapy should be delivered within 1 to 2 weeks toward the end of or after chemoradiotherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In limited-size tumors, brachytherapy may start earlier during chemoradiotherapy.For the tumor-related targets (GTV-Tres, CTV-THR,CTV-TIR), the use of external beam therapy for giving extra dose (eg, parametrial boost, cervix boost) is discouraged, even when using advanced EBRT technology such as stereotactic radiotherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The use of a midline block for boosting the parametrium is discouraged when applying advanced IGRT, in particular beyond 45 to 50 Gy.Care should be taken to optimize patient comfort during (fractionated) brachytherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Preferably this includes a multidisciplinary approach.# 6.4 Adjuvant radiotherapy or chemoradiotherapy based on intensity modulated radiotherapy and image guided radiotherapy Adjuvant radiotherapy or chemoradiotherapy follows analog principles for target selection and dose and fractionation as outlined for definitive treatment.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The application of IMRT and IGRT is to be considered as treatment-related morbidity may be reduced.Adjuvant (additional) brachytherapy should be considered only if a well-defined limited area - accessible through a brachytherapy technique - is at high risk of local recurrence (eg, vagina, parametrium).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Such adjuvant brachytherapy should follow the major principles outlined above for image-guided brachytherapy.# 6.5 Definitive 3D conformal external beam radiotherapy or chemoradiotherapy and radiography-based brachytherapy Three-dimensional conformal radiotherapy alone or as definitive concomitant chemoradiotherapy (platinum based) $\\pm$ para-aortic radiotherapy and/or 2D radiography-based brachytherapy is recommended, if IMRT and/or IGABT are not available.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In case of 3D conformal radiotherapy and/or radiography based brachytherapy, the recommendations for EBRT and IGABT as outlined above in regard to target, dose, fractionation, and overall treatment time have to be respected as much as possible.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A sequential LN boost is applied as appropriate after completion of 3D EBRT Planning aim for brachytherapy should be based on point A.Dose to point A should be equal to or greater than 75 Gy (EQD2) in limited width adaptive CTV- $\\cdot \\mathrm { T } _ { \\mathrm { H R } }$ $\\left[ \\leq 3 \\mathrm { \\ c m } \\right]$ and should aim at higher doses in large width adaptive CTV- $\\cdot \\mathrm { T } _ { \\mathrm { H R } }$ $\\left[ > 4 \\mathrm { c m } \\right]$ .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In addition, dose for the maximum width of the adaptive CTV- $\\cdot \\mathrm { T } _ { \\mathrm { H R } }$ should be reported.Radiography based dose point constraints - plus 3D dose volume constraints as available - for rectum, bladder, vagina, sigmoid, and bowel are recommended, and they have to be based on the published clinical evidence10-12.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 6.6 Comment of the radiation oncology subgroup of the development group The radiation oncology subgroup of the multidisciplinary international development group designed this section on principles of radiotherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "This chapter on principles of radiotherapy is mainly based on the progress achieved in chemoradiotherapy, brachytherapy and external beam radiotherapy during the last two decades.Progress in chemoradiotherapy has been driven through several phase III trials and metaanalyses providing level 1 evidence which resulted in grade A recommendations (see 13.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1.5).The progress in brachytherapy and external beam radiotherapy has followed the classical pathways of technology innovations and developments in clinical settings and is ongoing.MRI image guidance, applicator development and adaptive treatment planning for brachytherapy have played a major role in the development of image guided adaptive brachytherapy and started from monoinstitutional innovations.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Several mono-institutional evaluations at various clinical departments in Europe and beyond could prove the new method of image guided brachytherapy to be feasible, reproducible, reliable and clinically valuable.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The European Gyn GEC ESTRO group has become the major driving force in this development, providing essential recommendations to guide this treatment as early as 2005 and 2006.This group also started large multi-center retrospective and prospective clinical trials and evaluations of image guided adaptive brachytherapy (RetroEMBRACE, EMBRACE I (2008-2015) and EMBRACE II (since 2016)) benchmarking these innovations in a multicentre clinical setting13.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In parallel, the International Commission of Radiation Units finished a revision on their recommendations from 1985 (ICRU report 38) in 2016 (ICRU report 89) which was based on the Gyn GEC ESTRO Recommendations.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Therefore, at present there is a methodology for image guided brachytherapy available, agreed upon on the international level, how to treat cervical cancer through an advanced adaptive approach.The method is comprehensively described in ICRU report 89 and additionally allows to integrate recent volumetric (3D/4D) and traditional (2D, point A) treatment approaches.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In addition, there is major high quality clinical evidence coming up from scientific reports on large cohorts of the EMBRACE clinical trial experience in regard to patient, tumour and treatment parameters and oncological, morbidity and quality of life outcomes.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "This ongoing increasing evidence (see 13.1.4) makes image guided brachytherapy to become the new clinical standard of care in a large growing number of centers in Europe and in many centers and countries all over the world.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Therefore, the radiotherapy subgroup decided - in agreement with a large amount of radiation oncology reviewers of this guideline - to make this new method and the clinical evidence achieved so far to become the backbone of these guidelines and to declare this new paradigm the new standard of care for cervix cancer brachytherapy in Europe.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Image guided external beam radiotherapy using advanced imaging as well as advanced hard and software technology for radiation application (IMRT, IGRT) also has entered the field of gynaecologic radiation therapy for cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "IMRT and IGRT provide several advantages in dose distribution in regard to sparing of organs at risk without compromising clinical outcome compared to traditional 3D conformal radiotherapy.In addition, IMRT and IGRT are increasingly spread in Europe and all over the world.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "For these reasons advanced methodology for external beam radiotherapy application was selected to form the basis for these European guidelines, although there is at present much “work in progress” and the clinical evidence for dose and volume prescription for IMRT and IGRT including lymph node boosting is limited.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The radiotherapy subgroup took the decision - again in agreement with a large amount of radiation oncology reviewers of this guideline - to allocate IMRT with IGRT including simultaneous lymph node boosting to represent the “preferred treatment” for external beam radiotherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 7 Principles of pathological evaluation The pathology report represents a key component in the management of cancer patients.The completeness and accuracy of the pathology report derives from several factors.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Pre-analytical steps must be carried out in an optimal way to allow for adequate pathological evaluation.The inclusion of informative clinical and surgical data on the pathology request form and accurate sampling and processing of the specimens are the basis for a correct histological diagnosis and the provision of information on tumour staging and prognosis.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The pathology report should be comprehensive of all the features which allow a cervical carcinoma patient to be placed into a risk group which ensures the appropriate management.It should include all the parameters impinging on tumour staging and patient management.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The histological subtype is important since some uncommon tumour types are associated with aggressive (e.g.high grade neuroendocrine carcinoma, small cell or large cell neuroendocrine carcinoma) or favourable (e.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "g.adenoid-basal carcinoma) behaviour and may be considered for different treatment.Histological tumour grade is generally reported in squamous cell carcinomas and adenocarcinomas but in general this does not affect the treatment and the prognosis, especially since there is no validated grading system for cervical squamous cell carcinomas or adenocarcinomas.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Accurate tumour measurement, which often requires correlation of the gross and microscopic features, is important for substaging of tumours (for example IA1 versus IA2 versus IB1, IB1 versus IB2).The presence or absence of LVSI, the LN status (number of nodes retrieved, number involved, presence of extracapsular extension), involvement of extracervical tissues and the margin status, including the distance of tumour and preinvasive disease to various margins is also critical for patient management.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The use of immunohistochemical markers in a prognostic and/or predictive role is not currently established but this may change in the future.However, pathologists often use immunohistochemical stains as a diagnostic tool.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Intraoperative evaluation of a sentinel (or other) LN with obvious gross tumour may be done with a single section to confirm the presence of metastasis.Frozen section examination is optional for non-suspicious SNs.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "At frozen section, there is no evidence for the exact number of histological sections to be examined, but the number should be adequate to pick up macro- and micrometastasis since the presence of metastatic tumour within a LN changes the management with abandonment of surgery and instigation of chemoradiotherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Full pathological examination of SNs (outside of the intraoperative setting) involves serial sectioning of the LN(s) with multiple levels, sometimes with the performing of immunohistochemical staining with pancytokeratin antibodies (e.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "g.AE1/AE3) if tumour is not identified on examination of routinely stained sections.To rule out micrometastasis, which measure from greater than $0 .2 \\ \\mathrm { m m }$ to $2 \\ \\mathrm { m m }$ it is useful to cut the node grossly into $2 \\ \\mathrm { m m }$ sections and to perform serial sectioning on each block at $2 0 0 ~ { \\mu \\mathrm { m } }$ levels.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Immunohistochemistry with cytokeratin antibodies is useful to confirm metastasis which are uncertain on haematoxylin and eosin (H&E) stained sections.Immunohistochemistry also helps to detect isolated tumour cells (up to $0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "2 ~ \\mathrm { m m }$ in diameter).These are regarded as node negative and $\\mathrm { \\ p N { 0 } ( i { + } ) }$ but their clinical impact has not yet been determined.# 7.1 Requirements for specimen submitted for pathological evaluation Patient information, previous cervical cytology, histological specimens, clinical and radiological data, and colposcopic findings need to be included on the specimen request form.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Details of cytology, biopsy, and surgical specimen (cone/loop specimen, trachelectomy, type of hysterectomy, presence of ovaries and fallopian tubes, presence of LNs and designation of the LN sites, presence of vaginal cuff, and presence of parametria) need to be itemized in the specimen request form.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Biopsies and surgical specimens should be sent to the pathology department in a container with liquid fixative (‘‘clamping’’ of the specimen on cork may be done).Cytology specimens should be sent to the pathology department either as a smear preparation (exfoliative cytology on a clearly designated and identifiable slide with patient’s name and birth date) or as liquidbased cytology.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The latter is necessary when an HPV test is requested.Cone/loop specimen should ideally be sent intact with a suture to identify the 12-o’clock position.# 7.2 Specimen grossing and sampling Small biopsy specimens should be enumerated and measured.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The diameter (2 dimensions) and depth of cone/loop specimens should be measured.It should be recorded if the specimen is complete or fragmented.If more than 1 piece of tissue is received, every piece should be measured in 3 dimensions and entirely examined.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Inking of the surgical margins of cone/loop specimens is optional.Dissection of cone/loop specimens should be performed in an appropriate fashion.All the pieces submitted should be in consecutive numerical order.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "This is important because if tumor is present in more than 1 piece, it needs to be known whether these are consecutive pieces and thus a single tumor or represents multifocal tumor.It is recommended to place only 1 piece of tissue in each cassette.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "There are also techniques that allow embedding of more than 1 piece in a cassette if they are small enough.In cases that do not comprise intact cone/loops, serial radial sectioning and placing of each slice of tissue in a single cassette should be performed.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The description of the specimen (hysterectomy, trachelectomy, presence of ovaries and fallopian tubes, presence of LNs and indication of the LN sites, presence of vaginal cuff, presence of parametria) should be recorded and checked for consistency with the description given in the specimen request form.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The presence of any gross abnormality in any organ should be documented.The dimensions of the uterus for a hysterectomy specimen and the cervix for a trachelectomy specimen should be documented.The minimum and maximal length of the vaginal cuff should be documented.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The size of the parametria should be documented in 2 dimensions (vertical and horizontal).Gross tumor involvement of the parametrium, vagina, uterine corpus, or other organs should be documented.The relationship of the cervical tumor to the vaginal and parametrial margins (and upper margin in case of a trachelectomy specimen) should be measured and appropriate sections taken to demonstrate this.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Parametrial and vaginal margins should be inked.Parametria should be submitted totally for histological examination.The upper surgical margin of a trachelectomy specimen should be inked.The upper margin of a trachelectomy specimen should be sampled in its entirety in away that demonstrates the distance of the tumor to the margin.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The vaginal margin should be examined totally as radial sections if no tumor is seen grossly.When the tumor is small (or with tumors that cannot be identified macroscopically), the cervix should be separated from the corpus, opened and processed as for a cone/loop specimen.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In the case of a large tumor, the hysterectomy or trachelectomy specimen should be opened in the sagittal plane.The description of the cervix and measurement of any gross tumor mass should be documented.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gross tumors should be measured in 3 dimensions, namely, 2 measurements of horizontal extent and the depth of invasion.The tumor site within the cervix should be documented.The cervical tumor should be sampled in order to demonstrate the maximum depth of invasion, the relationship of the tumor with the surgical borders, and the extension to other organs.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "If visible, the site of a previous cone biopsy should be documented.At least 1 block per centimeter of the greatest tumor dimension for large tumors should be taken.Additional blocks including the cervix adjacent to the tumor should be taken in order to demonstrate precursor lesions.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The whole cervix should be sampled in the case of a small tumor or where no macroscopic tumor is identified.The uterine corpus, vagina, and adnexa should be sampled according to standard protocols if not involved by tumor.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "If the uterine corpus and/or adnexa are grossly involved, additional blocks should be sampled.The entire vaginal margin should be blocked.All the LNs should be submitted for histological examination.If the LNs are grossly involved, representative samples are sufficient.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "If grossly uninvolved, each node should be sliced at $2 \\cdot \\mathrm { m m }$ intervals and totally embedded.From each block, H&E sections should be taken.LNs should be submitted in separate cassettes according to the site recorded on the specimen request form.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 7.3 Pathological analysis of sentinel lymph node Intraoperative assessment should be performed on a grossly suspicious SN and may be performed on a “nonsuspicious” SLN(s) because the confirmation of tumor involvement will result in abandoning a hysterectomy or trachelectomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "For intraoperative evaluation, the SLN(s) needs to be sent to the pathology department in a container without liquid fixative.Intraoperative analysis requires gross dissection of the resected adipose tissue by the pathologist with the selection of the LN(s).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "For a LN with obvious gross tumor, a single section is adequate for frozen section.Frozen section may be combined with imprint cytology.Any nonsuspicious SN should be bisected (if small) or sliced at $2 \\mathrm { - m m }$ thickness and entirely frozen.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "From each sample, histological sections should be cut and stained by H&E.After frozen section analysis, the tissue should be put into a cassette, fixed in liquid fixative and subsequently processed and embedded in paraffin.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "SLN(s) tissue blocks should be entirely analyzed by examining multiple serial sections at different levels with H&E stains.Cytokeratin stains should be performed on all blocks.The detection of micrometastases and isolated tumor cells should be improved by immunohistochemistry with pancytokeratinantibodies (e.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "g.AE1/AE3).Different procedures have been published, and there is no standard method.Cytokeratin-positive cells should always be correlated with themorphology.Müllerian inclusions (endosalpingiosis, endometriosis) and mesothelial cells may rarely be present in PLNs and PALNs and be cytokeratin positive.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 7.4 Requirements for pathology report Description of the specimen(s) submitted for histological evaluation.Macroscopic description of specimen(s) (biopsy, loop/cone, trachelectomy, hysterectomy) including specimen dimensions (3 dimensions), number of tissue pieces for loop/cones, and maximum and minimum length of vaginal cuff and the parametria in 2 dimensions.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Macroscopic tumor site(s), if the tumor is visible grossly, in trachelectomy and hysterectomy specimens.Tumor dimensions including 2 measurements of horizontal extent and depth of invasion or thickness (tumor dimension should be based on a correlation of the gross and histological features).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Whenmultifocal separate tumors are present, each should be described and measured separately, and the largest used for tumor staging.Specimens from prior conization and subsequent conization, trachelectomy, or hysterectomy should be correlated for estimation of the tumor size.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "This is of importance because different specimens may have been reported at different institutions.It should also be recognized that simply adding the maximum tumor size in separate specimens may significantly overestimate the maximum tumor dimension.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Histological tumor type and tumor grade.The presence or absence of LVSI.Coexisting pathology (squamous intraepithelial lesion/cervical intraepithelial neoplasia, adenocarcinoma in situ, stratified mucin-producing intraepithelial lesion).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Minimum distance of uninvolved cervical stroma.Margin status (invasive and preinvasive diseases).Specify the margin(s).LN status including SLN status, the total number of nodes found and the number of positive LNs, and the presence of extranodal extension (list for all separates sites).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Micrometastasis ( $\\mathrm { 9 0 .2 ~ m m }$ and up to $2 ~ \\mathrm { m m } ^ { \\cdot }$ ) are reported as pN1(mi).Isolated tumor cells no greater than $0 .2 \\ \\mathrm { m m }$ in regional nodes should be reported as pN0 $( \\mathrm { i } + )$ .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Pathologically confirmed distant metastases.Provisional pathological staging pretumor board/multidisciplinary teammeeting (American Joint Committee on Cancer, eighth edition).7.5 Items to be included on pathology report of carcinomas of the cervix \\* Tumor dimension should be based on a correlation of the gross and histological features <html><body><table><tr><td>CLINICAL/SURGICAL</td><td>MACROSCOPIC</td><td>MICROSCOPIC</td></tr><tr><td>Specimen(s) submitted</td><td>Specimen dimensions Number of tissue pieces (for loops/cones).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Tissus piece dimensions (for loops/cones).oDiameterofectocervix(two measurements).o Depth of specimen.Vaginal cuff.OMinimum length.0Maximum length.Size of parametria in two dimensions (vertical and horizontal).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Macroscopic tumor site(s)</td><td>Tumour dimensions* Horizontal extent (two measurements).Depth of invasion or thickness.Histological tumor type Histological tumor grade LVSI Coexistent pathology Squamous intraepithelial lesion/cervical intraepithelial neoplasia.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Adenocarcinoma in situ.Stratified mucin-producing intraepithelial lesion.Minimum distance of uninvolved cervical stroma Margin status (invasive and preinvasive diseases).Specify the margin(s) LNs status (SLN status, number involved/number retrieved and presence of extranodal extension) Pathologically confirmed distant metastases</td></tr></table></body></html> # 8 Staging # 8.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1 Summary of available scientific evidence # 8.1.1 Prognostic factors Many studies14-118 have pointed out since the last four decades the independent prognostic LoE $^ { 1 + }$ significance of LN involvement, stage, histological type, tumour size, LVSI, stromal invasion, parametrial invasion, grade, and/or age in patients with cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The LN involvement appears as the most powerful prognostic factors14-53,83,86,87,93,96-102,105,108,109,112-114,118 influencing survival rate.An early stage is associated with an improvement of survival rates18,28,32,33,42,43,45,54-63,86,87,89,92,95-97,101,103-105,107,109,110,115.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The presence of a large tumour (especially tumour size $>$ 4 cm)14,17-21,23,25,26,30,34,39,55,59,63-69,84,88,91,96,97,101,106,114-116,118, LVSI16,18,19,22,30,36,39,47,52,59,62,64,66,70-73,82,83,90,112, stromal invasion depth19,39,44,56,62,66,70,74-76, parametrial invasion19,22,36,39,40,44,47,62,77,78,90,94,99, and a high grade15,39,42,60,65,67,71,85,87,90,97,104 are independent factors in decreasing survival rates.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Prognostic significance of age for survival remains controversial.The majority of identified studies23,46,54,55,57,65,68,73,79,80,83,85,89,109,116 reporting the prognostic significance of age in patients with cervical cancer reported that the young patient age at presentation is an independent factor in improving survival.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "But other identified studies20,45,48,60 observed that the young age is independently associated with a higher risk of death.# 8.1.2 Detection of advanced disease (FIGO stage $\\geq$ IIB) Using the technique of meta-analysis, Thomeer et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "119 assessed the diagnostic performance of LoE 1- clinical examination (sixteen studies120-135) and MRI (twenty studies121-123,127-143) in detecting advanced stage disease (FIGO stage $\\geq$ IIB).Authors showed that MRI is significantly better than clinical examination in ruling out advanced disease in patients with cervical carcinoma (Table 1).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted that (1) three included studies had a sensitivity of $0 \\%$ and specificity of $1 0 0 \\%$ , which was mainly because most patients were not operated on when advanced disease was clearly present during clinical examination, (2) different technical aspects of MRI influenced the summary results, (3) the prevalence of disease in the studies had a significant effect on the summary results on clinical examination, (4) the presence of verification bias had a negative effect on the summary results of MRI, (5) the use of anaesthesia had a positive effect on the summary results of clinical examination, and (6) the use of an fast spin echo sequence, higher magnetic field and an additional coil had a significant positive influence on the summary results of MRI.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "One study144 not included in the meta-analysis119 mentioned above was identified and presents LoE 2- consistent findings with those previously reported.# 8.1.3 Detection of parametrial invasion Thomeer et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "119 assessed also the diagnostic performance of clinical examination (seven LoE 1 studies120,123,127,128,131,145,146) and MRI (twenty-nine studies122,123,127,128,131,135-142,145-160) in detecting parametrial invasion in patients with cervical carcinoma.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Their analyses revealed that MRI has a higher sensitivity than clinical examination for staging cervical carcinoma and the both tests have comparably high specificity (Table 1).It should be noted that (1) details of the examination were often not reported in studies, with the exception of the three largest studies120,121,125 ( $6 2 \\%$ of the patients) where most details were described, (2) in most of the studies it was not evident whether the results of MRI and clinical examination data influenced each other, (3) different technical aspects of MRI influenced the summary results, (4) the prevalence of disease in the included studies had a significant effect on the summary results of MRI concerning parametrial invasion, (5) the presence of verification bias has a negative effect on the summary results of MRI concerning parametrial invasion and advanced disease, (6) the use of an fast spin echo sequence, higher magnetic field and an additional coil had a significant positive influence on the summary results of MRI for both parametrial invasion and the detection of advanced disease, (7) the use of a slice thickness of $5 ~ \\mathrm { m m }$ or smaller also had a significant positive effect on the evaluation of parametrial invasion with MRI, (8) other parameters were not significant or not interpretable because of the low number of studies included, and (9) even with inclusion of studies with old MRI sequences the data are significantly favourable for MRI in comparison to clinial examination.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Six original studies161-166 not included in the meta-analysis119 mentioned above were identified.A study161 comparing these two techniques confirmed the superiority of MRI on clinical examination for detection of parametrial invasion.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Three small studies162-164 confirmed the reliability of MRI in detecting parametrial invasion.In the fifth identified original study165, there was agreement between MRI and histopathology for parametrial infiltration in $7 5 \\%$ of cases, with a tendency towards underestimation in $2 1 \\%$ of cases.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Discordant findings were reported in the sixth identified study166 indicating that the best diagnostic results in terms of sensitivity and specificity were achieved by clinical examination.Authors also evaluated CT and found that clinical examination was also better than CT.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted that all patients included in this sixth identified study166 underwent clinical examination and then on the basis of these findings, arrangements were made for further diagnosis, including imaging, for a large proportion of patients.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "So, selection bias cannot reliably be ruled out in the comparison of clinical staging and cross-sectional imaging.Five original studies149,167-170 comparing notably the diagnostic performance of US and MRI for LoE 2- detection of parametrial invasion were also identified and found that US was at least as sensitive as MRI.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Four149,167,169,170 of them showed that US was better than MRI in terms of specificity.The first of those studies149 employed a transrectal examination, while three reports167-169 used a transvaginal approach.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Patients were examined either transvaginally or transrecally in the fifth study170.Prasad et al.171 found poor agreement between CT and clinical examination in the evaluation of LoE 3 parametrial invasion $( 4 1 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "5 \\% )$ .Preliminary results concerning the value of integrated PET/MRI in the detection of the invasion of parametrium have been published by Grueneisen et al.172 and present a high diagnostic performance in terms of sensitivity and specificity ( $9 0 \\%$ $( 9 5 \\% \\mathrm { ~ C I ~ } = 5 5 \\ – 1 0 0 ]$ and $9 4 \\%$ ( $9 5 \\% \\mathrm { C I } = 7 1 – 1 0 0 \\mathrm { } )$ , respectively).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "PET-CT, MRI, and non-fused and fusion of PET and MRI for detecting parametrial invasion were investigated by Kitajima et al.173.The sensitivity for MRI, fused PET/MRI and non-fused PET/MRI was higher than that of PET-CT.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "However, none of the differences reached statistical significance.High diagnostic performance in terms of specificity was similar between them.# 8.1.4 Identification of tumour As part of a European multicenter trial170, the agreement between US and pathology was excellent for detecting tumours, correctly classifying bulky tumours $\\left( > \\ 4 \\ \\mathrm { c m } \\right)$ and good for classifying small tumours $\\left( < \\ 2 \\ \\mathrm { c m } \\right)$ (kappa values 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "84, 0.82, and 0.78, respectively).The agreement between MRI and histology was good for classifying tumour as $< 2$ cm or $> 4 \\ \\mathrm { c m }$ (kappa values 0.71 and 0.76, respectively).It was moderately accurate in tumour detection (kappa value 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "52).Authors found that cone biopsy prior to imaging did not affect the accuracy LoE 2- of US or MRI in detecting residual tumours.Using transrectal approach, Fischerova et al.149 also observed that US was more accurate to MRI in detection of residual tumours following conisation and evaluation of small tumour volume $\\left[ \\leq 1 \\mathrm { c m } ^ { 3 } \\right]$ in early-stage cervical cancers.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A third study167 was identified and reported similar sensitivity and specificity with regard to the detection of the presence of the tumour mass.# 8.1.5 Detection of stromal invasion LoE 2- Three original studies167,168,170 showed comparable performances between US and MRI for detecting stromal invasion.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Stromal infiltration, as document by MRI, agreed with the histopathological findings in $7 5 \\%$ of cases, whereas it was underestimated in $2 1 \\%$ of cases and overestimated in $4 \\%$ of patients in the study published by Manfredi et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "165.Yang et al.174 reported a high performance of PET-CT in terms of sensitivity for detecting stromal invasion before operation in cervical cancer $( 9 8 .4 \\% )$ but a low specificity $( 5 9 .2 \\% )$ .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 8.1.6 Determination of the proximal extension of early stage to the internal os A systematic review175 of the literature assessing the value of MRI for detecting involvement of Lo the uterine internal os was identified.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In the four included studies165,176-178 involvement of the internal os was present in $1 7 \\%$ $( 1 3 - 2 4 \\% )$ ) of the cases.For three studies165,176,178 summary estimates for specificity and sensitivity could be calculated and were $9 7 \\%$ and $9 1 \\% ,$ respectively.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Sensitivity and specificity of MRI could not be studied in a small identified study179 not LoE 3 included in the systematic review published by de Boer et al.179, due to the extreme low prevalence of involvement in the study population $( 3 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "7 \\% )$ .This study showed moderate to almost perfect interobserver values for MRI in visualization of the internal os (an agreement of $9 6 \\%$ was achieved) and the distance between tumour and the internal os (intraclass correlation coefficient was 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "752 ${ \\displaystyle [ 9 5 \\% ~ } \\mathrm { C I } = 0 .4 0 6 { - } 0 .9 0 9 ]$ ), in patients with early stage cervical carcinoma.The distance between tumour and the internal os measured on MRI was compared with pathological findings.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "For the two thresholds taken into account (5 mm or $1 \\mathrm { c m }$ ), no falsenegative findings were observed.It should be noted that authors evaluated interobserver variability of two radiologists with similar experiences.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 8.1.7 Lymph node status assessment Choi et al.180 performed a meta-analysis including forty-one studies122,128,136,138,140- 142,145,146,151,158,159,178,181-210 to compare diagnostic performances of computed tomography (CT), MRI and PET or PET-CT, for detection of metastatic LNs.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "PET or PET-CT had an overall higher diagnostic performance (patient-based data analysis and region- or node-based data analysis) than did CT or MRI in detecting metastatic LNs (Table 2).It should be noted that (1) this may be because the criteria of the LN size were used differently in each study, and also CT and MRI cannot readily differentiate metastatic nodes from hyperplastic nodes of the similar size, (2) in some studies, the mean size of a metastatic LN was smaller than $1 \\ \\mathrm { c m }$ (largest short axis diameter), that may also explain the low performance of CT and MRI when the largest short axis diameter is the diagnostic size criterion, and (3) authors did not evaluate a region-based or node-based data analysis separately because only three studies178,197,204 had reported the findings from a node-based data analysis.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "As part of a subgroup analysis based on the type of CT scanner (per-patient based comparison), sensitivity was $3 9 \\%$ ${ \\mathrm { 9 5 \\% C I } } = 3 0 { \\mathrm { - 4 9 } } ^ { \\cdot }$ ) for helical CT and $6 1 \\%$ ( $5 \\% \\mathrm { C I } = 5 2 – 7 1 \\mathrm { \\Omega }$ ) for non-helical CT, while specificity was similar between them $( 9 2 \\% ( 9 2 \\% \\mathrm { ~ C I } = 8 9 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "9 5 )$ and $9 2 \\%$ $9 5 \\% \\mathrm { C I } = 8 8 – 9 5$ ), respectively).Authors did not evaluate diagnostic performances by type of MRI scanner because only four of thirty-two MRI studies142,146,181,182 did not use 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "5-tesla MR scanners.Nine original studies162,165,166,174,211-215 not included in the meta-analysis180 mentioned above were identified.In the study published by Manfredi et al.165, MRI accuracy in evaluating nodal metastasis was $8 9 \\%$ , considering a cutoff of $1 \\ \\mathrm { c m }$ , and $8 3 \\%$ with a cutoff value of $0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "5 \\ \\mathrm { c m }$ .Lowering the cutoff value from $1 \\ \\mathrm { c m }$ to $0 .5 ~ \\mathrm { c m }$ led to a higher false positive rate, with consequent reduction in specificity ( $1 0 0 \\%$ to $9 2 \\%$ ) and a slight increase in sensitivity ( $2 8 \\%$ to $3 3 \\%$ ).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In the second identified study162, accuracy of MRI in detecting LN involvement was $8 6 \\%$ .Concordant findings with the meta-analysis180 mentioned above were described in five identified reports166,211-213,215 concerning the diagnostic performances of PET, PET-CT, CT and MRI for detecting LN involvement in terms of sensitivity and specificity.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Yang et al.174 and Signorelli et $a l .^ { 2 1 4 }$ reported consistent data with the meta-analysis180 mentioned above concerning the high diagnostic performance of PET-CT in terms of specificity ( $9 5 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 \\%$ and $9 7 \\% ,$ respectively).However, the authors reported a low sensitivity ( $5 3 .8 \\%$ and $3 2 \\% ,$ respectively) to diagnose LN metastasis.Ospina et al.216 described that when PET-CT (seven studies196,207-209,217-219) and PET (thirteen studies195,205-207,210,220-227) are evaluated for staging purposes, positive results seem to be useful to detect the stage of the disease for both techniques, but negative results are not.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Authors also described that there was no statistically significant difference of performance between PET-CT and PET in the overall staging of cervical cancer.PET-CT has limited sensitivity, but high specificity for predicting PLN metastasis in preoperative staging in two studies228,229 not included in the pooled analyses180,216 mentioned above.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Preliminary results concerning the value of integrated PET/MRI in the detection of nodal positive patients have been published by Grueneisen et $a l .^ { 1 7 2 }$ and present a high diagnostic performance in terms of sensitivity and specificity ( $91 \\%$ $( 9 5 \\% \\mathrm { C I } = 5 9 - 1 0 0 )$ ) and $9 4 \\%$ ( $9 5 \\%$ CI $= 7 0 – 1 0 0 \\dot s$ ), respectively).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "PET/MRI correctly identified regional metastatic disease (N1-stage) in $8 0 \\%$ of patients and non-regional LN metastases in all patients.PET-CT, MRI, and non-fused and fusion of PET and MRI for detecting nodal metastasis were investigated by Kitajima et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "173.On a per-patient basis, similar sensitivities and specificities were found for both the fused PET/MRI and PET-CT protocols Lower sensitivies and higher specificities were reported for non-fused PET/MRI and MRI.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A meta-analysis230 evaluating the accuracy of tests for LN status in cervical cancer and including seventy-two studies122,128,135,138,140-143,146,158,159,182-188,190-192,194,198,200,201,203,204,206,210,231- 273 was identified.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "SN biopsy was the most accurate test in determining LN status as compared to PET, MRI and CT (Table 3).The failure rate for the detection of the SN was $1 0 .9 \\%$ ( $9 5 \\%$ CI = 1.5-27.4).The failure rates were $8 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "4 \\%$ $( 9 5 \\% \\mathrm { C I } = 3 .3 – 1 5 .5 )$ for using blue dye alone and $4 .4 \\%$ ( $| 5 \\% \\mathrm { ~ C I } = 2 .0 – 7 .7 \\$ for use of a combined technique (blue dye/technetium $1 9 9 \\mathrm { m }$ colloid $\\big ( \\mathrm { 9 9 m T c } \\big ) ]$ .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "No difference was find in accuracy between these different techniques or between open and laparoscopic surgery.Authors also showed that PET was more accurate than MRI or CT.It should be noted that multivariable analysis explorating reasons for heterogeneity showed that the differences in accuracy among included studies could not be explained by the site of LN (pelvic or para-aortic).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Four other meta-analyses, published by Kadkhodayan et al.274, van de Lande et al.275, Wang et $a l .^ { 2 7 6 }$ , and Tax et al.277 (including sixty-seven studies231,232,234,235,238,245,246,249,251,254,257-259,278-331, twenty-four studies231,234-236,238,239,242,244-246,249-252,254,255,257-259,287,323,332-334, forty-nine studies235,236,238,239,243-246,249-252,254,255,257-259,280,284,287,288,291,292,297,298,302,307,310,311,316,318,322,323,326- 331,333,335-343, and forty-seven studies236,243,257-259,278,280,284,286,288,291,297,298,300-302,306,307,309- 311,316,317,320,322,328,333,335,337-340,342,344-358 respectively), and reviewing the diagnostic performance of SN detection for assessing the nodal status were identified and confirmed the high success rate in terms of detection rate and sensibility.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "SN detection and sensitivity were related to the mapping material, being lower with blue dye alone and highest in the combined tracer/blue dye method.A subgroup analysis on technique within a bilateral sentinel LN approach performed by Tax et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "277 showed that bilateral detection rate was highest when a combined tracer was used (Table 4).No statistical significant difference in terms of detection rate or sensitivity between laparotomy, laparoscopy, and robot-assisted method was reported.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "According to subgroup analyses regarding other potential factors associated with diagnostic performance provided by Kadkhodayan et al.274, previous conisations did not impact on the detection rate of SN mapping for prediction of LN status (Table 5).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "SN mapping had excellent detection rate and sensitivity in the setting of fertility-sparing surgery.Immunohistochemistry (IHC) in addition to the traditional H&E pathological examination of the SN improved the sensitivity.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Pooled SN detection rate in patients with a history of pre-operative treatments such as neoadjuvant chemotherapy or radiotherapy was low, however, pooled sensitivity remained high.Finally, larger tumour size $\\mathrm { ( > 2 ~ c m ) }$ ) and a more advanced stage ( $\\mathrm { \\hat { ~ } } >$ FIGO stage Ib2) were associated with low detection rate and sensitivity.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "As part of subgroup analyses performed by Tax et al.277, ultrastaging resulted in higher sensitivity compared to frozen section and/or H&E analysis $9 4 \\%$ $( 9 5 \\% \\mathrm { ~ C I ~ } = 8 0 { \\cdot } 9 9 )$ versus $6 8 \\%$ $9 \\% \\mathrm { C I } = 3 8 – 8 8 )$ ).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "This was due to correctly detecting metastases with ultrastaging in $8 0 \\%$ of false negative patients on frozen section and/or H&E analysis.The risk of under treatment on ultrastaging, i.e.not detecting PLN metastases due to false negative sentinel LN results and leaving out a full PLN dissection, was $1 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "5 \\%$ .Prerequisites such as early FIGO stage (IA2, IB1, IIA primary tumour size $< 4 0 ~ \\mathrm { m m } \\dot { }$ ), no suspicious pre-, and per-operative LNs, and bilateral negative sentinel LNs after ultra staging resulted in remaining false negative result in 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "08 of patients.The presence or absence of anaphylactic reactions due to a dye tracer was explicitly reported in ten studiesNA, with anaphylactic reaction in $0 .6 \\%$ .At least half of these reactions were serious leading to resuscitations and/or ICU admittance.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "One original study313 not included in the subgroup analyses mentioned above was identified and reported that patients with optimal bilateral SN detection were significantly more likely to have any metastasis detected ( $3 3 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "3 \\%$ versus $1 9 .2 \\% , \\mathrm { ~ p ~ < ~ } 0 .0 0 1 )$ as well as micrometastasis detected in their SN $3 9 .6 \\%$ versus $1 1 .4 \\%$ ).In this study published by Cibula et al.313, SN ultrastaging resulted in a low overall false-negative rate of $2 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "8 \\%$ and an even lower falsenegative rate of $1 .3 \\%$ for patients with optimal bilateral mapping.Sensitivity of SN ultrastaging was $91 \\%$ ( $9 5 \\% \\mathrm { C I } = 8 6 { - } 9 5 \\$ ) for the whole group and $9 7 \\%$ $( 9 5 \\% \\mathrm { C I } = 9 1 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "9 9 \\mathrm { \\ : ) }$ ) in the subgroup with bilateral SN detection.As part of another original study359 not included in the subgroup analyses mentioned above, intraoperative SN assessment established the SN status correctly in as few as $56 \\%$ of cases (or in $6 3 \\%$ of cases if isolated tumour cells had been excluded).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Ninetyfive per cent of metastases detected intraoperatively were macrometastases.Final ultrastaging of intraoperatively negative SN confirmed macrometastases, micrometastases and isolated tumour cells in additional $3 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "5 \\%$ , $8 \\%$ , and $3 .5 \\%$ of patients, respectively.The intraoperative examination of the SN (as compared with final SN ultrastaging) reached the sensitivity of $56 \\%$ and specificity of $1 0 0 \\%$ .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In a larger study360, there were $6 0 \\%$ of cases with micrometastases or isolated tumour cells in the SN, and none of them were detected intraoperatively.This study360 presented consistent results with those published by Slama et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "359 concerning inadequate intraoperative detection of micrometastases.One original study356 not included in the meta-analyses230,274-277 mentioned above was identified and presents consistent findings with those previously reported concerning the achievability and diagnostic performance of SLN biopsy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A small original study361 not included in the meta-analyses230,274-277 mentioned above was also LoE 3 identified and describes consistent findings with those previously reported.A systematic review362 evaluating the evidence regarding the technique and the effectiveness of indocyanine green (ICG) during sentinel LN biopsy was identified.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Sentinel LN was evaluated for cervical cancer in four articles308,325,326,363; in two studies364,365, endometrial cancer and cevical cancer were studied.These two studies364,365 did not report results separately from the endometrial cancer patients included in the study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Thus, data on the efficacy of ICG in cervical sentinel LN detection specifically cannot be drawn from these studies364,365.Data in terms of sensitivity and specificity were available in three studies308,325,326.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Sensitivity varied from $8 3 \\%$ to $1 0 0 \\%$ .All the three studies reported a specificity of $1 0 0 \\%$ .No complications related to ICG administration were described.Four reports366-369 not included in the systematic review362 mentioned above and assessing the feasibility and mapping using ICG for sentinel LN mapping were identified.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "However, one366 of them did not report results separately from the endometrial cancer patients included in the study.Thus, here again data on the efficacy of ICG in cervical sentinel LN detection specifically cannot be drawn from this study366.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Imboden et al.367 evaluated patients undergoing sentinel LN mapping for cervical cancer using ICG versus $^ { 9 9 \\mathrm { m T C } }$ with blue dye.The authors reported significantly better bilateral detection rates with ICG (95.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "5 versus $6 1 \\%$ , $\\mathrm { ~ p ~ < ~ } 0 .0 5 \\$ ) as well as a non-significant trend towards better bilateral detection rates in tumours larger than $2 \\ \\mathrm { c m }$ .Consistent findings were descrived by Buda et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "369 with a bilateral mapping achieved in $9 8 .5 \\%$ for ICG and $7 6 .3 \\%$ for $^ { 9 9 \\mathrm { m T C } }$ with blue dye $\\mathrm { ( p < 0 .0 0 0 1 } ^ { \\cdot }$ ).In this study369, the detection rate of sentinel LN mapping was $9 6 \\%$ and $1 0 0 \\%$ for $9 9 \\mathrm { m T C }$ with blue dye and ICG.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Data from the study published by Beavis et al.368 confirmed a high side-specific $( 9 3 .3 \\% )$ and bilateral mapping rate $( 8 7 \\% )$ with the use of ICG, and further demonstrated no difference in detection between small $: < 2 \\mathrm { c m } ]$ and large $[ \\geq 2 { \\mathrm { ~ c m } } ]$ cervical tumours ( $8 8 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "2 \\%$ versus $8 4 .6 \\% ,$ $\\mathrm { { p } } = 1 .0 \\dot { }$ ).A multicenter trial370 assessed if PET combined with diagnostic CT improves diagnostic CT accuracy to detect LN metastases in advanced cervical cancer (FIGO stages IB2, $\\mathrm { I I > 4 ~ c m } ,$ , and IIB-IVA) and concluded that addition of PET to diagnostic CT resulted in statistically borderline increase in sensitivity to detect LN metastasis in abdomen.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "This trial did not include any endpoints for recurrence or survival in these patients.LoE $^ { 2 + + }$ As part of a systematic review371 including 22 articles20,21,141,145,182,192,196,199,203,218,372-395 and evaluating the preoperative imaging and surgical staging of PALNs in locally advanced cervical cancer (FIGO stages IB2-IVA), the proportions of PALNs that were positive on histological analysis when findings on imaging were abnormal were $2 0 \\%$ to $6 6 \\%$ for CT scan, $0 \\%$ to $2 7 \\%$ for MRI, $8 6 \\%$ to $1 0 0 \\%$ for PET, and $5 0 \\%$ to $7 5 \\%$ for PET-CT.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Positive PALNs with normal findings on imaging was seen in $9 \\%$ to $3 5 \\%$ for CT scan and/or MRI, $4 \\%$ to $1 1 \\%$ for PET, and $6 \\%$ to $1 5 \\%$ for PET-CT.It should be noted that PALN metastases were present in $1 8 \\%$ (range, $8 \\% - 4 2 \\%$ ) of all patients.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Surgical staging led to a treatment modification in $7 \\%$ to $5 8 \\%$ of cases with a mean of $2 0 \\%$ .The most common operation technique used for PALN dissection was laparoscopy $( 7 5 \\% )$ with a conversion rate of less than $2 \\%$ .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Laparatomy and robot-assisted surgery were used as operating technique in $2 3 \\%$ and $2 \\%$ of the patients, respectively.The mean complication rate of PALNs was $4 \\%$ to $1 8 \\%$ in the laparoscopic approach.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Laparotomy resulted in a complication rate of $6 \\%$ to $2 4 \\%$ .Lymphocysts were the most common complication in all approaches.The complication rate in studies with routinely performed PLNs was $4 \\%$ to $2 4 \\%$ .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "This rate was $4 \\%$ to $1 3 \\%$ when only PALN dissection was performed.A systematic review386 was performed to evaluate the effectiveness and safety of pretreatment surgical PALN assessment for women with locallly advanced cervical cancer (FIGO stages IB2- IVA) and concluded that there was insufficient evidence of its potential beneficial effect.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted that this conclusion was based on analysis of a small single trial393 comparing clinical staging (CT or MRI) with surgical staging (laparoscopic or extraperitoneal surgical approach).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Kang et al.396 revealed that PET or PET-CT is a highly specific diagnostic tool in detecting PALN metastasis in cervical cancer whatever the probability of PALN metastasis (pooled data from ten studies28,32,33,44,45,48,93,96-98).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "However, authors mentioned that the diagnostic performance of PET or PET-CT in terms of sensitivity is low when it is performed in the population with a low prevalence of PALN metastasis $( \\leq 1 5 \\% )$ (Table 6).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Authors provided also the pooled comparison of diagnostic performance between PET-CT (five studies196,207,218,397,398) and PET (five studies198,199,206,210,272) and observed no statistical difference of specificity between the two techniques.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "( $9 8 \\%$ ( $9 5 \\% \\mathrm { C I } = 8 7 – 1 0 0$ ) and $9 7 \\%$ $9 5 \\% \\mathrm { C I } = 9 0 { \\cdot } 9 9 \\%$ ), respectively).It should be noted that as part of this subgroup analysis PET was significantly better than PET-CT in terms of sensitivity ( $6 6 \\%$ $( 9 5 \\% \\mathrm { C I } = 3 3 – 8 9 ]$ and $1 3 \\%$ ( $9 5 \\%$ $\\overline { { 5 } } \\% \\mathrm { C I } = 2 { - } 5 6 \\overline { { } }$ ), respectively).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be also noted that (1) although there was no detectable contributor to the between-study heterogeneity in the regression meta-analysis, the small number of included studies might have provided insufficient power to accurately judge the cause of the heterogeneity, (2) none node-by-node or region-by-region comparion analyses are available, and (3) the frequencies of FIGO stages III-IV disease in most of the studies were less than $2 0 \\%$ or more than $5 0 \\%$ that also might have played a role as a bias.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "As part of a $\\mathrm { R C T ^ { 3 9 9 } }$ not included in the systematic reviews371,396 mentioned above and adressing the question of the possible impact of PET on extrapelvic metastasis detection for patients with MRI-detected positive pelvic but negative para-aortic lymphadenectomy (pretreatment PET (study group) or not (control group)), PET detected PALN metastasis in $9 \\%$ of patients.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "All PALNs detected by PET could be identified on the CT images taken for virtual simulation and theor transverse diameters were reordered.Another original study400 not included in the systematic reviews371,396 mentioned above was LoE 3 identified and confirmed the pooled results presented above concerning the diagnostic performance in terms of sensitivity and specificity of PET-CT and MRI.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A meta-analysis401 assessing the diagnostic value of diffusion-weighted MRI for LoE 1- benign/malignant discrimination of PLNs was identified.Taking into account 15 articles402-416, authors concluded in a usefulness of diffusion-weighted imaging for differentiation between metastatic and benign LNs (pooled sensitivity and specificity were $8 6 \\%$ ( $9 5 \\% \\mathrm { C I } = 8 4 { - } 8 9 \\$ ) and $8 4 \\%$ ( $9 5 \\% \\mathrm { C I } = 8 3 – 8 6$ , respectively).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted that the results have to be interpreted with caution due to high heterogeneity between included studies.# 8.1.8 TNM classification and FIGO The TNM classification and the FIGO staging system classify cervical cancer on the basis of the size of the tumour (T), whether the cancer has spread to LNs (N), and whether it has spread to distant sites (M).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "An eighth edition of the TNM classification4 of malignant tumours as been published in december 2016.The FIGO staging system was last reviewed in 2009 by the FIGO Committee on gynecologic oncology5-7 in close collaboration with the American joint commission on cancer and the Union of international cancer control (Table 7).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The FIGO has invited the Gynecologic Cancer Intergroup (GCIG) to make contributions for possible changes of the current FIGO staging system417.The current FIGO staging, proposed changes and classification by the GCIG are listed in table 7 and table 8.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The GCIG recommended to continue to use a clinical staging in cervical cancer as many cervical cancers are not surgically staged or treated.A prospective study418 comparing the revised FIGO and TNM staging systems with regard to accuracy in pretreatment staging and their reliability in the prediction of prognosis has been identified.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Among the 54 included patients, 17 of 19 patients with early-stage disease underwent upfront radical surgery; and in $5 9 \\%$ of these, FIGO did not match with final histopathologic TNM (pTNM).Among these, 7 patients had nodal metastasis, 1 patient had microinvasion of the vaginal cuff, and 2 patients had microscopic invasion of parametria on histopathologic findings.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "When clinical TNM (cTNM) stage was considered, in 4 patients, pTNM was different and in 13 patients, the cTNM matched with pathological TNM compared with 7 patients $( 4 1 \\% )$ in FIGO.The difference between FIGO and pTNM was significant $\\mathrm { ( p = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 2 ) }$ , but that between cTNM and pTNM was not $( \\mathrm { p } = 0 .6 2 )$ .Among the 35 patients with advanced FIGO stage, 13 patients had different cTNM stage $( 3 7 \\% )$ .It was due to PLN involvement in FIGO stage IIB, where cTNM was upstaged to IIIB, and subjectively overestimated FIGO stage IIIB disease, which was actually T2 disease on imaging, thus downstaging to cTNM stage IIB.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Comparison of the overall recurrence rates between patients in whom FIGO and cTNM had matched with those in whom FIGO and cTNM did not match was statistically insignificant ${ \\mathrm { ( p > } }$ 0.05).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Stagewise comparison of recurrence also was mostly insignificant except for recurrence rates in the patients with FIGO IIB disease $[ \\mathrm { p } = 0 .0 2 3 ]$ ).Similarly, comparison of mortality rates between the 2 groups was statistically insignificant $( \\mathrm { p } ~ = ~ 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "8 4 )$ .Comparison of overall recurrence rates and mortality was done between patients in whom FIGO and cTNM had matched with those in whom cTNM was upstaged.Again, although the percentage of recurrence was more in the upstaged group, it failed to achieve statistical significance ${ \\mathrm { ( p ~ ) } } =$ 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "19).Comparison of mortality rates between patients in whom FIGO and cTNM had matched with those in whom cTNM was upstaged did not reveal a significant result $\\left( \\mathrm { { p } = 0 .8 } \\right)$ .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 8.2 Previous initiatives Seven previous initiatives419-426 presenting guidelines for staging were identified.# 8.3 Development group comments The main purpose of cancer staging is to help clinicians to predict the prognosis for a cancer patient, to guide treatment planning, to evaluate and compare treatment results, to facilitate exchange of information between health professionals and to help in identifying clinical trials that may be appropriate for the patient.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "FIGO staging system is the first staging system developed to compare treatment results, however, it is subjective and mainly based on clinical findings by gynaecological examination.LN status is not taken into account.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "On the other hand, TNM classification is capable to include information to compare to historical results.TNM classification has not been extensively used, hence it is difficult to compare to historical results.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted that TNM classification more accurately reflects the status of the primary tumour and LNs than the FIGO staging system.FIGO staging should also be documented, since both provide complementary information.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "As previously mentioned, the LN involvement appears the most powerful prognostic factor influencing survival rate.The presence of a large tumour (especially tumour size $> 4 ~ \\mathrm { c m } \\dot { }$ ), LVSI, deep stromal invasion and parametrial invasion are other independent factors decreasing survival rates.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "On the contrary, an early stage is associated with a improvement of survival rates.The nodal metastasis rate, paracervical invasion and 5-year cancer death rate are increased with a decrease in the thickness of the remaining intact cervical fibromuscular stroma.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The minimum thickness of uninvolved stroma seems to be more useful and objective parameter than the depth of the cancer invasion, however, the threshold value of the thickness of cervical fibromuscular stroma sufficient as a barrier against extrauterine spread is not know.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The prognosis of some rare tumours such as neuroendocrine carcinoma of the cervix is worse compared with cervical squamous cell carcinomas or adenocarcinomas.Non HPV-related adenocarcinomas or adenosquamous carcinomas have worse survival than squamous cell carcinomas.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Grade has little direct influence on survival within any stage.The role of pelvic examination is to assess the presence ot tumour and provide a tumour biopsy.Clinical examination is insufficient to assess tumour size and rule out parametrial invasion and locally advanced disease.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "For local staging purposes, MRI or US performed by trained sonographer provide the highest diagnostic performance, therefore extensive clinical examination using general anesthesia should be omitted.CT is inferior to MRI to document local tumour extension, similarly the PET-CT has scan value in terms of detection of local spread because of limited spatial resolution.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The implementation of MRI or US in preoperative workup make the use of cystoscopy, proctoscopy or intravenous urography redundant.Both imaging modalities can detect the depth of tumour invasion into bladder or rectosigmoid.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Biopsy guided by endoscopy might be only required to exclude secondary cancer.The detection rate of imaging regarding LN and other distant spread depends on their prevalence regarding tumour stage and on size of metastasis.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Imaging (US, MRI, CT or PET-CT) shows high specificity in detection of nodal metastases $( > 9 0 \\% )$ but very low sensitivity in detection of micrometastases ( $\\lg \\lg$ mm) and small volume metastases $\\mathrm { : } 5 \\mathrm { m m }$ ).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In early stage, the micrometastases are often undetected on imaging and surgical LN assessment is the gold standard for the diagnosis of LN node metastasis(es) in this patient population.Stage T1a1 with no LVSI is associated with extremely low incidence of lymphatic metastases and LN staging is abundant in this category.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In LACC, the incidence of extrapelvic disease at the time of initial management is ranging from $1 0 \\%$ to $3 0 \\% ,$ particularly in PALNs and/or chest.The heterogenous data concerning the diagnostic performance of conventional and functional techniques in nodal staging makes any conclusion regarding the routine diagnostic method unreliable.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "PET-CT can detect PALN metastases only in patient populations with high probability for metastases.The novel imaging, whole-body diffusion weighted MRI or hybrid MRI-PET seem to be useful for differentiation between metastatic and benign LNs and may reduce false readings but their diagnostic performances will require to be evaluated in large, multicentre, prospective studies.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 8.4 Guidelines # 8.4.1 General recommendations ![](images/f441c52754da1f6ecccace12cd2908b1857b7fe7c514de225d49942063fb3690.jpg) Treatment planning should be made on a multidisciplinary basis (generally at a tumor board meeting) and based on the comprehensive and precise knowledge of prognostic and predictive factors for oncological outcome, morbidity, and quality of life.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Patients should be carefully counseled on the suggested treatment plan and potential alternatives, including risks and benefits of all options.Treatment should be undertaken by a dedicated team of specialists in the diagnosis and management of gynecologic cancers.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 8.4.2 TNM classification and FIGO Patients with cervical cancer should be staged according to the TNM classification.Clinical staging (FIGO) should also be documented (Figure 2).TNM should be based on a correlation of various modalities (integrating physical examination, imaging and pathology) after discussion in a multidisciplinary forum.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "![](images/24b8714ec486a99bd900c519c7df6bab06a965092e63598cc4e15caab03e3edd.jpg) The method used to determine tumor status (T), lymph node status (N), and systemic status (M), that is, clinical (c), imaging (i), and/or pathological (p) should be recorded.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "LN metastases should be classified according to the TNM classification (see Principles of pathological evaluation).# 8.4.3 Prognostic factors Proper documentation of the following major tumorrelated prognostic factors is recommended: TNM and FIGO stage, including a maximum tumor size and detailed description of extracervical tumor extension and nodal involvement (number, size, location).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Pathological tumor type.Depth of cervical stromal invasion and a minimum thickness of uninvolved cervical stroma Presence or absence of LVSI.Presence or absence of distant metastases.# 8.4.4 Local clinical and radiological diagnostic workup Pelvic examination and biopsy $+ / -$ colposcopy are mandatory components to diagnose cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "![](images/a2efa96303b76326f1c70015dec284c729f889be90c302e4ef2a6ca5ca192176.jpg) Mandatory initial workup for assessment of pelvic tumor extent and to guide treatment options is pelvic MRI.Endovaginal/transrectal US is an option if performed by a properly trained sonographer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cystoscopy or rectoscopy may be considered to provide a biopsy if suspicious lesions in the urinary bladder or rectum are documented on MRI or US.# 8.4.5 Nodal/distant diagnostic workup In early stage (T1a, T1b1, T2a1), surgical/pathological staging of PLNs is the criterion standard to assess the prognosis and guide treatment (except of T1a1 and no LVSI).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# B In LACC (T1b2 and higher (except T2a1)) or in early-stage disease with suspicious LNs on imaging, PET-CT, or chest/abdomen CT is recommended for assessment of nodal and distant disease.# B PET-CT is the preferred option for treatment planning before chemoradiotherapy with curative intent.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# PALN dissection, at least up to inferior mesenteric artery, may be considered in LACC with negative PALNs on imaging for staging purposes.Equivocal extrauterine disease is to be considered for biopsy to confirm or rule out metastatic disease and to avoid inappropriate treatment.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Tru-Cut (core-cut) biopsy is the preferred option than fine-needle aspiration biopsy because it allows histological assessment of the tissue.Figure 5.FIGO staging and TNM classification <html><body><table><tr><td>T category4</td><td> FIGO stage5-7</td><td>Definition</td></tr><tr><td>TX</td><td></td><td>Primary tumour cannot be assessed</td></tr><tr><td>TO</td><td></td><td>No evidence of primary tumour</td></tr><tr><td>T1</td><td></td><td>Cervical carcinoma confined to the uterus (extension to corpus should be disregarded)</td></tr><tr><td>T1a</td><td>IA</td><td>Invasive carcinoma diagnosed only by microscopy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Stromal invasion with a maximum depth of 5.0 mm measured from the base of the epithelium and a horizontal spread of 7.0 mm or less; vascular space involvement, venous or</td></tr><tr><td>T1a1</td><td>IA1</td><td>lymphatic, does not affect classification.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Measured stromal invasion of 3.0 mm or less in depth and 7.0 mm or less in</td></tr><tr><td>T1a2</td><td>IA2</td><td>horizontal spread Measured stromal invasion of more than 3.0 mm and not more than 5.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0</td></tr><tr><td>T1b</td><td>IB</td><td>mm, with a horizontal spread of 7.0 mm or less Clinically visible lesion confined to the cervix or microscopic lesion greater than T1a2/IA2.Includes all macroscopically visible lesions, even those with</td></tr><tr><td>T1b1</td><td>IB1</td><td>superficial invasion.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Clinically visible lesion 4.0 cm or less in greatest dimension</td></tr><tr><td>T1b2</td><td>IB2</td><td>Clinically visible lesion more than 4.0 cm in greatest dimension</td></tr><tr><td>T2</td><td>11</td><td>Cervical carcinoma invading beyond the uterus but not to the pelvic wall or</td></tr><tr><td>T2a</td><td>IIA</td><td>to lower third of the vagina Tumour without parametrial invasion</td></tr><tr><td>T2a1</td><td>IIA1</td><td>Clinically visible lesion 4.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 cm or less in greatest dimension</td></tr><tr><td>T2a2</td><td>IIA2</td><td>Clinically visible lesion more than 4.0 cm in greatest dimension</td></tr><tr><td>T2b</td><td>IIB</td><td>Tumour with parametrial invasion</td></tr><tr><td>T3</td><td>III</td><td>Tumour extending to the pelvic sidewall* and/or involving the lower third of the vagina and/or causing hydronephrosis or nonfunctioning kidney</td></tr><tr><td>T3a</td><td>IIIA</td><td>Tumour involving the lower third of the vagina but not extending to the pelvic wall</td></tr><tr><td>T3b</td><td>IIIB</td><td>Tumour extending to the pelvic wall and/or causing hydronephrosis or nonfunctioning kidney</td></tr><tr><td>T4</td><td>IVA</td><td>Tumour invading the mucosa of the bladder or rectum and/or extending beyond the true pelvis (bullous edema is not sufficient to classify a tumour</td></tr><tr><td></td><td>IVB</td><td>as T4) Tumour invading distant organs</td></tr></table></body></html> Table 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Pooled data published by Thomeer et $a l .^ { 1 1 9 }$ on the performance of clinical examination and MRI for detection of parametrial invasion and advanced disease (FIGO stage $\\geq$ IIB) <html><body><table><tr><td>Diagnostic test</td><td>Sensitivity</td><td>Specificity</td></tr><tr><td>Parametrial invasion</td><td></td><td></td></tr><tr><td>Clinical examination</td><td>40% (95% CI= 25-58)</td><td>93% (95% CI=83-89)</td></tr><tr><td>MRI</td><td>84% (95% CI= 76-90)</td><td>92% (95% CI= 90-95)</td></tr><tr><td>Advanced disease</td><td></td><td></td></tr><tr><td>Clinical examination</td><td>53% (95% CI= 41-66)</td><td>97% (95% CI = 91-99)</td></tr><tr><td>MRI</td><td>79% (95% CI= 64-89)</td><td>93% (95% CI= 88-96)</td></tr></table></body></html> CI confidence interval, MRI magnetic resonance imaging Table 2.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Pooled data published by Choi et al.180 on the performance of CT, MRI, and PET or PET-CT for detection of metastatic LNs <html><body><table><tr><td>Diagnostic test</td><td>Sensitivity</td><td>Specificity</td></tr><tr><td>Patient-based comparison</td><td></td><td></td></tr><tr><td>CT</td><td>50% (95% CI= 43-57)</td><td>92% (95% CI= 90-94)</td></tr><tr><td>MRI</td><td>56% (95% CI = 51-62)</td><td>91% (95% CI= 90-93)</td></tr><tr><td>PET or PET-CT</td><td>82% (95% CI= 75-87)</td><td>95% (95% CI = 93-97)</td></tr><tr><td>Region/node-based comparison</td><td></td><td></td></tr><tr><td>CT</td><td>52% (95% CI = 42-62)</td><td>92% (95% CI = 90-94)</td></tr><tr><td>MRI</td><td>38% (95% CI= 32-43)</td><td>97% (95% CI= 97-98)</td></tr><tr><td>PET or PET-CT</td><td>54% (95% CI = 46-61)</td><td>97% (95% CI = 96-98)</td></tr></table></body></html> CI confidence interval, CT computed tomography, MRI magnetic resonance imaging, PET or PET-CT positron emission tomography or positron emission tomographycomputed tomography Table 3.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Pooled data published by Selman et $a l .^ { 2 3 0 }$ on the performance of sentinel node biopsy, PET, MRI and CT for prediction of LN status <html><body><table><tr><td>Diagnostic test</td><td>Sensitivity</td><td>Specificity</td></tr><tr><td>SN biopsy</td><td>91.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "4% (95% CI = 87.1-94.6)</td><td>100% (95% CI = 99.6-100)</td></tr><tr><td>PET or PET-CT</td><td>74.7% (95% CI = 63.3-84.0)</td><td>97.6% (95% CI = 95.4-98.9)</td></tr><tr><td>MRI</td><td>55.5% (95% CI = 49.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "2-61.7)</td><td>93.2% (95% CI = 91.4-94.0)</td></tr><tr><td>CT</td><td>57.5% (95% CI = 53.5-61.4)</td><td>92.3% (95% CI = 91.1-3.5)</td></tr><tr><td colspan=\"3\">CI confidence interval, CT computed tomography, MRI magnetic resonance imaging, PET or PET-CT positron emission tomography or positron emission tomography-computed tomography,SN sentinel node</td></tr></table></body></html> Table 4.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Pooled data regarding the potential impact of mapping method and type of surgery on diagnostic performance of SN biopsy for prediction of LN status <html><body><table><tr><td>Authorreference</td><td>Year</td><td>Detection rate</td><td>Sensitivity</td></tr><tr><td colspan=\"4\">Mapping method</td></tr><tr><td colspan=\"4\">Blue dye</td></tr><tr><td>Kadkhodayan et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "274</td><td>2015</td><td>80.9% (95% CI = 75.7-85.2)</td><td>86.3% (95% CI = 79.9-91.2)</td></tr><tr><td>Wang et al.276</td><td>2015</td><td>87% (95% CI= 84-90)</td><td>87% (95% CI= 79-93)</td></tr><tr><td>Tax et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "277,a</td><td>2015</td><td>85% (95% CI = 81-87)</td><td>NA</td></tr><tr><td>Tax et al.277,b</td><td>2015</td><td>56% (95% CI = 50-61)</td><td>NA</td></tr><tr><td>van de Lande et al.275</td><td>2007</td><td>84% (95% CI = 79-89)</td><td>81% (95% CI = 67-95)</td></tr><tr><td colspan=\"4\">Radiotracer</td></tr><tr><td>Kadkhodayan et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "274</td><td>2015</td><td>90.9% (95% CI = 87.7-93.3)</td><td>92% (95% CI = 84.3-96.7)</td></tr><tr><td>van de Lande et al.275</td><td>2007</td><td>88% (95% CI = 83-92)</td><td>92% (95% CI= 79-98)</td></tr><tr><td>Wang et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "276</td><td>2015</td><td>90% (95% CI = 87-93)</td><td>87% (95% CI = 78-93)</td></tr><tr><td>Tax et al.277,a</td><td>2015</td><td>89% (95% CI = 85-92)</td><td>NA</td></tr><tr><td>Tax et al.277,b</td><td>2015</td><td>54% (95% CI = 48-60)</td><td>NA</td></tr><tr><td>van de Lande et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "275</td><td>2007</td><td>88% (95% CI = 83-92)</td><td>92% (95% CI= 79-98)</td></tr><tr><td colspan=\"4\">Combined</td></tr><tr><td>Kadkhodayan et al.274</td><td>2015</td><td>92.3% (95% CI = 90.2-93.9)</td><td>91.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "3% (95% CI = 87.5-94.2)</td></tr><tr><td>Wang et al.276</td><td>2015</td><td>97% (95% CI = 96-98)</td><td>88% (95% CI = 84-91)</td></tr><tr><td>Tax et al.277,a</td><td>2015</td><td>94% (95% CI= 93-95)</td><td>NA</td></tr><tr><td>Tax et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "277,b</td><td>2015</td><td>72% (95% CI = 69-74)</td><td>NA</td></tr><tr><td>van de Lande et al.275</td><td>2007</td><td>97% (95%CI = 95-98)</td><td>92% (95% CI = 84-98)</td></tr><tr><td>Fluorescent imaging</td><td>2015</td><td></td><td></td></tr><tr><td colspan=\"4\">Kadkhodayan et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "274</td></tr><tr><td>Type of surgery Open</td><td></td><td></td><td></td></tr><tr><td>Kadkhodayan et al.274</td><td>2015</td><td>88.5% (95% CI = 84.6-91.4)</td><td>91.7% (95% CI = 87.7-94.7)</td></tr><tr><td>Wang et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "276</td><td>2015</td><td>87% (95% CI = 83-90)</td><td>86% (95% CI = 80-90)</td></tr><tr><td>van de Lande et al.275</td><td>2007</td><td>93% (95% CI= 90-96)</td><td>90% (95% CI = 82-95)</td></tr><tr><td colspan=\"4\">Laparoscopic</td></tr><tr><td>Kadkhodayan et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "274</td><td>2015</td><td>93.9% (95 % CI = 88.2-96.9)</td><td>93.2% (95% CI = 87-97)</td></tr><tr><td>Wang et al.276</td><td>2015</td><td>93% (95% CI = 90-96]</td><td>90% (95% CI = 86-94)</td></tr><tr><td>van de Lande et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "275</td><td>2007</td><td>92% (95% CI = 87-96)</td><td>81% (95% CI = 65-92)</td></tr><tr><td colspan=\"4\">Robotic-assisted</td></tr><tr><td>Kadkhodayan et al.274</td><td>2015</td><td>90.8% (95% CI = 85.3-94.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "3)</td><td>NA</td></tr><tr><td>Wang et al.276</td><td>2015</td><td>92% (95% CI = 88-95]</td><td>84% (95% CI= 72-92)</td></tr></table></body></html> at least one sentinel lymph node, b bilateral detection, CI confidence interval, NA not available, Table 5.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Pooled data published by Kadkhodayan et $a l .^ { 2 7 4 }$ regarding other potential factors associated with diagnostic performance of SN biopsy for prediction of LN status <html><body><table><tr><td>Factor</td><td>Detection rate</td><td>Sensitivity</td></tr><tr><td>History of conisation</td><td></td><td></td></tr><tr><td>Yes</td><td>90.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "9% (95% CI =84.3-94.9)</td><td>NA</td></tr><tr><td>No</td><td>91.7% (95% CI = 85.6-95.4)</td><td>NA</td></tr><tr><td>History of pre-surgical therapy</td><td>73.8% (95% CI = 65.8-80.4)</td><td>94.7% (95% CI = 74-99.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "9)</td></tr><tr><td>FIGO stage</td><td></td><td></td></tr><tr><td>≤Ib2</td><td>93.6% (95% CI = 88.8-96.5)</td><td>91.4% (95% CI = 87.3-94.4)</td></tr><tr><td>>Ib2</td><td>65.9% (95% CI = 59-72.3)</td><td>87% (95% CI = 66.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "4-97.2)</td></tr><tr><td>Tumour size</td><td></td><td></td></tr><tr><td>≤2 cm</td><td>93.4% (95% CI = 90.8-95.2)</td><td>94.7% (95% CI = 89.3-97.8)</td></tr><tr><td>>2 cm</td><td>73.9% (95% CI = 66.4-80.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "2)</td><td>81.7% (95% CI = 74.6-87.5)</td></tr><tr><td>Timing of radiotracer injection</td><td></td><td></td></tr><tr><td>The day before the surgery</td><td>90% (95% CI = 87.6-91.8)</td><td>90.2% (95% CI = 85.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "5-93.7)</td></tr><tr><td>The same day</td><td>93.4% (95% CI = 90.1-95.6)</td><td>92.5% (95% CI = 86.9-96.2)</td></tr><tr><td>IHC</td><td></td><td></td></tr><tr><td>Yes</td><td>NA</td><td>91.5% (95% CI = 88.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "3-94)</td></tr><tr><td>No</td><td>NA</td><td>88.6% (95% CI = 85.2-91.5)</td></tr><tr><td>Fertility sparing surgery</td><td>95.8% (95% CI = 91-98.1)</td><td>95.5% (77.2-99.9)</td></tr></table></body></html> CI confidence interval, IHC immunohistochemistry, NA not available Table 6.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Pooled data published by Kang et al.396 on the performance of PET or PET-CT for detection of PALN metastasis <html><body><table><tr><td>Prevalence of PALN metastasis</td><td>Sensitivity</td><td>Specificity</td></tr><tr><td>≤15%</td><td>5% (95% CI = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "5.5)</td><td>99% (95% CI = 90-100)</td></tr><tr><td>>15%</td><td>73% (95% CI = 53-87)</td><td>93% (95% CI = 86-97)</td></tr><tr><td>No restriction</td><td>34% (95% CI = 10-72)</td><td>97% (95% CI = 93-99)</td></tr><tr><td colspan=\"3\">CI confidence interval, PALN para-aortic lymph node</td></tr></table></body></html> Table 7.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "FIGO staging and TNM classification <html><body><table><tr><td>T category4</td><td>FIGO stage5-7</td><td>Definition</td></tr><tr><td>TX</td><td></td><td>Primary tumour cannot be assessed</td></tr><tr><td>TO</td><td></td><td> No evidence of primary tumour</td></tr><tr><td>T1</td><td></td><td>Cervical carcinoma confined to the uterus (extension to corpus should be disregarded)</td></tr><tr><td>T1a</td><td>IA</td><td>Invasive carcinoma diagnosed only by microscopy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Stromal invasion with a maximum depth of 5.0 mm measured from the base of the epithelium and a horizontal spread of 7.0 mm orless vascular space involvement, venous or lymphatic, does not affect classification.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "</td></tr><tr><td>T1a1</td><td>IA1</td><td>Measured stromal invasion of 3.0 mm or less in depth and 7.0 mm or less in horizontal spread</td></tr><tr><td>T1a2</td><td>IA2</td><td>Measured stromalinvasion of more than 3.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 mm and not more than 5.0 mm, witha horizontal spread of 7.0 mm or less</td></tr><tr><td>T1b</td><td>IB</td><td>Clinically visible lesion confined to the cervix or microscopic lesion greater than Tla/IA2.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Includes all macroscopically visible lesions, even those with superficial invasion.</td></tr><tr><td>T1b1</td><td>IB1</td><td>Clinically visible lesion 4.0 cm or less in greatest dimension</td></tr><tr><td>T1b2</td><td>IB2</td><td>Clinically visible lesion more than 4.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 cm in greatest dimension</td></tr><tr><td>T2</td><td></td><td>Cervical carcinoma invading beyond the uterus but not to the pelvic wall or to lower third of the vagina</td></tr><tr><td>T2a</td><td>IIA</td><td> Tumour without parametrial invasion</td></tr><tr><td>T2a1</td><td>IIA1</td><td>Clinically visible lesion 4.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 cm or less in greatest dimension</td></tr><tr><td>T2a2</td><td>IIA2</td><td>Clinically visible lesion more than 4.0 cm in greatest dimension</td></tr><tr><td>T2b</td><td>IIB</td><td>Tumour with parametrial invasion</td></tr><tr><td>T3</td><td>II </td><td>Tumour extending to the pelvic sidewall* and/or involving the lower third of the vagina and/or causing hydronephrosis or nonfunctioning kidney</td></tr><tr><td>T3a</td><td>IIIA</td><td>Tumour involving the lower third of the vagina but not extending to the pelvic wall</td></tr><tr><td>T3b</td><td>IIIB</td><td>Tumour extending to te pelvic wall and/or causing hydronephrosis or nonfunctioning kidney</td></tr><tr><td>T4</td><td>IVA</td><td>Tumour invading the mucosa of the bladder or rectum and/or extending beyond the true pelvis (bullous edema is not sufficient to classify a tumour as T4)</td></tr><tr><td></td><td>IVB</td><td>Tumour invading distant organs</td></tr></table></body></html> \\* the pelvic sidewall is defined as the muscle, fascia, neurovascular structures, and skeletal portions of the bony pelvis.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Table 8.The proposed changes and classification(s) by the GCIG417 <html><body><table><tr><td>FIGO stage</td><td>Definition</td><td>Proposed staging</td><td>Proposed classification(s)</td></tr><tr><td>IB1</td><td>Clinically visible lesion ≤ 4.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 cm in greatest dimension</td><td>FIGO stage IB1-A</td><td>Tumour size ≤2 cm</td></tr><tr><td></td><td></td><td>FIGO stage IB1-B</td><td>Tumour size > 2 cm</td></tr><tr><td>IB2</td><td>Clinically visible lesion > 4.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 cm in greatest dimension</td><td>FIGO stage IB2-A</td><td>Tumour size >4 cm ≤6 cm</td></tr><tr><td></td><td></td><td>FIGO stage IB2-B</td><td>Tumour size >6 cm</td></tr><tr><td>IIB</td><td>With obvious parametrial invasion</td><td>FIGO stage IIB-1</td><td>Tumour size ≤ 6 cm</td></tr><tr><td></td><td></td><td>FIGO stage IIB-2</td><td>Tumour size > 6 cm</td></tr><tr><td>IIIB</td><td>Extension to the pelvic wall and/or hydronephrosis or non-functioning kidney</td><td>FIGO stage IIIB-1</td><td>Unilateral pelvic sidewall involvement/unilateral</td></tr><tr><td></td><td></td><td>FIGO stage IIB-2</td><td>hydronephrosis Bilateral pelvic sidewall involvement/bilateral</td></tr></table></body></html> # 9 Management of stage T1a <html><body><table><tr><td>9.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1 Summary of available scientific evidence</td></tr><tr><td>9.1.1 Lymph-vascular space involvement</td></tr><tr><td>As part of a pooled analysis427 including 40 reports53,428-466, LVSI was identified in only 8 IA1 LoE 1- microinvasive cases (2.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1%) where radical hysterectomy ± LN dissection, trachelectomy, or parametrectomy was performed.Although none of them had nodal involvement, it should be noted that two patients recurred.</td></tr><tr><td>Bisseling et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "454 reviewed the literature for LVSI status in relation to LN involvement (16 LoE2+ reports35,43446,44-452,454,46465 including ther own original data).LVSI was present in 25 of 458 (5.5%) IA1-IA2 cases, none having positive LNs; seven cases with an invasion depth ≤ 3.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 mm, five cases with an invasion depth ≤ 5 mm, ten cases with an invasion depth between 3.1 and 5.0 mm, and three cases with an invasion depth based on tumour volume.It should be noted that absence of LVSI does not exclude the LN involvement, as is illustrated by the 4 cases</td></tr><tr><td>(0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "9%) without LVSI but with LN involvement; two cases with an invasion depth ≤ 3 mm and two cases with an invasion depth based on tumour volume.A meta-analysis published by Reynolds et al467 (13 reports435,44,445,446,449,450,454,460,461,464-46,48 LoE 1- including their own original data) was identified and presents concordant data with those previously mentioned (it should be noted that 10 reports435,44,446,449,450,454,460461,464,465 were also included in the review published by Bisseling et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "454).Of the 279 IA cases with reported LVSI, only 12 had positive LVSI (pooled proportion 5.1% (95% CI = 2.9-7.9)).There were 368 cases with known depth of invasion less than 5 mm but uncertain width of the tumour.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "For</td></tr><tr><td>these 368 cases with unknown lateral extent of tumour, the presence of LVSI was nearly double (pooled proportion 9.3% (95% CI = 5.1-14.4)).Twenty-five original studies82,469-492 not included in the studies427,454,467 mentioned above were | LoE 2- identified and present concordant data with those previously reported.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "</td></tr><tr><td>9.1.2 Lymph node involvement Of the 383-385 IA1 cases identified by Hou et al.427 and who underwent LN dissection, 4-5 LoE 1- (1.2%) were identified with one or more positive regional nodes.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Only three patients have</td></tr><tr><td>been reported to have more than one LN involvement, and only one with bilateral pelvic nodal involvement.Compared with IA1 microinvasive adenocarcinoma, significantly more IA2 patients had one or more positive regional nodes (1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "2% versus 3.7%, p = 0.002).</td></tr><tr><td>Fifteen original studies82,467,469-481 not included in the study published by Hou et al.427 and LoE 2- presenting data on LN involvement in IA1 and/or IA2 patients were identified (Table 9, Table 10).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Of the 418 IA1 patients and the 343 IA2 patients who underwent LN dissection, only 8 and 13 were identified with one or more positive LNs (1.9% versus 3.8%, respectively).</td></tr><tr><td>PLN dissection was performed in more than half of the literature cases of microinvasive LoE2+ adenocarcinoma identified by Bisseling et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "454, with a similar low incidence of positives nodes (1.5%) in both FIGO stage IA1 and IA2 disease.Of the 210 IA patients who underwent lymphadenectomy identified by Reynolds et al.467, two LoE 1-</td></tr><tr><td>patients demonstrated LN metastasis (pooled proportion 2.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "2% (95% CI = 0.8-4.3).Authors reported that the rate of LN metastasis was not appreciably different from cases with known depth of invasion less than 5 mm but uncertain width of the tumour (pooled proportion 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "9%</td></tr></table></body></html> $[ 9 5 \\% \\mathrm { C I } = 0 .6 \\ – 4 .0 ] \\}$ .# 9.1.3 Parametrial invasion Hou et al.427 identified 373 cases (IA1 and IA2, $< 5 ~ \\mathrm { m m }$ invasion) for whom the status of the LoE 1- parametrium was specifically addressed.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Of these, parametrial invasion has been specifically identified in only one $( 0 .2 7 \\% )$ , a patient with FIGO stage IB1 adenocarcinoma diagnosed at one year after conisation for adenocarcinoma in situ.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "As part of their literature review (fifteen reports433,438,439,446,448,450-452,454,461-465,468 including their LoE $^ { 2 + + }$ own original data), Bisseling et al.454 identified a removal of parametria in 713 cases during radical surgery with comment on involvement in only half of these cases, none of which were involved.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Reynolds et al.467 reported that there was no appreciably difference between the pooled rates LoE 1- of parametrial involvement between patients with known depth of invasion less than $5 \\mathrm { m m }$ but uncertain width of the tumour and patients who met strict FIGO definition of IA adenocarcinoma of the cervix ( $1 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "6 \\%$ $9 5 \\%$ $_ { 0 } ^ { \\prime } \\mathrm { C I } \\ = \\ 0 .3 \\ – 4 .0 \\$ ) and $1 .8 \\%$ ( $9 5 \\%$ $\\mathrm { ~ \\ ; ~ } \\mathrm { C I } ~ = ~ 0 .5 \\substack { - 4 .1 }$ ), respectively).Seventeen original studies82,469,470,474,475,479,481,482,489,493-500 not included in the studies427,454,467 LoE 2- mentioned above were also identified and all of them showed that less than $1 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "5 \\%$ of patients had parametrial involvement.# 9.1.4 Cone margin status In a pooled analysis501 enrolling 962 patients with FIGO stage IA1 disease501-504, $8 8 .5 \\%$ of LoE 1- patients with a clear resection margin after conisation had no dysplasia in the repeat conisation/hysterectomy specimen; $4 5 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "2 \\%$ and $1 0 .9 \\%$ of patients with cervical intraepithelial neoplasia (CIN) I-III at the conisation resection margin had residual CIN I-III and invasive cancer in the repeat conisation/hysterectomy specimen, respectively.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Twenty-six identified studies82,432,433,460,465,468,469,471,474,487,488,505-519 have reported a relationship LoE 2- between cone margin status and the presence of residual disease in hysterectomy specimens after a LEEP or CKC.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The frequencies of residual disease have been reported to be clearly higher in patients with positive margins than those with negative margins.It should be noted that the available data does not allow to known if the relatively high percentage of residual disease in case of free margins in some studies is due to inadequate sampling rather than to “skip lesions”.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 9.1.5 Recurrence Despite of significantly more IA2 patients having positive regional LNs ( $1 .2 \\%$ (IA1) versus LoE 1- $3 .7 \\%$ (IA2), $\\mathrm { ~ p ~ } = \\ 0 .0 0 2 \\$ , the recurrence rates between IA1 and IA2 patients were not significantly different in the pooled analysis published by Hou et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "427 ( $1 .6 \\%$ versus $2 .8 \\%$ ${ \\bf p } = { \\bf \\Phi }$ 0.15, respectively).With respect to fertility-sparing surgery, of 102-138 managed by cone/LEEP/LLETZ, a recurrence has been observed in only four IA1 patients $( 3 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "4 \\% ) ^ { 4 3 6 , 4 3 8 , 4 4 7 , 4 4 9 }$ .Three patients had either residual glandular and squamous dysplasia, close margin, or persistently abnormal cervical cytology436,447,449.No data was available with respect to margins for the fourth438.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "One case of recurrence has been observed in the 45 IA2 cases managed by local excision $( 2 .2 \\% ) ^ { 4 6 5 }$ .As part of their literature review, Bisseling et al.454 noted a recurrence in $2 .4 \\%$ of IA1-IA2 L patients.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Recurrence was reported in 6 of the 383 patients $( 1 .6 \\% )$ with a known invasion depth $\\leq 3 ~ \\mathrm { m m } ,$ , and in 5 of the 336 patients $( 1 .5 \\% )$ with a known invasion depth between 3.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1 and 5.0 mm.No recurrences occurred in 59 FIGO stage IA1 cases with a known initial treatment of conisation alone.Of the 217 cases of FIGO stage IA1, 47 cases of FIGO stage IA2, and 103 cases defined as FIGO LoE 1- stage IA but were not further stratified, 7 cases of recurrences (2, 1, and 4, respectively) were identified by Reynolds et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "467.For the cases with known depth of invasion less than $5 \\mathrm { m m }$ but uncertain width of the tumour, the pooled recurrence rate was more than double as compared with those for the cases that met criteria for FIGO stage IA ( $4 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "9 \\%$ $( 9 5 \\% \\mathrm { C I } = 2 .6 { - } 8 .0 )$ and $2 .2 \\%$ $9 5 \\% \\mathrm { C I } = 0 .8 – 4 .2 ]$ , respectively).Thirty original studies82,469-471,473-487,489-492,509,520-525 not included in the studies427,454,467 LoE 2- mentioned above were identified and present concordant data with those previously reported concerning the low recurrence rates of the FIGO stage IA1 (1,594 cases82,469-471,473-476,482- 487,489,520,521,525, mean: $2 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "3 \\%$ ) and IA2 patients (714 cases82,469,473,475,477-482,487,490-492,509,520,522-524, mean: $3 .1 \\%$ ) (Table 9, Table 10).# 9.1.6 Survival Of the 814-862 IA1 cases53,428-466 and the 487-493 IA2 cases53,429,432,434,435,437-439,441-444,446,449- LoE 1- 451,453,454,456,459,462-465,526,527 identified by Hou et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "427, the overall survival (OS) rates were $9 9 \\%$ and $9 8 \\% ,$ respectively.Although comparable to IA1 microinvasive adenocarcinoma, the IA2 patients received more aggressive therapy.The number of IA1 and IA2 patients managed by conisation, SH, RH, or other procedures (that included trachelectomy, abdominal or vaginal, and parametrectomy, usually after hysterectomy or conisation as the initial procedure) was 102-138 $( 1 2 - 1 7 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "2 \\% )$ , 159-205 (mean: $2 2 .6 \\%$ ), 343-389 $( 4 3 .9 \\% )$ , and 14-19 $( 2 .0 \\% )$ for IA1 patients (Table 9), and 49 $( 1 0 \\% )$ , 142-162 $( 3 0 .9 \\% )$ , 265-276 $( 5 5 .1 \\% )$ , and 15 $( 3 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1 \\% )$ for IA2 patients, respectively (Table 10).More IA2 patients underwent radical surgeries (IA2, $5 5 .1 \\%$ versus IA1, $4 3 .9 \\%$ , $\\mathrm { ~ p ~ } = 0 .0 3 \\mathrm { ~ .~ }$ ).It should be noted that radiotherapy was employed more often for IA2 than IA1 patients $5 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "7 \\%$ versus $1 .9 \\substack { - 2 .0 \\% }$ , $\\mathrm { p } < 0 .0 0 1 \\$ ).Twenty-three original studies469,471-478,480-482,484-487,489-492,520-522 not included in the study published by Hou et al.427 were identified and present concordant data with those previously reported concerning the high survival rates of the FIGO stage IA1 (1,131 cases471,472,474- 476,482,484-486,489,520,521, mean OS rate: $9 9 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "6 \\%$ ) and IA2 patients (617 cases469,472,473,475,477,478,480- 482,487,490-492,520,522, mean OS rate: $9 7 .6 \\%$ ) (Table 9, Table 10).Four identified studies46,82,438,528 have suggested that oncologic outcomes are equivalent for conisation and hysterectomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "As part of a large-scale study46 (3,987 patients from the Surveillance, Epidemiology, and End Results (SEER) database), survival was similar for conisation and hysterectomy for FIGO stages IA1 and IA2 adenocarcinoma (FIGO stage IA1: HR $= 1 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "8 4$ $9 5 \\% \\mathrm { ~ C I } = 0 .6 6 – 5 .1 7 .$ ) and FIGO stage IA2: $\\mathrm { { H R = 0 .8 7 } }$ ( $9 5 \\% \\mathrm { C I } = 0 .3 3 { - 2 .2 6 }$ )).Survival was also examined in a Cox proportional hazards model in a second large-scale study (1,409 women aged 40 years or younger with FIGO stage IA1 cervical cancer)528.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Accounting for other prognostic variables, there was no difference in survival between conisation and hysterectomy $\\mathrm { \\tilde { H } R } = 0 .6 5$ , $9 5 \\%$ $\\mathrm { C I } = 0 .2 3$ -1.47).At 5 years, $9 8 \\%$ $9 5 \\% \\mathrm { C I } = 9 6 { - } 9 9 \\%$ ) of patients who underwent hysterectomy and $9 9 \\%$ ( $9 5 \\% \\mathrm { C I } = 9 7 – 9 9$ ) of those who underwent conisation were alive.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In the study published by Qian et al.82, there was no statistically significant difference in progression-free survival (PFS) between the FIGO stage IAI patients treated by conisation and hysterectomy ( $9 2 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "3 \\%$ versus $9 8 .8 \\%$ , $\\mathrm { p } = 0 .0 7 \\$ ).# 9.2 Previous initiatives Nine previous initiatives419,420,422-426,529-531 presenting guidelines for management of stage T1a were identified.# 9.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "3 Development group comments Diagnosis and management of T1a cervical cancer should be based on an accurate pathology examination by an expert pathologist.Histologic specimen should be intact on a conisation or excisional form.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Fragmentation of the specimen and thermal artefacts should be avoided as they can adversely influence the pathology interpretation of the actual extent of the tumour and the marginal status.Loop or laser conisations is preferable to CKC for young women desiring fertility preservation.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Orientation of the specimen is also necessary for the pathologist to determine the exact location of the tumour.A specialist pathology review should accurate measure the depth of invasion, the horizontal dimension, the marginal status and a reliable assessment of LVSI.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cone marging status represents a strong predictive factor of residual disease since it has been shown that patients with positive resection margins have a higher frequency of residual disease in hysterectomy specimens after a LEEP or CKC.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The frequencies of residual disease have been reported to be clearly higher in patients with positive margins than those with negative margins.The reported relatively high percentage of residual disease in cases of free margins could be attributed to either inadequate sampling or to “skip lesions”.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted that the available scientific data are inconclusive.Management of patients with stage T1a1 cervical cancer should be individualised.Management should depend on the age of the patient and the desire for fertility preservation.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The presence or absence of LVSI should also be considered for treatment decision.LVSI has been reported as strong predictor of LN involvement for T1a1 cervical cancer patients.LN involvement is reported of low incidence for patients with T1a disease.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Based on the available scientific evidence for T1a1 LVSI- patients, LN staging is not indicated.For $\\mathrm { L V S I + }$ patients, LN staging can be considered.Management of T1a1 cervical cancer by conisation can be considered as definitive treatment as hysterectomy does not improve survival.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Recurrence rates for patients with T1a1 cervical cancer were reported low with different treatment modalities either radical or conservative.In patients with stage T1a2 disease without LVSI, conisation alone or simple hysterectomy is an adequate treatment with an excellent local control.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "There is no need for parametrial resection since involvement of the parametria is not reported.LN staging for LVSI- patients can be considered since the negative LVSI status does not necessarily exclude LN involvement.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In patients with stage T1a2 $\\mathsf { L V S I + } ,$ it should be noted that even if parametrial involvement is rare, it can not be excluded.LN staging should be performed in $\\mathsf { L V S I + }$ patients due to the possibility of LN involvement.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "SLN biopsy without additional PLND is an acceptable method of LN staging in experienced centers.There are no evidence to support routine completion surgery by hysterectomy after conservative management of stage T1a2.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 9.4 Guidelines # 9.4.1 Diagnosis of stage T1a disease Diagnosis of T1a cancer should be based on a conization (or excision) specimen examined by an expert pathologist.Management must be based on an expert pathology review, with accurate measurement of the maximum horizontal 2 dimensions, depth of invasion, margin status, coexisting pathology, and reliable assessment of LVSI.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Loop or laser conization is preferable to CKC in women desiring fertility preservation.Maximum care should be taken to provide an intact (unfragmented) specimen with minimal thermal artifact.The cone specimen should be oriented for the pathologist.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# Surgical margins of the cone specimen should be clear of both invasive and preinvasive disease (except for preinvasive disease in ectocervix).# 9.4.2 Management of stage T1a1 disease Management of patients with stage T1a1 disease should be individualized depending on the age, the desire for fertility preservation, and the presence or absence of LVSI.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In case of positive margins (except for preinvasive disease in ectocervix), a repeat conization should be performed to rule out more extensive invasive disease.# B LN staging is not indicated in T1a1 LVSI-negative patients but can be considered in T1a1 LVSIpositive patients.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "SLN biopsy (without additional PLN dissection) is an acceptable method of LN staging.Conization can be considered a definitive treatment as hysterectomy does not improve the outcome.# C Radical surgical approaches such as radical hysterectomy or parametrectomy represent overtreatment for patients with T1a1 disease.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 9.4.3 Management of stage T1a2 disease In patients with stage T1a2 disease, conization alone or simple hysterectomy is an adequate treatment.Parametrial resection is not indicated.# B LN staging can be considered in LVSI-negative patients but should be performed in LVSI-positive patients.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "SLN biopsy alone (without additional PLN dissection) appears to be an acceptable method of LN staging.Routine completion of hysterectomy is not recommended after conservative management of stage T1a disease.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Table 9.Original studies presenting data for treatment modalities, involved parametria, lymph-vascular space and LNs, recurrences and survivals in FIGO stage IA1 patients <html><body><table><tr><td>Lee et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "472</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Webb et al.439,b</td><td></td><td></td><td></td><td></td><td>Elliott et al.449.a</td><td></td><td></td><td></td><td></td><td>Ostor et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "432,a</td><td>Kaku et al.435.a</td><td></td><td></td><td>Ostor et al.482</td><td>Kaspar et al.459.a</td><td>Jones et al.440.a</td><td>Matthews et al.53a</td><td></td><td>Rollason et al.47.a</td><td>Matsukuma et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "445,c</td><td></td><td></td><td>Teshima et al.434a</td><td></td><td></td><td>Sachs et al.41.a</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>2006</td><td>2006</td><td>2006</td><td>2005</td><td>2004</td><td>2003</td><td>2002 2002</td><td>2002</td><td></td><td>2001 2001</td><td>2001</td><td>2000</td><td>2000</td><td>2000</td><td>2000</td><td>2000</td><td>1999</td><td>1999</td><td>1999</td><td>1999</td><td>1997</td><td>1997</td><td>1996 1995</td><td>1995</td><td>1994</td><td>1993</td><td>1993</td><td>1993</td><td>1992</td><td>1989 1989</td><td>1989</td><td>1987</td><td>1989</td><td>1985</td><td>1986</td><td>1985</td><td>1975</td><td>Year</td></tr><tr><td>174</td><td></td><td></td><td>9</td><td>0</td><td>0</td><td>6 200</td><td>亿9</td><td></td><td>131</td><td></td><td></td><td></td><td>9</td><td>L</td><td>6</td><td></td><td></td><td>7</td><td></td><td>43</td><td></td><td></td><td>L</td><td>109</td><td></td><td></td><td></td><td>6</td><td>W</td><td>乙</td><td></td><td></td><td>8</td><td>11</td><td>9 9</td><td>0</td><td>N</td></tr><tr><td></td><td>L</td><td></td><td>9</td><td></td><td></td><td></td><td>0</td><td></td><td></td><td>20</td><td></td><td></td><td></td><td>0</td><td></td><td>0</td><td>L</td><td>I</td><td>L</td><td>12</td><td></td><td>0</td><td></td><td>0</td><td>16 0</td><td></td><td>0</td><td>0</td><td>0</td><td>0</td><td>L</td><td></td><td>L</td><td>0</td><td>0 0</td><td>0</td><td>Cone</td></tr><tr><td>106</td><td>+</td><td></td><td>0</td><td>0</td><td>0 乙</td><td>nr 8</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>1</td><td></td><td>0</td><td></td><td></td><td></td><td></td><td></td><td></td><td>0</td><td></td><td>18</td><td></td><td>0 0</td><td>L</td><td>0</td><td>L</td><td></td><td>0</td><td>L</td><td>0</td><td>0 0</td><td>0 0</td><td>Type of surgical therapy</td></tr><tr><td></td><td></td><td>0</td><td>0 0</td><td>0</td><td>0</td><td>y nr 11</td><td>0</td><td></td><td>nr</td><td></td><td>0</td><td></td><td>0 0</td><td>0 0 0 0</td><td></td><td>0</td><td>0</td><td>0</td><td>0</td><td>10 0</td><td>0 0</td><td>0</td><td>0</td><td>0</td><td></td><td>2</td><td>0</td><td>L</td><td></td><td>L</td><td></td><td>0 0</td><td>0</td><td></td><td>0 9</td><td>0 0</td><td>SH RH other</td></tr><tr><td>9</td><td></td><td>0</td><td></td><td>0</td><td>0</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>0</td><td>0</td><td>0</td><td></td><td>0</td><td>0</td><td>0 L</td><td>0</td><td>0</td><td>0</td><td></td><td>0</td><td>0</td><td>0 0</td><td></td><td></td></tr><tr><td>L</td><td>0</td><td></td><td>50</td><td></td><td></td><td>nr</td><td></td><td></td><td></td><td></td><td></td><td></td><td>nr</td><td>0 L</td><td>0</td><td>L</td><td>0</td><td>0</td><td>0</td><td></td><td></td><td></td><td></td><td>0</td><td>0</td><td>0</td><td>0 0</td><td>0</td><td>0</td><td>0</td><td>0</td><td></td><td></td><td>0</td><td>0 nr</td><td>nr</td><td>LVSI</td></tr><tr><td>116</td><td>忆</td><td>切 0</td><td></td><td></td><td>0</td><td></td><td></td><td></td><td></td><td>50</td><td></td><td></td><td>0</td><td>0</td><td></td><td></td><td></td><td></td><td></td><td></td><td>0</td><td>0</td><td>0</td><td>L</td><td></td><td>9</td><td>24</td><td></td><td></td><td>L</td><td></td><td>0</td><td>0</td><td></td><td>9</td><td>0</td><td>LND LN+</td></tr><tr><td>L</td><td></td><td>0</td><td>nr 9</td><td>0 0</td><td></td><td>nr 0 W</td><td>0</td><td></td><td></td><td></td><td>0</td><td></td><td>0</td><td></td><td></td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td></td><td>L</td><td>0</td><td>0</td><td>0</td><td>nr</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0 0</td><td>0 0</td><td></td></tr><tr><td>ⅢL</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>0</td><td></td><td>0</td><td>0</td><td></td><td></td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td></td><td>I</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>3-6</td><td>0</td><td></td><td>0 0</td><td>0 0</td><td>Number of cases per parameter Recurr.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "</td></tr><tr><td>乙</td><td>L 0.25-18</td><td>0</td><td></td><td>0</td><td>0</td><td>0 W</td><td>L</td><td></td><td>0</td><td></td><td></td><td></td><td>0 0</td><td>0</td><td></td><td>0</td><td>0</td><td>0</td></table></body></html> a study included in the review published by Hou et $a l .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "^ { 4 2 7 }$ , b study included in the review published by Bisseling et al.454, c study included in the review published by Reade et al.532, Cone (cone, loop electrosurgical excision procedure, large loop excision of the transformation zone), DOD dead of disease, $\\mathrm { L N } +$ positive lymph nodes, LND lymph node dissection, LVSI lymph-vascular space involvement, nr not reported, Recurr.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "recurrence, RH radical hysterectomy $\\pm$ LND, SH simple hysterectomy (abdominal or vaginal ± LND) Original studies presenting data for treatment modalities, involved parametria, lymph-vascular space and LNs, recurrences and survivals in FIGO stage IA1 patients (continued) <html><body><table><tr><td rowspan=\"2\">Authorreference</td><td rowspan=\"2\">Year</td><td rowspan=\"2\">N</td><td colspan=\"4\">Type of surgical therapy</td><td colspan=\"5\">Number of cases per parameter</td><td rowspan=\"2\">Follow-up</td></tr><tr><td>Cone</td><td>SH</td><td>RH</td><td>other</td><td>LVSI</td><td>LND</td><td>LN+</td><td>Recurr.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "</td><td>DOD</td></tr><tr><td>Tseng et al.520</td><td>2006</td><td>41</td><td>41</td><td>0</td><td>0</td><td>0</td><td>nr</td><td>nr</td><td>nr</td><td>0</td><td>0</td><td>3.1</td></tr><tr><td>Bisseling et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "454,a,b,c</td><td>2007</td><td>29</td><td>16</td><td>9</td><td>4</td><td>0</td><td>2</td><td>10</td><td>0</td><td>0</td><td>0</td><td>6</td></tr><tr><td>Yahata et al.466,a.c</td><td>2008</td><td>16</td><td>4</td><td>0</td><td>3</td><td>nr</td><td>0</td><td>3</td><td>0</td><td>0</td><td>0</td><td>2-13</td></tr><tr><td>Singh et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "428,a</td><td>2008</td><td>1</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>1</td><td>1</td><td>4</td></tr><tr><td>Lee et al.485</td><td>2009</td><td>85</td><td>85</td><td>0</td><td>0</td><td>0</td><td>0</td><td>nr</td><td>nr</td><td>1</td><td>0</td><td>6.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "75</td></tr><tr><td>Lee et al.484</td><td>2009</td><td>75</td><td>22</td><td>27</td><td>26</td><td>0</td><td>29</td><td>nr</td><td>nr</td><td>0</td><td>0</td><td>3</td></tr><tr><td>Yahata et al.471</td><td>2010</td><td>27</td><td>10</td><td>0</td><td>17</td><td>0</td><td>0</td><td>17</td><td>0</td><td>0</td><td>0</td><td>6.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "25</td></tr><tr><td>Reynolds et al.467,c</td><td>2010</td><td>52</td><td>7</td><td>16</td><td>29</td><td>0</td><td>3</td><td>34</td><td>1</td><td>0</td><td>nr</td><td>6</td></tr><tr><td>Baalbergen et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "473,c</td><td>2011</td><td>33</td><td>15</td><td>14</td><td>4</td><td>0</td><td>2</td><td>4</td><td>0</td><td>1</td><td>nr</td><td>6</td></tr><tr><td>Yoshinaga et al.486</td><td>2011</td><td>84</td><td>19</td><td>4</td><td>61</td><td>0</td><td>5</td><td>0</td><td>0</td><td>6</td><td>0</td><td>nr</td></tr><tr><td>Haller et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "474</td><td>2011</td><td>276</td><td>152</td><td>112</td><td>12</td><td>0</td><td>11</td><td>52</td><td>0</td><td>12</td><td>3</td><td>5</td></tr><tr><td>Al-Kalbani et al.475,c</td><td>2012</td><td>36</td><td>23</td><td>5</td><td>8</td><td>0</td><td>1</td><td>11</td><td>0</td><td>0</td><td>0</td><td>3</td></tr><tr><td>Sopracordevole et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "487</td><td>2012</td><td>6</td><td>6</td><td>0</td><td>0</td><td>0</td><td>0</td><td>nr</td><td>nr</td><td>2</td><td>nr</td><td>nr</td></tr><tr><td>Chen et al.489</td><td>2013</td><td>81</td><td>0</td><td>60</td><td>21</td><td>0</td><td>7</td><td>nr</td><td>nr</td><td>0</td><td>0</td><td>nr</td></tr><tr><td>He et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "476</td><td>2014</td><td>108</td><td>25</td><td>78</td><td>5</td><td>0</td><td>5</td><td>19</td><td>0</td><td>0</td><td>0</td><td>≥1</td></tr><tr><td>Qian et al.82</td><td>2014</td><td>280</td><td>41</td><td>200</td><td>39</td><td>0</td><td>20</td><td>39</td><td>0</td><td>5</td><td>0</td><td>2.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "7</td></tr><tr><td>Sopracordevole et al.488</td><td>2014</td><td>60</td><td>16</td><td>37</td><td>6</td><td>1</td><td>2</td><td>nr</td><td>nr</td><td>nr</td><td>nr</td><td>nr</td></tr><tr><td>Lee et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "470</td><td>2014</td><td>169</td><td>18</td><td>55</td><td>96</td><td>0</td><td>3</td><td>116</td><td>0</td><td>2</td><td>nr</td><td>nr</td></tr><tr><td>Yoneda et al.469</td><td>2015</td><td>10</td><td>10</td><td>0</td><td>0</td><td>0</td><td>10</td><td>10</td><td>0</td><td>0</td><td>0</td><td>4.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "25</td></tr><tr><td>Day et al.521</td><td>2016</td><td>25</td><td>25</td><td>0</td><td>0</td><td>0</td><td>nr</td><td>nr</td><td>nr </td><td>0</td><td>0</td><td>7</td></tr></table></body></html> a study included in the review published by Hou et $a l .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "4 2 7 ,$ , b study included in the review published by Bisseling et al.454, c study included in the review published by Reade et al.532, Cone (cone, loop electrosurgical excision procedure, large loop excision of the transformation zone), DOD dead of disease, $\\mathrm { L N } +$ positive lymph nodes, LND lymph node dissection, LVSI lymph-vascular space involvement, nr not reported, Recurr.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "recurrence, RH radical hysterectomy $\\pm$ LND, SH simple hysterectomy (abdominal or vaginal ± LND) Table 10.Original studies presenting data for treatment modalities, involved parametria, lymph-vascular space and LNs, recurrences and survivals in FIGO stage IA2 patients <html><body><table><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>Poyoe</td><td></td><td></td><td></td><td></td><td>Erzen et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "453.a Kasamatsu et al.45.ab,c</td><td>Smith et al.438.a.b</td><td>Webb et al.439,b</td><td>Lee et al.462,a</td><td></td><td>Covotstaet</td><td>Kuran ae.</td><td></td><td>Ostor et al.432,a</td><td></td><td></td><td>Wolf e al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "429 a</td><td></td><td></td><td>Kaspar et al.459.a</td><td>Jones et al.527.a Sevvin et al.490</td><td></td><td></td><td></td><td>Burghardt et al.442.a</td><td></td><td>Sachs et al.441a</td><td></td><td></td></tr><tr><td>2011</td><td>2011</td><td>2003</td><td>2010</td><td>2009 2007</td><td>2006</td><td>2006</td><td>2006</td><td>2006</td><td>2004 2003</td><td>2003</td><td>2002</td><td>2002</td><td>2002</td><td>2001</td><td>2000</td><td>2000</td><td>1999</td><td>1999</td><td>1999</td><td>1997</td><td>1997</td><td></td><td>1996</td><td></td><td>1994</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>1985</td><td></td><td></td><td>1975</td></tr><tr><td></td><td>9</td><td></td><td></td><td>6 0</td><td>6</td><td>2</td><td></td><td></td><td></td><td>8</td><td>9 8</td><td>4</td><td>286</td><td>170</td><td></td><td></td><td>29 Z</td><td>+</td><td></td><td></td><td></td><td></td><td>1996 6</td><td>W</td><td>1996 L 16</td><td>1994</td><td>1993</td><td>1993</td><td>1992</td><td>1991</td><td>1991</td><td>1990</td><td>1989</td><td>1989</td><td>1983 6 L</td><td>Year N</td></tr><tr><td>+</td><td>L 9</td><td>L</td><td></td><td>W</td><td>6</td><td>0</td><td>0</td><td>L</td><td>0 0</td><td>0</td><td>8</td><td>0</td><td></td><td>6</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td></td><td>8</td><td>0</td><td>0</td><td>0</td><td>8</td><td>L</td><td></td><td>0</td><td>0</td><td>0</td><td>6</td><td>0</td><td>L</td><td>0</td><td>0</td><td>0 0</td></tr><tr><td>0</td><td>9</td><td>0</td><td>6</td><td>+ S</td><td>0 0</td><td></td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td></td><td>116</td><td>9</td><td></td><td></td><td>0</td><td>0</td><td></td><td>14 L</td><td></td><td>0</td><td></td><td>L</td><td></td><td></td><td>0</td><td>0</td><td>0</td><td></td><td>0</td><td>0</td><td>L</td><td>0 0</td><td>Cone 0 SH</td></tr><tr><td>0</td><td>6 0</td><td></td><td>0</td><td>L</td><td>0</td><td>0</td><td>0</td><td></td><td>0</td><td>0</td><td>9 0</td><td>+</td><td>134 L</td><td></td><td>88</td><td>0</td><td></td><td></td><td>+</td><td>0</td><td></td><td></td><td>6</td><td>L</td><td>0</td><td></td><td></td><td></td><td></td><td></td><td>6</td><td></td><td></td><td>0</td><td>+</td><td></td></tr><tr><td>0</td><td>0 0</td><td></td><td></td><td>乙</td><td></td><td>+</td><td>0</td><td>L</td><td>+</td><td>L</td><td>0</td><td></td><td></td><td></td><td>S</td><td>0</td><td></td><td>0</td><td>0</td><td>0</td><td>0</td><td></td><td>0</td><td>0</td><td>0</td><td></td><td>0</td><td>W 0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0 0</td><td>Type of surgical therapy RH other 0</td></tr><tr><td></td><td>0</td><td></td><td>+</td><td>L</td><td></td><td>乙</td><td></td><td></td><td></td><td></td><td>9</td><td>0</td><td></td><td></td><td></td><td>乙</td><td></td><td></td><td>0</td><td>0</td><td></td><td>L</td><td></td><td>0</td><td>0</td><td></td><td>0</td><td>0</td><td></td><td></td><td></td><td></td><td>0</td><td></td><td>0 0</td><td>0 LVSI</td></tr><tr><td></td><td>9</td><td>0</td><td>0</td><td>0</td><td></td><td></td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td></td><td></td><td></td><td></td><td>0</td><td></td><td></td><td>0</td><td>0</td><td></td><td></td><td>6</td><td>乙</td><td>0</td><td></td><td>0</td><td></td><td></td><td></td><td></td><td>mm</td><td></td><td></td><td>0</td><td>L</td></tr><tr><td>nr</td><td>0 0</td><td>0</td><td>0</td><td>0</td><td></td><td></td><td>0</td><td>0</td><td>0</td><td>0</td><td></td><td>0 0</td><td></td><td>L</td><td>L</td><td>0 0</td><td></td><td></td><td>0</td><td></td><td>0</td><td></td><td>L</td><td>0</td><td></td><td>0</td><td>1-10</td><td>0</td><td>0</td><td>nr</td><td></td><td></td><td>0</td><td>0</td><td>0 0</td><td>LND LN+ 0</td></tr><tr><td>0</td><td>0 0</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>0</td><td>0</td><td></td><td></td><td></td><td>0</td><td>0</td><td>0</td><td></td><td>0</td><td>0</td><td></td><td>S</td><td></td><td>0</td><td>0</td><td>0</td><td>Number of cases per parameter 0 Recurr.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "</td></tr><tr><td></td><td>0</td><td></td><td></td><td>0</td><td></td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td></td><td>0</td><td></td><td></td><td>0</td><td></td><td></td><td>0</td><td>0</td><td>0</td><td></td><td></td><td>0</td><td>0</td><td></td><td>0</td><td></td><td>0</td><td></td><td></td><td>zm</td><td>0</td><td>0</td><td>0 0</td><td>0 DOD</td></tr><tr><td></td><td>9 +</td><td>9</td><td>5.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "75</td><td>9</td><td></td><td></td><td>0.42-13</td><td>C</td><td>0.5-10.3</td><td>+</td><td></td><td>3.59 ± 16.2</td><td>0.75-29</td><td>0.08-9.9</td><td></td><td>2.16</td><td></td><td></td><td>1/4-9.7</td><td></td><td>1/4-12</td><td>2-19.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "3</td><td></td><td>10</td><td>0.58-11</td><td>8</td><td></td><td></td><td></td><td></td><td>0.6-18</td><td></td></table></body></html> a study included in the review published by Hou et al.427, b study included in the review published by Bisseling et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "454, c study included in the review published by Reade et al.532, Cone (cone, loop electrosurgical excision procedure, large loop excision of the transformation zone), DOD dead of disease, $\\mathrm { L N } +$ positive lymph nodes, LND lymph node dissection, LVSI lymph-vascular space involvement, nr not reported, Recurr.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "recurrence, RH radical hysterectomy $\\pm$ LND, SH simple hysterectomy (abdominal or vaginal ± LND) Original studies presenting data for treatment modalities, involved parametria, lymph-vascular space and LNs, recurrences and survivals in FIGO stage IA2 patients (continued) <html><body><table><tr><td rowspan=\"2\">Authorreference</td><td rowspan=\"2\">Year</td><td rowspan=\"2\">N</td><td colspan=\"4\">Type of surgical therapy</td><td colspan=\"5\">Number of cases per parameter</td><td rowspan=\"2\">Follow-up</td></tr><tr><td>Cone</td><td>SH</td><td>RH</td><td>other</td><td>LVSI</td><td>LND</td><td>LN+</td><td>Recurr.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "</td><td>DOD</td></tr><tr><td>Al-Kalbani et al.475,c</td><td>2012</td><td>9</td><td>1</td><td>0</td><td>8</td><td>0</td><td>1</td><td>9</td><td>0</td><td>0</td><td>0</td><td>3</td></tr><tr><td>Palaia et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "492</td><td>2012</td><td>5</td><td>0</td><td>5</td><td>0</td><td>0</td><td>0</td><td>5</td><td>nr</td><td>0</td><td>0</td><td>3.17</td></tr><tr><td>Raju et al.524</td><td>2012</td><td>7</td><td>0</td><td>5</td><td>2</td><td>0</td><td>nr</td><td>nr</td><td>nr</td><td>0</td><td>nr</td><td>8</td></tr><tr><td>Smrkolj et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "480</td><td>2012</td><td>89</td><td>66</td><td>15</td><td>8</td><td>0</td><td>12</td><td>46</td><td>0</td><td>1</td><td>1</td><td>18.78</td></tr><tr><td>Sopracordevole et al.487</td><td>2012</td><td>1</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>nr</td><td>nr</td><td>0</td><td>0</td><td>7.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "2</td></tr><tr><td>Mahawerawat et al.481</td><td>2013</td><td>58</td><td>0</td><td>0</td><td>58</td><td>0</td><td>6</td><td>58</td><td>2</td><td>1</td><td>1</td><td>6</td></tr><tr><td>Qian et al.82</td><td>2014</td><td>44</td><td>2</td><td>9</td><td>32</td><td>1</td><td>5</td><td>34</td><td>1</td><td>0</td><td>0</td><td>2.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "9</td></tr><tr><td>Sopracordevole et al.488</td><td>2014</td><td>9</td><td>0</td><td>2</td><td>7</td><td>0</td><td>3</td><td>nr</td><td>nr</td><td>nr</td><td>nr</td><td>nr</td></tr><tr><td>Yoneda et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "469</td><td>2015</td><td>40</td><td>40</td><td>0</td><td>0</td><td>0</td><td>5</td><td>40</td><td>2</td><td>1</td><td>0</td><td>4.25</td></tr></table></body></html> c study included in the review published by Reade et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "532, Cone (cone, loop electrosurgical excision procedure, large loop excision of the transformation zone), DOD dead of disease, $\\mathrm { L N } +$ positive lymph nodes, LND lymph node dissection, LVSI lymphvascular space involvement, nr not reported, Recurr.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "recurrence, RH radical hysterectomy $\\pm$ LND, SH simple hysterectomy (abdominal or vaginal $\\pm$ LND) # 10 Management of stages T1b1/T2a1 # 10.1 Summary of available scientific evidence # 10.1.1 Primary radiotherapy A $\\mathrm { R C T ^ { 8 4 } }$ comparing the effectiveness and safety of primary surgery for early stage cervical cancer (FIGO stages IB-IIA) with primary radiotherapy was identified.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The median total dose of external pelvic irradiation was 47 (range 40-53) Gy during 3-5 weeks, depending on the tumour volume and nodal status.Radical surgery consisted of a radical hysterectomy and PLN dissection.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Adjuvant radiotherapy was delivered after surgery for women with surgical stage pT2b or greater, less than $3 \\ \\mathrm { m m }$ of safe cervical stroma, cut-through, or positive nodes.The paraortic region was irradiated in case of metastases in the surgical specimen in common iliac or paraortic nodes.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Fifty-four percent of patients with cervical diameter $\\leq 4$ cm who underwent radical surgery also received adjuvant external pelvic irradiation (total dose : 50.4 Gy over 5-6 weeks).Among patients with cervical diameter $\\leq 4 \\ \\mathrm { c m } ,$ pelvic or distant relapses were observed in $1 3 \\%$ of patients who underwent radical surgery alone and in $1 8 \\%$ of patients who received radiotherapy after a median follow-up of 87 months.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Five-year actuarial survival stratified by cervical diameter for the surgery ( $\\dot { \\mathbf { \\Sigma } } _ { \\pm }$ radiotherapy) and radiotherapy groups was $8 7 \\%$ and $9 0 \\%$ , respectively.Five-year actuarial disease-free survival (DFS) for the surgery ( $\\cdot \\pm$ radiotherapy) and radiotherapy groups was $8 0 \\%$ and $8 2 \\%$ , respectively.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The between-group differences were not significant.In the surgery alone group, $3 1 \\%$ of patients with cervical diameter $\\leq 4 \\ \\mathrm { c m }$ showed severe (grade 2-3) short-term or long-term morbidity that required medical or surgical treatment compared with $2 9 \\%$ of patients in the surgery $^ +$ adjuvant radiotherapy, and $12 \\%$ of patients in the radiotherapy group.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A systematic review533 was identified but is not described because it contains only the $\\mathrm { R C T ^ { 8 4 } }$ mentionned above.As part of a large-scale study (3,551 patients with tumour size $< 4 \\mathrm { c m }$ from the SEER database), Bansal et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "85 performed a Cox proportional hazards model that was adjusted for other prognostic variables (age, race, SEER registry, marital status, histologic finding, tumour grade, adjuvant radiation, tumour size, and stage) and observed that performance of radical hysterectomy was associated with a $6 2 \\%$ reduction in mortality compared with radiation for women with tumour size $< 4 ~ \\mathrm { c m }$ $\\mathrm { \\Delta } \\mathrm { \\cdot } \\mathrm { H R } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "3 8$ $9 5 \\% \\mathrm { C I } = 0 .3 0 { - 0 .4 8 } ]$ ).It should be noted that no information concerning the radiation therapy protocols evaluated is available.Another study534 was identified and present concordant data with those mentioned above.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In this study, PFS, OS and disease-specific survival (DSS) were all longer for patients treated primarily with radical hysterectomy compared with patients treated primarily with radiotherapy $8 9 \\%$ versus $7 0 \\% ,$ $\\mathrm { p } < 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 0 1$ ; $9 5 \\%$ versus $7 0 \\% ,$ $\\cdot \\mathrm { ~ p ~ } < 0 .0 0 1$ ; $9 6 \\%$ versus $7 8 \\% ,$ p < 0.001; respectively).It should be noted that $2 2 \\%$ of patients received postoperative radiation, (2) some patients treated primarily with radiotherapy also received chemotherapy, and (3) patients treated by primary radiotherapy were older, had larger tumours, and were more likely to have medical comorbidities than patients treated primarily with radical surgery.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Derks et al.535 compared long-term morbidity and quality of life after primary surgery or primary radiotherapy for stage IB/II cervical cancer.Although global health scores were not significantly different, multivariate analysis showed that primary (chemo)radiotherapy had a negative impact on physocal and social functioning, financial problems and symptom experience and leads to more diarrhea, sexual/vaginal symptoms, and sexual worry.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Lymphedema was significantly associated with radical hysterectomy with pelvic lymphadenectomy.# 10.1.2 Primary chemoradiotherapy Kong et al.536 compared treatment outcomes and treatment–related morbidities of radical hysterectomy followed by adjuvant therapy (radiotherapy or chemoradiotherapy) and primary chemoradiotherapy in patients with FIGO stages IB-IIA cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Adjuvant chemoradiotherapy using a 5-FU and cisplatin regimen was given to patients who had one or more high-risk pathological features, including microscopic parametrial invasion, LN metastasis, or involvement of the resection margin.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Postoperative radiotherapy was given as whole pelvix external-beam radiation therapy with or without brachytherapy with a total median pelvic dose of 49.30 Gy over 6 weeks.Brachytherapy boosts, in combination with external-beam radiotherapy, were considered for patients with tumour extension to the vaginal cuff margin.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Primary chemoradiotherapy was administered with a total median pelvic dose 81.50 Gy.Both the local recurrence $5 .6 \\%$ in the primary chemoradiotherapy group versus $1 1 .1 \\%$ in the primary surgery group, $\\mathrm { p } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "4 8 9 _ { .} ^ { \\cdot }$ ) and distant metastasis ( $7 .4 \\%$ in both treatment groups, $\\mathrm { \\Delta p > \\ }$ 0.999) was similar for both treatment groups ( $1 3 .0 \\%$ versus $2 0 .4 \\%$ , respectively, $\\mathrm { ~ p ~ } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "3 0 2$ ).No significant difference with respect to 5-year DFS was also reported ( $8 3 .1 \\%$ versus $7 7 .4 \\% ,$ respectively, $\\mathrm { p } = 0 .2 2 8 \\mathrm { ^ { \\prime } }$ ).The incidence rates of late grade 3 genitourinary adverse reactions were significantly higher in the primary surgery group ( $0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 \\%$ versus $1 4 .8 \\% ,$ $\\mathrm { ~ p ~ } = \\ 0 .0 0 6 ^ { \\cdot }$ .However, no differences were observed for grade 3 hematological complications $( 1 8 .5 \\%$ versus $2 2 .2 \\% ,$ $\\mathrm { ~ p ~ } = \\mathrm { ~ 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "6 3 3 ~ } .$ ), gastrointestinal complications ( $1 .9 \\%$ versus $5 .6 \\% ,$ $\\mathrm { ~ p ~ = ~ } 0 .6 1 8 \\mathrm { ] }$ , and late grade 3 lower limb lymphedema ( $3 .7 \\%$ versus $1 3 .0 \\%$ , $\\mathrm { ~ p ~ = ~ 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1 6 1 } ^ { \\cdot }$ ) between treatment groups.Derks et al.537 compared survival and toxicity after abandoned hysterectomy and primary treatment with chemoradiotherapy versus completed hysterectomy followed by adjuvant (chemo)radiotherapy for patients with FIGO stage IB/IIA LN-positive cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Recurrences appeared to be more pelvic in the chemoradiotherapy group compared with the radical hysterectomy with pelvic lymphadenectomy group ( $1 6 \\%$ versus $2 \\%$ , ${ \\mathrm { p } } = 0 .0 1 4 { \\mathrm { \\ : } }$ ).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Time to recurrence was longer after radical hysterectomy with pelvic lymphadenectomy group (18 months versus 11 months, ${ \\mathrm { p } } = 0 .0 1 1 { \\mathrm { \\Omega } }$ ).As part of a multivariate analysis, treatment modality, adjusted for LN characteristics, was not associated with DFS.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In the abandoned hysterectomy and primary treatment with chemoradiotherapy group, more grades 3 and 4 toxicity was reported $5 9 \\%$ versus $3 0 \\% ,$ , $\\mathrm { p } = 0 .0 0 6 \\$ ).It should be noted that (1) the groups are significantly unbalanced in terms of administration of chemotherapy and/or brachytherapy, number of removed nodes and the number of positive nodes and (2) the used techniques for applying radiotherapy might be somewhat outdated.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 10.1.3 Neoadjuvant chemotherapy Kim et al.538 performed a meta-analysis to determine the efficacy of NACT in patients with FIGO stages IB1 to IIA cervical cancer when compared with primary surgical treatment.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "There were no differences in OS, PFS, overall and loco-regional recurrences between the two treatments.However, NACT was associated with a lower rate of distant metastasis ( $\\mathrm { \\Delta O R } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "6 1 \\$ ( $9 5 \\%$ CI = 0.42-0.89).The authors also mentionned that NACT decreased the need for adjuvant radiotherapy when compared with primary surgical treatment ( $\\mathrm { \\Delta O R } \\ : = \\ : 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "5 7$ $( 9 5 \\% \\mathrm { C I } = 0 .3 3 -$ 0.98).It should be noted that these results have to be interpreted cautiously due to (1) the heterogeneity of NACT regimens used in the nine included studies77,539-546, and (2) the heterogeneity in terms of indications for adjuvant radiotherapy after surgery among studies.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Among the nine studies77,539-546 included in this meta-analysis538, two $\\mathrm { R C T S } ^ { 7 7 , 5 4 0 }$ present data taking into account patients with FIGO stage IB1 cervical cancer specifically.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In the first one, Sardi et $a l .^ { 5 4 0 }$ assessed if NACT consisting of ciplatinum $\\mathrm { ( 5 0 ~ m g / m ^ { 2 } }$ ), vincristine $( 1 ~ \\mathrm { m g } / \\mathrm { m } ^ { 2 } )$ ), and bleomycin $( 2 5 ~ \\mathrm { m g } / \\mathrm { m } ^ { 2 }$ , day 1-3) for 3 courses at 10-day intervals can improve survival before surgery $^ +$ adjuvant whole-pelvis external irradiation (50 Gy).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A complete or partial response was observed in $9 0 .2 \\%$ of patients with FIGO stage IB1.No cases of grade 3 or 4 hematological or gastrointestinal toxicity were observed.After 8 years of follow-up, the OS was not statistically significant between the control group and the NACT group.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Pelvic recurrences were almost the same in both groups ( $1 0 .6 \\%$ versus $9 .8 \\% ,$ respectively).It should be noted that DFS and OS rates between the control group and the chemotherapy responders in the NACT group were not significantly different.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should also be noted that (1) the operative rate was not increased by the use of NACT (all patients in both groups were treated surgically), and (2) LVSI and LN metastases were significantly more frequent in the control group $\\mathrm { [ p < 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 0 7 }$ and $\\mathrm { p } < 0 .0 4$ , respectively).In the second one77, the NACT schedule was cisplatin $( 7 5 ~ \\mathrm { m g } / \\mathrm { m } ^ { 2 }$ on day 1) and 5-FU (24 $\\mathrm { m g / k g / d }$ from day 1 to day 5).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "This treatment was repeated at 3-week intervals for two courses.After NACT, all patients underwent radical hysterectomy and PLN dissection.Within the NACT group, surgery was followed by pelvic radiation in $6 1 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "5 \\%$ of patients.In the primary surgery group, $5 3 .7 \\%$ of patients received adjuvant whole pelvic radiation.The overall clinical response rate to NACT was $8 4 .6 \\%$ and included complete response in $7 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "7 \\%$ of patients, partial response in $7 6 .9 \\%$ of patients, and stable disease in the remaining patients $( 1 5 .4 \\% )$ .None of the patients showed progressive disease.For patients whose cervical diameter was $4 ~ \\mathrm { c m }$ or smaller, the 5-year actuarial survival for NACT and primary surgery groups was $8 5 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "7 \\%$ and $7 5 .0 \\% ,$ respectively, with no significant difference between the groups $( \\mathrm { p } = 0 .1 7 )$ ).Results from the sixteen other identified studies547-562 are limited notably by the small number LoE 3 of patients evaluated and the heterogeneity of NACT regimens used.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 10.1.4 Neoadjuvant brachytherapy Preliminay results of a $\\mathrm { R C T } ^ { 5 6 3 }$ comparing preoperative brachytherapy followed by surgery LoE 1- with surgery alone were identified.The study included patients with operable cervical carcinoma from FIGO stage IA2 to proximal IIB.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The preoperative high-dose rate brachytherapy delivered two fractions of 8 Gy followed by Piver class III radical hysterectomy and pelvic lymphadenectomy.Concerning the IB1 subgroup ( $5 3 .3 \\%$ of the patients), pathologic complete response was $3 8 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "5 \\%$ after brachytherapy versus $1 2 .8 \\%$ without brachytherapy (where the tumour was probably removed after preliminary excision or conisation) and $2 5 .6 \\%$ of the patients needed adjuvant therapy in the brachytherapy with surgery arm versus $3 4 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "6 \\%$ in the surgery alone arm.A study564 comparing the oncologic outcomes in patients with early stage cervical carcinoma without PLN involvement, when treated by combined treatment associating an intracavitary brachytherapy followed by a simple hysterectomy or by a radical hysterectomy alone was identified.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "An extra fascial hysterectomy was performed 6-8 weeks after uterovaginal brachytherapy.In the other group, proximal radical hysterectomies have been performed.Tumour was classified as FIGO stage IB1 in $8 6 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "4 8 \\%$ and $8 3 .1 1 \\%$ of patients, respectively.Tumour was classified as FIGO stages IA1-IIA in other patients.A complete response was observed in almost half of patients $( 4 7 .3 \\% )$ .One pelvic node recurrence and one local recurrence were reported $( 2 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "7 \\% )$ .Concerning brachytherapy toxicity, only 2 grade 4 complications $( 2 .7 \\% )$ were found.The actuarial OS rate was $9 2 .3 \\%$ in patients treated with preoperative brachytherapy followed by simple hysterectomy and $1 0 0 \\%$ in patients treated by a radical hysterectomy ${ \\mathrm { ( p = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 4 6 ) } }$ ) and the DFS rate was $9 2 .3 \\%$ and $9 8 .7 \\% ,$ respectively ${ \\mathrm { ( p = 0 .1 8 ) } }$ .Escande et al.565 examined the clinical results of a preoperative image-guided pulse-dose-rate brachytherapy in early stage cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Tumour was classified as FIGO stage IB1 and IIA1 in $9 6 .1 \\%$ and $3 .9 \\%$ of patients, respectively.Brachytherapy procedure consisting of intracavitary uterovaginal implantation was followed, 6-8 weeks later, by a radical hysterectomy/bilateral salpingo-oophorectomy plus pelvic $\\pm$ para-aortic LN dissection.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Patients with positive LNs had postoperative chemoradiation.On hysterectomy specimen $7 0 .1 \\%$ presented a complete histological response.After median follow-up of 3.9 years, only one local recurrence $( 1 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "3 \\% )$ was observed.Most radiation-related acute toxicities were mild to moderate.In a log rank analysis, time interval between brachytherapy and surgery longer than nine weeks was significantly associated with a worse OS and DFS (4.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "7 years versus 9.5 years, $\\mathrm { ~ p ~ } = \\ 0 .0 2$ and 4.7 years versus 9.0 years, $\\mathrm { ~ p ~ = ~ } 0 .0 5 ,$ respectively).It should be noted that (1) $1 5 .6 \\%$ of patients received a postoperative external beam radiation therapy to the pelvis $\\pm$ concurrent chemotherapy $\\pm$ para-aortic irradiation, and (2) no multivariate analysis was performed given the low number of events.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In another non-comparative study566, the patients with FIGO stage IB1 cervical cancer received preoperative uterovaginal brachytherapy followed by a radical hysterectomy with bilateral salpingo-oophorectomy $\\pm$ lymphadenectomy about 6 weeks later.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "No patients received adjuvant treatment except for those with nodal involvement who were treated with chemoradiotherapy.A relapse of disease was observed in $5 .5 \\%$ of patients.It should be noted that no patient whose tumour size was $< 2 \\ \\mathrm { c m }$ experienced relapse.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "At 5 years, OS and DFS rates were $9 5 .0 \\%$ and $9 4 .3 \\%$ , respectively.Results from the other identified studies567,568 are limited notably by the small number of LoE 3 patients evaluated.# 10.1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "5 Types of hysterectomy Many radical procedures that accord with different degrees of radicality have been described and done.To date, three classifications of radical hysterectomies wich are used for the simplification of the surgical protocols were idenfitied: Piver-Rutledge-Smith classification569 which is the oldest, the classification proposed by the European Organization for Research and Treatment of Cancer-Gynecological Cancer Group (EORTC-GCG)570,571, and Querleu-Morrow classification8 (Table 11, Table 12, Table 13).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The last one is the most evolved and recent classification.Its techniques can be adapted for conservative operations and for different types of surgical approaches: abdominal, vaginal, laparoscopic or robotic.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Two $\\operatorname { R C T } s ^ { 3 8 , 9 1 }$ assessing the role of the primary surgical radicality in patients with FIGO stages LoE $^ { 1 + }$ IB1-IIA cervical carcinoma with respect to survival, pattern of relapse, and morbidity were identified.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In the first one91, patients were randomized to receive either class II or class III radical hysterectomy.All operations were performed by the same surgical team according to the Piver-Rutledge-Smith classification569 (Table 11).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Mean blood loss, number of patients requiring blood transfusions and mean postoperative length of stay were similar between patients undergoing class II hysterectomy compared to patients undergoing class III hysterectomy ( $\\cdot 5 3 0 \\mathrm { m l }$ versus $5 8 0 ~ \\mathrm { m l }$ $( \\mathrm { p } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "2 )$ , $3 5 \\%$ versus $4 3 \\%$ ${ \\mathrm { ( p = 0 .3 \\mathrm { \\cdot } } }$ ), and 9.1 versus 9.5 (p $\\mathbf { \\Psi } = \\mathbf { \\Psi } 0 .4 \\mathbf { \\dot { \\Psi } } _ { \\mathcal { I } }$ ), respectively).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The authors reported significantly shorter mean operative time in the group of patients undergoing class II hysterectomy ( $\\dot { 1 } 3 5 \\ \\mathrm { m i n }$ versus $1 8 0 \\ \\mathrm { m i n } ,$ , $\\mathrm { ~ p ~ = ~ 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 4 } ]$ .Positive surgical resection margins did not appear to be significantly related to the surgical procedure adopted.Intraoperative and early complications were similar between the two groups of patients ( $5 \\%$ versus $4 \\%$ ).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The incidence of late morbidity differed between the two groups, affecting $2 8 \\%$ of patients in the class II group compared with $3 8 \\%$ in the class III group.However, the difference did not reach statistical significance.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted that vesical complications were significantly more frequent in the class III group, as demonstrated by a longer selfcatheterization time $( \\mathrm { p } = 0 .0 2 )$ ) and a higher rate of bladder dysfunctions (atonic bladder, stress incontinence, low-complicance bladder, $\\mathrm { p } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 2 \\$ ).Concerning the pattern of recurrences and survival, the extension of the surgical dissection did not appear to significantly influence pelvic recurrences, as $3 4 \\%$ of recurrences were observed inside the pelvis after a class II operation compared with $4 2 \\%$ after a class III operation $[ { \\mathfrak { p } } =$ 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "7).Similarly, sites of pelvic recurrences are equally shared between the two groups ( $7 0 \\%$ versus $6 9 \\%$ ).The recurrence rate in patients with small $[ \\leq 4 \\mathrm { c m } ]$ cervical diameter was $2 1 \\%$ in the class II group and $2 4 \\%$ in the class III group $\\left( \\mathrm { p } \\ : = \\ : 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "8 \\right)$ .Patients with a large cervical diameter $\\left( > 4 \\mathrm { c m } \\right)$ had a higher recurrence rate $3 4 \\%$ in the class II group and $3 3 \\%$ in the class III arm $[ \\mathrm { p } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "8 ]$ .In both cases, however, no significant difference between the two classes could be found and survival within each group of cervical diameter did not depend on the type of surgery performed.Five-year OS was 81 and $7 7 \\% ,$ and DFS was 75 and $7 3 \\% ,$ respectively, in the group of patients submitted to class II and class III radical hysterectomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "These differences were not statistically significant.Multivariate was carried out and confirmed the lack of benefit of more radical surgery (class III hysterectomy) across all subgroups of patients.In the second identified RCT38, patients were randomized to receive either class I or class III radical hysterectomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Both surgical treatments included bilateral pelvic lymphadenectomy and were performed according to the Piver-Rutledge-Smith classification569 by the same surgical team by means of laparotomy through a midline incision (Table 11).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Recurrences were observed in $2 4 \\%$ and $1 3 \\%$ of patients in the class I group and class III group, respectively ${ \\mathrm { ( p ~ ) } } =$ 0.11).Pelvic recurrences were equal in both groups.Seventy-three percent and $7 5 \\%$ of the relapsed patients in class I and class III group respectively, were alive with no evidence of disease after salvage therapy after a minimum follow-up time of 280 months.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Survival curves of tumours measuring $\\leq 3 \\ \\mathrm { c m }$ did not show statistical differences, as the 15- year survival is $7 6 \\%$ and $8 0 \\%$ for the class I group and class III group, respectively $\\left( \\mathrm { { p } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "8 8 } \\right)$ .A significant difference can be observed between the two treatment groups in patients with cervical size between 3.1 and $4 \\ \\mathrm { c m }$ (15-year OS: $7 4 \\%$ versus $9 7 \\%$ respectively, ${ \\mathrm { ~ p ~ } } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 3 { \\mathrm { ~ } }$ .A multivariate analysis confirmed that OS did not depend on the degree of surgical radicality.The type of surgery influenced deeply the rate of morbidity (double as much in the class III group compared to class I).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 10.1.6 Surgical approaches for hysterectomy Perioperative outcomes: using the technique of meta-analysis, Cao et al.572 (twenty-two studies14,320,573-592) and Wang et al.593 (eleven studies573,575,576,578,580-584,590,592,594) examined the effectiveness and safety of laparoscopic radical hysterectomy compared to abdominal radical hysterectomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Laparoscopic radical hysterectomy was systematically associated with a significant reduction of intraoperative blood loss, a shorter length of hospital stay, and a longer operative time.It should be noted that ten573,575,576,578,580-584,590,592 of the eleven studies573,575,576,578,580-584,590,592,594 included in the pooled analyses performed by Wang et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "593 have also been taken into account by Cao et al.572.No significant differences in terms of need for blood transfusion (eight studies573,575,576,578,580,584,592,594) or number of total LNs (nine studies573,575,578,580-583,592,594), PLNs (sixteen studies14,320,573,575,577-583,585,586,589,590,592), or PALNs (two studies580,583) were described between the two surgical techniques (Table 14).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Two original studies595,596 not included in the meta-analyses572,593 mentioned above and comparing laparoscopic and open hysterectomy were identified.Consistent findings were observed by the first one595 with respect to LNs.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The second one596 describes consistent findings with the pooled data previously presented concerning the blood loss, and the hospital stay.However, the authors found significantly shorter operative time ( $2 7 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "8 \\ \\mathrm { m i n }$ versus 310.2 min), higher mean number of dissected LNs (20.5 versus 24.3, $\\mathrm { ~ p ~ = ~ 0 .0 0 8 } ^ { \\cdot }$ ) and lower blood transfusion rate ( $1 3 .2 \\%$ versus $5 2 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "3 \\%$ ) for patients in laparoscopy group compared with those in the laparotomy group.As part of another meta-analysis, Park et al.597 included ten studies3,4,7,15-17,20-23 reporting comparative data about perioperative outcomes between robotic-assisted laparoscopic and conventional laparoscopic hysterectomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The pooled data showed significantly shorter length of stay (six studies594,598-602), and decreased transfusion rate (five studies594,598,599,603,604) with robotic-assisted laparoscopic hysterectomy than conventional laparoscopic hysterectomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "No significant differences in terms of operative time (seven studies594,598-602,605), estimated blood loss (six studies594,598-601,605) or number of total or PLNs (four studies594,598,602,605 and three studies599-601, respectively) were described between the two surgical techniques.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Fully consistent data are provided with respect to duration of operation (four studies598,606-608), need for blood transfusion (two studies598,606), and the number of LNs resected (three studies598,606,607) by a second identified meta-analysis609.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "However, no significant difference in length of stay (three studies598,606,607) was found by the authors609 and the use of the robot was associated with reduced blood loss during surgery (three studies598,606,607) (Table 15).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Shazly et al.610 reported also no differences in terms of operative time (thirteen studies594,598-600,603-608,611- 613), blood loss (twelve studies594,598-600,603-607,611-613), number of LNs (eleven studies594,598-600,603- 606,611-613), and length of stay (eleven studies594,598-600,604-607,611-613) between robotic-assisted laparoscopic and conventional laparoscopic hysterectomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Another identified meta-analysis614, including sixteen studies594,598-601,603,605,607,612,613,615-620, reported consistent results with respect to operative time (thirteen studies594,598- 601,603,605,612,613,615,616,619,620) and number of LNs harvested (fourteen studies594,598- 601,603,605,607,612,613,615,616,618,619) with the three meta-analyses597,609,610 mentioned above (Table 15).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "As Park et al.597, Zhou et al.614 found that the use of robot was associated with a shorter length of stay (twelve studies594,598-601,607,612,613,615,616,618,619).But like Reza et al.609, this metaanalysis614 found that the use of the robot was associated with reduced blood loss during surgery (thirteen studies594,598-601,603,605,607,612,613,615,618).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted that Zhou et al.614 and Shazly et al.610 reported no significant difference in need for blood transfusion between the two surgical techniques (Table 15).A systematic review published by Kruijdenberg et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "621 (twenty-seven studies576,578,587,598,606,607,622-638 including their own original data) was also identified and presents fully concordant data with the pooled findings mentioned above in terms of operative time ( $2 3 1 \\mathrm { m i n }$ versus $2 0 2 \\mathrm { m i n } .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "$ , $\\mathrm { p } = 0 .2 2 \\$ ), and number of LNs retrieved (24 versus 21 $, \\mathrm { { p } } = 0 .2 8 { \\dot { } }$ .The authors reported also a lower blood transfusion rate (17 versus 72, ${ \\mathrm { p } } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 2 { \\mathrm { \\cdot } }$ ) and shorter length of hospital stay (3.3 days versus 6.2 days, $\\mathrm { \\Delta p = 0 .0 4 \\AA }$ with robotic-assisted laparoscopic hysterectomy.Fifteen studies594,598,600,602,603,627,633,635,639-645 reporting data about perioperative outcomes of LoE robotic-assisted laparoscopic and open hysterectomy were examined by Park et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "597.The pooled data showed significantly shorter length of stay (seven studies594,598,600,602,635,642,644), lower estimated blood loss (eight studies594,598,600,627,635,640,642,644), decreased transfusion rate (ten studies594,598,603,627,633,635,641-644), and lower number of retrieved PLNs (three studies600,603,640) with robotic-assisted laparoscopic hysterectomy than open hysterectomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "No significant differences in terms of operative time (twelve studies594,598,600,602,603,627,633,635,639,640,642,644) or number of total LNs (nine studies594,598,602,627,633,635,642,644,645) were described between the two surgical techniques.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Fully consistent data are provided with respect to length of stay, operative time, blood loss, transfusion rate, and number of LNs by the meta-analysis published by Shazly et al.610 (Table 16).It should be noted that eleven594,598,600,602,603,627,633,635,639,642,644 of the thirteen studies594,598,600,602,603,606,627,633,635,639,642,644,646 from which these analyses are based on have also been taken into account by Park et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "597.Fully consistent data are also provided with respect to hospital stay, blood loss during surgery, need for blood transfusion, duration of operation, and number of LNs resected by another identified meta-analysis609 (Table 16).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted that (1) all the studies598,606,627,633,635 from which these analyses are based on have also been taken into account by Shazly et al.610, and (2) four598,627,633,635 of these five studies598,606,627,633,635 have also been taken into account by Park et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "597.One original study647 not included in the meta-analyses597,609,610 mentioned above and comparing robotic-assisted laparoscopic and open hysterectomy was identified and presents consistent findings concerning the length of surgery, the number of LNs retrieved, the blood loss, and the transfusion rates.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "However, the authors found that the use of robot was associated with a longer mean operative time ( $2 2 0 \\mathrm { m i n }$ versus $1 5 6 \\mathrm { m i n }$ , $\\mathrm { p } < 0 .0 0 1 \\$ ).As part of a systematic review including twenty-one studiesNA of laparoscopic radical hysterectomy, fourteen studiesNA of open radical hysterectomy and twelve studiesNA of robotic radical hysterectomy, Geetha et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "648 reported that mean blood loss is significantly higher in abdominal radical hysterectomy compared to both laparoscopic radical hysterectomy and robotic radical hysterectomy.This difference between laparoscopic and robotic radical hysterectomy was not statistically significant.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Both laparoscopic and robotic radical hysterectomy had significantly lower proportion of patients with blood transfusion compared to open method.Although the robotic radical hysterectomy appeared to require less blood transfusion, the difference between laparoscopic and robotic radical hysterectomy was not big enough to be statistically significant.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Though laparoscopic and robotic radical hysterectomy appeared to take more time compared to open radical hysterectomy, the difference was not big enough to be statistically significant.Duration of stay in hospital for robotic radical hysterectomy was significantly less than the other two methods.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The mean numbers of LNs obtained across the three surgical techniques were similar.A health technology assessment report649 was identified but is not described because it presents only pooled data about endometrial and cervical cancers.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "No separate data, taking into account data about cervical cancers specifically, is available.Another identified systematic review650 is not described because it contains no additional studies beyond those already captured by the systematic reviews/meta-analyses mentioned above.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Kim et al.651 performed a meta-analysis (twenty studies652-671) to compare notably perioperative outcomes between conventional radical surgery and nerve-sparing radical surgery in patients with cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Crude analyses showed that blood loss and hospital stay were significantly less in patients treated with nerve-sparing radical surgery.The length of the resected vagina was significantly shorth in nerve-sparing radical surgery than in conventional radical surgery.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "However, there were no significant differences in operative time and the length of the resected parametrium between the two surgical techniques (Table 17).Fully concordant data by respect to hospital stay are provided by a second identified metaanalysis672 (twenty-seven studies656-661,665,666,668,669,673-689).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "However, nerve-sparing radical surgery was associated with a significantly longer operative time.Moreover, no differences of blood loss were found between the two surgical techniques (Table 17).Results of the three identified studies690-692 evaluating the feasibility of performing a nerve- LoE sparing radical hysterectomy robotically and assessing the oncological and functional outcomes associated with this surgery are limited notably by the very small number of patients evaluated (all studies have accrued less than 15 patients).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "LoE 2- One original study693 not included in the meta-analyses651,672 mentioned above and comparing conventional radical surgery and nerve-sparing radical surgery was identified and presents consistent findings with those reported by van Gent et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "672 concerning the blood loss and length of surgery.A study694 comparing vaginal-assisted laparoscopic radical hysterectomy (VALRH) and laparoscopic-assisted radical vaginal hysterectomy (LARVH) was also identified.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The mean duration of the surgery was significantly shorter in the VALRH group than in the LARVH group $( 2 9 8 ~ \\mathrm { \\ m i n }$ versus $3 3 3 ~ \\mathrm { \\ m i n }$ , $\\mathrm { ~ \\textbf ~ { ~ p ~ } ~ } < \\mathrm { ~ 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 0 1 } ]$ .No significant difference in terms of pelvic lymphadenectomy was reported between the groups (21 versus 22, $\\mathrm { ~ ~ p ~ } = \\mathrm { ~ 0 .6 8 4 } )$ ).It should be noted that the significant difference in the paraortic LNs count is due to the learning curve of the surgeons.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The mean blood loss and prevalence of blood transfusion due to surgery were significantly lower in the VALRH group (1.9 versus $3 .2 ~ \\mathrm { g / d l } ,$ p $< 0 .0 0 1$ and 2 versus 39, $\\mathrm { ~ p ~ } <$ 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "001, respectively).After VALRH, the matched patients were discharged after a median of 10 days that was significantly earlier than after the LARVH with a median hospital stay of 14 days $\\mathrm { ( p < 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 0 1 } \\dot { \\mathrm { \\Omega } }$ ).A study695 comparing LARVH and time-matched radical abdominal hysterectomy was also identified.The median operative time was significantly longer in the LARVH group (3.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "5h versus $2 .5 \\mathrm { h } .$ , $\\mathrm { ~ p ~ < ~ } 0 .0 0 1 \\dot { \\mathrm { ~ _ { \\it ~ \\cdot ~ } ~ } }$ .However, the median blood loss was significantly less in the LARVH group ( $3 0 0 \\ \\mathrm { m l }$ versus $5 0 0 \\ \\mathrm { m l }$ , $\\mathrm { ~ p ~ < ~ } 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 0 1 \\mathrm { ~ \\AA ~ }$ .It should be noted that the incidence of blood transfusion was not statistically different between the groups $7 \\%$ versus $8 \\%$ , $\\mathrm { \\Delta p } > 0 .0 5 \\dot \\$ ).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The median postoperative hospital stay was significantly shorter for the LARVH (1 day versus 5 days, $\\mathrm { p } < 0 .0 0 1 \\dot \\$ ).Results from the nine other identified studies632,696-703 are limited notably by the number of LoE 3 patients evaluated.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "LoE 1- Complication rate/Quality of life: Park et al.597 provided also pooled data about the surgical safety in terms of intra- and post-operative major complications and postoperative minor complications of the three surgical techniques mentioned above.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The pooled estimate demonstrated a significantly lower overall complication rate (seven studies594,602,603,627,633,643,645) with robotic-assisted laparoscopic hysterectomy compared to open hysterectomy $\\mathrm { ( R R = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "5 9 }$ $( 9 5 \\% \\mathrm { ~ C I } = 0 .3 5 \\ – 0 .9 9 )$ )).No significant differences were reported in terms of intraoperative (nine studies594,598,600,602,633,639-641,644) or postoperative (six studies $5 9 4 , 5 9 8 , 6 0 2 , 6 3 3 , 6 3 9 , 6 4 1 \\big )$ complications between these two surgical techniques $\\mathrm { { R R } } = 1 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1 8$ ( $9 5 \\% \\mathrm { C I } = 0 .4 3 – 3 .2 7$ ) and $\\mathrm { R R } = 0 .7 8$ ( $9 5 \\% { \\mathrm { C I } } = 0 .4 2 { \\mathrm { - } }$ 1.43), respectively).Among the individual complications, robotic-assisted hysterectomy showed a lower incidence of wound infection (five studies594,603,627,633,642), fever (four studies598,603,635,642), and urinary tract infection (three studies600,603,642) but a higher risk of vaginal cuff complications (six studies598,603,627,635,639,643) (Table 18).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The conversion rate of robotic-assisted laparoscopic hysterectomy to open hysterectomy was reported in 9 studies594,602,603,627,633,635,640,642,643.Of these, eight reported zero conversion594,602,627,633,635,640,642,643.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In only one study603, the conversion rate for this surgical technique was $2 .9 \\%$ .No significant differences were seen with respect to the proportion of patients with complications (five studies598,606,627,633,635, $\\mathrm { O R } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "6 6$ (M-H: 0.36, FEM: 1.21)) or the need to resort to another type of surgery (two studies606,633, $\\mathrm { R D } = 0 .0 0$ (M-H: -0.05, FEM: 0.05)) in the second identified meta-analysis published by Reza et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "609.Fully consistent findings with respect to intraoperative complications were reported by Shazly et al.610 (ten studies594,598,600,602,603,606,617,633,635,644, $0 \\mathrm { R } = 1 .0 7 \\$ $\\mathopen { } \\mathclose \\bgroup \\left( 9 5 \\% \\aftergroup \\egroup \\mathrm { C I } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "5 5 - 2 .0 6 \\aftergroup \\egroup \\right)$ )).Although it was not statistically significant, the pooled prevalence of aggregate complications was lower among women treated with robotic-assisted hysterectomy and the effect estimate was close to significance (fourteen studies594,598,600,602,603,606,617,627,633,639,642-644,646, $\\mathrm { O R } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "5 6$ $\\begin{array} { r } { [ 9 5 \\% \\mathrm { C I } = 0 .3 0 \\ \\AA } \\end{array}$ 1.03)).Both techniques were comparable with respect to pelvic infection and abscess formation, cardiopulmonary complications, cuff-related complications, intestinal obstruction/ileus, lymphovascular complications, thrombotic events, uretero-renal complications, urinary retention, readmission and reoperation.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "However, robotic-assisted hysterectomy was associated with significantly lower febrile morbidity and wound-related complications compared to abdominal radical hysterectomy (Table 19).In a original study647 not included in the meta-analyses597,609 mentioned above and comparing robotic-assisted laparoscopic and open hysterectomy, although overall complications were similar, the use of robot was associated with lower intra-operative complication rate $( 4 \\%$ versus $1 0 \\% , \\mathrm { p } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 0 4 \\$ ).There were no significant differences between robotic-assisted laparoscopic hysterectomy and conventional laparoscopic hysterectomy in the overall (three studies594,599,602, $\\mathrm { R R } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "6 2$ ( $9 5 \\%$ $\\mathrm { C I } = 0 .3 0 \\ – 1 .2 8 )$ ), intra-operative (nine studies594,598-604,607, $\\mathrm { R R } = 0 .8 7$ ( $9 5 \\% \\mathrm { C I } = 0 .4 3 – 1 .7 7 )$ ), and postoperative complications (seven studies594,598-600,602,604,607, $\\mathrm { R R } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "7 8$ $9 5 \\% { \\mathrm { C I } } = 0 .4 9 { - } 1 .2 { \\zeta }$ 3)).There were also no significant differences between these two surgical techniques in the rate of individual major or minor complications.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The conversion rate of robotic-assisted laparoscopic hysterectomy to laparotomy was reported in five studies594,601,602,607,704 and the pooled analysis showed a lower trend with robotic-assisted laparoscopic hysterectomy than conventional laparoscopic hysterectomy $\\mathrm { { R R } } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "2 3$ ( $9 5 \\% \\mathrm { C I } = 0 .0 4 { - 1 .2 9 }$ )).No significant differences in the proportion of patients with complication (four studies598,606-608, $0 \\mathrm { R } = 1 .0 7 \\$ (M-H: 0.53, FEM: 2.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "15)) or the need for conversion to another type of surgery (three studies598,606,607, $\\mathrm { R D } = - 0 .0 2$ (M-H: -0.09, FEM: 0.05)) were reported in the second identified meta-analysis published by Reza et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "609.Fully consistent findings with respect to intraoperative complications were also reported by Shazly et al.610 (fourteen studies594,598-601,603,604,606-608,611-613,617, $0 \\mathrm { R } = 1 .0 5$ ( $9 5 \\% { \\mathrm { C I } } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "5 8 – 1 .{ \\mathrm { .} }$ 92)).No differences in aggregate complications were also observed (fourteen studies594,598- 601,603,604,606-608,611-613,617, $\\begin{array} { r l r } { 0 \\mathrm { R } } & { { } = } & { 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "9 6 } \\end{array}$ $9 5 \\%$ CI = 0.55-1.66)).Individual postoperative complications did not differ between both techniques (Table 19).The use of robot was associated with higher proportions of major postoperative complications $9 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "6 \\%$ versus $5 .5 \\%$ , p $< 0 .0 5 \\vec { \\mathrm { ] } }$ in the systematic review published by Kruijdenberg et al.621.The authors reported no significant difference in the proportion of reoperation after complications.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Concerning the comparison of complications of laparoscopic radical hysterectomy and abdominal radical hysterectomy, Cao et al.572 and Wang et al.593 reported no difference with respect to intraoperative complication between the two surgical techniques (ten studies14,573,576,578,580,581,586,587,589,592, $\\begin{array} { r l r } { 0 \\mathrm { R } } & { { } = } & { 1 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "4 8 } \\end{array}$ ( $9 5 \\%$ $\\begin{array} { r l r } { \\mathrm { C I } } & { { } = } & { 0 .7 5 \\ – 2 .9 1 } \\end{array}$ ), and nine studies573,576,578,580,581,583,584,592,594, $0 \\mathrm { R } \\ = \\ 1 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "3 6 \\$ $( 9 5 \\% \\mathrm { ~ C I ~ = ~ } 0 .8 6 { - 2 .1 5 } )$ , respectively).However, laparoscopic radical hysterectomy was systematically associated with lower postoperative complications (eighteen studies14,573-582,584-587,589,591,592, $\\mathrm { O R } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "7 5$ $9 5 \\% \\mathrm { C I } = 0 .6 2 – 0 .9 1$ ), and ten studies573,575,576,580-584,592,594, $\\mathrm { O R } = 0 .4 6$ ( $9 5 \\% \\mathrm { C I } = 0 .3 4 – 0 .6 3$ ), respectively).Laparoscopic radical hysterectomy was associated with lower perioperative complication rates (four studies14,584- 586, $\\mathrm { O R } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "6$ $9 5 \\% \\mathrm { C I } = 0 .3 6 \\ – 0 .9 0 )$ ).No significant differences were found for the recovery of bladder function (three studies580,587,588, WMD $) = - 2 .4 8$ $( 9 5 \\% \\mathrm { C I } = - 5 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1 6 – 0 .1 9 )$ ), but a significant difference was found in the number of days for anorectal function recovery (three studies580,583,588, WMD $= - 0 .8 0$ ( $9 5 \\% \\mathrm { C I } = - 1 .1 6 \\cdots 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "4 4 )$ ).One original study596 not included in the meta-analyses572,593 mentioned above and comparing LoE 2- laparoscopic and open hysterectomy was identified and presents consistent findings concerning the intraoperative and postoperative complications.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "LoE 1- Geetha et al.648 found that postoperative infectious morbidity was significantly higher among patients who underwent open radical hysterectomy compared to the other two surgical techniques and a higher rate of cystotomy in laparoscopic radical hysterectomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "As showed by Kim et al.651, nerve-sparing radical surgery was associated with less common intraoperative complications compared to conventional radical surgery.However there were no significant differences in postoperative complications between the two surgical techniques.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In regard to urinary dysfunctions, crude analyses demonstrated that duration of postoperative catheterization was shorter and urinary frequency and abnormal sensation were less commen in nerve-sparing radical surgery.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "However, there were no significant differences in urinary incontinence, urinary retention, dysuria, and urinary urgerncy between the two surgical techniques.In terms of anorectal dysfunctions, there were also no significant differences in constipation, diarrhea, and fecal incontinence between the two treatments.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Furthermore, a decrease in sexual interest, dyspareunia, a decrease in orgasm, or sexual satisfaction, and vaginal dryness were not significantly different between the two surgical techniques (Table 20).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Van Gent et al.672 found that the time to micturition after surgery was significantly shorter in patients treated with nerve-sparing radical hysterectomy $( \\mathrm { S D M } ~ = ~ - 0 .8 4 ~ \\$ ( $9 5 \\%$ $\\mathrm { C I } ~ = ~ - 1 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 7 \\mathrm { - - }$ 0.60)).One original study693 not included in the meta-analyses651,672 mentioned above and comparing these two surgical methods was identified and presents consistent findings with those previously concerning the postoperative complications.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In the identified study694 comparing VALRH and LARVH, no conversion to laparotomy due to intraoperative complication was reported.Bladder function was restored significantly earlier after VALRH with a mean of 8 postoperative days than after LARVH with a mean of 11 days (p $< 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 0 1 ]$ .In the VALRH group, no intraoperative injuries of bladder, ureter, blood vessel or bowel occurred.In the LARVH group, the most frequent intraoperative injuries occurred to the bladder while opening the cervico-vesical space in $7 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 \\%$ of patients.Further intraoperative complications in the LARVH group were injury of the ureter $( 3 .5 \\% )$ , a blood vessel $( 2 .0 \\% )$ and of the bowel $( 0 .5 \\% )$ .The difference of complications during the surgery between the groups was significant $( \\mathrm { p } < 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 0 1 \\$ .The difference between the groups and the matched pairs among the groups concerning the rate of postoperative complications failed significance.Only a trend in favour of VALRH was reported.In the study695 comparing LARVH and time-matched radical abdominal hysterectomy, all laparoscopic procedures were completed successfully with no conversions to laparotomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The intraoperative complication rate was greater for the LARVH patients ( $1 3 \\%$ versus $4 \\%$ , $\\mathrm { ~ p ~ } <$ 0.03).Postoperative infectious and non-infectious morbidity was not significantly different between the groups $9 \\%$ versus $5 \\% ,$ $\\mathrm { \\Delta p > 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 5 }$ and $5 \\%$ versus $2 \\%$ $\\mathrm { \\Delta p } > 0 .0 5 \\mathrm { \\Delta }$ , respectively).The median number of days to a urinary residual ${ < } 1 0 0 ~ \\mathrm { m l }$ for the LARVH was significantly longer (10 days versus 5 days, $\\mathrm { p } < 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 0 1 \\dot { } _ { - }$ ).Oncologic outcomes : as part of the meta-analysis published by Park et al.597, no significant LoE 1- differences were found in survival outcomes between robot-assisted laparoscopic hysterectomy compared to conventional laparoscopy or laparotomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Concerning the comparison of robotic-assisted laparoscopic hysterectomy versus open hysterectomy, the OS and DFS rates were examined in three studies598,602,639, though they provide no significant clinical meaning because the follow-up periods differed between the two treatment groups in the studies.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Four studies598,600,603,633 reported a positive resection margin rate, and the pooled analysis showed no significant difference $[ \\mathrm { R R } = 0 .6 6$ ( $9 5 \\%$ $\\breve { 5 } ^ { 0 } / 0 ~ \\mathrm { C I } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "2 2 \\cdot 1$ .96)).Once again, fully consistent data are provided with respect to rate of positive margins by Reza et al.609 (two studies598,633, $\\mathrm { O R } = 0 .5 8$ (M-H: 0.14, FEM: 2.33)).It should be noted that the two studies598,633 from which this analysis is based on have also been taken into account by Park et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "597.One original study647 not included in the meta-analyses597,609 mentioned above and comparing LoE 2- robotic-assisted laparoscopic and open hysterectomy was identified and presents consistent findings.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "LoE 1- Concerning the comparison of robotic-assisted laparoscopic hysterectomy versus conventional laparoscopic hysterectomy, the OS and DFS rates were examined in two studies598,602 and four studies598,601,602,604 respectively, and no significant differences were observed between these two surgical approaches.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Five studies598-600,607,704 reported a positive resection margin rate.The positive margin rate was also not significantly different between these surgical techniques (RR $= 0 .8 7$ $9 5 \\% \\mathrm { C I } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "2 9 – 2 .6 2$ )).Fully consistent data are provided with respect to rate of positive margins by Reza et al.609 (two studies598,607, $\\mathrm { O R } = 0 .8 4 \\$ (M-H: 0.20, FEM: 3.42)).It should be noted that the two studies27,36 from which this analysis is based on have also been taken into account by Park et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "597.Both methods were similar in respect to recurrence rate ( $5 .2 \\%$ versus $5 .6 \\% , \\mathrm { p } = 0 .8 8$ ) in the systematic review published by Kruijdenberg et al.621.Concerning the comparison of laparoscopic radical hysterectomy versus abdominal radical hysterectomy, ten studies14,573,575,579,580,583-587, six studies14,573,575,584-586, and thirteen studies14,575,577,579-587,590 included in the meta-analysis published by Cao et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "572, assessed 5- year DFS, 5-year OS and recurrence rate, respectively.No significant differences were found between the two surgical techniques ( $\\operatorname { T H R } = 0 .0 1$ $9 5 \\% \\mathrm { C I } = - 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1 0 { - 0 .1 1 }$ ), $\\mathrm { H R } = - 0 .0 2$ $( 9 5 \\% \\thinspace \\mathrm { C I } = -$ 0.14-0.10), and $\\mathrm { O R } \\ = \\ 0 .8 2$ ( $9 5 \\%$ $, \\mathrm { C I } ~ = ~ 0 .6 1 \\AA ^ { - }$ 1.11), respectively).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Fully consistent data are provided in terms of DFS and OS by Wang et al.593 (five studies573,575,580,583,584, $\\mathrm { { H R } } = 0 .9 7$ ( $9 5 \\%$ $\\mathrm { C I } = 0 .5 6 \\ – 1 .6 8 \\$ ), and three studies573,575,584, $\\mathrm { H R } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "9 1$ ( $5 \\% \\mathrm { ~ C I ~ } = 0 .4 8 – 1 .7 1$ ), respectively).It should be noted that all the studies573,575,580,583,584 from which these analyses are based on have also been taken into account by Cao et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "572.Wang et al.593 also pooled data relative to the positive resection margins (four studies576,578,584,590).Here again, no significant differences were reported ( $\\mathrm { O R } = 1 .2 4 \\$ ( $9 5 \\% \\mathrm { C I } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "4 6 { - 3 .3 5 } )$ ).Two original studies596,705 not included in the meta-analyses572,593 mentioned above and comparing laparoscopic and open hysterectomy were identified.In the first one596, consistent findings concerning the DFS, OS, and recurrence rates were reported.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In the second one705, the authors found that the experienced surgeon was more likely to select patients with earlierstage disease and resect tumours with shorter vaginal tumour-free margin using laparoscopic radical hysterectomy the the inexperienced surgeons.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "After matching, which equalized stage and risk factors between the two surgeon groups, vaginal tumour-free margin of the laparoscopic radical hysterectomy approach was shorter than that of abdominal radical hysterectomy in the experienced surgeon group, while even longer than that of abdominal radical hysterectomy in the inexperienced surgeon group.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Although PFS of laparoscopic radical hysterectomy in the experienced surgeon group was significantly better than that in the inexperienced surgeon group’s laparoscopic radical hysterectomy patients, statistical significance of the difference disappeared after matching.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Mean positive margin and recurrence rate across the three types of radical hysterectomy LoE 1- studies were similar in the systematic review published by Geetha et al.648.The authors mentioned that positive margin was zero in all except one studyNA pertaining to robotic radical hysterectomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "According to the two identified meta-analyses651,672 comparing nerve-sparing radical surgery and conventional radical surgery, no significant differences in DFS or OS were found between the two surgical techniques (Table 21).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "One original study693 not included in these two meta-analyses651,672 was identified and presents LoE 2- fully consistent findings.In the study695 comparing LARVH and time-matched radical abdominal hysterectomy, there was no statistically significant difference in actuarial 2-year recurrence-free survival ( $9 4 \\%$ for both groups, $\\mathrm { \\Delta p > 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 5 } ^ { \\cdot }$ ).There were no port-site recurrence, nor was there a difference in the pattern of recurrences between the two procedures.In the identified study694 comparing VALRH and LARVH, no difference with respect to the 5- year recurrence-free survival rate and OS for FIGO stage IB1 cervical cancer were reported ( $9 2 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "8 \\%$ versus $8 8 .2 \\%$ , $\\mathrm { p } = 0 .5 8 9$ and $9 5 .2 \\%$ versus $9 0 .5 \\% , \\mathrm { p } = 0 .7 4 0$ , respectively).# 10.1.7 Adjuvant radiotherapy Meta-analysis706 of two $\\mathrm { R C T s ^ { 7 0 7 - 7 0 9 } }$ indicated no significant differences in survival at 5 years LoE 1- between women with FIGO stage IB cervical cancer who received radiation and those who received no further treatment after radical hysterectomy and PLN dissection ( $\\mathrm { \\ R R } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "8$ ( $9 5 \\%$ CI $= 0 .3 \\ – 2 .4 )$ ).Patients in the radiation therapy group received EBRT in doses between 46 Gy in 23 fractions to 50.4 Gy in 28 fractions, and no brachytherapy in the first included $\\mathrm { R C T } ^ { 7 0 7 , 7 0 8 }$ .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Women received 52 Gy of whole pelvic EBRT, at a rate of 2 Gy per day in the second trial709.Women who received radiation had a significantly lower risk of disease progression at 5 years $\\mathrm { R R } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "6$ ( $9 5 \\% \\mathrm { C I } = 0 .4 { - } 0 .9 )$ ).In the first included $\\mathrm { R C T } ^ { 7 0 7 , 7 0 8 }$ , only $9 \\%$ of the patients with adenocarcinoma or adenosquamous tumours who received radiotherapy had disease recurrence, compared with $4 4 \\%$ in those who did not, suggesting that radiotherapy may be beneficial for patients with non-squamous histology.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Although the risk of serious adverse events was consistently higher if women received radiotherapy rather than no further treatment, these increased risks were not statistically significant, probably because the rate of adverse events was low.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted that although the authors found no statistically significant difference in risk of grade 3 and 4 adverse events in women who did and did not receive radiotherapy, this might be because the trials reported very few side effects and so lacked the statistical power to detect any difference in risk that might be present.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Fully consistant results are provided by Sandadi et al.710 with respect to the absence of impact of an adjuvant radiotherapy on OS ( $91 \\%$ versus $9 6 \\%$ , $\\mathrm { p } = 0 .3 3 2 \\mathrm { \\ : }$ ) and rate of grade 3 or higher complication rates ( $4 \\%$ versus $5 \\% ,$ $\\mathrm { p = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "9 9 9 }$ ).However, no significant difference in 5-year PFS was observed ( $9 0 \\%$ versus $9 3 \\%$ , $\\mathrm { p } = 0 .1 7 2 \\mathrm { \\cdot }$ ).As part of the large-scale study85 mentionned above, multivariate analysis showed that adjuvant radiation was associated with a reduction in mortality rate for women with tumour size $< 4 \\ \\mathrm { c m }$ ( $\\mathrm { \\cdot H R } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "4 5$ $( 9 5 \\% \\mathrm { ~ C I } = 0 .3 8 – 0 .5 4 )$ ) after controlling for age, race, SEER registry, marital status, histologic finding, tumour grade, adjuvant radiation, and stage.Adjuvant radiation therapy was also associated with improved OS $\\mathrm { { \\tilde { H } R } } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1 7$ ( $9 5 \\% \\mathrm { C I } = 0 .0 4 \\ – 0 .6 9$ , ${ \\mathrm { ~ p ~ } = }$ 0.01) on multivariate analysis after adjustment for age, stage, histology, type of surgery, grade, tumour size, and LVSI in the study published by Fleming et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "711.However, it was not significantly associated with PFS.Discordent data were provided as part of a study published by Ayhan et al.64, mentioning that adjuvant radiotherapy was not found as independent prognostic factor in OS and DFS for women with FIGO stage IB cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In a study712 evaluating extended-field irradiation in patients with stages FIGO IB-IIB after radical surgery, the 5-year DFS rates were significantly different between squamous cell carcinomas and nonsquamous cell carcinomas ( $7 2 \\%$ versus $2 7 \\%$ , $\\mathrm { p } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 0 5 1 _ { .} ^ { \\cdot }$ ).In the subset of pT1b cases with one or two risk factors on the surgical specimen (LVSI and/or stromal invasion $> 1 / 3$ of total cervical stroma) in the study published by Sartori et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "44, there was no difference in DFS between the patients treated or not with adjuvant pelvic radiotherapy (50.4 Gy).Richard et al.713 compared the 5-year surival rates for women with FIGO stage IB cervical cancer who had a completed versus abandoned RH with postoperative radiotherapy in the presence of positive LNs.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "No statistically significant differences were noted in terms of median survival, DFS, OS, mean number of LNs dissected, and mean number of positive LNs.Results from the six other identified studies714-719 are limited notably by the small number of LoE 3 patients evaluated.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 10.1.8 Adjuvant chemo(radio)therapy A systematic review720 of RCTs was performed to evaluate the effectiveness and safety of adjuvant platinum-based chemotherapy after radical hysterectomy, radiotherapy, or both in the treatment of early stage (FIGO stages IA2-IIA) cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In this review, four small trials721-724 were analysed.All of them used chemotherapy regimens consisting of cisplatin alone or in combination with other agents and all included women underwent surgery first.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Three721-723 of them compared chemotherapy combined with radiotherapy versus radiotherapy alone, and one trial724 compared chemotherapy (given sequentially) followed by radiotherapy versus radiotherapy alone.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted that (1) no trials compared adjuvant platinum-based chemotherapy with no adjuvant chemotherapy after surgery for early cervical cancer with risk factors for recurrence, (2) the available results were based on an interim analysis of the data for one trial721, (3) another trial was closed early due to lack of accrual722, and (4) none of the included studies reported data on long-term toxicities or quality of life.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Compared with adjuvant radiotherapy, chemotherapy combined with radiotherapy significantly reduced the risk of death (pooled $\\mathrm { H R } = 0 .5 6$ $\\left( 9 5 \\% \\mathrm { C I } = 0 .3 6 – 0 .8 7 \\right)$ ) and disease progression (pooled $\\mathrm { H R } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "4 7$ $9 5 \\% \\mathrm { C I } = 0 .3 0 – 0 .7 4$ )).The combined therapy was associated with more severe side effects (grade 4) than radiotherapy alone (pooled $\\mathrm { R R } = 6 .2 6$ $9 5 \\%$ CI = 2.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "50-15.67)).In the trial724 that compared adjuvant chemotherapy followed by radiotherapy with adjuvant radiotherapy alone there was no difference in disease recurrence between the groups $\\mathrm { \\tilde { H } R } = 1 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "3 4$ $9 5 \\% \\mathrm { C I } = 0 .2 4 – 7 .6 6 )$ ).It should be noted that these results have to be interpreted cautiously because since subgroup analyses according to stage and size were not possible, it is not clear that the survival benefits apply equally to all early stage lesions.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Six $\\mathrm { R C T s ^ { 8 3 , 7 2 5 - 7 2 9 } }$ not included in the systematic review720 mentionned above were also identified.In the first one725, women randomly received adjuvant chemotherapy $( 4 0 0 ~ \\mathrm { m g / m ^ { 2 } }$ carboplatin, and $3 0 ~ \\mathrm { m g }$ bleomycin), external pelvic radiation therapy (mean dose : 50 Gy), or no further treatment.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "After a median follow-up of 4.1 years there were no significant differences in rates of recurrence or death between in the three study arms.It should be noted that these results have to be interpreted cautiously notably due to the small number of patients in the three treatment arms and the ensuing statistical power.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Patients with FIGO stages IB-IIA cevical cancer initially treated with radical hysterectomy and pelvic lymphadenectomy were randomized to receive single agent cisplatin and radiotherapy or docetaxel/cisplatin and radiotherapy in the second identified $\\mathrm { R C T ^ { 7 2 6 } }$ .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Radiotherapy in both groups was external radiation (46-54 Gy) followed by high-dose rate brachytherapy (12-24 Gy).Patients were given cisplatin $( 4 0 ~ \\mathrm { m g / m ^ { 2 } }$ ) every week for 5 cycles of docetaxel $( 3 0 \\mathrm { m g } / \\mathrm { m } ^ { 2 } )$ and cisplatin $( 3 0 ~ \\mathrm { m g / m ^ { 2 } }$ every week for 5 cycles.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The addition of docetaxel did not increase OS $\\mathrm { T H R } = 0 .6 5$ ( $9 5 \\% \\mathrm { C I } = 0 .3 9 – 1 .0 9$ ), $\\mathrm { \\Delta p = 0 .0 9 8 ) }$ but had the trend of increasing relapse-free survival (RFS) $\\mathrm { ( H R ~ = ~ } 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "6 4$ ( $9 5 \\%$ $5 \\% \\mathrm { ~ C I ~ } = \\ 0 .4 0 { - 1 .0 3 }$ ), $\\mathrm { ~ p ~ } = \\ 0 .0 6 1 ]$ .There were no significant differences in the seriousness of late grade 3-4 side effects between the treatment groups.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A $\\mathrm { R C T ^ { 8 3 } }$ was conducted to compare paclitaxel $( 1 7 5 ~ \\mathrm { m g } / \\mathrm { m } ^ { 2 \\cdot }$ ) plus carboplatin (area under the curve 5) followed by radiation (50.4 Gy) versus simultaneous radiochemotherapy with cisplatin $( 4 0 ~ \\mathrm { \\ m g / m ^ { 2 } } )$ in patients with FIGO stages IB-IIB after surgery.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Sequential chemotherapy and radiation could not show any significant survival benefit in terms of 2-year PFS and 5-year survival rates.The sequential arm appeared to have a significantly more favorable toxicity profile when compared with the simultaneous arm regarding the rate of overall hematological grade 3-4 toxicity ( $3 4 \\%$ versus $4 8 \\%$ , $\\mathrm { \\Delta p = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 2 8 \\mathrm { \\Omega } }$ ).In terms of quality of life, no significant changes were recorded regarding the functional assessment of cancer therapy-anemia (FACT–An) scores.As part of a large $\\mathrm { R C T ^ { 7 2 7 } }$ , patients with FIGO stage IB or FIGO stage II cervical cancer having surgery alone or surgery and radiotherapy (SR) were randomly assigned to receive or not oral 5-FU for one year.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Patients who received surgery obtained no benefit from 5-FU $[ \\mathrm { R R } = 0 .8 2 6$ $[ 9 5 \\% \\mathrm { C I } = 0 .4 2 1 \\ – 1 .5 9 6$ ), $\\mathrm { p } = 0 .5 7 5 \\$ ), wheras 5-FU-treated SR patients had significantly better 5- year survival than those not receiving chemotherapy $\\mathrm { \\Delta R R } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "7 4 4$ $( 9 5 \\% \\mathrm { C I } = 0 .5 5 8 – 0 .9 9 1$ ), ${ \\bf p } = { \\bf \\Phi }$ 0.043).The SR patients without nodal metastases had a better survival rate if they received 5- FU ( $\\mathrm { R R } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "4 2 3$ $( 9 5 \\% \\mathrm { C I } = 0 .2 7 3 – 0 .6 5 6 )$ , $\\mathrm { p } < 0 .0 0 1 \\dot { \\mathrm { \\Omega } } _ { \\mathrm { \\Omega } }$ ), wheras those with nodal metastases dit not $\\mathrm { \\mathrm { R R } } = 1 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "2 4 7$ ( $9 5 \\% \\mathrm { C I } = 0 .8 3 1 { - 1 .8 7 1 }$ ), $\\mathrm { p } = 0 .2 8 6 \\$ ).It should be noted that the results reported by these three identified $\\mathrm { R C T S ^ { 8 3 , 7 2 6 , 7 2 7 } }$ have also to be interpreted cautiously because since subgroup analyses according to stage and/or size were not possible, it is not clear if the data apply equally to all stage lesions.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The fifth identified $\\mathrm { R C T ^ { 7 2 8 } }$ , comparing concurrent chemoradiotherapy (CCRT) versus chemotherapy or radiotherapy alone after radical hysterectomy in FIGO stages IB-IIA cervical carcinoma patients, was prematurely closed due to suboptimal accrual and protocol violation.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The sixth and last identified RCT729 comparing adjuvant chemotherapy alone versus chemotherapy plus whole pelvic radiation therapy in patients with FIGO stages IB-IIA who underwent radical hysterectomy and pelvic lymphadenectomy was also prematurely closed due to less than optimal accrual.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Six non-randomized studies730-735 were also identified.Iwasaka et al.730 compared the efficacy of adjuvant chemotherapy (combination of $5 0 ~ \\mathrm { m g }$ of cisplatin, $1 \\mathrm { m g }$ of vincristine, $8 ~ \\mathrm { m g / m } ^ { 2 }$ of mitomycin c, and $5 ~ \\mathrm { m g }$ of peplomycin) after radical hysterectomy with that of adjuvant radiotherapy (41-50 Gy).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The overall cumulative survival rate in the chemotherapy group was significantly higher than that in the radiotherapy group, which reflects different survival rates over the 5-year period.In the chemotherapy group, intra- and extrapelvic recurrences accounted for $8 5 \\%$ and $2 3 \\%$ of all recurrences, respectively, whereas recurrences were noted for $3 8 \\%$ and $7 1 \\%$ in the radiotherapy group, respectively $( \\mathrm { p } < 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 1 )$ .As part of a comparison731 of adjuvant chemotherapy with two other therapeutic approaches (radiation and chemoirradiation), no significant differences among these three groups in the 5- year RFS rate and recurrence rates were reported.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The authors observed that most of the recurrence in patients who had received pelvic radiation was at a distant site as compared to the patients who had received chemotherapy only.The adoption of adjuvant chemotherapy which included cisplatin, bleomycin and vinblastine did not produce statistically significant results in terms of OS and DFS in the study published by Mossa et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "732.Park et $a l .^ { 7 3 3 }$ mentionned that postoperative adjuvant CCRT (cisplatin $( 1 0 0 ~ \\mathrm { \\ m g / m ^ { 2 } } )$ , or paraplatin $( 3 5 0 ~ \\mathrm { \\ m g / m ^ { 2 } } )$ , 5-FU $[ 1 , 0 0 0 ~ \\mathrm { m g / m } ^ { 2 } ]$ , radiation therapy (45 Gy)) appears to be superior to postoperative radiotherapy or postoperative adjuvant chemotherapy alone in terms of survival rates in patients with histopathologic high-risk factors.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "However, due to the small numbers of patients included in the subgroups of each treament modality according to histopathologic high-risk factors, they were unable to prove statistical significance.It should be noted that the results reported by these two non-randomized studies732,733 have to be interpreted cautiously due to the small number of patients included.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In a study evaluating CCRT according to the SWOG #87-97 (GOG #109) protocol721 in patients with high-risk factors who had underwent radical abdominal hysterectomy with pelvic lymphadenectomy and PALN dissection, Ryu et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "734 did not observe any statisically significant difference in the OS rate or PFS rate between these patients and patients who did not receive adjuvant therapy after surgery.It should be noted that significantly increased number of patients with lesion size, parametrial invasion, deep stromal invasion, PLN involvement, and LVSI was observed in the patients treated with adjuvant therapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In the sixth non-randomized study735, chemotherapy was compared with CCRT after radical hysterectomy and lymphadenectomy in patients with FIGO stages IB1-IIB cervical cancer.CCRT consisted of radiotherapy, which was given as whole-pelvis external irradiation (50.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "4 Gy in 28 fractions), combined with 5-FU $( 7 0 0 ~ \\mathrm { m g / m } ^ { 2 } )$ ) and cisplatin $\\mathrm { ( 7 0 ~ m g / m ^ { 2 } }$ .No significant differences between the two arms in terms of recurrence and death rates were reported.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The chemotherapy group contained significantly more patients with severe neutropenia than the CCRT group ( $6 6 .7 \\%$ versus $2 3 .0 \\%$ , respectively $\\mathrm { ~ p ~ } < \\ 0 .0 0 1 \\$ while this group contained significantly more patients with diarrhea than the chemotherapy group ( $1 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "8 \\%$ versus $0 \\% ,$ respectively, $\\mathrm { p } = 0 .0 4 \\mathrm { \\ : _ { \\cdot } }$ ).Results from the fifteen other identified studies80,736-749 are limited notably by (1) the LoE 3 heterogeneity in the chemo(radio)therapy regimens, and (2) the small number of patients evaluated (only five studies741,742,744,748,749 have accrued in excess of 60 patients).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 10.2 Previous initiatives Eight previous initiatives419,420,422-426,529,531 presenting guidelines for management of stages T1b1/T2a1 were identified.# 10.3 Development group comments There was unanimous agreement with the overall statement that the treatment strategy should aim to avoid combining radical surgery and radiotherapy because of the highest morbidity.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The majority of patients that present with T1b1/T2a1, determined by combined gynaecological examination and optimal imaging, will have no suspicious LNs on imaging (cN0) and will not have an indication for postoperative radiotherapy and can be managed effectively with lymphadenectomy (pN0) and radical hysterectomy alone, which is the preferred treatment approach.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Small tumours without deep stromal invasion have a low incidence of LN metastasis and surgery alone provides excellent outcomes.In contrast, larger tumours with deep stromal invasion, and especially in the presence of LVSI, are associated with a higher incidence of nodal involvement and a higher risk of recurrence.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In patients that are node negative on imaging, the first priority is to rule out nodal involvement and the standard surgical procedure is systematic lymphadenectomy.SN technique has the highest sensitivity and specificity in detecting nodal involvement compared to optimal imaging and has less morbidity compared to systematic lymphadenectomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Therefore, SN technique is strongly recommended as a first step to rule out nodal involvement in patients that are node negative on imaging.SN technique has the advantage that in case of detection of an involved node, further more radical surgical procedures can be avoided since there is already an indication for radiotherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "With regard to optimal type of radical hysterectomy for T1b1/T2a1 tumours there was more debate among the gynaecological oncologists.This resulted in the proposed tailored approach that takes tumour size, depth of stromal invasion and presence of LVSI into account, with less radical hysterectomy for favourable tumours.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The excellent outcomes with surgery alone in small tumours and the risk of surgical morbidity after the standard radical hysterectomy, have inspired the development of less radical hysterectomy approaches.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Several series find that less radical, nerve sparing, hysterectomy seem not to compromise oncological outcomes while associated with less post-surgical morbidity.This concept is currently a subject of research.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "On the other hand, despite the great improvement in modern imaging techniques for assessment of local tumour status (MRI, US) over the last decades, these techniques are not $1 0 0 \\%$ accurate in ruling out adverse prognostic factors.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Especially in larger T1b1/T2a1 tumours with deep stromal invasion, radical hysterectomy may unintentionally result, through histopathological examination, in the detection of involved parametria or surgical margins, or a combination of unfavourable risk factors (tumour size, deep stromal invasion, LVSI).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Therefore, in these patients, less radical hysterectomy approaches should be avoided.A surgical approach can be recommended only in those centers that are experienced with surgery alone in the presence of a combination of risk factors (tumour size, deep stromal invasion, LVSI).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Given the excellent oncological outcomes after definite chemoradiotherapy and brachytherapy for T1b1/T2a1 tumours this represents an alternative approach, especially if a combination of risk factors is known at diagnosis, which would require an adjuvant treatment.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Another alternative option, which is used in a limited number of centers, is preoperative brachytherapy followed by surgery.This is an acceptable alternative option only in team experienced with this approach.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Although there was unanimous agreement in favour of adjuvant (chemo)radiotherapy in case of involved LN(s), parametria or surgical margin, there was debate regarding the role of adjuvant radiotherapy in case of combinations of risk factors (tumour size, deep stromal invasion, LVSI).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Despite evidence from a randomized trial in favour of adjuvant radiotherapy in these patients, good results with surgery alone were reported in selected centers, experienced with this strategy.This is, however, applicable using appropriately tailored surgery.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 10.4 Guidelines # 10.4.1 General recommendation # B Treatment strategy should aim for the avoidance of combining radical surgery and radiotherapy because of the highest morbidity after combined treatment.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 10.4.2 Negative lymph nodes on radiological staging # 10.4.2.1 Surgical treatment Radical surgery by a gynecologic oncologist is the preferred treatment modality.Minimally invasive approach is favored.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The standard LN staging procedure is systematic pelvic lymphadenectomy.SN biopsy before pelvic lymphadenectomy is strongly recommended.Combination of blue dye with radiocolloid or use of indocyanine green alone is the recommended technique.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "LN assessment should be performed as the first step of surgical management.Intraoperative assessment of LN status (frozen section) is recommended.All SNs from both sides of the pelvis and/or any suspicious LNs should be sent for frozen section.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "If SN is not detected, intraoperative assessment of the PLNs should be considered.If intraoperative LN assessment is negative or not done, systematic PLN dissection should be performed.At present, SN biopsy alone cannot be recommended outside prospective clinical trials.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Systematic LN dissection should include the removal of lymphatic tissue from regions with the most frequent occurrence of positive LNs (SNs) including obturator fossa, external iliac regions, common iliac regions bilaterally, and presacral region.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Distal external iliac LNs (so-called circumflex iliac LNs) should be spared if they are not macroscopically suspicious.The type of radical hysterectomy (extent of parametrial resection, type A-C2) should be based on the presence of prognostic risk factors identified preoperatively (Figure 3).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Major prognostic factors for oncological outcome as tumor size, maximum stromal invasion, and LVSI are used to categorize patients at high, intermediate, and low risk of treatment failure.Complete description of the template used for radical hysterectomy should be present in the surgical report.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The 2017 modification of the Querleu-Morrow classification is recommended as a tool (Figure 4).Ovarian preservation should be offered to premenopausal patients with squamous cell carcinoma and usual-type (HPV-related) adenocarcinoma.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Bilateral salpingectomy should be considered.If LN involvement is detected intraoperatively including macrometastases or micrometastases, further PLN dissection and radical hysterectomy should be avoided.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Patients should be referred for definitive chemoradiotherapy.PALN dissection, at least up to inferior mesenteric artery, may be considered for staging purposes.If a combination of risk factors is known at diagnosis, which would require an adjuvant treatment, definitive radiochemotherapy and brachytherapy can be considered without previous radical pelvic surgery.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "PLN dissection should be avoided.PALN dissection, at least up to inferiormesenteric artery,may be considered in patients with negative PALN on imaging.Figure 6.Risk groups according to prognostic factors: suggested type(s) of radical hysterectomy <html><body><table><tr><td>Risk group</td><td>Tumour sizeLvSI</td><td></td><td>Stromal invasion</td><td>Type of radical hysterectomy*</td></tr><tr><td>Low risk</td><td><2 cm</td><td>Negative</td><td>Inner 1/3</td><td>B1 (A)</td></tr><tr><td>Intermediate risk</td><td>≥2 cm</td><td>Negative</td><td>Any</td><td>B2 (C1)</td></tr><tr><td></td><td><2 cm</td><td>Positive</td><td>Any</td><td></td></tr><tr><td>High risk</td><td>≥2 cm</td><td>Positive</td><td>Any</td><td>C1 (C2)</td></tr><tr><td colspan=\"5\"> * according to the Querleu-Morrow classification (see Figure 4)</td></tr></table></body></html> Figure 7.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Querleu-Morrow classification8 <html><body><table><tr><td>Type of radical hysterectomy</td><td>Paracervix or lateral parametrium</td><td>Ventral parametrium</td><td>Dorsal parametrium</td></tr><tr><td>Type A</td><td>Halfway between the cervix and Minimal excision ureter (medial to the ureter-ureter identified but not mobilized)</td><td></td><td>Minimal excision</td></tr><tr><td>Type B1</td><td>At the ureter (at the level of the ureteral bed-ureter mobilized from the cervix and lateral parametrium)</td><td>Partial vesicouterine ligament</td><td>excision of thePartial resection of the rectouterine-rectovaginal ligament and uterosacral peritoneal fold</td></tr><tr><td>Type B2</td><td>Identical to B1 plus paracervical lymphadenectomy without resection of vascular/nerve structures</td><td>vesicouterine ligament</td><td>Partial excision of the Partial resection of the rectouterine-rectovaginal ligament and uterosacral fold</td></tr><tr><td>Type C1</td><td>At the iliac vessels transversally, caudal part is preserved</td><td>Excision of the vesicouterine ligament (cranial to the ureter) at the bladder.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Proximal part ofthe vesicovaginal ligament (bladder nerves are dissected and spared)</td><td>At the rectum (hypogastric nerve is dissected and spared)</td></tr><tr><td>Type C2</td><td>At the level of the medial aspect of At the bladder (bladder At the sacrum (hypogastric iliac vessels completely (including the caudal part)</td><td>nerves are sacrificed)</td><td>nerve is sacrificed)</td></tr><tr><td>Type D</td><td>Atthe pelvic wall, including Atthe resection of the internal iliac vessels and/or components of the pelvic sidewall</td><td>bladder.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Not applicable if part of exenteration</td><td>the sacrum.Not applicable if part exenteration</td></tr></table></body></html> # C Definitive radiotherapy including brachytherapy represents effective alternative treatment (see Principles of radiotherapy).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It can be considered in particular in case of unfavorable prognostic and predictive factors for oncological and morbidity outcome.For high risk and intermediate risk, preoperative brachytherapy followed by surgery (type A) is used in a limited number of centers.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It is an acceptable alternative option only in teams experienced in this approach.# C NACT followed by surgery is not recommended.# 10.4.3 Positive pelvic lymph nodes on radiological staging In patients with unequivocally involved PLNs on imaging, definitive chemoradiotherapy is recommended (see Principles of radiotherapy).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "PALN dissection, at least up to inferior mesenteric artery, may be considered in patients with negative PALNs on imaging.Debulking of suspicious PLNs may be considered.# 10.4.4 Adjuvant treatment # B Adjuvant radiotherapy should be considered in the presence of combination of risk factors at final pathology such as tumor size, LVSI, and depth of stromal invasion.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "When in these situations an adequate type of radical hysterectomy has been performed (Figure 3), observation is an alternative option, especially in teams experienced in this approach.After primary radical surgery, adjuvant chemoradiotherapy is indicated in the following groups of patients (see Principles of radiotherapy): metastatic involvement of PLNs, including the presence of macrometastases pN1 or micrometastases pN1(mi) in either SN or any other PLNs detected by intraoperative or final pathologic assessment $\\Rightarrow$ chemoradiotherapy positive surgical margins (vagina/parametria) $\\Rightarrow$ chemoradiotherapy, brachytherapy boost may be considered parametrial involvement $\\Rightarrow$ chemoradiotherapy # 10.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "4.5 Cervical stump cancer Management of cervical stump cancer follows the recommendations for patients without previous subtotal hysterectomy.Adaptation of radiotherapy may be necessary, in particular for brachytherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Table 11.Piver-Rutledge-Smith classification569 <html><body><table><tr><td>Class I</td><td>Extrafascial hysterectomy: ·The identification of ureters through transparency and avoiding the ureters' injury by running them outside the operator field, without a dissection; The uterine artery is laterouterine sectioned and ligated;</td></tr><tr><td>Class II</td><td>·No vaginal portion is excised.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Modified radical hysterectomy (Wertheim): ·Ureters are dissected in the paracervical region but are not resected from the pubovesical ligament; ·The uterine arteries are sectioned beside and medial the ureter; Uterosacral ligament are excised midway from their sacral insertion; Resection of the cardinal ligaments up to their medial half; Removal of the upper third of the vagina;</td></tr><tr><td>Class III</td><td>·Pelvic lymphadenectomy Classical radical hysterectomy (Meigs): Complete dissection of ureters pubovesical ligaments except for a small part where the umbilical bladder artery is situated to the level of their penetration into the bladder; Uterine arteries are cut off at the origin of a hypogastric region (a.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "umbilical bladder); Uterosacral ligaments are excised at their sacred insertion; Cardinal ligaments are resected as close to the pelvic wall; Removing the upper half of the vagina;</td></tr><tr><td>Class IV</td><td>Routine pelvic lymphadenectomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It differs from the previous class according to the following aspects which give a higher radicality: Complete dissection of the ureter from the pubovesical ligament; Umbilical-vesical artery is sacrificed; · Removal of the 3/4 of the upper vagina.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "</td></tr><tr><td>Class V</td><td>It is more radical than the previous class with the addition of excision of a portion of the ureter or bladder which is invaded and then the reimplantation of the ureter into the bladder.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "</td></tr></table></body></html> Table 12.EORTC-GCG classification570,571 <html><body><table><tr><td>Type I</td><td>Simple hysterctomy</td></tr><tr><td>Type II</td><td>Modified radical hysterectomy: · Ureters are dissected up to the point they enter the bladder; ·Uterine arteries are sectioned and ligated at the medial half of parameters; · Proximal uterosacral ligament resection; · The medial half of the cardinal ligament is excised; · 1-2 cm from the upper portion of the vagina is removed.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "</td></tr><tr><td>Type III</td><td>Radical hysterectomy: ·Removal as far as possible from the uterosacral ligaments; ·Parameter is resected as near as possible to the pelvic wall; · Uterine vessels are ligated at the origin; ·1/3 of the upper vagina is removed.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "</td></tr><tr><td>Type IV</td><td>Extended radical hysterectomy: ·Similar to type Ill with the removal of 3/4 of the vagina and paravaginal tissue counterpart.</td></tr><tr><td>Type V</td><td>Partial pelvectomy: · Terminal ureter or a portion of the bladder or rectum is resected together with the uterus and parameters (supralevatorial).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "</td></tr></table></body></html> Table 13.Querleu-Morrow classification8 <html><body><table><tr><td>Type of radical hysterectomy</td><td>Paracervix or lateral parametrium</td><td>Ventral parametrium</td><td> Dorsal parametrium</td></tr><tr><td>Type A</td><td>Halfway between the cervix and ureter (medial to the ureter-ureter identified but not mobilized)</td><td>Minimal excision</td><td>Minimal excision</td></tr><tr><td>Type B1</td><td>At the ureter (at the level of the ureteral bed-ureter mobilized from the cervix and lateral parametrium)</td><td>Partial excision of the vesicouterine ligament</td><td>Partial resection of the rectouterine- rectovaginal ligament and uterosacral peritoneal fold</td></tr><tr><td>Type B2</td><td>Identical to B1 plus paracervical lymphadenectomy without resection of vascular/nerve structures</td><td>Partial excision of the vesicouterine ligament</td><td>Partial resection of the rectouterine- rectovaginal ligament and uterosacral fold</td></tr><tr><td>Type C1</td><td>At the iliac vessels transversally, caudal part is preserved</td><td>Excision of the vesicouterine ligament at the bladder.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Proximal part of the vesicovaginal ligament (bladder nerves are dissected and spared)</td><td>At the rectum (hypogastric nerve is dissected and spared)</td></tr><tr><td>Type C2</td><td>At the level of the medial aspect of iliac vessels completely (including the caudal part)</td><td>At the bladder (bladder nerves are sacrificed)</td><td>At the sacrum (hypogastric nerve is sacrificed)</td></tr><tr><td>Type D</td><td>At the pelvic wall,including resection of the internal iliac vessels and/or components of the pelvic sidewall</td><td>At the bladder.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Not applicable if part of exenteration</td><td>At the sacrum.Not applicable if part of exenteration</td></tr></table></body></html> Table 14.Pooled data on the perioperative outcomes of laparoscopic radical hysterectomy compared to abdominal radical hysterectomy <html><body><table><tr><td>Authorreference</td><td>Year</td><td>LRH versus ARH</td></tr><tr><td>Length of stay</td><td></td><td></td></tr><tr><td>Cao et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "572</td><td>2015</td><td>WMD = -4.36 (95% CI = -5.38--3.34)</td></tr><tr><td>Wang et al.593</td><td>2015</td><td>MD = -3.22 (95% CI = -4.21--2.23)</td></tr><tr><td>Operative time</td><td></td><td></td></tr><tr><td>Cao et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "572</td><td>2015</td><td>WMD = 18.76 (95% CI = 2.13-35.39)</td></tr><tr><td>Wang et al.593</td><td>2015</td><td>MD = 26.95 (95% CI = 8.08-45.82)</td></tr><tr><td>Blood loss</td><td></td><td></td></tr><tr><td>Cao et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "572</td><td>2015</td><td>WMD = -193.61 (95% CI = -236.80--150.43)</td></tr><tr><td>Wang et al.593</td><td>2015</td><td>MD = -268.36 (95% CI = -361.60--175.11)</td></tr><tr><td>Transfusion</td><td></td><td></td></tr><tr><td>Wang et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "593</td><td>2015</td><td>OR = 0.11 (95% CI = 0.01-1.01)</td></tr><tr><td>Total LNs</td><td></td><td></td></tr><tr><td>Wang et al.593</td><td>2015</td><td>MD = -1.06 (95% CI = -4.03-1.91)</td></tr><tr><td>PALNs</td><td></td><td></td></tr><tr><td>Cao et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "572</td><td>2015</td><td>WMD = -1.79 (95% CI = -6.39-2.82)</td></tr><tr><td>PLNs</td><td></td><td></td></tr><tr><td>Cao et al.572</td><td>2015</td><td>WMD = -1.44 (95% CI = -4.14-1.27)</td></tr></table></body></html> ARH abdominal radical hysterectomy, CI confidence interval, LN lymph node, LRH laparoscopic radical hysterectomy, MD mean difference, OR odds ratio, PALNs para-aortic lymph nodes, PLNs pelvic lymph nodes, WMD weighted mean difference Table 15.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Pooled data on the perioperative outcomes of robotic-assisted laparoscopic hysterectomy compared to conventional laparoscopy <html><body><table><tr><td>Authorreference</td><td>Year</td><td>RH versus LH</td></tr><tr><td>Length of stay</td><td></td><td></td></tr><tr><td>Park et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "597</td><td>2016</td><td>WMD = -1.39 (95% CI = -2.44--0.35)</td></tr><tr><td>Zhou et al.614</td><td>2016</td><td>MD = -1.10 (95% CI = -1.71--0.48)</td></tr><tr><td>Shazly et al.610</td><td>2015</td><td>MD = -0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "51 (95% CI = -1.57-0.55)</td></tr><tr><td>Reza et al.609</td><td>2010</td><td>MD = -0.52 (IV: -1.24, REM: 0.21)</td></tr><tr><td>Operative time</td><td></td><td></td></tr><tr><td>Park et al.597</td><td>2016</td><td>WMD = -24.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "90 (95% CI = -78.96-29.16)</td></tr><tr><td>Zhou et al.614</td><td>2016</td><td>MD = -13.30 (95% CI = -40.39-13.79)</td></tr><tr><td>Shazly et al.610</td><td>2015</td><td>WMD = -14.59 (95% CI = -41.30-12.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "13)</td></tr><tr><td>Reza et al.609</td><td>2010</td><td>MD = -14.01 (IV: -42.85, REM: 14.82)</td></tr><tr><td>Blood loss</td><td></td><td></td></tr><tr><td>Park et al.597</td><td>2016</td><td>WMD = -78.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "08 (95% CI = -192.08-35.92)</td></tr><tr><td>Zhou et al.614</td><td>2016</td><td>MD = -66.37 (95% CI = -115.45--17.30)</td></tr><tr><td>Shazly et al.610</td><td>2015</td><td>WMD = -44.31 (95% CI = -89.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "19-0.56)</td></tr><tr><td>Reza et al.609</td><td>2010</td><td>MD = -63.52 (IV: -100.49, FEM: -26.54)</td></tr><tr><td>Transfusion</td><td></td><td></td></tr><tr><td>Park et al.597</td><td>2016</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "32 (95% CI = 0.13-0.77)</td></tr><tr><td>Zhou et al.614</td><td>2016</td><td>OR = 0.57 (95% CI = 0.28-1.15)</td></tr><tr><td>Shazly et al.610</td><td>2015</td><td>OR = 0.61 (95% CI = 0.30-1.26)</td></tr><tr><td>Reza et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "609</td><td>2010</td><td>OR = 2.46 (M-H: 0.25, FEM: 24.36)</td></tr><tr><td>Total LNs</td><td></td><td></td></tr><tr><td>Park et al.597</td><td>2016</td><td>WMD = 2.81 (95% CI = -3.68-9.30)</td></tr><tr><td>Zhou et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "614</td><td>2016</td><td>MD = 1.33 (95% CI = -0.72-3.38)</td></tr><tr><td>Shazly et al.610</td><td>2015</td><td>MD = 2.62 (95% CI = -0.42-5.65)</td></tr><tr><td>Reza et al.609</td><td>2010</td><td>MD = 2.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "73 (IV: -8.39, REM: 13.85)</td></tr><tr><td>PLNs</td><td></td><td></td></tr><tr><td>Park et al.597</td><td>2016</td><td>WMD = 0.44 (95% CI = 3.46-4.35)</td></tr></table></body></html> CI confidence interval, FEM fixed-effects method, IV inverse variance, LH conventional laparoscopic hysterectomy, LNs lymph nodes, MD mean difference, M-H Mantel- Haenszel, nr not reported, OR odds ratio, PLNs pelvic lymph nodes, REM random-effects method, RH robot-assisted laparoscopic hysterectomy, RR relative risk, WMD weighted mean difference Table 16.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Pooled data on the perioperative outcomes of robotic-assisted laparoscopic hysterectomy compared to open hysterectomy <html><body><table><tr><td>Authorreference</td><td>Year</td><td>RH versus OH</td></tr><tr><td>Length of stay</td><td></td><td></td></tr><tr><td>Park et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "597</td><td>2016</td><td>WMD = -4.33 (95% CI = -5.96--2.70)</td></tr><tr><td>Shazly et al.610</td><td>2015</td><td>MD = -3.55 (95% CI = -5.00--2.10)</td></tr><tr><td>Reza et al.609</td><td>2010</td><td>MD = -2.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "05 (IV: -2.80, REM: -1.29)</td></tr><tr><td>Operative time</td><td></td><td></td></tr><tr><td>Park et al.597</td><td>2016</td><td>WMD = 16.76 (95% CI = -11.87-45.38)</td></tr><tr><td>Shazly et al.610</td><td>2015</td><td>MD = 28.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "79 (95% CI = -2.15-59.74)</td></tr><tr><td>Reza et al.609</td><td>2010</td><td>MD = 31.39 (IV: -10.33, REM: 73.11)</td></tr><tr><td>Blood loss</td><td></td><td></td></tr><tr><td>Park et al.597</td><td>2016</td><td>WMD = -409.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "04 (95% CI = -551.97--266.11)</td></tr><tr><td>Shazly et al.610</td><td>2015</td><td>WMD = -384.29 (95% CI = -534.84--233.73)</td></tr><tr><td>Reza et al.609</td><td>2010</td><td>MD = -334.17 (IV: -459.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "44, REM: -208.91)</td></tr><tr><td>Transfusion</td><td></td><td></td></tr><tr><td>Park et al.597</td><td>2016</td><td>RR = 0.12 (95% CI = 0.07-0.2)</td></tr><tr><td>Shazly et al.610</td><td>2015</td><td>OR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "12 (95% CI = 0.06-0.25)</td></tr><tr><td>Reza et al.609</td><td>2010</td><td>OR = 0.18 (M-H: 0.07, FEM: 0.44)</td></tr><tr><td>Total LNs</td><td></td><td></td></tr><tr><td>Park et al.597</td><td>2016</td><td>WMD = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "56 (95% CI = -2.76-3.88)</td></tr><tr><td>Shazly et al.610</td><td>2015</td><td>MD = -0.69 (95% CI = -3.37-1.99)</td></tr><tr><td>Reza et al.609</td><td>2010</td><td>MD = 1.29 (IV: -4.16, REM: 6.73)</td></tr><tr><td>PLNs</td><td></td><td></td></tr><tr><td>Park et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "597</td><td>2016</td><td>WMD = -3.71 (95% CI = -5.88--1.53)</td></tr></table></body></html> CI confidence interval, FEM fixed-effects method, IV inverse variance, LNs lymph nodes, MD mean difference, M-H Mantel- Haenszel, nr not reported, OH open hysterectomy, OR odds ratio, PLNs pelvic lymph nodes, REM random-effects method, RH robot-assisted laparoscopic hysterectomy, RR relative risk, WMD weighted mean difference Table 17.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Pooled data on the perioperative outcomes of nervesparing radical surgery compared to conventional radical surgery <html><body><table><tr><td>Perioperative outcomes</td><td>Year</td><td>NSRSversusCRS</td></tr><tr><td>Length of stay</td><td></td><td></td></tr><tr><td>Van Gent et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "672</td><td>2016</td><td>SDM = -0.82 (95% CI = -1.50--0.15)</td></tr><tr><td>Kim et al.651</td><td>2015</td><td>SDM = -0.224 (95% CI = -0.400--0.047)</td></tr><tr><td>Operative time</td><td></td><td></td></tr><tr><td>Van Gent et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "672</td><td>2016</td><td>SDM = 0.48 (95% CI = 0.16-0.79)</td></tr><tr><td>Kim et al.651</td><td>2015</td><td>SDM = -0.047 (95% CI = -0.635-0.542)</td></tr><tr><td>Blood loss</td><td></td><td></td></tr><tr><td>Van Gent et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "672</td><td>2016</td><td>SDM = -0.30 (95% CI = -0.64-0.04)</td></tr><tr><td>Kim et al.651</td><td>2015</td><td>SDM = -0.251 (95% CI = -0.391--0.110)</td></tr><tr><td>Length of the resected vagina</td><td></td><td></td></tr><tr><td>Kim et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "651</td><td>2015</td><td>SDM = -0.498 (95% CI = -0.795--0.201)</td></tr><tr><td>Length of the parametrium</td><td></td><td></td></tr><tr><td>Kim et al.651</td><td>2015</td><td>SDM = -0.320 (95% CI = -0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "707-0.064)</td></tr></table></body></html> CI confidence interval, CRS conventional radical surgery, NSRS nerve-sparing radical surgery, SDM standard differences in means Table 18.Pooled data published by Park et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "597 about the complications relative to the robotic-assisted laparoscopic hysterectomy compared to conventional laparoscopy and laparotomy <html><body><table><tr><td>Complications</td><td>RH versus OH</td><td>RH versus LH</td></tr><tr><td>Intra-operative major complications</td><td></td><td></td></tr><tr><td>Bladder injury</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "14 (95% CI = 0.01-2.68)</td><td>RR = 0.14 (95% CI = 0.01-2.70)</td></tr><tr><td>Ureteral injury</td><td>RR = 1.03 (95% CI = 0.26-4.06)</td><td>RR = 0.91 (95% CI = 0.14-6.09)</td></tr><tr><td>Cystotomy</td><td>RR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "65 (95% CI = 0.36-7.61)</td><td>RR = 1.18 (95% CI = 0.48-2.89)</td></tr><tr><td>Post-operative major complications</td><td></td><td></td></tr><tr><td>Vaginal complications</td><td>RR = 3.16 (95% CI = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "00-9.99)</td><td>RR = 1.48 (95% CI = 0.31-7.02)</td></tr><tr><td>Thromboembolism</td><td>RR = 0.74 (95% CI = 0.17-3.24)</td><td>RR = 0.43 (95% CI = 0.07-2.56)</td></tr><tr><td>Ileus/bowel obstruction</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "57 (95% CI = 0.25-1.31)</td><td>RR = 1.40 (95% CI = 0.34-5.81)</td></tr><tr><td>Wound infection</td><td>RR = 0.27 (95% CI = 0.08-0.90)</td><td>nr</td></tr><tr><td>Post-operative minor complications</td><td></td><td></td></tr><tr><td>Fever</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "28 (95% CI = 0.12-0.69)</td><td>RR = 0.45 (95% CI = 0.09-2.10)</td></tr><tr><td>Urinary tract infection</td><td>RR = 0.27 (95% CI= 0.09-0.82)</td><td>RR = 0.37 (95% CI = 0.09-1.48)</td></tr></table></body></html> CI confidence interval, LH conventional laparoscopic hysterectomy, nr not reported, OH open hysterectomy, RH robot-assisted laparoscopic hysterectomy, RR relative risk Table 19.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Pooled data published by Shazly et al.610 about the complications relative to the robotic-assisted laparoscopic hysterectomy compared to conventional laparoscopy and laparotomy <html><body><table><tr><td>Complications</td><td>RH versus OH</td><td>RH versus LH</td></tr><tr><td>Pelvic infection and abscess formation</td><td>OR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "58 (95% CI = 0.58-4.35)</td><td>OR = 1.09 (95% CI = 0.23-5.03)</td></tr><tr><td>Cardiopulmonary complications</td><td>OR = 0.84 (95% CI = 0.34-2.07)</td><td>OR = 1.83 (95% CI = 0.45-7.47)</td></tr><tr><td>Cuff related complications</td><td>OR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "79 (95% CI = 0.54-5.93)</td><td>OR = 0.79 (95% CI = 0.19-3.21)</td></tr><tr><td>Febrile morbidity</td><td>OR = 0.43 (95% CI = 0.20-0.89)</td><td>OR = 0.47 (95% CI = 0.20-1.09)</td></tr><tr><td>Intestinal obstruction</td><td>OR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "71 (95% CI = 0.29-1.71)</td><td>OR = 1.14 (95% CI = 0.28-4.61)</td></tr><tr><td>Lymphovascular complications</td><td>OR = 1.00 (95% CI = 0.41-2.46)</td><td>OR = 0.80 (95% CI = 0.36-1.74)</td></tr><tr><td>Thrombotic events</td><td>OR = 2.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "27 (95% CI = 0.76-6.82)</td><td>OR = 1.10 (95% CI = 0.30-1.26)</td></tr><tr><td>Readmission</td><td>OR = 1.11 (95% CI = 0.36-3.36)</td><td>OR = 1.26 (95% CI = 0.31-5.16)</td></tr><tr><td>Reoperation</td><td>OR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "62 (95% CI = 0.21-1.82)</td><td>nr</td></tr><tr><td>Uretero-renal complications</td><td>OR = 0.80 (95% CI = 0.24-2.68)</td><td>OR = 0.94 (95% CI = 042-2.12)</td></tr><tr><td>Urinary retention</td><td>OR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "35 (95% CI = 0.20-8.85)</td><td>OR = 0.62 (95% CI = 0.21-1.86)</td></tr><tr><td>Wound related complications</td><td>OR= 0.31 (95% CI = 0.13-0.73)</td><td>OR = 0.49 (95% CI = 0.13-1.80)</td></tr></table></body></html> CI confidence interval, LH conventional laparoscopic hysterectomy, nr not reported, OH open hysterectomy, RH robot-assisted laparoscopic hysterectomy Table 20.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Pooled data published by Kim et $a l .^ { 6 5 1 }$ on the complication of nerve-sparing radical surgery compared to conventional radical surgery <html><body><table><tr><td>Complications</td><td>CRS versus NSRS</td></tr><tr><td>Postoperative complications</td><td>OR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "750 (95% CI = 0.527-1.068)</td></tr><tr><td>Duration of postoperative catheterization</td><td>SDM = -1.369 (95% CI = -1.865--0.873)</td></tr><tr><td>Urinary frequency</td><td>OR = 0.347 (95% CI = 0.183-0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "658)</td></tr><tr><td>Urinary incontinence</td><td>SDM = 0.595 (95% CI = 0.294-1.207)</td></tr><tr><td>Urinary retention</td><td>OR = 0.130 (95% CI = 0.015-1.116)</td></tr><tr><td>Dyuria</td><td>SDM = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "220 (95% CI = 0.012-4.145)</td></tr><tr><td>Urinary urgency</td><td>OR = 0.711 (95% CI = 0.377-1.341)</td></tr><tr><td>Abnormal sensation</td><td>OR = 0.067 (95% CI = 0.013-0.340)</td></tr><tr><td>Constipation</td><td>OR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "409 (95% CI = 0.150-1.113)</td></tr><tr><td>Diarrhea</td><td>OR = 0.407 (95% CI = 0.094-1.758)</td></tr><tr><td>Fecal incontinence</td><td>OR = 0.258 (95% CI = 0.030-2.199)</td></tr><tr><td>Decrease in sexual interest</td><td>OR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "525 (95% CI = 0.237-1.160)</td></tr><tr><td>Dyspareunia</td><td>OR = 0.683 (95% CI = 0.378-1.233)</td></tr><tr><td>Decrease in orgasm</td><td>OR = 0.846 (95% CI = 0.430-1.663)</td></tr><tr><td>Decrease in sexual satisfaction</td><td>OR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "666 (95% CI = 0.330-1.341)</td></tr><tr><td>Vaginal dryness</td><td>OR = 0.843 (95% CI = 0.264-2.689)</td></tr></table></body></html> CI confidence interval, CRS conventional radical surgery, NSRS nerve-sparing radical surgery, OR odds ratio, SDM standard differences in means Table 21.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Pooled data on the oncologic outcomes of nervesparing radical surgery compared to conventional radical surgery <html><body><table><tr><td>Oncologic outcomes</td><td>Year</td><td>NSRSversus CRS</td></tr><tr><td colspan=\"3\">OS</td></tr><tr><td>Kim et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "651</td><td>2015</td><td>HR =1.030 (95% CI = 0.646-1.641)</td></tr><tr><td colspan=\"3\">2-year OS</td></tr><tr><td>Van Gent et al.672</td><td>2016</td><td>RR = 1.02 (95% CI = 0.99-1.05)</td></tr><tr><td colspan=\"3\">3-year OS</td></tr><tr><td>Van Gent et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "672</td><td>2016</td><td>RR = 1.01 (95% CI = 0.95-1.08)</td></tr><tr><td colspan=\"3\">5-year OS</td></tr><tr><td>Van Gent et al.672</td><td>2016</td><td>RR= 1.03 (95% CI = 0.99-1.08)</td></tr><tr><td colspan=\"3\">DFS</td></tr><tr><td>Kim et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "651</td><td>2015</td><td>HR = 1.056 (95% CI = 0.700-1.593)</td></tr><tr><td colspan=\"3\">2-year DFS</td></tr><tr><td>Kim et al.651</td><td>2015</td><td>RR = 1.01 (95% CI = 0.95-1.05)</td></tr><tr><td colspan=\"3\">3-year DFS</td></tr><tr><td>Kim et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "651</td><td>2015</td><td>RR = 0.99 (95% CI = 0.94-1.03)</td></tr><tr><td colspan=\"3\">5-year DFS</td></tr><tr><td>Kim et al.651</td><td>2015</td><td>RR = 1.00 (95% CI = 0.95-1.06)</td></tr></table></body></html> CI confidence interval, CRS conventional radical surgery, DFS diseasefree survival, HR hazard ratio, NSRS nerve-sparing radical surgery, OS overall survival, RR relative risk # 11 Fertility sparing treatment # 11.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1 Summary of available scientific evidence # 11.1.1 Simple trachelectomy or conisation Fertility outcomes: Bentivegna et al.750 performed a systematic review of the literature to evaluate the fertility results, obstetric outcomes, and the managment of infertility in patients with FIGO stage IB submitted to FSS.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Five different FSS procedures were studied (simple trachelectomy or conisation, vaginal radical trachelectomy, laparotomic radical trachelectomy, pure or robot-assisted laparoscopic radical trachelectomy, and NACT followed by conservative surgery).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The authors reported fertility results and obstetric outcomes from ten included series285,350,492,510,523,524,751-757 evaluating simple trachelectomy285,350,524,751,752, cone resection (conisation, CKC, LEEP, LLETZ, or laser conisation)510,523,753-757, or extrafascial trachelectomy492 (Table 22).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Exclusion for oncologic reasons (nodal involvement, involvement of the upper part of the trachelectomy specimen, inadequate margins, other histologic poor prognostic factors) depriving of FSS management was observed in $5 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "7 \\%$ of patients.The rate of postoperative morbidity exerting an impact on subsequent fertility was low $( 3 \\% ,$ only cervical stenoses).Only four492,523,524,754,757 of ten series285,350,492,510,523,524,751-757 mentioned the number of patients who attempted to become pregnant.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "This may explains why the overall pregnancy rate seems to be artificially low $( 5 6 \\% )$ , even if the crude number of pregnancies per total number of procedures is high (Table 22).No discriminative fertility rates were described according to the type of cervical procedure used (cone resection versus simple trachelectomy).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The prematurity rate was low compared with that observed after vaginal radical trachelectomy ( $1 5 \\%$ versus $3 9 \\%$ , $\\mathrm { p } < 0 .0 0 1 \\dot { }$ ).Using the technique of meta-analysis, Kyrgiou et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "758 investigated the effect of excisional techniques (CKC (ten studies759-768), LLETZ (ten studies508,769-777), laser conisation (seven studies773,778-783)) and destructive techniques (laser ablation (four studies773,782-784)) on subsequent maternal and fetal outcomes.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted that the authors included studies considering conservative methods of FIGO stage IA1 cervical cancer and/or cervical intraepithelial neoplasia and that no separate analyses taking into account only patients with FIGO stage IA1 cervical cancer is available.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "LLETZ and CKC were associated with a significant increase in the risk of preterm delivery.The association between laser conisation and preterm delivery was marginally non-significant (Table 23).Significant interstudy heterogeneity was observed for the laser conisation studies, which was due to one conflicting study783.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The exclusion of this outlying study reduced the heterogeneity and resulted in a significant effect $\\mathrm { { R R } } = 1 .9 1 \\$ $9 5 \\% \\mathrm { C I } = 1 .0 3 – 3 .5 5$ )).It should be noted that authors did not provide a clear reason for these outlying results.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "They mentioned that it could be possibly caused by the study design (the study selected controls matched for age and parity from the prelaser interval of the same women).Laser ablation was not significantly associated with this outcome.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In three included studies773,774,778, the risk of preterm delivery associated with LLETZ or laser conisation was specified according to the depth of the excised cone (less versus more than 10 mm).In all three studies, authors recorded a significantly increased risk if the depth was more than $1 0 ~ \\mathrm { m m }$ (pooled RR $= 2 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "6$ $( 9 5 \\% \\mathrm { ~ C I } = 1 .3 – 5 .3 )$ ).If the cone depth was less than $1 0 \\ \\mathrm { m m } ,$ results were heterogeneous; two studies773,778 did not identify a raised risk, whereas one774 did not show a significant association, resulting in a non significant association (pooled RR $\\mathbf { \\Sigma } = \\mathbf { \\Sigma }$ 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "5 ( $9 5 \\% \\mathrm { C I } = 0 .6 { - 3 .9 } ) ]$ ).LLETZ and CKC were associated with a significant increase in the risk of low birthweight ( $\\dot { } <$ $2 { , } 5 0 0 \\ \\mathrm { g } )$ .For laser conisation and laser ablation, the pooled estimates of relative risk did not reach statistical significance (Table 23).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Among the four procedures (CKC, LLETZ, laser conisation, laser ablation), CKC was the only one for which an association with a significant increase in the risk of caesarean section was reported.Among the three procedures (LLETZ, laser conisation, laser ablation) investigated in the meta-analysis758 mentioned above, LLETZ was the only one for which an association with a significant increase in the risk of pPROM was reported.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "None association with a significant increase in the risk of perinatal mortality was reported for the four procedures.It should be noted that the association between laser conisation and perinatal mortality was marginally non-significant.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Another meta-analysis785 examining the association of LEEP and subsequent pregnancy outcomes was identified but is not described because it contains no additional studies beyond those already captured by the meta-analysis758 mentioned above.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Four original studies454,468,471,473 not included in the systematic reviews/meta-analyses750,758 L mentioned above and reporting data about childbearing after conservative treatment by conisation only were identified.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Of the 30 patients with FIGO stage IA1 disease evaluated in three of them454,468,471, fifteen patients had twenty-one pregnancies resulting in sixteen live births, and the two patients with FIGO stage IA2 disease had together three successful pregnancies.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Of the 22 patients treated by conisation in the fourth identified study473, fifteen had a FIGO stage IA1 and seven had FIGO stage IA2 disease.Eleven of these women had eighteen pregnancies with thirteen live births and four spontaneous abortions.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "As part of a large-scale study786, deliveries subsequent to LEEP had a significantly increased risk of subsequent spontaneous preterm delivery $\\mathrm { { .O R } } = 2 .0 7$ ( $9 5 \\%$ $_ { 0 } ^ { \\prime } \\mathrm { C I } = 1 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "8 8 { - 2 .2 7 }$ )).Comparing deliveries subsequent to LEEP with deliveries subsequent to biopsy only, the risk was still significantly increased $\\mathrm { { O R } } = 1 .6 6 \\$ $9 5 \\% \\mathrm { C I } = 1 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "4 9 – 1 .8 4 )$ ).Both ablation and biopsy before delivery were associated with significantly higher risks for spontaneous preterm delivery, compared with deliveries with no previous procedure $\\operatorname { O R } = 1 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "4 0$ ( ${ \\sf I } 5 \\% { \\sf C I } = 1 .1 3 \\cdot$ 1.73) and OR $= ~ 1 .2 8$ $( 9 5 \\% \\mathrm { C I } = 1 .2 0 – 1 .3 5 )$ , respectively).The risk for spontaneous preterm delivery subsequent to a LEEP, compared with no LEEP, was significantly increased in all 3 categories of gestational age (moderately preterm (32-36 weeks): $0 \\mathrm { R } = 1 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "8 9 \\$ $( 9 5 \\% \\mathrm { C I } = 1 .7 1 \\cdot 2 .0 9$ ), very preterm (28-31 weeks): $0 \\mathrm { R } \\ = \\ 3 .2 8$ $( 9 5 \\% \\mathrm { C I } = 2 .5 6 { - 4 .1 9 } )$ , and extremely preterm (21-27 weeks): $0 \\mathrm { R } = 3 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1 6$ ( $9 5 \\% \\mathrm { C I } = 2 .2 7 – 4 .4 0 ]$ ).When the deliveries of primiparous women were included, the increased risk for preterm delivery was attenuated only marginally for the LEEP group $\\operatorname { \\mathrm { { O R } } } = 1 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "9 8$ $( 9 5 \\% \\mathrm { C I } = 1 .7 5 \\ – 2 .2 3$ )).When only the deliveries of women who had at least one delivery both before LEEP and after LEEP were included, the increase risk was still significant $\\mathrm { \\Delta } \\mathrm { Q R } = 2 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "5 5$ $9 5 \\% \\mathrm { C I } = 1 .4 2 – 4 .5 7 \\$ ).However, no significant association was observed when only the deliveries of women who had at least one delivery both before biopsy and after biopsy were included $\\mathrm { \\Delta O R } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "7 1 \\$ $9 5 \\%$ $\\mathrm { C I } =$ 0.45-1.11)).# LoE 3 Quality of life: only one small study787 analyzing the quality of life in terms of sexual and reproductive outcome in patients suffering from early stage cervical cancer, submitted to an excisional cone as fertility-sparing treatment, was identified.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "After surgery, all women had regular menstruation after a median time of 30 days.One patient $( 4 .4 \\% )$ had trouble in lubricating, 3 $( 1 3 \\% )$ had anxiety about performance, 6 $( 2 6 .1 \\% )$ complained of dyspareunia which was resolved within 3 subsequent months.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Overall, 11 $( 4 8 \\% )$ showed concerns about a future pregnancy, of whom 7 $3 0 \\% )$ had a fear of possible inability to conceive, 1 $( 4 .4 \\% )$ to maintain the pregnancy, 2 $( 8 .7 \\% )$ to have a recurrence during the pregnancy and 1 $( 4 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "4 \\% )$ had the fear of possible negative impact of their cancer history on the baby.Sixteen women $( 7 0 \\% )$ had an immediate psychological and physical recovery, 4 $( 1 7 \\% )$ after 3 months and 2 $( 9 \\% )$ after 12 months.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "No patient wrote to have concerns about choosing this fertility-sparing treatment.Oncologic outcomes: as part of another systematic review (13 series or case LoE 1- reports285,475,492,510,523,524,751,753,755-757,788,789), Bentivegna et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "790 covered the oncologic outcomes after such management in patients with FIGO stage IB1 tumours of $2 \\ \\mathrm { c m }$ or smaller (Table 24).All patients except four $( 9 8 \\% )$ underwent PLN dissection (total pelvic lymphadenectomy or SN dissection).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Five per cent of patients were excluded because of nodal involvement.Four patients (three local and one nodal) had recurrent disease $( 1 .7 \\% )$ .No invasive recurrence was seen in patients without LVSI.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted that initial data are missing for one patient.# 11.1.2 Vaginal radical trachelectomy (Dargent’s operation) Fertility outcomes: nearly half of the FSS modalities identified by Bentivegna et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "750 were Lo performed using vaginal radical trachelectomy.The authors reported fertility result cases and obstetric outcomes from 19 series70,477,524,791-826 (Table 22).Oncologic reasons led to abandon the FSS procedure in $1 1 \\%$ of patients.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Seventeen70,477,524,791-823 of the nineteen teams70,477,524,791- 826 used a prophylactic cerclage at the end of the procedure.It should be noted that this information was not mentioned by three teams524,811,823.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cervical stenoses were the most common complication likely to impact fertility $( 8 \\% )$ ).The infertility after the surgical procedure was related to cervical factors in at least $4 9 \\%$ of cases (it should be noted that the cause of infertility was not reported in about one fifth of cases).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Fifty-three per cent of these patients had achieved at least one pregnancy after management of infertility.Two other systematic reviews827,828 found are not described because they contain no additional studies beyond those already captured by the systematic review750 mentioned above.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "An original study829 not included in the systematic reviews750,827,828 mentioned above was LoE 2- identified and presents consistent findings with those previously reported.Two other original studies830,831 not included in the systematic reviews750,827,828 mentioned LoE 3 above were also identified but its results are limited notably by the very small number of patients evaluated.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Perioperative outcomes: as part of a systematic review comparing the effects of vaginal radical L trachelectomy and radical hysterectomy (five studies799,801,803,808,832), Han et al.833 revealed that radical vaginal trachelectomy was associated with fewer blood transfusions, less blood loss, and a shortened hospital stay.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted that need for blood transfusion is the only criterion for which pooled data are reported $\\operatorname { R R } = 0 .3 3$ $9 5 \\% \\mathrm { C I } = 0 .1 2 – 0 .9 0$ )).Blood loss was recorded in four studies799,801,803,832.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The data from three studies799,801,803 showed a lower volume of blood loss in radical vaginal trachelectomy compared with radical hysterectomy.Statistical analysis was not performed in the remaining study832.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Four of the included studies799,801,803,832 presented data on the duration of hospital stays.The overall collected data on hospital stay strongly favored radical vaginal trachelectomy.Lastly, data on the duration of the operation were available in the 5 included studies799,801,803,808,832.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Two of these studies803,808 revealed that there was no significant difference in the duration of the operation, whereas two studies799,801 indicated that the duration of the operation for radical vaginal trachelectomy was longer than that for radical hysterectomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The other study832 did not provide statistical results.Complication rate/Quality of life: pooled analyses, performed by Han et al.833, of radical vaginal LoE 1- trachelectomy in comparison with radical hysterectomy failed to detect significant differences in intraoperative (five studies799,801,803,808,832, RR $\\mathbf { \\Phi } = \\mathbf { \\Phi } 1 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "9 9$ $\\big ( 9 5 \\% \\quad \\mathrm { C I } \\ = \\ 0 .6 1 { - 6 .2 5 } \\big )$ ) and postoperative complications (four studies801,803,808,832, $\\mathrm { R R } \\ = \\ 0 .3 6$ $[ 9 5 \\% \\mathrm { C I } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1 0 { - } 1 .2 7 ) ]$ ).Intraoperative complications included vascular injury resulting from LN dissection and injury to the bladder or ureter resulting from surgical manipulation of the vagina or abdominal cavity.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In a study describing the quality of life after radical vaginal trachelectomy, Alenxander-Sefre et LoE 2- $a l .^ { 7 9 9 }$ showed that there was a higher incidence of psychological problems ( $1 7 \\%$ versus $1 0 \\%$ ) and dyspareunia in patients after radical vaginal trachelectomy ( $2 0 \\%$ versus $2 \\%$ ).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Oncologic outcomes: based on 21 series70,477,524,791-793,795-820,822-826,834-837, Bentivegna et $a l .^ { 7 9 0 }$ LoE 1- reported positive or close margins $\\cdot < 5 \\mathrm { m m } )$ in $3 \\%$ of patients.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Among patients with FIGO stage IB1 tumours larger than $2 \\ \\mathrm { c m }$ , $1 7 \\%$ of patients had recurrent disease, compared with $4 \\%$ of patients with FIGO stage IB1 tumours $2 \\mathrm { c m }$ or smaller $[ \\mathrm { p } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 0 1 \\$ ).None of the included studies provided the number, locations (inside the tumour or around it), and type (vascular or lymphatic) of LVSI foci.Five per cent of LVSI negative cases with tumours of $2 \\ \\mathrm { c m }$ or smaller had recurrent disease as compared to $7 \\%$ of LVSI positive cases $[ \\mathrm { p } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1 5 ]$ ).Data from four trials801,803,808,832 included in the systematic review performed by Han et al.833 were available to calculate the relative risk for 5-year PFS rate.There was no significant difference in 5-year PFS rate between radical vaginal trachelectomy and radical hysterectomy $\\operatorname { R R } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "9 9$ $( 9 5 \\% \\mathrm { ~ C I } = 0 .9 5 – 1 .0 2 )$ ).The 5-year OS rate, based on three studies803,808,832, did not differ between radical vaginal trachelectomy and radical hysterectomy ( $\\mathrm { R R } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "9 7$ ( $9 5 \\%$ $\\mathrm { C I } =$ 0.93-1.02)).Six original studies477,798,809,810,814,838 not included in the systematic review published by Han et LoE 2- $a l .^ { 8 3 3 }$ have also been identified and revealed that vaginal radical trachelectomy does not increase recurrence rate compared with radical hysterectomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 11.1.3 Abdominal radical trachelectomy Fertility outcomes: Bentivegna et al.750 provided also fertility results, obstetric outcomes, and the managment of infertility in patients with FIGO stage IB submitted to laparotomic radical trachelectomy from twenty-one series291,693,815,824,839-869 (Table 22).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Exclusion for oncologic reasons depriving of FSS management was observed in $1 2 .5 \\%$ of patients.Cervical stenoses were the most common complication likely to impact fertility $( 8 \\% )$ .Several cases of severe intra-abdominal sepsis were reported (tubo-ovarian abscess or intra-abdominal abscess/local peritonitis $\\left( 1 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "7 \\% \\right) .$ ), likely to impact on subsequent fertility, were reported with this surgical approach.The fertility rate in patients submitted to a laparotomic radical trachelectomy was $4 4 \\%$ versus $5 7 \\%$ and $6 5 \\%$ $( \\mathrm { p } < 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 0 1 \\$ in patients treated with a vaginal or a minimally invasive radical trachelectomy (minimally invasive laparoscopy), respectively.Similar pregnancy rates in cases of preservation or ligation of uterine arteries were reported $45 \\%$ versus $4 4 \\%$ , $\\mathrm { ~ p ~ } > 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 5 \\dot { }$ ).Regarding the impact of uterine cerclage on the live birth rate, these rates were, respectively $6 1 \\%$ and $7 0 \\%$ in series mentioning the use or not of a prophylactic cerclage $\\mathrm { ~ ( ~ p ~ > ~ } \\ 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 5 )$ .The prematurity rate was higher in patients undergoing radical trachelectomy by laparotomy as compared to those undergoing vaginal or minimally invasive radical trachelectomy but without any difference on live birth rate (Table 22).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cervical stenoses $( 9 .5 \\% )$ were also the most common complication likely to impact fertility in the systematic review published by Pareja et al.870 (twelve reports of case series291,842,843,846,847,852,853,855,857,858,862,871 and seventeen case reportsNA).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Eighty-five per cent of patients were able to maintain their fertility.Thirty-eight per cent attempted to get pregnant, and $5 9 .3 \\%$ of them were able to conceive.Concerning the minimally invasive radical trachelectomy, Bentivegna et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "750 included 10 series76,819,826,856,867,872-880 evaluating pure laparoscopic surgery and/or robot-assisted laparoscopic surgery.Exclusion for oncologic reasons depriving of FSS management was observed in $7 \\%$ of patients.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "All the teams used a prophylactic cerclage at the end of the procedure.Eight teams preserved the uterine arteries.It should be noted that this information was not mentioned by one team.All but two teams856,873 preserved the uterine arteries (one team856 did not mention these data).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Here again, cervical stenoses were the most common complication likely to impact fertility $( 5 \\% )$ .Cervical erosion was the second most commom complication likely to impact fertility $( 3 .8 \\% )$ .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Another systematic review881 was identified but is not described because (1) it contains no additional studies beyond those already described above and (2) no separate data taking into account the type of radical trachelectomy are described.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "An original study882 not included in the systematic reviews750,881 mentioned above was identified.Among the 34 patients who attempted to conceive after abdominal radical trachelectomy, eight patients achieved pregnancy $( 2 4 \\% )$ .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "All infants were delivered by cesarean section.An original study883 not included in the systematic reviews750,881 mentioned above and LoE 3 evaluating the surgical and obstetrical outcomes of patients who underwent laparoscopic radical trachelectomy was also identified but its results are limited notably by the very small number of patients evaluated.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Perioperative outcomes: a meta-analysis884 of three controlled clinical trials70,803,808 assessed LoE 1 the efficacy and safety of radical trachelectomy and radical hysterectomy for patients with early cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "No difference in blood transfusion ( $\\mathrm { \\Delta } \\mathrm { \\left[ O R \\right] } = 0 .2 9$ $9 5 \\% \\mathrm { C I } = 0 .0 6 { - 1 .3 6 } \\$ )) was reported.The authors could not performed meta-analysis concerning the operative time, blood loss, LNs count, and hospital stay.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In the first trial70, the operative time of radical trachelectomy was significantly longer, but this was not the case in the two other trials803,808.One trial803 provided data concerning the postoperative hospital stay and duration to normal urine residual volumes, both of which were significantly shorter for radical trachelectomy (1 day versus 6 days, $\\mathrm { p } < 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 0 1$ for both).Discordant findings70,808 were observed with respect to the count of LNs removed.Consistent findings were reported in terms of blood transfusion by an original study published LoE 2- by Li et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "885 which is not included in the meta-analysis884 mentioned above.No differences with respect to the operative time, the estimated blood loss, and hospital stay were noted.Complication rate: the meta-analysis884 of three controlled clinical trials70,803,808 mentioned LoE 1- above showed also no significant between radical trachelectomy and radical hysterectomy in terms of intra- and post-operative overall complications ( $\\operatorname { T O R } = 1 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "6 6$ $9 5 \\% \\mathrm { C I } = 0 .1 1 { - 2 5 .2 8 }$ ) and $0 \\mathrm { R } = 0 .5 2$ $( 9 5 \\% \\mathrm { C I } = 0 .1 1 { - 2 .4 8 } )$ , respectively).Compared with radical hysterectomy, radical trachelectomy neither increased nor decreased the risk of postoperative infectious and noninfestious complications $\\mathrm { { ( 0 R = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "4 6 } }$ ( $\\begin{array} { r } { { 1 } 5 \\% \\mathrm { C I } = 0 .1 6 { - 1 .3 } \\hat { \\Omega } } \\end{array}$ 3) and $\\mathrm { O R } = 0 .5 3 \\$ ( $9 5 \\% \\%$ $\\mathrm { C I } = 0 .0 9 .$ - 3.03), respectively).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Fully consistent findings were described by Li et al.885 in terms of intra- and post-operative LoE 2- complications.# LoE 3 Quality of life: the quality of life after radical trachelectomy was described in four identified studies813,886-889.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In the first one813,886, the authors reported that there was a reduction in the proportion of patients who were afraid to have sex, from $8 3 \\%$ to $2 3 \\%$ after surgery at the 12- month assessment.Dyspareunia decreased over time and lessened along with the fear of intercourse.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The mean sexual activity of patients was found to rise from $3 7 \\%$ to $7 0 \\%$ by the 6- month follow-up assessment.The second one887 documented preoperative struggles faced by all young patients in the midst of considering treatment options (radical trachelectomy or radical hysterectomy), and their vulnerability during the immediate postoperative period.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Women choosing radical hysterectomy and those choosing radical trachelectomy demonstrated scores suggestive of depression and distress preoperatively (based on the Center for epidemiologic studies depression scale (CES-D) and the Impact of events scale (IES), respectively).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Measurements of mood, distress, sexual function and quality of life did not differ significantly by surgical type.Both groups had a decline in quality of life and sexual dysfunction postoperatively compared to preoperative baseline measures (as measured by the Functional assessment of cancer therapycervix (FACT-Cx), CES-D, IES, and Female sexual functioning index (FSFI)).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "However, both groups demonstrated adaptive processes over the next 2 years with improvement in scores from the initial postoperative decline.The third identified study888 used several validated questionnaires including the FSFI, the Sexual function-vaginal changes questionnaire, and the EORTC cervical cancer module.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "This study demonstrated that patients undergoing radical vaginal trachelectomy had a significant decline in secual dysfunction and global health status during the 12 months post-treatment.However, despite sexual activity increasing over the follow-up period, the scores never reached those of healthy controls.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Using the FACT-Cx, FSFI, General health-related quality of life (SF-12), MD Anderson symptom inventory, and Satisfaction with decision scale the fourth identified study889 showed that several quality of life, sexual, and functional assessments decline immediately postoperatively after radical trachelectomy, however, most return to baseline measures by 6 months postoperatively.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A persistent decline in emotional well-being was seen up to 4 years after the radical trachelectomy procedure.Oncologic outcomes: after a median follow-time of 31.6 months, the systematic review published by Pareja et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "870 (twelve reports of case series291,842,843,846,847,852,853,855,857,858,862,871 and seventeen case reportsNA) identified a recurrence in $3 .8 \\%$ of patients.Death from cervical cancer after abdominal radical trachelectomy was reported in $0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "4 \\%$ of patients.Bentivegna et al.790 (twenty-eight series291,693,700,824,839,843-847,849-852,855-858,860,862-869,871,890-895) observed a recurrent disease in $5 \\%$ of cases, of which $2 9 \\%$ died.Among at least 167 patients with FIGO stage IB1 tumours specified as measuring $2 { \\cdot } 4 ~ \\mathrm { c m } _ { \\cdot }$ , eight $( 5 \\% )$ had recurrent disease.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The authors provided also data on pure laparoscopic radical trachelectomy (eighteen series76,826,856,867,872-874,877,878,896-902).All except four teams856,873,899,900 preserved the uterine artery, and four874,898,901,902 also used nerve-sparing surgery.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Six per cent of patients had recurrent disease, of whom $1 7 \\%$ had FIGO stage IB1 tumours larger than $2 \\mathrm { c m }$ (Table 24).Only one819,879,880 from the nine series555,819,855,856,879,880,898,903-908 providing data on robot-assisted laparoscopic radical trachelectomy reported a follow-up longer than 24 months.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Four905-908 of them did not report any follow-up.It should be noted that available data suggest that robotassisted laparoscopic radical trachelectomy is still in the feasibility stage with no clear data on specific outcomes or the usefulness of this procedure compared with pure laparoscopic radical trachelectomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "As part of the meta-analysis884 of three controlled clinical trials70,803,808 mentioned above, radical trachelectomy neither increased nor decreased the risk of recurrence ( $\\operatorname { \\mathrm { ~ \\sc ~ O R } } = 1 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "3 8$ ( $9 5 \\%$ $\\mathrm { C I } = 0 .5 8 \\ – 3 .2 8 )$ ), the risk of postoperative mortality ( $\\mathrm { O R } = 1 .1 4$ ( $9 5 \\%$ $\\mathrm { C I } = 0 .4 2 \\cdot 3$ .11)), the 5- year RFS ( $\\mathrm { { O R } } = 1 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1 7 \\$ ( $9 5 \\% \\mathrm { C I } = 0 .5 4 – 2 .5 3 )$ ), and the 5-year OS $\\mathrm { \\Delta O R } = 0 .8 6 \\$ ( $9 5 \\% \\mathrm { C I } = 0 .3 0 { - 2 .4 3 } \\$ ) compared with radical hysterectomy.Here again, Li et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "885 described fully consistent findings with those reported by the meta- LoE 2- analysis884 mentioned above.In the series published by Okugawa et al.882, the relapse rate after abdominal radical trachelectomy was $1 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1 \\%$ with no mortality.# 11.1.4 Neoadjuvant chemotherapy followed by conservative surgery Fertility outcomes: Bentivegna et al.750 reported fertility results and obstetric outcomes from 9 included series547,548,550-552,557-560,693,795,909-911 evaluating NACT followed by conservative surgery (Table 22).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Two surgical procedures were used: a simple trachelectomy/cone resection $( 3 1 \\% )$ and a radical trachelectomy $( 6 9 \\% )$ .When a radical trachelectomy was performed after NACT, all the teams used a prophylactic cerclage at the end of the procedure.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "FSS procedure was abandoned or not retained for oncologic reasons in $8 \\%$ of patients.Cervical stenoses were observed in $8 \\%$ of patients.Among patients who had at least one pregnancy, $4 8 \\%$ and $3 8 \\%$ of patients had respectively undergone a simple cervical resection and a radical trachelectomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The prematurity rate was lower compared with that observed after a vaginal or an abdominal radical trachelectomy ( $1 5 \\%$ versus $3 9 \\%$ and $5 7 \\% ,$ , $\\mathrm { p } < 0 .0 0 1 \\mathrm { ] }$ .Eighty-two per cent of preterm deliveries were related to pPROM.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The reported fertility rate was high in patients who had received NACT before FSS, but it may be due to a very recent series911 that comprised nearly half of the NACT cases reported in the literature identified by Bentivegna et $a l .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "7 5 0$ and included $8 6 \\%$ of patients wishing to become pregnant who had achieved at least one pregnancy.The rate after excluding this recent series was similar to that obtained with the other radical trachelectomy techniques.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "As part of another systematic review, Pareja et al.912 identified 14 reports548-560,913 adressing the use of NACT in patients with early-stage (FIGO stages IB1-IIA) cervical cancer interested in future fertility.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A total of 8 patients did not preserve fertility and among the remaining 65 patients $( 8 9 \\% )$ who preserved fertility after NACT, 20 pregnancies were reported $( 3 0 .7 \\% ) ,$ with 16 deliveries (6 preterm and 10 at term), 2 ongoing pregnancies, 1 ectopic pregnancy, and 3 miscarriages (some women delivered more than one baby).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted that the results described in the systematic reviews750,912 mentioned above have to be interpreted cautiously due to (1) the heterogeneity of NACT regimens used in the included studies, (2) the heterogeneity concerning the type of surgical procedures used after NACT, and (3) the number of patients evaluated (only one study911 has accrued at least 60 patients).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Results from two identified studies914,915 not included in the systematic reviews750,912 mentioned above and evaluating outcomes of fertility and pregnancy in patients with cervical cancer after undergoing NACT are limited notably by the very small number of patients evaluated.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In eight $( 6 7 \\% )$ patients seeking pregnancy after the treatments, four pregancies occurred in three women.# LoE 3 Oncologic outcomes: Bentivegna et al.790 included seventeen series or case reports547-549,551- 556,558-560,693,795,822,896,909,910,913,916,917 assessing NACT to promote fertility preservation in patients with invasive cervical cancer of whom $8 7 \\%$ underwent uterine conservation.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Among the patients with FIGO stage IB1 disease $( 7 5 \\% )$ , $6 1 \\%$ had tumours of $2 { \\cdot } 4 ~ \\mathrm { c m }$ .The most frequently used neoadjuvant regimen was three courses of platinum-based chemotherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Nineteen per LoE 1- cent of patients required adjuvant therapy, with $7 9 \\%$ of them requiring hysterectomy.A recurrent disease was observed in $6 \\%$ of patients who underwent uterine conservation, of whom one third died (Table 24).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Two recurrences $( 3 3 \\% )$ were seen in patients with initial FIGO stage IB2 disease (with residual disease measuring $3 \\mathrm { m m }$ and $1 5 \\mathrm { m m } ^ { \\cdot }$ ), three $( 5 0 \\% )$ in patients with initial FIGO stage IB1 tumours of $2 \\mathrm { c m }$ or larger, and one $( 1 7 \\% )$ in a patient with an initial FIGO stage IB1 tumour smaller than $2 \\mathrm { c m }$ .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The case of a patient with FIGO stage IB2 who exhibited pathological complete regression to LoE 3 NACT, published by Feng et al.915, did not show any recurrent disease 72 months after surgery.# 11.1.5 Other fertility sparing techniques LoE 1- Ovarian preservation: including 5 studies918-922, Jiao et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "923 evaluate the safety of ovarian preservation according to the histological type.The incidence of ovarian metastasis of patients with early-stage adenocarcinoma and squamous cell carcinoma were $2 \\%$ and $0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "4 \\% ,$ respectively ( $\\mathrm { { ( 0 R = 5 .2 7 } }$ $( 9 5 \\% \\mathrm { C I } = 2 .1 4 \\ – 1 3 .4 5$ ).In 1,427 patients with adenocarcinoma or squamous cell carcinoma of the cervix (FIGO stage IIA disease) who underwent hysterectomy, no ovarian recurrences were observed after unilateral or bilateral ovarian preservation in adenocarcinoma patients in the follow-up (30-68 months).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "However, it should be noted that 15 patients with squamous cell carcinoma developed pelvic recurrence.Based of data from six studies919,920,922,924-926, Touhami et al.927 observed that at least one of the following risk factors was present in $9 7 \\%$ of patients with ovarian metastasis from adenocarcinoma of the cervix: age $> 4 5$ years, FIGO stage $> \\mathrm { I B } .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "$ positive LNs, deep stromal invasion, LVSI, corpus invasion, parametrial invasion or tumour size $> 4$ cm.All included FIGO stage IB adenocarcinoma series919-922,925,928 report an incidence of ovarian metastasis under $4 \\%$ , with an overall global incidence of $2 \\%$ .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In 119 patients with adenocarcinoma of the cervix (FIGO stage IIA) included by Touhami et al.927 (five studies919,929-932), none developed an ovarian relapse after ovarian preservation with a mean follow-up time of 56 months.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "An original study933 not included in the systematic review/meta-analysis923,927 mentioned LoE 2- above was also identified.As part of this study evaluating the impact of ovarian preservation on prognosis in women with cervical adenocarcinoma, no significant difference in DFS or OS between women with bilateral salpingo-oophorectomy and ovarian preservation was found.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Ovarian transposition: the available data934-954 evaluating the OT for preserving ovarian function in cervical cancer patients are limited notably due to (1) the very small number of patients included in the majority of identified studies, (2) the wide variation in the type of ovarian transposition surgery performed (bilateral robotic OT, unilateral laparoscopic OT, unilateral laparoscopic OT with contralateral oophorectomy, bilateral laparoscopic OT, unilateral OT via laparotomy, bilateral OT via laparotomy), and (3) the absence of analysis taking into account the type of postoperative treatments performed (vaginal brachytherapy, external radiation therapy, external radiation therapy and vaginal brachytherapy).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The available data investigating the potential risk factors related to the recurrence of cervical cancer following ovarian transposition are also too limited to define a pattern of particular risk factors.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# LoE 3 Uterine transplantation: to date, 11 uterine transplantations955-957 were performed worldwide in patients (only one patient had previously undergone radical hysterectomy for cervical cancer of an unspecified stage).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Of these, seven maintained their reproductive potential, with viable transplanted uteri and regular menstrual cycles.All the women received immunosuppression to prevent rejection of the transplant.Their uterine artery blood flow was unchanged.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In september 2014, Brännström et al.958 reported the first live birth (with normal weight for gestational age (31 weeks and 5 days)) after uterus transplantion, in a patient suffering from Rokytanski syndrome, after in vitro fertilization treatment of both the patient and her partner.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Pregnancy had no complications, with a benign fetal evaluation and uneventful throughout pregnancy.# 11.1.6 Vaginal progesterone prophylaxis Past history of spontaneous preterm birth: as part of a systematic review959 assessing the benefits and harms of progesterone for the prevention of preterm birth for women considered to be at increased risk of preterm birth and including eleven $\\operatorname { R C T s 9 6 0 - 9 9 4 }$ , there was a statistically significant reduction in perinatal mortality overall for women administered progesterone during pregnancy (Table 25).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "There were also significant differences in preterm birth less than 34 weeks’ gestation, infant birthweight less than $^ { 2 , 5 0 0 } \\ \\mathrm { g } ,$ use of assisted ventilation, necrotizing enterocolitis, neonatal death, NICU admission, and pregnancy prolongation in weeks between progesterone and placebo.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "However, for infant outcomes Apgar score $< 7$ at 5 minutes, respiratory distress syndrome, intrauterine fetal death, intraventricular haemorrhage (all grades, grade III or IV), periventricular leucomalacia, retinopathy of prematurity, neonatal sepsis, patent ductus arteriosus, intrauterine fetal death, neonatal length of hospital stay, threatened preterm labour, spontaneous vaginal birth, adverse drug reaction, caesarean birth, use of antenatal corticosteroids, the use of antenatal tocolysis, developmental delay, intellectual impairment, motor impairment, visual impairment, hearing impairment, cerebral palsy, learning difficulties, height less than $5 ^ { \\mathrm { t h } }$ centile, weight les than the $5 ^ { \\mathrm { t h } }$ centile, infant weight at 6, 12 and 24 months’ follow-up, ingant length at 6, 12, and 24 months’ follow-up, or infant head circumference at 6, 12 and 24 months’ follow-up, there were no statistically significant differences identified.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted also that the authors found no differential effect on the majority of outcomes examined when considering route of administration of progesterone (intramuscular, vaginal or oral).Women with a short cervix identified on ultrasound: the systematic review959 mentioned above provided also data on the benefits and harms of progesterone for women with a short cervix identified on ultrasound (four $\\mathrm { R C T s ^ { 9 9 5 - 1 0 0 0 } }$ ).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Women administered progesterone were significantly less likely to have a preterm birth at less than 34 weeks’ gestation, less than 28 weeks’ gestation, and more likely to experience the adverse drug reaction urticaria (Table 26).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "For perinatal death, preterm less than 37 weeks’ gestation, infant birthweifht less than $2 { , } 5 0 0 \\ \\mathrm { g } ,$ respiratory distress syndrome, Apgar score less than 7 at 5 minutes, need for assisted ventilation, intraventricular haemorrhage (all grades, and grades III or IV), periventricular leucomalacia, retinopathy of prematurity, necrotizing enterocolitis, neonatal sepsis, intrauterine fetal death, neonatal death, NICU admission, threatened preterm labour, pPROM, adverse drug reactions (any, injection site, nausea), pregnancy prolongation, caesarean section, or antenatal tocolysis, there were no statistically significant differences identified.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The authors found no differential effect on the outcomes examined (periventricular leucomalacia, retinopathy of prematurity, and necrotizing enterocolitis) when considering route of administration of progesterone (intramuscular versus vaginal) (Table 26).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Subgroup analyses by total cumulative dose of progesterone $\\mathrm { ~ \\textbar { ~ } { ~ } ~ } 5 0 0 \\mathrm { ~ m g }$ versus $> 5 0 0 ~ \\mathrm { m g } )$ were also performed.No differential effect for the two outcomes examined was reported (periventricular leucomalacia: $\\operatorname { R R } = 1 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "4 9$ ${ \\displaystyle [ 9 5 \\% ~ } \\mathrm { C I } = 0 .1 3 { - } 1 6 .8 7$ ) and NICU admission: $\\mathrm { R R } = 1 .0 9 \\$ ( $9 5 \\% \\mathrm { C I } = 0 .7 2 \\cdot$ 1.65)).It should be noted that the authors could not assess the effect of gestational age at commencing therapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Women with multiple pregnancy: ten RCTs972,1001-1022 were included in the meta-analysis performed by Dodd et al.959.For women administered progesterone during pregnancy, perinatal death, preterm birth less than 34 weeks’ gestation, preterm birth less than 37 weeks’ or 28 weeks’ gestation, infant birthweight less than $_ { 2 , 5 0 0 \\ \\mathrm { g } , }$ Apgar score less than 7 at 5 minutes, respiratory distress syndrome, need for ventilation, intraventricular haemorrhage, periventricular leucomalacia, retinopathy of prematurity, chronic lung disease, necrotizing enterocolitis, neonatal death, NICU admission, pPROM, adverse drug reaction, caesarean section, spontaneous birth, assisted birth, satisfaction with the therapy, antenatal tocolysis or antenatal corticosteroids, there were no statistically significant differences identified when compared with placebo (Table 27, Table 28).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "No differential effect was found on the majority of outcomes examined when considering route of administration of progesterone (intramuscular versus vaginal).However, for spontaneous birth, infant birthweight less than $_ { 2 , 5 0 0 \\mathrm { ~ g ~ } }$ and NICU admission, the subgroup analyses indicated a differential effect between the two routes of administration (Table 27).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted that for two outcomes, some of the subgroups contained only one trial.No effect of time of commencement of supplementation (prior to 20 weeks’ gestation versus after 20 weeks’ gestation) on preterm birth less than 37 weeks’ gestation $\\mathrm { { ( R R = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "9 9 } }$ ( $9 5 \\%$ $_ { 0 } ^ { \\prime } ~ { \\bf C I } = 0 .8 2 \\cdot$ 1.20)), neonatal death $\\mathrm { ( R R = 0 .9 5 }$ $\\left( 9 5 \\% \\mathrm { ~ C I } = 0 .4 7 – 1 .9 3 \\right)$ ), and NICU admission ( $\\mathrm { R R } = 1 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1 6$ ( $9 5 \\%$ CI = 0.95-1.43)) was reported.Subgroup analyses by total weekly cumulative dose of progesterone ( $\\leq 5 0 0 ~ \\mathrm { m g }$ versus $> 5 0 0$ mg) were also performed.No differential effect was observed for the 8 outcomes examined (perinatal death, preterm birth less than 34 weeks’ gestation, antenatal tocolysis, preterm birth less than 37 weeks’ gestation, respiratory distress syndrome, fetal death, infant birthweight less than $2 { , } 5 0 0 \\mathrm { g } ,$ and NICU admission).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Women following presentation with threatened preterm labour: the systematic review959 mentioned above provided also data on the benefits and harms of progesterone for women following presentation with threatened preterm labour (five RCTs1023-1032).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "For women administered progesterone during pregnancy, when compared with placebo, there was a significant reduction in the risk of infant birthweight less than $2 { , } 5 0 0 \\mathrm { g }$ .However, there were no statistically significant differences for any of the other outcomes analysed (perinatal death, preterm birth less than 34 weeks’ gestation, preterm birth less than 37 weeks’ gestation, respiratory distress syndrome, intraventricular haemorrhage (grades III or IV), periventricular leucomalacia, need for mechanical ventilation, necrotizing enterocolitis, neonatal sepsis, fetal death, neonatal death, neonatal length of hospital stay, pregnancy prolongation, spontaneous vaginal birth, caesarean section, and use of tocolysis) (Table 29).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "No differential effect on some of the outcomes examined was found when considering route of administration of progesterone (intramuscular versus vaginal).However, for pregnancy prolongation and preterm birth less than 37 weeks’ gestation, the subgroup analyses indicated a differential effect between the different routes of administration.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted that in both analyses the subgroups contained only one trial.Subgroup analyses by total weekly cumulative dose of progesterone $\\leq 5 0 0 ~ \\mathrm { m g }$ versus $> 5 0 0$ mg) were also performed.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "No differential effect was observed for the 5 outcomes examined (pregnancy prolongation, preterm birth less than 37 weeks’ gestation, respiratory distress syndrome, neonatal sepsis, and neonatal death).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted that the authors could not assess the effect of gestational age at commencing therapy.Women at risk of preterm birth: including women at risk of preterm birth (because of previous LoE 1- spontaneous birth (≤ 34 weeks and à days of gestation, or a cervical length $\\leq 2 5 \\ \\mathrm { m m }$ , or because of a positive fetal fibronectin test combined with other clinical risk factors for preterm birth (any one of a history in a previous pregnancy of preterm delivery birth, second trimester loss, preterm premature fetal membrane rupture, or a history of a cervical procedure to treate abnormal smears)), a RCT1033 not included in the systematic review959 mentioned above revealed that vaginal progesterone was not associated with reduced risk of fetal death or birth before 34 weeks and 0 days gestation, or composite neonatal adverse outcomes (a composite of death, brain injury, or bronchopulmonary dysplasia) and had no long-term benefit or harm on outcomes in children at 2 years of age (Bayley-III cognitive composite score at 22-26 months of choronological age).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted that no subgroup analyses taking into account the type of risk of preterm birth specifically are available.# 11.1.7 Cervical stitch (cerclage) Singleton pregnancy: Alfirevic et al.1034 assessed whether the use of cervical stitch in singleton pregnancy at high risk of pregnancy loss based on a woman’s history and/or ultrasound finding of “short cervix” improves subsequent obstetric care and fetal outcome.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Compared with expectant management (no treatment, nine studies1035-1075), the cerclage was associated with a significant reduction in preterm births consistent across all gestation time points and all clinical subgroups.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The cerclage was also associated with higher caesarean section rates (elective and emergency), and higher rates of pyrexia.Although there is no conclusive evidence of a difference between cerclage and expectant management (no treatment), it should be noted that there were fewer perinatal deaths in the cerclage group (RR $= 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "7 8$ ( $9 5 \\% \\mathrm { C I } = 0 .6 1 – 1 .0 0$ )).No conclusive evidence of a difference between the two groups was also reported with respect to serious neonatal morbidity, stillbirths, neonatal deaths before discharge, miscarriages, serious intracranial pathology (intraventricular hemorrhage or periventricular leucomalacia), serious respiratory morbidity (respiratory distress syndrome or oxygen dependency after 28 days of life), necrotising enterocolitis, retinopathy of prematurity, maternal side effects (vaginal discharge, bleeding, pyrexia not requiring antibiotics), pPROM, and chorioamnionitis (Table 30).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "There was no evidence of any important differences across all prespecified clinical subgroups (history-indicated, ultrasound-indicated).The sole included study1076 comparing cerclage with weekly intramuscular injection of $1 7 \\ \\alpha \\cdot$ hydroxyprogesterone caproate in women with a short cervix detected by transvaginal ultrasound scan was interrupted after 3 years of recruitment because interim analysis did not reveal any obvious differences in obstetric and neonatal outcomes.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Multiple pregnancy: Rafael et al.1077 assessed whether the use of cervical stitch in multiple pregnancy at high risk of pregnancy loss based on just the multiple gestation (history-indicated cerclage), or the ultrasound findings of “short cervix” improves subsequent obstetric and perinatal outcomes.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Compared with expectant management (no treatment, five studies1035-1041,1043,1044,1047-1050,1068- 1070,1072-1074,1078-1080), there is no evidence that cerclage is an effective intervention for preventing preterm birth and reducing perinatal deaths or neonatal morbidity.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "No conclusive evidence of a difference between the two groups was also reported with respect to serious neonatal morbidity, stillbirths, neonatal deaths, mean gestational age at delivery, low birthweight $\\left( < \\ 2 , 5 0 0 \\ \\mathrm { g } \\right)$ , very low birthweight $\\mathrm { ( < ~ 1 , 5 0 0 ~ g ) }$ , respiratory distress syndrome, intraventricular hemorrhage, sepsis, NICU admission, caesarean section (elective and emergency), or maternal side-effects (vaginal discharge, bleeding, pyrexia not requiring antibiotics) (Table 31).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Data relative to the differences between prespecified subgroups have to be interpreted caustiously due to the low number of trials and/or substantial heterogeneity and subgroup differences.It should also be noted that no study comparing cervical stitch versus any other preventative therapy (e.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "g.progesterone) in multiple gestations was included by the authors.# 11.2 Previous initiatives Nine previous initiatives419,420,422-424,529,531,1081-1083 presenting guidelines for fertility sparing treatment were identified.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 11.3 Development group comments In highly industrialized countries, FST is gaining more and more importance, since more than $4 0 \\%$ of early stage invasive cervical carcinomas occur in patients under the age of 44 and women’s age at first pregnancy/delivery increases.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Given the possible spectrum of FST patient’s councelling and treatment should only be done in centers, which can offer all kinds of FST (sentinel and full pelvic lymphadenectomy, conisation, simple trachelectomy, radical trachelectomy, FST following NACT, comprehensive staging in patients with necessity to abandone FST).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Recurrence rate after conisation as FST ranges from $0 \\%$ to $1 3 \\%$ .However, in a considerable percentage of patients repeated conisation is necessary to reach aim of FST, sometimes 3 times.Of note conisation itself is associated with higher likelyhood of PROM and/or preterm delivery.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "To date, four different approaches are establised for radical trachelectomy.Most data with longest follow-up exist for radical vaginal trachelectomy, less for abdominal radical trachelectomy, few for total laparoscopic radical trachelectomy and only small series for robotic-assisted radical trachelectomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Techniques for different approaches are standardized and permanent cerclage should be placed in all patients.However, best material for permanent cerclage is undecided.Coverage of residual tumour with adequate vaginal cuff and avoidance of uterine manipulator use seems to be advantageous.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It is undecided which of primary radical trachelectomy or NACT followed by FST is superior to the other in women with proven cervical cancer $> 2 \\ \\mathrm { c m }$ .Rate of possible fertility preserving surgery and obstetrical outcomes seems superior after NACT compared to upfront radical trachelectomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "However, there is a couple of unclear issues in the concept of NACT: Should lymphadenectomy be performed as staging procedure before NACT?Is radical trachelectomy superior to simple trachelectomy after good response to NACT?",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Is radical trachelectomy superior to simple trachelectomy after good response to NACT? What is the best management in suboptimal responders? Which is the best NACT regimen?No recommendation can be provided for earliest possible realization of childbearing following FST.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "After finishing of wound healing pregnancy seems possible, also use of in vitro fertilisation techniques.Radical trachelectomy inherently has increased risk of premature delivery and second trimester miscarriage due to PROM and/or ascending infection.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "These problems are probably associated with shortened remaining cervix and/or permanent cerclage and represent major challenges in obstetrical management of women following trachelectomy.Various preventive methods can be discussed with the patient (e.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "g.regular measurement of vaginal pH- value, laparoscopic placement of cerclage, bed-rest and abstain from sexual intercourse, sick note, progesteron application, etc.).Routine hysterectomy following FST and finished family planning is not generally recommended because it does not seem to increase oncologic safety despite limited available data.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Secondary hysterectomy should only applied in patients with recurrent clinical symptoms such as dysmenorrhoea, dyspareunia, vaginal discharge, irregular bleeding or repeated cevical stenosis.Repeated abnormal Pap test after FST is frequently observed with lower clinical relevance.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Patient’s strong wish can be another reason for secondary hysterectomy.# 11.4 Guidelines Before starting FST, consultation at a fertility center is recommended.FST should exclusively be undertaken in gynecologic-oncological centers with comprehensive expertise in this kind of oncologic therapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "For patients who consider FST, prognostic factors, clinical staging, and preoperative workup do not differ from those who do not consider this (see above).Every woman with a desire to spare fertility and histologically proven squamous cell carcinoma or usual-type (HPV-related) adenocarcinoma equal to or less than $2 \\ \\mathrm { c m }$ of the largest diameter should be counseled about the possibility of FST.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "This consultation should encompass the risk of FST abandonment if there are positive margins or LN involvement and oncologic and obstetric risks related to this type of management.FST should not be recommended for rare histological subtypes of cervical cancer including neuroendocrine carcinomas and non-HPV-related adenocarcinomas (except for adenoid basal carcinoma), which tend to exhibit aggressive behavior.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Expert sonography and/or pelvic MRI are recommended imaging tests to measure remaining (after cone biopsy) cervical length and noninvolved cervical length.However, no imaging system can exactly predict the extent of necessary local resection in order to reach sound margins with adequate safety distance.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Negative PLN status is the precondition for any FST.Therefore, PLN (SLN) staging should always be the first step in each FST procedure.Identification of SLN and its ultrastaging is highly recommended because it increases staging accuracy, namely, the identification of micrometastases and small macrometastases.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The involvement of suspicious LNs should be confirmed by histology.Intraoperative assessment of LN status is highly recommended.All SLNs from both sides of the pelvis or any suspicious LNs should be sent for frozen section.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "If bilateral SLN is not detectable, intraoperative assessment of PLNs should be considered (see Management of stages T1b1/T2a1).LN staging is not indicated in stage T1a1 LVSI negative.In case of intraoperatively proven lymph node involvement, fertility-sparing surgery should be abandoned, and the patient referred to definitive chemoradiotherapy (see above).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The specific aim of fertility-sparing surgery must be the resection of invasive tumor with adequate free margins and preservation of the upper part of the cervix.Intraoperative frozen section is a reliable way of assessing the upper resection margin in trachelectomy specimen and should be considered.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Conization and simple trachelectomy are adequate fertility sparing procedures for stages T1a1 and T1a2, LN-negative, LVSI-negative patients.Radical trachelectomy (type A) can be considered for stages T1a1 and T1a2, LN-negative, LVSIpositive patients.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Conization or simple trachelectomy is an option.Radical trachelectomy (type B) should be performed for patients with cervical cancer stage T1b1 equal to or less than $2 \\mathrm { c m }$ of the largest diameter, LN-negative, $\\mathrm { \\ L V S I \\pm }$ Intraoperative placement of permanent cerclage should be performed during simple or radical trachelectomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "FST in patients with tumors greater than $2 \\mathrm { c m }$ cannot be recommended and is considered as an experimental approach.In more advanced cases, different propositions for fertility preservation should be discussed.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The goal of the fertility preservation should be to offer the most efficient approach related to the legal aspects of the country while not increasing the oncological risk.Any pregnancy following FST should be considered as a high-risk pregnancy, and delivery should be performed in a perinatal center.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Following simple or radical trachelectomy with its inherent placement of a permanent cerclage delivery can be performed only by cesarean section.Routine hysterectomy after finishing fertility plans is not necessary.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Table 22.Fertility outcomes published by Bentivegna et $\\mathbf { \\Delta } _ { a l } 7 5 0$ according to fertility-sparing surgery procedures <html><body><table><tr><td>Parameter</td><td>Simple trachelectomy</td><td>Dargent</td><td colspan=\"2\">Radical trachelectomy</td><td>NACT</td></tr><tr><td></td><td>/cone resection</td><td>procedure</td><td>Laparotomy</td><td>Mini invasive</td><td></td></tr><tr><td>N</td><td>200</td><td>1,205</td><td>643</td><td>292</td><td>148</td></tr><tr><td> Pregnancies</td><td>103</td><td>499</td><td>175</td><td>74</td><td>93</td></tr><tr><td>Fetal loss (1st trimester)</td><td>9</td><td>67</td><td>18</td><td>15</td><td>12</td></tr><tr><td>Fetal loss (2nd trimester)</td><td>5</td><td>34</td><td>8</td><td>2</td><td>5</td></tr><tr><td> Fetal loss (1st or 2nd trimester)</td><td>0</td><td>0</td><td>11</td><td>0</td><td>0</td></tr><tr><td>Interruption-abortion</td><td>2</td><td>21</td><td>1</td><td>0</td><td>0</td></tr><tr><td>Ectopic pregnancy</td><td>1</td><td>6</td><td>0</td><td>0</td><td>1</td></tr><tr><td> Ongoing pregnancy</td><td>14</td><td>18</td><td>17</td><td>7</td><td>4</td></tr><tr><td>Preterm delivery (< 36 WG)</td><td>8</td><td>120</td><td>59</td><td>25</td><td>11</td></tr><tr><td>between 22 and 28 WG</td><td>1</td><td>11</td><td>8</td><td>6</td><td>2</td></tr><tr><td>between 29 and 33 WG</td><td>3</td><td>25</td><td>15</td><td>5</td><td>5</td></tr><tr><td>between34 and 36 WG</td><td>0</td><td>24</td><td>26</td><td>12</td><td>2</td></tr><tr><td>undetermined or other cutoff</td><td>4</td><td>60</td><td>10</td><td>2</td><td>2</td></tr><tr><td>Pregnancy rate</td><td>22/39 (56%)</td><td>241/424 (57%)</td><td>135/310 (44%)</td><td>57/87 (65%)</td><td>60/78 (77%)</td></tr><tr><td>Live birth rate</td><td>51/69 (74%)</td><td>308/460 (67%)</td><td>120/175 (68%)</td><td>50/64 (78%)</td><td>71/93 (76%)</td></tr><tr><td>Prematurity rate</td><td>8/51 (15%)</td><td>113/285 (39%)</td><td>59/104 (57%)</td><td>25/50 (50%)</td><td>11/71 (15%)</td></tr></table></body></html> NACT neoadjuvant chemotherapy, WG weeks gestation Table 23.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Pooled data published by Kyrgiou et $\\mathbf { \\Delta } _ { a l .7 5 8 }$ on the obstetric outcomes after LLETZ, laser conisation, laser ablation and CKC <html><body><table><tr><td>Obstetric outcomes</td><td colspan=\"2\">LLETZ</td><td colspan=\"2\">Laser conisation</td><td colspan=\"2\">Laser ablation</td><td colspan=\"2\">CKC</td></tr><tr><td></td><td>RR</td><td>95% CI</td><td>RR</td><td>95% CI</td><td>RR</td><td>95% CI</td><td>RR</td><td>95% CI</td></tr><tr><td>Preterm delivery (<37 weeks)</td><td>1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "70</td><td>1.24-2.35</td><td>1.71</td><td>0.93-3.14</td><td>0.87</td><td>0.63-1.20</td><td>2.59</td><td>1.80-3.72</td></tr><tr><td>Low birthweight (< 2,500 g)</td><td>1.82</td><td>1.09-3.06</td><td>1.23</td><td>0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "39-3.94</td><td>0.84</td><td>0.45-1.58</td><td>2.53</td><td>1.19-5.36</td></tr><tr><td>Caesarean delivery</td><td>0.88</td><td>0.71-1.09</td><td>1.16</td><td>0.64-2.09</td><td>0.79</td><td>0.49-1.25</td><td>3.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "17</td><td>1.07-9.40</td></tr><tr><td>Precipitous delivery (< 2 h)</td><td>1.26</td><td>0.75-2.11</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>pPROM</td><td>2.69</td><td>1.62-4.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "46</td><td>2.18</td><td>0.77-6.16</td><td>1.23</td><td>0.56-2.70</td><td></td><td></td></tr><tr><td>NICU admission</td><td>1.25</td><td>0.93-1.67</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Perinatal mortality</td><td>3.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "40</td><td>0.62-18.63</td><td>8.00</td><td>0.91-70.14</td><td>0.67</td><td>0.11-3.96</td><td>1.89</td><td>0.77-4.65</td></tr></table></body></html> CI confidence interval, CKC cold knife conisation, LLETZ large loop excision of the transformation zone, NICU neonatal intensive care unit, pPROM preterm spontaneous rupture of membranes, RR relative risk Table 24.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Oncologic outcomes published by Bentivegna et al.790 according to fertility-sparing surgery procedures <html><body><table><tr><td>Parameter</td><td>Simple trachelectomy</td><td>Dargent</td><td colspan=\"3\">Radical radical trachelectomy</td><td>NACT</td></tr><tr><td></td><td>/coneresection</td><td>procedure</td><td>Laparotomic</td><td>laparoscopic</td><td>Robot-assisted</td><td></td></tr><tr><td>N</td><td>230</td><td>1,364</td><td>660</td><td>238</td><td>89</td><td>99</td></tr><tr><td>FIGO stage</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>IA</td><td>not included</td><td>316</td><td>153</td><td>55</td><td>25</td><td>0</td></tr><tr><td> IB1 (all)</td><td>228</td><td>1,065</td><td>559</td><td>215</td><td>54</td><td>85</td></tr><tr><td>IB1 (> 2 cm)</td><td>0</td><td>≥84</td><td>≥167</td><td>≥42</td><td>unknown</td><td>≥52</td></tr><tr><td>IB2</td><td>0</td><td>3</td><td>19</td><td>2</td><td>1</td><td>25</td></tr><tr><td>IIA</td><td>0</td><td>9</td><td>4</td><td>1</td><td>0</td><td>3</td></tr><tr><td>Tumour type</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Squamous-cell carcinoma</td><td>60</td><td>892</td><td>549</td><td>167</td><td>37</td><td>70</td></tr><tr><td>Adenocarcinoma</td><td>25</td><td>432</td><td>168</td><td>50</td><td>29</td><td>41</td></tr><tr><td> Other, mixed, or unknown</td><td>157</td><td>199</td><td>44</td><td>35</td><td>35</td><td>3</td></tr><tr><td>LVSI positive</td><td>≥71</td><td>401</td><td>≥198</td><td>≥52</td><td>≥5</td><td>nr</td></tr><tr><td>Recurrent disease</td><td>4</td><td>58</td><td>31</td><td>15</td><td>2</td><td>6-7</td></tr><tr><td>Died from disease</td><td>0</td><td>24</td><td>9</td><td>3</td><td>0</td><td>2</td></tr></table></body></html> LVSI lymp-vascular space involvement, NACT neoadjuvant chemotherapy, nr not reported Table 25.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Pooled data published by Dodd et $\\mathbf { \\Delta } _ { a l } .\\mathbf \\{ \\mathcal { I } \\Xi ^ { 5 9 } \\$ on the effectiveness and safety of progesterone for preventing preterm birth in women with a past history of spontaneous preterm birth compared to placebo/no treatment <html><body><table><tr><td>Parameter</td><td>Progesterone versus placebo</td><td>Parameter</td><td>Progesterone versus placebo</td></tr><tr><td> Perinatal mortality</td><td></td><td>Preterm birth (<34 weeks)</td><td></td></tr><tr><td>Intramuscular</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "41 (95% CI = 0.23-0.73)</td><td> Intramuscular</td><td>not estimable</td></tr><tr><td>Vaginal</td><td>RR = 0.67 (95% CI = 0.34-1.29)</td><td>Vaginal</td><td>RR = 0.21 (95% CI= 0.10-0.44)</td></tr><tr><td>Oral</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "43 (95% CI = 0.12-1.59)</td><td>Oral</td><td>RR = 0.59 (95% CI = 0.39-0.90)</td></tr><tr><td>Total</td><td>RR = 0.50 (95% CI = 0.33-0.75)</td><td>Total</td><td>RR = 0.31 (95% CI= 0.14-0.69)</td></tr><tr><td>Preterm birth (<37 weeks)</td><td></td><td> Threatened preterm labour</td><td></td></tr><tr><td> Intramuscular</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "62 (95% CI = 0.52-0.75)</td><td> Intramuscular</td><td>RR = 1.17 (95% CI = 0.73-1.87)</td></tr><tr><td>Vaginal</td><td>RR = 0.52 (95% CI = 0.29-0.92)</td><td>Vaginal</td><td>RR = 0.62 (95% CI = 0.35-1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "11)</td></tr><tr><td>Oral</td><td>RR = 0.46 (95% CI = 0.19-1.11)</td><td>Oral</td><td>not estimable</td></tr><tr><td>Total </td><td>RR = 0.55 (95% CI = 0.42-0.74)</td><td>Total</td><td>RR = 0.87 (95% CI = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "47-1.62)</td></tr><tr><td>Spontaneous vaginal delivery</td><td></td><td>Caesarean section</td><td></td></tr><tr><td> Intramuscular</td><td>Not estimable</td><td> Intramuscular</td><td>RR = 0.94 (95% CI= 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "68-1.30)</td></tr><tr><td>Vaginal</td><td>RR = 1.07 (95% CI = 0.97-1.18)</td><td>Vaginal</td><td>RR = 1.01 (95% CI = 0.79-1.30)</td></tr><tr><td>Oral</td><td> Not estimable</td><td>Oral</td><td>not estimable</td></tr><tr><td>Total</td><td>RR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "07 (95% CI = 0.97-1.18)</td><td>Total</td><td>RR = 0.98 (95% CI = 0.81-1.20)</td></tr><tr><td>Antenatal corticosteroids</td><td></td><td> Antenatal tocolysis</td><td></td></tr><tr><td>Intramuscular</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "87 (95% CI = 0.58-1.30)</td><td>Intramuscular</td><td>RR = 1.12 (95% CI = 0.73-1.72)</td></tr><tr><td>Vaginal</td><td>RR = 0.95 (95% CI = 0.72-1.26)</td><td>Vaginal</td><td>RR = 1.10 (95% CI = 0.70-1.74)</td></tr><tr><td>Oral</td><td>not estimable</td><td>Oral</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "75 (95% CI = 0.42-1.35)</td></tr><tr><td>Total</td><td>RR = 0.92 (95% CI = 0.73-1.16)</td><td>Total</td><td>RR = 1.03 (95% CI= 0.78-1.35)</td></tr><tr><td>Infant birthweight (< 2,500 g)</td><td></td><td>Respiratory distress syndrome</td><td></td></tr><tr><td> Intramuscular</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "63 (95% CI = 0.49-0.81)</td><td> Intramuscular</td><td>RR = 0.63 (95% CI = 0.38-1.04)</td></tr><tr><td>Vaginal</td><td>RR = 0.22 (95% CI = 0.07-0.74)</td><td>Vaginal</td><td>RR = 0.92 (95% CI = 0.59-1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "43)</td></tr><tr><td>Oral</td><td>not estimable</td><td>Oral</td><td>RR = 0.10 (95% CI= 0.03-0.30)</td></tr><tr><td>Total</td><td>RR = 0.58 (95% CI = 0.42-0.79)</td><td>Total</td><td>RR = 0.45 (95% CI = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "17-1.16)</td></tr><tr><td>Use of assisted ventilation</td><td></td><td>Preiventricular leucomalacia</td><td></td></tr><tr><td>Intramuscular</td><td>RR = 0.59 (95% CI = 0.35-1.01)</td><td>Intramuscular</td><td>not estimable</td></tr><tr><td>Vaginal</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "24 (95% CI = 0.07-0.81)</td><td>Vaginal</td><td>RR = 3.13 (95% CI = 0.13-75.52)</td></tr><tr><td> Oral</td><td>RR = 0.11 (95% CI = 0.01-1.92)</td><td>Oral</td><td>not estimable</td></tr><tr><td>Total</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "40 (95% CI = 0.18-0.90)</td><td>Total</td><td>RR = 3.13 (95% CI = 0.13-75.52)</td></tr><tr><td>Intraventricular haemorrhage (all grades)</td><td></td><td>Intraventricular haemorrhage (grades III or IV)</td><td></td></tr><tr><td> Intramuscular</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "25 (95% CI = 0.08-0.82)</td><td> Intramuscular</td><td>RR = 2.52 (95% CI = 0.12-52.09)</td></tr><tr><td>Vaginal</td><td>RR = 1.31 (95% CI = 0.46-3.77)</td><td>Vaginal</td><td>RR = 0.98 (95% CI = 0.06-15.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "55)</td></tr><tr><td>Oral</td><td>not estimable</td><td>Oral</td><td>not estimable</td></tr><tr><td>Total</td><td>RR = 0.70 (95% CI = 0.20-2.46)</td><td>Total</td><td>RR = 1.59 (95% CI = 0.21-11.75)</td></tr><tr><td> Retinopathy of prematurity</td><td></td><td>Necrotising enterocolitis</td><td></td></tr><tr><td>Intramuscular</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "50 (95%CI = 0.15-1.69)</td><td> Intramuscular</td><td>RR = 0.06 (95% CI= 0.00-1.03)</td></tr><tr><td>Vaginal</td><td>not estimable</td><td>Vaginal</td><td>RR = 0.53 (95% CI = 0.15-1.92)</td></tr><tr><td>Oral</td><td>not estimable</td><td>Oral</td><td>not estimable</td></tr><tr><td>Total</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "50 (95%CI = 0.15-1.69)</td><td>Total</td><td>RR = 0.30 (95% CI= 0.10-0.89)</td></tr><tr><td>Neonatal sepsis</td><td></td><td>Patent ductus arteriosus</td><td></td></tr><tr><td> Intramuscular</td><td>RR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "13 (95% CI= 0.35-3.59)</td><td> Intramuscular</td><td>RR = 0.44 (95% CI = 0.16-1.18)</td></tr><tr><td>Vaginal</td><td>RR = 0.13 (95% CI = 0.02-1.01)</td><td>Vaginal</td><td>not estimable</td></tr><tr><td>Oral</td><td>not estimable</td><td>Oral</td><td>not estimable</td></tr><tr><td>Total</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "42 (95% CI = 0.08-2.23)</td><td>Total</td><td>RR = 0.44 (95% CI = 0.16-1.18)</td></tr><tr><td>Intrauterine fetal death</td><td></td><td> Neonatal death</td><td></td></tr><tr><td> Intramuscular</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "49 (95% CI = 0.14-1.69)</td><td> Intramuscular</td><td>RR = 0.38 (95% CI = 0.17-0.87)</td></tr><tr><td>Vaginal</td><td>RR = 1.22 (95% CI = 0.33-4.51)</td><td>Vaginal</td><td>RR = 0.53 (95% CI = 0.24-1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "18)</td></tr><tr><td> Oral</td><td>not estimable</td><td>Oral</td><td>RR = 0.43 (95% CI = 0.12-1.59)</td></tr><tr><td>Total</td><td>RR = 0.66 (95% CI = 0.26-1.69)</td><td>Total</td><td>RR = 0.45 (95% CI = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "27-0.76)</td></tr></table></body></html> CI confidence interval, RR risk ratio Pooled data published by Dodd et al.959 on the effectiveness and safety of progesterone for preventing preterm birth in women with a past history of spontaneous preterm birth compared to placebo/no treatment (continued) <html><body><table><tr><td>Parameter</td><td>Progesterone versus placebo</td><td>Parameter</td><td>Progesterone versus placebo</td></tr><tr><td> Development delay</td><td></td><td>Intellectual impairment</td><td></td></tr><tr><td> Intramuscular</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "85 (95% CI = 0.36-2.04)</td><td> Intramuscular</td><td>RR = 1.29 (95% CI = 0.05-31.34)</td></tr><tr><td>Vaginal</td><td>not estimable</td><td>Vaginal</td><td>not estimable</td></tr><tr><td>Oral</td><td>not estimable</td><td> Oral</td><td> not estimable</td></tr><tr><td>Total</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "85 (95% CI = 0.36-2.04)</td><td>Total</td><td>RR =1.29 (95% CI= 0.05-31.34)</td></tr><tr><td>Motor impairment</td><td></td><td>Visual impairment</td><td></td></tr><tr><td> Intramuscular</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "64 (95% CI= 0.11-3.76)</td><td> Intramuscular</td><td>RR = 0.85 (95% CI = 0.16-4.57)</td></tr><tr><td>Vaginal</td><td>not estimable</td><td>Vaginal</td><td>not estimable</td></tr><tr><td>Oral</td><td>not estimable</td><td> Oral</td><td>not estimable</td></tr><tr><td>Total</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "64 (95% CI = 0.11-3.76)</td><td>Total</td><td>RR = 0.85 (95% CI= 0.16-4.57)</td></tr><tr><td>Hearing impairment</td><td></td><td>Cerebral palsy</td><td></td></tr><tr><td> Intramuscular</td><td>RR = 0.34 (95% CI = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "09-1.24)</td><td> Intramuscular</td><td>RR = 0.14 (95% CI = 0.01-3.48)</td></tr><tr><td>Vaginal</td><td>not estimable</td><td>Vaginal</td><td>not estimable</td></tr><tr><td> Oral</td><td>not estimable</td><td> Oral</td><td>not estimable</td></tr><tr><td>Total</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "34 (95% CI = 0.09-1.24)</td><td>Total</td><td>RR = 0.14 (95% CI = 0.01-3.48)</td></tr><tr><td>Learning difficulties</td><td></td><td>Height (< 5th centile)</td><td></td></tr><tr><td> Intramuscular</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "85 (95% CI = 0.38-1.92)</td><td> Intramuscular</td><td>RR = 0.75 (95% CI = 0.23-2.49)</td></tr><tr><td>Vaginal</td><td>not estimable</td><td>Vaginal</td><td>not estimable</td></tr><tr><td>Oral Total</td><td>not estimable</td><td>Oral</td><td> not estimable</td></tr><tr><td>Weight (< 5th centile)</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "85 (95% CI = 0.38-1.92)</td><td>Total</td><td>RR = 0.75 (95% CI = 0.23-2.49)</td></tr><tr><td></td><td></td><td>Adverse drug reactions</td><td></td></tr><tr><td>Intramuscular</td><td>RR = 0.79 (95% CI= 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "30-2.05)</td><td> Intramuscular</td><td>not estimable</td></tr><tr><td>Vaginal</td><td>not estimable</td><td>Vaginal</td><td>not estimable</td></tr><tr><td>Oral</td><td> not estimable</td><td> Oral</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "71 (95% CI = 0.24-2.15)</td></tr><tr><td>Total</td><td>RR = 0.79 (95% CI= 0.30-2.05)</td><td>Total</td><td>RR = 0.71 (95% CI = 0.24-2.15)</td></tr><tr><td> Pregnancy prolongation</td><td></td><td>Apgar score < 7</td><td></td></tr><tr><td> Intramuscular</td><td>not estimable</td><td> Intramuscular</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "55 (95% CI = 0.24-1.25)</td></tr><tr><td>Vaginal</td><td>not estimable</td><td>Vaginal</td><td>not estimable</td></tr><tr><td>Oral</td><td>RR = 4.47 (95% CI = 2.15-6.79)</td><td>Oral Total</td><td>not estimable</td></tr><tr><td>Total NICU admission</td><td>RR = 4.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "47 (95% CI = 2.15-6.79)</td><td></td><td>RR = 0.55 (95% CI = 0.24-1.25)</td></tr><tr><td></td><td></td><td> Neonatal length of hospital stay</td><td></td></tr><tr><td> Intramuscular</td><td>not estimable</td><td> Intramuscular</td><td>not estimable</td></tr><tr><td>Vaginal</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "21 (95% CI= 0.09-0.49)</td><td>Vaginal</td><td>not estimable</td></tr><tr><td> Oral</td><td>RR = 0.26 (95% CI= 0.14-0.49)</td><td> Oral</td><td>RR = -1.00 (95% CI = -7.67-5.67)</td></tr><tr><td>Total</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "24 (95% CI= 0.14-0.40)</td><td>Total</td><td>RR = -1.00 (95% CI = -7.67-5.67)</td></tr><tr><td>Infant weight (6 months follow-up)</td><td></td><td>Infant length (6 monthsfollow-up)</td><td></td></tr><tr><td> Intramuscular</td><td>not estimable</td><td> Intramuscular</td><td>not estimable</td></tr><tr><td>Vaginal</td><td>RR = 29.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "00 (95% CI = -209.62-267.62)</td><td>Vaginal</td><td>RR = 0.10 (95% CI = -0.59-0.79)</td></tr><tr><td>Oral</td><td>not estimable</td><td>Oral</td><td>not estimable</td></tr><tr><td>Total</td><td>RR = 29.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "00 (95% CI = -209.62-267.62)</td><td>Total</td><td>RR = 0.10 (95% CI= -0.59-0.79)</td></tr><tr><td> Infant weight</td><td></td><td> Infant length</td><td></td></tr><tr><td>(12 months follow-up)</td><td></td><td>(12 months follow-up)</td><td></td></tr><tr><td> Intramuscular</td><td>not estimable</td><td> Intramuscular</td><td>not estimable</td></tr><tr><td>Vaginal</td><td>RR = -88.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "00 (95% CI = -381.48-205.48)</td><td>Vaginal</td><td>RR = -0.10 (95% CI = -0.80-0.60)</td></tr><tr><td>Oral</td><td>not estimable</td><td>Oral</td><td>not estimable</td></tr><tr><td>Total</td><td>RR = -88.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "00 (95% CI = -381.48-205.48)</td><td>Total</td><td>RR = -0.10 (95% CI = -0.80-0.60)</td></tr><tr><td> Infant weight</td><td></td><td> Infant length</td><td></td></tr><tr><td>(24 months follow-up)</td><td></td><td>(24 months follow-up)</td><td></td></tr><tr><td> Intramuscular</td><td>not estimable</td><td> Intramuscular</td><td>not estimable</td></tr><tr><td>Vaginal</td><td>not estimable</td><td>Vaginal</td><td>RR = -0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "20 (95% CI= -1.23-0.83)</td></tr><tr><td>Oral</td><td>RR = -40.00 (95% CI = -482.41-402.41)</td><td> Oral</td><td>not estimable</td></tr><tr><td>Total</td><td>RR = -40.00 (95% CI = -482.41-402.41)</td><td>Total</td><td>RR = -0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "20 (95% CI = -1.23-0.83)</td></tr></table></body></html> CI confidence interval, NICU neonatal intensive care unit, RR risk ratio Pooled data published by Dodd et $\\mathbf { \\Delta } _ { a l } \\mathbf \\{ \\mathcal { I } \\Xi ^ { 5 9 } \\$ on the effectiveness and safety of progesterone for preventing preterm birth in women with a past history of spontaneous preterm birth compared to placebo/no treatment (continued) <html><body><table><tr><td>Parameter</td><td>Progesterone versus placebo</td><td>Parameter</td><td>Progesterone versus placebo</td></tr><tr><td>Infant length (24 months follow-up)</td><td></td><td>Infant head circumference (6 months follow-up)</td><td></td></tr><tr><td>Intramuscular</td><td>not estimable</td><td>Intramuscular</td><td>not estimable</td></tr><tr><td>Vaginal</td><td>RR = -0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "20 (95% CI = -1.23-0.83)</td><td>Vaginal</td><td>RR = 0.10 (95% CI = -0.23-0.43)</td></tr><tr><td>Oral</td><td>not estimable</td><td>Oral</td><td>not estimable</td></tr><tr><td>Total</td><td>RR = -0.20 (95% CI = -1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "23-0.83)</td><td>Total</td><td>RR = 0.10 (95% CI = -0.23-0.43)</td></tr><tr><td>Infant head circumference (at 12 monthsfollow-up)</td><td></td><td>Infant head circumference (24 months follow-up)</td><td></td></tr><tr><td> Intramuscular</td><td>not estimable</td><td>Intramuscular</td><td>not estimable</td></tr><tr><td>Vaginal</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "10 (95% CI= -0.26-0.46)</td><td>Vaginal</td><td>RR = 0.20 (95% CI= -0.21-0.61)</td></tr><tr><td>Oral</td><td>not estimable</td><td>Oral</td><td>not estimable</td></tr><tr><td>Total</td><td>RR = 0.10 (95% CI = -0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "26-0.46)</td><td>Total</td><td>RR = 0.20 (95% CI = -0.21-0.61)</td></tr></table></body></html> CI confidence interval, RR risk ratio Table 26.Pooled data published by Dodd et $\\mathbf { \\Delta } _ { a l } \\mathbf \\{ \\mathcal { I } \\Xi ^ { 5 9 } \\$ on the effectiveness and safety of progesterone for preventing preterm birth in women with a short cervix identified on ultrasound compared to placebo/no treatment <html><body><table><tr><td>Parameter</td><td>Progesterone versus placebo</td><td>Parameter</td><td>Progesterone versus placebo</td></tr><tr><td> Perinatal death</td><td></td><td>Preterm birth (< 34 weeks)</td><td></td></tr><tr><td> Intramuscular</td><td>RR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "12 (95% CI = 0.46-2.72)</td><td> Intramuscular</td><td>RR = 0.79 (95% CI = 0.43-1.46)</td></tr><tr><td>Vaginal</td><td>RR = 0.56 (95% CI = 0.27-1.17)</td><td>Vaginal</td><td>RR = 0.58 (95% CI = 0.38-0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "87)</td></tr><tr><td>Total</td><td>RR = 0.74 (95% CI = 0.42-1.29)</td><td>Total</td><td>RR = 0.64 (95% CI = 0.45-0.90)</td></tr><tr><td> Preterm labour</td><td></td><td> pPROM</td><td></td></tr><tr><td>Intramuscular</td><td>RR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "05 (95% CI = 0.63-1.74)</td><td>Intramuscular</td><td>RR = 1.33 (95% CI = 0.68-2.62)</td></tr><tr><td>Vaginal</td><td>not estimable</td><td>Vaginal</td><td>not estimable</td></tr><tr><td>Total</td><td>RR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "05 (95% CI= 0.63-1.74)</td><td>Total</td><td>RR = 1.33 (95% CI = 0.68-2.62)</td></tr><tr><td>Side effets (any)</td><td></td><td>Side effects (injection site)</td><td></td></tr><tr><td> Intramuscular</td><td>RR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "02 (95% CI = 0.92-1.13)</td><td> Intramuscular</td><td>RR = 1.04 (95% CI = 0.93-1.17)</td></tr><tr><td>Vaginal</td><td>not estimable</td><td>Vaginal</td><td>not estimable</td></tr><tr><td>Total</td><td>RR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "02 (95% CI = 0.92-1.13)</td><td>Total</td><td>RR = 1.04 (95% CI = 0.93-1.17)</td></tr><tr><td>Side effects (urticaria)</td><td></td><td>Side effects (nausea)</td><td></td></tr><tr><td> Intramuscular</td><td>RR = 5.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "03 (95% CI = 1.11-22.78)</td><td> Intramuscular</td><td>RR = 0.70 (95% CI = 0.27-1.83)</td></tr><tr><td>Vaginal</td><td>not estimable</td><td>Vaginal</td><td>not estimable</td></tr><tr><td>Total</td><td>RR = 5.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "03 (95% CI = 1.11-22.78)</td><td>Total</td><td>RR = 0.70 (95% CI= 0.27-1.83)</td></tr><tr><td>Pregnancy prolongation</td><td></td><td>Caesarean section</td><td></td></tr><tr><td>Intramuscular</td><td>RR = -2.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "00 (95% CI = -10.29-6.29)</td><td> Intramuscular</td><td>RR = 1.05 (95% CI = 0.79-1.40)</td></tr><tr><td>Vaginal</td><td>not estimable</td><td>Vaginal</td><td>not estimable</td></tr><tr><td>Total</td><td>RR = -2.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "00 (95% CI = -10.29-6.29)</td><td>Total</td><td>RR = 1.05 (95% CI = 0.79-1.40)</td></tr><tr><td>Antenatal tocolysis</td><td></td><td>Preterm birth (< 37 weeks)</td><td></td></tr><tr><td> Intramuscular</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "81 (95% CI = 0.60-1.11)</td><td>Intramuscular</td><td>RR = 1.03 (95% CI = 0.83-1.28)</td></tr><tr><td>Vaginal</td><td>not estimable</td><td>Vaginal</td><td>RR = 0.89 (95% CI = 0.68-1.16)</td></tr><tr><td>Total</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "81 (95% CI = 0.60-1.11)</td><td>Total</td><td>RR = 0.97 (95% CI = 0.82-1.15)</td></tr><tr><td>Preterm birth (< 28 weeks)</td><td></td><td> Infant birweight (< 2,500 g)</td><td></td></tr><tr><td>Intramuscular</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "69 (95% CI = 0.36-1.30)</td><td> Intramuscular</td><td>RR = 0.97 (95% CI = 0.73-1.30)</td></tr><tr><td>Vaginal</td><td>RR = 0.50 (95% CI = 0.25-0.97)</td><td>Vaginal</td><td>RR = 0.89 (95% CI = 0.73-1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "09)</td></tr><tr><td>Total</td><td>RR = 0.59 (95% CI = 0.37-0.93)</td><td>Total</td><td>RR = 0.92 (95% CI = 0.78-1.09)</td></tr><tr><td>Respiratory distress syndrome</td><td></td><td>Apgar score < 7</td><td></td></tr><tr><td> Intramuscular</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "95 (95% CI = 0.58-1.58)</td><td> Intramuscular</td><td>RR = 0.80 (95% CI = 0.41-1.55)</td></tr><tr><td>Vaginal</td><td>RR = 0.49 (95% CI = 0.290.85)</td><td>Vaginal</td><td>not estimable</td></tr><tr><td>Total</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "69 (95% CI = 0.48-1.00)</td><td>Total</td><td>RR = 0.80 (95% CI = 0.41-1.55)</td></tr><tr><td> Need for assisted ventilation</td><td></td><td> Periventricular leucomalacia</td><td></td></tr><tr><td>Intramuscular</td><td>not estimable</td><td>Intramuscular</td><td>RR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "78 (95% CI = 0.38-8.24)</td></tr><tr><td>Vaginal</td><td>RR = 0.65 (95% CI = 0.36-1.16)</td><td>Vaginal</td><td>not estimable</td></tr><tr><td>Total</td><td>RR = 0.65 (95% CI = 0.36-1.16)</td><td>Total</td><td>RR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "78 (95% CI = 0.38-8.24)</td></tr><tr><td>Intraventricular haemorrhage</td><td></td><td> Intraventricular haemorrhage</td><td></td></tr><tr><td>(grades IIl or IV)</td><td></td><td>(all grades)</td><td></td></tr><tr><td> Intramuscular</td><td>RR = 2.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "01 (95% CI = 0.18-22.08)</td><td> Intramuscular</td><td>not estimable</td></tr><tr><td>Vaginal</td><td>RR = 0.32 (95% CI = 0.01-7.73)</td><td>Vaginal</td><td>RR = 0.51 (95% CI = 0.05-5.53)</td></tr><tr><td>Total</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "98 (95% CI= 0.17-5.60)</td><td>Total</td><td>RR = 0.51 (95% CI = 0.05-5.53)</td></tr><tr><td> Retinopathy of prematurity</td><td></td><td>Necrotising enterocolitis</td><td></td></tr><tr><td> Intramuscular</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "34 (95% CI = 0.04-3.21)</td><td> Intramuscular</td><td>RR = 0.40 (95% CI = 0.08-2.06)</td></tr><tr><td>Vaginal</td><td>RR = 5.07 (95% CI= 0.25-104.70)</td><td>Vaginal</td><td>RR = 0.96 (95% CI = 0.30-3.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "11)</td></tr><tr><td>Total</td><td>RR = 1.01 (95% CI = 0.23-4.42)</td><td>Total</td><td>RR = 0.70 (95% CI = 0.27-1.78)</td></tr><tr><td>Neonatal sepsis</td><td></td><td>Intrauterine fetal death</td><td></td></tr><tr><td> Intramuscular</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "27 (95% CI = 0.08-0.97)</td><td> Intramuscular</td><td>RR = 4.04 (95% CI = 0.45-35.92)</td></tr><tr><td>Vaginal</td><td>RR = 0.58 (95% CI = 0.15-2.25)</td><td>Vaginal</td><td>RR = 0.82 (95% CI = 0.28-2.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "42)</td></tr><tr><td>Total</td><td>RR = 0.46 (95% CI = 0.18-1.20)</td><td>Total</td><td>RR = 1.21 (95% CI = 0.48-3.04)</td></tr><tr><td> Neonatal death</td><td></td><td>NICU admission</td><td></td></tr><tr><td> Intramuscular</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "76 (95% CI = 0.27-2.16)</td><td> Intramuscular</td><td>RR = 0.76 (95% CI = 0.27-2.16)</td></tr><tr><td>Vaginal</td><td>RR = 0.41 (95% CI = 0.15-1.15)</td><td>Vaginal</td><td>RR = 0.41 (95% CI = 0.15-1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "15)</td></tr><tr><td>Total</td><td>RR = 0.55 (95% CI= 0.26-1.13)</td><td>Total</td><td>RR = 0.55 (95% CI = 0.26-1.13)</td></tr></table></body></html> CI confidence interval, NICU neonatal intensive care unit, pPROM preterm spontaneous rupture of membranes, RR risk ratio Table 27.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Pooled data published by Dodd et $\\mathbf { \\Delta } _ { a l } \\mathbf \\{ \\mathcal { I } \\Xi ^ { 5 9 } \\$ on the effectiveness and safety of progesterone $\\bf { [ 2 0 0 ~ m g ] }$ for preventing preterm birth in women with multiple pregnancy compared to placebo/no treatment <html><body><table><tr><td>Parameter</td><td>Progesterone versus placebo</td><td>Parameter</td><td>Progesterone versus placebo</td></tr><tr><td> Perinatal death</td><td></td><td>Preterm birth (< 34 weeks)</td><td></td></tr><tr><td> Intramuscular</td><td>RR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "06 (95% CI = 0.30-3.71)</td><td>Intramuscular</td><td>RR = 1.37(95% CI = 0.74-1.27)</td></tr><tr><td>Vaginal</td><td>RR = 0.75 (95% CI = 0.24-2.41)</td><td>Vaginal</td><td>RR = 0.92 (95% CI = 0.69-1.23)</td></tr><tr><td>Total pPROM</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "93 (95% CI = 0.45-1.94)</td><td>Total</td><td>RR = 0.97 (95% CI = 0.74-1.27)</td></tr><tr><td></td><td></td><td>Adverse drug reaction</td><td></td></tr><tr><td> Intramuscular</td><td>RR = 1.11 (95% CI = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "72-1.71)</td><td> Intramuscular</td><td>RR = 0.74 (95% CI = 0.54-1.01)</td></tr><tr><td>Vaginal</td><td>RR = 1.32 (95% CI = 0.30-5.74)</td><td>Vaginal</td><td>RR = 0.98 (95% CI = 0.89-1.08)</td></tr><tr><td>Total</td><td>RR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "12 (95% CI = 0.74-1.70)</td><td>Total</td><td>RR = 0.88 (95% CI = 0.64-1.19)</td></tr><tr><td>Caesarean section</td><td></td><td>Spontaneous birth</td><td></td></tr><tr><td> Intramuscular</td><td>RR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "01 (95% CI= 0.94-1.09)</td><td> Intramuscular</td><td>RR = 0.88 (95% CI = 0.75-1.04)</td></tr><tr><td>Vaginal</td><td>RR = 0.91 (95% CI = 0.84-0.98)</td><td>Vaginal</td><td>RR = 1.74 (95% CI = 1.21-2.49)</td></tr><tr><td>Total Assisted birth</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "96 (95% CI = 0.91-1.02)</td><td>Total</td><td>RR = 1.22 (95% CI = 0.62-2.38)</td></tr><tr><td></td><td></td><td> Satisfaction with therapy</td><td></td></tr><tr><td>Intramuscular</td><td>RR = 1.31 (95% CI = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "86-1.99)</td><td> Intramuscular</td><td>not estimable</td></tr><tr><td>Vaginal</td><td>RR = 0.73 (95% CI = 0.44-1.24)</td><td>Vaginal</td><td>RR = 0.0 (95% CI= -0.35-0.35)</td></tr><tr><td>Total</td><td>RR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "00 (95% CI = 0.57-1.76)</td><td>Total</td><td>RR = 0.0 (95% CI = -0.35-0.35)</td></tr><tr><td>Antenatal tocolysis</td><td></td><td>Antenatal corticosteroids</td><td></td></tr><tr><td>Intramuscular</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "98 (95% CI = 0.82-1.17)</td><td> Intramuscular</td><td>RR = 0.91 (95% CI = 0.70-1.17)</td></tr><tr><td>Vaginal</td><td>RR = 0.75 (95% CI = 0.55-1.03)</td><td>Vaginal</td><td>RR = 1.68 (95% CI = 0.81-3.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "49)</td></tr><tr><td>Total</td><td>RR = 0.94 (95% CI = 0.80-1.10)</td><td>Total</td><td>RR = 0.98 (95% CI = 0.77-1.26)</td></tr><tr><td>Preterm birth (<37weeks)</td><td></td><td>Preterm birth (< 28 weeks)</td><td></td></tr><tr><td> Intramuscular</td><td>RR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "09 (95% CI = 0.96-1.22)</td><td>Intramuscular</td><td>RR = 1.19 (95% CI = 0.68-2.07)</td></tr><tr><td>Vaginal</td><td>RR = 0.98 (95% CI = 0.85-1.13)</td><td>Vaginal</td><td>RR = 1.27 (95% CI = 0.51-3.19)</td></tr><tr><td>Total</td><td>RR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "04 (95% CI = 0.95-1.14)</td><td>Total</td><td>RR = 1.21 (95% CI = 0.75-1.95)</td></tr><tr><td>Infant birthweight (< 2,500 g)</td><td></td><td>Apgar score < 7 at 5 minutes</td><td></td></tr><tr><td> Intramuscular</td><td>RR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "02 (95% CI = 0.91-1.14)</td><td> Intramuscular</td><td>RR = 0.98 (95% CI = 0.70-1.38)</td></tr><tr><td>Vaginal</td><td>RR = 0.86 (95% CI = 0.80-0.94)</td><td>Vaginal</td><td>RR = 0.59 (95% CI = 0.28-1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "23)</td></tr><tr><td>Total</td><td>RR = 0.95 (95% CI = 0.88-1.03)</td><td>Total</td><td>RR = 0.89 (95% CI = 0.66-1.21)</td></tr><tr><td> Respiratory distress syndrome</td><td></td><td>Use of assisted ventilation</td><td></td></tr><tr><td> Intramuscular</td><td>RR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "13 (95% CI = 0.91-1.42)</td><td> Intramuscular</td><td>RR = 0.99 (95% CI = 0.80-1.22)</td></tr><tr><td>Vaginal</td><td>RR = 1.08 (95% CI = 0.79-1.48)</td><td>Vaginal</td><td>RR = 0.78 (95% CI = 0.45-1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "36)</td></tr><tr><td>Total</td><td>RR = 1.13 (95% CI = 0.94-1.35)</td><td>Total</td><td>RR = 0.95 (95% CI = 0.78-1.16)</td></tr><tr><td>Intraventricular haemorrhage</td><td></td><td>Intraventricular haemorrhage</td><td></td></tr><tr><td>(grades IIl or IV) Intramuscular</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "93 (95% CI = 0.45-1.92)</td><td>(all grades) Intramuscular</td><td>RR = 1.98 (95% CI = 0.36-10.77)</td></tr><tr><td>Vaginal</td><td>not estimable</td><td>Vaginal</td><td>RR = 1.70 (95% CI = 0.62-4.66)</td></tr><tr><td>Total</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "93 (95% CI = 0.45-1.92)</td><td>Total</td><td>RR =1.77 (95% CI = 0.75-4.21)</td></tr><tr><td>Periventricularleucomalacia</td><td></td><td>Retinopathy of prematurity</td><td></td></tr><tr><td> Intramuscular</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "37 (95% CI= 0.05-3.02)</td><td> Intramuscular</td><td>RR = 0.64 (95% CI = 0.20-2.06)</td></tr><tr><td>Vaginal</td><td>not estimable</td><td>Vaginal</td><td>RR = 1.02 (95% CI = 0.26-4.07)</td></tr><tr><td>Total</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "37 (95% CI= 0.05-3.02)</td><td>Total</td><td></td></tr><tr><td>Chronic lung disease</td><td></td><td>Necrotising enterocolitis</td><td>RR = 0.79 (95% CI = 0.32-1.91)</td></tr><tr><td> Intramuscular</td><td>RR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "91 (95% CI = 0.13-27.80)</td><td> Intramuscular</td><td>RR = 0.98 (95% CI = 0.52-1.88)</td></tr><tr><td>Vaginal</td><td>not estimable</td><td>Vaginal</td><td>RR = 0.51 (95% CI = 0.05-5.63)</td></tr><tr><td>Total</td><td>RR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "91 (95% CI= 0.13-27.80)</td><td>Total</td><td>RR = 0.94 (95% CI = 0.50-1.75)</td></tr><tr><td>Neonatal sepsis</td><td></td><td></td><td></td></tr><tr><td> Intramuscular</td><td></td><td>Fetal death</td><td></td></tr><tr><td>Vaginal</td><td>RR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "22 (95% CI = 0.87-1.72)</td><td> Intramuscular</td><td>RR = 1.55 (95% CI = 0.77-3.12)</td></tr><tr><td></td><td>RR = 1.14 (95% CI = 0.61-2.13)</td><td>Vaginal</td><td>RR = 0.83 (95% CI = 0.35-1.95)</td></tr><tr><td>Total</td><td>RR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "20 (95% CI = 0.89-1.62)</td><td>Total</td><td>RR = 1.22 (95% CI = 0.71-2.09)</td></tr><tr><td>Neonatal death</td><td></td><td>NICU admission</td><td></td></tr><tr><td> Intramuscular</td><td>RR = 0.81 (95% CI = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "31-2.10)</td><td> Intramuscular</td><td>RR = 1.31 (95% CI = 1.05-1.62)</td></tr><tr><td>Vaginal</td><td>RR = 1.34 (95% CI = 0.36-4.95)</td><td>Vaginal</td><td>RR = 0.87 (95% CI= 0.71-1.07)</td></tr><tr><td>Total</td><td>RR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "01 (95% CI = 048-2.10)</td><td>Total</td><td>RR = 0.94 (95% CI = 1.05-1.62)</td></tr></table></body></html> CI confidence interval, NICU neonatal intensive care unit, pPROM preterm spontaneous rupture of membranes, RR risk ratio Table 28.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Pooled data published by Dodd et al.959 on the effectiveness and safety of progesterone $\\bf { ( 4 0 0 ~ m g ) }$ for preventing preterm birth in women with multiple pregnancy compared to placebo/no treatment <html><body><table><tr><td>Parameter</td><td>Progesterone versus placebo</td><td>Parameter</td><td>Progesterone versus placebo</td></tr><tr><td> Perinatal death</td><td colspan=\"3\">Preterm birth (<34 weeks)</td></tr><tr><td> Intramuscular</td><td>RR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "06 (95% CI= 0.30-3.71)</td><td> Intramuscular</td><td>RR = 1.37 (95% CI = 0.73-2.59)</td></tr><tr><td>Vaginal</td><td>RR = 1.25 (95% CI = 0.67-2.35)</td><td>Vaginal</td><td>RR = 0.88 (95% CI = 0.65-1.19)</td></tr><tr><td>Total</td><td>RR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "13 (95% CI = 0.61-2.08)</td><td>Total</td><td>RR = 0.94 (95% CI = 0.71-1.24)</td></tr><tr><td>pPROM</td><td colspan=\"3\">Caesarean section</td></tr><tr><td> Intramuscular</td><td>RR = 1.11 (95% CI = 0.72-1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "71)</td><td> Intramuscular</td><td>RR = 1.01 (95% CI = 0.94-1.09)</td></tr><tr><td>Vaginal</td><td>RR = 0.33 (95% CI = 0.03-3.12)</td><td>Vaginal</td><td>RR = 0.90 (95% CI= 0.84-0.98)</td></tr><tr><td>Total</td><td>RR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "05 (95% CI = 0.69-1.60)</td><td>Total</td><td>RR = 0.96 (95% CI= 0.91-1.01)</td></tr><tr><td>Antenatal tocolysis</td><td colspan=\"3\">Antenatal corticosteroids</td></tr><tr><td> Intramuscular</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "98 (95% CI = 0.82-1.17)</td><td> Intramuscular</td><td>RR = 0.91 (95% CI = 0.70-1.17)</td></tr><tr><td>Vaginal</td><td>RR = 0.77 (95% CI = 0.56-1.05)</td><td>Vaginal</td><td>RR = 1.58 (95% CI = 0.76-3.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "31)</td></tr><tr><td>Total</td><td>RR = 0.94 (95% CI = 0.80-1.10)</td><td>Total</td><td>RR = 0.97 (95% CI = 0.76-1.24)</td></tr><tr><td>Pretermbirth (<37weeks)</td><td colspan=\"3\">Preterm birth (< 28 weeks)</td></tr><tr><td> Intramuscular</td><td>RR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "09 (95% CI = 0.96-1.22)</td><td> Intramuscular</td><td>RR = 1.19 (95% CI = 0.68-2.07)</td></tr><tr><td>Vaginal</td><td>RR = 0.97 (95% CI = 0.84-1.11)</td><td>Vaginal</td><td>RR = 1.52 (95% CI = 0.63-3.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "69)</td></tr><tr><td>Total</td><td>RR = 1.04 (95% CI = 0.95-1.13)</td><td>Total</td><td>RR = 1.28 (95% CI = 0.80-2.04)</td></tr><tr><td>Infant birthweight (< 2,500g)</td><td colspan=\"3\">Apgar score < 7 at 5 minutes</td></tr><tr><td>Intramuscular</td><td>RR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "02 (95% CI = 0.91-1.14)</td><td>Intramuscular</td><td>RR = 0.98 (95% CI = 0.70-1.38)</td></tr><tr><td>Vaginal</td><td>RR = 0.89 (95% CI = 0.82-0.96)</td><td>Vaginal</td><td>RR = 0.81 (95% CI = 0.41-1.58)</td></tr><tr><td>Total</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "96 (95% CI = 0.89-1.04)</td><td>Total</td><td>RR = 0.94 (95% CI = 0.70-1.27)</td></tr><tr><td>Use of assisted ventilation</td><td colspan=\"3\">Fetal death</td></tr><tr><td>Intramuscular</td><td>RR = 0.99 (95% CI = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "80-1.22)</td><td>Intramuscular</td><td>RR = 1.55 (95% CI = 0.77-3.12)</td></tr><tr><td>Vaginal</td><td>RR = 0.93 (95% CI = 0.55-1.59)</td><td>Vaginal</td><td>RR = 1.10 (95% CI = 0.49-2.48)</td></tr><tr><td>Total</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "98 (95% CI = 0.81-1.19)</td><td>Total</td><td>RR = 1.35 (95% CI = 0.79-2.29)</td></tr><tr><td>Neonatal death</td><td colspan=\"3\">NICU admission</td></tr><tr><td> Intramuscular</td><td>RR = 0.81 (95% CI = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "31-2.10)</td><td> Intramuscular</td><td>RR = 1.31 (95% CI = 1.05-1.62)</td></tr><tr><td>Vaginal</td><td>RR = 1.77 (95% CI = 0.84-3.72)</td><td>Vaginal</td><td>RR = 0.86 (95% CI = 0.70-1.07)</td></tr><tr><td>Total</td><td>RR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "17 (95% CI = 0.62-2.21)</td><td>Total</td><td>RR = 0.93 (95% CI = 0.75-1.17)</td></tr></table></body></html> CI confidence interval, NICU neonatal intensive care unit, pPROM preterm spontaneous rupture of membranes, RR risk ratio Table 29.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Pooled data published by Dodd et $a l .^ { 9 5 9 }$ on the effectiveness and safety of progesterone for preventing preterm birth in women following presentation with threatened preterm labour compared to placebo/no treatment <html><body><table><tr><td>Parameter</td><td>Progesterone versus placebo</td><td>Parameter</td><td>Progesterone versus placebo</td></tr><tr><td> Perinatal death</td><td></td><td>Use of tocolysis</td><td></td></tr><tr><td> Intramuscular</td><td>RR = 2.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "00 (95% CI = 0.16-24.33)</td><td> Intramuscular</td><td>RR = 1.20 (95% CI = 0.55-2.62)</td></tr><tr><td>Vaginal</td><td>not estimable</td><td>Vaginal</td><td>RR = 0.93 (95% CI = 0.50-1.73)</td></tr><tr><td>Total Pregnancy prolongation</td><td>RR = 2.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "00 (95% CI = 0.16-24.33)</td><td>Total</td><td>RR = 0.98 (95% CI = 0.58-1.65)</td></tr><tr><td></td><td></td><td>Pregnancy prolongation (<1 week)</td><td></td></tr><tr><td>Intramuscular</td><td>RR = -3.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "30 (95% CI = -7.41-0.81)</td><td>Intramuscular</td><td>RR = 0.40 (95% CI = 0.07-2.37)</td></tr><tr><td>Vaginal</td><td>RR = 7.21 (95% CI = 2.39-12.03)</td><td>Vaginal</td><td>not estimable</td></tr><tr><td>Total</td><td>RR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "88 (95% CI = -8.42-12.17)</td><td>Total</td><td>RR = 0.40 (95% CI = 0.07-2.37)</td></tr><tr><td>Pregnancy prolongation (1.0 to 1.9 weeks)</td><td></td><td>Pregnancy prolongation (≥ 2 weeks)</td><td></td></tr><tr><td> Intramuscular</td><td>RR = 2.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "00 (95% CI = 0.16-24.33)</td><td>Intramuscular</td><td>RR = 2.00 (95% CI = 0.42-9.42)</td></tr><tr><td>Vaginal</td><td>not estimable</td><td>Vaginal</td><td>not estimable</td></tr><tr><td>Total</td><td>RR = 2.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "00 (95% CI = 0.16-24.33)</td><td>Total</td><td>RR = 2.00 (95% CI = 0.42-9.42)</td></tr><tr><td> Spontaneous birth</td><td></td><td>Caesarean section</td><td></td></tr><tr><td>Intramuscular</td><td>RR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "09 (95% CI = 0.80-1.49)</td><td>Intramuscular</td><td>RR = 0.90 (95% CI = 0.51-1.60)</td></tr><tr><td>Vaginal</td><td>not estimable</td><td>Vaginal</td><td>not estimable</td></tr><tr><td>Total</td><td>RR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "09 (95% CI = 0.80-1.49)</td><td>Total</td><td>RR = 0.90 (95% CI = 0.51-1.60)</td></tr><tr><td>Preterm birth (<34 weeks)</td><td></td><td>Preterm birth (< 37weeks)</td><td></td></tr><tr><td>Intramuscular</td><td>RR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "00 (95% CI = 0.72-1.39)</td><td>Intramuscular</td><td>RR = 0.29 (95% CI = 0.12-0.69)</td></tr><tr><td>Vaginal </td><td>RR = 0.92 (95% CI= 0.37-2.27)</td><td>Vaginal</td><td>RR = 0.76 (95% CI = 0.55-1.06)</td></tr><tr><td>Total</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "95 (95% CI = 0.55-1.65)</td><td>Total</td><td>RR = 0.51 (95% CI = 0.20-1.31)</td></tr><tr><td>Use of assisted ventilation</td><td></td><td>Respiratory distress syndrome</td><td></td></tr><tr><td> Intramuscular</td><td> not estimable</td><td>Intramuscular</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "86 (95% CI = 0.66-1.12)</td></tr><tr><td>Vaginal</td><td>RR = 0.30 (95% CI = 0.06-1.37)</td><td>Vaginal</td><td>RR = 10.48 (95% CI= 0.20-1.15)</td></tr><tr><td>Total</td><td>RR = 0.30 (95% CI = 0.06-1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "37)</td><td>Total</td><td>RR = 0.74 (95% CI = 0.49-1.10)</td></tr><tr><td>Infant birthweight</td><td></td><td>Intraventricular haemorrhage</td><td></td></tr><tr><td>(<2,500 g) Intramuscular</td><td>not estimable</td><td>(grades III or IV) Intramuscular</td><td>RR = 9.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "00 (95% CI = 0.53-152.93)</td></tr><tr><td>Vaginal</td><td>RR = 0.52 (95% CI = 0.28-0.98)</td><td>Vaginal</td><td>not estimable</td></tr><tr><td>Total</td><td>RR = 0.52 (95% CI = 0.28-0.98)</td><td>Total</td><td>RR = 9.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "00 (95% CI = 0.53-152.93)</td></tr><tr><td> Necrotizing enterocolitis</td><td></td><td> Neonatal sepsis</td><td></td></tr><tr><td> Intramuscular</td><td>RR = 3.06 (95% CI = 0.50-18.69)</td><td>Intramuscular</td><td>RR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "09 (95% CI = 0.39-3.05)</td></tr><tr><td>Vaginal</td><td>not estimable</td><td>Vaginal</td><td>RR = 0.26 (95% CI = 0.07-1.00)</td></tr><tr><td>Total</td><td>RR = 3.06 (95% CI = 0.50-18.69)</td><td>Total</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "54 (95% CI = 0.17-1.68)</td></tr><tr><td>Fetal death</td><td></td><td>Neonatal death</td><td></td></tr><tr><td> Intramuscular</td><td>RR = 1.09 (95% CI = 0.07-16.75)</td><td>Intramuscular</td><td>RR = 2.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "00 (95% CI = 0.16-24.33)</td></tr><tr><td>Vaginal</td><td>not estimable</td><td>Vaginal</td><td>RR = 0.17(95% CI= 0.02-1.40)</td></tr><tr><td>Total</td><td>RR = 1.09 (95% CI = 0.07-16.75)</td><td>Total</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "54 (95% CI = 0.05-6.24)</td></tr><tr><td>Neonatal length of hospital stay</td><td></td><td>Apgar score < 7 at 5 minutes</td><td></td></tr><tr><td> Intramuscular</td><td>RR = -2.16 (95% CI = -15.84-11.53)</td><td>Intramuscular</td><td>not estimable</td></tr><tr><td>Vaginal</td><td>not estimable</td><td>Vaginal</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "26 (95% CI = 0.03-2.27)</td></tr><tr><td>Total</td><td>RR = -2.16 (95% CI = -15.84-11.53)</td><td>Total</td><td>RR = 0.26 (95% CI = 0.03-2.27)</td></tr><tr><td> pPROM</td><td></td><td>Preterm birth (< 28 weeks)</td><td></td></tr><tr><td>Intramuscular</td><td>not estimable</td><td>Intramuscular</td><td>not estimable</td></tr><tr><td>Vaginal</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "52 (95% CI = 0.19-1.45)</td><td>Vaginal</td><td>RR = 0.99 (95% CI = 0.06-15.60)</td></tr><tr><td>Total</td><td>RR = 0.52 (95% CI = 0.19-1.45)</td><td>Total</td><td>RR = 0.99 (95% CI = 0.06-15.60)</td></tr><tr><td>Apgar score <7 at 5 minutes</td><td></td><td>NICU admission</td><td></td></tr><tr><td> Intramuscular</td><td></td><td>Intramuscular</td><td>not estimable</td></tr><tr><td>Vaginal</td><td>not estimable RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "26 (95% CI= 0.03-2.27)</td><td>Vaginal</td><td>RR = 1.56 (95% CI = 0.27-9.07)</td></tr><tr><td>Total</td><td>RR = 0.26 (95% CI = 0.03-2.27)</td><td>Total</td><td>RR = 1.56 (95% CI = 0.27-9.07)</td></tr></table></body></html> CI confidence interval, NICU neonatal intensive care unit, pPROM preterm spontaneous rupture of membranes, RR risk ratio Table 30.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Pooled data published by Alfirevic et al.1034 on the effectiveness and safety of cervical cerlage (stitch) for preventing birth in singleton pregnancy compared to expectant management (no treatment) <html><body><table><tr><td>Parameter</td><td>Cerclage versus no treatment</td><td>Parameter</td><td>Cerclage versus no treatment</td></tr><tr><td colspan=\"4\">All peritoneal losses</td></tr><tr><td>History-indicated</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "80 (95% CI = 0.58-1.10)</td><td>History-indicated</td><td>not estimable</td></tr><tr><td>One-off ultrasound-indicated (high risk for PTL)</td><td>RR = 0.77 (95% CI = 0.14-4.25)</td><td>One-off ultrasound-indicated (high risk for PTL)</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "77 (95% CI = 0.14-4.25)</td></tr><tr><td>Serial ultrasound-indicated (high risk for PTL)</td><td>RR = 0.66 (95% CI = 0.41-1.06)</td><td>Serial ultrasound-indicated (high risk for PTL)</td><td>RR = 0.84 (95% CI = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "51-1.37)</td></tr><tr><td>One-off ultrasound-indicated (low/unspecified riskfor PTL)</td><td>RR = 1.01 (95% CI = 0.46-2.22)</td><td>One-off ultrasound-indicated (low/unspecified risk for PTL)</td><td>RR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "40 (95% CI = 0.61-3.23)</td></tr><tr><td>Total</td><td>RR = 0.78 (95% CI = 0.61-1.00)</td><td>Total</td><td>RR = 0.95 (95% CI= 0.63-1.43)</td></tr><tr><td colspan=\"4\">Stillbirths</td></tr><tr><td>History-indicated</td><td>RR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "00 (95% CI = 0.45-2.20)</td><td>Neonatal deaths before discharge History-indicated</td><td>RR = 0.67 (95% CI = 0.33-1.36)</td></tr><tr><td>One-off ultrasound-indicated (high risk for PTL)</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "23 (95% CI = 0.01-4.58)</td><td>One-off ultrasound-indicated (high risk for PTL)</td><td>RR = 2.31 (95% CI = 0.22-24.01)</td></tr><tr><td>Serial ultrasound-indicated (high risk for PTL)</td><td>not estimable</td><td>Serial ultrasound-indicated (high risk for PTL)</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "87 (95% CI= 0.13-5.89)</td></tr><tr><td>One-off ultrasound-indicated (low/unspecified risk for PTL)</td><td>RR = 0.95 (95% CI = 0.20-4.59)</td><td>One-off ultrasound-indicated</td><td>RR = 0.63 (95% CI= 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "18-2.18)</td></tr><tr><td>Total</td><td>RR = 0.89 (95% CI = 0.45-1.75)</td><td>(low/unspecified risk for PTL) Total</td><td>RR = 0.73 (95% CI = 0.42-1.28)</td></tr><tr><td colspan=\"4\">Miscarriages</td></tr><tr><td>History-indicated</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "86 (95% CI = 0.57-1.30)</td><td>Preterm birth (<37 completed weeks) History-indicated</td><td>RR = 0.86 (95% CI = 0.59-1.27)</td></tr><tr><td>One-off ultrasound-indicated (high risk for PTL)</td><td>not estimable</td><td>One-off ultrasound-indicated (high risk for PTL)</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "55 (95% CI= 0.30-0.99)</td></tr><tr><td>Serial ultrasound-indicated (high risk for PTL)</td><td>RR = 0.65 (95% CI = 0.25-1.66)</td><td>Serial ultrasound-indicated (high risk for PTL)</td><td>RR = 0.78 (95% CI= 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "60-1.02)</td></tr><tr><td>One-off ultrasound-indicated (low/unspecified risk for PTL)</td><td>RR = 1.72 (95% CI = 0.16-18.22)</td><td>One-off ultrasound-indicated (low/unspecified risk for PTL)</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "80 (95% CI = 0.55-1.16)</td></tr><tr><td>Total</td><td>RR = 0.84 (95% CI = 0.58-1.22)</td><td>Total</td><td>RR = 0.80 (95% CI = 0.69-0.95)</td></tr><tr><td colspan=\"4\">Preterm birth (<28 completed weeks)</td></tr><tr><td>History-indicated One-off ultrasound-indicated</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "82 (95% CI = 0.59-1.13)</td><td>Serious intracranial pathology History-indicated</td><td>RR = 1.02 (95% CI= 0.06-16.09)</td></tr><tr><td>(high risk for PTL)</td><td>RR = 0.69 (95% CI = 0.18-2.62)</td><td>One-off ultrasound-indicated (high risk for PTL)</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "38 (95% CI= 0.02-9.01)</td></tr><tr><td>Serial ultrasound-indicated (high risk for PTL)</td><td>RR = 0.71 (95% CI = 0.48-1.04)</td><td>Serial ultrasound-indicated (high risk for PTL)</td><td>RR = 0.96 (95% CI= 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "05-19.53)</td></tr><tr><td>One-off ultrasound-indicated (low/unspecified risk for PTL)</td><td>RR = 1.01 (95% CI = 0.55-1.83)</td><td>One-off ultrasound-indicated (low/unspecified risk for PTL)</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "95 (95% CI= 0.06-14.98)</td></tr><tr><td>Total Serious respiratory morbidity</td><td>RR = 0.80 (95% CI = 0.64-1.00)</td><td>Total Necrositing enterocolitis</td><td>RR = 0.83 (95% CI= 0.2-3.09)</td></tr><tr><td colspan=\"4\"></td></tr><tr><td>History-indicated</td><td>RR = 3.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "06 (95% CI = 0.32-28.93)</td><td>History-indicated</td><td>not estimable</td></tr><tr><td>One-off ultrasound-indicated (high risk for PTL)</td><td>RR = 0.58 (95% CI = 0.06-6.00)</td><td>One-off ultrasound-indicated (high risk for PTL)</td><td>not estimable</td></tr><tr><td>Serial ultrasound-indicated (high risk for PTL)</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "98 (95% CI = 0.53-1.81)</td><td>Serial ultrasound-indicated (high risk for PTL)</td><td>RR = 0.81 (95% CI = 0.16-4.12)</td></tr><tr><td>One-off ultrasound-indicated (low/unspecified risk for PTL)</td><td>RR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "63 (95% CI = 0.39-6.86)</td><td>One-off ultrasound-indicated (low/unspecified risk for PTL)</td><td>not estimable</td></tr><tr><td>Total</td><td>RR = 1.11 (95% CI = 0.66-1.88)</td><td>Total</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "81 (95% CI= 0.16-4.12)</td></tr><tr><td colspan=\"4\">Retinopathy of prematurity</td></tr><tr><td>History-indicated</td><td>not estimable</td><td>Caesarean section History-indicated</td><td>RR = 1.21 (95% CI= 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "96-1.52)</td></tr><tr><td>One-off ultrasound-indicated (high risk for PTL)</td><td>RR = 0.23 (95% CI = .01-4.58)</td><td>One-off ultrasound-indicated (high risk for PTL)</td><td>RR = 1.35 (95% CI = 0.52-3.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "50)</td></tr><tr><td>Serial ultrasound-indicated (high risk for PTL)</td><td>RR = 0.62 (95% CI = 0.15-2.53)</td><td>Serial ultrasound-indicated (high risk for PTL)</td><td>RR = 1.10 (95% CI = 0.82-1.46)</td></tr><tr><td>One-off ultrasound-indicated (low/unspecified risk for PTL)</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "32 (95% CI = 0.01-7.69)</td><td>One-off ultrasound-indicated</td><td>RR = 1.31 (95% CI = 0.84-2.04)</td></tr><tr><td>Total</td><td>RR = 0.46 (95% CI = 0.14-1.48)</td><td>(low/unspecified risk for PTL) Total</td><td>RR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "19 (95% CI = 1.01-1.40)</td></tr></table></body></html> CI confidence interval, PTL preterm labour, RR risk ratio Pooled data published by Alfirevic et al.1034 on the effectiveness and safety of cervical cerlage (stitch) for preventing birth in singleton pregnancy compared to expectant management (no treatment) (continued) <html><body><table><tr><td>Parameter</td><td>Cerclage versus no treatment</td><td>Parameter</td><td>Cerclage versus no treatment</td></tr><tr><td>Preterm birth (<34 completed weeks)</td><td colspan=\"3\">Pyrexia</td></tr><tr><td>History-indicated</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "76 (95% CI = 0.40-1.46)</td><td>History-indicated</td><td>RR = 2.22 (95% CI) 1.22-4.01)</td></tr><tr><td>One-off ultrasound-indicated (high risk for PTL)</td><td>RR = 0.63 (95% CI = 0.27-1.46)</td><td>One-off ultrasound-indicated (high risk for PTL)</td><td>RR = 3.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "44 (95% CI = 0.15-81.09)</td></tr><tr><td>Serial ultrasound-indicated (high riskforPTL)</td><td>RR = 0.77 (95% CI = 0.55-1.10)</td><td>Serial ultrasound-indicated (high riskfor PTL)</td><td>not estimable</td></tr><tr><td>One-off ultrasound-indicated (low/unspecified risk forPTL)</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "82 (95% CI = 0.55-1.22)</td><td>One-off ultrasound-indicated (low/unspecified risk forPTL)</td><td>RR = 6.66 (95% CI = 0.35- 127.20)</td></tr><tr><td>Total</td><td colspan=\"3\">RR = 0.79 (95% CI = 0.68-0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "93) Total</td></tr><tr><td>Chorioamnionitis History-indicated</td><td colspan=\"3\">Maternal side effects</td></tr><tr><td>One-off ultrasound-indicated</td><td>RR = 2.97 (95% CI = 0.12-72.81) not estimable</td><td>History-indicated One-off ultrasound-indicated</td><td>RR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "57 (95% CI = 0.76-3.24) not estimable</td></tr><tr><td>(high risk for PTL) Serial ultrasound-indicated</td><td></td><td>(high risk for PTL) Serial ultrasound-indicated</td><td>not estimable</td></tr><tr><td>(high risk for PTL) One-off ultrasound-indicated</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "41 (95% CI = 0.03-6.21)</td><td>(high risk for PTL)</td><td></td></tr><tr><td>(low/unspecified risk forPTL)</td><td>RR = 1.29 (95% CI = 0.39-4.23)</td><td>One-off ultrasound-indicated (low/unspecified riskforPTL) Total</td><td>RR = 5.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "95 (95% CI = 1.36-26.06)</td></tr><tr><td>Total pPROM</td><td colspan=\"3\">RR = 0.84 (95% CI = 0.26-2.72)</td></tr><tr><td>History-indicated</td><td colspan=\"3\">RR = 1.63 (95% CI = 0.71-3.70)</td></tr><tr><td>One-off ultrasound-indicated</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "49 (95% CI = 0.14-1.72)</td><td></td><td></td></tr><tr><td>(high risk for PTL) Serial ultrasound-indicated</td><td>RR = 0.51 (95% CI = 0.18-1.45)</td><td></td><td></td></tr><tr><td>(high risk for PTL) One-off ultrasound-indicated</td><td>RR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "32 (95% CI = 0.78-2.23)</td><td></td><td></td></tr><tr><td>(low/unspecified risk forPTL)</td><td></td><td></td><td></td></tr><tr><td>Total</td><td>RR = 0.96 (95% CI = 0.62-1.48)</td><td></td><td></td></tr></table></body></html> CI confidence interval, pPROM preterm spontaneous rupture of membranes, PTL preterm labour, RR risk ratio Table 31.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Pooled data published by Rafael et al.1077 on the effectiveness and safety of cervical cerlage (stitch) for preventing birth in multiple pregnancy compared to expectant management (no treatment) <html><body><table><tr><td>Parameter</td><td>Cerclage versus no treatment</td><td>Parameter</td><td>Cerclage versus no treatment</td></tr><tr><td> All peritoneal losses</td><td></td><td> Serious neonatal morbidity</td><td></td></tr><tr><td>Twin only-indicated</td><td>RR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "19 (95% CI = 0.47-3.02)</td><td> Twin only-indicated</td><td> not estimable</td></tr><tr><td> Twin and history-indicated</td><td>RR = 1.33 (95% CI = 0.20-8.80)</td><td> Twin and history-indicated</td><td>not estimable</td></tr><tr><td> Ultrasound-indicated</td><td>RR = 2.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "66 (95% CI = 0.83-8.54)</td><td>Ultrasound-indicated</td><td>RR = 2.59 (95% CI= 0.85-7.86)</td></tr><tr><td>Triplets</td><td>RR = 3.00 (95% CI= 0.38-23.68)</td><td>Triplets</td><td>RR = 0.11 (95% CI= 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "01-1.80)</td></tr><tr><td>Total</td><td>RR = 1.74 (95% CI = 0.92-3.28)</td><td>Total</td><td>RR = 0.96 (95% CI = 0.13-7.10)</td></tr><tr><td> Stillbirths</td><td></td><td>Neonatal deaths</td><td></td></tr><tr><td>Twin only-indicated</td><td>not estimable</td><td>Twin only-indicated</td><td>RR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "19 (95% CI= 0.47-3.02)</td></tr><tr><td>Twin and history-indicated</td><td>RR = 0.26 (95% CI = 0.01-5.26)</td><td> Twin and history-indicated</td><td>not estimable</td></tr><tr><td>Ultrasound-indicated</td><td>not estimable</td><td>Ultrasound-indicated</td><td>RR = 5.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "57 (95% CI = 0.44-70.55)</td></tr><tr><td>Triplets</td><td>not estimable</td><td>Triplets</td><td>not estimable</td></tr><tr><td>Total</td><td>RR = 0.26 (95% CI = 0.01-5.26)</td><td>Total</td><td>RR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "60 (95% CI = 0.69-3.74)</td></tr><tr><td>Preterm birth (< 28 completed weeks)</td><td></td><td>Preterm birth (< 32 completed weeks)</td><td></td></tr><tr><td>Twin only-indicated</td><td>RR = 0.52 (95% CI = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "05-5.36)</td><td>Twin only-indicated</td><td>not estimable</td></tr><tr><td>Twin and history-indicated</td><td>RR = 1.33 (95% CI = 0.09-19.23)</td><td> Twin and history-indicated</td><td>RR = 0.33 (95% CI=0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "04-2.61)</td></tr><tr><td>Ultrasound-indicated</td><td>RR = 2.62 (95% CI = 0.72-9.51)</td><td>Ultrasound-indicated</td><td>RR = 2.48 (95% CI = 0.96-6.37)</td></tr><tr><td>Triplets</td><td>RR = 1.00 (95% CI = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "10-9.61)</td><td>Triplets</td><td>RR = 1.00 (95% CI= 0.32-3.10)</td></tr><tr><td>Total</td><td>RR = 1.54 (95% CI = 0.63-3.81)</td><td>Total</td><td>RR = 1.43 (95% CI = 0.72-2.83)</td></tr><tr><td> Preterm birth (< 34 completed weeks)</td><td></td><td>Preterm birth (< 35 completed weeks)</td><td></td></tr><tr><td>Twin only-indicated</td><td>not estimable</td><td> Twin only-indicated</td><td> not estimable</td></tr><tr><td>Twin and history-indicated</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "27 (95% CI = 0.04-1.99)</td><td> Twin and history-indicated</td><td>RR = 0.22 (95% CI= 0.03-1.61)</td></tr><tr><td> Ultrasound-indicated</td><td>RR = 2.19 (95% CI = 0.72-6.63)</td><td>Utrasound-indicated</td><td>RR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "63 (95% CI= 0.88-3.02)</td></tr><tr><td>Triplets</td><td>RR = 0.71 (95% CI = 0.31-1.66)</td><td>Triplets</td><td>RR = 0.71 (95% CI = 0.31-1.66)</td></tr><tr><td>Total</td><td>RR = 1.16 (95% CI = 0.44-3.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "06)</td><td>Total</td><td>RR = 1.11 (95% CI = 0.58-2.14)</td></tr><tr><td>Preterm birth (< 37 completed weeks)</td><td></td><td>Mean gestational age at delivery</td><td></td></tr><tr><td>Twin only-indicated</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "95 (95% CI = 0.51-1.78)</td><td>Twin only-indicated</td><td>not estimable</td></tr><tr><td>Twin and history-indicated</td><td>RR = 1.33 (95% CI = 0.71-2.51)</td><td>Twin and history-indicated </td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "70 (95% CI = -3.50-4.90)</td></tr><tr><td>Utrasound-indicated</td><td>RR = 1.18 (95% CI = 0.91-1.53)</td><td>Utrasound-indicated</td><td>RR = -1.24 (95% CI= -3.13-0.66)</td></tr><tr><td>Triplets</td><td>RR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "00 (95% CI = 0.59-1.69)</td><td>Triplets</td><td>RR = -2.00 (95% CI = 11.23-7.23)</td></tr><tr><td>Total</td><td>RR = 1.13 (95% CI = 0.89-1.43)</td><td>Total</td><td>RR = -0.95 (95% CI = -2.64-0.75)</td></tr><tr><td>Low birthweight (< 2,500 g)</td><td></td><td>Very low birthweight (< 1,500 g)</td><td></td></tr><tr><td>Twin only-indicated</td><td> not estimable</td><td>Twin only-indicated</td><td> not estimable</td></tr><tr><td> Twin and history-indicated</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "91 (95% CI = 0.62-1.34)</td><td> Twin and history-indicated</td><td>RR = 0.19 (95% CI= 0.03-1.45)</td></tr><tr><td> Ultrasound-indicated</td><td>RR = 1.39 (95% CI = 1.06-1.83)</td><td>Ultrasound-indicated</td><td>RR = 3.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "31 (95% CI = 1.58-6.91)</td></tr><tr><td>Triplets</td><td>RR = 0.79 (95% CI = 0.54-1.16)</td><td>Triplets</td><td>RR = 1.00 (95% CI= 0.52-1.92)</td></tr><tr><td>Total</td><td>RR = 1.10 (95% CI = 0.82-1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "48)</td><td>Total</td><td>RR = 1.42 (95% CI = 0.52-3.85)</td></tr><tr><td> Respiratory distress syndrome</td><td></td><td> Intraventricular hemorrhage</td><td></td></tr><tr><td>Twin only-indicated</td><td>not estimable</td><td> Twin only-indicated</td><td>not estimable</td></tr><tr><td>Twin and history-indicated</td><td>not estimable</td><td>Twin and history-indicated</td><td>not estimable</td></tr><tr><td>Utrasound-indicated</td><td>RR = 5.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "07 (95% CI = 1.75-14.70)</td><td>Ultrasound-indicated</td><td>RR = 1.13 (95% CI = 0.27-4.74)</td></tr><tr><td>Triplets</td><td>RR = 0.11 (95% CI = 0.01-1.80)</td><td>Triplets</td><td>RR = 0.33 (95% CI= 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "02-7.24)</td></tr><tr><td>Total Sepsis</td><td>RR = 1.70 (95% CI = 0.15-18.77)</td><td>Total</td><td>RR = 0.88 (95% CI= 0.25-3.12)</td></tr><tr><td></td><td></td><td>NICU admission</td><td></td></tr><tr><td>Twin only-indicated</td><td>not estimable</td><td>Twin only-indicated</td><td>not estimable</td></tr><tr><td>Twin and history-indicated</td><td>not estimable</td><td>Twin and history-indicated </td><td>not estimable</td></tr><tr><td>Utrasound-indicated</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "23 (95% CI = 0.01-4.58)</td><td> Ultrasound-indicated</td><td>RR = 0.35 (95% CI = 0.06-2.12)</td></tr><tr><td>Triplets</td><td>RR = 0.33 (95% CI = 0.02-7.24)</td><td>Triplets</td><td>not estimable</td></tr><tr><td>Total</td><td>RR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "27 (95% CI = 0.03-2.31)</td><td>Total</td><td>RR = 0.35 (95% CI= 0.06-2.12)</td></tr><tr><td>Caesarian section</td><td></td><td>Maternal side-effects</td><td></td></tr><tr><td>Twin only-indicated</td><td>RR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "34 (95% CI = 0.61-2.98)</td><td> Twin only-indicated</td><td>not estimable</td></tr><tr><td>Twin and history-indicated</td><td>RR = 1.07 (95% CI = 0.36-3.14)</td><td> Twin and history-indicated</td><td>RR = 3.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "92 (95% CI = 0.17-88.67)</td></tr><tr><td>Ultrasound-indicated</td><td>not estimable</td><td>Ultrasound-indicated</td><td> not estimable</td></tr><tr><td>Triplets</td><td>not estimable</td><td>Triplets</td><td>not estimable</td></tr><tr><td>Total</td><td>RR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "24 (95% CI = 0.65-2.35)</td><td>Total</td><td>RR = 3.92 (95% CI = 0.17-88.67)</td></tr></table></body></html> CI confidence interval, NICU neonatal intensive care unit, RR risk ratio # 12 Clinically occult carcinoma diagnosed after simple hysterectomy # 12.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1 Summary of available scientific evidence # 12.1.1 Reoperation Three studies1084-1086 comparing reoperation with other therapeutic options in patients with occult invasive cervical cancer found after inadvertent simple hysterectomy were identified.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In the first identified study1084, the treatment groups (radical parametrectomy, radiation therapy, and CCRT) were similar for age, body mass index (BMI), FIGO stage, tumour diameter, and LVSI.The decision regarding the type of treatment to be used was not made based on patient characteristics (BMI, age), or the disease status (tumour diameter, FIGO stage, pathology).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In case of local residual macroscopic disease, concomitant chemoradiation were preferentially performed, if possible.Surgical reoperation effectively decreased the risk of local recurrence ( $0 \\%$ versus $3 7 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "5 \\%$ ), and secondarily, it significantly increased survival (5-year OS, $1 0 0 \\%$ versus $7 7 \\%$ ${ \\mathrm { ( p } } = 0 .0 4 { \\mathrm { ) } } $ ), and 5-year DFS, $8 6 \\%$ versus $3 7 \\%$ $\\left( \\mathrm { p } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 2 \\right)$ ).It should be noted that complementary treatment was necessary in $3 8 \\%$ of the patients, and adjuvant external radiation therapy was required in $3 0 \\%$ of the patients in the surgical group.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The gain in terms of 10-year DFS and 10-year OS in favor of surgical group as compared to radiation therapy group (radiation therapy or CCRT therapy) and observation group (no definitive group) did not reached statistical significance in the second identified study1085 (10- year DFS: $1 0 0 \\%$ , $9 3 \\%$ and $6 3 \\% ,$ respectively ${ \\mathrm { ( p = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1 9 9 } } ^ { \\prime } $ ); 10-year-OS: $1 0 0 \\%$ , $9 4 \\% ,$ and $8 4 \\% ,$ respectively $( \\mathrm { p } ~ = ~ 0 .2 7 6 )$ ).The treatment groups were similar notably for age, FIGO stage, tumour diameter, and LVSI.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted that in the study published by Narducci et al.1084, there were (1) bigger tumours $2 2 \\AA - 3 1 ~ \\mathrm { m m }$ versus $1 1 - 1 7 ~ \\mathrm { m m } ^ { \\cdot }$ ) and (2) more LVSI $5 5 \\substack { - 6 0 \\% }$ versus $3 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "8 \\substack { - 2 2 .7 \\% }$ ).That might have explained the significance of the difference observed by Narducci et al.1084 with less follow-up.The survival differences reported by Park et al.1085 may have become significant for these smaller lesions with a longer follow-up period.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "After a median follow-up of 116 months, there was no recurrence in the surgical group, versus $6 .8 \\%$ in the radiation therapy group and $3 4 .6 \\%$ in the observation group.The third identified study1086 reported a higher 5-year OS rate in case of surgical treatment as compared to radiation therapy ( $6 1 \\%$ versus $3 0 \\%$ ).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted that these results have to be interpreted cautiously notably due to the obsolescence of the radiation therapy used in this study published almost 50 years ago.# LoE 3 Results from the eighteen other identified studies1087-1104 evaluating reoperation as therapeutic option are limited notably by the heterogeneity and the number of patients evaluated (seventeen studies1087,1088,1090-1104 have accrued less than 40 patients).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Among these identified studies, eight reports1087-1094 provide data on survival after at least 5-year follow-up period.Five-year OS rates after radical parametrectomy for occult cervical cancer have been found to range from $3 2 \\%$ to $1 0 0 \\%$ .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Taking into account the only four studies1087,1088,1093,1094 published in the last two decades, 5-year OS rates have been found to range from $8 8 .9 \\%$ to $1 0 0 \\%$ .Seventeen identified studies described perioperative complications up to $4 0 \\%$ of patients1084- 1088,1090-1093,1096-1100,1102-1104.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted that most complications were easily managed, either intraoperatively or conservatively.The occurrence of long-term morbidity after radical parametrectomy was rare.# 12.1.2 Adjuvant treatment Eighteen studies37,1105-1121 using only a single modality were identified.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Results from these LoE 3 studies are limited notably by the heterogeneity and the number of patients evaluated (seven studies1108,1109,1113,1115,1118-1120 have accrued less than 40 patients), and by the heterogeneity in the radiation therapy protocols used.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Five-year OS rates after radiation therapy (EBRT with or without intracavitary radiotherapy or chemoradiation) for occult cervical cancer have been found to range from $5 4 \\%$ to $1 0 0 \\%$ .Taking into account the only ten studies37,1112-1120 published in the last two decades, 5-year OS rates have been found to range from $5 9 \\%$ to $1 0 0 \\%$ .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Radioinduced complications were observed from $1 \\%$ to $2 7 \\%$ of patients in the identified studies published in the last two decades reporting such information.Treatment-related complications requiring hospitalization or surgical intervention were ranged from $1 \\%$ to $6 \\%$ of patients.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 12.1.3 No adjuvant treatment Based on the pathologic findings, Suh et al.1119 used the following criteria for risk scoring: one for depth of invasion is between $3 { \\cdot } 5 ~ \\mathrm { m m } ,$ and 2 for depth of invasion greater than 5 mm; one for longest diameter is between $0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "7 { - } 2 0 ~ \\mathrm { m m }$ , and 2 for longest diameter greater than 5 mm; one for lymphovascular space invasion positive  three each for parametrium, resection margin, and LN positive.The final score was calculated by summing up the risk scores.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Patient whose score was 1 to 3, 4 to 5, and 6 or higher was classified into low-risk, intermediate-risk, and high-risk groups, respectively.After a median follow-up of 67 months, all included patients in the low-risk group did not recur without any adjuvant treatment.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Among the eleven patients who did not receive any further treatment, no patient died of the disease.One recurrence was observed.Carcinoma in situ at resection margin was newly detected during the slide review, which made the score of the patient 4.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "However, resection margin had been initially negative on the pathology report after simple hysterectomy.That was the reason why the doctor did not consider any adjuvant treatment.After a mean follow-up period of 52.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "7 months, none of the patients with a tumour width $\\leq 2 0$ LoE 3 mm and superficial stromal invasion developed recurrence or died of the disease in the study published by Bai et al.1120.Taking into account all the patients who did not receive adjuvant treatment, 5-year OS and 5-year PFS were $9 7 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "4 \\%$ and $9 7 .8 \\%$ , respectively.# 12.2 Previous initiatives One previous initiative424 presenting guidelines for management of patients with clinically occult carcinoma diagnosed after simple hysterectomy was identified.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 12.3 Development group comments Occult cervical cancer lesions are generally asymptomatic small lesions found after simple hysterectomy (e.g.for myoma) and reported outcomes are therefore favourable.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "However, the few series reported in literature mainly consist of small retrospective series with heterogeneous cohorts consisting of mixed stages, histology and treatment, with inherent bias.The risk of potential disease in the parametria and LNs become relevant from tumour stage pT1a2 LVSI $^ +$ and beyond.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Radiotherapy alone or combined with chemotherapy (usually applied in those with gross residual disease or involved LNs at time of radiotherapy) is an effective alternative for radical surgery followed by adjuvant therapy in patients with risk factors (avoiding morbidity of combined radical surgery and radiotherapy).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Both treatment options have distinct profiles of treatment related morbidity and the limited literature in occult disease reflects the main findings from non-occult disease with highest morbidity rates in those with combined radical surgery and radiotherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Therefore, similar to non-occult disease, the treatment strategy should aim for the avoidance of combining radical surgery and radiotherapy.Established risk factors and indications for adjuvant radiotherapy based on combinations of tumour size, depth of invasion and the presence of LVSI should be taken into account.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "General recommendations regarding te workup and management follow the same principles to those of non-occult disease.# 12.4 Guidelines # 12.4.1 General recommendations Management of occult disease should be based on expert pathology review and discussed in a multidisciplinary tumor board.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Prior to making further management decisions, optimal imaging to evaluate the local and regional (nodal) disease status is necessary.Optimal imaging follows the same recommendations as that for nonoccult disease (see above).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# In general, management of occult disease follows the same principles as that of nonoccult disease.Treatment strategy should aim for the avoidance of combining radical surgery and radiotherapy because of the highest morbidity after combined treatment.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 12.4.2 Management of patients with pT1a1, LVSI $\\pm$ and pT1a2 LVSI-negative, with clear margins ![](images/4085c2fd567affbb525dcd32cd303961663d993726e6e11487bea282de072e41.jpg) In patients with tumor stage pT1a1 regardless of LVSI status and pT1a2 LVSI negative with clear margins in the hysterectomy specimen, no additional treatment is recommended.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 12.4.3 Management of patients with pT1a2 LVSI-positive or pT1b1 or pT2a1, with clear margins In patients with tumor stage pT1a2 LVSI positive or pT1b1 or pT2a1 after simple hysterectomy, potential disease in the parametria and LNs has to be addressed.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Radiotherapy or chemoradiotherapy is recommended as an effective treatment option that avoids further surgery.In absence of residual tumor on imaging (including suspicious LNs), radiotherapy alone is recommended.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In case of residual tumor on imaging, including suspicious LNs, chemoradiotherapy is recommended.PALN dissection, at least up to inferior mesenteric artery, may be considered in patients without suspicious para-aortic nodes on imaging for staging purposes.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Debulking of suspicious PLNs may be considered.Radical surgery is an option in patients without LN involvement on imaging and in the absence of an upfront indication for adjuvant radiotherapy (combination of negative prognostic factors.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "PLN dissection should be performed as the first step of the surgery.Intraoperative assessment of PLNs may be considered.If intraoperative LN assessment is negative or is not performed, radical parametrectomy with the resection of the upper vagina should be performed preferably using minimally invasive techniques.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The type of radical parametrectomy (extent of parametrial resection) should be tailored to the presence of prognostic risk factors of the primary tumor as described above (Figure 3).Complete description of the template used for radical parametrectomy should be present in the operative report.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The 2017 modification of the Querleu-Morrow classification is recommended as a tool (Figure 4).If LN involvement, including macrometastases or micrometastases, is detected intraoperatively, further surgery (PLN dissection and radical parametrectomy) should be avoided, and chemoradiotherapy is recommended.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# PALN dissection, at least up to inferior mesenteric artery, may be considered for staging purposes.Debulking of suspicious nodes may be considered.# 12.4.4 Management of patients with stage pT1b2 and higher or involved surgical margins or residual tumour including involved lymph node on imaging In patients with stage pT1b2 and higher, involved surgical margins or in those with residual tumor including involved lymph node on imaging, chemoradiotherapy is recommended, and further surgery should be avoided.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# C PALN dissection, at least up to inferior mesenteric artery, may be considered for staging purposes in patients with negative PALNs on imaging.Debulking of suspicious PLNs may be considered.# 13 Management of locally advanced cervical cancer # 13.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1 Summary of available scientific evidence # 13.1.1 Neoadjuvant chemotherapy A systematic review1122 of RCTs assessing the effect of NACT in two comparisons was identified.In the first comparison, NACT followed by radical radiotherapy was compared with the same radiotherapy alone (eighteen studies540,1123-1136 including three unpublished data).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cisplatin was the main drug in all the chemotherapy regimens.It should be noted that both the external beam radiation therapy dose and intracavitary radiotherapy dose varied (40-60.8 and 18-80 Gy, respectively), with a total dose in the range 55-80 Gy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Considering all trials together, there was no evidence of an effect of NACT on survival, or any of the other endpoints taken into account.However, there was a very high level of statistical heterogeneity, suggesting strongly that the results should not be combined in this way.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A substantial proportion of heterogeneity was explained by prespecified analyses grouping trials according to the way they delivered the chemotherapy.Trials which gave more intensive chemotherapy in terms of shorter cycle length and/or a higher dose intensity tended to show an advantage for NACT, whereas those that delivered chemotherapy in a less intensive and more prolonged manner, with a longer cycle length or a lower dose intensity, tended to show a detrimental effect of chemotherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "For trials giving cycles greater than 14 days, a detriment was observed in overall and locoregional DFS and metastases-free survival.In contrast, trials using shorter cycle lengths observed an improvement in 5-year OS.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Results for overall and locoregional DFS and metastases-free survival similarly suggested a benefit for short-cycle chemotherapy.Trials using less than $2 5 \\mathrm { \\ m g } / \\mathrm { m } ^ { 2 } ,$ /wk suggested a significant reduction in 5-year survival, with comparable reductions in overall and locoregional DFS and metastases-free survival.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "On the other hand, trials using dose intensities of cisplatin greater than $2 5 ~ \\mathrm { m g / m ^ { 2 } / w k }$ suggested a potential improvement in 5-year survival, but this is not conventionally statistically significant.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Similar improvements in overall, locoregional disease-free and metastases-free survival were found, but again these results were not conventionally significant.A RCT1137 not included in the systematic review1122 mentioned was also identified.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Despite the high response rate of NACT (bleomycin, vincristine, mitomycin and cisplatin chemotherapy: $7 2 \\%$ ), the combination (NACT plus radiotherapy) failed to improve the 5-year survival rates of patients with LACC when compared with radiotherapy alone.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It was also noteworthy that the incidence of distant metastasis was not reduced by the use of NACT.In the second comparison described in the systematic review1122 mentioned above, NACT followed by surgery was compared with radical radiotherapy alone (five studies1125,1126,1138- 1140).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Here again, cisplatin was the main drug in all of the chemotherapy regimens.But, contrary to the first comparison, external beam radiation therapy and intracavitary radiotherapy doses in the control arm were very similar across trials (45-60 and 25-40 Gy, respectively).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Combining the results of all trials indicated a high significant reduction in the risk of death with NACT.The results for overall DFS and locoregional DFS are very similar to those for survival, although there was a greater degree of heterogeneity.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "There was no evidence to suggest that the effect of NACT on survival varied across groups of patients defined by age, stage, histology, grade or performance status.It should be noted that (1) there was a greater proportion of stage IB-II patients than in the first comparison, (2) intra-arterial chemotherapy and pelvic radiotherapy were used in the NACT plus surgery arm in one trial1138, (3) almost all patients received pelvic radiotherapy in two trials1125,1126, and (4) pelvic radiotherapy was given to approximately $3 0 \\%$ of patients in another two trials1138,1139.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A $\\mathrm { R C T } ^ { 5 4 1 }$ comparing NACT followed by radical surgery or external-beam radiation therapy followed by brachytherapy in patients suffering from cervical cancer in stages IB-III was also identified.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A 5-year DFS rate for the NACT arm and radiotherapy arm, respectively, of $7 7 .1 \\%$ and $6 4 .3 \\%$ in stages IB-IIA $\\mathrm { ( p < 0 .0 5 ) }$ ), $5 6 .2 \\%$ and $5 7 .1 \\%$ in stage IIB $\\mathrm { ( p > 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 5 \\vec { \\bf { \\sigma } } }$ ) was found.No significant differences in terms of 5-year OS rates were identified between the two treatment arms whatever the stages taken into account.A systematic review1141 assessing the effects of NACT in women with LACC compared with planned surgery alone was also identified (six RCTs77,540-542,1142,1143).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Both OS and PFS were significantly improved with NACT $\\mathrm { ( H R = 0 .7 6 }$ ( $9 5 \\%$ $\\mathrm { C I } = 0 .5 9 – 0 .9 \\mathrm { \\ : } .$ 9), $\\mathrm { ~ p ~ = ~ 0 .0 4 ~ }$ and $\\mathrm { H R } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "7 2$ ( $9 5 \\% \\mathrm { C I } = 0 .5 5 – 0 .9 5$ ), $\\mathrm { \\ p } = 0 .0 2$ , respectively).A non-significant trend was observed in terms of local recurrence, distant recurrence and rates of radical resection in favour of NACT.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "There was also no significant differences in the effect of NACT on survival according to total cisplatin dose, chemotherapy cycle length or by cervical cancer stage.Yang et al.1144 performed a RCT to evaluate the toxicity and curative effect of NACT for stage IB2, IIA2, and IIB cervical cancer patients.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Patients were randomly assigned to received NACT or to be treated directly with surgery.Survival analysis revealed no significant difference in DFS or OS between the two treatment groups.It should be noted that the LVSI and deep stromal invasion rates were significantly lower in the NACT group.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Patients in the NACT group were then randomly assigned to be treated with irinotecan plus cisplatin followed by surgery or to be treated with paclitaxel plus cisplatin followed by surgery.Here again, no significant difference in DFS or OS between the two treatment groups were reported.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "No statistically significant difference in response rate between the two groups was also observed.The irinotecan/cisplatin regimen was associated with higher grade 3-4 neutropenia and grade 3-4 diarrhea compared to paclitaxel/cisplatin combination ( $1 6 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "3 \\%$ versus $1 .7 \\% ,$ , $\\mathrm { ~ p ~ } = \\ 0 .0 0 5$ and $1 2 .2 \\%$ versus $0 \\%$ , ${ \\mathrm { p } } = 0 .0 0 8$ , respectively).# LoE 2- NACT did not significantly improve long-term PFS and/or OS of patients with LACC compared to primary surgery in seven other identified studies543,1145-1150.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted that (1) when OS rates among patients with stage IB2 squamous cell carcinoma were specifically compared by Abou-Taleb et al.1145, patients treated with NACT followed by surgery had significantly higher OS rates than those treated with primary surgery ${ \\mathrm { ( p = 0 } } .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 3 4 { \\cdot }$ ), and (2) the gain in OS did not reached statistical significance in the study published by Behtash et al.543 probably due to the very small number of patients who received NACT.Yamakawa et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1151 found that neoadjuvant intraarterial chemotherapy was able to improve the prognosis of patients with LACC.The estimated 5-year OS rate was significantly higher for patients who received neoadjuvant intraarterial chemotherapy than for the patients who underwent conventional treatment ( $8 0 \\%$ versus $5 9 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "6 \\%$ $\\mathrm { p } = 0 .0 0 4 \\mathrm { \\AA }$ .In stage II and III, the 5- year survival rate for patients who received neoadjuvant intraarterial chemotherapy was significantly higher than that in the control group ( $8 3 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "3 \\%$ versus $6 8 .1 \\%$ $\\mathrm { p } = 0 .0 2 9$ and $7 7 .8 \\%$ versus $4 9 .8 \\% ,$ $\\mathrm { p } = 0 .0 1 3$ , respectively).Two RCTs95,1152 comparing two NACT regimens were identified.The first one1152 compared a three-drug combination of paclitaxel, ifosfamide, and cisplatin versus paclitaxel and cisplatin followed by surgery.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The three-drug combination confirmed its activity (optimal response rate: $4 3 \\%$ versus $2 5 \\%$ ) but was associated with higher grade 3-4 haematological toxicity than the paclitaxel/cisplatin regimen ( $78 \\%$ versus $2 9 \\%$ , $\\mathrm { ~ p ~ } < 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 0 0 1 \\$ ).The overall optimal response OR showed a significant benefit of three-drug combination over doublet in a logistic multivariate analysis which contained grade and age as covariates ( $\\mathrm { \\Delta O R } = 2 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "3$ ( $9 5 \\% \\mathrm { C I } = 1 .1 { - } 4 .7$ ), $\\mathrm { p } = 0 .0 2 7 \\mathrm { .}$ ).It should be noted that the gain in failure rate and OS in favor of the three-drug combination did not reach statistical significance.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In the second identified RCT95, the optimal pathologic response rate was higher with the paclitaxel/ifosfamide/cisplatin combination than with the ifosfamide/cisplatin doublet ( $\\mathbf { \\mathrm { { O R } = } }$ 3.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "22 ( $9 5 \\%$ $\\mathrm { ~ , ~ } \\mathrm { C I } = 1 .6 9 \\mathrm { - } 5 .8 \\&$ ), $\\mathrm { p } = 0 .0 0 0 3 ^ { \\cdot }$ ) but no difference in survival was observed.Moreover, the triplet was associated with significant higher rates of severe (grade 3-4) neutropenia, thrombocytopenia, and anemia than the ifosfamide/cisplatin schedule ( $5 5 \\%$ versus $4 1 \\%$ $[ { \\mathfrak { p } } =$ 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "02), $1 3 \\%$ versus $7 \\%$ ${ \\mathrm { ( p = 0 } } .0 2 { \\mathrm { ) } }$ , and $1 7 \\%$ versus $1 1 \\%$ ${ \\mathrm { ~ \\sigma ~ } } _ { \\mathrm { { p } } } = 0 .0 5 { \\mathrm { ~ \\sigma ~ } }$ ), respectively).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Yin et al.1153 found that nedaplatin and paclitaxel followed by surgery offers a higer response LoE 2- rate $8 0 .7 7 \\%$ versus $6 8 .2 4 \\%$ , $\\mathrm { p } = 0 .0 2 6 7 \\mathrm { .}$ ), lower incidence of grade 3-4 toxic reactions $( 3 2 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "6 9 \\%$ versus $8 5 .1 4 \\%$ , $\\mathrm { p } < 0 .0 0 0 1 \\dot { \\mathrm { \\Omega } }$ , and better 5-year DFS ( $8 1 .4 1 \\%$ versus $6 7 .2 8 \\%$ , $\\mathrm { p } = 0 .0 1 4 \\mathrm { \\cdot }$ ) and 5- year OS ( $9 3 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "8 9 \\%$ versus $8 1 .5 4 \\%$ , $\\mathrm { p } = 0 .0 0 8 4 \\dot { }$ ) for patients with LACC compared with the NACT regimen of paclitaxel and cisplatin followed by surgery.A third systematic review1154 (thirty studies77,540-542,545,1139,1140,1155-1177) evaluating the effectiveness of NACT for the management of LACC from stage IB2 to IIIB was identified.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Twenty-nine studies77,540-542,545,1139,1140,1155-1175,1177 used chemotherapy doublets, or triplets.The most commonly used chemotherapy agents were platinum derivatives (cisplatin77,540- 542,545,1139,1140,1156,1159-1161,1163-1169,1171-1175,1177, carboplatin1155,1170, or nedaplatin1157).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The authors reported an overall response rate of $8 4 \\%$ .Trials that included platinum derivatives had an overall response rate of $7 9 \\%$ .Trials based on cisplatin had an overall response rate of $7 6 \\%$ , whereas studies that did not include cisplatin achieved an overall response rate of $78 \\%$ ${ \\mathrm { ( p ~ } } =$ 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "07).While included studies that did not include platinum derivatives had an overall response rate of $8 0 \\%$ .Considering survival results (twenty-one studies77,541,542,1139,1140,1155,1157-1160,1162,1164- 1166,1168,1169,1171-1173,1175,1177), the mean 5-year PFS was $5 8 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "9 \\% ,$ and the mean 5-year OS was $6 2 \\%$ .For stage IB2-IIA, the mean 2-year PFS was $7 9 .1 \\%$ and the 2-year OS was $8 6 \\%$ .The mean 5- year PFS was $7 2 \\%$ and the mean 5-year OS was $8 3 .4 \\%$ .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "For stage IIB-III, the mean 2-year PFS was $6 9 \\%$ and the mean 2-year OS was $7 5 \\%$ .All the 21 studies that assessed survival reported relapse data.During the 2-year follow-up period, the locoregional pattern occurred in $6 0 \\%$ of relapsed patients, whereas a disseminated relapse occurred in $4 0 \\%$ of them.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "For the 5-year follow-up period, locoregional relapse occurred in $5 2 \\%$ of the relapsed patients, whereas a disseminated relapse occurred in $2 8 \\%$ of them.These 21 included studies also reported data about early toxicities.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Leucopenia and neutropenia were the most common grade 3-4 early toxicities and occurred in $1 8 .3 \\%$ and $3 3 .3 \\%$ of chemotherapy cycles respectively.No grade 3-4 late toxicities were reported.A meta-analysis1178 (seven studies541,1139,1140,1164,1179-1181) was identified but is not described due to major methodological limitations.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Twenty-nine other studies746,1182-1209 not included in the systematic reviews mentioned above, LoE 3 and evaluating combinations of drugs were also identified.Corresponding response rates and survival are summarized in table 32.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 13.1.2 Surgery Two $\\operatorname { R C T S } ^ { 9 4 , 9 5 }$ comparing preoperative radiotherapy and radical hysterectomy versus LoE 1- radiotherapy alone, were identified.In the first one68, patients with “bulky” stage IB cervical cancer were randomized to either external and intracavitary irradiation or attenuated irradiation followed by extrafacial hysterectomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The addition of extrafascial hysterectomy to standardized radiation therapy did not improve PFS or OS.It should be noted that (1) there was a lower cumulative incidence of local relapse at five years in the combined treatment regimen ( $2 7 \\%$ versus $1 4 \\%$ ) and (2) hysterectomy did not increase the frequency of reported grade 3-4 adverse effects.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In the second one1210, patients with stage IB-IIA cervical cancer were randomized to either irradiation alone or irradiation and radical hysterectomy.No differences in terms of tumour-free actuarial survival at five years and severe complications were observed.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Another identified RCT1211 compared hysterectomy (extrafascial or radical) with no hysterectomy in patients with a (clinical and radiological) complete response after chemoradiotherapy for stage IB2-II cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "There was no difference in OS or RFS at three years between treatment groups.It should be noted that adverse events and morbidity were not reported.The fourth identified RCT1212 found no difference in the risk of death, disease progression or severe late complications between women who received standard brachytherapy versus radical hysterectomy after both groups had received identical external beam chemoradiotherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A systematic review1213 was identified but is not described because it contains only the four RCTs68,1210-1212 mentionned above.# LoE 3 As part of a small study, Okame et al.1214 compared radiotherapy and surgery as a primary treatment of LACC.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Three-year locoregional control rates were significantly better in patients who underwent radical hysterectomy in comparison with patients treated with radiotherapy $( 7 9 .0 \\%$ versus $4 6 .2 \\%$ , $\\mathrm { \\Delta p = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 3 } ^ { \\cdot }$ ).The advantage in terms of 5-year OS rates in favour of radical hysterectomy did not reach statistical significance ( $7 0 .7 \\%$ versus $3 8 .5 \\%$ , ${ \\mathrm { p } } = 0 .0 9$ ).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted that these results have to be interpreted cautiously notably because (1) NACT and/or adjuvant chemotherapy was conducted in most radical hysterectomy cases, and this might had contributed to the improved results in comparison with radiotherapy, and (2) adjuvant chemotherapy regimens varied between the two groups.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "As part of another small study, Sarraf et al.1215 compared patients treated with EBRT and brachytherapy with EBRT and extrafascial hysterectomy in LACC.There were no significant differences between the two groups in metastasis, recurrence, and survival rates.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "LoE 2- Comparing radical hysterectomy after CCRT versus CCRT alone, Fanfani et al.1216 observed no difference in terms of DFS or OS at 3 years between the two groups.Additionally, they observed no differences in terms of distant recurrence rate, and a significantly higher rate of local recurrences for patients treated with hysterectomy after CCRT than those treated with CCRT alone ( $2 2 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1 \\%$ versus $1 0 .9 \\%$ , $\\mathrm { p } < 0 .0 0 2 \\$ ).In a study1217 comparing outcomes of patients with and without completion surgery after CCRT, survival was not statistically improved by completion surgery, although there was a trend to significance.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The gain in terms of recurrence rate for patients who did have a completion surgery did also not reach statistical significance.It should be noted that completion surgery after CCRT improved local disease control in patients with a partial patholofic response, and enhanced survival in the study published by Sun et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "108.In this study108, the DFS rates among patients who underwent extrafascial hysterectomy, extended hysterectomy, ot no completion surgery were $8 3 .2 \\%$ $7 1 .7 \\% ,$ and $5 4 .1 \\% ,$ respectively, at three years, and $6 6 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "4 \\% ,$ , $5 0 .7 \\%$ and $3 7 .2 \\%$ at five years ${ \\mathrm { ( p } } < 0 .0 5$ for all comparisons).The respective OS rates among patients who underwent extrafascial hysterectomy, extended hysterectomy, or no completion surgery were $7 2 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "2 \\% ,$ $6 0 .1 \\% ,$ and $4 5 .9 \\%$ at three years, and $5 3 .5 \\%$ , $4 0 .7 \\% ,$ and $3 2 .2 \\%$ at five years $\\mathrm { { \\bar { p } } } < 0 .0 5$ for all comparisons).Comparing DFS and OS of two groups of patients, with or without additional surgery, Lèguevaque et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "116 reported a relative risk of disease progression or death in favor of completion surgery $[ \\mathrm { R R } ~ = ~ 0 .4 1$ ( $9 5 \\% \\mathrm { ~ C I ~ } = \\ 0 .2 0 { - 0 .8 5 }$ ), $\\mathrm { ~ p ~ } = \\ 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 1 )$ .A significant benefit of completion surgery was seen in DFS ${ \\mathrm { ( p = 0 .0 1 } } { \\cdot }$ ).However, completion surgery did not improve OS.Four studies1217-1220 evaluating the feasibility and safety of different types of hysterectomy in the management of patients affected by LACC were identified.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In the first one1218, patients undergoing type C2 total extraperitoneal abdominal radical hysterectomy were compared with a historical control group of patients undergoing intraperitoneal radical hysterectomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In all patients tumour resection with disease free margins was achieved.No significant differences in terms of surgical data (except concerning the mean operative time in favour of total extraperitoneal abdominal radical hysterectomy: $1 9 5 ~ \\mathrm { { \\ m i n } }$ versus $2 3 5 \\ \\mathrm { m i n }$ $\\mathrm { ~ p ~ } < \\ 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 5 ^ { \\cdot }$ ) or complications were found.The second one1219 showed that the patients treated with type C2/III radical hysterectomy had same sexual activity and sexual enjoyment data compared with patients surgically treated for gynaecological benign disease.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted that oncologic group patients had clinically worse problems with symptom experience, body image, and sexual/vaginal functioning than benign gynaecological disease group $\\left( \\mathrm { p } < 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 5 \\right)$ .Oncologic group patients also reported more severe lymphedema, peripheral neuropathy, menopausal symptoms, and sexual worry.The third one1217 showed no significant differences in terms of recurrence, survival and late complication rates after radical hysterectomy than after extrafascial hysterectomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Panici et al.1220 evaluated the feasibility and safety of type B radical hysterectomy in the management of patients affected by LACC with favorable prognostic factors (tumour diameter $< 4 ~ \\mathrm { c m }$ , negative nodes, or LVSI).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Patients were compared with historical cohort of patients undergoing type C radical hysterectomy.Type B radical hysterectomy was associated with reduced operative time ( $1 0 5 ~ \\mathrm { m i n }$ versus $2 0 6 ~ \\mathrm { { m i n } }$ , $\\mathrm { ~ p ~ < ~ } 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 0 0 1 ^ { \\cdot }$ ) and hospital stay (4.6 days versus 6.3 days, $\\mathrm { ~ p ~ } \\leq \\ 0 .0 0 0 1 _ { .} ^ { \\cdot }$ ), without detrimental effect on survival or late postoperative morbidity.# LoE 3 Vizza et $a l .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "^ { 1 1 5 9 }$ evaluated the feasibility and morbidity of total laparoscopic radical hysterectomy with pelvic lymphadenectomy in LACC patients (stage IB2-IIB) with complete clinical response after NACT.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A conversion to laparotomy was required in $1 0 \\%$ of patients.No reoperation was noticed.Pathological evaluation showed complete response in $2 2 .5 \\%$ of patients, a partial response with microscopic tumour in $2 2 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "5 \\%$ of patients, and a partial response with macroscopic tumour in $3 7 .5 \\%$ of patients.No response was observed in $7 .5 \\%$ of patients.Favero et al.1221 evaluated the feasibility and safety of laparoscopic extrafascial hysterectomy and bilateral salpingo-oophorectomy after primary chemoradiotherapy in patients with LACC without evidence of nodal metastasis.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "No casualty related to surgery, intraoperative complication, or conversion to laparotomy occurred.Significant complication occurred in $12 \\%$ of the cases.All patients had free margins.Four studies577,1222-1224 assessing laparoscopic hysterectomy after NACT577,1222 or CCRT1223,1224 in LACC compared to laparotomy, were identified.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Considering the two identified studies577,1222 assessing laparoscopic hysterectomy after $\\mathsf { N A C T } ^ { 5 7 7 , 1 2 2 2 }$ compared to laparotomy, Cai et al.1222 reported that median operative time, number of harvested LNs, and rate of positive surgical margins did not differ significantly between the groups, but laparoscopic hysterectomy resulted in less median blood loss ( $3 0 0 ~ \\mathrm { m l }$ versus $3 7 5 \\ \\mathrm { m l } .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "$ , $\\mathrm { ~ p ~ } = \\ 0 .0 2 7 )$ .Laparoscopic radical hysterectomy offered less blood loss and lower transfusion rate in the study published by Ghezzi et al.577 ( $2 6 5 \\ \\mathrm { m l }$ versus $4 0 0 \\ \\mathrm { m l }$ $\\mathrm { ( p < 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 0 0 1 } \\AA \\mathrm { ) }$ and $1 .5 \\%$ versus $1 1 .3 \\%$ $( \\mathrm { p } = 0 .0 0 9 ]$ , respectively).No difference was found between open surgery and laparoscopy in intra- or post-operative complications.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "No patient had her radical surgery converted to an open procedure in both identified studies577,1222.In the first identified study1223 assessing laparoscopic hysterectomy after CCRT, there was no difference in operative time, or intra- and post-operative complication rates between the two groups.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Intraoperative transfusion and abdominal drain were significantly lower in the laparoscopy group, as well as the duration of hospital stay ( $0 \\%$ versus $1 3 \\%$ ${ \\mathrm { ( p = 0 .0 4 4 6 } } ^ { \\cdot }$ ), $7 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "5 \\%$ versus $7 8 .3 \\%$ $[ \\mathrm { p } < 0 .0 0 0 1 ]$ , and 5.7 days versus 7.3 days $\\mathrm { ( p < 0 .0 0 1 \\dot { } }$ ), respectively).Assessment of quality of life using EORTC QLQ-C30 at one week after surgery was better for patients having undergone laparoscopy compared to laparotomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "At one month, global health and quality of life, physical functioning and role functioning were better in the laparoscopy group $\\mathrm { { [ p = 0 .0 1 } }$ , $\\mathrm { p } = 0 .0 1$ , and $\\mathrm { p } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 5$ , respectively).At six months, the measurable benefits remained for patients who underwent laparoscopy, in particular ther experienced less fatigue than patients who underwent laparotomy $\\mathrm { ~ ( ~ p ~ \\ = ~ \\ } 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 4 )$ .Using the specific cervical cancer questionnaire, CX24, only sexual activity was significantly better at six months for the laparoscopy group ${ \\mathrm { ( p ~ = ~ } 0 .0 1 \\mathrm { ) } }$ .Consistent findings were described in the second identified study1224 in terms of duration of hospital stay (5 days versus 8 days, $\\mathrm { { p < 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 1 } }$ ), operative time, blood transfusion ( $2 .2 \\%$ versus $7 .1 \\%$ , $\\mathrm { ~ p ~ } = 0 .0 2$ ).However, postoperative complications were significantly reduced in the laparoscopic group $2 8 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "3 \\%$ versus $4 8 .1 \\%$ ${ \\mathrm { ~ p ~ } = \\mathrm { ~ 0 .0 4 } }$ ).It should be noted that the average estimated blood loss was significantly lower in this group ( $\\cdot 2 0 0 \\ \\mathrm { m l }$ versus $4 0 0 ~ \\mathrm { { m l } }$ , $\\mathrm { \\Delta p } < 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 1 \\dot { \\mathrm { \\Omega } }$ ) and the median duration of urinary catheterization was significantly shorter in this group (4 days versus 6 days, $\\mathrm { \\ p } < 0 .0 1 \\dot \\$ ).Four studies1225-1228 evaluating the feasibility and safety of robotic radical hysterectomy with pelvic lymphadenectomy for LACC after NACT1225-1227 or chemoradiotherapy1228 were also identified (Table 33).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In two100,101 of them, surgical outcomes were compared to those achieved by women undergoing robotic surgery for an early stage disease during the same temporal interval.In the first one1225, all but one of the procedures were successfully completed with robotic surgery in patients with LACC.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "No intraoperative complications or conversion to emergency laparotomy occurred in this group.No differences were encoutered between groups in terms of operative time, blood loss, hospitalization, nodal yield, parametrial and vaginal cuff length, and early postoperative complications.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Consistent findings were reported by Minig et al.1226 in terms of estimated blood loss, length of hospital stay, conversion to laparotomy, intra- and post-operative complications.However, the mean operative time was significantly longer in the robotic surgery group ( $3 0 7 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "8 ~ \\mathrm { m i n }$ versus $2 7 7 .4 ~ \\mathrm { m i n }$ $\\mathrm { ~ p ~ } { \\leq } \\ 0 .0 0 1 \\dot { }$ ).No conversion to laparotomy/laparoscopy was also necessary in the third identified study1227.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The authors experienced one intra-operative complication $( 1 .7 \\% )$ and nineteen early postoperative complications $( 3 1 .7 \\% )$ , but no conversion to laparotomy were necessary to manage these complications.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The surgical lateral margins of parametria were free of disease in all cases.As part of a small study, Gallotta et al.1228 reported a feasibility rate of robotic radical surgery in patients with LACC who received chemoradiotherapy of $9 7 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "5 \\%$ .No intraoperative complications were recorded.During the observation period, $2 2 .5 \\%$ of patients experienced postoperative complications.A study613 comparing the surgical outcome of robotic radical hysterectomy versus laparoscopic radical hysterectomy for the treatment of LACC after NACT, was also identified.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "No differences in terms ot median operative time, median length, and intra- and post-operative complications were observed between the two groups.However, the median estimated blood loss was statistically significant in favour of robotic radical hysterectomy group ( $\\mathrm { 1 6 0 ~ m l }$ versus $2 4 0 ~ \\mathrm { m l } .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "$ $\\mathrm { p } \\leq 0 .0 5 )$ .Corrado et al.1229 compared the surgical and oncological results of robotic surgery with a historical cohort of patients undergoing laparoscopic or abdominal hysterectomy plus pelvic lymphadenectomy for LACC after NACT.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Significant differences were found between the robotic surgery group and the two other groups in terms of operative time ( $\\mathrm { 1 8 0 ~ m i n }$ versus $2 2 0 ~ \\mathrm { { m i n } }$ versus $2 9 0 ~ \\mathrm { { m i n } }$ , $\\mathrm { ~ p ~ } < 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 0 1 \\$ ), estimated blood loss ( $\\mathrm { 1 5 0 ~ m l }$ versus $2 5 0 ~ \\mathrm { m l }$ versus 480 ml, $\\mathrm { p } < 0 .0 0 1 \\dot { }$ ), median hospital stay (4 days versus 6 days versus 8 days, $\\mathrm { p } < 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 0 1 \\$ ), and major late postoperative complications (5 versus 13 versus 28, $\\mathrm { ~ p ~ } < \\ 0 .0 0 1 \\dot { }$ ).No conversion to laparotomy in the robotic group was necessary.The median number of removed PLNs was statistically higher in the abdominal surgery group compared with the laparoscopic surgery group (25 versus 20, $\\mathrm { ~ p ~ } { < } 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 5 \\$ ), whereas no differences were observed between the abdominal surgery group and robotic surgery group and between the laparoscopic surgery group and the robotic surgery group.It should be noted that there were no significant differences between the 3-year OS and DFS rates in the minimally invasive groups.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 13.1.3 Radiotherapy Meta-analysis1213 of three RCTs1139,1140,1180 comparing NACT and hysterectomy versus radiotherapy alone, found that women who received NACT plus hysterectomy had less risk of death than those who received radiotherapy alone $[ \\mathrm { H R } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "7 1$ ( $9 5 \\% \\mathrm { C I } = 0 .5 5 \\ – 0 .9 3$ )).However, no difference in the risk of disease progression or recurrence between the two groups were reported.It should be noted that a significant number of the participants who received NACT plus hysterectomy had radiotherapy as well.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In terms of acute toxicity, only one1139 of the three1139,1140,1180 included RCTs provided data, and described no significant difference between the two groups.None of the two1139,1140 included RCTs reporting data on long-term complications and toxicity described significant difference between the two treatment groups.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A meta-analysis1230 evaluating the impact of the extension of the radiotherapy field cranially toward PALNs in LACC was also identified.All patients had undergone pelvic radiotherapy and the same systemic therapy (or not) in both treatment arms.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The radiotherapy technique was conventional in three included $\\mathrm { R C T s ^ { 1 2 3 1 - 1 2 3 4 } }$ and conformational in the last one399,1235.Extented-field irradiation significantly reduced the rate of para-aortic failure $\\mathrm { ( H R = 0 } .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "3 5$ ( $9 5 \\ \\%$ $\\mathsf { C I } = 0 .1 9 \\ – 0 .6 4 \\$ ), $\\mathrm { ~ p ~ } < 0 .0 1 \\dot { \\bf \\mathrm { ~ \\Omega ~ } }$ ) and the incidence of other distant metastases $[ \\mathrm { H R } = 0 .6 9$ ( $9 5 \\%$ CI = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "50-0.96), $\\mathrm { ~ p ~ } = \\mathrm { ~ 0 .0 3 ~ } \\cdot$ ).Locoregional failure and cancer-related death were not significantly altered.The increase number of treatment-related death due to extended-field irradiation reported by two included $\\mathrm { R C T s ^ { 1 2 3 1 - 1 2 3 3 } }$ did not statistically significant.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "More bone fractures were recorded in the extended-field irradiation arm of one $\\mathrm { R C T ^ { 1 2 3 4 } }$ but not in the second $\\mathsf { R C T } ^ { 1 2 3 1 }$ reporting such events.It should be noted (1) the absence of included RCTs that directly compared pelvic versus extended-field radiation with standard cisplatin chemotherapy in both treatment arms and (2) older radiotherapy techniques likely achieved the proximity to abdominal organs at risk, which might have caused the limiting high-grade toxicity events, such as bone fractures.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Dobrowsky et al.1236 randomized patients with stage IIIA or IIIB cervical cancer to either radical radiotherapy alone or radical radiotherapy and additional administration of AK-2123.The addition of AK-2123 to radical radiotherapy significantly increased local tumour control ( $6 1 \\%$ versus $4 6 \\%$ $\\mathrm { ~ p ~ } = \\ : 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 0 6$ ) and 5-year actuarial survival ( $5 7 \\%$ versus $4 1 \\%$ $\\mathrm { ~ p ~ } = 0 .0 1 \\dot { \\bf \\Phi } .$ ).AK2123 did neither increase local toxicity nor was it attributed to haematological toxicity.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A mild peripheral toxicity, usually completely reversible, was infrequently seen after AK-2123 administration.# 13.1.4 Brachytherapy A meta-analysis1237 (four studies1238-1241) showed no significant differences between high dose rate and low dose rate intracavity brachytherapy in combination with EBRT when considering OS, DSS, RFS, local control rate, recurrence, metastasis and treatment related complications for women with LACC.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "However, increased small bowel complications with high dose rate intracavity brachytherapy were described $[ \\mathrm { R R } = 3 .3 7$ $[ 9 5 \\% \\mathrm { C I } = 1 .0 6 \\ – 1 0 .7 2 ]$ ), $\\mathrm { ~ p ~ = ~ 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 4 ) }$ ).It should be noted that (1) there were broad differences in trial design, particularly with regard to the timing and total dose of EBRT and the fractionation schedules, (2) in one $\\mathrm { R C T ^ { 1 2 4 0 } }$ the subgroup radiotherapy schedules were based on tumour volume and local cervical anatomy rather than on disease stage1238,1239,1241.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "One previously published meta-analysis1242 showed also no differences between high dose-rate and low dose-rate intracavity brachytherapy in the survival and complication rates.It should be noted that four1238-1241 of the five RCTs1238-1241,1243 included in this meta-analysis1242 were also included in the meta-analysis published by Liu et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1237.The results mentioned above have been confirmed with a more recently published meta-analysis1244 including fifteen studies1240,1241,1245-1257, which also showed no difference in terms of OS, DFS, local recurrence, and complication rates.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Investigating whether high dose-rate intracavitary brachytherapy dose ratios can predict treatment outcomes in patients with stage IIB cervical cancer, Cho et al.1258 found that the 5- year DSS and PFS rates were significantly lower in the group with low high-dose rate intracavitary brachytherapy ratio compared to the group with the high high-dose rate intracavitary brachytherapy ratio (5-year DSS: $7 8 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "3 \\%$ versus $9 3 .1 \\%$ , $\\mathrm { p } = 0 .0 0 3$ and 5-year PFS: $7 2 .7 \\%$ versus $9 0 .7 \\% , \\mathrm { ~ p ~ } \\ = \\ 0 .0 0 7 .$ , respectively).A high high-dose rate intracavitary brachytherapy was confirmed as an independent prognostic factor for PFS $\\mathrm { \\tilde { H } R } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "2 5$ ( $9 5 \\%$ CI $= \\ 0 .0 6 \\substack { - 0 .9 6 }$ ), $\\mathrm { ~ p ~ = ~ } 0 .0 4 3 \\mathrm { ] }$ after controlling for age, pathological subtype, tumour size, PLN involvement, squamous cell carcinoma antign/haemoglobin levels, overall treatment durations, and total dose.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Comparing radiotherapy with chemoradiotherapy with high-dose-rate brachytherapy, the pooled analysis published by Mayadev et al.1259 (eighty studies11,98,114,1238,1239,1246,1260-1335) reported an improvement in pelvic control and DFS in favour of chemoradiotherapy with highdose-rate brachytherapy whereas the OS of the groups were similar, whatever the study type taken into account: Prospective studies: pelvic control: $8 1 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "2 7 \\%$ versus $7 3 .4 9 \\%$ , DFS: $6 5 .4 4 \\%$ versus 55.23, OS: $7 0 .1 5 \\%$ versus $6 6 .0 6 \\%$ Retrospective studies: pelvic control: $8 0 .5 1 \\%$ versus $7 4 .8 2 \\%$ , DFS: $6 3 .0 2 \\%$ versus $5 5 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "7 2 \\% ,$ OS: $6 6 .1 9 \\%$ versus $5 4 .0 5 \\%$ Comparing patients receiving CCRT and image-based brachytherapy to traditional Point A dose specification, significant improvements in pelvic control ( $8 6 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 0 \\%$ versus $8 3 .8 4 \\%$ , $\\mathrm { { p } } < 0 .0 1 \\dot { }$ ) and DFS ( $7 2 .4 6 \\%$ versus $6 9 .5 1 \\%$ $\\mathrm { \\ p } < 0 .0 1 \\dot { }$ ) were described with image-based brachytherapy.The OS of the groups were statistically different, with the mean OS better in the Point A dose group versus the image-based brachytherapy group ( $7 3 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "3 6 \\%$ versus $6 4 .3 3 \\%$ , $\\mathrm { { p < 0 .0 1 } }$ ).As part of a systematic review, Mendez et al.1336 evaluated local control and toxicities of perineal-based interstitial brachytherapy in patients treated with three-dimensional imagebased planning.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "All patients received EBRT $( 4 5 - 5 0 .4 ~ \\mathrm { G y } )$ as a first phase of treatment and $7 7 .8 \\%$ of patients that had chemotherapy information available received concomitant chemotherapy with EBRT.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Sixty per cent of patients treated with perineal-based interstitial brachytherapy had stage IIIB disease or higher and yet a local control rate of $7 9 \\%$ was found (eleven studies1270,1289,1309,1337-1344).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Patients receiving equivalent 2 Gy dose $\\geq 7 6$ Gy and $> 7 6$ Gy had local control of $8 4 \\%$ and $67 \\%$ , respectively (fifteen studies1289,1309,1337,1339-1341,1343,1345-1352).Only grade 3-4 gastro-intestinal, genitourany and vaginal late toxicities were described (eleven studies1270,1289,1309,1337-1344).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Three quarters of these related to gastrointestinal toxicity.Genitourinary and vaginal late toxicities were $2 1 .3 \\%$ and $4 .3 \\% ,$ , respectively.It should be noted (1) that the majority of the included studies1270,1289,1309,1337-1340,1344-1346,1348-1350 based their treatment on computed tomography imaging, (2) an observed heterogeneity of the template types used (Syed-Neblett1289,1309,1340,1341,1344-1347,1350,1351, custom-made1342,1348,1349,1352, Martinez universal perineal interstitial template1270,1338, free hand1339, Benidorm template1343, unspecified template type1337), and (3) the small sample size of the majority of the enrolled studies1270,1289,1337-1342,1344,1346-1352.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "All the fourteen identified studies1260,1285,1353-1364 of image-guided adaptive brachytherapy reporting outcomes according to Groupe européen de curiethérapie - European society for radiotherapy and oncology (GEC-ESTRO) recommendations10,11 published in 2005 reported high local control rates with a low radiation-induced morbidity (Table 34).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "At the exception of the study published by Charra-Brunaud et al.1364 which reported the lowest doses, the local control rates at 2-3 years ranged between 86.4 and $1 0 0 \\% ,$ whereas the severe morbidity rates remained below or close to $1 0 \\%$ .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Three1310,1355,1358 of the four identified studies1310,1355,1358,1364 describing comparisons with historical cohorts of patients treated with radiographs-based brachytherapy reported a significant improvement of OS rates with the use of image-guided adaptive brachytherapy at 3 years ( $6 4 \\%$ versus $5 3 \\%$ $( \\mathrm { p } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 3 ) ^ { 1 3 1 0 }$ , $7 9 \\%$ versus $6 3 \\%$ $( \\mathrm { p } = 0 .0 0 5 ) ^ { 1 3 5 5 }$ , $8 6 \\%$ versus $4 3 \\%$ ( $\\mathrm { ~ \\widehat ~ { ~ p ~ } ~ } <$ 0.01)1358).In addition, the severe morbidity rates were decreased in the image-guided adaptive brachytherapy cohorts, by 8 to $1 8 \\%$ $7 \\%$ versus $1 5 \\%$ ${ \\mathrm { ( p = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 0 2 } }$ )1355, $3 \\%$ versus $2 1 .4 \\%$ ${ \\mathrm { ( p ~ < ~ } }$ 0.01)1358, $2 .6 \\%$ versus $2 2 .7 \\%$ $( \\mathrm { p } ~ = ~ 0 .0 0 4 ) ^ { 1 3 6 4 } .$ ).It should be noted unbalanced uses of concomitant chemotherapy in the groups of these studies.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Several identified studies1365-1370 have shown dose-effect relationships for the rectum1365-1369 and the bladder1365,1367,1370.It should be noted that they are based on limited samples of patients, and evaluations relied on heterogeneous methods (eligibility, endpoint, and scoring systems).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 13.1.5 Chemoradiotherapy LoE $^ { 1 + }$ On the basis of thirteen RCTs67,1261,1266,1267,1269,1371-1378 that compared chemoradiotherapy versus the same radiotherapy, a meta-analysis1379 found that there was a $1 9 \\%$ relative reduction in the risk of death with chemoradiotherapy and translated to an absolute survival benefit of $6 \\%$ at five years.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A larger survival benefit was seen for the two further $\\mathrm { R C T s ^ { 7 2 1 , 1 3 8 0 } }$ in which chemotherapy was administered after chemoradiotherapy $[ \\mathrm { H R } = 0 .4 6$ $9 5 \\% \\mathrm { C I } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "3 2 \\cdot$ 0.66)).The authors found no evidence of a difference in the size of the effect of chemoradiotherapy when RCTs were grouped according to the type of chemotherapy they had used (platinum based or non platinum based), the planned radiotherapy dose or the total planned duration of radiation.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Similarly, for the ten RCTs67,1261,1266,1269,1372,1374-1378 that used cisplatin-based chemoradiotherapy, the authors found no evidence that the effect of chemoradiotherapy differed according to the cycle length or the dose intensity of cisplatin used (Table 35).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "An absolute DFS benefit of $8 \\%$ at 5 years was also reported $\\left( \\mathrm { p } = 0 .0 0 0 0 0 5 ^ { \\cdot } \\right)$ ).There were similar and significant absolute benefits of chemoradiotherapy on 5-year locoregional DFS $( 9 \\% , \\mathrm { ~ p ~ } <$ 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "001), time to locoregional recurrence/progression $( 6 \\% , \\mathrm { ~ p ~ = ~ } 0 .0 0 0 0 9 )$ and metastase-free survival $7 \\% , \\mathrm { p } < 0 .0 0 1 \\mathrm { \\Omega }$ ).A smaller improvement in time to metastases at five years was also described $( 4 \\% , \\texttt { p } = \\ 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 4 )$ .There was a suggestion of trend in the relative effect of chemoradiotherapy by tumour stage $( \\mathrm { p } ~ = ~ 0 .0 1 7 )$ ), with the benefit of chemoradiotherapy decreasing with increasing stage (stage IB-IIA: $1 0 \\%$ , stage IIB: $7 \\% ,$ stage III-IVA: $3 \\%$ ).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted that there was no significant trend for the analysis of DFS by stage.This meta-analysis described no evidence to suggest that the effect of chemoradiotherapy differed in groups of women defined by age, histology, tumour grade or whether they had PLN involvement.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A second identified meta-analysis1381 (eighteen $\\operatorname { R C T } s ^ { 6 7 , 7 2 1 , 1 1 2 9 , 1 2 6 9 , 1 3 8 2 - 1 3 9 5 } )$ comparing the effectiveness and safety of chemoradiotherapy with radiotherapy alone in LACC reported significant differences in terms of response rate, 3-year OS rates, and 5-year OS rates in favour of patients in the chemoradiotherapy group ( $\\mathrm { R R } = 1 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1 7$ ( $9 5 \\%$ $\\% \\mathrm { C I } = 1 .1 1 { - } 1 .2$ 3), $\\mathrm { R R } = 1 .1 3$ ( $9 5 \\%$ $\\mathsf { C I } = 1 .0 4 \\cdot 1 .2 4 \\rfloor$ , and $\\mathrm { R R } = 1 .2 2$ $9 5 \\% \\mathrm { C I } = 1 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1 3 \\ – 1 .3 1$ ), respectively).Evaluating the efficacy and safety of cisplatin-based CCRT in patients with high-risk cervical carcinoma compared with exclusive radiotherapy, the meta-analysis published by Meng et $a l .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "^ { 1 3 9 6 }$ revealed a statistically significant difference in OS in favor of cisplatin-based CCRT over exclusive radiotherapy (eight studies721,1269,1273,1279,1387,1388,1397,1398, $\\mathrm { H R } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "6 8$ ( $9 5 \\%$ $\\mathrm { C I } = 0 .5 7 \\$ - 0.80)).Similar results were observed for PFS (six studies721,1269,1273,1388,1397,1398, $\\mathrm { H R } = 0 .6 3$ ( $9 5 \\%$ $\\mathrm { C I } = 0 .5 0 \\ – 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "7 6 ]$ ).It should be noted that a minor heterogeneity among the included six studies was observed.Their pooled analysis showed significantly enhanced treatment-related grade 3- 4 adverse events in the CCRT group compared with the exclusive radiotherapy group (five studies67,721,1387,1397,1398, $0 \\mathrm { R } \\ = \\ 3 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1 3$ ( $9 5 \\% \\mathrm { ~ C I ~ } = 2 .3 7 – 4 .1 3$ )).Data on tumour response (five studies1387,1397-1400) and treatment failures (five studies1273,1279,1387,1388,1397) were also reported.The pooled analysis showed that statistical significance was reached in none of the different comparisons.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Fully consistent data are also provided by Uppal et al.1401 with respect to decreased OS rate LoE 2- with radiotherapy alone as compared to CCRT $\\mathrm { { [ H R = 1 .4 7 } }$ ( $9 5 \\% \\mathrm { C I } = 1 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "4 { - } 1 .5 6 )$ ).A meta-analysis1402 of twenty-two randomized comparisons727,1123,1125-1130,1133- 1137,1261,1267,1269,1373,1397,1403-1406 of chemotherapy plus radiotherapy versus the same radiotherapy alone in advanced cervical cancer found no statistically significant overall benefit from chemotherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Analyses according to the type of regimen showed a significant benefit only for non-platinum regimens $\\mathrm { { [ H R = 0 .7 3 } }$ ( $9 5 \\% \\mathrm { C I } = 0 .5 7 – 0 .9 5$ )).There was no evidence for any survival benefit in trials of platinum monotherapy plus radiotherapy versus radiotherapy alone and in trials of combinations of platinum plus non-platinum agents plus radiotherapy versus radiotherapy alone.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted that significant between-study heterogeneities were described.A marginally significant survival benefit was found in trials using cisplatin-based regimens with short length cycles $[ \\mathrm { H R } ~ = ~ 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "8 0$ $( 9 5 \\% \\mathrm { ~ C I ~ } = \\ 0 .6 6 \\ – 0 .9 7 )$ ), while a marginally significant deterioration of survival was observed in trials using platinum-based regimens with longer cycles $\\mathrm { { \\tilde { H R } } } = 1 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1 8$ $[ 9 5 \\% \\mathrm { ~ C I } = 1 .0 2 – 1 .3 8 )$ ).It should be noted that the survival benefit with short length cisplatin cycles was driven largely by a trial1125 that had reported only preliminary interim analysis results.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "CCRT did also not result in a significant improvement in pelvic control rate, response rate, LoE 2- and/or survival compared to standard conventional radiotherapy in two studies115,1407 not included in the meta-analyses1379,1381,1402 mentioned above.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "As part of another meta-analysis of RCTs67,721,1267,1269,1373,1374,1383,1397,1408-1421 comparing LoE $^ { 1 + }$ concomitant chemotherapy and radiation therapy for LACC, Green et al.1422 reported statistically significant increases in the rate of grade 1-2 haematological (unspecified), white blood cell, haemoglobin, platelet, gastrointestinal, skin and neurological toxicities with CCRT and grade 1-2 nausea and vomiting.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "These ranged from a $2 9 \\%$ increase in the risk of white blood cell toxicity up to a freater than three-fold increase in the risk of nausea and vomiting on the CCRT arm compared with that on control.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Rates of grade 3-4 haematological, white blood cell, haemoglobin, platelet and gastrointestinal toxicity and nausea and vomiting toxicity were also significantly increased with CCRT.These ranged from around a two-fold increase in gastrointestinal toxicity up to more than four times the risk of nausea and vomiting.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Late effects of treatment were not well reported and so the impact of chemoradiotherapy on these effects could not be determined adequately (Table 36).Kirwan et al.1423 described fully consistent toxicity pooled data with those reported in the meta-analysis1422 mentioned above.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted that thirteen67,721,1383,1397,1409- 1411,1413,1415,1416,1418,1420,1421 of the nineteen RCTs67,721,1371,1383,1397,1409- 1411,1413,1415,1416,1418,1420,1421,1424-1428 from which these analyses are based on have also been taken into account by Green et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1422.A RCT1429 not included in the meta-analyses19,1379,1381,1402,1422,1423 mentioned above and comparing chemoradiotherapy versus radiotherapy, was also identified.Their results showed that compared with control group, the overall short-term outcomes, 1- and 3-year survival rates of experimental group were significantly higher ( $8 8 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "5 7 \\%$ versus $7 0 .7 7 \\% , \\mathrm { ~ p ~ < ~ } 0 .0 5$ and $8 2 .1 4 \\%$ versus $5 7 .6 9 \\% ,$ $\\mathrm { ~ p ~ } < 0 .0 5$ , respectively), which was similar to the results presented above.Stage-based stratified analysis showed that in stage III patients, the differences in shortterm efficacy, 1-year survival and local control rates between experimental group and control group were significant ( $7 6 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "4 7 \\%$ versus $4 5 .4 5 \\%$ , $\\mathrm { { p < 0 .0 5 } }$ and $6 1 .7 6 \\%$ versus $3 6 .3 6 \\%$ , $\\mathrm { ~ p ~ < ~ } 0 .0 5 ,$ respectively), whereas the differences in 3-year survival and local control rates were not significant.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted that there was no significant difference on short-term efficacy in stage II patients between the two treatment groups.For the stage II patients who had followed up for over three years, the difference of 3-year survival and local control rates between the two groups were significant ( $9 3 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "7 5 \\%$ versus $6 4 .2 9 \\%$ , $\\mathrm { { p < 0 .0 5 } }$ and $9 3 .7 5 \\%$ versus $6 4 .2 9 \\%$ $\\mathrm { ~ p ~ } <$ 0.05, respectively).The quality of life of patients in both the control group and the experimental group was significantly improved after treatment $\\mathrm { ( p < 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 5 ) }$ .However, it should be noted that the difference between the two groups was not significant.Using the technique of meta-analysis (nineteen studies1261,1265,1269,1273,1279,1371,1397,1399,1418,1420,1430-1438), Fu et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1439 compared different CCRT regimens in the treatment of advanced cervical cancer (radiotherapy, CCRT (cisplatin), CCRT (vinorelbine), CCRT (paclitaxel), CCRT (hydroxyurea), CCRT (cisplatin $+ ~ 5$ fluorouracil), CCRT (cisplatin $^ +$ gemcitabine), CCRT (cisplatin $^ +$ docetaxel), CCRT (cisplatin $^ +$ paclitaxel), CCRT (cisplatin $^ +$ amifostine), CCRT (cisplatin $+ 5$ fluorouracil $^ +$ hydroxyurea), and CCRT (cisplatin $^ +$ vincristine $^ +$ bleomycin)).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In terms of efficacy, pairwise meta-analyses showed that the 5-year OS rates of CCRT (cisplatin) and CCRT (cisplatin $+ ~ 5$ fluorouracil $^ +$ hydroxyurea) were higher than CCRT (hydroxyrea).There were no significant differences in (1) the 5-year OS rates among the other CCRT regimens tested and (2) the overall response rates and 5-year DFS rate among the evaluated CCRT regimens (Table 37).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The network meta-analyses showed that the overall response rates of CCRT (cisplatin $^ +$ docetaxel) was higher than radiotherapy $\\mathrm { { \\bar { O } R = } }$ 23.63 $( 9 5 \\% \\mathrm { C I } = 1 .2 9 – 4 3 3 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 2 )$ ).Compared with CCRT (hydroxyurea), the 5-year OS rate of CCRT (cisplatin $+ ~ 5$ fluorouracil $^ +$ hydroxyurea) was higher ( $\\mathrm { \\Delta } \\mathrm { \\stackrel { .} { O R } } = 2 .3 6$ ( $9 5 \\% \\mathrm { C I } = 1 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "5 4 – 3 .6 3$ )).Compared with radiotherapy and CCRT (cisplatin), the 5-year OS rate of CCRT (hydroxyurea) was lower $\\mathrm { \\Delta } \\operatorname { \\left[ O R \\right] } = 0 .4 9$ $9 5 \\% \\mathrm { C I } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "2 8 – 0 .8 7 .$ ) and $\\mathrm { O R } = 0 .4 4$ $[ 9 5 \\% \\mathrm { C I } = 0 .2 9 \\ – 0 .6 8 ]$ , respectively).It should be noted that there was no significant difference of 5-year DFS rate among the evaluated CCRT regimens).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "As for hematotoxicity, compared with CCRT (cisplatin), the incidences of anemia, neutropenia, and thrombocytopenia with CCRT (cisplatin $^ +$ gemcitabine) were higher (Table 38).The addition of 5 fluorouracil to CCRT (cisplatin) was associated with higher incidence of leucopenia.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The same increase was reported in case of addition of cisplatin to radiotherapy.Compared with CCRT (cisplatin $\\mathit { \\Theta } + \\mathit { \\Theta } 5$ fluorouracil), the incidences of leucopenia with CCRT (hydroxyurea) and CCRT (cisplatin $^ +$ paclitaxel) were higher (Table 38).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "As far as gastrointestinal toxicity, compared with CCRT (cisplatin), the incidence of diarrhea with CCRT (cisplatin $^ +$ gemcitabine) was higher, and the incidence of nausea with CCRT (cisplatin $+ ~ 5$ fluorouracil) was higher.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted that there was no significant difference of the incidence of vomiting among the evaluated CCRT regimens.The network meta-analyses showed that compared with CCRT (cisplatin), the incidences of leucopenia with CCRT (hydroxyurea), CCRT (cisplatin $+ ~ 5$ fluorouracil) and CCRT (cisplatin $^ +$ paclitaxel) were higher ( $\\mathrm { { O R } } = 2 1 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "3 0 \\$ ( $9 5 \\% \\mathrm { C I } = 6 .4 4 – 7 0 .4 5$ , $0 \\mathrm { R } = 2 .4 2$ $9 5 \\% \\mathrm { C I } = 1 .0 8 – 5 .4 4$ ), $\\mathrm { O R } = 7 3 .5 9 \\$ ( $9 5 \\%$ $\\mathrm { C I } =$ 17.86-303.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "31), respectively), and the incidence of thrombocytopenia with CCRT (cisplatin $^ +$ gemcitabine) was higher $\\mathrm { { O R } = 4 .4 4 }$ $[ 9 5 \\% \\mathrm { C I } = 1 .6 3 \\ – 1 2 .0 7 )$ ).In terms of gastrointestinal toxicity, the incidence of diarrhea and vomiting with CCRT (cisplatin $^ +$ gemcitabine) was higher than CCRT (cisplatin) $\\mathrm { \\Delta O R } = 3 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "8 0 \\$ $9 5 \\% \\mathrm { C I } = 2 .0 8 { - } 6 .9 5$ 5, $0 \\mathrm { R } = 2 .9 4$ $9 5 \\% \\mathrm { C I } = 1 .2 6 – 6 .8 6$ ), respectively).Compared with radiotherapy, the incidence of nausea with CCRT (cisplatin $+ ~ 5$ fluorouracil) was higher $\\mathrm { \\cdot } 0 \\mathrm { R } = 2 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "5 3$ $( 9 5 \\% \\mathrm { ~ C I } = 1 .1 3 – 5 .6 6 )$ ).It should be noted that ther was no significant difference among the evaluated CCRT regimens in terms of anemia and neutropenia.Another meta-analysis1440 (fifteen RCTs1266,1430,1431,1441-1452) comparing the efficacy and safety between different single-agent regimens (cisplatin, nedaplatin, docetaxel, paclitaxel, paclitaxel liposome, 5 fluorouracil, vinorelbine, and irinotecan) in the chemoradiation system was identified.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "When the research focused on OS or local recurrent rate, no significant advantage existed when the other single-agent regimen was used in the concurrent chemoradiotherapy compared with cisplatin.It should be noted that when aimed at distant metastasis rate, fluoropyrimidine showed a disadvantage to cisplatin, whereas others showed equal efficacy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "With regard to the response rate, only nedaplatin showed a significant improvement compared with cisplatin.Docetaxel, fluoropyrimidine, paclitaxel, paclitaxel liposome, and irinotecan di not show any advantages.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Nedaplatin, docetaxel, paclitaxel, and fluoropyrimidine showed a better effect on reducing chemotherapy toxicity than cisplatin (Table 39).Sebastiao et al.1453 and Nam et al.1454 found also that patients treated with CCRT (carboplatin) had survival and response rate when compared to CCRT (cisplatin).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Similarly, with postoperative CCRT, Kagabu et al.1455 described no significant differences in recurrence rate, PFS, and OS between patients treated with CCRT (nedaplatin) compared with those treated with CCRT (cisplatin).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Pooled survival rates published by Lukka et al.1456 from six RCTs1383,1397,1413,1416,1418,1420 that evaluated the role of cisplatin, alone or in combination with other chemotherapy agents, administered concurrently with EBRT, showed a statistically significant effect in favour of cisplatin-based chemoradiotherapy compared with radiotherapy without cisplatin $\\mathrm { { R R = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "7 8 } }$ $[ 9 5 \\% \\mathrm { C I } = 0 .6 7 – 0 .9 0 ]$ ).Petrelli et al.1457 evaluated whether cisplatin-based doublet therapy improved survival compared to weekly cisplatin plus radiotherapy in patients with cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Meta-analysis of eight studies726,1265,1433,1437,1458-1461 showed that for LACC, CCRT and with cisplatin-based doublet chemotherapy significantly improved the OS ( $\\mathrm { { O R } } = 0 .6 5$ $\\left[ 9 5 \\% \\mathrm { C I } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "5 1 – 0 .8 1 \\right]$ ), ${ \\mathrm { ~ p ~ } = }$ 0.0002), PFS $\\mathrm { \\Delta O R } = 0 .7 1 \\$ $\\left[ 9 5 \\% \\right.\\mathrm { C I } = 0 .5 5 \\ – 0 .9 1 \\$ ), ${ \\mathrm { p } } = 0 .0 0 6 ]$ ), and rate of locoregional relapse (OR $= 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "6 4$ ( $9 5 \\%$ $5 \\% \\mathrm { C I } = 0 .4 7 – 0 .8 9$ ), $\\mathrm { ~ p ~ = ~ 0 .0 0 8 } \\mathrm { ^ \\prime }$ , compared to radiotherapy with concurrent weekly cisplatin alone.However, the rate of distant metastases was similar between the study arms.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted that toxicities were largely underreported in the included studies.Thrombocytopena and neutropenia were worse in the experimental arms $\\mathrm { [ p = 0 .0 1 }$ and ${ \\bf p } = { \\bf \\Phi }$ 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "02, respectively).Acute gastrointestinal toxicity, including grade 3 or 4 vomiting or nausea plus diarrhea, occurred more frequently in the polychemotherapy arms ${ \\mathrm { ( p = 0 } } .0 1 6 { \\mathrm { ) } }$ ).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A systematic review1462 aiming to assess the effectiveness of concomitant radiation and hydroxyurea compared with radiotherapy alone in treating LACC was identified but is not described because the authors did not found studies meeting their inclusion criteria.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Seven RCTs1463-1469 not included in the systematic reviews/metaanalyses1379,1381,1402,1422,1423,1439,1440,1456,1457,1462 mentioned above was also identified.Kim et al.1463 designed a RCT for prophylactic para-aortic irradiation on the basis of hypoxia marker, CA9, to test whether concomitant cisplatin and extended-field irradiation can reduce para-aortic recurrences and increase disease-free survival rate in LACC.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Patients were randomized to either extended-field irradiation or pelvic radiotherapy in each CA9 group.Para-aortic recurrence-free survival was significantly higher for extended-field irradiation compared to pelvic radiotherapy in CA9-positive group ( $1 0 0 \\%$ versus $8 1 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "7 \\%$ , $\\mathrm { p } = 0 .0 0 7 \\mathrm { \\ : }$ ), while there was non such difference in CA9-negative group.There was no significant benefit in terms of DFS by extended-field irradiation in CA9-positive groups, while DFS was significantly higher in patients who received extended-field irradiation in CA9-negative groups ( $1 0 0 \\%$ versus $7 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "7 \\%$ , $\\mathrm { { p = 0 .0 1 8 } } ^ { \\mathrm { { } } }$ ).It should be noted that the number of CA9-negative patients was too small to compare the effect of extended-field irradiation against the CA9-positive group.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In the second one1464, patients were randomized to receive cisplatin with concurrent EBRT, followed by brachytherapy or gemcitabine with the same radiation therapy.Although it was observed more frequent complete pathological response in the study arm (gemcitabine) than in the control arm $9 6 \\%$ versus $8 8 \\%$ ), no difference in terms of DFS or OS was reported between the two treatment groups.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Occurrence of toxicities were significantly high in the study group compared to the control group in the case of leucopenia $[ \\mathrm { p } = 0 .0 1 5 ]$ ), skin reaction $[ { \\mathfrak { p } } =$ 0.03), and bleeding $\\mathrm { { ( p = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 1 9 } } ^ { \\cdot }$ ).The third one1465 randomly assigned patients to receive weekly (cisplatin $4 0 ~ \\mathrm { m g } / \\mathrm { m } ^ { 2 }$ , six cycles) or triweekly (cisplatin $7 5 ~ \\mathrm { m g } / \\mathrm { m } ^ { 2 }$ , three cycles) chemotherapy during concurrent radiotherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The 5 year-OS rate was significantly higher in the triweekly arm than in the weekly arm $\\mathrm { { \\cdot H R } = }$ 0.375 $( 9 5 \\% \\mathrm { C I } = 0 .1 5 4 – 0 .9 1 4 )$ ), $\\mathrm { ~ p ~ = ~ } 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 3 ]$ .In this trial, despite the survival difference, the recurrence rate and PFS were almost identical in both arms.Grade 3-4 neutropenia was more frequent in the weekly arm than in the triweekly arm ( $3 9 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "2 \\%$ versus $2 2 .6 \\%$ ${ \\mathrm { ~ p ~ } } = \\ 0 .0 3 ]$ .No statistical differences in gastrointestinal, renal, and neurosensory toxicities between the two arms.As part of another trial1466, FIGO stage IIB-IIIB cervical cancer patients were randomized to have tegafur-uracil plus carboplatin concurrent with radiotherapy or carboplatin alone concurrent with radiotherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "CCRT by tegafur-uracil and carboplatin did not show any significant advantage in tumour response rate, PFS, OS or treatment toxicity over CCRT with carboplatin alone.The RCT1467 comparing, showed that treatment with interferon alpha-2b plus 13-cis-retinoic acid with radiation did not demonstrate survival or response rate advantage over cisplatin plus radiation despite being less toxic.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In a small $\\mathrm { R C T ^ { 1 4 6 8 } }$ aiming to compare three-dimensional conformal radiotherapy and intensitymodulated radiotherapy combined with concurrent chemotherapy, no significant difference was observed in OS and DFS in first, second, and third years in both groups.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Another small identified RCT1469 concerned the feasibility of concurrent chemotherapy and interspacing brachytherapy during the course of external radiotherapy to reduce the overall treatment time and compare the normal tissue toxicity and locoregional control with a conventional schedule.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Arm I treatment consisted of irradiation of the whole pelvis, and weekly cisplatin.High-dose intracavitary brachytherapy was performed after one week of completion of EBRT.Arm II treatment consisted of irradiation of the whole pelvis.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cisplatin was administered from day 1-5 and day 24-28.Overall treatment time was taken from first day of EBRT to last day of high-dose rate brachytherapy.In this RCT interspacing brachytherapy with EBRT and concurrent chemotherapy resulted in significantly shorter treatment duration as compared to the standard practice (48 days versus 65 days, $\\mathrm { p } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 0 1 \\mathrm { \\Omega } .$ ).The response rates and toxicities were comparable.# LoE 3 A study1470,1471 exploring the safety and efficacy of the addition of bevacizumab to standard CCRT in LACC was identified.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "This study included patients with stage FIGO IIB-IIIB, or with FIGO stage IB-IIA with biopsy-proven PLN metastases and/or tumour size $\\geq 5 \\ \\mathrm { c m }$ (but with negative PALN).There were no treatment-related serious adverse events, and protocolspecified treatment related adverse events within 90 days of treatment start were reported in $3 1 \\%$ of patients (most common were hematologic: $8 0 \\%$ ).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Two years later, the same authors published data concerning secondary efficacy endpoints.These were OS, locoregional failure, para-aortic failure, distant failure, and DFS in the same patients who participated in the trial.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Three-year OS and DFS were $8 1 .3 \\%$ and $6 8 .7 \\% ,$ respectively.Three-year locoregional failure was $2 3 .2 \\%$ , while 3-year para-aortic node failure was $8 .4 \\%$ .# 13.1.6 Hyperthermia Using the technique of meta-analysis (six RCTs1374,1472-1476), Datta et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1477 assessed whether adding hyperthermia to standard (chemo)radiotherapy had an impact on outcomes for patients with LACC.Patients treated with thermoradiotherapy had superior outcomes in terms of complete response $\\mathrm { ( O R = 2 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "6 7 }$ (9 ${ \\mathrm { 1 5 ~ C I } } = 1 .5 7 { \\mathrm { - 4 .5 4 } }$ ), $\\mathrm { ~ p ~ < ~ } 0 .0 0 1 ^ { \\cdot }$ ) and long-term locoregional control $\\mathrm { { O R } } = 2 .6 1 \\$ $( 9 5 \\% \\mathrm { C I } = 1 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "5 5 \\ – 4 .3 9$ ), $\\mathrm { ~ p ~ < ~ } 0 .0 0 1 \\$ ) when compared with radiotherapy for patients surviving at the end of follow-up without improvement of grade 3-4 acute and late toxicities.The survival advantage observed with thermoradiotherapy did not reach statistical significance.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted that the outcomes of thermochemoradiotherapy compared to radiotherapy could only be computed from one small $\\mathrm { R C T ^ { 1 3 7 4 } }$ .A total of $8 3 .3 \\%$ of the patients treated with thermochemoradiotherapy achieved a complete response compared with $4 6 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "7 \\%$ of the patients treated with radiotherapy alone $_ { \\mathrm { O R } } = 5 .7 1$ ( $9 5 \\%$ $\\mathrm { C I } = 1 .7 2$ -18.94), $\\mathrm { ~ p ~ = ~ 0 .0 0 4 \\AA ~ }$ .No other parameters were reported in this study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Network meta-analyses, allowing both direct and indirect comparisons of various treatment approaches, were also performed for two endpoints (complete response and patients alive at the end of the study period).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "For the first one (thirteen $\\mathrm { R C T s ^ { 1 3 7 4 , 1 4 7 2 - 1 4 7 4 , 1 4 7 8 , 1 4 7 9 } } \\Big )$ , a significant advantage of thermochemoradiotherapy was found over radiotherapy $\\mathrm { \\Delta O R } = 4 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "5 2 \\$ ( $9 5 \\%$ CI = 1.93-11.78)) and over chemoradiotherapy $\\begin{array} { r l r } { ( 0 \\mathrm { R } } & { { } = } & { 2 .9 1 } \\end{array}$ $\\begin{array} { r c l } { { \\big ( 9 5 \\% } } & { { \\mathrm { C I } } } & { { = } } & { { 1 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "9 7 \\mathrm { - } 4 .3 1 \\big ) } } \\end{array}$ ).Thermoradiotherapy also demonstrated a significantly higher probably of a complete response over radiotherapy alone $\\mathrm { { O R } \\ = \\ 2 .8 5 }$ $( 9 5 \\% \\mathrm { C I } \\ = \\ 1 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "6 3 – 5 .0 8 )$ ).There were no significant differences observed for the remaining three comparisons (thermochemoradiotherapy versus thermoradiotherapy, thermoradiotherapy versus chemoradiotherapy, and chemoradiotherapy versus radiotherapy).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The network meta-analysis for patients remaining alive at the end of the study follow-up period was performed with data from twelve RCTs1472-1474,1476,1478,1479 showed that thermochemoradiotherapy provided a significant advantage over chemoradiotherapy (OR $= 2 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "6 5$ $( 9 5 \\% \\mathrm { ~ C I } = 1 .5 1 – 4 .8 7 )$ ) or radiotherapy ( $\\mathrm { \\Delta O R } = 5 .5 7 \\$ $[ 9 5 \\% \\mathrm { C I } = 1 .2 2 \\ – 2 3 .4 2 )$ ).There were no significant differences for the remaining four comparisons between therapies (thermoradiotherapy versus radiotherapy, thermoradiotherapy versus chemoradiotherapy, thermochemoradiotherapy versus thermoradiotherapy, and chemoradiotherapy versus radiotherapy).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Another identified meta-analysis1478 (nine $\\mathrm { R C T } s ^ { \\mathrm { N A } } .$ ) showed that, compared with the chemoradiotherapy alone, thermochemoradiotherapy had significant increased 1-year surival rates $\\mathrm { \\Delta O R } = 3 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 5 \\$ $9 5 \\% \\mathrm { C I } = 1 .7 0 – 6 .6 8$ ), $\\mathrm { p } = 0 .0 0 5 \\mathrm { \\cdot }$ ), 2-year survival rates ( $\\operatorname { \\mathrm { ~ \\sc ~ O R } } = 2 .2 9$ $9 5 \\%$ $\\mathrm { C I } =$ 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "19-4.38), $\\mathrm { { p = 0 .0 1 j } }$ ), and overall effective rates ( $\\mathrm { \\Delta O R } = 3 .6 6 \\$ ( $9 5 \\%$ $5 \\% \\mathrm { C I } = 2 .3 1 { - } 5 .8 1$ ), $\\mathrm { p } < 0 .0 0 0 0 1 \\dot { \\mathrm { \\Omega } }$ ).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The incidence of adverse reactions was no statistically significant between the two treatment groups.A third identified systematic review1480 is not described because it contains no additional studies beyond those already captured by the meta-analysis1477 mentioned above.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted that Datta et al.1477 replaced (1) the original reports published by van der Zee et al.1481 and by Harima et al.1482 in 2001, included in this third identified systematic review1480, by updated reports published by Franckena et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1472 and by Harima et al.1473 in 2009, respectively.A $\\mathrm { R C T ^ { 1 4 8 3 } }$ not included in the systematic reviews/meta-analyses1477,1478,1480 mentioned above, and evaluating the effectiveness of hyperthermia added to standard chemoradiotherapy, was also identified.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Consistently with the network meta-analyses’ results described by Datta et $a l .^ { 1 4 7 7 }$ , complete response was significantly more likely to be achieved in patients treated with thermochemoradiotherapy than in the chemoradiotherapy group $\\mathrm { { ( 0 R \\ = \\ 3 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "9 9 3 } }$ $9 5 \\% \\mathrm { C I } \\ =$ 1.018-15.67), $\\mathrm { p } = 0 .0 4 7 \\mathrm { \\ : ] }$ ).It should be noted that (1) the advantages in terms of 5-year OS, DFS and local relapse-free survival in favor of patients treated with thermochemoradiotherapy compared to those who underwent chemoradiotherapy did not reach statistical significance and (2) the addition of hyperthermia was well tolerated and caused no additional acute or long-term toxicity compared with chemoradiotherapy alone.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A recently reported RCT1484 comparing brachytherapy versus brachytherapy and hyperthermia following priori chemoradiotherapy in patients with stage II-III cervical cancer failed to demonstrate any therapeutic benefit in terms of DFS or local control with the addition of hyperthermia.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In a single arm study1485,1486 including patients treated with thermochemoradiotherapy, $8 9 .7 \\%$ of patients achieved a complete response.A locoregional control was observed in $5 8 .8 \\%$ of patients while $6 9 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1 \\%$ of patients were surviving at the end of the study period (median followup: 81 months).A total of $3 3 \\%$ of the patients experienced grade 3-4 acute toxicities in the form of leucopenia, fatigue, nausea, emesis and diarrhea but these did not result in withholding hyperthermia treatment.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "As part of a single arm study1487,1488, a complete response was achieved in $78 \\%$ of patients treated with thermoradiotherapy.At five years, pelvic tumour control, DSS, and incidence of grade 3-4 acute and late hyperthermia-related toxicity were $6 5 \\%$ , $4 7 \\%$ , $1 1 \\%$ and $1 2 \\% ,$ respectively.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Sreenivasa et al.1489 evaluated preoperative chemoradiotherapy combined with hyperthermia in patients with nonresectable stage $\\geq$ IIB “bulky” cervical cancer.Preoperative thermochemoradiotherapy induced a response rate of $7 5 \\%$ and enabled curative surgery in $6 2 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "5 \\%$ of patients.# 13.1.7 Adjuvant/consolidation chemotherapy Two RCTs1267,1435,1490-1492 evaluating the effect of adjuvant chemotherapy after concurrent $|$ LoE 1- chemoradiotherapy on outcomes of women with LACC compared with concurrent chemoradiotherapy alone, were identified.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In the first identified RCT1267, the patients were randomized into four arms (conventional radiotherapy, conventional radiotherapy and adjuvant chemotherapy, convention radiotherapy plus concurrent chemotherapy, conventional radiotherapy plus concurrent chemotherapy and adjuvant chemotherapy).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Concurrent chemotherapy consisted of mitomycin C and 5-FU.Adjuvant chemotherapy consisted of 5-FU.There was no significant difference in survival when comparing radiotherapy alone with radiotherapy and adjuvant chemotherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "There was also no significant difference in survival when comparing radiotherapy plus concurrent chemotherapy with conventional radiotherapy plus concurrent chemotherapy and adjuvant chemotherapy.Moreover, this RCT1267 did not demonstrated that the addition of chemotherapy could decrease total failure rate or locoregional or distant failure after concurrent chemoradiotherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted that at the time of analysis, there were no increases in late side effects.The second one1435,1490-1492 showed significant improvement in PFS and OS among those who received concurrent chemoradiotherapy plus adjuvant chemotherapy compared with those given concurrent chemoradiotherapy alone $\\mathrm { \\Delta } [ \\mathrm { H R } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "6 8$ ( $9 5 \\ \\% \\mathrm { C I } = 0 .4 9 – 0 .9 5$ ), $\\mathrm { p } = 0 .0 2 7$ and HR $= 0 .6 8$ ( $9 5 \\% \\mathrm { C I } = 0 .4 9 – 0 .9 5$ ), $\\mathrm { ~ p ~ } = \\ 0 .0 2 2 ,$ respectively).Subsequent analyses1492 showed that benefit from adjuvant chemotherapy, PFS in particular, was greater in women with more advanced disease, larger tumour size and age younger than 55 years.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Respones rates and rates of local failure were similar.However, distant failure rate was lower in the study arm $8 .1 \\%$ versus $1 6 .4 \\%$ $\\mathrm { p } = 0 .0 0 5$ ).More women who had concurrent chemoradiotherapy plus adjuvant chemotherapy were hospitalised (30 versus 11, $\\mathrm { p } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 0 3 \\mathrm { \\cdot }$ ), had a greater number of grade 3-4 overall toxicities ( $8 7 \\%$ versus $4 6 \\% ,$ $\\mathrm { ~ p ~ } < \\ 0 .0 0 1 \\$ , and/or received one or more blood transfusions ( $4 9 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "2 \\%$ versus $2 7 .5 \\% ,$ $\\mathrm { ~ p ~ } < \\ 0 .0 0 1 \\$ ).It should be noted that chemotherapy used concurrently with radiotherapy included cisplatin plus gemcitabine in the study arm and only cisplatin in the control arm.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A systematic review1493 was identified but is not described because it contains only the two RCTs1267,1435,1490-1492 mentionned above.A part of another $\\mathrm { R C T ^ { 1 4 9 4 } } ,$ , incorporating adjuvant chemotherapy into chemoradiotherapy was associated with a signicantly longer disease-free, cumulative survival and long-term local tumour control but it should be noted that NACT was given along with additional chemotherapy after concurrent chemoradiotherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "As the second identified RCT mentioned above, Choi et al.1495 found that (1) the complete response rate was similar between the two groups and (2) the addition of the adjuvant chemotherapy was associated with an increased OS after a median follow-up period of 35 months without significant additional toxicities ( $9 2 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "7 \\%$ versus $6 9 .9 \\%$ $\\mathrm { p } = 0 .0 4 2 \\cdot$ ).However, it should be noted that the difference in PFS did not reach statistical significance.Six other studies1496-1503 evaluating adjuvant chemotherapy after concurrent LoE 3 chemoradiotherapy were also identified.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Corresponding response rates and survival are summarized in table 40.A RCT1504 comparing four versus six courses of adjuvant chemotherapy (cisplatin) after NACT LoE 1- plus radical surgery was identified.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The two chemotherapy regimens showed similar results in terms of recurrence rate, OS and DFS, with a favorable toxicity profile in favour of the first one.# 13.2 Previous initiatives Eleven previous initiatives419,422-425,529,531,1505-1510 presenting guidelines on the management of LACC were identified.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 13.3 Development group comments There was uniform agreement in the development group based on level 1 evidence (meta-analyses and phase III chemoradiotherapy trials) that combined chemoradiotherapy and brachytherapy is the method of choice for the management of stage T2b-T4a cervical cancer and also for stage T1b2/T2a2 with involved LNs on radiological staging (iN1).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Therefore the management recommendation in the guidelines has become a grade A recommendation.There was considerable discussion in the development group as to the management of stage T1b2/T2a2 with negative LNs on radiological staging (iN0), in particular in regard to the options of chemoradiotherapy and brachytherapy and of surgery.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Finally, agreement was reached allocating chemoradiotherapy and brachytherapy to the “preferred treatment” whereas an “alternative option” was seen for radical surgery, in particular for patients with negative risk factors (tumor size, LVSI, stromal invasion) and in centers where high quality surgery is available in regard to parametrectomy and LN dissection.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "This statement has to be seen in comparison with the recommendations for the management of stage T1b1/T2a1 iN0 allocating radical surgery to the “preferred treatment” and whereas an “alternative option” was seen for radiotherapy, in particular in patients with risk factors (compare 10.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "3).There was unconfined agreement in the development group that for management of patients with localized cervical cancer combination of radical surgery and postoperative external beam radiotherapy has to be avoided as - according to widespread clinical evidence - this combination mainly contributes to a significant increase in morbidity and has no evident impact on survival.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Such combination occurs in a considerable proportion of patients with stage T1b1/T2a1 iN0 and stage T1b2/T2a2 iN0 because risk factors detected in these stages during radical surgery often lead to the addition of postoperative external beam radiotherapy (based on evidence from multiple clinical trials).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Therefore the development group discussed in depth the necessity of upfront multidisciplinary communication on tumour extent and staging using MRI - within a multidisciplinary tumour board - in order to reduce the amount of patients undergoing combined radical surgery and postoperative external beam radiotherapy (compare staging guidelines and 10.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "3).The discovery that cervical cancer cells were sensitive to chemotherapy led to the initiation of studies investigating the efficacy of NACT before surgery in patients with LACC over the past two decades.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The potential advantage of NACT is to potentially decrease tumour volume, eliminate distant metastasis, to increase the tumour vascularization, reduce the number of hypoxic cells and to increase the possibility of obtaining a wider uninvolved resection margins, thereby avoiding adjuvant radiotherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "On the opposite, the delay in surgery, the prolonged duration of treatment with potentially an accelerated repopulation of resistant cancer cells and the toxicity have been considered as disadvantages of NACT.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "But up to now there are no RCTs comparing NACT plus surgery versus primary chemoradiotherapy which is considered the standard of care for locally advanced cervical cancer all over the word.Two recently concluded phase III trials ((EORTC 55994) will hopefully delineate the impact of NACT followed by radical surgery versus chemoradiotherapy in women with LACC.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Adjuvant chemotherapy may be beneficial because a significant proportion of patients experience disease progression after chemoradiotherapy.Although this is included in routine practice in some patients with cervical cancer at very high risk of recurrence, there are only limited data from controlled studies with small numbers of patients.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Future large trials are therefore required to demonstrate its efficacy, toxicities and quality of life.# 13.4 Guidelines # 13.4.1 Stage T1b2/T2a2 and negative lymph nodes on radiological staging Treatment strategy should aim for avoiding the combination of radical surgery and postoperative external radiotherapy because of the significant increase in morbidity and no evident impact on survival.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# A Definitive platinum-based chemoradiotherapy and brachytherapy are the preferred treatment (see Principles of radiotherapy).PALN dissection, at least up to inferior mesenteric artery, may be considered before chemoradiotherapy and brachytherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "PLN dissection is not required.Radical surgery is an alternative option, in particular in patients without negative risk factors (combinations of tumor size, LVSI, and/or depth of stromal invasion).Quality of surgery, both parametrectomy and LN dissection, is, however, of key importance in the management of large tumors.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Intraoperative assessment of LN status (frozen section) is recommended as the first step.If LN involvement is detected intraoperatively, including macrometastases or micrometastases, further PLN dissection and radical hysterectomy should be avoided, and patients should be referred for definitive chemoradiotherapy and brachytherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "PALN dissection, at least up to inferior mesenteric artery, may be considered for staging purposes.If intraoperative LN assessment is negative or is not done, systematic PLN dissection should be performed.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Type C2 radical hysterectomy is recommended.NACT followed by radical surgery is a controversial alternative.The benefit of tumor downsizing with regard to prognosis has not been proven.# 13.4.2 Stage T1b2/T2a2 and involved lymph nodes on radiological staging # Definitive chemoradiotherapy and brachytherapy are recommended in patients with unequivocally involved PLNs on imaging (see Principles of radiotherapy).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "C An additional radiation boost to the involved LNs should be applied (see Principles of radiotherapy).# C PALN dissection, at least up to inferior mesenteric artery, may be considered before treatment for staging purposes in patients with negative PALN on imaging.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Debulking of suspicious PLNs may be considered.# 13.4.3 Stage T2b, T3a/b, T4a Definitive platinum-based chemoradiotherapy and brachytherapy are recommended (see Principles of radiotherapy).An additional radiation boost to the involved LNs should be applied (see Principles of radiotherapy).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# PALN dissection, at least up to inferior mesenteric artery, may be considered before treatment in patients with negative PALNs on imaging.Debulking of suspicious PLNs may be considered.Pelvic exenteration is an option in selected cases with stage T4 N0 M0 disease.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 13.4.4 Cervical stump cancer Management of cervical stump cancer follows the recommendations for patients without previous subtotal hysterectomy.Adaptation of radiotherapy may be necessary, in particular for brachytherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Table 32.Original studies presenting survival and response rates data according to NACT regimens administered in patients with LACC <html><body><table><tr><td>Authorreference</td><td>Year</td><td>N</td><td></td><td>Response</td><td>Survival (%)</td><td></td></tr><tr><td>Abou-Taleb et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1145</td><td>2016</td><td></td><td>Irinotecan/nedaplatin</td><td>rate (%) 75</td><td>PFS nr</td><td>OS nr</td></tr><tr><td> Shimada et al.1207</td><td>2016</td><td>48 52</td><td>Docetaxel/carboplatin</td><td>69</td><td>2-year: 67.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "9</td><td>2-year: 85.9</td></tr><tr><td>Yang et al.1144</td><td>2016</td><td>49</td><td>Irinotecan/cisplatin</td><td>67.3</td><td></td><td>3-year: 96</td></tr><tr><td>Yang et al.1144</td><td>2016</td><td>58</td><td> Paclitaxel/cisplatin</td><td>75.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "7</td><td>nr</td><td>3-year: 89.5</td></tr><tr><td>Benedetti Panici et al.1182</td><td>2015</td><td>22</td><td>Paclitaxel/cisplatin</td><td>52.6</td><td>nr nr</td><td>nr </td></tr><tr><td>Li et al.1183</td><td>2015</td><td>72</td><td>Paclitaxel/cisplatin</td><td>86.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1</td><td>nr</td><td>nr </td></tr><tr><td>Yang et al.1148</td><td>2015</td><td>116</td><td> Paclitaxel/carboplatin</td><td>71.3</td><td> 5-year: 86</td><td>5-year: 85</td></tr><tr><td>Angioli et al.1184</td><td>2014</td><td>35</td><td>Carboplatin/paclitaxel</td><td>78.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "3</td><td>nr</td><td>nr</td></tr><tr><td>McCormack et al.1185</td><td>2013</td><td>46</td><td>Paclitaxel/carboplatin</td><td>70</td><td>5-year: 68</td><td>5-year: 67</td></tr><tr><td>Singh et al.1186</td><td>2013</td><td></td><td>Paclitaxel/carboplatin</td><td>67.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "8</td><td></td><td></td></tr><tr><td>Mousavia et al.1187</td><td></td><td>28</td><td> Paclitaxel/cisplatin</td><td></td><td>nr</td><td>nr</td></tr><tr><td></td><td>2013</td><td>19</td><td></td><td>79</td><td>nr</td><td>nr</td></tr><tr><td> Ferrandina et al1188</td><td>2013</td><td>75 18</td><td>Paclitaxel/epirubicin/cisplatin</td><td>56.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1</td><td> 5-year: 51</td><td>5-year: 53</td></tr><tr><td>Shoji et al.155.a Heijkoop et al.189</td><td>2013 2012</td><td>43b</td><td>Carboplatin/paclitaxel/docetaxel Cisplatin/paclitaxel (N = 25) Cisplatin/etoposide (N = 8)</td><td>78.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "3 83.7</td><td>5-year: 60 5-year: 45</td><td>5-year: 68 5-year: 55</td></tr><tr><td></td><td></td><td></td><td>Carboplatin/paclitaxel (N = 6) Carboplatin/5 fluorouracil (N = 1) Methotrexate/vinblastin/doxorubicin/cisplatin (N = 3) Cisplatin/paclitaxel</td><td></td><td></td><td></td></tr><tr><td>Moioli et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1190 Gong et al.147</td><td>2012 2012</td><td>14 202</td><td>Cisplatin/bleomycin (or pingyangmycin) (N = 159) 5 fluorouracil/cisplatin (N = 12) 5 fluorouracil/cisplatin/ifosfamide/mesna (N = 11)</td><td>85.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "7 90</td><td>nr 2-year: 93</td><td>nr 2-year: 95.5</td></tr><tr><td>Yamaguchi et al.1157.a</td><td></td><td></td><td>Paclitaxel/cisplatin/carboplatin (N = 9) Cisplatin/vincristine/bleomycin (N = 6) Nedaplatin/irinotecan</td><td></td><td></td><td></td></tr><tr><td>Yin et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1153</td><td>2012 2012</td><td>66</td><td>Nedaplatin/paclitaxel</td><td>75.8 80.77%</td><td>2-year: 73.8</td><td>2-year: 76 5-year: 93.89</td></tr><tr><td>Yin et al.1153</td><td>2012</td><td>104 148</td><td>Paclitaxel/cisplatin</td><td>68.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "24%</td><td>nr nr </td><td>5-year: 81.54</td></tr><tr><td>Ren et al.1191</td><td>2011</td><td>52</td><td> Irinotecan/cisplatin</td><td>78.8</td><td>nr</td><td></td></tr><tr><td> Pinheiro et al.1158.a</td><td>2011</td><td>27</td><td>Mitomycin-C/methotrexate/bleomycin</td><td>81</td><td> 5-year: 59</td><td>nr 5-year: 67</td></tr><tr><td> Manci et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1192</td><td>2011</td><td>46</td><td>Topotecan/cisplatin</td><td>89.5</td><td>2-year: 70</td><td>2-year: 81</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Huang et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1193</td><td>2011</td><td>52</td><td>Docetaxel/cisplatin</td><td>86.5</td><td>2-year: 87.2</td><td>2-year: 94.4</td></tr><tr><td>Vizza et al.1159,a McCaffrey et al.746</td><td>2011</td><td>40</td><td>Cisplatin/paclitaxel/ifosfamide</td><td>82.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "5</td><td>2-year: 87.5</td><td>2-year: 90</td></tr><tr><td>Raspagliesi et al.1194</td><td>2011</td><td>42</td><td>Cisplatin/bleomycin/methotrexate/5 fluorouracil</td><td>79%</td><td>nr</td><td>nr</td></tr><tr><td>Mori et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1195</td><td>2010</td><td>71</td><td>Irinotecan/cisplatin</td><td>73.2 87</td><td>nr 5-year: 79.2</td><td>4-year: 87 5-year: 83.1</td></tr><tr><td>Mossa et al.1160,a</td><td>2010</td><td>30</td><td> Paclitaxel/carboplatin</td><td></td><td> 5-year: 65.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "4</td><td>5-year: 70.4</td></tr><tr><td>Kumar et al.1196</td><td>2010</td><td>153</td><td>Cisplatin/vincristine/bleomycin Paclitaxel/ifosfamide/cisplatin</td><td>nr</td><td></td><td>nr</td></tr><tr><td>Bae et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1197</td><td>2009</td><td>56</td><td>Cisplatin/etoposide</td><td>87.5 69.7</td><td>nr 5-year: 60.5</td><td> 5-year: 88.1</td></tr><tr><td>Benedetti Panici et al.1198</td><td>2008</td><td>99</td><td> Paclitaxel/cisplatin</td><td>66.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "7</td><td>nr</td><td> 5-year: 31.6</td></tr><tr><td>Eddy et al.542.a</td><td>2007</td><td>18</td><td>Cisplatin/vincristine</td><td>52</td><td> 5-year: 71</td><td>5-year: 78</td></tr><tr><td>Kokawa et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1162,a</td><td>2007 2007</td><td>145 33</td><td>Mitomycin-C/irinotecan</td><td>85.7</td><td>5-year: 69</td><td> 5-year: 72</td></tr><tr><td>Choi et al.1164.a</td><td>2006</td><td>94</td><td>Cisplatin/ 5 fluorouracil</td><td>66</td><td> 5-year: 71</td><td>5-year: 76.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "4</td></tr><tr><td>Cai et al.77,a</td><td>2006</td><td>52</td><td>Cisplatin/ 5 fluorouracil</td><td>84.6</td><td>5-year: 72.7</td><td>5-year: 84.7</td></tr><tr><td>Behtash et al.543</td><td>2006</td><td>22</td><td>Cisplatin/vincristine</td><td>nr </td><td>nr</td><td>5-year: 28</td></tr><tr><td> Termrungruanglert et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "165.a</td><td>2005</td><td>27</td><td>Cisplatin/gemcitabine</td><td>88.9</td><td> 2-year: 81</td><td>2-year: 88.9</td></tr></table></body></html> a study included in the systematic review published by Osman et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1154 (2014), OS overall survival, nr not reported, PFS progression-free survival Original studies presenting survival and response rates data according to NACT regimens administered in patients with LACC (continued) <html><body><table><tr><td>Authorreference</td><td>Year</td><td>N</td><td>Drugs</td><td>Response</td><td colspan=\"2\">Survival (%)</td></tr><tr><td></td><td></td><td></td><td></td><td>rate (%)</td><td>PFS</td><td>OS</td></tr><tr><td>Taneja et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1166,a</td><td>2005</td><td>22</td><td>Cisplatin/bleomycin/vincristine</td><td>nr</td><td>5-year: 62</td><td>5-year: 69</td></tr><tr><td>Buda et al.95</td><td>2005</td><td>100</td><td>Ifosfamide/cisplatin</td><td>23</td><td>nr</td><td>nr</td></tr><tr><td>Buda et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "95</td><td>2005</td><td>89</td><td>Paclitaxel/ifosfamide/cisplatin</td><td>48</td><td>nr </td><td>nr</td></tr><tr><td>Motoyama et al.1199</td><td>2004</td><td>23</td><td>Cisplatin/mitomycin C/pepleomycin</td><td>87</td><td>5-year: 47</td><td>5-year: 74</td></tr><tr><td>Huang et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "117a</td><td>2003</td><td>102</td><td>Cisplatin/bleomycin/vincristine</td><td>nr</td><td>5-year: 65</td><td>5-year: 69</td></tr><tr><td>Napolitano et al.541,a</td><td>2003</td><td>106</td><td>Cisplatin/bleomycin/vincristine</td><td>nr</td><td>5-year: 71.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "7</td><td>5-year: 76.4</td></tr><tr><td>Kobayashi et al.1200</td><td>2003</td><td>34</td><td>Cisplatin/mitomycin C/bleomycin (N = 11) Cisplatin/doxorubin/5 fluorouracil/mitomycin C (or cyclophosphamide) (N = 23)</td><td>82</td><td>nr</td><td>nr</td></tr><tr><td>Di Vagno et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1201</td><td>2003</td><td>58</td><td>Cisplatin/vinorelbine</td><td>85</td><td>nr</td><td>nr</td></tr><tr><td>D'Agostino et al.1169,a</td><td>2002</td><td>42</td><td>Cisplatin/epirubicin/paclitaxel</td><td>78.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "5</td><td>5-year: 85</td><td>5-year: 90</td></tr><tr><td>Benedetti Panici et al.1140.a</td><td>2002</td><td>152</td><td>Cisplatin/vincristine/bleomycin</td><td>nr</td><td>5-year: 56.5</td><td>5-year: 61</td></tr><tr><td>Duenas-Gonzalez et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1171.a</td><td>2002</td><td>41</td><td>Cisplatin/gemcitabine</td><td>95</td><td>2-year: 65</td><td>2-year: 69</td></tr><tr><td>MacLeod et al.1173,a</td><td>2001</td><td>106</td><td>Cisplatin/vinblastine/bleomycin (N = 97) Cisplatin/epirubicin (N = 4)</td><td>58.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "5</td><td> 5-year: 54</td><td> 5-year: 60</td></tr><tr><td>Costa et al.1172,a</td><td>2001</td><td>16</td><td>Etoposide/vincristine/cyclophosphamide/adriamycin (N = 5) Cisplatin/epirubicine/etoposide/bleomycin</td><td>66.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "7</td><td>5-year: 67</td><td>5-year: 71</td></tr><tr><td>Hwang et al1168.a</td><td>2001</td><td></td><td>Cisplatin/vinblastine/bleomycin</td><td>93.7</td><td>5-year: 78.7</td><td>5-year: 82</td></tr><tr><td>Lopez-Graniel et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1208</td><td>2001</td><td>80 41</td><td>Cisplatin/gemcitabine</td><td>95</td><td>nr</td><td>2-year: 91</td></tr><tr><td>Chang et al.1139.a</td><td>2000</td><td>68</td><td>Cisplatin/vincristine/bleomycin</td><td>82.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "4</td><td>5-year: 68</td><td>5-year: 70</td></tr><tr><td>Etcheverry et al.1202</td><td>2000</td><td>47</td><td>Cisplatin/5 fluorouracil/ifosfamide/mesna</td><td>85</td><td>nr</td><td></td></tr><tr><td>Yamakawa et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1151</td><td>2000</td><td>26</td><td> Bleomycin/mitomycin C/cisplatin</td><td>73.1</td><td></td><td>nr</td></tr><tr><td>Sugiyama et al.1511</td><td>1999</td><td>23</td><td>Cisplatin/irinotecan</td><td>78</td><td>nr nr </td><td>5-year: 80</td></tr><tr><td>Zanetta et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1175,a</td><td>1998</td><td>32</td><td>Cisplatin/paclitaxel/ifosfamide</td><td>84.2</td><td>2-year: 76</td><td>nr 2-year: 90</td></tr><tr><td>Sugiyama et al.1203</td><td>1998</td><td>48</td><td>Cisplatin (or carboplatin)/peplomycin (± doxorubicin)</td><td>77.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1</td><td></td><td></td></tr><tr><td>Giardina et al.1204</td><td>1997</td><td></td><td>Cisplatin</td><td>85</td><td>nr nr</td><td>nr</td></tr><tr><td>Lai et al.1205,1512</td><td>1997</td><td>23</td><td>Cisplatin/vincristine/bleomycin</td><td>81.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "4</td><td></td><td>nr 5-year: 69.7</td></tr><tr><td>Toita et al.1209</td><td></td><td>59</td><td>Cisplatin</td><td>47.6</td><td>nr</td><td>5-year: 47.1</td></tr><tr><td>Eddy et al.1206</td><td>1997 1995</td><td>51 34</td><td>Cisplatin/vincristine</td><td>88</td><td>nr nr</td><td>nr</td></tr></table></body></html> a study included in the systematic review published by Osman et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1154 (2014), OS overall survival, nr not reported, PFS progression-free survival Table 33.Original data on the perioperative outcomes of laparoscopic or robotic radical hysterectomy after NACT or CCRT in patients with LACC <html><body><table><tr><td>Authorreference</td><td>Year</td><td>N</td><td>Previous treatment</td><td>Operative</td><td>Blood loss</td><td>Transfusion</td><td>Conversion to</td><td>Removed</td><td>Hospital</td></tr><tr><td>Laparoscopic surgery</td><td></td><td></td><td></td><td>time (min)</td><td>loss (ml)</td><td>(N)</td><td>laparotomy (N)</td><td>PLNs (N)</td><td>stay (d)</td></tr><tr><td>Corrado et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1229</td><td>2016</td><td>41</td><td>NACT</td><td>Median: 220</td><td>Median: 250</td><td>2</td><td>2</td><td>Median: 20</td><td> Median: 6</td></tr><tr><td>Cai et al.122</td><td>2016</td><td>99</td><td>NACT</td><td>Median: 240</td><td>Median: 300</td><td>nr </td><td>0</td><td>nr</td><td>nr</td></tr><tr><td>Vizza et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "613</td><td>2015</td><td>25</td><td>NACT</td><td>Median: 188</td><td>Median: 220</td><td>2</td><td>0</td><td>Median: 21</td><td> Median: 6</td></tr><tr><td>Ghezzi et al.577</td><td>2013</td><td>68</td><td>NACT</td><td>217</td><td>265</td><td>1</td><td>0</td><td>nr</td><td>nr</td></tr><tr><td>Vizza et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1159</td><td>2011</td><td>40</td><td>NACT</td><td>Median: 305</td><td>Median: 250</td><td>4</td><td>4</td><td>Median: 25</td><td>Median: 6</td></tr><tr><td>Favero et al.1221</td><td>2014</td><td>33</td><td>CCRT</td><td>Mean: 104</td><td>Mean: 80</td><td>nr </td><td>0</td><td>nr</td><td>Mean: 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "7</td></tr><tr><td>Baffert et al.1223</td><td>2016</td><td>39</td><td>CCRT</td><td>Mean: 258</td><td>nr</td><td>0</td><td>3</td><td>nr </td><td>Mean: 5.7</td></tr><tr><td>Colombo et al.124</td><td>2009</td><td>46</td><td>CCRT</td><td>Mean: 157</td><td>Median: 200</td><td>1</td><td>7</td><td>Mean: 11</td><td>Mean: 5</td></tr><tr><td>Robotic surgery</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Siesto et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1513</td><td>2016</td><td>32</td><td>NACT</td><td>Median: 264</td><td>Median: 100</td><td>3</td><td>0</td><td>Median: 28</td><td> Median: 4</td></tr><tr><td>Corrado et al.1229</td><td>2016</td><td>41</td><td>NACT</td><td>Median: 180</td><td>Median: 150</td><td>3</td><td>0</td><td>Median: 23</td><td>Median: 4</td></tr><tr><td>Minig et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1226</td><td>2016</td><td>30</td><td>NACT</td><td>Mean: 307.8</td><td>Mean: 111</td><td>3</td><td>0</td><td>Mean: 22.8</td><td>Mean: 4.1</td></tr><tr><td>Vizza et al.613</td><td>2015</td><td>25</td><td>NACT</td><td>Median: 190</td><td>Median: 160</td><td>3</td><td>0</td><td>Median: 23</td><td>Median: 4</td></tr><tr><td>Vizza et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1227</td><td>2014</td><td>60</td><td>NACT</td><td>Median: 225</td><td>Median: 150</td><td>6</td><td>0</td><td>Median: 23</td><td>Median: 4</td></tr><tr><td>Vitobello et al.1225</td><td>2013</td><td>18</td><td>NACT</td><td>Median: 260</td><td>Median: 100</td><td>0</td><td>0</td><td>Median: 26</td><td>Median: 4</td></tr><tr><td>Gallotta et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1228</td><td>2017</td><td>40</td><td>CCRT</td><td>Median: 185</td><td>Median: 100</td><td>0</td><td>1</td><td>Median: 21</td><td>Median: 2</td></tr></table></body></html> CCRT concurrent chemoradiotherapy, NACT neoadjuvant chemotherapy, nr not reported, PLNs pelvic lymph nodes Table 34.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Original studies of image-guided adaptive brachytherapy reporting outcomes according to GEC - ESTRO recommendations135,244 <html><body><table><tr><td>Authorreference</td><td>Year</td><td>N</td><td>Dose</td><td>Image guidance</td><td>Median follow-up</td><td>Local control</td><td>OS</td><td>Actuarial grade 3-4</td></tr><tr><td></td><td></td><td></td><td>rate</td><td>Modality</td><td>(months)</td><td>rate (%)</td><td>(%)</td><td>Morbidity rate (%)</td></tr><tr><td>Ribeiro et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1362</td><td>2016</td><td>154</td><td>PDR:100%</td><td>MRI: 100%</td><td>37</td><td>95.5</td><td>nr</td><td>11</td></tr><tr><td>Sturdza et al.1363</td><td>2016</td><td>731</td><td>HDR: 58.7% PDR: 40.4% LDR: 1%</td><td>MRI: 80.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "9% CT: 19.1%</td><td>43</td><td>91</td><td>74</td><td>11</td></tr><tr><td>Lakosi et al.1361</td><td>2015</td><td>85</td><td>PDR:100%</td><td>MRI: 100%</td><td>36</td><td>94</td><td>81</td><td>nr</td></tr><tr><td>Castelnau-Marchand et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1360</td><td>2015</td><td>225</td><td>PDR:100%</td><td>MRI: 89.3% CT: 10.7%</td><td>38.8</td><td>86.4</td><td>76.1</td><td>6.6</td></tr><tr><td>Simpson et al.1359</td><td>2015</td><td>76</td><td>HDR: 100%</td><td>CT:100%</td><td>10</td><td>94.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "2</td><td>75</td><td>2.2</td></tr><tr><td>Gill et al.1285</td><td>2015</td><td>128</td><td>HDR: 100%</td><td>MRI: 100%</td><td>24.4</td><td>91.6</td><td>87.7</td><td>0.9</td></tr><tr><td>Rijkmans et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1358</td><td>2014</td><td>83</td><td>HDR: 100%</td><td>MRI: 86.7% CT: 13.3%</td><td>42.3</td><td>93</td><td>86</td><td>8.4</td></tr><tr><td>Kharofa et al.1357</td><td>2014</td><td>18</td><td>HDR: 100%</td><td>MRI: 100%</td><td>20</td><td>100</td><td>93</td><td>11.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1</td></tr><tr><td>Tharavichitkul et al.1356</td><td>2013</td><td>17</td><td>HDR: 100%</td><td>CT: 100%</td><td>19</td><td>100</td><td>94.1</td><td>11.8</td></tr><tr><td>Lindegaard et al.1355</td><td>2013</td><td>140</td><td>PDR:100%</td><td>MRI: 98% CT: 2%</td><td>36</td><td>91</td><td>79</td><td>７</td></tr><tr><td>Nomden et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1354</td><td>2013</td><td>46</td><td>HDR: 10.9% PDR: 84.8% PDR + HDR: 4.3%</td><td>MRI: 100%</td><td>41</td><td>93</td><td>65</td><td>9.5</td></tr><tr><td>Mahantshetty et al.1353</td><td>2011</td><td>24</td><td>HDR: 100%</td><td>MRI: 100%</td><td>24</td><td>87.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "5</td><td>96</td><td>4.1</td></tr><tr><td>Potter et al.1260</td><td>2011</td><td>156</td><td>HDR: 100%</td><td>MRI: 100%</td><td>42</td><td>95</td><td>68</td><td>5.6</td></tr></table></body></html> CT computed tomography, HDR high-dose rate, LDR low-dose rate, MRI magnetic resonance imaging, nr not reported, PDR pulsed-dose rate Table 35.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Pooled data published by the chemoradiotherapy for cervical cancer meta-analysis collaboration1379 regarding the efficacy of chemoradiotherapy for patients with LACC <html><body><table><tr><td>Parameter</td><td>CCRT versus radiotherapy</td></tr><tr><td>Planned chemotherapy type</td><td></td></tr><tr><td>Platinum based</td><td>HR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "84 (95% CI= 0.72-0.98)</td></tr><tr><td>Non-platinum based</td><td>HR = 0.76 (95% CI = 0.62-0.94)</td></tr><tr><td>Planned radiotherapy dose</td><td></td></tr><tr><td>> 45 Gy + brachytherapy</td><td>HR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "78 (95% CI = 0.68-0.89)</td></tr><tr><td>< 45 Gy + brachytherapy</td><td>HR = 0.93 (95% CI = 0.70-1.24)</td></tr><tr><td>Planned chemotherapy cycle length</td><td></td></tr><tr><td><1 week</td><td>HR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "74 (95% CI = 0.60-0.92)</td></tr><tr><td>>1 week</td><td>HR = 0.95 (95% CI = 0.72-1.25)</td></tr><tr><td>Planned cisplatin dose intensity</td><td></td></tr><tr><td><25 mg/m²/week</td><td>HR = 0.93 (95% CI = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "70-1.24)</td></tr><tr><td>> 25 mg/m²/week</td><td>HR = 0.76 (95% CI = 0.62-0.96)</td></tr><tr><td>Cisplatin regimen</td><td></td></tr><tr><td>Single agent</td><td>HR = 0.75 (95% CI = 0.63-0.88)</td></tr><tr><td>Combination</td><td>HR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "86 (95% CI = 0.71-1.04)</td></tr></table></body></html> CCRT concurrent chemoradiotherapy, CI confidence interval, HR hazard ratio Table 36.Pooled data published by Green et al.1422 on the safety of chemoradiotherapy in patients with LACC <html><body><table><tr><td>Outcome</td><td>CCRT versus radiotherapy</td></tr><tr><td>Acute haematological toxicity</td><td></td></tr><tr><td>(non-specified)</td><td>OR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "60 (95% CI = 1.26-2.03)</td></tr><tr><td>Grade 1-2 Grade 3-4</td><td>OR = 3.42 (95% CI = 2.59-4.51)</td></tr><tr><td>Acute haemoglobin toxicity</td><td></td></tr><tr><td>Grade 1-2</td><td>OR = 1.71 (95% CI = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "33-2.21)</td></tr><tr><td>Grade 3-4</td><td>OR = 3.66 (95% CI = 1.72-7.77)</td></tr><tr><td>Acute gastrointestinal toxicity</td><td></td></tr><tr><td></td><td>OR = 1.33 (95% CI = 1.11-1.58)</td></tr><tr><td>Grade 1-2 Grade 3-4</td><td>OR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "98 (95% CI = 1.49-2.63)</td></tr><tr><td>Acute genitourinary toxicity</td><td></td></tr><tr><td></td><td>OR = 1.14 (95% CI = 0.90-1.45)</td></tr><tr><td>Grade 1-2 Grade 3-4</td><td>OR = 1.08 (95% CI = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "57-2.04)</td></tr><tr><td>Acute neurologic toxicity</td><td></td></tr><tr><td>Grade 1-2</td><td>OR = 1.82 (95% CI = 1.16-2.85)</td></tr><tr><td>Grade 3-4</td><td>OR = 0.95 (95% CI= 0.29-3.08)</td></tr><tr><td>Acute white blood cell toxicity</td><td></td></tr><tr><td>Grade 1-2</td><td>OR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "29 (95% CI= 1.08-1.53)</td></tr><tr><td>Grade 3-4</td><td>OR = 2.20 (95% CI = 1.72-2.80)</td></tr><tr><td>Acute platelet toxicity</td><td></td></tr><tr><td>Grade 1-2</td><td>OR = 2.30 (95% CI = 1.81-2.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "94)</td></tr><tr><td>Grade 3-4</td><td>OR = 2.44 (95% CI = 1.18-5.06)</td></tr><tr><td>Acute nausea/vomiting</td><td></td></tr><tr><td>Grade 1-2</td><td>OR = 3.09 (95% CI = 2.27-4.21)</td></tr><tr><td>Grade 3-4</td><td>OR = 4.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "09 (95% CI= 2.34-7.16)</td></tr><tr><td>Acute skin toxicity</td><td></td></tr><tr><td>Grade 1-2</td><td>OR = 1.37 (95% CI= 1.05-1.78)</td></tr><tr><td>Grade 3-4</td><td>OR = 1.36 (95% CI = 0.74-2.50)</td></tr></table></body></html> CCRT concurrent chemoradiotherapy, CI confidence interval, OR odd ratio Table 37.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Pooled data published by Fu et $\\mathbf { \\Delta } a l .^ { 1 4 3 9 }$ regarding the efficacy of different concurrent chemoradiotherapy regimens in the treatment of advanced cervical cancer <html><body><table><tr><td>Authorreference</td><td>Year</td><td>Treatment 1</td><td>Treatment 2</td><td>Pairwise meta-analysis</td></tr><tr><td> Overall response rate</td><td></td><td></td><td></td><td></td></tr><tr><td>Ke et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1399</td><td>2012</td><td>Radiotherapy</td><td>CCRT (cisplatin + docetaxel)</td><td>OR = 0.70 (95% CI= 0.33-1.55)</td></tr><tr><td>Sol et al.1436</td><td>2009</td><td>CCRT (cisplatin + 5 fluorouracil)</td><td>CCRT (cisplatin + paclitaxel)</td><td>OR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "00 (95% CI= 0.56-1.78)</td></tr><tr><td>Kim et al.1265</td><td>2008</td><td>CCRT (cisplatin)</td><td>CCRT (cisplatin + 5 fluorouracil)</td><td>OR = 1.00 (95% CI = 0.61-1.65)</td></tr><tr><td>Tseng et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1397</td><td>1997</td><td>Radiotherapy</td><td> CCRT (cisplatin + vincristine + bleomycin)</td><td>OR = 0.84 (95% CI = 0.49-1.43)</td></tr><tr><td>Wong et al.1420</td><td>1989</td><td>Radiotherapy</td><td>CCRT (cisplatin)</td><td>OR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "84 (95% CI = 0.46-1.55)</td></tr><tr><td>5-year OS rate</td><td></td><td></td><td></td><td></td></tr><tr><td>Zuliani et al.1273</td><td>2014</td><td>Radiotherapy</td><td>CCRT (cisplatin)</td><td>OR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "95 (95% CI= 0.70-1.30)</td></tr><tr><td>Garipagaoglu et al.1261</td><td>2004</td><td>Radiotherapy</td><td>CCRT (cisplatin)</td><td></td></tr><tr><td>Pearcey et al.1269</td><td>2002</td><td>Radiotherapy</td><td>CCRT (cisplatin)</td><td></td></tr><tr><td>Kong et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1434</td><td>2012</td><td>CCRT (cisplatin)</td><td>CCRT (cisplatin + 5 fluorouracil)</td><td>OR = 1.08 (95% CI= 0.73-1.58)</td></tr><tr><td>Geara et al.1430</td><td>2010</td><td>CCRT (cisplatin)</td><td>CCRT (paclitaxel)</td><td>OR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "41 (95% CI = 0.40-4.91)</td></tr><tr><td>Sol et al.1436</td><td>2009</td><td>CCRT (cisplatin + 5 fluorouracil)</td><td>CCRT (cisplatin + paclitaxel)</td><td>OR = 0.98 (95% CI = 0.54-1.81)</td></tr><tr><td>Rose et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1437</td><td>2007</td><td>CCRT (cisplatin)</td><td>CCRT (hydroxyurea)</td><td>OR = 1.50 (95% CI = 1.04-2.16)</td></tr><tr><td>Rose et al.1437</td><td>2007</td><td>CCRT (cisplatin)</td><td>CCRT (cisplatin + 5 fluorouracil + hydroxyurea)</td><td>OR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "98 (95% CI = 0.70-1.38)</td></tr><tr><td>Rose et al.1437</td><td>2007</td><td>CCRT (hydroxyurea)</td><td>CCRT (cisplatin + 5 fluorouracil + hydroxyurea)</td><td>OR = 0.65 (95% CI= 0.45-0.94)</td></tr><tr><td> 5-year DFS rate</td><td></td><td></td><td></td><td></td></tr><tr><td>Zuliani et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1273</td><td>2014</td><td>Radiotherapy</td><td>CCRT (cisplatin)</td><td>OR = 0.76 (95% CI= 0.48-1.19)</td></tr><tr><td>Garipagaoglu et al.1261</td><td>2004</td><td>Radiotherapy</td><td>CCRT (cisplatin)</td><td>OR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "76 (95% CI = 0.48-1.19)</td></tr><tr><td>Sol et al.1436</td><td>2009</td><td>CCRT (cisplatin + 5 fluorouracil)</td><td>CCRT (cisplatin + paclitaxel)</td><td>OR = 0.84 (95% CI = 0.45-1.58)</td></tr><tr><td>Thomas et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1371</td><td>1998</td><td>Radiotherapy</td><td>CCRT (cisplatin + 5 fluorouracil)</td><td>OR = 0.68 (95% CI = 0.35-1.30)</td></tr></table></body></html> CCRT concurrent chemoradiotherapy, CI confidence interval, DFS disease-free survival, OR odd ratio, OS overall survival Table 38.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Pooled data published by Fu et al.1439 regarding the toxicity of different concurrent chemoradiotherapy regimens in the treatment of advanced cervical cancer <html><body><table><tr><td>Authorreference</td><td>Year</td><td>Treatment 1</td><td>Treatment 2</td><td>Pairwise meta-analysis</td></tr><tr><td>Anemia</td><td></td><td></td><td></td><td></td></tr><tr><td>Wang et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1432</td><td>2015</td><td>CCRT (cisplatin)</td><td>CCRT (cisplatin + gemcitabine)</td><td>OR = 0.33 (95% CI = 0.15-0.75)</td></tr><tr><td>Duenas-Gonzalez et al.1435</td><td>2011</td><td>CCRT (cisplatin)</td><td>CCRT (cisplatin + gemcitabine)</td><td></td></tr><tr><td>Coronel et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1431</td><td>2013</td><td>CCRT (cisplatin)</td><td>CCRT (vinorelbine)</td><td>OR = 0.95 (95% CI= 0.06-16.29)</td></tr><tr><td>Kong et al.1434</td><td>2012</td><td>CCRT (cisplatin)</td><td>CCRT (cisplatin + 5 fluorouracil)</td><td>OR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "29 (95% CI= 0.07-1.15)</td></tr><tr><td>Sol et al.1436</td><td>2009</td><td>CCRT (cisplatin + 5 fluorouracil)</td><td>CCRT (cisplatin + paclitaxel)</td><td>OR= 1.07 (95% CI = 0.20-5.56)</td></tr><tr><td>Gallardo et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1438</td><td>1999</td><td>CCRT (cisplatin)</td><td>CCRT (cisplatin + amifostine)</td><td>OR = 2.00 (95% CI = 0.16-25.75)</td></tr><tr><td>Leucopenia</td><td></td><td></td><td></td><td></td></tr><tr><td>Wang et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1432</td><td>2015</td><td>CCRT (cisplatin)</td><td>CCRT (cisplatin + gemcitabine)</td><td>OR = 0.73 (95% CI = 0.30-1.78)</td></tr><tr><td>Coronel et al.1431</td><td>2013</td><td>CCRT (cisplatin)</td><td>CCRT (vinorelbine)</td><td>OR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "19 (95% CI = 0.01-4.22)</td></tr><tr><td>Nedovic et al.1433</td><td>2012</td><td>CCRT (cisplatin)</td><td>CCRT (cisplatin + 5 fluorouracil)</td><td>OR = 0.44 (95% CI = 0.20-0.99)</td></tr><tr><td>Kong et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1434</td><td>2012</td><td>CCRT (cisplatin)</td><td>CCRT (cisplatin + 5 fluorouracil)</td><td></td></tr><tr><td>Sol et al.1436</td><td>2009</td><td>CCRT (cisplatin + 5 fluorouracil)</td><td>CCRT (cisplatin + paclitaxel)</td><td>OR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "14 (95% CI= 0.05-0.39)</td></tr><tr><td>Whitney et al.1418</td><td>1999</td><td>CCRT (hydroxyurea)</td><td>CCRT (cisplatin + 5 fluorouracil)</td><td>OR = 6.89 (95% CI = 2.87-16.54)</td></tr><tr><td>Tseng et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1397</td><td>1997</td><td>Radiotherapy</td><td>CCRT (cisplatin + vincristine + bleomycin)</td><td>OR = 0.70 (95% CI = 0.26-1.87)</td></tr><tr><td>Wong et al.1420</td><td>1989</td><td>Radiotherapy</td><td>CCRT (cisplatin)</td><td>OR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "06 (95% CI = 0.01-0.47)</td></tr><tr><td>Neutropenia</td><td></td><td></td><td></td><td></td></tr><tr><td>Wang et al.1432</td><td>2015</td><td>CCRT (cisplatin)</td><td>CCRT (cisplatin + gemcitabine)</td><td>OR= 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "15 (95% CI = 0.09-0.24)</td></tr><tr><td>Duenas-Gonzalez et al.1435</td><td>2011</td><td>CCRT (cisplatin)</td><td>CCRT (cisplatin + gemcitabine)</td><td></td></tr><tr><td>Coronel et al.1431</td><td>2013</td><td>CCRT (cisplatin)</td><td>CCRT (vinorelbine)</td><td>OR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "19 (95% CI = 0.01-4.22)</td></tr><tr><td>Gallardo et al.1438</td><td>1999</td><td>CCRT (cisplatin)</td><td>JCCRT (cisplatin + amifostine)</td><td>OR = 2.00 (95% CI= 0.30-13.51)</td></tr><tr><td>Thrombocytopenia</td><td></td><td></td><td></td><td></td></tr><tr><td>Wang et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1432</td><td>2015</td><td>CCRT (cisplatin)</td><td>CCRT (cisplatin + gemcitabine)</td><td>OR= 0.24 (95% CI= 0.09-0.64)</td></tr><tr><td>Duenas-Gonzalez et al.1435</td><td>2011</td><td>CCRT (cisplatin)</td><td>CCRT (cisplatin + gemcitabine)</td><td></td></tr><tr><td>Coronel et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1431</td><td>2013</td><td>CCRT (cisplatin)</td><td>CCRT (vinorelbine)</td><td>OR = 9.50 (95% CI= 0.41-217.61)</td></tr><tr><td>Nedovic et al.1433</td><td>2012</td><td>CCRT (cisplatin)</td><td>CCRT (cisplatin + 5 fluorouracil)</td><td>OR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "33 (95% CI = 0.07-1.50)</td></tr><tr><td>Kong et al.1434</td><td>2012</td><td>CCRT (cisplatin)</td><td>CCRT (cisplatin + 5 fluorouracil)</td><td></td></tr></table></body></html> CCRT concurrent chemoradiotherapy, CI confidence interval, OR odd ratio Pooled data published by Fu et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1439 regarding the toxicity of different concurrent chemoradiotherapy regimens in the treatment of advanced cervical cancer (continued) <html><body><table><tr><td>Authoreference</td><td>Year</td><td>Treatment 1</td><td>Treatment 2</td><td>Pairwise meta-analysis</td></tr><tr><td>Thrombocytopenia (continued)</td><td></td><td></td><td></td><td></td></tr><tr><td>Sol et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1436</td><td>2009</td><td>CCRT (cisplatin + 5 fluorouracil)</td><td>CCRT (cisplatin + paclitaxel)</td><td>OR = 0.36 (95% CI = 0.01-8.95)</td></tr><tr><td>Whitney et al.1418</td><td>1999</td><td>CRT (hydroxyurea)</td><td>CCRT (cisplatin + 5 fluorouracil)</td><td>OR = 2.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "70 (95% CI = 0.11-66.67)</td></tr><tr><td>Gallardo et al.1438</td><td>1999</td><td>CCRT (cisplatin)</td><td>CCRT (cisplatin + amifostine)</td><td>OR = 1.00 (95% CI = 0.05-18.30)</td></tr><tr><td>Tseng et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1397</td><td>1997</td><td>Radiotherapy</td><td>CCRT (cisplatin + vincristine + bleomycin)</td><td>OR = 0.48 (95% CI= 0.09-2.74)</td></tr><tr><td>Wong et al.1420</td><td>1989</td><td>Radiotherapy</td><td>CCRT (cisplatin)</td><td>OR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "77 (95% CI = 0.10-5.75)</td></tr><tr><td>Diarrhea</td><td></td><td></td><td></td><td></td></tr><tr><td>Wang et al.1432</td><td>2015</td><td>CCRT (cisplatin)</td><td>CCRT (cisplatin + gemcitabine)</td><td>OR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "30 (95%CI= 0.16-0.54)</td></tr><tr><td>Duenas-Gonzalez et al.1435</td><td>2011</td><td>CCRT (cisplatin)</td><td>CCRT (cisplatin + gemcitabine)</td><td></td></tr><tr><td>Coronel et al.1431</td><td>2013</td><td>CCRT (cisplatin)</td><td>CCRT (vinorelbine)</td><td>OR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "95 (95% CI = 0.06-16.29)</td></tr><tr><td>Nedovic et al.1433</td><td>2012</td><td>CCRT (cisplatin)</td><td>CCRT (cisplatin + 5 fluorouracil)</td><td>OR = 0.32 (95% CI= 0.10-1.04)</td></tr><tr><td>Kong et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1434</td><td>2012</td><td>CCRT (cisplatin)</td><td>CCRT (cisplatin + 5 fluorouracil)</td><td></td></tr><tr><td>Geara et al.1430</td><td>2010</td><td>CCRT (cisplatin)</td><td>CCRT (paclitaxel)</td><td>OR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "70 (95% CI= 0.20-2.51)</td></tr><tr><td>Sol et al.1436</td><td>2009</td><td>CCRT (cisplatin + 5 fluorouracil)</td><td>CCRT (cisplatin + paclitaxel)</td><td>OR = 1.19 (95% CI = 0.44-3.18)</td></tr><tr><td>Tseng et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1397</td><td>1997</td><td>Radiotherapy</td><td>CCRT (cisplatin + vincristine + bleomycin)</td><td>OR = 1.61 (95% CI = 0.55-4.71)</td></tr><tr><td>Wong et al.1420 Nausea</td><td>1989</td><td>Radiotherapy</td><td>CCRT (cisplatin)</td><td>OR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "77 (95% CI = 0.10-5.75)</td></tr><tr><td>Wang et al.1432</td><td>2015</td><td>CCRT (cisplatin)</td><td>CCRT (cisplatin + gemcitabine)</td><td>OR = 0.57 (95% CI = 0.23-1.42)</td></tr><tr><td>Duenas-Gonzalez et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1435</td><td>2011</td><td>CCRT (cisplatin)</td><td>CCRT (cisplatin + gemcitabine)</td><td></td></tr><tr><td>Coronel et al.1431</td><td>2013</td><td>CCRT (cisplatin)</td><td>CCRT (vinorelbine)</td><td>OR = 2.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "85 (95% CI = 0.11-74.34)</td></tr><tr><td>Kong et al.1434</td><td>2012</td><td>CCRT (cisplatin)</td><td>CCRT (cisplatin + 5 fluorouracil)</td><td>OR = 0.44 (95% CI= 0.20-0.97)</td></tr><tr><td>Sol et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1436</td><td>2009</td><td>CCRT (cisplatin + 5 fluorouracil)</td><td>CCRT (cisplatin + paclitaxel)</td><td>OR = 2.29 (95% CI = 0.85-6.12)</td></tr><tr><td>Vomiting</td><td></td><td></td><td></td><td></td></tr><tr><td>Wang et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1432</td><td>2015</td><td>CCRT (cisplatin)</td><td>CCRT (cisplatin + gemcitabine)</td><td>OR = 0.36 (95% CI = 0.15-0.84)</td></tr><tr><td>Coronel et al.1431</td><td>2013</td><td>CCRT (cisplatin)</td><td>CCRT (vinorelbine)</td><td>OR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "90 (95% CI = 0.16-22.72)</td></tr><tr><td>Kong et al.1434</td><td>2012</td><td>CCRT (cisplatin)</td><td>CCRT (cisplatin + 5 fluorouracil)</td><td>OR = 0.43 (95% CI = 0.16-1.15)</td></tr><tr><td>Sol et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1436</td><td>2009</td><td>CCRT (cisplatin + 5 fluorouracil)</td><td>CCRT (cisplatin + paclitaxel)</td><td>OR = 7.46 (95% CI = 0.37-148.48)</td></tr></table></body></html> CCRT concurrent chemoradiotherapy, CI confidence interval, OR odd ratio Table 39.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "pooled data published by Zhang et al.1440 regarding the efficacy and toxicity of different concurrent single-agent chemotherapy and radiotherapy in the treatment of LACC <html><body><table><tr><td>Outcome</td><td> Pooled data</td></tr><tr><td colspan=\"2\"> Nedaplatin versus cisplatin</td></tr><tr><td>OS</td><td>OR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "27 (95% CI = 0.73-2.22)</td></tr><tr><td> Response rate</td><td>OR = 3.71 (95% CI = 0.66-8.29)</td></tr><tr><td>Local recurrent rate</td><td>OR = 0.46 (95% CI = 0.20-1.06)</td></tr><tr><td>Distant metastasis rate</td><td>OR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "34 (95% CI = 0.12-1.01)</td></tr><tr><td>Nausea and vomiting</td><td>OR = 0.21 (95% CI = 0.13-0.36)</td></tr><tr><td>Leucopenia</td><td>OR = 0.84 (95% CI = 0.48-1.49)</td></tr><tr><td>Thrombocytopenia</td><td>OR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "84 (95% CI = 1.14-2.97)</td></tr><tr><td>Renal dysfunction</td><td>OR = 0.41 (95% CI= 0.23-0.74)</td></tr><tr><td>Liver dysfunction</td><td>OR = 0.40 (95% CI = 0.19-0.86)</td></tr><tr><td>Diarrhea</td><td>OR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "41 (95% CI = 0.19-0.91)</td></tr><tr><td colspan=\"2\"> Docetaxel versus cisplatin</td></tr><tr><td>OS</td><td>OR = 2.142 (95% CI= 0.789-5.820)</td></tr><tr><td> Response rate</td><td>OR = 1.928 (95% CI= 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "396-9.379)</td></tr><tr><td>Local recurrent rate</td><td>OR = 0.602 (95% CI = 0.163-2.227)</td></tr><tr><td>Distant metastasis rate</td><td>OR = 0.783 (95% CI= 0.164-3.741)</td></tr><tr><td>Myelosuppression</td><td>OR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "21 (95% CI = 0.09-0.47)</td></tr><tr><td>Gastrointestinal toxicity</td><td>OR = 0.19 (95% CI = 0.08-0.44)</td></tr><tr><td>Renal dysfunction</td><td>OR = 0.46 (95% CI = 0.10-2.20)</td></tr><tr><td colspan=\"2\"> Paclitaxel versus cisplatin</td></tr><tr><td>OS</td><td>OR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "653 (95% CI= 0.285-1.496]</td></tr><tr><td>Response rate</td><td>OR = 0.892 (95% CI = 0.290-2.743)</td></tr><tr><td>Local recurrent rate</td><td>OR = 0.850 (95% CI = 0.320-2.260)</td></tr><tr><td>Distant metastasis rate</td><td>OR =1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "008 (95% CI= 0.335-3.033)</td></tr><tr><td>Myelosuppression</td><td>OR = 0.37 (95% CI = 0.17-0.81)</td></tr><tr><td>Nausea and vomiting</td><td>OR = 0.40 (95% CI = 0.17-0.92)</td></tr><tr><td>Diarrhea</td><td>OR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "07 (95% CI= 0.46-2.50)</td></tr><tr><td colspan=\"2\"> 5 fluorouracil</td></tr><tr><td>OS</td><td>OR = 0705 (95% CI = 0.467-1.065)</td></tr><tr><td> Response rate</td><td>OR = 1.190 (95% CI = 0.242-5.844)</td></tr><tr><td>Local recurrent rate</td><td>OR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "873 (95% CI= 0.471-1.625)</td></tr><tr><td>Distant metastasis rate</td><td>OR = 1.858 (95% CI= 1.094-3.154)</td></tr><tr><td>Myelosuppression</td><td>OR = 0.24 (95% CI = 0.14-0.43)</td></tr><tr><td>Nausea and vomiting</td><td>OR = 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "70 (95% CI = 0.43-1.14)</td></tr><tr><td>Overall grade 3-4 toxicity Paclitaxel liposome versus cisplatin</td><td>OR = 0.34 (95% CI = 0.22-0.52)</td></tr><tr><td colspan=\"2\">Response rate Vinorelbine versus cisplatin</td></tr><tr><td>OS</td><td>OR = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "607 (95% CI = 0.373-6.919)</td></tr><tr><td colspan=\"2\">Irinotecan versus cisplatin</td></tr><tr><td>Response rate</td><td>OR = 1.625 (95% CI = 0.408-6.469)</td></tr></table></body></html> OR odd ratio, OS overall survival Table 40.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Original studies presenting survival and response rates data according to adjuvant chemotherapy after chemoradiotherapy in patients with LACC <html><body><table><tr><td>Authorreference</td><td>Year</td><td>N</td><td>Adjuvant chemotherapy</td><td>Response</td><td>Survival (%)</td></tr><tr><td>Jelavic et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1496,1497</td><td>2015</td><td>118</td><td>Cisplatin/ifosfamide</td><td>100</td><td>8-year 0s: 74.6</td></tr><tr><td>Angioli et al.1504</td><td>2015</td><td>95</td><td>Cisplatin (4 courses) Cisplatin (6 courses)</td><td></td><td>4-year 0S: 84.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "21 4-year 0S: 83.87 4-year DFS: 80</td></tr><tr><td>Duenas-Gonzalez et al.1435,1490-1492</td><td>2012</td><td>259</td><td>Cisplatin/gemcitabine</td><td>95.8</td><td>4-year DFS: 79.56 3-year 0S: 78 3-year PFS: 74.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "4</td></tr><tr><td>Tang et al.1494</td><td>2012</td><td>440</td><td>Cisplatin/paclitaxel</td><td>100</td><td>DFS: 71.4</td></tr><tr><td>Kim et al.1498</td><td>2012</td><td>19</td><td>Paclitaxel/carboplatin</td><td>77.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "8</td><td>3-year 0S :90.9 3-year PFS : 62.7</td></tr><tr><td>Choi et al.1495</td><td>2011</td><td>39</td><td>Cisplatin/5 fluorouracil</td><td>92.3</td><td>OS: 92.7 PFS: 70.1</td></tr><tr><td>Zhang et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1499</td><td>2010</td><td>34</td><td>Paclitaxel/nedaplatin</td><td>100</td><td>2-year OS:93 2-year PFS: 82</td></tr><tr><td>Domingo et al.1500</td><td>2009</td><td>60</td><td>Capecitabine</td><td>88</td><td>1-year 0S: 95 1-year PFS: 86</td></tr><tr><td>Choi et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1501</td><td>2007</td><td>30</td><td>Cisplatin/5 fluorouracil</td><td>87</td><td>3-year 0S: 91 3-year PFS:83</td></tr><tr><td>Vrdoljak et al.1502,1503</td><td>2006</td><td>62</td><td>Cisplatin/ifosfamide</td><td>100</td><td>0S:88.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "7 DFS: 88.7</td></tr><tr><td>Lorvidhaya et al.1267</td><td>2003</td><td>230</td><td>5 fluorouracil</td><td>nr</td><td>3-year 0S: 79 5-year 0s: 73.6 3-year PFS:63</td></tr></table></body></html> DFS disease-free survival, nr not reported, OS overall survival, PFS progression-free survival # 14 Distant metastatic disease at presentation & recurrent disease # 14.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1 Summary of available scientific evidence # 14.1.1 Neoadjuvant chemotherapy A study published by Landoni et al.1514 investigated the role of preoperative chemotherapy LoE 2- prior to pelvic exenteration in patients presenting with poor prognostic factors such as tumour size larger than $5 ~ \\mathrm { c m } ,$ lateral pelvic extension of tumour and recurrence less than a year after initial treatment.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The chemotherapy was prescribed as 3 cycles of paclitaxel, ifosfamide and cyclophosphamide.All patients had either pelvic radiotherapy or concurrent chemotherapy and pelvic radiotherapy prior to their exenteration or NACT followed by exenteration.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Tumour shrinkage was observed in $6 1 \\%$ of patients with a rate of uninvolved margins, complications, OS and DFS comparable to patients who initially presented with a better prognosis.As part of a small previous study1515, 17 patients with recurrent or persistent disease and no LoE 3 evidence of systemic disease, considered not be candidates for pelvic exenteration because of the extent of pelvic tumour, received courses of platinum-based chemotherapy for a maximum of 6 courses.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Nine reponses to chemotherapy were observed, including 4 pathological complete responses.At a median follow-up of 11 months, the median survival for the whole group was 11 months, 3 months for those who did not responded to chemotherapy and 32 months for those who underwent exenteration.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 14.1.2 Pelvic exenteration As part of a systematic review, Sardain et al.1516,1517 reported that $7 .3 6 \\%$ of exenterations performed with a curative intent after preoperative radiation, were found to have tumour present at the surgical resection margin after thorough pathological evaluation (ten studies1518- 1527).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The authors described a rate of early postoperative complications (within 30 days of the surgery) ranging from 16 to $8 3 \\%$ (eight studies1519,1520,1522-1527).The most frequent complications were gastrointestinal fistulas with connections to the skin, urinary system or vagina, blood clots and leaking anastomoses.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The rate of late postoperative complications (occuring more than 30 days after surgery) ranged from 36 to $6 1 \\%$ including notably enterocutaneous and vaginal fistulas, ureteral obstruction, bowel obstruction and pyelonephritis (five studies1519,1520,1522,1523,1527).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "For patients where exenteraton was the final therapeutic option, the 5-year OS rate varied from 24.7 to $6 4 \\%$ (seven studies1518,1522-1524,1527- 1529).It should be noted that these results have to be interpreted with caution notably because there is a large heterogeneity among included studies with respect to the type of procedure that was performed and the type of cancer that is being investigated (cervical, endometrial, vulvar or ovarian).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Studies rarely focused uniquely on cervical cancer and even more rarely on cervical cancer recurrences.Moreover, the authors rarely explained how and/or why anterior, posterior, total, supra or infralevator exenterations with or without perineal resection were chosen.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A systematic review1530 aiming to evaluate the effectiveness and safety of exenterative surgery versus other treatment modalities for women with recurrent gynaecological cancer was identified but is not described because the authors did not found studies meeting their inclusion criteria.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The outcomes of patients who underwent pelvic exenteration for recurrent and/or persistent LoE 3 cervical cancer, assessed by the nine other identified studies93,1531-1538, are summarized in the table 41.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 14.1.3 Intraoperative radiotherapy Barney et al.1539 assessed the outcomes of women with recurrent cervical cancer who received intraoperative radiation therapy (IORT) as a component of therapy.Of the 86 patients who met criteria for inclusion in this study, 73 had locally recurrent cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "To date, this represents the largest series evaluating the role of IORT in the treatment of recurrent cervical carcinoma.For this group of patients, the 3-year cumulative incidences of central relapse, locoregional relapse and distant relapse were 23, 39 and $4 4 \\%$ , respectively.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The authors noted an OS of $2 5 \\%$ at 3 years.LoE 2- Mahe et al.1540,1541 reported their experience with IORT in 70 patients with recurrent cervical carcinoma.Mean follow-up after IORT was 11 months.Treatment modalities consisted of IORT alone in 40 out of 70 patients.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Thirty of the women also received external-beam radiation therapy.Additional chemotherapy in the form of 5-FU and cisplatin or a cisplatin-containing regimen was given to 20 of the patients.With a mean follow-up of 15 months, the authors found median survival to be 11 months and local control to be $2 1 \\%$ .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "At 3 years, the reported OS was $8 \\%$ .Local and distant relapses were seen in $7 5 \\%$ and $3 3 \\%$ of the women, respectively (Table 42).It should be noted that (1) 40 of these patients did not receive external-beam radiation therapy and 37 of them had gross residual tumour and (2) the results documented may be a reflection of inclusion of all patients without selecting for tumour volume and site of recurrence.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The Mayo Clinic1542-1544 published data concerning a documented series that included 36 patients with recurrent cervical cancer.At five years, local relapse was seen in $5 0 \\% ,$ central relapse in $4 0 \\%$ , and distant relapse in $5 8 \\%$ .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Median survival was 15 months.Five-year survival was $2 5 \\% ,$ with a reported DFS at 5 years of $2 1 \\%$ .As part of another small studies10,11, 38 patients with recurrent cervical cancer were treated with both chemotherapy (cisplatin and 5-FU) and external-beam radiation therapy followed by surgery with or without IORT to high-risk areas for recurrence.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Complete and quasi-complete response was documented pathologically in $7 4 \\%$ of the surgical specimen.A partial response was noted in $2 6 \\%$ .Median follow-up was 27 months, with an actuarial DFS of $8 0 \\%$ and a locoregional control rate of $9 3 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "4 \\%$ .Stelzer et al.1545 evaluated also the contribution of IORT in the management of recurrent cervical cancer.Twenty-two patients were treated with IORT for recurrent cervical cancers that were confined to the pelvis but were too extensive to be adequately treated by radical surgery alone.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The 5-year disease-specific survival was $4 3 \\% ,$ with a median survival of 26 months.The 5-year local control was $4 8 \\%$ , with a median time to local failure of 22 months.Comparison of the 15 patients who received previous pelvic radiation with those who did not showed no difference in disease-specific survival $[ \\mathrm { p } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "4 6 ]$ ).Likewise, there was no significant difference in disease-specific survival between those patients who underwent total pelvic exenteration and those who had less than exenterative surgery $\\mathrm { ( p = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1 8 ) }$ .In an older small study1546, local relapse in the field of IORT was observed in $1 8 \\%$ of patients.At 4 years, the authors reported an OS of $3 2 \\%$ .Results of other identified studies1547-1558 are limited notably due to the very small number of patients evaluated, the heterogeneity in the IORT modality used (orthovoltage, high-dose rate brachytherapy, intraoperative electron beam radiation therapy), and/or the absence of data taking into account specifically patients with cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# LoE 3 # 14.1.4 Chemotherapy Single agent chemotherapy: Bonomi et al.1559 conducted a RCT comparing 3 cisplatin single agent chemotherapy regimens $\\mathrm { 5 0 ~ m g / m ^ { 2 } }$ every 21 days, $1 0 0 \\mathrm { m g / m } ^ { 2 }$ every 21 days, $2 0 ~ \\mathrm { m g / m ^ { 2 } }$ for five consecutive days repeated every 21 days) in patients who where considerd incurable with surgery or radiation therapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The regimen consisting of a $1 0 0 \\mathrm { \\ m g / m } ^ { 2 }$ single dose produced a statistically significant higher response rate than the $5 0 ~ \\mathrm { m g } / \\mathrm { m } ^ { 2 }$ regimen $( 3 1 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "4 \\%$ versus $2 0 .7 \\%$ , $\\mathrm { ~ p ~ = ~ } 0 .0 1 5 \\mathrm { \\ : ] }$ ).However, higher dose produced no appreciable differences in complete remission rate, response duration, PDF or OS.In addition, the higher dose regimen was associated with greater myelosuppression and nephrotoxicity.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "As part of another ${ \\mathrm { R C T } } ^ { 1 5 6 0 } ,$ the 24-hour continuous infusion of cisplatin $( 5 0 ~ \\mathrm { m g / m ^ { 2 } } )$ offered an advantage over more rapid infusions $( 1 \\mathrm { m g / m i n } )$ in terms of reduced gastrointestinal toxicity in patients with advanced or recurrent cervical cancer no longer amenable to control with surgery or radiation therapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "There were significantly more patients who experienced no nausea and vomiting on the continuous infusion regimen ( $3 4 \\%$ versus $1 8 \\%$ $\\mathrm { p } = 0 .0 0 2 \\mathrm { \\cdot }$ ).However, no differences in terms of response to treatment or survival were observed between the two treatment regimens.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "McGuire et al.1561 studied two alternative platinum agents (carboplatin, iproplatin) in patients with advanced or recurrent cervical cancer.Both platinum analogs were given every 28 days with starting doses of $4 0 0 ~ \\mathrm { m g / m ^ { 2 } }$ for carboplatin $( 3 4 0 ~ \\mathrm { m g / m ^ { 2 } }$ if the patient underwent prior radiation) and $2 7 0 ~ \\mathrm { m g / m ^ { 2 } }$ for iproplatin $\\mathrm { ( 2 3 0 ~ m g / m ^ { 2 } }$ if the patient underwent prior radiation).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "These doses were equivalent to cisplatin doses of 75 to $1 0 0 ~ \\mathrm { m g / m ^ { 2 } }$ .Although this RCT was not designed to compare either analog with cisplatin, the authors noted that overall response rates and complete response rates for both carboplatin and iproplatin were not superior and possibly inferior to those previously reported for the parent, cisplatin.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Many other single agent chemotherapies1562-1621 were also evaluated in patients with advanced, persistent, or recurrent cervical cancer during the last five decades.Corresponding response rates and survival are summarized in table 43.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The identified studies evaluating single agents in patients who have progressed after first-line chemotherapy have reported rather modest efficacy.Overall, the responses were partial and had short duration, with a median OS not exceeding 16 months.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted that higher response rates have been reported for lesions in previously unirradiated areas.As part of a subgroup meta-analysis (ten studies1568,1622-1631) Scatchard et al.1632 did not find statistically significant difference in response rate between women who received single-agent chemotherapy and those who received combination therapy $\\mathrm { { R R } } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "9 4$ ( $9 5 \\% \\mathrm { C I } = 0 .5 7 – 1 .5$ 5)).It should be noted that (1) there was a wide variety of chemotherapy agents and doses used across trials and (2) many of the trials were from an era when activity of agents was not known and so included inactive agents.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "However, the authors found that the proportion of women who responded to treatment was significantly lower in the group who received chemotherapy as a single agent than in the group who received combination chemotherapy $[ \\mathrm { R R } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "6 0$ $9 5 \\%$ $\\mathsf { C I } = 0 .4 4 \\mathsf { - } 0 .8 1$ ), 5 studies1622,1624,1628-1630,1633-1635).Other subgroup analyses found that there was significantly less risk of severe neutropenia (four studies1622,1628-1630,1633-1635, $\\mathrm { R R } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 4$ ( $9 5 \\%$ $\\mathrm { C I } = 0 .0 2 – 0 .1 2 )$ ), severe thrombocytopenia (three studies1622,1628-1630,1633-1635, $\\mathrm { R R } = 0 .1 6$ $( 9 5 \\% \\mathrm { ~ C I } = 0 .0 5 \\ – 0 .4 8 )$ ), and severe infection (two studies1628,1629,1633-1635, $\\mathrm { R R } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "4 2$ $9 5 \\% \\mathrm { C I } = 0 .2 2 – 0 .8 1$ )) in women who received chemotherapy as a single agent than those who received combination chemotherapy.However, they did not find any statistically significant difference in the risk of severe renal dysfunction (three studies1628-1630,1633-1635, RR $\\mathrm { ~ ~ { ~ \\ ?",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "~ } ~ } = \\mathrm { ~ \\ 0 .8 1 }$ $( 9 5 \\% \\mathrm { C I } = 0 .4 6 \\ – 1 .4 1 )$ ) and severe neuropathy (two studies1628,1629,1633-1635, $\\operatorname { R R } = 1 .3 9$ $9 5 \\% \\mathrm { C I } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "4 5 – 4 .3 3$ ) between women who received singleagent chemotherapy and those who received combination chemotherapy.Combination chemotherapy: Scatchard et al.1632 did also not find any statistically significant difference in response rate between women who received platinum-based chemotherapy and those who received non-platinum chemotherapy (three studies1623,1633-1637, $\\mathrm { R R } = 1 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "3 3$ ( $9 5 \\%$ CI $= 0 .5 0 { - 3 } .5 4 )$ ).The authors found that the proportion of women who responded to treatment was statistically significantly lower in the group who received platinum plus paclitaxel than in the group who received combination platinum-containing regimens that did not included paclitaxel $\\mathrm { { R R } } = 1 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "4 7$ $\\left( 9 5 \\% \\mathrm { C I } = 1 .0 1 { - 2 .1 5 } \\right)$ ).It should be noted that in one1638 of the two studies1638,1639 included in this subgroup analysis a paclitaxel triplet was compared with a nopaclitaxel doublet.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The authors performed another subgroup meta-analysis to compare inradiotherapy-field versus out-of-field responses rates and found that the proportion of women who responded to treatment was significantly lower for recurrences within the pelvic field compared with disease outside of the pelvic radiotherapy field (six studies1561,1624,1628,1629,1640- 1642, $\\mathrm { R R } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "6 2$ ( $9 5 \\%$ $\\mathsf { C I } = 0 .4 6 \\small { - 0 .8 3 } ]$ ).Of note the majority of patients had not received prior chemotherapy $( 7 7 .2 \\% )$ with their radiotherapy.Where patients had had previous chemotherapy this was generally cisplatin as part of chemoradiotherapy, rather than chemotherapy alone with palliative intent.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Lorusso et al.1643 performed a systematic review of the literature (seventeen studies1629,1638,1644- 1658) comparing cisplatin and carboplatin based chemotherapy for recurrent, persistent or metastatic cervical cancers.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Objective response rates ranged from $3 3 \\%$ to $6 7 .9 \\%$ for carboplatin studies and from $2 9 .1 \\%$ to $67 \\%$ for cisplatin/paclitaxel studies, resulting in combined objective response rates of $4 8 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "5 \\%$ $( 9 5 \\% \\mathrm { ~ C I } = 3 7 .9 { - } 5 9 .3 )$ for carboplatin and $4 9 .3 \\%$ $9 5 \\% \\mathrm { C I } = 4 1 .1 { - } 5 7 .5$ ) for cisplatin-based chemotherapy.After exclusion of studies that used a triple combination the results were slightly better for carboplatin combinations $( 5 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "3 \\%$ versus $4 3 \\%$ ) but it may be related to the greater number of patients exposed to chemotherapy in carboplatin-doublets arms (median: $5 5 \\%$ versus $2 4 \\%$ ).The response rates for patients previously treated with cisplatin-based chemoradiation were $4 2 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "3 \\%$ and $4 3 .9 \\%$ in carboplatin and cisplatin arms respectively $\\mathrm { ( p } = 0 .5 4 )$ .In the same way, the response rates for patients not previously treated with cisplatin-based therapy were $6 8 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "3 \\%$ and $5 9 .1 \\%$ for carboplatin-based chemotherapy and cisplatin-based chemotherapy, respectively ${ \\mathrm { ( p = 0 .7 3 } } ^ { \\cdot }$ ).Twelve RCTs1629,1630,1633-1635,1640,1644,1659-1668 evaluating combination of drugs that have demonstrated single agent-activity in order to improve response rates and potentially survival were also identified.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Following the demonstration of activity of ifosfamide and mitolactol, a $\\mathrm { R C T ^ { 1 6 3 0 } }$ evaluated cisplatin alone or with each of these two agents.Including patients not suitable for curative treatment with surgery and/or radiotherapy, the addition of ifosfamide to cisplatin led to higher response rate ( $3 1 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1 \\%$ versus $1 7 .8 \\% ,$ $\\mathrm { p } = 0 .0 0 4 \\mathrm { ] }$ and PFS (4.6 months versus 3.2 months, $\\mathrm { ~ p ~ } = \\mathrm { ~ 0 .0 0 3 ~ } ^ { \\cdot }$ ) compared with cisplatin alone.The addition of mitolactol to cisplatin showed no significant improvement in these parameteres compared with cisplatin alone.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "There was also no significant difference in OS between cisplatin and either of the combinations.Another identified RCT1640 reported that the addition of bleomycin to the cisplatin/ifosfamide combination in this category of patients had no benefit in term of response rate, PFS or OS compared with the cisplatin/ifosfamide regimen.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "As shown by Bloss et al.1640, the addition of bleomycin in the cisplatin/ifosfamide doublet did not improve outcome in terms of response rates, PFS and OS in patients with histologically confirmed, advanced (FIGO stage IVB), recurrent, or persistent squamous cell carcinoma of the cervix not suitable for curative treatment with surgery and/or radiotherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Moore et al.1629 assessed if adding paclitaxel to cisplatin improve outcomes of patients with FIGO stage IVB, recurrent, or persistent cervical cancer compared with cisplatin alone.Objective reponses occurred in $1 9 \\%$ of patients receiving cisplatin alone versus $3 6 \\%$ receiving cisplatin $^ +$ paclitaxel ${ \\mathrm { ( p } } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 0 2 { \\mathrm { ) } }$ ).The median PFS was 2.8 and 4.8 months, respectively, for cisplatin versus combined regimen $\\mathrm ( p < 0 .0 0 1 \\} \\$ ).However, no OS difference was noted.In a RCT1633,1635 enrolling patients with FIGO stage IVB, recurrent, or persistent cervical cancer, topotecan plus cisplatin was compared with cisplatin monotherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Median OS was 9.5 months in the combined regimen, compared to 6.5 months with cisplatin alone.The unadjusted HR for OS between treatments arms was 0.76 $9 5 \\%$ $\\mathrm { C I } ~ = ~ 0 .5 9 \\ – 0 .9 8$ , $\\mathrm { ~ p ~ } = \\mathrm { ~ 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 3 3 }$ ) favoring the combination arm.It should be noted that there were no statistically significant differences in quality of life up to 9 months after randomization despite more hematologic toxicity in the combination arm.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Long et al.1634 undertook a RCT comparing methotrexate, vinblastine, doxorubicin, and cisplatin or topotecan plus cisplatin versus cisplatin alone in patients with FIGO stage IVB recurrent or persistent cervical cancer who where unsuitable candidates for curative treatment with surgery and/or radiotherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Patients receiving cisplatin plus topotecan had statistically superior outcomes to those receiving cisplatin alone, with median OS of 9.4 and 6.5 months $[ \\mathrm { p } = 0 .0 1 7 ]$ , median PFS of 4.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "6 and 2.9 months ${ \\mathrm { ( p = 0 } } .0 1 4 { \\mathrm { ) } }$ ), and response rates of $2 7 \\%$ and $1 3 \\%$ $( \\mathrm { p } ~ = ~ 0 .0 0 4 ^ { \\cdot }$ ), respectively.It should be noted that the third arm (methotrexate, vinblastine, doxorubicin, and cisplatin) was closed after treatment-related deaths occurred among $6 \\%$ of patients.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Vermorken et al.1667 found that the addition of bleomycin, vindesine, and mitomycin C to cisplatin had no impact in survival as compared to cisplatin alone in patients who had histologically confirmed advanced (FIGO stage IVB) or recurrent cervical cancer not suitable for curative treatment woth surgery and/or radiotherapy even if the combination regimen induced a significantly higher response rate than cisplatin alone ( $4 2 \\%$ versus $2 5 \\%$ $\\mathrm { p } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 0 6 \\dot { }$ ).Based on these results, Monk et al.1644,1659 undertook a RCT comparing four cisplatincontaining doublet combinations in FIGO stage IVB, recurrent, or persistent cervical cancer (paclitaxel/cisplatin, vinorelbine/cisplatin, gemcitabine/cisplatin, topotecan/cisplatin).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The different combinations were not superior to paclitaxel/cisplatin regimen in termes of OS.However, trends in favor of paclitaxel/cisplatin regimen were noted in terms of OR, PFS and response rate.Patients receiving experimental doublets did not report significant differences in health-related quality of life, neuropathy, or pain from those who received the control doublet (paclitaxel/cisplatin).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Patients receiving paclitaxel/cisplatin doublet tended to report worse neuropathy during treatment than patients who received other doublets (especially gemcitabine/cisplatin and topotecan/cisplatin), but the differences were not statistically significant.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted that this result was potentially compromised by reduced power due to earlier termination of study.Kitagawa et al.1660,1661 published results from a RCT evaluating the clinical benefits of carboplatin plus paclitaxel compared with cisplatin plus paclitaxel for patients with FIGO stage IVB, persistent or recurrent cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "After a median follow-up of 17.6 months, both PFS and OS were similar.It should be noted that the interim analysis demonstrated that the substitution of carboplatin for cisplatin did not result in inferior outcomes.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Observed toxicities were similar in severity and frequency based on previous experiences with these compounds.In a secondary analysis of patients that had not received prior platinum, the cisplatin/paclitaxel doublet appeared to be superior to carboplatin/paclitaxel with a median OS of 23.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "2 versus 13.0 months $\\mathrm { { [ H R = 1 .5 7 } }$ $9 5 \\% \\mathrm { C I } = 1 .0 6 { - 2 .3 2 } )$ ).Using a 2-by-2 factorial design, Tewari et al.1662,1663 randomly assigned patients with recurrent, persistent, or metastatic cervical cancer to chemotherapy (cisplatin plus paclitaxel or topotecan plus paclitaxel) with or without bevacizumab.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "With the data for the two chemotherapy regimens combined, the addition of bevacizumab to chemotherapy was associated with an increased OS $\\mathrm { { T H R } } = 0 .7 1$ $[ 9 8 \\% \\mathrm { C I } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "5 4 – 0 .9 5$ ), $\\mathrm { p } = 0 .0 0 4 \\mathrm { \\AA }$ , an increased PFS $\\mathrm { ( H R = 0 .6 7 }$ ( $9 5 \\% \\mathrm { C I } = 0 .5 4 – 0 .8 2$ ), $\\mathrm { ~ p ~ } = \\ 0 .0 0 2 \\$ ), and higher response rates ( $4 8 \\%$ versus $3 6 \\% ,$ relative probability of a response: 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "35 $9 5 \\% \\mathrm { ~ C I ~ } = \\ 1 .0 8 – 1 .6 8$ ), $\\mathrm { ~ p ~ = ~ 0 .0 0 8 } ^ { \\cdot }$ .Treatment with cisplatin/paclitaxel/bevacizumab, as compared with cisplatin/paclitaxel alone, was associated with a HR for death of 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "68 $9 5 \\% \\mathrm { C I } = 0 .4 8 – 0 .9 7 .$ $\\mathrm { { p = 0 .0 4 } } ]$ ).The response rates were $5 0 \\%$ and $45 \\%$ , respectively $\\mathrm { ~ ( ~ p ~ \\ = ~ \\ } \\ 0 .5 1 )$ .Topotecan/paclitaxel/bevacizumab, as compared with topotecan/paclitaxel alone, was associated with a HR for death of 0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "74 $9 5 ~ \\mathrm { C I } = 0 .5 3 \\substack { - 1 .0 5 }$ , ${ \\bf p } = { \\bf \\Phi }$ 0.09).The response rates were $4 7 \\%$ and $2 7 \\% .$ , respectively $[ \\mathrm { p } = 0 .0 0 2 \\AA$ .It should be noted that as compared with cisplatin/paclitaxel (either with or without bevacizumab) topotecan/paclitaxel was associated with (1) a significantly higher risk of progression $[ \\mathrm { H R } =$ 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "39 $( 9 5 \\ \\% \\ \\mathrm { C I } = 1 .0 9 – 1 .7 7 )$ ) and (2) a non significant risk of death $\\mathrm { { ( H R = 1 .2 0 } }$ $( 9 9 \\% \\mathrm { ~ C I } = 0 .8 2 \\$ 1.76)).There was also no significant difference in mortality between the chemotherapy regimens in the subgroup of patients with previous exposure to platinum $\\mathrm { { [ H R = 1 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1 8 } }$ $9 5 \\% \\mathrm { C I } =$ 0.84-1.65)) and in the subgroup with no previous exposure to platinum $[ \\mathrm { H R } = 1 .3 5$ $9 5 \\% \\mathrm { C I } =$ 0.68-2.69)).In term of quality of life, FACT-Cx-TOI and Brief pain inventory scores indicated that the addition of bevacizumab did not adversly affect health-related quality of life.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should also be noted that hypertension of grade 2 or higher was significantly more common with bevacizumab containing regimens that with regimens that did not contain the anti-angiogenic drug ( $2 5 \\%$ versus $2 \\%$ , $\\mathrm { ~ p ~ } < \\ 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 0 1 \\}$ , but no patients discontinued bevacizumab because of hypertension.Gastrointestinal or genitourinary fistulas of grade 3 or higher were significantly increased with the bevacizumab-containing regimens ( $6 \\%$ versus $0 \\%$ , $\\mathrm { ~ p ~ } = \\ 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 0 2 ^ { \\cdot }$ ), as were thomboembolic events of grade 3 or higher ( $8 \\%$ versus $1 \\%$ , $\\mathrm { p } = 0 .0 0 1 \\mathrm { \\Omega }$ ).As part of another RCT, Symonds et al.1664 assessed the effect of the addition of cediranib to carboplatin and paclitaxel chemotherapy in patients with metastatic carcinoma or who subsequently developed metastatic disease or local pelvic recurrence after radical treatment that was not amenable to exenterative surgery.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted that the trial closed prematurely owing to withdrawal of drug supply.After a median follow-up of 24.2 months, median PFS was longer in the cediranib group (8.1 months) than in the placebo group (6.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "7 months) with a HR of 0.58 ( $8 0 \\%$ $\\% \\mathrm { C I } ~ = ~ 0 .4 0 – 0 .8 5$ , $\\mathrm { ~ p ~ } = \\ 0 .0 3 2 \\mathrm { ~ .~ }$ ).Median OS did not differ significantly between the two treatment groups.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The authors suggested that the effect of cediranib on OS might depend on disease site.Patients with extra-pelvic metatatic disease only had derive a greater benefit compared to those with local relapse (with or without metastatic disease).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The proportion of patients with an overall response in the cediranib group was $6 4 \\%$ compared with $45 \\%$ in the placebo group.Using the EORTC QLQ-C30, the authors reported a significantly worse quality of life associated with diarrhoea in the cediranib group $\\mathrm { ( p = 0 } .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 3 0 \\mathrm { ) }$ ).No other scales derived from the EORTC QLQ-C30 or EORTC QLQX24 questionnaires had significant differences between the study groups.Monk et al.1665,1666 reported on a head-to-head RCT comparing an oral multitargeted antivascular agent (pazopanib) with an oral dual anti-EGFR and anti-HER2/neu tyrosine kinase inhibitor (lapatinib) among women with advanced and recurrent cervical ancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "At the time of interim analysis, Pazopanib improved PFS $\\mathrm { ( H R = 0 .6 6 }$ ( $9 5 \\% \\mathrm { C I } = 0 .4 8 – 0 .9 1$ ), ${ \\mathrm { p } } = 0 .0 1 3 { \\mathrm { \\ : } }$ ) and OS $\\mathrm { { [ H R = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "6 7 } }$ ( $) 5 \\% \\mathrm { C I } = 0 .4 6 { - 0 .9 9 }$ ), $\\mathrm { p } = 0 .0 4 5 ^ { \\cdot }$ ).It should be noted that (1) responses rates were $9 \\%$ and $5 \\%$ for pazopanib and lapatinib, respectively, and (2) the final analysis1666 confirmed the improvement in PFS with pazopanib compared with lapatinib but the improvement in OS lost its statistical significance $[ \\mathrm { H R } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "9 6$ $9 5 \\% \\mathrm { C I } = 0 .7 1 { - } 1 .3 0$ ), $\\mathrm { p } = 0 .4 0 7 \\mathrm { \\cdot }$ ).Including women with histologically confirmed, advanced (FIGO stage IVB) recurrent or persistent carcinoma of the uterine cervix who were unsuitable candidates for curative treatment with surgery and/or radiotherapy, Coronel et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1668 found a significant advantage in PFS (10 months versus 6 months, $\\mathrm { ~ p ~ = ~ } 0 .0 3 8 4 \\dot { }$ ) for epigenetic therapy with hydralazine valproate over a combination chemotherapy (cisplatin plus topotecan).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "No significant differences in terms of response to treatment or incidence of grades 3-4 toxicity was described between the two treatment arms.Forty-one small studies1511,1669-1708 not included in the systematic reviews1632,1643 mentioned LoE 3 above, and evaluating combinations of drugs that have demonstrated single-agent activity were also identified.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Corresponding response rates and survival are summarized in table 44 and table 45.# 14.1.5 (chemo)radiotherapy # LoE 3 As part of a small study, Marnitz et al.1709 evaluated the use of extended-field chemoradiation with concomitant chemotherapy in patients with histologically confirmed para-aortic metastases after laparoscopic para-aortic and pelvic lymphadenectomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In all, $9 3 \\%$ of the patients underwent intensity-modulated radiotherapy-based treatment.All patients underwent brachytherapy based on MRI planning encompassing the residual tumour at the time of brachytherapy planning and received cisplatin-based chemotherapy, except for five patients $( 1 1 \\% )$ who received carboplatin and one patient who received radiation only $( 2 \\% )$ .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "There was no grade 4 or 5 acute radiation toxicity.In all, $1 1 \\%$ of the patients had grade 3 gastrointestinal late toxicities, and $1 9 \\%$ of the patients had grade 3 genitourinary late toxicities.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Para-aortic control rate was $9 8 \\%$ .The estimated distant metastases-free survival rates were 63.8 and $3 4 \\%$ after 2 and 5 years and correspond to disease-free survival rates of 61.4 and $2 9 .1 \\%$ after 2 and 5 years, respectively.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The 2 and 5 years OS rates were $6 8 .4 \\%$ and $5 4 .1 \\%$ , respectively.In a study published by Jeon et al.1710, 22 cervical cancer patients with LN recurrence who had previously undergone radical hysterectomy and PLN dissection were treated with salvage radiotherapy with or without chemotherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Various chemotherapy regimens were used (5- FU/cisplatin, paclitaxel/carboplatin).Treatment failure after salvage radiotherapy occurred in $6 3 .6 \\%$ of patients.A significant longer PFS was observed for patients treated with concurrent chemotherapy ( $6 4 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "8 \\%$ versus $8 .3 \\%$ , $\\mathrm { p } = 0 .0 1$ ).$\\mathrm { N g }$ et al.1711 reviewed the outcomes of extended field radiotherapy and concurrent chemotherapy with extended field radiotherapy in patients with positive PALN at diagnosis.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Patients were treated with a combination of EBRT and intracavitary brachytherapy.Concurrent chemotherapy consisted of cisplatin.The 5-year OS were $4 0 \\%$ for patients who underwent concurrent chemotherapy and extended field radiotherapy as compared to $1 8 \\%$ for patients who had extended field radiotherapy alone, with median survival of 29 months and 13 months, respectively.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The 5-year PFS for patients who underwent concurrent chemotherapy and extended field radiotherapy was $3 2 \\%$ and $1 8 \\%$ for those who had extended field radiotherapy alone.Acute toxicities were observed in $6 9 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "7 \\%$ of patients who underwent extended field radiotherapy alone and $8 9 .5 \\%$ who underwent concurrent chemotherapy and extended field radiotherapy.Kim et al.1712 aimed to determine whether CCRT is efficient for improving prognosis compared to chemotherapy in patients with FIGO stage IVB cervical cancer who have distant lymphatic metastasis.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Radiation therapy consisted of external-beam radiotherapy to the whole pelvis and intra-cavitary irradiation.Depending on the decision by radiation oncologists, additional radiation was applied to the parametrium, PALNs, and supraclavicular LNs.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Chemotherapeutic regimens consisted of paclitaxel/carboplatin, 5-FU/cisplatin, cisplatin or carboplatin.Although no difference was observed in the overall response rate ( $8 0 \\%$ versus $5 0 \\%$ , $\\mathrm { ~ p ~ } = \\ 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "2 1 \\mathrm { { \\dot { \\mathstrut } } }$ , the complete response rate was higher in patients treated with CCRT ( $6 0 \\%$ versus $0 \\%$ $\\mathrm { p } < 0 .0 1 \\dot { }$ ).It should be noted that chemotherapy using paclitaxel/carboplatin was administered more frequently in patients who received CCRT than in those who received systemic chemotherapy ( $7 0 \\%$ versus $2 8 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "6 \\%$ , $\\mathrm { p } = 0 .0 4 \\mathrm { ] }$ .Grade 3 or 4 leucopenia was more common in patients treated with CCRT ( $2 4 .4 \\%$ versus $9 .1 \\%$ , $\\mathrm { ~ p ~ } = \\ 0 .0 3 \\$ ), whereas grade 3 or 4 neutropenia was more frequent in those treated with systemic chemotherapy $( 2 8 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "4 \\%$ versus $1 1 .1 \\% ,$ $\\mathrm { ~ p ~ } = \\ 0 .0 3 \\mathrm { ] }$ .However, no differences in grade 3 or 4 anemia and thrombocytopenia were observed between the two treatments.Concurrent chemotherapy was favorable prognostic factor for the improvement of PFS $[ \\mathrm { H R } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1 2$ ( $9 5 \\% \\mathrm { C I } = 0 .0 3 – 0 .6 1$ ), $\\mathrm { ~ p ~ } = 0 .0 1 \\$ ) and OS $\\mathrm { \\tilde { H } R } = 0 .1 5$ ( $9 5 \\%$ $\\mathrm { C I } =$ 0.02-0.90), $\\mathrm { ~ p ~ = ~ 0 .0 4 \\AA }$ ).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted that no differences in the site and pattern of disease recurrence were observed between the two treatments.Another identified study1713 evaluated the efficacy of CCRT with curative intent in patients with FIGO stage IVB cervical cancer initially presenting with para-aortic and left supraclavicular LN metastases (groupe I) and compared these findings with those in patients with PALN without left supraclavicular LN metastases who received extended-field CCRT (group II).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "All patients were presribed external beam radiation therapy, high-dose rate brachytherapy and platinumbased chemotherapy (cisplatin, 5-FU/cisplatin, paclitaxel/cisplatin, or paclitaxel/carboplatin).The authors found that $5 2 \\%$ of patients in group I and $78 \\%$ of patients in group II achieved overall complete response $[ \\mathrm { p } < 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 1 ]$ .The 3-year OS rates were similar for patients who achieved overall complete response in both groups ( $6 8 \\%$ versus $7 6 \\%$ , $\\mathrm { { ~ p ~ } } = 0 .9 8 \\dot { \\mathrm { { ~ \\Omega ~ } } }$ ).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Group II had significantly better 3-year local recurrence-free survival ( $5 3 \\%$ versus $7 0 \\% ,$ $\\mathrm { ~ p ~ } = \\ 0 .0 3 \\dot { }$ ) and distant metastasis-free survival ( $4 1 \\%$ versus $7 3 \\%$ , $\\mathrm { { p < 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 1 } }$ ) rates than group I.The 3-year DFS rate was significantly higher in group II than in group I ( $3 3 \\%$ versus $5 7 \\% ,$ $\\mathrm { \\Delta p } < 0 .0 1 \\mathrm { \\dot { \\Omega } } .$ , but the difference in 3-year OS rate did not reach statistical significance ( $4 9 \\%$ versus $6 9 \\%$ , $\\mathrm { p } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "2 4 \\dot { }$ ).In a study1714 evaluating the role of paclitaxel and cisplatin chemotherapy concurrent with extended-field irradiation in women with cervical cancer metastatic to the PALNs, there were 27 patients evaluable for survival, of which fifteen were alive $( 5 6 \\% )$ after a median follow-up of 46 months.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Grigsby et al.1715 evaluated outcomes in 36 patients initially treated with a radical hysterectomy and LN dissection who developed a pelvic recurrence and were subsequently treated with irradiation (pelvic irradiation and brachytherapy).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Ten patients developed recurrent disease after irradiation.The sites of failure in these patients were pelvis only in two, pelvis and distant metastases in five, and distant metastases only in three.Severe complications occurred in $1 1 \\%$ of the patients.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In this study, pelvic irradiation and brachytherapy resulted in a 5-year OS of $7 4 \\%$ .As part of a study evaluating the efficacy of radiation therapy in patients treated for pelvic recurrence after hysterectomy, Ijaz et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1716 reported a 5-year OS rate of $3 3 \\%$ for all 50 enrolled patients, $3 9 \\%$ for the patients treated with curative intent, and $2 5 \\%$ for patients with isolated sidewall recurrences treated with curative intent.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Only 3 patients had major, late, treatment complications.It should be noted that chemoradiation was used in $2 0 \\%$ of patients.# 14.2 Previous initiatives Eight previous initiatives419,422-426,529,531,1717 presenting guidelines on the management of primary metastatic disease and/or recurrent disease were identified.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 14.3 Development group comments Many of the trials in advanced and metastatic disease were undertaken prior to the adoption of concomitant chemotherapy into radiotherapy protocols and therefore the response rates to single agent cisplatin may differ according to whether patients received prior chemoradiotherapy or not.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Furthermore, there was considerable heterogeneity between the trials precluding meaningful analysis.Many of the drugs used in the older combinations (doublet/triplet) are more toxic than the current recommended regimens.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Widespread use of the platinum/taxane combination in other gynaecological cancers means that there is considerable experience in both recognising and managing the associated toxicities.The outcome of curative treatment for recurrent disease depends on type of recurrence (central/lateral), primary treatment received, patient symptoms and performance, thorough workup and a multidisciplinary approach.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Curative treatments especially surgical should be carried out in a super-specialty hospital and high volume centers for optimal oncological outcome and complications.In patients with central recurrence after primary surgery, definitive chemoradiotherapy including brachytherapy is offered.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Although there are no RCTs reported in the literature, the understanding is that the recurrent tumours are still relatively radio-sensitivie and achieve good response rates and outcome.Also, brachytherapy allows for radiation dose escalation and improves the therapeutic ratio.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Extended pelvic surgery in highly selected patients has been reported.Mono-institutional series have been reported for surgery, however, these series report a very high margin positivity rates and severe post operative complications.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "To improve the surgical margin positivity rates, preoperative radiotherapy or chemotherapy has been tried.Although the response rates were better, the oncological outcomes still remain dismal.Moreover, the early and late postoperative severe complications were very high.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Intraoperative radiotherapy was also attempted in small mono-institutional series with limited success.Exenterative surgeries when performed result in optimal outcome.However, the severe complication rates still remain a concern.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Hence, these should be restricted to a highly specialized and high volume centers.There are limited series reported on reirradiation for local recurrences after definitive radiation therapy or postoperative radiation scenarios.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "This is increasingly being explored in modern radiation era with possibility of reducing doses to critical organs and achieving reasonably adequate doses to the recurrent gross disease.Palliative care clinics and holistic approach plays a vital role in patients deemed for palliative treatment only.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The role of specialist palliative care physicians (where available) in contributing to the overall management of the patient with recurrent and metastatic disease must be emphasized.Their involvement alongside the oncologist can contribute to overall excellent care and even enhance the potential benefits of radiotherapy /chemotherapy in this setting.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The evidence for palliative radiotherapy schedules for effective palliation for pain and bleeding is robust and may not be specific for metastatic disease from cervical cancer.# 14.4 Guidelines # 14.4.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1 Distant metastatic disease at presentation Patients with distant metastatic disease at presentation should have a full diagnostic workup (see Staging) to assess extent of disease, suitability for active treatment, and treatment modality including best supportive care.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# B In medically fit patients with widespread distant metastatic disease at presentation (visceral $+ /$ nodal), combination chemotherapy is recommended.Carboplatin/paclitaxel and cisplatin/paclitaxel are preferred regimens in the first-line treatment.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# Addition of bevacizumab to standard chemotherapy is recommended in patients with good performance status and where the risk of significant gastrointestinal/genitourinary toxicity has been carefully assessed and discussed with the patient.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# D Patients with limited distant metastatic disease at presentation, confined to the PALN region, should be treated with curative intent with definitive extended field chemoradiotherapy including brachytherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Treatment algorithm may also include surgical debulking of enlarged LN and additional chemotherapy.Patients with supraclavicular LN as the only site of distant disease can be considered for chemoradiotherapy with curative intent.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Treatment algorithm may include additional chemotherapy.C Adjuvant chemotherapy may be considered in cases carrying a high risk of recurrence such as positive margins, positive LN, or LVSI-positive tumors.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The role of radiotherapy in palliating symptoms such as bleeding and pain must be considered especially in radiotherapy naive patients.# 14.4.2 Recurrent disease 14.4.2.1 Curative intent treatment Treatment of recurrent disease with curative intent requires centralization and involvement of a broad multidisciplinary team including gynecologic oncologist, radiation oncologist, radiologist, pathologist, medical oncologist, urologist, and plastic surgeon.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A structured program for multidisciplinary diagnostic workup, treatment, and follow-up must be present in centers responsible for the treatment.Each center involved in the primary treatment of cervical cancer should have an established network for discussion of difficult cases and willingness for referring patients with recurrence for treatment to highly specialized units.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Participation in clinical trials is encouraged to improve the clinical evidence for the effect of curative treatment of recurrent disease.14.4.2.1.1 Diagnostic workup The aim of the diagnostic workup is to exclude distant metastases and locoregional tumor extension beyond curative treatment.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "![](images/ed1039cbb7736747bd68a1bae54c7c27639eb816157930da4909d02c2d4c2f5b.jpg) The recurrence should be confirmed by histological examination.Patients with multiple nodal/distant metastases or multifocal local disease with extensive pelvic wall involvement are usually not considered candidates for curative treatment.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The prognostic factors should be carefully evaluated and balanced in relation to the major morbidity caused by the treatment.![](images/08e03fb067e45898bf16046ee9f2c71f592d2695dbfa576b75927eb1fc39beaf.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "jpg) A full diagnostic package consisting of relevant imaging is recommended to establish the status of the disease locally, regionally, and systemically (see Staging).Patient should be carefully counseled regarding not only treatment options but also the involved risks and consequences.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "14.4.2.1.2 Central pelvic recurrence after primary surgery # D Definitive chemoradiotherapy combined with image guided adaptive brachytherapy is the treatment of choice (see Principles of radiotherapy).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The use of boost by external beam techniques to replace brachytherapy is not recommended.For brachytherapy, small superficial lesions (ie, $< 5 \\mathrm { - m m }$ thickness) in the vagina may be treated using a vaginal cylinder, ovoids, or mold, whereas other lesions usually require combined intracavitary-interstitial techniques.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "14.4.2.1.3 Pelvic sidewall recurrence after primary surgery Definitive chemoradiotherapy is the preferred option.![](images/4f0c924f8d06cac2a2c4266dce4f962bbf298097f4d974a67951c3c1cef56a06.jpg) Extended pelvic surgery may be considered in highly selected patients provided that the tumor does not invade extensively into the pelvic sidewall.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# D Combined operative-radiotherapy procedures using intraoperative radiotherapy or brachytherapy are an option if free surgical margins are not achievable.Definitive radiotherapy or chemoradiotherapy followed by a stereotactic ablative boost/imageguided interstitial brachytherapy/particle beam therapy is an emerging option.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "14.4.2.1.4 Central pelvic or pelvic sidewall recurrence after radiotherapy or chemoradiotherapy Pelvic exenteration is recommended for central pelvic recurrence where there is no involvement of the pelvic sidewall and extrapelvic nodes.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "![](images/22177910c29caada030cb6a73d6e5ea4201b4576c537f0d44e0e37335d8db61d.jpg) Laterally extended endopelvic resection may be considered for a recurrence that extends close to or involves the pelvic sidewall.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Reirradiation with image guided adaptive brachytherapy for central recurrences is an alternative option especially in patients unfit for or refusing exenteration surgery, which should be restricted to highly specialized centers.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "14.4.2.1.5 Role of chemotherapy If further surgery or radiotherapy is considered, no more than 2 to 4 courses of combination chemotherapy should be given to avoid unnecessary long interval before definitive treatment.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Locoregional recurrences, which at diagnosis appear incurable, should be reassessed for the possibility of radical treatment if major response is obtained.Suitable candidates for adjuvant chemotherapy are patients who recover well within 2 months after primary treatment for recurrence.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "14.4.2.1.6 Nodal and oligometastatic recurrences Localized para-aortic, mediastinal, and/or periclavicular recurrences above previously irradiated fields may be treated by radical EBRT if possible in combination with concomitant chemotherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It is recommended to electively irradiate the immediate regional nodal stations below and upstream.The therapeutic effect of nodal resection/debulking is unclear and should, if possible, always be followed by radiotherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The management of isolated organ metastases (lung, liver, etc) should be discussed in a multidisciplinary team involved in the treatment of the specific organ affected by the metastasis and should be treated according to the preferred method for that organ involving local resection, radiofrequency ablation, interventional brachytherapy, or stereotactic ablative radiotherapy according to size and anatomical position.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 14.4.2.2 Palliative treatment Recommendations for palliative treatment should be made only after a thorough review of the case by a specialist multidisciplinary team and taking into account the performance status, comorbidities, patient’s symptoms, and wishes of the patient.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The palliative care specialist should be actively involved.Palliative taxane/platinum combination chemotherapy with/without bevacizumab is the preferred option.There is currently no standard second-line chemotherapy, and such patients should be considered for clinical trials.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In symptomatic patients, palliative treatment should be tailored according to clinical situations.In patients with disseminated disease at presentation, radiotherapy (usually a fractionated course) should be considered for effective palliation.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Palliative radiotherapy (single fraction/short course) to control bleeding, discharge, and pain due to pelvic disease or bone metastases should be considered.For spinal cord compression due to bone metastases, neurosurgical intervention or short-course fractionated radiotherapy schedule should be considered.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "![](images/fddfab304efe920eb98661cd16246b74ff4f99d3fa19c295e60b5c7a7ae7edae.jpg) Surgical interventions including diversion stoma and/or stenting should be considered as appropriate, for example, in case of obstructive symptomatic disease.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "able 41.Original studies presenting data in oncologic outcomes in patients treated with pelvic exenteratio <html><body><table><tr><td rowspan=\"2\">Authorreference</td><td rowspan=\"2\">Year</td><td rowspan=\"2\">N</td><td rowspan=\"2\">Preop RT (%)</td><td colspan=\"2\">Surgeries (%)</td><td rowspan=\"2\">Recurrence before exenteration (months)</td><td rowspan=\"2\">Types of exenteration (%)</td><td rowspan=\"2\"> Positive surgical</td><td colspan=\"2\">Complications (%)</td><td rowspan=\"2\">Perioperative death (%)</td><td rowspan=\"2\">Follow-up (months)</td><td rowspan=\"2\"></td><td rowspan=\"2\">Survival (%) </td></tr><tr><td>cur.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "</td><td>pal.</td><td>margins (%)</td><td>Early Late</td></tr><tr><td>Capilna et al.132</td><td>2015</td><td>Cervix: N = 9 Other: N = 6</td><td>nr</td><td>nr</td><td>nr</td><td>nr</td><td>Total: N = 6 Anterior: N = 4 Posterior: N = 5</td><td>nr</td><td>40</td><td>nr</td><td>13</td><td>nr</td><td></td><td>OS:53</td></tr><tr><td>Moreno-Palacios et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1538</td><td>2015</td><td>Cervix: N =3 Other: N = 7</td><td>50</td><td>nr</td><td>nr</td><td>Average: 43.4</td><td></td><td>Total: 80 Anterior: 10 Posterior: 10</td><td>nr</td><td>80</td><td>80</td><td>0</td><td>Median: 14</td><td>OS:60</td></tr><tr><td>Tanaka et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1525,*</td><td>2014</td><td>Cervix: N = 12</td><td>100</td><td>100</td><td>0</td><td>nr</td><td></td><td>Total: 25 Anterior:67 Posterior: 8</td><td>33</td><td>83</td><td>nr</td><td>0</td><td>Median: 22</td><td>nr </td></tr><tr><td>Chiantera et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1526*</td><td>2014</td><td>Cervix: N = 177 Other: N = 53</td><td>70.3</td><td>97</td><td>3</td><td>Median: 14</td><td></td><td>Total: 57 Anterior: 29.6 Posterior:13.5</td><td>27.8</td><td>21.3</td><td>nr</td><td>3</td><td>Median: 68</td><td>nr</td></tr><tr><td> Chiantera et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1534</td><td>2014</td><td>Cervix: N = 167</td><td>nr</td><td>nr</td><td>nr</td><td>nr</td><td></td><td>Total: 61.1 Anterior: 28.1 Posterior: 10.8</td><td>27.5</td><td>nr</td><td>nr</td><td>nr</td><td>Median: 68</td><td> 5-year OS: 38</td></tr><tr><td> Sardain et al1537</td><td>2014</td><td>Cervix: N = 13 Other: N = 3</td><td>nr</td><td>100</td><td>0</td><td>nr</td><td></td><td>Total: 68.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "75 Anterior: 12.5 Posterior:18.75</td><td>0</td><td>75</td><td>68.75</td><td>0</td><td>Median: 11.5</td><td>5-year OS: 34.1</td></tr><tr><td> Jager et al.1535</td><td>2013</td><td>Cervix: N = 10 Other: N =18</td><td>71</td><td>96</td><td>4</td><td>nr</td><td></td><td>Total: 39 Anterior: 7 Posterior: 54</td><td>18</td><td>100</td><td>79</td><td>0</td><td>Median: 27</td><td> 5-year OS: 70</td></tr><tr><td>Kaur et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1527*</td><td>2012</td><td>Cervix: N = 18 Other: N =18</td><td>89</td><td>100</td><td>0</td><td>Median: 34.8</td><td></td><td>Total: 88 Anterior: 12</td><td>16</td><td>58</td><td>50</td><td>2</td><td>Median: 78</td><td> 5-year OS: 38</td></tr><tr><td>Baiocchi et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1522*</td><td>2012</td><td>Cervix: N = 73 Other: N = 34 </td><td>nr</td><td>100</td><td>0</td><td>Median: 18.8</td><td></td><td>Total: 52.3 Anterior: 29.3 Posterior: 9.3</td><td>7.9</td><td>53.3</td><td>44.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "8</td><td>12</td><td>Median: 23.7</td><td>5-year OS: 24.7</td></tr><tr><td>Yoo et al.1523*</td><td>2012</td><td>Cervix: N = 61</td><td>98</td><td>100</td><td>0</td><td> Median: 34.1</td><td></td><td>Total: 69 Anterior: 28 Posterior: 3</td><td>14.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "7</td><td>16</td><td>36</td><td>0</td><td>Median: 22</td><td> 5-year OS: 56</td></tr><tr><td>Schmidt et al.1524*</td><td>2012</td><td>Cervix: N = 282</td><td>73.5</td><td>50</td><td>50</td><td></td><td>Median: 18</td><td>Total: 93 Anterior: 5 Posterior: 2</td><td>36</td><td>51</td><td>nr</td><td>5</td><td>Median: 17</td><td> 5-year OS: 64</td></tr></table></body></html> \\* study included in the systematic review published by Sardain et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1516,1517 (2015), cur.curative, nr not reported, OS overall survival, pal.palliative, Preop RT preoperative radiation therapy Original studies presenting data in oncologic outcomes in patients treated with pelvic exenteration (continued) <html><body><table><tr><td>Authorreference</td><td>Year N</td><td></td><td>Preop</td><td></td><td>Surgeries (%)</td><td>Recurrence before</td><td>Types of</td><td> Positive surgical</td><td></td><td>Complications (%)</td><td>Perioperative</td><td>Follow-up</td><td>Survival</td></tr><tr><td></td><td>2011</td><td>Cervix: N = 40</td><td>RT (%)</td><td>cur.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "96</td><td>pal.4</td><td>exenteration (months) Median: 32</td><td>exenteration (%) Total: 67</td><td> margins (%)</td><td>Early</td><td>Late</td><td>death (%)</td><td>(months)</td><td>(%) </td></tr><tr><td>Benn et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1520,*</td><td></td><td>Other: N = 14</td><td>87</td><td></td><td></td><td></td><td>Anterior: 25 Posterior:10</td><td>13</td><td>50</td><td>61</td><td>0</td><td>Median: 12.5</td><td>nr</td></tr><tr><td>McLean et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1521,*</td><td>2011</td><td>Cervix: N = 29 Other: N = 15</td><td>100</td><td>100</td><td>0</td><td>Average: 74</td><td>Total: 77 Anterior:11.5 Posterior: 11.5</td><td>7</td><td>nr</td><td>nr</td><td>2</td><td>nr</td><td>nr</td></tr><tr><td>Jurado et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1536</td><td>2010</td><td>Cervix: N = 48</td><td>100</td><td>nr</td><td>nr </td><td>Average: 16</td><td>nr</td><td>56.3</td><td>nr</td><td>nr</td><td>nr</td><td>Median: 114.6</td><td>10-year DSS: 20.5</td></tr><tr><td>Maggioni et l.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1519*</td><td>2009</td><td>Cervix: N = 62 Other: N = 43</td><td>97</td><td>97</td><td>3</td><td>Median: 16.7</td><td>Total: 45 Anterior: 49 Posterior: 6</td><td>7</td><td>44.8</td><td>48.5</td><td>0</td><td>Median: 22.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "3</td><td>0S:52</td></tr><tr><td> Spahn et al.1531</td><td>2010</td><td>Cervix: N = 41 Other: N = 2 </td><td>51</td><td>nr</td><td>nr</td><td>Median: 16</td><td>Total: 14 Anterior: 86</td><td>21</td><td>51</td><td>35</td><td>0</td><td>Median: 30.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "5</td><td> 5-year DSS: 36.5</td></tr><tr><td>Park et al.93</td><td>2007</td><td>Cervix: N = 33 Other: N = 11</td><td>86.4</td><td>nr</td><td>nr</td><td>nr</td><td>Total:68.2 Anterior: 27.3 Posterior: 4.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "5</td><td>16</td><td>nr</td><td>nr</td><td>0</td><td>Median: 24</td><td>5-year OS: 54</td></tr><tr><td>Golberg et al1528,*</td><td>2006</td><td>Cervix: N = 97 Other: N = 8</td><td>95</td><td>95</td><td>0</td><td>nr</td><td>Total: 100</td><td>nr</td><td>nr</td><td>nr</td><td>0.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "9</td><td>nr</td><td> 5-year OS: 48</td></tr><tr><td>Teran-Porcayo et al.1533</td><td>2006</td><td>Cervix: N = 42</td><td>100</td><td>100</td><td>0</td><td>Average: 8.5</td><td>Total: 47.6 Anterior: 52.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "4</td><td>6.6</td><td>9.5</td><td>14.3</td><td>4.8</td><td>Average: 56.3</td><td> 5-year OS: 65.8</td></tr><tr><td>Berek et al.1518,*</td><td>2005</td><td>Cervix: N = 53 Other: N = 22</td><td>nr</td><td>100</td><td>0</td><td>Average: 45.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "5</td><td>Total: 61 Anterior: 31 Posterior: 8</td><td>12</td><td>nr</td><td>nr</td><td>4</td><td>Median: 50</td><td>5-year OS: 54 3-year OS : 57</td></tr><tr><td>Shingleton et al.1529,*</td><td>1989</td><td>Cervix: N = 143</td><td>nr</td><td>nr</td><td>nr</td><td>nr</td><td>Total: 54.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "5 Anterior: 44.1 Posterior: 1.4</td><td>nr</td><td>nr</td><td>nr</td><td>6.3</td><td>nr</td><td> 5-year OS: 50</td></tr></table></body></html> \\* study included in the systematic review published by Sardain et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1516,1517 (2015), cur.curative, DSS disease-specific survival, nr not reported, OS overall survival, pal.palliative, Preop RT preoperative radiation therap Table 42.Original studies presenting data in oncologic outcomes in patients with recurrent cervical cancer treated with IORT <html><body><table><tr><td>Authorreference</td><td>Year</td><td>N</td><td>Local relapse</td><td>Central relapse</td><td>Distant relapse</td><td>Survival (months)</td></tr><tr><td>Barney et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1539</td><td>2013</td><td>73</td><td> 3-year: 39%</td><td>3-year: 23%</td><td>3-year: 44%</td><td>Median: 17 3-year: 23%</td></tr><tr><td>Mahe et al.1540,1541</td><td>1997</td><td>70</td><td>3-year: 75%</td><td>nr</td><td>3-year: 33%</td><td>Median: 11 3-year: 8%</td></tr><tr><td>Garton et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1542-1544</td><td>1997</td><td>36</td><td>5-year: 50%</td><td>5-year: 40%</td><td>5-year: 58%</td><td>Median: 15 5-year: 25%</td></tr><tr><td>Martinez Monge et al.1718,1719</td><td>1997</td><td>141 242</td><td>4-year: 60% 4-year: 16%</td><td>4-year: 22% 4-year: 5%</td><td>4-year: 20% 4-year: 11%</td><td>Median: 71, 382 4-year: 7%1, 47%2</td></tr><tr><td>Stelzer et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1545</td><td>1995</td><td>22</td><td>5-year: 27%</td><td>nr</td><td>5-year: 9%</td><td>Median: 26 5-year: 43%</td></tr><tr><td>Gerard et al.1546</td><td>1994</td><td>34</td><td>4-year: 18%</td><td>nr</td><td>nr</td><td>Median: nr 4-year: 32%</td></tr></table></body></html> 1 prior external-beam radiation therapy, 2 no prior external-beam radiation therapy, nr not reported Table 43.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Response rates and survival according to single agent chemotherapy administered in patients with advanced, persistent, or recurrent cervical cancer <html><body><table><tr><td>Authorreference</td><td>Year N</td><td></td><td>Drugs</td><td>Response</td><td>Survival</td></tr><tr><td></td><td></td><td></td><td></td><td>rate (%)</td><td>(months)</td></tr><tr><td> Platinum compounds</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Long et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1634</td><td>2005</td><td>146</td><td>Cisplatin</td><td>13</td><td>6.5</td></tr><tr><td>Moore et al.1629</td><td>2004</td><td>134</td><td>Cisplatin</td><td>19</td><td>8.8</td></tr><tr><td>Omura et al.1630</td><td>1997</td><td>140</td><td>Cisplatin</td><td>17.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "8</td><td>8.0</td></tr><tr><td>Thigpen et al.1560</td><td>1989</td><td>164</td><td>Cisplatin1</td><td>17</td><td>6.2</td></tr><tr><td></td><td></td><td>156</td><td>Cisplatin2</td><td>18</td><td>6.4</td></tr><tr><td>Lele et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1720</td><td>1989</td><td>67</td><td>Cisplatin</td><td>27</td><td>nr</td></tr><tr><td>Potter et al.1721</td><td>1989</td><td>74</td><td>Cisplatin Cisplatin1</td><td>40.2</td><td>nr</td></tr><tr><td> Bonomi et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1559</td><td>1985</td><td>150 166</td><td>Cisplatin3</td><td>20.7 31.4</td><td>7.1 7.0</td></tr><tr><td></td><td></td><td>128</td><td>Cisplatin4</td><td>25</td><td>6.1</td></tr><tr><td>Thigpen et al.1722</td><td>1981</td><td>34</td><td>Cisplatin</td><td>38</td><td>nr </td></tr><tr><td>Weiss et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1723</td><td>1990</td><td>41</td><td>Carboplatin</td><td>15</td><td>nr</td></tr><tr><td>McGuire et al.1561</td><td>1989 1986</td><td>175</td><td>Carboplatin</td><td>15.4</td><td>6.2</td></tr><tr><td>Arseneau et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1724</td><td>1989</td><td>39</td><td> Carboplatin</td><td>28.2</td><td>nr</td></tr><tr><td>McGuire et al.1561</td><td>2003</td><td>177</td><td>Iproplatin</td><td>10.8</td><td>5.5</td></tr><tr><td>Fracasso et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1562 Anthracyclines</td><td></td><td>28</td><td>Oxaliplatin</td><td>8.3</td><td>nr</td></tr><tr><td>Chauvergne et al.1572</td><td>1993</td><td>31</td><td>Pirarubicin</td><td>31</td><td>nr</td></tr><tr><td>Muss et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1571</td><td>1985</td><td>25</td><td>Mitoxantrone</td><td>8</td><td>nr</td></tr><tr><td>van der Burg et al.1570</td><td>1992</td><td>24</td><td>Epidoxorubicin</td><td>4</td><td>nr</td></tr><tr><td>Hakes et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1573</td><td>1986</td><td>18</td><td>Idarubicin</td><td>0</td><td>nr</td></tr><tr><td>McGuire et al.1574</td><td>1989</td><td>28</td><td>Esorubicin</td><td>0</td><td>nr</td></tr><tr><td>Rose et al.11</td><td>2006</td><td>26</td><td>Doxil</td><td>11</td><td>nr</td></tr><tr><td> Alkylating agents</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Sutton et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1565</td><td>1993</td><td>51</td><td>Ifosfamide</td><td>15.7</td><td>nr</td></tr><tr><td>Sutton et al.1566</td><td>1989</td><td>27</td><td>Ifosfamide</td><td>11.1</td><td>nr</td></tr><tr><td>Meanwell et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1564</td><td>1986</td><td>30</td><td>Ifosfamide</td><td>33</td><td>nr</td></tr><tr><td>Omura et al.1568</td><td>1981</td><td>30</td><td>Cyclophosphamide</td><td>7</td><td>6.5</td></tr><tr><td>Smith et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1567</td><td>1967</td><td>76</td><td> Cyclophosphamide</td><td>20</td><td>15</td></tr><tr><td> Stehman et al.1596</td><td>1989</td><td>60</td><td>Mitolactol</td><td>29</td><td>5.3</td></tr><tr><td>Rose et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1612</td><td>1996</td><td>29</td><td>Altretamine</td><td>0</td><td>4.6</td></tr><tr><td>Camptothecins Lorusso et al.1621</td><td>2011</td><td>18</td><td>Topotecan</td><td>0</td><td>7</td></tr><tr><td>Coronel et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1610</td><td>2009</td><td>18</td><td>Topotecan</td><td>nr</td><td>7.0</td></tr><tr><td>Fiorica et al.1595</td><td>2009</td><td>27</td><td>Topotecan</td><td>0</td><td>nr</td></tr><tr><td>Muderspach et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1594</td><td>2001</td><td>43</td><td>Topotecan</td><td>18.6</td><td>6.4</td></tr><tr><td>Bookman et al.1593</td><td>2000</td><td>41</td><td>Topotecan</td><td>12.5</td><td>6.6</td></tr><tr><td>Abu-Rustum et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1609</td><td>2000</td><td>12</td><td>Topotecan</td><td>17</td><td>nr</td></tr><tr><td>Lhomme et al.1600</td><td>1999</td><td>51</td><td>Irinotecan</td><td>15.7</td><td>8.2</td></tr><tr><td> Irvin et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1597</td><td>1998</td><td></td><td>Irinotecan</td><td>0</td><td>nr</td></tr><tr><td>Look et al.1598</td><td>1998</td><td>16</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>54</td><td>Irinotecan</td><td>13.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "3</td><td>nr</td></tr><tr><td>Verschraegen et al.1599</td><td>1997</td><td>42</td><td>Irinotecan</td><td>21</td><td>nr</td></tr><tr><td>Takeuchi et al.1604</td><td>1991</td><td>55</td><td>Irinotecan</td><td>23.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "6</td><td>nr</td></tr></table></body></html> 1 50 mg/m²/ 3 wk, 2 50 mg/m²/24h/3 wk, $\\mathrm { ~ \\ i ~ } 1 0 0 \\mathrm { m g / m } ^ { 2 } / 3$ wk , $^ 4 2 0 \\mathrm { m g } / \\mathrm { m } ^ { 2 } / \\mathrm { d } \\mathrm { x } 5 / 3$ wk, Doxil pegylated liposomal doxorubicin, nr not reported Response rates and survival according to single agent chemotherapy administered in patients with advanced, persistent, or recurrent cervical cancer (continued) <html><body><table><tr><td>Authorreference</td><td>Year</td><td>N</td><td>Drugs</td><td>Response</td><td>Survival</td></tr><tr><td></td><td></td><td></td><td></td><td>rate (%)</td><td>(months)</td></tr><tr><td>Epipodophylotoxins</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Morris et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1583</td><td>1998</td><td>44</td><td>Etoposide</td><td>9.1</td><td>7.7</td></tr><tr><td>Rose et al.1584</td><td>1998</td><td>17</td><td>Etoposide</td><td>11.8</td><td>nr</td></tr><tr><td>Pfeiffer et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1585</td><td>1990</td><td>32</td><td>Teniposide</td><td>22</td><td>28</td></tr><tr><td>Vinca alkaloids</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Muggia et al.1582</td><td>2005</td><td>30</td><td>Vinorelbine</td><td>7.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1</td><td>nr </td></tr><tr><td>Muggia et al.1581</td><td>2004</td><td>44</td><td>Vinorelbine</td><td>13.7</td><td>nr </td></tr><tr><td>Lhomme et al.1579</td><td>2000</td><td>41</td><td>Vinorelbine</td><td>17</td><td>nr</td></tr><tr><td>Morris et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1580</td><td>1998</td><td>33</td><td>Vinorelbine</td><td>18.2</td><td>11</td></tr><tr><td>Sutton et al.1578</td><td>1990</td><td>30</td><td>Vinblastine</td><td>0</td><td>nr</td></tr><tr><td>Kavanagh et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1577</td><td>1985</td><td>20</td><td>Vinblastine</td><td>10</td><td>nr</td></tr><tr><td>Rhomberg et al.1575</td><td>1986</td><td>20</td><td>Vindesine</td><td>30</td><td>7</td></tr><tr><td>Antimetabolites Lorusso et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1602</td><td>2010</td><td>43</td><td> Pemetrexed</td><td>13.9</td><td>nr </td></tr><tr><td>Miller et al.1576</td><td>2008</td><td>29</td><td>Pemetrexed</td><td>15</td><td>7.4</td></tr><tr><td>Schilder et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1587</td><td>2005</td><td>22</td><td>Gemcitabine</td><td>4.5</td><td>6.5</td></tr><tr><td>Schilder et al.1586</td><td>2000</td><td>24</td><td>Gemcitabine</td><td>8.4</td><td>4.9</td></tr><tr><td>de Palo et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1588</td><td>1973</td><td>23</td><td>Methotrexate</td><td>16</td><td>nr</td></tr><tr><td>Lorvidhaya et al.1603</td><td>2010</td><td>37</td><td>Capecitabine</td><td>13</td><td>9.3</td></tr><tr><td>Look et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1608</td><td>2008</td><td>21</td><td>Capecitabine</td><td>0</td><td>nr</td></tr><tr><td>Garcia et al.1607</td><td>2007</td><td>26</td><td>Capecitabine</td><td>15.4</td><td>5.9</td></tr><tr><td>Katsumata et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1606</td><td>2011</td><td>37</td><td>S-1</td><td>30.6</td><td>15.4</td></tr><tr><td>Vermorken et al.1613</td><td>1991</td><td>15</td><td>Decitabine</td><td>0</td><td>nr</td></tr><tr><td>Taxanes</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Curtin et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1590</td><td>2001</td><td>42</td><td> Paclitaxel</td><td>31</td><td>nr</td></tr><tr><td>Kudelka et al.1592</td><td>1997</td><td>32</td><td> Paclitaxel</td><td>26</td><td>nr</td></tr><tr><td>McGuire et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1589</td><td>1996</td><td>43</td><td> Paclitaxel</td><td>17</td><td>nr</td></tr><tr><td>Kudelka et al.1591</td><td>1996</td><td>24</td><td> Paclitaxel</td><td>21</td><td>7.3</td></tr><tr><td>Minion et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1620</td><td>2016</td><td>12</td><td> NAB-paclitaxel</td><td>nr</td><td>8.9</td></tr><tr><td>Garcia et al.1569</td><td>2007</td><td>27</td><td>Docetaxel</td><td>8.7</td><td>7</td></tr><tr><td>Angiogenesis inhibitors</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Monk et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1601</td><td>2009</td><td>46</td><td> Bevacizumab</td><td>10.9</td><td>7.3</td></tr><tr><td>Santin et al.1616</td><td>2011</td><td>38</td><td>Cetuximab</td><td>0</td><td>6.7</td></tr><tr><td>Hertlein et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1617</td><td>2011</td><td>5</td><td>Cetuximab</td><td>0</td><td>8.6</td></tr><tr><td>Monk et al.1665,1666</td><td>2015</td><td>74</td><td> Pazopanib</td><td>9</td><td>13</td></tr><tr><td>Monk et al.1665,1666</td><td>2015</td><td>78</td><td>Lapatinib</td><td>5</td><td>10</td></tr><tr><td>Candelaria et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1605</td><td>2009</td><td>12</td><td> Imatinib mesylate</td><td>0</td><td>6.4</td></tr><tr><td>Schilder et al.14</td><td>2009</td><td>28</td><td>Erlotinib</td><td>0</td><td>4.96</td></tr><tr><td>Goncalves et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1615</td><td>2008</td><td>28</td><td> Gefitinib</td><td>0</td><td>3.56</td></tr><tr><td>Mackay et al.1618</td><td>2010</td><td>19</td><td> Sunitinib</td><td>0</td><td>nr</td></tr><tr><td>Tinker et al.1619</td><td>2013</td><td>38</td><td>Temsirolimus</td><td>3</td><td>nr</td></tr><tr><td>Mitomycins</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Thigpen et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1563</td><td>1995</td><td>56</td><td>Mitomycin-C</td><td>12</td><td>4.9</td></tr></table></body></html> NAB-paclitaxel nano-particule albumin bound paclitaxel, nr not reported Table 44.Response rates and survival according to doublet combination chemotherapy administered in patients with advanced, persistent, or recurrent cervical cancer <html><body><table><tr><td>Authorreference</td><td>Year</td><td>N</td><td>Drugs</td><td>Response</td><td>Survival</td></tr><tr><td></td><td></td><td></td><td></td><td>rate (%)</td><td>(months)</td></tr><tr><td>Ghaemmaghami et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1708,*</td><td>2003</td><td>10</td><td>Cisplatin/5 Fluorouracil</td><td>30</td><td>nr</td></tr><tr><td>Kaern et al.1671</td><td>1996</td><td>37</td><td>Cisplatin/5 Fluorouracil</td><td>49</td><td>16</td></tr><tr><td>Kaern et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1670</td><td>1990</td><td>72</td><td>Cisplatin/5 Fluorouracil</td><td>68</td><td>18</td></tr><tr><td>Bonomi et al.1672</td><td>1989</td><td>55</td><td>Cisplatin/5 Fluorouracil</td><td>22</td><td>6.4</td></tr><tr><td>Daghestani et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1673</td><td>1983</td><td>24</td><td>Cisplatin/bleomycin</td><td>54</td><td>６</td></tr><tr><td>Cervellino et al.1674</td><td>1995</td><td>30</td><td>Cisplatin/ifosfamide</td><td>50</td><td>25</td></tr><tr><td>Coleman et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1675</td><td>1990</td><td>44</td><td>Cisplatin/ifosfamide</td><td>38</td><td>8</td></tr><tr><td>Omura et al.1630</td><td>1997</td><td>151</td><td>Cisplatin/ifosfamide</td><td>31.1</td><td>8.3</td></tr><tr><td>Bloss et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1640</td><td>2002</td><td>146</td><td>Cisplatin/ifosfamide</td><td>32</td><td>8.5</td></tr><tr><td>Duenas-Gonzalez et al.1676</td><td>2001</td><td>40</td><td>Cisplatin/gemcitabine</td><td>57</td><td>nr</td></tr><tr><td>Duenas-Gonzalez et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1677</td><td>2001</td><td>11</td><td>Cisplatin/gemcitabine</td><td>37</td><td>6</td></tr><tr><td>Burnett et al.1678</td><td>2000</td><td>17</td><td>Cisplatin/gemcitabine</td><td>41</td><td>nr</td></tr><tr><td>Monk et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "164,1659</td><td>2009</td><td>112</td><td>Cisplatin/gemcitabine</td><td>22.3</td><td>10.3</td></tr><tr><td>Pignata et al.1679</td><td>1999</td><td>50</td><td>Cisplatin/vinorelbine</td><td>64</td><td>nr</td></tr><tr><td>Morris et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1680</td><td>2004</td><td>67</td><td>Cisplatin/vinorelbine</td><td>30</td><td>nr</td></tr><tr><td>Monk et al.1644,1659</td><td>2009</td><td>108</td><td>Cisplatin/vinorelbine</td><td>25.9</td><td>10.0</td></tr><tr><td>Rose et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1655</td><td>1999</td><td>41</td><td>Cisplatin/paclitaxel</td><td>46.3</td><td>10</td></tr><tr><td>Papadimitriou et al.1654</td><td>1999</td><td>34</td><td>Cisplatin/paclitaxel</td><td>7</td><td>9</td></tr><tr><td>Piver et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1681</td><td>1999</td><td>20</td><td>Cisplatin/paclitaxel</td><td>45</td><td>7</td></tr><tr><td>Moore et al.1629</td><td>2004</td><td>130</td><td>Cisplatin/paclitaxel</td><td>35</td><td>9.7</td></tr><tr><td>Monk et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1644,1659</td><td>2009</td><td>103</td><td> Cisplatin/paclitaxel</td><td>29.1</td><td>12.9</td></tr><tr><td>Kitagawa et al.1660,161</td><td>2015</td><td>123</td><td>Cisplatin/paclitaxel</td><td>58.8</td><td>18.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "3</td></tr><tr><td>Tewari et al.1662,1663</td><td>2014</td><td>114</td><td>Cisplatin/paclitaxel</td><td>45</td><td>14.3</td></tr><tr><td>Suprasert et al.1706</td><td>2010</td><td>21</td><td>Cisplatin/topotecan</td><td>28.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "6</td><td>11</td></tr><tr><td>Fiorica et al.1685</td><td>2002</td><td>32</td><td>Cisplatin/topotecan</td><td>28</td><td>10</td></tr><tr><td>Monk et al.144,1659</td><td>2009</td><td>111</td><td>Cisplatin/topotecan</td><td>23.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "4</td><td>10.3</td></tr><tr><td>Long et al.1634</td><td>2005</td><td>147</td><td> Cisplatin/topotecan</td><td>26.7</td><td>9.4</td></tr><tr><td>Shimada et al.1669</td><td>2016</td><td>15</td><td>Cisplatin/topotecan</td><td>27</td><td>nr</td></tr><tr><td> Sugiyama et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "11</td><td>1999</td><td>23</td><td>Cisplatin/irinotecan</td><td>78</td><td>nr</td></tr><tr><td>Sugiyama et al.1686</td><td>2000</td><td>29</td><td>Cisplatin/irinotecan</td><td>59</td><td>nr</td></tr><tr><td>Chitapanarux et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1695</td><td>2003</td><td>30</td><td>Cisplatin/irinotecan</td><td>66.7</td><td>16.9</td></tr><tr><td>Malviya et al.1687</td><td>1989</td><td>20</td><td>Cisplatin/mitomycin-C</td><td>35</td><td>10.3</td></tr><tr><td>Wagenaar et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1688</td><td>2001</td><td>33</td><td>Cisplatin/mitomycin-C</td><td>42</td><td>11.2</td></tr><tr><td>Omura et al.1630</td><td>1997</td><td>147</td><td>Cisplatin/mitolactol</td><td>21.1</td><td>7.3</td></tr><tr><td>Mannel et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1697</td><td>2000</td><td>44</td><td>Cisplatin/pentoxifylline</td><td>9</td><td>６</td></tr><tr><td>Farley et al.1698</td><td>2011</td><td>44</td><td>Cisplatin/cetuximab</td><td>9</td><td>nr</td></tr><tr><td>Nezhat et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1703</td><td>2004</td><td>14</td><td>Cisplatin/bryostatin-1</td><td>0</td><td>nr</td></tr><tr><td>Maluf et al.1707</td><td>2006</td><td>36</td><td>Cisplatin/tirapazamine</td><td>27.8</td><td>nr</td></tr><tr><td>Takekuma et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1704</td><td>2012</td><td>45</td><td> Paclitaxel/nedaplatin</td><td>44.4</td><td>15.7</td></tr><tr><td>Li et al.1682</td><td>2017</td><td>27</td><td>Nab-paclitaxel/nedaplatin</td><td>50</td><td>16.6</td></tr><tr><td>Tinker et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1656</td><td>2005</td><td>25</td><td> Carboplatin/paclitaxel</td><td>40</td><td>21</td></tr></table></body></html> \\* two patients with impaired renal function were treated with carboplatin followed by 5 Fluorouracil, nab-paclitaxel nanoparticle albumin-bound paclitaxel, nr not reported Response rates and survival according to doublet combination chemotherapy administered in patients with advanced, persistent, or recurrent cervical cancer (continued) <html><body><table><tr><td>Authorreference</td><td>Year</td><td>N</td><td>Drugs</td><td>Response rate (%)</td><td>Survival (months)</td></tr><tr><td>Pectasides et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1683</td><td>2009</td><td>51</td><td>Carboplatin/paclitaxel</td><td>53</td><td>13</td></tr><tr><td>Kitagawa et al.1702</td><td>2012</td><td>39</td><td>Carboplatin/paclitaxel</td><td>59</td><td>9.6</td></tr><tr><td>Kitagawa et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1660,1661</td><td>2015</td><td>123</td><td>Carboplatin/paclitaxel</td><td>62.6</td><td>17.5</td></tr><tr><td>Hisamatsu et al.1705</td><td>2012</td><td>61</td><td>Carboplatin/paclitaxel</td><td>60.7</td><td>14</td></tr><tr><td>Nagao et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1684</td><td>2005</td><td>17</td><td>Carboplatin/docetaxel</td><td>76</td><td>nr</td></tr><tr><td>Tewari et al.1662,1663</td><td>2014</td><td>111</td><td>Topotecan/paclitaxel</td><td>27</td><td>12.7</td></tr><tr><td>Look et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1700</td><td>1996</td><td>45</td><td>5 Fluorouracil/leucovorin</td><td>9</td><td>nr</td></tr><tr><td>Look et al.1701</td><td>1998</td><td>34</td><td>Isotretinoin/ interferon alfa</td><td>3</td><td>3.9</td></tr></table></body></html> nr not reported Table 45.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Response rates and survival according to triplet combination chemotherapy administered in patients with advanced, persistent, or recurrent cervical cancer <html><body><table><tr><td>Authorreference</td><td>Year</td><td>N</td><td>Drugs</td><td>Response rate (%)</td><td>Survival (months)</td></tr><tr><td>Bloss et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1640</td><td>2002</td><td>141</td><td>Cisplatin/ifosfamide/bleomycin</td><td>31.2</td><td>8.4</td></tr><tr><td>Ramm et al.1689</td><td>1992</td><td>20</td><td>Cisplatin/ifosfamide/bleomycin</td><td>15</td><td>9</td></tr><tr><td>Buxton et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1690</td><td>1989</td><td>49</td><td>Cisplatin/ifosfamide/bleomycin</td><td>69</td><td>10.2</td></tr><tr><td>Murad et al.1691</td><td>1994</td><td>36</td><td>Carboplatin/ifosfamide/bleomycin</td><td>60</td><td>11</td></tr><tr><td>Fanning et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1692</td><td>1995</td><td>30</td><td>Cisplatin/ifosfamide/5-Fluorouracil</td><td>53</td><td>12</td></tr><tr><td>Choi et al.1646</td><td>2006</td><td>45</td><td>Cisplatin/ifosfamide/paclitaxel</td><td>47</td><td>19</td></tr><tr><td>Dimopoulos et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1647</td><td>2002</td><td>57</td><td>Cisplatin/ifosfamide/paclitaxel</td><td>46</td><td>18.6</td></tr><tr><td>Zanetta et al.1649</td><td>1999</td><td>45</td><td>Cisplatin/ifosfamide/paclitaxel</td><td>67</td><td>nr</td></tr><tr><td>Serkies et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1693</td><td>2006</td><td>44</td><td>Cisplatin/ifosfamide/mitomycin-C</td><td>34</td><td>10</td></tr><tr><td>Tewari et al.1662,1663</td><td>2014</td><td>115</td><td>Cisplatin/paclitaxel/bevacizumab</td><td>50</td><td>17.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "5</td></tr><tr><td>Hainsworth et al.1694</td><td>2001</td><td>60</td><td>Carboplatin/paclitaxel/5-Fluorouracil</td><td>65</td><td>nr</td></tr><tr><td>Symonds et al.1664</td><td>2015</td><td>34</td><td>Carboplatin/paclitaxel/cediranib</td><td>64</td><td>13.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "6</td></tr><tr><td>Kurtz et al.1699</td><td>2009</td><td>19</td><td>Cisplatin/topotecan/cetuximab</td><td>32</td><td>7.3</td></tr><tr><td>Tewari et al.1662,1663</td><td>2014</td><td>112</td><td>Topotecan/paclitaxel/bevacizumab</td><td>47</td><td>16.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "2</td></tr><tr><td>Hsiao et al.1696</td><td>2008</td><td>21</td><td>Cisplatin/5-Fluorouracil/leucovorin</td><td>25</td><td>10.5</td></tr><tr><td colspan=\"6\">nr not reported</td></tr></table></body></html> # 15 Follow-up # 15.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1 Summary of available scientific evidence # 15.1.1 Timing and location of recurrence As part of a systematic review published by Elit et al.1725, $6 2 \\%$ to $8 9 \\%$ of cervical cancer LoE 1- recurrences were detected within 2 years of primary treatment.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In year three, the proportion rose to $7 5 \\%$ to $8 5 \\%$ of cervical cancer recurrences detected, and by year five, $89 \\%$ to $9 9 \\%$ of recurrent disease had been detected by that time (Table 46).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted that no subgroup analyses by stage is available.The location of recurrence was reported in $1 5 ^ { 1 7 2 6 - 1 7 4 0 }$ of the 17 included studies1726-1742.Overall, $1 5 \\%$ to $6 1 \\%$ of patient had recurrences that were distant or detected at multiple sites and $1 4 \\%$ to $5 7 \\%$ of patients had a central recurrence.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 15.1.2 Follow-up strategy Most studies included in the systematic review published by Elit et al.1725.followed similar L intervals: follow-up visits every 3 to 4 months within the first 2 years, every 6 months for the next 3 years, and then annually thereafter or until year 10 or discharge at the discretion of the treating physician (Table 47).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Scheduled follow-up visits ranged from a low of nine visits over a 5-year period to a high of potentially 28 visits over a 5-year perriod.No discernable pattern emerged from the included studies for the most appropriate follow-up strategy for patients with cervical cancer who are clinically disease free after receiving primary treatment.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "All but one1742 of the included studies reported scheduled follow-up beyond year 5, but in the majority of studies the termination of specialized follow-up was not clearly reported.Two included studies1739,1740 reported that scheduled follow-up visits extended to year 10 after primary treatment.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Two other systematic reviews1743,1744 were also identified: The first one1743 aimed to evaluate notably the benefits and harms of different follow-up protocols for women who have completed primary treatment for cervical cancer The second one1744 aimed to evaluated the effectiveness of patient-reported outcome measures as an alternative to routine follow-up of women after treatment for gynaecological cancers.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The authors did not found studies meeting their inclusion criteria.Therefore no data were analyzed.# 15.1.3 Physical exam All seventeen trials1726-1742 included in the systematic review published by Elit et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1725, LoE 1- reported that a physical exam (with or without patient histories) was performed at each follow-up visit (Table 48).Physical exam, with patient history, led to a sizable proportion of recurrences being detected in patients who were asymptomatic at follow-up.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Upon exclusion of one study in which only two patients had an asymptomatic recurrence, asymptomatic recurrent disease was detected using physical exam in $2 9 - 7 1 \\%$ of patients (median detection rate: $5 2 \\%$ ).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 15.1.4 Vaginal vault cytology Vaginal vault cytology were the second most common follow-up surveillance method reported LoE 1- in the studies included in the systematic review published by Elit et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1725 (thirteen1726-1728,1730- 1732,1734,1735,1737-1741 of the seventeen included studies1726-1742).The detection rates of asymptomatic recurrent disease with vaginal vault cytology ( $0 { - } 1 7 \\%$ , median: $6 \\%$ ) were considerably lower than those with physical exams (Table 48).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted that the accuracy of the cervico-vaginal cytology may be compromised by anatomical and tissue changes from the radiation in post-radiated patients.Gupta et al.1745 assessed the utility of cervico-vaginal/vault cytology in the follow-up of women treated for cervical cancer and benign gynaecological conditions.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Confirmatory biopsies were conducted for smears that were indicative of malignancy or were inconclusive.In 1,972 women who had previously been treated for gynaecological malignancies, 140 recurrences were detected.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In all cases in which a biopsy was conducted based on a smear malignancy, the diagnosis was confirmed (specificity: $1 0 0 \\%$ ).However, a confirmatory biopsy was conducted in $7 2 \\%$ of positive smears.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted that sensitivity and false-negative rates could not be calculated because negative smears were not followed up with biopsy.Of the 140 women who tested positive for recurrence with cytology, $6 5 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "7 \\%$ presented with advanced disease, most within 2 years $( 9 2 .1 \\% )$ of initial treatment.In nearly $2 4 \\%$ of cases, cytology testing was the method of detection.As part of an evaluation of the utility of liquid-based cytology in detecting recurrent cervical cancer, Rimel et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1746 documented cancer recurrence in $1 5 .8 \\%$ of the women in their study population, with $8 .1 \\%$ being detecting by Pap test.When stratified notably by stage and compared with patients treated using radiation therapy, patients treated with surgery were less likely to have abnormal results ( $\\mathrm { { O R } } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "4 1$ $( 9 5 \\% \\mathrm { ~ C I } = 0 .2 9 \\ – 0 .5 9 )$ ), $\\mathrm { p } < 0 .0 0 1 \\dot { }$ ).In this study, Pap surveillance appeared to have led to salvage for recurrence in $0 .3 \\%$ of patients.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted that no data on recurrences detected by other methods were provided.Another study1747 not included in the systematic review mentioned above was identified and found a very low yield with continued cytology surveillance among women who had completed 5 years of post-treatment surveillance without recurrence.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "No cases of cancer were diagnosed in the study population.Of the 4,376 vaginal smears reviewed by Injumpa et al.1748, 5 $\\left( 0 .1 \\% \\right)$ showed abnormal cytology but only 1 had malignant cells and tumour recurrence.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In this study, the sensitivity and specificity of vaginal vault cytology for detection of recurrence were $4 .3 \\%$ and $9 9 .3 \\% ,$ respectively.The results of the other identified studies1749-1753 are limited notably due to the very small LoE 3 number of patients evaluated.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 15.1.5 HPV DNA testing Despite the increasing interest in the clinical uses of HPV testing, only two follow-up LoE studies1754,1755 of patients conservatively treated for FIGO stage IA have been identified.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In the first one1754, HPV was detected in $8 7 \\%$ of the initial diagnostic specimens.HPV testing showed a sensitivity of $1 0 0 \\%$ for recurrent disease.In the second one1755, the valued of HPV testing for residual disease and recurrence detection was higher than of cytology and colposcopy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "HPV testing showed $1 0 0 \\%$ sensitivity.In this study Hybrid Capture 2 test was more useful for residual disease and recurrence detection than PCR, showed higher specificity ( $9 6 \\%$ versus $7 9 .2 \\%$ ).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted that this second study assessed the performance of HPV DNA testing in follow-up after treatment of high-grade cervical lesions, adenocarcinoma in situ, and microinvasive carcinoma and no subgroup analysis taking into account specifically microinvasive carcinoma is available.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A systematic review1756 assessing the performance of HPV DNA testing in follow-up after LoE 1- treatment of microinvasive carcinoma was identified but is not described because it contains no additional studies beyond those already described above.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "As part of another systematic review1757 (fifteen studies1758-1772) investigating notably the potential correlation of HPV LNs infection and cancer recurrence, was identified.The authors reported discordant results affected by the bias linked to the different techniques used and the non-homogeneous and comparable cohort of patients investigated.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Large part of included reports1759,1761,1764-1767,1770-1772 noticed that the presence of HPV DNA in LNs increase the risk of recurrences and reduce the OS.Some authors1759,1761,1764-1767,1770-1772 confirmed the role of HPV LNs positivity in worsening the oncological prognosis demonstrating that both disease recurrence and OS resulted negatively affected by viral LNs spread (both in case of negative or positive histology).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Singh et al.1773 suggested that in post-radiotherapy cervical cancer patients, high viral load in LoE 3 exfoliated cells and HPV DNA in plasma samples could be used to identified patients at increased risk for disease recurrence and progression.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The recurrence of the disease was significantly associated with the presence of HPV in the exfoliated cell ${ \\mathrm { ( p = 0 .0 1 ) } }$ and plasma (p $\\mathbf { \\varepsilon } = 0 .0 0 7 \\mathbf { \\vec { \\mathbf { \\varepsilon } } }$ ) as well as high viral load in the exfoliated cell $[ \\mathrm { p } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 0 0 2 ]$ .The HPV prevalence in exfoliated cell and their high viral load had very high sensitivity $( 1 0 0 \\% )$ in detecting recurence, but their specificities were low ( $2 9 \\%$ and $3 7 \\% ,$ respectively).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Plasma samples have higher specificity $( 9 3 \\% )$ than sensitivity $( 5 7 \\% )$ .Song et al.1774 reported higher sensitivity and specificity at 3 months ater radiotherapy than at LoE 2- 1 month after radiotherapy, possibly as a result of the presence of cellular debris after radiotherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A patient’s HPV status at 24 months was significantly associated with local relapse after radiotherapy.Pornthanakasem et al.1775 have reported that the presence of plasma HPV DNA after complete LoE 3 treatment was an indicator to develop recurrence or to have distant metastasis.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Fifty per cent of plasma HPV DNA positive patients but none of the other patients with HPV associated cancers had distant metastasis at the time of blood analysis $[ \\mathrm { R R } = 1 5 .6 7 \\$ $[ 9 5 \\% \\mathrm { C I } = 5 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "2 4 – 4 6 .8 3$ ), $\\mathrm { p } < 0 .0 0 1 \\dot { \\mathrm { \\Omega } }$ ).The amount of plama HPV DNA from metastatic patients was three times more than other patients without metastases.The later cases had tendency to develop recurrence distant metastases within one year after complete treatment when compared with other HPV associated cervical cancer patietns with the same stage but without the presence of plasma HPV DNA.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Another identified study1776 found that high-risk HPV status was predictive of 3-year survival rate and disease recurrence $( \\mathrm { p } < 0 .0 5 \\$ ).Pelvic recurrence $\\mathrm { ( p = 0 } .0 1 8 \\mathrm { ) }$ ), but not distant metastasis $\\mathrm { ( p = 0 } .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "2 3 2 \\mathrm { ) }$ , was influenced by high-risk HPV status.The authors also found that high-risk HPV had a significant higher sensitivity $7 1 .4 3 \\%$ versus $6 2 .8 6 \\%$ , ${ \\mathrm { p } } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 3 6 { \\mathrm { \\Omega } }$ ) and specificity $( 9 4 .2 0 \\%$ versus $7 8 .2 6 \\%$ , $\\mathrm { p } = 0 .0 .2 8 \\mathrm { ^ { \\prime } }$ thanh cervical or vaginal vault cytology with respect to predicting recurrence.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted that rates of abnormal cytology were found higher among those with positive high-risk HPV compared to those with negative high-risk HPV $( 8 7 .8 8 \\%$ versus $1 6 .4 3 \\%$ , $\\mathrm { { p < 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 5 } }$ ).Regarding the correlation between high-risk HPV testing and prognosis, Yu et al.1777 studied the role of high-risk HPV testing in predicting cervical cancer recurrence and noticed that of patients whose disease recurred, $4 2 \\%$ of patients had tested positive for highrisk HPV during their surveillance period, compared to $1 1 \\%$ for whom disease did not recur (p $\\mathbf { \\epsilon } = \\mathbf { \\epsilon } _ { 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 0 2 } )$ .On mutivariate logistic regression, high-risk HPV status remained significantly predictive of disease recurrence $\\mathrm { O R } \\ = \\ 1 2 .3$ $( 9 5 \\% \\mathrm { ~ C I ~ } = 1 .5 \\ – 9 9 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "6 )$ , $\\mathrm { ~ p ~ } = \\ 0 .0 2 )$ .In all cases, persistence of high-risk HPV preceded the diagnosis of recurrence by a range of 0 to 11 months with a mean of 2.8 months.The authors also found that while cervicovaginal cytology had limited specificity $5 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "7 \\%$ ( $9 5 \\% \\mathrm { C I } = 2 .4 \\$ -11.6)), the combination of cytology with high-risk HPV testing increased the specificity of testing ( $8 9 .3 \\%$ ( $9 5 \\%$ CI = 82.3-94.2).Badaracco et al.1778 suggested that the HPV DNA persistence may represent an indicator of risk LoE 3 of recurrence.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Sixty per cent of patients for whom HPV DNA persisted, recurred whereas twothirds of patients for whom HPV DNA cleared had no recurrence of disease.# 15.1.6 Serum biomarkers SCC-Ag: a multivariate analysis, performed by Hoogendam et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1779 indicated that elevated serum level of SCC-Ag was associated with increased odd of experiencing a disease recurrence in all histological types $( 0 \\mathrm { R } = 1 .1 4 0 \\$ $( 9 5 \\% \\mathrm { C I } = 1 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 5 1 – 1 .2 3 5 )$ ).The adjusted OR specific to the subgroup with only squamous cell carcinoma cases was highly similar $\\mathrm { O R } = 1 .1 5 0 \\$ ( $9 5 \\%$ CI ) 1.058-1.251)).As part of another multivariate analysis, performed by Shimura et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1780, an elevated serum SCC-Ag level was also an independent prognostic factor for poor postrecurrence survival.In this study, serum SCC-Ag levels were elevated in $7 5 \\%$ of patients when recurrence was diagnosed.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Bonfrer et al.1781 and Yen et al.1782 observed that an elevated posttreatment serum SCC-Ag level was also associated with a poor survival rate.However, Juang et $a l .^ { 1 7 8 3 }$ and Molina et al.1784 observed that SCC-Ag level was not a significant predictor of survival outcome.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Oh et al.1785 reported that the first indicator of relapse was abnormal serum SCC-Ag level in $4 0 \\%$ of patients.Adding SCC-Ag measurement to the basic follow-up protocol improved the sensitivity for detecting recurrence ( $8 8 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "7 \\%$ versus $4 9 .1 \\%$ , $\\mathrm { p } < 0 .0 0 1 \\dot { \\mathrm { \\Omega } }$ ).In the study published by Pras et al.1786, elevated SCC-Ag post-treatment indicated residual tumour in $9 2 \\%$ of patients.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "At recurrence, $7 0 \\%$ of patients developing recurrent disease during follow-up had a rise of SCCAg.Nineteen of 25 patients $( 7 6 \\% )$ with a local recurrence only as the first sign of recurrent disease had elevated pretreatment SCC-Ag levels.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Of 22/25 patients post-treatment SCC-Ag data were available: 17/22 $( 7 7 \\% )$ had elevated SCC-Ag during follow-up.A raised SCC-Ag was observed before the clinical manifestation of recurrence in $4 3 \\%$ of cases whereas in $1 5 \\%$ of cases, the clinical recurrence preceded the SCC-Ag rise.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Comparably, Forni et al.1787 published a $7 9 \\%$ sensitivity for detection of recurrences (histological distribution unknown) with all of these cases showing SCC-Ag elevation prior to clinical symptoms by a mean lead time of 5 months.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Equally in line with the data mentioned above, Yoon et al.1788 reported a sensitivity and specificity of $6 1 \\%$ and $9 8 \\%$ for the detection of 18 recurrences in their population, composed of all histological tumour types.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Eleven recurrence case showed elevated SCC-Ag serum levels with a median of 2 months before clinical manifestation.Duk et al.1789 present also consistent findings with those previously reported.After treatment, the sensitivity was $7 9 \\%$ and the specificity was $91 \\%$ .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "During follow-up, the sensitivity of the assay was $8 5 .5 \\%$ in patients with recurrent disease.Bolli et al.1790 observed that in patients with recurrence, $8 1 \\%$ had elevated values.SCC-Ag predicted recurrence an average of 6.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "9 months prior to detection of clinically evident disease.In another identified study1791, the authors showed that $9 0 .0 \\%$ of the patients whose disease recurred or progressed, had a significant increase of this marker compared to $1 3 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "9 \\%$ of patients without evidence of disease.Only $2 7 \\%$ of patients with nonsquamous carcinoma of the cervix enrolled in the report published by Rose et al.1792 had elevated SCC-Ag levels.SCC-Ag levels were elevated in $5 0 \\%$ of patients with recurrent disease.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The small study published by Meier et al.1793 presents also consistent findings with those previously reported.Roijer et al.1794 studied whether any of the SCC-Ag isoforms (SCC-Ag1 and SCC-Ag2) would provide additional and more specific/sensitive clinical information than SCCAg.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Rising levels of SCC-Ag1 and SCC-Ag2 were seen in patients with recurrence or progressive disease.The rise in SCC-Ag2 was usually more prominent than in SCC-Ag1.However, SCC-Ag2 did not show improved tumour specificity as compared with SCC-Ag1 or total SCC-Ag.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In the ten other identified studies1736,1795-1803, increasing serum SCC-Ag preceeded the clinical diagnosis of relapse in $4 6 \\substack { - 9 2 \\% }$ of the cases, with a mean lead time ranging from 2 to 7.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "8 months.Dodd et al.1801 found elevated SCC-Ag levels before the clinical evidence of recurrence in $5 0 \\%$ of patients and at the time of recurrence in $2 5 \\%$ of patients with fatal squamous cell cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In the study published by Esajas et al.1736, recurrent disease occurred in $1 6 \\%$ of patients and was preceded or accompanied by serum SCC-Ag elevation 26 times (sensitivity, $7 4 \\%$ ).Increasing serum SCC-Ag was the first indicator of relapse in $1 4 \\%$ of these patients.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In $12 \\%$ of the patients without recurrences, serum SCC-Ag values became falsely elevated.The repeat sample after 6 weeks showed a normal SCC-Ag in 7 out of 10 cases.Raised SCC levels were detected in $7 2 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "7 \\%$ of patients with locoregional failures, $8 0 \\%$ of patients with distant failures and $67 \\%$ of patients with both locoregional and distant failures.Although the SCC-Ag level just at the end of radiation therapy was not correlated with local control, Abe et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1798 observed that re-elevation of the SCC-Ag was highly associated with early relapse.CYFRA 21-1: eleven1779,1781,1784,1786,1797,1804-1809 of twelve1779,1781,1784,1786,1797,1804-1810 identified LoE 2- studies reported that CYFRA 21-1 was a less sensitive serum marker than SCC-Ag for detecting squamous cell cervical cancer and recognizing tumour progression or recurrence, as well as the absence of a relationship of CYFRA 21-1 with histological type.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Moreover, the addition of CYFRA 21-1 did not significantly increase the sensitivity of SCC-Ag.CA 125: seven1779,1796,1811-1815 of the eight identified studies1779,1796,1801,1811-1815 suggested that LoE 2- rising serum CA 125 during follow-up may be coincident with or precede the clinical diagnosis or recurrent cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In the study published by Duk et al.1811, rising CA 125 levels were measured in all patients with abdominal recurrence.Leminen et al.1812 reported that serum CA 125 levels increased in $7 1 \\%$ of the patients with progressive disease.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Borras et al.1815 detected all cases with recurrence or progression by elevation of CA 125.This biomarker showed an intermediate diagnostic accuracy with an AUC of 0.730 $9 5 \\% \\mathrm { ~ C I } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "6 4 2 – 0 .8 1 8 )$ in the study published by Hoogendam et al.1779.Other biomarkers: fifteen studies1779,1781,1783,1784,1793,1798,1800-1802,1807,1812,1813,1815-1817 investigating LoE 2- the potential usefulness of other biomarkers (hsCRP, CA 15-3, CA 19-9, CA 125, CEA, CYFRA 21-1, IL-6, TNF- $\\cdot \\alpha ,$ VEGF, IAP, TPA, TATI, and CIC) aimed at identifying recurrence in cervical cancer patients, were also identified.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "As part of the multivariate analysis performed by Hoogendam et al.1779, elevated serum level of hsCRP was associated with increased odd of experiencing a disease recurrence in all histological types $[ 0 \\mathrm { R } ~ = ~ 1 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 2 7 ~ \\$ $( 9 5 \\% \\mathrm { C I } = 1 .0 1 3 \\ – 1 .0 4 0 )$ ).The adjusted OR specific to the subgroup with only squamous cell carcinoma cases was highly similar $\\mathrm { { O R } } = 1 .0 2 5$ ( $9 5 \\%$ CI = 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "010-1.039)).The diagnostic accuracy of hsCRP and $\\operatorname { s c c } - \\operatorname { A g }$ combined was 0.87 ( $9 5 \\%$ $\\mathrm { C I } =$ 0.805-0.935).Seven other biomarkers tested in the same study (CA 15-3, CA 125, CEA, CYFRA 21-1, IL-6, TNF- $\\alpha$ and VEGF) did not add significantly to the ability to predict recurrence.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In a small series1817, the median time to progression was 5 months in patients with LoE 3 pretreatment serum $\\mathrm { V E G F } > 2 4 4 ~ \\mathrm { p g / m l }$ compared to 19 months in those with lower antigen levels ${ \\mathrm { ( p ~ = ~ } 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 0 3 \\mathrm { ) } }$ ), and this serum marker retained a prognostic relevance at multivariate analysis.Juang et al.1783 built a multivariate Cox model by forward and backward selection with survival LoE 2- as the dependent variable including TPA, CEA, and SCC-Ag markers as covariates.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In this model, TPA was the only significant predictor of survival outcome $\\mathrm { { \\ : { H R } = 2 2 .3 } }$ ( $9 5 \\% \\mathrm { ~ C I } = 2 .1 9 - 2 2 6 .$ 3), p $\\mathbf { \\tau } = 0 .0 3 1 \\dot { }$ ).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A report published by Gaarenstroom et al.1807 indicated that the clinical performance of post-treatment SCC-Ag levels in predicting complete remission versus the presence of tumour during follow-up was better than TPA.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "For squamous cell carcinoma of the cervix, SCCAg was also better tumour marker than TPA in the study published by Ngan et al.1802.In this study, the addition of TPA to SCC-Ag in serial monitoring increased the sensitivity of detection of recurrence but decreased its specificity.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Bonfrer et al.1781 observed also that SCC-Ag appeared to be a better parameter than TPA in LoE 3 predicting the presence of tumour during follow-up and survival of patients with cervical cancer.Dodd et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1801 reported that the data for CIC, CA125, and CEA were not individually useful as a marker.Furthermore, combining the data from all analytes to give a panel of potential markers did not improve the prognosis already evident with SCC-Ag alone.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "As part of a multivariate analysis, Molina et al.1784 observed that CEA was not a significant LoE 2- predictor of survival outcome.Pectasides et al.1800 indicated that patients who has a renewed progression after a complete remission with normal marker levels, showed an increase in SCC$\\mathrm { A g }$ in $9 5 \\%$ and CEA in $2 5 \\%$ .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "TATI did not vary in these patients.In patients whose disease did not respond to treatment, a change in serum marker levels cannot be evidenced with the available numbers.CEA levels increased in $3 6 \\%$ of the patients with progressive disease, serum TATI levels in LoE 3 $4 6 \\% ,$ and urine TATI levels in $2 0 \\%$ of the patients in the study published by Leminen et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1812.In all patients with regressive disease, the tumour markers levels decreased or stayed unchanged.Among patients with recurrent adenocarcinoma investigated by Tabata et al.1813, the positive rates were $6 2 \\%$ for CA 19-9 and $2 9 \\%$ for CEA.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "There were $7 1 \\%$ of cases positive for CA 19-9 and/or CEA.In patients with recurrent adenosquamous carcinoma, the corresponding positive rates were $4 6 \\%$ (CA 19-9) and $6 4 \\%$ (CEA), with $1 0 0 \\%$ positive for CA 19-9, CEA, and/or SCC-Ag.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Abe et al.1798 suggested that follow-up of patients by periodical serum examination for CA 19-9 LoE 2- biomarker may be useful for the early detection of tumour relapse.Borras et al.1815 reported a specificity during follow-up of $9 2 \\%$ for CEA and $9 2 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "6 \\%$ for CA 19-9.Furthermore, CA 19-9 and/or CEA detected all mestastases.One study1816 investigating the potential usefulness of IAP in the follow-up of cervical cancer was identified.As for the monitoring of the disease, raised serum IAP was measured in all patients with recurrent cervical cancer compared with $1 7 \\%$ of the patients who were free of recurrence.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 15.1.7 Imaging CT and/or MRI: as part of a meta-analysis, Meads et al.1818 evaluated notably the diagnostic accuracy of CT scan and MRI as surveillance in women with suspected recurrent or persistent cervical cancer and in asymptomatic women.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Among the seven included studies1819-1825, four1819-1822 evaluated CT, two1823,1824 evaluated MRI, and one1825 evaluated both MRI and CT.The sensitivity and specificity for detection of cervical cancer recurrence with CT ranged between $78 \\%$ and $9 3 \\%$ and $5 0 \\%$ and $1 0 0 \\% ,$ , respectively.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The summary estimate of the sensitivity of CT for detection of recurrence based on the bivariate hierarchical model was $8 9 .6 4 \\%$ $[ 9 5 \\% \\mathrm { C I } = 8 1 .5 9 \\ – 9 4 .4 1$ ) and specificity was $7 6 \\%$ $( 9 5 \\% \\mathrm { C I } = 4 3 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "6 8 – 9 2 .8 2$ ).The authors could not performed meta-analysis for MRI test accuracy due to clinical heterogeneity.The sensitivity and specificity of MRI in pelvic recurrence varied between 82 and $1 0 0 \\%$ and LoE 1- between $78 \\%$ and $1 0 0 \\%$ , respectively.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted that (1) most included studies1820-1825 were published in 2000 or earlier and most did not use standard imaging methods, and (2) no subgroup analyses taking into account specifically asympatomatic or symptomatic women, is available.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A health technology assessment1826 report published by the same team was identified but is not described because it contains no additional studies beyond those already captured by their meta-analysis1818 mentioned above.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "As part of a systematic review, Elit et al.1725 evaluated accuracy of several follow-up tests, including notably CT (four studies1738-1740,1742) and MRI (three studies1735,1738,1740), for detecting asymptomatic recurrences among patients with cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Asymptomatic recurrent disease was detected using CT in $0 .1 0 0 \\%$ and MRI in $0 .9 \\%$ of patients.Of note, there were only two patients with asymptomatic recurrence in the study1742 were $1 0 0 \\%$ of recurrence was detected using CT, and upon exclusion of this study1742 the range of recurrent disease detection with CT was $0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "3 4 \\%$ (Table 48).PET(-CT): among the nine studies217,226,1819,1827-1832 included in the meta-analysis published by Meads et al.1818, the sensitivitives and specificities of detection of local and distant recurrence combined with PET-CT ranged between 83 and $1 0 0 \\%$ and between 50 and $1 0 0 \\%$ respectively.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "For distant recurrence alone, the sensitivity of PET-CT was $8 6 \\%$ and the specificty was $1 0 0 \\%$ .The overall estimated of sensitivity was $9 4 .8 \\%$ $9 5 \\% \\mathrm { C I } = 9 1 .2 – 9 6 .9$ ), and the specificity, $8 6 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "9 \\%$ $9 5 \\% \\mathrm { C I } = 8 2 .2 – 9 0 .5$ ).A sensitivity analysis omitting one study217 that reported accuracy for distant recurrence only did not affect accuracy estimates to any significant degree (sensitivity $= 9 5 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 \\%$ $( 9 5 \\% \\ \\mathrm { C I } = 9 1 .4 – 9 7 .2 )$ ), specificity $= 8 6 .7 \\%$ $( 9 5 \\% \\ \\mathrm { C I } = 8 1 .9 – 9 0 .4 )$ ).It should be noted that (1) eight217,226,1819,1828-1832 of nine included studies217,226,1819,1827-1832 in the analysis included suspected and/or symptomatic patients and (2) no subgroup analyses taking into account specifically this population is available.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Only three226,1819,1831 of the nine included studies provided results for both standard imaging alone and standard imaging with the addition of whole body PET-CT with the same reference standard of histology or clinical evidence of disease.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The addition of PET-CT resulted systematically in improving sensitivity.However, there was no difference in specificity between the two imaging strategies.It should be noted that the numbers of women imaged in all three studies226,1819,1831 were small.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The minimum important elicited increase in accuracy of the addition of PET-CT to CT and/or MRI considered necessary to warrant the introduction of PET-CT as a routine investigation in this sample of clinical experts was similar for asymptomatic women (a mean $8 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "7 \\%$ reduction in false positives and $6 .3 \\%$ reduction in false negatives) and symptomatic women (a mean $7 .7 \\%$ reduction in false positives and $6 .4 \\%$ reduction in false negatives).Here again, the identified health technology assessment1826 report published by the same team is not described because it contains no additional studies beyond those already captured by their meta-analysis1818 mentioned above.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A meta-analysis1833 comparing the overall value of PET and PET-CT in diagnosing recurrent cervical cancer (eighteen studies204,217,225,226,1782,1819,1820,1828-1830,1832,1834-1840) was also identified.No statistical differences between PET and PET-CT in terms of its pooled sensitivity $91 \\%$ $9 5 \\% \\mathrm { C I } = 8 7 { - } 9 4 )$ versus $9 4 \\%$ ( $9 5 \\% \\mathrm { C I } = 8 9 - 9 7 \\mathrm { \\Omega }$ ), $\\mathrm { p } > 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 5 \\$ ) or pooled specificity ( $9 2 \\%$ $9 5 \\% \\mathrm { C I } =$ 91-94) versus $8 4 \\%$ ( $9 5 \\% \\mathrm { C I } = 7 4 – 9 1 ]$ , $\\mathrm { \\Delta p > 0 .0 5 \\dot { 2 } \\Omega }$ ) were observed.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "These results are consistent with the results of another identified meta-analysis1841 reporting pooled sensitivity and specificity of PET stand alone for diagnosing recurrent cervical cancer of $91 \\%$ and $9 2 \\% ,$ respectively, compared with $9 4 \\%$ and $8 4 \\%$ for PET-CT.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "This meta-analysis showed also that the pooled sensitivity and specificity of PET and PET-CT to detect distant metastasis in recurrent cervical cancer were $8 7 \\%$ $9 5 \\% \\mathrm { C I } = 8 0 { - } 9 2 \\$ and $9 7 \\%$ $9 5 \\% \\mathrm { C I } = 9 6 { - } 9 8 \\mathrm { \\Omega }$ ), respectively.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The pooled sensitivity and speciticity for local regional recurrence were $8 2 \\%$ ( $9 5 \\%$ $_ { 0 } ^ { \\prime } \\mathrm { C I } = 7 2 { \\cdot } 9 0 _ { \\cdot } \\$ ) and $9 8 \\%$ $9 5 \\% \\mathrm { C I } = 9 6 { - } 9 9 \\mathrm { ) }$ , respectively.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In one study1828 included in the meta-analyses mentioned above, PET-CT accurately detects LoE 2- lung metastasis, local recurrence, LN metastasis, and even peritoneal dissemination that may be missed by PET alone.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The sensitivity and specificity were $9 2 \\%$ and $9 2 .6 \\% ,$ respectively while for PET, the corresponding figures were $8 0 .0 \\%$ and $7 7 .8 \\%$ , respectively.As part of a small study published by Lai et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "225, the sensitivity of PET was greater than that of LoE 3 CT-MRI in terms of overall lesion detection ( $91 \\%$ versus $67 \\%$ $\\mathrm { ~ p ~ } = \\ 0 .0 0 1 \\dot { }$ ), and the difference was even greater for detection of metastatic lesions ( $9 2 \\%$ versus $6 0 \\%$ , $\\mathrm { p } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 0 0 3 \\mathrm { \\cdot }$ ).It should be noted that the difference in terms of sensitivity for detection of recurrent/persistent local tumours did not reached statistical significance maybe due to the small number of patients enrolled in the study ( $9 0 \\%$ versus $8 4 \\%$ , $\\mathrm { p } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "6 3 1 \\mathrm { \\ i }$ ).Thirteen studies219,1842-1853 not included in the meta-analyses mentioned above were also identified.Yen et al.1842 compared the diagnostic value of PET and CT-MRI in documented or suspected recurrence after primary treatment.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Of the final diagnoses, there was additional benefit from PET over CT-MRI in $7 3 .8 \\% ,$ with PET correcting falsed-negatives on CT-MRI in $7 4 .2 \\%$ and correcting false-positives on CT-MRI in $2 5 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "8 \\%$ .Among lesions confirmed by PET, $7 5 .4 \\%$ were extrapelvic.In the study published by Brooks et al.1843, PET findings indicative of recurrence (confirmed by tissue biopsy) were mentioned in $8 4 \\%$ of symptomatic patients at the time of surveillance.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Tumour recurrence detected by PET was described in $12 \\%$ of asymptomatic patients.All recurrences were confirmed by biopsy or radiologic progression.Eighty percent of asymptomatic recurrences detected by PET were isolated to either the cervix, pelvic, or paraaortic nodes.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "There were 38 patients whose first surveillance PET scan was negative for recurrent disease who subsequently underwent a second surveillance PET study.The median time from the first surveillance PET to the second was 6.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "5 months.All of the patients with symptoms had evidence of tumour recurrence by PET.There were 28 asymptomatic patients of whom 24 had negative PET findings and 4 had evidence of recurrent tumour.Three of the four patients with asymptomatic recurrences had isolated sites disease recurrence.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A study1844 investigating the detection of relapse with PET scan in patients treated with curative intent chemoradiotherapy, was also identified.After complete metabolic response, only $1 .6 \\%$ of patients relapsed without symptoms and were detected through physical examination.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Patients with a partial metabolic response had a HR for distant failure 36 times $[ 9 5 \\% \\mathrm { C I } = 7 \\mathrm { - } 1 9 1 ]$ ) the HR of patients with a complete metabolic response $[ \\mathrm { p } < 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 0 0 1 \\ ]$ .Patients with a partial metabolic response had a HR for nodal failure that was 51 times $( 9 5 \\% \\ \\mathrm { C I } = 3 .$ - 846) the rate of patients with a complete metabolic response $\\mathrm { ( p = 0 0 0 6 1 } \\dot { }$ .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A multivariate analysis performed by Schwarz et al.1845, demonstrated that the HR for risk of recurrence based on the post-therapy metalobic response showing progressive disease was 32.57 ( $9 5 \\%$ $\\mathrm { C I } =$ 10.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "22-103.82).The HR for a partial metabolic response on the 3-month post-therapy PET was 6.30 $( 9 5 \\% \\mathrm { C I } = 2 .7 3 – 1 4 .5 6 ,$ , $\\mathrm { ~ p ~ } < 0 .0 0 1 \\dot { \\mathrm { ~ } }$ ).The same team1846 found that a majority of failures within complete metabolic response patients were distant $( 8 5 \\% )$ .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Of failures within the partial metabolic response patients, $5 8 \\%$ of them were isolated local failures, and $4 2 \\%$ were distant.A Cox proportional hazards model of survival outcome, performed by Grigsby et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1847, indicated that any abnormal post-therapy FDG uptake (persistent or new) was the most significant prognostic factor for developing metastastic disease and death from cervical cancer when compared with pretreatment and treatment-related prognostic factors $( \\mathrm { p } < 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 0 0 1 )$ .Another identified study1848 evaluated the clinical impact of PET as a post-therapy surveillance of cervical cancer especially in asymptomatic patients who reached complete response after primary treatment.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The PET scan detected $9 6 .1 \\%$ of patients with recurrent disease.The sensitivity and specificity of PET scan in assessment of recurrence were $9 6 .1 \\%$ and $8 4 .4 \\% ,$ respectively.PET scan detected recurrent lesions in $8 5 \\%$ of asymptomatic patients.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The results of the other identified studies219,1849-1853 are limited notably due to the very small LoE 3 number of patients evaluated.Chest radiography: Elit et al.1725 mentioned that the detection of asymptomatic recurrences LoE 1- with chest x-rays was effective in a sizable proportion of asymptomatic patients tested.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Based on data from six studies1728,1730,1732,1734,1735,1738, chest x-ray detected asymptomatic recurrent disease in $1 9 .4 7 \\%$ of patients (Table 48).Of 817 patients with carcinoma of the uterine cervix that were followed-up by Imachi et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1854, LoE 2- 50 $( 6 .1 \\% )$ developed pulmonary metastases.Of the patients in whom lung metastases were detected, $4 1 .7 \\%$ had no symptoms.Ninety-six per cent was diagnosed within 2 years from the initiation of treatment.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "All the patients had abnormal shadows in chest x-rays.US: US was not generally employed as a surveillance tool in the seventeen studies1726-1742 LoE 1- included in the systematic review published by Elit et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1725 (Table 48), nor was it effective where it was used as a part of routine follow-up.US detected only 4 of the 179 asymptomatic recurrences observed ( $2 \\%$ , three studies1734,1738,1740).Intravenous pyelography: the three studies1726,1728,1732 included in the systematic review LoE 1- published by Elit et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1725, did not reported any asymptomatic recurrences with the routine use of intravenous pyelography (Table 48).# 15.1.8 Hormonal replacement therapy Ploch et al.1855 studied the use of HRT in cervical cancer survivors.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "All patients enrolled were younger than 45 years of age and had FIGO stage I/II disease treated with surgery or radiotherapy.After treatment, no significant difference in DFS or OS at 5 years was noted betweeen patients treated with HRT and controls.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "HRT resulted in significantly lower radiotherapy-related complications rates in those patients who required radiotherapy ( $1 7 \\%$ versus $4 5 \\% , \\mathrm { p } \\leq 0 .0 1 \\mathrm { \\AA }$ ).Lacey et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1856 reported that women with adenocarcinoma given unopposed oestrogen HRT had a significant increased risk of recurrence $\\mathrm { \\Delta } \\mathrm { \\stackrel { .} { O R } = 2 .7 }$ $( 9 5 \\% \\mathrm { ~ C I } = 1 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1 \\ – 6 .8 ) \\$ ).It should be noted that this association lost its statistical significance in case of combined oestrogen and progesteron HRT and/or when analysis was restricted to the HPV positive controls.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should also be noted that no such association was reported for women with squamous cell carcinoma.Menopausal status was not associated with adenocarcinoma or squamous cell carcinomas and did not modify the other associations.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "After multivariate analysis, a longer duration of follow-up was significantly associated an increased likelihood of receiving counseling or a prescription for HRT ( $\\operatorname { \\mathrm { ~ \\sc ~ O R } } = 1 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 1 1$ ( $9 5 \\%$ CI = 1.001-1.020), $\\mathrm { ~ p ~ } = 0 .0 2 5 2$ ) in a study published more recently by Rauh et al.1857.Patients with recurrent disease showed a non significant trend towards reduced odds of being counseled and/or prescribed HRT ( $\\mathrm { \\Delta O R } = 0 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "4 5 0$ $( 9 5 \\% \\mathrm { C I } = 0 .1 9 3 – 1 .0 4 8 )$ ), $\\mathrm { p } = 0 .0 6 4 3 \\AA$ ).# 15.2 Previous initiatives Eleven previous initiatives419,421-426,529,531,1858,1859 presenting guidelines for follow-up were identified.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 15.3 Development group comments There is no evidence for most appropriate follow-up strategy.The risk of recurrence and disease- and treatment-related morbidity is individual, and depends on prognostic factors, treatment modality and patients´ characteristics.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Follow-up schemes for cervical cancer patients may therefore be individualized taken these aspects into account.The start off for further follow-up should be the treatment evaluation, with documentation of tumor response as well as disease- and treatment related morbidity.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Since the majority of recurrences appear within 2-3 years after primary treatment, follow-up should be more intense within this period.With the exception of follow-up after fertility-sparing surgery, recurrence-free patients rarely need to be followed more than 5 years after primary treatment, unless treatment-related long-term or late side effect exists.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Prospective studies adressing new follow-up strategies are warranted.Evidence suggest that patient-reported outcome measures are important to supplement physicianreported adverse events, improving the precision of capturing symptomatic adverse events concerning e.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "g.frequency, severity and interference with daily activities.The effectiveness of patient-reported outcome as an alternative to routine follow-up however needs to be explored in prospective trials.Follow-up visits should be conducted or coordinated by a physician experienced in the surveillance of gynecological cancer patients.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The vaginal vault cytology has low positive predictive value to detect recurrence post chemoradiotherapy and post-surgery and is therefore not routinely recommended.Instead of use of vaginal cytology, HPV testing may be useful in identification of vaginal cancer precursors and tumor recurrence, but the robust evidence is still missing.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The clinical relevance of tumor markers, such as SCC-Ag is controversial.Although the SCC-Ag may precede clinical diagnosis of recurrence in 46- $9 2 \\%$ of cases (median lead time of 2-8 months)1860 there is no strong evidence that earlier detection of recurrence is associated with better survival in recurrent cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Tumour markers, such as SCCAg, are therefore not recommended in a routine follow-up.Likewise imaging and laboratory tests are not routinely advocated in asymptomatic patients.Recurrences should be proven by biopsy before treatment planning.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 15.4 Guidelines # 15.4.1 General recommendations Primary objectives of follow-up for patients with cervical cancer should include the following:  Early detection of recurrent disease. Patient education and support.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": " Cancer rehabilitation with the goal to prevent and reduce psychosocial, physical, social, and existential consequences of cancer and its treatment starts at time of diagnosis.The efforts should optimize the physical abilities and quality of life of women affected by cervical cancer and include family members/care givers.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Several professions for counseling should be available, for example, psychologist, sexual therapist, physiotherapist, and dietitian.Assessment of long-term outcome of novel treatment strategies.Quality control of care.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Each visit should be composed of the following: Patient history (including elicitation of relevant symptoms) Physical examination (including a speculum examination and bimanual pelvic examination)  Physician assessment of adverse events using validated scales (eg, Common Terminology Criteria for Adverse Events)  Prevention and management of cancer- and treatment-related adverse effects, for example, sexual dysfunction (eg, counseling, vaginal lubricants, local estrogen) In case of the appearance of treatment-related symptoms, a referral to a dedicated specialist (eg, gastroenterologist, urologist/gynecologist) should be considered.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Patients should be educated about symptoms of potential recurrence and potential long-term and late effects of treatment.Patients should also be counseled on sexual health, lifestyle adaptation, nutrition, exercise, obesity, and cessation of smoking.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Follow-up schemes may be individualized, taking into account prognostic factors, treatment modality, and estimated risk and/or occurrence of adverse effects.In general, follow-up intervals of 3 to 4 (6) months for the first 2 years and then 6 to 12 months up to 5 years are recommended.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Prescription of hormonal replacement treatment to cervical cancer survivors with premature menopause is advocated and should be according to regular menopausal recommendation.Combined estrogen and progestin replacement therapy should be prescribed if uterus is in situ (including after definitive radiotherapy).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Monotherapy with estrogen is recommended after hysterectomy.Imaging and laboratory tests should be performed based on symptoms or findings suggestive of recurrence or morbidity.In symptomatic women, MRI or CT should be considered to assess potential clinical recurrence.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "If positive, whole body PET-CT should be performed in patients in whom salvage therapy (surgery or radiotherapy) is being considered.Similarly, for suspected recurrence, PET-CT can be added when other imaging finding is equivocal.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Pathologic confirmation of any persistent or recurrent tumor should be considered.If a lesion is located deeply in the endocervix (in case of conservative treatment or definitive chemoradiotherapy), ultrasound-guided Tru-Cut biopsy is the preferred method.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "For any disease beyond the primary tumor site, ultrasound or CT-guided methods can be used to achieve pathologic confirmation.In case of clinically or radiologically suspicious disease, a negative biopsy may not be conclusive.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 15.4.2 Follow-up after fertility sparing treatment All women remain at risk of tumor recurrence following FST and must be carefully followed up.Follow-up should be carried out by a provider with specific expertise in detection of lower genital tract dysplasia (eg, gynecologic oncologist, colposcopy expert).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Follow-up intervals should be 3 to 4 months for the first 2 years postoperatively, and then 6 to 12 months up to 5 years.Thereafter the patient may return to population-based screening.The duration of follow-up, however, may be individualized depending on the risk of recurrence or persistence of treatment-related complications.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Follow-up should include HPV testing (with or without cytology).Colposcopy in combination with HPV testing in parallel performed by an experienced colposcopist is an option.The incorporation of high-risk HPV testing at 6, 12, and 24 months after treatment is advocated.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "If HPV testing is negative, then every 3 to 5 years as long as follow-up is indicated.# 15.4.3 Follow-up after simple or radical hysterectomy Follow-up should be carried out by physician experienced with follow-up care after surgery following the general recommendations (see above).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The vaginal vault cytology is not recommended.# 15.4.4 Follow-up after definitive chemoradiotherapy The same imaging method should be used for evaluation of tumor response as was used at baseline.Imaging should be performed not earlier than 3 months following completion of treatment.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In dubious cases, a reevaluation should be performed not before 8 weeks thereafter.# B For re-evaluation purposes, the optimal diagnostic workup for local extent is pelvic MRI, and for distant spread, it is chest/abdomen CT or PET-CT (preferred after definitive chemoradiotherapy or in high-risk patients).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "![](images/51e715ab121f7c7b635e8ef3fc497fc41765a40ad1dc5386c5eadcdc51466170.jpg) Follow-up should be performed by a physician experienced with follow-up care after radiotherapy.Cytology is not recommended in these patients.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Providers should inform and educate on sexual and vaginal health because vaginal stenosis and dryness may occur.Vaginal dilation should be offered, as well as vaginal lubricants and local estrogen.Table 46.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Original studies presenting data on location and timing of recurrence for patients with cervical cancer after receiving primary treatment <html><body><table><tr><td>Authorreference</td><td>Year</td><td>N</td><td colspan=\"3\">Recurrent disease</td><td colspan=\"3\">Location of recurrence</td><td colspan=\"5\">Timing of recurrence</td></tr><tr><td></td><td></td><td></td><td>Total</td><td>Sympt.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "</td><td>Asympt.</td><td>Central</td><td>Sidewall</td><td>Distant/multiple sites</td><td>2 years*</td><td>3 years*</td><td>5 years*</td><td>Sympt.**</td><td>Asympt.**</td></tr><tr><td>Krebs et al.1726</td><td>1982</td><td>312</td><td>327</td><td>164</td><td>163</td><td>187</td><td>31</td><td>109</td><td>nr</td><td>nr</td><td>nr</td><td>36</td><td>24</td></tr><tr><td>Muram et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1727</td><td>1982</td><td>323</td><td>47</td><td>nr</td><td>nr </td><td>40</td><td>27</td><td>29</td><td>78%</td><td>nr</td><td>98%</td><td>19-24</td><td></td></tr><tr><td>Larson et al.1728</td><td>1988</td><td>249</td><td>27</td><td>17</td><td>10</td><td>6</td><td>10</td><td>11</td><td>89%</td><td>nr </td><td>96%</td><td>14</td><td>11</td></tr><tr><td>Rintala et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1729</td><td>1989</td><td>89</td><td>44</td><td>nr</td><td>nr </td><td>17</td><td></td><td>27</td><td>nr</td><td>nr </td><td>nr</td><td>7</td><td></td></tr><tr><td> Soisson et al.1730</td><td>1990</td><td>203</td><td>31</td><td>22</td><td>9</td><td>13</td><td></td><td>18</td><td>71%</td><td>87%</td><td>97%</td><td>15</td><td></td></tr><tr><td>Look et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1731</td><td>1990</td><td>96</td><td>21</td><td>14</td><td>7</td><td>3</td><td>9</td><td>9</td><td>81%</td><td>nr</td><td>nr</td><td>11</td><td>10</td></tr><tr><td>Tinga et al.1732</td><td>1992</td><td>367</td><td>71</td><td>55</td><td>16</td><td>17</td><td>15</td><td>39</td><td>nr</td><td>nr </td><td>nr</td><td>12</td><td>12</td></tr><tr><td>Gerdin et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1733</td><td>1994</td><td>167</td><td>19</td><td>16</td><td>3</td><td>5</td><td>8</td><td>6</td><td>74%</td><td>nr</td><td>nr</td><td>15</td><td></td></tr><tr><td>Ansink et al.1741</td><td>1996</td><td>674</td><td>112</td><td>92</td><td>20</td><td>nr </td><td>nr</td><td>nr</td><td>62%</td><td>75%</td><td>nr</td><td>25</td><td></td></tr><tr><td>Samlal et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1734</td><td>1998</td><td>271</td><td>27</td><td>18</td><td>9</td><td>5</td><td>9</td><td>13</td><td>nr</td><td>77%</td><td>nr</td><td>14</td><td></td></tr><tr><td>Bodurka-Bevers et al.1735</td><td>2000</td><td>993</td><td>133</td><td>114</td><td>19</td><td>37</td><td>21</td><td>75</td><td>nr</td><td>nr</td><td>nr</td><td>17</td><td>16</td></tr><tr><td>Esajas et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1736</td><td>2001</td><td>225</td><td>35</td><td>16</td><td>19</td><td>22</td><td></td><td>13</td><td>nr</td><td>nr </td><td>nr</td><td>11</td><td></td></tr><tr><td>Duyn et al.1737</td><td>2002</td><td>277</td><td>47</td><td>41</td><td>６</td><td>16</td><td>7</td><td>24</td><td>nr</td><td>nr</td><td>nr</td><td>18</td><td></td></tr><tr><td>Lim et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1742</td><td>2004</td><td>291</td><td>53</td><td>45</td><td>2</td><td>nr</td><td>nr</td><td>nr</td><td>63%</td><td>77%</td><td>98%</td><td>18</td><td></td></tr><tr><td>Morice et al.1738</td><td>2004</td><td>583</td><td>45</td><td>38</td><td>7</td><td>25</td><td>13</td><td>7</td><td>64%</td><td>78%</td><td>89%</td><td>16</td><td>13</td></tr><tr><td>Sartori et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1739</td><td>2007</td><td>63</td><td>63</td><td>41</td><td>22</td><td>36</td><td></td><td>27</td><td>nr</td><td>87%</td><td>nr</td><td>28</td><td>23</td></tr><tr><td>Zola et al.1740</td><td>2007</td><td>327</td><td>327</td><td>164</td><td>163</td><td>187</td><td>31</td><td>109</td><td>nr</td><td>nr</td><td>nr</td><td>36</td><td>24</td></tr></table></body></html> \\* recurrences diagnosed yearly after primary treatment $( \\% ) .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "$ , \\*\\* median timing to recurrence (months), Asympt.asymptomatic, nr not reported, Sympt.symptomatic Table 47.Original studies presenting data on follow-up strategy for patients with cervical cancer who are clinically disease free after receiving primary treatment <html><body><table><tr><td>Authorreference</td><td>Year</td><td>N</td><td>Year</td><td>Year</td><td>Year</td><td>Year</td><td>Year</td><td>Total</td><td>Year</td></tr><tr><td>Krebs et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1726</td><td></td><td></td><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td><td>(years 1 to 5)</td><td>6+</td></tr><tr><td>Muram et al.1727</td><td>1982</td><td>312 323</td><td>12</td><td>3-4</td><td>3-4</td><td>3-4</td><td>3-4</td><td>24-28</td><td>2</td></tr><tr><td>Larson et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1728</td><td>1982</td><td>249</td><td>nr 4</td><td>nr 3</td><td>nr 2</td><td>nr 2</td><td>nr</td><td>nr 13</td><td>nr</td></tr><tr><td>Rintala et al.1729</td><td>1988</td><td>89</td><td>4</td><td>4</td><td></td><td></td><td>2</td><td></td><td>1</td></tr><tr><td>Soisson et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1730</td><td>1989 1990</td><td>203</td><td>4</td><td>3</td><td>2 2</td><td>2</td><td>2</td><td>14 13</td><td>2</td></tr><tr><td>Look et al.1731</td><td>1990</td><td>96</td><td>5</td><td>4</td><td>2</td><td>2 2</td><td>2</td><td>15</td><td>1</td></tr><tr><td>Tinga et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1732</td><td>1992</td><td>367</td><td>4</td><td>3</td><td>2</td><td>2</td><td>2</td><td>13</td><td>1</td></tr><tr><td>Gerdin et al.1733</td><td>1994</td><td>167</td><td>4</td><td>3</td><td>2</td><td>2</td><td>2 2</td><td>13</td><td>1</td></tr><tr><td>Ansink et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1741</td><td>1996</td><td>674</td><td>4</td><td>2</td><td>1</td><td>1</td><td>1</td><td>9</td><td>1</td></tr><tr><td>Samlal et al.1734</td><td>1998</td><td>271</td><td>4</td><td>2</td><td>2</td><td>1</td><td>1</td><td>10</td><td>1 1</td></tr><tr><td>Bodurka-Bevers et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1735</td><td>2000</td><td>993</td><td>4</td><td>3</td><td>3</td><td>2</td><td>2</td><td>14</td><td>1</td></tr><tr><td>Esajas et al.1736</td><td>2001</td><td>225</td><td>6</td><td>4</td><td>3</td><td>2</td><td>2</td><td>17</td><td>2</td></tr><tr><td>Duyn et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1737</td><td>2002</td><td>277</td><td>4</td><td>3</td><td>2</td><td>2</td><td>2</td><td>13</td><td>1</td></tr><tr><td>Lim et al.1742</td><td>2004</td><td>291</td><td>4</td><td>2</td><td>1</td><td>1</td><td>1</td><td>9</td><td>0</td></tr><tr><td>Morice et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1738</td><td>2004</td><td>583</td><td>4</td><td>3</td><td>2</td><td>1</td><td>1</td><td>11</td><td></td></tr><tr><td>Sartori et al.1739</td><td>2007</td><td>63</td><td>4</td><td>3</td><td>2</td><td>2</td><td>2</td><td>13</td><td>1</td></tr><tr><td>Zola et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1740</td><td></td><td></td><td>3-4</td><td>3-4</td><td>2</td><td>2</td><td>2</td><td></td><td>1</td></tr><tr><td></td><td>2007</td><td>327</td><td></td><td></td><td></td><td></td><td></td><td>12-14</td><td>1</td></tr></table></body></html> Table 48.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Original studies included in the systematic review published by Elit et al.1725, presenting data on the detection of asymptomatic recurrences by type of follow-up test <html><body><table><tr><td>Authorreference</td><td>Year</td><td>N</td><td colspan=\"2\">Disease recurrence</td><td>Physical</td><td>Vaginal vault</td><td>CT</td><td>MRI</td><td>Chest</td><td>US</td><td>Intravenous</td></tr><tr><td>Krebs et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1726</td><td>1982</td><td>312</td><td>All 40</td><td>Asymptomatic 10</td><td>exam nr</td><td>cytology nr</td><td></td><td></td><td>x-ray</td><td></td><td>pyelography nr</td></tr><tr><td>Muram et al.1727</td><td>1982</td><td>323</td><td>47</td><td>nr</td><td>nr</td><td>3</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Larson et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1728</td><td>1988</td><td>249</td><td>27</td><td>10</td><td>7</td><td>1</td><td></td><td></td><td></td><td></td><td>0</td></tr><tr><td> Rintala et al.1729</td><td>1989</td><td>44</td><td></td><td>nr</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Soisson et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1730</td><td>1990</td><td>203</td><td>31</td><td>9</td><td>nr</td><td>nr</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Look et al.1731</td><td>1990</td><td>96</td><td>21</td><td>7</td><td>5</td><td>0</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Tinga et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1732</td><td>1992</td><td>367</td><td>71</td><td>16</td><td>12</td><td>1</td><td></td><td></td><td>3</td><td></td><td>0</td></tr><tr><td>Gerdin et al.1733</td><td>1994</td><td>167</td><td>19</td><td>3</td><td>2</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Ansink et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1741</td><td>1996</td><td>674</td><td>112</td><td>29</td><td>nr</td><td>nr</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Samlal et al.1734</td><td>1998</td><td>271</td><td>27</td><td>9</td><td>4</td><td>1</td><td></td><td></td><td>3</td><td>0</td><td></td></tr><tr><td>Bodurka-Bevers et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1735</td><td>2000</td><td>993</td><td>133</td><td>19</td><td>8</td><td>0</td><td>0</td><td>0</td><td>9</td><td></td><td></td></tr><tr><td>Esajas et al.1736</td><td>2001</td><td>225</td><td>35</td><td>19</td><td>nr</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Duyn et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1737</td><td>2002</td><td>277</td><td>47</td><td>6</td><td>4</td><td>1</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Lim et al.1742</td><td>2004</td><td>291</td><td>53</td><td>2</td><td>0</td><td></td><td>2</td><td></td><td></td><td>2</td><td></td></tr><tr><td>Morice et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1738</td><td>2004</td><td>583</td><td>45</td><td>7</td><td>2</td><td>1</td><td>2</td><td>0</td><td>2</td><td>0</td><td></td></tr><tr><td>Sartori et al.1739</td><td>2007</td><td>63</td><td>63</td><td>22</td><td>9</td><td>0</td><td>10</td><td></td><td></td><td></td><td></td></tr><tr><td>Zola et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1740</td><td>2007</td><td>327</td><td>327</td><td>163</td><td>85</td><td>5</td><td>55</td><td>15</td><td></td><td>4</td><td></td></tr></table></body></html> CT computed tomography, MRI magnetic resonance imaging, nr not reported, US ultrasonography # 16 Cervical cancer in pregnancy # 16.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1 Summary of available scientific evidence # 16.1.1 Imaging # LoE 3 MRI: two small studies1861,1862 evaluating the possible usefulness of MRI (without injection of intravenous contrast agent) for the management of patients with cervical cancer during pregnancy were identified.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In the first one1861, the six enrolled subjects underwent MRI at the time of first referral.Five patients underwent a second MRI examination before surgery.The final histopathological staging and the final MRI staging agreed in five cases.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In one case, MRI suggested parametrial infiltration which was not confirmed in the surgical specimen, and the tumour volume suggested by MRI markedly exceeded the volume measured after the excision.In the second identified study, Balleyguier et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1862 assessed the role of MRI in decision making regarding treatments options for twelve patients with uterine cervical cancer during pregnancy.The mean term of pregnancy at the time of the diagnosis was the early second trimester (9 to 28 weeks).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In the five patients with localized disease discovered on the Pap smear during the first trimester of pregnancy, MRI was normal $( \\Nu = 4 )$ ) or detected a small lesion (FIGO stage IB1, ${ \\sf N } = 1 \\dot { \\sf \\Phi } .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "$ ), and pregnancies were allowed to continue.In the seven patients with invasive disease revealed later, during the second or third trimester, MRI detected a lesion in every case, and positive LNs were depicted in 2 cases.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "the physical examination revealed four cases of parametrial extension (MRI, ${ \\ N = 4 } \\dot { }$ ) and two cases of vaginal extension (MRI, $\\mathrm { ~ N ~ } = \\mathrm { ~ 1 ~ } \\dot { }$ ).Suspected bladder extension (MRI, $\\mathrm { ~ N ~ } = \\mathrm { ~ 1 ~ } \\dot { }$ ) was confirmed by cystoscopy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "MRI examination of cervical cancers during pregnancy helped the authors to decided upon adequate treatment in all cases and modified management in two cases $( 1 7 \\% )$ .PET-CT: two studies1863,1864 assessing the fetal radiation exposure resulting from PET LoE 3 procedures performed in pregnant patients with cervical cancer were identified.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The first one1863 enrolling 5 pregnant patients with malignancies including 2 patients with cervical cancer.All patients underwent PET studies with a reduced FDG dose (except for one patient who had a negative pregnancy test immediately before the FDG PET procedure but was conformed to be pregnant a few weeks later), including vigorous hydration and diuresis to minimize radiation exposure to the fetus.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Six PET studies were analyzed.The PET scans were obtained in early pregnancy $( \\Nu = 1 )$ , the second trimester $( \\Nu = 2 )$ ), and the third trimester $\\mathrm { \\Delta N = }$ 3).In the patient who underwent PET early during pregnancy, the fetus was not clearly visualized, and only diffusely increased FDG activity was noted in the uterine region.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In all other patients, the fetus was clearly delineated with FDG uptake.The fetal dose exposure from FDG PET studies was estimated to range from 1.1 to $2 .4 3 \\mathrm { \\ m G y }$ for various trimesters in pregnancy (except for the patient in the early stage of pregnancy, in whom activity in the whole uterus was considered, and the fetal dose was estimated to be $9 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "0 4 \\mathrm { m G y }$ ).All patients delivered healthy infants with no visible abnormalities al term.The second identified study1864 enrolled six pregnant patients including one patient with cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Three patients were scanned during the first trimester (one with PET and 2 with PET-CT), two patients were scanned during the second trimester with PET-MRI, and one was scanned during the third trimester with PET.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The fetus was clearly visible on the PET images from all patients except for one patient, for whom the whole uterus was used for dosimetric calculation.The two fetuses imaged with PET-MRI were visible in fine detail on the MRI.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Therefore, fetal contours could be delineated precisely.The fetal absorbed doses from FDG injection were consistent with those published by Takalkar et al.1863, ranging from approximately 1.4 to $5 .1 \\ \\mathrm { m G y } ,$ according to the activity administered, with the highest values generally being found in early pregnancy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The placenta concentrated $0 .2 7 \\%$ of the injected activity of FDG.# 16.1.2 Laparoscopic lymph node staging Feasibility and satefy of laparoscopic pelvic (± para-aortic) lymphadenectomy during LoE 3 pregnancy were assessed in a few pregnant patients1865-1872 with cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Eighteen patients with cervical cancer who underwent laparoscopic pelvic lymphadenectomy during pregnancy (6 to 23 weeks of gestation) were analyzed by Favero et al.1865.All laparoscopic procedures were successfully completed without surgery-associated mortality, morbidity, or conversion to laparotomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "There were no complications for either mother of child related to the general anesthesia.Except for three patients, all women were diagnosed and operated in the second trimester of gestation.The three patients with LN involvement received immediate cancer treatment.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "One patient decided to interrupt the gestation before delivery despite negative LNs.Fourteen patients reached fetal maturity (32 to 36 weeks of gestation) and gave birth to healthy babies by cesarean section.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "All patients were alive without evidence of disease at a mean follow-up time of 38 months.Vercellino et al.1866 described successful laparoscopic pelvic lymphadenectomies performed in 32 pregnant women with cervical cancer (mean gestational week $= 1 7 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "5$ weeks).No maternal and neonatal complications related to anesthesia or directly to the surgical procedure arose.Of the 32 patients, 4 had LN metastases (FIGO stage IB1: ${ \\ N } = 3$ , FIGO stage IIA: ${ \\sf N } = 1 \\dot { \\sf \\Phi }$ ).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "They all interrupted the pregnancy.All children born through cesarean delivery at a mean 34 gestational weeks were well and showed normal clinical neurological development.Alouini et al.1867 reported successful procedures for the eight patients undergoing laparoscopic pelvic ( $\\cdot \\pm$ para-aortic) lymphadenectomy during pregnancy (12 to 32 weeks of gestation), without maternal or fetal complications, or conversion.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Here again, no complications for either mother or child related to the general anesthesia were also described.The three patients with LN involvement died from recurrence of the disease.Seven patients out of eight reached fetal maturity (28 to 36 weeks of gestation) and gave birth by cesarean section to healthy babies.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "All women presented in the idenfied case reports1868-1872 were also treated successfully during pregnancy (10 to 22 weeks of gestation).The authors did not reported any complications connected with the laparoscopic procedure.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 16.1.3 Sentinel node detection # LoE 3 In 2006, Silva et al.1873 have reported the sole case of SN detection by technetium-labelled radiocolloid lymphoschintigraphy in a pregnant woman with cervical cancer (14 weeks’ gestation, FIGO stage IB2).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Two unilateral positive SNs were detected during radical surgery, which included complete pelvic lymphadenectomy and radical hysterectomy with the fetus in situ (14 weeks’ gestation).The patient evolved well postoperatively without complications and was submitted to adjuvant treatment.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "She remains without evidence of disease at 30 months of follow-up.More recently, Papadia et al.1874 presented cases of two pregnant patients with early-stage cervical cancer who have undergone ICG sentinel LN mapping followed by laparoscopic sentinel LN biopsy, pelvic lymphadenectomy, and cervical conisation.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Sentinel LNs were identified in both hemipelvises in both patients.In the final pathologic analysis, both sentinel LNs and non-sentinel LNs were negative for metastatic disease.No adverse events from ICG injection were recorded.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 16.1.4 Delayed treatment Twenty-seven studies1861,1865,1867,1868,1875-1897 presenting maternal outcome data in patients LoE 3 managed with delay before definitive treatment of the cervical tumour post-partum were identified (Table 49).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Ninety-nine per cent of described patients had FIGO stage I-II disease, and most had very early-stage disease (FIGO stage IA and small FIGO stage IB1), for which the risk of clinical significant disease progression was small.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted that data on treatment delay during pregnancy for patients with advanced-stage disease are very limited.Treatment of the identified patients with FIGO stages I-II was delayed for between 3 and 56 weeks.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Of the 100 patients for whom the outcome is known, only 4 died of the disease.Eighteen studies1861,1865,1867,1868,1875,1879,1883-1892,1894,1896 described reports of delays in treatment exceeding 6 weeks in patients with FIGO stages I-II.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Of the 70 patients for whom the outcome is known, only 2 $( 2 .9 \\% )$ died of the disease.It should be noted that 16 $( 2 3 \\% )$ of these cases were diagnosed in first trimester.# 16.1.5 Neoadjuvant chemotherapy To date, less than 60 cases562,1205,1898-1924 of cervical cancer in pregnancy that have been treated LoE 3 with NACT, were identified.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The stage at diagnosis during pregnancy was early (FIGO stages I and II) in $9 6 \\%$ of women.The most commonly used drug was cisplatin administered either as monotherapy562,1898,1899,1903-1906,1909,1910,1919,1921,1924 or combined with vincristine1900,1904,1908,1916,1920,1922,1923, paclitaxel1901,1902,1904,1911,1912,1918, adriamycin1913, etoposide1914, bleomycin1917, vincristine $^ +$ bleomycin1205, or etoposide $^ +$ dactinomycin $^ +$ cyclophosphamide1915 (Table 50).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The vast majority of the patients responded to chemotherapy, which prolonged the pregnancies.Fetal well-being was not compromised in any of the cases reported.Two systematic reviews1925,1926 were identified but are not described because they contain no additional studies beyond those already described above.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 16.1.6 Radical hysterectomy LoE 3 In the small study published by Bigelow et al.1927, complication rates in pregnant women undergoing radical hysterectomy were similar to those outside of pregnancy.Time to treatment was significantly longer for pregnant women compared to nonpregnant patients (20.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "8 weeks versus 7.9 weeks, ${ \\mathrm { ~ p ~ } } = \\ 0 .0 0 1 4 { \\mathrm { ~ } }$ ) but there was no survival difference between groups.Women who underwent gravid radical hysterectomy had significantly higher estimated blood loss than those who had a radical hysterectomy in the postpartum period ( $2 0 3 3 \\ \\mathrm { m l }$ versus $4 2 5 \\ \\mathrm { m l } .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "$ , ${ \\mathrm { ~ p ~ } } = \\ 0 .0 0 6 4 ^ { \\cdot }$ ), but operative characteristics were otherwise similar.None of the pregnant women who died delayed treatment due to pregnancy.Oncologic outcomes were similar between pregnant patients and nonpregnant control subjects.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "As part of another small study1886 enrolling thirteen patients treated with radical hysterectomy and bilateral PLND with the fetus in situ and eight others with cesarean delivery followed by radical hysterectomy and bilateral PLND, no perioperative deaths occurred.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "After documentation of maturity, seven healthy infants were delivered with no major morbidity.Twenty patients $( 9 5 \\% )$ were alive and free of disease with a mean follow-up of 40 months.Except for the increased blood loss in conjunction with cesarean section, Monk et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1886 reported that the outcome of radical hysterectomy with the fetus in situ or after cesarean delivery did not differ significantly from that of radical hysterectomy in the nonpregnant state.A study1893 evaluating the morbidity of radical hysterectomy and PLND or simple hysterectomy for patients with cervical cancer treated during pregnancy was also identified.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "No differences in operative morbidity and major complication rate between pregnant and nonpregnant patients were described.Results of the other identified studies1872,1875,1877,1928-1930 are limited notably by (1) the very small number of patients evaluated, (2) the inclusion of patients as much as 18 months’ postpartum, and/or (2) the absence of details regarding the surgical management.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 16.1.7 Abdominal radical trachelectomy In 2006, Ungar et al.1931 first published the use of abdominal radical trachelectomy in five LoE 3 pregnant patients with cervical cancer between 7 and 18 weeks’ gestation.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "All the patients were in FIGO stage IB1.Three of the cases resulted in miscarriage after surgery.Four case reports858,1932-1934 describing this procedure were also identified (Table 51).# 16.1.8 Radical vaginal trachelectomy In 2008, van de Nieuwenhof et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1935 reported the first radical vaginal trachelectomy LoE 3 performed in a pregnant patient with cervical cancer.To date, eight identified reports1867,1870,1935-1940 described fifteen cervical cancer cases managed with vaginal radical trachelectomy during pregnancy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "At the time of delivery, the gestational age ranged between 26 and 37 weeks (Table 51).# 16.1.9 Simple trachelectomy Two case reports1869,1941 presenting pregnant patients treated by a simple trachelectomy were LoE 3 identified.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In the first published case1869, simple trachelectomy and cerclage were performed in the $2 2 ^ { \\mathrm { n d } }$ week of pregnancy.Adjuvant chemotherapy with tree cycles of cisplatin was performed after surgery.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Delivery was performed by cesarean section followed by radical hysterectomy in the $3 2 ^ { \\mathrm { n d } }$ week of pregnancy.The newborn developed normally and showed no chemotherapically related side effects.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Patient had no surgery related complications.No relapse of cancer has been diagnosed during the following 16 months.The second case1941 was a patient treated by a simple trachelectomy and cercalge during 24th week of pregnancy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The woman gave borth to a healthy baby at the end of her pregnancy.Definitive treatment was completed three months after giving birth.After 17 months of monitoring, the patient showed no signs of recurrence.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 16.1.10 Radiotherapy # LoE 3 Among the 26 pregnant patients with cervical carcinoma managed primarily with radiation therapy in the study published by Sood et al.1881, three patients were diagnosed in the first trimester, 6 in the second, and 17 in the third.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "All patients in the second trimester underwent hysterotomy prior to radiation, and in all cases the infant died.Among the 15 patients for whom there was not a planned delay in treatment, 2 infants born at 27 and 29 weeks died of complications related to prematurity.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "All other infants were 34 weeks at birth and had no significant morbidity or mortality.All the patients diagnosed during the first trimester were treated with radiation with the fetus in situ, and all had spontaneous abortions 20-24 days after the start of radiation (mean dose: 34 Gy).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The authors reported no statistically significant differences in recurrence rates or survival between the pregnant group and the controls.Short term toxicity was comparable in pregnant and nonpregnant patients and easily controlled.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Long term complications were more common in controls but the difference was not statistically significant.It should be noted that their observations of patients irradiated in the first trimester of pregnancy were consistent with two previous reports1883,1942.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Another previous study reported that in the second trimester, fetal issues appear to be less sensitive to radiation, and spontaneous abortion is more delayed and occurs les reliably1875.It should be noted that the results of these previous reports1875,1883,1942 and those of the other previous identified studies1876,1877,1928,1943,1944 evaluating the radiotherapeutic management of cervical carcinoma diagnosed during pregnancy are limited notably by (1) the very small number of patients evaluated, (2) the inclusion of patients treated up to several months postpartum, and/or (2) the heterogeneity of radiotherapy protocols used.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 16.1.11 Chemoradiotherapy # LoE 3 Very few cases1945,1946 of cervical cancer in pregnant patients treated with chemoradiation have been identified.The first published article1945 focused on the modalities of uterine evacuation and not on the impact on the outcomes of two patients (patients were followed up only 12 months after the end of treatment).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In this report, women diagnosed with FIGO stage IB2 cervical cancer at approximately 15 weeks gestation, underwent radiotherapy with radiosensitizing chemotherapy.After intrauterine fetal demise was detected, both women underwent induction with misoprostol.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Results included one complete abortion and one incomplete abortion withou complications or delays in treatment.In the second report1946, two patients were treated using chemoradiation therapy with fetus in utero for advanced-stage squamous cervical carcinoma diagnosed during the first trimester of pregnancy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The first patient with a FIGO stage IVA disease diagnosed at 12 weeks of gestation recurred 20 months after the end of the treatment and died of the disease.The second patient had a FIGO stage IIB disease diagnosed at 12 weeks of gestation and was treated by chemoradiation therapy followed by completion surgery (radical hysterectomy and para-aortic lymphadenectomy) due to the presence of a suspicous residual disease.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "This patient was alive and free of disease 24 months after surgery.In this report, the uterine evacuation occurred spontaneously in one case and was performed surgically in the other case.# 16.1.12 Mode of delivery As part of multivariate analysis, Sood et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1947 reported that vaginal delivery was the most LoE 2- significant predictor of recurrence ( $\\mathrm { \\Delta } \\operatorname { \\left[ 0 R \\right.} = 6 .9 1$ ( $9 5 \\%$ $5 \\% \\mathrm { C I } = 1 .4 5 – 3 2 .",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "8 ]$ ), followed by high stage ( $\\mathrm { \\cdot } \\mathrm { O R } = 4 .6 6$ ( $9 5 \\% \\mathrm { C I } = 1 .0 5 – 2 0 .8 ]$ ).Survival after vaginal delivery appeared to be worse than after a cesarean section in two LoE 3 studies1948,1949, but it should be noted that (1) the p value was not specified and (2) seven other identified studies1883,1884,1892,1894,1928,1944,1950 did not report a significant difference in survival between vaginal delivery and abdominal delivery.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Several case reports1943,1951-1954 have described tumour implantation in episiotomy sites with a poor prognosis.Only one identified report1955 described a recurrence where the cesarean section had been performed.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "It should be noted that two cases1956,1957 of placental metastasis of cervical cancer have been published.# 16.2 Previous initiatives Eight previous initiatives presenting guidelines423,424,426,529,531,1958-1960 on the management of cervical cancer in pregnancy were identified.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 16.3 Development group comments Today due to improved prenatal care, majority of cervical cancers coincidental diagnosed in pregnancy are detected in early stages.In the last century, oncologic therapy has predominantly focussed on women‘s outcome and radical hysterectomy (following cesarean section or primary with fetus in situ) was first recommendation undependent from week of pregnancy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Given the limited number of studies and case reports even today there is a low level of evidence for following recommendations.Nearly all women with histological proven lymph node metastases of cervical cancer in pregnancy recur or die post partum.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Therefore and due to limited validity of imaging systems in pregnancy, surgical lymph node staging predominantly done by minimal-invasive approach can be safely performed.In pregnancies later than 24 weeks of gestation (fetal viability) lymph node dissection is not indicated.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Conisation in pregnancy for diagnostic or therapeutic purposes can be associated with considerable bleeding and higher rates for non in sano resection of CIN III and invasive cancer.Vaginal, total laparoscopic or abdominal trachelectomy are challenching procedures in pregnancy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Especially abdominal radical trachelectomy can induce second trimester miscarriages or accompanied by live-threatening bleeding.Radical hysterectomy in graviditate following cesarean section or with fetus in situ is feasible without increased intra- or postoperative morbidity and does not worse oncologic outcome.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Primary chemoradiotherapy in early pregnancy induces spontaneous abortion and use of misoprostol can simplify uterine evacuation.Depending on tumor stage and gestations age at diagnosis delay of oncologic therapy between 3-29 weeks does seems to have no negative effect on maternal outcome.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Available data are inconsistent with respect to best regimen and maximal number of NACT cycles.In accordance to other gynecologic tumor entities in pregnancy different neoadjuvant combination schemata empirical do not cause permanent development delay of fetus/children.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "However, potential risks and benefits of cumulative chemotherapy have to be balanced with possible problems of fetal prematurity.MRT can be used to monitor effect of NACT in pregnant patients with proven cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "There are conflicting data with respect to mode of delivery.Occurrence of episiotomy scar recurrence can be associated with negative oncologic outcome.Until more valid data available, cesarean section should be preferred mode of delivery.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# 16.4 Guidelines Every patient diagnosed with CCIP must be counseled by a multidisciplinary team.This team should consist of experts in the fields of gynecologic oncology, neonatology, obstetrics, anesthesiology, radiation oncology, medical oncology, psychooncology, and, if requested, theology or ethics.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Given the large spectrum of described therapeutic options, the multidisciplinary team recommends an individual consensual treatment plan according to patient’s intention, tumor stage, and gestational age of pregnancy at cancer diagnosis.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Primary aims of recommended treatment plan are oncological safety of the pregnant woman, as well as survival without additional morbidity of the fetus.Treatment of patients with CCIP should exclusively be done in gynecologic oncology centers associated with a highest level perinatal center with expertise in all aspects of oncologic therapy in pregnancy and intensive medical care of premature neonates.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Because of the low incidence of CCIP, centralization in a few well-equiped facilities is compulsory.Besides clinical examination and histologic verification of invasive cervical cancer, preferred imaging modalities for clinical staging in patients with CCIP include MRI or expert ultrasound.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Because of limited experience and inherent radioactivity PET-CT (PET-MRI) should be indicated only under very selected circumstances.Tumor involvement of suspicious nodes should be verified histologically because of its prognostic significance and the impact on the management up to $2 4 ^ { \\mathrm { t h } }$ week of gestation (fetal viability), preferably by minimally invasive approach.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Depending on tumor stage and gestational week of pregnancy, the following treatment options have to be discussed with the patient including risks and benefits of individual approaches: Adapted surgery including removal of the tumor: conization, trachelectomy, and lymph node staging (see above) according to the stage of the disease with the intent to preserve the pregnancy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": " Radical surgery or definitive chemoradiation as recommended for the stage of the disease without preservation of the pregnancy, with or without previous pregnancy termination. Delay of oncological treatment until fetal maturity (if possible $> 3 2$ weeks of gestation) and beginning of cancer-specific treatment immediately after delivery by cesarean section.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": " Chemotherapy until fetal maturity and beginning of cancer specific treatment immediately after delivery by cesarean section.Treatment after delivery must consider application of previous chemotherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In patients with locally advanced stage or with residual tumor after conization that cannot be completely excised (risk of premature rupture of membranes (PROM) and/or cervical insufficiency), platinum-based chemotherapy can be considered starting earliest at 14 weeks of gestation.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Spontaneous delivery seems to have negative prognostic impact in patients with CCIP.Thus, cesarean section after the $3 2 ^ { \\mathrm { n d } }$ week of gestation (if possible) is the recommended mode of delivery.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "At the time of or following casarean section, definitive stage-adjusted oncologic therapy has to be performed corresponding to that of nonpregnant women, taking into account therapy that has already been given during pregnancy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Table 49.Original studies presenting maternal outcome data in patients managed with delay before definitive treatment of the cervica tumour post-partum <html><body><table><tr><td>Authorreference</td><td>Year</td><td>N</td><td>Histologic subtype</td><td>Gestational age at</td><td>Delay</td><td>Follow-up</td><td>Progression</td><td>Status</td></tr><tr><td></td><td></td><td></td><td></td><td>diagnosis (weeks)</td><td>(weeks)</td><td>(months)</td><td> during delay</td><td></td></tr><tr><td>FIGO stage I</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Prem et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1875</td><td>1966</td><td>5</td><td>nr </td><td>20-34</td><td>11-17</td><td>34-64</td><td>nr</td><td>NED</td></tr><tr><td>Dudan et al.1876</td><td>1973</td><td>2</td><td>nr</td><td>nr</td><td>8-16</td><td>nr</td><td>IIA,IIB</td><td>nr</td></tr><tr><td> FIGO stage IA</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Thompson et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1877</td><td>1975</td><td>7</td><td>nr </td><td>nr</td><td>5-28</td><td>3-120</td><td>no</td><td>NED</td></tr><tr><td>FIGO stage IA1</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Boutselis et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1878</td><td>1972</td><td>5</td><td>nr </td><td>8-24</td><td>nr</td><td>72-180</td><td>no</td><td>NED</td></tr><tr><td>Lee et al.1879</td><td>2008</td><td>4</td><td>SCC (2),ACC (1),AM (1)</td><td>11, 6, 6, 18</td><td>27, 9, 34, 18</td><td>27, 9, 34, 18</td><td>nr</td><td>NED</td></tr><tr><td>Lin et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1880</td><td>2013</td><td>1</td><td>SCC</td><td>10</td><td>nr</td><td>7</td><td>nr</td><td>NED</td></tr><tr><td> FIGO stage IA2</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Sood etal.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "181</td><td>1997</td><td>2</td><td>SCC</td><td> 3rd trimester</td><td>3,3</td><td>nr</td><td>nr</td><td>NED</td></tr><tr><td>Ben-Arie et al.1882</td><td>2004</td><td>1</td><td>SCC</td><td>15</td><td>nr</td><td>24</td><td>nr</td><td>NED</td></tr><tr><td> FIGO stage IB</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Lee et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "183</td><td>1981</td><td>1</td><td>SCC</td><td>24</td><td>12</td><td>120</td><td>no</td><td>NED</td></tr><tr><td>Nisker et al.1884</td><td>1983</td><td>1</td><td>nr</td><td> 2nd trimester</td><td>24</td><td>nr</td><td>nr</td><td>DOD</td></tr><tr><td>Greer et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1885</td><td>1989</td><td>1 4</td><td>GCC SCC (4)</td><td>22 20, 21, 24, 24</td><td>6 17, 14, 10, 11</td><td>15 13, 26, 27,35</td><td>nr nr </td><td>DOD NED</td></tr><tr><td>Monk et al.1886</td><td>1992</td><td>3</td><td>nr</td><td>19-23</td><td>10-16</td><td>2-6</td><td>nr</td><td>NED</td></tr><tr><td>Duggan et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1887</td><td>1993</td><td>5</td><td>nr </td><td>19, 15, 30, 28, 27</td><td>12, 21, 24, 19, 7</td><td>16, 34,10,30,34</td><td>nr</td><td>NED</td></tr><tr><td>Allen et al.1888</td><td>1995</td><td>2</td><td>SCC (2)</td><td>16, 16</td><td>18, 19</td><td>69,62</td><td>nr</td><td>NED</td></tr><tr><td>Sorosky et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1889</td><td>1995</td><td>7</td><td>nr</td><td>18,8, 16,21, 28, 18, nr</td><td>15, 22,29, 16,7,19, 40</td><td>68, 60, 43,42,23,19,13</td><td>nr</td><td>NED</td></tr><tr><td>Sorosky et al.1890</td><td>1996</td><td>5</td><td>nr</td><td>18, 18, 32,16,8</td><td>15, 15, 9, 22, 28</td><td>67,12, 120, 52,48</td><td>nr </td><td>NED</td></tr><tr><td>Van Vliet et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1891</td><td>1998</td><td>2</td><td></td><td>23, 26</td><td>6,10</td><td>16,106</td><td>nr</td><td>NED</td></tr><tr><td>Germann et al.1892</td><td>2005</td><td>4</td><td>nr nr</td><td> 2nd trimester</td><td>4-16</td><td>60</td><td>nr</td><td>NED</td></tr></table></body></html> ACC adenocarcinoma, AM adenoma malignum, DOD dead of disease, GCC glassy cell carcinoma, NED no evidence of disease, nr not reported, SCC squamous cell carcinoma Original studies presenting maternal outcome data in patients managed with delay before definitive treatment of the cervical tumour postpartum (continued) <html><body><table><tr><td>Authorreference</td><td>Year</td><td>N</td><td>Histologic subtype</td><td>Gestational age at</td><td>Delay</td><td>Follow-up</td><td>Progression</td><td>Status</td></tr><tr><td></td><td></td><td></td><td></td><td>diagnosis (weeks)</td><td>(weeks)</td><td>(months)</td><td>during delay</td><td></td></tr><tr><td> FIGO stage IB1</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Sood et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1893</td><td>1996</td><td>3</td><td>SCC</td><td>nr</td><td>3-32</td><td>12-360</td><td>no</td><td>NED</td></tr><tr><td>Zanetta et al.1861</td><td>1998</td><td>3</td><td>ACC (3)</td><td>20,20, 25</td><td>18, 15, 13</td><td>49, 40, 55</td><td>no</td><td>NED</td></tr><tr><td>Takushi et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1894</td><td>2002</td><td>2</td><td>SCC</td><td>18,17</td><td>13,15</td><td>97,108</td><td>nr</td><td>NED</td></tr><tr><td>Germann et al.1892</td><td>2005</td><td>5</td><td>nr</td><td>1st trimester</td><td>12-24</td><td>60</td><td>nr</td><td>NED</td></tr><tr><td>Traen et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1895</td><td>2006</td><td>1</td><td>SCC</td><td>14</td><td>16</td><td>30</td><td>nr</td><td>NED</td></tr><tr><td>Lee et al.1879</td><td>2008</td><td>4 1</td><td>SCC (2), CC (1), SMC (1) ASqC (1)</td><td>11, 14, 23, 23 25</td><td>25, 18, 13, 14 6</td><td>58, 15, 22, 12 34</td><td>nr nr </td><td>NED (4) DOD (1)</td></tr><tr><td>Alouini et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1867</td><td>2008</td><td>3</td><td>SCC (2), ACC (1)</td><td>15, 20, 2</td><td>9, 12, 15</td><td>14, 26, 84</td><td>nr</td><td>NED</td></tr><tr><td>Ishioka et al.1896</td><td>2009</td><td>2</td><td>SCC (2)</td><td>21, 25</td><td>6, 9</td><td>17,120</td><td></td><td>NED</td></tr><tr><td>Gurney et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1897</td><td>2009</td><td>1</td><td>SCC</td><td>21</td><td>nr</td><td>10</td><td>no</td><td>NED</td></tr><tr><td>Favero et al.1865</td><td>2010</td><td>６</td><td>SCC (5), ACC (1)</td><td>12,14,14, 22, 23, 23</td><td>9,11, 13, 18, 26,28</td><td>9, 11, 13,18, 26, 28</td><td>nr </td><td>NED</td></tr><tr><td> FIGO stage IB2</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Takushi et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1894</td><td>2002</td><td>1</td><td>SCC</td><td>26</td><td>6</td><td>84</td><td>nr</td><td>NED</td></tr><tr><td>Stan et al.1868</td><td>2005</td><td>1</td><td>SCC</td><td>16</td><td>20</td><td>48</td><td>no</td><td>NED</td></tr><tr><td>Alouini et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1867</td><td>2008</td><td>1</td><td>SCC</td><td>25</td><td>7</td><td>62</td><td>nr</td><td>NED</td></tr><tr><td></td><td></td><td>1</td><td>SCC</td><td>20</td><td>8</td><td>17</td><td>nr </td><td>DOD</td></tr><tr><td>Ishioka et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1896</td><td>2009</td><td>1</td><td>SCC</td><td>11</td><td>19</td><td>111</td><td>no</td><td>NED</td></tr><tr><td>Favero et al.1865</td><td>2010</td><td>1</td><td>ACC</td><td>23</td><td>12</td><td>68</td><td>nr</td><td>NED</td></tr><tr><td> FIGO stage IIA</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Allen et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1888</td><td>1995</td><td>1</td><td>SCC</td><td>21</td><td>56</td><td>88</td><td>nr</td><td>NED</td></tr><tr><td>Lee et al.1879</td><td>2008</td><td>1</td><td>SCC</td><td>20</td><td>17</td><td>75</td><td>nr</td><td>NED</td></tr><tr><td>FIGO stage IIB</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Ishioka et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1896</td><td>2009</td><td>1</td><td>ACC</td><td>25</td><td>3</td><td>10</td><td>no</td><td>NED</td></tr><tr><td> FIGO stage IIIB</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Lee et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1879</td><td>2008</td><td>1</td><td>SCC</td><td>32</td><td>3</td><td>104</td><td>nr</td><td>NED</td></tr></table></body></html> ACC adenocarcinoma, ASqC adenosquamous carcinoma, CC clear cell carcinoma, DOD dead of disease, NED no evidence of disease, nr not reported, SCC squamous cell carcinoma, SMC small cell carcinoma Table 50.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Original studies presenting data in patients treated with NACT during pregnancy <html><body><table><tr><td>Authorreference</td><td>Year</td><td>N</td><td>NACT</td><td>Response</td><td>Treatment</td><td>Follow-up (months)</td><td>Status</td><td>Baby</td></tr><tr><td> FIGO stage IB1</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Giacalone et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1898</td><td>1996</td><td>1</td><td>CisP</td><td>CR</td><td>CS/RH/PLND/PALND</td><td>12</td><td>NED</td><td>well</td></tr><tr><td>Caluwaerts et al.1899</td><td>2006</td><td>1</td><td>CisP</td><td>PR</td><td>CS/RH/PLND/PALND</td><td>10</td><td>NED</td><td>well</td></tr><tr><td>de Lima et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1900</td><td>2013</td><td>1</td><td>CisP, VinC</td><td>PR</td><td>CS/RH/PLND/CT</td><td>24</td><td>NED</td><td>well</td></tr><tr><td>Chun et al.1901</td><td>2010</td><td>1</td><td>CisP Tax</td><td> PR </td><td> CS/RH/PLND/PALND</td><td>49</td><td>DOD</td><td>well</td></tr><tr><td>Kong et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1902</td><td>2014</td><td>2</td><td>CisP, Tax</td><td>PR</td><td>CS/RH/PLND/CT</td><td>24,104</td><td>NED</td><td>well</td></tr><tr><td>Favero et al.1903</td><td>2010</td><td>5</td><td>CisP</td><td>nr</td><td>nr </td><td>5, 10, 12</td><td>NED (3)</td><td>nr</td></tr><tr><td>Fruscio et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1904</td><td>2010</td><td>4</td><td>CisP</td><td>PR (3), SD (1)</td><td>CS/RH (4)</td><td>41-65</td><td>nr (2) NED</td><td>well</td></tr><tr><td>Lanowska et al.1905</td><td>2011</td><td>7</td><td>CisP</td><td>nr</td><td>CS/RH (6) CS/RH/CT/RT (1)</td><td>1, 1, 3, 3,7, 12, 17</td><td>NED</td><td>well</td></tr><tr><td>Ayhan et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1924</td><td>2012</td><td>1</td><td>CisP</td><td>CR</td><td> CS/RH/PLND</td><td>36</td><td>NED</td><td>well</td></tr><tr><td>Hecking et al.1906</td><td>2016</td><td>1</td><td>CisP</td><td>SD</td><td>CS/RH/CT/RT</td><td>26</td><td>NED</td><td>well</td></tr><tr><td>FIGO stage IB2</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Lai et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1205</td><td>1997</td><td>2</td><td>CisP, VinC, Bleo</td><td>SD (1), PR (1)</td><td>CS/RH (2) </td><td>52,59</td><td>DOD</td><td>nr </td></tr><tr><td>Tewari et al.1908</td><td>1998</td><td>1</td><td>CisP, VinC</td><td> PR</td><td> CS/RH/PLND</td><td>24</td><td>NED</td><td>well</td></tr><tr><td>Karam et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1909</td><td>2007</td><td>1</td><td>CisP</td><td>nr </td><td>CS/RH/PLND/PALND</td><td>14</td><td>NED</td><td>well</td></tr><tr><td>Smyth et al.1907</td><td>2010</td><td>1</td><td>Adria, Cyclo</td><td>PR</td><td>CS</td><td>nr</td><td>NED</td><td>well</td></tr><tr><td>Chun et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1901</td><td>2010</td><td>1</td><td>CisP, Tax</td><td>PR</td><td> CS/RH/PLND/PALND</td><td>60</td><td>NED</td><td>well</td></tr><tr><td> Rabaiotti et al.1910</td><td>2010</td><td>1</td><td>CisP</td><td>SD</td><td>CS/RT</td><td>24</td><td>DOD</td><td>well</td></tr><tr><td>Li et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1911</td><td>2011</td><td>2</td><td>CisP, Tax</td><td>PR (2)</td><td>CS/RT (1), CS (1)</td><td>13, 21</td><td>NED</td><td>well</td></tr><tr><td>Lanowska et al.1905</td><td>2011</td><td>1</td><td>CisP</td><td>Nr</td><td>CS/RH/CT/RT</td><td>1</td><td>NED</td><td>well</td></tr><tr><td>Islam et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "562 Fruscio et al.1904</td><td>2011 2012</td><td>1</td><td>CisP Cisp, Vinc (1)</td><td>PR PR (3)</td><td>CS/RH/CT/RT/PLND</td><td>36</td><td>NED</td><td>well</td></tr><tr><td></td><td></td><td>5</td><td>CisP (2) CisP, Tax (2)</td><td>SD (2)</td><td>CS/RH/RT (2) CS/RH (3)</td><td>13,21, 27,113, 153</td><td>NED (4) DOD (1)</td><td>well</td></tr><tr><td>Yousefi et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1912</td><td>2013</td><td>1</td><td>CisP, Tax</td><td>nr</td><td>CS/RH</td><td>nr</td><td>nr</td><td>well</td></tr><tr><td>Kong et al.1902</td><td>2014</td><td>1</td><td>CisP, Tax</td><td>PR</td><td>CS/RH/PLND/CT</td><td>35</td><td>NED</td><td>well</td></tr><tr><td> Peculis et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1913</td><td>2015</td><td>1</td><td>CisP, Adria</td><td>CR</td><td> CS/RH/PLND</td><td>20</td><td>NED</td><td>well</td></tr><tr><td>Wang et al.1914</td><td>2015</td><td>1</td><td>CisP, Eto</td><td>CR</td><td>RT/BT</td><td>8</td><td>NED</td><td>nr</td></tr><tr><td>FIGO stage IIA Tewari et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1908</td><td>1998</td><td>1</td><td>CisP, VinC</td><td>PR</td><td>CS/RH/PLND</td><td>5</td><td>DOD</td><td>well</td></tr><tr><td>Balderston et al.1915</td><td>1998</td><td>1</td><td>CisP,Eto, Dac, Cyclo</td><td>PR</td><td>CS/CT/RT</td><td>66</td><td>NED</td><td>well</td></tr><tr><td>Bader et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1916</td><td>2007</td><td>1</td><td>CisP, VinC</td><td> PR </td><td> CS/RH/PLND</td><td>80</td><td>NED</td><td>well</td></tr><tr><td>Chun et al.1901</td><td>2010</td><td>1</td><td>Carbo, Tax</td><td>PR</td><td> CS/RH/PLND/PALND</td><td>48</td><td>AWD</td><td>well</td></tr><tr><td> FIGO stage IIB</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Marana et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1917</td><td>2001</td><td>1</td><td>CisP, Bleo</td><td>nr</td><td>CS</td><td>13</td><td>DOD</td><td>well</td></tr><tr><td> Palaia et al.1918</td><td>2007</td><td>1</td><td>CisP, Tax</td><td> PR </td><td>RH/PLND</td><td>10</td><td>NED</td><td>well</td></tr><tr><td>Boyd et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1919</td><td>2009</td><td>1</td><td>CisP</td><td>nr</td><td>RT</td><td>15</td><td>NED</td><td>well</td></tr><tr><td>Lanowska et al.1905</td><td>2011</td><td>1</td><td>CisP</td><td>nr</td><td>CS/RH/CT/RT</td><td>3</td><td>NED</td><td>well</td></tr><tr><td>da Fonseca et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1920</td><td>2011</td><td>1</td><td>CisP, VinC</td><td>CR</td><td> CS/RH/PLND/PALND</td><td>12</td><td>NED</td><td>well</td></tr><tr><td> Dawood et al.1921</td><td>2013</td><td>1</td><td>CisP</td><td>PD</td><td>CS/CT/RT/BT</td><td>24</td><td>DOD</td><td>well</td></tr><tr><td>FIGO stage IIB</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Benhaim et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1922</td><td>2008</td><td>1</td><td>CisP, VinC</td><td>PD</td><td>CT/RT</td><td>10</td><td>DOD</td><td>well</td></tr><tr><td>Seamon et al.1923</td><td>2009</td><td>1</td><td>CisP, VinC</td><td>PR</td><td>RT</td><td>48</td><td>NED</td><td>well</td></tr></table></body></html> Adria adriamycin, AWD alive with disease, Bleo bleomycin, BT brachytherapy, Carbo carboplatin, CisP cisplatin, CR complete response, CS cesarean section, CT chemotherapy, Cyclo cyclophosphamide, Dac dactinomycin, DOD dead of disease, Eto etoposide, NACT neoadjuvant chemotherapy, NED no evidence of disease, nr not reported, PALND para-aortic lymph node dissection, PLND pelvic lymph node dissection, PR partial response, RH radical hysterectomy, RT radiation therapy, SD stable disease, Tax paclitaxel, VinC vincristine Table 51.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Original studies presenting data in patients treated with radical trachelectomy as a fertility-preserving alternative to radical hysterectomy <html><body><table><tr><td rowspan=\"2\">Authoreference</td><td rowspan=\"2\">Year</td><td rowspan=\"2\">N</td><td rowspan=\"2\">Age (years)</td><td colspan=\"2\">Pre-trachelectomy</td><td rowspan=\"2\">Intraop.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "compl.</td><td rowspan=\"2\">Post-trachelectomy diagnosis</td><td rowspan=\"2\">Tumour size</td><td rowspan=\"2\">Cancer recur.</td><td rowspan=\"2\">Follow-up (months)</td><td rowspan=\"2\">Fetal demise</td><td rowspan=\"2\">Gestational age (weeks) at trachelectomy</td><td rowspan=\"2\"></td><td rowspan=\"2\">Cesarean at delivery section</td></tr><tr><td>Type</td></tr><tr><td> Abdominal radical trachelectomy</td><td></td><td></td><td></td><td></td><td>FIGO stage</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Ungar et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1931</td><td>2006 5</td><td></td><td>25 (1) nr(4)</td><td>SCC(5)</td><td>IB1 (5)</td><td>none</td><td>no change</td><td>nr</td><td>none</td><td>40 (10-60)</td><td>yes (3) no (2)</td><td>7,8, 9, 13, 18</td><td>38, 39 NA (3)</td><td>yes (2) NA (3)</td></tr><tr><td>Mandic et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1934</td><td>2009 1</td><td>27</td><td></td><td></td><td>IB1</td><td>none</td><td>no change</td><td>4 mm</td><td>none</td><td>12</td><td>no</td><td>19</td><td>36</td><td>yes</td></tr><tr><td>Karateke et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "858</td><td>2010 1</td><td>25</td><td></td><td></td><td></td><td>none</td><td>SCC, stage IB2</td><td>5 x5 cm</td><td>nr</td><td>nr</td><td>yes</td><td>22</td><td>22</td><td>NA</td></tr><tr><td>Abu-Rustum et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "132</td><td>2010 1</td><td>37</td><td></td><td>LE-like</td><td></td><td>nr </td><td>no change</td><td>12 mm</td><td>none</td><td>12</td><td>no</td><td>15</td><td>39</td><td>yes</td></tr><tr><td>Enomoto et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1933</td><td>2011 1</td><td>27</td><td></td><td>SCC</td><td>IB1</td><td>nr</td><td>SCC, pT2a1, pNO, pMO</td><td>nr</td><td>none</td><td>6</td><td>no</td><td>15</td><td>37</td><td>yes</td></tr><tr><td>Radical vaginal trachelectomy Van de Nieuwenhof et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1935</td><td>2008 1</td><td></td><td></td><td>SCC</td><td></td><td>none</td><td> Severe cervical dysplasia</td><td>8 x 2.3 mm</td><td>none</td><td></td><td>no</td><td>18</td><td>36</td><td>yes</td></tr><tr><td>Alouini et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1867</td><td>2008 2</td><td>30 28</td><td></td><td>SCC</td><td></td><td>none</td><td>no change</td><td>20 mm</td><td>1</td><td>9 132</td><td>yes(1]</td><td>12</td><td>12</td><td>yes (1)</td></tr><tr><td></td><td></td><td>32</td><td></td><td>ACC</td><td></td><td></td><td></td><td>25 mm nr</td><td></td><td>36 14</td><td>no[1)</td><td>12 16</td><td>30 34</td><td>NA (1)</td></tr><tr><td>Iwami et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1936 Sioutas et al.1870</td><td>2011 1 2011 3</td><td>32 34</td><td></td><td>ACC ASqC (1)</td><td>IB1 (2)</td><td>none none</td><td>no change SCCin situ</td><td>nr nr.</td><td>none</td><td>47 30</td><td>no no (3)</td><td>13+5</td><td>37 + 4 29 + 4 </td><td>yes yes (3)</td></tr><tr><td>Ferriaioli et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1937</td><td>2012 5</td><td>36 37 29 28</td><td></td><td>ACC (1) SCC (1) SCC (3) ACC (2)</td><td>IA2 (1) IB1 (3) 1A2(2)</td><td>none</td><td>Atypical glandular cells Mild cervical dysplasia no change</td><td>3.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "6 mm 12 x 7 mm 10 x 4 mm 4 x 2 mm</td><td>none 1</td><td>204 240</td><td>yes (2) no (3)</td><td>13+1 12+6</td><td>37 + 2 34 36</td><td>yes (3) NA (2)</td></tr><tr><td>Bravo et al138</td><td>2012</td><td>30 30 41</td><td></td><td>NK SCC</td><td>IB1</td><td>none</td><td>NK SCC with grade II CIN</td><td>27 x 18 mm 12 x 5 mm 35 x 30 x 30 mm</td><td>none</td><td>nro 200 40</td><td></td><td>6:220% 26 11</td><td>NA: N = 2 36</td><td>yes</td></tr><tr><td>Kolomainen et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1939</td><td>2013</td><td>27</td><td></td><td>ACC</td><td>nr</td><td>none</td><td>ACC, IB2</td><td>42 mm</td><td>none</td><td>46</td><td>no no</td><td>16</td><td>26</td><td>yes</td></tr><tr><td>Saso et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1940</td><td>2015</td><td>22</td><td></td><td>SCC</td><td>IB1</td><td>none</td><td> no change</td><td>nr</td><td>none</td><td>16</td><td>no</td><td>19</td><td>36</td><td> yes</td></tr></table></body></html> ACC adenocarcinoma, ASqC adenosquamous carcinoma, CIN cervical intra-epithelial neoplasia, Intraop.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "compl.Intraoperative complications, LE Lymphoepithelioma, NA not applicable, NK non-keratinizing, nr not reported, PC planocellular carcinoma, recurr.recurrence, SCC squamous cell carcinoma # 17 Acronyms and abbreviations 3D 3-dimensional 5-FU 5-fluorouracil ACC adenocarcinoma ACPG alberta clinical practice guidelines AGDH australian government department of health AHRQ agency for healthcare research and quality AM adenoma malignum AQuAS agència de qualitat i avaluació sanitàries de Catalunya ARH abdominal radical hysterectomy ASqC adenosquamous carcinoma ASCO american society of clinical oncology AWD alive with disease BCCA british columbia cancer agency BMI body mass index BT brachytherapy CA 125 cancer antigen 125 CA 15-3 cancer antigen 15-3 CADTH canadian agency for drugs and technologies in health CCIP cervical cancer in pregnancy CCO cancer care ontario CCRT concurrent chemoradiotherapy CEA carcinoembryonic antigen CEPO comité de l’évolution des pratiques en oncologie CES-D epidemiologic studies depression scale CI confidence interval CIC circulating immune complexes CIN cervical intraepithelial neoplasia CKC cold knife conisation CoCanCPG coordination of cancer clinical practice guidelines COMPAQ-HPST coordination pour la mesure de la performance et l’amélioration de la qualité, hôpital, patient, sécurité, territoire CR complete response CRS conventional radical surgery CS cesarean section CT computed tomography CTV-THR high-risk clinical target volume CTV-TIR intermediate-risk clinical target volume CYFRA 21-1 cytokeratin fragment 21-1 DFS disease-free survival DOD dead of disease DSS disease-specific survival EBRT external beam radiotherapy EORTC european organization for research and treatment of cancer EORTC-CGC european organization for research and treatment of cancer-gynecological cancer group EQD2 equi-effective dose to 2 Gy ESGO european society of gynaecological oncology ESMO european society of medical oncology ESP european society of pathology ESTRO european society for radiotherapy and oncology FACT- $.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "\\mathrm { C x }$ functional assessment of cancer therapy-cervix FEM fixed-effects method <html><body><table><tr><td></td><td></td></tr><tr><td>FIGO fédération internationale de gynecologie et d'obstétrique</td><td>KCE centre fédéral d'expertise des soins de santé</td></tr><tr><td>FSFI female sexual functioning index</td><td>LACC locally advanced cervical cancer</td></tr><tr><td>FSS fertility sparing surgery</td><td>LARVH laparoscopic-assisted radical vaginal hysterectomy</td></tr><tr><td>FST fertility sparing treatment</td><td>LDR low-dose rate</td></tr><tr><td>GCC glassy cell carcinoma</td><td>LEEP loop electrosurgical excision procedure</td></tr><tr><td>GCIG gynecologic cancer intergroup</td><td>LH laparoscopic hysterectomy</td></tr><tr><td>GEC-ESTRO groupe européen de curiethérapie - european society for radiotherapy and oncology</td><td>LLETZ large loop excision of the transformation zone</td></tr><tr><td>GIN guidelines international network</td><td>LN lymph node</td></tr><tr><td>GTV-Tres residual gross tumor volume</td><td>LN+ positive lymph nodes</td></tr><tr><td>HAS haute autorité de santé</td><td>LND lymph node dissection</td></tr><tr><td>HDR high-dose rate</td><td>LVSI lymphovascular space involvement</td></tr><tr><td>H&E haematoxylin and eosin</td><td>M-H mantel- haenszel</td></tr><tr><td>HPV human papillomarivus</td><td>MD mean difference</td></tr><tr><td> HR hazard ratio</td><td> MRI magnetic resonance imaging</td></tr><tr><td>hsCRP high sensitivity C-reactive protein</td><td>MSAC medical services advisory committee</td></tr><tr><td> IAP immunosuppressive acidic protein</td><td> NA not available</td></tr><tr><td>ICG indocyanine green</td><td>NAB-paclitaxel nano-particule albumin bound paclitaxel</td></tr><tr><td>IES impact of events scale</td><td> NACT neoadjuvant chemotherapy</td></tr><tr><td>IGABT image guided adaptive brachytherapy</td><td>NCCN national comprehensive cancer network</td></tr><tr><td>IGRT image guided radiotherapy</td><td>NED no evidence of disease</td></tr><tr><td>IHC immunohistochemistry</td><td>NHMRC national health and medical research</td></tr><tr><td>IL-6 interleukin 6 IMRT intensity modulated radiotherapy</td><td>council</td></tr><tr><td>INAHTA international network of agencies for</td><td>NHS national health service NICE national institute for health and care</td></tr><tr><td>health technology assessment INCa institut national du cancer</td><td>excellence NICU neonatal intensive care unit</td></tr><tr><td>INESSS institut national d'excellence en sante et</td><td>nr not reported</td></tr><tr><td>en services sociaux IORT intraoperative radiation therapy</td><td>NSRS nerve-sparing radical surgery</td></tr><tr><td> IV inverse variance</td><td>NZGG new zealand guidelines group</td></tr></table></body></html> <html><body><table><tr><td>OH open hysterectomy</td><td>RR relative risk</td></tr><tr><td>OR odd ratio</td><td>RT radiation therapy</td></tr><tr><td>OS overall survival</td><td>SCC squamous cell carcinoma</td></tr><tr><td>OT ovarian transposition</td><td>SCC-Ag squamous cell carcinoma antigen</td></tr><tr><td>PALN para-aortic lymph node</td><td>SD stable disease</td></tr><tr><td>PALND para-aortic lymph node dissection</td><td>SDM standard differences in means</td></tr><tr><td>PDR pulsed-dose rate</td><td>SEER surveillance, epidemiology, and end results</td></tr><tr><td>PET positron emission tomography</td><td>SH simple hysterectomy</td></tr><tr><td>PET-CT positron emission tomography-</td><td> SIGN scottish intercollegiate guidelines network</td></tr><tr><td>computed tomography</td><td>SLN sentinel lymph node</td></tr><tr><td>PFS progression-free survival</td><td>SMC small cell carcinoma</td></tr><tr><td>PLN pelvic lymph node</td><td>SN sentinel node</td></tr><tr><td>PLND pelvic lymph node dissection</td><td> TATI tumour-associated trypsin inhibitor</td></tr><tr><td>pPROM preterm spontaneous rupture of membranes</td><td>TNF-α tumour necrosis factor alpha</td></tr><tr><td>PR partial response</td><td>TPA tissue polypeptide antigen</td></tr><tr><td>PROM premature rupture of membranes</td><td>US ultrasound</td></tr><tr><td>PTL preterm labour</td><td>VALRH vaginal-assisted laparoscopic radical</td></tr><tr><td>RCT randomized controlled trial</td><td>hysterectomy</td></tr><tr><td>REM random-effects method</td><td>VEGF vascular endothelial growth factor</td></tr><tr><td>RFS relapse-free survival</td><td>WG weeks gestation</td></tr><tr><td>RH radical hysterectomy</td><td>WMD weighted mean difference</td></tr></table></body></html> 18 References 1.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Ferlay, J., et al.Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012.Eur J Cancer 49, 1374-1403 (2013).2.International Agency for Research on Cancer, EUCAN Cancer Factsheets: Cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "http://eco.iarc.fr/eucan/CancerOne.aspx?Cancer=25&Gender=2.3.Sant, M., et al.Survival of women with cancers of breast and genital organs in Europe 1999-2007: Results of the EUROCARE-5 study.Eur $J$ Cancer 51, 2191-2205 (2015).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "4.UICC.Union for International Cancer Control.8th edition of the UICC TNM classification of malignant tumours.(2016).5.Pecorelli, S.Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynaecol Obstet 105, 103-104 (2009).6.Pecorelli, S., Zigliani, L.& Odicino, F.Revised FIGO staging for carcinoma of the cervix.Int $J$ Gynaecol Obstet 105, 107-108 (2009).7.Pecorelli, S.Corrigendum to \"Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynaecol Obstet 108, 176 (2010).8.Querleu, D., Cibula, D.& Abu-Rustum, N.R.2017 Update on the QuerleuMorrow Classification of Radical Hysterectomy.Ann Surg Oncol (2017).9.ICRU.International Commission on Radiation Units and Measurements “Prescribing, recording, and reporting photon-beam intensity-modulated Radiation therapy (IMRT),” ICRU Report 83.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J.ICRU 10(2010).10.Haie-Meder, C., et al.Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Radiother Oncol 74, 235- 245 (2005).11.Potter, R., et al.Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Radiother Oncol 78, 67-77 (2006).12.ICRU.International Commission on Radiation Units and Measurements “Prescribing, recording, and reporting brachytherapy for cancer of the cervix, ICRU Report 89.J.ICRU 13(2013).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "13.Potter, R., et al.The EMBRACE II study: The outcome and prospect of two decades of evolution within the GECESTRO GYN working group and the EMBRACE studies.Clin Transl Radiat Oncol 9, 48-60 (2018).14.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Park, J.Y., et al.Laparoscopic versus open radical hysterectomy in patients with stage IB2 and IIA2 cervical cancer.J Surg Oncol 108, 63-69 (2013).15.Baalbergen, A., Ewing-Graham, P.C., Hop, W.C., Struijk, P.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "& Helmerhorst, T.J.Prognostic factors in adenocarcinoma of the uterine cervix.Gynecol Oncol 92, 262-267 (2004).16.Alfsen, G.C., Kristensen, G.B., Skovlund, E., Pettersen, E.O.& Abeler, V.M.Histologic subtype has minor importance for overall survival in patients with adenocarcinoma of the uterine cervix: a population-based study of prognostic factors in 505 patients with nonsquamous cell carcinomas of the cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cancer 92, 2471-2483 (2001).17.Grisaru, D., et al.Does histology influence prognosis in patients with early-stage cervical carcinoma?Cancer 92, 2999-3004 (2001).18.Ishikawa, H., Nakanishi, T., Inoue, T.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "& Kuzuya, K.Prognostic factors of adenocarcinoma of the uterine cervix.Gynecol Oncol 73, 42-46 (1999).19.Bai, H., et al.The potential for less radical surgery in women with stage IA2-IB1 cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int $J$ Gynaecol Obstet 130, 235-240 (2015).20.Stehman, F.B., et al.Carcinoma of the cervix treated with radiation therapy.I.A multi-variate analysis of prognostic variables in the Gynecologic Oncology Group.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cancer 67, 2776-2785 (1991).21.Leblanc, E., et al.Therapeutic value of pretherapeutic extraperitoneal laparoscopic staging of locally advanced cervical carcinoma.Gynecol Oncol 105, 304-311 (2007).22.Burghardt, E.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", Baltzer, J., Tulusan, A.H.& Haas, J.Results of surgical treatment of 1028 cervical cancers studied with volumetry.Cancer 70, 648-655 (1992).23.Alvarez, R.D., et al.Identification of prognostic factors and risk groups in patients found to have nodal metastasis at the time of radical hysterectomy for early-stage squamous carcinoma of the cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 35, 130-135 (1989).24.Kodama, J., et al.Prognostic factors in node-positive patients with stage IB-IIB cervical cancer treated by radical hysterectomy and pelvic lymphadenectomy.Int J Gynaecol Obstet 93, 130-135 (2006).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "25.Kamura, T., et al.Multivariate analysis of the histopathologic prognostic factors of cervical cancer in patients undergoing radical hysterectomy.Cancer 69, 181- 186 (1992).26.van de Lande, J., von Mensdorff-Pouilly, S.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", Lettinga, R.G., Piek, J.M.& Verheijen, R.H.Open versus laparoscopic pelvic lymph node dissection in early stage cervical cancer: no difference in surgical or disease outcome.Int J Gynecol Cancer 22, 107-114 (2012).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "27.Ditto, A., et al.The role of lymphadenectomy in cervical cancer patients: the significance of the number and the status of lymph nodes removed in 526 cases treated in a single institution.Ann Surg Oncol 20, 3948- 3954 (2013).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "28.Grigsby, P.W., et al.Lack of effect of tumor size on the prognosis of carcinoma of the uterine cervix Stage IB and IIA treated with preoperative irradiation and surgery.Int $J$ Radiat Oncol Biol Phys 45, 645-651 (1999).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "29.Graflund, M., Sorbe, B., Hussein, A., Bryne, M.& Karlsson, M.The prognostic value of histopathologic grading parameters and microvessel density in patients with early squamous cell carcinoma of the uterine cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int $J$ Gynecol Cancer 12, 32-41 (2002).30.Ho, C.M., et al.Multivariate analysis of the prognostic factors and outcomes in early cervical cancer patients undergoing radical hysterectomy.Gynecol Oncol 93, 458-464 (2004).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "31.Hopkins, M.P.& Morley, G.W.Prognostic factors in advanced stage squamous cell cancer of the cervix.Cancer 72, 2389- 2393 (1993).32.Horn, L.C., Hentschel, B., Fischer, U., Peter, D.& Bilek, K.Detection of micrometastases in pelvic lymph nodes in patients with carcinoma of the cervix uteri using step sectioning: Frequency, topographic distribution and prognostic impact.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 111, 276-281 (2008).33.Horn, L.C., Hentschel, B., Galle, D.& Bilek, K.Extracapsular extension of pelvic lymph node metastases is of prognostic value in carcinoma of the cervix uteri.Gynecol Oncol 108, 63-67 (2008).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "34.Horn, L.C., Bilek, K., Fischer, U., Einenkel, J.& Hentschel, B.A cut-off value of $2 ~ \\mathrm { c m }$ in tumor size is of prognostic value in surgically treated FIGO stage IB cervical cancer.Gynecol Oncol 134, 42-46 (2014).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "35.Hosaka, M., et al.Survival and prognosticators of node-positive cervical cancer patients treated with radical hysterectomy and systematic lymphadenectomy.Int J Clin Oncol 16, 33-38 (2011).36.Kato, T.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Multivariate prognostic analysis of adenocarcinoma of the uterine cervix treated with radical hysterectomy and systematic lymphadenectomy.J Gynecol Oncol 24, 222-228 (2013).37.Koh, H.K., et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Outcome analysis of salvage radiotherapy for occult cervical cancer found after simple hysterectomy.Jpn J Clin Oncol 43, 1226-1232 (2013).38.Landoni, F., Maneo, A., Zapardiel, I., Zanagnolo, V.& Mangioni, C.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Class I versus class III radical hysterectomy in stage IB1-IIA cervical cancer.A prospective randomized study.Eur $J$ Surg Oncol 38, 203-209 (2012).39.Li, S., et al.Development and validation of a surgical-pathologic staging and scoring system for cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Oncotarget 7, 21054-21063 (2016).40.Liu, M.T., et al.Prognostic factors affecting the outcome of early cervical cancer treated with radical hysterectomy and post-operative adjuvant therapy.Eur J Cancer Care (Engl) 17, 174-181 (2008).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "41.Mabuchi, S., et al.Impact of histological subtype on survival of patients with surgically-treated stage IA2-IIB cervical cancer: adenocarcinoma versus squamous cell carcinoma.Gynecol Oncol 127, 114-120 (2012).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "42.Metindir, J.& Bilir Dilek, G.Evaluation of prognostic significance in extracapsular spread of pelvic lymph node metastasis in patients with cervical cancer.Eur J Gynaecol Oncol 29, 476-478 (2008).43.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Park, J.W.& Bae, J.W.Prognostic significance of positive lymph node number in early cervical cancer.Mol Clin Oncol 4, 1052-1056 (2016).44.Sartori, E., et al.Early stage cervical cancer: adjuvant treatment in negative lymph node cases.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 107, S170-174 (2007).45.Song, S., et al.The size of the metastatic lymph node is an independent prognostic factor for the patients with cervical cancer treated by definitive radiotherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Radiother Oncol 108, 168- 173 (2013).46.Spoozak, L., et al.Microinvasive adenocarcinoma of the cervix.Am $J$ Obstet Gynecol 206, 80 e81-86 (2012).47.Takeda, N., et al.Multivariate analysis of histopathologic prognostic factors for invasive cervical cancer treated with radical hysterectomy and systematic retroperitoneal lymphadenectomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Acta Obstet Gynecol Scand 81, 1144-1151 (2002).48.Turan, T., Yildirim, B.A., Tulunay, G., Boran, N.& Kose, M.F.Prognostic effect of different cut-off values ( $2 0 \\mathrm { m m } ,$ $3 0 \\mathrm { m m }$ and $4 0 \\mathrm { m m } )$ for clinical tumor size in FIGO stage IB cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Surg Oncol 19, 106-113 (2010).49.Yan, M., Zhang, Y.N., He, J.H., Sun, J.R.& Sun, X.M.Influence of lymph vascular space invasion on prognosis of patients with early-stage cervical squamous cell carcinoma.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Chin $J$ Cancer 29, 425-430 (2010).50.Yan, X., et al.Twelve-year experience with laparoscopic radical hysterectomy and pelvic lymphadenectomy in cervical cancer.Gynecol Oncol 120, 362-367 (2011).51.Yan, X.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Outcome and prognostic factors of laparoscopic radical hysterectomy and pelvic lymphadenectomy in 148 patients with stage IB1 cervical cancer.Int J Gynecol Cancer 22, 286-290 (2012).52.Obermair, A.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.The influence of vascular space involvement on the prognosis of patients with stage IB cervical carcinoma: correlation of results from hematoxylin and eosin staining with results from immunostaining for factor VIII-related antigen.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cancer 82, 689-696 (1998).53.Matthews, C.M., et al.Stage I cervical adenocarcinoma: prognostic evaluation of surgically treated patients.Gynecol Oncol 49, 19-23 (1993).54.Attanoos, R., et al.Primary adenocarcinoma of the cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A clinicopathologic study of prognostic variables in 55 cases.Int $J$ Gynecol Cancer 5, 179-186 (1995).55.Shingleton, H.M., et al.Is there really a difference in survival of women with squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma of the cervix?",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cancer 76, 1948-1955 (1995).56.Behtash, N., Karimi Zarchi, M.& Deldar, M.Preoperative prognostic factors and effects of adjuvant therapy on outcomes of early stage cervical cancer in Iran.Asian Pac J Cancer Prev 10, 613-618 (2009).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "57.Cibula, D., et al.Prognostic significance of low volume sentinel lymph node disease in early-stage cervical cancer.Gynecol Oncol 124, 496-501 (2012).58.Landoni, F., et al.Is there a role for postoperative treatment in patients with stage Ib2-IIb cervical cancer treated with neo-adjuvant chemotherapy and radical surgery?",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "An Italian multicenter retrospective study.Gynecol Oncol 132, 611-617 (2014).59.Lennox, G.K.& Covens, A.Can sentinel lymph node biopsy replace pelvic lymphadenectomy for early cervical cancer?Gynecol Oncol 144, 16-20 (2017).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "60.Monk, B.J., Tian, C., Rose, P.G.& Lanciano, R.Which clinical/pathologic factors matter in the era of chemoradiation as treatment for locally advanced cervical carcinoma?Analysis of two Gynecologic Oncology Group (GOG) trials.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 105, 427- 433 (2007).61.Perez, C.A., et al.Effect of tumor size on the prognosis of carcinoma of the uterine cervix treated with irradiation alone.Cancer 69, 2796-2806 (1992).62.Twu, N.F.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Prognostic factors and adjuvant therapy on survival in earlystage cervical adenocarcinoma/adenosquamous carcinoma after primary radical surgery: A Taiwanese Gynecologic Oncology Group (TGOG) study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Surg Oncol 25, 229-235 (2016).63.Nakano, T., Arai, T., Morita, S.& Oka, K.Radiation therapy alone for adenocarcinoma of the uterine cervix.Int J Radiat Oncol Biol Phys 32, 1331- 1336 (1995).64.Ayhan, A.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", Al, R.A., Baykal, C., Demirtas, E.& Yuce, K.Prognostic factors in FIGO stage IB cervical cancer without lymph node metastasis and the role of adjuvant radiotherapy after radical hysterectomy.Int J Gynecol Cancer 14, 286-292 (2004).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "65.Silver, D.F., Hempling, R.E., Piver, M.S., Recio, F.O.& Eltabbakh, G.H.Stage I adenocarcinoma of the cervix: does lesion size affect treatment options and prognosis?Am J Clin Oncol 21, 431-435 (1998).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "66.Delgado, G., et al.Prospective surgicalpathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.Gynecol Oncol 38, 352-357 (1990).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "67.Keys, H.M., et al.Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma.N Engl J Med 340, 1154-1161 (1999).68.Keys, H.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "M., et al.Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group.Gynecol Oncol 89, 343- 353 (2003).69.Kim, H.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J., et al.Clinical outcomes of adjuvant radiation therapy and prognostic factors in early stage uterine cervical cancer.Radiat Oncol J 33, 126- 133 (2015).70.Diaz, J.P., et al.Oncologic outcome of fertility-sparing radical trachelectomy versus radical hysterectomy for stage IB1 cervical carcinoma.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 111, 255-260 (2008).71.Pol, F.J., et al.Satellite lymphovascular space invasion: An independent risk factor in early stage cervical cancer.Gynecol Oncol 138, 579-584 (2015).72.Rutledge, T.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "L., et al.A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy.Is size the real difference?Gynecol Oncol 95, 70-76 (2004).73.Singh, P., Tripcony, L.& Nicklin, J.Analysis of prognostic variables, development of predictive models, and stratification of risk groups in surgically treated FIGO early-stage (IA-IIA) carcinoma cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int $J$ Gynecol Cancer 22, 115-122 (2012).74.Chittithaworn, S., Hanprasertpong, J., Tungsinmunkong, K.& Geater, A.Association between prognostic factors and disease-free survival of cervical cancer stage IB1 patients undergoing radical hysterectomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Asian Pac J Cancer Prev 8, 530-534 (2007).75.Martin-Loeches, M., Orti, R.M., Cazorla, E., Asins, E.& Llixiona, J.Multivariate analysis of the morphometric characteristics of tumours as prognostic factors in the survival of patients with uterine cervix cancer treated with radical surgery.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Eur $J$ Obstet Gynecol Reprod Biol 105, 170-176 (2002).76.Park, J.Y., et al.Long-term outcomes after fertility-sparing laparoscopic radical trachelectomy in young women with early-stage cervical cancer: an Asan Gynecologic Cancer Group (AGCG) study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Surg Oncol 110, 252-257 (2014).77.Cai, H.B., Chen, H.Z.& Yin, H.H.Randomized study of preoperative chemotherapy versus primary surgery for stage IB cervical cancer.J Obstet Gynaecol Res 32, 315-323 (2006).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "78.Jeon, H.W., Suh, D.H., Kim, K., No, J.H.& Kim, Y.B.Lymphadenectomy alone is a feasible option in managing incidentally-detected early-stage cervical cancer after simple hysterectomy without intermediate-risk factors: An application of the concept of less radical surgery.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Anticancer Res 33, 5135-5141 (2013).79.Chen, R.J., et al.Influence of histologic type and age on survival rates for invasive cervical carcinoma in Taiwan.Gynecol Oncol 73, 184-190 (1999).80.Wakayama, A.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Concurrent chemoradiotherapy for non-bulky stage IB/II cervical cancer without pelvic node enlargement.Anticancer Res 33, 5123-5126 (2013).81.Vinh-Hung, V., et al.Prognostic value of histopathology and trends in cervical cancer: a SEER population study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "BMC Cancer 7, 164 (2007).82.Qian, Q., et al.Analysis of treatment modalities and prognosis on microinvasive cervical cancer: a 10-year cohort study in China.J Gynecol Oncol 25, 293-300 (2014).83.Sehouli, J.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (SRC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup Study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Ann Oncol 23, 2259- 2264 (2012).84.Landoni, F., et al.Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer.Lancet 350, 535-540 (1997).85.Bansal, N., et al.Primary therapy for early-stage cervical cancer: radical hysterectomy vs radiation.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am J Obstet Gynecol 201, 485 e481-489 (2009).86.Chargui, R., et al.Prognostic factors and clinicopathologic characteristics of invasive adenocarcinoma of the uterine cervix.Am J Obstet Gynecol 194, 43-48 (2006).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "87.Chen, R.J., et al.Prognostic factors of primary adenocarcinoma of the uterine cervix.Gynecol Oncol 69, 157-164 (1998).88.Li, C., Liu, W.& Cheng, Y.Prognostic significance of metastatic lymph node ratio in squamous cell carcinoma of the cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Onco Targets Ther 9, 3791-3797 (2016).89.Fyles, A.W., et al.Prognostic factors in patients with cervix cancer treated by radiation therapy: results of a multiple regression analysis.Radiother Oncol 35, 107-117 (1995).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "90.Metindir, J.& Bilir, G.Prognostic factors affecting disease-free survival in earlystage cervical cancer patients undergoing radical hysterectomy and pelvic-paraaortic lymphadenectomy.Eur J Gynaecol Oncol 28, 28-32 (2007).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "91.Landoni, F., et al.Class II versus class III radical hysterectomy in stage IB-IIA cervical cancer: a prospective randomized study.Gynecol Oncol 80, 3- 12 (2001).92.Eralp, Y., et al.Prognostic factors and survival in patients with metastatic or recurrent carcinoma of the uterine cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 13, 497-504 (2003).93.Park, J.Y., et al.The role of pelvic exenteration and reconstruction for treatment of advanced or recurrent gynecologic malignancies: Analysis of risk factors predicting recurrence and survival.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "$J$ Surg Oncol 96, 560-568 (2007).94.Luvero, D., et al.Patients treated with neoadjuvant chemotherapy $^ +$ radical surgery $^ +$ adjuvant chemotherapy in locally advanced cervical cancer: longterm outcomes, survival and prognostic factors in a single-center 10-year followup.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Med Oncol 33, 110 (2016).95.Buda, A., et al.Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio NeoAdjuvante Portio) Italian Collaborative Study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Clin Oncol 23, 4137-4145 (2005).96.Horn, L.C., Fischer, U., Raptis, G., Bilek, K.& Hentschel, B.Tumor size is of prognostic value in surgically treated FIGO stage II cervical cancer.Gynecol Oncol 107, 310-315 (2007).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "97.Rose, P.G., et al.Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized Trials of Chemoradiotherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "$J$ Clin Oncol 33, 2136-2142 (2015).98.Chen, C.C., Wang, L., Lin, J.C.& Jan, J.S.The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Formos Med Assoc 114, 231-237 (2015).99.Li, J., et al.Pretreatment serum lactate dehydrogenase is an independent prognostic factor for patients receiving neoadjuvant chemotherapy for locally advanced cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cancer Med 5, 1863-1872 (2016).100.Kawaguchi, R., Furukawa, N., Kobayashi, H.& Asakawa, I.Posttreatment cut-off levels of squamous cell carcinoma antigen as a prognostic factor in patients with locally advanced cervical cancer treated with radiotherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "$J$ Gynecol Oncol 24, 313-320 (2013).101.Kyung, M.S., et al.Tumor size and lymph node status determined by imaging are reliable factors for predicting advanced cervical cancer prognosis.Oncol Lett 9, 2218-2224 (2015).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "102.Touboul, C., et al.Prognostic factors and morbidities after completion surgery in patients undergoing initial chemoradiation therapy for locally advanced cervical cancer.Oncologist 15, 405-415 (2010).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "103.Klimek, M., et al.Clinico-morphological parameters affecting survival of patients with advanced cervical cancer.Pol $J$ Pathol 62, 250-256 (2011).104.Nugent, E.K., et al.Chemoradiation in locally advanced cervical carcinoma: an analysis of cisplatin dosing and other clinical prognostic factors.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 116, 438-441 (2010).105.Narayan, K., Fisher, R.J., Bernshaw, D., Shakher, R.& Hicks, R.J.Patterns of failure and prognostic factor analyses in locally advanced cervical cancer patients staged by positron emission tomography and treated with curative intent.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 19, 912-918 (2009).106.Khalil, J., El Kacemi, H., Afif, M., Kebdani, T.& Benjaafar, N.Five years' experience treating locally advanced cervical cancer with concurrent chemoradiotherapy: results from a single institution.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Arch Gynecol Obstet 292, 1091-1099 (2015).107.Showalter, T.N., Camacho, F., Cantrell, L.A.& Anderson, R.T.Determinants of Quality Care and Mortality for Patients With Locally Advanced Cervical Cancer in Virginia.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Medicine (Baltimore) 95, e2913 (2016).108.Sun, L., et al.Surgical morbidity and oncologic results after concurrent chemoradiation therapy for advanced cervical cancer.Int $J$ Gynaecol Obstet 125, 111-115 (2014).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "109.Ferrandina, G., et al.Completion surgery after concomitant chemoradiation in locally advanced cervical cancer: a comprehensive analysis of pattern of postoperative complications.Ann Surg Oncol 21, 1692-1699 (2014).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "110.Christie, D.R., Bull, C.A., Gebski, V.& Langlands, A.O.Concurrent 5- fluorouracil, mitomycin C and irradiation in locally advanced cervix cancer.Radiother Oncol 37, 181-189 (1995).111.Yokoi, E., et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Impact of histological subtype on survival in patients with locally advanced cervical cancer that were treated with definitive radiotherapy: adenocarcinoma/adenosquamous carcinoma versus squamous cell carcinoma.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "$J$ Gynecol Oncol 28, e19 (2017).112.Benito, V., et al.Should the Presence of Metastatic Para-Aortic Lymph Nodes in Locally Advanced Cervical Cancer Lead to More Aggressive Treatment Strategies?J Minim Invasive Gynecol 24, 609-616 (2017).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "113.Chereau, E., et al.The role of completion surgery after concurrent radiochemotherapy in locally advanced stages IB2-IIB cervical cancer.Anticancer Res 33, 1661-1666 (2013).114.Lee, H.J., et al.Long-term outcomes of concomitant chemoradiotherapy incorporating high-dose-rate brachytherapy to treat locally advanced cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Tumori 98, 615-621 (2012).115.Park, J.H., et al.Concurrent chemoradiotherapy or radiotherapy alone for locally advanced cervical cancer in elderly women.Tumori 96, 959-965 (2010).116.Leguevaque, P., et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Completion surgery or not after concurrent chemoradiotherapy for locally advanced cervical cancer?Eur $J$ Obstet Gynecol Reprod Biol 155, 188-192 (2011).117.Kamran, S.C., et al.Comparison of outcomes for MR-guided versus CTguided high-dose-rate interstitial brachytherapy in women with locally advanced carcinoma of the cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 145, 284-290 (2017).118.Endo, D., et al.Prognostic factors for patients with cervical cancer treated with concurrent chemoradiotherapy: a retrospective analysis in a Japanese cohort.J Gynecol Oncol 26, 12-18 (2015).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "119.Thomeer, M.G., et al.Clinical examination versus magnetic resonance imaging in the pretreatment staging of cervical carcinoma: systematic review and meta-analysis.Eur Radiol 23, 2005- 2018 (2013).120.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Qin, Y., et al.Discrepancies between clinical staging and pathological findings of operable cervical carcinoma with stage IB-IIB: a retrospective analysis of 818 patients.Aust N Z J Obstet Gynaecol 49, 542-544 (2009).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "121.Hricak, H., et al.Role of imaging in pretreatment evaluation of early invasive cervical cancer: results of the intergroup study American College of Radiology Imaging Network 6651- Gynecologic Oncology Group 183.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Clin Oncol 23, 9329-9337 (2005).122.Hricak, H., et al.Invasive cervical carcinoma: comparison of MR imaging and surgical findings.Radiology 166, 623-631 (1988).123.Yang, W.T., et al.Transrectal ultrasound in the evaluation of cervical carcinoma and comparison with spiral computed tomography and magnetic resonance imaging.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Br J Radiol 69, 610-616 (1996).124.Averette, H.E., Dudan, R.C.& Ford, J.H., Jr.Exploratory celiotomy for surgical staging of cervical cancer.Am J Obstet Gynecol 113, 1090-1096 (1972).125.Sudarsanam, A.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Influence of exploratory celiotomy on the management of carcinoma of the cervix.A preliminary report.Cancer 41, 1049- 1053 (1978).126.Maggino, T., et al.Clinical staging versus operative staging in cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Clin Exp Obstet Gynecol 10, 201-204 (1983).127.Togashi, K., et al.Uterine cervical cancer: assessment with high-field MR imaging.Radiology 160, 431-435 (1986).128.Waggenspack, G.A., Amparo, E.G.& Hannigan, E.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "V.MR imaging of uterine cervical carcinoma.J Comput Assist Tomogr 12, 409-414 (1988).129.Soeters, R.P., Beningfield, S.J., Dehaeck, K., Levin, W.& Bloch, B.The value of magnetic resonance imaging in patients with carcinoma of the cervix (a pilot study).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Eur J Surg Oncol 17, 119-124 (1991).130.Preidler, K.W., Tamussino, K., Szolar, D.M., Ranner, G.& Ebner, F.Staging of cervical carcinomas.Comparison of body-coil magnetic resonance imaging and endorectal surface coil magnetic resonance imaging with histopathologic correlation.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Invest Radiol 31, 458-462 (1996).131.Kim, M.J., Chung, J.J., Lee, Y.H., Lee, J.T.& Yoo, H.S.Comparison of the use of the transrectal surface coil and the pelvic phased-array coil in MR imaging for preoperative evaluation of uterine cervical carcinoma.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "AJR Am J Roentgenol 168, 1215-1221 (1997).132.Van Vierzen, P.B., Massuger, L.F., Ruys, S.H.& Barentsz, J.O.Fast dynamic contrast enhanced MR imaging of cervical carcinoma.Clin Radiol 53, 183- 192 (1998).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "133.Postema, S., et al.Effect of MRI on therapeutic decisions in invasive cervical carcinoma.Direct comparison with the pelvic examination as a preperative test.Gynecol Oncol 79, 485- 489 (2000).134.Hansen, M.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A., Pedersen, P.H., Andreasson, B., Bjerregaard, B.& Thomsen, H.S.Staging uterine cervical carcinoma with low-field MR imaging.Acta Radiol 41, 647-652 (2000).135.Wang, L.J., Wong, Y.C., Chen, C.J., Huang, K.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "G.& Hsueh, S.Cervical carcinoma: MR imaging with integrated endorectal/phased-array coils: a pilot study.Eur Radiol 11, 1822-1827 (2001).136.Choi, S.H., Kim, S.H., Choi, H.J., Park, B.K.& Lee, H.J.Preoperative magnetic resonance imaging staging of uterine cervical carcinoma: results of prospective study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Comput Assist Tomogr 28, 620-627 (2004).137.Oberoi, R., Vohra, S., Jain, P.& Jena, A.Staging of carcinoma cervix with MRI and histopathological correlation in 105 cases.Asian Oceanian J Radiol 7, 88-94 (2002).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "138.Yu, K.K., Hricak, H., Subak, L.L., Zaloudek, C.J.& Powell, C.B.Preoperative staging of cervical carcinoma: phased array coil fast spinecho versus body coil spin-echo T2- weighted MR imaging.AJR Am J Roentgenol 171, 707-711 (1998).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "139.Ng, H.T., Chen, S.L., Wang, J.C.& Sheu, M.H.¨Preoperative examination with CT, MRI and comparison of both to histopathologic findings in cervical carcinoma.CME J Gynecol Oncol 3, 256- 257 (1998).140.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Hawighorst, H., et al.Staging of invasive cervical carcinoma and of pelvic lymph nodes by high resolution MRI with a phased-array coil in comparison with pathological findings.J Comput Assist Tomogr 22, 75-81 (1998).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "141.Subak, L.L., Hricak, H., Powell, C.B., Azizi, L.& Stern, J.L.Cervical carcinoma: computed tomography and magnetic resonance imaging for preoperative staging.Obstet Gynecol 86, 43-50 (1995).142.Kim, S.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "H., et al.Preoperative staging of uterine cervical carcinoma: comparison of CT and MRI in 99 patients.J Comput Assist Tomogr 17, 633-640 (1993).143.Togashi, K., et al.Carcinoma of the cervix: staging with MR imaging.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Radiology 171, 245-251 (1989).144.Dhoot, N.M., et al.Evaluation of carcinoma cervix using magnetic resonance imaging: correlation with clinical FIGO staging and impact on management.J Med Imaging Radiat Oncol 56, 58-65 (2012).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "145.Chung, H.H., et al.Can preoperative MRI accurately evaluate nodal and parametrial invasion in early stage cervical cancer?Jpn J Clin Oncol 37, 370- 375 (2007).146.Kim, S.H., et al.Uterine cervical carcinoma: comparison of CT and MR findings.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Radiology 175, 45-51 (1990).147.Hori, M., et al.Uterine tumors: comparison of 3D versus 2D T2- weighted turbo spin-echo MR imaging at $3 .0 \\ \\mathrm { T } \\cdot$ -initial experience.Radiology 258, 154-163 (2011).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "148.Hori, M., et al.Uterine cervical carcinoma: preoperative staging with 3.0-T MR imaging--comparison with 1.5- T MR imaging.Radiology 251, 96-104 (2009).149.Fischerova, D., et al.Transrectal ultrasound and magnetic resonance imaging in staging of early cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 18, 766-772 (2008).150.deSouza, N.M., Dina, R., McIndoe, G.A.& Soutter, W.P.Cervical cancer: value of an endovaginal coil magnetic resonance imaging technique in detecting small volume disease and assessing parametrial extension.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 102, 80-85 (2006).151.Sheu, M.H., Chang, C.Y., Wang, J.H.& Yen, M.S.Preoperative staging of cervical carcinoma with MR imaging: a reappraisal of diagnostic accuracy and pitfalls.Eur Radiol 11, 1828-1833 (2001).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "152.Shiraiwa, M., et al.Cervical carcinoma: efficacy of thin-section oblique axial T2- weighted images for evaluating parametrial invasion.Abdom Imaging 24, 514-519 (1999).153.Scheidler, J., Heuck, A.F.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", Steinborn, M., Kimmig, R.& Reiser, M.F.Parametrial invasion in cervical carcinoma: evaluation of detection at MR imaging with fat suppression.Radiology 206, 125-129 (1998).154.Hawighorst, H., et al.Cervical carcinoma: comparison of standard and pharmacokinetic MR imaging.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Radiology 201, 531-539 (1996).155.Kaji, Y., Sugimura, K., Kitao, M.& Ishida, T.Histopathology of uterine cervical carcinoma: diagnostic comparison of endorectal surface coil and standard body coil MRI.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Comput Assist Tomogr 18, 785-792 (1994).156.Lien, H.H., et al.Clinical stage I carcinoma of the cervix.Value of MR imaging in determining invasion into the parametrium.Acta Radiol 34, 130- 132 (1993).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "157.Sironi, S., Belloni, C., Taccagni, G.L.& DelMaschio, A.Carcinoma of the cervix: value of MR imaging in detecting parametrial involvement.AJR Am J Roentgenol 156, 753-756 (1991).158.Greco, A., et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Staging of carcinoma of the uterine cervix: MRI-surgical correlation.Clin Radiol 40, 401-405 (1989).159.Janus, C.L., et al.Staging of cervical carcinoma: accuracy of magnetic resonance imaging and computed tomography.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Clin Imaging 13, 114-116 (1989).160.Javitt, M.C., Stein, H.L.& Lovecchio, J.L.MRI in staging of endometrial and cervical carcinoma.Magn Reson Imaging 5, 83-92 (1987).161.Bourgioti, C., et al.Incremental prognostic value of MRI in the staging of early cervical cancer: a prospective study and review of the literature.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Clin Imaging 40, 72-78 (2016).162.Pakkal, M.V., Rudralingam, V., McCluggage, W.G.& Kelly, B.E.MR staging in carcinoma of the endometrium and carcinoma of the cervix.Ulster Med J 73, 20-24 (2004).163.Shirazi, A.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "S., et al.Diagnostic accuracy of magnetic resonance imaging versus clinical staging in cervical cancer.Asian Pac J Cancer Prev 15, 5729-5732 (2014).164.Shweel, M.A., Abdel-Gawad, E.A., Abdelghany, H.S.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", Abdel-Rahman, A.M.& Ibrahim, E.M.Uterine cervical malignancy: diagnostic accuracy of MRI with histopathologic correlation.J Clin Imaging Sci 2, 42 (2012).165.Manfredi, R., et al.Localized cervical cancer (stage <IIB): accuracy of MR imaging in planning less extensive surgery.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Radiol Med 114, 960-975 (2009).166.Hancke, K., Heilmann, V., Straka, P., Kreienberg, R.& Kurzeder, C.Pretreatment staging of cervical cancer: is imaging better than palpation?: Role of CT and MRI in preoperative staging of cervical cancer: single institution results for 255 patients.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Ann Surg Oncol 15, 2856-2861 (2008).167.Testa, A.C., et al.Transvaginal ultrasonography and magnetic resonance imaging for assessment of presence, size and extent of invasive cervical cancer.Ultrasound Obstet Gynecol 34, 335-344 (2009).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "168.Moloney, F., Ryan, D., Twomey, M., Hewitt, M.& Barry, J.Comparison of MRI and high-resolution transvaginal sonography for the local staging of cervical cancer.J Clin Ultrasound 44, 78- 84 (2016).169.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Byun, J.M., et al.Three-dimensional transvaginal ultrasonography for locally advanced cervical cancer.Int J Gynecol Cancer 23, 1459-1464 (2013).170.Epstein, E., et al.Early-stage cervical cancer: tumor delineation by magnetic resonance imaging and ultrasound - a European multicenter trial.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 128, 449-453 (2013).171.Prasad, T.V., Thulkar, S., Hari, S., Sharma, D.N.& Kumar, S.Role of computed tomography (CT) scan in staging of cervical carcinoma.Indian $J$ Med Res 139, 714-719 (2014).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "172.Grueneisen, J., et al.Integrated PET/MRI for whole-body staging of patients with primary cervical cancer: preliminary results.Eur J Nucl Med Mol Imaging 42, 1814-1824 (2015).173.Kitajima, K., et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Fusion of PET and MRI for staging of uterine cervical cancer: comparison with contrast-enhanced (18)F-FDG PET/CT and pelvic MRI.Clin Imaging 38, 464-469 (2014).174.Yang, Z., et al.(18)F-FDG PET/CT can correct the clinical stages and predict pathological parameters before operation in cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Eur J Radiol 85, 877-884 (2016).175.de Boer, P., et al.Role of MRI in detecting involvement of the uterine internal os in uterine cervical cancer: systematic review of diagnostic test accuracy.Eur $J$ Radiol 82, e422-428 (2013).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "176.Peppercorn, P.D., et al.Role of MR imaging in the selection of patients with early cervical carcinoma for fertilitypreserving surgery: initial experience.Radiology 212, 395-399 (1999).177.Mitchell, D.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "G., et al.Early invasive cervical cancer: tumor delineation by magnetic resonance imaging, computed tomography, and clinical examination, verified by pathologic results, in the ACRIN 6651/GOG 183 Intergroup Study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Clin Oncol 24, 5687-5694 (2006).178.Sahdev, A., Sohaib, S.A., Wenaden, A.E., Shepherd, J.H.& Reznek, R.H.The performance of magnetic resonance imaging in early cervical carcinoma: a long-term experience.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 17, 629-636 (2007).179.Bipat, S., van den Berg, R.A., van der Velden, J., Stoker, J.& Spijkerboer, A.M.The role of magnetic resonance imaging in determining the proximal extension of early stage cervical cancer to the internal os.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Eur J Radiol 78, 60-64 (2011).180.Choi, H.J., Ju, W., Myung, S.K.& Kim, Y.Diagnostic performance of computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with cervical cancer: metaanalysis.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cancer Sci 101, 1471-1479 (2010).181.Bellomi, M., et al.Accuracy of computed tomography and magnetic resonance imaging in the detection of lymph node involvement in cervix carcinoma.Eur Radiol 15, 2469-2474 (2005).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "182.Hertel, H., et al.Laparoscopic staging compared with imaging techniques in the staging of advanced cervical cancer.Gynecol Oncol 87, 46-51 (2002).183.Vas, W., Wolverson, M., Freel, J., Salimi, Z.& Sundaram, M.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Computed tomography in the pretreatment assessment of carcinoma of the cervix.$J$ Comput Tomogr 9, 359-368 (1985).184.Grumbine, F.C., Rosenshein, N.B., Zerhouni, E.A.& Siegelman, S.S.Abdominopelvic computed tomography in the preoperative evaluation of early cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 12, 286- 290 (1981).185.Walsh, J.W.& Goplerud, D.R.Prospective comparison between clinical and CT staging in primary cervical carcinoma.AJR Am J Roentgenol 137, 997-1003 (1981).186.Brenner, D.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "E., Whitley, N.O., Prempree, T.& Villasanta, U.An evaluation of the computed tomographic scanner for the staging of carcinoma of the cervix.Cancer 50, 2323-2328 (1982).187.Villasanta, U., Whitley, N.O.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", Haney, P.J.& Brenner, D.Computed tomography in invasive carcinoma of the cervix: an appraisal.Obstet Gynecol 62, 218-224 (1983).188.van Engelshoven, J.M., Versteege, C.W., Ruys, J.H., de Haan, J.& Sanches, H.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Computed tomography in staging untreated patients with cervical cancer.Gynecol Obstet Invest 18, 289-295 (1984).189.Bandy, L.C., Clarke-Pearson, D.L., Silverman, P.M.& Creasman, W.T.Computed tomography in evaluation of extrapelvic lymphadenopathy in carcinoma of the cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Obstet Gynecol 65, 73-76 (1985).190.Camilien, L., Gordon, D., Fruchter, R.G., Maiman, M.& Boyce, J.G.Predictive value of computerized tomography in the presurgical evaluation of primary carcinoma of the cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 30, 209-215 (1988).191.Matsukuma, K., Tsukamoto, N., Matsuyama, T., Ono, M.& Nakano, H.Preoperative CT study of lymph nodes in cervical cancer--its correlation with histological findings.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 33, 168-171 (1989).192.Heller, P.B., Maletano, J.H., Bundy, B.N., Barnhill, D.R.& Okagaki, T.Clinicalpathologic study of stage IIB, III, and IVA carcinoma of the cervix: extended diagnostic evaluation for paraaortic node metastasis--a Gynecologic Oncology Group study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 38, 425-430 (1990).193.Chu, K.K., Chang, S.D., Chen, F.P.& Soong, Y.K.Laparoscopic surgical staging in cervical cancer--preliminary experience among Chinese.Gynecol Oncol 64, 49-53 (1997).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "194.Yang, W.T., Lam, W.W., Yu, M.Y., Cheung, T.H.& Metreweli, C.Comparison of dynamic helical CT and dynamic MR imaging in the evaluation of pelvic lymph nodes in cervical carcinoma.AJR Am J Roentgenol 175, 759-766 (2000).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "195.Park, W., et al.The usefulness of MRI and PET imaging for the detection of parametrial involvement and lymph node metastasis in patients with cervical cancer.Jpn J Clin Oncol 35, 260- 264 (2005).196.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Choi, H.J., et al.Comparison of the accuracy of magnetic resonance imaging and positron emission tomography/computed tomography in the presurgical detection of lymph node metastases in patients with uterine cervical carcinoma: a prospective study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cancer 106, 914-922 (2006).197.Choi, H.J., et al.MRI for pretreatment lymph node staging in uterine cervical cancer.AJR Am J Roentgenol 187, W538- 543 (2006).198.Reinhardt, M.J., et al.Metastatic lymph nodes in patients with cervical cancer: detection with MR imaging and FDG PET.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Radiology 218, 776-782 (2001).199.Narayan, K., Hicks, R.J., Jobling, T., Bernshaw, D.& McKenzie, A.F.A comparison of MRI and PET scanning in surgically staged loco-regionally advanced cervical cancer: potential impact on treatment.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 11, 263-271 (2001).200.Ho, C.M., et al.Staging of cervical cancer: comparison between magnetic resonance imaging, computed tomography and pelvic examination under anesthesia.J Formos Med Assoc 91, 982-990 (1992).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "201.Hawnaur, J.M., Johnson, R.J., Buckley, C.H., Tindall, V.& Isherwood, I.Staging, volume estimation and assessment of nodal status in carcinoma of the cervix: comparison of magnetic resonance imaging with surgical findings.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Clin Radiol 49, 443-452 (1994).202.Kim, S.H., Kim, S.C., Choi, B.I.& Han, M.C.Uterine cervical carcinoma: evaluation of pelvic lymph node metastasis with MR imaging.Radiology 190, 807-811 (1994).203.Yeh, L.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "S., et al.Detecting para-aortic lymph nodal metastasis by positron emission tomography of 18Ffluorodeoxyglucose in advanced cervical cancer with negative magnetic resonance imaging findings.Oncol Rep 9, 1289-1292 (2002).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "204.Belhocine, T., et al.Contribution of whole-body 18FDG PET imaging in the management of cervical cancer.Gynecol Oncol 87, 90-97 (2002).205.Ma, S.Y., et al.Delayed (18)F-FDG PET for detection of paraaortic lymph node metastases in cervical cancer patients.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Nucl Med 44, 1775-1783 (2003).206.Roh, J.W., et al.Role of positron emission tomography in pretreatment lymph node staging of uterine cervical cancer: a prospective surgicopathologic correlation study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Eur J Cancer 41, 2086- 2092 (2005).207.Wright, J.D., et al.Preoperative lymph node staging of early-stage cervical carcinoma by [18F]-fluoro-2-deoxy-Dglucose-positron emission tomography.Cancer 104, 2484-2491 (2005).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "208.Sironi, S., et al.Lymph node metastasis in patients with clinical early-stage cervical cancer: detection with integrated FDG PET/CT.Radiology 238, 272-279 (2006).209.Loft, A., et al.The diagnostic value of PET/CT scanning in patients with cervical cancer: a prospective study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 106, 29-34 (2007).210.Lin, W.C., et al.Usefulness of (18)Ffluorodeoxyglucose positron emission tomography to detect para-aortic lymph nodal metastasis in advanced cervical cancer with negative computed tomography findings.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 89, 73-76 (2003).211.Zhang, W., et al.The role of magnetic resonance imaging in pretreatment evaluation of early-stage cervical cancer.Int $J$ Gynecol Cancer 24, 1292-1298 (2014).212.Klerkx, W.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "M., et al.The value of 3.0Tesla diffusion-weighted MRI for pelvic nodal staging in patients with early stage cervical cancer.Eur J Cancer 48, 3414- 3421 (2012).213.Kitajima, K., et al.Preoperative nodal staging of uterine cancer: is contrastenhanced PET/CT more accurate than non-enhanced PET/CT or enhanced CT alone?",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Ann Nucl Med 25, 511-519 (2011).214.Signorelli, M., et al.Preoperative staging of cervical cancer: is 18-FDG-PET/CT really effective in patients with early stage disease?Gynecol Oncol 123, 236- 240 (2011).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "215.Grigsby, P.W., Siegel, B.A.& Dehdashti, F.Lymph node staging by positron emission tomography in patients with carcinoma of the cervix.J Clin Oncol 19, 3745-3749 (2001).216.Ospina, M.B., et al.Positron Emission Tomography for Nine Cancers (Bladder, Brain, Cervical, Kidney, Ovarian, Pancreatic, Prostate, Small Cell Lung, Testicular) [Internet].",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "(2008).217.Amit, A., et al.The role of hybrid PET/CT in the evaluation of patients with cervical cancer.Gynecol Oncol 100, 65- 69 (2006).218.Yildirim, Y., et al.Integrated PET/CT for the evaluation of para-aortic nodal metastasis in locally advanced cervical cancer patients with negative conventional CT findings.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 108, 154-159 (2008).219.Bjurberg, M., Kjellen, E., Ohlsson, T., Ridderheim, M.& Brun, E.FDG-PET in cervical cancer: staging, re-staging and follow-up.Acta Obstet Gynecol Scand 86, 1385-1391 (2007).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "220.Chou, H.H., et al.Low value of [18F]- fluoro-2-deoxy-D-glucose positron emission tomography in primary staging of early-stage cervical cancer before radical hysterectomy.J Clin Oncol 24, 123-128 (2006).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "221.Hope, A.J., Saha, P.& Grigsby, P.W.FDGPET in carcinoma of the uterine cervix with endometrial extension.Cancer 106, 196-200 (2006).222.Tran, B.N., Grigsby, P.W., Dehdashti, F., Herzog, T.J.& Siegel, B.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A.Occult supraclavicular lymph node metastasis identified by FDG-PET in patients with carcinoma of the uterine cervix.Gynecol Oncol 90, 572-576 (2003).223.Unger, J.B., Ivy, J.J., Ramaswamy, M.R., Charrier, A.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "& Connor, P.Whole-body [18F]fluoro-2-deoxyglucose positron emission tomography scan staging prior to planned radical hysterectomy and pelvic lymphadenectomy.Int $J$ Gynecol Cancer 15, 1060-1064 (2005).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "224.Yen, T.C., et al.Value of dual-phase 2- fluoro-2-deoxy-d-glucose positron emission tomography in cervical cancer.J Clin Oncol 21, 3651-3658 (2003).225.Lai, C.H., et al.Restaging of recurrent cervical carcinoma with dual-phase [18F]fluoro-2-deoxy-D-glucose positron emission tomography.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cancer 100, 544- 552 (2004).226.Grisaru, D., et al.The diagnostic accuracy of 18F-fluorodeoxyglucose PET/CT in patients with gynecological malignancies.Gynecol Oncol 94, 680- 684 (2004).227.Wong, T.Z., Jones, E.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "L.& Coleman, R.E.Positron emission tomography with 2- deoxy-2-[(18)F]fluoro-D-glucose for evaluating local and distant disease in patients with cervical cancer.Mol Imaging Biol 6, 55-62 (2004).228.Goyal, B.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "K., Singh, H., Kapur, K., Duggal, B.S.& Jacob, M.J.Value of PET-CT in avoiding multimodality therapy in operable cervical cancer.Int J Gynecol Cancer 20, 1041-1045 (2010).229.Chung, H.H., et al.Role of integrated PET-CT in pelvic lymph node staging of cervical cancer before radical hysterectomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Obstet Invest 67, 61-66 (2009).230.Selman, T.J., Mann, C., Zamora, J., Appleyard, T.L.& Khan, K.Diagnostic accuracy of tests for lymph node status in primary cervical cancer: a systematic review and meta-analysis.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "CMAJ 178, 855-862 (2008).231.Echt, M.L., et al.Detection of sentinel lymph nodes with lymphazurin in cervical, uterine, and vulvar malignancies.South Med J 92, 204-208 (1999).232.Dargent, D., Martin, X.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "& Mathevet, P.Laparoscopic assessment of the sentinel lymph node in early stage cervical cancer.Gynecol Oncol 79, 411-415 (2000).233.Kamprath, S., Possover, M.& Schneider, A.Laparoscopic sentinel lymph node detection in patients with cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am J Obstet Gynecol 182, 1648 (2000).234.O'Boyle, J.D., et al.Intraoperative lymphatic mapping in cervix cancer patients undergoing radical hysterectomy: A pilot study.Gynecol Oncol 79, 238-243 (2000).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "235.Lantzsch, T., et al.Sentinel node procedure in Ib cervical cancer: a preliminary series.Br J Cancer 85, 791- 794 (2001).236.Malur, S., Krause, N., Kohler, C.& Schneider, A.Sentinel lymph node detection in patients with cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 80, 254-257 (2001).237.Altgassen, C., Gottschild, D.& Durst, M.Sentinel lymph node detection in women with cervical cancers, a prospective multicentre study, Uters III (AGO).Geburtshilfe Frauenheilkd 62, 358-362 (2002).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "238.Levenback, C., et al.Lymphatic mapping and sentinel node identification in patients with cervix cancer undergoing radical hysterectomy and pelvic lymphadenectomy.J Clin Oncol 20, 688- 693 (2002).239.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Rhim, C.C., Park, J.S., Bae, S.N.& Namkoong, S.E.Sentinel node biopsy as an indicator for pelvic nodes dissection in early stage cervical cancer.J Korean Med Sci 17, 507-511 (2002).240.Barranger, E., et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Laparoscopic sentinel lymph node procedure using a combination of patent blue and radioisotope in women with cervical carcinoma.Cancer 97, 3003-3009 (2003).241.Buist, M.R., et al.Laparoscopic detection of sentinel lymph nodes followed by lymph node dissection in patients with early stage cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 90, 290-296 (2003).242.Chung, Y.A., et al.Usefulness of lymphoscintigraphy and intraoperative gamma probe detection in the identification of sentinel nodes in cervical cancer.Eur J Nucl Med Mol Imaging 30, 1014-1017 (2003).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "243.Dargent, D.& Enria, R.Laparoscopic assessment of the sentinel lymph nodes in early cervical cancer.Technique-- preliminary results and future developments.Crit Rev Oncol Hematol 48, 305-310 (2003).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "244.Hubalewska, A., et al.Use of Tc99mnanocolloid for sentinel nodes identification in cervical cancer.Nucl Med Rev Cent East Eur 6, 127-130 (2003).245.Lambaudie, E., et al.Laparoscopic identification of sentinel lymph nodes in early stage cervical cancer: prospective study using a combination of patent blue dye injection and technetium radiocolloid injection.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 89, 84-87 (2003).246.van Dam, P.A., et al.Intraoperative sentinel node identification with Technetium-99m-labeled nanocolloid in patients with cancer of the uterine cervix: a feasibility study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 13, 182-186 (2003).247.Barranger, E., et al.Histopathological validation of the sentinel node concept in cervical cancer.Ann Oncol 15, 870- 874 (2004).248.Li, B., Zhang, W.H., Liu, L.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "& Wu, L.Y.[A pilot study on the detection of sentinel lymph nodes in early stage cervical cancer].Zhonghua Fu Chan Ke Za Zhi 39, 4-6 (2004).249.Marchiole, P., Buenerd, A., Scoazec, J.Y., Dargent, D.& Mathevet, P.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Sentinel lymph node biopsy is not accurate in predicting lymph node status for patients with cervical carcinoma.Cancer 100, 2154-2159 (2004).250.Martinez-Palones, J.M., Gil-Moreno, A., Perez-Benavente, M.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A., Roca, I.& Xercavins, J.Intraoperative sentinel node identification in early stage cervical cancer using a combination of radiolabeled albumin injection and isosulfan blue dye injection.Gynecol Oncol 92, 845-850 (2004).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "251.Niikura, H., et al.Sentinel lymph node detection in early cervical cancer with combination 99mTc phytate and patent blue.Gynecol Oncol 94, 528-532 (2004).252.Pijpers, R., et al.The sentinel node in cervical cancer: scintigraphy and laparoscopic gamma probe-guided biopsy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Eur J Nucl Med Mol Imaging 31, 1479-1486 (2004).253.Wang, H.Y., Sun, J.M.& Tang, J.[Sentinel lymph nodes detection in patients with cervical cancer undergoing radical hysterectomy].Zhonghua Fu Chan Ke Za Zhi 39, 7-9 (2004).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "254.Angioli, R., et al.Role of sentinel lymph node biopsy procedure in cervical cancer: a critical point of view.Gynecol Oncol 96, 504-509 (2005).255.Gil-Moreno, A., et al.Total laparoscopic radical hysterectomy with intraoperative sentinel node identification in patients with early invasive cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 96, 187-193 (2005).256.Yin, S.Y., Tzeng, C.C.& Huang, K.Sentinel node detection with radiocolloid lymphatic mapping in early invasive cervical cancer.Int J Gynecol Cancer 15, 273-277 (2005).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "257.Rob, L., et al.Study of lymphatic mapping and sentinel node identification in early stage cervical cancer.Gynecol Oncol 98, 281-288 (2005).258.Di Stefano, A.B., et al.Lymph node mapping and sentinel node detection in patients with cervical carcinoma: a 2- year experience.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 99, 671- 679 (2005).259.Silva, L.B., et al.Sentinel node detection in cervical cancer with (99m)Tcphytate.Gynecol Oncol 97, 588-595 (2005).260.Jing, B., Wallace, S.& Zornoza, J.Metastases to retroperitoneal and pelvic lymph nodes: computed tomography and lymphangiography.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Radiol Clin North Am 20, 511-530 (1982).261.Marincek, B., Devaud, M.C., Triller, J.& Fuchs, W.A.Value of computed tomography and lymphography in staging carcinoma of the uterine cervix.Eur J Radiol 4, 118-121 (1984).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "262.King, L.A., Talledo, O.E., Gallup, D.G.& el Gammal, T.A.Computed tomography in evaluation of gynecologic malignancies: a retrospective analysis.Am J Obstet Gynecol 155, 960-964 (1986).263.Raber, G.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", Luning, M., Potzschke, B.& Natho, W.[The place of lymphography and computed tomography in the determination of lymph node status in primary cancer of the cervix].Radiol Diagn (Berl) 27, 449-459 (1986).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "264.Feigen, M., Crocker, E.F., Read, J.& Crandon, A.J.The value of lymphoscintigraphy, lymphangiography and computer tomography scanning in the preoperative assessment of lymph nodes involved by pelvic malignant conditions.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Surg Gynecol Obstet 165, 107-110 (1987).265.Oellinger, J.J., et al.Pre-operative staging of cervical cancer: comparison of magnetic resonance imaging (MRI) and computed tomography (CT) with histologic results.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Zentralbl Gynakol 122, 82-91 (2000).266.Vorgias, G., et al.Preoperative imaging of primary intra-abdominal gynaecological malignancies.Diagnostic accuracy of CT-scan and MRI.A Greek cohort study.Eur J Gynaecol Oncol 23, 139-144 (2002).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "267.Kokka, F., et al.Preoperative work-up of early cervical cancer (stages Ib-IIa).Eur J Gynaecol Oncol 24, 175-177 (2003).268.Ozsarlak, O., et al.The correlation of preoperative CT, MR imaging, and clinical staging (FIGO) with histopathology findings in primary cervical carcinoma.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Eur Radiol 13, 2338- 2345 (2003).269.Heuck, A., et al.[Lymph node staging in cervix carcinomas: the results of highresolution magnetic resonance tomography (MRT) with a phased-array body coil].Rofo 166, 210-214 (1997).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "270.Beyersdorff, D., Bahnsen, J.& Frischbier, H.J.Nodal involvement in cancer of the uterine cervix: value of lymphography and MRI.Eur J Gynaecol Oncol 16, 274- 277 (1995).271.Sheu, M.H., Chang, C.Y., Wang, J.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "H.& Yen, M.S.Cervical carcinoma: assessment of parametrial invasion and lymph node metastasis with magnetic resonance imaging.Zhonghua Yi Xue Za Zhi (Taipei) 63, 634-640 (2000).272.Rose, P.G., et al.Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: a surgicopathologic study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Clin Oncol 17, 41-45 (1999).273.Kuhnel, G., et al.[18F-FDG positronemission-tomography in cervical carcinoma: preliminary findings].Zentralbl Gynakol 123, 229-235 (2001).274.Kadkhodayan, S., et al.Sentinel node biopsy for lymph nodal staging of uterine cervix cancer: a systematic review and meta-analysis of the pertinent literature.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Eur J Surg Oncol 41, 1-20 (2015).275.van de Lande, J., et al.Sentinel lymph node detection in early stage uterine cervix carcinoma: a systematic review.Gynecol Oncol 106, 604-613 (2007).276.Wang, X.J., Fang, F.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "& Li, Y.F.Sentinellymph-node procedures in early stage cervical cancer: a systematic review and meta-analysis.Med Oncol 32, 385 (2015).277.Tax, C., Rovers, M.M., de Graaf, C., Zusterzeel, P.L.& Bekkers, R.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "L.The sentinel node procedure in early stage cervical cancer, taking the next step; a diagnostic review.Gynecol Oncol 139, 559-567 (2015).278.Schwendinger, V., Muller-Holzner, E., Zeimet, A.G.& Marth, C.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Sentinel node detection with the blue dye technique in early cervical cancer.Eur $J$ Gynaecol Oncol 27, 359-362 (2006).279.dos Reis, R., Tavares, E.B.& Amaral, B.Sentinel lymph node identification in patients with stage IB1invasive cervical carcinoma.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Curr Cancer Ther Rev 3, 209- 214 (2007).280.Vieira, S.C., et al.Preoperative pelvic lymphoscintigraphy is of limited usefulness for sentinel lymph node detection in cervical cancer.Eur J Obstet Gynecol Reprod Biol 145, 96-99 (2009).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "281.Vieira, S.C., et al.[Sentinel node study with patent blue in cervical cancer].Rev Assoc Med Bras (1992) 50, 302-304 (2004).282.Khinkova, N., Gorchev, G., Tsvetkov, C.& Tomov, S.[Sentinel lymph dissection in cervical cancer--prognostic factors].",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Akush Ginekol (Sofiia) 44, 13-18 (2005).283.Belhocine, T.Z., et al.Added-value of SPECT/CT to lymphatic mapping and sentinel lymphadenectomy in gynaecological cancers.Am J Nucl Med Mol Imaging 3, 182-193 (2013).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "284.Roy, M., et al.Value of sentinel node mapping in cancer of the cervix.Gynecol Oncol 122, 269-274 (2011).285.Plante, M., et al.Simple vaginal trachelectomy in early-stage low-risk cervical cancer: a pilot study of 16 cases and review of the literature.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int $J$ Gynecol Cancer 23, 916-922 (2013).286.Hauspy, J., et al.Sentinel lymph nodes in early stage cervical cancer.Gynecol Oncol 105, 285-290 (2007).287.Li, B., et al.Sentinel lymph node identification in patients with early stage cervical cancer undergoing radical hysterectomy and pelvic lymphadenectomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Chin Med J (Engl) 117, 867-870 (2004).288.Yuan, S.H., et al.Sentinel lymph node detection using methylene blue in patients with early stage cervical cancer.Gynecol Oncol 106, 147-152 (2007).289.Zhu, T.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", Lou, H.M.& Yang, Z.Y.Sentinel lymph node detection in patients with early stage cervical cancer.Chin J Cancer Prev Treat 18, 805-807 (2011).290.Sheng, X.G., et al.[Clinical significance of sentinel lymph nodes detection in patients with early stage cervical cancer].",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Zhonghua Fu Chan Ke Za Zhi 39, 10-13 (2004).291.Du, X.L., et al.Sentinel lymph node biopsy as guidance for radical trachelectomy in young patients with early stage cervical cancer.BMC Cancer 11, 157 (2011).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "292.Wang, H.Y., et al.Micrometastases detected by cytokeratin 19 expression in sentinel lymph nodes of patients with early-stage cervical cancer.Int J Gynecol Cancer 16, 643-648 (2006).293.Zhang, Z.& Chang, Q.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Clinical analysis of sentinel lymph node identification in patients with cervical cancer.Eur $J$ Gynaecol Oncol 35, 26-31 (2014).294.Liu, K.J., et al.[Application of carbon nanoparticles in the laparoscopic sentinel lymph node detection in patients with cervical cancer].",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Zhongguo Yi Xue Ke Xue Yuan Xue Bao 35, 150-154 (2013).295.Holub, Z., Jabor, A., Lukac, J.& Kliment, L.laparoscopic detection of sentinel lymph nodes using blue dye in women with cervical and endometrial cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Med Sci Monit 10, CR587-591 (2004).296.Bournaud, C., Le Bail-Carval, K., Scheiber, C., de Charry, C.& Mathevet, P.Value of SPECT/CT in lymphatic mapping in cervix and endometrial cancer.Med Nucl 37, 387-396 (2013).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "297.Lecuru, F., et al.Bilateral negative sentinel nodes accurately predict absence of lymph node metastasis in early cervical cancer: results of the SENTICOL study.J Clin Oncol 29, 1686- 1691 (2011).298.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Bats, A.S., et al.Limits of day-before lymphoscintigraphy to localize sentinel nodes in women with cervical cancer.Ann Surg Oncol 15, 2173-2179 (2008).299.Lelievre, L., et al.Sentinel lymph node biopsy in cervix and corpus uteri cancers.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 14, 271- 278 (2004).300.Klapdor, R., et al.Value and advantages of preoperative sentinel lymph node imaging with SPECT/CT in cervical cancer.Int J Gynecol Cancer 24, 295-302 (2014).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "301.Altgassen, C., et al.Multicenter validation study of the sentinel lymph node concept in cervical cancer: AGO Study Group.J Clin Oncol 26, 2943-2951 (2008).302.Fotiou, S., et al.Clinical value of preoperative lymphoscintigraphy in patients with early cervical cancer considered for intraoperative lymphatic mapping.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Anticancer Res 30, 183-188 (2010).303.Somashekhar, S.P., Naikoo, Z.A., Zaveri, S.S., Parameswaran, R.V.& Jaka, R.C.Role of sentinel lymph node biopsy in early cervical cancer.Indian J Surg Oncol 3, 317-320 (2012).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "304.Rajaram, S., et al.Mapping the extent of disease by multislice computed tomography, magnetic resonance imaging and sentinel node evaluation in stage I and II cervical carcinoma.$J$ Cancer Res Ther 6, 267-271 (2010).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "305.Shiravani, Z., Hasanzadeh, M.& Yousefi, Z.The value of lateral lymphoscintigraphy images of the pelvis for gynecological cancers: are they necessary.Iran J Nucl Med 22, 46-50 (2014).306.Yamashita, T.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Management of pelvic lymph nodes by sentinel node navigation surgery in the treatment of invasive cervical cancer.Int $J$ Gynecol Cancer 19, 1113-1118 (2009).307.Ogawa, S., et al.Sentinel node detection with (99m)Tc phytate alone is satisfactory for cervical cancer patients undergoing radical hysterectomy and pelvic lymphadenectomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Clin Oncol 15, 52-58 (2010).308.Furukawa, N., et al.The usefulness of photodynamic eye for sentinel lymph node identification in patients with cervical cancer.Tumori 96, 936-940 (2010).309.Kato, H.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Previous conization on patient eligibility of sentinel lymph node detection for early invasive cervical cancer.Int J Gynecol Cancer 21, 1491- 1494 (2011).310.Seong, S.J., et al.Detection of sentinel lymph nodes in patients with early stage cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "$J$ Korean Med Sci 22, 105-109 (2007).311.Lee, Y.S., et al.HPV status in sentinel nodes might be a prognostic factor in cervical cancer.Gynecol Oncol 105, 351- 357 (2007).312.Maffuz, A., Quijano, F., Lopez, D.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "& Hernandez-Ramirez, D.[Laparoscopic radical hysterectomy with lymphatic mapping and sentinel lymph node biopsy in early cervical cancer].Ginecol Obstet Mex 78, 345-351 (2010).313.Cibula, D., et al.Bilateral ultrastaging of sentinel lymph node in cervical cancer: Lowering the false-negative rate and improving the detection of micrometastasis.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 127, 462-466 (2012).314.Acharya, B.C.& Jihong, L.Sentinel lymph node detection in patients with early cervical cancer.JNMA J Nepal Med Assoc 48, 287-291 (2009).315.Sniadecki, M., Sawicki, S.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", Wojtylak, S., Liro, M.& Wydra, D.Clinical feasibility and diagnostic accuracy of detecting micrometastatic lymph node disease in sentinel and non-sentinel lyph nodes in cervical cancer: outcomes and implications.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Ginekol Pol 85, 10-13 (2014).316.Wydra, D., Sawicki, S., Wojtylak, S., Bandurski, T.& Emerich, J.Sentinel node identification in cervical cancer patients undergoing transperitoneal radical hysterectomy: a study of 100 cases.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 16, 649-654 (2006).317.Basta, A., et al.Sentinel node in gynaecological oncology.Pract Oncol Radiother 10, 91-94 (2005).318.Diaz-Feijoo, B., et al.Change in clinical management of sentinel lymph node location in early stage cervical cancer: the role of SPECT/CT.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 120, 353-357 (2011).319.Fuste, P., et al.[Feasibility of the sentinel lymph node technique in cervical and vulvar cancers].Med Clin (Barc) 128, 569-571 (2007).320.Diaz-Feijoo, B., et al.Sentinel lymph node identification and radical hysterectomy with lymphadenectomy in early stage cervical cancer: laparoscopy versus laparotomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "$J$ Minim Invasive Gynecol 15, 531-537 (2008).321.Vidal-Sicart, S., et al.[Sentinel node in gynaecological cancers.Our experience].Rev Esp Med Nucl 28, 221-228 (2009).322.Darlin, L., et al.The sentinel node concept in early cervical cancer performs well in tumors smaller than 2 cm.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 117, 266-269 (2010).323.Lin, Y.S., et al.Sentinel node detection with radiocolloid lymphatic mapping in early invasive cervical cancer.Int $J$ Gynecol Cancer 15, 273-277 (2005).324.Crane, L.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "M., et al.Intraoperative multispectral fluorescence imaging for the detection of the sentinel lymph node in cervical cancer: a novel concept.Mol Imaging Biol 13, 1043-1049 (2011).325.van der Vorst, J.R.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Optimization of near-infrared fluorescent sentinel lymph node mapping in cervical cancer patients.Int J Gynecol Cancer 21, 1472- 1478 (2011).326.Schaafsma, B.E., et al.Randomized comparison of near-infrared fluorescence lymphatic tracers for sentinel lymph node mapping of cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 127, 126-130 (2012).327.Kara, P.P., et al.Sentinel lymph node detection in early stage cervical cancer: a prospective study comparing preoperative lymphoscintigraphy, intraoperative gamma probe, and blue dye.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Ann Nucl Med 22, 487-494 (2008).328.Devaja, O., et al.A prospective singlecenter study of sentinel lymph node detection in cervical carcinoma: is there a place in clinical practice?Int J Gynecol Cancer 22, 1044-1049 (2012).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "329.Fader, A.N., et al.Sentinel lymph node biopsy in early-stage cervical cancer: utility of intraoperative versus postoperative assessment.Gynecol Oncol 111, 13-17 (2008).330.Frumovitz, M., et al.\"Triple injection\" lymphatic mapping technique to determine if parametrial nodes are the true sentinel lymph nodes in women with cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 127, 467-471 (2012).331.Kushner, D.M., et al.Laparoscopic sentinel lymph node mapping for cervix cancer--a detailed evaluation and time analysis.Gynecol Oncol 106, 507-512 (2007).332.Barranger, E.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", Cortez, A., Uzan, S., Callard, P.& Darai, E.Value of intraoperative imprint cytology of sentinel nodes in patients with cervical cancer.Gynecol Oncol 94, 175-180 (2004).333.Roca, I., et al.Usefulness of sentinel lymph node detection in early stages of cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Eur J Nucl Med Mol Imaging 32, 1210-1216 (2005).334.Yong, W.S., et al.Single institution's initial experience with sentinel lymph node biopsy in breast cancer patients.ANZ J Surg 73, 416-421 (2003).335.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Altgassen, C., et al.Dilution of dye improves parametrial SLN detection in patients with cervical cancer.Gynecol Oncol 105, 329-334 (2007).336.Bats, A.S., et al.Sentinel lymph node biopsy improves staging in early cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 105, 189- 193 (2007).337.Darai, E., et al.Contribution of the sentinel node procedure to tailoring the radicality of hysterectomy for cervical cancer.Gynecol Oncol 106, 251-256 (2007).338.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Pluta, M., et al.Less radical surgery than radical hysterectomy in early stage cervical cancer: a pilot study.Gynecol Oncol 113, 181-184 (2009).339.Gortzak-Uzan, L., et al.Sentinel lymph node biopsy vs.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "pelvic lymphadenectomy in early stage cervical cancer: is it time to change the gold standard?Gynecol Oncol 116, 28- 32 (2010).340.Cormier, B., et al.Establishing a sentinel lymph node mapping algorithm for the treatment of early cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 122, 275-280 (2011).341.Niikura, H., et al.Prospective study of sentinel lymph node biopsy without further pelvic lymphadenectomy in patients with sentinel lymph nodenegative cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int $J$ Gynecol Cancer 22, 1244-1250 (2012).342.Hoogendam, J.P., et al.Preoperative sentinel node mapping with $( 9 9 \\mathrm { m } ) \\mathrm { T c } .$ nanocolloid SPECT-CT significantly reduces the intraoperative sentinel node retrieval time in robot assisted laparoscopic cervical cancer surgery.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 129, 389-394 (2013).343.Verheijen, R.H., et al.Sentinel node detection in cervical cancer.Obstet Gynecol 96, 135-138 (2000).344.de Freitas, R.R., et al.Can a sentinel node mapping algorithm detect all positive lymph nodes in cervical cancer?",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Ann Surg Oncol 22, 1564-1569 (2015).345.Plante, M., Renaud, M.C., Tetu, B., Harel, F.& Roy, M.Laparoscopic sentinel node mapping in early-stage cervical cancer.Gynecol Oncol 91, 494-503 (2003).346.Frumovitz, M.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Usefulness of preoperative lymphoscintigraphy in patients who undergo radical hysterectomy and pelvic lymphadenectomy for cervical cancer.Am J Obstet Gynecol 194, 1186-1193; discussion 1193-1185 (2006).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "347.Marnitz, S., et al.Topographic distribution of sentinel lymph nodes in patients with cervical cancer.Gynecol Oncol 103, 35-44 (2006).348.Coutant, C., et al.Laparoscopic sentinel node biopsy in cervical cancer using a combined detection: 5-years experience.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Ann Surg Oncol 14, 2392-2399 (2007).349.Euscher, E.D., et al.Ultrastaging improves detection of metastases in sentinel lymph nodes of uterine cervix squamous cell carcinoma.Am J Surg Pathol 32, 1336-1343 (2008).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "350.Rob, L., et al.A less radical treatment option to the fertility-sparing radical trachelectomy in patients with stage I cervical cancer.Gynecol Oncol 111, S116-120 (2008).351.Strnad, P., et al.A prospective study of sentinel lymph node status and parametrial involvement in patients with small tumour volume cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 109, 280-284 (2008).352.Cibula, D., et al.Sentinel node (SLN) biopsy in the management of locally advanced cervical cancer.Gynecol Oncol 115, 46-50 (2009).353.Pazin, V., et al.The value of sentinel lymphadenectomy in radical operative treatment of cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Vojnosanit Pregl 66, 539-543 (2009).354.van de Lande, J., et al.SCC-Ag, lymph node metastases and sentinel node procedure in early stage squamous cell cervical cancer.Gynecol Oncol 112, 119- 125 (2009).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "355.Zarganis, P., et al.The sentinel node in cervical cancer patients: role of tumor size and invasion of lymphatic vascular space.In Vivo 23, 469-473 (2009).356.Diaz, J.P., et al.Sentinel lymph node biopsy in the management of early-stage cervical carcinoma.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 120, 347-352 (2011).357.Bats, A.S., et al.The sentinel node technique detects unexpected drainage pathways and allows nodal ultrastaging in early cervical cancer: insights from the multicenter prospective SENTICOL study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Ann Surg Oncol 20, 413-422 (2013).358.Klat, J., et al.What is the risk for parametrial involvement in women with early-stage cervical cancer with tumour $< 2 0 ~ \\mathrm { ~ m m }$ and with negative sentinel lymph nodes?",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Aust N Z J Obstet Gynaecol 52, 540-544 (2012).359.Slama, J., Dundr, P., Dusek, L.& Cibula, D.High false negative rate of frozen section examination of sentinel lymph nodes in patients with cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 129, 384-388 (2013).360.Bats, A.S., et al.Diagnostic value of intraoperative examination of sentinel lymph node in early cervical cancer: a prospective, multicenter study.Gynecol Oncol 123, 230-235 (2011).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "361.Deng, X., et al.Abdominal radical trachelectomy guided by sentinel lymph node biopsy for stage IB1 cervical cancer with tumors $^ { > 2 }$ cm.Oncotarget (2016).362.Rocha, A., Dominguez, A.M., Lecuru, F.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "& Bourdel, N.Indocyanine green and infrared fluorescence in detection of sentinel lymph nodes in endometrial and cervical cancer staging - a systematic review.Eur J Obstet Gynecol Reprod Biol 206, 213-219 (2016).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "363.Crane, L.M., et al.Multispectral real-time fluorescence imaging for intraoperative detection of the sentinel lymph node in gynecologic oncology.J Vis Exp (2010).364.Jewell, E.L., et al.Detection of sentinel lymph nodes in minimally invasive surgery using indocyanine green and near-infrared fluorescence imaging for uterine and cervical malignancies.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 133, 274-277 (2014).365.Rossi, E.C., Ivanova, A.& Boggess, J.F.Robotically assisted fluorescenceguided lymph node mapping with ICG for gynecologic malignancies: a feasibility study.Gynecol Oncol 124, 78- 82 (2012).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "366.Buda, A., et al.Impact of Indocyanine Green for Sentinel Lymph Node Mapping in Early Stage Endometrial and Cervical Cancer: Comparison with Conventional Radiotracer (99m)Tc and/or Blue Dye.Ann Surg Oncol 23, 2183-2191 (2016).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "367.Imboden, S., et al.A Comparison of Radiocolloid and Indocyanine Green Fluorescence Imaging, Sentinel Lymph Node Mapping in Patients with Cervical Cancer Undergoing Laparoscopic Surgery.Ann Surg Oncol 22, 4198-4203 (2015).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "368.Beavis, A.L., et al.Sentinel lymph node detection rates using indocyanine green in women with early-stage cervical cancer.Gynecol Oncol 143, 302-306 (2016).369.Buda, A., et al.From Conventional Radiotracer Tc-99(m) with Blue Dye to Indocyanine Green Fluorescence: A Comparison of Methods Towards Optimization of Sentinel Lymph Node Mapping in Early Stage Cervical Cancer for a Laparoscopic Approach.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Ann Surg Oncol 23, 2959-2965 (2016).370.Atri, M., et al.Utility of PET-CT to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer: Results of ACRIN6671/GOG0233 trial.Gynecol Oncol 142, 413-419 (2016).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "371.Smits, R.M., Zusterzeel, P.L.& Bekkers, R.L.Pretreatment retroperitoneal paraaortic lymph node staging in advanced cervical cancer: a review.Int J Gynecol Cancer 24, 973-983 (2014).372.Vidaurreta, J.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", Bermudez, A., di Paola, G.& Sardi, J.Laparoscopic staging in locally advanced cervical carcinoma: A new possible philosophy?Gynecol Oncol 75, 366-371 (1999).373.Odunsi, K.O., Lele, S., Ghamande, S., Seago, P.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "& Driscoll, D.L.The impact of pre-therapy extraperitoneal surgical staging on the evaluation and treatment of patients with locally advanced cervical cancer.Eur J Gynaecol Oncol 22, 325-330 (2001).374.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Del Pino, M., et al.Laparoscopic lymphadenectomy in advanced cervical cancer: prognostic and therapeutic value.Int $J$ Gynecol Cancer 23, 1675- 1683 (2013).375.Mortier, D.G., et al.Laparoscopic paraaortic lymphadenectomy and positron emission tomography scan as staging procedures in patients with cervical carcinoma stage IB2-IIIB.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 18, 723-729 (2008).376.Leblanc, E., et al.Accuracy of 18-fluoro2-deoxy-D-glucose positron emission tomography in the pretherapeutic detection of occult para-aortic node involvement in patients with a locally advanced cervical carcinoma.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Ann Surg Oncol 18, 2302-2309 (2011).377.Ramirez, P.T., et al.Laparoscopic extraperitoneal para-aortic lymphadenectomy in locally advanced cervical cancer: a prospective correlation of surgical findings with positron emission tomography/computed tomography findings.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cancer 117, 1928-1934 (2011).378.Fastrez, M., et al.Multi-center experience of robot-assisted laparoscopic para-aortic lymphadenectomy for staging of locally advanced cervical carcinoma.Acta Obstet Gynecol Scand 92, 895-901 (2013).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "379.Marnitz, S., et al.Is there a benefit of pretreatment laparoscopic transperitoneal surgical staging in patients with advanced cervical cancer?Gynecol Oncol 99, 536-544 (2005).380.Berman, M.L., et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Survival and patterns of recurrence in cervical cancer metastatic to periaortic lymph nodes (a Gynecologic Oncology Group study).Gynecol Oncol 19, 8-16 (1984).381.Chism, S.E., Park, R.C.& Keys, H.M.Prospects for para-aortic irradiation in treatment of cancer of the cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cancer 35, 1505-1509 (1975).382.Gouy, S., et al.Nodal-staging surgery for locally advanced cervical cancer in the era of PET.Lancet Oncol 13, e212-220 (2012).383.Denschlag, D., et al.Evaluation of patients after extraperitoneal lymph node dissection for cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 96, 658-664 (2005).384.Hasenburg, A., et al.Evaluation of patients after extraperitoneal lymph node dissection and subsequent radiotherapy for cervical cancer.Gynecol Oncol 84, 321-326 (2002).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "385.Goff, B.A., et al.Impact of surgical staging in women with locally advanced cervical cancer.Gynecol Oncol 74, 436- 442 (1999).386.Brockbank, E., Kokka, F., Bryant, A., Pomel, C.& Reynolds, K.Pre-treatment surgical para-aortic lymph node assessment in locally advanced cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cochrane Database Syst Rev, CD008217 (2013).387.Gold, M.A., Tian, C., Whitney, C.W., Rose, P.G.& Lanciano, R.Surgical versus radiographic determination of paraaortic lymph node metastases before chemoradiation for locally advanced cervical carcinoma: a Gynecologic Oncology Group Study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cancer 112, 1954-1963 (2008).388.Kim, S.K., et al.Additional value of MR/PET fusion compared with PET/CT in the detection of lymph node metastases in cervical cancer patients.Eur J Cancer 45, 2103-2109 (2009).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "389.Cosin, J.A., et al.Pretreatment surgical staging of patients with cervical carcinoma: the case for lymph node debulking.Cancer 82, 2241-2248 (1998).390.Piver, M.S.& Barlow, J.J.Para-aortic lymphadenectomy in staging patients with advanced local cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Obstet Gynecol 43, 544-548 (1974).391.Cuschieri, A.Technology for minimal access surgery.Interview by Judy Jones.BMJ 319, 1304 (1999).392.Nagao, S., et al.Feasibility of extraperitoneal laparoscopic para-aortic and common iliac lymphadenectomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 103, 732-735 (2006).393.Lai, C.H., et al.Randomized trial of surgical staging (extraperitoneal or laparoscopic) versus clinical staging in locally advanced cervical cancer.Gynecol Oncol 89, 160-167 (2003).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "394.Gil-Moreno, A., et al.Pretherapeutic extraperitoneal laparoscopic staging of bulky or locally advanced cervical cancer.Ann Surg Oncol 18, 482-489 (2011).395.Worley Jr, M.J., et al.A pilot study of laparoscopic extraperitoneal lymph node dissection in patients with locally advanced cervical cancer: a trial design report.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Clinical Ovarian Cancer 3, 113- 117 (2010).396.Kang, S., et al.Diagnostic value of (18)FFDG PET for evaluation of paraaortic nodal metastasis in patients with cervical carcinoma: a metaanalysis.$J$ Nucl Med 51, 360-367 (2010).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "397.Boughanim, M., et al.Histologic results of para-aortic lymphadenectomy in patients treated for stage IB2/II cervical cancer with negative [18F]fluorodeoxyglucose positron emission tomography scans in the paraaortic area.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Clin Oncol 26, 2558-2561 (2008).398.Vergote, I., et al.Value of positron emission tomography of the para-aortic lymph nodes in cervical carcinoma stage IB2-IIIB.$J$ Clin Oncol 26, 5654-5655; author reply 5655-5657 (2008).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "399.Tsai, C.S., et al.A prospective randomized trial to study the impact of pretreatment FDG-PET for cervical cancer patients with MRI-detected positive pelvic but negative para-aortic lymphadenopathy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int $J$ Radiat Oncol Biol Phys 76, 477-484 (2010).400.Monteil, J., et al.Lymph node assessment with (18)F-FDG-PET and MRI in uterine cervical cancer.Anticancer Res 31, 3865-3871 (2011).401.Shen, G., Zhou, H.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", Jia, Z.& Deng, H.Diagnostic performance of diffusionweighted MRI for detection of pelvic metastatic lymph nodes in patients with cervical cancer: a systematic review and meta-analysis.Br J Radiol 88, 20150063 (2015).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "402.Kim, J.K., Kim, K.A., Park, B.W., Kim, N.& Cho, K.S.Feasibility of diffusionweighted imaging in the differentiation of metastatic from nonmetastatic lymph nodes: early experience.J Magn Reson Imaging 28, 714-719 (2008).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "403.Kim, M.H., et al.Diagnosis of lymph node metastasis in uterine cervical cancer: usefulness of computer-aided diagnosis with comprehensive evaluation of MR images and clinical findings.Acta Radiol 52, 1175-1183 (2011).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "404.Chen, Y.B., Hu, C.M., Chen, G.L., Hu, D.& Liao, J.Staging of uterine cervical carcinoma: whole-body diffusionweighted magnetic resonance imaging.Abdom Imaging 36, 619-626 (2011).405.Chen, Y.B., Liao, J.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", Xie, R., Chen, G.L.& Chen, G.Discrimination of metastatic from hyperplastic pelvic lymph nodes in patients with cervical cancer by diffusion-weighted magnetic resonance imaging.Abdom Imaging 36, 102-109 (2011).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "406.Choi, E.K., et al.Node-by-node correlation between MR and PET/CT in patients with uterine cervical cancer: diffusion-weighted imaging versus sizebased criteria on T2WI.Eur Radiol 19, 2024-2032 (2009).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "407.Liu, Y., et al.Differentiation of metastatic from non-metastatic lymph nodes in patients with uterine cervical cancer using diffusion-weighted imaging.Gynecol Oncol 122, 19-24 (2011).408.Park, S.O.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Relative apparent diffusion coefficient: determination of reference site and validation of benefit for detecting metastatic lymph nodes in uterine cervical cancer.J Magn Reson Imaging 29, 383-390 (2009).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "409.Xue, H.D., et al.Clinical application of body diffusion weighted MR imaging in the diagnosis and preoperative N staging of cervical cancer.Chin Med Sci J 23, 133-137 (2008).410.Hu, C.M., Chen, Y.B.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "& Chen, J.L.Study of the application of whole body diffusion weighted magnetic resonance imaging in staging of uterine cervical carcinoma.MD thesis.Fujian: Fujian Medical University (2009).411.Liao, J.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "& Chen, Y.B.Study of diffusionweighted MR imaging for pelvic lymph node in patients with cervical carcinoma.MD thesis.Fujian: Fujian Medical University (2008).412.Ling, R.N., Gong, J.S., Wang, X.M., Yang, L.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "& Wu, M.X.The application of diffusion weighted imaging (DWI) in the diagnosis of lymph node metastases in patients with uterine cervical cancer.$J$ Qiqihar Univ Med 33, 441-443 (2012).413.Liu, L., et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Diagnostic value of 3T diffusion-weighted MR imaging for metastatic pelvic lymph nodes in cervical cancer patients.J Sichuan Univ 45, 159-163 (2014).414.Liu, Y., Bai, R.J., Liu, H.D., Wang, D.H.& Ye, Z.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "X.Evaluation of metastatic lymph nodes in patients with uterine cervical cancer by DWI.J Clin Radiol 30, 834-838 (2011).415.Ren, C., Jin, Z.Y., Xue, H.D.& Shen, J.The application of DWI in preoperative evaluation and accessing therapeutic response to concurrent chemoradiotherapy in patients with cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "MD thesis.Beijing: Peking Union Medical College (2013).416.Zhang, J., et al.Value of diffusionweighted imaging in diagnosis of lymph node metastasis in patients with cervical cancer.Acta Academiae Med Sci 36, 73-78 (2014).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "417.Petru, E., et al.Gynecologic Cancer Intergroup (GCIG) proposals for changes of the current FIGO staging system.Eur J Obstet Gynecol Reprod Biol 143, 69-74 (2009).418.Meva, J., et al.Lacunae in International Federation of Gynecology and Obstetrics (FIGO) classification for cervical carcinoma: observational study using TNM classification as comparator.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int $J$ Gynecol Cancer 23, 1071-1077 (2013).419.Chuang, L.T., Feldman, S., Nakisige, C., Temin, S.& Berek, J.S.Management and Care of Women With Invasive Cervical Cancer: ASCO Resource-Stratified Clinical Practice Guideline.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Clin Oncol 34, 3354-3355 (2016).420.Chuang, L.T., Temin, S.& Berek, J.S.Management and Care of Women With Invasive Cervical Cancer: American Society of Clinical Oncology ResourceStratified Clinical Practice Guideline Summary.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Oncol Pract 12, 693-696 (2016).421.Balleyguier, C., et al.Staging of uterine cervical cancer with MRI: guidelines of the European Society of Urogenital Radiology.Eur Radiol 21, 1102-1110 (2011).422.Marth, C.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol 28, iv72-iv83 (2017).423.Vergote, I., et al.Recommandations de bonne pratique pour la prise en charge du cancer du col de l'utérus.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Good Clinical Practice (GCP).Bruxelles: Centre fédéral d'expertise des soins de santé (KCE).KCE report 168B.(2011).424.NCCN.Cervical Cancer - NCCN Clinical Practice Guidelines in Oncology (version I.2017 - October 10, 2016).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "https://www.nccn.org/professionals/phy sician_gls/pdf/cervical.pdf (2017).425.Oaknin, A., et al.SEOM guidelines for cervical cancer.Clin Transl Oncol 17, 1036-1042 (2015).426.WHO.Comprehensive Cervical Cancer Control.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A guide to essential practice.Second edition.http://www.who.int/reproductivehealth /publications/cancers/cervical-cancerguide/en/ (2014).427.Hou, J., et al.Risk factors for poor prognosis in microinvasive adenocarcinoma of the uterine cervix (IA1 and IA2): a pooled analysis.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 121, 135-142 (2011).428.Singh, P., Scurry, J.& Proietto, A.Lethal endometrial recurrence after cone biopsy for microinvasive cervical adenocarcinoma.J Obstet Gynaecol Res 34, 413-417 (2008).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "429.Wolf, J.K., et al.Adenocarcinoma in situ of the cervix: significance of cone biopsy margins.Obstet Gynecol 88, 82-86 (1996).430.Berek, J.S., et al.Adenocarcinoma of the uterine cervix: histologic variables associated with lymph node metastasis and survival.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Obstet Gynecol 65, 46-52 (1985).431.Fu, Y.S., Berek, J.S.& Hilborne, L.H.Diagnostic problems of in situ and invasive adenocarcinomas of the uterine cervix.Appl Pathol 5, 47-56 (1987).432.Ostor, A., Rome, R.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "& Quinn, M.Microinvasive adenocarcinoma of the cervix: a clinicopathologic study of 77 women.Obstet Gynecol 89, 88-93 (1997).433.Ostor, A.G.Early invasive adenocarcinoma of the uterine cervix.Int J Gynecol Pathol 19, 29-38 (2000).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "434.Teshima, S., et al.Early stage adenocarcinoma of the uterine cervix.Histopathologic analysis with consideration of histogenesis.Cancer 56, 167-172 (1985).435.Kaku, T., et al.Early adenocarcinoma of the uterine cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 65, 281-285 (1997).436.Van den Broek, N.R., Lopes, A.D., Ansink, A.& Monaghan, J.M.\"Microinvasive\" adenocarcinoma of the cervix implanting in an episiotomy scar.Gynecol Oncol 59, 297-299 (1995).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "437.Kurian, K.& al-Nafussi, A.Relation of cervical glandular intraepithelial neoplasia to microinvasive and invasive adenocarcinoma of the uterine cervix: a study of 121 cases.J Clin Pathol 52, 112- 117 (1999).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "438.Smith, H.O., et al.Is there a difference in survival for IA1 and IA2 adenocarcinoma of the uterine cervix?Gynecol Oncol 85, 229-241 (2002).439.Webb, J.C., Key, C.R., Qualls, C.R.& Smith, H.O.Population-based study of microinvasive adenocarcinoma of the uterine cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Obstet Gynecol 97, 701- 706 (2001).440.Jones, W.B., Mercer, G.O., Lewis, J.L., Jr., Rubin, S.C.& Hoskins, W.J.Early invasive carcinoma of the cervix.Gynecol Oncol 51, 26-32 (1993).441.Sachs, H., Ikeda, J.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "& Brachetti, A.K.[Microinvasive adenocarcinoma and adenocarcinoma in situ of the cervix uteri].Med Welt 26, 1181-1183 (1975).442.Burghardt, E.Pathology of preclinical invasive carcinoma of cervix.(Microinvasive and occult invasive carcinoma).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In Fu, Y., Reagan, J.W., Bennington, J.L., editors.Pathology of the Uterine Cervix, Vagina, and Vulva.Philadelphia: Saunders.447-449 (1989).443.Nicklin, J.L., Perrin, L.C., Crandon, A.J.& Ward, B.G.Microinvasive adenocarcinoma of the cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Aust N Z J Obstet Gynaecol 39, 411-413 (1999).444.Nakajima, H.Clinicopathological study on early adenocarcinoma.Nagasaki Med J 58, 218-233 (1983).445.Matsukuma, K., et al.Early adenocarcinoma of the uterine cervix-- its histologic and immunohistologic study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 35, 38-43 (1989).446.Ceballos, K.M., Shaw, D.& Daya, D.Microinvasive cervical adenocarcinoma (FIGO stage 1A tumors): results of surgical staging and outcome analysis.Am J Surg Pathol 30, 370-374 (2006).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "447.Kennedy, A.W., elTabbakh, G.H., Biscotti, C.V.& Wirth, S.Invasive adenocarcinoma of the cervix following LLETZ (large loop excision of the transformation zone) for adenocarcinoma in situ.Gynecol Oncol 58, 274-277 (1995).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "448.Nagarsheth, N.P., Maxwell, G.L., Bentley, R.C.& Rodriguez, G.Bilateral pelvic lymph node metastases in a case of FIGO stage IA(1) adenocarcinoma of the cervix.Gynecol Oncol 77, 467-470 (2000).449.Elliott, P.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Early invasive (FIGO stage IA) carcinoma of the cervix: a clinico-pathologic study of 476 cases.Int J Gynecol Cancer 10, 42-52 (2000).450.Kasamatsu, T., et al.Early invasive adenocarcinoma of the uterine cervix: criteria for nonradical surgical treatment.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 85, 327-332 (2002).451.Covens, A., Kirby, J., Shaw, P., Chapman, W.& Franseen, E.Prognostic factors for relapse and pelvic lymph node metastases in early stage I adenocarcinoma of the cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 74, 423-427 (1999).452.Utsugi, K., Shimizu, Y., Akiyama, F.& Hasumi, K.Is the invasion depth in millimeters valid to determine the prognosis of early invasive cervical adenocarcinoma?A case of recurrent FIGO stage IA1 cervical adenocarcinoma.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 82, 205- 207 (2001).453.Erzen, M., Mozina, A., Bertole, J.& Syrjanen, K.Factors predicting disease outcome in early stage adenocarcinoma of the uterine cervix.Eur J Obstet Gynecol Reprod Biol 101, 185-191 (2002).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "454.Bisseling, K.C., Bekkers, R.L., Rome, R.M.& Quinn, M.A.Treatment of microinvasive adenocarcinoma of the uterine cervix: a retrospective study and review of the literature.Gynecol Oncol 107, 424-430 (2007).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "455.Simon, N.L., et al.Study of superficially invasive carcinoma of the cervix.Obstet Gynecol 68, 19-24 (1986).456.Andersen, E.S.& Arffmann, E.Adenocarcinoma in situ of the uterine cervix: a clinico-pathologic study of 36 cases.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 35, 1-7 (1989).457.Rollason, T.P., Cullimore, J.& Bradgate, M.G.A suggested columnar cell morphological equivalent of squamous carcinoma in situ with early stromal invasion.Int J Gynecol Pathol 8, 230-236 (1989).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "458.Angel, C., DuBeshter, B.& Lin, J.Y.Clinical presentation and management of stage I cervical adenocarcinoma: a 25 year experience.Gynecol Oncol 44, 71- 78 (1992).459.Kaspar, H.G., Dinh, T.V., Doherty, M.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "G., Hannigan, E.V.& Kumar, D.Clinical implications of tumor volume measurement in stage I adenocarcinoma of the cervix.Obstet Gynecol 81, 296-300 (1993).460.Schorge, J.O., Lee, K.R., Flynn, C.E., Goodman, A.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "& Sheets, E.E.Stage IA1 cervical adenocarcinoma: definition and treatment.Obstet Gynecol 93, 219-222 (1999).461.Schorge, J.O., Lee, K.R.& Sheets, E.E.Prospective management of stage IA(1) cervical adenocarcinoma by conization alone to preserve fertility: a preliminary report.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 78, 217-220 (2000).462.Lee, K.R.& Flynn, C.E.Early invasive adenocarcinoma of the cervix.Cancer 89, 1048-1055 (2000).463.Balega, J., et al.The risk of nodal metastasis in early adenocarcinoma of the uterine cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 14, 104-109 (2004).464.Hirai, Y., et al.Early invasive cervical adenocarcinoma: its potential for nodal metastasis or recurrence.BJOG 110, 241-246 (2003).465.Poynor, E.A., et al.Clinicopathologic features of early adenocarcinoma of the cervix initially managed with cervical conization.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 103, 960-965 (2006).466.Yahata, T., et al.Conservative treatment of stage IA1 adenocarcinoma of the cervix during pregnancy.Gynecol Oncol 109, 49-52 (2008).467.Reynolds, E.A., et al.Analysis of outcomes of microinvasive adenocarcinoma of the uterine cervix by treatment type.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Obstet Gynecol 116, 1150-1157 (2010).468.McHale, M.T., et al.Fertility sparing treatment for in situ and early invasive adenocarcinoma of the cervix.Obstet Gynecol 98, 726-731 (2001).469.Yoneda, J.Y., et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Surgical treatment of microinvasive cervical cancer: analysis of pathologic features with implications on radicality.Int J Gynecol Cancer 25, 694-698 (2015).470.Lee, J.Y., et al.Safety of less aggressive surgery for stage IA1 squamous cell carcinoma of the cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Obstet Gynaecol Res 40, 1382-1388 (2014).471.Yahata, T., et al.Conservative treatment of stage IA1 adenocarcinoma of the uterine cervix with a long-term followup.Int J Gynecol Cancer 20, 1063-1066 (2010).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "472.Lee, K.B., Lee, J.M., Park, C.Y., Cho, H.Y.& Ha, S.Y.Lymph node metastasis and lymph vascular space invasion in microinvasive squamous cell carcinoma of the uterine cervix.Int $J$ Gynecol Cancer 16, 1184-1187 (2006).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "473.Baalbergen, A., Smedts, F.& Helmerhorst, T.J.Conservative therapy in microinvasive adenocarcinoma of the uterine cervix is justified: an analysis of 59 cases and a review of the literature.Int $J$ Gynecol Cancer 21, 1640-1645 (2011).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "474.Haller, H., et al.Treatment and outcome of stage Ia1 squamous cell carcinoma of the uterine cervix.Int J Gynaecol Obstet 113, 72-75 (2011).475.Al-Kalbani, M., McVeigh, G., Nagar, H.& McCluggage, W.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "G.Do FIGO stage IA and small $( < / = 2$ cm) IB1 cervical adenocarcinomas have a good prognosis and warrant less radical surgery?Int J Gynecol Cancer 22, 291-295 (2012).476.He, Y., et al.Clinical value of cold knife conization as conservative management in patients with microinvasive cervical squamous cell cancer (stage IA1).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int $J$ Gynecol Cancer 24, 1306-1311 (2014).477.Schlaerth, J.B., Spirtos, N.M.& Schlaerth, A.C.Radical trachelectomy and pelvic lymphadenectomy with uterine preservation in the treatment of cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am J Obstet Gynecol 188, 29-34 (2003).478.Buckley, S.L., et al.Lymph node metastases and prognosis in patients with stage IA2 cervical cancer.Gynecol Oncol 63, 4-9 (1996).479.van Meurs, H., Visser, O., Buist, M.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "R., Ten Kate, F.J.& van der Velden, J.Frequency of pelvic lymph node metastases and parametrial involvement in stage IA2 cervical cancer: a population-based study and literature review.Int J Gynecol Cancer 19, 21-26 (2009).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "480.Smrkolj, S., Pogacnik, R.K., Slabe, N.& Rakar, S.Clinical outcome of patients with FIGO stage IA2 squamous cell carcinoma of the uterine cervix.Gynecol Oncol 124, 68-71 (2012).481.Mahawerawat, S., et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Surgical outcomes of patients with stage IA2 cervical cancer treated with radical hysterectomy.Asian Pac J Cancer Prev 14, 5375-5378 (2013).482.Ostor, A.G.& Rome, R.M.Micro-invasive squamous cell carcinoma of the cervix: a clinico-pathologic study of 200 cases with long-term follow-up.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 4, 257-264 (1994).483.Raspagliesi, F., et al.Prognostic factors in microinvasive cervical squamous cell cancer: long-term results.Int J Gynecol Cancer 15, 88-93 (2005).484.Lee, S.W.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.The efficacy of conservative management after conization in patients with stage IA1 microinvasive cervical carcinoma.Acta Obstet Gynecol Scand 88, 209-215 (2009).485.Lee, S.J., et al.Conization using electrosurgical conization and cold coagulation for international federation of gynecology and obstetrics stage IA1 squamous cell carcinomas of the uterine cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 19, 407-411 (2009).486.Yoshinaga, M., et al.Clinical outcome of stage Ia1 squamous cell carcinoma of the uterine cervix and pathological findings of initial conization.$J$ Obstet Gynaecol Res 37, 1645-1649 (2011).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "487.Sopracordevole, F., et al.Conservative treatment of microinvasive adenocarcinoma of uterine cervix: longterm follow-up.J Low Genit Tract Dis 16, 381-386 (2012).488.Sopracordevole, F., et al.Surgical approach and long-term clinical outcome in women with microinvasive cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Anticancer Res 34, 4345-4349 (2014).489.Chen, J.R., et al.Is conization once following by simple hysterectomy sufficient for all clinical stage IA1 cervical squamous cell carcinoma?Taiwan $J$ Obstet Gynecol 52, 385-388 (2013).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "490.Sevin, B.U., et al.Microinvasive carcinoma of the cervix.Cancer 70, 2121-2128 (1992).491.Yaegashi, N., Sato, S., Inoue, Y., Noda, K.& Yajima, A.Conservative surgical treatment in cervical cancer with 3 to 5 mm stromal invasion in the absence of confluent invasion and lymph-vascular space involvement.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 54, 333-337 (1994).492.Palaia, I., et al.Simple extrafascial trachelectomy and pelvic bilateral lymphadenectomy in early stage cervical cancer.Gynecol Oncol 126, 78- 81 (2012).493.Covens, A.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.How important is removal of the parametrium at surgery for carcinoma of the cervix?Gynecol Oncol 84, 145-149 (2002).494.Stegeman, M., et al.The incidence of parametrial tumor involvement in select patients with early cervix cancer is too low to justify parametrectomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 105, 475-480 (2007).495.Wright, J.D., et al.Utility of parametrectomy for early stage cervical cancer treated with radical hysterectomy.Cancer 110, 1281-1286 (2007).496.Frumovitz, M., et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Parametrial involvement in radical hysterectomy specimens for women with early-stage cervical cancer.Obstet Gynecol 114, 93- 99 (2009).497.Smith, A.L., et al.Conservative surgery in early-stage cervical cancer: what percentage of patients may be eligible for conization and lymphadenectomy?",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 119, 183-186 (2010).498.Steed, H., et al.Early cervical cancer and parametrial involvement: is it significant?Gynecol Oncol 103, 53-57 (2006).499.Hasumi, K., Sakamoto, A.& Sugano, H.Microinvasive carcinoma of the uterine cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cancer 45, 928-931 (1980).500.Vranes, B., Milenkovic, S., Radojevic, M., Soldatovic, I.& Kesic, V.Risk of Parametrial Spread in Small Stage I Cervical Carcinoma: Pathology Review of 223 Cases With a Tumor Diameter of $2 0 ~ \\mathrm { m m }$ or Less.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 26, 416-421 (2016).501.Hefler, L.A., et al.Repeat surgery in patients with cervical cancer stage FIGO IA1: a series of 156 cases and a review of the literature.Anticancer Res 30, 565- 568 (2010).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "502.Mota, F.Microinvasive squamous carcinoma of the cervix: treatment modalities.Acta Obstet Gynecol Scand 82, 505-509 (2003).503.Chang, D.Y., Cheng, W.F., Torng, P.L., Chen, R.J.& Huang, S.C.Prediction of residual neoplasia based on histopathology and margin status of conization specimens.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 63, 53-56 (1996).504.Phongnarisorn, C., et al.The risk of residual neoplasia in women with microinvasive squamous cervical carcinoma and positive cone margins.Int J Gynecol Cancer 16, 655-659 (2006).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "505.Andersen, E.S., Nielsen, K.& Pedersen, B.Combination laser conization as treatment of microinvasive carcinoma of the uterine cervix.Eur $J$ Gynaecol Oncol 19, 352-355 (1998).506.Bertelsen, B., Tande, T.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", Sandvei, R.& Hartveit, F.Laser conization of cervical intraepithelial neoplasia grade 3: free resection margins indicative of lesion free survival.Acta Obstet Gynecol Scand 78, 54-59 (1999).507.Murdoch, J.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "B., Morgan, P.R., Lopes, A.& Monaghan, J.M.Histological incomplete excision of CIN after large loop excision of the transformation zone (LLETZ) merits careful follow up, not retreatment.Br $J$ Obstet Gynaecol 99, 990-993 (1992).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "508.Paraskevaidis, E., et al.Delivery outcomes following loop electrosurgical excision procedure for microinvasive (FIGO stage IA1) cervical cancer.Gynecol Oncol 86, 10-13 (2002).509.Greer, B.E., Figge, D.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "C., Tamimi, H.K., Cain, J.M.& Lee, R.B.Stage IA2 squamous carcinoma of the cervix: difficult diagnosis and therapeutic dilemma.Am J Obstet Gynecol 162, 1406-1409; discussion 1409-1411 (1990).510.Andikyan, V.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Cervical conization and sentinel lymph node mapping in the treatment of stage I cervical cancer: is less enough?Int $J$ Gynecol Cancer 24, 113-117 (2014).511.Bai, H., et al.Accuracy of conization procedure for predicting pathological parameters of radical hysterectomy in stage Ia2-Ib1 ( $\\cdot < / { = } 2$ cm) cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Sci Rep 6, 25992 (2016).512.Paterson-Brown, S., et al.The significance of cone biopsy resection margins.Gynecol Oncol 46, 182-185 (1992).513.Kim, W.Y., Chang, S.J., Chang, K.H., Yoo, S.C.& Ryu, H.S.Conservative management of stage IA1 squamous cell carcinoma of the cervix with positive resection margins after conization.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynaecol Obstet 109, 110-112 (2010).514.Creasman, W.T., Fetter, B.F., ClarkePearson, D.L., Kaufmann, L.& Parker, R.T.Management of stage IA carcinoma of the cervix.Am J Obstet Gynecol 153, 164-172 (1985).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "515.Felix, J.C., Muderspach, L.I., Duggan, B.D.& Roman, L.D.The significance of positive margins in loop electrosurgical cone biopsies.Obstet Gynecol 84, 996- 1000 (1994).516.Suri, A., Frumovitz, M., Milam, M.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "R., dos Reis, R.& Ramirez, P.T.Preoperative pathologic findings associated with residual disease at radical hysterectomy in women with stage IA2 cervical cancer.Gynecol Oncol 112, 110-113 (2009).517.Tamauchi, S.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Oncologic and obstetric outcomes of early stage cervical cancer with abdominal radical trachelectomy: Single-institution experience.J Obstet Gynaecol Res 42, 1796-1801 (2016).518.Wong, A.S., Li, W.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "H.& Cheung, T.H.Predictive factors for residual disease in hysterectomy specimens after conization in early-stage cervical cancer.Eur J Obstet Gynecol Reprod Biol 199, 21-26 (2016).519.Costa, S., et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Outcome of conservatively treated microinvasive squamous cell carcinoma of the uterine cervix during a 10-year follow-up.Int J Gynecol Cancer 19, 33-38 (2009).520.Tseng, C.J., et al.Loop conization for the treatment of microinvasive carcinoma of the cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int $J$ Gynecol Cancer 16, 1574-1578 (2006).521.Day, E., et al.Multifocal FIGO Stage IA1 Squamous Carcinoma of the Cervix: Criteria for Identification, Staging, and its Good Clinical Outcome.Int J Gynecol Pathol 35, 467-474 (2016).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "522.Burghardt, E., Girardi, F., Lahousen, M., Pickel, H.& Tamussino, K.Microinvasive carcinoma of the uterine cervix (International Federation of Gynecology and Obstetrics Stage IA).Cancer 67, 1037-1045 (1991).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "523.Fagotti, A., et al.Excisional cone as fertility-sparing treatment in early-stage cervical cancer.Fertil Steril 95, 1109- 1112 (2011).524.Raju, S.K., et al.Fertility-sparing surgery for early cervical cancer-approach to less radical surgery.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 22, 311-317 (2012).525.Bekkers, R.L., et al.The value of loop electrosurgical conization in the treatment of stage IA1 microinvasive carcinoma of the uterine cervix.Int $J$ Gynecol Cancer 12, 485-489 (2002).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "526.Piura, B., Dgani, R., Yanai-Inbar, I., Cohen, Y.& Glezerman, M.Adenocarcinoma of the uterine cervix: a study of 37 cases.J Surg Oncol 61, 249- 255 (1996).527.Jones, M.W., Silverberg, S.G.& Kurman, R.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J.Well-differentiated villoglandular adenocarcinoma of the uterine cervix: a clinicopathological study of 24 cases.Int J Gynecol Pathol 12, 1-7 (1993).528.Wright, J.D., et al.Fertility-conserving surgery for young women with stage IA1 cervical cancer: safety and access.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Obstet Gynecol 115, 585-590 (2010).529.Ebina, Y., et al.Japan Society of Gynecologic Oncology guidelines 2011 for the treatment of uterine cervical cancer.Int $J$ Clin Oncol 20, 240-248 (2015).530.NICE.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cervical Cancer.http://pathways.nice.org.uk/pathways/c ervical-cancer (2015).531.SIGN.Management of cervical cancer.http://www.sign.ac.uk/pdf/sign99.pdf (2008).532.Reade, C.J., Eiriksson, L.R.& Covens, A.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Surgery for early stage cervical cancer: how radical should it be?Gynecol Oncol 131, 222-230 (2013).533.Baalbergen, A., Veenstra, Y.& Stalpers, L.Primary surgery versus primary radiotherapy with or without chemotherapy for early adenocarcinoma of the uterine cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cochrane Database Syst Rev, CD006248 (2013).534.Doll, K.M., et al.Radical hysterectomy compared with primary radiation for treatment of stage IB1 cervix cancer.Am J Clin Oncol 37, 30-34 (2014).535.Derks, M.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Long-Term Morbidity and Quality of Life in Cervical Cancer Survivors: A Multicenter Comparison Between Surgery and Radiotherapy as Primary Treatment.Int J Gynecol Cancer 27, 350-356 (2017).536.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Kong, T.W., et al.Treatment outcomes in patients with FIGO stage IB-IIA cervical cancer and a focally disrupted cervical stromal ring on magnetic resonance imaging: A propensity score matching study.Gynecol Oncol 143, 77-82 (2016).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "537.Derks, M., et al.Completing or Abandoning Radical Hysterectomy in Early-Stage Lymph Node-Positive Cervical Cancer: Impact on Disease-Free Survival and Treatment-Related Toxicity.Int J Gynecol Cancer 27, 1015- 1020 (2017).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "538.Kim, H.S., et al.Efficacy of neoadjuvant chemotherapy in patients with FIGO stage IB1 to IIA cervical cancer: an international collaborative metaanalysis.Eur J Surg Oncol 39, 115-124 (2013).539.Katsumata, N.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", Yoshikawa, H.& Kobayashi, H.Phase III randomized trial of neoadjuvant chemotherapy (NAC) followed by radical hysterectomy (RH) versus RH for bulky stage I/II cevical cancer: update of Japan Clinical Oncology Group (JCOG) protocol 0102.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Clin Oncol 28, 362-369 (2010).540.Sardi, J.E., et al.Long-term follow-up of the first randomized trial using neoadjuvant chemotherapy in stage Ib squamous carcinoma of the cervix: the final results.Gynecol Oncol 67, 61-69 (1997).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "541.Napolitano, U., et al.The role of neoadjuvant chemotherapy for squamous cell cervical cancer (Ib-IIIb): a long-term randomized trial.Eur $J$ Gynaecol Oncol 24, 51-59 (2003).542.Eddy, G.L., et al.Treatment of (\"bulky\") stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: a phase III trial of the gynecologic oncology group.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 106, 362- 369 (2007).543.Behtash, N., et al.Neoadjuvant chemotherapy and radical surgery compared to radical surgery alone in bulky stage IB-IIA cervical cancer.Eur J Surg Oncol 32, 1226-1230 (2006).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "544.Kim, H.S., et al.Matched-case comparison for the efficacy of neoadjuvant chemotherapy before surgery in FIGO stage IB1-IIA cervical cancer.Gynecol Oncol 119, 217-224 (2010).545.Cho, Y.H., et al.Comparative study of neoadjuvant chemotherapy before radical hysterectomy and radical surgery alone in stage IB2-IIA bulky cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Gynecol Oncol 20, 22- 27 (2009).546.Ryu, H.S., et al.Efficacy of different types of treatment in FIGO stage IB2 cervical cancer in Korea: results of a multicenter retrospective Korean study (KGOG1005).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 17, 132-136 (2007).547.Lu, Q., et al.Neoadjuvant intra-arterial chemotherapy followed by total laparoscopic radical trachelectomy in stage IB1 cervical cancer.Fertil Steril 101, 812-817 (2014).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "548.Plante, M., et al.Neoadjuvant chemotherapy followed by vaginal radical trachelectomy in bulky stage IB1 cervical cancer: case report.Gynecol Oncol 101, 367-370 (2006).549.Liu, H., Peng, Z.L., Lou, J.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Y.& Ping, W.Pregnancy after neoadjuvant chemotherapy followed by pelvic lymphadenectomy and radical trachelectomy in bulky stage IB1 cervical cancer: a case report.Aust N Z J Obstet Gynaecol 48, 517-518 (2008).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "550.Gottschalk, E., Mangler, M., Schneider, A., Koehler, C.& Lanowska, M.Pregnancy after lymphadenectomy and neoadjuvant chemotherapy followed by radical vaginal trachelectomy in FIGO stage IB1 cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Fertil Steril 95, 2431 e2435-2437 (2011).551.Marchiole, P., et al.Neoadjuvant chemotherapy and vaginal radical trachelectomy for fertility-sparing treatment in women affected by cervical cancer (FIGO stage IB-IIA1).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 122, 484-490 (2011).552.Vercellino, G.F., et al.Laparoscopic lymph node dissection should be performed before fertility preserving treatment of patients with cervical cancer.Gynecol Oncol 126, 325-329 (2012).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "553.Kobayashi, Y., Akiyama, F.& Hasumi, K.A case of successful pregnancy after treatment of invasive cervical cancer with systemic chemotherapy and conization.Gynecol Oncol 100, 213-215 (2006).554.Singh, P.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", Nicklin, J.& Hassall, T.Neoadjuvant chemotherapy followed by radical vaginal trachelectomy and adjuvant chemotherapy for clear cell cancer of the cervix: a feasible approach and review.Int $J$ Gynecol Cancer 21, 137-140 (2011).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "555.Hamed, A.H., Shepard, M.K., Maglinte, D.D., Ding, S.& Del Priore, G.Neoadjuvant chemotherapy followed by simultaneous robotic radical trachelectomy and reversal of tubal sterilization in stage IB2 cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "JSLS 16, 650-653 (2012).556.Wang, D., Yang, J., Shen, K.& Xiang, Y.Neoadjuvant chemotherapy followed by fertility-sparing surgery for women with stage IB1 cervical cancer.J Gynecol Oncol 24, 287-290 (2013).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "557.Landoni, F., et al.Chemo-conization in early cervical cancer.Gynecol Oncol 107, S125-126 (2007).558.Maneo, A., Chiari, S., Bonazzi, C.& Mangioni, C.Neoadjuvant chemotherapy and conservative surgery for stage IB1 cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 111, 438- 443 (2008).559.Lanowska, M., et al.Radical vaginal trachelectomy after laparoscopic staging and neoadjuvant chemotherapy in women with early-stage cervical cancer over $2 \\mathrm { c m }$ : oncologic, fertility, and neonatal outcome in a series of 20 patients.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 24, 586- 593 (2014).560.Robova, H., et al.Oncological and pregnancy outcomes after high-dose density neoadjuvant chemotherapy and fertility-sparing surgery in cervical cancer.Gynecol Oncol 135, 213-216 (2014).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "561.Robova, H., et al.High-dose density neoadjuvant chemotherapy in bulky IB cervical cancer.Gynecol Oncol 128, 49- 53 (2013).562.Islam, S., Mukhopadhyay, L.& Howells, R.Neo-adjuvant chemotherapy and radical surgery for stage 1B cervical cancer in pregnancy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Obstet Gynaecol 32, 191-192 (2012).563.Vizkeleti, J., et al.Pathologic complete remission after preoperative high-doserate brachytherapy in patients with operable cervical cancer: preliminary results of a prospective randomized multicenter study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Pathol Oncol Res 21, 247-256 (2015).564.Lacorre, A., et al.Early stage cervical cancer: Brachytherapy followed by type a hysterectomy versus type B radical hysterectomy alone, a retrospective evaluation.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Eur J Surg Oncol 42, 376-382 (2016).565.Escande, A., et al.Preoperative imageguided brachytherapy in early stage cervical cancers.Radiother Oncol 120, 455-459 (2016).566.Uzan, C., et al.Laparoscopic radical hysterectomy after preoperative brachytherapy for stage IB1 cervical cancer: feasibility, results, and surgical implications in a large bicentric study of 162 consecutive cases.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Ann Surg Oncol 20, 872-880 (2013).567.Hannoun-Levi, J.M., et al.Interstitial preoperative high-dose-rate brachytherapy for early stage cervical cancer: dose-volume histogram parameters, pathologic response and early clinical outcome.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Brachytherapy 12, 148-155 (2013).568.Lamblin, G., et al.[Surgery alone or in association with preoperative uterovaginal brachytherapy for stage IB1 cervical cancer: Toxicities profiles].Gynecol Obstet Fertil 43, 485-490 (2015).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "569.Piver, M.S., Rutledge, F.& Smith, J.P.Five classes of extended hysterectomy for women with cervical cancer.Obstet Gynecol 44, 265-272 (1974).570.Webb, M.J.Radical hysterectomy.Baillieres Clin Obstet Gynaecol 11, 149- 166 (1997).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "571.Verleye, L., Vergote, I., Reed, N.& Ottevanger, P.B.Quality assurance for radical hysterectomy for cervical cancer: the view of the European Organization for Research and Treatment of Cancer--Gynecological Cancer Group (EORTC-GCG).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Ann Oncol 20, 1631-1638 (2009).572.Cao, T., Feng, Y., Huang, Q., Wan, T.& Liu, J.Prognostic and Safety Roles in Laparoscopic Versus Abdominal Radical Hysterectomy in Cervical Cancer: A Meta-analysis.J Laparoendosc Adv Surg Tech A 25, 990-998 (2015).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "573.Bogani, G., et al.Laparoscopic versus open abdominal management of cervical cancer: long-term results from a propensity-matched analysis.$J$ Minim Invasive Gynecol 21, 857-862 (2014).574.Campos, L.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "S., Limberger, L.F., Stein, A.T.& Kalil, A.N.Postoperative pain and perioperative outcomes after laparoscopic radical hysterectomy and abdominal radical hysterectomy in patients with early cervical cancer: a randomised controlled trial.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Trials 14, 293 (2013).575.Ditto, A., et al.Implementation of laparoscopic approach for type B radical hysterectomy: a comparison with open surgical operations.Eur J Surg Oncol 41, 34-39 (2015).576.Frumovitz, M.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Comparison of total laparoscopic and abdominal radical hysterectomy for patients with earlystage cervical cancer.Obstet Gynecol 110, 96-102 (2007).577.Ghezzi, F., et al.Laparoscopic versus open radical hysterectomy for stage IB2-IIB cervical cancer in the setting of neoadjuvant chemotherapy: a multiinstitutional cohort study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Ann Surg Oncol 20, 2007-2015 (2013).578.Ghezzi, F., et al.Surgicopathologic outcome of laparoscopic versus open radical hysterectomy.Gynecol Oncol 106, 502-506 (2007).579.Kong, T.W., Chang, S.J., Lee, J.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", Paek, J.& Ryu, H.S.Comparison of laparoscopic versus abdominal radical hysterectomy for FIGO stage IB and IIA cervical cancer with tumor diameter of $3 \\mathrm { c m }$ or greater.Int J Gynecol Cancer 24, 280-288 (2014).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "580.Lee, E.J., Kang, H.& Kim, D.H.A comparative study of laparoscopic radical hysterectomy with radical abdominal hysterectomy for early-stage cervical cancer: a long-term follow-up study.Eur J Obstet Gynecol Reprod Biol 156, 83-86 (2011).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "581.Li, G., et al.A comparison of laparoscopic radical hysterectomy and pelvic lymphadenectomy and laparotomy in the treatment of Ib-IIa cervical cancer.Gynecol Oncol 105, 176-180 (2007).582.Lim, Y.K., Chia, Y.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "N.& Yam, K.L.Total laparoscopic Wertheim's radical hysterectomy versus Wertheim's radical abdominal hysterectomy in the management of stage I cervical cancer in Singapore: a pilot study.Singapore Med J 54, 683-688 (2013).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "583.Malzoni, M., Tinelli, R., Cosentino, F., Fusco, A.& Malzoni, C.Total laparoscopic radical hysterectomy versus abdominal radical hysterectomy with lymphadenectomy in patients with early cervical cancer: our experience.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Ann Surg Oncol 16, 1316-1323 (2009).584.Nam, J.H., et al.Laparoscopic versus open radical hysterectomy in earlystage cervical cancer: long-term survival outcomes in a matched cohort study.Ann Oncol 23, 903-911 (2012).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "585.Park, J.Y., et al.Laparoscopic compared with open radical hysterectomy in obese women with early-stage cervical cancer.Obstet Gynecol 119, 1201-1209 (2012).586.Park, J.Y., et al.Laparoscopic versus open radical hysterectomy for elderly patients with early-stage cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am J Obstet Gynecol 207, e1-e8 (2012).587.Sobiczewski, P., et al.Early cervical cancer managed by laparoscopy and conventional surgery: comparison of treatment results.Int J Gynecol Cancer 19, 1390-1395 (2009).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "588.Stanciu, P., et al.Laparoscopic radical hysterectomy vs.classical radical hysterectomy.Comparative study of complications and quality of life in patients with early stage cervical cancer.Obstet Ginecol 61, 221-225 (2013).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "589.Taylor, S.E., McBee, W.C., Jr., Richard, S.D.& Edwards, R.P.Radical hysterectomy for early stage cervical cancer: laparoscopy versus laparotomy.JSLS 15, 213-217 (2011).590.Toptas, T.& Simsek, T.Total laparoscopic versus open radical hysterectomy in stage IA2-IB1 cervical cancer: disease recurrence and survival comparison.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Laparoendosc Adv Surg Tech A 24, 373-378 (2014).591.Uccella, S., et al.A comparison of urinary complications following total laparoscopic radical hysterectomy and laparoscopic pelvic lymphadenectomy to open abdominal surgery.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 107, S147-149 (2007).592.Zakashansky, K., et al.A case-controlled study of total laparoscopic radical hysterectomy with pelvic lymphadenectomy versus radical abdominal hysterectomy in a fellowship training program.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int $J$ Gynecol Cancer 17, 1075-1082 (2007).593.Wang, Y.Z., Deng, L., Xu, H.C., Zhang, Y.& Liang, Z.Q.Laparoscopy versus laparotomy for the management of early stage cervical cancer.BMC Cancer 15, 928 (2015).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "594.Chen, C.H., et al.Comparing robotic surgery with conventional laparoscopy and laparotomy for cervical cancer management.Int J Gynecol Cancer 24, 1105-1111 (2014).595.Simsek, T., Ozekinci, M., Saruhan, Z.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", Sever, B.& Pestereli, E.Laparoscopic surgery compared to traditional abdominal surgery in the management of early stage cervical cancer.Eur $J$ Gynaecol Oncol 33, 395-398 (2012).596.Xiao, M.& Zhang, Z.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Total Laparoscopic Versus Laparotomic Radical Hysterectomy and Lymphadenectomy in Cervical Cancer: An Observational Study of 13-Year Experience.Medicine (Baltimore) 94, e1264 (2015).597.Park, D.A., Yun, J.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "E., Kim, S.W.& Lee, S.H.Surgical and clinical safety and effectiveness of robot-assisted laparoscopic hysterectomy compared to conventional laparoscopy and laparotomy for cervical cancer: A systematic review and meta-analysis.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Eur J Surg Oncol (2016).598.Estape, R., et al.A case matched analysis of robotic radical hysterectomy with lymphadenectomy compared with laparoscopy and laparotomy.Gynecol Oncol 113, 357-361 (2009).599.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Chong, G.O., et al.Robot versus laparoscopic nerve-sparing radical hysterectomy for cervical cancer: a comparison of the intraoperative and perioperative results of a single surgeon's initial experience.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int $J$ Gynecol Cancer 23, 1145-1149 (2013).600.Sert, M.B.& Abeler, V.Robot-assisted laparoscopic radical hysterectomy: comparison with total laparoscopic hysterectomy and abdominal radical hysterectomy; one surgeon's experience at the Norwegian Radium Hospital.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 121, 600-604 (2011).601.Tinelli, R., et al.Robotics versus laparoscopic radical hysterectomy with lymphadenectomy in patients with early cervical cancer: a multicenter study.Ann Surg Oncol 18, 2622-2628 (2011).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "602.Gortchev, G., Tomov, S., Tantchev, L., Velkova, A.& Radionova, Z.Robotassisted radical hysterectomyperioperative and survival outcomes in patients with cervical cancer compared to laparoscopic and radical surgery.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Surg 9, 81-88 (2012).603.Soliman, P.T., et al.Radical hysterectomy: a comparison of surgical approaches after adoption of robotic surgery in gynecologic oncology.Gynecol Oncol 123, 333-336 (2011).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "604.Kim, T.H., et al.Robotic versus laparoscopic radical hysterectomy in cervical cancer patients: a matched-case comparative study.Int J Gynecol Cancer 24, 1466-1473 (2014).605.Desille-Gbaguidi, H., et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Overall care cost comparison between robotic and laparoscopic surgery for endometrial and cervical cancer.Eur J Obstet Gynecol Reprod Biol 171, 348-352 (2013).606.Magrina, J.F., Kho, R.M., Weaver, A.L.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", Montero, R.P.& Magtibay, P.M.Robotic radical hysterectomy: comparison with laparoscopy and laparotomy.Gynecol Oncol 109, 86-91 (2008).607.Nezhat, F.R., Datta, M.S., Liu, C., Chuang, L.& Zakashansky, K.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Robotic radical hysterectomy versus total laparoscopic radical hysterectomy with pelvic lymphadenectomy for treatment of early cervical cancer.JSLS 12, 227-237 (2008).608.Sert, B.& Abeler, V.Robotic radical hysterectomy in early-stage cervical carcinoma patients, comparing results with total laparoscopic radical hysterectomy cases.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "The future is now?Int J Med Robot 3, 224-228 (2007).609.Reza, M., Maeso, S., Blasco, J.A.& Andradas, E.Meta-analysis of observational studies on the safety and effectiveness of robotic gynaecological surgery.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Br J Surg 97, 1772-1783 (2010).610.Shazly, S.A., Murad, M.H., Dowdy, S.C., Gostout, B.S.& Famuyide, A.O.Robotic radical hysterectomy in early stage cervical cancer: A systematic review and meta-analysis.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 138, 457- 471 (2015).611.Corrado, G., et al.Mini-laparoscopic versus robotic radical hysterectomy plus systematic pelvic lymphadenectomy in early cervical cancer patients.A multi-institutional study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Eur J Surg Oncol 41, 136-141 (2015).612.Yim, G.W., et al.Surgical outcomes of robotic radical hysterectomy using three robotic arms versus conventional multiport laparoscopy in patients with cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Yonsei Med $J$ 55, 1222- 1230 (2014).613.Vizza, E., et al.Laparoscopic versus robotic radical hysterectomy after neoadjuvant chemotherapy in locally advanced cervical cancer: a case control study.Eur J Surg Oncol 41, 142-147 (2015).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "614.Zhou, J., et al.Robotic vs laparoscopic radical hysterectomy for cervical cancer: a meta-analysis.Int J Med Robot 12, 145-154 (2016).615.Goud, J.G., Gottapu, K.& Kumar, V.M.B.Robotic versus total laparoscopic radical hysterectomy with pelvic lymphadenectomy for the treatment of early cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Reprod Contracept Obstet Gynecol 3, 34-39 (2014).616.Diaz-Feijoo, B., et al.Comparison of robotic-assisted vs conventional laparoscopy for extraperitoneal paraaortic lymphadenectomy.Gynecol Oncol 132, 98-101 (2014).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "617.Wright, J.D., et al.Comparative effectiveness of minimally invasive and abdominal radical hysterectomy for cervical cancer.Gynecol Oncol 127, 11- 17 (2012).618.Lim, P.C.& Kang, E.Y.The learning curve and surgical outcome for robotic assisted radical hysterectomy with lymphadenectomy: a case-matched controlled comparison to laparoscopy and laparotomy for treatment of cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Minim Invasive Gynecol 18, S156-168 (2011).619.Lambaudie, E., et al.Role of robotassisted laparoscopy in adjuvant surgery for locally advanced cervical cancer.Eur J Surg Oncol 36, 409-413 (2010).620.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Stroup, D.F., et al.Meta-analysis of observational studies in epidemiology: a proposal for reporting.Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.JAMA 283, 2008-2012 (2000).621.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Kruijdenberg, C.B., van den Einden, L.C., Hendriks, J.C., Zusterzeel, P.L.& Bekkers, R.L.Robot-assisted versus total laparoscopic radical hysterectomy in early cervical cancer, a review.Gynecol Oncol 120, 334-339 (2011).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "622.Abu-Rustum, N.R., et al.Total laparoscopic radical hysterectomy with pelvic lymphadenectomy using the argon-beam coagulator: pilot data and comparison to laparotomy.Gynecol Oncol 91, 402-409 (2003).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "623.Chong, G.O., et al.Learning curve of laparoscopic radical hysterectomy with pelvic and/or para-aortic lymphadenectomy in the early and locally advanced cervical cancer: comparison of the first 50 and second 50 cases.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 19, 1459- 1464 (2009).624.Pellegrino, A., et al.Total laparoscopic radical hysterectomy and pelvic lymphadenectomy in patients with Ib1 stage cervical cancer: analysis of surgical and oncological outcome.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Eur J Surg Oncol 35, 98-103 (2009).625.Pomel, C., et al.Laparoscopic radical hysterectomy for invasive cervical cancer: 8-year experience of a pilot study.Gynecol Oncol 91, 534-539 (2003).626.Spirtos, N.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "M., Eisenkop, S.M., Schlaerth, J.B.& Ballon, S.C.Laparoscopic radical hysterectomy (type III) with aortic and pelvic lymphadenectomy in patients with stage I cervical cancer: surgical morbidity and intermediate follow-up.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am J Obstet Gynecol 187, 340-348 (2002).627.Boggess, J.F., et al.A case-control study of robot-assisted type III radical hysterectomy with pelvic lymph node dissection compared with open radical hysterectomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am J Obstet Gynecol 199, 357 e351-357 (2008).628.Puntambekar, S.P., et al.Laparoscopic total radical hysterectomy by the Pune technique: our experience of 248 cases.J Minim Invasive Gynecol 14, 682-689 (2007).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "629.Persson, J., et al.Robot assisted laparoscopic radical hysterectomy and pelvic lymphadenectomy with short and long term morbidity data.Gynecol Oncol 113, 185-190 (2009).630.Obermair, A., Ginbey, P.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "& McCartney, A.J.Feasibility and safety of total laparoscopic radical hysterectomy.$J A m$ Assoc Gynecol Laparosc 10, 345-349 (2003).631.Fanning, J., Fenton, B.& Purohit, M.Robotic radical hysterectomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am $J$ Obstet Gynecol 198, 649 e641-644 (2008).632.Kim, Y.T., et al.Robotic radical hysterectomy with pelvic lymphadenectomy for cervical carcinoma: a pilot study.Gynecol Oncol 108, 312-316 (2008).633.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Ko, E.M., Muto, M.G., Berkowitz, R.S.& Feltmate, C.M.Robotic versus open radical hysterectomy: a comparative study at a single institution.Gynecol Oncol 111, 425-430 (2008).634.Lowe, M.P., Chamberlain, D.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "H., Kamelle, S.A., Johnson, P.R.& Tillmanns, T.D.A multi-institutional experience with robotic-assisted radical hysterectomy for early stage cervical cancer.Gynecol Oncol 113, 191-194 (2009).635.Maggioni, A.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Robotic approach for cervical cancer: comparison with laparotomy: a case control study.Gynecol Oncol 115, 60-64 (2009).636.Gil-Moreno, A., et al.Total laparoscopic radical hysterectomy (type II-III) with pelvic lymphadenectomy in early invasive cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Minim Invasive Gynecol 12, 113-120 (2005).637.Kim, D.H.& Moon, J.S.Laparoscopic radical hysterectomy with pelvic lymphadenectomy for early, invasive cervical carcinoma.J Am Assoc Gynecol Laparosc 5, 411-417 (1998).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "638.Lee, C.L., Huang, K.G., Wang, C.J., Lee, P.S.& Hwang, L.L.Laparoscopic radical hysterectomy using pulsed bipolar system: comparison with conventional bipolar electrosurgery.Gynecol Oncol 105, 620-624 (2007).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "639.Cantrell, L.A., Mendivil, A., Gehrig, P.A.& Boggess, J.F.Survival outcomes for women undergoing type III robotic radical hysterectomy for cervical cancer: a 3-year experience.Gynecol Oncol 117, 260-265 (2010).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "640.Geisler, J.P., Orr, C.J., Khurshid, N., Phibbs, G.& Manahan, K.J.Robotically assisted laparoscopic radical hysterectomy compared with open radical hysterectomy.Int J Gynecol Cancer 20, 438-442 (2010).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "641.Gocmen, A., Sanlikan, F.& Ucar, M.G.Comparison of outcomes between laparotomy and robotic technique for cervical cancer.J Robot Surg 4, 123-128 (2010).642.Halliday, D., et al.Robotic radical hysterectomy: comparison of outcomes and cost.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Robot Surg 4, 211-216 (2010).643.Lowe, M.P., et al.A comparison of robotassisted and traditional radical hysterectomy for early-stage cervical cancer.J Robot Surg 3, 19 (2009).644.Nam, E.J., et al.A case-control study of robotic radical hysterectomy and pelvic lymphadenectomy using 3 robotic arms compared with abdominal radical hysterectomy in cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int $J$ Gynecol Cancer 20, 1284-1289 (2010).645.Schreuder, H.W., et al.From open radical hysterectomy to robot-assisted laparoscopic radical hysterectomy for early stage cervical cancer: aspects of a single institution learning curve.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Surg 7, 253-258 (2010).646.Pilka, R., Marek, R., Dzvincuk, P., Kudela, M.& Neubert, D.[\"Learning curve\" robotic radical hysterectomy compared to standardized laparoscopy assisted radical vaginal and open radical hysterectomy].",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Ceska Gynekol 78, 20-27 (2013).647.Sert, B.M., et al.Robot-assisted versus open radical hysterectomy: A multiinstitutional experience for early-stage cervical cancer.Eur J Surg Oncol 42, 513-522 (2016).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "648.Geetha, P.& Nair, M.K.Laparoscopic, robotic and open method of radical hysterectomy for cervical cancer: A systematic review.J Minim Access Surg 8, 67-73 (2012).649.Medical Advisory Secretariat.Roboticassisted minimally invasive surgery for gynecologic and urologic oncology: an evidence-based analysis.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Ont Health Technol Assess Ser 10, 1-118 (2010).650.Kucukmetin, A., Biliatis, I., Naik, R.& Bryant, A.Laparoscopically assisted radical vaginal hysterectomy versus radical abdominal hysterectomy for the treatment of early cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cochrane Database Syst Rev, CD006651 (2013).651.Kim, H.S., et al.Conventional versus nerve-sparing radical surgery for cervical cancer: a meta-analysis.J Gynecol Oncol 26, 100-110 (2015).652.Trimbos, J.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "B., Maas, C.P., Deruiter, M.C., Peters, A.A.& Kenter, G.G.A nervesparing radical hysterectomy: guidelines and feasibility in Western patients.Int $J$ Gynecol Cancer 11, 180- 186 (2001).653.Pieterse, Q.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "D., et al.Vaginal blood flow after radical hysterectomy with and without nerve sparing.A preliminary report.Int J Gynecol Cancer 18, 576-583 (2008).654.Raspagliesi, F., et al.Type II versus Type III nerve-sparing radical hysterectomy: comparison of lower urinary tract dysfunctions.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 102, 256- 262 (2006).655.Li, B., et al.[A prospective study on nerve-sparing radical hysterectomy in patients with cervical cancer].Zhonghua Fu Chan Ke Za Zhi 43, 606-610 (2008).656.Chen, C.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Classical and nervesparing radical hysterectomy: an evaluation of the nerve trauma in cardinal ligament.Gynecol Oncol 125, 245-251 (2012).657.Possover, M., Stober, S., Plaul, K.& Schneider, A.Identification and preservation of the motoric innervation of the bladder in radical hysterectomy type III.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 79, 154-157 (2000).658.van den Tillaart, S.A., et al.Nervesparing radical hysterectomy: local recurrence rate, feasibility, and safety in cervical cancer patients stage IA to IIA.Int J Gynecol Cancer 19, 39-45 (2009).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "659.Skret-Magierlo, J., et al.Radical hysterectomy during the transition period from traditional to nerve-sparing technique.Gynecol Oncol 116, 502-505 (2010).660.Tseng, C.J., Shen, H.P., Lin, Y.H., Lee, C.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Y.& Wei-Cheng Chiu, W.A prospective study of nerve-sparing radical hysterectomy for uterine cervical carcinoma in Taiwan.Taiwan J Obstet Gynecol 51, 55-59 (2012).661.Bogani, G., et al.Nerve-sparing versus conventional laparoscopic radical hysterectomy: a minimum 12 months' follow-up study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 24, 787-793 (2014).662.Querleu, D., et al.Modified radical vaginal hysterectomy with or without laparoscopic nerve-sparing dissection: a comparative study.Gynecol Oncol 85, 154-158 (2002).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "663.Todo, Y., et al.Urodynamic study on postsurgical bladder function in cervical cancer treated with systematic nervesparing radical hysterectomy.Int $J$ Gynecol Cancer 16, 369-375 (2006).664.Cibula, D.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Factors affecting spontaneous voiding recovery after radical hysterectomy.Int $J$ Gynecol Cancer 20, 685-690 (2010).665.Espino-Strebel, E.E., Luna, J.T.& Domingo, E.J.A comparison of the feasibility and safety of nerve-sparing radical hysterectomy with the conventional radical hysterectomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 20, 1274-1283 (2010).666.Liang, Z., Chen, Y., Xu, H., Li, Y.& Wang, D.Laparoscopic nerve-sparing radical hysterectomy with fascia space dissection technique for cervical cancer: description of technique and outcomes.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 119, 202-207 (2010).667.Cibula, D., et al.Local control after tailored surgical treatment of early cervical cancer.Int J Gynecol Cancer 21, 690-698 (2011).668.Ditto, A., et al.Class III nerve-sparing radical hysterectomy versus standard class III radical hysterectomy: an observational study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Ann Surg Oncol 18, 3469-3478 (2011).669.Ceccaroni, M., et al.Pelvic dysfunctions and quality of life after nerve-sparing radical hysterectomy: a multicenter comparative study.Anticancer Res 32, 581-588 (2012).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "670.Pieterse, Q.D., et al.Self-reported sexual, bowel and bladder function in cervical cancer patients following different treatment modalities: longitudinal prospective cohort study.Int J Gynecol Cancer 23, 1717-1725 (2013).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "671.Wang, W., et al.Evaluation of pelvic visceral functions after modified nervesparing radical hysterectomy.Chin Med J (Engl) 127, 696-701 (2014).672.van Gent, M.D., Romijn, L.M., van Santen, K.E., Trimbos, J.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "B.& de Kroon, C.D.Nerve-sparing radical hysterectomy versus conventional radical hysterectomy in early-stage cervical cancer.A systematic review and metaanalysis of survival and quality of life.Maturitas 94, 30-38 (2016).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "673.Wu, J., et al.Effect of nerve-sparing radical hysterectomy on bladder function recovery and quality of life in patients with cervical carcinoma.Int $J$ Gynecol Cancer 20, 905-909 (2010).674.Chen, L.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", Zhang, W.N., Zhang, S.M., Yang, Z.H.& Zhang, P.Effect of laparoscopic nerve-sparing radical hysterectomy on bladder function, intestinal function recovery and quality of sexual life in patients with cervical carcinoma.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Asian Pac J Cancer Prev 15, 10971-10975 (2014).675.Roh, J.W., et al.Efficacy and oncologic safety of nerve-sparing radical hysterectomy for cervical cancer: a randomized controlled trial.J Gynecol Oncol 26, 90-99 (2015).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "676.Hockel, M., et al.Nerve-sparing radical hysterectomy: II.Results after three years [German].Geburtshilfe Frauenheilkd 60, 320-325 (2000).677.Kuwabara, Y., et al.New method to prevent bladder dysfunction after radical hysterectomy for uterine cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Obstet Gynaecol Res 26, 1-8 (2000).678.Sakuragi, N., Todo, Y., Kudo, M., Yamamoto, R.& Sato, T.A systematic nerve-sparing radical hysterectomy technique in invasive cervical cancer for preserving postsurgical bladder function.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 15, 389- 397 (2005).679.Chen, Y., et al.[Laparoscopic anatomical nerve sparing radical hysterectomy for cervical cancer: a clinical analysis of 37 cases].Zhonghua Fu Chan Ke Za Zhi 44, 359-363 (2009).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "680.Sun, L., et al.[Preliminary study of nerve sparing radical hysterectomy in patients with cervical cancer].Zhonghua Zhong Liu Za Zhi 31, 607-611 (2009).681.Runnebaum, I.B., Camara, O.& Diebolder, H.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Nerve-sparing vaginal assisted laparoscopic radical hysterectomy (VALRH): evaluation of type C1 radicality for low and high-risk early cervical cancer.Arch Gynecol Obstet, S170 (2010).682.Merlot, B., et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Robotic nerve-sparing versus laparoscopic without nervesparing radical hysterectomy in early cervical cancer: urinary diseases.Int $J$ Gynecol Conf, S105 (2011).683.Prajwala, R., Tsang, J., Thangavelu, A.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "& Abu, J.I.Feasibility of laparoscopic nerve sparing radical hysterectomy in the management of early cervical cancer, International Journal of Gynecological Cancer Conference: 18th International Meeting of the European Society of Gynaecological Oncology: October 2013.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "(2013).684.Bogani, G., et al.Nerve-sparing approach reduces sexual dysfunction in patients undergoing laparoscopic radical hysterectomy.J Sex Med 11, 3012-3020 (2014).685.Kanao, H., et al.Various types of total laparoscopic nerve-sparing radical hysterectomies and their effects on bladder function.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "$J$ Gynecol Oncol 25, 198-205 (2014).686.Makowski, M., et al.Classical radical hysterectomy and nerve-sparing radical hysterectomy in the treatment of cervical cancer.Prz Menopauzalny 13, 180-185 (2014).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "687.Rademaker, M., et al.Long-term followup after nerve sparing radical hysterectomy in patients with stage IAIIA cervical cancer.Int J Gynecol Cancer Conf., 3 (2014).688.Wenwen, W., et al.[Evaluation of postoperative bladder function and prognosis after modified nerve sparing radical hysterectomy].",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Zhonghua Fu Chan Ke Za Zhi 49, 341-347 (2014).689.Shi, R., Wei, W.& Jiang, P.Laparoscopic Nerve-Sparing Radical Hysterectomy for Cervical Carcinoma: Emphasis on Nerve Content in Removed Cardinal Ligaments.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 26, 192- 198 (2016).690.Puntambekar, S.P., et al.Nerve-sparing robotic radical hysterectomy: our technique.J Robot Surg 8, 43-47 (2014).691.Magrina, J.F., Pawlina, W., Kho, R.M.& Magtibay, P.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "M.Robotic nerve-sparing radical hysterectomy: feasibility and technique.Gynecol Oncol 121, 605-609 (2011).692.Gil-Ibanez, B., et al.Nerve sparing technique in robotic-assisted radical hysterectomy: results.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Med Robot 9, 339-344 (2013).693.van Gent, M.D., et al.Nerve-sparing radical abdominal trachelectomy versus nerve-sparing radical hysterectomy in early-stage (FIGO IA2-IB) cervical cancer: a comparative study on feasibility and outcome.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int $J$ Gynecol Cancer 24, 735-743 (2014).694.Lanowska, M., et al.Vaginal-assisted laparoscopic radical hysterectomy (VALRH) versus laparoscopic-assisted radical vaginal hysterectomy (LARVH) in the treatment of cervical cancer: surgical results and oncologic outcome.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Arch Gynecol Obstet 289, 1293-1300 (2014).695.Steed, H., et al.A comparison of laparascopic-assisted radical vaginal hysterectomy and radical abdominal hysterectomy in the treatment of cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 93, 588- 593 (2004).696.Garabedian, C., et al.Minimally invasive surgical management of early-stage cervical cancer: an analysis of the risk factors of surgical complications and of oncologic outcomes.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 25, 714-721 (2015).697.Oleszczuk, A., Kohler, C., Paulick, J., Schneider, A.& Lanowska, M.Vaginal robot-assisted radical hysterectomy (VRARH) after laparoscopic staging: feasibility and operative results.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int $J$ Med Robot 5, 38-44 (2009).698.Fagotti, A., et al.Minilaparoscopic radical hysterectomy (mLPS-RH) vs laparoendoscopic single-site radical hysterectomy (LESS-RH) in early stage cervical cancer: a multicenter retrospective study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Minim Invasive Gynecol 21, 1005-1009 (2014).699.Chen, C.H., Wang, P.H., Chiu, L.H.& Chang, W.H.Comparing thermal welding instrument-assisted laparoscopic radical hysterectomy versus conventional radical hysterectomy in the management of FIGO IB1 squamous cell cervical carcinoma.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Eur J Gynaecol Oncol 34, 442-445 (2013).700.Lim, Y.K., Chia, Y.N., Quek, S.C.& Yam, K.L.Radical abdominal trachelectomy for stage IB1 cervical cancer in Singapore.Singapore Med J 54, e204- 207 (2013).701.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Chen, Y., et al.The outcome of laparoscopic radical hysterectomy and lymphadenectomy for cervical cancer: a prospective analysis of 295 patients.Ann Surg Oncol 15, 2847-2855 (2008).702.Segaert, A., et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Robot-Assisted Radical Hysterectomy in Cervical Carcinoma: The Belgian Experience.Int $J$ Gynecol Cancer 25, 1690-1696 (2015).703.Yang, L., et al.Laparoscopic radical hysterectomy and pelvic lymphadenectomy can be routinely used for treatment of early-stage cervical cancer: a single-institute experience with 404 patients.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "$J$ Minim Invasive Gynecol 22, 199-204 (2015).704.Soliman, P.T., et al.Analgesic and antiemetic requirements after minimally invasive surgery for early cervical cancer: a comparison between laparoscopy and robotic surgery.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Ann Surg Oncol 20, 1355-1359 (2013).705.Suh, D.H., Cho, H.Y., Kim, K., No, J.H.& Kim, Y.B.Matched-Case Comparisons in a Single Institution to Determine Critical Points for Inexperienced Surgeons' Successful Performances of Laparoscopic Radical Hysterectomy versus Abdominal Radical Hysterectomy in Stage IA2-IIA Cervical Cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "PLoS One 10, e0131170 (2015).706.Rogers, L., Siu, S.S., Luesley, D., Bryant, A.& Dickinson, H.O.Radiotherapy and chemoradiation after surgery for early cervical cancer.Cochrane Database Syst Rev, CD007583 (2012).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "707.Rotman, M., et al.A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study.Int J Radiat Oncol Biol Phys 65, 169-176 (2006).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "708.Sedlis, A., et al.A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 73, 177-183 (1999).709.Bilek, K., Ebeling, K., Leitsmann, H.& Seidel, G.Radical pelvic surgery versus radical surgery plus radiotherapy for stage Ib carcinoma of the cervix uteri.Preliminary results of a prospective randomized clinical study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Arch Geschwulstforsch 52, 223-229 (1982).710.Sandadi, S., et al.Radical surgery with individualized postoperative radiation for stage IB cervical cancer: oncologic outcomes and severe complications.Int J Gynecol Cancer 23, 553-558 (2013).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "711.Fleming, N.D., et al.Significance of lymph node ratio in defining risk category in node-positive early stage cervical cancer.Gynecol Oncol 136, 48- 53 (2015).712.Inoue, T.& Morita, K.Long-term observation of patients treated by postoperative extended-field irradiation for nodal metastases from cervical carcinoma stages IB, IIA, and IIB.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 58, 4-10 (1995).713.Richard, S.D., et al.Survival for stage IB cervical cancer with positive lymph node involvement: a comparison of completed vs.abandoned radical hysterectomy.Gynecol Oncol 109, 43-48 (2008).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "714.Nakamura, K., et al.Analysis of the effect of adjuvant radiotherapy on outcomes and complications after radical hysterectomy in FIGO stage IB1 cervical cancer patients with intermediate risk factors (GOTIC Study).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "World J Surg Oncol 14, 173 (2016).715.Barter, J.F., Soong, S.J., Shingleton, H.M., Hatch, K.D.& Orr, J.W., Jr.Complications of combined radical hysterectomypostoperative radiation therapy in women with early stage cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 32, 292-296 (1989).716.Fiorica, J.V., et al.Morbidity and survival patterns in patients after radical hysterectomy and postoperative adjuvant pelvic radiotherapy.Gynecol Oncol 36, 343-347 (1990).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "717.Rushdan, M.N., et al.Tailoring the field and indication of adjuvant pelvic radiation for patients with FIGO stage Ib lymph nodes-negative cervical carcinoma following radical surgery based on the GOG score--a pilot study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Ann Acad Med Singapore 33, 467-472 (2004).718.Frigerio, L., Busci, L., Rabaiotti, E.& Mariani, A.Adjunctive radiotherapy after radical hysterectomy in high risk early stage cervical carcinoma.Assessment of morbidity and recurrences.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Eur $J$ Gynaecol Oncol 15, 132-137 (1994).719.Uno, T., et al.Postoperative radiation therapy for stage IB-IIB carcinoma of the cervix with poor prognostic factors.Anticancer Res 20, 2235-2239 (2000).720.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Falcetta, F.S., et al.Adjuvant platinumbased chemotherapy for early stage cervical cancer.Cochrane Database Syst Rev 11, CD005342 (2016).721.Peters, W.A., 3rd, et al.Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Clin Oncol 18, 1606-1613 (2000).722.CE3005, P.Cancer Research UK.A prospective randomised trial of adjuvant chemotherapy in node positive early stage carcinoma of the cervix - Protocol CE3005.UK Clinical Trials Register.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "(2001).723.Sun, W., et al.Randomized phase III trial of radiotherapy or chemoradiotherapy with topotecan and cisplatin in intermediate-risk cervical cancer patients after radical hysterectomy.BMC Cancer 15, 353 (2015).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "724.Tattersall, M.H., Ramirez, C.& Coppleson, M.A randomized trial of adjuvant chemotherapy after radical hysterectomy in stage Ib-IIa cervical cancer patients with pelvic lymph node metastases.Gynecol Oncol 46, 176-181 (1992).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "725.Lahousen, M., et al.Chemotherapy versus radiotherapy versus observation for high-risk cervical carcinoma after radical hysterectomy: A randomized, prospective, multicenter trial.Gynecol Oncol 73, 196-201 (1999).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "726.Pu, J., et al.A randomized controlled study of single-agent cisplatin and radiotherapy versus docetaxel/cisplatin and radiotherapy in high-risk earlystage cervical cancer after radical surgery.$J$ Cancer Res Clin Oncol 139, 703-708 (2013).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "727.Yamamoto, K., et al.Adjuvant oral 5- fluorouracil for cervical cancer: Japanese Gynecologic Oncology Group report.Int J Oncol 24, 1175-1179 (2004).728.Lai, C.H., et al.Implications of a failed prospective trial of adjuvant therapy after radical hysterectomy for stage IbIIa cervical carcinoma with pelvic node metastases.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Changgeng Yi Xue Za Zhi 21, 291-299 (1998).729.Curtin, J.P., et al.Adjuvant chemotherapy versus chemotherapy plus pelvic irradiation for high-risk cervical cancer patients after radical hysterectomy and pelvic lymphadenectomy (RH-PLND): a randomized phase III trial.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 61, 3-10 (1996).730.Iwasaka, T., et al.Adjuvant chemotherapy after radical hysterectomy for cervical carcinoma: a comparison with effects of adjuvant radiotherapy.Obstet Gynecol 91, 977- 981 (1998).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "731.Lin, H., ChangChien, C.C., Chang, S.Y.& Leung, S.W.Survival advantages and complications of adjuvant therapy in early-stage cervical cancer with pelvic node metastasis.Changgeng Yi Xue Za Zhi 21, 383-390 (1998).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "732.Mossa, B., et al.Does adjuvant chemotherapy improve the prognosis of cervical carcinoma with lymph-node metastasis?A long-term follow-up.Eur J Gynaecol Oncol 24, 33-40 (2003).733.Park, T.K., Kim, S.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "N., Kwon, J.Y.& Mo, H.J.Postoperative adjuvant therapy in early invasive cervical cancer patients with histopathologic high-risk factors.Int $J$ Gynecol Cancer 11, 475-482 (2001).734.Ryu, H.S., Chun, M.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", Chang, K.H., Chang, H.J.& Lee, J.P.Postoperative adjuvant concurrent chemoradiotherapy improves survival rates for high-risk, early stage cervical cancer patients.Gynecol Oncol 96, 490-495 (2005).735.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Takekuma, M., et al.Adjuvant chemotherapy versus concurrent chemoradiotherapy for high-risk cervical cancer after radical hysterectomy and systematic lymphadenectomy.Int $J$ Clin Oncol 21, 741-747 (2016).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "736.Wertheim, M.S., et al.A pilot study of adjuvant therapy in patients with cervical cancer at high risk of recurrence after radical hysterectomy and pelvic lymphadenectomy.J Clin Oncol 3, 912-916 (1985).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "737.Sivanesaratnam, V., Sen, D.K.& Jayalakshmi, P.Adjuvant cytotoxic chemotherapy following Wertheim radical hysterectomy for cervical cancer.Aust N Z J Obstet Gynaecol 27, 231-233 (1987).738.Sivanesaratnam, V.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "& Jayalakshmi, P.Mitomycin C adjuvant chemotherapy after Wertheim's hysterectomy for stage IB cervical cancer.Cancer 64, 798-800 (1989).739.Killackey, M.A., Boardman, L.& Carroll, D.S.Adjuvant chemotherapy and radiation in patients with poor prognostic stage Ib/IIa cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 49, 377-379 (1993).740.Zanetta, G., Colombo, A., Milani, R., Placa, F.& Mangioni, C.Long-term results of sequential postoperative treatment with vincristine, bleomycin, mitomycin c, cisplatin and radiotherapy after surgery for high-risk patients with cervical carcinoma stage IB-IIA.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int $J$ Gynecol Cancer 5, 40-44 (1995).741.Ng, H.T., et al.An evaluation of chemotherapy in patients with cancer of the cervix and lymph node metastases.Arch Gynecol Obstet 256, 1-4 (1995).742.Sivanesaratnam, V.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Adjuvant chemotherapy in \"high risk\" patients after Wertheim hysterectomy--10-year survivals.Ann Acad Med Singapore 27, 622-626 (1998).743.Argenta, P.A., et al.Radiation therapy with concomitant and adjuvant cisplatin and paclitaxel in high-risk cervical cancer: long-term follow-up.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Eur $J$ Gynaecol Oncol 27, 231-235 (2006).744.Takeshima, N., et al.Treatment results of adjuvant chemotherapy after radical hysterectomy for intermediate- and high-risk stage IB-IIA cervical cancer.Gynecol Oncol 103, 618-622 (2006).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "745.Fabrini, M.G., et al.Clinical outcome of tailored adjuvant postoperative chemoradiotherapy in IB FIGO stage cervical cancer.Anticancer Res 29, 4205-4210 (2009).746.McCaffrey, R., et al.Neoadjuvant and adjuvant chemotherapy of cervical cancer: mature results of the phase 2 PBM-PFU protocol.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 21, 535-544 (2011).747.Folkert, M.R., et al.Postoperative pelvic intensity-modulated radiotherapy and concurrent chemotherapy in intermediate- and high-risk cervical cancer.Gynecol Oncol 128, 288-293 (2013).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "748.Lee, T.S., et al.Chemoradiation with paclitaxel and carboplatin in high-risk cervical cancer patients after radical hysterectomy: a Korean Gynecologic Oncology Group study.Int J Radiat Oncol Biol Phys 86, 304-310 (2013).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "749.Wang, X., et al.Adjuvant intensitymodulated radiotherapy (IMRT) with concurrent paclitaxel and cisplatin in cervical cancer patients with high risk factors: A phase II trial.Eur J Surg Oncol 41, 1082-1088 (2015).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "750.Bentivegna, E., et al.Fertility results and pregnancy outcomes after conservative treatment of cervical cancer: a systematic review of the literature.Fertil Steril 106, 1195-1211 e1195 (2016).751.Rob, L.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", Skapa, P.& Robova, H.Fertilitysparing surgery in patients with cervical cancer.Lancet Oncol 12, 192-200 (2011).752.Rob, L., et al.Less radical fertilitysparing surgery than radical trachelectomy in early cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 17, 304-310 (2007).753.Maneo, A., et al.Simple conization and lymphadenectomy for the conservative treatment of stage IB1 cervical cancer.An Italian experience.Gynecol Oncol 123, 557-560 (2011).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "754.Ferrandina, G., Salutari, V., Petrillo, M., Carbone, A.& Scambia, G.Conservatively treated glassy cell carcinoma of the cervix.World J Surg Oncol 6, 92 (2008).755.Biliatis, I., et al.Small volume stage 1B1 cervical cancer: Is radical surgery still necessary?",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 126, 73-77 (2012).756.Lindsay, R., et al.Fertility conserving management of early cervical cancer: our experience of LLETZ and pelvic lymph node dissection.Int $J$ Gynecol Cancer 24, 118-123 (2014).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "757.Ditto, A., et al.Fertility-sparing surgery in early-stage cervical cancer patients: oncologic and reproductive outcomes.Int J Gynecol Cancer 25, 493-497 (2015).758.Kyrgiou, M., et al.Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and metaanalysis.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Lancet 367, 489-498 (2006).759.Jones, J.M., Sweetnam, P.& Hibbard, B.M.The outcome of pregnancy after cone biopsy of the cervix: a case-control study.Br J Obstet Gynaecol 86, 913-916 (1979).760.Kuoppala, T.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "& Saarikoski, S.Pregnancy and delivery after cone biopsy of the cervix.Arch Gynecol 237, 149-154 (1986).761.Weber, T.& Obel, E.B.Pregnancy complications following conization of the uterine cervix (II).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Acta Obstet Gynecol Scand 58, 347-351 (1979).762.Buller, R.E.& Jones, H.W., 3rd.Pregnancy following cervical conization.Am J Obstet Gynecol 142, 506-512 (1982).763.Kasum, M.& Kuvacic, I.[Pregnancy outcome after conization].",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Jugosl Ginekol Perinatol 31, 31-34 (1991).764.Kristensen, G.B.The outcome of pregnancy and preterm delivery after conization of the cervix.Arch Gynecol 236, 127-130 (1985).765.Kristensen, J., Langhoff-Roos, J.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "& Kristensen, F.B.Increased risk of preterm birth in women with cervical conization.Obstet Gynecol 81, 1005- 1008 (1993).766.Larsson, G., Grundsell, H., Gullberg, B.& Svennerud, S.Outcome of pregnancy after conization.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Acta Obstet Gynecol Scand 61, 461-466 (1982).767.Ludviksson, K.& Sandstrom, B.Outcome of pregnancy after cone biopsy--a casecontrol study.Eur J Obstet Gynecol Reprod Biol 14, 135-142 (1982).768.Praest, J.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Conizatio cervicis uteri.Ugeskrift For Laeger 51, 3509-3511 (1979).769.Tan, L., Pepra, E.& Haloob, R.K.The outcome of pregnancy after large loop excision of the transformation zone of the cervix.J Obstet Gynaecol 24, 25-27 (2004).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "770.Braet, P.G., Peel, J.M.& Fenton, D.W.A case controlled study of the outcome of pregnancy following loop diathermy excision of the transformation zone.$J$ Obstet Gynecol 14, 79-82 (1994).771.Haffenden, D.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "K., Bigrigg, A., Codling, B.W.& Read, M.D.Pregnancy following large loop excision of the transformation zone.Br J Obstet Gynaecol 100, 1059-1060 (1993).772.Blomfield, P.I., Buxton, J., Dunn, J.& Luesley, D.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "M.Pregnancy outcome after large loop excision of the cervical transformation zone.Am J Obstet Gynecol 169, 620-625 (1993).773.Sadler, L., et al.Treatment for cervical intraepithelial neoplasia and risk of preterm delivery.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "JAMA 291, 2100-2106 (2004).774.Samson, S.L., Bentley, J.R., Fahey, T.J., McKay, D.J.& Gill, G.H.The effect of loop electrosurgical excision procedure on future pregnancy outcome.Obstet Gynecol 105, 325-332 (2005).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "775.Cruickshank, M.E., Flannelly, G., Campbell, D.M.& Kitchener, H.C.Fertility and pregnancy outcome following large loop excision of the cervical transformation zone.Br J Obstet Gynaecol 102, 467-470 (1995).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "776.Turlington, W.T., Wright, B.D.& Powell, J.L.Impact of the loop electrosurgical excision procedure on future fertility.$J$ Reprod Med 41, 815-818 (1996).777.Bigrigg, A., Haffenden, D.K., Sheehan, A.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "L., Codling, B.W.& Read, M.D.Efficacy and safety of large-loop excision of the transformation zone.Lancet 343, 32-34 (1994).778.Raio, L., Ghezzi, F., Di Naro, E., Gomez, R.& Luscher, K.P.Duration of pregnancy after carbon dioxide laser conization of the cervix: influence of cone height.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Obstet Gynecol 90, 978-982 (1997).779.Bekassy, Z.& Iosif, C.S.Laser \"miniconisation' and the outcome of subsequent pregnancy.Arch Gynecol Obstet 258, 75-79 (1996).780.Sagot, P., Caroit, Y., Winer, N., Lopes, P.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "& Boog, G.Obstetrical prognosis for carbon dioxide laser conisation of the uterine cervix.Eur $J$ Obstet Gynecol Reprod Biol 58, 53-58 (1995).781.Hagen, B.& Skjeldestad, F.E.The outcome of pregnancy after CO2 laser conisation of the cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Br J Obstet Gynaecol 100, 717-720 (1993).782.Forsmo, S., Hansen, M.H., Jacobsen, B.K.& Oian, P.Pregnancy outcome after laser surgery for cervical intraepithelial neoplasia.Acta Obstet Gynecol Scand 75, 139-143 (1996).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "783.Spitzer, M., Herman, J., Krumholz, B.A.& Lesser, M.The fertility of women after cervical laser surgery.Obstet Gynecol 86, 504-508 (1995).784.van Rooijen, M.& Persson, E.Pregnancy outcome after laser vaporization of the cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Acta Obstet Gynecol Scand 78, 346-348 (1999).785.Crane, J.M.Pregnancy outcome after loop electrosurgical excision procedure: a systematic review.Obstet Gynecol 102, 1058-1062 (2003).786.Noehr, B., Jensen, A.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", Frederiksen, K., Tabor, A.& Kjaer, S.K.Loop electrosurgical excision of the cervix and subsequent risk for spontaneous preterm delivery: a population-based study of singleton deliveries during a 9- year period.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am J Obstet Gynecol 201, 33 e31-36 (2009).787.Fanfani, F., et al.Sexual and Reproductive Outcomes in Early Stage Cervical Cancer Patients after Excisional Cone as a Fertility-sparing Surgery: An Italian Experience.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Reprod Infertil 15, 29-34 (2014).788.Dhar, K.K., Byrom, J., Todd, R.W.& Redman, C.W.In conisation with pelvic lymphadenectomy adequate for FIGO stage 1B1 cervical cancer?Case report and review of the literature.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Obstet Gynaecol 23, 81-83 (2003).789.Bouchard-Fortier, G., Reade, C.J.& Covens, A.Non-radical surgery for small early-stage cervical cancer.Is it time?Gynecol Oncol 132, 624-627 (2014).790.Bentivegna, E.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Oncological outcomes after fertility-sparing surgery for cervical cancer: a systematic review.Lancet Oncol 17, e240-253 (2016).791.Dargent, D., Martin, X., Sacchetoni, A.& Mathevet, P.Laparoscopic vaginal radical trachelectomy: a treatment to preserve the fertility of cervical carcinoma patients.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cancer 88, 1877- 1882 (2000).792.Roy, M.& Plante, M.Pregnancies after radical vaginal trachelectomy for earlystage cervical cancer.Am J Obstet Gynecol 179, 1491-1496 (1998).793.Tanguay, C., Plante, M., Renaud, M.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "C., Roy, M.& Tetu, B.Vaginal radical trachelectomy in the treatment of cervical cancer: the role of frozen section.Int J Gynecol Pathol 23, 170-175 (2004).794.Plante, M., Renaud, M.C., Hoskins, I.A.& Roy, M.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Vaginal radical trachelectomy: a valuable fertility-preserving option in the management of early-stage cervical cancer.A series of 50 pregnancies and review of the literature.Gynecol Oncol 98, 3-10 (2005).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "795.Plante, M., Gregoire, J., Renaud, M.C.& Roy, M.The vaginal radical trachelectomy: an update of a series of 125 cases and 106 pregnancies.Gynecol Oncol 121, 290-297 (2011).796.Shepherd, J.H., Crawford, R.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A.& Oram, D.H.Radical trachelectomy: a way to preserve fertility in the treatment of early cervical cancer.Br J Obstet Gynaecol 105, 912-916 (1998).797.Shepherd, J.H., Mould, T.& Oram, D.H.Radical trachelectomy in early stage carcinoma of the cervix: outcome as judged by recurrence and fertility rates.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "BJOG 108, 882-885 (2001).798.Shepherd, J.H., Spencer, C., Herod, J.& Ind, T.E.Radical vaginal trachelectomy as a fertility-sparing procedure in women with early-stage cervical cancercumulative pregnancy rate in a series of 123 women.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "BJOG 113, 719-724 (2006).799.Alexander-Sefre, F., Chee, N., Spencer, C., Menon, U.& Shepherd, J.H.Surgical morbidity associated with radical trachelectomy and radical hysterectomy.Gynecol Oncol 101, 450- 454 (2006).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "800.Knight, L.J., et al.Obstetric management following fertility-sparing radical vaginal trachelectomy for cervical cancer.J Obstet Gynaecol 30, 784-789 (2010).801.Covens, A., et al.Is radical trachelectomy a safe alternative to radical hysterectomy for patients with stage IAB carcinoma of the cervix?",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cancer 86, 2273-2279 (1999).802.Bernardini, M., Barrett, J., Seaward, G.& Covens, A.Pregnancy outcomes in patients after radical trachelectomy.Am J Obstet Gynecol 189, 1378-1382 (2003).803.Beiner, M.E.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Radical vaginal trachelectomy vs.radical hysterectomy for small early stage cervical cancer: a matched case-control study.Gynecol Oncol 110, 168-171 (2008).804.Helpman, L., Grisaru, D.& Covens, A.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Early adenocarcinoma of the cervix: is radical vaginal trachelectomy safe?Gynecol Oncol 123, 95-98 (2011).805.Dargent, D.[Radical trachelectomy: an operation that preserves the fertility of young women with invasive cervical cancer].",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Bull Acad Natl Med 185, 1295- 1304; discussion 1305-1296 (2001).806.Martin, X.J., Golfier, F., Romestaing, P.& Raudrant, D.First case of pregnancy after radical trachelectomy and pelvic irradiation.Gynecol Oncol 74, 286-287 (1999).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "807.Mathevet, P., Laszlo de Kaszon, E.& Dargent, D.[Fertility preservation in early cervical cancer].Gynecol Obstet Fertil 31, 706-712 (2003).808.Marchiole, P., et al.Oncological safety of laparoscopic-assisted vaginal radical trachelectomy (LARVT or Dargent's operation): a comparative study with laparoscopic-assisted vaginal radical hysterectomy (LARVH).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 106, 132-141 (2007).809.Burnett, A.F., Roman, L.D., O'Meara, A.T.& Morrow, C.P.Radical vaginal trachelectomy and pelvic lymphadenectomy for preservation of fertility in early cervical carcinoma.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 88, 419-423 (2003).810.Hertel, H., et al.Radical vaginal trachelectomy (RVT) combined with laparoscopic pelvic lymphadenectomy: prospective multicenter study of 100 patients with early cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 103, 506-511 (2006).811.Pahisa, J., Alonso, I.& Torne, A.Vaginal approaches to fertility-sparing surgery in invasive cervical cancer.Gynecol Oncol 110, S29-32 (2008).812.Chen, Y., et al.A fertility-preserving option in early cervical carcinoma: laparoscopy-assisted vaginal radical trachelectomy and pelvic lymphadenectomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Eur J Obstet Gynecol Reprod Biol 136, 90-93 (2008).813.Carter, J., Sonoda, Y.& Abu-Rustum, N.R.Reproductive concerns of women treated with radical trachelectomy for cervical cancer.Gynecol Oncol 105, 13- 16 (2007).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "814.Sonoda, Y., Chi, D.S., Carter, J., Barakat, R.R.& Abu-Rustum, N.R.Initial experience with Dargent's operation: the radical vaginal trachelectomy.Gynecol Oncol 108, 214-219 (2008).815.Einstein, M.H.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Radical vaginal versus abdominal trachelectomy for stage IB1 cervical cancer: a comparison of surgical and pathologic outcomes.Gynecol Oncol 112, 73-77 (2009).816.Speiser, D., et al.Fertility outcome after radical vaginal trachelectomy: a prospective study of 212 patients.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 21, 1635-1639 (2011).817.Lanowska, M., et al.Radical vaginal trachelectomy (RVT) combined with laparoscopic lymphadenectomy: prospective study of 225 patients with early-stage cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 21, 1458-1464 (2011).818.Mangler, M., et al.Pattern of cancer recurrence in 320 patients after radical vaginal trachelectomy.Int J Gynecol Cancer 24, 130-134 (2014).819.Persson, J.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Reproducibility and accuracy of robot-assisted laparoscopic fertility sparing radical trachelectomy.Gynecol Oncol 127, 484-488 (2012).820.Uzan, C., et al.Analysis of a continuous series of 34 young patients with earlystage cervical cancer selected for a vaginal radical trachelectomy: should \"staging\" conization be systematically performed before this procedure?",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 23, 331-336 (2013).821.Kim, M., et al.Importance of uterine cervical cerclage to maintain a successful pregnancy for patients who undergo vaginal radical trachelectomy.Int J Clin Oncol 19, 906-911 (2014).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "822.Hauerberg, L., et al.Vaginal Radical Trachelectomy for early stage cervical cancer.Results of the Danish National Single Center Strategy.Gynecol Oncol 138, 304-310 (2015).823.Massa, L.A., et al.Vaginal radical trachelectomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A 10 years experience of 3 centers in Chile: IGCS-0076 Cervical Cancer.Int J Gynecol Cancer 25 Suppl 1, 28 (2015).824.Cao, D.Y., et al.Comparisons of vaginal and abdominal radical trachelectomy for early-stage cervical cancer: preliminary results of a multi-center research in China.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Br J Cancer 109, 2778-2782 (2013).825.Ma, L.K., et al.Pregnancy outcome and obstetric management after vaginal radical trachelectomy.Eur Rev Med Pharmacol Sci 18, 3019-3024 (2014).826.Yoon, A., et al.Perioperative Outcomes of Radical Trachelectomy in Early-Stage Cervical Cancer: Vaginal Versus Laparoscopic Approaches.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 25, 1051-1057 (2015).827.Dursun, P., LeBlanc, E.& Nogueira, M.C.Radical vaginal trachelectomy (Dargent's operation): a critical review of the literature.Eur J Surg Oncol 33, 933-941 (2007).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "828.Schneider, A., et al.Clinical recommendation radical trachelectomy for fertility preservation in patients with early-stage cervical cancer.Int J Gynecol Cancer 22, 659-666 (2012).829.Zusterzeel, P.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "L., et al.Vaginal Radical Trachelectomy for Early-Stage Cervical Cancer: Increased Recurrence Risk for Adenocarcinoma.Int $J$ Gynecol Cancer 26, 1293-1299 (2016).830.Bratila, E., Bratila, C.P.& Coroleuca, C.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "B.Radical Vaginal Trachelectomy with Laparoscopic Pelvic Lymphadenectomy for Fertility Preservation in Young Women with Early-Stage Cervical Cancer.Indian $J$ Surg 78, 265-270 (2016).831.Faber-Swensson, A.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "P., Perrin, L.C.& Nicklin, J.L.Radical trachelectomy for early stage cervical cancer: the Queensland experience.Aust N Z J Obstet Gynaecol 54, 450-452 (2014).832.Renaud, M.C., Plante, M.& Roy, M.Combined laparoscopic and vaginal radical surgery in cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 79, 59-63 (2000).833.Han, L., et al.Systematic comparison of radical vaginal trachelectomy and radical hysterectomy in the treatment of early-stage cervical cancer.Int $J$ Gynaecol Obstet 112, 149-153 (2011).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "834.Ishioka, S., et al.Pregnancy-related complications after vaginal radical trachelectomy for early-stage invasive uterine cervical cancer.Int J Clin Oncol 12, 350-355 (2007).835.Jolley, J.A., Battista, L.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "& Wing, D.A.Management of pregnancy after radical trachelectomy: case reports and systematic review of the literature.Am J Perinatol 24, 531-539 (2007).836.Morice, P., Dargent, D., Haie-Meder, C., Duvillard, P.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "& Castaigne, D.First case of a centropelvic recurrence after radical trachelectomy: literature review and implications for the preoperative selection of patients.Gynecol Oncol 92, 1002-1005 (2004).837.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Piketty, M., Barranger, E., Najat, M., Francois, P.& Darai, E.Ovarian recurrence after radical trachelectomy for adenocarcinoma of the cervix.Am J Obstet Gynecol 193, 1382-1383 (2005).838.Plante, M., Renaud, M.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "C., Francois, H.& Roy, M.Vaginal radical trachelectomy: an oncologically safe fertility-preserving surgery.An updated series of 72 cases and review of the literature.Gynecol Oncol 94, 614-623 (2004).839.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Smith, J.R., et al.Abdominal radical trachelectomy: a new surgical technique for the conservative management of cervical carcinoma.Br J Obstet Gynaecol 104, 1196-1200 (1997).840.Palfalvi, L., Ungar, L.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", Boyle, D.C., Del Priore, G.& Smith, J.R.Announcement of healthy baby boy born following abdominal radical trachelectomy.Int $J$ Gynecol Cancer 13, 250 (2003).841.Del Priore, G., Ungar, L., Boyle, D.& Smith, R.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Abdominal radical trachelectomy for fertility preservation in cervical cancer.Obstet Gynecol 101, S2-3 (2003).842.Ungar, L., et al.Abdominal radical trachelectomy: a fertility-preserving option for women with early cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "BJOG 112, 366-369 (2005).843.Saso, S., et al.Abdominal radical trachelectomy in West London.BJOG 119, 187-193 (2012).844.Lintner, B., et al.Use of abdominal radical trachelectomy to treat cervical cancer greater than $2 \\ \\mathrm { c m }$ in diameter.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int $J$ Gynecol Cancer 23, 1065-1070 (2013).845.Rodriguez, M., Guimares, O.& Rose, P.G.Radical abdominal trachelectomy and pelvic lymphadenectomy with uterine conservation and subsequent pregnancy in the treatment of early invasive cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am J Obstet Gynecol 185, 370-374 (2001).846.Pareja, F.R., Ramirez, P.T., Borrero, F.M.& Angel, C.G.Abdominal radical trachelectomy for invasive cervical cancer: a case series and literature review.Gynecol Oncol 111, 555-560 (2008).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "847.Nishio, H., et al.Abdominal radical trachelectomy as a fertility-sparing procedure in women with early-stage cervical cancer in a series of 61 women.Gynecol Oncol 115, 51-55 (2009).848.Nishio, H., et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Reproductive and obstetric outcomes after radical abdominal trachelectomy for earlystage cervical cancer in a series of 31 pregnancies.Hum Reprod 28, 1793- 1798 (2013).849.Kasuga, Y., et al.Pregnancy Outcomes After Abdominal Radical Trachelectomy for Early-Stage Cervical Cancer: A 13- Year Experience in a Single TertiaryCare Center.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int $J$ Gynecol Cancer 26, 163-168 (2016).850.Olawaiye, A., et al.Abdominal radical trachelectomy: Success and pitfalls in a general gynecologic oncology practice.Gynecol Oncol 112, 506-510 (2009).851.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cibula, D., et al.Abdominal radical trachelectomy in fertility-sparing treatment of early-stage cervical cancer.Int $J$ Gynecol Cancer 19, 1407-1411 (2009).852.Yao, T., Mo, S.& Lin, Z.The functional reconstruction of fertility-sparing radical abdominal trachelectomy for early stage cervical carcinoma.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Eur $J$ Obstet Gynecol Reprod Biol 151, 77-81 (2010).853.Li, J., et al.Radical abdominal trachelectomy for cervical malignancies: surgical, oncological and fertility outcomes in 62 patients.Gynecol Oncol 121, 565-570 (2011).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "854.Li, J., Wu, X., Li, X.& Ju, X.Abdominal radical trachelectomy: Is it safe for IB1 cervical cancer with tumors $> / = \\ : 2 \\ : \\ : \\mathrm { c m ?}$ Gynecol Oncol 131, 87-92 (2013).855.Nick, A.M., Frumovitz, M.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "M., Soliman, P.T., Schmeler, K.M.& Ramirez, P.T.Fertility sparing surgery for treatment of early-stage cervical cancer: open vs.robotic radical trachelectomy.Gynecol Oncol 124, 276-280 (2012).856.Vieira, M.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A., et al.Radical trachelectomy in early-stage cervical cancer: A comparison of laparotomy and minimally invasive surgery.Gynecol Oncol 138, 585-589 (2015).857.Muraji, M., et al.Type II versus type III fertility-sparing abdominal radical trachelectomy for early-stage cervical cancer: a comparison of feasibility of surgical outcomes.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 22, 479-483 (2012).858.Karateke, A., et al.Radical trachelectomy in late pregnancy: is it an option?Eur J Obstet Gynecol Reprod Biol 152, 112-113 (2010).859.Abu-Rustum, N.R., et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Fertility-sparing radical abdominal trachelectomy for cervical carcinoma: technique and review of the literature.Gynecol Oncol 103, 807-813 (2006).860.Abu-Rustum, N.R., et al.Surgical and pathologic outcomes of fertility-sparing radical abdominal trachelectomy for FIGO stage IB1 cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 111, 261-264 (2008).861.Kim, C.H., et al.Reproductive outcomes of patients undergoing radical trachelectomy for early-stage cervical cancer.Gynecol Oncol 125, 585-588 (2012).862.Wethington, S.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "L., et al.An international series on abdominal radical trachelectomy: 101 patients and 28 pregnancies.Int $J$ Gynecol Cancer 22, 1251-1257 (2012).863.Wethington, S.L., et al.Expanding the indications for radical trachelectomy: a report on 29 patients with stage IB1 tumors measuring 2 to 4 centimeters.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int $J$ Gynecol Cancer 23, 1092-1098 (2013).864.Demirkiran, F., et al.The surgical outcomes of abdominal radical trachelectomy: does transrectal ultrasonography determine the cervical incision site during surgery?",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Eur $J$ Gynaecol Oncol 35, 566-570 (2014).865.Testa, R., et al.Abdominal radical trachelectomy: a safe and feasible option for fertility preservation in developing countries.$J$ Low Genit Tract Dis 17, 378-384 (2013).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "866.Capilna, M.E., Rusu, S.C., Puiac, C.I., Daniilidis, A.& Szabo, B.Spontaneous intrauterine pregnancy following abdominal radical trachelectomy--a case report.Eur J Gynaecol Oncol 36, 229-230 (2015).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "867.Kucukmetin, A., et al.Laparoscopic radical trachelectomy is an alternative to laparotomy with improved perioperative outcomes in patients with early-stage cervical cancer.Int J Gynecol Cancer 24, 135-140 (2014).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "868.Soderini, A., et al.The abdominal radical trachelectomy sparing the uterine arteries (A.R.T.- S.U.A) & the pelvic autonomic plexus (P.P.A.P.) in cervical cancer (CC): oncological & fertility outcomes of this novel surgical technique: IGCS-0105 Cervical Cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 25 Suppl 1, 40-41 (2015).869.Tokunaga, H., et al.Outcomes of abdominal radical trachelectomy: results of a multicenter prospective cohort study in a Tohoku Gynecologic Cancer Unit.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Clin Oncol 20, 776-780 (2015).870.Pareja, R., Rendon, G.J., Sanz-Lomana, C.M., Monzon, O.& Ramirez, P.T.Surgical, oncological, and obstetrical outcomes after abdominal radical trachelectomy - a systematic literature review.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 131, 77-82 (2013).871.Jeremic, K., et al.Radical abdominal trachelectomy in managing early cervical invasion.Eur J Gynaecol Oncol 30, 309-312 (2009).872.Pomel, C., et al.Laparoscopic (type III Piver like) radical trachelectomy [updated in J Gynecol Obstet Biol Reprod 2006; 35:696-701].",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Eur J Surg Oncol 28, 302 (2002).873.Park, N.Y., Chong, G.O., Cho, Y.L., Park, I.S.& Lee, Y.S.Total laparoscopic nervesparing radical trachelectomy.$J$ Laparoendosc Adv Surg Tech A 19, 53-58 (2009).874.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Martin, A.& Torrent, A.Laparoscopic nerve-sparing radical trachelectomy: surgical technique and outcome.J Minim Invasive Gynecol 17, 37-41 (2010).875.Kim, J.H., et al.Fertility-sparing laparoscopic radical trachelectomy for young women with early stage cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "BJOG 117, 340-347 (2010).876.Park, J.Y., et al.Reproductive outcomes after laparoscopic radical trachelectomy for early-stage cervical cancer.J Gynecol Oncol 25, 9-13 (2014).877.Lu, Q., et al.Total laparoscopic radical trachelectomy in the treatment of early squamous cell cervical cancer: a retrospective study with 8-year followup.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 130, 275-279 (2013).878.Ebisawa, K., et al.Obstetric outcomes of patients undergoing total laparoscopic radical trachelectomy for early stage cervical cancer.Gynecol Oncol 131, 83- 86 (2013).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "879.Persson, J., Kannisto, P.& Bossmar, T.Robot-assisted abdominal laparoscopic radical trachelectomy.Gynecol Oncol 111, 564-567 (2008).880.Johansen, G., Lonnerfors, C., Falconer, H.& Persson, J.Reproductive and oncologic outcome following robotassisted laparoscopic radical trachelectomy for early stage cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 141, 160-165 (2016).881.Gizzo, S., et al.Radical trachelectomy: the first step of fertility preservation in young women with cervical cancer (Review).Oncol Rep 30, 2545-2554 (2013).882.Okugawa, K.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Oncologic and obstetric outcomes and complications during pregnancy after fertility-sparing abdominal trachelectomy for cervical cancer: a retrospective review.Int J Clin Oncol (2016).883.Yoo, S.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "E., et al.Surgical and obstetrical outcomes after laparoscopic radical trachelectomy and pelvic lymphadenectomy for early cervical cancer.Obstet Gynecol Sci 59, 373-378 (2016).884.Xu, L., Sun, F.Q.& Wang, Z.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "H.Radical trachelectomy versus radical hysterectomy for the treatment of early cervical cancer: a systematic review.Acta Obstet Gynecol Scand 90, 1200- 1209 (2011).885.Li, X., et al.The Survival Rate and Surgical Morbidity of Abdominal Radical Trachelectomy Versus Abdominal Radical Hysterectomy for Stage IB1 Cervical Cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Ann Surg Oncol 23, 2953-2958 (2016).886.Carter, J., Sonoda, Y., Chi, D.S., Raviv, L.& Abu-Rustum, N.R.Radical trachelectomy for cervical cancer: postoperative physical and emotional adjustment concerns.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 111, 151-157 (2008).887.Carter, J., et al.A 2-year prospective study assessing the emotional, sexual, and quality of life concerns of women undergoing radical trachelectomy versus radical hysterectomy for treatment of early-stage cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 119, 358-365 (2010).888.Froeding, L.P., et al.Sexual functioning and vaginal changes after radical vaginal trachelectomy in early stage cervical cancer patients: a longitudinal study.J Sex Med 11, 595-604 (2014).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "889.Fleming, N.D., et al.Quality of life after radical trachelectomy for early-stage cervical cancer: A 5-year prospective evaluation.Gynecol Oncol 143, 596-603 (2016).890.Bader, A.A., Tamussino, K.F., Moinfar, F.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", Bjelic-Radisic, V.& Winter, R.Isolated recurrence at the residual uterine cervix after abdominal radical trachelectomy for early cervical cancer.Gynecol Oncol 99, 785-787 (2005).891.Wan, X.P., Yan, Q.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", Xi, X.W.& Cai, B.Abdominal radical trachelectomy: two new surgical techniques for the conservation of uterine arteries.Int $J$ Gynecol Cancer 16, 1698-1704 (2006).892.Zhang, D., et al.Surgical and pathological outcomes of abdominal radical trachelectomy versus hysterectomy for early-stage cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 24, 1312-1318 (2014).893.Karimi Zarchi, M., Mousavi, A.S.& Dehghani, A.Conservative surgery in cervical cancer: report of two radical abdominal trachelectomies and literature review.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Eur J Gynaecol Oncol 32, 710-712 (2011).894.Singh, S., Redline, R.& Resnick, K.E.Fertility-sparing management of a stage IB1 small cell neuroendocrine cervical carcinoma with radical abdominal trachelectomy and adjuvant chemotherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol Rep 13, 5- 7 (2015).895.Salman, M.C., Ozgul, N.& Yuce, K.Widespread recurrence 7 years after radical abdominal trachelectomy for early cervical adenocarcinoma.Case Rep Obstet Gynecol 2015, 517496 (2015).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "896.Saadi, J.M., et al.Laparoscopic radical trachelectomy: technique, feasibility, and outcomes.JSLS 19, e2013 00248 (2015).897.Bafghi, A., Castaigne, D.& Pomel, C.[Radical trachelectomy: From the laparoscopic approach to the vaginal route].",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Gynecol Obstet Biol Reprod (Paris) 35, 696-701 (2006).898.Hong, D.G., et al.Robotic uterine artery preservation and nerve-sparing radical trachelectomy with bilateral pelvic lymphadenectomy in early-stage cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 21, 391-396 (2011).899.Cibula, D., Ungar, L., Palfalvi, L., Bino, B.& Kuzel, D.Laparoscopic abdominal radical trachelectomy.Gynecol Oncol 97, 707-709 (2005).900.Rendon, G.J., Ramirez, P.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "T., Frumovitz, M., Schmeler, K.M.& Pareja, R.Laparoscopic radical trachelectomy.JSLS 16, 503-507 (2012).901.Wang, Y.F., Chen, G.W., Li, W.S., Weng, H.N.& Lu, X.G.Total laparoscopic radical trachelectomy with ascending branches of uterine arteries preservation.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Chin Med J (Engl) 124, 469-471 (2011).902.Schneider, A.& Kohler, C.Locoregional recurrence after laparoscopic radical trachelectomy: the vaginal cuff must be closed to avoid tumor cell contamination of the peritoneal cavity.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 25, 550 (2015).903.Burnett, A.F., Stone, P.J., Duckworth, L.A.& Roman, J.J.Robotic radical trachelectomy for preservation of fertility in early cervical cancer: case series and description of technique.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Minim Invasive Gynecol 16, 569-572 (2009).904.Ramirez, P.T., Schmeler, K.M., Malpica, A.& Soliman, P.T.Safety and feasibility of robotic radical trachelectomy in patients with early-stage cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 116, 512-515 (2010).905.Andou, M., Yamanaka, A., Kodama, K., Shirane, A.& Fukuta, M.RoboticallyAssisted Radical Trachelectomy.J Minim Invasive Gynecol 22, S11-S12 (2015).906.Geisler, J.P.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", Orr, C.J.& Manahan, K.J.Robotically assisted total laparoscopic radical trachelectomy for fertility sparing in stage IB1 adenosarcoma of the cervix.J Laparoendosc Adv Surg Tech A 18, 727-729 (2008).907.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Chuang, L.T., Lerner, D.L., Liu, C.S.& Nezhat, F.R.Fertility-sparing roboticassisted radical trachelectomy and bilateral pelvic lymphadenectomy in early-stage cervical cancer.J Minim Invasive Gynecol 15, 767-770 (2008).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "908.Madhuri, T.K., Hamzawala, I., Tailor, A.& Butler-Manuel, S.Robot assisted surgery in gynaecologic oncology - starting a program and initial learning curve from a UK tertiary referral centre: the Guildford perspective.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Med Robot 8, 496-503 (2012).909.Landoni, F., et al.Conservative surgery associated with chemotherapy in early stage cervical cancer.Gynecol Oncol 125, S58-59 (2012).910.Salihi, R., et al.Neoadjuvant chemotherapy followed by large cone resection as fertility-sparing therapy in stage IB cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 139, 447-451 (2015).911.Yan, H., et al.Long-term outcomes of radical vaginal trachelectomy and laparoscopic pelvic lymphadenectomy after neoadjuvant chemotherapy for the IB1 cervical cancer: A series of 60 cases.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Surg 29, 38-42 (2016).912.Pareja, R., et al.Immediate radical trachelectomy versus neoadjuvant chemotherapy followed by conservative surgery for patients with stage IB1 cervical cancer with tumors 2cm or larger: A literature review and analysis of oncological and obstetrical outcomes.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 137, 574-580 (2015).913.Palaia, I., et al.Neoadjuvant chemotherapy plus fertility-sparing surgery in locally advanced cervical cancer: case report.$J$ Minim Invasive Gynecol 18, 121-122 (2011).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "914.Yao, Y.Y., Wang, Y., Wang, J.L., Zhao, C.& Wei, L.H.Outcomes of fertility and pregnancy in patients with early-stage cervical cancer after undergoing neoadjuvant chemotherapy.Eur J Gynaecol Oncol 37, 109-112 (2016).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "915.Feng, Y., et al.Neoadjuvant chemotherapy followed by conization to spare fertility in cases of locally advanced cervical cancer: A case report and review of the literature.Mol Clin Oncol 5, 411-416 (2016).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "916.Tsubamoto, H., et al.Fertility-sparing management for bulky cervical cancer using neoadjuvant transuterine arterial chemotherapy followed by vaginal trachelectomy.Int J Gynecol Cancer 22, 1057-1062 (2012).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "917.Tsuji, N., Butsuhara, Y., Yoshikawa, H., Terakawa, K.& Nagano, T.Pregnancy after neoadjuvant chemotherapy followed by abdominal radical trachelectomy in stage IB2 cervical cancer: A case report.Gynecol Oncol Case Rep 4, 13-15 (2012).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "918.Tabata, M., et al.Incidence of ovarian metastasis in patients with cancer of the uterine cervix.Gynecol Oncol 28, 255- 261 (1987).919.Sutton, G.P., et al.Ovarian metastases in stage IB carcinoma of the cervix: a Gynecologic Oncology Group study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am J Obstet Gynecol 166, 50-53 (1992).920.Yamamoto, R., et al.A study of risk factors for ovarian metastases in stage Ib-IIIb cervical carcinoma and analysis of ovarian function after a transposition.Gynecol Oncol 82, 312-316 (2001).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "921.Kasamatsu, T., et al.Radical hysterectomy for FIGO stage I-IIB adenocarcinoma of the uterine cervix.Br J Cancer 100, 1400-1405 (2009).922.Hu, T., et al.Development of criteria for ovarian preservation in cervical cancer patients treated with radical surgery with or without neoadjuvant chemotherapy: a multicenter retrospective study and meta-analysis.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Ann Surg Oncol 20, 881-890 (2013).923.Jiao, X.B., Hu, J.& Zhu, L.R.The Safety of Ovarian Preservation in Early-Stage Adenocarcinoma Compared With Squamous Cell Carcinoma of Uterine Cervix: A Systematic Review and MetaAnalysis of Observational Studies.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int $J$ Gynecol Cancer 26, 1510-1514 (2016).924.Toki, N., et al.Microscopic ovarian metastasis of the uterine cervical cancer.Gynecol Oncol 41, 46-51 (1991).925.Natsume, N., et al.Ovarian metastasis in stage IB and II cervical adenocarcinoma.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 74, 255-258 (1999).926.Wu, H.S., Yen, M.S., Lai, C.R.& Ng, H.T.Ovarian metastasis from cervical carcinoma.Int $J$ Gynaecol Obstet 57, 173-178 (1997).927.Touhami, O.& Plante, M.Should ovaries be removed or not in (early-stage) adenocarcinoma of the uterine cervix: a review.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 136, 384-388 (2015).928.Kjorstad, K.E.& Bond, B.Stage IB adenocarcinoma of the cervix: metastatic potential and patterns of dissemination.Am J Obstet Gynecol 150, 297-299 (1984).929.Landoni, F.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Ovarian metastases in early-stage cervical cancer (IA2-IIA): a multicenter retrospective study of 1965 patients (a Cooperative Task Force study).Int J Gynecol Cancer 17, 623-628 (2007).930.Webb, G.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A.The role of ovarian conservation in the treatment of carcinoma of the cervix with radical surgery.Am J Obstet Gynecol 122, 476- 484 (1975).931.Windbichler, G.H., et al.Ovarian preservation in the surgical treatment of cervical carcinoma.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am J Obstet Gynecol 180, 963-969 (1999).932.Greer, B.E., Figge, D.C., Tamimi, H.K.& Cain, J.M.Stage IB adenocarcinoma of the cervix treated by radical hysterectomy and pelvic lymph node dissection.Am J Obstet Gynecol 160, 1509-1513; discussion 1513-1504 (1989).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "933.Chen, J., et al.Safety of ovarian preservation in women with stage I and II cervical adenocarcinoma: a retrospective study and meta-analysis.Am J Obstet Gynecol 215, 460 e461-460 e413 (2016).934.Morice, P.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Ovarian transposition for patients with cervical carcinoma treated by radiosurgical combination.Fertil Steril 74, 743-748 (2000).935.Feeney, D.D., Moore, D.H., Look, K.Y., Stehman, F.B.& Sutton, G.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "P.The fate of the ovaries after radical hysterectomy and ovarian transposition.Gynecol Oncol 56, 3-7 (1995).936.Anderson, B., LaPolla, J., Turner, D., Chapman, G.& Buller, R.Ovarian transposition in cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 49, 206-214 (1993).937.Owens, S., et al.Ovarian management at the time of radical hysterectomy for cancer of the cervix.Gynecol Oncol 35, 349-351 (1989).938.Chambers, S.K., Chambers, J.T.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", Kier, R.& Peschel, R.E.Sequelae of lateral ovarian transposition in irradiated cervical cancer patients.Int J Radiat Oncol Biol Phys 20, 1305-1308 (1991).939.Salih, S.M., et al.Diminished Utilization of in Vitro Fertilization Following Ovarian Transposition in Cervical Cancer Patients.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Reprod Med 60, 345- 353 (2015).940.Takahashi, N., et al.Five Cases of Cervical Cancer Where Laparoscopic Ovarian Transposition Was Performed Before Pelvic Radiotherapy.J Minim Invasive Gynecol 22, S203 (2015).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "941.Zhao, C., Wang, J.L., Wang, S.J., Zhao, L.J.& Wei, L.H.Analysis of the risk factors for the recurrence of cervical cancer following ovarian transposition.Eur J Gynaecol Oncol 34, 124-127 (2013).942.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Sicam, R.V., Huang, K.G., Chang, Y.C.& Lee, C.L.Maintenance of ovarian function in end-of-life cervical cancer patient following primary surgicoradiotherapy and ovarian transposition.J Gynecol Oncol 24, 204-207 (2013).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "943.Turan, A.T., et al.Ovarian transposition for stage Ib squamous cell cervical cancer - lack of effects on survival rates?Asian Pac J Cancer Prev 14, 133-137 (2013).944.Winarto, H., Febia, E., Purwoto, G.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "& Nuranna, L.The need for laparoscopic ovarian transposition in young patients with cervical cancer undergoing radiotherapy.Int J Reprod Med 2013, 173568 (2013).945.Sicam, R.V., Huang, K.G., Lee, C.L., Chen, C.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Y.& Ueng, S.H.Treatment of fallopian tube metastasis in cervical cancer after laparoscopic ovarian transposition.$J$ Minim Invasive Gynecol 19, 262-265 (2012).946.Bloemers, M.C., Portelance, L., Legler, C.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", Renaud, M.C.& Tan, S.L.Preservation of ovarian function by ovarian transposition prior to concurrent chemotherapy and pelvic radiation for cervical cancer.A case report and review of the literature.Eur J Gynaecol Oncol 31, 194-197 (2010).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "947.Salakos, N., et al.The role of ovarian transposition in patients with early stage cervical cancer--two case reports.Eur $J$ Gynaecol Oncol 29, 280-281 (2008).948.Zinger, M., Liu, J.H., Husseinzadeh, N.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "& Thomas, M.A.Successful surrogate pregnancy after ovarian transposition, pelvic irradiation and hysterectomy.$J$ Reprod Med 49, 573-574 (2004).949.Picone, O., Aucouturier, J.S., Louboutin, A., Coscas, Y.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "& Camus, E.Abdominal wall metastasis of a cervical adenocarcinoma at the laparoscopic trocar insertion site after ovarian transposition: case report and review of the literature.Gynecol Oncol 90, 446- 449 (2003).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "950.Giacalone, P.L., et al.[Surrogate mothers and ovarian transposition: two attitudes to be considered in young women with cervical carcinoma.A case report].Gynecol Obstet Fertil 31, 139-140 (2003).951.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Van Eijkeren, M.A., Van Der Wijk, I., El Sharouni, S.Y.& Heintz, A.P.Benefits and side effects of lateral ovarian transposition (LOT) performed during radical hysterectomy and pelvic lymphadenectomy for early stage cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 9, 396-400 (1999).952.Husseinzadeh, N., van Aken, M.L.& Aron, B.Ovarian transposition in young patients with invasive cervical cancer receiving radiation therapy.Int J Gynecol Cancer 4, 61-65 (1994).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "953.Pahisa, J., et al.Laparoscopic ovarian transposition in patients with early cervical cancer.Int J Gynecol Cancer 18, 584-589 (2008).954.Agorastos, T., Zafrakas, M.& Mastrominas, M.Long-term follow-up after cervical cancer treatment and subsequent successful surrogate pregnancy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Reprod Biomed Online 19, 250-251 (2009).955.Brannstrom, M., et al.First clinical uterus transplantation trial: a six-month report.Fertil Steril 101, 1228-1236 (2014).956.Fageeh, W., Raffa, H., Jabbad, H.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "& Marzouki, A.Transplantation of the human uterus.Int J Gynaecol Obstet 76, 245-251 (2002).957.Erman Akar, M., et al.Clinical pregnancy after uterus transplantation.Fertil Steril 100, 1358-1363 (2013).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "958.Brannstrom, M., et al.Livebirth after uterus transplantation.Lancet 385, 607- 616 (2015).959.Dodd, J.M., Jones, L., Flenady, V., Cincotta, R.& Crowther, C.A.Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cochrane Database Syst Rev, CD004947 (2013).960.Saghafi, N., Khadem, N., Mohajeri, T., Shakeri, M.T.& Amini, M.Efficacy of 17 alpha-hydroxyprogesterone caproate in preterm delivery prevention.Iran $J$ Obstet Gynecol Infertil 14, 28-33 (2011).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "961.Saghafi, N., Khadem, N., Mohajeri, T.& Shakeri, M.T.Efficacy of 17alphahydroxyprogesterone caproate in prevention of preterm delivery.J Obstet Gynaecol Res 37, 1342-1345 (2011).962.Rai, P., et al.Oral micronized progesterone for prevention of preterm birth.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynaecol Obstet 104, 40-43 (2009).963.O'Brien, J.M., Steichen, J.J., Phillips, J.A.& Creasy, G.W.Two year infant outcomes for children exposed to supplemental intravaginal progesterone gel in utero: secondary analysis of a multicenter, randomized, double-blind, placebocontrolled trial.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am J Obstet Gynecol 206, S223 (2012).964.O'Brien, J.M., et al.Effect of progesterone on cervical shortening in women at risk for preterm birth: secondary analysis from a multinational, randomized, double-blind, placebo-controlled trial.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Ultrasound Obstet Gynecol 34, 653-659 (2010).965.O'Brien, J.M., et al.Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebocontrolled trial.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Ultrasound Obstet Gynecol 30, 687-696 (2007).966.O'Brien, J., DeFranco, E., Hall, D., Phillips, J.& Creasy, G.Do other elements of the obstetrical history provide a possible indication for progesterone supplementation?",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Secondary analysis from the progesterone vaginal gel trial.Am J Obstet Gynecol 199, S42 (2008).967.O'Brien, J., DeFranco, E., Hall, D.& Creasy, G.Natural progesterone administration and the risk of medical complications of pregnancy: secondary analysis from a multinational, randomized, double blind, placebocontrolled trial.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am J Obstet Gynecol 199, S139 (2008).968.O'Brien, J., et al.Progesterone reduces the rate of cervical shortening in women at risk for preterm birth: secondary analysis from a randomized, doubleblind, placebo-controlled trial [abstract].",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am J Obstet Gynecol 197, S7 (2007).969.DeFranco, E., et al.Is there a racial disparity of progesterone to prevent preterm birth [abstract].Am J Obstet Gynecol 197, S200 (2007).970.DeFranco, E.A., et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, doubleblind, placebo-controlled trial.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Ultrasound Obstet Gynecol 30, 697-705 (2007).971.Akbari, S., Birjandi, M.& Mohtasham, N.Evaluation of the effect of progesterone on prevention of preterm delivery and its complications.Scientific journal of kurdistan university of medical sciences 14, 11-19 (2009).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "972.Cetingoz, E., et al.Progesterone effects on preterm birth in high-risk pregnancies: a randomized placebocontrolled trial.Arch Gynecol Obstet 283, 423-429 (2011).973.da Fonseca, E.B., Bittar, R.E., Carvalho, M.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "H.& Zugaib, M.Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled doubleblind study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am J Obstet Gynecol 188, 419-424 (2003).974.da Fonseca, E.B., Bittar, R.E., Carvalho, M.H.B., Martinelli, S.& Zugaib, M.Uterine contraction monitoring in pregnant women using vaginal natural progesterone.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Perinat Med 29 Suppl 1, 525 (2001).975.Glover, M., Croom, C.S., Sonek, J.D., Kovac, C.& McKenna, D.A randomized placebo controlled trial of oral micronized progesterone to prevent recurrent preterm birth.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am J Obstet Gynecol 201 S172 (2011).976.Glover, M.M., et al.A randomized trial of micronized progesterone for the prevention of recurrent preterm birth.Am J Perinatol 28, 377-381 (2011).977.Ibrahim, M.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Progesterone supplementation for prevention of preterm labor: a randomized controlled trial.Middle East Fert Soc $J$ 15, 39-41 (2010).978.Johnson, J.W., Austin, K.L., Jones, G.S., Davis, G.H.& King, T.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "M.Efficacy of 17alpha-hydroxyprogesterone caproate in the prevention of premature labor.$N$ Engl J Med 293, 675-680 (1975).979.Klebanoff, M.Impact of 17alpha hydroxyprogesterone caproate administration on salivary progesterone and estriol [abstract].",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am J Obstet Gynecol 195, S140 (2006).980.Majhi, P., Bagga, R., Kalra, J.& Sharma, M.Intravaginal use of natural micronised progesterone to prevent pre-term birth: a randomised trial in India.J Obstet Gynaecol 29, 493-498 (2009).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "981.Gyamfi, C., et al.The effect of 17-alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies.Am J Obstet Gynecol 201, 392 e391-395 (2009).982.Klebanoff, M.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A., et al.Salivary progesterone and estriol among pregnant women treated with 17-alphahydroxyprogesterone caproate or placebo.Am J Obstet Gynecol 199, 506 e501-507 (2008).983.Koontz, G.Does gestational age at randomization affect the efficacy of alpha hydroxyprogesterone caproate (17-OHCP) in preventing recurrent preterm delivery?",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "[abstract].Am J Obstet Gynecol 193, S55 (2005).984.Manuck, T.A., et al.Progesterone receptor polymorphisms and clinical response to 17-alphahydroxyprogesterone caproate.Am $J$ Obstet Gynecol 205, 135 e131-139 (2011).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "985.Spong, C.Y., et al.Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery.Am J Obstet Gynecol 193, 1127- 1131 (2005).986.Meis, P.More than one previous preterm delivery and the risk of preterm birth in women treated wih 17 alpha-hydroxyprogesterone (17P) [abstract].",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am J Obstet Gynecol 189, S168 (2003).987.Meis, P.J., et al.Does progesterone treatment influence risk factors for recurrent preterm delivery?Obstet Gynecol 106, 557-561 (2005).988.Meis, P.J., et al.Prevention of recurrent preterm delivery by 17 alphahydroxyprogesterone caproate.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "N Engl J Med 348, 2379-2385 (2003).989.Meis, P.J.17 alphahydroxprogesterone caproate prevents recurrent preterm birth [abstract].Am J Obstet Gynecol 187, S54 (2002).990.Northen, A.4-year follow-up of children exposed to 17 alpha hydroxyprogesterone caproate (17P) in utero.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am J Obstet Gynecol 195, S6 (2006).991.Northen, A.T., et al.Follow-up of children exposed in utero to 17 alphahydroxyprogesterone caproate compared with placebo.Obstet Gynecol 110, 864-872 (2007).992.Sibai, B.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Plasma CRH levels at 16-20 weeks do not predict preterm delivery in women at high-risk for preterm delivery [abstract].Am J Obstet Gynecol 191, S114 (2004).993.Sibai, B., et al.Plasma CRH measurement at 16 to 20 weeks' gestation does not predict preterm delivery in women at high-risk for preterm delivery.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am $J$ Obstet Gynecol 193, 1181-1186 (2005).994.Spong, C.Y.Progesterone for prevention of recurrent preterm birth: impact of gestational age at prior delivery [abstract].Am J Obstet Gynecol 191, S11 (2004).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "995.Fonseca, E.B., Celik, E., Parra, M., Singh, M.& Nicolaides, K.H.Progesterone and the risk of preterm birth among women with a short cervix.N Engl J Med 357, 462-469 (2007).996.Grobman, W.Randomized controlled trial of progesterone treatment for preterm birth prevention in nulliparous women with cervical length than 30 mm.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am $J$ Obstet Gynecol 206, S367 (2012).997.Grobman, W.A., et al.17 alphahydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than $3 0 ~ \\mathrm { m m }$ .Am J Obstet Gynecol 207, 390 e391-398 (2012).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "998.Hassan, S.S., et al.Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double blind, placebo-controlled trial.Ultrasound Obstet Gynecol 38, 18-31 (2011).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "999.Rozenberg, P., et al.Prevention of preterm delivery after successful tocolysis in preterm labor by 17 alphahydroxyprogesterone caproate: a randomized controlled trial.Am J Obstet Gynecol 206, 206 e201-209 (2012).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1000.Rozenberg, P., et al.Prevention of preterm delivery after successful tocolysis in preterm labour by 17 alphahydroxyprogesterone caproate: a randomized controlled trial.Am J Obstet Gynecol 206, S2-S3 (2012).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1001.Aboulghar, M.M., et al.The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies.Reprod Biomed Online 25, 133-138 (2012).1002.Caritis, S.N., et al.Prevention of preterm birth in triplets using 17 alphahydroxyprogesterone caproate: a randomized controlled trial.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Obstet Gynecol 113, 285-292 (2009).1003.Combs, C.A., Garite, T., Maurel, K., Das, A.& Porto, M.Failure of 17- hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double-blind, randomized clinical trial.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am J Obstet Gynecol 203, 248 e241-249 (2010).1004.Combs, C.A., Garite, T.& Porto, M.17- hydroxyprogesterone for triplet pregnancy does not reduce prematurity or neonatal morbidity, may increase midtrimester loss.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am J Obstet Gynecol 201, S168 (2009).1005.Heitmann, E., lu, G., Combs, C.A., Garite, T.J.& Maurel, K.The impact of maternal weight upon the effectiveness of 17- hydroxyprogesterone in preventing preterm birth among twin gestations.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am J Obstet Gynecol 206, S98 (2012).1006.Combs, C.A., Garite, T., Maurel, K., Das, A.& Porto, M.17-hydroxyprogesterone caproate for twin pregnancy: a doubleblind, randomized clinical trial.Am $J$ Obstet Gynecol 204, 221 e221-228 (2011).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1007.Combs, C.A., Maurel, K.& Garite, T.17- hydroxyprogesterone caproate for women with history of preterm birth in a prior pregnancy and twins in the current pregnancy.Am J Obstet Gynecol 206, S213 (2012).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1008.Combs, C.A., Maurel, K.& Garite, T.17- hydroxyprogesterone for twin pregnancy: no reduction in prematurity or neonatal morbidity.Am J Obstet Gynecol 204, S7 (2011).1009.Hartikainen-Sorri, A.L., Kauppila, A.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "& Tuimala, R.Inefficacy of 17 alphahydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy.Obstet Gynecol 56, 692-695 (1980).1010.Hartikainen-Sorri, A.L., Kauppila, A.& Tuimala, R.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Management of twin pregnancy with 17 alphahydroxyprogesterone caproate [abstract].9th World Congress of Gynecology and Obstetrics 1979 October 26-31, Tokyo, Japan.298-299 (1979).1011.Lim, A.C.The effect of 17-alpha hydroxyprogesterone caproate on cervical length in multiple pregnancies.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Reprod Sci 17, 282A (2010).1012.Lim, A.C., et al.Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial.BMC Pregnancy Childbirth 7, 7 (2007).1013.Lim, A.C.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.17alphahydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: a randomized controlled trial.Obstet Gynecol 118, 513-520 (2011).1014.Willekes, C., et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Mid-pregnancy cervical length as a predictor of preterm birth in multiple pregnancies.Am J Obstet Gynecol 204, S54 (2011).1015.Eddama, O., et al.Study of progesterone for the prevention of preterm birth in twins (STOPPIT): findings from a trialbased cost-effectiveness analysis.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int $J$ Technol Assess Health Care 26, 141-148 (2010).1016.Norman, J.E., et al.Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double-blind, placebo-controlled study and meta-analysis.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Lancet 373, 2034- 2040 (2009).1017.Norman, J.E., et al.Effect of prolonged in vivo administration of progesterone in pregnancy on myometrial gene expression, peripheral blood leukocyte activation, and circulating steroid hormone levels.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Reprod Sci 18, 435-446 (2011).1018.Klein, K., et al.Vaginal progesterone and the risk of preterm delivery in high-risk twin gestations - secondary analysis of a placebo-controlled randomized trial.Ultrasound Obstet Gynecol 38, 11 (2011).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1019.Klein, K., Rode, L., Nicolaides, K.H., Krampl-Bettelheim, E.& Tabor, A.Vaginal micronized progesterone and risk of preterm delivery in high-risk twin pregnancies: secondary analysis of a placebo-controlled randomized trial and meta-analysis.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Ultrasound Obstet Gynecol 38, 281-287 (2011).1020.Rode, L., et al.Prevention of preterm delivery in twin gestations (PREDICT): a multicentre randomised placebocontrolled trial on the effect of vaginal micronised progesterone.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Ultrasound Obstet Gynecol 38, 1 (2011).1021.Rode, L., Klein, K., Nicolaides, K.H., Krampl-Bettelheim, E.& Tabor, A.Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo-controlled trial on the effect of vaginal micronized progesterone.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Ultrasound Obstet Gynecol 38, 272-280 (2011).1022.Serra, V., et al.Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double-blind multicentre trial.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "BJOG 120, 50-57 (2013).1023.Borna, S.& Sahabi, N.Progesterone for maintenance tocolytic therapy after threatened preterm labour: a randomised controlled trial.Aust N Z J Obstet Gynaecol 48, 58-63 (2008).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1024.Borna, S., Shakoie, S.& Borna, H.Progesterone for maintenance tocolytic therapy after threatened preterm labor.Randomized controlled trial.Journal of Maternal-Fetal and Neonatal Medicine 21, 151-152 (2008).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1025.Briery, C., et al.Women with prolonged premature rupture of the membrane do not benefit from weekly progesterone: a randomized clinical trial.Am J Obstet Gynecol 201, S189 (2009).1026.Briery, C.M.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Progesterone does not prevent preterm births in women with twins.South Med J 102, 900-904 (2009).1027.Briery, C.M., et al.Women with preterm premature rupture of the membranes do not benefit from weekly progesterone.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am J Obstet Gynecol 204, 54 e51-55 (2011).1028.Combs, C.A., et al.17- Hydroxyprogesterone caproate to prolong pregnancy after preterm rupture of the membranes: early termination of a double-blind, randomized clinical trial.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "BMC Res Notes 4, 568 (2011).1029.Facchinetti, F., Dante, G., Venturini, P., Paganelli, S.& Volpe, A.17alphahydroxy-progesterone effects on cervical proinflammatory agents in women at risk for preterm delivery.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am J Perinatol 25, 503-506 (2008).1030.Facchinetti, F., Paganelli, S., Comitini, G., Dante, G.& Volpe, A.Cervical length changes during preterm cervical ripening: effects of 17-alphahydroxyprogesterone caproate.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am $J$ Obstet Gynecol 196, 453 e451-454; discussion 421 (2007).1031.Facchinetti, F., Paganelli, S., Venturini, P.& Dante, G.17 alpha hydroxyprogesterone caproate (17P) treatment reduced cervical shortening inhibiting cervical interleukin-1 secretion.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am J Obstet Gynecol 195, S5 (2006).1032.Sharami, S.H., Zahiri, Z., Shakiba, M.& Milani, F.Maintenance therapy by vaginal progesterone after threatened idiopathic preterm labor: a randomized placebo-controlled double-blind trial.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Fertil Steril 4, 45-50 (2010).1033.Norman, J.E., et al.Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial.Lancet 387, 2106-2116 (2016).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1034.Alfirevic, Z., Stampalija, T., Roberts, D.& Jorgensen, A.L.Cervical stitch (cerclage) for preventing preterm birth in singleton pregnancy.Cochrane Database Syst Rev, CD008991 (2012).1035.Althuisius, S.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Cervical Incompetence Prevention Randomized Cerclage Trial (CIPRACT): effect of therapeutic cerclage with bed rest vs.bed rest only on cervical length.Ultrasound Obstet Gynecol 20, 163-167 (2002).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1036.Althuisius, S., Dekker, G., Hummel, P., Bekedam, D.& Van Geijn, H.CIPRACT (cervical incompetence prevention randomized cerclage trial): final results [abstract].Am J Obstet Gynecol 184, S2 (2001).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1037.Althuisius, S., Dekker, G., Hummel, P.& Van Geijn, H.Cervical incompetence prevention randomized cerclage trial (cipract): emergency cerclage with bed rest versus bed rest alone [abstract].Am J Obstet Gynecol 187, S86 (2002).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1038.Althuisius, S.M., Dekker, G.A., Hummel, P., Bekedam, D.J.& van Geijn, H.P.Final results of the Cervical Incompetence Prevention Randomized Cerclage Trial (CIPRACT): therapeutic cerclage with bed rest versus bed rest alone.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am $J$ Obstet Gynecol 185, 1106-1112 (2001).1039.Althuisius, S.M., Dekker, G.A., Hummel, P.& van Geijn, H.P.Cervical incompetence prevention randomized cerclage trial: emergency cerclage with bed rest versus bed rest alone.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am $J$ Obstet Gynecol 189, 907-910 (2003).1040.Althuisius, S.M., Dekker, G.A., van Geijn, H.P., Bekedam, D.J.& Hummel, P.Cervical incompetence prevention randomized cerclage trial (CIPRACT): study design and preliminary results.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am J Obstet Gynecol 183, 823-829 (2000).1041.Bowes, W.A.Cervical incompetence prevention randomized cerclage trial (CIPRACT): effect of therapeutic cerclage with bed rest vs.bed rest only on cervical length.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Obstet Gynecol Surv 58, 88-89 (2003).1042.Berghella, V., Figueroa, D.& Szychowski, J.17-Alpha-hydroxyprogesterone caproate for the prevention of preterm birth in women with prior preterm birth and a short cervical length.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am J Obstet Gynecol 201, S7 (2009).1043.Berghella, V., Odibo, A.& Tolosa, J.Cerclage for prevention of preterm birth with a short cervix on transvaginal ultrasound: a randomized trial [abstract].Am J Obstet Gynecol 189, S167 (2003).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1044.Berghella, V., Odibo, A.O.& Tolosa, J.E.Cerclage for prevention of preterm birth in women with a short cervix found on transvaginal ultrasound examination: a randomized trial.Am J Obstet Gynecol 191, 1311-1317 (2004).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1045.Ezechi, O.C., Kalu, B.K.& Nwokoro, C.A.Prophylactic cerclage for the prevention of preterm delivery.Int $J$ Gynaecol Obstet 85, 283-284 (2004).1046.Lazar, P., et al.Multicentred controlled trial of cervical cerclage in women at moderate risk of preterm delivery.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Br J Obstet Gynaecol 91, 731-735 (1984).1047.MRC/RCOG.Final report of the Medical Research Council/Royal College of Obstetricians and Gynaecologists multicentre randomised trial of cervical cerclage.MRC/RCOG Working Party on Cervical Cerclage.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Br J Obstet Gynaecol 100, 516-523 (1993).1048.MRC/RCOG.Interim report of the Medical Research Council/Royal College of Obstetricians and Gynaecologists multicentre randomized trial of cervical cerclage.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "MRC/RCOG Working Party on Cervical Cerclage.Br J Obstet Gynaecol 95, 437-445 (1988).1049.MRC/RCOG.MRC/RCOG randomised trial of cervical cerclage.Proceedings of 23th British Congress of Obstetrics and Gynaecology, 1983 July 12-15, Birmingham, UK.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "(1983).1050.MRC/RCOG.MRC/RCOG randomised trial of cervical cerclage.Proceedings of the 24th British Congress of Ostetrics and Gynaecology; 1986 April 15-18; Cardiff, UK.(1986).1051.Szeverenyi, M., et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "[Surgical cerclage in the treatment of cervical incompetence during pregnancy (determining the legitimacy of the procedure)].Orv Hetil 133, 1823-1826 (1992).1052.Farinelli, C., Wing, D., Owen, J.& Szychowski, J.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Association between Body Mass Index (BMI) and pregnancy outcome in a randomized trial of cerclage for short cervix.Reprod Sci 18, 305A (2011).1053.Figueroa, D., Mancuso, M., Maddox Paden, M., Szychowski, J.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "& Owen, J.Does mid-trimester Nugent score or vaginal pH predict gestational age at delivery in women at risk for preterm birth.Am J Obstet Gynecol 199, S215 (2008).1054.Mancuso, M., Szychowski, J.& Owen, J.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cervical funneling: effect on gestational length and ultra-sound indicated cerclage in high-risk women.Am J Obstet Gynecol 201, S23 (2009).1055.Mancuso, M., Szychowski, J.& Owen, J.Dynamic cervical shortening in high-risk women: effect on gestational length and ultrasound-indicated cerclage.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am $J$ Obstet Gynecol 203, S130 (2009).1056.Mancuso, M.S., et al.Cervical funneling: effect on gestational length and ultrasound-indicated cerclage in highrisk women.Am J Obstet Gynecol 203, 259.e251-295.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "e255 (2010).1057.Owen, J.Multicenter randomized trial of cerclage for preterm birth prevention in high-risk women with shortened midtrimester cervical length.Am J Obstet Gynecol 199, S3 (2008).1058.Owen, J.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Multicenter randomized trial of cerclage for preterm birth prevention in high-risk women with shortened midtrimester cervical length.Am J Obstet Gynecol 201, 375 e371-378 (2009).1059.Owen, J.& Szychowski, J.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Association between post-randomization sonographic cervical length and birth gestational age in a multicenter trial of ultrasound-indicated cerclage.Am $J$ Obstet Gynecol 201, S197 (2009).1060.Owen, J.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "& Szychowski, J.Can the optimal cervical length for placing ultrasound-indicated cerclage be identified?Am J Obstet Gynecol 204, S198-S199 (2011).1061.Owen, J.& Szychowski, J.Does midtrimester cervical length $2 5 ~ \\mathrm { m m }$ predict preterm birth in high risk women?",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am J Obstet Gynecol 201, S9-S10 (2009).1062.Owen, J.& Szychowski, J.Neonatal morbidities in a multicenter randomized trial of ultrasoundindicated cerclage for shortened cervical length (CL).Am J Obstet Gynecol 204, S17-S18 (2011).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1063.Owen, J.& Szychowski, J.Scheduled timing of and patient compliance with longitudinal sonographic cervical length (CL) measurement in a multicenter randomized trial of ultrasoundindicated cerclage.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am J Obstet Gynecol 204, S98 (2011).1064.Szychowski, J.M., et al.Timing of midtrimester cervical length shortening in high-risk women.Ultrasound Obstet Gynecol 33, 70-75 (2009).1065.Wing, D.& Szychowski, J.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Influence of earliest gestational age of prior spontaneous birth on subsequent midtrimester cervical length, pregnancy duration and cerclage efficacy.Am J Obstet Gynecol 201, S 190 (2009).1066.Rush, R.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "W.& Isaacs, S.Prophylactic cervical cerclage and gestational age at delivery.Proceedings of the 2nd Conference on Priorities in Perinatal Care, 1983; South Africa.132-137 (1983).1067.Rush, R.W., et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A randomized controlled trial of cervical cerclage in women at high risk of spontaneous preterm delivery.Br J Obstet Gynaecol 91, 724-730 (1984).1068.Rust, O., Atlas, R., Jones, K., Benham, B.& Balducci, J.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A randomized trial of cerclage vs.no cerclage in patients with sonographically detected 2nd trimester premature dilation of the internal os.Am J Obstet Gynecol 182, S13 (2000).1069.Rust, O., Atlas, R., Reed, J.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", Van Gaalen, J.& Balducci, J.Regression analysis of perinatal morbidity for secondtrimester sonographic evidence of internal os dilation and shortening of the distal cervix [abstract].Am J Obstet Gynecol 184, S26 (2001).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1070.Rust, O., Atlas, R., Wells, M.& Kimmel, S.Does cerclage location influence perinatal outcome [abstract].Am J Obstet Gynecol 185, S111 (2001).1071.Rust, O., et al.A randomized trial of cerclage versus 17- hydroxyprogesterone (17p) for the treatment of short cervix [abstract].",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am J Obstet Gynecol 195, S112 (2006).1072.Rust, O.A., Atlas, R.O., Jones, K.J., Benham, B.N.& Balducci, J.A randomized trial of cerclage versus no cerclage among patients with ultrasonographically detected secondtrimester preterm dilatation of the internal os.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am J Obstet Gynecol 183, 830-835 (2000).1073.Rust, O.A., Atlas, R.O., Reed, J., van Gaalen, J.& Balducci, J.Revisiting the short cervix detected by transvaginal ultrasound in the second trimester: why cerclage therapy may not help.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am $J$ Obstet Gynecol 185, 1098-1105 (2001).1074.Rust, O.A., Atlas, R.O., Wells, M.& Kimmel, S.Second trimester dilatation of the internal os and a history of prior preterm birth [abstract].Obstet Gynecol 99, 14S (2002).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1075.To, M.S., et al.Cervical cerclage for prevention of preterm delivery in women with short cervix: randomised controlled trial.Lancet 363, 1849-1853 (2004).1076.Keeler, S.M., et al.A randomized trial of cerclage vs.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "17 alphahydroxyprogesterone caproate for treatment of short cervix.J Perinat Med 37, 473-479 (2009).1077.Rafael, T.J., Berghella, V.& Alfirevic, Z.Cervical stitch (cerclage) for preventing preterm birth in multiple pregnancy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cochrane Database Syst Rev, CD009166 (2014).1078.Althuisius, S.M., Dekker, G.A., van Geijn, H.P., Bekedam, D.J.& Hummel, P.Cervical incompetence prevention randomized cerclage trial, preliminary results.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am J Obstet Gynecol 182, S20 (2000).1079.Dor, J., Shalev, J., Mashiach, S., Blankstein, J.& Serr, D.M.Elective cervical suture of twin pregnancies diagnosed ultrasonically in the first trimester following induced ovulation.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Obstet Invest 13, 55-60 (1982).1080.Rust, O., Atlas, R., Wells, M.& Rawlinson, K.Cerclage in multiple gestation with midtrimester dilatation of the internal os [abstract].Am J Obstet Gynecol 185, S111 (2001).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1081.PCASRM/SART.Mature oocyte cryopreservation: a guideline.Fertil Steril 99, 37-43 (2013).1082.PCASRM/ASRM.Ovarian tissue cryopreservation: a committee opinion.Fertil Steril 101, 1237-1243 (2014).1083.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "ACOG.Committee Opinion No.584: oocyte cryopreservation.Obstet Gynecol 123, 221-222 (2014).1084.Narducci, F., et al.Occult invasive cervical cancer found after inadvertent simple hysterectomy: is the ideal management: systematic parametrectomy with or without radiotherapy or radiotherapy only?",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Ann Surg Oncol 22, 1349-1352 (2015).1085.Park, J.Y., et al.Management of occult invasive cervical cancer found after simple hysterectomy.Ann Oncol 21, 994-1000 (2010).1086.Green, T.H., Jr.& Morse, W.J.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", Jr.Management of invasive cervical cancer following inadvertent simple hysterectomy.Obstet Gynecol 33, 763- 769 (1969).1087.Leath, C.A., 3rd, et al.The role of radical parametrectomy in the treatment of occult cervical carcinoma after extrafascial hysterectomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 92, 215-219 (2004).1088.Ayhan, A., Otegen, U., Guven, S.& Kucukali, T.Radical reoperation for invasive cervical cancer found in simple hysterectomy.J Surg Oncol 94, 28-34 (2006).1089.Barber, H.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "R., Pece, G.V.& Brunschwig, A.Operative management of patients previously operated upon for a benign lesion with cervical cancer as a suprise finding.Am J Obstet Gynecol 101, 959- 965 (1968).1090.Orr, J.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "W., Jr., et al.Surgical treatment of women found to have invasive cervix cancer at the time of total hysterectomy.Obstet Gynecol 68, 353-356 (1986).1091.Kinney, W.K., Egorshin, E.V., Ballard, D.J.& Podratz, K.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "C.Long-term survival and sequelae after surgical management of invasive cervical carcinoma diagnosed at the time of simple hysterectomy.Gynecol Oncol 44, 24-27 (1992).1092.Chapman, J.A., Mannel, R.S., DiSaia, P.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J., Walker, J.L.& Berman, M.L.Surgical treatment of unexpected invasive cervical cancer found at total hysterectomy.Obstet Gynecol 80, 931- 934 (1992).1093.Lu, H.W., et al.Can radical parametrectomy be omitted in occult cervical cancer after extrafascial hysterectomy?",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Chin J Cancer 34, 413- 419 (2015).1094.Gori, J.R., Fritsches, H.G., Castanno, R., Toziano, M.& Habich, D.Radical parametrectomy for occult cervical carcinoma detected posthysterectomy.J Low Genit Tract Dis 8, 102-105 (2004).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1095.Lee, Y.S., Lee, T.H., Koo, T.B., Cho, Y.L.& Park, I.S.Laparoscopic-assisted radical parametrectomy including pelvic and/or paraaortic lymphadenectomy in women after prior hysterectomy-three cases.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 91, 619-622 (2003).1096.Kohler, C., Tozzi, R., Klemm, P.& Schneider, A.\"Schauta sine utero\": technique and results of laparoscopicvaginal radical parametrectomy.Gynecol Oncol 91, 359-368 (2003).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1097.Fleisch, M.C.& Hatch, K.D.Laparoscopic assisted parametrectomy/upper vaginectomy (LPUV)-technique, applications and results.Gynecol Oncol 98, 420-426 (2005).1098.Liang, Z., et al.Laparoscopic radical trachelectomy or parametrectomy and pelvic and para-aortic lymphadenectomy for cervical or vaginal stump carcinoma: report of six cases.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int $J$ Gynecol Cancer 16, 1713- 1716 (2006).1099.Ramirez, P.T., Schmeler, K.M., Wolf, J.K., Brown, J.& Soliman, P.T.Robotic radical parametrectomy and pelvic lymphadenectomy in patients with invasive cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 111, 18-21 (2008).1100.Vitobello, D., Siesto, G., Bulletti, C., Accardi, A.& Ieda, N.Robotic radical parametrectomy with pelvic lymphadenectomy: our experience and review of the literature.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Eur J Surg Oncol 38, 548-554 (2012).1101.Kanao, H., et al.Total laparoscopic nerve-sparing radical parametrectomy for occult early-stage cervical cancer: surgical technique and postoperative bladder function.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Obstet Invest 80, 128-133 (2015).1102.Li, J., et al.Laparoscopic nerve-sparing radical parametrectomy for occult earlystage invasive cervical cancer after simple hysterectomy.Int $J$ Gynecol Cancer 22, 1383-1388 (2012).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1103.Geisler, J.P., Orr, C.& Manahan, K.J.Robotically-assisted laparoscopic radical parametrectomy and radical vaginectomy.Eur J Gynaecol Oncol 32, 674-676 (2011).1104.Buda, A., et al.Total laparoscopic radical parametrectomy, partial colpectomy, and pelvic lymphadenectomy in patients with occult cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int $J$ Gynaecol Obstet 107, 73-76 (2009).1105.Cosbie, W.G.Radiotherapy following hysterectomy performed for or in the presence of cancer of the cervix.Am $J$ Obstet Gynecol 85, 332-337 (1963).1106.Andras, E.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J., Fletcher, G.H.& Rutledge, F.Radiotherapy of carcinoma of the cervix following simple hysterectomy.Am $J$ Obstet Gynecol 115, 647-655 (1973).1107.Davy, M., Bentzen, H.& Jahren, R.Simple hysterectomy in the presence of invasive cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Acta Obstet Gynecol Scand 56, 105-108 (1977).1108.Papavasiliou, C., Yiogarakis, D., Pappas, J.& Keramopoulos, A.Treatment of cervical carcinoma by total hysterectomy and postoperative external irradiation.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 6, 871-874 (1980).1109.Heller, P.B., et al.Cervical carcinoma found incidentally in a uterus removed for benign indications.Obstet Gynecol 67, 187-190 (1986).1110.Roman, L.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "D., et al.Prognostic factors for patients undergoing simple hysterectomy in the presence of invasive cancer of the cervix.Gynecol Oncol 50, 179-184 (1993).1111.Fang, F.M., Yeh, C.Y., Lai, Y.L., Chiou, J.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "F.& Chang, K.H.Radiotherapy following simple hysterectomy in patients with invasive carcinoma of the uterine cervix.J Formos Med Assoc 92, 420-425 (1993).1112.Choi, D.H., Huh, S.J.& Nam, K.H.Radiation therapy results for patients undergoing inappropriate surgery in the presence of invasive cervical carcinoma.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 65, 506-511 (1997).1113.Crane, C.H.& Schneider, B.F.Occult carcinoma discovered after simple hysterectomy treated with postoperative radiotherapy.Int J Radiat Oncol Biol Phys 43, 1049-1053 (1999).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1114.Huerta Bahena, J., Labastida Almendaro, S., Cortez Arroyo, H.& Calva, A.[Postoperative radiotherapy in patients with invasive uterine cervix cancer treated previously with simple hysterectomy.Results from the Hospital de Oncologia, Centro Medico Nacional SXXI.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "].Ginecol Obstet Mex 71, 304-311 (2003).1115.Chen, S.W., Liang, J.A., Yang, S.N.& Lin, F.J.Postoperative radiotherapy for patients with invasive cervical cancer following treatment with simple hysterectomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Jpn J Clin Oncol 33, 477- 481 (2003).1116.Munstedt, K., Johnson, P., von Georgi, R., Vahrson, H.& Tinneberg, H.R.Consequences of inadvertent, suboptimal primary surgery in carcinoma of the uterine cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 94, 515-520 (2004).1117.Hsu, W.L., et al.Long-term treatment results of invasive cervical cancer patients undergoing inadvertent hysterectomy followed by salvage radiotherapy.Int $J$ Radiat Oncol Biol Phys 59, 521-527 (2004).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1118.Smith, K.B., et al.Postoperative radiotherapy for cervix cancer incidentally discovered after a simple hysterectomy for either benign conditions or noninvasive pathology.Am J Clin Oncol 33, 229-232 (2010).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1119.Suh, D.H., et al.An occult invasive cervical cancer found after a simple hysterectomy: a 10-year experience in a single institution.Int J Gynecol Cancer 21, 1646-1653 (2011).1120.Bai, H., et al.Occult invasive cervical cancer after simple hysterectomy: a multi-center retrospective study of 89 cases.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "BMC Cancer 16, 507 (2016).1121.Ampil, F., Datta, R.& Datta, S.Elective postoperative external radiotherapy after hysterectomy in early-stage carcinoma of the cervix.Is additional vaginal cuff irradiation necessary?",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cancer 60, 280-288 (1987).1122.NCCCMC.Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials.Neoadjuvant Chemotherapy for Cervical Cancer Metaanalysis Collaboration.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Eur J Cancer 39, 2470-2486 (2003).1123.Tattersall, M.H., et al.Randomized trial of epirubicin and cisplatin chemotherapy followed by pelvic radiation in locally advanced cervical cancer.Cervical Cancer Study Group of the Asian Oceanian Clinical Oncology Association.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Clin Oncol 13, 444-451 (1995).1124.Kumar, L., et al.Neoadjuvant chemotherapy in locally advanced cervical cancer: two randomised studies.Aust N Z J Med 28, 387-390 (1998).1125.Sardi, J., et al.Randomized trial with neoadjuvant chemotherapy in stage IIIB squamous carcinoma cervix uteri: an unexpected therapeutic management.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 6, 85-93 (1996).1126.Sardi, J.E., et al.Neoadjuvant chemotherapy in cervical carcinoma stage IIB: a randomized controlled trial.Int J Gynecol Cancer 8, 441-450 (1998).1127.Chauvergne, J.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.[Neoadjuvant chemotherapy of stage IIb or III cancers of the uterine cervix.Long-term results of a multicenter randomized trial of 151 patients].Bull Cancer 80, 1069-1079 (1993).1128.Souhami, L.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.A randomized trial of chemotherapy followed by pelvic radiation therapy in stage IIIB carcinoma of the cervix.J Clin Oncol 9, 970-977 (1991).1129.Herod, J., et al.A randomised, prospective, phase III clinical trial of primary bleomycin, ifosfamide and cisplatin (BIP) chemotherapy followed by radiotherapy versus radiotherapy alone in inoperable cancer of the cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Ann Oncol 11, 1175-1181 (2000).1130.Tattersall, M.H., Ramirez, C.& Coppleson, M.A randomized trial comparing platinum-based chemotherapy followed by radiotherapy vs.radiotherapy alone in patients with locally advanced cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int $J$ Gynecol Cancer 2, 244-251 (1992).1131.Cardenas, J., et al.A randomized trial of chemotherapy (CT) followed by radiotherapy (RT) vs radiotherapy alone in stage IIIb cervical carcinoma: preliminary results.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Fourth International Congress on Anti-Cancer Chemotherapy.87(1993).1132.Cardenas, J., Olguin, A., Figueroa, F., Beccerra, F.& Huizar, R.Randomized neoadjuvant chemotherapy in cervical carcinoma stage IIb.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "PEC $^ +$ RT vs RT.Proceedings of the American Society of Clinical Oncology.10, A620 (1991).1133.Chiara, S., et al.Randomized study comparing chemotherapy plus radiotherapy versus radiotherapy alone in FIGO stage IIB-III cervical carcinoma.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "GONO (North-West Oncologic Cooperative Group).Am J Clin Oncol 17, 294-297 (1994).1134.Sundfor, K., et al.Radiotherapy and neoadjuvant chemotherapy for cervical carcinoma.A randomized multicenter study of sequential cisplatin and 5- fluorouracil and radiotherapy in advanced cervical carcinoma stage 3B and 4A.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cancer 77, 2371-2378 (1996).1135.Symonds, R.P., et al.The Scottish and Manchester randomised trial of neoadjuvant chemotherapy for advanced cervical cancer.Eur J Cancer 36, 994- 1001 (2000).1136.Leborgne, F.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Induction chemotherapy and radiotherapy of advanced cancer of the cervix: a pilot study and phase III randomized trial.Int $J$ Radiat Oncol Biol Phys 37, 343-350 (1997).1137.Tabata, T., Takeshima, N.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", Nishida, H., Hirai, Y.& Hasumi, K.A randomized study of primary bleomycin, vincristine, mitomycin and cisplatin (BOMP) chemotherapy followed by radiotherapy versus radiotherapy alone in stage IIIB and IVA squamous cell carcinoma of the cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Anticancer Res 23, 2885-2890 (2003).1138.Kigawa, J., et al.The role of neoadjuvant intraarterial infusion chemotherapy with cisplatin and bleomycin for locally advanced cervical cancer.Am J Clin Oncol 19, 255-259 (1996).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1139.Chang, T.C., et al.Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer.J Clin Oncol 18, 1740-1747 (2000).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1140.Benedetti-Panici, P., et al.Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Clin Oncol 20, 179- 188 (2002).1141.Rydzewska, L., Tierney, J., Vale, C.L.& Symonds, P.R.Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer.Cochrane Database Syst Rev 12, CD007406 (2012).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1142.Chen, H., Liang, C., Zhang, L., Huang, S.& Wu, X.Clinical efficacy of modified preoperative neoadjuvant chemotherapy in the treatment of locally advanced (stage IB2 to IIB) cervical cancer: randomized study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 110, 308-315 (2008).1143.Katsumata, N., et al.Phase III randomized trial of neoadjuvant chemotherapy (NAC) followed by radical hysterectomy (RH) versus RH for bulky stage I/II cervical cancer (JCOG 0102).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition).J Clin Oncol 24, 5013 (2006).1144.Yang, Z., et al.The efficacy and safety of neoadjuvant chemotherapy in the treatment of locally advanced cervical cancer: A randomized multicenter study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 141, 231-239 (2016).1145.Abou-Taleb, H.A., et al.Clinical efficacy of neoadjuvant chemotherapy with irinotecan (CPT-11) and nedaplatin followed by radical hysterectomy for locally advanced cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "$J$ Int Med Res 44, 346-356 (2016).1146.Gong, L., et al.Safety and Efficacy of Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Radical Surgery Alone in Locally Advanced Cervical Cancer Patients.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 26, 722-728 (2016).1147.Gong, L., et al.Clinical evaluation of neoadjuvant chemotherapy followed by radical surgery in the management of stage IB2-IIB cervical cancer.Int $J$ Gynaecol Obstet 117, 23-26 (2012).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1148.Yang, L., et al.Clinical efficacy and safety of paclitaxel plus carboplatin as neoadjuvant chemotherapy prior to radical hysterectomy and pelvic lymphadenectomy for Stage IB2-IIB cervical cancer.Int $J$ Clin Exp Med 8, 13690-13698 (2015).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1149.Xiong, Y., Liang, L.Z., Cao, L.P., Min, Z.& Liu, J.H.Clinical effects of irinotecan hydrochloride in combination with cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer.Gynecol Oncol 123, 99-104 (2011).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1150.Musaev, A., et al.Assessment of primary radical hysterectomy and neoadjuvant chemotherapy followed by radical hysterectomy in Stage IB2, IIA bulky cervical cancer.Eur J Gynaecol Oncol 36, 579-584 (2015).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1151.Yamakawa, Y., Fujimura, M., Hidaka, T., Hori, S.& Saito, S.Neoadjuvant intraarterial infusion chemotherapy in patients with stage IB2-IIIB cervical cancer.Gynecol Oncol 77, 264-270 (2000).1152.Lissoni, A.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A., et al.A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Ann Oncol 20, 660- 665 (2009).1153.Yin, M., et al.The toxicity and long-term efficacy of nedaplatin and paclitaxel treatment as neoadjuvant chemotherapy for locally advanced cervical cancer.J Surg Oncol 105, 206- 211 (2012).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1154.Osman, M.The role of neoadjuvant chemotherapy in the management of locally advanced cervix cancer: a systematic review.Oncol Rev 8, 250 (2014).1155.Shoji, T., et al.Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cancer Chemother Pharmacol 71, 657-662 (2013).1156.Shen, Y., Yang, L.& Wang, Z.Treatment of early bulky cervical cancer with neoadjuvant paclitaxel, carboplatin and cisplatin prior to laparoscopical radical hysterectomy and pelvic lymphadenectomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Oncol Lett 3, 641- 645 (2012).1157.Yamaguchi, S., et al.Phase II study of neoadjuvant chemotherapy with irinotecan hydrochloride and nedaplatin followed by radical hysterectomy for bulky stage Ib2 to IIb, cervical squamous cell carcinoma: Japanese Gynecologic Oncology Group study (JGOG 1065).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Oncol Rep 28, 487-493 (2012).1158.Pinheiro, W., Pereira, A.K., Soares, J.M., Jr.& Baracat, E.C.Is the combination of mitomycin C, bleomycin and methotrexate effective as a neoadjuvant treatment for cervical cancer in women?",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Eur J Gynaecol Oncol 32, 37-39 (2011).1159.Vizza, E., et al.Total laparoscopic radical hysterectomy and pelvic lymphadenectomy in locally advanced stage IB2-IIB cervical cancer patients after neoadjuvant chemotherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Eur J Surg Oncol 37, 364-369 (2011).1160.Mossa, B., Mossa, S., Corosu, L.& Marziani, R.Follow-up in a long-term randomized trial with neoadjuvant chemotherapy for squamous cell cervical carcinoma.Eur J Gynaecol Oncol 31, 497-503 (2010).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1161.Shoji, T., et al.Phase II study of triweekly cisplatin and irinotecan as neoadjuvant chemotherapy for locally advanced cervical cancer.Oncol Lett 1, 515-519 (2010).1162.Kokawa, K., Nishimura, R., Fujii, T.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "& Umesaki, N.Neoadjuvant chemotherapy with irinotecan and mitomycin-C for locally advanced squamous cell carcinoma of the uterine cervix.Anticancer Res 27, 2721-2727 (2007).1163.Slama, J., et al.[Contribution of neoadjuvant chemotherapy for operability of cancers of the uterine cervix].",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Ceska Gynekol 72, 116-119 (2007).1164.Choi, Y.S., et al.Survival benefits of neoadjuvant chemotherapy followed by radical surgery versus radiotherapy in locally advanced chemoresistant cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Korean Med Sci 21, 683-689 (2006).1165.Termrungruanglert, W., et al.Neoadjuvant gemcitabine and cisplatin followed by radical surgery in (bulky) squamous cell carcinoma of cervix stage IB2.Gynecol Oncol 97, 576-581 (2005).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1166.Taneja, A., Rajaram, S.& Agarwal, S.'Quick Cycle' neoadjuvant chemotherapy in squamous cell carcinoma of cervix.Indian J Pharmacol 37, 320-324 (2005).1167.deSouza, N.M., et al.Use of neoadjuvant chemotherapy prior to radical hysterectomy in cervical cancer: monitoring tumour shrinkage and molecular profile on magnetic resonance and assessment of 3-year outcome.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Br J Cancer 90, 2326-2331 (2004).1168.Hwang, Y.Y., et al.Ten-year survival of patients with locally advanced, stage ibiib cervical cancer after neoadjuvant chemotherapy and radical hysterectomy.Gynecol Oncol 82, 88-93 (2001).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1169.D'Agostino, G., et al.Neoadjuvant treatment of locally advanced carcinoma of the uterine cervix with epirubicin, paclitaxel and cisplatin.Cancer Chemother Pharmacol 49, 256- 260 (2002).1170.Duenas-Gonzalez, A.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.A phase II study of multimodality treatment for locally advanced cervical cancer: neoadjuvant carboplatin and paclitaxel followed by radical hysterectomy and adjuvant cisplatin chemoradiation.Ann Oncol 14, 1278-1284 (2003).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1171.Duenas-Gonzalez, A., et al.Concomitant chemoradiation versus neoadjuvant chemotherapy in locally advanced cervical carcinoma: results from two consecutive phase II studies.Ann Oncol 13, 1212-1219 (2002).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1172.Costa, S., et al.Neoadjuvant chemotherapy in cervical carcinoma: regulators of cell cycle, apoptosis, and proliferation as determinants of response to therapy and disease outcome.Am J Clin Pathol 116, 729-737 (2001).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1173.MacLeod, C., O'Donnell, A., Tattersall, M.H., Dalrymple, C.& Firth, I.Locally advanced cervix cancer: chemotherapy prior to definitive surgery or radiotherapy.A single institutional experience.Australas Radiol 45, 491- 495 (2001).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1174.Aoki, Y., et al.Neoadjuvant chemotherapy for patients younger than 50 years with high-risk squamous cell carcinoma of the cervix.Gynecol Oncol 83, 263-267 (2001).1175.Zanetta, G., et al.Neoadjuvant chemotherapy with cisplatin, ifosfamide and paclitaxel for locally advanced squamous-cell cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Ann Oncol 9, 977-980 (1998).1176.Lacava, J.A., et al.Vinorelbine as neoadjuvant chemotherapy in advanced cervical carcinoma.J Clin Oncol 15, 604- 609 (1997).1177.Huang, H.J., et al.Prognostic value of age and histologic type in neoadjuvant chemotherapy plus radical surgery for bulky $( > / = 4$ cm) stage IB and IIA cervical carcinoma.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 13, 204-211 (2003).1178.Osman, M.A.Defining the Role of Neoadjuvant Chemotherapy Followed by Surgery in Locally Advanced Cancer Cervix: A Meta-analysis of Phase III Trials.J Obstet Gynaecol India 66, 352- 357 (2016).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1179.Kornovski, Y.& Gorchev, G.Neoadjuvant chemotherapy followed by radical surgery and radiotherapy vs.pelvic irradiation in patients with cervical cancer FIGO stage IIB - IVA.J BUON 11, 291-297 (2006).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1180.Yamauchi, N., Sameshima, H., Fukushima, K., Nagai, K.& Ikenoue, T.A randomized trial of neoadjuvant chemotherapy followed by radical surgery versus radiotherapy alone in stage IIIb carcinoma of the uterine cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Gynecol Surg 26, 105-113 (2010).1181.Yin, M., et al.The long-term efficacy of neoadjuvant chemotherapy followed by radical hysterectomy compared with radical surgery alone or concurrent chemoradiotherapy on locally advanced-stage cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int $J$ Gynecol Cancer 21, 92-99 (2011).1182.Benedetti Panici, P., et al.Dose-Dense Neoadjuvant Chemotherapy plus Radical Surgery in Locally Advanced Cervical Cancer: A Phase II Study.Oncology 89, 103-110 (2015).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1183.Li, Y., Wang, X., Li, J.& Ding, W.Combination therapy of liposomal paclitaxel and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer.Eur J Gynaecol Oncol 36, 54-58 (2015).1184.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Angioli, R., et al.Feasibility and safety of carboplatin plus paclitaxel as neoadjuvant chemotherapy for locally advanced cervical cancer: a pilot study.Tumour Biol 35, 2741-2746 (2014).1185.McCormack, M.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer.Br J Cancer 108, 2464-2469 (2013).1186.Singh, R.B., et al.Neoadjuvant chemotherapy with weekly paclitaxel and carboplatin followed by chemoradiation in locally advanced cervical carcinoma: a pilot study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 129, 124-128 (2013).1187.Mousavia, A.S., Vahidi, S., Karimi-Zarchi, M., Modarress-Gilania, M.& Ghaemmaghamia, F.Response to neoadjuvant chemotherapy with paclitaxel and cisplatin in locally advanced cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Eur J Gynaecol Oncol 34, 527-531 (2013).1188.Ferrandina, G., et al.Paclitaxel, epirubicin, and cisplatin (TEP) regimen as neoadjuvant treatment in locally advanced cervical cancer: long-term results.Gynecol Oncol 128, 518-523 (2013).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1189.Heijkoop, S.T., et al.Neoadjuvant chemotherapy followed by radiotherapy and concurrent hyperthermia in patients with advanced-stage cervical cancer: a retrospective study.Int $J$ Hyperthermia 28, 554-561 (2012).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1190.Moioli, M., et al.Chemotherapy with cisplatin and paclitaxel in locally advanced cervical cancer: has this regimen still a role as neoadjuvant setting?Minerva Ginecol 64, 95-107 (2012).1191.Ren, Y.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", Li, Y.& Liu, J.A modified shortened administration schedule for neoadjuvant chemotherapy with irinotecan and cisplatin in locally advanced cervical cancer.Int J Gynecol Cancer 21, 685-689 (2011).1192.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Manci, N., et al.A prospective phase II study of topotecan (Hycamtin(R)) and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer.Gynecol Oncol 122, 285-290 (2011).1193.Huang, X., et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Neoadjuvant docetaxel combined with cisplatin and followed by radical surgery for the treatment of locally advanced (stage IB2 - IIB) cervical cancer: preliminary results of a single-institution experience.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Expert Opin Pharmacother 12, 165-173 (2011).1194.Raspagliesi, F., et al.A phase 2 multicenter study of irinotecan and cisplatinum as neoadjuvant treatment in patients with locally advanced cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int $J$ Gynecol Cancer 20, 1569- 1575 (2010).1195.Mori, T., et al.Neoadjuvant weekly carboplatin and paclitaxel followed by radical hysterectomy for locally advanced cervical cancer: long-term results.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 20, 611-616 (2010).1196.Kumar, J.V., Doval, D.C., Rao, R.& Rawal, S.A retrospective study of patients with locally advanced cancer of the cervix treated with neoadjuvant chemotherapy followed by radical surgery.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 19, 417-422 (2009).1197.Bae, J.H., et al.Neoadjuvant cisplatin and etoposide followed by radical hysterectomy for stage 1B-2B cervical cancer.Gynecol Oncol 111, 444-448 (2008).1198.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Benedetti Panici, P., et al.Neoadjuvant chemotherapy followed by radical surgery in patients affected by FIGO stage IVA cervical cancer.Ann Surg Oncol 14, 2643-2648 (2007).1199.Motoyama, S., et al.Neoadjuvant highdose intraarterial infusion chemotherapy under percutaneous pelvic perfusion with extracorporeal chemofiltration in patients with stages IIIa-IVa cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 95, 576-582 (2004).1200.Kobayashi, K., Furukawa, A., Takahashi, M.& Murata, K.Neoadjuvant intraarterial chemotherapy for locally advanced uterine cervical cancer: clinical efficacy and factors influencing response.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cardiovasc Intervent Radiol 26, 234-241 (2003).1201.Di Vagno, G., et al.Cisplatin and vinorelbine as neoadjuvant chemotherapy in locally advanced cervical cancer: a phase II study.Int $J$ Gynecol Cancer 13, 308-312 (2003).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1202.Etcheverry, M.G., et al.Neoadjuvant chemotherapy with cisplatin, ifosfamide and 5-fluorouracil in the treatment of locally advanced cervical cancer.Int $J$ Gynecol Cancer 10, 53-58 (2000).1203.Sugiyama, T.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", Nishida, T., Hasuo, Y., Fujiyoshi, K.& Yakushiji, M.Neoadjuvant intraarterial chemotherapy followed by radical hysterectomy and/or radiotherapy for locally advanced cervical cancer.Gynecol Oncol 69, 130-136 (1998).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1204.Giardina, G., et al.Weekly cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer: a welltolerated alternative.Eur $J$ Gynaecol Oncol 18, 173-176 (1997).1205.Lai, C.H., et al.Prognostic factors in patients with bulky stage IB or IIA cervical carcinoma undergoing neoadjuvant chemotherapy and radical hysterectomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 64, 456- 462 (1997).1206.Eddy, G.L., Manetta, A., Alvarez, R.D., Williams, L.& Creasman, W.T.Neoadjuvant chemotherapy with vincristine and cisplatin followed by radical hysterectomy and pelvic lymphadenectomy for FIGO stage IB bulky cervical cancer: a Gynecologic Oncology Group pilot study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 57, 412-416 (1995).1207.Shimada, M., et al.Neoadjuvant chemotherapy with docetaxel and carboplatin followed by radical hysterectomy for stage IB2, IIA2, and IIB patients with non-squamous cell carcinoma of the uterine cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Clin Oncol 21, 1128-1135 (2016).1208.Lopez-Graniel, C., et al.Type III radical hysterectomy after induction chemotherapy for patients with locally advanced cervical carcinoma.Int $J$ Gynecol Cancer 11, 210-217 (2001).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1209.Toita, T., et al.Therapeutic value of neoadjuvant intra-arterial chemotherapy (cisplatin) and irradiation for locally advanced uterine cervical cancer.Gynecol Oncol 65, 421- 424 (1997).1210.Perez, C.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A., Camel, H.M., Kao, M.S.& Hederman, M.A.Randomized study of preoperative radiation and surgery or irradiation alone in the treatment of stage IB and IIA carcinoma of the uterine cervix: final report.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 27, 129-140 (1987).1211.Morice, P., et al.Results of the GYNECO 02 study, an FNCLCC phase III trial comparing hysterectomy with no hysterectomy in patients with a (clinical and radiological) complete response after chemoradiation therapy for stage IB2 or II cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Oncologist 17, 64-71 (2012).1212.Cetina, L., et al.Brachytherapy versus radical hysterectomy after external beam chemoradiation with gemcitabine plus cisplatin: a randomized, phase III study in IB2-IIB cervical cancer patients.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Ann Oncol 24, 2043-2047 (2013).1213.Kokka, F., Bryant, A., Brockbank, E., Powell, M.& Oram, D.Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.Cochrane Database Syst Rev, CD010260 (2015).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1214.Okame, S., et al.Type C2 radical hysterectomy may improve outcomes of locally advanced mucinous adenocarcinoma of the uterine cervix.Int J Clin Oncol 21, 723-729 (2016).1215.Sarraf, Z., et al.The Effect of Extrafascial Hysterectomy After Completion of External Beam Radiotherapy for Treatment of Locally Advanced Stages (IIB-III) of Cervical Cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Iran Red Crescent Med J 15, e10758 (2013).1216.Fanfani, F., et al.Radical hysterectomy after chemoradiation in FIGO stage III cervical cancer patients versus chemoradiation and brachytherapy: Complications and 3-years survival.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Eur J Surg Oncol 42, 1519-1525 (2016).1217.Motton, S., et al.Results of surgery after concurrent chemoradiotherapy in advanced cervical cancer: comparison of extended hysterectomy and extrafascial hysterectomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 20, 268-275 (2010).1218.Panici, P.B., et al.Feasibility and safety of type C2 total extraperitoneal abdominal radical hysterectomy (TEARH) for locally advanced cervical cancer.Gynecol Oncol 120, 423-429 (2011).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1219.Plotti, F., et al.Quality of life and sexual function after type C2/type III radical hysterectomy for locally advanced cervical cancer: a prospective study.J Sex Med 8, 894-904 (2011).1220.Panici, P.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "B., et al.Type B versus Type C Radical Hysterectomy After Neoadjuvant Chemotherapy in Locally Advanced Cervical Carcinoma: A Propensity-Matched Analysis.Ann Surg Oncol 23, 2176-2182 (2016).1221.Favero, G.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Laparoscopic extrafascial hysterectomy (completion surgery) after primary chemoradiation in patients with locally advanced cervical cancer: technical aspects and operative outcomes.Int J Gynecol Cancer 24, 608-614 (2014).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1222.Cai, J., et al.Retrospective comparison of laparoscopic versus open radical hysterectomy after neoadjuvant chemotherapy for locally advanced cervical cancer.Int $J$ Gynaecol Obstet 132, 29-33 (2016).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1223.Baffert, S., et al.Laparoscopic hysterectomy after concurrent radiochemotherapy in locally advanced cervical cancer compared to laparotomy: A multi institutional prospective pilot study of cost, surgical outcome and quality of life.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Eur J Surg Oncol 42, 391-399 (2016).1224.Colombo, P.E., et al.Total laparoscopic radical hysterectomy for locally advanced cervical carcinoma (stages IIB, IIA and bulky stages IB) after concurrent chemoradiation therapy: surgical morbidity and oncological results.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 114, 404-409 (2009).1225.Vitobello, D., Siesto, G., Pirovano, C.& Ieda, N.Surgical outcomes of robotic radical hysterectomy after neoadjuvant chemotherapy for locally advanced cervical cancer: comparison with early stage disease.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Eur J Surg Oncol 39, 87-93 (2013).1226.Minig, L., Zanagnolo, V., CardenasRebollo, J.M., Colombo, N.& Maggioni, A.Feasibility of robotic radical hysterectomy after neoadjuvant chemotherapy in women with locally advanced cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Eur J Surg Oncol 42, 1372-1377 (2016).1227.Vizza, E., et al.Neoadjuvant chemotherapy followed by robotic radical hysterectomy in locally advanced cervical cancer: a multiinstitution study.Gynecol Oncol 133, 180-185 (2014).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1228.Gallotta, V., et al.Robotic Radical Hysterectomy After Concomitant Chemoradiation in Locally Advanced Cervical Cancer: A Prospective Phase II Study.J Minim Invasive Gynecol 24, 133- 139 (2017).1229.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Corrado, G., et al.Surgical and Oncological Outcome of Robotic Surgery Compared With Laparoscopic and Abdominal Surgery in the Management of Locally Advanced Cervical Cancer After Neoadjuvant Chemotherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int $J$ Gynecol Cancer 26, 539-546 (2016).1230.Sapienza, L.G., Gomes, M.J., Calsavara, V.F., Leitao, M.M., Jr.& Baiocchi, G.Does para-aortic irradiation reduce the risk of distant metastasis in advanced cervical cancer?",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A systematic review and metaanalysis of randomized clinical trials.Gynecol Oncol 144, 312-317 (2017).1231.Haie, C., et al.Is prophylactic para-aortic irradiation worthwhile in the treatment of advanced cervical carcinoma?",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Results of a controlled clinical trial of the EORTC radiotherapy group.Radiother Oncol 11, 101-112 (1988).1232.Rotman, M., et al.Prophylactic irradiation of the para-aortic lymph node chain in stage IIB and bulky stage IB carcinoma of the cervix, initial treatment results of RTOG 7920.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 19, 513-521 (1990).1233.Rotman, M., et al.Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas.Ten-year treatment results of RTOG 79-20.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "JAMA 274, 387-393 (1995).1234.Chatani, M., et al.Prophylactic irradiation of para-aortic lymph nodes in carcinoma of the uterine cervix.A prospective randomized study.Strahlenther Onkol 171, 655-660 (1995).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1235.Lin, S.Y., et al.The Role of Pretreatment FDG-PET in Treating Cervical Cancer Patients With Enlarged Pelvic Lymph Node(s) Shown on MRI: A Phase 3 Randomized Trial With Long-Term Follow-Up.Int J Radiat Oncol Biol Phys 92, 577-585 (2015).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1236.Dobrowsky, W., et al.AK-2123 (Sanazol) as a radiation sensitizer in the treatment of stage III cervical cancer: results of an IAEA multicentre randomised trial.Radiother Oncol 82, 24-29 (2007).1237.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Liu, R., et al.High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer.Cochrane Database Syst Rev, CD007563 (2014).1238.Hareyama, M., et al.High-dose-rate versus low-dose-rate intracavitary therapy for carcinoma of the uterine cervix: a randomized trial.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cancer 94, 117-124 (2002).1239.Lertsanguansinchai, P., et al.Phase III randomized trial comparing LDR and HDR brachytherapy in treatment of cervical carcinoma.Int J Radiat Oncol Biol Phys 59, 1424-1431 (2004).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1240.Patel, F.D., Sharma, S.C., Negi, P.S., Ghoshal, S.& Gupta, B.D.Low dose rate vs.high dose rate brachytherapy in the treatment of carcinoma of the uterine cervix: a clinical trial.Int J Radiat Oncol Biol Phys 28, 335-341 (1994).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1241.Teshima, T., et al.High-dose rate and low-dose rate intracavitary therapy for carcinoma of the uterine cervix.Final results of Osaka University Hospital.Cancer 72, 2409-2414 (1993).1242.Viani, G.A.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", Manta, G.B., Stefano, E.J.& de Fendi, L.I.Brachytherapy for cervix cancer: low-dose rate or high-dose rate brachytherapy - a meta-analysis of clinical trials.J Exp Clin Cancer Res 28, 47 (2009).1243.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Shrivastava, S., et al.Comparing lowdose-rate and high-dose-rate intracavitary brachytherapy in carcinoma cervix: Results from a randomized controlled study.Int $J$ Radiat Biol Phys 66, S42 (2006).1244.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Lee, K.K., Lee, J.Y., Nam, J.M., Kim, C.B.& Park, K.R.High-dose-rate vs.low-doserate intracavitary brachytherapy for carcinoma of the uterine cervix: Systematic review and meta-analysis.Brachytherapy 14, 449-457 (2015).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1245.Hareyama, M., et al.A prospective, randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in patients with advanced nasopharyngeal carcinoma.Cancer 94, 2217-2223 (2002).1246.Ferrigno, R.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Comparison of low and high dose rate brachytherapy in the treatment of uterine cervix cancer.Retrospective analysis of two sequential series.Int J Radiat Oncol Biol Phys 62, 1108-1116 (2005).1247.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Hsu, W.L., et al.Twice-per-day fractionated high versus continuous low dose rate intracavitary therapy in the radical treatment of cervical cancer: a nonrandomized comparison of treatment results.Int J Radiat Oncol Biol Phys 32, 1425-1431 (1995).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1248.Arai, T., et al.High-dose-rate remote afterloading intracavitary radiation therapy for cancer of the uterine cervix.A 20-year experience.Cancer 69, 175- 180 (1992).1249.Orton, C.G., Seyedsadr, M.& Somnay, A.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Comparison of high and low dose rate remote afterloading for cervix cancer and the importance of fractionation.Int J Radiat Oncol Biol Phys 21, 1425-1434 (1991).1250.Cai, S.M., Wang, X.E.& Wang, Q.High dose-rate afterloading in the treatment of cervical cancer of the uterus.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int $J$ Radiat Oncol Biol Phys 16, 335-338 (1989).1251.Vahrson, H.& Romer, G.5-year results with HDR afterloading in cervix cancer: dependence on fractionation and dose.Sonderb Strahlenther Onkol 82, 139-146 (1988).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1252.Cikaric, S.Radiation therapy of cervical carcinoma using either HDR or LDR afterloading: comparison of 5-year results and complications.Sonderb Strahlenther Onkol 82, 119-122 (1988).1253.Akine, Y.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.High-dose-rate intracavitary irradiation in the treatment of carcinoma of the uterine cervix: early experience with 84 patients.Int J Radiat Oncol Biol Phys 14, 893-898 (1988).1254.Glaser, F.H.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Comparison of HDR afterloading with 192Ir versus conventional radium therapy in cervix cancer: 5-year results and complications.Sonderb Strahlenther Onkol 82, 106-113 (1988).1255.Sato, S., Yajima, A.& Suzuki, M.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Therapeutic results using high-doserate intracavitary irradiation in cases of cervical cancer.Gynecol Oncol 19, 143- 147 (1984).1256.Kuipers, T.High dose-rate intracavitary irradiation: Results of treatment.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In Mould R, editor.Brachytherapy.Leersum.The Netherlands: Nucleotron Trading BV.169-175 (1984).1257.Rotte, K.A randomized clinical trial comparing a high dose-rate with a conventional dose-rate technique.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "In: Bates TD, Berry RJ, editors.Hgh dose rate afterloading in the treatment of cancer of the uterus.Wurzberg, West Germany.75-79 (1984).1258.Cho, O., Noh, O.K., Oh, Y.T., Chang, S.J.& Chun, M.Clinical Impact of Escalating Relative High-dose-rate Intracavitary Brachytherapy Dose in Stage IIB Cervical Cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Anticancer Res 37, 327- 334 (2017).1259.Mayadev, J., et al.American Brachytherapy Task Group Report: A pooled analysis of clinical outcomes for high-dose-rate brachytherapy for cervical cancer.Brachytherapy 16, 22- 43 (2017).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1260.Potter, R., et al.Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Radiother Oncol 100, 116-123 (2011).1261.Garipagaoglu, M., et al.Adding concurrent low dose continuous infusion of cisplatin to radiotherapy in locally advanced cervical carcinoma: a prospective randomized pilot study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Br J Radiol 77, 581-587 (2004).1262.Huang, E.Y., et al.A prospective cohort study to compare treatment results between 2 fractionation schedules of high-dose-rate intracavitary brachytherapy (HDR-ICBT) in patients with cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 85, 123-128 (2013).1263.Kato, S., et al.Long-term follow-up results of a multi-institutional phase 2 study of concurrent chemoradiation therapy for locally advanced cervical cancer in east and southeast Asia.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 87, 100-105 (2013).1264.Kim, Y.S., et al.A preliminary results of a randomized trial comparing monthly 5- flourouracil and cisplatin to weekly cisplatin alone combined with concurrent radiotherapy for locally advanced cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cancer Res Treat 37, 37-43 (2005).1265.Kim, Y.S., et al.Prospective randomized comparison of monthly fluorouracil and cisplatin versus weekly cisplatin concurrent with pelvic radiotherapy and high-dose rate brachytherapy for locally advanced cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 108, 195-200 (2008).1266.Lanciano, R., et al.Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a gynecologic oncology group study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Clin Oncol 23, 8289-8295 (2005).1267.Lorvidhaya, V., et al.Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial.Int J Radiat Oncol Biol Phys 55, 1226-1232 (2003).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1268.Nam, T.K.& Ahn, S.J.A prospective randomized study on two dose fractionation regimens of high-dose-rate brachytherapy for carcinoma of the uterine cervix: comparison of efficacies and toxicities between two regimens.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "$J$ Korean Med Sci 19, 87-94 (2004).1269.Pearcey, R., et al.Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Clin Oncol 20, 966- 972 (2002).1270.Sharma, D.N., et al.High-dose rate interstitial brachytherapy using two weekly sessions of 10 Gy each for patients with locally advanced cervical carcinoma.Brachytherapy 10, 242-248 (2011).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1271.Toita, T., et al.Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: efficacy and toxicity of a low cumulative radiation dose schedule.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 126, 211-216 (2012).1272.Yoon, S.M., et al.Six fractions per week of external beam radiotherapy and highdose-rate brachytherapy for carcinoma of the uterine cervix: A phase I/II study.Int J Radiat Oncol Biol Phys 65, 1508- 1513 (2006).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1273.Zuliani, A.C., et al.Concomitant cisplatin plus radiotherapy and high-dose-rate brachytherapy versus radiotherapy alone for stage IIIB epidermoid cervical cancer: a randomized controlled trial.$J$ Clin Oncol 32, 542-547 (2014).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1274.Al Asiri, M., et al.Five-year outcome of concurrent radiotherapy and chemotherapy in Saudi women with locally advanced cervical cancer: singleinstitution experience.Ann Saudi Med 33, 327-333 (2013).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1275.Atahan, I.L., et al.Long-term outcome and prognostic factors in patients with cervical carcinoma: a retrospective study.Int J Gynecol Cancer 17, 833-842 (2007).1276.Azad, S.K.& Choudhary, V.Treatment results of radical radiotherapy of carcinoma uterine cervix using external beam radiotherapy and high dose rate intracavitary radiotherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Cancer Res Ther 6, 482-486 (2010).1277.Beriwal, S., et al.Three-dimensional high dose rate intracavitary imageguided brachytherapy for the treatment of cervical cancer using a hybrid magnetic resonance imaging/computed tomography approach: feasibility and early results.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Clin Oncol (R Coll Radiol) 23, 685-690 (2011).1278.Chatani, M., Tsuboi, K., Yagi, M., Fujiwara, K.& Tachimoto, R.Radiation therapy for carcinoma of the uterine cervix: comparison of two brachytherapy schedules.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "$J$ Radiat Res 55, 748-753 (2014).1279.Chen, S.W., et al.Concurrent weekly cisplatin plus external beam radiotherapy and high-dose rate brachytherapy for advanced cervical cancer: a control cohort comparison with radiation alone on treatment outcome and complications.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 66, 1370-1377 (2006).1280.Das, D., et al.Treatment of cervical carcinoma with high-dose rate intracavitary brachytherapy: two years follow-up study.Asian Pac J Cancer Prev 12, 807-810 (2011).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1281.Demanes, D.J., Rodriguez, R.R., Bendre, D.D.& Ewing, T.L.High dose rate transperineal interstitial brachytherapy for cervical cancer: high pelvic control and low complication rates.Int J Radiat Oncol Biol Phys 45, 105-112 (1999).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1282.Falkenberg, E., Kim, R.Y., Meleth, S., De Los Santos, J.& Spencer, S.Low-doserate vs.high-dose-rate intracavitary brachytherapy for carcinoma of the cervix: The University of Alabama at Birmingham (UAB) experience.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Brachytherapy 5, 49-55 (2006).1283.Ferrigno, R., et al.High-dose-rate brachytherapy in the treatment of uterine cervix cancer.Analysis of dose effectiveness and late complications.Int J Radiat Oncol Biol Phys 50, 1123-1135 (2001).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1284.Gerszten, K., Gooding, W.E., Lin, Y., Heron, D.E.& Faul, C.A single institutional experience with definitive radiotherapy for cervical cancer using both high- and low-dose-rate brachytherapy.Gynecol Oncol 102, 500- 507 (2006).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1285.Gill, B.S., et al.MRI-guided high-doserate intracavitary brachytherapy for treatment of cervical cancer: the University of Pittsburgh experience.Int J Radiat Oncol Biol Phys 91, 540-547 (2015).1286.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Hama, Y., et al.Carcinoma of the uterine cervix: twice- versus once-weekly highdose-rate brachytherapy.Radiology 219, 207-212 (2001).1287.Jain, V.S., et al.Radical radiotherapy treatment (EBRT $^ +$ HDR-ICRT) of carcinoma of the uterine cervix: outcome in patients treated at a rural center in India.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Cancer Res Ther 3, 211- 217 (2007).1288.Kang, H.C., Shin, K.H., Park, S.Y.& Kim, J.Y.3D CT-based high-dose-rate brachytherapy for cervical cancer: clinical impact on late rectal bleeding and local control.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Radiother Oncol 97, 507-513 (2010).1289.Kannan, N., et al.High-dose-rate interstitial computed tomographybased brachytherapy for the treatment of cervical cancer: early results.Brachytherapy 11, 408-412 (2012).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1290.Kato, S., et al.CT-based 3D dose-volume parameter of the rectum and late rectal complication in patients with cervical cancer treated with high-dose-rate intracavitary brachytherapy.J Radiat Res 51, 215-221 (2010).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1291.Khor, T.H., Tuan, J.K., Hee, S.W.& Tham, I.W.Radical radiotherapy with highdose-rate brachytherapy for uterine cervix cancer long-term results.Australas Radiol 51, 570-577 (2007).1292.Kim, D.H., et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "High-dose rate brachytherapy using inverse planning simulated annealing for locoregionally advanced cervical cancer: a clinical report with 2-year follow-up.Int $J$ Radiat Oncol Biol Phys 75, 1329-1334 (2009).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1293.Kim, T.E., et al.Outcomes and prognostic factors of cervical cancer after concurrent chemoradiation.J Obstet Gynaecol Res 38, 1315-1320 (2012).1294.Kucera, H., Potter, R., Knocke, T.H., Baldass, M.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "& Kucera, E.High-dose versus low-dose rate brachytherapy in definitive radiotherapy of cervical cancer.Wien Klin Wochenschr 113, 58- 62 (2001).1295.Kudaka, W., et al.Long-term results and prognostic factors in patients with stage III-IVA squamous cell carcinoma of the cervix treated with concurrent chemoradiotherapy from a single institution study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Clin Oncol 18, 916-921 (2013).1296.Kuroda, Y., et al.Impact of concurrent chemotherapy on definitive radiotherapy for women with FIGO IIIb cervical cancer.J Radiat Res 53, 588-593 (2012).1297.Liang, J.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A., et al.Risk stratification for failure in patients with advanced cervical cancer after concurrent chemoradiotherapy: another way to optimise treatment results.Clin Oncol (R Coll Radiol) 20, 683-690 (2008).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1298.Lorvidhaya, V., et al.High-dose-rate afterloading brachytherapy in carcinoma of the cervix: an experience of 1992 patients.Int J Radiat Oncol Biol Phys 46, 1185-1191 (2000).1299.Mayer, A., et al.Primary radiotherapy of stage IIA/B-IIIB cervical carcinoma.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A comparison of continuous versus sequential regimens.Strahlenther Onkol 180, 209-215 (2004).1300.Nakano, T., et al.Long-term results of high-dose rate intracavitary brachytherapy for squamous cell carcinoma of the uterine cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cancer 103, 92-101 (2005).1301.Niibe, Y., et al.High-dose-rate intracavitary brachytherapy combined with external beam radiotherapy for stage IIIb adenocarcinoma of the uterine cervix in Japan: a multi-institutional study of Japanese Society of Therapeutic Radiology and Oncology 2006-2007 (study of JASTRO 2006-2007).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Jpn J Clin Oncol 40, 795-799 (2010).1302.Novetsky, A.P., et al.Efficacy and toxicity of concomitant cisplatin with external beam pelvic radiotherapy and two highdose-rate brachytherapy insertions for the treatment of locally advanced cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 105, 635- 640 (2007).1303.Ogawa, Y., et al.Results of radiation therapy for uterine cervical cancer using high dose rate remote after loading system.Tohoku J Exp Med 199, 229-238 (2003).1304.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Okkan, S., et al.Results and complications of high dose rate and low dose rate brachytherapy in carcinoma of the cervix: Cerrahpasa experience.Radiother Oncol 67, 97-105 (2003).1305.Okuda, T., et al.Long-term result of high dose-rate afterloading brachytherapy in squamous cell carcinoma of the cervix: relationship between facility structure and outcome.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Jpn J Clin Oncol 34, 142- 148 (2004).1306.Ozsaran, Z., Kamer, S., Yalman, D., Akagunduz, O.& Aras, A.Treatment results and prognostic factors for cervical cancer patients treated by radiochemotherapy with weekly cisplatin.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Eur J Gynaecol Oncol 28, 196- 200 (2007).1307.Parker, K., Gallop-Evans, E., Hanna, L.& Adams, M.Five years' experience treating locally advanced cervical cancer with concurrent chemoradiotherapy and high-dose-rate brachytherapy: results from a single institution.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int $J$ Radiat Oncol Biol Phys 74, 140-146 (2009).1308.Patel, F.D., Rai, B., Mallick, I.& Sharma, S.C.High-dose-rate brachytherapy in uterine cervical carcinoma.Int J Radiat Oncol Biol Phys 62, 125-130 (2005).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1309.Pinn-Bingham, M., et al.Outcomes of high-dose-rate interstitial brachytherapy in the treatment of locally advanced cervical cancer: longterm results.Int J Radiat Oncol Biol Phys 85, 714-720 (2013).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1310.Potter, R., et al.Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer.Radiother Oncol 83, 148-155 (2007).1311.Potter, R., et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Definitive radiotherapy based on HDR brachytherapy with iridium 192 in uterine cervix carcinoma: report on the Vienna University Hospital findings (1993-1997) compared to the preceding period in the context of ICRU 38 recommendations.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cancer Radiother 4, 159-172 (2000).1312.Sakata, K., et al.Results of concomitant chemoradiation for cervical cancer using high dose rate intracavitary brachytherapy: study of JROSG (Japan Radiation Oncology Study Group).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Acta Oncol 47, 434-441 (2008).1313.Schmid, M.P., et al.Local recurrences in cervical cancer patients in the setting of image-guided brachytherapy: a comparison of spatial dose distribution within a matched-pair analysis.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Radiother Oncol 100, 468-472 (2011).1314.Sood, B.M., et al.Extended-field radiotherapy and high-dose-rate brachytherapy in carcinoma of the uterine cervix: clinical experience with and without concomitant chemotherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cancer 97, 1781-1788 (2003).1315.Sorbe, B., Bohr, L., Karlsson, L.& Bermark, B.Combined external and intracavitary irradiation in treatment of advanced cervical carcinomas: predictive factors for local tumor control and early recurrences.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int $J$ Oncol 36, 371-378 (2010).1316.Souhami, L., et al.Long-term results of high-dose rate brachytherapy in cervix cancer using a small number of fractions.Gynecol Oncol 97, 508-513 (2005).1317.Teh, J.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Concurrent chemoradiotherapy incorporating highdose rate brachytherapy for locally advanced cervical carcinoma: survival outcomes, patterns of failure, and prognostic factors.Int J Gynecol Cancer 20, 428-433 (2010).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1318.Wong, F.C., et al.Treatment results of high-dose-rate remote afterloading brachytherapy for cervical cancer and retrospective comparison of two regimens.Int J Radiat Oncol Biol Phys 55, 1254-1264 (2003).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1319.Yamashita, H., et al.High-dose-rate intra-cavitary brachytherapy combined with external beam radiation therapy for under 40-year-old patients with invasive uterine cervical carcinoma: clinical outcomes in 118 Patients in a Japanese multi-institutional study, JASTRO.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Jpn J Clin Oncol 43, 547-552 (2013).1320.Zhang, G., et al.Definitive extended field intensity-modulated radiotherapy and concurrent cisplatin chemosensitization in the treatment of IB2-IIIB cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Gynecol Oncol 25, 14-21 (2014).1321.Zuliani, A.C., Cunha Mde, O., Esteves, S.C.& Teixeira, J.C.Brachytherapy for stage IIIB squamous cell carcinoma of the uterine cervix: survival and toxicity.Rev Assoc Med Bras (1992) 56, 37-40 (2010).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1322.Lee, H.J., et al.Individualized prediction of overall survival after postoperative radiation therapy in patients with earlystage cervical cancer: a Korean Radiation Oncology Group study (KROG 13-03).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 87, 659-664 (2013).1323.Noda, S.E., et al.Late rectal complications evaluated by computed tomography-based dose calculations in patients with cervical carcinoma undergoing high-dose-rate brachytherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int $J$ Radiat Oncol Biol Phys 69, 118-124 (2007).1324.Fujikawa, K., Miyamoto, T., Ihara, Y., Matsui, Y.& Takeuchi, H.High incidence of severe urologic complications following radiotherapy for cervical cancer in Japanese women.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 80, 21-23 (2001).1325.Huh, S.J., et al.Pelvic insufficiency fracture after pelvic irradiation in uterine cervix cancer.Gynecol Oncol 86, 264-268 (2002).1326.Cheng, J.C., et al.Unique role of proximal rectal dose in late rectal complications for patients with cervical cancer undergoing high-dose-rate intracavitary brachytherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int $J$ Radiat Oncol Biol Phys 57, 1010-1018 (2003).1327.Chun, M., et al.Rectal bleeding and its management after irradiation for uterine cervical cancer.Int $J$ Radiat Oncol Biol Phys 58, 98-105 (2004).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1328.Chen, S.W., et al.Late toxicities in concurrent chemoradiotherapy using high-dose-rate intracavitary brachytherapy plus weekly cisplatin for locally advanced cervical cancer: a historical cohort comparison against two previous different treatment schemes.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Eur J Gynaecol Oncol 31, 504- 509 (2010).1329.Tokumaru, S., et al.Insufficiency fractures after pelvic radiation therapy for uterine cervical cancer: an analysis of subjects in a prospective multiinstitutional trial, and cooperative study of the Japan Radiation Oncology Group (JAROG) and Japanese Radiation Oncology Study Group (JROSG).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int $J$ Radiat Oncol Biol Phys 84, e195-200 (2012).1330.Trifiletti, D.M., Tyler Watkins, W., Duska, L., Libby, B.B.& Showalter, T.N.Severe gastrointestinal complications in the era of image-guided high-dose-rate intracavitary brachytherapy for cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Clin Ther 37, 49-60 (2015).1331.Yang, L.& Lv, Y.Possible risk factors associated with radiation proctitis or radiation cystitis in patients with cervical carcinoma after radiotherapy.Asian Pac J Cancer Prev 13, 6251-6255 (2012).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1332.Yoshida, K., et al.Role of vaginal pallor reaction in predicting late vaginal stenosis after high-dose-rate brachytherapy in treatment-naive patients with cervical cancer.J Gynecol Oncol 26, 179-184 (2015).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1333.Kirchheiner, K., et al.Manifestation pattern of early-late vaginal morbidity after definitive radiation (chemo)therapy and image-guided adaptive brachytherapy for locally advanced cervical cancer: an analysis from the EMBRACE study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 89, 88-95 (2014).1334.Bohr Mordhorst, L., Karlsson, L., Barmark, B.& Sorbe, B.Combined external and intracavitary irradiation in treatment of advanced cervical carcinomas: predictive factors for treatment outcome and early and late radiation reactions.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 24, 1268-1275 (2014).1335.Georg, P., et al.Time course of late rectal- and urinary bladder side effects after MRI-guided adaptive brachytherapy for cervical cancer.Strahlenther Onkol 189, 535-540 (2013).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1336.Mendez, L.C., et al.Three-dimensionalguided perineal-based interstitial brachytherapy in cervical cancer: A systematic review of technique, local control and toxicities.Radiother Oncol 123, 312-318 (2017).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1337.Eisbruch, A., et al.Customized gynecologic interstitial implants: CTbased planning, dose evaluation, and optimization aided by laparotomy.Int J Radiat Oncol Biol Phys 40, 1087-1093 (1998).1338.Isohashi, F.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.High-dose-rate interstitial brachytherapy for previously untreated cervical carcinoma.Brachytherapy 8, 234-239 (2009).1339.Wang, Y., Ye, W.& Du, L.Dose-volumes parameters and clinical outcome of CTguided free-hand high-dose-rate interstitial brachytherapy for cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Chin J Cancer (2012).1340.Lee, L.J., Damato, A.L.& Viswanathan, A.N.Clinical outcomes of high-dose-rate interstitial gynecologic brachytherapy using real-time CT guidance.Brachytherapy 12, 303-310 (2013).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1341.Viswanathan, A.N., Szymonifka, J., Tempany-Afdhal, C.M., O'Farrell, D.A.& Cormack, R.A.A prospective trial of realtime magnetic resonance-guided catheter placement in interstitial gynecologic brachytherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Brachytherapy 12, 240-247 (2013).1342.Yoshida, K., et al.Preliminary results of MRI-assisted high-dose-rate interstitial brachytherapy for uterine cervical cancer.Brachytherapy 14, 1-8 (2015).1343.Rodriguez Villalba, S.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", Richart Sancho, J., Otal Palacin, A., Perez-Calatayud, J.& Santos Ortega, M.Development and clinical implementation of a new template for MRI-based intracavitary/interstitial gynecologic brachytherapy for locally advanced cervical cancer: from CT-based MUPIT to the MRI compatible Template Benidorm.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Ten years of experience.$J$ Contemp Brachytherapy 8, 404-414 (2016).1344.Murakami, N., et al.The role of interstitial brachytherapy in the management of primary radiation therapy for uterine cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "$J$ Contemp Brachytherapy 8, 391-398 (2016).1345.Fallon, J., et al.Long term results from a prospective database on high dose rate (HDR) interstitial brachytherapy for primary cervical carcinoma.Gynecol Oncol (2016).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1346.Shah, A.P., Strauss, J.B., Gielda, B.T.& Zusag, T.W.Toxicity associated with bowel or bladder puncture during gynecologic interstitial brachytherapy.Int J Radiat Oncol Biol Phys 77, 171-179 (2010).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1347.Thibault, I., Lavallee, M.C., Aubin, S., Laflamme, N.& Vigneault, E.Inverseplanned gynecologic high-dose-rate interstitial brachytherapy: clinical outcomes and dose--volume histogram analysis.Brachytherapy 11, 181-191 (2012).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1348.D'Souza, D., et al.CT-based interstitial brachytherapy in advanced gynecologic malignancies: outcomes from a single institution experience.Brachytherapy 13, 225-232 (2014).1349.Dyk, P.T., et al.Outpatient-based highdose-rate interstitial brachytherapy for gynecologic malignancies.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Brachytherapy 14, 231-237 (2015).1350.Amsbaugh, M.J., et al.Computed tomography-planned interstitial brachytherapy for locally advanced gynecologic cancer: Outcomes and dosimetric predictors of urinary toxicity.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Brachytherapy 15, 49-56 (2016).1351.Aridgides, P., et al.Institutional experience using interstitial brachytherapy for the treatment of primary and recurrent pelvic malignancies.J Contemp Brachytherapy 8, 173-180 (2016).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1352.Bailleux, C., et al.Concomitant cervical and transperineal parametrial highdose-rate brachytherapy boost for locally advanced cervical cancer.J Contemp Brachytherapy 8, 23-31 (2016).1353.Mahantshetty, U.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Reporting and validation of gynaecological Groupe Euopeen de Curietherapie European Society for Therapeutic Radiology and Oncology (ESTRO) brachytherapy recommendations for MR image-based dose volume parameters and clinical outcome with high dose-rate brachytherapy in cervical cancers: a single-institution initial experience.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 21, 1110-1116 (2011).1354.Nomden, C.N., et al.Clinical outcome and dosimetric parameters of chemoradiation including MRI guided adaptive brachytherapy with tandem-ovoid applicators for cervical cancer patients: a single institution experience.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Radiother Oncol 107, 69-74 (2013).1355.Lindegaard, J.C., Fokdal, L.U., Nielsen, S.K., Juul-Christensen, J.& Tanderup, K.MRI-guided adaptive radiotherapy in locally advanced cervical cancer from a Nordic perspective.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Acta Oncol 52, 1510-1519 (2013).1356.Tharavichitkul, E., et al.Intermediateterm results of image-guided brachytherapy and high-technology external beam radiotherapy in cervical cancer: Chiang Mai University experience.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 130, 81-85 (2013).1357.Kharofa, J., et al.3-T MRI-based adaptive brachytherapy for cervix cancer: treatment technique and initial clinical outcomes.Brachytherapy 13, 319-325 (2014).1358.Rijkmans, E.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "C., et al.Improved survival of patients with cervical cancer treated with image-guided brachytherapy compared with conventional brachytherapy.Gynecol Oncol 135, 231- 238 (2014).1359.Simpson, D.R., et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Clinical Outcomes of Computed Tomography-Based Volumetric Brachytherapy Planning for Cervical Cancer.Int J Radiat Oncol Biol Phys 93, 150-157 (2015).1360.Castelnau-Marchand, P., et al.Clinical outcomes of definitive chemoradiation followed by intracavitary pulsed-dose rate image-guided adaptive brachytherapy in locally advanced cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 139, 288- 294 (2015).1361.Lakosi, F., et al.Clinical efficacy and toxicity of radio-chemotherapy and magnetic resonance imaging-guided brachytherapy for locally advanced cervical cancer patients: A monoinstitutional experience.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Acta Oncol 54, 1558-1566 (2015).1362.Ribeiro, I., et al.Long term experience with 3D image guided brachytherapy and clinical outcome in cervical cancer patients.Radiother Oncol 120, 447-454 (2016).1363.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Sturdza, A., et al.Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study.Radiother Oncol 120, 428-433 (2016).1364.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Charra-Brunaud, C., et al.Impact of 3D image-based PDR brachytherapy on outcome of patients treated for cervix carcinoma in France: results of the French STIC prospective study.Radiother Oncol 103, 305-313 (2012).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1365.Georg, P., et al.Dose effect relationship for late side effects of the rectum and urinary bladder in magnetic resonance image-guided adaptive cervix cancer brachytherapy.Int $J$ Radiat Oncol Biol Phys 82, 653-657 (2012).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1366.Lee, L.J.& Viswanathan, A.N.Predictors of toxicity after image-guided highdose-rate interstitial brachytherapy for gynecologic cancer.Int $J$ Radiat Oncol Biol Phys 84, 1192-1197 (2012).1367.Mazeron, R.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Pulsed-dose rate image-guided adaptive brachytherapy in cervical cancer: Dose-volume effect relationships for the rectum and bladder.Radiother Oncol 116, 226-232 (2015).1368.Chopra, S., et al.Late rectal toxicity after image-based high-dose-rate interstitial brachytherapy for postoperative recurrent and/or residual cervical cancers: EQD2 predictors for Grade $> / \\mathrm { = } \\mathrm { I I }$ toxicity.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Brachytherapy 14, 881- 888 (2015).1369.Mazeron, R., et al.Dose-volume effect relationships for late rectal morbidity in patients treated with chemoradiation and MRI-guided adaptive brachytherapy for locally advanced cervical cancer: Results from the prospective multicenter EMBRACE study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Radiother Oncol 120, 412-419 (2016).1370.ICRU.Dose and volume specification for reporting intracavitary therapy in gynaecology.ICRU report 38.Bethesda, Maryland, USA.(1985).1371.Thomas, G., et al.A randomized trial of standard versus partially hyperfractionated radiation with or without concurrent 5-fluorouracil in locally advanced cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 69, 137-145 (1998).1372.Onishi, H., et al.Effect of concurrent intra-arterial infusion of platinum drugs for patients with stage III or IV uterine cervical cancer treated with radical radiation therapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cancer J Sci Am 6, 40- 45 (2000).1373.Roberts, K.B., et al.Interim results of a randomized trial of mitomycin C as an adjunct to radical radiotherapy in the treatment of locally advanced squamous-cell carcinoma of the cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Cancer 90, 206-223 (2000).1374.Chen, H.W., Jei, J.& Wei, L.A randomized trial of hyperthermoradiochemotherapy for uterine cervix.Chin J Oncol 24, 249- 251 (1997).1375.Pras, E.Unpublished.(1995).1376.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cikaric, S., Petrovic-Stupar, S.& Marjanov, I.Radiotherapy vs.radiotherapy $^ +$ chemotherapy of advanced cervical cancer.Regression of tumour, early and late sequalaes, relapses of disease and 3 years survival (the third phase).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Eur J Cancer 3, 266 (suppl) (2005).1377.Leborgne, F.Unpublished.(1995).1378.Lal, P., Saibish Kumar, E.& Tiwari, A.Chemoradiation versus radiotherapy alone in locally advanced carcinoma of the uterine cervix: An ongoing phase III trial.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Presented at the 23th Annual Meeting of the European Society for Therapeutic Radiology and Oncology, Amsterdam, the Netherlands, October 24-28 (abstr 673).(2004).1379.Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data metaanalysis.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cochrane Database Syst Rev, CD008285 (2010).1380.Kantardzic, N., Beslija, S.& Begic, D.Comparison of parameters of myelotoxicity in patients treated with concomitant chemotherapy and radiotherapy versus radiotherapy alone.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Medicinska Arhiv 58, 19-22 (2004).1381.Wang, N., et al.Radiochemotherapy versus radiotherapy in locally advanced cervical cancer: a meta-analysis.Arch Gynecol Obstet 283, 103-108 (2011).1382.Yazigi, R.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Phase III randomized pilot study comparing interferon alpha2b in combination with radiation therapy versus radiation therapy alone in patients with stage III-B carcinoma of the cervix.Int J Gynecol Cancer 13, 164- 169 (2003).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1383.Morris, M., et al.Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.N Engl J Med 340, 1137-1143 (1999).1384.Ma, A.P., Li, X.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "F.& Li, F.Clinical analysis of concurrent chemotherapy and radiotherapy for advanced cervical cancer.J Hainan Med Coll 15, 138-141 (2009).1385.Fu, H.X.Clinical analysis of BP chemotherapy plus radiotherapy for middle and advanced cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Med Inform 20, 1680-1681 (2007).1386.Monk, B.J., et al.Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinicalpathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 96, 721-728 (2005).1387.Nagy, V., et al.Radiotherapy versus concurrent 5-day cisplatin and radiotherapy in locally advanced cervical carcinoma.Long-term results of a phase III randomized trial.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Strahlenther Onkol 185, 177-183 (2009).1388.Stehman, F.B., et al.Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am J Obstet Gynecol 197, 503 e501-506 (2007).1389.Yang, S.L.The analysis of radiotherapy alone with radiotherapy and chemotherapy in patients with advanced cervical cancer.Henan J Oncol 116, 135-136 (2003).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1390.Fu, W.H., Chen, L.P., Huang, S.S.& Lin, L.Synchronous radiotherapy and chemotherapy for advanced cervical cancers.Int Med Health Guid News 14, 23-25 (2008).1391.Wang, X., Zhang, L., Du , X.P., Zhang, L.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Q.& Zhang, L.Z.Clinical study on concurrent chemoradiotherapy for locally advanced cervical cancer.Acta Acad Med Xuzhou 27, 387-388 (2007).1392.Chen, Y.J., Zhang, Y.& Zhou, W.Clinical analysis of concurrent chemoradiation in middle and advanced cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Yangtze Univ 5, 6-9 (2008).1393.Chen, Y.J.& Xu, Y.H.Clinical analysis of chemoradiation in advanced cervical cancer.Shandong Med J 48, 113 (2008).1394.Gao, Y., Liu, Z.& Chen, H.W.The study of concurrent chemoradiotherapy in medium-term and advanced cervical carcinoma of the uterine cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Chin $J$ Pract Gynecol Obstet 5, 46-48 (2009).1395.Lu, Y.F., et al.Concurrent chemotherapy plus radiotherapy for stage II-III cervical cancer.Chin J Oncol Rehabil 11, 438-439 (2004).1396.Meng, X.Y., et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Concurrent cisplatinbased chemoradiotherapy versus exclusive radiotherapy in high-risk cervical cancer: a meta-analysis.Onco Targets Ther 9, 1875-1888 (2016).1397.Tseng, C.J., et al.A randomized trial of concurrent chemoradiotherapy versus radiotherapy in advanced carcinoma of the uterine cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 66, 52- 58 (1997).1398.Torbe, B., Falco, M., Torbe, A., Ciepiela, P.& Kurzawa, R.Radiotherapy versus radiochemotherapy with cisplatin in treatment of cervical cancer.Med Oncol 27, 1-8 (2010).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1399.Ke, Q.H., et al.Early efficacy of taxotere and cisplatin chemo-radiotherapy for advanced cervical cancer.Asian Pac J Cancer Prev 13, 617-619 (2012).1400.Han, C.& Kong, W.M.[Retrospective study of chemoradiotherapy based on cisplatin compared with radiotherapy alone for cervical cancer].",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Zhonghua Fu Chan Ke Za Zhi 42, 723-726 (2007).1401.Uppal, S., et al.Variation in care in concurrent chemotherapy administration during radiation for locally advanced cervical cancer.Gynecol Oncol 142, 286-292 (2016).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1402.Tzioras, S., Pavlidis, N., Paraskevaidis, E.& Ioannidis, J.P.Effects of different chemotherapy regimens on survival for advanced cervical cancer: systematic review and meta-analysis.Cancer Treat Rev 33, 24-38 (2007).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1403.Kumar, L., et al.Chemotherapy followed by radiotherapy versus radiotherapy alone in locally advanced cervical cancer: a randomized study.Gynecol Oncol 54, 307-315 (1994).1404.Piver, M., Khalil, M.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "& Emrich, L.J.Hydroxyurea plus pelvic irradiation versus placebo plus pelvic irradiation in nonsurgically staged stage IIIB cervical cancer.J Surg Oncol 42, 120-125 (1989).1405.Piver, M.S., Barlow, J.J.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", Vongtama, V.& Blumenson, L.Hydroxyurea: a radiation potentiator in carcinoma of the uterine cervix.A randomized double-blind study.Am J Obstet Gynecol 147, 803-808 (1983).1406.Hreshchyshyn, M.M., et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Hydroxyurea or placebo combined with radiation to treat stages IIIB and IV cervical cancer confined to the pelvis.Int J Radiat Oncol Biol Phys 5, 317-322 (1979).1407.Colombo, A., et al.Concurrent carboplatin/5FU and radiotherapy compared to radiotherapy alone in locally advanced cervical carcinoma: a case-control study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Tumori 83, 895-899 (1997).1408.Eifel, P.J., et al.Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Clin Oncol 22, 872-880 (2004).1409.leborgne, F.Unpublished.(2000).1410.Lira Puerto, V., et al.Cisplatin (CDDP) plus radiotherapy (RT) vs radiotherapy alone in locally advanced cervical cancer.Proceedings of the Annual Meeting of the American Society of Clinical Oncology 9, A633 (1990).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1411.Lorvidhaya, V., Tonusin, A., Sukthomya, W., Changwiwit, W.& Nimmolrat, A.Induction chemotherapy and irradiation in advanced carcinoma of the cervix.Gan To Kagaku Ryoho 22 Suppl 3, 244- 251 (1995).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1412.Onishi, H., et al.Effect of concurrent intra-arterial infusion of platinum drugs for patients with stage III or IV uterine cervical treated with radical radiation therapy.The Cancer journal from Scientific American 5, 40-45 (1999).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1413.Pearcey, R.G., et al.A clinical trial comparing concurrent cisplatin and radiation therapy versus radiation alone for locally advanced squamous cell carcinoma of the cervix carried out by the National Cancer Institute of Canada clinical trials group.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Proceedings of the Annual Meeting of the American Society of Clinical Oncologists.19, 378a (2000).1414.Peters, W.A., et al.Cisplatin, 5- fluorouracil plus radiation therapy are superior to radiation therapy as adjunctive therapy in high risk, early stage carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: Report of a Phase III inter group study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Society of Gynecologic Oncologists 30th Annual Meeting.5-9 (1999).1415.Pras, E.Unpublished.(2000).1416.Rose, P.G., et al.Concurrent cisplatinbased radiotherapy and chemotherapy for locally advanced cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "N Engl J Med 340, 1144-1153 (1999).1417.Singh, T.T., Singh, I.Y., Sharma, D.T.& Singh, N.R.Role of chemoradiation in advanced cervical cancer.Indian J Cancer 40, 101-107 (2003).1418.Whitney, C.W., et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Clin Oncol 17, 1339-1348 (1999).1419.Choo, Y.C., Choy, T.K., Wong, L.C.& Ma, H.K.Potentiation of radiotherapy by cisdichlorodiammine platinum (II) in advanced cervical carcinoma.Gynecol Oncol 23, 94-100 (1986).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1420.Wong, L.C., Choo, Y.C., Choy, D., Sham, J.S.& Ma, H.K.Long-term follow-up of potentiation of radiotherapy by cisplatinum in advanced cervical cancer.Gynecol Oncol 35, 159-163 (1989).1421.Wong, L.C.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Chemoradiation and adjuvant chemotherapy in cervical cancer.J Clin Oncol 17, 2055-2060 (1999).1422.Green, J., et al.Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cochrane Database Syst Rev, CD002225 (2005).1423.Kirwan, J.M., et al.A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer.Radiother Oncol 68, 217-226 (2003).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1424.Fernandez, D.J., Vidyasagar, M.S., Rao, K.K., Shenoy, A.& Kasturi, D.P.Synchronous 5-fluorouracil, mitomycinc and radiation therapy in the treatment of locally advanced carcinoma of the cervix.Radiotherapy and Oncology: Association of Radiation Oncologists of India, 16th Annual Meeting and Roentgen Centenary Celebration, 1995; February 2-4, 97-103 (1995).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1425.Ayala Hernandez, J.R., de la Huerta Sanchez, R., Morales Canfield, F.& Fernandez Orozco, A.[Uterine cervix cancer.Clinical stage III.Combined radiotherapy and chemotherapy treatment].Ginecol Obstet Mex 59, 238- 242 (1991).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1426.Hongwei, C., Junjie, F.& Mingzhong, L.The effect of randomized trial of hyperthermo-radiochemotherapy for carcinoma of the cervix.Chin J Oncol 24, 249-251 (1997).1427.Roberts, K.B., Urdaneta, N.& Vera, P.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Preliminary results of a randomised trial of mitomycin-C as an adjunct to radical radiotherapy in the treatment of locally advanced carcinoma of the cervix (Abstract).Gynecol Oncol 64, 347 (1997).1428.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Singh, P., Dharmalingam, S.K., Tan, M.K.& Tan, C.K.Chemotherapy-radiotherapy combination in the treatment of carcinoma of the cervix.Southeast Asian J Trop Med Public Health 16, 665-668 (1985).1429.Wang, S.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", Zhang, D.S., Pan, T., Liu, S.& Wang, M.K.Efficacy of concurrent chemoradiotherapy plus adjuvant chemotherapy on advanced cervical cancer.Chin J Cancer 101498232, 959- 963 (2010).1430.Geara, F.B., et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A phase II randomized trial comparing radiotherapy with concurrent weekly cisplatin or weekly paclitaxel in patients with advanced cervical cancer.Radiat Oncol 5, 84 (2010).1431.Coronel, J.A., et al.A randomized comparison of cisplatin and oral vinorelbine as radiosensitizers in aged or comorbid locally advanced cervical cancer patients.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 23, 884-889 (2013).1432.Wang, C.C., et al.A randomized trial comparing concurrent chemoradiotherapy with single-agent cisplatin versus cisplatin plus gemcitabine in patients with advanced cervical cancer: An Asian Gynecologic Oncology Group study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 137, 462-467 (2015).1433.Nedovic, J., et al.Cisplatin monotherapy with concurrent radiotherapy versus combination of cisplatin and 5- fluorouracil chemotherapy with concurrent radiotherapy in patients with locoregionally advanced cervical carcinoma.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J BUON 17, 740-745 (2012).1434.Kong, T.W., et al.Comparison of concurrent chemoradiation therapy with weekly cisplatin versus monthly fluorouracil plus cisplatin in FIGO stage IIB-IVA cervical cancer.J Gynecol Oncol 23, 235-241 (2012).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1435.Duenas-Gonzalez, A., et al.Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Clin Oncol 29, 1678-1685 (2011).1436.Sol, E.S., et al.Comparison of concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil versus cisplatin plus paclitaxel in patients with locally advanced cervical carcinoma.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Gynecol Oncol 20, 28-34 (2009).1437.Rose, P.G., et al.Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Clin Oncol 25, 2804-2810 (2007).1438.Gallardo, D., et al.Cisplatin, radiation, and amifostine in carcinoma of the uterine cervix.Int J Gynecol Cancer 9, 225-230 (1999).1439.Fu, Z.Z., et al.Efficacy and toxicity of different concurrent chemoradiotherapy regimens in the treatment of advanced cervical cancer: A network meta-analysis.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Medicine (Baltimore) 96, e5853 (2017).1440.Zhang, Y., Yang, Z., Zhou, Y., Pan, J.& Liu, Y.Efficacy of concurrent single-agent chemotherapy using radiotherapy in patients with cervical cancer: a metaanalysis.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Clin Exp Med 8, 8661-8673 (2015).1441.Wang, H.R., Yu, C.H., Zhu, W.G.& Li, T.Comparison of the effect of nedaplatin and cisplatin in the concurrent chemoradiotherapy of cervical cancer.Chin J Pract Obstet Gyneco 27, 771-774 (2011).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1442.Cheng, X.W., Yang, Y.X.& Yu, X.Y.A comparative study of concurrent chemo-radiotherapy with cisplatin versus nedaplatin for patients with middle-advanced stage uterine cervical cancer.Chin J Tumor 31, 662-664 (2011).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1443.Lou, P.R., et al.Clinical study of concurrent cisplatin or nedaplatinbased chemoradiation for locally advanced cervical cancer.J Clin Oncol 17, 93-96 (2011).1444.Wang, C.X., Lv, H.Q., Zhu, S.M., Zhang, F.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Q.& Shang, C.J.Comparison of the clinical efficacy between nedaplatin and cisplatin concurrent chemoradiotherapy in the treatment of advanced cervical carcinoma.Anti-tumor Pharm 4, 290- 293 (2014).1445.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Li, L.Evaluation of curative effect of nedaplatin concurrent chemoradiotherapy in the treatment of 48 cases of cervical cancer.Chin J Med Front 6, 74-76 (2014).1446.Jiang, L., Hao, Q.& Wang, H.Y.Curative effect of three chemotherapy programs in concurrent with radiotherapy on medium and advanced stage cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Chin J Pract Obstet Gyneco 25, 293-295 (2009).1447.Li, Q.F., Jin, G.W., Bai, X.J.& Jiang, C.H.Effect of cisplatin and docetaxel concurrent chemotherapy and radiotherapy in local advanced cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Modern Oncol 19, 1827-1830 (2011).1448.Wan, Y.H., et al.Curative effect of cisplatin or paclitaxel in concurrent chemoradiotherapy for cervical cancer: a report of 58 cases.J Chin Tradit Chin Med Inform 3, 162 (2011).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1449.Narayanan, V., Bista, B.& Sharma, S.External Beam Therapy in a Four-Field Box Technique with Paclitaxel versus a Two-Field Technique with Cisplatin in Locally Advanced Carcinoma Cervix: A Phase II Monocentric Trial.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "ISRN Oncol 2012, 390193 (2012).1450.Nagai, N., et al.Radiotherapy combined with transcatheter arterial infusion of cisplatin versus oral fluoropyrimidine anticancer agent for locally advanced carcinoma of the uterine cervix: a prospective follow-up study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Oncol Rep 8, 119-125 (2001).1451.Xin, S.B., Lin, B.H., Lin, S.F.& Li, H.J.Comparison of the effect between weekly paclitaxel liposome and weekly cisplatin in concurrent radiotherapy in advanced cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Guangdong Med 35, 761 (2014).1452.Wang, H.J.& Shu, C.R.Irinotecan combined with radiotherapy for locally advanced cervical carcinoma.$J$ Nanchang Univ (Med Sci) 52, 52-57 (2012).1453.Sebastiao, A.M., et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Carboplatin-based chemoradiotherapy in advanced cervical cancer: an alternative to cisplatin-based regimen?Eur $J$ Obstet Gynecol Reprod Biol 201, 161-165 (2016).1454.Nam, E.J., et al.Comparison of carboplatin- and cisplatin-based concurrent chemoradiotherapy in locally advanced cervical cancer patients with morbidity risks.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Oncologist 18, 843-849 (2013).1455.Kagabu, M., et al.Clinical efficacy of nedaplatin-based concurrent chemoradiotherapy for uterine cervical cancer: a Tohoku Gynecologic Cancer Unit Study.Int J Clin Oncol 21, 735-740 (2016).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1456.Lukka, H., et al.Concurrent cisplatinbased chemotherapy plus radiotherapy for cervical cancer--a meta-analysis.Clin Oncol (R Coll Radiol) 14, 203-212 (2002).1457.Petrelli, F., De Stefani, A., Raspagliesi, F.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", Lorusso, D.& Barni, S.Radiotherapy with concurrent cisplatin-based doublet or weekly cisplatin for cervical cancer: a systematic review and meta-analysis.Gynecol Oncol 134, 166-171 (2014).1458.Lee, Y.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Y., et al.Platinum-based combination chemotherapy vs.weekly cisplatin during adjuvant CCRT in early cervical cancer with pelvic LN metastasis.Anticancer Res 33, 4675- 4681 (2013).1459.Donnelly, E.D., et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Evaluation of Outcomes in Patients With Carcinoma of the Cervix Treated With Concurrent Radiation and Cisplatin Versus Cisplatin/5-FU Compared With Radiation Alone.Am J Clin Oncol 38, 437-441 (2015).1460.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Torres, M.A., et al.Comparison of treatment tolerance and outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy in a prospective randomized trial or with standard treatment.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 70, 118-125 (2008).1461.Duenas-Gonzalez, A., et al.Pathologic response and toxicity assessment of chemoradiotherapy with cisplatin versus cisplatin plus gemcitabine in cervical cancer: a randomized Phase II study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 61, 817-823 (2005).1462.Symonds, P., et al.Concomitant hydroxyurea plus radiotherapy versus radiotherapy for carcinoma of the uterine cervix.Cochrane Database Syst Rev, CD003918 (2004).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1463.Kim, J.H., et al.Prophylactic irradiation of para-aortic lymph nodes for patients with locally advanced cervical cancers with and without high CA9 expression (KROG 07-01): A randomized, openlabel, multicenter, phase 2 trial.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Radiother Oncol 120, 383-389 (2016).1464.Roy, S., et al.Addition of gemcitabine to standard therapy in locally advanced cervical cancer: A randomized comparative study.Indian J Med Paediatr Oncol 32, 133-138 (2011).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1465.Ryu, S.Y., et al.Randomized clinical trial of weekly vs.triweekly cisplatin-based chemotherapy concurrent with radiotherapy in the treatment of locally advanced cervical cancer.Int $J$ Radiat Oncol Biol Phys 81, e577-581 (2011).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1466.Veerasarn, V., et al.A randomized phase III trial of concurrent chemoradiotherapy in locally advanced cervical cancer: preliminary results.Gynecol Oncol 104, 15-23 (2007).1467.Basu, P., et al.Phase 2 Randomized Controlled Trial of Radiation Therapy Plus Concurrent Interferon-Alpha and Retinoic Acid Versus Cisplatin for Stage III Cervical Carcinoma.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 94, 102-110 (2016).1468.Yu, C., et al.A comparative study of intensity-modulated radiotherapy and standard radiation field with concurrent chemotherapy for local advanced cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Eur J Gynaecol Oncol 36, 278-282 (2015).1469.Pathy, S., et al.Impact of Treatment Time on Chemoradiotherapy in Locally Advanced Cervical Carcinoma.Asian Pac J Cancer Prev 16, 5075-5079 (2015).1470.Schefter, T.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "E., et al.A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 83, 1179-1184 (2012).1471.Schefter, T., et al.RTOG 0417: efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 88, 101-105 (2014).1472.Franckena, M., et al.Long-term improvement in treatment outcome after radiotherapy and hyperthermia in locoregionally advanced cervix cancer: an update of the Dutch Deep Hyperthermia Trial.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 70, 1176-1182 (2008).1473.Harima, Y., et al.A randomized clinical trial of radiation therapy versus thermoradiotherapy in stage IIIB cervical carcinoma.2001.Int $J$ Hyperthermia 25, 338-343 (2009).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1474.Datta, N.R., Bose, A.K.& Kapoor, N.K.Thermoradiotherapy in the management of carcinoma cervix (stage IIIB): a controlled clinical study.Ind Med Gazette 121, 68-71 (1987).1475.Vasanthan, A., et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Regional hyperthermia combined with radiotherapy for uterine cervical cancers: a multi-institutional prospective randomized trial of the international atomic energy agency.Int J Radiat Oncol Biol Phys 61, 145-153 (2005).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1476.Sharma, S., et al.Local thermoradiotherapy in carcinoma cervix: improved local control versus increased incidence of distant metastasis.Asia Oceania $J$ Obstet Gynaecol 17, 5-12 (1991).1477.Datta, N.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "R., et al.Hyperthermia and radiotherapy with or without chemotherapy in locally advanced cervical cancer: a systematic review with conventional and network metaanalyses.Int $J$ Hyperthermia 32, 809- 821 (2016).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1478.Yan, X., Liu, W.& Yan, Z.Efficacy and safety radio-chemotherapy combined with thermotherapy for cervical cancer: a meta-analysis.Chin J Evid-based Med 14, 752-758 (2014).1479.Lutgens, L.C., et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Radiation therapy combined with hyperthermia versus cisplatin for locally advanced cervical cancer: Results of the randomized RADCHOC trial.Radiother Oncol 120, 378-382 (2016).1480.Lutgens, L., et al.Combined use of hyperthermia and radiation therapy for treating locally advanced cervix carcinoma.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cochrane Database Syst Rev, CD006377 (2010).1481.van der Zee, J., et al.Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Dutch Deep Hyperthermia Group.Lancet 355, 1119-1125 (2000).1482.Harima, Y., et al.A randomized clinical trial of radiation therapy versus thermoradiotherapy in stage IIIB cervical carcinoma.Int $J$ Hyperthermia 17, 97-105 (2001).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1483.Harima, Y., et al.A multicentre randomised clinical trial of chemoradiotherapy plus hyperthermia versus chemoradiotherapy alone in patients with locally advanced cervical cancer.Int J Hyperthermia 32, 801-808 (2016).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1484.Zolciak-Siwinska, A., et al.HDR brachytherapy combined with interstitial hyperthermia in locally advanced cervical cancer patients initially treated with concomitant radiochemotherapy--a phase III study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Radiother Oncol 109, 194-199 (2013).1485.Westermann, A.M., et al.First results of triple-modality treatment combining radiotherapy, chemotherapy, and hyperthermia for the treatment of patients with stage IIB, III, and IVA cervical carcinoma.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cancer 104, 763- 770 (2005).1486.Westermann, A., et al.Long-term survival data of triple modality treatment of stage IIB-III-IVA cervical cancer with the combination of radiotherapy, chemotherapy and hyperthermia an update.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int $J$ Hyperthermia 28, 549-553 (2012).1487.Franckena, M., et al.Hyperthermia doseeffect relationship in 420 patients with cervical cancer treated with combined radiotherapy and hyperthermia.Eur $J$ Cancer 45, 1969-1978 (2009).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1488.Franckena, M., et al.Radiotherapy and hyperthermia for treatment of primary locally advanced cervix cancer: results in 378 patients.Int J Radiat Oncol Biol Phys 73, 242-250 (2009).1489.Sreenivasa, G.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Radiochemotherapy combined with regional pelvic hyperthermia induces high response and resectability rates in patients with nonresectable cervical cancer $>$ or $\\mathbf { \\Sigma } = \\mathbf { \\Sigma }$ FIGO IIB \"bulky\".",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 66, 1159-1167 (2006).1490.Duenas-Gonzalez, A., et al.A phase III study comparing concurrent gemcitabine (Gem) plus cisplatin (Cis) and radiation followed by adjuvant Gem plus Cis versus concurrent Cis and radiation in patients with stage IIB to IVA carcinoma of the cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Eur J Cancer Suppl 2-3, 7 (2009).1491.Duenas-Gonzalez, A., et al.A phase III study comparing concurrent gemcitabine (Gem) plus cisplatin (Cis) and radiation followed by adjuvant Gem plus Cis versus concurrent Cis and radiation in patients with stage IIB to IVA carcinoma of the cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Clin Oncol 18, CRA5507 (2009).1492.Duenas-Gonzalez, A., Orlando, M., Zhou, Y., Quinlivan, M.& Barraclough, H.Efficacy in high burden locally advanced cervical cancer with concurrent gemcitabine and cisplatin chemoradiotherapy plus adjuvant gemcitabine and cisplatin: prognostic and predictive factors and the impact of disease stage on outcomes from a prospective randomized phase III trial.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 126, 334-340 (2012).1493.Tangjitgamol, S., et al.Adjuvant chemotherapy after concurrent chemoradiation for locally advanced cervical cancer.Cochrane Database Syst Rev, CD010401 (2014).1494.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Tang, J., Tang, Y., Yang, J.& Huang, S.Chemoradiation and adjuvant chemotherapy in advanced cervical adenocarcinoma.Gynecol Oncol 125, 297-302 (2012).1495.Choi, C.H., et al.A matched-case comparison to explore the role of consolidation chemotherapy after concurrent chemoradiation in cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 81, 1252-1257 (2011).1496.Jelavic, T.B., Mise, B.P., Strikic, A., Ban, M.& Vrdoljak, E.Adjuvant Chemotherapy in Locally Advanced Cervical Cancer After Treatment with Concomitant Chemoradiotherapy--Room for Improvement?",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Anticancer Res 35, 4161- 4165 (2015).1497.Petric Mise, B., et al.Long follow-up of patients with locally advanced cervical cancer treated with concomitant chemobrachyradiotherapy with cisplatin and ifosfamide followed by consolidation chemotherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 25, 315-319 (2015).1498.Kim, H.S., Kim, M.K., Kim, H.J., Han, S.S.& Kim, J.W.Phase II Study of Consolidation Chemotherapy after Adjuvant or Primary Concurrent Chemoradiation Using Paclitaxel and Carboplatin to Treat High-Risk Early-Stage or Locally Advanced Cervical Cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cancer Res Treat 44, 97-103 (2012).1499.Zhang, M.Q., Liu, S.P.& Wang, X.E.Concurrent chemoradiotherapy with paclitaxel and nedaplatin followed by consolidation chemotherapy in locally advanced squamous cell carcinoma of the uterine cervix: preliminary results of a phase II study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 78, 821-827 (2010).1500.Domingo, E., et al.Capecitabine-based chemoradiotherapy with adjuvant capecitabine for locally advanced squamous carcinoma of the uterine cervix: phase II results.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Oncologist 14, 828-834 (2009).1501.Choi, C.H., et al.Phase II study of consolidation chemotherapy after concurrent chemoradiation in cervical cancer: preliminary results.Int J Radiat Oncol Biol Phys 68, 817-822 (2007).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1502.Vrdoljak, E., et al.Concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy for women with locally advanced carcinoma of the uterine cervix--final results of a prospective phase II-study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 103, 494-499 (2006).1503.Vrdoljak, E., et al.Concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy in locally advanced squamous cell carcinoma of the uterine cervix: results of a phase II study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 61, 824-829 (2005).1504.Angioli, R., et al.A randomized controlled trial comparing four versus six courses of adjuvant platinum-based chemotherapy in locally advanced cervical cancer patients previously treated with neo-adjuvant chemotherapy plus radical surgery.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 139, 433-438 (2015).1505.Viswanathan, A.N.& Thomadsen, B.American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix.Part I: general principles.Brachytherapy 11, 33-46 (2012).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1506.Viswanathan, A.N., et al.American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix.Part II: highdose-rate brachytherapy.Brachytherapy 11, 47-52 (2012).1507.Lee, L.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J., et al.American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix.Part III: low-dose-rate and pulsed-dose-rate brachytherapy.Brachytherapy 11, 53-57 (2012).1508.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Small, W., Jr., et al.American Brachytherapy Society consensus guidelines for adjuvant vaginal cuff brachytherapy after hysterectomy.Brachytherapy 11, 58-67 (2012).1509.Suneja, G., et al.American Brachytherapy Society: Brachytherapy treatment recommendations for locally advanced cervix cancer for low-income and middle-income countries.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Brachytherapy 16, 85-94 (2017).1510.Dimopoulos, J.C., et al.Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (IV): Basic principles and parameters for MR imaging within the frame of image based adaptive cervix cancer brachytherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Radiother Oncol 103, 113-122 (2012).1511.Sugiyama, T., et al.Combination therapy with irinotecan and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer.Br J Cancer 81, 95-98 (1999).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1512.Chang, H.C., et al.Neoadjuvant chemotherapy with cisplatin, vincristine, and bleomycin and radical surgery in early-stage bulky cervical carcinoma.Cancer Chemother Pharmacol 30, 281-285 (1992).1513.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Siesto, G., et al.Robotic Surgery in Patients With Locally Advanced Cervical Cancer After Neoadjuvant Chemotherapy: Survival Outcomes.Int J Gynecol Cancer 26, 521-527 (2016).1514.Landoni, F., et al.Neoadjuvant chemotherapy prior to pelvic exenteration in patients with recurrent cervical cancer: single institution experience.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 130, 69-74 (2013).1515.Lopez-Graniel, C., et al.Pre-exenterative chemotherapy, a novel therapeutic approach for patients with persistent or recurrent cervical cancer.BMC Cancer 5, 118 (2005).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1516.Sardain, H., et al.Curative pelvic exenteration for recurrent cervical carcinoma in the era of concurrent chemotherapy and radiation therapy.A systematic review.Eur J Surg Oncol 41, 975-985 (2015).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1517.Sardain, H., Lavoue, V., Foucher, F.& Leveque, J.[Curative pelvic exenteration for recurrent cervical carcinoma in the era of concurrent chemotherapy and radiation therapy.A systematic review].J Gynecol Obstet Biol Reprod (Paris) 45, 315-329 (2016).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1518.Berek, J.S., Howe, C., Lagasse, L.D.& Hacker, N.F.Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLA.Gynecol Oncol 99, 153-159 (2005).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1519.Maggioni, A., et al.Pelvic exenteration: ten-year experience at the European Institute of Oncology in Milan.Gynecol Oncol 114, 64-68 (2009).1520.Benn, T., et al.Pelvic exenteration in gynecologic oncology: a single institution study over 20 years.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 122, 14-18 (2011).1521.McLean, K.A., et al.Pelvic exenteration in the age of modern chemoradiation.Gynecol Oncol 121, 131-134 (2011).1522.Baiocchi, G., et al.Prognostic factors in pelvic exenteration for gynecological malignancies.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Eur J Surg Oncol 38, 948- 954 (2012).1523.Yoo, H.J., et al.Pelvic exenteration for recurrent cervical cancer: ten-year experience at National Cancer Center in Korea.J Gynecol Oncol 23, 242-250 (2012).1524.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Schmidt, A.M., Imesch, P., Fink, D.& Egger, H.Indications and long-term clinical outcomes in 282 patients with pelvic exenteration for advanced or recurrent cervical cancer.Gynecol Oncol 125, 604-609 (2012).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1525.Tanaka, S., et al.Clinical outcome of pelvic exenteration in patients with advanced or recurrent uterine cervical cancer.Int J Clin Oncol 19, 133-138 (2014).1526.Chiantera, V., et al.Morbidity after pelvic exenteration for gynecological malignancies: a retrospective multicentric study of 230 patients.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 24, 156-164 (2014).1527.Kaur, M., et al.Pelvic exenterations for gynecological malignancies: a study of 36 cases.Int J Gynecol Cancer 22, 889- 896 (2012).1528.Goldberg, G.L., et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Total pelvic exenteration: the Albert Einstein College of Medicine/Montefiore Medical Center Experience (1987 to 2003).Gynecol Oncol 101, 261-268 (2006).1529.Shingleton, H.M., et al.Clinical and histopathologic factors predicting recurrence and survival after pelvic exenteration for cancer of the cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Obstet Gynecol 73, 1027-1034 (1989).1530.Ang, C., Bryant, A., Barton, D.P., Pomel, C.& Naik, R.Exenterative surgery for recurrent gynaecological malignancies.Cochrane Database Syst Rev, CD010449 (2014).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1531.Spahn, M., et al.The role of exenterative surgery and urinary diversion in persistent or locally recurrent gynecological malignancy: complications and survival.Urol Int 85, 16-22 (2010).1532.Capilna, M.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "E., Moldovan, B.& Szabo, B.Pelvic exenteration--our initial experience in 15 cases.Eur J Gynaecol Oncol 36, 142-145 (2015).1533.Teran-Porcayo, M.A., Zeichner-Gancz, I., del-Castillo, R.A., Beltran-Ortega, A.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "& Solorza-Luna, G.Pelvic exenteration for recurrent or persistent cervical cancer: experience of five years at the National Cancer Institute in Mexico.Med Oncol 23, 219-223 (2006).1534.Chiantera, V., et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Survival after curative pelvic exenteration for primary or recurrent cervical cancer: a retrospective multicentric study of 167 patients.Int J Gynecol Cancer 24, 916- 922 (2014).1535.Jager, L., Nilsson, P.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J.& Radestad, A.F.Pelvic exenteration for recurrent gynecologic malignancy: a study of 28 consecutive patients at a single institution.Int J Gynecol Cancer 23, 755- 762 (2013).1536.Jurado, M., Alcazar, J.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "L.& MartinezMonge, R.Resectability rates of previously irradiated recurrent cervical cancer (PIRCC) treated with pelvic exenteration: is still the clinical involvement of the pelvis wall a real contraindication?",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "a twenty-year experience.Gynecol Oncol 116, 38-43 (2010).1537.Sardain, H., et al.Prognostic factors for curative pelvic exenterations in patients with recurrent uterine cervical or vaginal cancer.Int J Gynecol Cancer 24, 1679-1685 (2014).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1538.Moreno-Palacios, E., Diestro, M.D., De Santiago, J., Hernandez, A.& Zapardiel, I.Pelvic Exenteration in Gynecologic Cancer: La Paz University Hospital Experience.Int $J$ Gynecol Cancer 25, 1109-1114 (2015).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1539.Barney, B.M., et al.Intraoperative Electron Beam Radiotherapy (IOERT) in the management of locally advanced or recurrent cervical cancer.Radiat Oncol 8, 80 (2013).1540.Mahe, M.A., et al.Intraoperative radiation therapy in recurrent carcinoma of the uterine cervix: report of the French intraoperative group on 70 patients.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 34, 21-26 (1996).1541.Mahe, M.A., et al.Prognostic factors for local control in recurrent cervical carcinoma treated with IORT: report of the French IORT Group.Front Radiat Ther Oncol 31, 267-270 (1997).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1542.Garton, G.R., et al.Intraoperative radiation therapy in gynecologic cancer: the Mayo Clinic experience.Gynecol Oncol 48, 328-332 (1993).1543.Garton, G.R., et al.Intraoperative radiation therapy in gynecologic cancer: update of the experience at a single institution.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 37, 839-843 (1997).1544.Haddock, M.G., et al.IORT for locally advanced gynecological malignancies.Front Radiat Ther Oncol 31, 256-259 (1997).1545.Stelzer, K.J., et al.The use of intraoperative radiation therapy in radical salvage for recurrent cervical cancer: outcome and toxicity.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am $J$ Obstet Gynecol 172, 1881-1886; discussion 1886-1888 (1995).1546.Gerard, J.P., et al.[Role of peroperative radiotherapy in the treatment of uterine cancers.Preliminary experience in Lyon].Bull Cancer Radiother 81, 186- 195 (1994).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1547.Dosoretz, D.E., Tepper, J.E.& Shim, D.S.Intraoperative electronbeam irradiation in gynecologic malignant disease.Appl Radiol 13, 61-63 (1984).1548.Tran, P.T., et al.Long-term survivors using intraoperative radiotherapy for recurrent gynecologic malignancies.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 69, 504-511 (2007).1549.Gemignani, M.L., et al.Radical surgical resection and high-dose intraoperative radiation therapy (HDR-IORT) in patients with recurrent gynecologic cancers.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 50, 687-694 (2001).1550.Roth, T.M., Secord, A.A., Havrilesky, L.J., Jones, E.& Clarke-Pearson, D.L.High dose rate intraoperative radiotherapy for recurrent cervical cancer and nodal disease.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 91, 258-260 (2003).1551.Martinez-Monge, R., et al.Intraoperative electron beam radiotherapy during radical surgery for locally advanced and recurrent cervical cancer.Gynecol Oncol 82, 538-543 (2001).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1552.del Carmen, M.G., McIntyre, J.F., Fuller, A.F., Nikrui, N.& Goodman, A.Intraoperative radiation therapy in the treatment of pelvic gynecologic malignancies: a review of fifteen cases.Gynecol Oncol 79, 457-462 (2000).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1553.Hicks, M.L., et al.Intraoperative orthovoltage radiation therapy in the treatment of recurrent gynecologic malignancies.Am J Clin Oncol 16, 497- 500 (1993).1554.Konski, A., Neisler, J., Phibbs, G.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", Bronn, D.& Dobelbower, R.R., Jr.The use of intraoperative electron beam radiation therapy in the treatment of para-aortic metastases from gynecologic tumors: a pilot study.Am J Clin Oncol 16, 67-71 (1993).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1555.Backes, F.J., et al.Does intra-operative radiation at the time of pelvic exenteration improve survival for patients with recurrent, previously irradiated cervical, vaginal, or vulvar cancer?Gynecol Oncol 135, 95-99 (2014).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1556.Hockel, M.Laterally extended endopelvic resection.Novel surgical treatment of locally recurrent cervical carcinoma involving the pelvic side wall.Gynecol Oncol 91, 369-377 (2003).1557.Hockel, M., et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Five-year experience with combined operative and radiotherapeutic treatment of recurrent gynecologic tumors infiltrating the pelvic wall.Cancer 77, 1918-1933 (1996).1558.Andikyan, V., et al.Extended pelvic resections for recurrent or persistent uterine and cervical malignancies: an update on out of the box surgery.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 125, 404-408 (2012).1559.Bonomi, P., et al.Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study.J Clin Oncol 3, 1079-1085 (1985).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1560.Thigpen, J.T., Blessing, J.A., DiSaia, P.J., Fowler, W.C., Jr.& Hatch, K.D.A randomized comparison of a rapid versus prolonged ( $( 2 4 \\ \\mathrm { \\ h r } )$ infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 32, 198-202 (1989).1561.McGuire, W.P., 3rd, et al.A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "$J$ Clin Oncol 7, 1462-1468 (1989).1562.Fracasso, P.M., et al.Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: a gynecologic oncology group study.Gynecol Oncol 90, 177-180 (2003).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1563.Thigpen, T., Blessing, J.A., Gallup, D.G., Maiman, M.& Soper, J.T.Phase II trial of mitomycin-C in squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study.Gynecol Oncol 57, 376-379 (1995).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1564.Meanwell, C.A., et al.Phase II study of ifosfamide in cervical cancer.Cancer Treat Rep 70, 727-730 (1986).1565.Sutton, G.P., Blessing, J.A., DiSaia, P.J.& McGuire, W.P.Phase II study of ifosfamide and mesna in nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 49, 48-50 (1993).1566.Sutton, G.P., Blessing, J.A., Adcock, L., Webster, K.D.& DeEulis, T.Phase II study of ifosfamide and mesna in patients with previously-treated carcinoma of the cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A Gynecologic Oncology Group study.Invest New Drugs 7, 341-343 (1989).1567.Smith, J.P., Rutledge, F., Burns, B.C., Jr.& Soffar, S.Systemic chemotherapy for carcinoma of the cervix.Am J Obstet Gynecol 97, 800-807 (1967).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1568.Omura, G.A., Velez-Garcia, E.& Birch, R.Phase II randomized study of doxorubicin, vincristine, and 5-FU versus cyclophosphamide in advanced squamous cell carcinoma of the cervix.Cancer Treat Rep 65, 901-903 (1981).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1569.Garcia, A.A., Blessing, J.A., Vaccarello, L.& Roman, L.D.Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study.Am J Clin Oncol 30, 428-431 (2007).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1570.van der Burg, M.E., et al.Phase II study of weekly $4 ^ { \\prime }$ -epidoxorubicin in patients with metastatic squamous cell cancer of the cervix: an EORTC Gynaecological Cancer Cooperative Group Study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Eur J Cancer 29A, 147-148 (1992).1571.Muss, H.B., Sutton, G.P., Bundy, B.& Hatch, K.D.Mitoxantrone (NSC 301739) in patients with advanced cervical carcinoma.A phase II study of the Gynecologic Oncology Group.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am J Clin Oncol 8, 312-315 (1985).1572.Chauvergne, J., et al.Phase II study of pirarubicin (THP) in patients with cervical, endometrial and ovarian cancer: study of the Clinical Screening Group of the European Organization for Research and Treatment of Cancer (EORTC).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Eur J Cancer 29A, 350-354 (1993).1573.Hakes, T.B., Dougherty, J.B.& Raymond, V.Phase II study of idarubicin in advanced cervical carcinoma.Am J Clin Oncol 9, 262-263 (1986).1574.McGuire, W.P., Blessing, J.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A., Yordan, E.& Beecham, J.Phase II study of esorubicin (4'-deoxydoxorubicin) in advanced or metastatic squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.Invest New Drugs 7, 235-238 (1989).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1575.Rhomberg, W.U.Vindesine for recurrent and metastatic cancer of the uterine cervix: a phase II study.Cancer Treat Rep 70, 1455-1457 (1986).1576.Miller, D.S., Blessing, J.A., Bodurka, D.C., Bonebrake, A.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J.& Schorge, J.O.Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.Gynecol Oncol 110, 65-70 (2008).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1577.Kavanagh, J.J., et al.Continuous-infusion vinblastine in refractory carcinoma of the cervix: a phase II trial.Gynecol Oncol 21, 211-214 (1985).1578.Sutton, G.P., Blessing, J.A., Barnes, W.& Ball, H.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Phase II study of vinblastine in previously treated squamous carcinoma of the cervix.A Gynecologic Oncology Group study.Am J Clin Oncol 13, 470- 471 (1990).1579.Lhomme, C., et al.Phase II trial of vinorelbine in patients with advanced and/or recurrent cervical carcinoma: an EORTC Gynaecological Cancer Cooperative Group Study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Eur J Cancer 36, 194-199 (2000).1580.Morris, M., et al.Phase II study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix.$J$ Clin Oncol 16, 1094-1098 (1998).1581.Muggia, F.M.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.Gynecol Oncol 92, 639-643 (2004).1582.Muggia, F.M., et al.Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group Study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 96, 108-111 (2005).1583.Morris, M., Brader, K.R., Burke, T.W., Levenback, C.F.& Gershenson, D.M.A phase II study of prolonged oral etoposide in advanced or recurrent carcinoma of the cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 70, 215-218 (1998).1584.Rose, P.G., Blessing, J.A., Van Le, L.& Waggoner, S.Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 70, 263-266 (1998).1585.Pfeiffer, P., et al.Teniposide in recurrent or advanced cervical carcinoma: a phase II trial in patients not previously treated with cytotoxic therapy.Gynecol Oncol 37, 230-233 (1990).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1586.Schilder, R.J., Blessing, J.A., Morgan, M., Mangan, C.E.& Rader, J.S.Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: a Phase II study of the gynecologic oncology group.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 76, 204-207 (2000).1587.Schilder, R.J., Blessing, J.& Cohn, D.E.Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 96, 103-107 (2005).1588.de Palo, G.M., et al.Methotrexate (NSC740) and bleomycin (NSC-125066) in the treatment of advanced epidermoid carcinoma of the uterine cervix.Cancer Chemother Rep 57, 429-435 (1973).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1589.McGuire, W.P., Blessing, J.A., Moore, D., Lentz, S.S.& Photopulos, G.Paclitaxel has moderate activity in squamous cervix cancer.A Gynecologic Oncology Group study.J Clin Oncol 14, 792-795 (1996).1590.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Curtin, J.P., et al.Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study.J Clin Oncol 19, 1275-1278 (2001).1591.Kudelka, A.P., et al.Activity of paclitaxel in advanced or recurrent squamous cell cancer of the cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Clin Cancer Res 2, 1285-1288 (1996).1592.Kudelka, A.P., et al.An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix.Anticancer Drugs 8, 657-661 (1997).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1593.Bookman, M.A., Blessing, J.A., Hanjani, P., Herzog, T.J.& Andersen, W.A.Topotecan in squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group.Gynecol Oncol 77, 446-449 (2000).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1594.Muderspach, L.I., Blessing, J.A., Levenback, C.& Moore, J.L., Jr.A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study.Gynecol Oncol 81, 213-215 (2001).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1595.Fiorica, J.V., et al.A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a Gynecologic Oncology Group study.Gynecol Oncol 115, 285-289 (2009).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1596.Stehman, F.B., Blessing, J.A., McGehee, R.& Barrett, R.J.A phase II evaluation of mitolactol in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study.$J$ Clin Oncol 7, 1892-1895 (1989).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1597.Irvin, W.P., et al.A phase II study of irinotecan (CPT-11) in patients with advanced squamous cell carcinoma of the cervix.Cancer 82, 328-333 (1998).1598.Look, K.Y., et al.A phase II trial of CPT11 in recurrent squamous carcinoma of the cervix: a gynecologic oncology group study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 70, 334-338 (1998).1599.Verschraegen, C.F., et al.Phase II study of irinotecan in prior chemotherapytreated squamous cell carcinoma of the cervix.J Clin Oncol 15, 625-631 (1997).1600.Lhomme, C.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Clin Oncol 17, 3136-3142 (1999).1601.Monk, B.J., et al.Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Clin Oncol 27, 1069-1074 (2009).1602.Lorusso, D., et al.Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Ann Oncol 21, 61-66 (2010).1603.Lorvidhaya, V., et al.Phase II study of capecitabine (Ro 09-1978) in patients who have failed first line treatment for locally advanced and/or metastatic cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gan To Kagaku Ryoho 37, 1271-1275 (2010).1604.Takeuchi, S., et al.[A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer.Research Groups of CPT11 in Gynecologic Cancers].Gan To Kagaku Ryoho 18, 1681-1689 (1991).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1605.Candelaria, M., et al.Lack in efficacy for imatinib mesylate as second-line treatment of recurrent or metastatic cervical cancer expressing plateletderived growth factor receptor alpha.Int $J$ Gynecol Cancer 19, 1632-1637 (2009).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1606.Katsumata, N., et al.Phase II study of S1, an oral fluoropyrimidine, in patients with advanced or recurrent cervical cancer.Ann Oncol 22, 1353-1357 (2011).1607.Garcia, A.A., et al.Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 104, 572-579 (2007).1608.Look, K.Y., Blessing, J.A., Michener, C.M., Rubin, S.& Ramirez, P.T.Phase II evaluation of capecitabine in refractory nonsquamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 18, 773-778 (2008).1609.Abu-Rustum, N.R., Lee, S.& Massad, L.S.Topotecan for recurrent cervical cancer after platinum-based therapy.Int $J$ Gynecol Cancer 10, 285-288 (2000).1610.Coronel, J.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Weekly topotecan as second- or third-line treatment in patients with recurrent or metastatic cervical cancer.Med Oncol 26, 210-214 (2009).1611.Rose, P.G., Blessing, J.A., Lele, S.& Abulafia, O.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Evaluation of pegylated liposomal doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.Gynecol Oncol 102, 210-213 (2006).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1612.Rose, P.G., Blessing, J.A.& Arseneau, J.Phase II evaluation of altretamine for advanced or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study.Gynecol Oncol 62, 100-102 (1996).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1613.Vermorken, J.B., et al.5-aza-2'- deoxycytidine in advanced or recurrent cancer of the uterine cervix.Eur J Cancer 27, 216-217 (1991).1614.Schilder, R.J., Sill, M.W., Lee, Y.C.& Mannel, R.A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 19, 929-933 (2009).1615.Goncalves, A., et al.A phase II trial to evaluate gefitinib as second- or thirdline treatment in patients with recurring locoregionally advanced or metastatic cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 108, 42- 46 (2008).1616.Santin, A.D., et al.Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or nonsquamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 122, 495-500 (2011).1617.Hertlein, L., et al.Cetuximab monotherapy in advanced cervical cancer: a retrospective study with five patients.Arch Gynecol Obstet 283, 109- 113 (2011).1618.Mackay, H.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J., et al.A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184.Gynecol Oncol 116, 163-167 (2010).1619.Tinker, A.V., et al.Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199).Gynecol Oncol 130, 269-274 (2013).1620.Minion, L.E., Chase, D.M., Farley, J.H., Willmott, L.J.& Monk, B.J.Safety and efficacy of salvage nano-particle albumin bound paclitaxel in recurrent cervical cancer: a feasibility study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol Res Pract 3, 4 (2016).1621.Lorusso, D., et al.Phase II study on weekly bolus topotecan in advanced or recurrent cervical cancer.Oncology 80, 390-394 (2011).1622.Alberts, D.S., et al.Phase II randomized trial of cisplatin chemotherapy regimens in the treatment of recurrent or metastatic squamous cell cancer of the cervix: a Southwest Oncology Group Study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Clin Oncol 5, 1791-1795 (1987).1623.Bezwoda, W.R., Nissenbaum, M.& Derman, D.P.Treatment of metastatic and recurrent cervix cancer with chemotherapy: a randomised trial comparing hydroxyurea with cisdiamminedichloro-platinum plus methotrexate.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Med Pediatr Oncol 14, 17- 19 (1986).1624.Cadron, I., Jakobsen, A.& Vergote, I.Report of an early stopped randomized trial comparing cisplatin vs.cisplatin/ifosfamide/ 5-fluorouracil in recurrent cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Obstet Invest 59, 126-129 (2005).1625.Greenberg, B.R., Kardinal, C.G., Pajak, T.F.& Bateman, J.R.Adriamycin versus adriamycin and bleomycin in advanced epidermoid carcinoma of the cervix.Cancer Treat Rep 61, 1383-1384 (1977).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1626.Long, H.J., 3rd, et al.Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A Gynecologic Oncology Group study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 100, 537-543 (2006).1627.Malkasian, G.D., Jr., et al.Treatment of recurrent and metastatic carcinoma of the cervix: comparison of doxorubicin with a combination of vincristine and 5- fluorouracil.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 11, 235-239 (1981).1628.McQuellon, R.P., Thaler, H.T., Cella, D.& Moore, D.H.Quality of life (QOL) outcomes from a randomized trial of cisplatin versus cisplatin plus paclitaxel in advanced cervical cancer: a Gynecologic Oncology Group study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 101, 296-304 (2006).1629.Moore, D.H., et al.Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Clin Oncol 22, 3113-3119 (2004).1630.Omura, G.A., et al.Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Clin Oncol 15, 165-171 (1997).1631.Wallace, H.J., Jr., et al.Comparison of the therapeutic effects of adriamycin alone versus adriamycin plus vincristine versus adriamycin plus cyclophosphamide in the treatment of advanced carcinoma of the cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cancer Treat Rep 62, 1435-1441 (1978).1632.Scatchard, K., Forrest, J.L., Flubacher, M., Cornes, P.& Williams, C.Chemotherapy for metastatic and recurrent cervical cancer.Cochrane Database Syst Rev 10, CD006469 (2012).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1633.Brave, M., et al.Topotecan in combination with cisplatin for the treatment of stage IVB, recurrent, or persistent cervical cancer.Oncology (Williston Park) 20, 1401-1404, 1410; discussion 1410-1411, 1415-1406 (2006).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1634.Long, H.J., 3rd, et al.Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.J Clin Oncol 23, 4626-4633 (2005).1635.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Monk, B.J., Huang, H.Q., Cella, D.& Long, H.J., 3rd.Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Clin Oncol 23, 4617-4625 (2005).1636.Pfeiffer, P., Thomsen, K.& Bertelsen, K.Teniposide or carboplatin in patients with recurrent or advanced cervical carcinoma.Int $J$ Gynecol Cancer 7, 1 (1997).1637.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Thomsen, T.K., Pfeiffer, P.& Bertelsen, K.Teniposide or carboplatin in patients with recurrent or advanced cervical carcinoma: a randomized phase II trial.Int J Gynecol Cancer 8, 310-314 (1998).1638.Mountzios, G.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Randomized multicenter phase II trial of cisplatin and ifosfamide with or without paclitaxel in recurrent or metastatic carcinoma of the uterine cervix: a Hellenic Cooperative Oncology Group (HeCOG) study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Ann Oncol 20, 1362- 1368 (2009).1639.Monk, B.J.A randomised phase III trial of four cisplatin containing doublet combinations in stage IVB, recurrent or persistent cervical carcinoma: a GOG study.01/06/2008.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "(2008).1640.Bloss, J.D., et al.Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study.J Clin Oncol 20, 1832-1837 (2002).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1641.Edmonson, J.H., et al.Phase II studies of bleomycin, cyclophosphamide, doxorubicin and cisplatin, and bleomycin and cisplatin in advanced cervical carcinoma.Am J Clin Oncol 11, 149-151 (1988).1642.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Lira-Puerto, V., et al.Phase II trial of carboplatin or iproplatin in cervical cancer.Cancer Chemother Pharmacol 28, 391-396 (1991).1643.Lorusso, D., Petrelli, F., Coinu, A., Raspagliesi, F.& Barni, S.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer.Gynecol Oncol 133, 117-123 (2014).1644.Monk, B.J., et al.Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "$J$ Clin Oncol 27, 4649-4655 (2009).1645.Kitagawa, R., et al.A randomized, phase III trial of paclitaxel plus carboplatin (TC) versus paclitaxel plus cisplatin (TP) in stage IVb, persistent or recurrent cervical cancer: Japan Clinical Oncology Group study (JCO0505).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Clin Oncol 30, [Abstr 5006] (2012).1646.Choi, C.H., et al.Salvage chemotherapy with a combination of paclitaxel, ifosfamide, and cisplatin for the patients with recurrent carcinoma of the uterine cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int $J$ Gynecol Cancer 16, 1157- 1164 (2006).1647.Dimopoulos, M.A., et al.Combination of ifosfamide, paclitaxel, and cisplatin for the treatment of metastatic and recurrent carcinoma of the uterine cervix: a phase II study of the Hellenic Cooperative Oncology Group.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 85, 476-482 (2002).1648.Kosmas, C., et al.Evaluation of the paclitaxel-ifosfamide-cisplatin (TIP) combination in relapsed and/or metastatic cervical cancer.Br J Cancer 101, 1059-1065 (2009).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1649.Zanetta, G., et al.Paclitaxel, ifosfamide and cisplatin (TIP) chemotherapy for recurrent or persistent squamous-cell cervical cancer.Ann Oncol 10, 1171- 1174 (1999).1650.Downs, L.S., Jr., et al.Ifosfamide, paclitaxel, and carboplatin, a novel triplet regimen for advanced, recurrent, or persistent carcinoma of the cervix: a phase II trial.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 120, 265- 269 (2011).1651.Mabuchi, S., et al.The activity of carboplatin and paclitaxel for recurrent cervical cancer after definitive radiotherapy.Gynecol Oncol 113, 200- 204 (2009).1652.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Torfs, S., et al.Evaluation of paclitaxel/carboplatin in a dose dense or weekly regimen in 66 patients with recurrent or primary metastatic cervical cancer.Eur J Cancer 48, 1332-1340 (2012).1653.Garces, A.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "H., et al.First-line paclitaxel and carboplatin in persistent/recurrent or advanced cervical cancer: retrospective analysis of patients treated at Brazilian National Cancer Institute.Int J Gynecol Cancer 23, 743- 748 (2013).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1654.Papadimitriou, C.A., et al.Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix.J Clin Oncol 17, 761-766 (1999).1655.Rose, P.G., Blessing, J.A., Gershenson, D.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "M.& McGehee, R.Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study.J Clin Oncol 17, 2676-2680 (1999).1656.Tinker, A.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "V., Bhagat, K., Swenerton, K.D.& Hoskins, P.J.Carboplatin and paclitaxel for advanced and recurrent cervical carcinoma: the British Columbia Cancer Agency experience.Gynecol Oncol 98, 54-58 (2005).1657.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Kitagawa, R., et al.Phase II trial of paclitaxel and carboplatin in patients with recurrent or metastatic cervical carcinoma.Proc Am Soc Clin Oncol 23, 5048 (2004).1658.Moore, K.N., et al.A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 105, 299-303 (2007).1659.Cella, D., et al.Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 119, 531-537 (2010).1660.Kitagawa, R., et al.Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Clin Oncol 33, 2129-2135 (2015).1661.Saito, I., et al.A phase III trial of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in stage IVB, persistent or recurrent cervical cancer: Gynecologic Cancer Study Group/Japan Clinical Oncology Group Study (JCOG0505).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Jpn J Clin Oncol 40, 90-93 (2010).1662.Tewari, K.S., et al.Improved survival with bevacizumab in advanced cervical cancer.N Engl J Med 370, 734-743 (2014).1663.Penson, R.T., et al.Bevacizumab for advanced cervical cancer: patientreported outcomes of a randomised, phase 3 trial (NRG OncologyGynecologic Oncology Group protocol 240).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Lancet Oncol 16, 301-311 (2015).1664.Symonds, R.P., et al.Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Lancet Oncol 16, 1515-1524 (2015).1665.Monk, B.J., et al.Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Clin Oncol 28, 3562- 3569 (2010).1666.Monk, B.J.& Pandite, L.N.Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Clin Oncol 29, 4845 (2011).1667.Vermorken, J.B., et al.Randomized phase III trial of bleomycin, vindesine, mitomycin-C, and cisplatin (BEMP) versus cisplatin (P) in disseminated squamous-cell carcinoma of the uterine cervix: an EORTC Gynecological Cancer Cooperative Group study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Ann Oncol 12, 967-974 (2001).1668.Coronel, J., et al.A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Preliminary results.Med Oncol 28 Suppl 1, S540- 546 (2011).1669.Shimada, M., et al.Feasibility study on combination chemotherapy using nogitecan hydrochloride (topotecan) and cisplatin for patients with metastatic, persistent, or recurrent uterine cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Clin Oncol 21, 969-974 (2016).1670.Kaern, J., Trope, C., Abeler, V., Iversen, T.& Kjorstad, K.A phase II study of 5- fluorouracil/cisplatinum in recurrent cervical cancer.Acta Oncol 29, 25-28 (1990).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1671.Kaern, J., Trope, C., Sundfoer, K.& Kristensen, G.B.Cisplatin/5-fluorouracil treatment of recurrent cervical carcinoma: a phase II study with longterm follow-up.Gynecol Oncol 60, 387- 392 (1996).1672.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Bonomi, P., Blessing, J., Ball, H., Hanjani, P.& DiSaia, P.J.A phase II evaluation of cisplatin and 5-fluorouracil in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 34, 357-359 (1989).1673.Daghestani, A.N., Hakes, T.B., Lynch, G.& Lewis, J.L., Jr.Cervix carcinoma: treatment with combination cisplatin and bleomycin.Gynecol Oncol 16, 334- 339 (1983).1674.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cervellino, J.C., Araujo, C.E., Sanchez, O., Miles, H.& Nishihama, A.Cisplatin and ifosfamide in patients with advanced squamous cell carcinoma of the uterine cervix.A phase II trial.Acta Oncol 34, 257-259 (1995).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1675.Coleman, R.E., et al.A phase II study of ifosfamide and cisplatin chemotherapy for metastatic or relapsed carcinoma of the cervix.Cancer Chemother Pharmacol 27, 52-54 (1990).1676.Duenas-Gonzalez, A.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.A phase II study of gemcitabine and cisplatin combination as induction chemotherapy for untreated locally advanced cervical carcinoma.Ann Oncol 12, 541-547 (2001).1677.Duenas-Gonzalez, A., et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Weekly cisplatin/low-dose gemcitabine combination for advanced and recurrent cervical carcinoma.Am J Clin Oncol 24, 201-203 (2001).1678.Burnett, A.F., et al.A phase II study of gemcitabine and cisplatin in patients with advanced, persistent, or recurrent squamous cell carcinoma of the cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 76, 63-66 (2000).1679.Pignata, S., et al.Phase II study of cisplatin and vinorelbine as first-line chemotherapy in patients with carcinoma of the uterine cervix.$J$ Clin Oncol 17, 756-760 (1999).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1680.Morris, M., Blessing, J.A., Monk, B.J., McGehee, R.& Moore, D.H.Phase II study of cisplatin and vinorelbine in squamous cell carcinoma of the cervix: a gynecologic oncology group study.J Clin Oncol 22, 3340-3344 (2004).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1681.Piver, M.S., Ghamande, S.A., Eltabbakh, G.H.& O'Neill-Coppola, C.First-line chemotherapy with paclitaxel and platinum for advanced and recurrent cancer of the cervix--a phase II study.Gynecol Oncol 75, 334-337 (1999).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1682.Li, Y., et al.A phase 2 study of nanoparticle albumin-bound paclitaxel plus nedaplatin for patients with advanced, recurrent, or metastatic cervical carcinoma.Cancer 123, 420- 425 (2017).1683.Pectasides, D.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Carboplatin and paclitaxel in metastatic or recurrent cervical cancer.Int J Gynecol Cancer 19, 777-781 (2009).1684.Nagao, S., et al.Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A pilot study.Gynecol Oncol 96, 805-809 (2005).1685.Fiorica, J., et al.Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix.Gynecol Oncol 85, 89-94 (2002).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1686.Sugiyama, T., et al.Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer.Oncology 58, 31-37 (2000).1687.Malviya, V.K., Deppe, G.& Schoenmaker, M.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Treatment of recurrent cervical cancer with cis-platinum and mitomycin C: a phase II study.Am J Clin Oncol 12, 438-441 (1989).1688.Wagenaar, H.C., et al.Phase II study of mitomycin-C and cisplatin in disseminated, squamous cell carcinoma of the uterine cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group study.Eur J Cancer 37, 1624-1628 (2001).1689.Ramm, K., Vergote, I.B., Kaern, J.& Trope, C.G.Bleomycin-ifosfamide-cisplatinum (BIP) in pelvic recurrence of previously irradiated cervical carcinoma: a second look.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 46, 203-207 (1992).1690.Buxton, E.J., et al.Combination bleomycin, ifosfamide, and cisplatin chemotherapy in cervical cancer.J Natl Cancer Inst 81, 359-361 (1989).1691.Murad, A.M., Triginelli, S.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A.& Ribalta, J.C.Phase II trial of bleomycin, ifosfamide, and carboplatin in metastatic cervical cancer.J Clin Oncol 12, 55-59 (1994).1692.Fanning, J., Ladd, C.& Hilgers, R.D.Cisplatin, 5-fluorouracil, and ifosfamide in the treatment of recurrent or advanced cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 56, 235-238 (1995).1693.Serkies, K., Jassem, J.& Dziadziuszko, R.Chemotherapy with mitomycin c, ifosfamide, and cisplatin for recurrent or persistent cervical cancer.Int $J$ Gynecol Cancer 16, 1152-1156 (2006).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1694.Hainsworth, J.D., et al.Paclitaxel, carboplatin, and long-term continuous infusion of 5-fluorouracil in the treatment of advanced squamous and other selected carcinomas: results of a Phase II trial.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cancer 92, 642-649 (2001).1695.Chitapanarux, I., et al.Phase II clinical study of irinotecan and cisplatin as firstline chemotherapy in metastatic or recurrent cervical cancer.Gynecol Oncol 89, 402-407 (2003).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1696.Hsiao, S.M., et al.Weekly cisplatin, infusional high-dose 5-fluorouracil and leucovorin for advanced, recurrent and metastatic cervical carcinoma.Anticancer Res 28, 1887-1891 (2008).1697.Mannel, R.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "S., Blessing, J.A.& Boike, G.Cisplatin and pentoxifylline in advanced or recurrent squamous cell carcinoma of the cervix: a phase II trial of the Gynecologic Oncology Group.Gynecol Oncol 79, 64-66 (2000).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1698.Farley, J., et al.Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 121, 303-308 (2011).1699.Kurtz, J.E., et al.Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial.Gynecol Oncol 113, 16-20 (2009).1700.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Look, K.Y., Blessing, J.A., Gallup, D.G.& Lentz, S.S.A phase II trial of 5- fluorouracil and high-dose leucovorin in patients with recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am J Clin Oncol 19, 439-441 (1996).1701.Look, K.Y., et al.A phase II trial of isotretinoin and alpha interferon in patients with recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am J Clin Oncol 21, 591-594 (1998).1702.Kitagawa, R., et al.A multi-institutional phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer.Gynecol Oncol 125, 307-311 (2012).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1703.Nezhat, F., et al.Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study.Gynecol Oncol 93, 144-148 (2004).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1704.Takekuma, M., et al.Phase II trial of paclitaxel and nedaplatin in patients with advanced/recurrent uterine cervical cancer: a Kansai Clinical Oncology Group study.Gynecol Oncol 126, 341-345 (2012).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1705.Hisamatsu, T., et al.Prediction of progression-free survival and response to paclitaxel plus carboplatin in patients with recurrent or advanced cervical cancer.Int J Gynecol Cancer 22, 623-629 (2012).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1706.Suprasert, P., Charoenkwan, K.& Cheewakriangkrai, C.Outcomes of advanced and recurrent cervical cancer treated with cisplatin and generic topotecan: retrospective analysis in a tertiary care hospital in Thailand.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "$J$ Gynecol Oncol 21, 237-240 (2010).1707.Maluf, F.C., et al.Phase II study of tirapazamine plus cisplatin in patients with advanced or recurrent cervical cancer.Int J Gynecol Cancer 16, 1165- 1171 (2006).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1708.Ghaemmaghami, F., et al.First-line chemotherapy with 5-FU and platinum for advanced and recurrent cancer of the cervix: a phase II study.$J$ Obstet Gynaecol 23, 422-425 (2003).1709.Marnitz, S., et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Extended field chemoradiation for cervical cancer patients with histologically proven paraaortic lymph node metastases after laparaoscopic lymphadenectomy.Strahlenther Onkol 191, 421-428 (2015).1710.Jeon, W.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Salvage radiotherapy for lymph node recurrence after radical surgery in cervical cancer.J Gynecol Oncol 23, 168-174 (2012).1711.Ng, B.H., Rozita, A., Adlinda, A., Lee, W.C.& Wan Zamaniah, W.Extended field radiotherapy with or without chemotherapy in patients with cervical cancer and positive para-aortic lymph nodes: a single institution retrospective review.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Asian Pac J Cancer Prev 16, 3827-3833 (2015).1712.Kim, H.S., et al.Impact of Chemoradiation on Prognosis in Stage IVB Cervical Cancer with Distant Lymphatic Metastasis.Cancer Res Treat 45, 193-201 (2013).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1713.Kim, J.Y., Kim, J.H., Yoon, M.S., Kim, J.& Kim, Y.S.Curative chemoradiotherapy in patients with stage IVB cervical cancer presenting with paraortic and left supraclavicular lymph node metastases.Int J Radiat Oncol Biol Phys 84, 741-747 (2012).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1714.Walker, J.L., Morrison, A., DiSilvestro, P.& von Gruenigen, V.E.A phase I/II study of extended field radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in patients with cervical carcinoma metastatic to the para-aortic lymph nodes: a Gynecologic Oncology Group study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 112, 78-84 (2009).1715.Grigsby, P.W.Radiotherapy for pelvic recurrence after radical hysterectomy for cervical cancer.Radiat Med 23, 327- 330 (2005).1716.Ijaz, T., Eifel, P.J., Burke, T.& Oswald, M.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J.Radiation therapy of pelvic recurrence after radical hysterectomy for cervical carcinoma.Gynecol Oncol 70, 241-246 (1998).1717.Hirte, H., Kennedy, E.B., Elit, L.& Fung Kee Fung, M.Systemic therapy for recurrent, persistent, or metastatic cervical cancer: a clinical practice guideline.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Curr Oncol 22, 211-219 (2015).1718.Martinez Monge, R.IORT in the management of locally advanced or recurrent gynecologic cancer at high risk of locoregional relapse (doctoral thesis).University of Navarro (Spain).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "(1994).1719.Martinez Monge, R., et al.Preoperative chemoradiation and adjuvant surgery in locally advanced or recurrent cervical carcinoma.Rev Med Univ Navarra 41, 19-26 (1997).1720.Lele, S.B.& Piver, M.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "S.Weekly cisplatin induction chemotherapy in the treatment of recurrent cervical carcinoma.Gynecol Oncol 33, 6-8 (1989).1721.Potter, M.E., Hatch, K.D., Potter, M.Y., Shingleton, H.M.& Baker, V.V.Factors affecting the response of recurrent squamous cell carcinoma of the cervix to cisplatin.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cancer 63, 1283-1286 (1989).1722.Thigpen, T., Shingleton, H., Homesley, H., Lagasse, L.& Blessing, J.Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cancer 48, 899-903 (1981).1723.Weiss, G.R., et al.A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: a Southwest Oncology Group study.Gynecol Oncol 39, 332-336 (1990).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1724.Arseneau, J., Blessing, J.A., Stehman, F.B.& McGehee, R.A phase II study of carboplatin in advanced squamous cell carcinoma of the cervix (a Gynecologic Oncology Group Study).Invest New Drugs 4, 187-191 (1986).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1725.Elit, L., Fyles, A.W., Devries, M.C., Oliver, T.K.& Fung-Kee-Fung, M.Follow-up for women after treatment for cervical cancer: a systematic review.Gynecol Oncol 114, 528-535 (2009).1726.Krebs, H.B.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Recurrent cancer of the cervix following radical hysterectomy and pelvic node dissection.Obstet Gynecol 59, 422-427 (1982).1727.Muram, D., Curry, R.H.& Drouin, P.Cytologic follow-up of patients with invasive cervical carcinoma treated by radiotherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am J Obstet Gynecol 142, 350-354 (1982).1728.Larson, D.M., et al.Diagnosis of recurrent cervical carcinoma after radical hysterectomy.Obstet Gynecol 71, 6-9 (1988).1729.Rintala, M.A., Rantanen, V.T., Salmi, T.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A., Klemi, P.J.& Grenman, S.E.PAP smear after radiation therapy for cervical carcinoma.Anticancer Res 17, 3747- 3750 (1997).1730.Soisson, A.P., Geszler, G., Soper, J.T., Berchuck, A.& Clarke-Pearson, D.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "L.A comparison of symptomatology, physical examination, and vaginal cytology in the detection of recurrent cervical carcinoma after radical hysterectomy.Obstet Gynecol 76, 106- 109 (1990).1731.Look, K.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Y.& Rocereto, T.F.Relapse patterns in FIGO stage IB carcinoma of the cervix.Gynecol Oncol 38, 114-120 (1990).1732.Tinga, D.J., Bouma, J., Boonstra, H.& Aalders, J.G.Symptomatology, localization and treatment of recurrent cervical carcinoma.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 2, 179-188 (1992).1733.Gerdin, E., Cnattingius, S., Johnson, P.& Pettersson, B.Prognostic factors and relapse patterns in early-stage cervical carcinoma after brachytherapy and radical hysterectomy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 53, 314-319 (1994).1734.Samlal, R.A., et al.Recurrent cervical carcinoma after radical hysterectomy: an analysis of clinical aspects and prognosis.Int J Gynecol Cancer 8, 78-84 (1998).1735.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Bodurka-Bevers, D., et al.Posttherapy surveillance of women with cervical cancer: an outcomes analysis.Gynecol Oncol 78, 187-193 (2000).1736.Esajas, M.D., et al.Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with early-stage cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Clin Oncol 19, 3960-3966 (2001).1737.Duyn, A., Van Eijkeren, M., Kenter, G., Zwinderman, K.& Ansink, A.Recurrent cervical cancer: detection and prognosis.Acta Obstet Gynecol Scand 81, 759-763 (2002).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1738.Morice, P., et al.Value of routine followup procedures for patients with stage I/II cervical cancer treated with combined surgery-radiation therapy.Ann Oncol 15, 218-223 (2004).1739.Sartori, E., et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Pattern of failure and value of follow-up procedures in endometrial and cervical cancer patients.Gynecol Oncol 107, S241-247 (2007).1740.Zola, P., et al.Could follow-up different modalities play a role in asymptomatic cervical cancer relapses diagnosis?",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "An Italian multicenter retrospective analysis.Gynecol Oncol 107, S150-154 (2007).1741.Ansink, A., de Barros Lopes, A., Naik, R.& Monaghan, J.M.Recurrent stage IB cervical carcinoma: evaluation of the effectiveness of routine follow up surveillance.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Br J Obstet Gynaecol 103, 1156-1158 (1996).1742.Lim, K.C., Howells, R.E.& Evans, A.S.The role of clinical follow up in early stage cervical cancer in South Wales.BJOG 111, 1444-1448 (2004).1743.Lanceley, A.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", Fiander, A., McCormack, M.& Bryant, A.Follow-up protocols for women with cervical cancer after primary treatment.Cochrane Database Syst Rev, CD008767 (2013).1744.Nama, V., Nordin, A.& Bryant, A.Patient-reported outcome measures for follow-up after gynaecological cancer treatment.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cochrane Database Syst Rev, CD010299 (2013).1745.Gupta, S., Sodhani, P., Singh, V.& Sehgal, A.Role of vault cytology in follow-up of hysterectomized women: results and inferences from a low resource setting.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Diagn Cytopathol 41, 762-766 (2013).1746.Rimel, B.J., et al.Cervicovaginal cytology in the detection of recurrence after cervical cancer treatment.Obstet Gynecol 118, 548-553 (2011).1747.Orr, J.M., Barnett, J.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "C.& Leath, C.A., 3rd.Incidence of subsequent abnormal cytology in cervical cancer patients completing five-years of post treatment surveillance without evidence of recurrence.Gynecol Oncol 122, 501-504 (2011).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1748.Injumpa, N., et al.Limited value of vaginal cytology in detecting recurrent disease after radical hysterectomy for early stage cervical carcinoma.Asian Pac J Cancer Prev 7, 656-658 (2006).1749.Lara, L.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A., de Andrade, J.M.& Dos Reis, F.J.Cytology for the detection of early recurrence of gynecologic cancer in the vaginal vault.Recent Pat Endocr Metab Immune Drug Discov 8, 135-139 (2014).1750.Chien, C.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "R., Ting, L.L., Hsieh, C.Y.& Lai, M.S.Post-radiation Pap smear for Chinese patients with cervical cancer: a ten-year follow-up.Eur J Gynaecol Oncol 26, 619-622 (2005).1751.Singh, N., et al.A review of posttrachelectomy isthmic and vaginal smear cytology.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cytopathology 15, 97- 103 (2004).1752.Feratovic, R., et al.Cytologic findings after fertility-sparing radical trachelectomy.Cancer 114, 1-6 (2008).1753.Slama, J., et al.Sensitivity of Follow-Up Methods in Patients After FertilitySparing Surgery for Cervical Cancers.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 27, 147-153 (2017).1754.Cairns, M., Cuschieri, K.S., Cubie, H.A.& Cruickshank, M.E.High-risk HPV genotyping in the follow-up of women treated conservatively for microinvasive cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 20, 154-157 (2010).1755.Korolenkova, L.I.[Value of HPV (hybrid capture 2) testing for assessing the effectiveness of conservative surgical treatment in CIN2-3/carcinoma in situ and microinvasive cervical cancer].",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Vopr Onkol 57, 322-326 (2011).1756.Costa, S., et al.Performance of HPV DNA testing in the follow-up after treatment of high-grade cervical lesions, adenocarcinoma in situ (AIS) and microinvasive carcinoma.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Ecancermedicalscience 9, 528 (2015).1757.Noventa, M., et al.Usefulness, methods and rationale of lymph nodes HPV-DNA investigation in estimating risk of early stage cervical cancer recurrence: a systematic literature review.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Clin Exp Metastasis 31, 853-867 (2014).1758.Fule, T., et al.Prognostic significance of high-risk HPV status in advanced cervical cancers and pelvic lymph nodes.Gynecol Oncol 100, 570-578 (2006).1759.Burnett, A.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "F., et al.Prognostic significance of polymerase chain reaction detected human papillomavirus of tumors and lymph nodes in surgically treated stage IB cervical cancer.Gynecol Oncol 47, 343- 347 (1992).1760.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Hording, U., Ravn, V., Knudsen, J.& Visfeldt, J.The use of polymerase chain reaction to detect metastatic cancer cells within lymph nodes in stage I cervical carcinoma.Int J Gynecol Pathol 14, 339-343 (1995).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1761.Ikenberg, H., et al.Human papillomavirus DNA in tumor-free regional lymph nodes: a potential prognostic marker in cervical carcinoma.Cancer J Sci Am 2, 28-34 (1996).1762.Baay, M.F., et al.Detection of HPV-16 DNA by PCR in histologically cancer free lymph nodes from patients with cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Clin Pathol 50, 960-961 (1997).1763.Czegledy, J., Iosif, C., Forslund, O., Willen, R.& Hansson, B.G.Detection of human papilloma virus DNA in lymph nodes extirpated at radical surgery for cervical cancer is not predictive of recurrence.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Med Virol 54, 183-185 (1998).1764.Kobayashi, Y., et al.Presence of human papilloma virus DNA in pelvic lymph nodes can predict unexpected recurrence of cervical cancer in patients with histologically negative lymph nodes.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Clin Cancer Res 4, 979-983 (1998).1765.Sapy, T., Hernadi, Z., Konya, J.& Lukacsko, L.Poor clinical outcome in early stage cervical cancer with human papillomavirus-18 positive lymph nodes.Eur J Obstet Gynecol Reprod Biol 90, 93-95 (2000).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1766.Pilch, H., et al.The presence of HPV DNA in cervical cancer: correlation with clinico-pathologic parameters and prognostic significance: 10 years experience at the Department of Obstetrics and Gynecology of the Mainz University.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 11, 39- 48 (2001).1767.Hernadi, Z., et al.The prognostic significance of HPV-16 genome status of the lymph nodes, the integration status and p53 genotype in HPV-16 positive cervical cancer: a long term follow up.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "BJOG 110, 205-209 (2003).1768.Chan, P.K., et al.Detection and quantitation of human papillomavirus DNA in primary tumour and lymph nodes of patients with early stage cervical carcinoma.J Clin Virol 33, 201- 205 (2005).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1769.Landro, M.E., et al.Human papillomavirus and mutated H-ras oncogene in cervical carcinomas and pathological negative pelvic lymph nodes: a retrospective follow-up.J Med Virol 80, 694-701 (2008).1770.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Park, J.S., et al.Presence of oncogenic HPV DNAs in cervical carcinoma tissues and pelvic lymph nodes associating with proliferating cell nuclear antigen expression.Gynecol Oncol 60, 418-423 (1996).1771.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Nawa, A., et al.Detection of human papillomaviruses from histologically normal lymph nodes of Japanese cervical cancer patients by nested polymerase chain-reaction assay.Int $J$ Cancer 53, 932-937 (1993).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1772.Lukaszuk, K., et al.Predictive value of HPV DNA in lymph nodes in surgically treated cervical carcinoma patients--a prospective study.Gynecol Oncol 104, 721-726 (2007).1773.Singh, R.K., et al.Human papillomavirus prevalence in postradiotherapy uterine cervical carcinoma patients: correlation with recurrence of the disease.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int $J$ Gynecol Cancer 16, 1048-1054 (2006).1774.Song, Y.J., et al.Persistent human papillomavirus DNA is associated with local recurrence after radiotherapy of uterine cervical cancer.Int J Cancer 129, 896-902 (2011).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1775.Pornthanakasem, W., et al.Human papillomavirus DNA in plasma of patients with cervical cancer.BMC Cancer 1, 2-13 (2001).1776.Song, D., et al.The negative conversion of high-risk human papillomavirus and its performance in surveillance of cervical cancer after treatment: a retrospective study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Arch Gynecol Obstet 295, 197-203 (2017).1777.Yu, M.C., et al.The Role of High-Risk Human Papilloma Virus Testing in the Surveillance of Cervical Cancer After Treatment.Arch Pathol Lab Med 139, 1437-1440 (2015).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1778.Badaracco, G., et al.Persistence of HPV after radio-chemotherapy in locally advanced cervical cancer.Oncol Rep 23, 1093-1099 (2010).1779.Hoogendam, J.P., et al.Detection of cervical cancer recurrence during follow-up: a multivariable comparison of 9 frequently investigated serum biomarkers.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 131, 655-660 (2013).1780.Shimura, $\\mathrm { K } ,$ et al.Utility of serum squamous cell carcinoma antigen levels at the time of recurrent cervical cancer diagnosis in determining the optimal treatment choice.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "$J$ Gynecol Oncol 24, 321-329 (2013).1781.Bonfrer, J.M., Gaarenstroom, K.N., Korse, C.M., Van Bunningen, B.N.& Kenemans, P.Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Anticancer Res 17, 2329-2334 (1997).1782.Yen, T.C., et al.Defining the priority of using 18F-FDG PET for recurrent cervical cancer.J Nucl Med 45, 1632- 1639 (2004).1783.Juang, C.M., et al.Application of tumor markers CEA, TPA, and SCC-Ag in patients with low-risk FIGO stage IB and IIA squamous cell carcinoma of the uterine cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 76, 103- 106 (2000).1784.Molina, R., et al.CYFRA 21.1 in patients with cervical cancer: comparison with SCC and CEA.Anticancer Res 25, 1765- 1771 (2005).1785.Oh, J., et al.Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with locally advanced cervical cancer treated with radiation or chemoradiation.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Obstet Gynecol Sci 59, 269-278 (2016).1786.Pras, E., et al.Serum squamous cell carcinoma antigen and CYFRA 21-1 in cervical cancer treatment.Int J Radiat Oncol Biol Phys 52, 23-32 (2002).1787.Forni, F.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Squamous cell carcinoma antigen in follow-up of cervical cancer treated with radiotherapy: evaluation of cost-effectiveness.Int J Radiat Oncol Biol Phys 69, 1145-1149 (2007).1788.Yoon, S.M., et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Use of serum squamous cell carcinoma antigen for follow-up monitoring of cervical cancer patients who were treated by concurrent chemoradiotherapy.Radiat Oncol 5, 78 (2010).1789.Duk, J.M., et al.Cancer of the uterine cervix: sensitivity and specificity of serum squamous cell carcinoma antigen determinations.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 39, 186- 194 (1990).1790.Bolli, J.A., et al.Squamous cell carcinoma antigen: clinical utility in squamous cell carcinoma of the uterine cervix.Gynecol Oncol 55, 169-173 (1994).1791.Brioschi, P.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A., Bischof, P., Delafosse, C.& Krauer, F.Squamous-cell carcinoma antigen (SCC-A) values related to clinical outcome of pre-invasive and invasive cervical carcinoma.Int J Cancer 47, 376-379 (1991).1792.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Rose, P.G., Baker, S., Fournier, L., Nelson, B.E.& Hunter, R.E.Serum squamous cell carcinoma antigen levels in invasive cervical cancer: prediction of response and recurrence.Am J Obstet Gynecol 168, 942-946 (1993).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1793.Meier, W., et al.Squamous cell carcinoma antigen and carcinoembryonic antigen levels as prognostic factors for the response of cervical carcinoma to chemotherapy.Gynecol Oncol 38, 6-11 (1990).1794.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Roijer, E., et al.Squamous cell carcinoma antigen isoforms in serum from cervical cancer patients.Tumour Biol 27, 142- 152 (2006).1795.Scambia, G., et al.The value of squamous cell carcinoma antigen in patients with locally advanced cervical cancer undergoing neoadjuvant chemotherapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am J Obstet Gynecol 164, 631-636 (1991).1796.Gocze, P.M., Vahrson, H.W.& Freeman, D.A.Serum levels of squamous cell carcinoma antigen and ovarian carcinoma antigen (CA 125) in patients with benign and malignant diseases of the uterine cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Oncology 51, 430-434 (1994).1797.Kainz, C., et al.Cytokeratin subunit 19 measured by CYFRA 21-1 assay in follow-up of cervical cancer.Gynecol Oncol 56, 402-405 (1995).1798.Abe, A., Nakano, T., Morita, S.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "& Oka, K.Clinical evaluation of serum and immunohistochemical expression of SCC and CA19-9 in radiation therapy for cervical cancer.Anticancer Res 19, 829- 836 (1999).1799.Micke, O., et al.The impact of squamous cell carcinoma (SCC) antigen in the follow-up after radiotherapy in patients with cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Anticancer Res 20, 5113-5115 (2000).1800.Pectasides, D., et al.Squamous cell carcinoma antigen, tumor-associated trypsin inhibitor, and carcinoembryonic antigen for monitoring cervical cancer.Am J Clin Oncol 17, 307-312 (1994).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1801.Dodd, J.K., Henry, R.J., Tyler, J.P.& Houghton, C.R.Cervical carcinoma: a comparison of four potential biochemical tumor markers.Gynecol Oncol 32, 248-252 (1989).1802.Ngan, H.Y., Cheng, G.T., Yeung, W.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "S., Wong, L.C.& Ma, H.K.The prognostic value of TPA and SCC in squamous cell carcinoma of the cervix.Gynecol Oncol 52, 63-68 (1994).1803.Chan, Y.M., Ng, T.Y., Ngan, H.Y.& Wong, L.C.Monitoring of serum squamous cell carcinoma antigen levels in invasive cervical cancer: is it cost-effective?",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 84, 7-11 (2002).1804.Ferdeghini, M., et al.Serum CYFRA 21-1 assay in squamous cell carcinoma of the cervix.Anticancer Res 13, 1841-1844 (1993).1805.Tsai, S.C., Kao, C.H.& Wang, S.J.Study of a new tumor marker, CYFRA 21-1, in squamous cell carcinoma of the cervix, and comparison with squamous cell carcinoma antigen.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Neoplasma 43, 27- 29 (1996).1806.Suzuki, Y., et al.Serum CYFRA 21-1 in cervical cancer patients treated with radiation therapy.J Cancer Res Clin Oncol 126, 332-336 (2000).1807.Gaarenstroom, K.N., Bonfrer, J.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "M., Korse, C.M., Kenter, G.G.& Kenemans, P.Value of Cyfra 21-1, TPA, and SCC-Ag in predicting extracervical disease and prognosis in cervical cancer.Anticancer Res 17, 2955-2958 (1997).1808.Yazigi, R., et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cyfra 21-1 marker in carcinoma of the cervix.Int $J$ Gynecol Cancer 10, 203-206 (2000).1809.de Bruijn, H.W., et al.The clinical value of squamous cell carcinoma antigen in cancer of the uterine cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Tumour Biol 19, 505-516 (1998).1810.Callet, N., Cohen-Solal Le Nir, C.C., Berthelot, E.& Pichon, M.F.Cancer of the uterine cervix: sensitivity and specificity of serum Cyfra 21.1 determinations.Eur J Gynaecol Oncol 19, 50-56 (1998).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1811.Duk, J.M., Aalders, J.G., Fleuren, G.J., Krans, M.& De Bruijn, H.W.Tumor markers CA 125, squamous cell carcinoma antigen, and carcinoembryonic antigen in patients with adenocarcinoma of the uterine cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Obstet Gynecol 73, 661-668 (1989).1812.Leminen, A.Tumor markers CA 125, carcinoembryonic antigen and tumorassociated trypsin inhibitor in patients with cervical adenocarcinoma.Gynecol Oncol 39, 358-363 (1990).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1813.Tabata, T., Takeshima, N., Tanaka, N., Hirai, Y.& Hasumi, K.Clinical value of tumor markers for early detection of recurrence in patients with cervical adenocarcinoma and adenosquamous carcinoma.Tumour Biol 21, 375-380 (2000).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1814.Niloff, J.M., et al.Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix.Am J Obstet Gynecol 148, 1057-1058 (1984).1815.Borras, G., Molina, R., Xercavins, J., Ballesta, A.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "& Iglesias, J.Tumor antigens CA 19.9, CA 125, and CEA in carcinoma of the uterine cervix.Gynecol Oncol 57, 205-211 (1995).1816.Sawada, M., Okudaira, Y., Matsui, Y.& Shimizu, Y.Immunosuppressive acidic protein in patients with gynecologic cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cancer 54, 652-656 (1984).1817.Bachtiary, B., Selzer, E., Knocke, T.H., Potter, R.& Obermair, A.Serum VEGF levels in patients undergoing primary radiotherapy for cervical cancer: impact on progression-free survival.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cancer Lett 179, 197-203 (2002).1818.Meads, C., et al.Evaluating PET-CT in the detection and management of recurrent cervical cancer: systematic reviews of diagnostic accuracy and subjective elicitation.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "BJOG 121, 398-407 (2014).1819.Cetina, L., et al.F18-FDG-PET/CT in the evaluation of patients with suspected recurrent or persistent locally advanced cervical carcinoma.Rev Invest Clin 63, 227-235 (2011).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1820.Park, D.H., et al.Diagnosis of recurrent uterine cervical cancer: computed tomography versus positron emission tomography.Korean J Radiol 1, 51-55 (2000).1821.Heron, C.W., Husband, J.E., Williams, M.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "P., Dobbs, H.J.& Cosgrove, D.O.The value of CT in the diagnosis of recurrent carcinoma of the cervix.Clin Radiol 39, 496-501 (1988).1822.Walsh, J.W., Amendola, M.A., Hall, D.J., Tisnado, J.& Goplerud, D.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "R.Recurrent carcinoma of the cervix: CT diagnosis.AJR Am J Roentgenol 136, 117-122 (1981).1823.Weber, T.M., et al.Cervical carcinoma: determination of recurrent tumor extent versus radiation changes with MR imaging.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Radiology 194, 135-139 (1995).1824.Hatano, K., et al.Evaluation of the therapeutic effect of radiotherapy on cervical cancer using magnetic resonance imaging.Int J Radiat Oncol Biol Phys 45, 639-644 (1999).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1825.Williams, M.P., Husband, J.E., Heron, C.W., Cherryman, G.R.& Koslin, D.B.Magnetic resonance imaging in recurrent carcinoma of the cervix.Br J Radiol 62, 544-550 (1989).1826.Meads, C., et al.Positron emission tomography/computerised tomography imaging in detecting and managing recurrent cervical cancer: systematic review of evidence, elicitation of subjective probabilities and economic modelling.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Health Technol Assess 17, 1- 323 (2013).1827.Chung, H.H., et al.Predictive role of post-treatment [18F]FDG PET/CT in patients with uterine cervical cancer.Eur J Radiol 81, e817-822 (2012).1828.Kitajima, K.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Performance of FDGPET/CT for diagnosis of recurrent uterine cervical cancer.Eur Radiol 18, 2040-2047 (2008).1829.Lee, M., Lee, Y., Hwang, K.H., Choe, W.& Park, C.Y.Usefulness of F-18 FDG PET/CT in assessment of recurrence of cervical cancer after treatment.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Nucl Med Mol Imaging 45, 111-116 (2011).1830.Mittra, E., et al.Efficacy of 18F-FDG PET/CT in the evaluation of patients with recurrent cervical carcinoma.Eur J Nucl Med Mol Imaging 36, 1952-1959 (2009).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1831.Pallardy, A., et al.Clinical and survival impact of FDG PET in patients with suspicion of recurrent cervical carcinoma.Eur J Nucl Med Mol Imaging 37, 1270-1278 (2010).1832.Sironi, S., et al.Post-therapy surveillance of patients with uterine cancers: value of integrated FDG PET/CT in the detection of recurrence.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Eur J Nucl Med Mol Imaging 34, 472-479 (2007).1833.Ding, X.P., Feng, L.& Ma, L.Diagnosis of recurrent uterine cervical cancer: PET versus PET/CT: a systematic review and meta-analysis.Arch Gynecol Obstet 290, 741-747 (2014).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1834.Sun, S.S., et al.Value of whole body 18Ffluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent cervical cancer.Anticancer Res 21, 2957-2961 (2001).1835.Nakamoto, Y., et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Prognostic value of positron emission tomography using F18-fluorodeoxyglucose in patients with cervical cancer undergoing radiotherapy.Gynecol Oncol 84, 289- 295 (2002).1836.Ryu, S.Y., Kim, M.H., Choi, S.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "C., Choi, C.W.& Lee, K.H.Detection of early recurrence with 18F-FDG PET in patients with cervical cancer.J Nucl Med 44, 347-352 (2003).1837.Havrilesky, L.J., et al.The role of PET scanning in the detection of recurrent cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 90, 186- 190 (2003).1838.Chang, W.C., Hung, Y.C., Lin, C.C., Shen, Y.Y.& Kao, C.H.Usefulness of FDG-PET to detect recurrent cervical cancer based on asymptomatically elevated tumor marker serum levels--a preliminary report.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cancer Invest 22, 180-184 (2004).1839.van der Veldt, A.A., et al.Clarifying the diagnosis of clinically suspected recurrence of cervical cancer: impact of 18F-FDG PET.J Nucl Med 49, 1936-1943 (2008).1840.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Chung, H.H., et al.Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence.Gynecol Oncol 104, 529-534 (2007).1841.Chu, Y., et al.Diagnostic value of 18FFDG-PET or PET-CT in recurrent cervical cancer: a systematic review and meta-analysis.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Nucl Med Commun 35, 144-150 (2014).1842.Yen, T.C., et al.Comparative benefits and limitations of 18F-FDG PET and CT-MRI in documented or suspected recurrent cervical cancer.Eur J Nucl Med Mol Imaging 33, 1399-1407 (2006).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1843.Brooks, R.A., et al.Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer.Gynecol Oncol 112, 104-109 (2009).1844.Siva, S., et al.Impact of post-therapy positron emission tomography on prognostic stratification and surveillance after chemoradiotherapy for cervical cancer.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cancer 117, 3981- 3988 (2011).1845.Schwarz, J.K., Siegel, B.A., Dehdashti, F.& Grigsby, P.W.Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "JAMA 298, 2289-2295 (2007).1846.Schwarz, J.K., Siegel, B.A., Dehdashti, F.& Grigsby, P.W.Metabolic response on post-therapy FDG-PET predicts patterns of failure after radiotherapy for cervical cancer.Int J Radiat Oncol Biol Phys 83, 185-190 (2012).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1847.Grigsby, P.W., Siegel, B.A., Dehdashti, F., Rader, J.& Zoberi, I.Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome.J Clin Oncol 22, 2167-2171 (2004).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1848.Chung, H.H., et al.Clinical impact of FDGPET imaging in post-therapy surveillance of uterine cervical cancer: from diagnosis to prognosis.Gynecol Oncol 103, 165-170 (2006).1849.Unger, J.B., et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Detection of recurrent cervical cancer by whole-body FDG PET scan in asymptomatic and symptomatic women.Gynecol Oncol 94, 212-216 (2004).1850.Jao, M.S., et al.Long-term follow up of cervical cancer patients with unexplained squamous cell carcinoma antigen elevation after post-therapy surveillance using positron emission tomography.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Obstet Gynaecol Res 36, 1003-1008 (2010).1851.Lin, C.T., et al.Role of [18F]fluoro-2- deoxy-D-glucose positron emission tomography in re-recurrent cervical cancer.Int J Gynecol Cancer 16, 1994- 2003 (2006).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1852.Chang, T.C., et al.Positron emission tomography for unexplained elevation of serum squamous cell carcinoma antigen levels during follow-up for patients with cervical malignancies: a phase II study.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cancer 101, 164-171 (2004).1853.Sakurai, H., et al.FDG-PET in the detection of recurrence of uterine cervical carcinoma following radiation therapy--tumor volume and FDG uptake value.Gynecol Oncol 100, 601-607 (2006).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1854.Imachi, M., Tsukamoto, N., Matsuyama, T.& Nakano, H.Pulmonary metastasis from carcinoma of the uterine cervix.Gynecol Oncol 33, 189-192 (1989).1855.Ploch, E.Hormonal replacement therapy in patients after cervical cancer treatment.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 26, 169-177 (1987).1856.Lacey, J.V., Jr., et al.Use of hormone replacement therapy and adenocarcinomas and squamous cell carcinomas of the uterine cervix.Gynecol Oncol 77, 149-154 (2000).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1857.Rauh, L.A., Pannone, A.F.& Cantrell, L.A.Hormone replacement therapy after treatment for cervical cancer: Are we adhering to standard of care?Gynecol Oncol (2017).1858.Salani, R., et al.Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am $J$ Obstet Gynecol 204, 466-478 (2011).1859.Elit, L., Kennedy, E.B., Fyles, A.& Metser, U.Follow-up for cervical cancer: a Program in Evidence-Based Care systematic review and clinical practice guideline update.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Curr Oncol 23, 109- 118 (2016).1860.Gadducci, A., Tana, R., Cosio, S.& Genazzani, A.R.The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Crit Rev Oncol Hematol 66, 10-20 (2008).1861.Zanetta, G., et al.Magnetic resonance imaging of cervical cancer in pregnancy.Int J Gynecol Cancer 8, 265-269 (1998).1862.Balleyguier, C., et al.Management of cervical cancer detected during pregnancy: role of magnetic resonance imaging.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Clin Imaging 37, 70-76 (2013).1863.Takalkar, A.M., Khandelwal, A., Lokitz, S., Lilien, D.L.& Stabin, M.G.18F-FDG PET in pregnancy and fetal radiation dose estimates.J Nucl Med 52, 1035-1040 (2011).1864.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Zanotti-Fregonara, P., Laforest, R.& Wallis, J.W.Fetal Radiation Dose from 18F-FDG in Pregnant Patients Imaged with PET, PET/CT, and PET/MR.J Nucl Med 56, 1218-1222 (2015).1865.Favero, G., et al.Invasive cervical cancer during pregnancy: laparoscopic nodal evaluation before oncologic treatment delay.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 118, 123-127 (2010).1866.Vercellino, G.F., et al.Laparoscopic pelvic lymphadenectomy in 32 pregnant patients with cervical cancer: rationale, description of the technique, and outcome.Int J Gynecol Cancer 24, 364- 371 (2014).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1867.Alouini, S., Rida, K.& Mathevet, P.Cervical cancer complicating pregnancy: implications of laparoscopic lymphadenectomy.Gynecol Oncol 108, 472-477 (2008).1868.Stan, C., et al.Cervical cancer in pregnant women: laparoscopic evaluation before delaying treatment.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Eur J Gynaecol Oncol 26, 649-650 (2005).1869.Chvatal, R., Oppelt, P., Koehler, C., Habelsberger, A.& Yaman, C.Simple trachelectomy of early invasive cervix carcinoma in the second trimester.J Turk Ger Gynecol Assoc 12, 121-123 (2011).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1870.Sioutas, A., Schedvins, K., Larson, B.& Gemzell-Danielsson, K.Three cases of vaginal radical trachelectomy during pregnancy.Gynecol Oncol 121, 420-421 (2011).1871.Herod, J.J., Decruze, S.B.& Patel, R.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "D.A report of two cases of the management of cervical cancer in pregnancy by cone biopsy and laparoscopic pelvic node dissection.BJOG 117, 1558-1561 (2010).1872.Hertel, H., Possover, M., Kuhne-Heid, R.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "& Schneider, A.Laparoscopic lymph node staging of cervical cancer in the 19th week of pregnancy.A case report.Surg Endosc 15, 324 (2001).1873.Silva, L.B., et al.Sentinel node mapping in a pregnant woman with cervical cancer: a case report.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int $J$ Gynecol Cancer 16, 1454-1457 (2006).1874.Papadia, A., et al.Laparoscopic Indocyanine Green Sentinel Lymph Node Mapping in Pregnant Cervical Cancer Patients.J Minim Invasive Gynecol 23, 270-273 (2016).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1875.Prem, K.A., Makowski, E.L.& McKelvey, J.L.Carcinoma of the cervix associated with pregnancy.Am J Obstet Gynecol 95, 99-108 (1966).1876.Dudan, R.C., Yon, J.L., Ford, J.H.& Averette, H.E.Carcinoma of the cervix and pregnancy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 1, 283- 289 (1973).1877.Thompson, J.D., Caputo, T.A., Franklin, E.W., 3rd & Dale, E.The surgical management of invasive cancer of the cervix in pregnancy.Am J Obstet Gynecol 121, 853-863 (1975).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1878.Boutselis, J.G.Intraepithelial carcinoma of the cervix associated with pregnancy.Obstet Gynecol 40, 657-666 (1972).1879.Lee, J.M., et al.Cervical cancer associated with pregnancy: results of a multicenter retrospective Korean study (KGOG1006).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am J Obstet Gynecol 198, 92 e91- 96 (2008).1880.Lin, C.H., Hsieh, J.C., Li, Y.T.& Kuo, T.C.Successful conservative treatment of microinvasive cervical cancer during pregnancy.J Chin Med Assoc 76, 232- 234 (2013).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1881.Sood, A.K., et al.Radiotherapeutic management of cervical carcinoma that complicates pregnancy.Cancer 80, 1073-1078 (1997).1882.Ben-Arie, A., Levy, R., Lavie, O., Edwards, C.& Kaplan, A.Conservative treatment of stage IA2 squamous cell carcinoma of the cervix during pregnancy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Obstet Gynecol 104, 1129-1131 (2004).1883.Lee, R.B., Neglia, W.& Park, R.C.Cervical carcinoma in pregnancy.Obstet Gynecol 58, 584-589 (1981).1884.Nisker, J.A.& Shubat, M.Stage IB cervical carcinoma and pregnancy: report of 49 cases.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am J Obstet Gynecol 145, 203-206 (1983).1885.Greer, B.E., et al.Fetal and maternal considerations in the management of stage I-B cervical cancer during pregnancy.Gynecol Oncol 34, 61-65 (1989).1886.Monk, B.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J.& Montz, F.J.Invasive cervical cancer complicating intrauterine pregnancy: treatment with radical hysterectomy.Obstet Gynecol 80, 199- 203 (1992).1887.Duggan, B., et al.Cervical cancer in pregnancy: reporting on planned delay in therapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Obstet Gynecol 82, 598-602 (1993).1888.Allen, D.G., Planner, R.S., Tang, P.T., Scurry, J.P.& Weerasiri, T.Invasive cervical cancer in pregnancy.Aust N Z J Obstet Gynaecol 35, 408-412 (1995).1889.Sorosky, J.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "I., et al.Stage I squamous cell cervical carcinoma in pregnancy: planned delay in therapy awaiting fetal maturity.Gynecol Oncol 59, 207-210 (1995).1890.Sorosky, J., Cherouny, P., Podczaski, E.& Hackett, T.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Stage IB cervical carcinoma in pregnancy: awaiting fetal maturity.$J$ Gynecol Tech 2, 155-158 (1996).1891.van Vliet, W., van Loon, A.J., ten Hoor, K.A.& Boonstra, H.Cervical carcinoma during pregnancy: outcome of planned delay in treatment.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Eur J Obstet Gynecol Reprod Biol 79, 153-157 (1998).1892.Germann, N., et al.Management and clinical outcomes of pregnant patients with invasive cervical cancer.Ann Oncol 16, 397-402 (2005).1893.Sood, A.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "K., et al.Surgical management of cervical cancer complicating pregnancy: a case-control study.Gynecol Oncol 63, 294-298 (1996).1894.Takushi, M., Moromizato, H., Sakumoto, K.& Kanazawa, K.Management of invasive carcinoma of the uterine cervix associated with pregnancy: outcome of intentional delay in treatment.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 87, 185-189 (2002).1895.Traen, K., Svane, D., Kryger-Baggesen, N., Bertelsen, K.& Mogensen, O.Stage Ib cervical cancer during pregnancy: planned delay in treatment--case report.Eur $J$ Gynaecol Oncol 27, 615-617 (2006).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1896.Ishioka, S., et al.Outcomes of planned delivery delay in pregnant patients with invasive gynecologic cancer.Int $J$ Clin Oncol 14, 321-325 (2009).1897.Gurney, E.P.& Blank, S.V.Postpartum radical trachelectomy for IB1 squamous cell carcinoma of the cervix diagnosed in pregnancy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am J Obstet Gynecol 201, e8- e10 (2009).1898.Giacalone, P.L., Laffargue, F., Benos, P., Rousseau, O.& Hedon, B.Cis-platinum neoadjuvant chemotherapy in a pregnant woman with invasive carcinoma of the uterine cervix.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Br $J$ Obstet Gynaecol 103, 932-934 (1996).1899.Caluwaerts, S., et al.Neoadjuvant chemotherapy followed by radical hysterectomy for invasive cervical cancer diagnosed during pregnancy: report of a case and review of the literature.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 16, 905- 908 (2006).1900.de Lima, C.A., et al.Conservative treatment of uterine cervical adenocarcinoma in pregnancy.Case Rep Obstet Gynecol 2013, 692017 (2013).1901.Chun, K.C., et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Neoadjuvant chemotherapy with paclitaxel plus platinum followed by radical surgery in early cervical cancer during pregnancy: three case reports.Jpn J Clin Oncol 40, 694-698 (2010).1902.Kong, T.W., et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Neoadjuvant and postoperative chemotherapy with paclitaxel plus cisplatin for the treatment of FIGO stage IB cervical cancer in pregnancy.Obstet Gynecol Sci 57, 539-543 (2014).1903.Favero, G., Lanowska, M.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", Schneider, A., Marnitz, S.& Kohler, C.Laparoscopic pelvic lymphadenectomy in a patient with cervical cancer stage Ib1 complicated by a twin pregnancy.J Minim Invasive Gynecol 17, 118-120 (2010).1904.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Fruscio, R., et al.Delivery delay with neoadjuvant chemotherapy for cervical cancer patients during pregnancy: a series of nine cases and literature review.Gynecol Oncol 126, 192-197 (2012).1905.Lanowska, M.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", et al.Addressing concerns about cisplatin application during pregnancy.J Perinat Med 39, 279-285 (2011).1906.Hecking, T., et al.Individual management of cervical cancer in pregnancy.Arch Gynecol Obstet 293, 931-939 (2016).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1907.Smyth, E.C., Korpanty, G., McCaffrey, J.A., Mulligan, N.& Carney, D.N.Small-cell carcinoma of the cervix at 23 weeks gestation.J Clin Oncol 28, e295-297 (2010).1908.Tewari, K., et al.Neoadjuvant chemotherapy in the treatment of locally advanced cervical carcinoma in pregnancy: a report of two cases and review of issues specific to the management of cervical carcinoma in pregnancy including planned delay of therapy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cancer 82, 1529-1534 (1998).1909.Karam, A., Feldman, N.& Holschneider, C.H.Neoadjuvant cisplatin and radical cesarean hysterectomy for cervical cancer in pregnancy.Nat Clin Pract Oncol 4, 375-380 (2007).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1910.Rabaiotti, E., et al.Management of locally advanced cervical cancer in pregnancy: a case report.Tumori 96, 623-626 (2010).1911.Li, J., Wang, L.J., Zhang, B.Z., Peng, Y.P.& Lin, Z.Q.Neoadjuvant chemotherapy with paclitaxel plus platinum for invasive cervical cancer in pregnancy: two case report and literature review.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Arch Gynecol Obstet 284, 779-783 (2011).1912.Yousefi, Z., et al.Neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer during pregnancy: case report and review of literature.Oman Med J 28, 60-62 (2013).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1913.Peculis, L.D., Ius, Y., Campion, M., Friedlander, M.& Hacker, N.Stage IB2 adenosquamous cervical cancer diagnosed at 19-weeks' gestation.Aust N Z J Obstet Gynaecol 55, 94-97 (2015).1914.Wang, Q., Liu, Y.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "H., Xie, L., Hu, W.J.& Liu, B.R.Small cell carcinoma of the uterine cervix in pregnancy: A case report and review of the literature.Oncol Lett 9, 91- 95 (2015).1915.Balderston, K.D., Tewari, K., Gregory, W.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "T., Berman, M.L.& Kucera, P.R.Neuroendocrine small cell uterine cervix cancer in pregnancy: long-term survival following combined therapy.Gynecol Oncol 71, 128-132 (1998).1916.Bader, A.A., Petru, E.& Winter, R.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Longterm follow-up after neoadjuvant chemotherapy for high-risk cervical cancer during pregnancy.Gynecol Oncol 105, 269-272 (2007).1917.Marana, H.R., et al.Chemotherapy in the treatment of locally advanced cervical cancer and pregnancy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 80, 272-274 (2001).1918.Palaia, I., Pernice, M., Graziano, M., Bellati, F.& Panici, P.B.Neoadjuvant chemotherapy plus radical surgery in locally advanced cervical cancer during pregnancy: a case report.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am J Obstet Gynecol 197, e5-6 (2007).1919.Boyd, A., Cowie, V.& Gourley, C.The use of cisplatin to treat advanced-stage cervical cancer during pregnancy allows fetal development and prevents cancer progression: report of a case and review of the literature.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 19, 273-276 (2009).1920.da Fonseca, A.J., Dalla-Benetta, A.C., Ferreira, L.P., Martins, C.R.& Lins, C.D.[Neoadjuvant chemotherapy followed by radical surgery in pregnant patient with invasive cervical cancer: case report and literature review].",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Rev Bras Ginecol Obstet 33, 43-48 (2011).1921.Dawood, R., Instone, M.& Kehoe, S.Neoadjuvant chemotherapy for cervical cancer in pregnancy: a case report and literature review.Eur J Obstet Gynecol Reprod Biol 171, 205-208 (2013).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1922.Benhaim, Y., et al.Neoadjuvant chemotherapy for advanced stage cervical cancer in a pregnant patient: report of one case with rapid tumor progression.Eur J Obstet Gynecol Reprod Biol 136, 267-268 (2008).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1923.Seamon, L.G., Downey, G.O., Harrison, C.R., Doss, B.& Carlson, J.W.Neoadjuvant chemotherapy followed by post-partum chemoradiotherapy and chemoconsolidation for stage IIIB glassy cell cervical carcinoma during pregnancy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Gynecol Oncol 114, 540-541 (2009).1924.Ayhan, A., Dursun, P., Karakaya, B.K., Ozen, O.& Tarhan, C.Neoadjuvant chemotherapy followed by cesarean radical hysterectomy in a triplet pregnancy complicated by clear cell carcinoma of the cervix: a case presentation and literature review.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 22, 1198-1202 (2012).1925.Azim, H.A., Jr., Peccatori, F.A.& Pavlidis, N.Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Part I: Solid tumors.Cancer Treat Rev 36, 101-109 (2010).1926.Zagouri, F., Sergentanis, T.N., Chrysikos, D.& Bartsch, R.Platinum derivatives during pregnancy in cervical cancer: a systematic review and meta-analysis.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Obstet Gynecol 121, 337-343 (2013).1927.Bigelow, C.A., et al.Management and outcome of cervical cancer diagnosed in pregnancy.Am J Obstet Gynecol 216, 276 e271-276 e276 (2017).1928.Zemlickis, D., et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Maternal and fetal outcome after invasive cervical cancer in pregnancy.J Clin Oncol 9, 1956-1961 (1991).1929.Sall, S., Rini, S.& Pineda, A.Surgical management of invasive carcinoma of the cervix in pregnancy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am J Obstet Gynecol 118, 1-5 (1974).1930.Watanabe, Y., et al.Radical hysterectomy for invasive cervical cancer during pregnancy: a retrospective analysis of a single institution experience.Eur $J$ Gynaecol Oncol 30, 79-81 (2009).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1931.Ungar, L., Smith, J.R., Palfalvi, L.& Del Priore, G.Abdominal radical trachelectomy during pregnancy to preserve pregnancy and fertility.Obstet Gynecol 108, 811-814 (2006).1932.Abu-Rustum, N.R., Tal, M.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "N., DeLair, D., Shih, K.& Sonoda, Y.Radical abdominal trachelectomy for stage IB1 cervical cancer at 15-week gestation.Gynecol Oncol 116, 151-152 (2010).1933.Enomoto, T., et al.A successful case of abdominal radical trachelectomy for cervical cancer during pregnancy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Eur J Obstet Gynecol Reprod Biol 158, 365-366 (2011).1934.Mandic, A., Novakovic, P., Nincic, D., Zivaljevic, M.& Rajovic, J.Radical abdominal trachelectomy in the 19th gestation week in patients with early invasive cervical carcinoma: case study and overview of literature.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Am J Obstet Gynecol 201, e6-8 (2009).1935.van de Nieuwenhof, H.P., van Ham, M.A., Lotgering, F.K.& Massuger, L.F.First case of vaginal radical trachelectomy in a pregnant patient.Int J Gynecol Cancer 18, 1381-1385 (2008).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1936.Iwami, N., et al.First case of vaginal radical trachelectomy in a pregnant Japanese woman.Int J Clin Oncol 16, 737-740 (2011).1937.Ferriaoli, D., et al.Early invasive cervical cancer during pregnancy: different therapeutic options to preserve fertility.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 22, 842-849 (2012).1938.Bravo, E., Parry, S., Alonso, C.& Rojas, S.Radical vaginal trachelectomy and laparoscopic pelvic lymphadenectomy in IB1 cervical cancer during pregnancy.Gynecol Oncol Case Rep 2, 78-79 (2012).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1939.Kolomainen, D.F., Bradley, R.J., LarsenDisney, P.& Shepherd, J.H.Radical vaginal trachelectomy at 16 weeks' gestation: A case report.Gynecol Oncol Case Rep 5, 28-30 (2013).1940.Saso, S., et al.Trachelectomy during pregnancy: what has experience taught us?",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "J Obstet Gynaecol Res 41, 640-645 (2015).1941.Moreno-Luna, E., Alonso, P., Santiago, J.D.& Zapardiel, I.Simple trachelectomy during pregnancy for cervical cancer.Ecancermedicalscience 10, 673 (2016).1942.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Creasman, W.T., Rutledge, F.N.& Fletcher, G.H.Carcinoma of the cervix associated with pregnancy.Obstet Gynecol 36, 495-501 (1970).1943.Hopkins, M.P.& Morley, G.W.The prognosis and management of cervical cancer associated with pregnancy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Obstet Gynecol 80, 9-13 (1992).1944.van der Vange, N., et al.The prognosis of cervical cancer associated with pregnancy: a matched cohort study.Obstet Gynecol 85, 1022-1026 (1995).1945.Ostrom, K., et al.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Uterine evacuation with misoprostol during radiotherapy for cervical cancer in pregnancy.Int $J$ Gynecol Cancer 13, 340-343 (2003).1946.Benhaim, Y., et al.Chemoradiation therapy in pregnant patients treated for advanced-stage cervical carcinoma during the first trimester of pregnancy: report of two cases.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 17, 270-274 (2007).1947.Sood, A.K., et al.Cervical cancer diagnosed shortly after pregnancy: prognostic variables and delivery routes.Obstet Gynecol 95, 832-838 (2000).1948.Jones, W.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "B., et al.Cervical carcinoma and pregnancy.A national patterns of care study of the American College of Surgeons.Cancer 77, 1479-1488 (1996).1949.Manuel-Limson, G.A., Ladines-Llave, C.A., Sotto, L.S.& Manalo, A.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "M.Cancer of the cervix in pregnancy: a 31-year experience at the Philippine General Hospital.J Obstet Gynaecol Res 23, 503- 509 (1997).1950.Nevin, J., Soeters, R., Dehaeck, K., Bloch, B.& Van Wyk, L.Advanced cervical carcinoma associated with pregnancy.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int J Gynecol Cancer 3, 57-63 (1993).1951.Cliby, W.A., Dodson, M.K.& Podratz, K.C.Cervical cancer complicated by pregnancy: episiotomy site recurrences following vaginal delivery.Obstet Gynecol 84, 179-182 (1994).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1952.Copeland, L.J., Saul, P.B.& Sneige, N.Cervical adenocarcinoma: tumor implantation in the episiotomy sites of two patients.Gynecol Oncol 28, 230-235 (1987).1953.Khalil, A.M., Khatib, R.A., Mufarrij, A.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "A., Tawil, A.N.& Issa, P.Y.Squamous cell carcinoma of the cervix implanting in the episiotomy site.Gynecol Oncol 51, 408-410 (1993).1954.Gordon, A.N., Jensen, R.& Jones, H.W., 3rd.Squamous carcinoma of the cervix complicating pregnancy: recurrence in episiotomy after vaginal delivery.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Obstet Gynecol 73, 850-852 (1989).1955.Sivanesaratnam, V., Jayalakshmi, P.& Loo, C.Surgical management of early invasive cancer of the cervix associated with pregnancy.Gynecol Oncol 48, 68-75 (1993).1956.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Cailliez, D., Moirot, M.H., Fessard, C., Hemet, J.& Philippe, E.[Placental localisation of cancer of the cervix (author's transl)].J Gynecol Obstet Biol Reprod (Paris) 9, 461-463 (1980).1957.Can, N.T., Robertson, P.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": ", Zaloudek, C.J.& Gill, R.M.Cervical squamous cell carcinoma metastatic to placenta.Int J Gynecol Pathol 32, 516-519 (2013).1958.Amant, F., et al.Gynecologic cancers in pregnancy: guidelines of a second international consensus meeting.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "Int $J$ Gynecol Cancer 24, 394-403 (2014).1959.Peccatori, F.A., et al.Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol 24 Suppl 6, vi160- 170 (2013).",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1960.Morice, P., et al.French recommendations on the management of invasive cervical cancer during pregnancy.Int $J$ Gynecol Cancer 19, 1638-1641 (2009).# 19 Appendices # 19.1 Appendix 1 - People involved in the development of the guidelines 19.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1.1 List of the international development group <html><body><table><tr><td>Name</td><td>Specialty</td><td>Affiliation</td></tr><tr><td>David Cibula</td><td>Surgeon (chair)</td><td>Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital, Prague (Czech Republic)</td></tr><tr><td>Richard Potter</td><td> Radiation oncologist (chair)</td><td> Medical University of Vienna, Vienna (Austria)</td></tr><tr><td>Maria Rosaria Raspollini</td><td>Pathologist (chair)</td><td> University Hospital, Careggi - Florence (Italy)</td></tr><tr><td>Francois Planchamp</td><td>Methodologist</td><td>Institut Bergonié, Bordeaux (France)</td></tr><tr><td> Elisabeth Avall-Lundqvist</td><td>Medical oncologist</td><td>Linkoping University, Linkoping (Sweden)</td></tr><tr><td>Daniela Fischerova</td><td>Radiologist</td><td>Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital, Prague (Czech Republic)</td></tr><tr><td>Christine Haie Meder</td><td>Radiation oncologist</td><td>Institut Gustave Roussy, Villejuif (France)</td></tr><tr><td>Christhardt Kohler</td><td>Surgeon</td><td>Asklepios Hambourg Altona and University of Cologne, Medical Faculty, Department of Gynecology (Germany)</td></tr><tr><td>Fabio Landoni</td><td>Surgeon</td><td> University of Milan Bicocca, Monza (Italy)</td></tr><tr><td>Sigurd Lax</td><td>Pathologist</td><td>General Hospital Graz Sued-West, Graz (Austria)</td></tr><tr><td>Jacob Christian Lindegaard</td><td>Radiation oncologist</td><td>Aarhus University, Aarhus (Denmark)</td></tr><tr><td>Umesh Mahantshetty</td><td>Radiation oncologist</td><td> Tata Memorial Hospital, Mumbai (India)</td></tr><tr><td>Patrice Mathevet</td><td>Surgeon</td><td>Lausanne University, Lausanne (Switzerland)</td></tr><tr><td>W Glenn McCluggage</td><td> Pathologist</td><td>Department of Pathology, Belfast Health And Social Care Trust,</td></tr><tr><td>Mary McCormack</td><td> Medical oncologist</td><td>Belfast (United Kingdom) University College Hospital London, London (United Kingdom)</td></tr><tr><td>Raj Naik</td><td>Surgeon</td><td>Queen Elizabeth Hospital, Gateshead (United Kingdom)</td></tr><tr><td>Remi Nout</td><td>Radiation oncologist</td><td>Leiden University, Leiden (Netherlands)</td></tr><tr><td>Sandro Pignata</td><td>Medical oncologist</td><td>Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G Pascale\", IRCCS, Naples (Italy)</td></tr><tr><td>Jordi Ponce</td><td>Surgeon</td><td>University Hospital of Bellvitge (IDIBELL), Barcelona (Spain)</td></tr><tr><td>Denis Querleu</td><td>Surgeon</td><td>Institut Bergonié, Bordeaux (France)</td></tr><tr><td>Francesco Raspagliesi</td><td>Surgeon</td><td>Fondazione IRCCS Istituto Nazionale Tumori, Milan (Italy)</td></tr><tr><td>Alexandros Rodolakis</td><td>Surgeon</td><td>Athens University, Athens (Greece)</td></tr><tr><td></td><td></td><td>Medical University of Graz, Graz (Austria)</td></tr><tr><td>Karl Tamussino Pauline Wimberger</td><td>Surgeon Surgeon</td><td>Dresden University, TU Dresden, Dresden (Germany)</td></tr></table></body></html> 19.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "1.2 List of external panel of physicians and patients (international reviewers) <html><body><table><tr><td>Name</td><td>Physician/Patient</td><td>Country</td></tr><tr><td> Jafaru Abu</td><td>Gynaecological oncology</td><td>United Kingdom</td></tr><tr><td>Patriciu Achimas-Cadariu</td><td>Obstetric & gynaecology</td><td>Romania</td></tr><tr><td>Stefan Aebi</td><td>Medical oncology</td><td>Switzerland</td></tr><tr><td>Anastazija Aleksandrova Stanojevic</td><td>Radiation oncology</td><td>Croatia</td></tr><tr><td>Igor Aluloski</td><td>Gynaecology</td><td> Republic of Macedonia</td></tr><tr><td>Frederic Amant</td><td>Gynaecological oncology</td><td> Belgium</td></tr><tr><td>Anonymous</td><td> Patient</td><td>United Kingdom</td></tr><tr><td>Natalia Artymuk</td><td>Obstetric & gynaecology</td><td>Russia</td></tr><tr><td>Syuzanna Babloyan</td><td>Obstetric & gynaecology</td><td>Armenia</td></tr><tr><td>Janos Balega</td><td>Gynaecological oncology</td><td>United Kingdom</td></tr><tr><td>Anne-Sophie Bats</td><td>Gynaecological oncology</td><td>France</td></tr><tr><td>Ergin Bengisu</td><td>Gynaecological oncology</td><td>Turkey</td></tr><tr><td>Virginia Benito</td><td>Gynaecological oncology</td><td> Spain</td></tr><tr><td>Margarida Bernardino</td><td>Gynaecological oncology</td><td> Portugal</td></tr><tr><td>Tatjana Bozanovic</td><td>Gynaecological oncology</td><td>Serbia</td></tr><tr><td>Maria Brito</td><td>Pathology</td><td> Portugal</td></tr><tr><td> Kjersti Bruheim</td><td>Clinical oncology</td><td>Norway</td></tr><tr><td>Katharina Buser</td><td>Medical oncology</td><td>Switzerland</td></tr><tr><td>Angelo Cagnacci</td><td>Obstetric & gynaecology</td><td>Italy</td></tr><tr><td>Rita Canas Marques</td><td>Pathology</td><td> Portugal</td></tr><tr><td>Cyrus Chargari</td><td>Radiation oncology</td><td>France</td></tr><tr><td>Annamaria Cerrotta</td><td>Radiation oncology</td><td>Italy</td></tr><tr><td>Karen Chatland-Svane</td><td>Patient</td><td>Denmark</td></tr><tr><td>Nicoletta Colombo</td><td>Gynaecological oncology</td><td>Italy</td></tr><tr><td> Ovidiu Florin Coza</td><td>Radiation oncology</td><td>Romania</td></tr><tr><td>Sabrina Croce</td><td> Pathology</td><td>France</td></tr><tr><td>Vasileia Damaskou</td><td>Pathology</td><td>Greece</td></tr><tr><td>Javier de Santiago Garcia</td><td>Gynaecological oncology</td><td> Spain</td></tr><tr><td>Suha Deen</td><td> Pathology</td><td>United Kingdom</td></tr></table></body></html> <html><body><table><tr><td>Name (continued)</td><td>Physician/Patient</td><td>Country</td></tr><tr><td>Hannelore Denys</td><td>Medical oncology</td><td>Belgium</td></tr><tr><td>Francois Desmons</td><td>Gynaecological oncology</td><td> France</td></tr><tr><td>Javier Diez Garcia</td><td>Gynaecological oncology</td><td>Spain</td></tr><tr><td> Johannes Dimopoulos</td><td> Radiation oncology</td><td>Greece</td></tr><tr><td>Geanina Dragnea</td><td>Obstetric & gynaecology</td><td>Romania</td></tr><tr><td>Andreas du Bois</td><td>Gynaecological oncology</td><td>Germany</td></tr><tr><td> Michael Eichbaum</td><td>Gynaecological oncology</td><td>Germany</td></tr><tr><td>Guenter Emons</td><td>Gynaecological oncology</td><td>Germany</td></tr><tr><td>Brynhildur Eyjolfsdottir</td><td>Gynaecological oncology</td><td>Norway</td></tr><tr><td>Henrik Falconer</td><td>Gynaecological oncology</td><td>Sweden</td></tr><tr><td>Daniela Fanni</td><td> Pathology</td><td>Italy</td></tr><tr><td>Afshin Fazel</td><td>Gynaecological oncology</td><td>France</td></tr><tr><td>Scott Fegan</td><td>Gynaecological oncology</td><td>United Kingdom</td></tr><tr><td>Tanja Fehm</td><td>Gynaecological oncology</td><td>Germany</td></tr><tr><td>Ana Felix</td><td> Pathology</td><td>Portugal</td></tr><tr><td>Elena Fidarova</td><td> Radiation oncology</td><td>Austria</td></tr><tr><td> Jose Fonseca-Moutinho</td><td>Gynaecological oncology</td><td> Portugal</td></tr><tr><td>Michael Friedrich</td><td>Gynaecological oncology</td><td>Germany</td></tr><tr><td> Raji Ganesan</td><td> Pathology</td><td>United Kingdom</td></tr><tr><td>Antonio Gil Moreno</td><td>Gynaecological oncology</td><td>Spain</td></tr><tr><td>Noreen Gleeson</td><td>Gynaecological oncology</td><td>Ireland</td></tr><tr><td>Frederic Goffin</td><td>Gynaecological oncology</td><td>Belgium</td></tr><tr><td>Marek Gogacz</td><td>Obstetric & gynaecology</td><td> Poland</td></tr><tr><td>Francois Golfier</td><td>Obstetric & gynaecology</td><td>France</td></tr><tr><td>Mikel Gorostidi</td><td>Gynaecological oncology</td><td>Spain</td></tr><tr><td>Bjorn Hagen</td><td>Gynaecological oncology</td><td>Norway</td></tr><tr><td>Michael Halaska</td><td>Gynaecology</td><td>Czech Republic</td></tr><tr><td>Herman Haller</td><td>Gynaecological oncology</td><td>Croatia</td></tr><tr><td>Sissi Hamnstrom Cole</td><td>Patient</td><td>Sweden</td></tr></table></body></html> <html><body><table><tr><td>Name (continued)</td><td>Physician/Patient</td><td>Country</td></tr><tr><td>Annette Hasenburg</td><td>Gynaecological oncology</td><td>Germany</td></tr><tr><td>Steffen Hauptmann</td><td> Pathology</td><td> Netherlands</td></tr><tr><td>Lukas Hefler</td><td>Gynaecological oncology</td><td>Germany</td></tr><tr><td>Gines Hernandez Cortes</td><td>Obstetric & gynaecology</td><td> Spain</td></tr><tr><td>Christoph Honegger</td><td>Gynaecological oncology</td><td>Switzerland</td></tr><tr><td>Lars-Christian Horn</td><td> Pathology</td><td>Germany</td></tr><tr><td>Peter Hoskin</td><td> Medical oncology</td><td>United Kingdom</td></tr><tr><td>Cem lyibozkurt</td><td>Gynaecological oncology</td><td>Turkey</td></tr><tr><td>Robert Jach</td><td>Gynaecological oncology</td><td> Poland</td></tr><tr><td>Matias Jurado</td><td>Gynaecological oncology</td><td> Spain</td></tr><tr><td> Ina-Maria Jurgenliemk-Schulz</td><td> Radiation oncology</td><td> Netherlands</td></tr><tr><td>loannis Kalogiannidis</td><td>Gynaecological oncology</td><td>Greece</td></tr><tr><td>Sean Kehoe</td><td>Gynaecological oncology</td><td>United Kingdom</td></tr><tr><td>Vesna Kesic</td><td>Gynaecological oncology</td><td>Serbia</td></tr><tr><td>Rainer Kimmig</td><td>Gynaecological oncology</td><td>Germany</td></tr><tr><td>Gurkan Kiran</td><td>Gynaecological oncology</td><td>Turkey</td></tr><tr><td>Christian Kirisits</td><td> Radiation oncology: Medical Physicist</td><td>Austra</td></tr><tr><td>Preben Kjolhede</td><td>Obstetric & gynaecology</td><td>Sweden</td></tr><tr><td>Maximilian Klar</td><td>Gynaecological oncology</td><td>Germany</td></tr><tr><td> Pawel Knapp</td><td>Gynaecological oncology</td><td> Poland</td></tr><tr><td> Jan Kotarski</td><td>Gynaecological oncology</td><td> Poland</td></tr><tr><td>Stefan Miladinov Kovachev</td><td>Gynaecological oncology</td><td>Bulgaria</td></tr><tr><td>Frederic Kridelka</td><td>Obstetric & gynaecology</td><td> Belgium</td></tr><tr><td>Gunnar Kristensen</td><td>Gynaecological oncology</td><td>Norway</td></tr><tr><td>Ali Kucukmetin</td><td>Gynaecological oncology</td><td>United Kingdom</td></tr><tr><td>Antonio Lagoa</td><td>Gynaecological oncology</td><td> Portugal</td></tr><tr><td>Luis Ignacio Lete Lasa</td><td>Gynaecological oncology</td><td> Spain</td></tr><tr><td>Fabrice Lécuru</td><td>Gynaecology</td><td>France</td></tr><tr><td>Tally Levy</td><td>Gynaecological oncology</td><td>Israel</td></tr></table></body></html> <html><body><table><tr><td>Name (continued)</td><td>Physician/Patient</td><td>Country</td></tr><tr><td>Kristina Lindemann</td><td>Gynaecological oncology</td><td>Norway</td></tr><tr><td>Kristina Loessl</td><td>Radiation oncology</td><td>Switzerland</td></tr><tr><td>Nunzia Simona Losito</td><td>Pathology</td><td>Italy</td></tr><tr><td>Tiziano Maggino</td><td>Gynaecological oncology</td><td>Italy</td></tr><tr><td> Aljosa Mandic</td><td>Gynaecological oncology</td><td>Serbia</td></tr><tr><td>Simone Marnitz</td><td> Radiation oncology</td><td>Germany</td></tr><tr><td> Christian Marth</td><td>Gynaecological oncology</td><td>Austria</td></tr><tr><td>Leon Massuger</td><td>Gynaecological oncology</td><td>Netherlands</td></tr><tr><td>Claudia Mateoiu</td><td>Pathology</td><td>Sweden</td></tr><tr><td>Xavier Matias-Guiu</td><td>Pathology</td><td> Spain</td></tr><tr><td>Mihai Meirovitz</td><td>Gynaecological oncology</td><td>Israel</td></tr><tr><td> Santosh Menon</td><td>Pathology</td><td> India</td></tr><tr><td>Milos Mlyncek</td><td>Gynaecological oncology</td><td> Slovakia</td></tr><tr><td>Rodolfo Montironi</td><td> Pathology</td><td>Italy</td></tr><tr><td>Bahar Muezzinoglu</td><td> Pathology</td><td>Turkey</td></tr><tr><td>Peter Niehoff</td><td> Radiation oncology</td><td>Germany</td></tr><tr><td>Zoltan Novak</td><td>Gynaecological oncology</td><td>Hungary</td></tr><tr><td>Ernst Oberlechner</td><td>Gynaecological oncology</td><td>Germany</td></tr><tr><td>Felipe Ojeda</td><td>Gynaecological oncology</td><td>Spain</td></tr><tr><td>Claudia Ordeanu</td><td>Radiation oncology</td><td>Romania</td></tr><tr><td>Theo Panoskaltsis</td><td>Gynaecological oncology</td><td>Greece</td></tr><tr><td>Anna Pesci</td><td>Pathology</td><td>Italy</td></tr><tr><td>Patrick Petignat</td><td>Gynaecological oncology</td><td>Switzerland</td></tr><tr><td>Primoz Petric</td><td>Radiation oncology</td><td>Qatar</td></tr><tr><td>Bradley Pieters</td><td>Radiation oncology</td><td>Netherlands</td></tr><tr><td>Radovan Pilka</td><td>Obstetric & gynaecology</td><td>Czech Republic</td></tr><tr><td>Eleonore Piot</td><td> Patient</td><td>France</td></tr><tr><td>Igor Pljesa</td><td>Gynaecology</td><td>Serbia</td></tr><tr><td>Robert Poka</td><td>Obstetric & gynaecology</td><td>Hungary</td></tr></table></body></html> <html><body><table><tr><td>Name (continued)</td><td>Physician/Patient</td><td>Country</td></tr><tr><td>Mario Preti</td><td>Gynecology</td><td>Italy </td></tr><tr><td>Anna Protasova</td><td>Gynaecological oncology</td><td>Russia</td></tr><tr><td>Athanasios Protopapas</td><td>Obstetric & gynaecology</td><td>Greece</td></tr><tr><td>Alin Cristian Rancea</td><td>Gynaecological oncology</td><td>Romania</td></tr><tr><td>Isabelle Ray-Coquard</td><td>Medical oncology</td><td>France</td></tr><tr><td> Nicholas Reed</td><td> Radiation oncology</td><td> United Kingdom</td></tr><tr><td>Alexader Reinthaller</td><td>Gynaecological oncology</td><td>Austria</td></tr><tr><td> Jose Ernesto Moro Rodriguez</td><td> Pathology</td><td> Spain</td></tr><tr><td>Angeles Rovirosa</td><td>Radiation oncology</td><td> Spain</td></tr><tr><td>Muzaffer Sancy</td><td>Gynaecological oncology</td><td>Turkey</td></tr><tr><td>Antonella Savio</td><td>Pathology</td><td>Italy</td></tr><tr><td>Wlodzimierz Sawicki</td><td>Gynaecological oncology</td><td> Poland</td></tr><tr><td>Sergio Schettini</td><td>Obstetric & gynaecology</td><td>Italy</td></tr><tr><td>Dietmar Schmidt</td><td>Pathology</td><td>Germany</td></tr><tr><td>Barbara Segedin</td><td> Radiation oncology</td><td> Slovenia</td></tr><tr><td>Cristiana Sessa</td><td>Medical oncology</td><td> Switzerland</td></tr><tr><td>Paul Sevelda</td><td>Gynaecological oncology</td><td>Austria</td></tr><tr><td>Alejandro Soderini</td><td>Gynaecological oncology</td><td>Argentina</td></tr><tr><td>Erik Soegard-Andersen</td><td>Gynaecological oncology</td><td>Denmark</td></tr><tr><td>Philippe Simon</td><td>Gynaecological oncology</td><td> Belgium</td></tr><tr><td>Tayup Simsek</td><td>Gynaecological oncology</td><td>Turkey</td></tr><tr><td>Naveena Singh</td><td>Pathology</td><td>United Kingdom</td></tr><tr><td> Piero Sismondi</td><td>Obstetric & gynaecology</td><td>Italy</td></tr><tr><td>Drago Sredanovic</td><td>Obstetric & gynaecology</td><td> Slovenia</td></tr><tr><td>Hana Stankusova</td><td>Radiation oncology</td><td>Czech Republic</td></tr><tr><td>Artem Stepanyan</td><td>Gynaecological oncology</td><td>Armenia</td></tr><tr><td>Simona Stolnicu</td><td> Pathology</td><td>Romania</td></tr><tr><td>Vratislav Strnad</td><td> Radiation oncology</td><td>Germany</td></tr><tr><td>Alina Sturdza</td><td> Radiation oncology</td><td>Austria</td></tr></table></body></html> <html><body><table><tr><td>Name (continued)</td><td>Physician/Patient</td><td>Country</td></tr><tr><td>Jacek Sznurkowski</td><td>Gynaecological oncology</td><td>Poland</td></tr><tr><td>Li Tee Tan</td><td>Clinical oncology</td><td>United Kingdom</td></tr><tr><td>Kari Tanderup</td><td>Radiation oncology: Medical Physicist</td><td>Denmark</td></tr><tr><td>Alexandra Taylor</td><td>Clinical oncology</td><td>United Kingdom</td></tr><tr><td>Ico Toth</td><td>Patient</td><td>Hungary</td></tr><tr><td>Jacobusvan der Velden</td><td>Gynaecological oncology</td><td>Netherlands</td></tr><tr><td>Rene Henricus Maria Verheijen</td><td>Gynaecological oncology</td><td>France</td></tr><tr><td>Elena Villafranca</td><td>Radiation oncology</td><td> Spain</td></tr><tr><td>Boris Vranes</td><td>Gynaecological oncology</td><td>Serbia</td></tr><tr><td>Jacek Wilczynski</td><td>Gynaecological oncology</td><td>Poland</td></tr><tr><td>Edward Wight</td><td>Epidemiology</td><td>Switzerland</td></tr><tr><td>Petronella Witteveen</td><td>Medical oncology</td><td>Netherlands</td></tr><tr><td>Gian Franco Zannoni</td><td> Pathology</td><td>Italy</td></tr><tr><td>Vanna Zanagnolo</td><td>Gynaecological oncology</td><td>Italy</td></tr></table></body></html> 19.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "2 Appendix 2 - List of evidence-based medicine websites consulted <html><body><table><tr><td>Organism/agency</td><td>Website</td></tr><tr><td>ACPG</td><td>http://www.topalbertadoctors.org/home/</td></tr><tr><td>AGDH</td><td>http://www.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "health.gov.au/</td></tr><tr><td>AHRQ</td><td>http://www.guideline.gov/</td></tr><tr><td>AQuAS</td><td>http://aquas.gencat.cat/ca/</td></tr><tr><td>ASCO</td><td>http://www.asco.org/</td></tr><tr><td>BCCA</td><td>http://www.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "bccancer.bc.ca/default.htm</td></tr><tr><td>CADTH</td><td>http://www.cadth.ca/</td></tr><tr><td>CCO</td><td>https://www.cancercare.on.ca/</td></tr><tr><td>CEPO</td><td>http://www.msss.gouv.qc.ca/index.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "php</td></tr><tr><td>COMPAQ-HPST</td><td>http://www.compaqhpst.fr/fr/</td></tr><tr><td>CoCanCPG</td><td>http://www.cocancpg.eu/</td></tr><tr><td>ESMO</td><td>http://www.esmo.org/</td></tr><tr><td>GIN</td><td>http://www.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "g-i-n.net/</td></tr><tr><td>HAS</td><td>http://www.has-sante.fr/portail/jcms/fc_1249588/fr/accueil</td></tr><tr><td>INAHTA</td><td>http://www.inahta.org/</td></tr><tr><td>INESSS</td><td>http://www.inesss.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "qc.ca/</td></tr><tr><td>INCa</td><td>http://www.e-cancer.fr/</td></tr><tr><td>KCE</td><td>https://kce.fgov.be /fr</td></tr><tr><td>MSAC</td><td>http://www.msac.gov.au/</td></tr><tr><td>NCCN</td><td>http://www.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "nccn.org/</td></tr><tr><td>NHMRC</td><td>http://www.nhmrc.gov.au/</td></tr><tr><td>NHS</td><td>http://www.nhs.uk/Pages/HomePage.aspx</td></tr><tr><td>NICE</td><td>http://www.nice.org.uk/</td></tr><tr><td>NZGG</td><td>http://www.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "health.govt.nz/</td></tr><tr><td>SIGN</td><td>http://www.sign.ac.uk/</td></tr></table></body></html> ACPG Alberta clinical practice guidelines, AGDH Australian government department of health, AHRQ agency for healthcare research and quality, AQuAS agència de qualitat i avaluació sanitàries de Catalunya, ASCO American society of clinical oncology, BCCA British Columbia cancer agency, CADTH Canadian agency for drugs and technologies in health, CCO cancer care Ontario, CEPO comité de l’évolution des pratiques en oncologie, CoCanCPG coordination of cancer clinical practice guidelines in Europe, COMPAQ-HPST coordination pour la mesure de la performance et l’amélioration de la qualité, hôpital, patient, sécurité, territoire, ESMO European society of medical oncology, GIN guidelines international network, HAS haute autorité de santé, INAHTA international network of agencies for health technology assessment, INCa institut national du cancer, INESSS institut national d’excellence en santé et en services sociaux, KCE centre fédéral d’expertise des soins de santé, MSAC medical services advisory committee, NCCN national comprehensive cancer network, NHMRC national health and medical research council, NHS national health service, NICE national institute for health and care excellence, NZGG New Zealand guidelines group, SIGN Scottish intercollegiate guidelines network.",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# LEVELS OF EVIDENCE <html><body><table><tr><td>1++</td><td>High quality meta-analyses, systematic reviews of randomized controlled trials (RCTs), or RCTs with a very low risk of bias</td></tr><tr><td>1+</td><td>Well conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias</td></tr><tr><td>1-</td><td>Meta-analyses, systematic reviews, or RCTs with a high risk of bias</td></tr><tr><td>2++</td><td>High quality systematic reviews of case control or cohort studies</td></tr><tr><td>2+</td><td>High quality case control or cohort studies with a very low risk of confounding or bias and a high probability that the relationship is causal Well conducted case control or cohort studies with a low risk of confounding or bias and a</td></tr><tr><td>2-</td><td>moderate probability that the relationship is causal Case control or cohort studies with a high risk of confounding or bias and a significant risk that</td></tr><tr><td>3</td><td>the relationship is not causal Non-analytic studies, eg case reports, case series</td></tr><tr><td>4</td><td>Expert opinion</td></tr></table></body></html> # GRADES OF RECOMMENDATIONS A At least one meta-analysis, systematic review, or RCT rated as $^ { 1 + + , }$ and directly applicable to the target population; or A body of evidence consisting principally of studies rated as $^ { 1 + , }$ directly applicable to the target population, and demonstrating overall consistency of results B A body of evidence including studies rated as $^ { 2 + + , }$ directly applicable to the target population, and demonstrating overall consistency of results; or Extrapolated evidence from studies rated as $1 { + } +$ or $^ { 1 + }$ C A body of evidence including studies rated as $^ { 2 + , }$ directly applicable to the target population and demonstrating overall consistency of results; or Extrapolated evidence from studies rates as $^ { 2 + + }$ D Evidence level 3 or 4; or Extrapolated evidence from studies rated as $^ { 2 + }$ # GOOD PRACTICE POINTS Recommended best practice based on the clinical experience of the guideline development group ![](images/bbf1af4172101b6731f963444b371424c5e6e7d8f9042764d7cabaf93ba3ab62.jpg)",
    "source": "CERVICAL CANCERGUIDELINES",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCERGUIDELINES/CERVICAL CANCERGUIDELINES.md"
  },
  {
    "text": "# FIGO GUIDELINES # FIGO staging for carcinoma of the vulva, cervix, and corpus uteri FIGO Committee on Gynecologic Oncology 1 Table 1 Cancer of the vulva.<html><body><table><tr><td>FIGO Stage</td><td>Description</td></tr><tr><td>一</td><td>Tumor confined to the vulva</td></tr><tr><td>IA</td><td>Lesions≤2 cmin size, confined to the vulva or perineum and with stromal invasion≤1.",
    "source": "FIGO staging for carcinoma of the vulva, cervix, and corpus uteri",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/FIGO staging for carcinoma of the vulva, cervix, and corpus uteri/FIGO staging for carcinoma of the vulva, cervix, and corpus uteri.md"
  },
  {
    "text": "0 mm, no nodal metastasis</td></tr><tr><td>IB</td><td>Lesions > 2 cm in size or with stromal invasion>1.0 mm, confined to the vulva or perineum, with negative nodes</td></tr><tr><td></td><td>Tumorfizwittetehfwfinsati</td></tr><tr><td>II</td><td>Tuf</td></tr><tr><td>IIIA</td><td>(i) With 1 lymph node metastasis (≥5 mm), or (i) With 1-2 lymph node metastasis(es) (<5 mm)</td></tr><tr><td>IIB</td><td>(i) With 2 or more lymph node metastases (≥5 m), or</td></tr><tr><td></td><td>(i) With 3 or more lymph node metastases (<5 mm)</td></tr><tr><td>IIIC</td><td>With positivenodes with extracapsular spread.",
    "source": "FIGO staging for carcinoma of the vulva, cervix, and corpus uteri",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/FIGO staging for carcinoma of the vulva, cervix, and corpus uteri/FIGO staging for carcinoma of the vulva, cervix, and corpus uteri.md"
  },
  {
    "text": "</td></tr><tr><td>IV</td><td>Tumor invades other regional (upper 2/3 urethra, upper 2/3 vagina), or distant structures</td></tr><tr><td>IVA</td><td>Tumor invades any of the following:</td></tr><tr><td></td><td>(i) upper urethral and/or vaginal mucosa,bladder mucosa, rectal mucosa, or fixed to pelvic bone, or (ii) fixed or ulcerated inguinofemoral lymph nodes</td></tr><tr><td>IVB</td><td>Any distant metastasis including pelvic lymph nodes</td></tr></table></body></html> a The depth of invasion is defined as the measurement of the tumor from the epithelial–stromal junction of the adjacent most superficial dermal papilla to the deepest point of invasio Table 2 Cancer of the cervix uteri.",
    "source": "FIGO staging for carcinoma of the vulva, cervix, and corpus uteri",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/FIGO staging for carcinoma of the vulva, cervix, and corpus uteri/FIGO staging for carcinoma of the vulva, cervix, and corpus uteri.md"
  },
  {
    "text": "<html><body><table><tr><td>Stage</td><td>Description</td></tr><tr><td></td><td>The carcinoma is strictly confined to the cervix (extension to the uterine corpus should be disregarded).</td></tr><tr><td>IA</td><td>asiveld</td></tr><tr><td></td><td>with a maximum depth of 5 mm?",
    "source": "FIGO staging for carcinoma of the vulva, cervix, and corpus uteri",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/FIGO staging for carcinoma of the vulva, cervix, and corpus uteri/FIGO staging for carcinoma of the vulva, cervix, and corpus uteri.md"
  },
  {
    "text": "and no wider than 7 mm.</td></tr><tr><td>IA1</td><td> Measured invasion of stroma ≤ 3 mm in depth and ≤ 7 mm width.</td></tr><tr><td>IA2</td><td>Measured invasion of stroma > 3 mm and < 5 mm in depth and ≤ 7 mm width.",
    "source": "FIGO staging for carcinoma of the vulva, cervix, and corpus uteri",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/FIGO staging for carcinoma of the vulva, cervix, and corpus uteri/FIGO staging for carcinoma of the vulva, cervix, and corpus uteri.md"
  },
  {
    "text": "</td></tr><tr><td>IB</td><td>Clinical lesions confined to the cervix, or preclinical lesions greater than stage IA.</td></tr><tr><td>IB1</td><td> Clinical lesions no greater than 4 cm in size.</td></tr><tr><td>IB2</td><td> Clinical lesions > 4 cm in size.",
    "source": "FIGO staging for carcinoma of the vulva, cervix, and corpus uteri",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/FIGO staging for carcinoma of the vulva, cervix, and corpus uteri/FIGO staging for carcinoma of the vulva, cervix, and corpus uteri.md"
  },
  {
    "text": "</td></tr><tr><td></td><td>The carcinoma extendsbeyond theuterus, but has not extendd onto the pelvic wall or tothe lower third of vagina.</td></tr><tr><td>IIA</td><td>Involvement of up to the upper 2/3 of the vagina.",
    "source": "FIGO staging for carcinoma of the vulva, cervix, and corpus uteri",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/FIGO staging for carcinoma of the vulva, cervix, and corpus uteri/FIGO staging for carcinoma of the vulva, cervix, and corpus uteri.md"
  },
  {
    "text": "No obvious parametrial involvement.</td></tr><tr><td>IIA1</td><td>Clinically visible lesion < 4 cm</td></tr><tr><td>IIA2 IIB</td><td> Clinically visible lesion > 4 cm</td></tr><tr><td>III</td><td>Obvious parametrial involvement but not onto the pelvic sidewall.",
    "source": "FIGO staging for carcinoma of the vulva, cervix, and corpus uteri",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/FIGO staging for carcinoma of the vulva, cervix, and corpus uteri/FIGO staging for carcinoma of the vulva, cervix, and corpus uteri.md"
  },
  {
    "text": "</td></tr><tr><td></td><td>Tharil thlwefis</td></tr><tr><td>IIIA IIB</td><td>Involvement of the lower vagina but no extension onto pelvic sidewall.</td></tr><tr><td>IV</td><td>Extension onto the pelvic sidewall, or hydronephrosis/non-functioning kidney.",
    "source": "FIGO staging for carcinoma of the vulva, cervix, and corpus uteri",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/FIGO staging for carcinoma of the vulva, cervix, and corpus uteri/FIGO staging for carcinoma of the vulva, cervix, and corpus uteri.md"
  },
  {
    "text": "</td></tr><tr><td></td><td>The carcinoma has extended beyond the true pelvis or has clinically involved the mucoa of thebladder and/or rectu.</td></tr><tr><td>IVA IVB</td><td>Spread to adjacent pelvic organs.",
    "source": "FIGO staging for carcinoma of the vulva, cervix, and corpus uteri",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/FIGO staging for carcinoma of the vulva, cervix, and corpus uteri/FIGO staging for carcinoma of the vulva, cervix, and corpus uteri.md"
  },
  {
    "text": "</td></tr></table></body></html> a The depth of invasion should not be more than 5 mm taken from the base of the epithelium, either surface of glandular, from which it originates.Vascular space invasion should no alter the staging.",
    "source": "FIGO staging for carcinoma of the vulva, cervix, and corpus uteri",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/FIGO staging for carcinoma of the vulva, cervix, and corpus uteri/FIGO staging for carcinoma of the vulva, cervix, and corpus uteri.md"
  },
  {
    "text": "Table 3 Cancer of the corpus uteri.<html><body><table><tr><td colspan=\"2\">FIGOStage</td></tr><tr><td>[</td><td>Tumor confined to the corpus uteri</td></tr><tr><td>IAa</td><td>No or less than half myometrial invasion</td></tr><tr><td>IBa</td><td>Invasion equal to or more than half of the myometrium</td></tr><tr><td>I1a</td><td>Tumor invades cervical stroma, but does not extend beyond the uterusb</td></tr><tr><td>Ia</td><td>Local and/or regional spread of the tumor</td></tr><tr><td>IIIAa</td><td>Tumor invades the serosa of the corpus uteri and/or adnexaec</td></tr><tr><td>IIIBa</td><td>Vaginal involvement and/orparametrialinvolvement</td></tr><tr><td>IICa</td><td>Metastases to pelvic and/or para-aortic lymph nodesc</td></tr><tr><td>IIIC1a</td><td>Positive pelvic nodes</td></tr><tr><td>IIIC2a</td><td>Positive para-aortic nodes with or without positive pelvic lymph nodes</td></tr><tr><td>IVa</td><td>Tumor invades bladder and/or bowel mucosa, and/or distant metastases</td></tr><tr><td>IVAa</td><td>Tumorinvasion ofbladder and/orbowel mucosa</td></tr><tr><td>IVBa</td><td>Distant metastasis, including intra-abdominal metastases and/or inguinal nodes)</td></tr></table></body></html> a Either G1, G2, or G3.b Endocervical glandular involvement only should be considered as Stage I and no longer as Stage II.c Positive cytology has to be reported separately without changing the stage.",
    "source": "FIGO staging for carcinoma of the vulva, cervix, and corpus uteri",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/FIGO staging for carcinoma of the vulva, cervix, and corpus uteri/FIGO staging for carcinoma of the vulva, cervix, and corpus uteri.md"
  },
  {
    "text": "# IA # Human Papillomavirus (HPV) Vaccine Coverage Monitoring Manual World Health Organization Department of Immunization, Vaccines and Biologicals # Human Papillomavirus (HPV) Vaccine Coverage Monitoring Manual World Health Organization Department of Immunization, Vaccines and Biologicals Human papillomavirus (HPV) vaccine coverage monitoring manua ISBN 978-92-4-000274-6 (electronic version) ISBN 978-92-4-000275-3 (print version) $\\circledcirc$ World Health Organization 2020 Some rights reserved.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "This work is available under the Creative Commons Attribution-NonCommercial-Share­ Alike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services.The use of the WHO logo is not permitted.If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO).WHO is not responsible for the content or accuracy of this translation.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "The original English edition shall be the binding and authentic edition”.Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Suggested citation.Human papillomavirus (HPV) vaccine coverage monitoring manual.Geneva: World Health Organization; 2020.Licence: CC BY-NC-SA 3.0 IGO.Cataloguing-in-Publication (CIP) data.CIP data are available at http://apps.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "who.int/iris.Sales, rights and licensing.To purchase WHO publications, see http://apps.who.int/bookorders.To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Third-party materials.If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.General disclaimers.The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.All reasonable precautions have been taken by WHO to verify the information contained in this publication.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "However, the published material is being distributed without warranty of any kind, either expressed or implied.The responsibility for the interpretation and use of the material lies with the reader.In no event shall WHO be liable for damages arising from its use.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Printed in Switzerland # Contents Preface 1 .Introduction 2 1.1 Background on HPV vaccination 3 1.2 Monitoring HPV vaccination coverage: Objectives, data needs and challenges 4 ...Objectives for monitoring HPV vaccination coverage 4 .",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "..Data required to meet these objectives 5 1.3 Considerations for school-based vaccination 6 \u00071.4 \u0007Considerations for continuous (routine) versus periodic (campaign-style) HPV vaccination 8 1.5 Determining denominators for monitoring HPV vaccination 10 # Tools for recording and reporting HPV vaccination 11 2.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "1 Types of data and reporting tools needed 12 ...Required tools 12 ...Data to collect 13 2.2 Tally sheets 14 2.3 Immunization registers 16 2.4 Home-based records 18 2.5 Stock records and wastage monitoring 21 2.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "6 Monthly Summary Reports 22 ...Data to include 22 ...Flow of data up the health system 24 2.7 Tracking doses and defaulters 25 3.Monitoring Coverage 26 3.1 Administrative coverage 27 3.2 Coverage surveys 32 3.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "3 Monitoring drop-out from HPV1 to HPV2 33 4.Final observations 34 Appendix 1.Data collection for HPV vaccination included in the WHO/UNICEF Join Reporting Form (JRF) 37 Appendix 2.Use of a summary indicator of HPV vaccine coverage 38 Appendix 3.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Generating estimates of the target population for HPV vaccination 39 ![](images/19ffe8b43f9afe351ae2a39c19fc9646cf69c9c4035e134b7873b1c01081032e.jpg) # Preface The World Health Organization (WHO) recommends the introduction of the Human Papillomavirus (HPV) vaccine into national immunization schedules as a means to address cervical cancer and other HPV-related diseases.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "The current recommendation is for two doses of HPV vaccine, targeted primarily towards girls aged 9 to 14 years in countries where the prevention of cervical cancer is a public health priority, and the introduction of the vaccine is programmatically and economically feasible.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "All countries should make efforts to monitor and evaluate HPV vaccine delivery, as well as the prevalence of cervical cancer; some countries may also be able to monitor type-specific HPV prevalence.Vaccine coverage information is of utmost importance to guide HPV vaccine strategies and to correctly interpret data on vaccine impact measures.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "However, assessing HPV vaccine coverage presents unique challenges given the different age groups being targeted and the variety of vaccine delivery strategies.This manual focuses on the routine monitoring of HPV vaccine coverage, discussing challenges and options for estimating coverage; which can be done effectively with good technical support and a clear understanding of potential caveats.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "HPV coverage monitoring by survey is discussed briefly as more details are covered in another WHO manual1.Similarly, further guidance on HPV vaccination impact monitoring is available in a separate WHO document2.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Note that, due to potential complexity and resource implications, HPV disease monitoring should not be considered a prerequisite or an essential requirement for an HPV vaccination programme.This manual is most useful when planning to introduce HPV vaccination into a country’s immunization schedule and in the event difficulties are experienced during monitoring its use and estimating coverage.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "It provides generic instructions and guidance on how to approach the routine monitoring of HPV vaccine coverage by vaccine dose and by age, from the vaccine delivery site up to the national level.It outlines the processes of data recording, aggregation and reporting and flags key issues to consider and clarify for this reporting.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Three reporting levels are highlighted for demonstration purposes (i.e., service delivery, district and national).The Manual highlights some of the most common challenges and presents possible solutions.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "The tally sheets, reporting forms, summary tables and other forms presented in this document are for illustration purposes only and should be adapted to suit local needs.Countries that have monitoring systems in place for HPV vaccination do not need to introduce the reporting instruments found in this document but should ensure that their current systems and tools can generate the data required to effectively monitor HPV vaccine coverage.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Introduction ![](images/074fda16f5c296af467c3207c676bfc0db57ffe167476f802af97641bf87a478.jpg) # Background on HPV vaccination Persistent infection with Human Papillomavirus (HPV) is the main cause of cervical cancer, with HPV types 16 and 18 accounting for $70 \\%$ of all cases worldwide.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "The disease burden of cervical cancer is highest among women in low-resource countries.In 2009, the World Health Organization (WHO) recommended that routine HPV vaccination be included in national immunization programmes in countries wherein the prevention of cervical cancer and/or other HPV-related diseases constitutes a public health priority.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Consideration should be given to vaccination cost-effectiveness, programmatic feasibility and sustainable financing.For the prevention of cervical cancer, the primary WHO recommended target group for HPV vaccination is girls aged 9-14 years, prior to becoming sexually active.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Since 2017, WHO also recommends that when HPV vaccine is first introduced, multiple cohorts of girls 9-14 years should be vaccinated.Vaccination of secondary target populations, such as older adolescent females or young women, is recommended only if feasible, affordable, cost-effective, and when resources are not diverted from vaccinating the primary target population or from effective cervical cancer screening programmes.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "HPV vaccination of males is currently not recommended as a priority.3,4 Initially, the recommended schedule included three HPV vaccine doses.This was changed in 2014 to two doses for children who are less than 15 years of age when they receive their first dose.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "The recommended minimum interval between the two doses is six months, and ideally no more than 12 to 15 months, though there is no maximum interval between doses for persons aged 9-14 years.The three-dose schedule is still recommended for HIV positive and immunocompromised persons and for those aged 15 years or more.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "This document focuses on HPV vaccination targeting girls 9-14 years using a two-dose schedule; some of the monitoring tools presented here could be adapted for other target groups and schedules.As of 2020, more than 100 countries had introduced HPV vaccine into their national immunization schedules.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "The most recent data on HPV vaccine use is available at: http://www.who.int/immunization/monitoring_surveillance/en/.While several examples of monitoring tools for HPV vaccination are presented in this manual, additional examples of monitoring tools from countries that have introduced HPV vaccine are available in the HPV section of the TechNet-21 website.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "# Monitoring HPV vaccination coverage: Objectives, data needs and challenges # Objectives for monitoring HPV vaccination coverage The primary purpose for monitoring HPV vaccination coverage at the country level is to monitor the performance of the vaccine programme, track vaccine uptake, and ensure that coverage is maximized and maintained.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Secondary purposes are to estimate the long-term impact of HPV vaccination on morbidity and mortality, demonstrate the vaccine’s effectiveness in real world settings, and understand epidemiologic changes in disease patterns after the vaccine’s introduction.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "This can include identifying changes in the age distribution of the disease or changes in disease-causing strains, as well as assessing herd immunity and long-term immunity.Coverage data are of paramount importance to correctly interpret measures of the vaccine’s impact, especially given that a reduction in cervical cancer incidence cannot be detected for many years after the vaccine has been introduced in a country.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Monitoring HPV vaccine coverage requires a different approach from the one used to monitor routine infant vaccines that are included in the Expanded Programme on Immunization (EPI) and, as such, it presents unique challenges.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "HPV vaccine can target a wide age range and there are several delivery strategies that can be used including school-, community- and health facility-based delivery.In addition, HPV vaccine doses administered in special settings, such as factories, hospitals and in the private sector, may not be routinely captured in the national immunization coverage data.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "The regional and global levels of WHO and other international agencies also need coverage data to assess the performance of country programmes and the impact of the vaccine, as well as to compare and monitor vaccine coverage across geographical areas and trends over time.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Since 2010, the WHO/UNICEF Joint Reporting Form (JRF) on immunization systematically collects information on HPV vaccine doses administered by age and by dose for a given calendar year.5 The JRF spread sheet, which includes female as well as male vaccination (for 2018 data) is shown in Appendix 1.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "# Data required to meet these objectives HPV vaccine coverage monitoring by dose and by age or year of birth is needed for country and international reporting.Date of birth (or an approximation), date of vaccine administration, and dose number should be recorded for every dose administered.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "One rationale for monitoring HPV vaccine by dose and by age or year of birth, as opposed to a broader age group, is that the vaccination targeting or eligibility criteria may change, resulting in challenges to monitor and compare coverage over time.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "This may include situations where catch-up vaccination of older age groups is done in the early years of vaccine introduction.It may also result from revising the eligibility criteria (age or school grade) for vaccination.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "One challenge that may arise in calculating coverage is when eligibility criteria include an age range, for example, when a school grade (class) is being targeted with girls who range in age from 9 to 12 years old.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "This may make it difficult to estimate and interpret coverage levels for the different ages separately.In this case, a school grade may be assigned a single age as a proxy for a single age cohort, though this is not preferred.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "For example, if vaccination is done in $6 ^ { \\mathrm { { t h } } }$ grade, for practical reasons, the data can be attributed to girls aged 11 years, even if in $6 ^ { \\mathrm { { t h } } }$ grade there are also girls who are 10, 12 and above.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "A summary indicator (the proportion of girls vaccinated with the complete series of HPV doses by age 15) to resolve this issue is presented in Appendix 2.As per WHO recommendations, this is the age by which all girls should have received the HPV vaccine.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "This summary indicator – similar to DPT3 coverage for infants – can be used to calculate in-country coverage when eligibility criteria include multiple age cohorts within a school grade-based vaccination approach, or when HPV vaccine introduction targets multiple age cohorts.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Countries may also want to monitor HPV vaccine coverage by delivery strategy in order to guide programme strategies.In this case, data on the delivery strategy (e.g., schoolbased outreach, community-based outreach, periodic campaigns, health facility-based) should also be collected.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Finally, as it will be discussed later in the document, the denominator to calculate coverage should be the total number of girls in a given geographic region by age.For example, a denominator based on the number of girls enrolled in school would not provide coverage data for the entire target population in a given community as it may exclude girls not attending school.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "“Date of birth, date of vaccine administration, and dose number should be recorded for every dose administered.” # Considerations for school-based vaccination There are special considerations and potential challenges for monitoring HPV vaccine coverage when a school-based vaccination strategy is used.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "While school grades are often used as a proxy for age for school-based immunization programmes, it is strongly recommended that vaccination data be recorded by year of birth or age, and dose, even when the vaccine is delivered by school grade.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Compared to age, the year of birth for each girl vaccinated can result in more accurate data, since it accounts for the following: \u0007The range of ages present in a single school grade which could include ages for which the HPV vaccine is not licenced (e.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "g., girls in fourth grade who are less than 9 years old); I\u0007n that girls can begin and complete the vaccination series over an age range, it is easier to follow a given birth cohort over time and estimate its cumulative coverage; \u0007Changes in the recommended school grade to target for HPV vaccination, especially if older girls tend to be in the grade initially targeted; \u0007To produce coverage data for the entire targeted population of girls, the ability to combine the number of girls vaccinated in schools and the number of girls absent from or not enrolled in school vaccinated through other delivery strategies (e.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "g., outreach, health centres).Of note: alternative strategies should be considered in cases wherein accurate dates of birth and age may be difficult to obtain, may not be well documented or culturally unimportant (see Section 2.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "1).“It is strongly recommended that vaccination data be recorded by year of birth or age, and dose, even when the vaccine is delivered by school grade.” Other challenges and special considerations for monitoring school-based vaccination coverage include: School year crosses over the reporting year.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "The school year may not align with the calendar reporting year.For example, the school year may start in September while the reporting year for immunization programmes usually begins in January.This can lead to variations in reporting HPV coverage.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Immunization programmes should consider this at the start of HPV vaccination and decide how the data will be collected.However, over time, given the similar size of age cohorts, the estimate of HPV coverage should become an adequate approximation, as for other infant vaccines.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "6 Deciding what to use for the denominators.Even when the main delivery strategy is school-based, monitoring HPV vaccine coverage should include vulnerable populations that may not attend school.The denominator, therefore, should include all girls eligible for HPV vaccination.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "See Section 1.5.![](images/9526e4b7cf361fc5ce8c504a6cc1bad9c53f10eb99e14c8edb4768c904e6b12d.jpg) # Challenges in correctly recording school-based HPV vaccination When vaccination takes place in schools, countries may target girls either by age or by grade.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "A coun­ try may establish a defined age for starting the HPV vaccination series, but the next dose may be given when the girl has already had her next birthday (e.g., HPV1 at 11 years and HPV2 at 12 years).",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Similarly, when the school year stretches over two calendar years, the first dose may be given during one calendar year and the second during the next (e.g., HPV1 in 2014 and HPV2 in 2015).Thus the doses reported for a calendar year may reflect the vaccination of different cohorts of girls.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Without a clear definition or guidance on how to collect and report HPV vaccine data, the resulting “number of doses administered” may be difficult to interpret.These challenges in reporting the numerators (number of doses) are in addition to the challenges discussed in this guide in accurately quantifying the population to be used as denominator for HPV vaccination.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "7 # Considerations for continuous (routine) versus periodic (campaign-style) HPV vaccination Different ways of delivering HPV vaccine may affect the design of the HPV vaccination reporting system.\u0007HPV vaccines delivered on a continuous basis (“routinely”) throughout the year like other childhood vaccines.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Girls who reach the defined eligible age (e.g., 12 years) go to the health facility and receive the first dose (HPV1).This strategy results in HPV vaccine being available and delivered throughout the year.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "In this situation, data on HPV vaccination flow through the country’s reporting system on a continuous basis, making it easier to integrate HPV monitoring with the monitoring of other routine vaccines or other health interventions.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "With contin­ uous vaccination, as for other vaccines, the annual target for HPV can be divided in 12 monthly targets to monitor the cumulative vaccination coverage by dose and by month.\u0007HPV vaccines delivered periodically in rounds, or “pulse campaign” style.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "In this scenario, a given period is established for delivering and receiving the first and second vaccine doses as separate “rounds”.When schools are used to deliver HPV vaccine, the timing often coincides with appropriate moments in the school calendar year, and the same period is used to vaccinate girls who do not attend school.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "For example, the first dose may be scheduled for the beginning of the school year (e.g., September or October in many countries), and the second dose towards the end of the school year (e.g., April or May).",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "In this case, the flow of HPV vaccination data will not be continuous.It will instead take place only during the months in which first and second dose are delivered, and the two vaccination “rounds” may fall in different reporting years.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Immunization registers and home-based records to track individual vaccination status become very important to determine who is due for a second dose in each round (see Sections 2.3 and 2.4).Also, it is important to note that the total target population will be used as the denominator to calculate coverage for each round.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "“While recognizing that a mix of delivery strategies for HPV vaccination exists, the rest of this document focuses on the design and use of a monitoring system that is based on the routine delivery of the vaccine in health facilities, given than several developing countries are using this strategy.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "” ![](images/202fcec7b291cc4e657f5603d28c12f14dd7893cf7faf846e6ac820cbe2d536a.jpg) \u0007A note about reporting by round instead of by calendar year: A monitoring system that reports HPV vaccination by round has advantages and disadvantages.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "One advantage is that it may align the reporting of HPV vaccination with that of other vaccines targeting school-aged children, such as tetanus-diphtheria-containing vaccines, or other school-based health interventions such as deworming.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "In this case, reporting can be integrated with these other vaccines and health interventions.Among the disadvantages, creating HPV vaccination forms that record and report by round may introduce a parallel reporting system (e.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "g., a new tally or reporting sheet), making it harder to integrate HPV vaccination data into the monitoring system for other childhood vaccines.It is important not to equate the first round of vaccination with the first dose of HPV vaccine.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Every round of vaccination is an opportunity for girls to receive a first or a second dose of HPV vaccine, and should thus be considered an opportunity to vaccinate any girl who was missed earlier or has not yet been fully vaccinated.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Monitoring forms should be designed to enable the delivery and recording of both HPV1 and HPV2.# Determining denominators for monitoring HPV vaccination As noted earlier, identifying accurate denominators for HPV vaccination poses challenges.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "The denominator for HPV vaccination differs from the one used for infant and childhood vaccination, being dependent on the eligibility criteria for the HPV vaccine.A country that chooses “all 12 year-old girls or girls born in year $\\mathsf { X } ^ { \\prime \\prime }$ to be eligible for vaccination may be able to obtain an estimate from the National Statistics Office for that single age cohort or use available United Nations population estimates or will have to estimate them (see appendix 3).",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "When the eligibility criteria include a population attending a specific class or grade, such as “Primary Grade $5 , \"$ then the Statistics Office may not be an adequate source for this information and data will need to be collected from the Ministry of Education.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Experiences from several countries, especially from low-income countries with rapidly improving enrol­ ment rates for girls, indicate the need to verify enrolment data with actual attendance in school through enumeration, i.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "e., head-counts.Challenges that have arisen include the fact that some schools, often private schools, have not yet been registered with the Ministry of Education, and enrolment numbers do not always match actual school attendance, among others.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Several countries have used field identification of every school and pre-registration of each eligible girl during the weeks preceding the vaccination as a way to establish more accurate denominators, especially when the vaccination has just been introduced.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Estimating the denominator can be particularly challenging when a country uses eligibility criteria that combine a grade with an age target for out-of-school girls.For example, “All girls in school attending Primary Grade 5 and 10 year-old girls not attending school” can be used as a proxy for the denominator of a single age cohort.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "In these cases, establishing the size of the out-of-school target population can be difficult.In some settings, Ministries of Education may be a good source of information on the size of the out-of-school population.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Also, some countries have conducted pre-registration activities to identify and count eligible girls not attending school, using village health workers or community organizations.WHO, in collaboration with UNESCO, has developed reports for Gavi-eligible countries8 that provide estimates on out-of-school populations.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "9 Experience in several countries has shown that denominator data for HPV coverage calculation are often less readily available and sometimes less accurate than data for younger children.The accuracy of target population estimates at the subnational level can be problematic.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "For example, they can be affected by population movements, including migration of adolescents from rural to urban areas for work or education (e.g., boarding at secondary and private schools).While no good solutions exist for better estimating target populations for HPV vaccination, having these challenges in mind will help better interpret coverage data.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "![](images/4f5137c026ec558e4e4dacb93a755e9fc4f15ac967cba7ea041d7520061159ef.jpg) Tools for recording and reporting HPV vaccination ![](images/100d1170efe70698e423b8dddc2cc2e37bf30b2ad33a30d4335c89e047036fb4.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "jpg) # Types of data and reporting tools needed # Required tools When introducing HPV vaccine, the existing recording tools used for immunization activities should be either adapted to include HPV vaccination, or new forms and data flows may be needed.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "The latter may be the case in settings where other vaccines or interventions targeting the same or a similar age group (e.g., young girls) do not exist.If a country uses an electronic aggregated information system, such as a health management information system (HMIS), or and electronic immunization registry that captures individual immunization data, it will be important to update these to include HPV vaccination.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "The main recording and reporting tools that will need to be adapted or created for HPV vaccination include: ![](images/e7fa4851b67ad5b4033e460aa4a5ec38a226d5188f5ed581ba777aadfe8d4b9d.jpg) ![](images/5d0e0b69be6b077040bf72c45bc6a9b1a47734e55763f7d94ac5585c51a3fd1a.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "jpg) ![](images/18811fbe51097c771bd86817182aa141761229b30302d39294fe9489777bebb9.jpg) Tally sheets Immunization registers Home-based records10 ![](images/44537d05620e6cfe998ee09162aac48e39fe7b29c89a56f571602da3c455fb06.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "jpg) ![](images/66803d3a53149bf162e448d67105d4650ef8abcd0c431c526383fadcb816d9f8.jpg) ![](images/83968528be59799427cd6b17460ec6fcf1a76381b029cce1b60b618e9166f1da.jpg) # Stock records for vaccines and related supplies Monthly summary reports Monitoring charts The tools will need to be designed based on the vaccination strategy in the country.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "For example, different tools will be needed if vaccination is done at health facilities continuously, or periodically at schools.# Data to collect Decisions must be made about the types of information and performance indicators that will be used to monitor HPV vaccination performance and guide action.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "This will serve as the basis for determining the data requirements.In this manual we focus on the minimum requirements needed to calculate HPV vaccination coverage and drop-out rates, i.e., sex, date/year of birth or age, date of vaccine administration, and dose number.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "The immunization records should be modified to include a space for entering the date of HPV vaccine administration and to allow disaggregation by sex, if HPV vaccination is offered to females and males, by age and dose.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "In settings where age is not always known, the country may have to decide whether to create an age category of “unknown” to record, and then report and aggregate, doses given to girls whose exact age is not known, but which likely is within the target age group for HPV vaccination.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "It may be preferable to instruct vaccinators to estimate, based on available information, the girls likely age, as doses reported in an unknown age category are likely to be disregarded in national reporting and in estimating global coverage data, since as no denominator can be assigned to this category.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "In some of the examples below the “unknown” category is not used.For school vaccination, the name of the school and grade level should also be routinely recorded to ensure that all eligible schools have been enumerated and included in the aggregated reports.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "In settings where other interventions or other vaccines, such as tetanus-diphtheria (Td), are already targeting a similar age group, HPV vaccine should be added to the existing data collection forms to reduce the reporting burden of health workers.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Forms should be designed with the vaccinator in mind (using user-centered design approaches11) and piloted before their printing and widespread use.Finally, it is good practice to always include the date or version of the data recording and reporting tools on the form, in order to monitor and avoid the use of outdated forms, which can create problems for monitoring.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "![](images/1263e71c59528048ccc7466a67ae9d16ec586acab13cff822ec4b6733f76ae62.jpg) It may be preferable to instruct vaccinator to estimate the girls’ likely age, based on available information, than to report these doses in the category “unknown age” !",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "[](images/95c36466069a0a84e1bba6763802bd38803da1d42981d7ea34332233e9559b7b.jpg) # Tally sheets Tally sheets or tally booklets are the forms that health workers use to document an immunization session by making a record of every dose of vaccine administered.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "They are used to enumerate doses administered at the time of vaccination, and each vaccination should therefore be marked (“tallied”) immediately following its administration.Tally sheets are often completed at the same time as the immuni­ zation register (see Section 2.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "3 below).Tally sheets can be kept by session or by month.They are useful because, unlike an immunization register, they make it easy to rapidly sum up the doses administered for preparing summary reports or monthly reports (see Section 2.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "6 below).Tally sheets should be used for all HPV vaccinations, whether at the health centre, fixed outreach site, school, or when conducted by mobile teams.It is recommended that the HPV vaccine tally sheet track the doses given by school and grade, dose number (1 or 2), age (which is particularly important if using a school class or grade as the target population), and sex (in case males and females are targeted or when the tally is integrated with other vaccines such as Td).",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "There are a variety of tally sheet designs (with , IIII, zeros or circles as tally marks), most of them are preprinted.If preprinted sheets are not used, all vaccinators in a health facility should use the same type of tally mark to make it easier to count the totals.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Tally sheets can also be useful in tracking vaccine doses that are wasted.# Completing the tally sheets 1.\u0007Fill out one sheet for each vaccination day.2.\u0007Write the date.3.\u0007Write down the geographical/ administrative area and the service delivery site (which can also be the school and grade).",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "4.\u0007Mark the tally sheet for each dose received in the appropriate category (and sex, if vaccine is also offered to boys), right after the dose is given.5.\u0007At the end of each immunization session, add up the number of marks recorded during the session.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "This gives the total number of immunizations given for each dose, i.e., HPV1 and HPV2.6.\u0007At the end of the reporting period (usually month), total all doses given by age to complete the monthly report.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Note that this step does not apply for HPV vaccines given in vaccination rounds.7.\u0007Keep the tally sheets for the supervisor to review.Archive them safely and in an orderly manner and keep for as long as required in the country (usually 3-5 years).",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Avoid these common mistakes in tallying the vaccine doses: \u0007Tallying before the vaccination is given, as the person may not receive the vaccination (if, for example, the vaccine runs out or the person or parent/caregiver refuses); \u0007Filling out the sheet at the end of a session based on the number of doses contained in the used vials, since wasted doses may be counted; \u0007Marking vaccinations under the wrong dose or age (or birth year).",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "This will result in inaccurate coverage data.As this process might be new for some national immunization programmes, it is advised that standard operating procedures (SOPs) be developed and that health worker trainings conducted prior to the introduction of HPV vaccine carefully review the proper method for using the HPV vaccine tally sheet.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "It is also worthwhile for supervisors to routinely spend time reviewing tally sheets with staff, in order to improve the quality of reporting.Below are two examples of tally sheets for HPV vaccination – one using the child’s age and the other, the year of birth.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "District: Town/Village Service Delivery Site: Example 1: Tally sheet, using age in years <html><body><table><tr><td>Age (years)</td><td colspan=\"2\">No.of HPV1 doses given</td><td colspan=\"2\">No.of HPV2 doses given</td><td>Optional Check Column (sum up rows)</td></tr><tr><td>9</td><td>00000 00 0 00000</td><td>9yrHPV1= 8</td><td>00000 00000 0 00 00000 00000</td><td>9yrHPV2= 10</td><td></td></tr><tr><td>10</td><td>00000 00000 00000 00000 00000 00000 00000</td><td>10yrHPV1= 0</td><td>00000 00000 00000 00000 00000 00000</td><td>10yrHPV2= 15 </td><td></td></tr><tr><td>11</td><td>00000 00000 00000 00000 00000 00000 00000</td><td>11yrHPV1=</td><td>00000 00000 00000 00000 00000 00000 00000</td><td>11yrHPV2=</td><td></td></tr><tr><td>12</td><td>00000 00000 00000 00000 00000 00000 00000 00000</td><td>12yrHPV1=</td><td>00000 00000 00000 00000 00000 00000 00000</td><td>12yrHPV2=</td><td></td></tr><tr><td>13</td><td>00000 00000 00000 00000 00000 00000 00000</td><td>13yrHPV1=</td><td>00000 0000 00000 00000 00000 00000 00000 00000</td><td>13yrHPV2=</td><td></td></tr><tr><td>14</td><td>00000 00000 00000 00000 00000 00000</td><td>14yrHPV1=</td><td>00000 00000 00000 00000 00000 00000</td><td>14yrHPV2=</td><td></td></tr><tr><td>≥15</td><td>00000 00000 00000 00000 00000 00000 00000 00000</td><td>15yrHPV1=</td><td>00000 00000 00000 00000 00000 00000 00000 00000</td><td>15yrHPV2=</td><td></td></tr><tr><td colspan=\"2\">Optional Check row (sum up columns)</td><td></td><td></td><td>=</td><td>Grand total=</td></tr></table></body></html> District: Town/Village Service Delivery Site: Example 2: Tally sheet, using birth year <html><body><table><tr><td>Birth year</td><td colspan=\"2\">No.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "of HPV1 doses given</td><td colspan=\"2\">No.of HPV2 doses given</td><td>Optional Check Column (sum up rows)</td></tr><tr><td>2009</td><td>00000 00000 00 00000 00000</td><td>9yrHPV1= 8</td><td>00000 00000 00 0.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "0 00000 00000</td><td>9yrHPV2= 10</td><td></td></tr><tr><td>2008</td><td>00000 00000 00 00000 00000</td><td>10yrHPV1= 0</td><td>0000 00000 09 00000 00000</td><td>10yrHPV2= 15 </td><td></td></tr><tr><td>2007</td><td>00000 0000 00000 00000 00000 00000 00000 00000</td><td>11yrHPV1=</td><td>0000 0000 00000 00000 00000 00000 00000</td><td>11yrHPV2=</td><td></td></tr><tr><td>.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": ".(add years)</td><td>00000 00000 00 00</td><td>(.) yrHPV1=</td><td>00000 00000 00 0 00000</td><td>(..) yrHPV2=</td><td></td></tr><tr><td>2003</td><td>0000 00000 00000 00000 00000 00000 00000</td><td>15yrHPV1=</td><td>00000 0000 00000 00000 00000 00000 00000</td><td>15yrHPV2=</td><td></td></tr><tr><td colspan=\"2\">Optional Check row (sum up columns)</td><td></td><td></td><td></td><td>Grand total=</td></tr></table></body></html> # Immunization registers # 2.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "3 Immunization registers record doses given to an individual and help health workers keep track of each dose that has been administered to each person.It is the basis for determining a person’s immunization status, if, for example, her home-based record, such as an immuni­ zation card, is lost, as well as for tracking defaulters.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "12 Most often immunization registers are organized as books in which individuals are registered in a line listing according to date of birth, some identifier (e.g., national ID number, health ID) or even barcodes linked to the home-based record, or the date of the person’s first visit for an immunization included in the register.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "In well-organized registers, when the person comes back, it is usually quite easy to locate and update her record with the next vaccine dose.In paperbased registers, it is unlikely that the same register that is available for early childhood vaccination is available for vaccinations given to older children and adolescents and thus, new registers for older persons may need to be established.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "# Completing the immunization register for HPV If the register includes addresses and/ or other contact information, such as a mobile phone number, then it can be used to actively find individuals who are overdue for their vaccinations.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "1.\u0007Identify the geographical/administrative area and the service delivery site or school, where appropriate.2.\u0007Register the person’s name, sex (in case males and females are targeted or when the registry is integrated with other vaccines such as Td), address and phone number, and date of birth.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "3.\u0007Write the date for each vaccine adminis­ tered in the column corresponding to the dose number (HPV1 or HPV2), as well as the age of the person at the time the vaccine is given.Enter the age that is reported by the person, the parent/ caregiver or teacher)13.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "4.\u0007Write down any other data of relevance to the immunization programme, such as adverse events or a vaccine contraindica­ tion in the Comment column).5.\u0007When a girl returns for the second dose of HPV, ask for the home-based record (e.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "g., immunization card) and look for a corresponding entry in the register.If the home-based record is not available, ask for the person’s name, age and the month and/or other details of the first immunization, then locate her line in the register.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Once the information is located in the immunization register, verify her eligibility for HPV2.6.\u0007Keep the immunization registers safe and stored in an orderly manner and for as long as required by the country (usually 3-5 years).",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Please note that a new entry in the register should not be created each time a girl comes to a clinic for the immunization or a session is held in the school, unless the girl received the first dose in another facility.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "In such cases, the register can be updated based on the infor­ mation available in the home-based record.For school vaccination, establishing school registers, which may or may not be by grade or age, may be useful.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Such registers should be similar in content to immunization registers used by health facilities, but they are organized by school instead of by health facility.Since there will always be girls who miss the second dose, even if given in the same school year, the registers or other similar tools should allow their easy identification to ensure follow-up.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "An example, is to check for unvaccinated girls in higher grades to see if mop-up vaccination is needed.# Example 1: Immunization register for HPV District: Town/Village Service Delivery Site: <html><body><table><tr><td>ID</td><td>Name</td><td>Address and phone number</td><td>Date of birth (dd/mm/yyy) Date given</td><td>HPV1</td><td>Age of girl</td><td>HPV2</td><td>Comments Age of girl</td></tr><tr><td></td><td></td><td></td><td></td><td>(dd/mm/yyy) (years)</td><td></td><td>Date given (dd/mm/yy) (years)</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table></body></html> !",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "[](images/6cc5cb2575cfd4d3f2226db36743a4c34fd31e0829134aae74d5951c9ae477cf.jpg) Example 2: Human Papillomavirus vaccination register South Africa uses a written consent form that pupils have signed at home before vaccination hence the register includes a column to register whether consent is provided.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "According to the WHO guidance note on consent, consenting practices differ between countries and many counties use implicit consent approaches in which case this column would not be needed.WHO recommends that the consent procedure for HPV vaccination follows the same process as for other vaccines as a way to encourage uptake.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Link: https://www.who.int/immunization/programmes_systems/policies_strategies/consent_note/en/) ![](images/a13daa24be603226bd86d85a3ed43a62d4afbf75d8d289a6e9dddfc577e4eb69.jpg) # Home-based records Home-based immunization or health records are cards or booklets that are given to the child or her parent or caregiver.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Home-based records (HBRs), which are easily modified to include HPV vaccination, keep track of all vaccinations provided and often other health interventions as well.There a several uses and advantages of HBRs, including that they: \u0007Enable health workers to determine which doses are due; \u0007Serve as a reminder for the next visit/dose; Facilitate coverage surveys; \u0007Serve as documented proof of immu­ nization status if required for school enrolment or for other reasons e.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "g., for cervical cancer screening later in life); \u0007Serve as a communication tool with the child and parents, if the card includes information about the vaccines and their recommended schedule, including when to go back for a subsequent dose.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "The style and functionality of home-based records differ from country to country.Examples of vaccination cards for HPV are shown below and included in the WHO guidance document on home-based records (See Key Resource box below).",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "In addition, a repository with samples from around the world can be found online14 and specific examples of HBRs, including ones for HPV, are available on the TechNet-21 website (https://www.technet-21.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "org/en/topics/hpv).# Completing home-based records for HPV vaccination ![](images/afb119fd2cbc127abd58e5a72b25caa818db53247fc2357951f536035ba42de6.jpg) 1.\u0007Clearly write the name of the girl and all other general information required in the card.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "2.\u0007Clearly write the date for each vaccine administered in its corre­ sponding section on the card.3.\u0007After HPV1, indicate the date for the second dose of HPV on the card, following the country schedule, and ensure that the girl and/or parent/ caregiver understands when and where to return for HPV2.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "4.\u0007Use the HBR to identify the girl in the immunization register, or to update the register if needed (see Section 2.3 above).5.\u0007Return the immunization card to the girl or parent/caregiver.A copy may also be kept in the school.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "6.\u0007Explain that the immunization card must be kept in good condition, safe and in a dry place, and that it should be brought for future health care visits, particularly to receive the second HPV dose.7.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "\u0007Remind the caregiver or the girl herself that the card should be taken to all of health care visits for review.# Example 1: comprehensive adolescent health card, including information on other health interventions (eg.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Nutrition) and other vaccines besides HPV — Mexico ![](images/f5d73f25791899071c749c8dfb353722585376d385e210fe9af0b6841427bb39.jpg) # Example 2: a dedicated HPV card including messages on cervical cancer and vaccination HP—V Zccinatimon Cbarda_HbPVwVaccein ti2on0Car1d 287/ !",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "[](images/8784a489f60c044442a84484e5016449bf258ec16c4eae2ef23382b814ea1574.jpg) ![](images/d80648dff08509f9b1ef4d761c5d989b0dfb905594b1a23159461292b2dad335.jpg) ![](images/e987f23e0039d35b07a5a9cc1118daad37d8524548b1c647b691407028240492.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "jpg) Cervical Cancer Prevention is everyone's responsibility.Get girls vaccinated against HPV!!!![](images/08bdf59062baf7449c4747f8b0f247c122b5ab5e22ab1de96cbf9f43014b505c.jpg) # LEARNER INFORMATION FOR OFFICIAL USE ONLY continued <html><body><table><tr><td>In the past, did the girl have:</td><td>Yes / No</td><td></td></tr><tr><td>An allergic reaction to a vaccine?",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "</td><td></td><td>NO</td></tr><tr><td>A severe illness in the last 7 days?</td><td></td><td>NO</td></tr><tr><td rowspan=\"3\">Completed by vaccinator</td><td colspan=\"2\">Dose1</td></tr><tr><td>YES No</td><td></td></tr><tr><td>Dose2</td><td></td></tr><tr><td></td><td>YESNO</td><td></td></tr></table></body></html> <html><body><table><tr><td>Dose</td><td>Batch No.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "</td><td>Date</td><td>Signature of vaccinator</td></tr><tr><td>HPV1</td><td></td><td></td><td></td></tr><tr><td>HPV 2</td><td></td><td></td><td></td></tr></table></body></html> <html><body><table><tr><td colspan=\"2\">Date of the next HPV vaccination</td></tr><tr><td></td><td>HPV2</td></tr></table></body></html> Notes !",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "[](images/2d742b7348a3ffdac5d5c0c2f0f49fffb71372c4478397243ce7bb571318cfdf.jpg) # KEY RESOURCE \u0007Practical guide for the design, use and promotion of home-based records in immunization programmes \u0007This document provides guidance to national immunization programmes on how to improve the design of home-based records and how to promote their use among health workers and caregivers.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "\u0007http://www.who.int/immunization/monitoring_ surveillance/routine/homebasedrecords/en/ To avoid missing any opportunity to vaccinate with HPV, health workers should get in the habit of asking for and reviewing home-based records for adolescent girls at each visit, regardless of the reason for coming.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "In some cases when HPV is delivered through schools, the vaccination card will be kept at school and given to take home only after both doses have been administered.In other cases, a separate school health record will be maintained serving a similar function as the immunization record kept at health facilities.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Nevertheless, as girls may change school or seek vaccination elsewhere the home-based record should always be given so that the person can carry her record.While it is always desirable to have an immunization card that includes vaccinations over a lifetime, following the “life-course” approach towards immunization, it is recognized that many countries use vaccination cards only for childhood vaccinations.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "In these cases, it will be necessary to create a new vaccination card for adolescent vaccinations that includes HPV.Even if HPV is the only vaccine currently administered to this age group, it may make sense to include options for other vaccines that can be added (e.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "g.Td).# Stock records and wastage monitoring Stock records or ledgers are books used to record all stock transactions (receipts, dispatches, physical stock counts, and spoilage) for all vaccines, including HPV, and related supplies (e.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "g., syringes) and to keep a running balance of the number of available doses by product and lot number (see the vaccine stock manage­ ment guidelines).15 Monthly stock reports are needed to ensure adequate supplies and avoid stock-outs.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "The same function is performed by bin cards or inventory control cards, which are often kept at the refrigerator or cold room.Below is a sample a health centre stock report, which provides an estimated monthly consumption requirement based on expected vaccination activities.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "The vaccine consumption figures in these records should correlate with the total number of doses used at immunization sessions held during the month.Each health centre should then report these figures according to national guidelines.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Stock report data may also be added to the monthly summary report (see Section 2.6 below) Example: Vaccine and Injection Materials Stock Register <html><body><table><tr><td>Received</td><td></td><td></td><td></td></tr><tr><td>Date</td><td></td><td></td><td></td></tr><tr><td>Name in Unit</td><td></td><td></td><td></td></tr><tr><td>Stock at hand</td><td></td><td></td><td></td></tr><tr><td>Doses received</td><td></td><td></td><td></td></tr><tr><td>Batch number</td><td></td><td></td><td></td></tr><tr><td>Expiry Date</td><td></td><td></td><td></td></tr></table></body></html> <html><body><table><tr><td>Issued</td><td></td><td></td><td></td></tr><tr><td>Doses issued</td><td></td><td></td><td></td></tr><tr><td>Batch number</td><td></td><td></td><td></td></tr><tr><td>Expiry date</td><td></td><td></td><td></td></tr><tr><td>Doses used</td><td></td><td></td><td></td></tr><tr><td>Doses wasted</td><td></td><td></td><td></td></tr><tr><td>Doses returned</td><td></td><td></td><td></td></tr><tr><td>Total balance</td><td></td><td></td><td></td></tr></table></body></html> <html><body><table><tr><td>Remarks</td></tr><tr><td></td></tr><tr><td></td></tr></table></body></html> # Monthly Summary Reports # Data to include The monthly immunization report contains critical data on most of the components of the immunization system in summary format for both easy recording and easy tracking.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "It is a valuable tool for managing the programme’s achievements and to monitor progress throughout the year.In general, an integrated monthly report that contains summary data on all immu­ nization, should contain the following elements with regards to HPV vaccination: \u0007The number of HPV1 and HPV2 doses by age or year of birth administered in the month (and by sex if males are also targeted); \u0007Stocks received and used, including vaccines and injection equipment, and wastage; \u0007The number of adverse events following immunization (AEFI) reported or identified.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Below are examples of the HPV section of monthly reports – it should be decided if the report will be by age or by year of birth.![](images/758a126b0e30bd4d34986e23f6b2a6c22e4808fed27b0ccc41fe892d29402ebb.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "jpg) # Quality checking of the reports Quality checking of reporting needs to happen at all levels of the health system, starting with health workers, and then up the chain to supervisors, district managers up to national immunization programme staff.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "# Reports should be: 1.\u0007Complete.All sections of the summary reports should be filled in and no parts left blank.All reports due from different services and/or outreach sites should be received and their data included in the summary report.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "2.\u0007Submitted in a timely fashion.All summary reports should be submitted to the next level by the assigned deadline.A standard procedure must be defined to deal with delayed reporting.3.\u0007Accurate.All summary reports should contain figures that correspond to the actual figures from health facilities.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "These figures should be double-checked to ensure that the calculations and totals are correct.# Example 1: Monthly report by age in years District: Town/Village: Service delivery site: Vaccination strategy: <html><body><table><tr><td>Year of birth/ Age</td><td colspan=\"6\">No.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "of HPV1 doses given</td><td colspan=\"5\">No.of HPV2 doses given</td><td rowspan=\"2\">Comments</td></tr><tr><td rowspan=\"2\">2009/ 9 years</td><td colspan=\"6\">9yrHPV1:</td><td colspan=\"5\">9yrHPV2:</td></tr><tr><td>8</td><td></td><td></td><td></td><td></td><td>Total </td><td>10</td><td></td><td></td><td></td><td></td><td>Total </td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=\"3\">2008/ 10 years</td><td colspan=\"6\"></td><td colspan=\"5\">10yrHPV2:</td><td></td></tr><tr><td>10yrHPV1:</td><td></td><td></td><td></td><td></td><td></td><td>15</td><td></td><td></td><td></td><td></td><td rowspan=\"2\"></td></tr><tr><td>0</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=\"2\">2007/ 11 years</td><td colspan=\"6\"></td><td colspan=\"5\">11yrHPV2:</td><td></td><td rowspan=\"2\"></td></tr><tr><td>11yrHPV1:</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=\"2\">2006/</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td rowspan=\"2\"></td></tr><tr><td>12yrHPV1:</td><td></td><td></td><td></td><td></td><td></td><td>12yrHPV2:</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=\"2\">12 years</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=\"2\">2005/ 13 years</td><td>13yrHPV1:</td><td></td><td></td><td></td><td></td><td></td><td>13yrHPV2:</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=\"3\">2004/ 14 years</td><td>14yrHPV1:</td><td></td><td></td><td></td><td></td><td></td><td></td><td>14yrHPV2:</td><td></td><td></td><td></td><td></td><td></td><td rowspan=\"3\"></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=\"3\">2003 or earlier/ 15 + years</td><td>15yrHPV1:</td><td></td><td></td><td></td><td></td><td></td><td></td><td>15yrHPV2:</td><td></td><td></td><td></td><td></td><td></td><td rowspan=\"3\"></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table></body></html> Completeness and timeliness of reporting refer to (1) the level to which facility data is aggregated (i.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "e., usually a district); (2) receiving all reports expected and by a set date; (3) and whether HPV vaccines were administered or not.These can be useful indicators for measuring the performance of the information system.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Completeness requires mecha­ nisms to ensure that all providers who administer HPV vaccines report all doses given.As with tally sheets and registers, supervisors must carefully check monthly report forms systematically.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "If the HPV vaccine delivery strategy is periodic vaccination only, for example every 6 months or annually and not continuously throughout the year, then “zero” reporting will be necessary for the months when HPV vaccine is not given.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Alternatively, summary reports may be used to quantify HPV doses by age or birth year (and by school and grade, where appropriate) for only those months when the vaccine is provided.# Flow of data up the health system Monthly reports should be submitted by all health facilities providing HPV vaccination, noting the delivery strategy used (health facility, school, outreach).",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Health facilities will follow their normal reporting procedures.Copies of reports with dates and signatures are usually sent to the next level (e.g., district, province) and the originals stored at the health facility (Figure 1).",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "The reports should be archived in an orderly manner for as long as required by the country (usually 3-5 years).It will be important to ensure that private and other non-public providers are integrated into the existing reporting structure and data flow.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "![](images/15787464c6abae83cd5979bc6df5a040dada47c7cc8aee25c97c8bbb752a930d.jpg) Figure 1.Examples of vaccination data flow using health management information systems.The exception to this type of data flow is the Electronic Immunization Registry (EIR)16.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "In these systems, the immunization records of each person are maintained in an electronic database, and all the data needed for monitoring can be extracted from this database at any time, including monthly reports if they are set to do so.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "# Tracking doses and defaulters As with other vaccinations, it is important to follow-up eligible girls who fail to present for either the first or second dose of HPV vaccine.A system to track dropouts is an integral part of the Reach Every District (RED) or Reach Every Community (REC) strategy.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "17 There are a number of tools to identify, track and follow up persons due for vaccination or “drop outs”.These include: ![](images/fb94ce6cd7f28dd3d7996674d31cd1218d8e54fb24bee66befb34f67b346cc66.jpg) (i) \u0007The immunization register.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Regularly review the immunization register to identify girls who may have failed to receive their second dose of HPV vaccine when due.(ii) \u0007Reminder cards or “tickler boxes”.Make copies of the vaccination card for HPV vaccine and file the copies in a box with dividers by month as shown below.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "The reminder card is placed in the month that the missed dose of vaccine is due.(iii) \u0007Electronic immunization registries (EIRs).More and more countries will be developing and implementing computerized registries that include records for each person with personal information as well as vaccination data.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "EIRs allow auto­ mating the generation of lists of persons who are due for a vaccine or who have missed a dose.These lists can be used to send recall/ reminders by phone, email or letter.Some systems can also send auto­ matic reminders directly from the EIR to consenting users.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "18 Once defaulters are identified through these tools, health workers can use com­ munity messaging, reminders to parents, mobile phone texts, or other mechanisms to send reminders of the need to come back to the vaccination site to receive the missed vaccine dose.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Tracking on a monthly basis will provide consistency and make the exercise a regular part of the work of the health centre staff.The use of recall/reminders, for example via SMS, has also proven to be a good tool to improve compliance and completion of the vaccination series.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "![](images/733fcb0c00182e7bf6dff5940d7975edd4dbaeba7352944d7a99b4dff2252b5f.jpg) # Monitoring Coverage Calculating HPV vaccine coverage is necessary: 1) to evaluate the performance of a vaccine programme towards meetings its objectives and 2) to monitor the impact of vaccine on a population.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "As with other EPI vaccines, administrative coverage can be supplemented by coverage surveys.# Administrative coverage In this method, the number of targeted persons (for HPV, often girls of a certain age) that have been vaccinated with a certain dose of vaccine (in this case HPV2) over a certain time (usually 1 calendar year) is obtained from facility reports.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "This number (the numerator), is then divided by an estimate of the target population in that same time period (the denominator).In many cases, aggregated data is entered into an electronic information system either at the level of district (or another intermediate administrative level) or at the level of health facility (at least in large ones).",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "These systems allow the automated aggregation of numerator data by health facility and/or district, and then province/state and finally at the national level.In some systems, denominators are fed to the system and the coverage calculation is done automatically, this should include calculation of HPV vaccination coverage by age.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "To calculate annual coverage, the consolidated number of HPV doses given, by age and dose, during the year is used as the numerator.Estimates of the target population19 are used as the denominator.As mentioned earlier, single-age estimates of the target population by district can usually be obtained from the National Statistics Office or when better options are not available derived from population estimates of five-year age groups.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "An alternative to estimate denominators is included in Appendix 3.WHO has a guide for the assessment of target population that can help assess the “quality” of available target population estimates.20 Grade-based estimates of the target population often cover multiple age cohorts (i.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "e.9-12 year olds).These numbers – including estimates of the out of school population – can be obtained from the Ministry of Education.To obtain potentially more accurate denominators to calculate coverage by school and grades, during the planning phase of a school vaccination activity, the target numbers can be verified with the schools in the relevant catchments areas when registers are developed (see see Section 2.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "3).# Example: Summary Table for a Year.Both birth year and age are presented in this example.Choose one of the other when preparing a summary table.Month/Year District: Town/Village: of report: Service delivery site: <html><body><table><tr><td rowspan=\"3\">Year of birth/ Age</td><td colspan=\"11\"></td></tr><tr><td rowspan=\"2\">No.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "of HPV1 doses given</td><td></td><td>Mar</td><td>Apr</td><td>May</td><td>Jun</td><td></td><td></td><td></td><td></td><td></td><td></td><td>Annual total</td></tr><tr><td>Jan </td><td>Feb </td><td></td><td></td><td></td><td>Jul </td><td>Aug </td><td>Sep </td><td>Oct</td><td>Nov</td><td>Dec</td><td>(by age, sum</td></tr><tr><td>2009/ 9 years</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>across months)</td></tr><tr><td>2008/ 10 years 2007/</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>11 years 2006/</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>12 years 2005/</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>13 years 2004/</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>14 years 2003 or</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>earlier/ 15 + years Total num-</td><td></td><td></td><td>(by mpnth, sum across ages)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>ber of HPV1 doses given to all girls</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan=\"12\"></td></tr><tr><td rowspan=\"2\">Year of birth/ Age</td><td colspan=\"4\">No.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "of HPV2 doses given</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Jan </td><td>Feb</td><td>Mar</td><td>Apr</td><td>May</td><td>Jun </td><td>Jul</td><td>Aug</td><td>Sep </td><td>Oct</td><td>Nov</td><td>Dec</td><td>Annual total</td></tr><tr><td>2009/ 9 years</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>2008/ 10 years</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>2007/ 11 years</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>2006/ 12 years</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>2005/ 13 years</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>2004/ 14 years 2003 or</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>earlier/ 15 + years</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table></body></html> \\*Total annual No.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "of HPV1 doses given to all girls.$\\star \\star$ Total annual No.of HPV2 doses given to all girls Obtaining an accurate estimate of HPV vaccination coverage by age may be difficult for the year of vaccine introduction, particularly if multiple age cohorts are initially targeted.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "One option to calculate the annual age-specific HPV vaccine coverage rates21 is presented below.The number of doses given by the age-specific population is divided by the estimates target population (Columns 4-5 below).",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Table: Calculating annual coverage by HPV dose <html><body><table><tr><td colspan=\"6\">Year of report (YYYY): Country:</td></tr><tr><td rowspan=\"2\">Age (years)</td><td rowspan=\"2\">Column 1 Total annual no.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "of HPV1 doses given</td><td rowspan=\"2\">Column 2 Total annual no.of HPV2 doses given</td><td rowspan=\"2\">Column 3 Estimated size of target population</td><td colspan=\"2\">Coverage (%)</td></tr><tr><td>HPV1 (Column 1÷ Column 3)*100</td><td>HPV2 (Column 2÷ Column 3)*100</td></tr><tr><td>9</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>10</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>11</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>12</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>13</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>14</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Total doses by <15 yrs (Sum of previous rows)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>≥15</td><td></td><td></td><td colspan=\"4\" rowspan=\"2\"></td></tr><tr><td>Total no.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "of doses (all girls)</td><td></td><td></td></tr></table></body></html> Table A: Example District Health Office Annual Reporting Form for a country vaccinating a single age cohort – eligible girls 10 years old.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "(filled out) <html><body><table><tr><td colspan=\"4\">Year of report (YYYY): _ 2014 Country:</td><td colspan=\"3\"></td></tr><tr><td>Age (years)</td><td>Column 1 Total annual no.of HPV1</td><td>Column 2 Total annual no.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "of HPV2</td><td>Column 3 Estimated size of target</td><td colspan=\"3\">Coverage (%) HPV1 HPV2</td></tr><tr><td></td><td>doses given</td><td>doses given</td><td>population</td><td>(Column 1÷ Column 3)*100</td><td></td><td>(Column 2÷ Column 3)*100</td></tr><tr><td>10</td><td>13.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "529</td><td>11.872</td><td>15.200</td><td>89%</td><td>78%</td><td></td></tr><tr><td>11</td><td>876</td><td>799</td><td></td><td></td><td></td><td></td></tr><tr><td>Other</td><td>2</td><td></td><td></td><td></td><td>No data here</td><td></td></tr><tr><td>Total doses by <15 yrs (Sum of previous rows)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table></body></html> Note 1: coverage level is only calculated for the eligible age group (10 years old).",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Note 2: Eligibility can be based on actual age (on day of vaccination) or year of birth (any girl that will become age 10 in 2018).The choice for one or the other will have implications for the programme delivery and the best approach needs to be identified in the country and clearly com­ municated to each health worker during the training Table B: Example District Health Office Annual Reporting Form for a country vaccinating a combination of age cohorts – girls in a grade VI (filled out) <html><body><table><tr><td colspan=\"6\">Country:</td></tr><tr><td colspan=\"2\">Year of report (YYYY):</td><td colspan=\"4\">Column3 Coverage (%)</td></tr><tr><td>Age (years)</td><td>Column 1 Total annual no.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "of HPV1 doses given</td><td>Column 2 Total annual no.of HPV2 doses given</td><td>Estimated size of target population</td><td>HPV1 (Column 1÷ Column 3)*100</td><td>HPV2 (Column 2÷ Column3)*100</td></tr><tr><td>9</td><td>20</td><td>18</td><td></td><td colspan=\"2\"></td></tr><tr><td>10 11</td><td>1000</td><td>900</td><td colspan=\"2\"></td><td></td></tr><tr><td>12</td><td>800</td><td>700</td><td rowspan=\"2\"></td><td colspan=\"2\" rowspan=\"2\">No data to be entered here, Calculation of coverage rates challenging if accurate target population by age is not available</td></tr><tr><td></td><td>200</td><td>200</td></tr><tr><td>13</td><td>２</td><td>1</td><td></td><td colspan=\"2\"></td></tr><tr><td>(.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": ")</td><td></td><td></td><td></td><td colspan=\"2\">83%</td></tr><tr><td>Total nal girls</td><td>2022</td><td>1819</td><td colspan=\"2\">2430</td><td>75%</td></tr></table></body></html> The examples above illustrate how to calculate cumulative coverage levels by cohorts over a several years in order to have an estimated coverage by age 15.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Nevertheless, over time, a country will likely be targeting one cohort per year and as such the estimated denominator will become relatively stable, thus allowing for simplifying the calculation to number of doses given divided by the average size of a cohort of girls aged between 9 and 14.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "A coverage monitoring wall chart for HPV vaccination could be maintained and displayed in the health facility and/or at the district level.This chart should include the target population of girls at the health facility or catchment area, and record the number of girls vaccinated per month, per dose, over time, until the target is reached.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "If periodic or campaign-style delivery is used, e.g., concentrated usually in two periods a year, then setting up the charts showing two time points, with full denominators, can be used to provide a visual record of the administrative coverage (per outreach per dose).",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "![](images/f36366325a852e6ef7f16d5aa9621b5c952584e881faa1805babfc9da15a8fe0.jpg) “A coverage monitoring wall chart for HPV vaccination could be maintained and displayed in the health facility and/or at the district level.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "” # Coverage surveys Coverage surveys estimate vaccine coverage based on the vaccination status of individuals in a randomly selected and representative sample, according to their vaccination record or recall.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "For the HPV vaccination, recall can be provided by the girl or her parents/ caregiver.It provides actual vaccination coverage; it is not an estimate.Surveys usually complement the administrative vaccination coverage estimates and provide an independent assessment of HPV vaccination.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Periodic immunization coverage surveys can assess HPV vaccination coverage, administration (completeness and timeliness), drop-out rates and knowledge, attitudes, practices and barriers related to HPV vaccination.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "They can also help differentiate immunization coverage by strategy (school, health facility, outreach) and provider (public, private, other).Ascertaining whether vaccination occurred may be an important challenge.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Traditionally, for infant vaccination, mothers or caregivers provide the card and/or recall on the doses received by their child.For pre-adolescents and adolescents, the interview may have to include the mother or caregiver, plus the girl, as the latter may provide better recall information.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "It may be useful to include more than one age group to monitor vaccine uptake over time, but interpretation must be careful as HBR availability and recall may vary depending on time since vaccination.If the survey is interviewing girls aged 15, to ascertain “vaccination with one and two HPV doses by age $1 5 \"$ , the availability of cards may be low, and recall of vaccination that took place up to 5 years before may not be reliable.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Furthermore, if the archiving of records is not good, going to health facilities to trace those doses may prove futile.The 2018 WHO Vaccination Coverage Cluster Survey Reference Manual includes provisions to estimate HPV coverage22 and both the Demographic and Health Surveys (DHS)23 and the Multiple Indicator Cluster Surveys $( { \\mathsf { M } } { \\mathsf { I C S } } ) ^ { 2 4 }$ are also starting to assess HPV coverage.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "It is important to ensure alignment between the year of vaccine introduction and target age groups, and the survey eligibility criteria and questionnaire.![](images/9091897f1423053630c997c5196aa9cc50198e9102c67240d2f8111fb5c38f99.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "jpg) # Monitoring drop-out from HPV1 to HPV2 Monitoring HPV drop-out rates, i.e., girls that received the first but not the second HPV dose, is important to flag potential problems.High levels of drop-out or defaulting could indicate systemic problems in the community, such as lack of confidence or trust in the vaccine, a negative experience with the first dose, problems in service delivery, such as stock outs, or a failure to convey the need to receive two doses to be fully vaccinated against HPV.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "The drop-out monitoring system in a district or higher level could resemble the standard wall monitoring chart that tracks DTP1 to DTP3 drop out with the important difference that it would likely refer to different birth cohorts.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Practical concerns such as printing of such monitoring charts – a new recurrent cost – and the added workload for health workers, as well as the usefulness of this method to monitor drop-out must be considered in deciding whether to do introduce such a chart.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Other approaches include exploring drop-out through surveys or using EIRs.“High levels of drop-out – or defaulting – could be an indication of more systemic problems with HPV vaccination in the community.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "” ![](images/503b12ffe5e3a0964faed2359bd29852088425f485b1a967096fc1e9a274b56b.jpg) # Final observations ![](images/025ffa448232551acae1d1493f93d7c4f0c554997938df9ea22d2bd92a17a0c4.jpg) “Information about coverage levels when collected, analysed and disseminated in a timely manner can be a powerful tool to assess the overall performance of the HPV vaccination programme.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "” This Manual provides guidance to immunization managers, mid-level managers, sub-national and national health officers on how to develop tools and SOPs to collect and record information on HPV vaccine coverage.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Countries need to adapt the coverage forms and reporting sheets to reflect national recommendations for the target population, vaccination schedule and administrative levels etc.As data is aggregated up, it is important to ensure coverage data is consistently reported by age and dose.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "This will enable the calculation of immunization coverage by birth cohort regardless of the age at vaccination.Collecting HPV vaccine coverage information by age and dose is therefore even more important when the vaccine is targeting multiple age cohorts and when all girls in a particular school grade are eligible for vaccination.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "In order to monitor trends in vaccine coverage among vulnerable populations, such as girls not attending school or girls in nomadic populations, and girls who are at increased risk of cervical cancer, specific adaptations in the monitoring system can be made to allow clear identification of these populations – particularly at the services delivery level.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Similarly, surveys will need to take these populations into consideration when designing the sampling strategy.Information about coverage levels when collected, analysed and disseminated in a timely manner can be a powerful tool to assess the overall performance of the HPV vaccination programme.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "First dose coverage at different ages indicates how well HPV is accepted in the community and how well the particular delivery strategy is reaching the eligible population.High dropout rates between first and second dose may indicate poor performance in one or several components of the vaccination programme or in case of HPV vaccination it can indicate problems with chosen delivery strategy (e.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "g.school absenteeism and drop-out during school year).In order for this information to influence future performance, timely feedback on the reported coverage from the national to district level and from the district to service delivery level is essential.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Supportive supervision is essential for establishing and maintaining a well-functioning HPV coverage monitoring system.This should include careful supervision of HPV coverage monitoring, particularly during the first year(s) after HPV vaccine’s introduction.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Key indicators on HPV vaccination coverage should be included in graphs and vaccination dashboards such as the annual charts at the various levels.This will help ensure HPV vaccination is successfully integrated as part of the routine vaccination programme.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "It is crucial to explain any changes in scheduling, delivery strategy or data collection, and to present metadata (i.e., a set of data describing the variables collected).HBRs play an important role in the delivery and monitoring of vaccination programmes.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "They are also essential for ensuring data quality in the recommended, periodical country-based coverage surveys.In addition, they also serve to document an individual’s vaccination status.In many countries the HPV vaccine is not included in HBRs that focus on childhood vaccines.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "A HRB for adolescents is often produced at the time of HPV vaccine introduction, or adapted if a HBR already exists for other vaccines.WHO guidance exists on how to develop practical HRBs.25 “Indicators on HPV vaccination cover­age should be included in coverage graphs and vaccination dashboards such as the annual charts at the various levels.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "This will be a step to ensure HPV vaccine successfully integrated as part of the routine vaccination system.” Appendix 1.# Data collection for HPV vaccination included in the WHO/UNICEF Join Reporting Form (JRF) HPVVaccineDosesadministered:2o18 [Tahle instructions) <html><body><table><tr><td rowspan=\"2\"></td><td colspan=\"4\">Females</td><td colspan=\"3\">Males</td></tr><tr><td>Vaccine administered (age in years)</td><td>A.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "1stdose</td><td>B.2d dose</td><td>c.3ddose*</td><td>A.1stdose</td><td>B.2ddose</td><td>c.3ddose</td></tr><tr><td>4440</td><td>9</td><td></td><td></td><td>NR </td><td>NR </td><td>NR</td><td>NR</td></tr><tr><td>4450</td><td>10</td><td></td><td></td><td>NR </td><td>NR</td><td>NR </td><td>NR </td></tr><tr><td>4460</td><td>11</td><td></td><td></td><td>NR </td><td>NR </td><td>NR </td><td>NR </td></tr><tr><td>4470</td><td>12</td><td></td><td></td><td>NR</td><td>NR</td><td>NR</td><td>NR</td></tr><tr><td>4480</td><td>13</td><td></td><td></td><td>NR </td><td>NR</td><td>NR </td><td>NR</td></tr><tr><td>4490</td><td>14</td><td></td><td></td><td>NR</td><td>NR</td><td>NR</td><td>NR</td></tr><tr><td>4500</td><td>15+</td><td></td><td></td><td>NR </td><td>NR </td><td>NR </td><td>NR </td></tr><tr><td>4510</td><td>unknown age</td><td></td><td></td><td>NR</td><td>NR</td><td>NR</td><td>NR</td></tr></table></body></html> WHrendhffPsblhdluse !",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "[](images/8ce74201f527d17fa784fe08e9bc4085bcd3dc0cea2b9b6625aa8a82cd4c66c5.jpg) # Appendix 2.# Use of a summary indicator of HPV vaccine coverage One of the indicators used by the World Health Organization to monitor HPV vaccine coverage is a summary indicator that measures the proportion of females vaccinated with a complete series of HPV vaccine doses or “fully vaccinated” by 15 years of age.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "This summary indicator may be used to compare coverage estimates across countries, as well as within countries over time, particularly if the target population changes from year to year.It is also useful for monitoring the vaccine impact by comparing incidence rates of cervical cancer and other HPV disease outcomes to HPV vaccine coverage rates.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "This approach can be used at an earlier age, depending on a country’s recommendations of target age for the HPV vaccine.Information from national annual reporting forms from previous years are needed to calculate this indicator.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "The number of girls vaccinated with complete doses of HPV vaccine by age 15 in the current reporting year is calculated as: $^ +$ the number of HPV2 doses given to 14-year-old girls in the current reporting year $^ +$ the number of HPV2 doses given to 13-year-old girls in the previous reporting year $^ +$ \u0007the number of HPV2 doses given to 12-year-old girls 2 years prior to the current reporting year, etc.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "If recording is done by year of birth, the aggregation by 15 years of age becomes more intuitive.For example, if the reporting year is 2018, add the number of girls born in 2003 and vaccinated in 2017, 2016 and 2015 to obtain the numerator.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "The proportion of girls vaccinated with two doses of HPV vaccine by age 15 in the current reporting year (e.g., 2018) would be this total divided by the estimated number of 15-yearolds in the current reporting year (e.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "g., 2018).Note that all data collection tools need to be adapted and aggregation processes revised if more than one age group is targeted and/or if changes occur over time.Appendix 3.# Generating estimates of the target population for HPV vaccination # Estimating the target population or the denominator for coverage calculations The target population is the total number of girls of each age for whom the HPV vaccine is recommended.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "This is also the denominator for calculating vaccine coverage for either of the two doses in the vaccine series.The number of girls vaccinated with the previous dose of HPV should not be used as the denominator for calculating the coverage for the next dose; i.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "e., the proportion completing dose 2 after dose 1 is the completion rate and NOT the population coverage rate.A potential resource available are the WHO Projected national annual population 9-14 years of age by sex and single year of age, 2019-203026 # Estimating population by single year of age Calculating age-specific coverage requires estimates of the population of females by single year of age.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "In many instances, these data are available from the National Statistical Office and they should be used whenever possible.In some instances, particularly at lower sub-national levels, estimates may be available only by five-year age groups.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "The following describes a simple method for roughly estimating population by single year of age from five-year age groups.Assume that the true, but unknown, population of females 0-24 years of age is given in Table A1.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Table A1: Females, 0-24 years of age <html><body><table><tr><td>Age</td><td>Females</td><td>Age</td><td>Females</td></tr><tr><td>0</td><td>3,829</td><td>13</td><td>3,175</td></tr><tr><td>1</td><td>3,687</td><td>14</td><td>3,079</td></tr><tr><td>2</td><td>3,817</td><td>15</td><td>2,435</td></tr><tr><td>3</td><td>3,512</td><td>16</td><td>2,607</td></tr><tr><td>4</td><td>3,694</td><td>17</td><td>2,445</td></tr><tr><td>5</td><td>3,575</td><td>18</td><td>1,626</td></tr><tr><td>6</td><td>3,769</td><td>19</td><td>1,888</td></tr><tr><td>7</td><td>3,666</td><td>20</td><td>1,375</td></tr><tr><td>8</td><td>3,270</td><td>21</td><td>1,834</td></tr><tr><td>9</td><td>2,810</td><td>22</td><td>1,673</td></tr><tr><td>10</td><td>2,597</td><td>23</td><td>1,866</td></tr><tr><td>11</td><td>3,354</td><td>24</td><td>1,773</td></tr><tr><td>12</td><td>2,937</td><td></td><td></td></tr></table></body></html> However, suppose we only have available population estimates of females by five-year age groups as shown in Table A2.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Table A2: Females, 0-24 years of age <html><body><table><tr><td>Age Group</td><td>Females</td></tr><tr><td>0-4</td><td>18,539</td></tr><tr><td>5-9</td><td>17,090</td></tr><tr><td>10-14</td><td>15,142</td></tr><tr><td>15-19</td><td>11,001</td></tr><tr><td>20-24</td><td>8,521</td></tr></table></body></html> Because there are five years of age in the 15-19 age group, it seems reasonable to simply divide the number of females 15-19 by 5 to estimate the number of girls who are 15 years old ( $1 1 , 0 1 1 / 5 = 2 , 2 0 0 )$ .",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "We see from Table A1 that the actual number of 15-year old girls is 2,435, so we have underestimated the number by 235.A method that provides more accurate estimates is to add the number of females in the age group that includes the single year of age being estimated (in this case, the group 15-19 years) to the number of females in the next younger age group (10-14 years) and the next older age group (20-24 years), then divide the resulting total by the total number of years included in these three age groups (fifteen in this case).",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Thus, to estimate the number of girls fifteen years of age: (females $1 5 - 1 9 +$ females $1 0 - 1 4 +$ females 20-24) / number of years in the three groups, or ( $1 1 , 0 0 1 + 1 5 , 1 4 2 + 8 , 5 2 1 ) / 1 5 = 2 , 3 1 \\$ females age 15.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "The difference between the estimated 2,311 females and the actual number, 2,435 is 124, much closer to the actual number than first estimate above.One important drawback to this method is that the single-year age estimate will be the same for each year of age in the five-year age group.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "In the example above, the estimate for the number 15-year old girls will be the same for 16-year old girls, 17-year old girls and so forth.More sophisticated methods such as the Sprague fifth-difference, Karup-King third-difference and other interpolation methods provide more realistic estimates.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "27 # Summary: 1.I\u0007f available, use single year of age population estimates from the National Statis­ tical Office.2.I\u0007f these data are not available, seek assistance from the National Statistical Office, the Ministry of Planning, or the statistics, demography or sociology departments of a university to produce such estimates.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Or use the WHO population estimates cited above.3.I\u0007f estimates of the number of females are only available by five-year age groups, use the method described above to estimate the number of females by single years of age.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "4.I\u0007f necessary, use more sophisticated methods such as the Sprague fifth-difference, Karup-King third-difference or other interpolation methods.In most instances, the accuracy of the initial estimates or projections does not warrant this addi­ tional complexity.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "This document was published by the Department of Immunization, Vaccines and Biologicals.Copies of this document, as well as additional materials on immunization, vaccines and biologicals may be requested from: World Health Organization Department of Immunization, Vaccines and Biologicals CH-1211 Geneva 27 Switzerland Email: vaccines@who.int Web: www.who.int/immunization/en",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园 ![](images/349541ed7784dcd3ac07b09b72cf01430471022480647c9dc2143720533a6d6a.jpg) 2021-08-16 19:19 来源：微信公众号 - oncolatdxy 作者：肿瘤时间 # WHO 发布筛查和治疗预防宫颈癌的新指南 字体大小 当地时间 7 月 6 日，世界卫生组织（WHO）和联合国人类生殖特别规划处（HRP；联合国系统内人类生殖研究的主要组织，汇集了决策者、科学家、卫生护理提供者、临床医生、消费者和社区代表确定和解决研究的优先事项，以改善性健康和生殖健康）共同发布宫颈癌防治新版指南。",
    "source": "WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园/WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园.md"
  },
  {
    "text": "![](images/6f6781b2d6b5f451a017cd377a7ad7c42097424b68d267a9969dfdde8605e570.jpg) # 宫颈癌发病现状 子宫颈癌是造成妇女死亡率的主要原因。2020 年，全球约有 60.4 万名妇女被诊断出患有子宫颈癌，约有 34.2 万名妇女死于子宫颈癌。宫颈癌是 23 个国家最常见的癌症，也是 36 个国家导致癌症死亡的主要原因。这些国家中的绝大多数分布在撒哈拉以南非洲、美拉尼西亚、南美洲和东南亚。",
    "source": "WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园/WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园.md"
  },
  {
    "text": "快速准确的筛查计划至关重要，这样每个患有宫颈疾病的女性都能得到她需要的治疗，并避免相关的死亡。WHO 全球消除宫颈癌战略 —— 由世界卫生大会于 2020 年批准 —— 呼吁全球 $70 \\%$ 的女性定期接受宫颈疾病筛查并进行高效检测，并要求 $90 \\%$ 的女性接受适当的治疗。除了为女孩接种人类乳头瘤病毒（HPV）疫苗外，实施这一全球战略可以在未来 100 年内防止超过 6200万人死于宫颈癌。",
    "source": "WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园/WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园.md"
  },
  {
    "text": "相关组织将在 2021 年底发布世界各国目前在宫颈癌负担和筛查和治疗覆盖率方面的状况的数据。这些国家概况可以帮助卫生部门确定其计划需要加强和衡量实现 2030年目标的进展情况。为了使宫颈癌预防和控制计划产生影响，加强患者保留率并确保对 HPV 或宫颈癌前期筛查呈阳性的女性进行快速治疗是一个基本的优先事项。这一新的世卫组织指南将指导公共卫生投资，以提供更好的诊断工具、更强大的实施过程和更可接受的筛查选择，以覆盖更多女性并挽救更多生命。",
    "source": "WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园/WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园.md"
  },
  {
    "text": "![](images/ab8f321c85760ace37002d77ebca41657cf36ce5499b65acecaf6a3f2eec0708.jpg) ![](images/9d024ccd7d3edc9e396457989828f3199d8b7b6bbbea6069d87eda344ae33820.jpg) 关注频道微信 纵览临床新进展 关注频道微博 快速获悉最新信息 这份 WHO 和 HRP 指南旨在帮助各国在宫颈癌筛查和治疗方面取得更快、更公平的进展。",
    "source": "WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园/WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园.md"
  },
  {
    "text": "它包括世卫组织推荐的宫颈癌筛查方法的一些重要转变，共包括 23 项建议和 7 项良好做法声明。在 23 条建议中，有 6 条对一般妇女和感染 HIV 的妇女是相同的，12 条是不同的，并且针对每个人群都有针对性。在 7 项良好做法声明中，3 项对于一般妇女群体和感染 HIV 的妇女是相同的，2 项针对每个群体是不同的和具体的。这一最新的预防宫颈癌筛查和治疗指南分三步制定： 审查当前的指导方针，并确定更新或重新制定的建议。",
    "source": "WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园/WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园.md"
  },
  {
    "text": "根据人群（P）、干预（I）、比较（C）和结果（O）（PICO 问题）为建议制定问题，并进行新的系统性审查或更新为先前指南进行的审查，以及在无法进行初步研究时模拟结果。应用建议分级评估、开发和评估（GRADE）方法来评估证据的确定性和利用证据决策表（EtD）制定建议。<html><body><table><tr><td>WHO对一般女性群体建议：</td><td>WHO对感染HIV的女性群体建议：</td></tr><tr><td>从30岁开始采用筛查-治疗方法，检测 HPVDNA，每5至10年定期筛查1次</td><td>从25岁开始采用筛查-分诊-治疗方法进</td></tr><tr><td>检测HPVDNA，每5至10年进行1次定次 期筛检</td><td>从 30岁开始采用筛检-分诊-治疗方法，行HPV DNA检测，每3至5年定期筛查1</td></tr></table></body></html> # Summary recommendation for the general population of women !",
    "source": "WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园/WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园.md"
  },
  {
    "text": "[](images/dc6a524bf16b3ae67dcc78a61ced206c3cfd9a22613c4cf4e6cc90eb52d0f745.jpg) WHO suggests using either of the following strategies for cervical cancer prevention among the general population of women: HPV DNA detection in a screen-and-treat approach starting at the age of 30 years with regular screening every 5 to 10 years HPV DNA detection in a screen, triage and treat approach starting at the age of 30 years with regularscreeningevery5to10years Summary recommendation for women living withHIV WHO suggests using the following strategy for cervical cancer prevention among women living with HIV: HPV DNA detection in a screen, triage and treat approach starting at the age of 25 years with regular screening every 3 to 5 years !",
    "source": "WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园/WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园.md"
  },
  {
    "text": "[](images/c6797d7b2d88c913a3ef5c334bcf3913ccfa7146591ef898263404efd5049ad9.jpg) # 相关的 Q & A 1.使用 「 筛查和治疗 」 方法的建议是什么？A.HPV 作为初步筛查试验呈阳性，在宫颈上放置醋酸确定治疗是否合格时，未见病变，但转化区（TZ）不完全可视化？（类型 3 TZ） 当转化区由于是宫颈内膜（2 型或 3 型转化区）而不完全可见时，应转诊患者进行阴道镜检查并进一步评估，以下标准有必要接受消融治疗： 不怀疑侵袭性癌症或腺体疾病（即腺癌或原位腺癌，AIS）。",
    "source": "WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园/WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园.md"
  },
  {
    "text": "转化区完全可见，整个病灶可见，不延伸到宫颈内。病变为 1 型转化区。当患者不符合消融条件且阴道镜检查不可用时该怎么办？干预措施可能受到可行性、培训、项目质量保证和资源的限制。在缺乏某些基础设施的情况下，例如阴道镜、转化区大环切除术（LLETZ）或安全的手术环境，可以在精心选择的情况下考虑桥接策略，以扩大获得治疗的机会，而不是不提供治疗。例如，对于选择的小型 2 型转化区，消融可能是一种选择，其中探针尖端将实现鳞柱交界上皮的完全消融，在那里它可以达到转化区的全部范围、深度和上限，以及提供足够的选择和后续随访。",
    "source": "WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园/WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园.md"
  },
  {
    "text": "# B.VIA 作为初步筛查试验，未见病变，但转化区（TZ）不完全可视化？（类型 3 TZ） 如上所述，在 VIA 阳性筛选测试后，需要评估消融治疗的资格。当转化区由于是宫颈内膜（2型或 3 型转化区）而不完全可见时，应转诊患者进行阴道镜检查和进一步评估。请注意上述（问题 1A）使患者有资格接受消融治疗的标准，以及当患者不具备消融资格和阴道镜检查服务不可用时该怎么办。2.使用 「 筛选 - 分类 - 治疗 」 方法的建议是什么？",
    "source": "WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园/WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园.md"
  },
  {
    "text": "# A.HPV 作为初步筛查试验呈阳性，VIA 分流试验未显示病变，但转化区不完全可视化？（类型 3 TZ） 与上述相同的答案将适用。无论是筛查还是分诊，当转化区不完全可见时，应将患者转诊进行阴道镜检查并进一步评估。如果主要筛查测试是 VIA 而不是 HPV，同样适用，并且 VIA 测试由于 3 型 TZ 而不确定。请注意上述（问题 1A）使患者有资格接受消融治疗的标准，以及当患者不具备消融资格和阴道镜检查服务不可用时该怎么办。",
    "source": "WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园/WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园.md"
  },
  {
    "text": "3.上述问题的答案在 HIV 感染的女性群体中会有所不同吗？否（基于目前可用的证据）。# 4.HPV 检测呈阳性后，我们应该何时进行分诊治疗？在筛查和治疗策略中单独使用 HPV 检测与在筛查、分诊和治疗策略中使用 HPV 检测，然后进行分诊的效果类似；两种策略分别使宫颈癌发病率减少了 $4 6 \\%$ 和 $45 \\%$ ，死亡率分别减少了$5 1 \\%$ 和 $4 9 \\%$ 。# $\\frac { x } { 2 5 }$ 本文仅供医疗卫生等专业人士参考 策划：GoEun，梅浙 投稿及合作：yinqihang@dxy.",
    "source": "WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园/WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园.md"
  },
  {
    "text": "cn 题图来源：站酷海洛 PLUS WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition.World Health Organization; 2021.编辑： 张佳钰 ![](images/55b13c64ef6710fe5928ea23bc269c66e147d2822d1328a404abe40c2a1f653f.",
    "source": "WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园/WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园.md"
  },
  {
    "text": "jpg) ![](images/9940e831eb8e4bd35249cade8f612785e4638c71f02d842e26584d3add85a206.jpg) # 版权声明 本网站所有注明“来源：丁香园”的文字、图片和音视频资料，版权均属于丁香园所有，非经授权，任何媒体、网站或个人不得转载，授权转载时须注明“来源：丁香园”。本网所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。",
    "source": "WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园/WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园.md"
  },
  {
    "text": "同时转载内容不代表本站立场。<html><body><table><tr><td colspan=\"4\"></td><td colspan=\"2\">关于丁香园</td><td>官方链接</td></tr><tr><td>丁香园旗下网站 丁香园</td><td>用药助手</td><td>丁香医生</td><td>丁香通</td><td>关于我们 友情链接</td><td></td><td>丁香医生</td></tr><tr><td>文献求助</td><td>Insight数据库</td><td>丁香人才</td><td>丁香导航</td><td>联系我们</td><td>加入丁香园</td><td>丁香园新浪微博</td></tr><tr><td>合作案例</td><td>丁香会议</td><td>丁香无线</td><td>丁当商城</td><td>网站声明</td><td>资料下载</td><td></td></tr><tr><td>调查派</td><td>丁香搜索</td><td>丁香云管家</td><td>丁香播咖</td><td>资格证书</td><td></td><td></td></tr><tr><td>智能皮肤</td><td>医院汇</td><td></td><td></td><td></td><td></td><td></td></tr></table></body></html> # WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园 Copyright $\\circledcirc$ 2000-2025 DXY All Rights Reserved浙B2-20070219(含BBS) | (浙) -经营性-2022-0030 | 浙公网备案 33010802004314 号 | 出版物经营许可证：新出发滨字第0064号网络文化经营许可证：浙网文 [2018]11330-875 号 | 食品许可证：JY13301080010985 号 | 人力资源许可证编号：330108202110270036 号第二类医疗器械经营备案凭证：浙杭食药监械经营备20153170号 | 医疗器械网络销售备案：(浙杭)网械企备字[2018]第00246号违法和不良信息举报电话：0571-28291519 举报邮箱：lawyer@dxy.cn 涉未成年人违法和不良信息举报专区本网站用字经北京北大方正电子有限公司授权许可",
    "source": "WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园/WHO 发布筛查和治疗预防宫颈癌的新指南 - 丁香园.md"
  },
  {
    "text": "·专家论坛· # 《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读 胡尚英 赵雪莲 张勇 乔友林 赵方辉 国家癌症中心 国家肿瘤临床医学研究中心 中国医学科学院北京协和医学院肿瘤医院 流行病学研究室，北京100021 通信作者：赵方辉，Email：zhaofangh@cicams.ac.cn 【摘要】 宫颈癌是严重威胁全球女性健康的恶性肿瘤之一，也是目前唯一可通过三级预防措施予以消除的恶性肿瘤。",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "2020 年11 月，“加速消除宫颈癌全球战略”正式启动，针对宫颈癌前病变的筛查和治疗是消除宫颈癌的关键举措。2021 年7 月，世界卫生组织（WHO）发布《预防宫颈癌：WHO 宫颈癌前病变筛查和治疗指南（第二版）》，为全球各国宫颈癌消除战略的制定提供重要方向和指导。本文将从指南制定方法学、指南中关于宫颈癌筛查和治疗策略方面的推荐/良好实践声明（包括筛查起止年龄、筛查方法、筛查间隔、筛查异常人群管理及癌前病变治疗等）以及指南的国际影响等方面进行解读，为我国宫颈癌防控指南的更新和相关策略的制定提供参考。",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "【关键词】 宫颈肿瘤； 癌前病变； 筛查； 治疗； 指南基金项目：国家自然科学基金（81761128006、81773533） Interpretation of“WHO guideline for screening and treatment of cervical pre‐cancer lesions for cervical cancer prevention，second edition” Hu Shangying, Zhao Xuelian, Zhang Yong, Qiao Youlin, Zhao Fanghui Department of Cancer Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China Corresponding author: Zhao Fanghui, Email: zhaofangh@cicams.",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "ac.cn 【Abstract】 Cervical cancer can be eliminated through primary, secondary, and tertiary prevention.Yet it remains one of the gravest threats to women′s lives worldwide.In November 2020, the World Health Organization (WHO) officially launched the global strategy to accelerate the elimination of cervical cancer, and underlined that screening and treatment for cervical pre‐cancer lesions are two of three key measures for the elimination.",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "In July 2021, WHO issued the second edition of\"WHO guideline for screening and treatment of cervical pre‐cancer lesions for cervical cancer prevention\"to provide important guidance to countries to support them in achieving the target of cervical cancer elimination in all women.",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "This article will interpret the methods for the guideline development, the recommendations/good practice statements on screening and treatment to prevent cervical cancer (including the age to start/stop screening, screening methods, screening interval, the management of screen‐positive women and treatment of the precancerous lesions, etc.",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": ") and its impact globally, providing reference for the updates of guideline and policy making on cervical cancer prevention and control in China.【Key words】 Uterine cervical neoplasms; Precancerous lesions; Screening; Treatment; Guideline Fund program: National Natural Science Foundation of China (81761128006, 81773533) 宫颈癌由高危型人乳头瘤病毒（HPV）持续感染引起，可通过三级预防措施得到有效控制。",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "但一些中低收入国家由于缺少高质量的筛查且覆盖率低，宫颈癌仍是主要的公共卫生问题［1］。为了改变这种健康不公平性，2018 年世界卫生组织（WHO）发布了消除宫颈癌的行动呼吁，并于2020 年11 月正式启动“加速消除宫颈癌全球战略”，提出到2030 年 达 到“90‑70‑90”目 标（即 $9 0 \\%$ 的女孩在15 岁之前完成HPV 疫苗接种， $70 \\%$ 的妇女在35 和45岁之前各接受一次高精度的筛查， $9 0 \\%$ 筛查阳性和宫颈癌变确诊病例得到有效治疗），才有望在本世纪末全球实现公共卫生问题层面的宫颈癌消除（即发病率降低至4/10 万以下）［2］。",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "然而，现实与这一目标存在较大差距。因此，WHO 组织全球专家，调研、整合最新研究证据和长期实践经验，对2013年发布的《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第一版）》进行更新，并于2021 年7 月6 日发布第二版，以期指导全球各国制定筛查和治疗策略，提高策略效率，助力实现2030 年战略目标［3］。本文将从指南制定方法学、对筛查和治疗策略的推荐/良好实践声明（包括筛查起止年龄、筛查方法、筛查间隔、筛查异常人群管理及癌前病变治疗等）等方面对第二版指南进行解读，为我国宫颈癌防控指南的更新和相关策略的制定提供参考。",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "# 一、指南制定方法 新版指南的制定遵循《WHO 指南制定手册》（第二版）的方法要求，分为以下3个步骤： 1.审查现有指南，确定需更新或新增的推荐和建议。指南制定小组（GDG）审查旧版指南，根据最新研究证据确定哪些推荐需要删除、验证、编辑或更新，以及是否添加新的推荐。推荐和建议涉及主要内容包括筛查起止年龄、优先考虑人群、筛查方法、治疗策略、随访间隔、筛查异常人群管理和癌前病变治疗策略。最终GDG 确定对两大类7 种筛查和治疗策略进行评价和比较（表1）。",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "GDG 由全球52 名成员组成（34 名女性，18 名男性），代表WHO全球6 大区域以及民间社会组织、妇女团体和人免疫缺陷病毒（HIV）感染女性人群。2.针对需更新或新增的推荐/建议，提出需要进行证据综述的研究问题。对应拟提出的每项推荐 ，根 据 PICO 原 则（P：population，研 究 对 象 ；I：intervention，干预措施；C：comparison，比较组；O：Outcome，结局）确定了14 个研究问题，并分别针对普通女性和HIV 感染女性人群进行系统综述。",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "在无 法 进 行 系 统 综 述 时 ，采 用 Policy‑Cervix 和Policy‑Cervix HIV‑HPV 数学模型估算各种策略在不同筛查年龄和筛查间隔情况下卫生经济学效果、宫颈癌发病死亡风险、癌前病变治疗以及所引发早产的影响等。此外，通过检索文献，评估各种策略的可接受性、可行性和成本。通过实施一项调查研究，收集策略的可行性、获益和风险的价值以及筛查女性、医生和其他利益相关方的偏好。3.",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "评价证据可靠性，制定推荐和建议。运用推荐、评估、制定与评价的分级体系（GRADE）评估证据的可靠性。采用证据‑决策（EtD）表汇总所有以上证据，经GDG 讨论后对各项推荐达成一致意见。最终推荐和建议将基于不同策略的收益和潜在危害、筛查方法的准确性、证据的可靠性、可获得的资源与花费的成本、可接受性、可行性与持续性、对公平性的影响等因素进行综合考虑。GDG 就这些推荐和建议或声明达成一致后，外部审查小组（ERG）对完整草案进行审查并给予反馈。",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "# 二、指南推荐和良好实践声明 指南主要面向国家、区域或地区各级机构负责宫颈癌防控战略规划的政策制定者、方案管理者和执行者以及卫生部门其他相关专业人员。从事生殖健康、产前和产后服务、计划生育服务、HIV/艾滋病（AIDS）控制以及在地区或初级保健机构为女性提供健康护理的医生、护士和社区保健工作者，也可查阅本指南，以了解指南制定过程，以及选择和执行以证据为基础的宫颈癌防控战略的重要性。表1 指南证据收集过程中评价的七种宫颈癌前病变筛查和治疗策略 <html><body><table><tr><td>治疗策略</td><td>具体方法</td></tr><tr><td>筛查-治疗策略：仅依靠初筛阳性结果，即可对女性进行治疗</td><td>VIA+治疗</td></tr><tr><td rowspan=\"5\">筛查-分流-治疗策略：对初筛阳性且分流阳性女性(有或无病细胞学检查+阴道镜分流+治疗 理)进行治疗</td><td>HPVDNA检测（自采样或医生采样)+治疗</td></tr><tr><td></td></tr><tr><td>HPVDNA检测（可同时实现HPV分型检测)+HPV16/18分流/非HPV16/18 阳性VIA分流+治疗</td></tr><tr><td>HPVDNA检测+VIA分流+治疗</td></tr><tr><td>HPVDNA检测+阴道镜分流+治疗 HPVDNA检测+细胞学分流+阴道镜+治疗</td></tr></table></body></html> 注：VIA为醋酸染色肉眼观察；HPV为人乳头瘤病毒 指南通过对两大类7 种宫颈癌前病变筛查和治疗策略进行评价和比较（表1），针对普通女性与HIV 感染女性提出23 项推荐和7 项良好实践声明。",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "在筛查方面主要涵盖：筛查策略，筛查方法（初筛技术和采样方式），筛查异常人群管理（分流、治疗、随访），筛查人群（起始年龄、终止年龄和优先考虑人群），筛查间隔，治疗后人群随访，并对HPV 引入过渡时期筛查技术的选择给出了良好实践声明；在治疗方面主要增加了既往指南中未涉及的针对宫颈病变治疗时限的良好实践声明，以及关于宫颈原位腺癌治疗方法的建议。本指南更新主要有两个方面的重要推荐：首先，WHO 推荐方法有重要转变，指南推荐基于HPV DNA 的检测技术作为宫颈癌筛查的首选方法，而不是目前全球常用的醋酸染色肉眼观察（VIA）或细胞学检查（通常称为“巴氏涂片”）。",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "指南强调，HPV DNA 检测可检测出高危型HPV，这些型别导致了几乎所有宫颈癌，其检测结果准确，同时可实现自我采样，在提高筛查准确性的同时可进一步提高宫颈癌筛查覆盖率，挽救更多生命，更具成本效益。其次，指南针对HIV感染女性给予了宫颈癌筛查和治疗方面的详细建议。免疫功能低下的女性，如HIV 感染者，比普通女性更有可能发生持续性HPV 感染，并更迅速地发展为宫颈癌前病变甚至宫颈癌，导致其罹患宫颈癌的风险较普通女性增加6 倍。",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "本指南针对HIV 感染妇女建议较普通女性提前筛查年龄（25 岁），缩短筛查间隔，采用HPV DNA检测初筛‑分流‑治疗的策略。总体来看，指南建议普通女性可采用以下任何一种策略预防宫颈癌的发生：（1）“筛查‑治疗”策略（即筛即治）：从30 岁开始，采用HPV DNA 检测进行初筛，每5\\~10年定期筛查一次；（2）筛查‑分流‑治疗策略：从30 岁开始，采用HPV DNA 检测进行初筛，并结合一定的分流方法，每5\\~10 年定期筛查一次。",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "建议HIV 感染女性采用筛查‑分流‑治疗策略，从25 岁开始，以HPV DNA 检测方法为初筛并结合一定的分流方法，每3\\~5 年定期筛查一次。针对普通女性与HIV 感染女性的具体筛查和治疗建议详见表2。在“加快消除宫颈癌全球战略”的国际背景下，这一指南的更新对于全球各个国家有计划地实现2030 年的阶段性目标尤为重要。指南中的建议将为各国宫颈癌消除战略规划的制定提供重要方向和指导，集全球权威证据助力各国更新或改进宫颈癌防控指南或相关政策。",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "本指南与其他指南［4］相比不同之处主要体现在：（1）初筛方法：明确推荐高准确性的HPV DNA检测作为初筛方法，有条件地区要尽快过渡到HPV检测；（2）筛查间隔：延长了HPV 检测阴性人群的再次筛查间隔，其他指南大多数是5 年，本指南中对普通女性是5\\~10 年，HIV 感染女性是3\\~5 年；延长了HPV 检测阳性但分流阴性人群的筛查间隔，大多数指南推荐为12 个月后复查，本指南对普通女性的推荐为 24 个月后复查，HIV 感染女性为12 个月后复查；（3）筛查起始和终止年龄：大多数指南中推荐宫颈癌筛查起始年龄为25 岁，终止年龄为65 岁。",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "本指南推荐对起始和终止年龄的推荐分别为30岁和49岁，在资源允许情况下，可考虑对50\\~65岁中从未接受筛查女性进行筛查；（4）对HIV感染人群的筛查推荐：针对HIV 感染女性，美国阴道镜和宫颈病理学会（ASCCP）建议在首次插入式性行为后1 年内开始接受筛查，采用细胞学检查（ $\\leq$ 30 岁女性）或HPV 和细胞学联合筛查策略（ $> 3 0$ 岁女性），起始筛查间隔为1 年1 次，如连续3 年检查结果正常，则转为3 年1 次。",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "其他指南对HIV 感染女性大多建议与普通女性相同的筛查策略，或缩短筛查间隔。本指南对HIV 感染妇女建议25 岁开始筛查，采用HPV DNA 检测初筛“筛查‑分流‑治疗”的策略，每3\\~5 年重复筛查，不建议采用“筛查‑治疗”策略。我国宫颈癌前病变筛查项目与相关指南的发展历经20余年的历程。2004年原国家卫生部疾病控制司委托中国癌症基金会组织全国专家制定了首个《中国子宫颈癌筛查及早诊早治技术指南》，并用于实践。",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "2006—2009 年开展中央财政地方转移支付癌症早诊早治项目，采用VIA 为筛查方法，子宫颈癌筛查项目点由2006 年的5 个增加到2009 年覆盖31 个省份的43 个点。2009 年，全国重大公共卫生专项农村“两癌检查”（宫颈癌和乳腺癌）项目启动，采用每3年进行1次细胞学检查；在资源匮乏和没有细胞学检查条件地区，采用每年1 次VIA/VILI 检查的宫颈癌筛查策略。2014 年起开展农村HPV 检测试点项目推广HPV 检测技术，2019年，农村“两癌检查”项目被纳入基本公共卫生服务，宫颈癌筛查工作的连续性得到提升［5］。",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "在此期间，原国家卫生计生委妇幼健康服务司委托中华预防医学会妇女保健分会组织制定的《子宫颈癌综合防控指南》于2017 年正式发布［6］；中国抗癌协会妇科肿瘤专业委员会组织编写的《宫颈癌诊断与治疗指南（第四版）》于2018年完成更新［7］。表2 《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》中针对普通女性与HIV感染女性宫颈癌前病变筛查和治疗方面的推荐和良好实践声明 <html><body><table><tr><td>项目</td><td></td><td>普通女性</td><td>HIV感染女性</td></tr><tr><td>筛查推荐和良好 实践声明</td><td>筛查策略</td><td>“筛查-治疗”或“筛查-分流（基因分型、阴仅“筛查-分流（基因分型、阴道镜检 道镜检查、VIA或细胞学检查)-治疗\"(推“查、VIA或细胞学检查)-治疗 荐3)</td><td>（推荐23）</td></tr><tr><td></td><td>筛查方法(初筛)</td><td>HPVDNA检测（自采样或医生采样均可），同普通女性 不推荐VIA或细胞学检查（推荐1,4;21， 24)</td><td></td></tr><tr><td></td><td>筛查异常人群的管理</td><td></td><td></td></tr><tr><td></td><td>HPV DNA初筛阳性</td><td>不分流或分流(推荐2)</td><td>分流(推荐22)</td></tr><tr><td></td><td>HPVDNA阳性-分流阳性</td><td>直接治疗或组织学诊断后治疗(推荐3)</td><td>同普通女性(推荐23)</td></tr><tr><td></td><td>HPVDNA阳性-分流阴性</td><td>24个月后重新HPVDNA检测，如阴性则转12个月后重新HPVDNA检测，如 到常规筛查(推荐11)</td><td>阴性则转到常规筛查(推荐31)</td></tr><tr><td></td><td>细胞学初筛异常-阴道镜正常</td><td>12个月后重新HPVDNA检测，如阴性则转同普通女性 到常规筛查(推荐12,32)</td><td></td></tr><tr><td></td><td>筛查人群</td><td></td><td></td></tr><tr><td>终止年龄</td><td>起始年龄</td><td>30岁(推荐5)</td><td>25岁(推荐25)</td></tr><tr><td></td><td></td><td>>50岁，按照推荐筛查间隔定期筛查连续同普通女性 两次筛查结果阴性即可停止筛查(推荐 6,26)</td><td></td></tr><tr><td></td><td>优先人群(良好实践声明)</td><td>30~49岁；资源允许时，可再考虑50-65岁25~49岁；资源允许时，可再考虑 中从未接受过筛查女性(声明7)</td><td>50-65岁中从未接受过筛查女性 （声明27)</td></tr><tr><td></td><td>筛查间隔</td><td></td><td></td></tr><tr><td></td><td>HPV DNA初筛</td><td>5~10年(推荐8)</td><td>3~5年(推荐28)</td></tr><tr><td></td><td>VIA和细胞学初筛（尚无条件开展 HPV DNA检测地区）</td><td>3年(推荐9,29)</td><td>同普通女性</td></tr><tr><td>良好实践声明</td><td></td><td>过渡到定期筛查前，一生两次筛查也是有同普通女性 益的（声明10,30）</td><td></td></tr><tr><td></td><td>治疗后人群随访</td><td>因组织学确诊CIN2/3/AIS治疗后的女性，因组织学确诊CIN2/3/AIS治疗后的 或因筛查结果阳性治疗的女性，12个月 后重新HPVDNA检测（非VIA或细胞 学），如阴性则转到常规筛查（推荐13)</td><td>女性,或因筛查结果阳性治疗的 女性12个月后重新HPVDNA检 测（非VIA或细胞学），如阴性 12个月后再次进行HPVDNA检 测，再次阴性后则转到常规筛查</td></tr><tr><td></td><td>HPV引I人过渡时期的方法选择</td><td>在HPVDNA检测可被引人时，即立即引同普通女性 人，无论之前采用何种检测方法；在其未 被引人前，应继续使用现有方案进行筛 查（以细胞学检查或VIA作为初筛方</td><td>（推荐33）</td></tr><tr><td>治疗推荐和良好</td><td>治疗时限</td><td>法），直到HPVDNA技术可被引人（声明 14,34) 确诊后6个月内尽快进行治疗；孕妇可推同普通女性</td><td></td></tr><tr><td>实践声明</td><td>原位腺癌治疗方法</td><td>迟至产后(声明41) 转化区环形切除术或冷刀锥切(推荐42) 同普通女性</td><td></td></tr></table></body></html> 注：括号中的推荐/声明序号与原版英文指南文件中的表1（针对普通女性和HIV感染女性的宫颈癌前病变筛查和治疗推荐和良好实践声明）和表2（第一版指南中未包括的治疗推荐和良好实践声明）中的序号相对应；VIA 为醋酸染色肉眼观察；HPV 为人乳头状瘤病毒；HIV 为人免疫缺陷病毒；CIN2为中度宫颈上皮内瘤样病变；CIN3为重度宫颈上皮内瘤样病变；AIS为原位腺癌 我国宫颈癌前病变筛查和治疗相关证据的更新为进一步指导和规范我国宫颈癌防控工作提供了重要依据。",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "截至目前，我国农村宫颈癌筛查项目已累计筛查1 亿余人次妇女［8］，十年数据（2009—2018 年）显示与细胞学检查比较，HPV 检测方法可检出更多的宫颈癌和癌前病变［9］。2020 年，1 项全国多中心、开放、随机临床研究也证实了高危型HPV DNA 检测是初级保健医疗中心一种有效的初筛方法，将高危型HPV DNA 检测纳入国家宫颈癌筛查计划是合理有效的［10］。2020—2021 年，我国学者结合国内宫颈癌防控情况进行策略分析的模型研究进一步验证了采用HPV DNA 检测作为初筛方法的筛查策略结合HPV 疫苗接种，是实现我国宫颈癌消除的最优路径［11‑12］。",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "然而，目前我国仍面临着宫颈癌筛查覆盖率低、大规模筛查所采用的技术落后、基层服务能力有限及妇女筛查可及性差等现实问题。最新数据显示，2015年我国20\\~64岁妇女既往接受过宫颈癌筛查的比例仅为 $2 5 .7 \\%$ ，其中35\\~64 岁筛查比例为 $3 1 .4 \\% ^ { [ 1 3 ] }$ ，距离2030 年拟实现的阶段性目标—— $7 0 \\%$ 宫颈癌筛查覆盖率仍有较大差距。全球宫颈癌消除战略及WHO指南更新对我国宫颈癌防控事业的借鉴意义。",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "2020 年，WHO 发布《加速消除宫颈癌全球战略》后，国务院于2020 年12月发布“中国支持《加速消除宫颈癌全球战略》”［14］，表明我国将与193个国家携手通过HPV 疫苗接种、筛查和治疗等三级防治路径，推动全球实现消除宫颈癌的目标。在此基础上，全国爱卫办、健康中国行动推进办正以宫颈癌防治为重点内容，在全国启动健康城市建设创新模式试点工作，探索在健康城市建设中推动健康中国行动的有效工作模式，进一步推动在全国范围内早日实现宫颈癌消除的2030 年阶段性目标。",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "本次WHO 指南的发布，可帮助我国在借鉴全球最新证据的同时，依据我国医疗资源配置现状，进一步更新我国宫颈癌筛查和治疗相关指南，助力我国早日实现消除宫颈癌的美好愿景。利益冲突 所有作者均声明不存在利益冲突 # 参 考 文 献 [1] Arbyn M, Weiderpass E, Bruni L, et al.Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis[J].",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "Lancet Glob Health, 2020, 8(2): e191‐e203.DOI: 10.1016/S2214‐109X(19)30482‐6.[2] World Health Organization.Global strategy to accelerate the elimination of cervical cancer as a public health problem [EB/OL].",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "[2021‐07‐14].https://www.who.int/ publications/i/item/9789240014107.[3] World Health Organization.WHO guideline for screening and treatment of cervical pre‐cancer lesions for cervical cancer prevention, second edition[EB/OL].",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "[2021‐07‐07].https://www.who.int/publications/i/item/ 9789240030824 [4] 任文辉, 赵雪莲, 赵方辉.全球宫颈癌筛查指南制定现状的 系统综述[J].中华医学杂志, 2021, 101(24):1882‐1889.DOI: 10.3760/cma.j.cn112137‐20210115‐00134.[5] 国家卫生健康委员会.关于做好2019 年基本公共卫生服 务 项 目 工 作 的 通 知 [EB/OL].",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "[2021‐07‐14].http://www.nhc.gov.cn/jws/s7881/201909/83012210b4564f26a 163408599072379.shtml.[6] 中华预防医学会妇女保健分会.子宫颈癌综合防控指南 [M].北京: 人民卫生出版社, 2017.[7] 中国抗癌协会妇科肿瘤专业委员会.宫颈癌诊断与治疗指 南(第四版)[J].中国实用妇科与产科杂志, 2018, 34(6): 613‐622.",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "DOI: 10.19538/j.fk2018060111.[8] 国家卫生健康委员会 .对十三届全国人大二次会议第 6194 号建议的答复[EB/OL].[2021‐07‐14].http://www.nhc.gov.cn/wjw/jiany/202007/f96cf2aa5e8b45c5a9d 176029194c4c4.shtml.[9] 赵艳霞, 马兰, 任文辉, 等.2009—2018 年中国农村妇女宫 颈癌检查项目数据分析[J].",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "中华医学杂志, 2021, 101(24): 1863‐1868.DOI: 10.3760/cma.j.cn112137‐ 20210111‐ 00075.[10] Zhang J, Zhao Y, Dai Y, et al.Effectiveness of high‐risk human papillomavirus testing for cervical cancer screening in China: a multicenter, open‐label, randomized clinical trial[J].",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "JAMA Oncol, 2021, 7(2): 263‐270.DOI: 10.1001/jamaoncol.2020.6575.[11] Xia C, Xu X, Zhao X, et al.Effectiveness and cost‐effectiveness of eliminating cervical cancer through a tailored optimal pathway: a modeling study[J].",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "BMC Med, 2021, 19(1):62.DOI: 10.1186/s12916‐021‐01930‐9.[12] Xia $\\mathsf { C } ,$ Hu S, Xu $\\mathrm { ~ X , }$ et al.Projections up to 2100 and a budget optimisation strategy towards cervical cancer elimination in China: a modelling study[J].",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "Lancet Public Health, 2019, 4(9): e462‐e472.DOI: 10.1016/ S2468‐2667(19)30162‐8.[13] Zhang M, Zhong Y, Zhao Z, et al.Cervical cancer screening rates among Chinese women — China, 2015[J].China CDC Weekly, 2020, 2(26): 481‐486.DOI: 10.46234/ ccdcw2020.128.[14] 国家人民政府网.中国支持《加速消除宫颈癌全球战略》 [EB/OL].[2021‐07‐16].http://www.gov.cn/xinwen/ 2020‐12/10/content_5568770.htm.",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "· 临床指南· # 中国子宫颈癌筛查及异常管理相关问题专家共识 ( 一 ) 中国优生科学协会阴道镜和宫颈病理学分会专家委员会 子宫颈癌仍然是当代严重威胁女性健康的妇科恶性肿瘤。2014 年末我国人口 13.7 亿，其中女性约 6.67 亿（http: //data.stats.gov.cn/search.htm），35\\~64 岁女性约 2.93 亿，子宫颈癌的防治工作任重而道远。2015 年我国成立了由妇科、妇科肿瘤、病理学、妇幼保健、流行病学及基础研究多学科组成的中国优生科学协会阴道镜和宫颈病理学分会（Chinese Society for Colposcopy and Cervical Pathology of ChinaHealthy Birth Science Association，CSCCP），旨在推动我国子宫颈癌的防治水平。",
    "source": "中国子宫颈癌筛查及异常管理相关问题专家共识(一)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌筛查及异常管理相关问题专家共识(一)/中国子宫颈癌筛查及异常管理相关问题专家共识(一).md"
  },
  {
    "text": "自2009 年我国政府开始推行子宫颈癌筛查试点项目，已经进行了 7 年多的探索，至今尚无基于中国数据的子宫颈癌筛查及异常结果管理指南。为了提高子宫颈癌筛查防治效力，有必要提出现阶段的我国子宫颈癌防治专家共识以规范化指导临床工作。这将为积累中国子宫颈癌防治数据，制定符合中国国情的指南提供证据。围绕这一目标，结合我国经验 [1- 2] 和国外文献，经过四轮专家讨论，形成CSCCP 中国子宫颈癌筛查及异常管理相关问题专家共识，重点包括筛查中细胞病理学的质控管理，筛查结果异常者的管理、阴道镜的规范化检查，以及组织学确诊的子宫颈上皮内瘤变（CIN）和原位腺癌（AIS）的处理建议。",
    "source": "中国子宫颈癌筛查及异常管理相关问题专家共识(一)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌筛查及异常管理相关问题专家共识(一)/中国子宫颈癌筛查及异常管理相关问题专家共识(一).md"
  },
  {
    "text": "根据我国子宫颈癌防治现状，CSCCP 与中华医学会病理学分会、国家卫生计生委病理质控中心专家组多次讨论，对于细胞病理学质控管理及筛查结果异常者的管理达成以下共识。在此刊登部分内容供相关人员在子宫颈癌筛查和防治的临床工作中参考（由于篇幅有限，阴道镜规范化检查及组织学确诊的CIN 处理详见下期）。# 一、中国子宫颈癌的疾病负担和筛查管理现状 世界卫生组织/国际癌症研究机构（WHO/IARC）发布的数据显示，2012 年我国子宫颈癌新发病例约为 62 000例，占全球新发病例的 $12 \\%$ ，死亡病例约为30 000 例，占全球死亡病例的 $1 1 \\% ^ { \\left[ 3 \\right] }$ 。",
    "source": "中国子宫颈癌筛查及异常管理相关问题专家共识(一)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌筛查及异常管理相关问题专家共识(一)/中国子宫颈癌筛查及异常管理相关问题专家共识(一).md"
  },
  {
    "text": "根据中国国家癌症中心公布的最新数据估计，2015 年我国子宫颈癌新发病例约为98 900 例，死亡病例约为 $3 0 5 0 0$ 例 [4]。目前总体人群筛查率处于低水平，2010 年，全国城市平均子宫颈癌筛查率为 $2 9 .1 \\%$ ，东部经济发达地区约为 $3 1 .3 \\%$ ，农村约为 $1 6 .9 \\% ^ { [ 5 ] } \\cdot$ 。我国面临着严峻的子宫颈癌防治形势。目前我国拥有国际上常用的子宫颈癌筛查、分流、转诊技术，例如子宫颈脱落细胞学、人乳头瘤病毒（HPV）检测、肉眼观察（VIA/VILI）、p16/ki- 67 双染和阴道镜检查等，还有一些我国自主研发的技术方法 [6]。",
    "source": "中国子宫颈癌筛查及异常管理相关问题专家共识(一)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌筛查及异常管理相关问题专家共识(一)/中国子宫颈癌筛查及异常管理相关问题专家共识(一).md"
  },
  {
    "text": "我国子宫颈癌筛查面临的主要问题是覆盖率不足，无全国性子宫颈癌筛查指南和管理规范，筛查诊治不规范，过度医疗、诊疗不足或缺乏随访等情况屡有发生。中国地域辽阔、资源分布不均，更需要采取多元化的筛查策略。目前适宜中国的筛查技术和策略缺乏数据支撑；HPV 检测产品众多，缺乏充分的临床验证数据；细胞学、组织病理学、阴道镜医师缺乏规范化培训。现有条件下，子宫颈癌筛查及病变的临床管理多参考欧美国家的指南进行[7- 10]。",
    "source": "中国子宫颈癌筛查及异常管理相关问题专家共识(一)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌筛查及异常管理相关问题专家共识(一)/中国子宫颈癌筛查及异常管理相关问题专家共识(一).md"
  },
  {
    "text": "# 二、子宫颈癌筛查中细胞病理学的质控管理 1.关于设立筛查机构的原则：子宫颈细胞病理学实验室应隶属于医疗机构的病理科或在国家认定的独立实验室。尚未具备条件或未设立独立细胞病理学实验室的医疗机构，其细胞病理学诊断任务应由具备相应资质的病理科医师，或二级以上医院或独立医学实验室的相关部门承担完成。工作中按医疗管理条例规定签订协议，确保送检资料安全，诊断报告正确及时。2.宫颈细胞及组织病理学相关人员：诊断医师应由具有医师执业资质、接受过细胞及组织病理学专门培训，且考试合格，并取得岗位培训合格证书者担任。",
    "source": "中国子宫颈癌筛查及异常管理相关问题专家共识(一)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌筛查及异常管理相关问题专家共识(一)/中国子宫颈癌筛查及异常管理相关问题专家共识(一).md"
  },
  {
    "text": "筛查员应由具有医学大专及以上学历，且经过细胞病理学培训基地专业培训 6 个月以上，考试合格后获得细胞病理学筛查合格证者担任。细胞及组织病理学技术员由具备医学大专及以上学历，从事相应技术者担任。3.筛查工作量及人员配比：每位细胞病理学工作人员（包括诊断医师和筛查员）每工作日（8 h）妇科细胞学涂片阅片量不超过100 张；采用电脑辅助阅片的部门允许每人每工作日（8 h）阅片量不超过 200 张。原则上每位技术人员每天制片量不超过250 张。",
    "source": "中国子宫颈癌筛查及异常管理相关问题专家共识(一)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌筛查及异常管理相关问题专家共识(一)/中国子宫颈癌筛查及异常管理相关问题专家共识(一).md"
  },
  {
    "text": "4.细胞学及组织病理人员培训：采用现场和网络培训相结合方式，设置国家及省市培训基地和网络培训机构。CSCCP 联合中华医学会病理学分会细胞学组、卫计委临床病理质控中心及各省级临床病理质控中心建立培训基地。拥有高级职称细胞病理学专科医师、具备教研工作能力和条件、年细胞学检查量 $> 1 0 0 0 0$ 例、已开展传统巴氏涂片（Pap smear）、液基细胞学、细胞蜡块制作、HPV 检测等项目的三级甲等医院病理科和（或）独立医学实验检测机构，具备申请培训基地的资格，经专家评审确定诊断质量和质控优秀的单位可以被认定具有培训基地资格并给予授牌，行使培训任务。",
    "source": "中国子宫颈癌筛查及异常管理相关问题专家共识(一)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌筛查及异常管理相关问题专家共识(一)/中国子宫颈癌筛查及异常管理相关问题专家共识(一).md"
  },
  {
    "text": "已授牌基地接受CSCCP 每两年一次的基地考核，对不能达到要求的单位，取消基地资格。5.质量控制及方案：质量控制方案包括实验室标准、人员资质、整体诊治流程质控、SOP 文件、室内质控及室间质控记录等一系列评价体系。通过数据库及相关文档回顾性评价以下指标。$\\textcircled{1}$ TBS 各级判读的阳性检出率 $c > 5$ 000 例样本统计量）； $\\textcircled{2}$ 非典型鳞状上皮细胞/鳞状上皮内病变（ASC/SIL）比值； $\\textcircled{3}$ TBS 分级判读为不能明确诊断意义的非典型鳞状上皮细胞（ASC- US）、非典型鳞状上皮细胞不除外高度鳞状上皮内病变（ASC- H）、低度鳞状上皮内病变（LSIL）、高度鳞状上皮内病变（HSIL）、鳞状细胞癌（SCC）的高危型HPV 阳性率等。",
    "source": "中国子宫颈癌筛查及异常管理相关问题专家共识(一)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌筛查及异常管理相关问题专家共识(一)/中国子宫颈癌筛查及异常管理相关问题专家共识(一).md"
  },
  {
    "text": "以上各项指标应达到相应检查要求； $\\textcircled { 4 } > 1 0 0$ 例细胞学阳性标本，包括ASC- US、ASC- H、LSIL、HSIL、SCC、非典型腺细胞（AGC）、腺癌（AC），组织学最终确认结果（即宫颈切除术或子宫切除术后的子宫颈组织病理学诊断）的符合率； $\\textcircled{5}$ 阳性病例的随访登记制度和随访比例； $\\textcircled{6}$ 现场督察随机抽取连续10\\~20例阳性病例、20\\~30 例阴性病例、20 例室间质控标准片作现场考核。",
    "source": "中国子宫颈癌筛查及异常管理相关问题专家共识(一)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌筛查及异常管理相关问题专家共识(一)/中国子宫颈癌筛查及异常管理相关问题专家共识(一).md"
  },
  {
    "text": "# 三、子宫颈癌筛查结果异常的管理 子宫颈癌筛查结果异常包括子宫颈细胞学异常、高危型HPV 阳性（包括HPV16、18 型阳性及其他12 型阳性）。1.高危型HPV 阳性作为初筛时的处理：高危型HPV阳性处理见图1。![](images/e458105ddb42257aec1f8360bd999e5685238b6e32ffc65c51d5b2d3095a7861.jpg) 图1 高危型HPV 阳性的处理流程 因年轻女性是HPV 感染的高峰年龄，建议高危型HPV 检测用于30 岁以上女性。",
    "source": "中国子宫颈癌筛查及异常管理相关问题专家共识(一)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌筛查及异常管理相关问题专家共识(一)/中国子宫颈癌筛查及异常管理相关问题专家共识(一).md"
  },
  {
    "text": "2.子宫颈细胞学异常的处理：子宫颈细胞学是以形态学的变化评估肿瘤的发生发展。子宫颈涂片取材自子宫颈鳞柱交接部位的脱落细胞，脱落细胞的特征与活体细胞的特征不完全相同，且无组织结构。因此，子宫颈细胞学结果作为筛查结果，不能作为疾病的确定诊断，不能以此作为临床处理的依据。子宫颈细胞学异常的处理是指以细胞学作为初筛方法的异常细胞学的处理，见图 $2 .$ （1）细胞学ASC- US 处理：在异常细胞涂片中，ASC-US 占 $5 0 \\%$ 以上，是最常见的细胞学异常类型。",
    "source": "中国子宫颈癌筛查及异常管理相关问题专家共识(一)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌筛查及异常管理相关问题专家共识(一)/中国子宫颈癌筛查及异常管理相关问题专家共识(一).md"
  },
  {
    "text": "人群中ASC- US 的发病率为 $5 \\%$ 左右。ASC- US 女性中 HR- HPV 感染率为 $3 1 \\% \\sim 6 0 \\%$ ，可反映不同病理变化过程，包括高危型HPV 感染、CIN、癌、炎症及萎缩等。ASC- US 的可重复性差。细胞学ASC- US 中经子宫颈活检诊断CIN2/3 的概率在 $1 0 \\%$ 以下，浸润癌风险低，为 $0 .1 \\% \\sim 0 .2 \\%$ 。",
    "source": "中国子宫颈癌筛查及异常管理相关问题专家共识(一)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌筛查及异常管理相关问题专家共识(一)/中国子宫颈癌筛查及异常管理相关问题专家共识(一).md"
  },
  {
    "text": "由于造成ASC- US 的原因诸多，容易发生诊断不足或过度诊断是临床处理中的难题。![](images/7762745919d531725c3769a4540b9992d9af9a2ab310421c985f5189505d7bf6.jpg) 图2 宫颈细胞学异常的处理流程 特殊人群的ASC- US 处理：妊娠期可以按照图2 处理，也可以延迟至产后处理。21\\~24 岁女性可选择细胞学随访。（2）细胞学ASC- H 的处理：ASC- H 在人群中的平均检 出 率 为 $0 .",
    "source": "中国子宫颈癌筛查及异常管理相关问题专家共识(一)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌筛查及异常管理相关问题专家共识(一)/中国子宫颈癌筛查及异常管理相关问题专家共识(一).md"
  },
  {
    "text": "4 2 \\%$ 。在 ASC 中 ASC- US 约 占 $9 0 \\%$ ，ASC- H约占 $1 0 \\%$ 。ASC- H 的细胞改变具有HSIL 的特征，但诊断HSIL 的证据不足，多与高危型HPV 感染有关。子宫颈活检诊断 CIN2/3 的概率为 $2 4 \\% \\sim 9 4 \\%$ ，不同医疗机构或医师之间变化较大。对于细胞学ASC- H，不论HR- HPV 是阳性或阴性，均应直接转诊阴道镜检查。",
    "source": "中国子宫颈癌筛查及异常管理相关问题专家共识(一)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌筛查及异常管理相关问题专家共识(一)/中国子宫颈癌筛查及异常管理相关问题专家共识(一).md"
  },
  {
    "text": "（3）细胞学LSIL 处理：LSIL 在人群中平均检出率为$0 .9 \\%$ ，LSIL 大多预示 HPV 感染。Meta分析显示，LSIL 的高危型HPV 阳性率为 $8 3 \\% _ { \\textmd o }$ 。初次阴道镜发现 $\\geq$ CIN2 的概率为 $1 2 \\% \\sim 1 6 \\%$ 。特殊人群的LSIL 处理： $\\textcircled{1}$ 妊娠期 LSIL 可以按照图 2处理，若孕妇不接受阴道镜检查，也可以延迟至产后处理；$\\textcircled{2}$ 21\\~24 岁：可选择细胞学随访，如随访中细胞学异常则转诊阴道镜； $\\textcircled{3}$ 老年妇女，若年龄 $> 6 0$ 岁，建议选择高危型HPV 检测，也可按照图2 处理。",
    "source": "中国子宫颈癌筛查及异常管理相关问题专家共识(一)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌筛查及异常管理相关问题专家共识(一)/中国子宫颈癌筛查及异常管理相关问题专家共识(一).md"
  },
  {
    "text": "（4）细胞学 HSIL 处理：细胞学HSIL 并不常见，国外有报道细胞学 HSIL 在人群中平均检出率为 $0 .4 5 \\% _ { s }$ 。阴道镜指导下子宫颈活检诊断 $\\geq$ CIN2 的概率为 $7 0 \\% \\sim 7 5 \\%$ ，宫颈环形电切除术（LEEP）切除标本诊断 $\\geq$ CIN2 的概率为$8 4 \\% \\sim 9 7 \\%$ ，浸润癌为 $1 \\% \\sim 2 \\% .",
    "source": "中国子宫颈癌筛查及异常管理相关问题专家共识(一)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌筛查及异常管理相关问题专家共识(一)/中国子宫颈癌筛查及异常管理相关问题专家共识(一).md"
  },
  {
    "text": "$ 。当细胞学为 HSIL 应立即转诊阴道镜检查。（5）细胞学 AGC 处理：细胞学AGC 约占受检人群的$0 .5 \\%$ ，其中高危型 HPV 感染率约为 $2 0 \\%$ 。细胞学 AGC 往往与子宫颈癌、子宫内膜癌、卵巢癌、输卵管腺癌等一系列肿瘤性病变相关，但也可由反应性细胞改变、息肉等良性病变造成。有研究报道细胞学AGC 经组织病理学诊断CIN2/3 的概率为 $9 \\% \\sim 5 4 \\%$ ，AIS 为 $0 \\sim 8 \\%$ ，宫颈浸润癌为$1 \\% \\sim 9 \\%$ ，不同医疗机构和医师之间差别较大。",
    "source": "中国子宫颈癌筛查及异常管理相关问题专家共识(一)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌筛查及异常管理相关问题专家共识(一)/中国子宫颈癌筛查及异常管理相关问题专家共识(一).md"
  },
  {
    "text": "如果细胞学考虑为子宫内膜来源的 AGC，可以选择先做分段诊刮，如未见异常，再做阴道镜检查。3.细胞学联合高危型HPV 检测进行联合筛查结果异常的处理：近50 年来，子宫颈细胞学对于降低子宫颈癌发病率和死亡率的有效性得到了时间的检验。国际上子宫颈癌筛查和管理指南主要基于单独细胞学筛查结果所提示的风险而定。随着 HPV 检测技术的出现，数据显示其可以显著提高细胞学的敏感性，细胞学和高危型HPV 联合检测成为宫颈癌筛查的策略之一 [11]。",
    "source": "中国子宫颈癌筛查及异常管理相关问题专家共识(一)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌筛查及异常管理相关问题专家共识(一)/中国子宫颈癌筛查及异常管理相关问题专家共识(一).md"
  },
  {
    "text": "对于联合筛查结果异常者的管理以单独细胞学筛查发生 ${ \\mathsf { C I N } } 3 +$ 的风险为参考依据，采用同等风险同等管理的方案指导临床。美国凯撒健康机构（KPNC）2014 年的一项汇总研究发现，对于 $3 0 \\sim 6 4$ 岁 965 360 例女性，细胞学 LSIL 的 5 年$\\mathsf { C I N 3 + }$ 的累积风险为 $5 .2 \\%$ ，临床处理为直接转诊阴道镜。",
    "source": "中国子宫颈癌筛查及异常管理相关问题专家共识(一)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌筛查及异常管理相关问题专家共识(一)/中国子宫颈癌筛查及异常管理相关问题专家共识(一).md"
  },
  {
    "text": "高 危 型 HPV 阳 性 /ASC- US 的 5 年 $\\mathsf { C I N 3 + }$ 的累积风险为$6 .8 \\%$ ，高于LSIL 风险，依据同等风险同等管理，支持直接转诊阴道镜。单独细胞学阴性者的风险为 $0 .2 6 \\%$ ，3 年重复宫颈癌筛查。高危型 HPV 阴性/细胞学阴性风险为 $0 .0 8 \\%$ ，远低于 $0 .2 6 \\%$ 的阈值，提示可以选择更长时间的筛查间隔（例如5 年）[12]。",
    "source": "中国子宫颈癌筛查及异常管理相关问题专家共识(一)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌筛查及异常管理相关问题专家共识(一)/中国子宫颈癌筛查及异常管理相关问题专家共识(一).md"
  },
  {
    "text": "结合我国目前HPV 检测现状及细胞学质量参差不齐的实际情况，提出图3 所示流程。![](images/2a29100a083df198a554cb337e0871ad417ad3850afd0e947f98e85bc30b2b4e.jpg) 图3 宫颈细胞学 $^ +$ 高危型HPV 联合检测结果异常的处理流程 4.子宫颈癌筛查结果异常处理中应注意的问题：在子宫颈癌筛查结果异常的处理中要遵循规范化的原则，但规范化不能覆盖全部女性的具体情况，应在规范化的基础上进行个体化处理，可以参考患者年龄、临床表现、细胞学检查质量、HPV 检测、患者意愿、随访依从性经济条件、医疗资源、大夫经验、医疗水平，以及妇科医师、细胞学医师、组织病理学医师的水平等因素进行个体化处理，其目的是最大限度地避免漏诊和处理过度的问题。",
    "source": "中国子宫颈癌筛查及异常管理相关问题专家共识(一)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌筛查及异常管理相关问题专家共识(一)/中国子宫颈癌筛查及异常管理相关问题专家共识(一).md"
  },
  {
    "text": "# 四、结语 在子宫颈癌筛查异常管理方案中，该共识意见适用于健康筛查人群，并不一定完全适合临床患者的管理。前者是健康人群，而后者是有症状的个体。前者是在无症状人群中寻找可能的患者，后者是在有症状个体中明确疾病来源。不同人群的检查目标不同，选择的方法不尽相同。对于医院就诊的有症状患者，推荐采用细胞学和HPV 联合筛查。目前全国范围内细胞学检查质量有限，高危型 HPV 检测方法众多，在没有获得中国国内临床验证数据之前，建议参考既往有充分临床数据验证研究的文献报道。",
    "source": "中国子宫颈癌筛查及异常管理相关问题专家共识(一)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌筛查及异常管理相关问题专家共识(一)/中国子宫颈癌筛查及异常管理相关问题专家共识(一).md"
  },
  {
    "text": "建议临床医师根据该共识意见进行管理的同时，一定结合当地实际情况对患者进行诊疗，以免漏诊。执笔者：魏丽惠、赵昀、沈丹华、赵方辉、耿力、毕 蕙、徐海苗、李静然；秘书：李明珠 致谢：感谢CSCCP 专家委员会全体成员在共识编写过程中付出的努力。# 参 考 文 献 [ 1] 魏丽惠，吴久玲 .子宫颈癌检查质量保障及质量控制指 南.北京: 人民卫生出版社，2015.[ 2] 毕蕙，赵更力.子宫颈癌综合防控技术培训教程.",
    "source": "中国子宫颈癌筛查及异常管理相关问题专家共识(一)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌筛查及异常管理相关问题专家共识(一)/中国子宫颈癌筛查及异常管理相关问题专家共识(一).md"
  },
  {
    "text": "北京: 人 民卫生出版社，2015.[ 3] Fer l ay J , Soer j omat ar am I , Er vi k M, et al .GLOBOCAN 2012 v1.0, Cancer i nci dence and mort al i t y worl dwi de: I ARC CancerBase No.11.Lyon, France: I nt ernat i onal Agency f or Research on Cancer; 2013[ EB/ OL] .",
    "source": "中国子宫颈癌筛查及异常管理相关问题专家共识(一)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌筛查及异常管理相关问题专家共识(一)/中国子宫颈癌筛查及异常管理相关问题专家共识(一).md"
  },
  {
    "text": "[ 2014- 11- 20] .ht t p: / / gl obocan.i ar c.f r .[ 4] 陈万青, 郑荣寿, 张思维, 等.2012 年中国恶性肿瘤发病和 死亡分析 .中国肿瘤 , 2016, 5：1- 8.[ 5] Wang B, He M, ChaoA, et al .Cervi cal cancer screeni ng among adul t women i n Chi na.",
    "source": "中国子宫颈癌筛查及异常管理相关问题专家共识(一)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌筛查及异常管理相关问题专家共识(一)/中国子宫颈癌筛查及异常管理相关问题专家共识(一).md"
  },
  {
    "text": "Oncol ogi st , 2015, 20：627- 634.[ 6] 王临虹，魏丽惠.妇女常见病筛查技术指南.北京：人民卫 生出版社，2013.[ 7] Wri ght TC J r, Massad LS, Dunt on CJ , et al .2006 consensus gui del i nes f or t he management of women wi t h cervi cal i ntraepi thel i al neopl asi a or adenocarci noma i n si tu.",
    "source": "中国子宫颈癌筛查及异常管理相关问题专家共识(一)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌筛查及异常管理相关问题专家共识(一)/中国子宫颈癌筛查及异常管理相关问题专家共识(一).md"
  },
  {
    "text": "AmJ Obstet Gynecol , 2007, 197：340- 345.[ 8] Apgar BS, Ki ttendorf AL, Bettcher CM, et al .Update on ASC P consensus gui del i nes for abnormal cervi cal screeni ng tests and cervi cal hi st ol ogy.AmFamPhysi ci an, 2009 , 80：147- 155.",
    "source": "中国子宫颈癌筛查及异常管理相关问题专家共识(一)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌筛查及异常管理相关问题专家共识(一)/中国子宫颈癌筛查及异常管理相关问题专家共识(一).md"
  },
  {
    "text": "[ 9] Massad LS, Ei nst ei n MH, Huh WK, et al .2012 updat ed consensus gui del i nes for the management of abnormal cervi cal cancer screeni ng tests and cancer precursors.J LowGeni t Tract Di s, 2013, 17：S1- S27.",
    "source": "中国子宫颈癌筛查及异常管理相关问题专家共识(一)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌筛查及异常管理相关问题专家共识(一)/中国子宫颈癌筛查及异常管理相关问题专家共识(一).md"
  },
  {
    "text": "[ 10] Ameri can Col l ege of Obstetri ci ans and Gynecol ogi sts.Practi ce Bul l eti n No.157: Cervi cal cancer screeni ng and preventi on.Obst et Gynecol , 2016, 127：e1- e20.[ 11] Kat ki HA, Schi f f man M, Cast l e PE, et al .",
    "source": "中国子宫颈癌筛查及异常管理相关问题专家共识(一)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌筛查及异常管理相关问题专家共识(一)/中国子宫颈癌筛查及异常管理相关问题专家共识(一).md"
  },
  {
    "text": "Benchmarki ng $\\square N B +$ ri sk as the basi s for i ncorporati ng HPV and Pap cotesti ng i nto cervi cal screeni ng and management gui del i nes.J Low Geni t Tract Di s, 2013 , 17：S28- 35.[ 12] Gage J C, Schi f f man M, Kat ki HA, et al .Reassurance agai nst future ri sk of precancer and cancer conferred by a negati ve human papi l l omavi rus t est .J Nat l Cancer I nst , 2014, 106.（待续）",
    "source": "中国子宫颈癌筛查及异常管理相关问题专家共识(一)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌筛查及异常管理相关问题专家共识(一)/中国子宫颈癌筛查及异常管理相关问题专家共识(一).md"
  },
  {
    "text": "# WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention Use of dual-stain cytology to triage women after a positive test for human papillomavirus (HPV) !",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "[](images/e0708725dfd6ecd4f3e548f6f5efd49460446f3c6a07099ffc194520c8ce89a6.jpg) # WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention Use of dual-stain cytology to triage women after a positive test for human papillomavirus (HPV) # WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention: use of dual-stain cytology to triage women after a positive test for human papillomavirus (HPV) (WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition) ISBN 978-92-4-009165-8 (electronic version) ISBN 978-92-4-009166-5 (print version) # $\\circledcirc$ World Health Organization 2024 Some rights reserved.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services.The use of the WHO logo is not permitted.If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO).WHO is not responsible for the content or accuracy of this translation.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The original English edition shall be the binding and authentic edition”.Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (http://www.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "wipo.int/amc/en/mediation/rules/).Suggested citation.WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention: use of dual-stain cytology to triage women after a positive test for human papillomavirus (HPV).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Geneva: World Health Organization; 2024 (WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition).Licence: CC BY-NC-SA 3.0 IGO.ataloguing-in-Publication (CIP) data.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "CIP data are available at https://iris.who.int/.Sales, rights and licensing.To purchase WHO publications, see https://www.who.int/publications/book-orders.To submit requests for commercial use and queries on rights and licensing, see https://www.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "who.int/copyright.Third-party materials.If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.General disclaimers.The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.All reasonable precautions have been taken by WHO to verify the information contained in this publication.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "However, the published material is being distributed without warranty of any kind, either expressed or implied.The responsibility for the interpretation and use of the material lies with the reader.In no event shall WHO be liable for damages arising from its use.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Design: Studio FFFOG Layout: Green Ink Publishing Services Ltd # Contents Acknowledgements v Abbreviations vii Executive summary viii ![](images/dcce4b0dad5f46499e482d3517461b62db22ec73457b62714d1ac7f660e4eb6b.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "jpg) 1.Introduction 1 1.1 Background 1 1.2 Dual-stain cytology and interpretation of test results 3 1.3 Phased approach for development of updated recommendations and purpose of this guideline 3 1.4 Previous and existing WHO recommendations for screening and treatment to prevent cervical cancer, and definitions 5 1.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "5 Target audience 8 # 2.Methods for development of recommendations on HPV mRNA testing 9 2.1 Groups contributing to the guideline development process 9 2.2 Priority questions for review of evidence 10 2.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "3 Priority algorithms 11 2.4 Outcomes 12 2.5 Syntheses of evidence 13 2.6 Development of the recommendations 16 2.7 Management of the external peer review 17 ![](images/9bd1b4229054c16108f7ae5993f815fa522b7e0b27dbda1edf565715ced4b95c.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "jpg) 3.Recommendations on dual-stain cytology to triage women after a positive HPV nucleic acid test (NAT) result 18 4.Research gaps and further considerations for dual-stain cytology 22 5.Dissemination and updating of the guideline 23 5.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "1 Guideline dissemination and impact 23 5.2 Guideline update 24 ![](images/86504f29e773828a475f9582dac50734ad64fb086c898e9658de53af04d27f13.jpg) References 25 Annexes 28 Annex 1.Guideline groups 29 Annex 2.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Evidence-gathering teams and guideline task groups 37 Annex 3.Declarations of interests 38 Annex 4.Algorithms for use of dual-stain cytology as a triage test in the general population of women 40 Annex 5.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Recommendations for the use of HPV DNA tests and HPV mRNA tests and other cervical screening methods 43 Web Annex A.Syntheses of evidence.Available at: https://iris.who.int/handle/10665/342366 (includes IARC handbook materials and Supplementary materials 1–13) Web Annex B.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Evidence summaries.Available at: https://iris.who.int/handle/10665/376493 Web Annex C.Evidence-to-decision framework for dual-stain cytology to triage women after a positive test for human papillomavirus (HPV).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Available at: https://iris.who.int/ handle/10665/376494 # Acknowledgements The Department of Sexual and Reproductive Health and Research, the Department of Global HIV, Hepatitis and Sexually Transmitted Infections Programmes and the Department of Noncommunicable Diseases, Rehabilitation and Disability at the World Health Organization (WHO) would like to thank members of the Guideline Development Group (GDG) for their consistent availability and commitment to making this guideline possible, and the members of the External Review Group (ERG) and all other external contributors for their work.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The Departments are also grateful to the International Agency for Research on Cancer (IARC) for the literature reviews performed in the context of the updating of the IARC handbooks of cancer prevention: cervical cancer screening, Vol.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "18 (2021), which were extremely useful for this guideline development process.Special thanks go to Nancy Santesso, the guideline methodologist from McMaster University.The names of the members of the GDG and the ERG and those of the other contributors, in particular systematic reviewers, modellers and costing teams, are listed below, with full details provided in Annexes 1–3.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "We appreciate the overall support of the WHO Guidelines Review Committee (GRC) Secretariat during the guideline development process, with grateful thanks to Rebekah Thomas Bosco, who is leading the GRC Secretariat.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The WHO Steering Group was composed of Nathalie Broutet, Shona Dalal, Linda Eckert (who also supported the GDG, the working groups for specific aspects of the guideline, and the WHO Secretariat), Morkor Newman and Ajay Rangaraj.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "This group was assisted by Myriam Cortes and Jane Werunga-Ndanareh.Nathalie Broutet and Shona Dalal also led the guideline development process.The members of the GDG were Claire Achieng, Silvina Arrossi, Muhammad Atif Waqar, Ruth Awori, Ruanne Barnabas, Itamar Bento Claro, Neerja Bhatla, Marie-Claude Boily, Laia Bruni, Joanna Cain, Lameck Chinula, Z.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Mike Chirenje (GDG Co-Chair), Michael Chung, Flavia Miranda Correa, Miriam Cremer, Teresa Darragh, Lynette Denny, Silvia de Sanjosé, Mamadou Diop, Wachara Eamratsameekool, Julia Gage, Ali Ghanbari-Motlagh, Patti Gravitt, Margaret Happy, Tarek Hashem, Rolando Herrero, Priscilla Ingbian, Ebony Johnson, Bayarsaikhan Luvsandorj, Anne Mackie, Mauricio Maza, Kelle Moley, Sebitloane Motshedisi, Nelly Mugo, Raul Murillo, Laura Muzingwani, Ashrafun Nessa, Dorcas Obiri-Yeboah, Gina Ogilvie, Patrick Petignat, Maria Alejandra Picconi, Leeya Pinder, Walter Prendiville, Veronica Reis, Gracia Violetta Ross Quiroga, Vikrant Sahasrabuddhe, Pete Sasieni, Netsanet Shiferaw, Rose Slavkovsky, Myint Myint Thinn, Kerry Thomson, Julie Torode (GDG Co-Chair), Nicolas Wentzensen and Fanghui Zhao.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The members of the ERG were Raveena Chowdhury, Heather Cubie, Suzanne Garland, Sarita Ghimire, Zaki El Hanchi, Ha Hyeong In, Oh Jin Kyoung, Alejandra Meglioli, Mohammed Moawia, Lim Myong Cheol, Angélica Nogueira, Mark Schiffman, Saritha Shamsunder, Vanita Suri, Carolina Teran, Ted Trimble, Gino Venegas and Heather White.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "External contributors to the evidence profiles were Marc Arbyn, Karen Canfell, Michael Caruana, Owen Demke, Cindy Gavreau, Michaela Hall, Adam Keane, James Killen, Beatrice Lauby-Secretan, Gigi Lui, Diep Nguyen and Kate Simms.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The following individuals acted as observers at the GDG meeting: Benjamin Anderson, Danielle Engel, J.(Hans) Berkhof, Michelle Chevalier, Smiljka de Lussigny, Eduardo Franco, Lisa Pei-Ching Huang, Krishna Jafa, Jose Jeronimo, Somesh Kumar, Ilana Lapidos-Salaiz, David Mesher, Jasantha Odayar, Groesbeck Parham, Carmen Perez Casas and Felipe Roitberg, Anna Shakarishvili and Petra ten Hoope-Bender.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The WHO Secretariat included Maribel Almonte Pacheco, Prebo Barango, Partha Basu, Paul Bloem, Nathalie Broutet, Gary Clifford, Marilys Corbex, Myriam Cortes, Shona Dalal, Jean-Marie Dangou, Maeve De Mello, Gampo Dorji, Linda Eckert, Fayad El Sheikh, Elena Fidarova, Massimo Ghidinelli, Karima Gholbzouri, Rodolfo Gómez Ponce de León, Sami Gottlieb, Joumana George Hermez, Raymond Hutubessy, Andre Ilbawi, Naoko Ishikawa, Chandani Anoma Jayathilaka, Sharon Kapambwe, Rajat Khosla, Stephanie Yetunde Kuku, Hugues Lago, Beatrice Lauby-Secretan, Silvana Luciani, Priya Mannava, Dara Masoud, Manjulaa Narasimhan, Elick Narayan, Morkor Newman, Leopold Ouedraogo, Tina Purnat, Neena Raina, Ajay Rangaraj, Leanne Margaret Riley, Anita Sands, Catherine Sauvaget, Tshidi Sebitloane, Mukta Sharma, Hai-rim Shin, Slim Slama, Vitaly Smelov, Howard Sobel, Ute Ströher, Josaia Tiko, Huong Tran, Adriana Velazquez Berumen, Lara Vojnov and Hongyi Xu.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Funding for the preparation, development and printing of the guideline was provided by the UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), with the support of the United States President’s Emergency Plan for AIDS Relief (PEPFAR) through the United States Agency for International Development (USAID), and Unitaid.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# Abbreviations AIS adenocarcinoma in situ CIN cervical intraepithelial neoplasia CKC cold knife conization DOI declaration of interest ERG External Review Group EtD evidence-to-decision GDG Guideline Development Group GRC Guidelines Review Committee GRADE Grading of Recommendations Assessment, Development and Evaluation HPV human papillomavirus HRP UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction IARC International Agency for Research on Cancer LBC liquid-based cytology LEEP loop electrosurgical excision procedure (also known as LLETZ) LLETZ large-loop excision of the transformation zone (also known as LEEP) mRNA messenger ribonucleic acid (referring to HPV E6/E7 messenger RNA) NAAT nucleic acid amplification test NAT nucleic acid test1 PEPFAR The United States President’s Emergency Plan for AIDS Relief PICO population (P), intervention (I), comparator (C), outcome (O) SDG Sustainable Development Goal UNDP United Nations Development Programme UNFPA United Nations Population Fund UNICEF United Nations Children’s Fund USAID United States Agency for International Development VIA visual inspection with acetic acid WHO World Health Organization # Executive summary # Background In 2022, cervical cancer was the fourth most commonly occurring cancer among women globally and also the fourth leading cause of cancer deaths among women, accounting for around 662 000 new cases and around 349 000 deaths.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "It is the most common cancer in women in 25 countries, many of which are in sub-Saharan Africa.Even while recognizing varying incidence levels, cervical cancer can be eliminated as a public health problem, through the scale-up of the World Health Organization (WHO) Cervical Cancer Elimination Initiative.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "In May 2018, Dr Tedros Adhanom Ghebreyesus, Director-General of WHO, issued a call to action for the elimination of cervical cancer.In November 2020, the Director-General launched the Global Strategy to accelerate the elimination of cervical cancer.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The targets of the Global Strategy are to achieve by 2030: • $90 \\%$ of girls fully vaccinated with human papillomavirus (HPV) vaccine by age 15 years; $70 \\%$ of women screened with a high-performance test by 35 years of age and again by 45 years of age; and $90 \\%$ of women identified with cervical disease receive treatment.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Following the launch of the Global Strategy, a large panel of experts met to define the key areas of focus to increase access to screening and treatment to reach the 2030 targets.One of the agreed areas of focus was to update the existing 2013 WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention, and to simplify the algorithms.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "It was decided that WHO’s updated cervical cancer screening and treatment guidance would be developed in four phases.The output of the first phase was a large set of recommendations and good practice statements on screening and treatment, with a primary focus on the use of HPV DNA tests, and key clinical algorithms for screening and triage strategies (primary screening with HPV DNA-based tests, VIA or cytology, and triage tests after a positive primary screen, including partial genotyping, colposcopy, VIA or cytology) for both the general population of women (i.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "e.women who are presumed or confirmed to be HIV-negative) and those living with HIV.This output was published in July 2021.1 # Two approaches to screening and treatment are distinguished: In the “screen-and-treat approach”, the decision to treat is based on a positive primary screening test only.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "In the “screen, triage and treat approach”, the decision to treat is based on a positive primary screening test followed by a positive second test (a “triage” test), with or without histologically confirmed diagnosis.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The second phase was to develop recommendations for the use of HPV mRNA (messenger ribonucleic acid) tests as a primary screening test and dual-stain cytology as a triage test to detect cervical pre-cancer and prevent cervical cancer.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The recommendations for the use of HPV mRNA tests were published in December 2021.2 This current guideline presents the recommendations for dual-stain cytology as a triage test, thus completing the second phase.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Dual-stain cytology can be used as a triage test in the “screen, triage and treat approach” to cervical cancer prevention.It is performed on liquid-based cytology (LBC) slides (not on conventional Pap smears) to detect the presence of two proteins: p16 and Ki-67.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "These two proteins are co-expressed in cells that have been transformed by high-risk HPV.When both proteins are detected in the same cell(s), this is interpreted as a positive dual-stain cytology result, meaning that there is an increased risk that cervical intraepithelial neoplasia 2/3 (CIN 2/3) lesions, also referred to as high-grade squamous intraepithelial lesions, are present.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# Methods The guideline has been developed according to the WHO handbook for guideline development, second edition (2014).The Guideline Development Group (GDG) for this guideline was formed in early 2019 and, based on their clinical expertise, research and knowledge of tests in development, identified 13 clinical algorithms (involving several different screening tests) for screening and treatment that could be evaluated.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Seven of these algorithms were addressed in the July 2021 edition of the updated guideline and another four were addressed in the December 2021 edition, while the final two algorithms are addressed in this current guideline publication.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The GDG, WHO Steering Group and WHO Secretariat, methodologists and technical groups (see Annex 1) met several times to discuss the evidence pertaining to the previously established PICO (population, intervention, comparator, outcome) questions related to the algorithms using dual-stain cytology as a triage test.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "A review of published and unpublished data from cross-sectional and longitudinal studies, and a systematic review and meta-analysis of the accuracy of dual-stain cytology as a triage test were conducted.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "A natural-history-based population simulation model was used to estimate the risk of important outcomes (e.g.primary and recurrent high-grade CIN and cervical cancer) with the use of different triage tests used in screening and treatment strategies.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "In addition, modelling evaluated the number of treatments and the cost-effectiveness of the different strategies.Due to the paucity of data for the acceptability, feasibility, resources and equity aspects of the use of dual-stain cytology as a triage test, the views of the GDG were used to inform decisions.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "During the GDG meetings, the GDG members reviewed the evidence and made the recommendations presented in this guideline, applying the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# Summary of recommendations for the use of dual-stain cytology as a triage test to prevent cervical cancer In this publication, only recommendations for the use of dual-stain cytology as a triage test are presented.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Please refer to the previous edition of the guidelines for recommendations on screening and treatment to prevent cervical cancer with a focus on HPV DNA testing published in July 2021, and for recommendations with a focus on HPV mRNA testing published in December 2021.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "When using the term HPV NATs, we are referring to molecular nucleic acid tests (NATs) for the detection of high-risk (i.e.cancer-causing or oncogenic) HPV types, including the two types of tests, such as HPV DNA-based molecular NATs or HPV mRNA-based molecular NATs.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "3 # Recommendation for the general population of women: In a screen, triage and treat approach using HPV NATs as the primary screening test among the general population of women, WHO suggests using partial genotyping, colposcopy, VIA, cytology or dual-stain cytology to triage women after a positive HPV NAT result.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "![](images/c76822e241bf324ddb69b7145675e485c63389e939c5b15c27f7ea3c7c31460d.jpg) When providing dual-stain cytology to triage women after a positive HPV NAT, WHO suggests: using samples collected by the health worker; and retesting with HPV NAT 24 months after a negative dual-stain cytology result.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "These are conditional recommendations based on low-certainty evidence for dual-stain cytology as a triage test.# Remarks: The benefits and harms of the triage options are similar; therefore, the choice of triage method will be dependent on feasibility, training, programme quality assurance, capacity for follow-up testing and resources in countries.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Dual-stain cytology and the other triage options are used in the context of screening algorithms using HPV NATs as the primary screening test, which recommend screening intervals of 5–10 years for HPV DNA tests and 5 years for HPV mRNA tests.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# Recommendation for women living with HIV: No recommendation was made for using dual-stain cytology to triage women living with HIV after a positive HPV DNA test, because evidence on the outcomes of using dual-stain cytology applicable to this population was minimal.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Therefore, the following recommendation remains current for the use of triage tests for this population.In a screen, triage and treat approach using HPV DNA detection as the primary screening test among women living with HIV, WHO suggests using partial genotyping, colposcopy, VIA or cytology to triage women after a positive HPV DNA test.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# Programme implementation considerations Considering the implications for programme implementation, dual-stain cytology is most similar to LBC, among existing screening and triage options.Dual-stain cytology has been developed and validated for LBC slides, not for conventional Pap smears.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Hence, dual-stain cytology requires an LBC infrastructure.Dual-stain cytology also requires infrastructure for immunostaining, which may include an autostainer, and training is required for correct interpretation of dual-stain slides.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Proficiency in reading dual-stain cytology can be achieved faster than for Pap cytology, and reproducibility of dual-stain cytology results is higher than that of cytology.Being a cytological method needing specific laboratory infrastructure, dual-stain cytology cannot be implemented as a point-of-care test, but can be implemented in centralized, high-standard laboratories that serve multiple screening sites.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Experience implementing this technology in low-resource settings is lacking.Dual-stain cytology has not yet been validated in self-collected samples.It is critically important that dual-stain cytology is implemented within a health system that ensures adequate laboratory infrastructure, quality assurance, management and monitoring of follow-up testing for those women referred to 24-month follow-up surveillance after a negative dual-stain result.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# Introduction # 1.1 Background In 2022, cervical cancer was the fourth most commonly occurring cancer among women globally and also the fourth leading cause of cancer deaths among women, accounting for around 662 000 new cases and around 349 000 deaths.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "It is the most common cancer in women in 25 countries, many of which are in sub-Saharan Africa $( 7 )$ .Even while recognizing varying incidence levels, cervical cancer can be eliminated as a public health problem, through the scale-up of the World Health Organization (WHO) Cervical Cancer Elimination Initiative.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "In May 2018, Dr Tedros Adhanom Ghebreyesus, Director-General of WHO, issued a call to action for the elimination of cervical cancer.A WHO Global Strategy to accelerate the elimination of cervical cancer as a public health problem was presented and unanimously endorsed by the Seventy-third World Health Assembly in August 2020.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Subsequently, WHO officially launched the Global Strategy to accelerate the elimination of cervical cancer on 17 November 2020 (2).The targets of the Global Strategy are to achieve, by 2030: 90% of girls fully vaccinated with human papillomavirus (HPV) vaccine by age 15 years; $70 \\%$ of women screened with a high-performance test by 35 years of age and again by 45 years of age; and $90 \\%$ of women identified with cervical disease receive treatment ( $90 \\%$ of women with pre-cancer treated, and $90 \\%$ of women with invasive cancer managed) $( 2 )$ In the context of this Global Strategy, countries are updating their protocols for the prevention of cervical cancer and for the care and treatment of affected women.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Cervical cancer prevention also plays an integral role in reaching the Sustainable Development Goals (SDGs), both for health (SDG 3) and gender equality (SDG 5).To prevent cervical cancer, women can be screened using various tests to identify those who have or are at risk of cervical pre-cancer (see Table 1.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "1).Cervical intraepithelial neoplasia (CIN) is characterized by cellular changes in the transformation zone of the cervix.CIN is typically caused by infections with HPV, especially the high-risk HPV types such as types 16 and 18 (these two types cause more than $70 \\%$ of cervical cancers) $( 3 ,$ 4).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "CIN1 lesions – also referred to as low-grade squamous intraepithelial lesions – are morphological correlates of HPV infections.CIN2/3 lesions – also referred to as high-grade squamous intraepithelial lesions – are correlates of cervical pre-cancers that, if left untreated, may progress to cervical cancer (for further details, refer to Chapter 1 of WHO’s Comprehensive cervical cancer control guidance $[ 5 ]$ ).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "![](images/25fca34f28ddebf6498771f490d3ea5ca5ec2fa261f42446c06afa1e07b2c80c.jpg) Table 1.1 Three approaches to cervical cancer screening and future tests <html><body><table><tr><td>Molecular</td><td>Cytologic</td><td>Visual inspection</td></tr><tr><td>Nucleic acid tests (NAT)a 》 HPV DNA</td><td>Conventional Pap smeara</td><td>Visual inspection with acetic acid (VIA)a or with</td></tr><tr><td rowspan=\"3\">》 HPV mRNA</td><td>Liquid-based cytology</td><td>Lugol's iodine (VILI)</td></tr><tr><td>(LBC)a</td><td>》 naked eye</td></tr><tr><td>Dual-stain cytology to</td><td>》 magnified by colposcope or camera</td></tr><tr><td>Protein biomarkersb</td><td>identify p16 and Ki-67a</td><td>Automated visual</td></tr><tr><td>》 HPV antibodies</td><td></td><td>evaluation of digital</td></tr><tr><td>》 oncoproteins</td><td></td><td>imagesb</td></tr></table></body></html> a Current tests b Tests under evaluation (future tests).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The traditional method to screen women for cervical cancer has been cytology.The Papanicolaou (Pap) smear or liquid-based cytology (LBC) smear test checks whether cells in the cervix are abnormal.Cells are collected via speculum examination with a brush and swab, and placed either directly onto a slide to which a fixative is added (conventional cytology) or in a bottle with a liquid storage medium (LBC).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Abnormal cervical cells testing as “atypical squamous cells of undetermined significance (ASCUS), low grade to high grade” may mean that there are pre-cancer changes in the cervix that may lead to cervical cancer.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "When cytology results are positive, the diagnosis is confirmed by colposcopy, and appropriate treatment is informed by biopsy of suspicious lesions for histological diagnosis.In this guideline, “cytology” refers to either conventional cytology or LBC.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Newer screening tests introduced in the last 15 years include visual inspection with acetic acid (VIA) and molecular tests – mainly high-risk HPV DNA-based tests,4 which are suitable for use in all settings (Table 1.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "1).More recently, additional tests and techniques have been developed: (i) molecular tests such as those based on HPV mRNA (messenger ribonucleic acid), oncoprotein detection or DNA methylation; (ii) tests performed on cytological samples, such as p16/Ki-67 dual-stain cytology; and (iii) visual tests based on artificial intelligence/machine learning platforms (e.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "g.automated visual evaluation of digital images) (6–9).# 1.2 Dual-stain cytology and interpretation of test results The focus of this edition of the updated guideline is the use of dual-stain cytology as a triage test.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Dual-stain cytology is performed on liquid-based cytology (LBC) slides (not on conventional Pap smears) to detect the presence of two proteins: p16 and Ki-67.p16 protein is expressed in cells that have been transformed by high-risk HPV due to actions of the HPV oncoprotein E7.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "p16 overexpression is shown in most cervical pre-cancer lesions and cancers, but it is rarely observed in normal tissue.Co-expression of the antiproliferative p16 protein and the proliferation marker Ki-67 within the same cervical epithelial cell can be used as a surrogate marker of cell-cycle deregulation mediated by HPV oncoproteins.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "When dual-stain cytology slides show cervical epithelial cells with brown cytoplasmic p16 immunostaining and red nuclear Ki-67 immunostaining in the same cell(s), this is interpreted as a positive dual-stain cytology result, meaning there is an increased risk that CIN2/3 lesions are present.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# 1.3 Phased approach for development of updated recommendations and purpose of this guideline Following the 2020 launch of the Global Strategy to accelerate the elimination of cervical cancer as a public health problem $( 2 ) ,$ a large panel of experts met to define the key areas of focus to increase access to screening and treatment to reach the 2030 targets.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "One of the agreed areas of focus was to update the existing 2013 WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention (10), and to simplify the algorithms.# Guideline objective: To improve national strategies for screening and treatment to prevent cervical cancer in all women, including women living with HIV.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "![](images/361147af4755d9731051704ed900b1018cd08861f44446a856e53eff27fb7848.jpg) It was decided that WHO’s updated cervical cancer screening and treatment guidance would be developed in four phases: # Phase 1 Updated recommendations on screening and treatment and the clinical algorithms for the most commonly used primary screening tests (HPV DNA tests, VIA and cytology) and triage strategies (partial genotyping, colposcopy, VIA and cytology) for both women in general (i.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "e.women who are presumed or confirmed to be HIV-negative) and those living with HIV.Phase 1 also addresses routine screening programmes, the ages at which to initiate and stop screening, and the frequency of screening.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# Phase 2 Evaluate the evidence and develop recommendations for the clinical algorithms using (a) HPV mRNA tests and (b) dual-stain cytology as a triage test in women testing HPV-NAT positive for the general population of women and for women living with HIV.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Phase 3 Develop recommendations for the implementation of these screening and treatment strategies.# Phase 4 Establish a consolidated “living guideline” for screening and treatment tests and algorithms (combining all the output from Phases 1–3), which will allow the recommendations to be updated as new evidence becomes available and is evaluated.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The output of Phase 1 was a guideline that was published and launched in July 2021, WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition, presenting a large set of recommendations and good practice statements on screening and treatment, with a primary focus on the use of HPV DNA tests, and key clinical algorithms for screening and triage strategies for both the general population of women (i.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "e.women who are presumed or confirmed to be HIV-negative) and those living with HIV.For the rationale for the development of the new edition of recommendations for screening and treatment to prevent cervical cancer, please refer to section 1.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "3 of that guideline (11).In December 2021, recommendations for the use of HPV mRNA tests as a primary screening test were published as part of the output of Phase 2, in WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention: use of mRNA tests for human papillomavirus (HPV) (12).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "A policy brief summarizing the use of HPV DNA and HPV mRNA tests to screen for cervical pre-cancer was also published in 2022 (13).Summary tables of the July/HPV DNA and December/HPV mRNA 2021 recommendations are provided in Annex 5.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The objective of this second part of Phase 2 was to develop recommendations for the use of dual-stain cytology as a triage test for cervical cancer prevention – both in the general population of women and in women living with HIV.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "In addition to evidence gathered for the first two sets of recommendations, this guideline is also supported by evidence compiled in the IARC handbooks of cancer prevention: cervical cancer screening, Vol.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "18, and by Bouvard et al.in a special report in the New England Journal of Medicine (14, 15).The clinical flowcharts for the algorithms presented in this guideline include strategies using dual-stain cytology as a triage test in women who have received a positive HPV NAT result (HPV DNA or mRNA test).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "In the near future, the recommendations in this guideline will be integrated with the recommendations recently published in the two 2021 guidelines mentioned above, on the use of HPV DNA tests $( 7 7 )$ and the use of HPV mRNA tests $( 7 2 ) .",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "$ along with the forthcoming recommendations on the implementation of screening and treatment strategies (Phase 3), to develop a full consolidated “living guidelines” version of this guidance (Phase 4).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# 1.4 Previous and existing WHO recommendations for screening and treatment to prevent cervical cancer, and definitions In 2006, WHO published Comprehensive cervical cancer control: a guide to essential practice (C4GEP), which was updated in a second edition in 2014 $( 5 ) ,$ consolidating all the recommendations for screening and treatment to prevent and treat cervical cancer up to that year.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The consolidated C4GEP included the WHO recommendations for HPV vaccination, treatment of cervical cancer and pre-cancer lesions, and palliative care, as well as the recommendations from the previous edition (2013) of this guideline, then titled WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention (10).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "In 2019, WHO published guidance on the use of thermal ablation for treatment of cervical pre-cancer lesions (16) and in 2020, WHO published guidance documents to support the introduction and scale-up of screening and treatment interventions, specifically relating to HPV testing and relevant medical devices $( 7 7 )$ .",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "In the updated second edition of the recommendations on screening and treatment for cervical cancer prevention, two populations of women are referred to: women living with HIV and the general population of women, which refers to women who are presumed or confirmed to be HIV-negative, or whose HIV status may be unknown.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "In addition, two approaches to screening and treatment are distinguished, the “screen-and-treat approach” and the “screen, triage and treat approach”.# Screening and treatment approaches In the “screen-and-treat approach”, the decision to treat is based on a positive primary screening test only.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "![](images/2fc2b075d873463b83e14d87181b2cde4dbb580fb84769390af240d6a89b7f54.jpg) In the “screen, triage and treat approach”, the decision to treat is based on a positive primary screening test followed by a positive second test (a “triage” test), with or without histologically confirmed diagnosis.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "![](images/3e4f02ae485d0e12b8fc01bade41e4ce5a9a45ec675ffe2717f697502443caa9.jpg) In a screen-and-treat approach, treatment is provided based on a positive primary screening test alone, without triage (i.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "e.no second screening test and no histopathological diagnosis).• When the patient is eligible for ablative treatment, this should ideally be done immediately, at the same visit as the screening test (the single-visit approach).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "At some facilities, this is not feasible and a second visit is needed (the two-visit approach).Women who are not eligible for ablation can have excisional treatment on the same day if the clinic has the capacity for large-loop excision of the transformation zone (LLETZ).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "5 If LLETZ is not available on-site, women need to be referred for the excisional treatment or for further evaluation.In a screen, triage and treat approach, the triage test is done if the primary screening test is positive, and the decision to treat is made when both the primary test and the triage test are positive.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "• A positive triage test can lead to colposcopy with biopsy and histopathological examination for diagnosis to determine the appropriate treatment.The implementation of colposcopy and biopsy can be challenging, however, so this guideline also considers triage strategies that are not dependent on the availability of colposcopy.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "• When the primary screening test is positive, and the triage test is negative, women need appropriate follow-up evaluation at a specified interval in accordance with the recommendations.If the triage test is visual, a single visit combining screening, triage and treatment is also feasible.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The publication of the output of Phase 1 of the update of the recommendations for screening and treatment to prevent cervical cancer (in July 2021) presented 23 recommendations and 7 good practice statements (11).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Those recommendations focused mainly on the use of HPV DNA testing as the primary screening test.In addition, one recommendation addressed the types of triage tests that could be used after a positive primary screening test.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Later, in December 2021, the output of the first part of Phase 2 was published, presenting one recommendation on the use of HPV mRNA testing as the primary screening test (12).Table 1.2 provides a summary of those recommendations.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Table 1.2 Summary recommendations from the WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition: (i) HPV DNA tests and (ii) HPV mRNA tests <html><body><table><tr><td>General population of women</td><td>Women living with HIV</td></tr><tr><td>WHO suggests using either of the following strategies for cervical cancer prevention among the general population of women: 》 HPV DNA detection in a screen-and-treat approach starting at the age of 30 years</td><td>WHO suggests using the following strategy for cervical cancer prevention among women living with HIV: 》 HPV DNA detection in a screen, triage</td></tr><tr><td>with regular screening every 5 to 10 years.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "》 HPV DNA detection in a screen, triage and treat approach starting at the age of 30 years with regular screening every 5 to 10 years.</td><td>and treat approach starting at the age of 25 years with regular screening every 3 to 5 years.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td></tr><tr><td>WHO suggests that HPV mRNA detection using samples taken by the health worker may be used as a primary screening test, either with or without triage, to prevent cervical cancer in the general population of women with regular screening every 5 years.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td><td>No recommendation was made for using HPV mRNA in women living with HIV.</td></tr><tr><td>In a screen, triage and treat approach using NATs for HPV detection as the primary screening test among the general population of women, WHO suggests using partial genotyping, colposcopy, VlA or cytology to triage women after a positive HPV test.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td><td>In a screen, triage and treat approach using HPV DNA detection as the primary screening test among women living with HIv, WHO suggests using partial genotyping, colposcopy, VlA or cytology to triage women after a positive HPV DNA test.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td></tr></table></body></html> Sources: WHO, 2021 (11), WHO, 2021 $( 1 2 )$ .The full set of recommendations, along with relevant remarks, is provided in the guidance published in 2021 focused on the use of HPV DNA tests and the use of HPV mRNA tests (11, 12), and also in Annex 5 of this guideline.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# 1.5 Target audience This document is intended primarily for policy-makers, programme managers, programme officers and other professionals in the health sector who have responsibility for choosing strategies for cervical cancer prevention, at country, regional and district levels.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Health workers – such as doctors, nurses and community health workers working in reproductive health programmes, antenatal and postnatal services, family planning services, HIV/AIDS control programmes and in clinics that care for women at the district and primary health care levels – may also consult this document to understand how recommendations are developed and why it is vitally important to select and implement evidence-based strategies to prevent cervical cancer.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "This document could be used as the basis for developing an adapted publication for women and their families to support them in making decisions about cervical cancer screening and treatment.All individuals have the right to equality and non-discrimination in sexual and reproductive health care.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "In this guideline, we recognize that most of the available evidence on cervical cancer is based on study populations of cisgender women, and we also recognize that cisgender women, transgender men, non-binary, gender fluid and intersex individuals born with a female reproductive system require cervical cancer prevention services.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "However, to be concise and facilitate readability, we use the term “women” to refer to all gender diverse people at risk for cervical cancer.Sexual and reproductive health service providers and cervical cancer prevention services must consider the needs of – and provide equal care to – all individuals independently of gender identity or its expression.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# 2.Methods for development of recommendations on HPV mRNA testing This updated guideline has been developed in accordance with the methods described in the WHO handbook for guideline development, second edition (18).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "More detailed methods are described in the recent publication of the outputs of the first phase of the guideline update (11).Information in this section focuses on methods specific to this phase of the guideline update: dual-stain cytology as a triage test.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# 2.1 Groups contributing to the guideline development process Lists of all members of the Guideline Development Group (GDG), External Review Group (ERG), systematic review teams, modelling teams and other contributors are provided in Annex 1, with details of their expertise and affiliations.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The WHO Secretariat consisted of staff from various relevant WHO departments, and staff from the International Agency for Research on Cancer (IARC).The Steering Group of the WHO Secretariat led the coordination of the development of this guideline.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Members of the Secretariat who were not part of the Steering Group were kept informed of the guideline development process and participated in the discussions, in particular during meetings of the various teams.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "For the evaluation of the evidence and formulation of recommendations relating to dual-stain cytology, the GDG comprised 53 members (35 women, 18 men), from across all six WHO regions, including representatives from civil society organizations and women’s groups, and women living with HIV.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The members brought to the table their varied expertise on cervical screening and treatment.Two members acted as co-chairs and moderated the GDG meetings.Observers who attended the GDG meetings did not participate in the GDG discussions or vote on recommendations.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The ERG provided peer review for the guideline document.Its 18 members, none of whom was also a member of the GDG, had expertise in research, policy development, programme implementation and clinical care.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Once the GDG had agreed on the recommendations, the ERG reviewed the full draft of the guideline and provided feedback.Multiple teams prepared evidence relevant to dual-stain cytology (see details in Annex 2).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Two teams conducted evidence reviews relevant to dual-stain cytology – one on test accuracy of dual-stain cytology as a triage test to detect $\\mathsf { C l N } 2 +$ and ${ \\mathsf { C l N } } 3 + ,$ and one on longitudinal evidence for the use of dual-stain cytology.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "One team adapted a pre-existing comprehensive natural history microsimulation model to simulate the use of dual-stain cytology in the general population of women.A guideline methodologist with experience of using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach (19) coordinated the presentation of evidence and decision-making processes that facilitated the development of the recommendations, as stipulated in the WHO handbook for guideline development, second edition (18).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# 2.1.1 Declarations and management of conflicts of interest Each invited GDG member completed a written declaration of interest (DOI) form (including those who had completed them prior to participation in the first phase of the guideline update).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The DOIs were reviewed by two members of the WHO Secretariat and no conflicts of interest were identified (see Annex 3).At the beginning of every GDG meeting, members were asked to declare any potential new conflicts of interest.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# 2.1.2 Confidentiality Each GDG member also signed a confidentiality agreement at the beginning of the guideline development process, and the WHO Secretariat restated at the start of each GDG meeting that all discussions and draft recommendations were to remain confidential until publication.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# 2.2 Priority questions for review of evidence The questions for dual-stain cytology are based on the scoping review and the prioritization of research questions and algorithms for screening and treatment, which were performed by GDG members in 2019 at the start of the process of updating the WHO recommendations on this topic.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The key questions relating to dual-stain cytology (see Table 2.1) followed a similar format to those assessed for the first phase of the guideline update (11), referring to both the general population of women and women living with HIV.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Table 2.1 PICO questions for the recommendations in women <html><body><table><tr><td>PICO1</td><td>After a positive HPV NAT result, should dual-stain cytology be used as a triage test versus the use of partial genotyping, colposcopy, VIA or cytology as a triage test?",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td></tr><tr><td>PICO2</td><td>Should women be followed up after 12 or 24 months after a positive HPV NAT and a negative dual-stain cytology result?</td></tr></table></body></html> NAT: nucleic acid test; VIA: visual inspection with acetic acid.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# 2.3 Priority algorithms Since screening and treatment can be done using different primary screening and triage tests, there are numerous possible combinations or algorithms.In December 2019, GDG members were surveyed to prioritize the screening and/or triage tests and the treatments that should be evaluated.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Following this prioritization exercise, a subgroup of GDG members met to review the results from the survey and to agree on the algorithms to be prioritized.They reached a consensus to address seven priority algorithms in the first phase of the guideline update (see Annex 4 in that publication) (11), and to address four algorithms relevant to HPV mRNA testing as part of the second phase of the guideline update (see Annex 4 in that publication) (12).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "It was also decided to address two algorithms for this continuation of the second phase of the guideline update, related to triage testing using dual-stain cytology after a positive result on primary screening using an HPV DNA or HPV mRNA nucleic acid test (NAT).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "A positive dual-stain cytology result is followed by colposcopy to determine further management; a negative dual-stain cytology result is followed by a repeat HPV test after 24 months, as presented in Table 2.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "2.Post-treatment follow-up remains as in the first phase of the guideline update (11); the algorithm for this follow-up is presented in Annex 4, along with a combined algorithm flow chart for the two algorithms relating to triage using dual-stain cytology.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Table 2.2 The two algorithms considered <html><body><table><tr><td colspan=\"2\">Screen, triage and treat approachesa</td></tr><tr><td>1</td><td>HPV DNA as the primary screening test, followed by triage using dual-stain cytology, then further followed by colposcopy to determine further management </td></tr><tr><td>2</td><td>HPV mRNA as the primary screening test, followed by triage using dual-stain cytology, then further followed by colposcopy to determine further management</td></tr></table></body></html> # 2.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "4 Outcomes The GDG agreed that the critical outcomes previously identified for the 2013 first edition of this guideline (10) and for the 2021 guideline which presented the output of the first phase of the guideline update $( 7 7 )$ continued to be the critical outcomes for the new PICO questions; they are listed below.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# Critical outcomes for the screening and treatment recommendations cervical cancer mortality high-grade cervical intraepithelial neoplasia or worse $( C l N 2 + )$ HPV infection preterm birth pre-cancer treatments adverse events (direct consequence of pre-cancer treatment): – major infections or bleeding procedure-associated pain cervical stenosis infertility spontaneous abortion perinatal deaths premature rupture of membrane unnecessary interventions – increased viral shedding in women living with HIV costs equity acceptability feasibility.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Adverse events were defined as outcomes that were a direct consequence of pre-cancer treatment and were grouped as one category, with the exception of preterm birth, which was considered a critical outcome.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "For additional details and definitions, see Annex 5 in the previous 2021 edition of the guideline providing the output of the first phase of the guideline update $( 7 7 )$ .# 2.5 Syntheses of evidence Evidence was synthesized according to the methods in the WHO handbook for guideline development (18), and the Cochrane handbook for systematic reviews of interventions (20).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The literature review performed for the development of the IARC handbooks of cancer prevention: cervical cancer screening, Vol.18 (14) was also part of the evidence synthesized for the development of this guideline – details of this review and its methods were published in a special report in 2021 (15).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "It should be noted that both published and unpublished data from studies were included in the literature review.Many longitudinal studies are currently under way.Unpublished longitudinal studies were identified as expansions of previously published cross-sectional studies.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Additional unpublished longitudinal studies were identified through presentations at scientific meetings.Primary data from longitudinal studies were analysed individually using prevalence–incidence mixture models that can account for undiagnosed prevalent disease and interval censoring.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Triage testing using dual-stain cytology was evaluated alone or in combination with partial HPV genotyping.A systematic review of the relative diagnostic accuracy of dual-stain cytology compared with cytology as a triage test for detecting $\\mathsf { C l N } 2 +$ and $\\mathsf { C l N 3 + }$ was also performed.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The literature search was conducted from 1994 up to December 2021 in PubMed/MEDLINE, Embase and Scopus, and the references of included studies were also searched for additional sources of evidence.Random effects meta-analyses were conducted on the absolute clinical sensitivity and specificity of dual-stain cytology and of the relative sensitivity and specificity of dual-stain cytology compared with conventionally stained cytology, considering cytology at the cut-off of or exceeding atypical squamous cells of undetermined significance (ASCUS) and considering $\\mathsf { C l N } 2 +$ or $\\mathsf { C l N 3 + }$ as disease outcome.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Further details about the methods are provided in Web Annex B.Evidence summaries.The certainty of the evidence from the systematic reviews and modelling was assessed using the GRADE methodology.The four levels of certainty of evidence are summarized in Table 2.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "3.![](images/0a7238d05949ef7510bf3768de9224464659673f417a7e8108e78857106b35e0.jpg) Table 2.3 Interpretation of the GRADE levels of certainty of evidence Source: Schünemann et al., GRADE handbook (GRADEpro, 2013) (19) # 2.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "5.1 Mathematical modelling We used the Policy1-Cervix platform (developed by the Daffodil Centre, a joint venture between the University of Sydney and Cancer Council NSW, Australia), an extensively validated dynamic model of HPV transmission, vaccination, type-specific natural history, cancer survival, screening, diagnosis and treatment (21–29) to predict outcomes in the general population of women across 78 low- and lower-middle-income countries.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The Policy1-Cervix model was one of three models used by the Cervical Cancer Elimination Modelling Consortium (CCEMC) to evaluate the impact of cervical cancer prevention interventions in the 78 countries (21, 23).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "For the baseline analysis, we assumed that $70 \\%$ of women attended screening at each routine screening event and $90 \\%$ of women complied with follow-up at 12 months.Outcomes were assessed over the lifetime of birth cohorts eligible for screening starting in 2030, and included cervical cancer incidence and mortality, pre-cancer treatments, additional preterm deliveries as a result of pre-cancer treatment and costeffectiveness.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The cost of dual-stain cytology used as a triage test was assumed to be equivalent to cytology as a triage test in the baseline.In the sensitivity analysis, we varied the performance of dual-stain cytology, considered a higher cost, and considered the impact of rescreening women 24 months after a negative dual-stain cytology result with a $70 \\%$ compliance rate for returning instead of the base-case assumption of 12 months with a $90 \\%$ compliance rate for returning.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "For the analysis of dual-stain cytology, a specific validation exercise was performed to demonstrate that the Policy1-Cervix model predictions matched the available longitudinal information on the performance of dual-stain cytology as a triage test in HPV-positive women.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "We also performed a validation against emerging unpublished data on longitudinal outcomes of dual-stain cytology as a triage test for HPV-positive women stratified by 16/18 positivity.Detailed methods for the simulation modelling are presented in Supplementary material 13a, in Web Annex A (pp.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "173–190), which accompanied the publication of the outputs of the first phase of the guideline update (11).# 2.5.2 Values and preferences A systematic review was performed for the first phase of the guideline update to address, among other considerations, the values and preferences of end-users, health workers and other stakeholders for cervical cancer screening and treatment strategies.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The results of the literature review were compiled according to study design and methodology, location and population, and presented to the GDG.The evidence was assessed using the GRADE-CERQual approach (Confidence in the Evidence from Reviews of Qualitative Research)6 and confidence in the evidence was rated from very low to high in the summary of findings.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "A summary is presented in the evidence-to-decision (EtD) framework, which informed the development of the recommendations by the GDG (see Web Annex C), and the evidence tables are presented in Supplementary material 10, in Web Annex A (pp.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "131–144), which accompanied the publication of the outputs of the first phase of the guideline update (11).We also collected primary data from a voluntary and anonymous survey distributed via SurveyMonkey during the first phase of the guideline update.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The survey was open to all women and girls aged 15 years and older, regardless of their prior cervical cancer screening or treatment status.The survey received approval from the WHO Ethics Review Committee and was run in English and French from 22 June to 18 September 2020.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Awareness of the survey had been raised among a wide range of civil society groups through a webinar.The survey was also promoted through the Union for International Cancer Control and the WHO advisory group of women living with HIV, and shared through WHO regional focal points for the WHO Cervical Cancer Elimination Initiative.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "7 The responses from the 561 respondents, including their qualitative responses to open-ended questions, were analysed.The detailed methods and results are available in Supplementary material 9, in Web Annex A (pp.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "119–130), which accompanied the publication of the outputs of the first phase of the guideline update (11).Both the systematic review and the survey considered screening with cytology, VIA and HPV testing.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "There were, however, no data specific to the values and preferences specifically related to different triage tests, and therefore the views of the GDG were used to inform the criteria for values and preferences.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# 2.5.3 Feasibility, acceptability, resources and equity considerations Evidence came from a review of systematic reviews (as presented in Web Annex A), and a survey of the GDG members.A review of systematic reviews of the acceptability, feasibility, resources and equity considerations for the use of different screening tests included systematic reviews published since 2010 that synthesized results from studies with quantitative or qualitative designs.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Evidence about the use of cytology as a triage test was used to inform decisions about the use of dual-stain cytology as a triage test.Further information about the methods and findings are provided in Supplementary material 12, in Web Annex A (pp.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "165–172), which accompanied the publication of the outputs of the first phase of the guideline update (11).The survey of GDG members was administered via SurveyMonkey to assess the implementation feasibility considerations for all of the priority algorithms – this included an algorithm for triage using cytology and this was used to inform the assessment of the feasibility of using dual-stain cytology for triage testing.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The survey was developed using the context and implementation of complex interventions (CICI) framework (30).Each GDG member was asked about their level of concern about each algorithm being able to sustainably meet the large-scale goal of cervical cancer elimination.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The following components of cervical cancer screening and management service delivery were queried separately according to the priority algorithm: demand generation, access to screening and the follow-up management of positives, workforce training, infrastructure development and maintenance, development and maintenance of the screening registry, and cost and integration with other priority health services.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The considerations of the GDG members were assessed for the following eight stakeholder groups: health authorities at the national level, health authorities at the regional level, professional societies, health workers at both the hospital and primary care levels, community health workers, clients (screened women) and the community.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The detailed methods and results of the survey are provided in Supplementary material 11, in Web Annex A (pp.145–164), which accompanied the publication of the outputs of the first phase of the guideline update (11).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "During GDG meetings, the views of the members were gathered to complement the data specific to the use of dual-stain cytology, as there were very limited data specific to dual-stain cytology in the survey and the reviews.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# 2.6 Development of the recommendations All the GDG meetings that focused on formulation of recommendations were held virtually.Tables to facilitate decision-making for recommendations – EtD frameworks – were produced by the guideline methodologist for each recommendation.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "These tables included a summary of the evidence (benefits and harms), information on relevant values and preferences, and information on other issues, including use of resources, cost, feasibility, equity and acceptability.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "During the meeting, the evidence was discussed with the GDG.Following the meeting, the methodologist, systematic reviewers, modellers and WHO Steering Group assessed the GDG input and used it to write the recommendations.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Agreement on the recommendations was made by consensus during the GDG meetings, and the final written recommendations were then approved electronically.The responses solicited via email were either to approve, approve “with the following remarks” or not approve.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The GDG had agreed that, if consensus could not be reached, a majority vote of $5 1 \\%$ would have been accepted to make recommendations – yet the group did reach a consensus on all the recommendations.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Strong recommendations (worded as “WHO recommends”) were made when all the desirable consequences of the intervention clearly outweighed the undesirable consequences in most settings.Conditional recommendations (worded as “WHO suggests”) were made when the desirable consequences of the intervention probably outweighed the undesirable consequences in most settings.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Table 2.4 describes how strong and conditional recommendations should be interpreted.Table 2.4 Interpretation of strong and conditional recommendations <html><body><table><tr><td>Implications</td><td>Strong recommendation (WHO recommends.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "..)</td><td>Conditional recommendation (WHO suggests..)</td></tr><tr><td>For individuals</td><td>Most individuals in this situation would want the recommended course of action, and only a small proportion would not.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Formal decision aids are not likely to be needed to help individuals make</td><td>The majority of individuals in this situation would want the suggested course of action, but some may not.</td></tr><tr><td rowspan=\"2\">For health workers</td><td>and preferences.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Most individuals should receive the recommended course of action.Adherence to this recommendation</td><td>Clinicians should recognize that different choices may be appropriate for different individuals and that clinicians must help each individual</td></tr><tr><td>(when it aligns with national guidelines) could be used as a quality criterion or performance indicator.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td><td>arrive at a management decision consistent with the individual's values and preferences.Decision aids may be useful to help individuals make decisions consistent</td></tr><tr><td>For policy- makers</td><td>The recommendation can be adopted as policy in most situations.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td><td>with their values and preferences.Policy-making will require discussion and involvement of various stakeholders.</td></tr></table></body></html> Source: Schünemann et al., GRADE handbook (GRADEpro, 2013) (19).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "For information on important considerations for the recommendations, please refer to Chapter 3 of the published guideline that delivered the outputs of the first phase of the guideline update (11).# 2.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "7 Management of the external peer review The draft guideline document was circulated to the External Review Group (ERG) for comment.The WHO Secretariat prepared a summary table with all ERG responses and sorted the comments by topic or section.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The WHO Secretariat then reviewed the comments, which were minor wording changes, without any implications for the substance of the recommendations themselves, and the guideline document was finalized.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# 3.Recommendations on dual-stain cytology to triage women after a positive HPV nucleic acid test (NAT) result In this present publication, only recommendations for the use of dual-stain cytology as a triage test are presented.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Please refer to the July 2021 edition of the guideline for recommendations on screening and treatment to prevent cervical cancer, with a focus on HPV DNA testing (11).For recommendations with a focus on HPV mRNA, refer to the recommendations published in the December 2021 edition (12).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Summary tables of the 2021 recommendations are provided in Annex 5.# Recommendations for the general population of women: In a screen, triage and treat approach using HPV NATs as the primary screening test among the general population of women, WHO suggests using partial genotyping, colposcopy, VIA, cytology or dual-stain cytology to triage women after a positive HPV NAT result.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "![](images/e33c7650d4fd5cd16cea81f384fb97e52c3b96bdedd77ae8671ac9ee9a84ca2c.jpg) When providing dual-stain cytology to triage women after a positive HPV NAT, WHO suggests: using samples collected by the health worker; and retesting with HPV NAT 24 months after a negative dual-stain cytology result.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "These are conditional recommendations based on low-certainty evidence for dual-stain cytology as a triage test.# Remarks: The benefits and harms of the triage options are similar; therefore, the choice of triage method will be dependent on feasibility, training, programme quality assurance, capacity for follow-up testing, and resources in countries.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Dual-stain cytology and the other triage options are used in the context of screening algorithms using HPV NATs as the primary screening test, which recommend screening intervals of 5–10 years for HPV DNA tests and 5 years for HPV mRNA tests.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "See Annex 4 for detailed algorithms.# Recommendation for women living with HIV: No recommendation was made for using dual-stain cytology to triage women living with HIV after a positive HPV DNA test, because evidence on the outcomes of using dual-stain cytology applicable to this population was minimal.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Therefore, the following recommendation remains current for the use of triage tests for this population.![](images/b84e886678176413f7e3058198b252c3539bd47a571e0c78916cae5ad1493aad.jpg) In a screen, triage and treat approach using HPV DNA detection as the primary screening test among women living with HIV, WHO suggests using partial genotyping, colposcopy, VIA or cytology to triage women after a positive HPV DNA test.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# Programme implementation considerations Considering the implications for programme implementation, dual-stain cytology is most similar to LBC, among existing screening and triage options.Dual-stain cytology has been developed and validated for LBC slides, not for conventional Pap smears.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Hence, dual-stain cytology requires an LBC infrastructure.Dual-stain cytology also requires infrastructure for immunostaining, which may include an autostainer, and training is required for correct interpretation of dual-stain slides.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Proficiency in reading dual-stain cytology can be achieved faster than for Pap cytology, and reproducibility of dual-stain cytology results is higher than that of cytology.Being a cytological method needing specific laboratory infrastructure, dual-stain cytology cannot be implemented as a point-of-care test, but can be implemented in centralized, high-standard laboratories that serve multiple screening sites.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Experience implementing this technology in low-resource settings is lacking.Dual-stain cytology has not yet been validated in self-collected samples.It is critically important that dual-stain cytology is implemented within a health system that ensures adequate laboratory infrastructure, quality assurance, management and monitoring of follow-up testing for those women referred for 24-month follow-up surveillance after a negative dual-stain result.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# Justification Overall, there is low-certainty evidence for the balance of the benefits, harms and cost-effectiveness of using dual-stain cytology as a triage test after positive HPV NAT testing.The longitudinal evidence for the benefits of dual-stain cytology found that, compared with cytology, the risk of pre-cancers after 3–5 years may be lower in women with a negative result on dual-stain cytology, and higher in women who are dual-stain positive.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Evidence on the sensitivity and specificity of dual-stain cytology is likely non-inferior to evidence on cytology.Sensitivity and specificity results were used for modelling.Modelling data suggest that, at a “whole-of-population” level, and when considered over a lifetime of screening, there may be similar reductions in cervical cancer cases and deaths when using dual-stain cytology as a triage test for HPV-positive women compared with other triage tests (partial genotyping, colposcopy, VIA or cytology).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "At a whole-of-population level, modelling also predicted similar cost-effectiveness outcomes when using dual-stain cytology as a triage test, if it is assumed that the dual-stain cytology costs would be similar to the costs of cytology.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Use of dual-stain cytology as a triage test requires similar infrastructure to LBC, with the additional need for staining kits and equipment.Implementing dual-stain cytology in a programme that does not currently use quality-assured LBC may be challenging.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The cost to perform dual-stain cytology will to a large extent depend on manufacturer pricing, which will likely vary across settings – and the actual price will impact cost-effectiveness.Using dual-stain assays approved by a regulatory agency is appropriate.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "There is a paucity of evidence available on dual-stain cytology in women living with HIV, and data from the general population of women are not applicable to that population.Therefore, no recommendation was made for women living with HIV.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# Summary of the evidence The GDG considered evidence from cross-sectional and longitudinal studies, and from simulation modelling of long-term outcomes (refer to Web Annex B for the evidence summaries and Web Annex C for the EtD framework).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Data from 11 cross-sectional studies at low-to-moderate risk of bias were pooled in a meta-analysis to calculate the sensitivity and specificity of p16 detection alone or dual-stain cytology (for p16 and Ki-67 detection) as a triage test after women test positive for HPV DNA.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The studies were conducted in Australia, China, Italy, Mexico and the United States of America (USA), among the general population of women.There is some heterogeneity among the studies, but the range of variation was narrow for sensitivity and moderate for specificity.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Few studies measured longitudinal outcomes after the use of dual-stain cytology as a triage test: data were used from published and unpublished studies from Italy and the USA that reported longitudinal outcomes.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The follow-up data suggest that women who test negative on dual-stain cytology have a lower risk of pre-cancer after 3–5 years $( 2 - 4 \\% )$ when compared with women who test positive using dual-stain cytology $( 1 2 - 1 5 \\% )$ .",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "These predictors of risk may be better than with cytology as a triage test.There are currently no data from longitudinal studies from low- and middle-income countries (LMICs), and there is a paucity of data for women living with HIV.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The simulation used data extracted from the cross-sectional studies included in the analysis of the 11 cross-sectional studies on sensitivity and specificity (see Web Annexes B and C).For the purposes of the model, the costs of dual-stain triage testing were assumed to be equivalent to those of LBC as a triage, and the model was validated against the available longitudinal evidence.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Real-life costs of dual-stain cytology are currently higher than LBC due to immunostaining, but they may vary across settings, within the high range.Sensitivity analyses were conducted assuming higher cost, and under those conditions the results showed dual-stain cytology to be far less cost-effective than other triage methods (partial genotyping, colposcopy, cytology and VIA).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Long-term outcomes using HPV NATs for primary screening and using VIA, cytology, HPV 16/18 testing (partial genotyping), colposcopy or dual-stain cytology for triage were modelled.Two principal algorithms using dual-stain cytology for triage were considered: primary HPV DNA testing followed by triage using dual-stain cytology; and primary HPV mRNA testing followed by triage using dual-stain cytology.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Both algorithms assumed 12-month follow-up testing for women with negative results on dual-stain cytology used for triage; 24-month follow-up was also explored in the analyses.The findings, which are based on low-certainty evidence, suggest that when comparing the long-term effects of repeated rounds of testing – when implemented programmatically at 5-year screening intervals – algorithms using dual-stain cytology as a triage test for HPV DNA-positive women reduced cervical cancer incidence and mortality by $6 4 \\%$ compared with no screening, and algorithms using dual-stain cytology as a triage test for HPV mRNA-positive women reduced cervical cancer incidence and mortality by $6 0 .",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "3 \\%$ compared with no screening.These ranges are similar to what was reported in earlier analyses involving either primary HPV DNA $( 7 7 )$ or primary HPV mRNA testing $( 7 2 )$ .Compared with cytology triage, algorithms involving dual-stain triage resulted in a $1 \\%$ greater reduction in long-term cervical cancer incidence and mortality (for detailed results, see Web Annex C).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The modelling evidence also suggests that the number of treatments for pre-cancer lesions may be slightly higher using algorithms with dual-stain cytology for triage versus algorithms with cytology for triage, but lower compared with algorithms that use other triage tests.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The lifetime discounted costs of algorithms using dual-stain cytology for triage are similar to algorithms using cytology for triage (if dual-stain cytology costs are assumed to be similar to cytology costs), and higher than algorithms using other triage tests.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Overall, given these cost assumptions, the cost-effectiveness may be similar when using dual-stain cytology for triage compared with other triage tests.When assuming 24-month follow-up for women with a negative result on dual-stain triage, and assuming that compliance with follow-up at the 24-month visit is reduced from $90 \\%$ to $70 \\%$ , the modelling predicted that the reduction in cervical cancer mortality is $6 2 .",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "7 \\%$ compared with no screening, which is less of a reduction $1 .5 \\%$ smaller) than the scenario of 12-month follow-up with $90 \\%$ compliance.Much of this loss in effectiveness was because of the assumption that compliance with follow-up at the 24-month visit was reduced from $90 \\%$ to $70 \\%$ .",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "In most studies, samples were taken by health workers and therefore the recommendations are for this sampling method.Because of the paucity of data on dual-stain cytology in women living with HIV, a separate analysis could not be performed.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The GDG agreed that the recommendation presented here does not apply to women living with HIV.The GDG also considered whether there are advantages to using dual-stain cytology for triage rather than other triage tests.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The findings of the surveys and systematic reviews for values and preferences, acceptability, feasibility and equity that were performed for the first phase of the guideline (see Web Annex A) were considered when formulating this recommendation by applying the findings for cytology to dual-stain cytology.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "There was little evidence specific to the use of dual-stain cytology for triage testing, but from the survey and views of the GDG, it was agreed that there could be challenges providing dual-stain cytology as a triage test where LBC services are not currently available, quality controlled and quality assured.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "If available and affordable, dual-stain cytology as a triage test would probably outperform triage with cytology.# 4.Research gaps and further considerations for dual-stain cytology Although cross-sectional accuracy data (e.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "g.sensitivity and specificity of the tests) were available for the general population of women, and were used to inform the evidence on dual-stain cytology presented in this guideline, the GDG noted that longitudinal data, with follow-up for more than 5 years, are needed regarding the impact of dual-stain cytology when used within cervical screening programmes.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The majority of studies have been conducted in high-income settings, and therefore data generation in LMIC settings, where diagnostic and treatment capacities may be different from high-income settings, is needed.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "More studies comparing the accuracy of testing using self-collected samples versus health provider-collected samples are needed.Among women living with HIV, trials assessing the test performance of dual-stain cytology, and trials comparing the screen, triage and treat approach using dual-stain cytology as a triage test versus other triage tests are urgently needed.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "It is also important to conduct studies among this population in LMIC settings, where diagnostic and treatment capacities may be different from high-income settings.Furthermore, longitudinal studies that assess outcomes among women living with HIV over longer periods of time (e.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "g.3–5 years), including with different screening intervals and collection techniques, will be important to ascertain the long-term benefits and risks of different screening tests and strategies.Studies evaluating the implementation of screening and treatment strategies using dual-stain cytology for triage testing are also needed.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The studies should address the feasibility (including training, infrastructure needs and quality assurance) of dual-stain cytology, the acceptability by different stakeholders (including women and health workers) and the effect on accessibility and equity.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# 5.Dissemination and updating of the guideline # 5.1 Guideline dissemination and impact This recommendation will be integrated into a full consolidated version of WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, along with the outputs of the previous and next phases of the guideline update, in the near future.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "In brief, the outputs of each phase and the final consolidated guideline will be disseminated using WHO’s worldwide network to make sure that the guideline reaches health workers and programme managers so that the most recent evidence is integrated and accessible for clinical decision-making to prevent cervical cancer.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The full dissemination strategy was approved for the second edition and includes dissemination on the WHO website and in the next edition of HRP News, and printed copies will be disseminated upon request to health ministries, WHO country and regional offices, WHO collaborating centres on cervical cancer, and other cervical cancer collaborators and partners.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Policy briefs and an app will also be produced.The guideline will be translated into the six WHO official languages.Dissemination plans also include partners involved in the implementation and roll-out of cervical cancer screening and treatment programmes.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "These include other United Nations agencies, the United States President’s Emergency Fund for AIDS Relief (PEPFAR), the Global Fund and Unitaid.WHO headquarters will work with WHO regional offices and country offices to ensure that countries will be supported in the adoption, implementation and monitoring of the guideline.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "For this purpose, regional workshops and webinars in different languages will be organized to present, discuss and plan guideline adaptation and implementation, as well as to update current national guidelines.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "In addition, impact of the fully updated and consolidated guideline will be measured by developing and disseminating surveys for both health workers and clients, as was done during the guideline development on the topic of values and preferences.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "This will be done a year after release to assess any changes in country policies and national guidelines.This will also assess the reach of the guideline and ultimately its impact in changing practice.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Over the next year, WHO’s Comprehensive cervical cancer control: a guide to essential practice, which was last published in 2014 $( 5 )$ , will be revised to provide an up-to-date and global consolidation of all recommendations to prevent cervical cancer.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# 5.2 Guideline update Evidence for the sensitivity and specificity of the different tests addressed in the full updated guideline (including in this present guidance, focusing on dual-stain cytology) and evidence on the impact of these tests on important outcomes is accumulating, and syntheses of this evidence are needed.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "These syntheses will be used in a continual process to develop new recommendations – as part of the “living guidelines” approach – in the final phase of the guideline update (31).The GDG will continue to work with the WHO Secretariat in an ad hoc manner, so that the research gaps identified during the process can be addressed.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The GDG anticipates that as data and experience with new screening tests and modalities advance, new recommendations will be needed through a living guideline process that is able to rapidly respond and evolve.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# References 1.Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L et al.Global Cancer Observatory: Cancer Today [website].Lyon: International Agency for Research on Cancer; 2024 (https://gco.iarc.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "fr/today, accessed 8 March 2024).2.Global strategy to accelerate the elimination of cervical cancer as a public health problem.Geneva: World Health Organization; 2020 (https://iris.who.int/handle/10665/336583).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "3.Human papillomaviruses.IARC monographs on the evaluation of carcinogenic risks to humans, Vol.90.Lyon: International Agency for Research on Cancer; 2007 (https://publications.iarc.fr/ Book-And-Report-Series/Iarc-Monographs-On-The-Identification-Of-Carcinogenic-HazardsTo-Humans/Human-Papillomaviruses-2007).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "4.de Martel C, Plummer M, Vignat J, Franceschi S.Worldwide burden of cancer attributable to HPV by site, country and HPV type.Int J Cancer.2017;141(4):664–70.doi:10.1002/ijc.30716.5.Comprehensive cervical cancer control: a guide to essential practice, second edition.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Geneva: World Health Organization; 2014 (https://apps.who.int/iris/handle/10665/144785).6.Clarke MA, Gradissimo A, Schiffman M, Lam J, Sollecito CC, Fetterman B et al.Human papillomavirus DNA methylation as a biomarker for cervical precancer: consistency across 12 genotypes and potential impact on management of HPV-positive women.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Clin Cancer Res.2018;24(9):2194–202.doi:10.1158/1078-0432.CCR-17-3251.7.Hu L, Bell D, Antani $\\mathsf { S } , \\mathsf { X u e } \\mathsf { Z } , \\mathsf { Y u } \\mathsf { K } ,$ Horning MP et al.An observational study of deep learning and automated evaluation of cervical images for cancer screening.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "J Natl Cancer Inst.2019;111(9):923–32.doi:10.1093/jnci/djy225.8.Lie AK, Kristensen G.Human papillomavirus E6/E7 mRNA testing as a predictive marker for cervical carcinoma.Expert Rev Mol Diagn.2008;8(4):405–15.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "doi:10.1586/14737159.8.4.405.9.Sorbye SW, Fismen S, Gutteberg TJ, Mortensen ES, Skjeldestad FE.Primary cervical cancer screening with an HPV mRNA test: a prospective cohort study.BMJ Open.2016;6(8):e011981.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "doi:10.1136/bmjopen-2016-011981.10.WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention.Geneva: World Health Organization; 2013 (https://apps.who.int/iris/ handle/10665/94830).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "11.WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition.Geneva: World Health Organization; 2021 (https://apps.who.int/iris/ handle/10665/342365).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "12.WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition: use of mRNA tests for human papillomavirus (HPV).Geneva: World Health Organization; 2021 (https://apps.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "who.int/iris/handle/10665/350652).13.Human papillomavirus (HPV) nucleic acid amplification tests (NAATs) to screen for cervical pre-cancer lesions and prevent cervical cancer: policy brief.Geneva: World Health Organization; 2022 (https://apps.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "who.int/iris/handle/10665/352495).14.International Agency for Research on Cancer.IARC handbooks of cancer prevention: cervical cancer screening, Vol.18.Lyon, France: IARC Press; 2021 (https://publications.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "iarc.fr/Book-AndReport-Series/Iarc-Handbooks-Of-Cancer-Prevention/Cervical-Cancer-Screening-2022).15.Bouvard V, Wentzensen N, Mackie A, Berkhof J, Brotherton J, Giorgi-Rossi P et al.The IARC perspective on cervical cancer screening.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Special report.N Engl J Med.2021;385:1908–18.doi:10.1056/NEJMsr2030640.16.WHO guidelines for the use of thermal ablation for cervical pre-cancer lesions.Geneva: World Health Organization; 2019 (https://apps.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "who.int/iris/handle/10665/329299).17.Introducing and scaling up testing for human papillomavirus as part of a comprehensive programme for prevention and control of cervical cancer: a step-by-step guide.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Geneva: World Health Organization: 2020 (https://apps.who.int/iris/handle/10665/336668).18.WHO handbook for guideline development, second edition.Geneva: World Health Organization; 2014 (https://apps.who.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "int/iris/handle/10665/145714).19.Schünemann H, Brożek J, Guyatt G, Oxman A.GRADE handbook: handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach.GRADEpro; updated October 2013 (https://gdt.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "gradepro.org/app/handbook/handbook.html).20.Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ et al., editors.Cochrane handbook for systematic reviews of interventions, version 6.4 (updated August 2023).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Cochrane; 2023 (www.training.cochrane.org/handbook).21.Brisson M, Kim JJ, Canfell K, Drolet M, Gingras G, Burger EA et al.Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Lancet.2020;395(10224):575–90.doi:10.1016/ S0140-6736(20)30068-4.22.Burger EA, Smith MA, Killen J, Sy S, Simms KT, Canfell K, Kim JJ.Projected time to elimination of cervical cancer in the USA: a comparative modelling study.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Lancet Public Health.2020.5(4):e213–e222.doi:10.1016/S2468-2667(20)30006-2.23.Canfell K, Kim JJ, Brisson M, Keane A, Simms KT, Caruana M et al.Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Lancet.2020;395(10224):591–603.doi:10.1016/S0140- 6736(20)30157-4.24.Hall MT, Simms KT, Lew JB, Smith MA, Brotherton JML, Saville M et al.The projected timeframe until cervical cancer elimination in Australia: a modelling study.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Lancet Public Health.2019;4(1):e19–e27.doi:10.1016/S2468-2667(18)30183-X.25.Kitchener HC, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, Peto J.The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Health Technol Assess.2014;18(23):1–196.doi:10.3310/hta18230.26.Lew J-B, Simms K, Smith M, Lewis H, Neal H, Canfell K.Effectiveness modelling and economic evaluation of primary HPV screening for cervical cancer prevention in New Zealand.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "PLoS ONE.2016;11(5):e0151619.doi:10.1371/journal.pone.0151619.27.Lew J-B, Simms KT, Smith MA, Hall M, Kang YJ, Xu XM et al.Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Lancet Public Health.2017;2(2):e96–e107.doi:10.1016/S2468-2667(17)30007-5.28.Shi JF, Canfell K, Lew JB, Zhao F-H, Legood R, Ning Y et al.Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "BMC Cancer.2011;11:239.doi:10.1186/1471- 2407-11-239.29.Simms KT, Steinberg J, Caruana M, Smith MA, Lew J-B, Soerjomataram I et al.Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020–99: a modelling study.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Lancet Oncol.2019;20:394–407.doi:10.1016/S1470-2045(18)30836-2.30.Pfadenhauer LM, Gerhardus A, Mozygemba K, Lysdahl KB, Booth A, Hofmann B et al.Making sense of complexity in context and implementation: the Context and Implementation of Complex Interventions (CICI) framework.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Implement Sci.2017;12(1):21.doi:10.1186/s13012-017-0552-5.31.Vogel J, Dowswell T, Lewin S, Bonet M, Hampson L, Kellie F et al.Developing and applying a “living guidelines” approach to WHO recommendations on maternal and perinatal health.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "BMJ Glob Health.2019;4(4):e001683.doi:10.1136/bmjgh-2019-001683.![](images/5a48efd133ca1e72be35f007bf0f26c154ca97e743c29078848a8b046b844a6a.jpg) # Annex 1.Guideline groups ![](images/989ae304d829115dd1d6917ff647e4233edd09eb3635aed94ed562ee54d43d46.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "jpg) Guideline Development Group (GDG) members <html><body><table><tr><td>WHO region</td><td>Last name</td><td>First name</td><td>Institution</td><td>Country</td></tr><tr><td>Africa</td><td>Achieng </td><td>Claire Judith Ikate</td><td>Uganda Cancer Society</td><td>Uganda</td></tr><tr><td>Africa </td><td>Awori</td><td>Ruth</td><td>Representative from communities of women living with HIV</td><td>Uganda </td></tr><tr><td>Africa</td><td> Chinula</td><td>Lameck </td><td>Kamuzu Central Hospital </td><td> Malawi</td></tr><tr><td>Africa</td><td>Chirenje</td><td>Z.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Mike </td><td>University of Zimbabwe</td><td>Zimbabwe </td></tr><tr><td>Africa</td><td>Denny </td><td>Lynette </td><td>University of Cape Town</td><td> South Africa</td></tr><tr><td>Africa</td><td>Diop</td><td>Mamadou</td><td>Joliot Curie Cancer Institute</td><td>Senegal</td></tr><tr><td>Africa</td><td>Happy </td><td>Margaret</td><td>Advocacy for Quality Health Uganda</td><td> Uganda</td></tr><tr><td>Africa </td><td>Ingbian</td><td> Priscilla</td><td>Community health support and empowerment initiative </td><td>Nigeria</td></tr><tr><td>Africa</td><td>Motshedisi</td><td>Sebitloane</td><td>University of Kwazulu-Natal</td><td>South Africa</td></tr><tr><td>Africa</td><td>Mugo</td><td>Nelly </td><td>Kenya Medical Research Institute</td><td>Kenya </td></tr><tr><td>Africa</td><td> Muzingwani</td><td>Laura </td><td>I-TECH Namibia</td><td>Namibia</td></tr><tr><td>Africa</td><td>Obiri-Yeboah</td><td>Dorcas</td><td>University of Cape Coast </td><td>Ghana</td></tr><tr><td>Africa</td><td> Shiferaw</td><td>Netsanet </td><td> Pathfinder International </td><td>Ethiopia</td></tr><tr><td>The Americas</td><td>Arrossi</td><td>Silvina</td><td>Centro de Estudios de Estado y Sociedad (CEDES)</td><td>Argentina</td></tr><tr><td>The Americas</td><td>Barnabas</td><td>Ruanne </td><td>University of Washington</td><td>United States of America (USA)</td></tr><tr><td>The Americas</td><td>Bento Claro</td><td>Itamar</td><td>National Cancer Institute José Alencar Gomes da Silva (INCA)</td><td>Brazil</td></tr><tr><td>The Americas</td><td>Chung</td><td>Michael</td><td>Emory University</td><td>USA</td></tr><tr><td>The Americas</td><td>Correa</td><td></td><td>Flavia Miranda Brazilian National Cancer Institute </td><td> Brazil</td></tr><tr><td>The Americas</td><td>Cremer </td><td>Miriam</td><td>Basic Health International</td><td>USA</td></tr></table></body></html> <html><body><table><tr><td></td><td></td><td></td><td></td><td>Country</td></tr><tr><td>The Americas</td><td>Darragh</td><td>Teresa </td><td>Urniersty ofCalfona san</td><td>USA</td></tr><tr><td>The Americas</td><td>de Sanjosé</td><td> Silvia</td><td>National Cancer Institute </td><td>USA</td></tr><tr><td>The Americas</td><td>Gage</td><td>Julia</td><td>National Cancer Institute</td><td>USA</td></tr><tr><td>The Americas</td><td> Gravitt </td><td>Patti</td><td>fortinaar stute ener</td><td>USA</td></tr><tr><td>The Americas</td><td></td><td>Rolando</td><td> Costa Rican Agency for</td><td>USA</td></tr><tr><td>The Americas</td><td></td><td></td><td>Biomedical Research Representatvfrm muniies</td><td></td></tr><tr><td></td><td>Johnson </td><td>Ebony</td><td></td><td>USA</td></tr><tr><td>The Americas The Americas</td><td>Maza Murillo</td><td>Mauricio Raul </td><td>Basic Health International Hospital Universitario San Ignacio</td><td>El Salvador Colombia</td></tr><tr><td>The Americas</td><td>Moley</td><td>Kelle</td><td>BiMein Gete Fuates</td><td>USA</td></tr><tr><td>The Americas</td><td> Ogilvie</td><td></td><td>BC Women's Hospital and Health </td><td></td></tr><tr><td>The Americas</td><td></td><td></td><td>Centre HPV Reference Laboratory.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Maria Alejandra National Institute for Infectious </td><td></td></tr><tr><td>The Americas</td><td></td><td></td><td>Diseases - ANLIS \"Dr Malbran\"</td><td></td></tr><tr><td>The Americas</td><td> Pinder </td><td>Leeya Veronica</td><td>University of Washington Jhpiego</td><td>USA USA</td></tr><tr><td></td><td>Reis</td><td></td><td> Bolivian Network of People Living</td><td></td></tr><tr><td>The Americas</td><td>Ross Quiroga</td><td>Gracia Violetta</td><td>with HIV/AIDS</td><td>Bolivia</td></tr><tr><td>The Americas The Americas</td><td>Sahasrabuddhe</td><td>Vikrant </td><td>National Cancer Institute PATH</td><td>USA USA</td></tr><tr><td>The Americas </td><td>Slavkovsky</td><td>Rose</td><td>PATH</td><td>USA</td></tr><tr><td>The Americas</td><td>Thomson Wentzensen </td><td>Kerry Nicolas</td><td>National Cancer Institute</td><td>USA</td></tr><tr><td>Eastern </td><td>Atif Waqar </td><td>Muhammad</td><td>Aga Khan University Hospital</td><td> Pakistan </td></tr><tr><td>Mediterranean Eastern </td><td>Ghanbari-Motlagh Ali </td><td></td><td>Ministry of Health </td><td>Iran </td></tr><tr><td>Eastern Mediterranean </td><td>Hashem </td><td>Tarek </td><td>Menofyia University</td><td>Egypt </td></tr></table></body></html> <html><body><table><tr><td>WHO region</td><td>Last name</td><td>First name</td><td>Institution</td><td>Country</td></tr><tr><td>Europe</td><td>Bruni</td><td>Laia</td><td>Catalan Institute of Oncology</td><td>Spain</td></tr><tr><td>Europe</td><td>Boily</td><td>Marie-Claude </td><td>Imperial College London</td><td>United Kingdom of Great Britain and Northern Ireland</td></tr><tr><td>Europe</td><td>Cain</td><td>Joanna</td><td>International Federation of Obstetrics and Gynecology (FIGO)</td><td>United Kingdom</td></tr><tr><td>Europe</td><td>Kelly</td><td>Helen </td><td>Trndien SchlofHygie and</td><td>United Kingdom</td></tr><tr><td>Europe</td><td>Mackie</td><td>Anne</td><td>Public Health England Screening and Screening Quality Assurance Service</td><td>United Kingdom</td></tr><tr><td>Europe</td><td>Petignat</td><td> Patrick</td><td>Hopitaux Universitaires de Geneve </td><td>Switzerland</td></tr><tr><td>Europe</td><td>Prendiville</td><td>Walter</td><td>International Agency for Research on Cancer (IARC)</td><td>France </td></tr><tr><td>Europe</td><td>Sasieni</td><td> Peter </td><td>King's College London</td><td>United Kingdom</td></tr><tr><td>Europe</td><td>Torode</td><td>Julie</td><td>King's College London</td><td>United Kingdom</td></tr><tr><td>South-East Asia</td><td>Bhatla</td><td>Neerja</td><td>All India Institute of Medical Sciences</td><td>India</td></tr><tr><td>South-East Asia</td><td>Eamratsameekool </td><td>Wachara</td><td>Phanomphrai Community Hospital Thailand </td><td></td></tr><tr><td>South-East Asia</td><td>Nessa</td><td>Ashrafun</td><td>Bangabandhu shih Mujib</td><td>Bangladesh</td></tr><tr><td>South-East Asia</td><td>Thinn </td><td>Myint Myint </td><td>Central Women's Hospital</td><td>Myanmar </td></tr><tr><td>Western Pacific</td><td>Luvsandorj</td><td>Bayarsaikhan</td><td>National Cancer Center of Mongolia</td><td>Mongolia</td></tr><tr><td>Western Pacific</td><td>Zhao</td><td> Fanghui</td><td>China Cancer Institute</td><td>China</td></tr></table></body></html> # External Review Group (ERG) members <html><body><table><tr><td>WHO region</td><td>Last name</td><td>First name</td><td>Institution</td><td>Country</td></tr><tr><td>The Americas</td><td>Meglioli</td><td>Alejandra</td><td>International Planned Parenthood Federation/Western Hemisphere Region </td><td>USA</td></tr><tr><td>The Americas</td><td>Nogueira</td><td>Angélica</td><td>Federal University of Mina Gerais, Brazilian Society of Medical Oncology</td><td>Brazil</td></tr><tr><td>The Americas</td><td>Schiffman </td><td>Mark</td><td>National Cancer Institute</td><td>USA</td></tr><tr><td>The Americas</td><td>Teran </td><td>Carolina</td><td>Universidad Mayor, Real y Pontificia de San Francisco Xavier de Chuquisaca</td><td>Bolivia</td></tr><tr><td>The Americas</td><td>Trimble</td><td>Ted </td><td>National Cancer Institute</td><td>USA</td></tr><tr><td>The Americas</td><td>Venegas</td><td>Gino</td><td>Facultad de Medicina, Universidad de Piura</td><td>Peru </td></tr><tr><td>The Americas</td><td>White</td><td>Heather</td><td>TogetHER for Health</td><td>USA</td></tr><tr><td>Eastern Mediterranean</td><td>El Hanchi</td><td>Zaki</td><td>National Institute of Oncology, CHU</td><td>Morocco</td></tr><tr><td>Eastern Mediterranean</td><td>Moawia</td><td>Mohammed</td><td>National Cancer Institute, University of Gezira</td><td>Sudan </td></tr><tr><td>Europe</td><td>Chowdhury</td><td>Raveena</td><td>MSI Reproductive Choices UK</td><td>United Kingdom</td></tr><tr><td>Europe</td><td>Cubie</td><td>Heather</td><td>University of Edinburgh</td><td>United Kingdom</td></tr><tr><td>South-East Asia</td><td>Ghimire </td><td> Sarita </td><td>Nepal Cancer Care Foundation</td><td>Nepal </td></tr><tr><td>South-East Asia</td><td>Shamsunder </td><td>Saritha </td><td>Safdarjung Hospital </td><td>India </td></tr><tr><td>South-East Asia</td><td>Suri </td><td>Vanita </td><td>Department of Obstetrics and Gynecology, Postgraduate Institute of Medical Education and Research</td><td>India</td></tr><tr><td>Western Pacific</td><td>Garland </td><td>Suzanne</td><td>University of Melbourne</td><td> Australia</td></tr><tr><td>Western Pacific</td><td>In </td><td>Ha Hyeong</td><td>Center for Gynecologic Cancer, National Cancer Center</td><td>Republic of Korea</td></tr><tr><td>Western Pacific</td><td> Jin-Kyoung</td><td>Oh</td><td>Department of Cancer Control and Population Health Research, National Cancer Center</td><td>Republic of Korea</td></tr><tr><td>Western Pacific</td><td>Myong Cheol </td><td>Lim</td><td>Center for Gynecologic Cancer, National Cancer Center</td><td>Republic of Korea</td></tr></table></body></html> # Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodologist supporting guideline development Nancy Santesso Department of Health Research Methods, Evidence and Impact McMaster University, Hamilton, Canada Area of expertise: guideline development, systematic reviews, clinical epidemiology # Systematic review teams <html><body><table><tr><td>Last name</td><td>Firstname</td><td>Institution</td><td>Country</td></tr><tr><td>Arbyn</td><td>Marc</td><td>Unit Cancer Epidemiology - Belgian Cancer Centre - Sciensano</td><td>Belgium</td></tr><tr><td>Lauby-Secretan</td><td>Beatrice</td><td>IARC</td><td>France</td></tr><tr><td>Wentzensen</td><td>Nicolas</td><td>National Cancer Institute</td><td>USA</td></tr></table></body></html> # Modelling team The modelling team supported the development of these guidelines for women in the general population and women living with HIV.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The modelling work was performed by the team led by Karen Canfell at Cancer Council NSW, Sydney, Australia (now the Daffodil Centre, a joint venture between the University of Sydney and Cancer Council NSW) using the Policy1-Cervix platform.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The team members are listed in the table below.The modelling team gratefully acknowledges: John Murray from the University of New South Wales, Sydney, who was also involved in the development of the HIV/HPV model used for the evaluation of screening in women living with HIV; Megan Smith from Cancer Council NSW, who contributed to past model development and discussions about model validation for newly emergent technologies; and Susan Yuill from Cancer Council NSW, who contributed to the systematic review of the evidence on HPV triage strategies led by Marc Arbyn of the Belgian Cancer Centre, which was used to inform the modelling.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "<html><body><table><tr><td>Last name</td><td>First name</td><td>Institution</td><td>Country</td></tr><tr><td>Canfell</td><td>Karen </td><td>The Daffodil Centre, a joint venture between the University of Sydney and Cancer Council NSW</td><td>Australia</td></tr><tr><td>Caruana</td><td>Michael </td><td>The Daffodil Centre</td><td>Australia</td></tr><tr><td>Hall</td><td>Michaela</td><td>The Daffodil Centre</td><td>Australia</td></tr><tr><td>Keane</td><td>Adam</td><td>The Daffodil Centre</td><td>Australia</td></tr><tr><td>Killen</td><td>James </td><td>The Daffodil Centre</td><td>Australia</td></tr><tr><td>Lui</td><td>Gigi</td><td>The Daffodil Centre</td><td>Australia</td></tr><tr><td>Nguyen</td><td>Diep </td><td>The Daffodil Centre</td><td>Australia</td></tr><tr><td>Simms</td><td>Kate</td><td>The Daffodil Centre</td><td>Australia</td></tr></table></body></html> # Costing expertise <html><body><table><tr><td>Last name</td><td>First name</td><td>Institution</td><td>Country</td></tr><tr><td>Demke</td><td>Owen</td><td>Clinton Health Access Initiative</td><td>Rwanda</td></tr><tr><td>Gauvreau</td><td>Cindy </td><td>Hospital for Sick Children/University of Toronto</td><td>Canada</td></tr></table></body></html> # Observers <html><body><table><tr><td>Last name</td><td>First name</td><td>Institution</td><td>Country</td></tr><tr><td>Anderson</td><td>Benjamin</td><td>University of Washington</td><td>USA</td></tr><tr><td>Berkhof</td><td>J.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "(Hans)</td><td>Vrije Universiteit</td><td>Kingdom of the Netherlands</td></tr><tr><td>Chevalier</td><td>Michelle</td><td>President's Emergency Plan for AIDS Relief (PEPFAR)</td><td>USA</td></tr><tr><td>de Lussigny</td><td> Smiljka</td><td>Unitaid </td><td>Switzerland </td></tr><tr><td>Engel </td><td>Danielle </td><td>United Nations Population Fund (UNFPA)</td><td>USA</td></tr><tr><td>Franco</td><td>Eduardo</td><td>Division of Cancer Epidemiology, McGill University</td><td>Canada</td></tr><tr><td>Huang</td><td>Lisa Pei-Ching</td><td>Expertise France</td><td>France </td></tr><tr><td>Jafa</td><td>Krishna</td><td>Bill & Melinda Gates Foundation</td><td>USA</td></tr><tr><td>Jeronimo</td><td>Jose</td><td>Cancer Consulting</td><td>USA</td></tr><tr><td>Kumar </td><td>Somesh</td><td>Jhpiego</td><td>USA</td></tr><tr><td>Lapidos-Salaiz</td><td>Illana </td><td>United States Agency for International Development (USAID)</td><td>USA</td></tr><tr><td>Mesher</td><td>David</td><td>Public Health England, International Agency for Research on Cancer (IARC)</td><td>United Kingdom</td></tr><tr><td> Odayar</td><td>Jasantha</td><td>University of Cape Town</td><td>South Africa</td></tr><tr><td> Parham</td><td>Groesbeck</td><td>University of North Carolina</td><td>USA</td></tr><tr><td>Perez Casas</td><td>Carmen </td><td>Unitaid</td><td>Switzerland</td></tr><tr><td>Roitberg</td><td>Felipe</td><td>WHO</td><td>Switzerland </td></tr><tr><td>Shakarishvili</td><td>Anna </td><td>Joint United Nations Programme on HIV/AIDS (UNAIDS)</td><td>Switzerland</td></tr><tr><td>ten Hoope-Bender</td><td>Petra</td><td>UNFPA</td><td>Switzerland</td></tr></table></body></html> WHO Secretariat – headquarters members (Geneva, Switzerland) <html><body><table><tr><td>Last name</td><td>First name</td><td>Departments</td></tr><tr><td>Almnte</td><td>Maribel </td><td>Deatment ofNoncommunicableDiseases eabitation and</td></tr><tr><td>Bloem</td><td> Paul</td><td>Department of Immunization, Vaccines and Biologicals </td></tr><tr><td>Broutet </td><td>Nathalie</td><td>Department of Sexual and Reproductive Health and Research</td></tr><tr><td>Cortes </td><td>Myriam </td><td>Department of Sexual and Reproductive Health and Research </td></tr><tr><td> Dalal</td><td> Shona</td><td>Department of Global HIV, Hepatitis and Sexually Transmitted Infections Programmes </td></tr><tr><td> De Mello</td><td>Maeve</td><td>Department of Global HIV, Hepatitis and Sexually Transmitted Infections Programmes </td></tr><tr><td>Eckert </td><td>Linda </td><td>Department of Sexual and Reproductive Health and Research</td></tr><tr><td> El Sheikh </td><td>Fayad </td><td>Department of Immunization, Vaccines and Biologicals </td></tr><tr><td>Fidarova </td><td>Elena </td><td>Deasblt</td></tr><tr><td>Gottlieb</td><td> Sami</td><td>Department of Sexual and Reproductive Health and Research</td></tr><tr><td>Hutubessy</td><td>Raymond </td><td>Department of Immunization, Vaccines and Biologicals </td></tr><tr><td>lbawi</td><td>Andre</td><td>Department of Noncommunicable Diseases, Rehabilitation and Disability</td></tr><tr><td>Khosla</td><td>Rajat </td><td>Department of Sexual and Reproductive Health and Research </td></tr><tr><td>Kuku </td><td>Stephanie Yetunde</td><td>Department of Digital Health and Innovation</td></tr><tr><td>Narasimhan </td><td>Manjulaa </td><td>Department of Sexual and Reproductive Health and Research</td></tr><tr><td>Newman </td><td>Morkor</td><td>Department of Global HIV, Hepatitis and Sexually Transmitted Infections Programmes</td></tr><tr><td> Purnat </td><td>Tina</td><td>Department of Digital Health and Innovation</td></tr><tr><td>Rangaraj</td><td>Ajay</td><td>Deertmsn ogGobal HIV epatis and eoual Transmited</td></tr><tr><td>Riley</td><td>Lanaret</td><td>Deartmen o loncom uniableDisases ehbitaton andl</td></tr><tr><td>Sands </td><td> Anita</td><td>Department of Regulation and Prequalification</td></tr><tr><td>Stroher</td><td>Ute</td><td>Department of Regulation and Prequalification</td></tr><tr><td>Velazquez Berumen </td><td>Adriana </td><td> Department of Health Product Policy and Standards</td></tr><tr><td>Vojnov</td><td>Lara </td><td>Dptl</td></tr><tr><td>Xu</td><td>Hongyi</td><td>Demenicaiseabit</td></tr></table></body></html> WHO Secretariat – regional advisers and International Agency for Research on Cancer (IARC) staff <html><body><table><tr><td>WHO region</td><td>Last name</td><td>First name</td></tr><tr><td>Africa</td><td>Barango</td><td> Prebo</td></tr><tr><td>Africa</td><td>Dangou </td><td>Jean-Marie</td></tr><tr><td>Africa</td><td>Kapambwe </td><td>Sharon </td></tr><tr><td>Africa </td><td>Lago</td><td>Hugues</td></tr><tr><td>Africa </td><td> Ouedraogo</td><td>Leopold </td></tr><tr><td>Africa</td><td>Sebitloane</td><td>Tshidi</td></tr><tr><td>The Americas</td><td>Ghidinelli </td><td>Massimo</td></tr><tr><td>The Americas</td><td>Gomez Ponce de Leon</td><td>Rodolfo</td></tr><tr><td>The Americas</td><td>Luciani </td><td>Silvana</td></tr><tr><td>Eastern Mediterranean</td><td>Gholbzouri</td><td>Karima</td></tr><tr><td>Eastern Mediterranean </td><td>Hermez </td><td>Joumana George</td></tr><tr><td> Eastern Mediterranean </td><td> Slama</td><td>Slim</td></tr><tr><td>Europe</td><td>Corbex </td><td>Marilys </td></tr><tr><td>Europe</td><td>Masoud</td><td>Dara </td></tr><tr><td>Europe</td><td> Smelov </td><td>Vitaly</td></tr><tr><td>South-East Asia</td><td>Dorji</td><td>Gampo </td></tr><tr><td>South-East Asia</td><td>Jayathilaka</td><td>Chandani Anoma</td></tr><tr><td>South-East Asia</td><td> Raina </td><td>Neena</td></tr><tr><td>South-East Asia</td><td> Sharma</td><td>Mukta</td></tr><tr><td>Western Pacific</td><td>Ishikawa</td><td>Naoko</td></tr><tr><td>Western Pacific</td><td>Mannava</td><td>Priya </td></tr><tr><td>Western Pacific</td><td> Narayan </td><td>Elick </td></tr><tr><td>Western Pacific</td><td>Shin </td><td>Hai-rim </td></tr><tr><td>Western Pacific</td><td>Sobel </td><td>Howard </td></tr><tr><td>Western Pacific</td><td>Tiko</td><td> Josaia</td></tr><tr><td>Western Pacific</td><td>Tran </td><td>Huong</td></tr><tr><td>IARC</td><td>Almonte Pacheco</td><td>Maribel </td></tr><tr><td>IARC</td><td>Basu</td><td> Partha</td></tr><tr><td>IARC</td><td>Clifford </td><td>Gary</td></tr><tr><td>IARC</td><td>Lauby-Secretan</td><td>Beatrice</td></tr><tr><td>IARC</td><td>Sauvaget </td><td>Catherine</td></tr></table></body></html> # Annex 2.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Evidence-gathering teams and guideline task groups <html><body><table><tr><td>Screen-and-treat Screen, triage and treat (follow-up studies)</td><td>Screen-and-treat Screen, triage and treat (diagnostic studies)</td></tr><tr><td>Lead: Nicolas Wentzensen</td><td>Lead: Marc Arbyn</td></tr><tr><td>Nicolas Wentzensen</td><td>Karen Canfell</td></tr><tr><td>IARC handbook Working Group (Lead: Beatrice Lauby-Secretan):</td><td>Silvia de Sanjosé</td></tr><tr><td>Julia Brotherton</td><td>Nicolas Wentzensen</td></tr><tr><td>Marta del Pino Chisato Hamashima</td><td></td></tr><tr><td>Anne Mackie</td><td></td></tr><tr><td>Walter Prendiville</td><td></td></tr><tr><td>Paolo Giorgi Rossi</td><td></td></tr><tr><td>Rengaswamy Sankaranarayanan</td><td></td></tr><tr><td></td><td></td></tr></table></body></html> <html><body><table><tr><td>Values and preferences</td><td>Feasibility and implementation</td><td>Clinical algorithms</td></tr><tr><td>Lead: Ajay Rangaraj</td><td>Leads: Patti Gravitt and</td><td>Lead: Partha Basu</td></tr><tr><td>WHO Advisory Group of Women</td><td>Nancy Santesso</td><td>Maribel Almonte</td></tr><tr><td>Living with HIV </td><td> Prajakta Adsul</td><td>Silvina Arrossi</td></tr><tr><td>Nathalie Broutet</td><td>Maribel Almonte</td><td>Neerja Bhatla</td></tr><tr><td>Shona Dalal</td><td>André Carvalho</td><td>Nathalie Broutet</td></tr><tr><td>Linda Eckert</td><td>Lisa Huang</td><td>Karen Canfell</td></tr><tr><td>Morkor Newman</td><td>José Jeronimo</td><td>Z.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Mike Chirenje</td></tr><tr><td>Nancy Santesso</td><td>Somesh Kumar</td><td>Miriam Cremer</td></tr><tr><td>Julie Torode</td><td>Najat Lahmi</td><td>Shona Dalal</td></tr><tr><td></td><td>Kelly McCrystal</td><td>Lynette Denny</td></tr><tr><td></td><td>Raul Murillo</td><td>Linda Eckert</td></tr><tr><td></td><td>Jasantha Odayar</td><td>Jose Jeronimo</td></tr><tr><td></td><td>Katayoun Taghavi</td><td>Beatrice Lauby</td></tr><tr><td></td><td></td><td>Raul Murillo</td></tr><tr><td></td><td></td><td>Laura Muzingwani </td></tr><tr><td></td><td></td><td>Groesbeck Parham</td></tr><tr><td></td><td></td><td>Walter Prendiville</td></tr><tr><td></td><td></td><td>Nancy Santesso</td></tr><tr><td></td><td></td><td>Nicolas Wentzensen</td></tr></table></body></html> # Annex 3.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Declarations of interests <html><body><table><tr><td>WHO region</td><td>Last name</td><td>First name</td><td>Declaration of interests</td><td>Confidentiality agreement</td></tr><tr><td>Africa</td><td>Achieng </td><td>Claire Judith Ikate</td><td>None </td><td>Received </td></tr><tr><td>Africa</td><td>Awori</td><td>Ruth </td><td>None </td><td>Received </td></tr><tr><td>Africa</td><td>Chinula</td><td>Lameck </td><td>None </td><td> Received </td></tr><tr><td>Africa</td><td>Chirenje</td><td>Z.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Mike </td><td>None </td><td> Received </td></tr><tr><td>Africa</td><td>Denny</td><td>Lynette</td><td>None </td><td>Received </td></tr><tr><td>Africa </td><td>Diop</td><td>Mamadou</td><td>None </td><td> Received </td></tr><tr><td>Africa</td><td>Happy</td><td>Margaret </td><td>None </td><td>Received </td></tr><tr><td>Africa</td><td>Ingbian </td><td>Priscilla</td><td>None </td><td>Received </td></tr><tr><td>Africa</td><td> Motshedisi</td><td>Sebitloane</td><td>None </td><td>Received </td></tr><tr><td>Africa</td><td>Mugo</td><td>Nelly</td><td>None </td><td>Received </td></tr><tr><td>Africa</td><td>Muzingwani</td><td>Laura </td><td>None </td><td>Received </td></tr><tr><td>Africa</td><td> Obiri-Yeboah</td><td>Dorcas</td><td>None </td><td>Received </td></tr><tr><td>Africa</td><td> Shiferaw</td><td>Netsanet </td><td>None</td><td>Received</td></tr><tr><td>The Americas</td><td>Arrossi</td><td>Silvina</td><td>None </td><td> Received</td></tr><tr><td>The Americas</td><td>Barnabas</td><td>Ruanne</td><td>None</td><td>Received </td></tr><tr><td>The Americas</td><td>Bento Claro</td><td>Itamar </td><td>None </td><td> Received </td></tr><tr><td>The Americas</td><td>Chung</td><td>Michael </td><td>None </td><td>Received </td></tr><tr><td>The Americas</td><td>Correa</td><td>Flavia Miranda</td><td>None </td><td>Received </td></tr><tr><td>The Americas</td><td>Cremer</td><td>Miriam</td><td>None </td><td>Received </td></tr><tr><td>The Americas</td><td>Darragh</td><td>Teresa </td><td>None </td><td>Received </td></tr><tr><td>The Americas</td><td>Gage</td><td>Julia</td><td>None</td><td>Received </td></tr><tr><td>The Americas</td><td>Gravitt </td><td> Patti</td><td>None </td><td>Received </td></tr><tr><td>The Americas</td><td>Herrero</td><td> Rolando</td><td>None</td><td>Received </td></tr><tr><td>The Americas</td><td>Johnson</td><td>Ebony</td><td>None</td><td>Received </td></tr><tr><td>The Americas</td><td>Maza</td><td>Mauricio</td><td>None </td><td>Received </td></tr><tr><td>The Americas</td><td>Murillo</td><td>Raul</td><td>None</td><td>Received </td></tr></table></body></html> <html><body><table><tr><td>WHO region</td><td>Last name</td><td>First name</td><td>Declaration of interests</td><td>Confidentiality agreement</td></tr><tr><td>The Americas</td><td>Moley</td><td>Kelle</td><td>None </td><td>Received</td></tr><tr><td>The Americas</td><td>Ogilvie</td><td>Gina </td><td>None</td><td>Received </td></tr><tr><td>The Americas </td><td> Picconi</td><td> Maria Alejandra </td><td>None </td><td>Received </td></tr><tr><td>The Americas</td><td> Pinder </td><td>Leeya</td><td>None</td><td>Received </td></tr><tr><td>The Americas</td><td>Reis</td><td>Veronica</td><td>None </td><td> Received </td></tr><tr><td>The Americas</td><td>Ross Quiroga</td><td>Gracia Violetta</td><td>None</td><td>Received </td></tr><tr><td>The Americas</td><td>Sahasrabuddhe</td><td>Vikrant </td><td>None</td><td>Received</td></tr><tr><td>The Americas</td><td> Slavkovsky</td><td>Rose</td><td>None </td><td>Received </td></tr><tr><td>The Americas</td><td>Thomson</td><td>Kerry</td><td>None</td><td> Received</td></tr><tr><td>The Americas</td><td>Wentzensen</td><td>Nicolas </td><td>None</td><td>Received </td></tr><tr><td>Eastern Mediterranean</td><td>Atif Waqar </td><td>Muhammad</td><td>None </td><td>Received </td></tr><tr><td>Eastern Mediterranean</td><td>Ghanbari-Motlagh</td><td>Ali</td><td>None </td><td>Received </td></tr><tr><td>Eastern Mediterranean </td><td>Hashem </td><td>Tarek </td><td>None</td><td> Received </td></tr><tr><td>Europe</td><td>Bruni</td><td>Laia </td><td>None</td><td>Received </td></tr><tr><td>Europe</td><td>Boily</td><td>Marie-Claude</td><td>None</td><td>Received </td></tr><tr><td>Europe</td><td>Cain </td><td>Joanna</td><td>None </td><td>Received</td></tr><tr><td>Europe</td><td>de Sanjosé </td><td> Silvia</td><td>None </td><td>Received</td></tr><tr><td>Europe</td><td>Kelly</td><td>Helen </td><td>None</td><td>Received</td></tr><tr><td>Europe</td><td>Mackie</td><td>Anne</td><td>None </td><td>Received </td></tr><tr><td>Europe</td><td> Petignat</td><td>Patrick</td><td>None</td><td>Received </td></tr><tr><td>Europe</td><td> Prendiville</td><td>Walter</td><td>None</td><td>Received </td></tr><tr><td>Europe</td><td>Sasieni</td><td> Peter </td><td>None </td><td> Received </td></tr><tr><td>Europe</td><td>Torode</td><td>Julie</td><td>None </td><td>Received </td></tr><tr><td> South-East Asia</td><td>Bhatla </td><td>Neerja </td><td>None </td><td>Received </td></tr><tr><td> South-East Asia</td><td> Eamratsameekool </td><td>Wachara</td><td>None </td><td>Received </td></tr><tr><td>South-East Asia </td><td>Nessa</td><td> Ashrafun </td><td>None</td><td> Received </td></tr><tr><td>South-East Asia </td><td>Thinn </td><td>Myint Myint </td><td>None </td><td> Received </td></tr><tr><td>Western Pacific</td><td>Luvsandorj</td><td>Bayarsaikhan</td><td>None</td><td>Received </td></tr><tr><td>Western Pacific</td><td>Zhao</td><td>Fanghui</td><td>None</td><td>Received </td></tr></table></body></html> # Annex 4.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Algorithms for use of dual-stain cytology as a triage test in the general population of women Screening and treatment approaches In the “screen-and-treat approach”, the decision to treat is based on a positive primary screening test only.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "![](images/842c1c9dfb7d3d43e4737c2cd33f18250497958567473f0cefdab6676b635512.jpg) In the “screen, triage and treat approach”, the decision to treat is based on a positive primary screening test followed by a positive second test (a “triage” test), with or without histologically confirmed diagnosis.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "![](images/df1050454230f5ebef34e7a7e98db7e769614486904e4228b65edd6bbdc09d4e.jpg) # Screen-and-treat approach: Dual-stain cytology was not assessed as part of a screen-and-treat approach.# Two algorithms for screen, triage and treat approach: 1.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "HPV DNA as the primary screening test, followed by triage using dual-stain cytology, then further followed by colposcopy to determine further management 2.HPV mRNA as the primary screening test, followed by triage using dual-stain cytology, then further followed by colposcopy to determine further management These two algorithms have been combined into one flow chart as presented on the next page.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "In addition, on p.42, an algorithm is presented for follow-up testing at 12 months post-treatment.# Algorithm for primary HPV DNA or HPV mRNA screening and dual-stain cytology as a triage test (screen, triage and treat approach) For the general population of women This flow chart combines the two algorithms that were assessed (see Table 2.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "2).![](images/a94aae00e3b665a999c13624f5cf8df0078a7a173facfb56ea8051a77d2a7952.jpg) a If using an HPV DNA nucleic acid test (NAT), rescreen in 5–10 years.If using an HPV mRNA NAT, rescreen in 5 years.# Algorithm for follow-up testing at 12 months post-treatment For the general population of women !",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "[](images/171edc463f252401ad898a25c837b932a036948416e40b3fa448e63653bfe3c2.jpg) # Annex 5.Recommendations for the use of HPV DNA tests and HPV mRNA tests and other cervical screening methods1 <html><body><table><tr><td>Recommendations for the general population of womena</td><td>Strength of recommendation and certainty of evidence</td><td>Recommendations for women living with HiVa</td><td>Strength of recommendat and certainty evidence</td></tr><tr><td>1.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "WHO recommends using HPV DNA detection as the primary screening test rather than VIA or cytology in screening and treatment approaches among both the general population of women and women living with HIV.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Remarks: Existing programmes with quality-assured cytology as the primary screening test should be continued until HPV DNA testing is operational; existing programmes using VIA as the primary screening test should transition rapidly</td><td>Strong recommendation, moderate-certainty evidence </td><td>21.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "WHO recommends using HPV DNA detection as the primary screening test rather than VIA or cytology in screening and treatment approaches among both the general population of women and women living with HIV.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Remarks: Existing programmes with quality-assured cytology as the primary screening test should be continued until HPV DNA testing is operational; existing programmes using VIA as the primary screening test should transition rapidly</td><td>Strong recommendatic moderate certa of evidence </td></tr><tr><td>2.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "WHO suggests using an HPV DNA primary screening test either with triage or without triage to prevent cervical cancer among the general population of women.</td><td>Conditional recommendation, moderate-certainty evidence</td><td>22.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "WHO suggests using an HPV DNA primary screening test with triage rather than without triage to prevent cervical cancer among women living with HIV.</td><td>Conditional recommendatic moderate certa of evidence</td></tr></table></body></html> a Rows shaded in pink indicate that the recommendation or good practice statement is identical for both the general population of women (left column) and women living with HIV (right column).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "In other rows, the wording of the recommendations differs for each population.四 <html><body><table><tr><td>Recommendations for the general population of women a</td><td>Strength of recommendation and certainty of evidence Conditional</td><td> Recommendations for women living with HIVa</td><td>Strength recomme and certa evidence Condition</td></tr><tr><td>3a.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "In a screen-and-treat approach using HPV DNA detection as the primary screening test, WHO suggests treating women who test positive for HPV DNA among the general population of women.3b.In a screen, triage and treat approach using HPV DNA detection as the primary screening test among the general population of women, WHO suggests using partial genotyping, colposcopy, VIA</td><td>recommendation, moderate-certainty evidence </td><td>23.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "In a screen, triage and treat approach using HPV DNA detection as the primary screening test among women living with HIV, WHO suggests using partial genotyping, colposcopy, VIA or cytology to triage women after a positive HPV DNA test (Annex 4).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Remarks: The benefits, harms and programmatic</td><td>recommel moderate evidence </td></tr><tr><td>feasibility, training, programme quality assurance and resources in countries.HPV16/18 genotyping could be integrated into the HPV DNA test (refer to Annex 4 for specific details of the algorithms).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "4.When providing HPV DNA testing, WHO suggests using either samples taken by a health-care provider or self-collected samples among both the general population of women and women living with HIV.</td><td>Conditional recommendation, low-certainty evidence</td><td>feasibility, training, programme quality assurance and resources in countries.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "HPV16/18 genotyping could be integrated into the HPV DNA test (refer to Annex 4 for specific details of the algorithms).24.When providing HPV DNA testing, WHO suggests using either samples taken by a health-care provider or self-collected samples among both the general population of women and women living with HIV.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td><td>Condition recommei low-certai evidence </td></tr></table></body></html> a Rows shaded in pink indicate that the recommendation or good practice statement is identical for both the general population of women (left column) and women living with HIV (right column).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "In other rows, the wording of the recommendations differs for each population.<html><body><table><tr><td>Recommendations for the general population of womena</td><td>Strength of recommendation and certainty of evidence</td><td> Recommendations for women living with HIVa</td><td>Strength of recommendati and certainty evidence</td></tr><tr><td>5.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "WHO recommends starting regular cervical cancer screening at the age of 30 years among the general population of women.</td><td>Strong recommendation, moderate-certainty evidence</td><td>25.WHO suggests starting regular cervical cancer screening at the age of 25 years among women living with HIV.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Remarks: Low-certainty evidence found that there are likely to be small numbers of women living with HIV with cervical cancer who are below the age of 25.This recommendation applies to women living with HIV regardless of when they first tested positive for HIV.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td><td>Conditional recommendatic low-certainty evidence</td></tr><tr><td>6.After the age of 50 years, WHO suggests screening is stopped after two consecutive negative screening results consistent with the recommended regular screening intervals among both the general population of women and women living with HIV.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Remarks: Neither VIA nor ablative treatment are suitable for screening or treatment of women in whom the transformation zone is not visible.</td><td>Conditional recommendation, low-certainty evidence </td><td>26.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "After the age of 50 years, WHO suggests screening is stopped after two consecutive negative screening results consistent with the recommended regular screening intervals among both the general population of women and women living with HIV.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Remarks: Neither VIA nor ablative treatment are suitable for screening or treatment of women in whom the transformation zone is not visible.</td><td>Conditional recommendatic very low-certair evidence </td></tr><tr><td>Inadequate visualization is typical after the menopause.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "7.Priority should be given to screening women aged 30-49 years in the general population of women.When tools are available to manage women aged 50-65 years, those in that age bracket who have never been screened should also be prioritized.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td><td>Good practice statement</td><td>Inadequate visualization is typical after the menopause.27.Priority should be given to screening women living with HIV aged 25-49 years.When tools are available to manage women living with HIV aged 50-65 years, those in that age bracket who have never been screened should also be prioritized.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td><td>Good practice statement </td></tr></table></body></html> a Rows shaded in pink indicate that the recommendation or good practice statement is identical for both the general population of women (left column) and women living with HIV (right column).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "In other rows, the wording of the recommendations differs for each population.<html><body><table><tr><td>Recommendations for the general population of womena</td><td>Strength of recommendation and certainty of evidence</td><td>Recommendations for women living with Hiva</td><td>Strength of recommendation and certainty of evidence</td></tr><tr><td>8.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "WHO suggests a regular screening interval of every 5 to 10 years when using HPV DNA detection as the primary screening test among the general population of women.</td><td>Conditional recommendation, low-certainty evidence</td><td>28.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "WHO suggests a regular screening interval of every 3 to 5 years when using HPV DNA detection as the primary screening test among women living with HIV.</td><td>Conditional recommendation, low-certainty evidence</td></tr><tr><td>9.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Where HPV DNA testing is not yet operational, WHO suggests a regular screening interval of every 3 years when using VIA or cytology as the primary screening test, among both the general population of women and women living with HIV.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td><td>Conditional recommendation, low-certainty evidence </td><td>29.Where HPV DNA testing is not yet operational, WHO suggests a regular screening interval of every 3 years when using VIA or cytology as the primary screening test, among both the general population of women and women living with HIV.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td><td>Conditional recommendation, low-certainty evidence</td></tr><tr><td>10.While transitioning to a programme with a recommended regular screening interval, screening even just twice in a lifetime is beneficial among both the general population of women and women living with HIV.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td><td>Good practice statement </td><td>30.While transitioning to a programme with a recommended regular screening interval, screening even just twice in a lifetime is beneficial among both the general population of women and women living with HIV.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td><td>Good practice statement </td></tr><tr><td>11.WHO suggests that the general population of women who have screened positive on an HPV DNA primary screening test and then negative on a triage test are retested with HPV DNA testing at 24 months and, if negative, move to the recommended regular screening interval.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td><td>Conditional recommendation, low-certainty evidence</td><td>31.WHO suggests that women living with HIV who have screened positive on an HPV DNA primary screening test and then negative on a triage test, are retested with HPV DNA testing at 12 months and, if negative, move to the recommended regular screening interval.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td><td>Conditional recommendation, low-certainty evidence</td></tr></table></body></html> a Rows shaded in pink indicate that the recommendation or good practice statement is identical for both the general population of women (left column) and women living with HIV (right column).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "In other rows, the wording of the recommendations differs for each population.HPV: human papillomavirus; VIA: visual inspection with acetic acid.<html><body><table><tr><td>Recommendations for the general population of womena</td><td>Strength of recommendation and certainty of evidence</td><td> Recommendations for women living with HIVa</td><td>Strength of recommendatio and certainty of evidence</td></tr><tr><td>12.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "WHO suggests that women from the general population and women living with HIV who have screened positive on a cytology primary screening test and then have normal results on colposcopy are retested with HPV DNA testing at 12 months and, if negative, move to the recommended regular screening interval.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td><td>Conditional recommendation, low-certainty evidence</td><td>32.WHO suggests that women from the general population and women living with HIV who have screened positive on a cytology primary screening test and then have normal results on colposcopy are retested with HPV DNA testing at 12 months and, if negative, move to the recommended regular screening interval.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td><td>Conditional recommendation low-certainty evidence </td></tr><tr><td>13.WHO suggests that women from the general population who have been treated for histologically confirmed CIN2/3 or adenocarcinoma in situ (AIS), or treated as a result of a positive screening test are retested at 12 months with HPV DNA testing when available, rather than with cytology or VlA or co-testing, and, if negative, move to the recommended regular screening interval.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td><td>Conditional recommendation, low-certainty evidence </td><td>33.WHO suggests that women living with HIV who have been treated for histologically confirmed CIN2/3 or adenocarcinoma in situ (AlS), or treated as a result of a positive screening test are retested at 12 months with HPV DNA testing when available, rather than with cytology or VIA or co-testing, and, if negative, are retested again at 12 months and, if negative again, move to the recommended regular screening interval.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td><td>Conditional recommendation low-certainty evidence </td></tr><tr><td>14.As programmes introduce HPV DNA testing, use this test at the woman's next routine screening date regardless of the test that was used at prior screening.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "In existing programmes with cytology or VIA as the primary screening test, rescreening with the same test should be continued until HPV DNA testing is operational among both the general population of women and women living with HIV.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td><td>Good practice statement </td><td>34.As programmes introduce HPV DNA testing, use this test at the woman's next routine screening date regardless of the test that was used at prior screening.In existing programmes with cytology or VIA as the primary screening test, rescreening with the same test should be continued until HPV DNA testing is operational among both the general population of women and women living with HIV.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td><td>Good practice statement </td></tr></table></body></html> Source: WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition.Geneva: World Health Organization; 2021 <html><body><table><tr><td>For both the general population and women living with Hiv</td><td>Strengthofrecommendation and certainty of evidence</td></tr><tr><td>41.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Once a decision to treat a woman is made - whether from the general population of women or women living with HIV - it is good practice to treat as soon as possible within six months to reduce the risk of los to follow-up.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "However, in women who are pregnant, good practice includes deferral until after pregnancy.In circumstances when treatmentis not provided within this time frame,it is good practice to re-evaluate the woman before treatment.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td><td>Good practice statement </td></tr><tr><td>42.WHO suggests large-loop excision of the transformation zone (LLETZ) or cold knife conization (CKC) for women from the general population and women living with HiV who have histologically confirmed adenocarcinoma in situ (AIS).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td><td>Conditional recommendation, low-certainty evidence </td></tr><tr><td>Remarks: Loop excision may be preferred in women of reproductive age, in setings with greater availability of LLETZ and by providers with greater expertise performing LLETZ.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "CKC may be prefeed when interpretation of the margins of the histological specimen is imperative.</td><td></td></tr></table></body></html> # Summary recommendation for the general population of women WHO suggests using either of the following strategies for cervical cancer prevention among the general population of women: HPV DNA detection in a screen-and-treat approach starting at the age of 30 years with regular screening every 5 to 10 years.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "HPV DNA detection in a screen, triage and treat approach starting at the age of 30 years with regular screening every 5 to 10 years.![](images/6177e7e584e5ce08e1c7a0cab3ea92dc8161fe81fbe3a0f45f58e7f5b2552981.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "jpg) Summary recommendation for women living with HIV WHO suggests using the following strategy for cervical cancer prevention among women living with HIV: HPV DNA detection in a screen, triage and treat approach starting at the age of 25 years with regular screening every 3 to 5 years.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "![](images/3657f20f41f4b516e908ea15e57151ffa9cacc4294ce6b8150a9c4db2cbe94bf.jpg) Table 3.Recommendation on HPV mRNA testing <html><body><table><tr><td>Recommendation for the general population of women</td><td>Strength of recommendation and certainty of evidence</td></tr><tr><td>WHO suggests that HPV mRNA detection using samples taken by the health worker may be used as a primary screening test, either with or without triage, to prevent cervical cancer in the general population of women with regular screening every 5 years.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Remarks: HPV DNA is the recommended screening test.Choosing the alternative option of HPV mRNA testing implies having the capacity to provide follow-up screening at 5-year intervals.</td><td>Conditional recommendation, low-certainty evidence</td></tr></table></body></html> Recommendation for women living with HIV: No recommendation was made for using HPV mRNA in women living with HIV because evidence on the outcomes of using HPV mRNA detection applicable to this population was not identified.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "For more information, please contact: World Health Organization Department of Noncommunicable Diseases, Rehabilitation and Disability 20 Avenue Appia 1211 Geneva 27 Switzerland Email: NCDdepartment@who.int Website: https://www.who.int/teams/surveillance-of-noncommunicable-diseases/about/ncds www.who.int",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "DOI:10.16506/j.109-639.202.10.01 # ·一切为了人民健康 我们这十年 专家共识· # 中国子宫颈癌综合防控路径建设专家共识 中国子宫颈癌综合防控路径建设专家共识编写组中华预防医学会肿瘤预防与控制专业委员会 摘要:子宫颈癌是威胁我国乃至全球女性健康的常见恶性肿瘤之一,防控形势严峻。立足全球消除子宫颈癌的战略背景以及后疫情时代对完善肿瘤防控体系的迫切需求下,亟需建立适宜我国国情且高效可行的子宫颈癌综合防控路径,为不同卫生资源地区落实子宫颈癌三级预防工作提供参考。",
    "source": "中国子宫颈癌综合防控路径建设专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌综合防控路径建设专家共识/中国子宫颈癌综合防控路径建设专家共识.md"
  },
  {
    "text": "本专家共识参考国内外子宫颈癌综合防控指南及最新研究进展,系统总结三级预防核心要素的最新证据,结合我国实际情况,从服务连通、多部门协同及信息系统互联互通三个维度构建子宫颈癌综合防控路径的建设框架,以期推动子宫颈癌不同防控措施融合,为促进我国不同地区子宫颈癌综合防控体系的建设及有效运行提供兼具科学性和实用性的指导意见。关键词:子宫颈癌;综合防控;路径;专家共识中图分类号:R737.3 文献标识码: 文章编号：1009-6639（2022）10-0721-06 # Expertconsensusonthepathconstructiontowardacomprehensive preventionandcontrolforcervicalcancerinChina Writinggroupoftheexpertconsensusonthepathconstructiontowardcomprehensivepreventionand controlforcervicalcancerinChinaSecializedCommite ofCancerPreventionandControl, ChinesePreventiveMedicineAsociation Corespondingauthors:ZHAOFang-hui,DepartmentofEpidemiology,NationalCancerCenter/National ClinicalResenchCenterforCancer/ConcerHospitol,ChineseAcademyofMedicalSciencesandPekingUnion MedicalColege,E-mail:zhaofangh $\\textcircled { \\omega }$ cicams.",
    "source": "中国子宫颈癌综合防控路径建设专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌综合防控路径建设专家共识/中国子宫颈癌综合防控路径建设专家共识.md"
  },
  {
    "text": "ac.cn;WANG Hua-qing,NationalImmunizationProgram Center,ChineseCenterforDiseaseControlandPrevention,Beijing, $E$ -mail:wanghq@chinacdc.cn;WANGLinhong,NationalCenterforChronicandNoncommunicableDiseaseControlandPrevention,ChineseCenterfor DiseaseControlandPrevention, $E$ -mail:linhong $_ - \\ w a n g ( \\textcircled { \\alpha } 1 2 6$ .",
    "source": "中国子宫颈癌综合防控路径建设专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌综合防控路径建设专家共识/中国子宫颈癌综合防控路径建设专家共识.md"
  },
  {
    "text": "com Abstract:Cervicalcancerisoneofthemostcommonmalinanttumorsthatthreatenwomen'shealthinChina andworldwide,anditscontrolfacesa reatchalene.Inthecontextofthe lobalstrate toeliminatecervical cancerandtheurentnedtoimrovethecancer reventionandcontrolssteminthe ost-eidemicera,itis necesarytoestablishaneficientandfeasiblecomprehensivepreventionandcontrolpathwayforcervical cancersuitableforourowncountr ,inorderto rovidereferencefortheimlementationofcervicalcancer tertiar revention roram indiferenthealthresourceareas.",
    "source": "中国子宫颈癌综合防控路径建设专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌综合防控路径建设专家共识/中国子宫颈癌综合防控路径建设专家共识.md"
  },
  {
    "text": "Basedonthedomesticandinternational guidelinesandthelatestresearchprogres onintegratedpreventionandcontrolofcervicalcancer,thisexpert consensussystematicalysummarizedthelatestevidenceonthecoreelementsoftertiaryprevention,andbuilt aframeworkfortheconstructionofaninterated reventionandcontrol athwa forcervicalcancerfromthe folowingthre dimensions:serviceconectivity, multi-sectoralcolaboration,andinformation system interconection,withtheaimofpromotingtheintegrationofdiferentpreventionandcontrolmeasures,and providingscientificandpracticalguidancefortheconstructionandefectiveoperationoftheintegratedcervical cancer reventionandcontrolsstemindiferentreionsofChina.",
    "source": "中国子宫颈癌综合防控路径建设专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌综合防控路径建设专家共识/中国子宫颈癌综合防控路径建设专家共识.md"
  },
  {
    "text": "Keywords:Uterinecervicalneoplasm;Comprehensivepreventionandcontrol;Pathway;Expertconsensus 子宫颈癌是全球面临的重要公共卫生议题,同时也是严重威胁全球女性健康的常见恶性肿瘤之一。2020年全球估计有60.4 万子宫颈癌新发病例, 万死亡病例,其中 $8 8 .1 \\%$ 的新发病例和$91 .4 \\%$ 的死亡病例发生在中、低收入国家[1]。",
    "source": "中国子宫颈癌综合防控路径建设专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌综合防控路径建设专家共识/中国子宫颈癌综合防控路径建设专家共识.md"
  },
  {
    "text": "为降低全球子宫颈癌疾病负担,世界卫生组织 (WorldHealthOranization,WHO)于2018年发起全球消除子宫颈癌的行动号召,并于 年发布 《加速消除子宫颈癌全球战略》[2],确立了 年需达到的包括 “ 疫苗接种、子宫颈癌筛查及治疗”三大关键措施的 “90-70-90”阶段性目标,该项战略在第 届世界卫生大会上得以批准通过,并获得全球194个国家的全力支持。中国作为全球子宫颈癌负担大国, 年子宫颈癌新增病例和死亡病例分别达到10.",
    "source": "中国子宫颈癌综合防控路径建设专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌综合防控路径建设专家共识/中国子宫颈癌综合防控路径建设专家共识.md"
  },
  {
    "text": "9万例和5.9万例,分别占全球的 $1 8 .2 \\%$ 和 $1 7 .3 \\% ^ { [ 2 ] }$ 。同时,近20年来我国子宫颈癌的发病率和死亡率仍呈现不同程度的上升[4],且发病年龄趋于年轻化,子宫颈癌防控形势严峻。人 乳 头 瘤 病 毒 (human ailomavirus,)疫苗接种、筛查和治疗三级预防策略的有效衔接和互联互通,是推动子宫颈癌疾病全周期管理、提升综合防控服务能力的关键举措。",
    "source": "中国子宫颈癌综合防控路径建设专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌综合防控路径建设专家共识/中国子宫颈癌综合防控路径建设专家共识.md"
  },
  {
    "text": "当前,我国子宫颈癌三级预防服务实施层面仍面临适龄女性疫苗接种和筛查覆盖率低、筛查诊治能力参差不齐等现实问题,加之综合防控服务体系的整合仍受限于不同分管部门缺乏高效沟通机制、医疗保健人员对子宫颈癌综合防控理念重视不足、多途径子宫颈癌防控信息交流共享存在壁垒等诸多挑战[5-7]。在全球加速消除子宫颈癌的战略背景以及后疫情时代对完善肿瘤防控体系的紧迫需求下,亟需建立适宜我国国情且高效可行的子宫颈癌综合防控路径,为不同卫生资源地区分阶段、分步骤推动防控工作落地实施提供参考。",
    "source": "中国子宫颈癌综合防控路径建设专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌综合防控路径建设专家共识/中国子宫颈癌综合防控路径建设专家共识.md"
  },
  {
    "text": "因此,本专家共识系统梳理了国内外子宫颈癌防控经验及最新进展,立足子宫颈癌综合防控核心环节,结合我国实际情况提出了子宫颈癌综合防控路径建设框架,旨在推动不同地区子宫颈癌综合防控服务体系的建设及有效运行,加速推动我国消除子宫颈癌进程。# 1 子宫颈癌三级预防核心要素 围绕子宫颈癌三级预防服务措施,立足消除子宫颈癌战略确立的三个阶段性目标包括疫苗接种、筛查和早期干预宫颈癌前病变以及对宫颈癌患者进行规范化治疗的服务内容,通过在上述预防全流程中融入健康教育行动,可促进子宫颈癌综合防控路径得以建立并有效运行,是实现子宫颈癌疾病全周期全方位管理的关键措施。",
    "source": "中国子宫颈癌综合防控路径建设专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌综合防控路径建设专家共识/中国子宫颈癌综合防控路径建设专家共识.md"
  },
  {
    "text": "1.1 健康教育及 HPV 疫苗接种 健康宣教是贯穿子宫颈癌疾病全周期综合防控策略的重要组成部分。其旨在基于卫生机构、社区、公共场所、学校及家庭等不同场所,分别从服务供方及服务需方出发,有针对性地应用大众传播、人际传播和组织传播等形式开展子宫颈癌防控知识的政策倡导及健康宣教,最终实现提高大众健康素养、降低危险因素暴露风险的目标,使其自觉采取有益于健康的行为生活方式。针对子宫颈癌健康教育行动传播的核心知识应紧密围绕子宫颈癌三级预防措施,涵盖子宫颈癌的可防可治性、常见的危险因素、HPV 疫苗接种 (如目标人群、接种程序、禁忌证、预约接种流程及异常反应处置)、筛查 (如目标人群、筛查流程、禁忌证)及宫颈病变的诊断治疗 (如常见症状和体征、手术及放化疗注意事项、随访管理的重要性及心理疏导)等内容。",
    "source": "中国子宫颈癌综合防控路径建设专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌综合防控路径建设专家共识/中国子宫颈癌综合防控路径建设专家共识.md"
  },
  {
    "text": "在发生性行为前接种 疫苗能够有效阻断感染,是预防子宫颈癌最根本且最有效的手段。WHO立场文件推荐将 $9 \\sim 1 4$ 岁女孩作为首要接种对象,且采用 剂次接种程序,男性或 $\\geqslant 1 5$ 岁女性为次要接种人群[8]。目前,我国已获批上市种 疫苗,其中进口双价疫苗 (希瑞适)、四价疫苗 (佳达修)及九价疫苗 (佳达修 )分别于 年、 年及 年获得我国药品监督管理局批准得以在中国大陆上市,3种疫苗分别能够预防2 种 (HPV16/18)、4 种 $\\mathrm { H P V 6 } / 1 1 / 1 6 /$ ) 和 种 $\\mathrm { H P V 6 / 1 1 / 1 6 / 1 8 / 3 1 / 3 3 / 4 5 / 5 2 / 5 8 ) }$ 基因型别引起的 HPV 相关疾病[9-11] 。",
    "source": "中国子宫颈癌综合防控路径建设专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌综合防控路径建设专家共识/中国子宫颈癌综合防控路径建设专家共识.md"
  },
  {
    "text": "此外,我国自主研发的两种双价疫苗 (馨可宁和沃泽惠)也分别于2019年及202 年在中国上市[12-13] 。双价、四价及九价疫苗均适用于 $9 \\sim 4 5$ 岁女性 (其中国产沃泽惠双价疫苗适用人群为 $9 \\sim 3 0$ 岁)。现阶段我国医疗场所开展 疫苗接种流程主要参照 《中华人民共和国疫苗管理法》[14]及 《预防接种工作规范》[15]等规范化文件执行。1.2 子宫颈癌筛查 子宫颈癌筛查是早发现、早诊断、早治疗宫颈病变的重要防控手段。",
    "source": "中国子宫颈癌综合防控路径建设专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌综合防控路径建设专家共识/中国子宫颈癌综合防控路径建设专家共识.md"
  },
  {
    "text": "在预防性HPV 疫苗尚未纳入国家免疫规划的背景下,子宫颈癌筛查仍是我国子宫颈癌防控的核心手段,其中子宫颈细胞学检查和 HPVDNA 检测是目前最主要的两种筛查方法。在 年 《世界卫生组织子宫颈癌前病变筛查和治疗指南》[16]中推荐筛查起始年龄为 岁,岁以上女性若连续两次筛查结果为阴性则可停止筛查,并优先推荐用 检测作为初筛方法,以 $5 \\sim 1 0$ 年作为筛查周期。我国在2017年 《子宫颈癌综合防控指南》[17]中推荐筛查起始年龄为 $2 5 \\sim 3 0$ 岁, 岁以上女性若过去 年筛查结果阴性 (每 年 次连续 次细胞学检查无异常或每 年 次连续 次联合筛查结果阴 性), 且 无 子 宫 颈 上 皮 内 瘤 变 (intraepithelialneoplasia，CIN）病史，则可以终止筛查,推荐的筛查方案包括 3 种: 细胞学筛查(3年1次)、HPV 筛查 (5 年1 次)、HPV 和细胞学联合筛查 ( 年 次)。",
    "source": "中国子宫颈癌综合防控路径建设专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌综合防控路径建设专家共识/中国子宫颈癌综合防控路径建设专家共识.md"
  },
  {
    "text": "同时,针对包括免疫缺陷人群在内的高危人群,推荐提前筛查起始年龄并缩短筛查间隔。我国组织性子宫颈癌筛查工作参考 《宫颈癌筛查工作方案 ( 版)》[18]实施,筛查服务对象为$3 5 \\sim 6 4$ 周岁女性,推荐每3年1次的细胞学筛查或每 年 次的高危型 检测为初筛技术的筛查流程。1.3 子宫颈癌及癌前病变诊断与治疗 对检出的子宫颈癌前病变及早期浸润癌进行及时有效的诊治和管理,是降低晚期子宫颈癌发病率及提高生存率的重要措施。",
    "source": "中国子宫颈癌综合防控路径建设专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌综合防控路径建设专家共识/中国子宫颈癌综合防控路径建设专家共识.md"
  },
  {
    "text": "其作为疾病全周期路径建设多源流防控的终点,在各级预防措施标准化路径实施之后,可以有效减轻疾病负担和经济负担。目前,子宫颈癌及癌前病变诊断主要通过宫颈活检、宫颈管搔刮或宫颈锥切组织样本进行病理诊断确诊。病理学诊断为鳞状上皮低级别病变 (radesuamousintraeitheliallesion,LSIL/CIN1)者通常不需要接受治疗, 建议 $6 \\sim 1 2$ 个月复查细胞学和 HPV 检测, 任一异常均需转诊阴道镜。",
    "source": "中国子宫颈癌综合防控路径建设专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌综合防控路径建设专家共识/中国子宫颈癌综合防控路径建设专家共识.md"
  },
  {
    "text": "子宫颈癌前病变, 包括阴道镜下活检病理证 实 为 鳞 状 上 皮 高 级 别 病 变 (hih radesuamousintraeitheliallesion, HSIL/CIN2,3)和原位腺癌 (adenocarcinomainsitu,AIS)。子宫颈癌前病变的治疗方法包括宫颈切除性治疗 [冷刀锥切 和 宫 颈 电 圈 环 切 术 (lopelectrosurgicalexcision rocedure,LEEP)]和消融治疗 (又称物理治疗,包括冷冻、热凝、激光等组织破坏性治疗)。",
    "source": "中国子宫颈癌综合防控路径建设专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌综合防控路径建设专家共识/中国子宫颈癌综合防控路径建设专家共识.md"
  },
  {
    "text": "具体处理原则参考 《子宫颈癌综合防控指南》[17]及 《中国子宫颈癌筛查及异常管理相关问题专家共识》[19-20]。目前,临床操作中针对浸润癌诊断原则主要依据国际妇产科联盟（theinternationalfederationofnecolo andobstetrics,FIGO)2018年发布的最新子宫颈癌分期规定[21-22] ,并参考相应的规范化诊疗指南执行。其中手术治疗主要适用于早期子宫颈癌,手术方式的选择需综合考虑患者的生育要求等诸多要素。",
    "source": "中国子宫颈癌综合防控路径建设专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌综合防控路径建设专家共识/中国子宫颈癌综合防控路径建设专家共识.md"
  },
  {
    "text": "对于中晚期子宫颈癌及复发的患者应首选同步放化疗或者免疫治疗,总体治疗原则参考《中国妇科恶性肿瘤临床实践指南第 版》[23]。对于局部晚期子宫颈癌及复发或转移的患者需直接转诊至有资质的上级医院进行诊治。# 2 子宫颈癌综合防控路径建设框架 子宫颈癌综合防控路径的建设需探索将子宫颈癌综合防控核心环节有效整合的创新机制,建设框架涵盖连通三级预防服务、建立多部门协同机制以及加强信息系统互联互通,为疾病全周期管理提供医疗服务基础,同时为路径建设提供保障平台和技术支持,最终形成全链条防控体系。",
    "source": "中国子宫颈癌综合防控路径建设专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌综合防控路径建设专家共识/中国子宫颈癌综合防控路径建设专家共识.md"
  },
  {
    "text": "2.1 连通三级预防服务 针对不同服务对象建立的标准化路径应紧密围绕健康教育、 疫苗接种、筛查及诊疗等核心要素。具体预防控制措施应对大众人群广泛适用,且又能基于服务对象个体基本特征和特殊健康需求兼顾针对性。三级预防服务作为综合路径建设的核心要素各自并非独立存在,通过有效整合和融会贯通将产生 $1 + 1 + 1 > 3 ^ { , }$ ”的健康收益和社会效益。2.1.1 健康教育在三级预防服务中的作用及实现路径 健康教育渗透在子宫颈癌三级预防服务的各个层面。",
    "source": "中国子宫颈癌综合防控路径建设专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌综合防控路径建设专家共识/中国子宫颈癌综合防控路径建设专家共识.md"
  },
  {
    "text": "从健康教育服务的供需双方出发,医务人员应接受健康教育相关规范化培训并通过业务能力考核,能够开展同质化、规范化和标准化的健康教育工作,除了掌握所提供的预防措施的核心知识外,同时应该熟悉其他各级预防措施的关键要点,主动为服务对象提供综合性的三级预防措施宣教;普通大众作为健康教育服务的终端,在接受子宫颈癌防控健康教育服务后,能够自觉采纳有益于健康的行为和生活方式 (如戒烟、安全性行为和疫苗接种等),形成自我健康管理模式。",
    "source": "中国子宫颈癌综合防控路径建设专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌综合防控路径建设专家共识/中国子宫颈癌综合防控路径建设专家共识.md"
  },
  {
    "text": "# 2.1.2 三级预防服务及其相互连通 # 2.1.2.1 三级预防核心服务内容 (1)HPV 疫苗接种:针对 $9 \\sim 4 5$ 岁女性,通过接种预约,接种门诊工作者对其健康状况和禁忌证进行综合评估后判断是否适合接种,对适宜接种者签署知情同意,进而按照规范化流程实施 HPV疫苗接种并完成安全性监测。同时,在接种留观期间,关注其女性亲属 疫苗接种需求,对于符合年龄适宜接种且尚未接种者,推荐其进行 HPV疫苗预约接种。",
    "source": "中国子宫颈癌综合防控路径建设专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌综合防控路径建设专家共识/中国子宫颈癌综合防控路径建设专家共识.md"
  },
  {
    "text": "()子宫颈癌筛查:针对 $2 5 \\sim 6 4$ 岁常规筛查人群,通过子宫颈癌筛查预约,筛查人员对其适应症进行综合判断,适宜筛查者应按照规范化流程进行筛查,筛查正常者进行定期随访,异常者推荐在本级妇科门诊或转诊至上级临床机构接受后续诊疗服务。同时,在筛查候诊期间,关注其女性亲属既往子宫颈癌筛查情况,对于满足筛查条件但既往未接受筛查者,推荐其进入常规筛查路径。(3)子宫颈癌前病变和子宫颈癌诊断与治疗:患者通过临床诊疗机构进行预约,医务人员对其症状和体征进行综合评估后确定临床诊断,按照规范化子宫颈癌前病变和子宫颈癌临床治疗指南进行诊疗和随访管理。",
    "source": "中国子宫颈癌综合防控路径建设专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌综合防控路径建设专家共识/中国子宫颈癌综合防控路径建设专家共识.md"
  },
  {
    "text": "同时,在治疗期间,关注其女性亲属是否有宫颈病变且未得到及时规范治疗的情况,符合相关症状和体征者,推荐其进入临床诊疗服务路径。2.1.2.2 三级预防服务互联互通 在子宫颈癌防控不同服务场所中,依托开展各级预防核心服务内容的同时,对不同年龄段及不同健康需求的服务对象及其女性亲属提供针对性的其他预防服务相关的健康教育,以此作为纽带引导服务人群参与子宫颈癌其他各级预防服务内容,进一步实现以女性为中心的子宫颈癌全疾病周期预防服务全覆盖,保障不同服务类型和不同机构所提供服务之间的紧密衔接。",
    "source": "中国子宫颈癌综合防控路径建设专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌综合防控路径建设专家共识/中国子宫颈癌综合防控路径建设专家共识.md"
  },
  {
    "text": "具体服务流程详见图1。2.2 建立多部门协同机制 子宫颈癌综合防控联动路径需联合卫生服务体系内疾病预防控制中心、妇幼保健机构、综合医疗机构和基层社区卫生服务中心等核心机构以及卫生系统外涉及卫生职能的相关部门形成整合型多部门协同机制,共同建立组织保障机制和医疗服务体系,为子宫颈癌综合防控服务的实施提供平台支撑。2.2.1 组织保障机制 组织保障机制的建立应在政府主导下,由卫生健康部门及卫生系统外相关协作机构 (包括宣传、财政、医保、教育、妇联、民政和慈善等)联动构成。",
    "source": "中国子宫颈癌综合防控路径建设专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌综合防控路径建设专家共识/中国子宫颈癌综合防控路径建设专家共识.md"
  },
  {
    "text": "通过将子宫颈癌防控作为政府部门的优先事项,出台并落实相关政策,可推动子宫颈癌综合防控工作高效可持续开展。各地区应根据实际情况明确卫生系统外相关协作机构的职能定位,提供的保障措施应围绕子宫颈癌综合防控关键环节,包括参与制定社会公众健康宣教的标准化材料,协助开展针对不同受众的健康宣教;组织开展基于学校或社区的适龄女孩 疫苗接种;协同筹集和提供相关医疗服务的专项经费;制定针对子宫颈癌患者的治疗补助制度等。",
    "source": "中国子宫颈癌综合防控路径建设专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌综合防控路径建设专家共识/中国子宫颈癌综合防控路径建设专家共识.md"
  },
  {
    "text": "2.2.2 医疗服务体系 通过建立各级各类医疗机构组成的医疗服务体系,可实现子宫颈癌分层、分级和分流管理。目前,我国 疫苗接种工作由注:a为其中 $2 5 \\sim 6 4$ 岁宫颈癌筛查告知和预约;b为其中 $9 \\sim 4 5$ 岁者 HPV 疫苗接种告知和预约。疫苗接种候种留观时,针对其监护人,HPV 疫苗接种告知和预约;筛查候诊时或筛查后,针对其同性女性亲属,筛查告知和预约;治疗候诊或者住院时,针对患者本人及陪护女性亲属;HPV 疫苗接种及筛查及筛查告知和预约。",
    "source": "中国子宫颈癌综合防控路径建设专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌综合防控路径建设专家共识/中国子宫颈癌综合防控路径建设专家共识.md"
  },
  {
    "text": "![](images/feed1ebda7f6301a2350cf26e0e15db823d543f43f7bed89f8f2b4293be9dc6d.jpg) 图1 三级预防服务及其互联互通示意图 疾病预防控制中心分管,筛查主要由妇幼保健机构及部分体检或医疗机构负责,诊治主要由临床医疗机构统一管理,不同医疗卫生机构的碎片化服务和分散式管理影响女性子宫颈癌全疾病周期服务的连贯性。因此,综合考虑不同地区医疗资源分布及不同医疗机构权责分工现状,推荐采用的服务体系建设路径包括:()建设区域子宫颈癌综合防控中心或一站式服务门诊:协同提供 疫苗接种、子宫颈癌筛查及宫颈病变治疗管理等综合防控全周期的服务。",
    "source": "中国子宫颈癌综合防控路径建设专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌综合防控路径建设专家共识/中国子宫颈癌综合防控路径建设专家共识.md"
  },
  {
    "text": "()搭建各级各类医疗机构间的合作机制:可通过建立机构间绿色通道转诊机制的形式实现,如在筛查机构及治疗机构之间建立双向或多向转诊救治绿色通道,对筛查阳性病例经绿色通道及时转诊至上级医疗机构进行规范治疗,再将诊断明确和治疗后病情稳定的患者及时转送基层医疗机构进行随访管理[24]。此外,还可建立或扩充医疗联合体,即整合区域内的医疗资源成立医疗机构联盟,采取人员进修、技术帮扶及转诊等多种形式的合作途径,最终形成综合防控协同网络[25]。",
    "source": "中国子宫颈癌综合防控路径建设专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌综合防控路径建设专家共识/中国子宫颈癌综合防控路径建设专家共识.md"
  },
  {
    "text": "2.3 实现信息系统互联互通 结合国家或地方卫生健康部门对于信息化建设的相关标准和要求,依托各地实际需求建设并逐步完善联动互通的子宫颈癌综合防控的区域化信息网络,可实现对妇女健康状态和疾病周期进行个体化的评估和管理,同时为规范子宫颈癌综合防控全链条服务质量以及评价各级预防措施的长期效果提供数据支撑。2.3.1 信息网络涵盖功能 子宫颈癌综合防控信息网络可涵盖的功能包括:()基本功能:基于个案的 疫苗接种、子宫颈癌筛查、诊断、治疗与随访全疾病周期信息的收集和管理。",
    "source": "中国子宫颈癌综合防控路径建设专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌综合防控路径建设专家共识/中国子宫颈癌综合防控路径建设专家共识.md"
  },
  {
    "text": "()服务实施及管理功能:针对子宫颈癌防控信息平台不同使用对象设置相应权限的功能端,支持实现健康宣教、 疫苗接种预约及不良反应监测、子宫颈癌筛查预约及异常人群管理、疾病诊疗意见决策及各级医疗机构绿色通道定向转诊机制等功能。(3)科学评价功能:数据分类汇总、数理统计和分析,依托大数据建设科学评估指标体系等。2.3.2 互联互通实现路径 实现子宫颈癌综合防控信息网络的上述功能,可采用建设或完善区域内子宫颈癌防控综合信息平台和促进相关医疗机构已有信息系统的数据共享和交互两种方法。",
    "source": "中国子宫颈癌综合防控路径建设专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌综合防控路径建设专家共识/中国子宫颈癌综合防控路径建设专家共识.md"
  },
  {
    "text": "(1)建立整合子宫颈癌综合防控信息平台:实现特定区域内适龄女性子宫颈癌综合防控全周期信息的采集、整合、分析、反馈和管理。()基于现有各级各类医疗机构信息系统进行数据共享和交互:联通疾病预防控制中心、妇幼保健机构、临床医疗机构及社区卫生服务中心等机构的现有信息平台,实现机构间的数据互联互通。不同机构的数据链接可依托信息系统外部接口实现,并基于目标人群的唯一识别码(如身份证号码)进行个案信息的联系。应建立统一的数据交互服务技术规范,统一各机构信息系统中涉及个人信息、预防接种、疾病报卡、门诊摘要和随访报告等接口的建设规范,保障数据通过接口进行共享和交互的安全性、及时性、有效性和一致性[26]。",
    "source": "中国子宫颈癌综合防控路径建设专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌综合防控路径建设专家共识/中国子宫颈癌综合防控路径建设专家共识.md"
  },
  {
    "text": "上述两种策略的实现均需涉及的目标人群全疾病周期防控的关键变量,包括基础信息 (一般人口学特征和危险因素等)、 疫苗接种信息(疫苗采购、接种疫苗类型、剂次、接种时间和不良反应监测等)、子宫颈癌筛查信息 (筛查时间、方法、结果及随访管理等)和临床诊疗信息 (诊疗时间、方法效果及随访监测)等,同时应注意其收集方法和质量要求标准 (包括编码标准和数据核查标准等)以确保数据质量。# 3 展 望 整合子宫颈癌综合防控全链条要素,构建适宜我国国情的子宫颈癌综合路径对促进全社会多部门形成合力、多措并举推动实现消除子宫颈癌阶段性目标至关重要。",
    "source": "中国子宫颈癌综合防控路径建设专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌综合防控路径建设专家共识/中国子宫颈癌综合防控路径建设专家共识.md"
  },
  {
    "text": "未来我国仍需在以下几方面加强建设以推动不同资源地区子宫颈癌综合防控路径的落地实施:搭建子宫颈癌综合防控路径实施的示范基地,积累适宜不同资源地区的防控经验;制定可行易行的资源保障机制,确保供给侧的卫生服务设施、人员、 疫苗及检测试剂等医疗产品的可及性和公平性,保障子宫颈癌防控服务的可持续性实施;及时评估并总结试点地区子宫颈癌防控服务效果与卫生经济学效益,了解综合防控路径的实施成效并助力优化防治策略;注重整合统筹医疗系统内部及外部资源,协同开展围绕女性全生命周期的健康服务,实现卫生资源投入的最大化收益。",
    "source": "中国子宫颈癌综合防控路径建设专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌综合防控路径建设专家共识/中国子宫颈癌综合防控路径建设专家共识.md"
  },
  {
    "text": "基于我国真实世界积累的子宫颈癌防控示范经验,可为健康中国癌症防治行动其他癌肿的防控工作树立典范,同时也通过传递中国经验助力全球实现加速消除子宫颈癌目标。# 编写顾问 (按姓氏拼音排序): 郎景和 (北京协和医院);乔友林 (中国医学科学院北京协和医学院群医学及公共卫生学院);魏丽惠 (北京大学人民医院);张勇 (国家癌症中心)编写专家名单 (按姓氏拼音排序): 陈飞 (北京协和医院);胡尚英 (中国医学科学院肿瘤医院);李燕 (中国疾病预防控制中心免疫规划中心);刘晓强 (云南省疾病预防控制中心);马兰 (中国疾病预防控制中心妇幼保健中心);热米拉·热扎克 (新疆医科大学附属肿瘤医院);苏小游 (中国医学科学院北京协和医学院群医学及公共卫生学院);王华庆 (中国疾病预防控制中心免疫规划中心);王岩 (新疆医科大学附属肿瘤医院);吴久玲 (中国疾病预防控制中心妇幼保健中心);许天敏 (吉林大学第二医院);余艳琴 (内蒙古科技大学包头医学院第一附属医院);张延炀 (河南省疾病预防控制中心);赵方辉、赵雪莲 (中国医学科学院肿瘤医院);赵昀 (北京大学人民医院) # 审校专家名单 (按姓氏拼音排序): 毕蕙 (北京大学第一医院);陈汶 (中国医学科学院肿瘤医院);韩历丽 (北京市妇幼保健院);吕敏(北京市疾病预防控制中心免疫所);乔友林 (中国医学科学院北京协和医学院群医学及公共卫生学院);王华庆 (中国疾病预防控制中心免疫规划中心);王临虹 (中国疾病预防控制中心慢性非传染性疾病预防控制中心);魏丽惠 (北京大学人民医院);吴久玲 (中国疾病预防控制中心妇幼保健中心);章文华 (中国医学科学院肿瘤医院);赵更力(北京大学第一医院) # 编写组秘书 任文辉、文天萌 (中国医学科学院肿瘤医院);陈号 (厦门大学公共卫生学院);司明玉 (中国医学科学院北京协和医学院群医学及公共卫生学院) # 参考文献 [1] SungH,FerlayJ,SiegelRL,etal.",
    "source": "中国子宫颈癌综合防控路径建设专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌综合防控路径建设专家共识/中国子宫颈癌综合防控路径建设专家共识.md"
  },
  {
    "text": "GlobalCancerStatistics2020 : GLOBOCAN estimates of incidence and mortalityworldwidefor36cancersin185countries [J].CACancerJClin,2021,71 (3):209-249.[2] World Health Organization.Global strategy to acelerate theelimination of cervical cancer as a ublic health roblem[Z].",
    "source": "中国子宫颈癌综合防控路径建设专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌综合防控路径建设专家共识/中国子宫颈癌综合防控路径建设专家共识.md"
  },
  {
    "text": "2020.[3] FerlayJEMLF.Globalcancerobservatory:cancertoday[EB/OL].[202-8-25].htps:/gco.iarc.fr/today.[4] 赵方辉,陈号,夏昌发,等 中国女性宫颈癌负担快速上升的原因及其应对措施 [] 中华流行病学杂志, ,(5)：761-765.[5] 韩雨廷,吕筠,余灿清,等 数字公共卫生的进展与应用[] 中华流行病学杂志, , (): [6] 朱碧帆,李芬,陈多,等 整合医疗卫生服务体系筹资激励机制现状、问题和优化策略 [J].",
    "source": "中国子宫颈癌综合防控路径建设专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌综合防控路径建设专家共识/中国子宫颈癌综合防控路径建设专家共识.md"
  },
  {
    "text": "中国卫生资源,2019,2 (6):410-414.[7] Xu X ,Wang Y ,Liu Y,et al.A nationwide post-marketingsurvey of knowledge ,atitudes and recommendations towardshumanpapilomavirusvacinesamonghealthcareprovidersinChina [J].",
    "source": "中国子宫颈癌综合防控路径建设专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌综合防控路径建设专家共识/中国子宫颈癌综合防控路径建设专家共识.md"
  },
  {
    "text": "PrevMed,2021,146:106484.[8] 胡尚英,乔友林.2017年 WHOHPV 疫苗立场文件的解读[J].中华预防医学杂志,2018,52 (5):464-468.[9] 上海葛兰素史克中国投资有限公司.双价人乳头瘤病毒吸附疫苗说明书 [Z].2018.[10] 上海默沙东中国有限公司.九价人乳头瘤病毒疫苗 (酿酒酵母)说明书 [Z].2018.[1] 上海默沙东中国有限公司.四价人乳头瘤病毒疫苗说明书(酿酒酵母)[Z].",
    "source": "中国子宫颈癌综合防控路径建设专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌综合防控路径建设专家共识/中国子宫颈癌综合防控路径建设专家共识.md"
  },
  {
    "text": "2020.[12] 厦门万泰沧海生物技术有限公司厦门.双价人乳头瘤病毒疫苗 (大肠杆菌)说明书 [Z].2020.[13] 玉溪泽润生物技术有限公司.双价人乳头瘤病毒疫苗 (毕赤酵母)[Z].202.[14] 全国人民代表大会.《中华人民共和国疫苗管理法》(国家主席令30号)[S].北京:全国人民代表大会,2019.[15] 国家卫生健康委员会.《预防接种异常反应鉴定办法》(卫生部令第60号)[S].",
    "source": "中国子宫颈癌综合防控路径建设专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌综合防控路径建设专家共识/中国子宫颈癌综合防控路径建设专家共识.md"
  },
  {
    "text": "北京:国家卫生健康委员会,208.[16] World HealthOrganization.WHOguidelineforscreningandtreatmentofcervicalpre-cancerlesionsforcervicalcancerprevention,secondedition [S].Generva: WorldHealthOrgaization,2021.[17] 中华预防医学会妇女保健分会.",
    "source": "中国子宫颈癌综合防控路径建设专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌综合防控路径建设专家共识/中国子宫颈癌综合防控路径建设专家共识.md"
  },
  {
    "text": "子宫颈癌综合防控指南[M].北京:人民卫生出版社,2017.[18] 国家卫生健康委员会.国家卫生健康委员会办公厅关于印发宫颈癌筛查工作方案和乳腺癌筛查工作方案的通知 (国卫办妇幼函 [2021]635号)[S].北京:国家卫生健康委员会,2021.[19] 魏丽惠,赵昀,沈丹华,等.中国子宫颈癌筛查及异常管理相关 问 题 专 家 共 识 (一) [J].中 国 妇 产 科 临 床 杂 志,2017,18 (2):190-192.",
    "source": "中国子宫颈癌综合防控路径建设专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌综合防控路径建设专家共识/中国子宫颈癌综合防控路径建设专家共识.md"
  },
  {
    "text": "[20] 魏丽惠,沈丹华,赵方辉,等.中国子宫颈癌筛查及异常管理相关问题专家共识 (二) [J].中国妇产科临床杂志,2017,18 (3):286-28.[21] BhatlaN,DenyL.FIGOCancerReport2018 [J].IntJGynaecolObstet,2018,143Supl2:2-3.[2 ] 李静,索红燕,孔为民.《国际妇产科联盟 (FIGO)2018癌症报告:宫颈癌新分期及诊治指南》解读 [J].",
    "source": "中国子宫颈癌综合防控路径建设专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌综合防控路径建设专家共识/中国子宫颈癌综合防控路径建设专家共识.md"
  },
  {
    "text": "中国临床医生杂志,2019,47 (6):646-649.[23] 中华医学会妇科肿瘤学分会.中国妇科恶性肿瘤临床实践指南 (第6版)[M].北京:人民卫生出版社,2015.[24] 曹红英,刘力松.发挥综合医院优势 畅通双向转诊绿色通道 [J].中华现代护理杂志,2012 (34):4182-4184.[25] 刘元杰,刘葭,宁静,等.妇幼专科联盟及分级诊疗模式实践探索 [J].中国妇幼卫生杂志,202 ,13 (1):75-78.[26] 吴亚, 顾嘉奇, 陈天逸, 等.苏州市公共卫生平台技术架构设计的实践 [J].中国公共卫生管理,2021,37 (4):560-563.收稿日期:202-08-23 修回日期:202-08-31 本文编辑:孙玉婷",
    "source": "中国子宫颈癌综合防控路径建设专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国子宫颈癌综合防控路径建设专家共识/中国子宫颈癌综合防控路径建设专家共识.md"
  },
  {
    "text": "·标准与规范· # 人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识（2022） 中华预防医学会肿瘤预防与控制专业委员会 中国医师协会妇产科医师分会阴道镜与宫颈病变专业委员会 中国优生科学协会阴道镜和子宫颈病理学分会 北京医师协会医学检验专科医师（技师）分会 通信作者：赵方辉， 国家癌症中心 国家肿瘤临床医学研究中心 中国医学科学院北京协和医学院肿瘤医院流行病学研究室，北京 100021，Email：zhaofangh@cicams.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "ac.cn；崔巍， 国家癌症中心 国家肿瘤临床医学研究中心 中国医学科学院北京协和医学院肿瘤医院检验科，北京 100021，Email：wendycuiwei@sina.cn；毕蕙，北京大学第一医院妇产科，北京 100034，Email：00999@pkufh.com 【摘要】 我国正处于加速消除宫颈癌的关键时期，使用高质量筛查方法提高筛查覆盖率是消除宫颈癌的主要手段之一。人乳头状瘤病毒（HPV）核酸检测是WHO推荐用于宫颈癌初筛的首选方法，但我国尚无将其用于宫颈癌筛查实践的指导性文件。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "因此，中华预防医学会肿瘤预防与控制专业委员会、中国医师协会妇产科医师分会阴道镜与宫颈病变专业委员会、中国优生科学协会阴道镜和子宫颈病理学分会、北京医师协会医学检验专科医师（技师）分会与中华医学杂志编辑委员会邀请国内50 余名公共卫生、妇产科、检验医学、病理学等多学科专家结合国内外指南、医学循证证据及我国实际情况形成专家共识，推荐将HPV 核酸检测作为我国宫颈癌筛查的主要方法，并针对其应用于宫颈癌筛查实践前评估和准备、具体用途和适用人群、实验室操作流程以及实施后监测和评估等方面提出了科学建议，以推动我国HPV 核酸检测全面、深入、规范、有序地高质量发展，为实现我国宫颈癌消除目标提供有力保障。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "【关键词】 人乳头状瘤病毒； 核酸检测； 宫颈癌； 筛查基金项目：中国医学科学院医学与健康科技创新工程项目（2021‑I2M‑1‑004） # Chinese expert consensus on the use of human papillomavirus nucleic acid testing for cervical cancer screening (2022) Branch of Cancer Prevention and Control, Chinese Preventive Medicine Association; Chinese Obstetrics and Gynecology Association Colposcopy and Cervical Neoplasia Committee; Chinese Society of Colposcopy and Cervical Pathology of China Health Birth Science Association; Beijing Medical Doctor (Technician) Society of Laboratory Medicine Corresponding authors: Zhao Fanghui, Department of Cancer Epidemiology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China, Email: zhaofangh@cicams.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "ac.cn; Cui Wei, Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 收稿日期 2023-01-17 本文编辑 梁明修 引用本文：中华预防医学会肿瘤预防与控制专业委员会，中国医师协会妇产科医师分会阴道镜与宫颈病变专业委员会，中国优生科学协会阴道镜和子宫颈病理学分会，等.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "人乳头状瘤病毒核酸检测用于宫颈癌 筛 查 中 国 专 家 共 识（2022）[J].中 华 医 学 杂 志 , 2023, 103(16): 1184-1195.DOI: $1 0 .3 7 6 0 / \\mathrm { c m a } .$ j.cn112137-20230117-00096.Beijing 100021, China, Email: wendycuiwei@sina.cn; Bi Hui, Department of Obstetrics and Gynecology, First Hospital of Peking University, Beijing 100034, Email: 00999@pkufh.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "com 【Abstract】 China is currently in a critical period of accelerating the elimination of cervical cancer, and scaling up screening coverage with high‑quality methods is one of the main approaches to achieve this goal.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "World Health Organization (WHO) recommended human papillomavirus (HPV) nucleic acid testing as the preferred primary screening method of cervical cancer.However, no guidelines exist for its use in cervical cancer screening in China.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "Therefore, Branch of Cancer Prevention and Control, Chinese Preventive Medicine Association, Chinese Obstetrics and Gynecology Association Colposcopy and Cervical Neoplasia Committee, Chinese Society of Colposcopy and Cervical Pathology of China Health Birth Science Association, Beijing Medical Doctor (Technician) Society of Laboratory Medicine, and the editorial board of the National Medical Journal of China convened more than 50 domestic experts from multiple disciplines, including public health, obstetrics and gynecology, laboratory medicine, and pathology, to form a consensus based on domestic and international guidelines, medical evidence, and China′s actual situation.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "These experts recommend HPV nucleic acid testing as the primary method for cervical cancer screening in China, and provide scientific suggestions on the pre‑implementation assessment and preparation, specific applications and target populations, laboratory operating procedures, and post‑implementation monitoring and assessment for the cervical cancer screening.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "These recommendations aim to promote a comprehensive, in‑depth, standardized, orderly and high-quality development of HPV nucleic acid testing in China, for providing a strong support for accelerating cervical cancer elimination in China.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "【Key words】 Human papillomavirus; Nucleic acid testing; Cervical cancer; Screening Fund program: Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (2021‑I2M‑1‑004) 宫颈癌病因明确，几乎 $100 \\%$ 的宫颈癌由人乳头状瘤病毒（HPV）感染引起［1‑2］。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "2020 年全球宫颈癌新发60.4 万例，死亡约34.2 万例，是全球女性常见的第四大恶性肿瘤［3］。我国宫颈癌发病和死亡例数在全球处于较高水平，2020年新发10.97万例，死亡5.91万例，发病和死亡例数已占到全球近 $1 8 \\% ^ { [ 4 ] }$ 。消除宫颈癌是全球范围内的一项重大公共卫生议题。2020 年世界卫生组织（WHO）发布了《加速消除子宫颈癌全球战略》，强调到2030 年实现“90‑70‑90”目标： $9 0 \\%$ 的适龄女孩在15 岁之前接种HPV 疫苗， $70 \\%$ 的女性在35 和45 岁之前各接受一次高效的宫颈癌筛查， $9 0 \\%$ 确诊为宫颈癌前病变或宫颈癌的女性接受规范治疗和管理［5‑6］。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "我国政府表示全力支持这一全球战略并制定了系列规划：2019 年 国 务 院 发 布《健 康 中 国 行 动（2019—2030 年）》，明确提出宫颈癌筛查县区覆盖率在2030 年达到 $9 0 \\%$ 以上［7］；2021 年 12 月 31 日国家卫生健康委员会（简称卫健委）印发《宫颈癌筛查工作方案》，提出到2025 年底实现适龄妇女宫颈癌筛查率达到 $5 0 \\%$ 以上、早诊率达到 $9 0 \\%$ 以上的目标，并强调要将宫颈癌核心知识知晓率、筛查率、早诊率纳入绩效考核［8］。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "2021 年WHO 发布第二版《预防宫颈癌：宫颈癌前病变筛查和治疗指南》，推荐以HPV DNA 检测作为宫颈癌筛查的首选方法［9‑10］。欧盟及美国、澳大利亚、法国、英国等发达国家和印度、巴西等部分发展中国家已颁布指南，推荐使用HPV 核酸检测作为宫颈癌的初筛方法［11‑17］。我国最新的《宫颈癌筛查工作方案》也将HPV 核酸检测列为初筛方法之一［8］。然而在这样的战略背景下，我国的宫颈癌筛查仍面临以下主要问题：（1）宫颈癌筛查覆盖率较低，2018—2019 年我国 35\\~44 岁女性筛查率为$4 3 .",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "4 \\%$ ，低于 WHO 提出的 $70 \\%$ 筛查率目标［18］；（2）细胞学检查存在灵敏度低、结果具有主观性、质量难以保证等问题，但目前仍是宫颈癌筛查的主要方法［19］；（3）HPV核酸检测技术具有灵敏度高、可重复性高等特点，相较于细胞学检查可检出更多的宫颈癌和癌前病变［20］，但尚未在我国宫颈癌筛查项目中广泛使用［21‑24］。基于此，中华预防医学会肿瘤预防与控制等专业委员会和《中华医学杂志》组织公共卫生、妇产、检验、病理等多学科专家共同撰写该共识，面向参与宫颈癌筛查的公共卫生人员、妇幼保健人员、妇产科临床医师、实验室检验人员等，旨在规范HPV核酸检测用于宫颈癌筛查的相关实践，制定符合我国国情、指导基层的共识意见，推动我国HPV 核酸检测全面、深入、规范、有序地高质量发展，为实现我国宫颈癌消除目标提供有力保障。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "# 第一部分 HPV型别和核酸检测概况 # 一、HPV型别与宫颈癌的关系 HPV 是一种嗜上皮组织的无包膜双链环状小DNA 病毒，病毒基因组约 $8 ~ \\mathrm { k b }$ ，可分为3 个区域：早期基因（包含开放阅读框E6、E7、E1、E8、E2、E4、E5）、晚期基因（包含开放阅读框L2 和L1），以及非编码上游调节区（URR）又称为长控制区（LCR）（图1），各基因的功能和特点见表1［25‑30］。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "![](images/5743fda894811ac5499ee9dab56e2dcb79f9570c8be638b3ed3839c51632c6a1.jpg) 图1 人乳头状瘤病毒基因组图谱 HPV 基因组序列存在 $10 \\%$ 以上的不同，即为不同的基因型别［31］。目前已发现并分离鉴定出200 多种HPV 型别，并按其诱发癌症的潜力，分为高危型与低危型［31‑32］。我国2015年发布的《人乳头瘤病毒（HPV）核酸检测及基因分型、试剂技术审查指导原则》中将 HPV16、18、31、33、35、39、45、51、52、56、58、59、68 等 13 种基因型列为高危型 HPV（HR‑HPV）［33］。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "WHO 在 2021 年发布的《预防宫颈癌：宫颈癌前病变筛查和治疗指南》中指出HR‑HPV 检测通常包括 14 种型别：HPV16、18、31、33、35、39、45、51、52、56、58、59、66、68 型［9］HR‑HPV持续感染过程中病毒的E6和E7基因可能与宿主DNA 发生整合，导致宫颈上皮内瘤样病变（CIN）甚至宫颈癌［25‑27］。低危型 HPV（LR‑HPV）主要包括HPV6、11、42、43、44 等，可能引起生殖器疣或其他良性病变。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "# 二、HPV分型检测对宫颈癌筛查的临床意义 女性生殖道HPV 感染较常见，但 $70 \\% { \\sim } 9 0 \\%$ 的感染无症状并可在1\\~2 年内消失， $5 \\% \\mathrm { \\sim } 1 0 \\%$ 感染女性会发生持续性HPV 感染，并有可能进一步进展为宫颈癌前病变甚至浸润癌。HPV 感染宫颈上皮后，因其基因型别不同、是否持续感染及持续感染时间不同，其致病风险也显著不同［34‑36］。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "因此，对HPV 进行分型检测并明确是否存在持续感染具有重要的临床意义。# （一）明确HR‑HPV 感染型别 进行风险分层管理 HR‑HPV 感染与宫颈癌发生密切相关，几乎所有宫颈癌中可检测到HR‑HPV。加泰罗尼亚肿瘤研究所和国际癌症研究署（ICO/IARC）2021 年发布的全球HPV 和相关疾病报告显示，宫颈癌中最常见的 HR‑HPV 型别为 HPV16（ $5 5 .2 \\%$ ）、 $.1 8 ( 1 4 .",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "2 \\% )$ 、$4 5 ( 5 .0 \\%$ ）、 $.3 3 ( 4 .2 \\% )$ ）和 $5 8 ( 3 .9 \\% )$ ），其中 $\\mathrm { { H P V 1 6 / 1 8 } }$ 占比约 $7 0 \\% ^ { [ 1 ] }$ 。我国宫颈癌最常见HR‑HPV 型别为HPV16（ $5 9 .5 \\%$ ）、 $1 8 ( 9 .6 \\%$ ）、 $.5 8 ( 8 .",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "2 \\% )$ ）、 $.5 2 ( 6 .5 \\% )$ ）和33（ $3 .5 \\%$ ）， $_ \\mathrm { H P V 1 6 / 1 8 }$ 占比与全球类似，但 HPV52/58 占比较高［4］。HR‑HPV 感染是宫颈高级别鳞状上皮内及以上病变（ ${ \\mathrm { .H S I L } } +$ ）发生的必要条件。通常以发生HSIL $^ +$ 的风险作为衡量指标，遵循“同等风险，同等管理”的原则对HR‑HPV 感染者进行进一步的分流或随访管理［12，37］。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "HPV16/18 型别导致 HSIL $.+$ 的风险最高，对HPV16/18 阳性感染者直接进行阴道镜转诊。除 HPV16/18 以外的其他 12 种 HR‑HPV 型别发生 HSIL $^ +$ 风险存在差异。HPV31、33、45、52、58 与 HPV18 感 染 者 发 生 CIN3 的 风 险 近 似 ，但HPV18 在浸润癌中占比更大而且致癌风险明显增加；而 HPV35、39、51、56、59、66、68 发生 $\\mathrm { C I N } 3 +$ 的风险较低，考虑可采取不同于高致病风险HR‑HPV 感染人群的管理措施［36，38‑40］。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "而HR‑HPV 阴性者发生HSIL $^ +$ 的风险极低，通常只需定期随访即可［35，41］。HR‑HPV 单一型别与多重型别感染对致癌性的影响，尚未形成统一结论。几项大型宫颈癌筛查研究提示多重感染特别是HR‑HPV 多重感染可能与细胞学异常或 ${ \\mathrm { H S I L } } +$ 发生风险更密切相关，但也有筛查研究显示多重感染对宫颈病变发生风险没有累加或协同作用［42‑45］。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "因此，目前对于多重感染者仍采用与单一型别感染者相同的管理模式。# （二）明确是否存在HPV 持续感染 采取更积极的管理措施 根据文献研究和临床经验，HPV持续感染可定义为：间隔6\\~12 个月的相邻2 次检测中，同一个体的宫颈检测样品显示为同种型别HPV 阳性［45‑48］。表1 HPV各基因的功能和特点［25‑30］ <html><body><table><tr><td>HPV基因</td><td>功能和特点</td></tr><tr><td>E6</td><td>可与E7蛋白协同驱动细胞周期进入S期以提供适合病毒DNA复制的环境,降解p53蛋白避免细胞凋亡,是与宫颈癌关联最紧密 的致癌基因之一</td></tr><tr><td>E7</td><td>可与E6蛋白协同驱动细胞周期进人S期以提供适合病毒DNA 复制的环境,靶向多个细胞周期调节通路蛋白引起细胞增殖失 调，是与宫颈癌关联最紧密的致癌基因之一</td></tr><tr><td>E8</td><td>功能尚未完全明确，可能参与控制HPV病毒复制和转录的相关机制</td></tr><tr><td>E1</td><td>编码ATP酶依赖的解旋酶，与病毒复制起点结合后参与病毒基因组复制</td></tr><tr><td>E2</td><td>编码E2蛋白可调控病毒基因转录,招募E1到病毒复制起点后增加病毒 DNA复制,并在宿主细胞分裂过程中将病毒基因组转移 到子细胞</td></tr><tr><td>E4</td><td>编码E4蛋白，调控病毒颗粒的组装及释放</td></tr><tr><td>E5</td><td>编码小跨膜蛋白E5,与生长因子信号通路的调节和免疫逃逸密切相关,与E6和E7协同驱动细胞的恶性进展,是HPV持续感染 的重要因素之一</td></tr><tr><td>L2 L1</td><td>编码次要衣壳蛋白L2,参与病毒DNA包埋，促进病毒入侵和传输，可诱发产生较长保护作用的中和抗体</td></tr><tr><td></td><td>编码主要衣壳蛋白L1,组装成五聚体衣壳形成二十面体病毒粒子,具有明显抗原性且是免疫细胞清除HPV的主要攻击位点，是 预防性疫苗的重要靶抗原</td></tr><tr><td>URR</td><td>包含调控元件,调控早期、晚期基因蛋白表达,对决定HPV宿主特异性范围具有重要意义</td></tr></table></body></html> 注：HPV为人乳头状瘤病毒；ATP为腺苷三磷酸；URR为非编码上游调节区 HR‑HPV 持续感染是发生宫颈高级别病变和宫颈癌的主要原因［26，35，46‑47］。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "研究显示 HR‑HPV 持续感染平均2\\~3 年可发生宫颈癌前病变，平均10\\~12 年可发展为宫颈癌［49］，并且HR‑HPV 持续感染者相较于不同型别的反复感染者，宫颈癌发病风险高出约4倍［50］。HR‑HPV 持续感染还可能影响宫颈病变治疗后女性的预后。如锥切术后发生与术前相同型别HPV 持续感染者，其残留或复发的风险更高，需更密切地关注存在治疗失败的可能性，并进行更严格的管理［51‑52］。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "因此，HR‑HPV 分型检测可明确是否存在同一型别持续感染，有助于采取更积极的干预治疗措施和更严格的随访管理。推荐意见1：（1）对HR‑HPV核酸检测阳性者遵循“同等风险，同等管理”的原则进行分层管理。HPV16/18 是致癌风险最高的型别，需及时转诊阴道镜以进一步评估。针对其他HR‑HPV 感染者，需积累更多致病风险的证据，并进行分流有效性的评估，从而提出适宜的分流策略。（2）HR‑HPV 持续感染者发生宫颈癌前病变及宫颈癌的风险增加，建议采取更加积极的管理策略。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "# 三、HPV核酸检测技术的分类和发展 根据是否对目的基因进行扩增，HPV核酸检测方法可以分为扩增法和非扩增法［53‑56］。（1）核酸扩增法：根据扩增的目的基因片段不同，可分为DNA扩增和RNA 扩增；根据扩增的方法不同，可分为聚合酶链反应（PCR）法和恒温扩增法等。（2）非扩增法：主要基于HPV 全片段基因利用检测信号放大的原理进行检测，包括杂交捕获、酶切信号放大法等。目前，我国HPV 核酸检测常用技术多以核酸扩增法及其衍生技术为主，包括：恒温扩增法、荧光PCR（PCR‑荧光探针法）、PCR‑毛细管电泳法、PCR‑微流控芯片法、PCR‑熔解曲线法、PCR‑反向点杂交/流式荧光杂交法等［55，57‑58］。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "总体而言，HPV 核酸检测向着更多分型、更高灵敏度、更高特异度、更加自动化方向发展（常用方法学见表2）。推荐意见2：HPV 核酸检测方法可以分为非扩增法和扩增法，这些方法可对HPV 全基因组或某一片段（例如：以 L1 DNA、E6/E7 DNA 或 mRNA 等为检测靶点）进行有效检测。# 第二部分 HPV核酸检测用于宫颈癌防治的实践指导 在加速消除宫颈癌全球战略背景下，我国宫颈癌初筛方法正在从以细胞学为主向以HPV 核酸检测为首选转变。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "当前阶段需要通过认真梳理现有供给系统，建立完善的实验室运行机制和监督管理体系，开展基于HPV 核酸检测筛查项目的同时建立高效的异常人群转诊路径，并为健康服务提供者提供规范化培训，为受众人群提供健康教育等，以建立 HPV 核酸检测所需的相关配套系统，加快HPV 核酸检测作为我国宫颈癌初筛方法的推广使用。一、宫颈癌防治中 HPV 核酸检测实施前的评估和准备 # （一）实验室质量保证 1.基本要求：HPV检测实验室应当根据各自条件，制定环境、安全、人员、仪器设备及试剂耗材等方面相关文件及管理制度，应建立包含检测全过程的标准操作程序，包括但不限于样品采集、运送、保存、样品前处理、核酸提取、核酸检测、结果报告和解释、仪器设备维护、质量控制、复检流程及防污染措施等。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "表2 人乳头状瘤病毒核酸检测常用方法学 <html><body><table><tr><td>方法学</td><td>检测原理</td><td>检测靶点</td></tr><tr><td>非扩增法</td><td></td><td></td></tr><tr><td>杂交捕获</td><td>采用RNA探针进行靶标杂交捕获,利用抗体和酶进行信号放大,荧光信号检测或化学发光全基因组 检测</td><td></td></tr><tr><td>扩增法</td><td></td><td></td></tr><tr><td></td><td>荧光PCR法(PCR-荧光探针法）使用特异引物和荧光标记探针,利用荧光信号实时监测病毒DNA序列扩增</td><td>L1 DNA</td></tr><tr><td>PCR-毛细管电泳法</td><td>采用多重PCR技术同时对多个靶点进行特异性扩增，通过毛细电泳，根据扩增片段长度的E6/E7DNA 不同对型别进行区分</td><td></td></tr><tr><td>PCR-微流控芯片法</td><td>在密闭芯片内全程全自动进行目的DNA提取纯化、多重PCR扩增和反向斑点杂交型别检测L1 DNA</td><td></td></tr><tr><td>荧光PCR-熔解曲线法</td><td>采用实时荧光PCR实时监测扩增曲线,并采用熔解曲线对应的溶解峰温度判定PCR产物L1DNA 的基因型信息</td><td></td></tr><tr><td>PCR-反向点杂交法</td><td>PCR扩增后将生物素标记的特异性PCR扩增产物与固定于膜上的探针杂交显色,进行基因L1 DNA 分型检测</td><td></td></tr><tr><td>PCR-流式荧光杂交法</td><td>PCR扩增产物和微球上交联的探针进行杂交,加入荧光标记反应后在流式荧光检测仪读取L1 DNA 荧光信号</td><td></td></tr><tr><td>恒温扩增-荧光法</td><td>恒定温度下，使用酶和特异引物进行快速核酸扩增</td><td>E6/E7 mRNA</td></tr></table></body></html> 注：PCR为聚合酶链反应 基于非基因扩增技术开展HPV 核酸检测的医疗机构和第三方检测机构需依据《病原微生物实验室生物安全管理条例》（国务院令第424 号）有关规定，具备经过卫生健康行政部门审核备案的生物安全二级及以上实验室条件。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "独立设置的医学检验实验室还应当符合《医学检验实验室基本标准（试行）》《医学检验实验室管理规范（试行）》等要求，在卫生行政部门进行相应技术审核和登记备案，才能开展检测。基于基因扩增技术开展HPV 核酸检测的医疗机构和第三方检测机构在满足如上要求的基础上，还需符合《医疗机构临床基因扩增实验室管理办法》（卫办医政发〔2010〕194 号）的有关规定，具备临床基因扩增检验实验室条件。2.性能验证：HPV核酸检测实验室应建立标准操作流程，并在开展临床检测前及检测过程中发现与检测系统可能相关的影响检测结果的问题时，均应对检测系统进行性能验证。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "目前HPV 检测性能验证按照定性检测项目的性能验证要求进行，包括测量精密度、符合率、检出下限、抗干扰能力、交叉反应等。建议针对中国人群常见型别进行性能验证，至少包括HPV16、18、52、58等。3.质量控制：基于基因扩增技术开展HPV 核酸检测的实验室应按照《医疗机构临床基因扩增检验工作导则》建立质量控制程序。（1）室内质控：每批检测至少应包含1 份阴性质控品和1 份阳性质控品。阳性质控应包含常见的 HPV 高危型别（如 HPV16、18、52、58 等）中的一种或多种。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "阴性和阳性质控均应参与从提取到扩增检测的全过程。（2）室间质评：实验室应参加国家级或省市级临床检验中心组织的室间质评，每年至少2次。# （二）HPV核酸检测试剂/检测系统的选择 1.分析性能：选择国家药品监督管理局（NMPA）批准的且通过实验室分析性能验证的试剂或检测系统，具体要求可参见《人乳头瘤病毒（HPV）核酸检测及基因分型、试剂技术审查指导原则》［33］。2.临床性能：HPV核酸检测试剂或检测系统应用于临床宫颈癌筛查时需验证临床性能，评估临床灵敏度、特异度、阴性预测值、阳性预测值等指标是否满足临床预期用途（如，初筛、ASC‑US人群分流、或与细胞学联合筛查等）。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "对于HPV 检测来说，要求有高度的临床灵敏度和阴性预测值，并且在保证较高检出率的同时尽量降低假阳性率。假阳性的HPV 检测结果，及对结果的误判和误导，都会引起公共卫生损害风险，导致治疗不当、频繁检查和侵袭性处置等过度诊断或治疗［33，59］。而假阴性的结果又会导致漏诊的情况。HPV 核酸检测对中度及以上宫颈上皮内瘤样病变和宫颈癌（ $\\mathrm { C I N } 2 +$ ）及高度及以上宫颈上皮内瘤样病变和宫颈癌（ $\\mathrm { \\ C I N } 3 +$ ）诊断的灵敏度应 $9 0 \\%$ 。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "临床性能验证指标的具体要求可参见WHO 筛查指南和我国《人乳头瘤病毒（HPV）核酸检测及基因分型、试剂技术审查指导原则》［9，33］。3.其他：根据国家制定的宫颈癌防治策略、当地的卫生资源与条件、实验室要求、目标人群和可用资源等因素，考虑方法学、检测靶点和分型的不同、自动化程度以及可及性等问题，选择合适的HPV核酸检测试剂/检测系统。推荐意见3：（1）HPV 核酸检测实验室应当制定环境、安全、人员、仪器设备及试剂耗材等方面相关文件及管理制度，建立包含检测全过程的标准操作程序以及完善的质量控制程序；（2）建议选择NMPA 批准且通过实验室分析性能验证的HPV 核酸检测试剂或检测系统；（3）HPV 核酸检测试剂或检测系统应用于临床宫颈癌筛查时需验证临床性能，评估是否满足临床预期用途。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "# （三）HPV核酸检测的相关支持要求 1.构建完善的随访管理体系：（1）完善宫颈癌筛查与随访信息管理系统，建立信息管理制度，加强筛查数据的标准化和规范化，搭建宫颈癌防治信息共享服务平台，实现筛查、诊断、治疗各环节数据的互联互通。（2）建立个人健康档案，记录妇女基本信息及检查、诊断、治疗情况，实现对定期筛查及后续随访的动态管理。（3）加大筛查、诊断、治疗数据的数字化投入，降低信息系统对接及信息共享的差异化。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "（4）做好宫颈癌筛查数据信息上报、审核、汇总和数据分析与评价工作，逐步实现区域内宫颈癌筛查人群的社会人口学和行为学因素、疫苗接种史、筛查与早诊早治等内容的动态信息联接、共享和管理［60‑61］。2.公众教育：（1）开展宫颈癌防治的社会动员，加强大众健康教育，促进广大妇女正确理解和提高对宫颈癌筛查、随访以及癌前病变治疗的意识，主动自觉接受宫颈癌筛查和随访、治疗服务。（2）采用多层次、多途径和适宜的方法进行相关知识的宣传和教育，使妇女掌握正确的知识：首先了解定期开展宫颈癌筛查的重要性，但无需频繁进行HPV 检测，其意义有限并造成医疗资源的浪费；降低妇女对HPV 检测异常的恐慌，使其了解筛查检测结果为HR‑HPV 阳性仅提示高风险，只要进行及时有效的随访和必要治疗，即可预防宫颈癌。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "（3）向公众强调自我管理的重要性，需明确个人是自身健康的首要负责人，要坚持定期进行宫颈癌筛查和随访。（4）医疗机构和医务工作者应在筛查和诊疗的同时为妇女提供相应的健康教育，并与各地妇联加强合作，辅助基层医务人员进行宣传教育。# 二、宫颈癌防治中HPV核酸检测的实施 # （一）HPV核酸检测在宫颈癌防治中的应用 1.HPV核酸检测用于宫颈癌初筛：中国在宫颈癌筛查策略方面与国际共识/指南的方向一致：推荐使用 HR‑HPV 核酸检测作为宫颈癌的初筛方法［8，11‑17，62‑63］。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "2021 年发布的我国多中心大样本宫颈癌筛查随机对照临床研究和大规模真实世界研究均已证实HR‑HPV DNA 检测用于宫颈癌初筛的有效性［64‑65］。同时模型研究进一步指出，采用基于“HPV 疫苗接种 $^ +$ 基于HPV 核酸检测的宫颈癌筛查”的优化路径可加速我国实现消除宫颈癌目标［66］。HPV 筛查的年龄和频次可参考WHO 发布的《预防宫颈癌：宫颈癌前病变筛查和治疗指南》和我国《宫颈癌筛查工作方案》《中国子宫颈癌综合防控指南》。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "鉴于我国人口基数大、卫生资源分布不均、宫颈癌筛查覆盖率和疫苗接种率仍比较低等现实问题，考虑在借鉴国际指南的基础上，依据我国医疗资源配置现状及宫颈癌前病变筛查和治疗相关证据的更新，探索更符合中国国情的HPV筛查方案。推荐意见4：（1）筛查人群： $\\textcircled{1}$ 优先对 35‑64 岁女性进行筛查； $\\textcircled{2}$ 条件允许可纳入常规体检；单位组织的体检中也建议遵循这一建议。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "（2）筛查方法：推荐将HR‑HPV 检测作为人群宫颈癌筛查的首选方法，筛查间隔为5 年。（3）HPV 检测方法的选择：$\\textcircled{1}$ 至少检测 13 种 HR‑HPV（HPV16、18、31、33、35、39、45、51、52、56、58、59、68）； $\\textcircled{2}$ 有条件时建议至少进行 HPV16/18 分型检测； $\\textcircled{3}$ 采用NMPA 批准且通过实验室分析性能验证和临床性能验证的HPV 检测方法。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "（4）对于筛查中检出的HPV 阳性者，应根据其发生 ${ \\mathrm { H S I L } } +$ 风险确定进一步管理建议：$\\textcircled { 1 } \\mathrm { H P V } 1 6 / 1 8$ 阳性者直接转诊阴道镜检查； $\\textcircled{2}$ 非HPV16/18 阳性者建议进行分流检测（细胞学检查或其他方法），分流检测阳性者转诊阴道镜检查；$\\textcircled{3}$ HR‑HPV持续感染者建议直接转诊阴道镜检查。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "2.HPV 核酸检测用于分流：ASC‑US 是最常见的细胞学异常类型［21］。目前临床对ASC‑US的分流建议首选HPV 检测，HPV 阳性建议转诊阴道镜检查，HPV 阴性者建议复查，以减少不必要的阴道镜转诊。有研究显示，HPV 分型检测可减少约 $4 0 \\%$ HPV 阳性ASC‑US 者的阴道镜转诊，且不会造成CIN3 $+$ 病变的延迟诊断［67］。推荐意见5：细胞学ASC‑US 者建议首选HPV核酸检测分流，并根据分流结果决定是否需要进行阴道镜转诊：（1）HPV 检测阴性者，3 年后复查，对于细胞学医生诊断水平及细胞学质控相对不足地区，复查间隔可为12 个月；（2）HPV 阳性者直接转诊阴道镜。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "3.HPV 核酸检测用于 ${ \\mathrm { H S I L } } +$ ［包括中度宫颈上皮内瘤样病变（CIN2）、高度宫颈上皮内瘤样病变（CIN3）、原位腺癌（AIS）及浸润癌］切除性治疗后的风险评估［29］：HPV 核酸检测可明显提高在 ${ \\mathrm { H S I L } } +$ 子宫颈切除性治疗后人群中识别复发病变的敏感性，并可忽略HSIL 者的切缘状况。对于全子宫切除的患者，若既往存在 ${ \\mathrm { H S I L } } +$ ，全子宫切除术后仍应定期进行细胞学联合HPV 检测，可及时发现下生殖道其他部位的HPV相关病变。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "推荐意见6：（1）HSIL 治疗后6 个月，采用基于HPV 核酸的单独检测或联合细胞学检测进行第一次监测，结果阴性者其后3年每年进行基于HPV 核酸检测的复查，结果均阴性者可将随访间隔延长至每3 年1 次，持续25 年。（2）AIS 患者宫颈切除性治疗后切缘阴性且有保留生育意愿者可行保留生育管理，建议术后前3 年每6 个月行细胞学联合HPV检测及子宫颈管评估；结果均阴性者，后2 年可每年行细胞学联合HPV 检测及子宫颈管评估；5 年内结果均阴性者，可将随访间隔继续延长至每3 年1次，长期随访。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "（3）全子宫切除者既往存在HSIL+，建议术后前3年每年行细胞学联合HPV 核酸检测，结果均阴性者可将随访间隔延长至每3 年一次，持续25年。4.HPV 筛查流程图：对适龄女性采用HPV 核酸检测进行初筛，阴性者间隔5 年后再次进行检测。对HPV 初筛阳性者采用HPV 基因分型和细胞学检测联合分流方法：HPV16/18 阳性者及HPV 持续感染者直接转诊阴道镜，非HPV16/18 阳性者采用细胞学检测进一步分流。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "细胞学阴性者12 个月后再次进行HPV 核酸检测，细胞学阳性者直接转诊阴道镜。对阴道镜检查结果为低度及以上病变者行病理检查，病理结果为宫颈正常或低级别鳞状上皮内病变者（≤LSIL）12 个月后再次进行HPV 核酸检测，病理结果为HSIL $.+$ 者进行治疗，并在 $6 \\sim$ 12 个月后采用HPV 核酸及细胞学联合检测进行随访，结果阳性者转诊阴道镜，阴性者每年进行1 次随访，连续3 年阴性则转为每3 年1 次随访，持续25年。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "流程见图2。接种人群：预防性 HPV 疫苗不能治疗已存在的HPV 感染及相关疾病，不能预防所有HPV 型别感染，也不能阻止HPV 感染进展至疾病。因此，接种过疫苗的女性，仍应定期进行HPV 检测，以预防宫颈癌的发生发展［66，68］。目前对于接种过HPV 疫苗人群仍建议采用与未接种HPV 疫苗人群相同的筛查策略。（2）免疫缺陷人群：免疫缺陷人群临床可包括：$\\textcircled{1}$ 免疫系统疾病：包括免疫缺陷性疾病、免疫增殖性疾病、自身免疫病3 种类型的患者； $\\textcircled{2}$ 因各种疾病应用免疫抑制剂者（包括器官移植患者）； $\\textcircled{3}$ 其他原因引起免疫缺陷的人群等。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "相较于免疫正常者，免疫缺陷人群发生HPV 感染、宫颈癌及癌前病变治疗失败风险更高［69‑72］。建议对免疫缺陷人群采用更早的起始筛查年龄，并缩短筛查间隔。目前针对免疫缺陷人群的筛查策略主要为人类免疫缺陷病毒（HIV）感染人群制定，其他类型免疫抑制人群则可遵循与HIV感染人群相同的筛查策略［9，73‑75］。（3）备孕期及孕期女性：妊娠妇女筛查措施的选择与一般风险人群相同。针对筛查阳性的妊娠期妇女，美国 ASCCP［12］、加拿大［76］和德国［77］发布的指南均建议采用与未妊娠妇女相同的原则进行管理，但需注意： $\\textcircled{1}$ 不能行宫颈管检查或子宫内膜搔刮/活检； $\\textcircled{2}$ 只有在怀疑宫颈癌时才建议进行切除性检查； $\\textcircled{3}$ 若相关检查排除了 ${ \\mathrm { H S I L } } +$ ，建议推迟到产后进行复查； $\\textcircled{4}$ 若相关检测怀疑或诊断为CIN2 或CIN3，建议持续监测并推迟到产后进行再评估或治疗。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "我国指南建议既往未规律筛查或从未筛查过的有妊娠意愿女性应在孕前检查或第一次产检时行宫颈癌筛查［73］。（4） ${ \\geqslant } 6 5$ 岁女性：既往未规律筛查，且近10年无3 次连续常规细胞学筛查阴性或连续两次常规HPV核酸检测阴性史者建议继续进行筛查。推荐意见7：（1）预防性HPV 疫苗接种人群：建议采用与未接种HPV 疫苗人群相同的筛查策略。（2）免疫缺陷人群： $\\textcircled { 1 } \\mathrm { H I V }$ 人群：建议25岁或有性生活的女性1 年内开始筛查［9，12］，每3\\~5 年定期筛查1 次，筛查结果为阳性或宫颈病变治疗后，应缩短筛查间隔；具体筛查时间应与专科医生讨论确定，通常筛查频次为一般人群的2 倍； $\\textcircled{2}$ 其他免疫缺陷人群：可遵循与HIV 感染人群相同的筛查策略。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "（3）备孕期及孕期女性建议采用与未妊娠女性相同的原则进行筛查与管理： $\\textcircled{1}$ 有妊娠意愿的女性应在孕前检查时询问近1 年内是否进行过宫颈癌筛查； ![](images/55c631368abfe56eb487c3a4396cd2ec1db43838e77fe14493c2be8bfb6ec4d4.jpg) 图2 HPV检测用于宫颈癌筛查流程图 注：HPV 为人乳头状瘤病毒；≤LSIL 为宫颈正常或低级别鳞状上皮内病变； ${ \\mathrm { H S I L } } +$ 为宫颈高级别鳞状上皮内或以上病变［包括中度宫颈上皮内瘤样病变（CIN2）、高度宫颈上皮内瘤样病变（CIN3）、宫颈原位腺癌（AIS）及浸润癌］ $\\textcircled{2}$ 对于既往没有筛查过或未定期筛查的女性，在孕前检查或第一次产检时进行筛查； $\\textcircled{3}$ 针对筛查阳性的妊娠期妇女，需注意：不能行宫颈管检查或子宫内膜搔刮/活检；只有在怀疑宫颈癌时才建议进行切除性检查；若相关检查排除了 ${ \\mathrm { H S I L } } +$ ，建议推迟到产后进行复查；若相关检测怀疑或诊断CIN2 或CIN3，建议持续监测并推迟到产后进行再评估或治疗。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "$( 4 ) { \\geqslant } 6 5$ 岁女性： $\\textcircled{1}$ 既往10年未进行过规律筛查者，应继续进行筛查； $\\textcircled{2} 1 0$ 年内连续3 次常规细胞学检查无异常结果或连续2 次常规HPV 筛查为阴性结果，且既往无CIN病史者，可停止筛查。# （二）HPV核酸检测的操作流程 HPV核酸检测可分为分析前、分析中以及分析后三个阶段，规范HPV 核酸检测操作流程有助于提升检测的质量，保证诊断的准确性。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "1.检测分析前：（1）取样： $\\textcircled{1}$ 取样前患者须知：需避开月经期进行采样；检查前 $4 8 \\mathrm { { h } }$ 内避免性生活、阴道冲洗和阴道内用药。$\\textcircled{2}$ 样品类型：宫颈脱落细胞、阴道脱落细胞（针对自采样）。$\\textcircled{3}$ 取样工具：宫颈刷。应获得NMPA 医疗器械注册证，建议结合检测试剂，选择配套或试剂盒推荐的取样工具。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "$\\textcircled{4}$ 取样步骤：根据说明书进行取样。$\\textcircled{5}$ 对于难以到医疗机构取样的女性，可按照自采样说明书自行取样。（2）样品的保存和运输：分析前样品应尽快送至实验室并以适当方式储存，以尽可能减少核酸降解。根据说明书要求进行样品保存。一般分析前样品在 $2 { \\sim } 8 \\mathrm { ~ } ^ { \\circ } \\mathrm { C }$ 条件下可保存$7 \\ \\mathrm { d } , \\leqslant - 2 0 \\ \\mathrm { ~ \\overset ~ { ~ } { ~ C ~ } ~ }$ 条件下可长期保存，应避免反复冻融。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "超长期储存后的样品，使用前应再次评估样品的完整性。如需长时间、长距离运输样品，应采用冰壶加冰或泡沫盒加冰密封运输。2.检测分析中：（1）样品前处理：样品送到实验室接收时，需审核样品状态，核实申请项目内容与所送检样品要求是否一致，核实采集容器及样品外观状态等是否合格。（2）样品检测过程：按照标准操作程序进行试剂准备、样品处理及检测。在PCR 检测过程中，应注意核酸提取需在生物安全柜内进行，也可使用自动核酸提取设备提取核酸，并按照要求进行室内质控。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "3.检测分析后：（1）结果判读：检测结果判读前，应确保阴性和阳性质控均在控，样品内参应在说明书要求的检测范围内，HPV靶标基因检测信号应正常；结果判读应根据说明书要求进行。以定性检测结果为例，HPV靶标基因检测值介于阴性和阳性判定值之间时，建议进行复检，复检时应对样品重新提取及扩增，复检后检测值仍介于阴性和阳性判定值之间，检测信号正常，可判定为阳性；复检后检测值为阴性或无检测信号则判定为阴性。（2）HPV 核酸检测报告：检测报告的内容包括但不限于： $\\textcircled{1}$ 患者基本信息，包括姓名、性别、年龄/出生日期、临床诊断等； $\\textcircled{2}$ 样品信息，包括样品类型、编号、申请时间、采集时间、送检时间、检测时间、报告时间等； $\\textcircled{3}$ 检测信息，包括试剂和仪器来源、检测方法、检测靶点、参考范围、操作者、审核者、实验室电话/地址等； $\\textcircled{4}$ 结果报告，包括是否存在 HPV 感染（阴性或阳性；可报告CT 值）、HPV 基因型状态（是否感染）等； $\\textcircled{5}$ 结果解释，包括HR‑HPV 感染的临床意义等； $\\textcircled{6}$ 备注信息，包括检测下限、检测靶点、检出HPV 型别范围，或对检测局限性的说明、检测过程中异常情况的说明等。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "（3）检测后样品保存：原始样品、核酸提取物/核酸扩增产物应规定保存期，便于复查。# 三、HPV核酸检测实施后的监测和评估 对 HPV 筛查工作进行长期的监测和评估。（1）建立数据库和信息处理系统，完善长期监测，持续改进相应质量评估指标，如假阴性结果、假阳性结果、脱落病例比例等；（2）定期进行实验室质量管理体系的风险评估；（3）注重人员资质与能力建设，进行定期的培训、考核和记录，储备充足的人力资源，保障大规模开展宫颈癌筛查的能力；（4）定期对HPV 感染率、宫颈癌前病变的检出率、宫颈癌的发病率和死亡率进行追踪和评估。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "# 第三部分 展望 # 一、HPV核酸检测创新技术发展 医疗卫生工作者可充分利用新型冠状病毒肺炎疫情期间我国积累的核酸检测硬件设施与软件能力，进一步推动HPV 核酸检测的常规化、规范化和普及化。同时，为适应我国庞大人口基数、复杂社会经济情况，一方面需要开发更加自动化、智能化、标准化的核酸检测一体机，更好地满足宫颈癌国家筛查计划对于大批量样品检测的需求；另一方面需要开发操作更便捷、更低成本、更省时的便携式、小型化即时检测（POCT）系统，满足对结果的及时性需求。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "探索将HPV 自采样方法应用于筛查实践的实施策略，以保障包括医疗资源相对不足地区在内的女性宫颈癌筛查的可及性。鼓励开展宫颈癌防控服务模式的实践应用与真实世界研究，应用模型预测宫颈癌防治效果和成本效益，为优化宫颈癌防控策略提供证据。# 二、HPV核酸检测的信息化管理 推动大数据、互联网等新一代信息技术与HPV核酸检测和宫颈癌筛查服务深度融合，推进电子病历、智慧服务、智慧管理的信息标准化建设。搭建宫颈癌防控信息共享服务平台，通过加强肿瘤登记系统、疫苗预防接种服务系统和癌症筛查管理服务系统等数据库的对接交换，不仅有助于开展HPV疫苗接种和宫颈癌筛查的实时动态监测，实现筛查、分流、治疗、随访的全程统一管理，避免重复筛查，而且通过监测HPV 感染和宫颈癌负担的变化趋势，科学评估 HPV 疫苗接种和宫颈癌筛查的效果。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "三、HPV 核酸检测在HPV 疫苗接种后时代的应用 随着HPV 疫苗接种的普及，我国将逐步进入后HPV 疫苗时代，HPV 疫苗覆盖型别感染及相关HSIL $^ { + }$ 发生率将下降，但是归因于非疫苗保护型别的宫颈病变问题将会日渐凸显，因此探索适合该阶段的基于HPV 核酸检测的筛查策略成为亟待解决的问题。国家相关部门、企业以及医疗机构应注意监测中国人群HPV 感染型别的变化趋势，因时制宜开展高质量的人群筛查研究，为更新相关风险分层和管理指南积累可靠证据。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "四、HPV 核酸检测在其他HPV 相关疾病防控中的应用 除宫颈病变外，HR‑HPV 感染还与肛门、阴茎、头颈等部位的癌前病变和浸润性癌相关，LR‑HPV感染可引起肛门‑生殖器疣和复发性呼吸道乳头状瘤等疾病。HPV 检测对于以上非宫颈部位的HPV相关疾病防控也具有重要意义。但对于相关人群如何选择采样方法、检测技术和试剂设备等问题，还需开展大规模人群研究获得更多高质量证据，以指导未来的临床实践。# 第四部分 总结 本共识是多学科专家团队基于国内外相关指南、最新研究进展及我国宫颈癌筛查实际情况形成的一致意见。",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "随着技术的发展和循证证据的增加，共识或指南有必要不断更新和补充。将高质量HPV 核酸检测用于宫颈癌筛查将加快实现我国宫颈癌筛查临床实践从形态学向分子生物学检测转化的进程，为扩大我国宫颈癌筛查覆盖率、提高筛查质量提供技术支撑，加速推进我国宫颈癌消除进程。编写顾问：郎景和（中国医学科学院北京协和医院妇产科）；乔友林（北京协和医学院群医学及公共卫生学院 全球健康学系）；魏丽惠（北京大学人民医院妇产科）；李金明（国家卫生健康委临床检验中心）；王临虹（中国疾病预防控制中心）；王传新（山东大学第二医院检验科） 执笔人：赵方辉（国家癌症中心 国家肿瘤临床医学研究中心 中国医学科学院北京协和医学院肿瘤医院流行病学研究室）；崔巍（国家癌症中心 国家肿瘤临床医学研究中心中国医学科学院北京协和医学院肿瘤医院检验科）；毕蕙（北京大学第一医院妇产科） 编写委员会（按姓氏汉语拼音排序）：陈飞（中国医学科学院北京协和医院妇产科）；陈罡（广西医科大学第一附属医院病理科）；陈汶（中国医学科学院肿瘤医院流行病学研究室）；程文俊（南京医科大学第一附属医院妇科）；丁海涛（内蒙古自治区人民医院检验科）；杜彬（上海市第一妇婴保健院 病理科）；段仙芝（首都医科大学附属北京同仁医院妇产科）；郭凌川（苏州大学附属第一医院病理科）；韩历丽（首都医科大学附属北京妇产医院保健部）；韩莉莉（新疆维吾尔自治区人民医院妇科）；洪颖（南京大学医学院附属鼓楼医院妇产科）；侯英勇（复旦大学附属中山医院病理科）；金木兰（首都医科大学附属北京朝阳医院病理科）；孔北华（山东大学齐鲁医院妇产科）；李斌（中国医学科学院肿瘤医院妇科）；李华（首都医科大学附属北京朝阳医院妇产科）；罗喜平（广东省妇幼保健院妇科）；吕卫国（浙江大学医学院附属妇产科医院）；欧阳能太（中山大学孙逸仙纪念医院细胞分子诊断中心）；潘秦镜（中国医学科学院肿瘤医院病理科）；宋建东（内蒙古医科大学附属医院妇科）；宋坤（山东大学齐鲁医院妇产科）；宋晓婕（武汉市妇幼保健院妇科）；孙蓬明（福建省妇幼保健院妇科）；孙青（山东第一医科大学第一附属医院病理科）；谭文华（哈尔滨医科大学附属第二医院妇科）；唐均英（重庆医科大学附属第一医院妇科）；王烈宏（青海红十字医院妇科）；王平（四川大学华西第二医院妇科）；王巍（四川大学华西第二医院病理科）；王新宇（浙江大学医学院附属第一医院妇科）；王学锋（上海交通大学医学院附属瑞金医院检验科）；王沂峰（南方医科大学珠江医院妇科）；向阳（中国医学科学院北京协和医院妇产科）；徐国兵（北京大学肿瘤医院检验科）；徐英春（中国医学科学院北京协和医院检验科）；徐志坚（中国医学科学院肿瘤医院防癌科）；薛凤霞（天津医科大学总医院妇产科）；尹如铁（四川大学华西第二医院妇科）；翟建军（首都医科大学附属北京同仁医院妇产科）；张瑞（国家卫生健康委临床检验中心）；张询（中国医学科学院肿瘤医院病理科）；张瑜（中南大学湘雅医院妇科）；赵昀（北京大学人民医院妇科）；周怀君（南京大学医学院附属鼓楼医院妇科） 编写秘书（按姓氏汉语拼音排序）：胡尚英（中国医学科学院肿瘤医院流行病学研究室）；王国婧（中国医学科学院肿瘤医院检验科）；赵雪莲（中国医学科学院肿瘤医院流行病学研究室） 利益冲突 所有作者均声明不存在利益冲突 # 参 考 文 献 [1] ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre).",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "Human Papillomavirus and Related Diseases in the World.[EB/OL].[2021‑10‑22].https:// hpvcentre.net/statistics/reports/XWX.pdf?t=1678773236590.[2] de Martel C, Georges D, Bray F, et al.Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis[J].",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "Lancet Glob Health, 2020, 8(2): e180‑e190.DOI: 10.1016/S2214‑109X(19)30488‑7.[3] Sung H, Ferlay J, Siegel RL, et al.Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J].",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "CA Cancer J Clin, 2021, 71(3):209‑249.DOI: 10.3322/caac.21660.[4] ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre).Human Papillomavirus and Related Diseases in China [EB/OL].[2021‑10‑22].",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "https://hpvcentre.net/statistics/reports/CHN.pdf?t=1678773276663.[5] World Health Organization.Global strategy to accelerate the elimination of cervical cancer as a public health problem [EB/OL].[2022‑11‑22].",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "https://www.who.int/ publications/i/item/9789240014107.[6] WHO.Cervical Cancer: An NCD We Can Overcome[EB/OL].[2022‑11‑22].https://www.who.int/director‑general/ speeches/detail/cervical‑cancer‑an‑ncd‑we‑can‑overcome.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "[7] 健康中国行动推进委员会.健康中国行动(2019‑2030 年) [EB/OL].[2022‑11‑22].http://www.gov.cn/xinwen/ 2019‑07/15/content_5409694.htm.[8] 国家卫生健康委员会.《宫颈癌筛查工作方案》[EB/OL].[2022‑11‑22].http://www.nhc.gov.cn/fys/s3581/ 202201/cad44d88acca4ae49e12dab9176ae21c.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "shtml.[9] WHO.WHO guideline for screening and treatment of cervical pre‑cancer lesions for cervical cancer prevention [EB/OL].[2022‑11‑22].https://www.who.int/ publications/i/item/9789240030824.[10] World Health Organization.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "WHO guideline for screening and treatment of cervical pre‑cancer lesions for cervical cancer prevention: use of mRNA tests for human papillomavirus (HPV) [EB/OL].[2022‑11‑22].https:// www.who.int/publications/i/item/9789240040434.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "[11] Ciavattini A, Delli Carpini G, Giannella L, et al.European Federation for Colposcopy (EFC) and European Society of Gynaecological Oncology (ESGO) joint considerations about human papillomavirus (HPV) vaccination, screening programs, colposcopy, and surgery during and after the COVID‑19 pandemic[J].",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "Int J Gynecol Cancer, 2020, 30(8):1097‑1100.DOI: 10.1136/ijgc‑2020‑001617.[12] Perkins RB, Guido RS, Castle PE, et al.2019 ASCCP Risk‑Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors[J].",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "J Low Genit Tract Dis, 2020, 24(2):102‑131.DOI: 10.1097/LGT.0000000000000525.[13] Hamers FF, Poullié AI, Arbyn M.Updated evidence‑based recommendations for cervical cancer screening in France [J].Eur J Cancer Prev, 2022, 31(3):279‑286.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "DOI: 10.1097/ CEJ.0000000000000701.[14] Fontham E, Wolf A, Church TR, et al.Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society[J].CA Cancer J Clin, 2020, 70(5):321‑346.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "DOI: 10.3322/caac.21628.[15] UK National Screening Committee.Guidance Cervical screening: programme overview[EB/OL].[2022‑11‑22].https://www.gov.uk/guidance/cervical‑screening‑programme‑overview.[16] Bhatla N, Singhal S, Saraiya U, et al.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "Screening and management of preinvasive lesions of the cervix: good clinical practice recommendations from the Federation of Obstetrics and Gynaecologic Societies of India (FOGSI)[J].J Obstet Gynaecol Res, 2020, 46(2): 201‑214.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "DOI: 10.1111/jog.14168.[17] Zeferino LC, Bastos JB, Vale D, et al.Guidelines for HPV‑DNA Testing for Cervical Cancer Screening in Brazil [J].Rev Bras Ginecol Obstet, 2018, 40(6): 360‑368.DOI: 10.1055/s‑0038‑1657754.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "[18] Zhang M, Zhong Y, Wang L, et al.Cervical Cancer Screening Coverage‑China, 2018‑2019[J].China CDC Wkly, 2022, 4(48): 1077‑1082.DOI: 10.46234/ccdcw2022.217.[19] 张梅, 包鹤龄, 王丽敏, 等.2015 年中国宫颈癌筛查现况及 相关因素分析[J].",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "中华医学杂志, 2021, 101(24):1869‑1874.DOI: 10.3760/cma.j.cn112137‑20210108‑00054.[20] 赵艳霞, 马兰, 任文辉, 等.2009—2018 年中国农村妇女宫 颈癌检查项目数据分析[J].中华医学杂志, 2021, 101(24): 1863‑1868.DOI: 10.3760/cma.j.cn112137‑20210111‑00075.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "[21] 中国优生科学协会阴道镜和宫颈病理学分会专家委员会.中国子宫颈癌筛查及异常管理相关问题专家共识(一)[J].中 国 妇 产 科 临 床 杂 志 , 2017, 18(2): 190‑192.DOI: 10.13390/j.issn.1672‑1861.2017.02.032.[22] 中国优生科学协会阴道镜和宫颈病理学分会(CSCCP)专家 委员会.中国子宫颈癌筛查及异常管理相关问题专家共识 (二)[J].",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "中国妇产科临床杂志, 2017, 18(3):286‑288.DOI: 10.13390/j.issn.1672‑1861.2017.03.041.[23] 中国医师协会全科医师分会, 北京妇产学会社区与基层分 会.子宫颈癌筛查结果异常人群社区管理专家建议[J].中 国 全 科 医 学 , 2021, 24(17): 2117‑2121, 2126.DOI: 10.12114/j.issn.1007‑9572.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "2021.00.531.[24] 中华预防医学会疫苗与免疫分会.子宫颈癌等人乳头瘤病 毒相关疾病免疫预防专家共识(简版)[J].中华预防医学 杂 志 , 2019, 53(12): 1218‑1235.DOI: 10.3760/cma.j.issn.0253‑9624.2019.12.006.[25] Burley M, Roberts S, Parish JL.Epigenetic regulation of human papillomavirus transcription in the productive virus life cycle[J].",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "Semin Immunopathol, 2020, 42(2): 159‑171.DOI: 10.1007/s00281‑019‑00773‑0.[26] Della Fera AN, Warburton A, Coursey TL, et al.Persistent Human Papillomavirus Infection[J].Viruses, 2021, 13(2).DOI: 10.3390/v13020321.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "[27] Doorbar J, Egawa N, Griffin H, et al.Human papillomavirus molecular biology and disease association [J].Rev Med Virol, 2015, 25Suppl 1(Suppl Suppl 1):2‑23.DOI: 10.1002/rmv.1822.[28] Harden ME, Munger K.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "Human papillomavirus molecular biology[J].Mutat Res Rev Mutat Res, 2017, 772:3‑12.DOI: 10.1016/j.mrrev.2016.07.002.[29] Tommasino M.The human papillomavirus family and its role in carcinogenesis[J].Semin Cancer Biol, 2014, 26: 13‑21.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "DOI: 10.1016/j.semcancer.2013.11.002.[30] IARC Working Group on the Evaluation of Carcinogenic Risks to Humans.Biological agents.Volume 100 B.A review of human carcinogens[J].IARC Monogr Eval Carcinog Risks Hum, 2012, 100(Part B): 1‑441.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "[31] de Villiers EM, Fauquet C, Broker TR, et al.Classification of papillomaviruses[J].Virology, 2004, 324(1):17‑27.DOI: 10.1016/j.virol.2004.03.033.[32] International Human Papillomavirus Reference Center.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "Human papillomavirus reference clones[EB/OL].[2022‑11‑22].https: //www.hpvcenter.se/human_reference_clones/.[33] 国家食品药品监督管理总局医疗器械技术审评中心.人乳 头瘤病毒(HPV)核酸检测及基因分型、试剂技术审查指导 原 则 (2015 年 第 93 号) [EB/OL].[2022‑11‑22].",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "https:// view.officeapps.live.com/op/view.aspx?sr $: =$ https% $3 A \\%$ $2 \\mathrm { F \\% }$ 2Fwww.nmpa.gov.$c n \\%$ 2Fdirectory% 2Fweb% 2Fnmpa% 2Fimages% 2FMjAxNcTqtdo5M7rFzai45ri9vP 4zLmRvY3g%3D.docx&wdOrigin $\\vDash$ BROWSELINK.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "[34] Li M, Liu T, Luo G, et al.Incidence, persistence and ill women in Guangdong, China 2007‑2018: a retrospective cohort study[J].J Infect Public Health, 2021, 14(1):42‑49.DOI: 10.1016/j.jiph.2020.11.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "011.[35] Bonde J, Bottari F, Iacobone AD, et al.Human Papillomavirus Same Genotype Persistence and Risk: a Systematic Review[J].J Low Genit Tract Dis, 2021, 25(1): 27‑37.DOI: 10.1097/LGT.0000000000000573.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "[36] Bonde JH, Sandri MT, Gary DS, et al.Clinical Utility of Human Papillomavirus Genotyping in Cervical Cancer Screening: a Systematic Review[J].J Low Genit Tract Dis, 2020, 24(1):1‑13.DOI: 10.1097/LGT.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "0000000000000494.[37] Katki HA, Schiffman M, Castle PE, et al.Benchmarking CIN3+risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines[J].J Low Genit Tract Dis, 2013, 17(5 Suppl 1): S28‑S35.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "DOI: 10.1097/LGT.0b013e318285423c.[38] Cuzick J, Wheeler C.Need for expanded HPV genotyping for cervical screening[J].Papillomavirus Res, 2016, 2: 112‑115.DOI: 10.1016/j.pvr.2016.05.004.[39] Dong $\\mathrm { L , }$ Hu SY, Zhang Q, et al.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "Risk Prediction of Cervical Cancer and Precancers by Type‑Specific Human Papillomavirus: Evidence from a Population‑Based Cohort Study in China[J].Cancer Prev Res (Phila), 2017, 10(12): 745‑751.DOI: 10.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "1158/1940‑6207.CAPR‑17‑0088.[40] 罗红学, 杜辉, 刘志红, 等.不同亚型人乳头状瘤病毒感染 合并细胞学异常者宫颈上皮内瘤变2级或3级及以上病变 的患病风险评估[J].中华肿瘤杂志, 2018, 40(3):232‑238.DOI: 10.3760/cma.j.issn.0253‑3766.2018.03.015.[41] 由婷婷, 夏昌发, 陈猛, 等.宫颈不同疾病状态年转归概率 的荟萃分析[J].",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "中华医学杂志, 2021, 101(24):1899‑1907.DOI: 10.3760/cma.j.cn112137‑20201216‑03372.[42] Salazar KL, Zhou HS, Xu J, et al.Multiple Human Papilloma Virus Infections and Their Impact on the Development of High‑Risk Cervical Lesions[J].",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "Acta Cytol, 2015, 59(5): 391‑398.DOI: 10.1159/000442512.[43] Dickson EL, Vogel RI, Geller MA, et al.Cervical cytology and multiple type HPV infection: a study of 8182 women ages 31‑65[J].Gynecol Oncol, 2014, 133(3):405‑408.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "DOI: 10.1016/j.ygyno.2014.03.552.[44] Adcock R, Cuzick J, Hunt WC, et al.Role of HPV Genotype, Multiple Infections, and Viral Load on the Risk of High‑Grade Cervical Neoplasia[J].Cancer Epidemiol Biomarkers Prev, 2019, 28(11):1816‑1824.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "DOI: 10.1158/ 1055‑9965.EPI‑19‑0239.[45] Kim M, Park NJ, Jeong JY, et al.Multiple Human Papilloma Virus (HPV) Infections Are Associated with HSIL and Persistent HPV Infection Status in Korean Patients[J].",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "Viruses, 2021, 13(7).DOI: 10.3390/v13071342.[46] Koshiol J, Lindsay L, Pimenta JM, et al.Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta‑analysis[J].Am J Epidemiol, 2008, 168(2):123‑137.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "DOI: 10.1093/aje/kwn036.[47] Rositch AF, Koshiol J, Hudgens MG, et al.Patterns of persistent genital human papillomavirus infection among women worldwide: a literature review and meta‑analysis [J].Int J Cancer, 2013, 133(6):1271‑1285.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "DOI: 10.1002/ ijc.27828.[48] Stanley M.Host defence and persistent human papillomavirus infection[J].Curr Opin Virol, 2021, 51: 106‑110.DOI: 10.1016/j.coviro.2021.09.010.[49] Snijders PJ, Steenbergen RD, Heideman DA, et al.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "HPV‑mediated cervical carcinogenesis: concepts and clinical implications[J].J Pathol, 2006, 208(2): 152‑164.DOI: 10.1002/path.1866.[50] Kjaer SK, van den Brule AJ, Paull G, et al.Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study[J].",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "BMJ, 2002, 325(7364): 572.DOI: 10.1136/bmj.325.7364.572.[51] Chua B, Ma VY, Alcántar‑Fernández J, et al.Is It Time to Genotype Beyond HPV16 and HPV18 for Cervical Cancer Screening?[J].Int J Public Health, 2022, 67:1604621.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "DOI: 10.3389/ijph.2022.1604621.[52] Huang HJ, Tung HJ, Yang LY, et al.Role of human papillomavirus status after conization for high‑grade cervical intraepithelial neoplasia[J].Int J Cancer, 2021, 148(3):665‑672.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "DOI: 10.1002/ijc.33251.[53] Cubie HA, Cuschieri K.Understanding HPV tests and their appropriate applications[J].Cytopathology, 2013, 24(5): 289‑308.DOI: 10.1111/cyt.12083.[54] Chrysostomou AC, Kostrikis LG.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "Methodologies of Primary HPV Testing Currently Applied for Cervical Cancer Screening[J].Life (Basel), 2020, 10(11).DOI: 10.3390/life10110290.[55] 田亚宾, 张春涛.人乳头状瘤病毒核酸分型检测试剂的研 究 进 展 [J].中 华 肿 瘤 杂 志 , 2018, 40(10): 729‑735.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "DOI: 10.3760/cma.j.issn.0253‑3766.2018.10.003.[56] Shah SS, Senapati S, Klacsmann F, et al.Current Technologies and Recent Developments for Screening of HPV‑Associated Cervical and Oropharyngeal Cancers[J].",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "Cancers (Basel), 2016, 8(9).DOI: 10.3390/cancers8090085.[57] Wei B, Mei P, Huang S, et al.Evaluation of the SureX HPV genotyping test for the detection of high‑risk HPV in cervical cancer screening[J].",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "Virol J, 2020, 17(1):171.DOI: 10.1186/s12985‑020‑01417‑8.[58] Wang R, Wu J, He X, et al.A Sample‑In‑Answer‑Out Microfluidic System for the Molecular Diagnostics of 24 HPV Genotypes Using Palm‑Sized Cartridge[J].",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "Micromachines (Basel), 2021, 12(3).DOI: 10.3390/mi12030263.[59] 郎景和院士谈子宫颈癌的防治策略[J].中国实用妇科与产 科杂志, 2021, 37(1):1‑6.DOI: 10.19538/j.fk2021010101.[60] 包鹤龄, 方利文, 王临虹.全球建立子宫颈癌防控体系的现 况及策略思考[J].中华预防医学杂志, 2017, 51(1):96‑100.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "DOI: 10.3760/cma.j.issn.0253‑9624.2017.01.019.[61] 薛鹏, 唐朝, 江宇, 等.数字化时代建设宫颈癌防治信息化 平 台 的 必 要 性 [J].中 国 医 学 科 学 院 学 报 , 2021, 43(4): 649‑652.DOI: 10.3881/j.issn.1000‑503X.13372.[62] 中华医学会妇产科学分会感染性疾病协作组.高危型人乳 头瘤病毒与女性下生殖道感染联合检测专家共识[J].",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "中国 实 用 妇 科 与 产 科 杂 志 , 2022, 38(5): 524‑528.DOI: 10.19538/j.fk2022050111.[63] 中国医师协会妇产科分会阴道镜及子宫颈病变专业委员 会, 《中华健康管理学杂志》编辑委员会.HPV DNA 检测应 用于健康体检人群子宫颈癌初筛的专家共识[J].中华健康 管理学杂志, 2022, 16(10):665‑672.DOI: 10.3760/cma.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "j.cn115624‑20220810‑00599.[64] Zhang J, Zhao Y, Dai Y, et al.Effectiveness of High‑risk Human Papillomavirus Testing for Cervical Cancer Screening in China: a Multicenter, Open‑label, Randomized Clinical Trial[J].",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "JAMA Oncol, 2021, 7(2): 263‑270.DOI: 10.1001/jamaoncol.2020.6575.[65] Zhao Y, Bao H, Ma L, et al.Real‑world effectiveness of primary screening with high‑risk human papillomavirus testing in the cervical cancer screening programme in China: a nationwide, population‑based study[J].",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "BMC Med, 2021, 19(1):164.DOI: 10.1186/s12916‑021‑02026‑0.[66] Xia C, Xu X, Zhao X, et al.Effectiveness and cost‑effectiveness of eliminating cervical cancer through a tailored optimal pathway: a modeling study[J].",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "BMC Med, 2021, 19(1):62.DOI: 10.1186/s12916‑021‑01930‑9.[67] Schiffman M, Vaughan LM, Raine‑Bennett TR, et al.A study of HPV typing for the management of HPV‑positive ASC‑US cervical cytologic results[J].",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "Gynecol Oncol, 2015, 138(3):573‑578.DOI: 10.1016/j.ygyno.2015.06.040.[68] 中华医学会妇科肿瘤学分会, 中国优生科学协会阴道镜和 宫颈病理学分会.人乳头瘤病毒疫苗临床应用中国专家共 识[J].中国医学前沿杂志(电子版), 2021, 13(2):1‑12.DOI: 10.12037/YXQY.2021.02-01.[69] Liu G, Sharma M, Tan N, et al.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "HIV‑positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer[J].AIDS, 2018, 32(6):795‑808.DOI: 10.1097/QAD.0000000000001765.[70] Reusser NM, Downing C, Guidry J, et al.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "HPV Carcinomas in Immunocompromised Patients[J].J Clin Med, 2015, 4(2):260‑281.DOI: 10.3390/jcm4020260.[71] Gravitt PE.The known unknowns of HPV natural history [J].J Clin Invest, 2011, 121(12):4593‑4599.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "DOI: 10.1172/ JCI57149.[72] Debeaudrap P, Sobngwi J, Tebeu PM, et al.Residual or Recurrent Precancerous Lesions After Treatment of Cervical Lesions in Human Immunodeficiency Virus‑infected Women: a Systematic Review and Meta‑analysis of Treatment Failure[J].",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "Clin Infect Dis, 2019, 69(9):1555‑1565.DOI: 10.1093/cid/ciy1123.[73] 任文辉, 赵雪莲, 赵方辉.全球宫颈癌筛查指南制定现状的 系统综述[J].中华医学杂志, 2021, 101(24):1882‑1889.DOI: 10.3760/cma.j.cn112137‑20210115‑00134.[74] 谢文娟, 刘玉林, 范爱萍, 等.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "免疫缺陷人群宫颈癌筛查进 展[J].现代妇产科进展, 2020, 29(5):392‑396, 399.DOI: 10.13283/j.cnki.xdfckjz.2020.05.032.[75] Chin‑Hong PV, Reid GE.Human papillomavirus infection in solid organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice[J].",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "Clin Transplant, 2019, 33(9): e13590.DOI: 10.1111/ctr.13590.[76] Bentley J.Colposcopic management of abnormal cervical cytology and histology[J].J Obstet Gynaecol Can, 2012, 34(12): 1188‑1202.DOI: 10.1016/S1701‑2163(16) 35468‑8.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "[77] Hillemanns P, Friese K, Dannecker C, et al.Prevention of Cervical Cancer: Guideline of the DGGG and the DKG (S3 Level, AWMF Register Number 015/027OL, December 2017)‑Part 1 with Introduction, Screening and the Pathology of Cervical Dysplasia[J].Geburtshilfe Frauenheilkd, 2019, 79(2): 148‑159.DOI: 10.1055/ a‑0818‑5440.",
    "source": "人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)/人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022).md"
  },
  {
    "text": "# 人乳头瘤病毒疫苗临床应用中国专家共识 中华医学会妇科肿瘤学分会ꎬ 中国优生科学协会阴道镜和宫颈病理学分会 通信作者: 马 丁1ꎬ 魏丽惠2ꎬ 谢 幸3ꎬ 孔北华41 华中科技大学同济医学院附属同济医院妇产科ꎬ 武汉 430030ꎬ E￣mail: dma＠tjh.tjmu.edu.cn2 北京大学人民医院妇产科ꎬ 北京 100044ꎬ E￣mail: weilhpku＠163.com3 浙江大学医学院附属妇产科医院ꎬ 杭州 310006ꎬ E￣mail: xiex＠zju.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "edu.cn4 山东大学齐鲁医院妇产科ꎬ 济南 250012ꎬ E￣mail: kongbeihua＠sdu.edu.cn 【摘要】 人乳头瘤病毒 (human papilloma virusꎬ HPV) 疫苗接种是预防 HPV 感染及相关疾病的有效方法ꎬ 是防控HPV 感染相关疾病的一级预防措施ꎮ 低龄人群接种效果优于高龄人群ꎬ 性暴露前接种免疫效果最佳ꎮ HPV 疫苗不仅适用于普通人群ꎬ 同样推荐用于高危、 特殊人群ꎮ 对于具有遗传易感、 高危生活方式和HIV 感染的适龄女性优先推荐接种HPV 疫苗ꎮ 适龄女性无论是否存在 HPV 感染、 细胞学是否异常均可接种 HPV 疫苗ꎮ 近期有妊娠计划、 妊娠期或哺乳期女性不宜接种 HPV 疫苗ꎮ 接种 HPV 疫苗后仍应进行子宫颈癌筛查ꎮ 【关键词】 人乳头瘤病毒ꎻ 疫苗ꎻ 临床应用ꎻ 高危ꎻ 特殊人群 【中图分类号】 R271􀆰 1ꎻ R711􀆰 74 【文献标志码】 A 【文章编号】 1674￣9081(2021)02￣0189￣13 DOI: 10􀆰 12290 / xhyxzz􀆰 2021￣ 0082 # Chinese Expert Consensus on Clinical Application of Human Papilloma Virus Vaccine Gynecological Oncology Society of Chinese Medical Associationꎬ Chinese Society for Colposcopy and Cervical Pathology Corresponding authors: MA Ding1 ꎬ WEI Li￣ hui $^ 2$ ꎬ XIE Xing $^ 3$ ꎬ KONG Bei￣hua4 $^ 1$ Department of Obstetrics and Gynecologyꎬ Tongji Hospitalꎬ Tongji Medical Collegeꎬ Huazhong University of Science ＆ Technologyꎬ Wuhan 430030ꎬ Chinaꎬ E￣mail: dma＠tjh.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "tjmu.edu.cn $^ 2$ Department of Obstetrics and Gynecologyꎬ Peking University People􀆳s Hospitalꎬ Beijing 100044ꎬ Chinaꎬ E￣mail: weilhpku＠163.com $^ 3$ Women􀆳s Hopitalꎬ School of Medicine Zhejiang Universityꎬ Hangzhou 310006ꎬ Chinaꎬ E￣mail: xiex＠zju.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "edu.cn Department of Obstetrics and Gynecologyꎬ Qilu Hospital of Shandong Universityꎬ Jinan 250012ꎬ Chinaꎬ E￣mail: kongbeihua＠sdu.edu.cn 【Abstract】 Human papilloma virus (HPV) vaccination is a primary preventive measure and an effective method to prevent HPV infection and the related diseases.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Its effect in young women is betterꎬ and the immune efficacy of vaccination for teenagers before sexual exposure is the best.HPV vaccine is not only suitable for the general populationꎬ but also recommended for high￣risk and special groups.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "HPV vaccination should be recom￣ mended for women at the appropriate age with genetic susceptibilityꎬ high￣ risk lifestyleꎬ or HIV infection.No matter whether they have HPV infection or abnormal cytologyꎬ women of appropriate ages can be vaccinated.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Women with a pregnancy plan in the near future and pregnant or lactating women should not be vaccinated.Recommendation of cervical cancer screening should be carried out after HPV vaccination.【Key words】 human papilloma virusꎻ vaccineꎻ clinical applicationꎻ high riskꎻ special populationMed J PUMCHꎬ 2021ꎬ12(2):189－201 人乳头瘤病毒 (human papilloma virusꎬ HPV) 疫苗接种是预防 HPV 感染的有效方法ꎬ 是防控 HPV 感染相关疾病的一级预防措施ꎮ 对于一般人群的 HPV疫苗接种已有规范性指南ꎬ 但对于高危、 特殊人群如何接种 HPV 疫苗ꎬ 尚未达成共识ꎮ 中华医学会妇科肿瘤学分会与中国优生科学协会阴道镜和宫颈病理学分会组织专家ꎬ 依循医学证据ꎬ 结合我国国情和临床实际ꎬ 达成以下共识 # 1 人乳头瘤病毒及其流行病学 HPV 是双链 DNA 病毒ꎬ 可引起人体皮肤黏膜上皮增生[1] ꎮ HPV 主要通过性生活或密切接触传播ꎮ$8 0 \\%$ 以上的女性一生中至少有过一次 HPV 感染ꎬ$9 0 \\%$ 以上的 HPV 可在感染 2 年内自然清除ꎬ 仅不足1％的患者发展至子宫颈癌前病变和子宫颈癌[2￣3] C高危型 HPV 持续性感染是下生殖道高级别上皮内病变和癌发生的必要因素ꎬ 已成为严重威胁女性健康的公共卫生问题 # 1􀆰1 基因型别和分类 目前已确定的 HPV 型别有 200 余种ꎬ 根据其致癌性分为高危型和低危型ꎮ 我国国家药品监督管理局根 据 世 界 卫 生 组 织 ( World Health OrganizationꎬWHO) 国际 癌 症 研 究 机 构 ( International Agency forResearch on Cancerꎬ IARC) 的建议ꎬ 将 HPV 16 / 18 /31 / 33 / 35 / 39 / 45 / 51 / 52 / 56 / 58 / 59 / 68 定 义 为 高 危 型ꎬ而将 HPV $2 6 / 5 3 / 6 6 / 7 3 / 8 2$ 定义为中危型[4] ꎬ 其中以HPV 16/ 18 诱发癌变的风险最高ꎮ # 1􀆰2 感染率和基因型分布 一项纳入了194 项研究、 1016719 名女性的荟萃分析结果显示ꎬ 子宫颈细胞学正常的女性ꎬ 高危型HPV 感染率为 $1 1 .",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "7 \\% ^ { [ 5 ] }$ ꎮ 随着病变级别的加重ꎬHPV 感染率明显上升ꎬ 其在子宫颈细胞学结果为无明确意义的非典型鳞状上皮细胞 ( atypical squamouscells of undetermined significanceꎬ ASCUS) 改 变 的 女性中为 $5 2 .5 \\%$ ꎬ 在低级别鳞状上皮内病变 (low￣gradesquamous intraepi￣thelial lesionꎬ LSIL ) 的 女 性 中 为$7 4 .",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "8 \\%$ ꎬ 在高级别鳞状上皮内病变 ( high￣grade squa￣mous intraepithelial lesionꎬ HSIL ) 的 女 性 中 高 达$8 8 .9 \\% ^ { [ 6 ] }$ ꎮ 子宫颈癌患者中 HPV 16 的感染率为$5 5 .2 \\%$ ꎬ HPV 18 的感染率为 $1 4 .2 \\%$ ꎬ 其他型别的HPV 按其感染率排序依次为 HPV 45、 33、 58、 31、52、 35、 39、 $5 9 ^ { [ 7 ] }$ ꎮ 此外ꎬ 关于 HPV 16 的感染率ꎬ鳞癌 ( $6 1 .",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "7 \\%$ ) 高于腺癌 ( $5 0 .0 \\% )$ ꎻ 而关于 HPV 18、 HPV 45 的感染率ꎬ 腺癌 ( $3 2 .3 \\%$ 、 $1 1 .9 \\%$ ) 高于鳞癌$( 8 .3 \\% , 5 .4 \\% )$ [8] 在中国170 万名一般人群中开展的 HPV 流行病学研究发现ꎬ 最常见的5 种 HPV 型别分别为 HPV 16$3 .5 2 \\%$ )、 HPV 52 ( $2 .",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "2 0 \\%$ )、 HPV 58 ( $2 .1 0 \\%$ )、HPV 18 ( $1 .2 0 \\%$ ) 和 HPV 33 ( $1 .0 2 \\% )$ ꎮ 我国子宫颈细胞学正常女性高危型 HPV 的感染率约为 $7 .1 \\%$ ꎬ 而ASCUS、 LSIL、 HSIL 女性高危型 HPV 的感染率分别为$3 7 .1 \\%$ 、 $9 0 .9 \\%$ 和 $9 3 .0 6 \\% ^ { [ 9 ] }$ ꎮ $6 9 .",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "1 \\%$ 的子宫颈浸润癌归因于 HPV 16/ 18 感染[8]ꎮ 子宫颈鳞癌中ꎬ HPV 16$7 6 .7 \\%$ ) 和 HPV 18 ( $7 .8 \\%$ ) 感染最常见ꎬ 其次是HPV 31 $3 .2 \\% )$ 、 HPV 52 $2 .2 \\%$ )、 HPV 58 ( $2 .2 \\% )$ 和 HPV 33 $( 1 .0 \\% )$ ꎻ 子宫颈腺癌中 HPV 16 和 HPV 18的感染率分别为 $3 5 .",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "1 \\%$ 和 $3 0 .6 \\% ^ { \\left[ 1 0 \\right] }$ # 1􀆰 3 感染相关疾病负担 HPV 感染相关疾病在世界范围内造成了巨大的卫生和经济负担ꎮ HPV 感染所致癌症比例存在显著地域差异ꎬ 在澳大利亚、 新西兰和美国ꎬ 不足 $3 \\%$ 的女性癌症归因于 HPV 感染ꎻ 在印度和撒哈拉以南的非洲地区ꎬ 超过 $3 0 \\%$ 的女性癌症归因于 HPV 感染[11] ꎮ 高危型 HPV 感染与全球约 $4 .",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "5 \\%$ 的癌症新发病例相 关 ( 约 63 万 例)ꎬ 其 中 女 性 约 57 万 例$( 8 .6 \\% )$ ꎬ 男性约 6 万例 $( 0 .8 \\% )$ [12] ꎮ 据报道ꎬ 2018年全球范围内子宫颈癌新发病例约 57􀆰 0 万例[13] ꎬ 死亡病例约 31􀆰 1 万例ꎬ 已成为 15\\~ 44 岁女性第 2 位常见肿瘤和第 3 位死亡原因[14] ꎮ 我国子宫颈癌新发病例约 10􀆰6 万例ꎬ 每年死亡病例约 4􀆰8 万例[15]ꎮ 几乎$100 \\%$ 的子宫颈癌 $8 8 \\%$ 的肛门癌 $5 0 \\%$ 的阴茎癌$4 3 \\%$ 的外阴癌以及口咽癌等肿瘤均与高危型 HPV 持续性感染有关[16] 低危型 HPV 感染引起生殖器疣等良性病变ꎬ 约$9 0 \\%$ 的生殖器疣由 $\\operatorname { H P V } 6 / 1 1$ 感染引起[17] ꎮ 全球生殖器疣患病率 ( 包括新发和复发病例) 为 ( $1 6 0 \\sim$ 289) / 10 万 (中位数为 194􀆰 51 / 10 万)ꎬ 其中男性新发生殖器疣发病率为 (103 \\~ 168) / 10 万 (中位数为137 / 10 万)ꎬ 女性发病率为 (76 \\~ 191) / 10 万 ( 中位数为 120􀆰 5 / 10 万) [12] # 2 人乳头瘤病毒疫苗 # 2􀆰 1 免疫机制 疫苗主要诱导机体体液免疫反应 产生的中和性抗体在 HPV 进入机体时即可与病毒抗原结合ꎬ从而防止 HPV 感染ꎮ 通过预防初次 HPV 感染和减少持续性 HPV 感染可阻断子宫颈癌前病变的发生和发展ꎮ 疫苗产生的抗体可透过血管壁ꎬ 在局部上皮组织形成较高浓度ꎮ 当 HPV 通过黏膜上皮的细微伤口接触基底层细胞时ꎬ 位于上皮组织中的抗体即可与病毒结合ꎬ 发挥中和作用 # 2􀆰 2 免疫原性 国内外研究显示ꎬ 双价、 四价和九价 HPV 疫苗在完成全程免疫接种后ꎬ 均可观察到较高的疫苗相关型别抗体转阳率 ( $9 6 \\% \\sim 1 0 0 \\%$ ) 和血清学抗体滴度[18￣20] ꎮ 我国临床研究结果显示ꎬ 9\\~ 17 岁女性接种双价和四价 HPV 疫苗后免疫应答较强ꎬ 血清学抗体滴度是 18\\~26 岁女性的 $1 .",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "4 2 \\sim 3 .0 0$ 倍ꎬ 而 18 \\~ 25 岁女性与 26\\~ 45 岁女性抗体滴度相似[21￣23] ꎮ 目前关于国内九价 HPV 疫苗免疫原性的数据有限ꎮ 一项国外Ⅲ期临床试验显示ꎬ $1 6 \\sim 1 7$ 岁女性接种九价 HPV 疫苗后 $\\mathrm { H P V } ~ { 6 / 1 1 / 1 6 / 1 8 }$ 的抗体滴度均高于 $1 8 \\sim 2 6$ 岁女性ꎬ 免疫应答与接种四价 HPV 疫苗相当[24] ꎮ 东亚女性的随机对照试验 (randomized controlled trialꎬ RCT)也显示ꎬ 接种四价和九价 HPV 疫苗后ꎬ 抗 HPV 6/$1 1 / 1 6 / 1 8$ 的抗体转阳率均 $> 9 6 \\%$ [25] # 2􀆰 3 保护效力 HPV 疫苗在预防 HPV 型别相关疾病的临床试验中显示出 $8 7 .",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "3 \\% \\sim 1 0 0 .0 \\%$ 的保护效力[26￣28] ꎮ # 2􀆰 3􀆰 1 双价 HPV 吸附疫苗 一项针对 18\\~ 25 岁中国女性的临床研究随访 72个月的结果显示ꎬ 双价 HPV 吸附疫苗对 HPV 16/ 18相关的子宫颈上皮内瘤变 ( cervical intraepithelial neo￣plasiaꎬ CIN) 2 \\~ 3 级或原位腺癌 ( adenocarcinoma insituꎬ AIS) 的保护效力为 87􀆰 3％[29] ꎮ # 2􀆰 3􀆰 2 国产双价 HPV 疫苗 (大肠杆菌) 国产双价 HPV 疫苗 (大肠杆菌) 对 18\\~ 45 岁中国女性的 HPV 16/ 18 相关 CIN 2\\~3 级、 AIS 或子宫颈癌的保护效力为 100％[30] # 2􀆰 3􀆰 3 四价 HPV 疫苗 四价 疫苗对 岁女性具有很好的保护作用ꎮ 一项针对 20\\~ 45 岁中国女性的临床研究随访 78 个月的结果显示ꎬ 四价 HPV 疫苗对 HPV 16/ 18相关 CIN 2\\~ 3 级、 AIS 和子宫颈癌的保护效力均为$1 0 0 \\% ^ { [ 2 0 ] }$ ꎮ 在完成针对小年龄组的免疫桥接和安全性试验后ꎬ 2020 年 11 月国家药品监督管理局批准四价HPV 疫苗应用于 $9 \\sim 1 9$ 岁女性ꎮ 全球针对 $1 6 \\sim 2 6$ 岁女性的Ⅲ期临床研究显示ꎬ 四价 HPV 疫苗对 HPV16 / 18 相关的 CIN $^ { 2 + }$ 的保护效力为 $9 8 .",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "2 \\% ^ { [ 3 1 ] }$ ꎮ 2020年ꎬ 一项纳入近170 万名女性的瑞典真实世界研究显示ꎬ 至少接种 1 剂四价 HPV 疫苗即可大幅降低浸润性子宫颈癌的患病风险ꎻ 17 岁之前接种的女性获益更显著ꎬ 浸润性子宫颈癌发病率降低达 $8 8 \\%$ [32] ꎮ # 2􀆰 3􀆰 4 九价 HPV 疫苗 目前尚无中国临床研究数据ꎮ 国外临床研究显示ꎬ 九价 HPV 疫苗对 $1 6 \\sim 2 6$ 岁女性的 $\\mathrm { H P V } 6 / 1 1 / 1 6 /$ 18 相关持续性感染和子宫颈癌的保护效力与四价HPV 疫苗相当[33] ꎮ 九价 HPV 疫苗对 16 \\~ 26 岁东亚女性亚组的 $\\mathrm { H P V } \\ 3 1 / 3 3 / 4 5 / 5 2 / 5 8$ 相关 CIN $^ { 1 + }$ 的保护效力为 $100 \\%$ ꎬ 对 $\\mathrm { H P V } 3 1 / 3 3 / 4 5 / 5 2 / 5 8$ 相关的6 个月及以上子宫颈、 阴道、 外阴、 肛门持续性感染的保护效力为 $9 5 .",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "8 \\% ^ { [ 3 4 ] }$ ꎮ 目前全球尚无关于 26\\~ 45 岁女性的九价 HPV 疫苗相关免疫原性和保护效力的数据ꎮ # 2􀆰 4 安全性 2017 年 WHO 发布的 HPV 疫苗立场文件指出ꎬ现有证据表明目前已上市的 HPV 疫苗安全性良好ꎬ不良反应与其他疫苗相似[20ꎬ35￣37] ꎮ # 3 普通人群人乳头瘤病毒疫苗接种 # 3􀆰 1 国内现有 HPV 疫苗 2019 年 «子宫颈癌等人乳头瘤病毒相关疾病免疫预防专家共识 (简版) » 指出: 接种 HPV 疫苗是子宫颈癌防控工作的重要组成部分[37] ꎮ 目前ꎬ HPV疫苗在我国属于非免疫规划疫苗 (第二类疫苗)ꎬ 接种单位应遵照 «疫苗流通和预防接种管理条例» 和«预防接种工作规范» 的要求ꎬ 按照疫苗说明书和“知情同意、 自愿自费” 原则ꎬ 科学告知受种者或其家长后ꎬ 为受种者及时提供疫苗接种ꎮ 目前ꎬ 我国国家药品监督管理局已批准上市 4 种 HPV 疫苗: 国产双价 HPV 疫苗 ( 大肠杆菌)、 双价 HPV 吸附疫苗、四价和九价 HPV 疫苗 (表 1)ꎮ # 3􀆰 2 普通人群 HPV 疫苗接种 # 3􀆰 2􀆰 1 国外权威指南对于成年女性接种 HPV 疫苗的推荐 WHO 建议主要目标接种人群为未暴露于疫苗相关 HPV 基因型的青春期女性[7] ꎮ 2019 年美国疫苗免疫实践咨询委员会 ( Advisory Committee on Immuniza￣tion Practicesꎬ ACIP) [39] 和美国疾病预防控制中心[40]均建议在11 岁或12 岁开始接种 HPV 疫苗ꎬ 也可从9岁开始接种ꎮ HPV 疫苗可对尚未感染的 HPV 型别提供保护ꎬ 即使感染了 1 种或多种 HPV 型别的受种者仍可从疫苗接种中获得保护ꎮ 2017 年美国妇产科医师协会 (American College of Obstetricians and Gynecolo￣gistsꎬ ACOG) 指南提出ꎬ 不论有无性行为或既往暴露于 HPVꎬ 均推荐接种 HPV 疫苗[41] ꎮ 2019 年 « 人乳头瘤病毒: 加拿大免疫指南» 提出在性行为开始后进行 HPV 疫苗接种也是有益的[42] 表 1 我国国家药品监督管理局批准上市的 HPV 疫苗特点和接种程序 <html><body><table><tr><td>项目</td><td>国产双价 HPV 疫苗 (大肠杆菌)</td><td>双价 HPV 吸附疫苗</td><td>四价 HPV 疫苗</td><td>九价 HPV 疫苗</td></tr><tr><td>全球上市时间</td><td></td><td>2007年</td><td>2006年</td><td>2014年</td></tr><tr><td>中国上市时间</td><td>2019年</td><td>2016年</td><td>2017年</td><td>2018年#</td></tr><tr><td>预防 HPV 型别</td><td>16/18</td><td>16/18</td><td>6/11/16/18</td><td>6/11/16/18/31/33/45/52/58</td></tr><tr><td>中国女性适宜接种年龄</td><td>9~45岁</td><td>9~45岁</td><td>9~45岁&</td><td>16~26岁</td></tr><tr><td>预防 HPV 感染相关 疾病 (中国批准)</td><td>子宫颈癌、CIN 1级、CIN 2/ 3级、AIS，HPV 16/18持续</td><td>子宫颈癌、CIN 1 级、CIN子宫颈癌、CIN 1级、 2/3级、AIS</td><td>CIN 2/3级、AIS</td><td>子宫颈癌、CIN1级、CIN 2/3级、AIS，9种HPV相</td></tr><tr><td>表达系统</td><td>性感染 大肠杆菌</td><td>杆状病毒</td><td>酿酒酵母</td><td>关亚型感染 酿酒酵母</td></tr><tr><td>免疫量</td><td>共接种3剂，每剂0.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "5mL</td><td>共接种3剂，每剂0.5mL</td><td>共接种3剂，每剂0.5mL</td><td>共接种3剂，每剂0.5mL</td></tr><tr><td>接种方法和部位</td><td>肌内注射，首选上臂三角肌</td><td></td><td>肌内注射，首选上臂三角肌肌内注射，首选上臂三角肌肌内注射，首选上臂三角肌</td><td></td></tr><tr><td>免疫程序（接种方案）*</td><td>第0、1、6个月，9~14岁 接种2剂</td><td>第0、1、6个月</td><td>第0、2、6个月</td><td>第0、2、6个月</td></tr></table></body></html> HPV: 人乳头瘤病毒ꎻ CIN: 子宫颈上皮内瘤变ꎻ AIS: 原位腺癌ꎻ $^ { \\# } 2 0 1 8$ 年 10 月美国食品药品监督管理局批准九价 HPV 疫苗可用于 9\\~ 45 岁女性[38] ꎻ $^ { \\mathrm { \\tiny ~ \\ 8 } } 2 0 2 0$ 年 11 月国家药品监督管理局批准四价 HPV 疫苗应用于 9\\~19 岁女性ꎻ $^ * 1$ 年内接种 3 剂为完成免疫接种 2020 年美国癌症协会 ( American Cancer SocietyꎬACS) 发布了 «人乳头瘤病毒疫苗接种指南更新»ꎬ其中最重要的变化是ꎬ 不再建议 $> 2 6$ 岁人群补种HPV疫苗[43] ꎮ 主要原因是: $\\textcircled{1}$ 此年龄段人群通过接种HPV 疫苗预防癌症的获益很低ꎻ $\\textcircled{2}$ 患者与医生沟通过程中的不同观点可能干扰常规人群接种ꎻ $\\textcircled{3}$ 对于究竟哪些人群接种 HPV 疫苗能获益缺乏充分指引ꎮ2019 年 ACIP 也明确指出: 不建议所有 $> 2 6$ 岁人群补种 HPV 疫苗ꎻ HPV 疫苗未批准用于 $> 4 5$ 岁人群[39] # 3􀆰 2􀆰 2 我国 HPV 疫苗接种背景 我国城市女性初次性行为中位年龄为 22 岁ꎬ 农村为 21 岁ꎬ 超过 $10 \\%$ 的 $1 5 \\sim 1 9$ 岁女性已有性生活[44] ꎮ 国产双价 HPV 疫苗 (大肠杆菌) 研究显示ꎬ9\\~14 岁女性接种 2 剂次可获得与接种 3 剂次相同的免疫效果[23] ꎮ 因此ꎬ 13\\~ 15 岁女性在首次性行为前接种 HPV 疫苗的获益可最大化ꎮ 纳入198 项研究约 5􀆰 1 万例中国女性的汇总数据显示ꎬ $2 5 \\sim 4 5$ 岁 女 性 高 危 型 HPV 感 染 率 高 达$1 9 .",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "9 \\% ^ { [ 4 5 ] }$ ꎻ 随着年龄变化ꎬ 高危型 HPV 感染呈现17\\~ 24 岁和 40 \\~ 44 岁双峰分布[46] ꎻ 且中国女性以单一 HPV 型别感染为主 ( $7 3 .6 \\%$ ) [19] ꎮ 结合我国女性高危型 HPV 感染流行病学特点和 HPV 疫苗在 27\\~ 45岁女性中的保护效力ꎬ 加之我国接种政策和子宫颈癌筛查覆盖率低等国情ꎬ 个体化接种策略是必要的ꎬ 不应完全否定27\\~45 岁女性接种 HPV 疫苗的意义ꎮ 推荐意见: 依据以上证据ꎬ 优先推荐 9\\~ 26 岁女性接种 HPV 疫苗ꎬ 特别是未满17 岁女性ꎻ 同时推荐27\\~45 岁有条件的女性接种 HPV 疫苗ꎮ # 4 高危、 特殊人群人乳头瘤病毒疫苗接种 # 4􀆰 1 HPV 感染/ 细胞学异常女性 因免疫原性过低ꎬ HPV 自然感染所产生的抗体难以预防相同型别 HPV 再次感染[18ꎬ47] ꎮ 然而ꎬ HPV疫苗对既往疫苗型别 HPV 再感染 (一过性或持续性HPV 感染) 的女性具有显著保护效力ꎮ 在 16\\~ 26 岁既往感染疫苗型别 HPV (血清 HPV 抗体阳性而子宫颈 HPV DNA 阴性) 的女性中ꎬ 四价 HPV 疫苗对疫苗型别 HPV 再感染或其他未感染疫苗型别 HPV 所致CIN $^ { 1 + }$ 的保护效力达 $1 0 0 \\% ^ { [ 2 8 ] }$ ꎮ 对 24 \\~ 45 岁既往感染疫苗型别 HPV 的女性ꎬ 四价 HPV 疫苗对 HPV 16/18 相关 CIN $^ { 1 + }$ 的保护效力为 $6 6 .",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "9 \\% ^ { [ 4 8 ] }$ ꎮ 对 16 \\~ 26 岁已感染疫苗型别 HPV 的女性ꎬ 九价 HPV 疫苗对覆盖型别中其他未感染型别所致的 CIN $^ { 2 + }$ 的保护效力为$9 1 .1 \\% ^ { [ 4 9 ] }$ ꎮ HPV 疫苗对细胞学异常女性同样具有较高保护效力ꎮ 一项针对约 1􀆰 4 万名 16\\~ 26 岁年轻女性的国际多中心 研究结果显示 接种九价疫苗6 个月后ꎬ 初始细胞学异常者 $\\mathrm { H P V } \\ 3 1 / 3 3 / 4 5 /$ 52/ 58 持续性感染率在 HPV 疫苗组和对照组分别为$8 / 6 3 9$ (42/ 万人􀅰年) 和 138/ 649 (770􀆰 5/ 万人􀅰年)ꎬ高危型 HPV 持续性感染风险在疫苗组下降 $9 4 .",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "6 \\%$ (95％ CI: 89􀆰 3％ \\~ 97􀆰 7％) [50] 推荐意见: 依据以上证据ꎬ 适龄女性无论是否存在 HPV 感染或细胞学异常ꎬ 均推荐接种 HPV 疫苗(接种前无需常规行细胞学及 HPV 检测)ꎮ # 4􀆰2 妊娠期与哺乳期女性 # 4􀆰 2􀆰 1 妊娠期女性 妊娠期女性接种 HPV 疫苗的研究数据有限ꎮ 虽然动物实验未发现接种 HPV 疫苗对母体和子代造成直接或间接不良影响ꎬ 然而囿于伦理ꎬ 不可能实施临床研究评估 HPV 疫苗接种对妊娠期女性及其子代预后的影响ꎮ 双价 HPV 疫苗在动物实验中未见不良妊娠和子代结局ꎬ 但缺乏人类研究数据ꎮ 2015 年的一项长期随访研究发现ꎬ 与未接种 HPV 疫苗的女性相比ꎬ 接种双价 HPV 疫苗且 3 个月内受孕女性的流产风险无明显增加[51] ꎮ 国际相关机构曾对妊娠期间意外接种双价 HPV 疫苗的女性进行注册随访ꎬ 发现此人群中胎儿先天畸形和自然流产的发生率与普通人群相比并无差异[52] 四价 HPV 疫苗在动物实验中亦未发现不良妊娠和子代结局ꎮ 国际相关机构同样对妊娠期间意外接种四价 HPV 疫苗的女性进行了注册随访[53] ꎮ 一项纳入 5 项 15\\~ 45 岁女性Ⅲ期临床试验的联合分析显示ꎬ 接种四价 HPV 疫苗组与安慰剂组女性妊娠后自然流产率 ( $1 8 .",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "2 \\%$ 比 $1 9 .5 \\%$ ) 和胎儿先天发育异常率 ( $2 .0 \\%$ 比 $1 .5 \\%$ ) 均无显著差异ꎬ 胎儿晚期死亡率均低于 $1 \\% ^ { [ 5 4 ] }$ ꎮ 丹麦对近 65 万名妊娠女性进行为期7 年的四价 HPV 疫苗接种的安全性观察ꎬ 未发现接种 HPV 疫苗会增加不良妊娠结局[55] 接种九价 疫苗是否会导致不良妊娠结局同样尚无定论ꎮ 2014 至 2017 年美国疫苗不良事件报告系统 (vaccine adverse event reporting systemꎬ VAERS)记录了 82 例接种九价 HPV 疫苗的妊娠女性信息ꎬ 自然流产 3 例 $( 3 .",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "7 \\% )$ ꎬ 阴道出血2 例 $( 2 .4 \\% )$ ꎬ 提示接种九价 HPV 疫苗未增加不良妊娠结局风险[56] ꎮ 然而ꎬ 也有研究发现受孕前或受孕后 $3 0 \\mathrm { ~ d ~ }$ 内接种九价HPV 疫苗者自然流产风险有所增加 ( $R R = 2 .0 4 \\rangle$ ) [57] 2014 年美国 $\\mathrm { A C I P ^ { [ 5 8 ] } }$ 和 2017 年 WHO 发表的 HPV疫苗立场文件[7] 声明ꎬ 基于妊娠期 HPV 疫苗接种数据有限ꎬ 不推荐妊娠期女性预防性接种 HPV 疫苗ꎬ应将疫苗接种推迟至妊娠结束后ꎮ 近期计划妊娠者不推荐接种 HPV 疫苗ꎬ 且在完成最后一剂接种 2 个月内应尽量避免受孕ꎮ 若疫苗接种后发现已怀孕ꎬ 应将未完成接种剂次推迟至分娩后再行补充接种ꎮ 接种HPV 疫苗前无需妊娠检测ꎮ 若妊娠期间完成接种ꎬ则无需干预ꎮ 推荐意见: 依据以上证据ꎬ 不推荐妊娠期女性预防性接种 HPV 疫苗ꎮ 若近期准备妊娠ꎬ 建议推迟至哺乳期后再行接种ꎮ 若接种后意外妊娠ꎬ 应停止未完成剂次的接种ꎻ 已完成接种者ꎬ 无需干预ꎮ # 4􀆰 2􀆰 2 哺乳期女性 哺乳期女性接种 HPV 疫苗研究数据尤为缺乏ꎮ2017 年 ACOG 指出哺乳期女性可接种 HPV 疫苗ꎬ 该重组疫苗不影响母乳喂养的安全性[41] ꎮ 韩国妇科肿瘤学会也认为哺乳期女性可接种九价 HPV 疫苗[59] O 推荐意见: 虽然目前临床试验尚未观察到血清HPV 抗体经母乳分泌ꎬ 但鉴于多种药物可经母乳分泌ꎬ 且缺乏哺乳期女性接种 HPV 疫苗的安全性研究数据ꎬ 因此ꎬ 慎重推荐哺乳期女性接种 HPV 疫苗ꎮ # 4􀆰 3 HPV 相关病变治疗史人群 # 4􀆰 3􀆰 1 下生殖道癌前病变/ 癌治疗史人群 既往下生殖道 HSIL 的女性是一类特殊群体ꎬ 治疗后可能再次发生 HPV 感染或感染持续存在ꎮ HSIL经局部保守治疗后ꎬ CIN $^ { 2 + }$ 复发率高达 $5 \\% \\sim 1 0 \\%$ ꎬ浸润癌风险较普通人群高 2\\~ 4 倍[25] ꎮ 一项在韩国开展的 $2 0 \\sim 4 5$ 岁既往 HSIL 行子宫颈环形电切术 (loopelectrosurgical excision procedureꎬ LEEP) 治疗后接种四价 HPV 疫苗的回顾性分析显示ꎬ 与未接种者相比ꎬ接种四价 HPV 疫苗可显著降低 HPV16/ 18 相关 HSIL( $\\mathrm { C I N } 2 \\sim 3 \\$ ) 复发风险 ( $\\textstyle P < 0 .",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "0 5 )$ ꎬ 治疗后未接种HPV 疫苗 是 CIN $^ { 2 + }$ 复发的独立危险因素 ( $H R =$ 2􀆰 840ꎬ $9 5 \\%$ CI: $1 .3 3 5 \\sim 6 .0 4 2$ ꎬ $\\textstyle P < 0 .0 1$ ) [60] ꎮ 一 项PATRICIA 研究的事后分析结果表明ꎬ 对于发生 HSIL(随访4 年) 且接受切除性治疗的 15\\~ 25 岁女性ꎬ 无论接种双价 HPV 疫苗前的 HPV DNA、 HPV 16/ 18 血清学或子宫颈细胞学状态如何ꎬ 术前接种 HPV 疫苗可使术后 CIN $^ { 2 + }$ 的复发风险降低 $8 8 .",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "2 \\%$ ( $9 5 \\%$ CI:$1 4 .8 \\% \\sim 9 9 .7 \\%$ ) [61] ꎮ 这表明接种 HPV 疫苗后接受LEEP 的HSIL 患者可能继续受益ꎬ 从而降低术后CIN 2$^ +$ 复发风险ꎮ 2018年意大利前瞻性病例对照研究表明ꎬ宫颈病变术后接种四价HPV 疫苗对于预防 CIN $^ { 2 + }$ 复发的保护效力达 $8 1 .2 \\%$ ( $9 5 \\%$ CI: $3 4 .",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "3 \\% \\sim 9 5 .7 \\%$ ) [62]2018 年意大利一项前瞻性 RCT 研究结果显示ꎬ 接种四价 HPV 疫苗可显著降低 HSIL 者接受 LEEP 术后的LSIL 复发率 ( $\\scriptstyle P < 0 .0 5 { \\mathrm { ) } }$ ) [63] ꎮ 既往 HSIL 患者手术治疗后立即接种 HPV 疫苗ꎬ 可诱导子宫颈基底层细胞产生大量抗体ꎬ 阻止再生组织自身感染ꎬ 避免 HPV 进入未感染的基底层细胞ꎬ 从而避免 CIN $^ { 2 + }$ 复发[60] 推荐意见: 依据以上证据ꎬ 推荐既往 HSIL 接受过消融或切除性治疗的适龄女性接种 HPV 疫苗ꎮ 对于子宫颈癌治疗后接种 HPV 疫苗是否获益尚需进一步研究证实ꎮ # 4􀆰3􀆰 2 肛门癌前病变/ 癌治疗史人群 目前 针 对 女 性 肛 门 上 皮 内 瘤 变 ( anal intraepithelial neoplasiaꎬ AIN) / 癌治疗史的临床研究有限ꎬ研究多以男性为主ꎮ 临床研究发现ꎬ 与未接种疫苗的男性相比ꎬ 接种四价 HPV 疫苗可显著降低男男性交(men who have sex with menꎬ MSM) 患者 AIN $^ { 2 + }$ 复发[64] ꎮ 对 27 岁以上既往 AIN $^ { 2 + }$ 的人类免疫缺陷病毒(human immunodeficiency virusꎬ HIV) 阳性的 MSM 患者接种四价 HPV 疫苗可使肛门癌的终身风险降低 60􀆰 77％[65] ꎮ 推荐意见: 依据以上证据ꎬ 推荐既往 AIN $^ { 2 + }$ 适龄女性ꎬ 特别是肛门鳞状上皮性癌高风险人群 [ 包括 HIV 阳性的女性ꎬ 既往阴道上皮内瘤变 (vaginalintraepithelial neoplasiaꎬ VaIN) $^ { 2 + }$ 和外阴上皮内瘤变(vulvar intraepithelial neoplasiaꎬ VIN) $^ { 2 + }$ 的女性患者]接种 HPV 疫苗ꎮ # 4􀆰4 遗传易感人群、 高危生活方式人群 # 4􀆰 4􀆰 1 遗传易感人群 遗传易感因素可能影响 HPV 感染的敏感性、 持续性以及子宫颈癌的发展速度ꎮ 环境因素是肿瘤发生的始动因素ꎬ 而个体遗传特征决定了肿瘤的易感性[66] ꎮ 瑞典国家癌症数据库登记了约 12􀆰 5 万例子宫颈原位癌和 1􀆰4 万例子宫颈浸润癌ꎬ 以此评估的子宫颈癌家族相关危险度 (familial relative riskꎬ FRR) 分别为 1􀆰 8 和 $2 .",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "3 ^ { [ 6 7 ] }$ ꎬ 共有基因遗传度占子宫颈癌易感性总变异的 $2 7 \\%$ ( $9 5 \\%$ CI: $2 6 \\% \\sim 2 9 \\%$ ) [68] ꎮ 子宫颈癌遗传度估计值明显高于结直肠癌、 肺癌和黑色素瘤[68] ꎮ 子宫颈癌的全基因组关联分析 ( genome￣wideassociation studyꎬ GWAS) 已识别多个遗传易感变异位点ꎬ 发现其多与免疫反应基因有关ꎮ 瑞典人群GWAS 发现 HLA 基因 ( HLA￣DPB2 等) 突变与子宫颈癌易感性显著相关ꎬ 可能通过免疫应答影响子宫颈癌的发生[69] ꎮ 中国人群 GWAS 除证实了先前报道的$6 \\mathrm { p } 2 1 .",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "3 2$ 位点突变ꎬ 新发现了 2 个位于 EXOC1 和 GS￣DMB 基因 (4q12 和 17q12) 区段的遗传易感变异位点ꎬ 其编码的蛋白分别与固有免疫和肿瘤细胞增殖有关[70] 推荐意见: 依据以上证据ꎬ 优先推荐遗传易感位点变异的适龄女性 ( HLA￣DPB2、 EXOC1 和 GSDMB基因突变等) 接种 HPV 疫苗ꎮ 建议遗传易感人群在首次性行为之前接种ꎬ 即使性暴露后亦应尽早接种ꎮ # 4􀆰 4􀆰 2 高危生活方式人群 性生活过早、 多性伴、 多孕、 多产、 吸烟、 长期口服避孕药、 性传播疾病者等是子宫颈癌的高危因素[71] ꎮ $5 0 \\%$ 以上的年轻女性在开始性行为后的 3 年内即会发生 HPV 感染[72] ꎮ 青春期女孩下生殖道发育尚未成熟ꎬ 过早性生活会使子宫颈上皮多次重复暴露于某些细菌或病毒ꎬ 产生潜在细胞变异[44] ꎮ 性生活过早、 多性伴等因素是 HPV 感染的重要协同因素[44] ꎮ 口服避孕药与 HPV 感染明显相关ꎬ 用药时间长 (5 年以上) 者 HPV 感染风险增加[73] 推荐意见: 依据以上证据ꎬ 优先推荐高危生活方式的适龄女性尽早接种 HPV 疫苗ꎬ 即使已知 HPV 感染/ 细胞学异常及既往接受过 HSIL 治疗者亦推荐接种ꎮ # 4􀆰 5 免疫功能低下人群 包括 HIV 感染者ꎻ 自身免疫性疾病患者ꎬ 如自身免 疫 炎 性 风 湿 病 ( autoimmune inflammatory rheu￣matic diseasesꎬ AIIRD)、 桥本甲状腺炎等ꎻ 肥胖、 糖尿病、 肾衰竭血液透析者ꎻ 器官/ 骨髓移植后长期服用免疫抑制剂患者ꎮ # 4􀆰 5􀆰 1 HIV 感染者 HIV 以人体免疫系统 $\\mathrm { C D 4 ^ { + } T }$ 细胞为攻击目标ꎬ缺乏 $\\mathrm { C D 4 ^ { + } T }$ 细胞辅助的免疫系统将难以杀灭入侵的病原体及体内癌细胞ꎬ 导致继发感染或恶性肿瘤$\\mathrm { C D 4 ^ { + } T }$ 细胞计数低于 $2 0 0 ~ \\mathrm { c e l l s } / \\mathrm { m L }$ 时ꎬ 细胞免疫几乎完全失去功能[74] ꎮ 18\\~25 岁 HIV 感染女性接种双价 HPV 疫苗后免疫反应不受 $\\mathrm { C D 4 ^ { + } T }$ 细胞计数和 HIV 病毒载量的影响[75] ꎮ 13\\~45 岁 HIV 感染女性接种四价 HPV 疫苗是安全的ꎬ 且具有免疫原性ꎬ 其中 $\\mathrm { C D 4 ^ { + } T }$ 细胞 $> 2 0 0$ cells/ mL 者的抗体应答率为 $8 5 \\% \\sim 1 0 0 \\%$ ꎬ $\\mathrm { C D 4 ^ { + } T }$ 细胞≤200 cells / mL 者的抗体应答率为 75％ \\~ 93％[76] 四价 HPV 疫苗可有效减少 HIV 感染女性的 HPV疫苗相关型别的持续性感染ꎬ 接种组 HIV 感染女性HPV 6/ 11/ 16/ 18 持 续 性 感 染 比 率 低 于 未 接 种 组[2􀆰 3/ (100 人􀅰年) 比 6􀆰 0/ (100 人􀅰年) ] [77] 推荐意见: 依据以上证据ꎬ 优先推荐 HIV 感染的适龄女性接种 HPV 疫苗ꎮ # 4􀆰 5􀆰 2 自身免疫性疾病患者 包括 AIIRD、 桥本甲状腺炎等ꎮ AIIRD 指系统性红斑狼疮 (systemic lupus erythematosusꎬ SLE)、 风湿性关节炎、 幼年特发性关节炎、 结缔组织病、 干燥综合征、 抗磷脂综合征、 系统性硬化、 大细胞动脉炎、多发性结节性动脉炎、 白塞综合征、 复发性多软骨炎、 周期性发热综合征等ꎮ 针对 AIIRD 患者的 HPV疫苗接种证据主要源于 SLE 的研究ꎮ 18\\~ 35 岁 SLE女性接种四价 HPV 疫苗后安全性良好ꎬ 疫苗相关型别的抗体应答率可达 $7 6 \\% \\sim 9 5 \\% ^ { [ 7 8 ] }$ 推荐意见: 依据以上证据ꎬ 推荐患有自身免疫性疾病的适龄女性接种 HPV 疫苗ꎮ # 4􀆰5􀆰 3 糖尿病患者、 肾衰竭接受血液透析者等 糖尿病是一种代谢性疾病ꎮ 1 型糖尿病属于自身免疫性疾病ꎻ 2 型糖尿病因体重过重或缺乏运动ꎬ 随病情进展胰岛素分泌逐渐不足ꎮ 糖尿病患者免疫力随血糖升高而下降ꎮ 推荐意见: 推荐患有1 型或2 型糖尿病的适龄女性接种 HPV 疫苗ꎮ 一项纳入57 例 $9 \\sim 2 1$ 岁慢性肾脏病 (chronic kid￣ney diseaseꎬ CKD)、 血液透析和肾移植患者的四价HPV 疫苗研究显示ꎬ CKD 组和透析组患者的 4 种抗体应答率均为 $100 \\%$ ꎻ 肾移植组患者抗体应答率为$5 0 \\% \\sim 7 5 \\% ^ { [ 7 9 ] }$ ꎮ 另一项纳入 60 例 $\\mathrm { I V }$ 期、 Ⅴ期和ⅤD期 CKD 患者的四价 HPV 疫苗研究显示ꎬ 接种后抗体应答率为 $9 8 .",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "2 \\% \\sim 1 0 0 .0 \\% ^ { [ 8 0 ] }$ 推荐意见: 依据以上证据ꎬ 推荐肾衰竭接受血液透析的适龄女性在病情允许时接种 HPV 疫苗ꎮ 对全身脏器功能差、 预期寿命有限者不推荐接种ꎮ # 4􀆰5􀆰 4 器官/ 骨髓移植术后长期服用免疫抑制剂者 器官/ 骨髓移植术后长期服用免疫抑制剂者在HPV 疫苗领域的临床试验样本量小ꎬ 与正常人群相比ꎬ 此类人群接种 HPV 疫苗的抗体应答率低ꎮ 肾移植者发生肛门生殖区癌前病变/ 癌的风险显著升高$H R = 2 .",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "\\ 1 \\sim 5 1 .\\ 1 \\ )$ [81] ꎮ $1 8 \\sim 3 5$ 岁接受过器官 ( 包括肾、 肺、 心、 肝) 移植的女性接种四价 HPV 疫苗安全性好ꎬ 接种后疫苗相关型别抗体应答率为 $5 2 \\%$ \\~$6 8 \\%$ ꎻ 与移植1 年后接种相比ꎬ 移植 1 年内接种 HPV疫苗呈低免疫反应 ( $8 5 .2 \\%$ 比 $5 4 .5 \\%$ ) [82] ꎬ 因此ꎬ 移植1 年后接种 HPV 疫苗更为有利ꎮ 推荐意见: 依据以上证据ꎬ 建议临床医生与患者共同探讨ꎬ 根据疾病轻重差别给予个体化建议ꎮ 对于预期寿命长的适龄女性ꎬ 推荐移植 1 年后接种 HPV疫苗ꎻ 对于预期寿命有限者ꎬ 不推荐接种ꎮ # 5 不良反应与不良事件及其处理 疫苗不良反应 (adverse reactionꎬ AR) 指合格疫苗在正常用法用量下出现与疫苗接种有明确因果关系的有害反应ꎬ 一般可预见ꎬ 与剂量相关ꎮ 疫苗所含外来抗原和佐剂均可引起 ARꎮ 疫苗不良事件 (adverseeventꎬ AE) 指疫苗接种过程中或之后出现的不良临床事件ꎬ 但该事件未必与疫苗接种有因果关系ꎮ 严重不良事件 ( serious adverse eventsꎬ SAE) 包括死亡、危及生命、 残疾或丧失劳动力等ꎮ AR 和 AE 均可发生在临床试验中和上市后两个阶段ꎮ 按国际医学科学组织委员会 ( Council for Interna￣tional Organizations of Medical Sciencesꎬ CIOMS) 的推荐描述 AR 和 AE 频率ꎬ 分为十分常见 ( $\\geqslant 1 0 \\%$ )、 常见 ( $1 \\% \\sim 1 0 \\%$ ꎬ 含 $1 \\%$ )、 偶 见 ( $0 .",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "1 \\% \\sim 1 .0 \\%$ ꎬ 含$0 .1 \\%$ )、 罕见 $( 0 .0 1 \\% \\sim 0 .1 0 \\%$ ꎬ 含 $0 .0 1 \\%$ ) 和十分罕见 ( $< 0 .0 1 \\%$ ) [83] # 5􀆰 1 临床试验中的疫苗不良反应/ 事件 与其他疫苗一样ꎬ HPV 疫苗在临床试验中出现的 AR 包括接种部位 AR 和全身 ARꎬ 接种部位 AR 更为常见ꎮ 十分常见的接种部位 AR 依次为局部疼痛、 肿胀和红斑ꎻ 常见的接种部位 AR 为瘙痒和硬结ꎮ 在四价HPV 疫苗的安慰剂对照临床试验中ꎬ 接种部位 AR 包括疼痛 ( $8 4 \\%$ )、 肿胀 ( $2 5 \\%$ ) 和红斑 ( $< 2 5 \\%$ )ꎻ 疫苗组疼痛较安慰剂组更常见: 生理盐水对照组疼痛发生率为 49％ꎬ 铝佐剂对照组疼痛发生率为75％[84] 九价HPV 疫苗组接种者局部 AR 发生率略高于四价 HPV 疫苗组[33]ꎻ 双价 HPV 疫苗组接种者局部 AR发生率也高于四价 HPV 疫苗组[85]ꎮ 双价 HPV 疫苗组接种者局部疼痛、 肿胀、 红斑发生率分别为 $9 2 .",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "9 \\%$ 、$3 6 .5 \\%$ 和 $4 4 .3 \\%$ ꎬ 四价 HPV 疫苗组分别为 $7 1 .6 \\%$ 、$2 1 .8 \\%$ 和 $2 5 .6 \\%$ ꎮ 约 $6 \\%$ 的接种者报告了严重疼痛[84]接种部位AR 多发生于接种后 $1 5 \\mathrm { ~ d ~ }$ 内ꎬ 多为轻、 中度ꎬ大多可自然缓解ꎬ 一般无需特殊处理ꎮ 全身 AR 有发热、 头痛、 眩晕、 疲劳、 肌肉痛、关节痛和胃肠道症状 ( 恶心、 呕吐、 腹痛) 等ꎮ 四价 HPV 疫苗临床试验中仅发热十分常见ꎬ 为 $1 0 .",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "1 \\%$ ꎬ对照组为 $8 .4 \\%$ ꎬ 其他 AR 的发生率均 $< 0 .5 \\% ^ { [ 8 4 ] }$ ꎮ 九价和四价 HPV 疫苗组接种者全身 AR 发生率相近ꎬ分别为 $2 9 .5 \\%$ 和 $2 7 .3 \\%$ ꎻ 常见的全身 AR 为头痛ꎬ 分别为 14􀆰 6％和 13􀆰 7％ꎬ 发热分别为 5􀆰 0％和 4􀆰 3％[33]双价和四价 HPV 疫苗的全身 AR 发生率也相似ꎬ 但双价 HPV 疫苗组接种者疲劳和肌肉痛较四价 HPV疫苗组多见 ( 分别为 $4 9 .",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "8 \\%$ 比 $3 9 .8 \\%$ 和 $2 7 .6 \\%$ 比$1 9 .6 \\%$ ) [86] ꎮ 眩晕或晕厥在青少年中更明显ꎮ 这些全身 AR 常很轻微ꎬ 有自限性ꎬ 一般无需特殊处理ꎮ 中国双价 HPV 疫苗临床试验显示总体耐受性良好ꎬ 尚无严重 $\\mathrm { A R } ^ { [ 8 7 ] }$ ꎮ 一项随访长达 90 个月的中国Ⅲ期 RCT 显示ꎬ 四价 HPV 疫苗在成年女性中耐受性良好ꎬ 安全性结果与全球临床试验和安全性监测研究所得结果一致[88] ꎮ 临床试验中四价和双价 HPV 疫苗未报告疫苗相关 $\\mathrm { S A E } ^ { [ 7 ] }$ ꎬ 九价疫苗相关的 SAE 发生率 $< 0 .",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "1 \\% ^ { [ 8 9 ] }$ ꎮ 死亡报告率极低ꎬ 且未证实与 HPV 疫苗接种相关[90] # 5􀆰2 上市后的疫苗不良反应/ 事件 全球已有超过 2 亿支 HPV 疫苗被使用ꎬ 迄今收集到的数据显示ꎬ 局部和全身 AR 与临床试验结果基本一致ꎮ 随着大规模人群接种ꎬ 也监测到一些罕见 AEꎬ如吉兰￣巴雷综合征 ( Guillain￣Barré syndromeꎬ GBS)、复杂性区域疼痛综合征、 体位性心动过速综合征、 静脉血栓栓塞、 卵巢功能早衰、 肌痛性脑脊髓炎、 慢性疲劳综合征等ꎬ 各国报道发生率不同ꎬ 但基本不超过$3 / 1 0 0$ 万剂次ꎮ 一项美国多中心研究显示ꎬ 2006 至2013 年 9\\~ 26 岁女性共接种四价 HPV 疫苗 1 423 399剂ꎬ 接种后 77 d 内 53 例确诊静脉血栓栓塞ꎬ 其中 30例接种前有静脉血栓栓塞风险ꎬ 发生率为 $0 .",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "2 / 1 0 0$ 万[91] ꎮ 目前尚无证据证明接种 HPV 疫苗增加这些疾病或症状的风险[92] ꎬ 也尚无证据证明其影响女性生殖功能ꎮ 由于现有 HPV 疫苗均由抗原蛋白与佐剂组成ꎬ 因此不能完全排除部分 AE 可能与佐剂有关ꎬ 需要加强监测予以排除ꎮ # 6 注意事项 # 6􀆰1 HPV 疫苗接种注意事项 对疫苗的活性成分或任何辅料成分有超敏反应者禁止接种 HPV 疫苗ꎬ 注射本品后有超敏反应症状者ꎬ 不应再次接种本品ꎮ 对于以下人群ꎬ 需慎用HPV 疫苗: (1) 有血小板减少症或其他可成为肌内注射禁忌证的凝血功能障碍者不宜接种ꎻ (2) 妊娠期女性或备孕女性推迟至妊娠期结束后再接种ꎬ 哺乳期女性接种时应谨慎ꎻ (3) 急性疾病常伴有发热等全身症状ꎬ 接种疫苗可能会加重症状ꎬ 建议痊愈后接种ꎻ (4) 因部分女性存在不同程度的经期不适ꎬ 建议非经期接种ꎮ # 6􀆰2 接种 HPV 疫苗后仍应进行子宫颈癌筛查 (1) HPV 疫苗对未暴露于疫苗相关 HPV 型别的人群保护效力较好ꎬ 但对于存在 HPV 感染或相关疾病危险因素 (如多性伴、 既往感染过疫苗相关 HPV型别、 免疫缺陷等) 的人群有效性降低ꎻ (2) HPV疫苗是预防性疫苗ꎬ 不能治疗已感染的 HPV 及相关疾病ꎬ 不能预防所有 HPV 型别感染ꎬ 也不能阻止HPV 感染至疾病进展ꎻ (3) 少数子宫颈癌可能与HPV 感染无关ꎬ 特别是 HPV 阴性的特殊类型癌ꎻ(4) 自2006 年 HPV 疫苗上市以来ꎬ 长期随访研究证实了 HPV 疫苗14 年的保护效力ꎬ 但目前尚无证据证实 HPV 疫苗有终身保护效力ꎻ (5) HPV 疫苗所含型别有限ꎬ 即使接种了 HPV 疫苗ꎬ 机体仍处于对非疫苗型别 HPV 的感染风险中ꎬ 因此ꎬ 接种 HPV 疫苗后仍需继续进行子宫颈癌筛查ꎮ HPV 疫苗接种是预防 HPV 感染和相关疾病的有效、 安全方法ꎮ 低龄人群接种效果优于高龄人群ꎬ 性暴露前接种免疫效果最佳ꎮ HPV 疫苗不仅适用于普通人群ꎬ 同样推荐用于高危、 特殊人群 (表 2)ꎮ 对于具有遗传易感、 高危生活方式和 HIV 感染的适龄女性应优先推荐接种 HPV 疫苗ꎮ 无论是否存在 HPV感染、 细胞学是否异常的适龄女性均可接种 HPV 疫苗ꎮ 有 HPV 相关病变治疗史的适龄女性患者ꎬ 接种HPV 疫苗可能降低复发率ꎮ 近期有妊娠计划和妊娠期、 哺乳期女性不宜接种 HPV 疫苗ꎮ 接种 HPV 疫苗后仍应进行子宫颈癌筛查ꎮ 表 2 普通和特殊人群 (女性) HPV 疫苗接种的推荐级别∗＃ <html><body><table><tr><td>不同人群</td><td>推荐级别</td></tr><tr><td>普通人群</td><td></td></tr><tr><td>9~26岁女性</td><td>优先推荐</td></tr><tr><td>27~45岁女性</td><td>推荐</td></tr><tr><td>特殊人群</td><td></td></tr><tr><td>HPV感染/细胞学异常的适龄女性</td><td>推荐</td></tr><tr><td>妊娠期女性</td><td>不推荐</td></tr><tr><td>哺乳期女性</td><td>谨慎推荐</td></tr><tr><td>有HPV相关病变治疗史的适龄女性</td><td>推荐</td></tr><tr><td>有遗传易感和子宫颈癌发病高危因素的 适龄女性*</td><td>优先推荐</td></tr><tr><td>免疫功能低下的适龄女性\"</td><td></td></tr><tr><td>HIV感染者</td><td>优先推荐</td></tr><tr><td>自身免疫性疾病患者：系统性红斑狼推荐</td><td></td></tr><tr><td>疮、风湿性关节炎、结缔组织病、干 燥综合征、桥本甲状腺炎等</td><td></td></tr><tr><td>1型和2型糖尿病患者</td><td>推荐</td></tr><tr><td>肾衰竭接受血液透析者</td><td>与临床医生共同探讨</td></tr><tr><td>器官/骨髓移植术后长期服用免疫抑制</td><td>与临床医生共同探讨</td></tr><tr><td>剂者</td><td></td></tr></table></body></html> HPV: 同表 1ꎻ HIV: 人类免疫缺陷病毒ꎻ ∗建议首次性暴露前或尽早接种 ＃全身脏器功能差 病情不乐观 预期寿命有限者 不推荐 # 共识专家组成员 (以姓氏笔画为序): 万小平 (上海市第一妇婴保健院)ꎬ 马丁 (华中科技大学同济医学院附属同济医院)ꎬ 王丹波 (辽宁省肿瘤医院)ꎬ 王世宣 (华中科技大学同济医学院附属同济医院)ꎬ 王建六 ( 北京大学人民医院)ꎬ 王临虹(中国疾病预防控制中心妇幼保健中心)ꎬ 王新宇(浙江大学医学院附属妇产科医院)ꎬ 尤志学 (南京医科大学第一附属医院/ 江苏省人民医院)ꎬ 尹如铁(四川大学华西第二医院)ꎬ 孔北华 (山东大学齐鲁医院)ꎬ 丛青 ( 复旦大学附属妇产科医院)ꎬ 毕蕙(北京大学第一医院)ꎬ 曲芃芃 (天津市中心妇产科医院)ꎬ 乔友林 (中国医学科学院肿瘤医院)ꎬ 向阳(中国医学科学院北京协和医院)ꎬ 刘红 (四川省肿瘤医院/ 四川省第二人民医院)ꎬ 刘继红 (中山大学肿瘤防治中心)ꎬ 李双 (华中科技大学同济医学院附属同济医院)ꎬ 李亚里 (中国人民解放军总医院第一医学中心)ꎬ 李克敏 ( 四川大学华西第二医院)ꎬ李明珠 (北京大学人民医院)ꎬ 李隆玉 (江西省妇幼保健院)ꎬ 杨帆 (中山大学肿瘤防治中心)ꎬ 杨佳欣(中国医学科学院北京协和医院)ꎬ 吴小华 (复旦大学附属肿瘤医院)ꎬ 吴令英 (中国医学科学院肿瘤医院)ꎬ 沈丹华 (北京大学人民医院)ꎬ 宋坤 (山东大学齐鲁医院)ꎬ 张国楠 (四川省肿瘤医院/ 四川省第二人民医院)ꎬ 张淑兰 ( 中国医科大学附属盛京医院)ꎬ 郄明蓉 (四川大学华西第二医院)ꎬ 周琦 (重庆大学附属肿瘤医院/ 重庆市肿瘤医院)ꎬ 赵霞 (四川大学华西第二医院)ꎬ 郝敏 (山西医科大学第二医院)ꎬ 哈春芳 ( 宁夏医科大学/ 宁夏医科大学总医院)ꎬ 徐丛剑 (复旦大学附属妇产科医院)ꎬ 高雨农(北京大学肿瘤医院)ꎬ 郭瑞霞 (郑州大学第一附属医院)ꎬ 崔恒 (北京大学人民医院)ꎬ 康山 (河北医科大学第四医院)ꎬ 梁志清 (陆军军医大学第一附属医院)ꎬ 隋龙 (复旦大学附属妇产科医院)ꎬ 程文俊(南京医科大学第一附属医院/ 江苏省人民医院)ꎬ谢幸 (浙江大学医学院附属妇产科医院)ꎬ 薛凤霞(天津医科大学总医院)ꎬ 魏丽惠 (北京大学人民医院) 执笔人 李双ꎬ 李明珠ꎬ 丛青ꎬ 杨帆ꎬ 刘红ꎬ 李克敏ꎬ 宋坤ꎬ尹如铁ꎬ 王新宇ꎬ 张国楠ꎬ 隋龙ꎬ 刘继红ꎬ 孔北华ꎬ谢幸ꎬ 魏丽惠ꎬ 马丁 利益冲突: 无 # 参 考 文 献 [1] McBride AA.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Oncogenic human papillomaviruses [ J ].Philos Trans R Soc Lond B Biol Sciꎬ 2017ꎬ 372: 20160273.[2] Chesson HWꎬ Dunne EFꎬ Hariri Sꎬ et al.The estimated li￣ fetime probability of acquiring human papillomavirus in the United States [J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Sex Transm Disꎬ 2014ꎬ 41: 660￣ 664.[3] Gargano Jꎬ Meites Eꎬ Watson Mꎬ et al.Manual for the Sur￣ veillance of Vaccine￣Preventable Diseases: Human Papillo￣ mavirus [EB / OL].(2020￣ 04￣ 28)[2020￣ 11￣ 28].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "https:/ / www.cdc.gov / vaccines / pubs / surv￣manual / chpt05￣hpv.html.[4] World Health Organization.Human papillomavirus vaccines: WHO position paperꎬ May 2017￣Recommendations [ J ].Vaccineꎬ 2017ꎬ 35: 5753￣ 5755.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "[5] Bruni Lꎬ Diaz Mꎬ Castellsagué Xꎬ et al.Cervical human papillomavirus prevalence in 5 continents: meta￣analysis of 1 million women with normal cytological findings [J].J Infect Disꎬ 2010ꎬ 202: 1789￣ 1799.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "[6] Guan Pꎬ Howell￣Jones Rꎬ Li Nꎬ et al.Human papillo￣ mavirus types in 115ꎬ 789 HPV￣positive women: a meta￣a￣ nalysis from cervical infection to cancer [ J].Int J Cancerꎬ 2012ꎬ 131: 2349￣ 2359.[7] World Health Organization.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Human papillomavirus vaccines: WHO position paperꎬ May 2017 [J].Wkly Epidemiol Recꎬ 2017ꎬ 92: 241￣ 268.[8] de Sanjose Sꎬ Quint WGꎬ Alemany Lꎬ et al.Human papillo￣ mavirus genotype attribution in invasive cervical cancer: a retrospective cross￣sectional worldwide study [ J ].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Lancet Oncolꎬ 2010ꎬ 11: 1048￣ 1056.[9] Wu EQꎬ Liu Bꎬ Cui JFꎬ et al.Prevalence of type￣specific human papillomavirus and pap results in Chinese women: a multi￣centerꎬ population￣based cross￣sectional study [ J ].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Cancer Causes Controlꎬ 2013ꎬ 24: 795￣ 803.[10] Chen Wꎬ Zhang Xꎬ Molijn Aꎬ et al.Human papillomavirus type￣distribution in cervical cancer in China: the importance of HPV 16 and 18 [J].Cancer Causes Controlꎬ 2009ꎬ 20: 1705￣ 1713.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "[11] de Martel Cꎬ Georges Dꎬ Bray Fꎬ et al.Global burden of cancer attributable to infections in 2018: a worldwide inci￣ dence analysis [ J ].Lancet Glob Healthꎬ 2020ꎬ 8: e180￣e190.[12] de Martel Cꎬ Plummer Mꎬ Vignat Jꎬ et al.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Worldwide burden of cancer attributable to HPV by siteꎬ country and HPV type [J].Int J Cancerꎬ 2017ꎬ 141: 664￣ 670.[13] Bruni Lꎬ Albero Gꎬ Serrano Bꎬ et al.ICO / IARC Information Centre on HPV and Cancer (HPV Information Centre).",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Hu￣ man Papillomavirus and Related Diseases in the World [R / OL].(2019￣ 06￣ 17) [2020￣ 11￣ 25].https:/ / hpvcentre.net / statistics / reports / XWX.pdf?$\\mathrm { t } =$ 1606721151283.[14] Bray Fꎬ Ferlay Jꎬ Soerjomataram Iꎬ et al.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Global cancer sta￣ tistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J].CA Cancer J Clinꎬ 2018ꎬ 68: 394￣ 424.[15] Bruni Lꎬ Albero Gꎬ Serrano Bꎬ et al.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "ICO / IARC Information Centre on HPV and Cancer (HPV Information Centre).Hu￣ man Papillomavirus and Related Diseases in China [ R / OL].(2019￣ 06￣ 17) [2020￣ 11￣ 25].https:/ / hpvcentre.net / statistics / reports / CHN.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "pdf?t ＝ 1606722464904.[16] Giuliano ARꎬ Nyitray AGꎬ Kreimer ARꎬ et al.EUROGIN 2014 roadmap: differences in human papill￣omavirus infection natural historyꎬ transmission and human papill￣ omavirus￣related cancer incidence by gender and anatomic site of infection [J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Int J Cancerꎬ 2015ꎬ 136: 2752￣2760.[17] Centers for Disease Control and Prevertion.Human Papill￣ omavirus ( HPV ) Infection [ EB / OL ].( 2015￣ 06￣ 04 ) [2020￣ 11￣ 25].https: / / www.cdc.gov / std / tg2015 / hpv.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "htm.[18] Colombara DVꎬ Wang SM.The impact of HPV vaccin￣ation delays in China: lessons from HBV control programs [ J].Vaccineꎬ 2013ꎬ 31: 4057￣ 4059.[19] Zeng ZYꎬ Yang HTꎬ Li ZBꎬ et al.Prevalence and Genotype Distribution of HPV Infection in China: Analysis of 51ꎬ 345 HPV Genotyping Results from China􀆳s Largest CAP Certified Laboratory [J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "J Cancerꎬ 2016ꎬ 7: 1037￣ 1043.[20] Wei LHꎬ Xie Xꎬ Liu JHꎬ et al.Efficacy of quadrivalent hu￣ man papill￣omavirus vaccine against persistent infection and genital disease in Chinese women: A randomizedꎬ placebo￣ controlled trial with 78￣month follow￣up [ J ].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Vaccineꎬ 2019ꎬ 37: 3617￣ 3624.[21] Zhu FCꎬ Li Jꎬ Hu YMꎬ et al.Immunogenicity and safety of the HPV￣16 / 18 AS04￣adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years [J].Hum VaccinImmu￣ notherꎬ 2014ꎬ 10: 1795￣ 1806.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "[22] Li RCꎬ Li YPꎬ Radley Dꎬ et al.Safety and immunogenicity of a vaccine targeting human papillomavirus types 6ꎬ 11ꎬ 16 and 18: a randomizedꎬ double￣blindꎬ placebo￣controlled trial in Chinese males and females [ J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Vaccineꎬ 2012ꎬ 30: 4284￣ 4291.[23] Hu YMꎬ Guo Mꎬ Li CGꎬ et al.Immunogenicity nonin￣ feriority study of 2 doses and 3 doses of an Escherichia coli￣ produced HPV bivalent vaccine in girls vs.3 doses in young women [J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Sci China Life Sciꎬ 2020ꎬ 63: 582￣ 591.[24] Van Damme Pꎬ Meijer CJLMꎬ Kieninger Dꎬ et al.A phase Ⅲ clinical study to compare the immunogenicity and safety of the 9￣valent and quadrivalent HPV vaccines in men [ J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Vaccineꎬ 2016ꎬ 34: 4205￣ 4212.[25] Joura EAꎬ Kyrgiou Mꎬ Bosch FXꎬ et al.Human papillo￣ma￣ virus vaccination: The ESGO￣EFC position paper of the Eu￣ ropean society of Gynaecologic Oncology and the European Federation for colposcopy [ J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Eur J Cancerꎬ 2019ꎬ 116: 21￣ 26.[26] Barr Eꎬ Gause CKꎬ Bautista OMꎬ et al.Impact of a prophy￣ lactic quadrivalent human papillomavirus (types 6ꎬ 11ꎬ 16ꎬ 18) L1 virus￣like particle vaccine in a sexually active popu￣ lation of North American women [J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Am J Obstet Gynecolꎬ 2008ꎬ 198: 261.e1￣e11.[27] Australian Government Department of Health.Human papil￣ lomavirus (HPV) immunization service [ EB / OL].(2019￣ 09￣ 26) [2020￣ 11￣ 25].https: / / www.health.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "gov.au / health￣ topics / immunisation / immunisation￣services / human￣papillo￣ mavirus￣hpv￣immunisation.[28] Olsson SEꎬ Kjaer SKꎬ Sigurdsson Kꎬ et al.Evaluation of quadrivalent HPV 6 / 11 / 16 / 18 vaccine efficacy against cer￣ vical and anogenital disease in subjects with serological evi￣ dence of prior vaccine type HPV infection [ J ].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Hum Vaccinꎬ 2009ꎬ 5: 696￣ 704.[29] Zhu FCꎬ Hu SYꎬ Hong Yꎬ et al.Efficacyꎬ immuno￣genicity and safety of the AS04￣HPV￣ 16 / 18 vaccine in Chinese women aged 18－25 years: End￣of￣study results from a phase Ⅱ / Ⅲꎬ rando￣misedꎬ controlled trial [ J ].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Cancer Medꎬ 2019ꎬ 8: 6195￣ 6211.[30] Qiao YLꎬ Wu Tꎬ Li RCꎬ et al.Efficacyꎬ Safetyꎬ and Immu￣ no￣genicity of an Escherichia coli￣Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial [ J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "J Natl Cancer Instꎬ 2020ꎬ 112: 145￣ 153.[31] Future Ⅱ Study Group.Quadrivalent vaccine against human papillomavirus to prevent high￣grade cervical lesions [J].N Engl J Medꎬ 2007ꎬ 356: 1915￣ 1927.[32] Lei JYꎬ Ploner Aꎬ Elfström KMꎬ et al.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "HPV Vaccination and the Risk of Invasive Cervical Cancer [ J].N Engl J Medꎬ 2020ꎬ 383: 1340￣ 1348.[33] Joura EAꎬ Giuliano ARꎬ Iversen OEꎬ et al.A 9￣valent HPV vaccine against infection and intraepithelial neoplasia in women [J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "N Engl J Medꎬ 2015ꎬ 372: 711￣ 723.[34] Garland SMꎬ Pitisuttithum Pꎬ Ngan HYSꎬ et al.Efficacyꎬ Immunogenicityꎬ and Safety of a 9￣Valent Human Papilloma￣ virus Vaccine: Subgroup Analysis of Participants From Asian [35] Ruiz￣Sternberg ÁMꎬ Moreira ED Jrꎬ Restrepo JAꎬ et al.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Ef￣ ficacyꎬ immunogenicityꎬ and safety of a 9￣valent human pap￣ illomavirus vaccine in Latin American girlsꎬ boysꎬ and young women [J].Papillomavirus Resꎬ 2018ꎬ 5: 63￣ 74.[36] International Federation of Gynecology ＆ Obstetrics.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Global Guidance For Cervical Cancer Prevention and Control (2009) [ EB / OL].[ 2020￣ 11￣ 25].https:/ / www.figo.org / sites / default / files / 2020￣ 07 / Control＿English＿version.pdf.[37] 中华预防医学会疫苗与免疫分会.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "子宫颈癌等人乳头瘤 病毒相关疾病免疫预防专家共识 (简版) [J].中华预 防医学杂志ꎬ 2019ꎬ 53: 1218￣ 1235.[38] U.S.Food ＆ Drug Administration.FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old [EB / OL].(2018￣10￣05)[2020￣11￣25].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "https:/ / www.fda.gov / news￣events / press￣announcements / fda￣approves￣ex￣ panded￣use￣gardasil￣ 9￣include￣individuals￣ 27￣through￣45￣ years￣old.[39] Meites Eꎬ Szilagyi PGꎬ Chesson HWꎬ et al.Human Papillo￣ mavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices [ J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "MMWR Morb Mortal Wkly Repꎬ 2019ꎬ 68: 698￣ 702.[40] Centers for Disease Control and Prevertion.Vaccines at 11 to 12 Years [EB / OL].(2020￣02￣25)[2020￣11￣25].https:/ / www.cdc.gov / vaccines / parents / by￣age / years￣ 11￣ 12.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "html.[41] Immunization Expert Work Groupꎬ Committee on Adolescent Health Care.Committee Opinion No.704: Human Papillo￣ mavirusVaccination [J].Obstet Gynecolꎬ 2017ꎬ 129: 1.[42] Government of Canada.Human papillomavirus vaccine: Ca￣ nadian Immunization Guide [ EB / OL ].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "[ 2020￣11￣25 ].https: / / www.canada.ca / en / public￣health / services / publica￣ tions / healthy￣living / canadian￣immunization￣guide￣part￣ 4￣ac￣ tive￣vaccines / page￣ 9￣human￣papillomavirus￣vaccine.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "html.[43] Saslow Dꎬ Andrews KSꎬ Manassaram￣Baptiste Dꎬ et al.Hu￣ man papillomavirus vaccination 2020 guideline update: American Cancer Society guideline adaptation [ J ].CA Cancer J Clinꎬ 2020ꎬ 70: 274￣ 280.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "[44] Zhao FHꎬ Tiggelaar SMꎬ Hu SYꎬ et al.A multi￣center survey of age of sexual debut and sexual behavior in Chinese women: suggestions for optimal age of human papillomavirus vacci￣nation in China [ J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Cancer Epidemiolꎬ 2012ꎬ 36: 384￣ 390.[45] Li Kꎬ Li Qꎬ Song Lꎬ et al.The distribution and prevalence of human papillomavirus in women in mainland China [ J].Cancerꎬ 2019ꎬ 125: 1030￣ 1037.[46] Zhao FHꎬ Lewkowitz AKꎬ Hu SYꎬ et al.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: a pooled analysis of 17 population￣based studies [J].Int J Cancerꎬ 2012ꎬ 131: 2929￣ 2938.[47] Viscidi RPꎬ Schiffman Mꎬ Hildesheim Aꎬ et al.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Seroreac￣ tivity to human papillomavirus ( HPV) types 16ꎬ 18ꎬ or 31 and risk of subsequent HPV infection: results from a popula￣ tion￣based study in Costa Rica [ J].Cancer Epidemiol Bio￣ markers Prevꎬ 2004ꎬ 13: 324￣ 327.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "[48] Castellsagué Xꎬ Muñoz Nꎬ Pitisuttithum Pꎬ et al.End￣of￣ study safetyꎬ immunogenicityꎬ and efficacy of quadrivalent HPV ( types 6ꎬ 11ꎬ 16ꎬ 18) recombinant vaccine in adult women 24－45 years of age [ J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Br J Cancerꎬ 2011ꎬ 105: 28￣ 37.[49] Giuliano ARꎬ Joura EAꎬ Garland SMꎬ et al.Nine￣valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo popul￣ation [ J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Gynecol Oncolꎬ 2019ꎬ 154: 110￣ 117.[50] Huh WKꎬ Joura EAꎬ Giuliano ARꎬ et al.Final efficacyꎬ im￣ munogenicityꎬ and safety analyses of a nine￣valent human papillomavirus vaccine in women aged 16－ 26 years: a ran￣ domisedꎬ double￣blind trial [ J ].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Lancetꎬ 2017ꎬ 390: 2143￣ 2159.[51] Panagiotou OAꎬ Befano BLꎬ Gonzalez Pꎬ et al.Effectof bi￣ valent human papillomavirus vaccination on pregnancy out￣ comes: long term observational follow￣up in the Costa Rica HPV Vaccine Trial [J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "BMJꎬ 2015ꎬ 351: h4358.[52] Angelo MGꎬ Zima Jꎬ Tavares Da Silva Fꎬ et al.Post￣licen￣ sure safety surveillance for human papillomavirus￣16 / 18￣ AS04￣adjuvanted vaccine: more than 4 years of experience [J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Pharmacoepidemiol Drug Safꎬ 2014ꎬ 23: 456￣ 465.[53] Centers for Disease Control and Prevention (CDC).FDA li￣ censure of bivalent human papillomavirus vaccine ( HPV2ꎬ Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immuniza￣ tion Practices ( ACIP ) [ J ].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "MMWR Morb Mortal Wkly Repꎬ 2010ꎬ 59: 626￣ 629.[54] Garland SMꎬ Ault KAꎬ Gall SAꎬ et al.Pregnancy and infant outcomes in the clinical trials of a human papilloma virus type 6 / 11 / 16 / 18 vaccine: a combined analysis of five ran￣ dom￣ized controlled trials [J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Obstet Gynecolꎬ 2009ꎬ 114: 1179￣ 1188.[55] Scheller NMꎬ Pasternak Bꎬ Mølgaard￣Nielsen Dꎬ et al.Quadrivalent HPV Vaccination and the Risk of Adverse Pregn￣ancyOutcomes [ J ].N Engl J Medꎬ 2017ꎬ 376: 1223￣ 1233.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "[56] Landazabal CSꎬ Moro PLꎬ Lewis Pꎬ et al.Safety of 9￣valent human papillomavirus vaccine administration among pregnant women: Adverse event reports in the Vaccine Adverse Event Reporting System ( VAERS)ꎬ 2014 － 2017 [ J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Vaccineꎬ 2019ꎬ 37: 1229￣ 1234.[57] Tan Jꎬ Xiong YQꎬ He Qꎬ et al.Peri￣conceptional or preg￣ nancy exposure of HPV vaccination and the risk of sponta￣ neous abortion: a systematic review and meta￣analysis [ J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "BMC Pregnancy Childbirthꎬ 2019ꎬ 19: 302.[58] Markowitz LEꎬ Dunne EFꎬ Saraiya Mꎬ et al.Human papillo￣ mavirus vaccination: recommendations of the Advisory Com￣ mittee on Immunization Practices ( ACIP ) [ J ].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "MMWR Recomm Repꎬ 2014ꎬ 63: 1￣ 30.[59] Min KJꎬ Kwon SHꎬ Kim Kꎬ et al.Clinical guideline for 9￣ valent HPV vaccine: Korean Society of Gynecologic Onco￣ logy Guideline [J].J Gynecol Oncolꎬ 2019ꎬ 30: e31.[60] Kang WDꎬ Choi HSꎬ Kim SM.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Is vaccination with quadriva￣ lent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high￣grade cervical intraepithelial neoplasia ( CIN2￣3 )?",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "[J].Gynecol Oncolꎬ 2013ꎬ 130: 264￣ 268.[61] Garland SMꎬ Paavonen Jꎬ Jaisamrarn Uꎬ et al.Prior human papillomavirus￣16 / 18 AS04￣adjuvanted vaccin￣ation prevents recurrent high grade cervical intraep￣ithelial neoplasia after definitive surgical therapy: Post￣hoc analysis from a random￣ ized controlled trial [ J ].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Int J Cancerꎬ 2016ꎬ 139: 2812￣ 2826.[62] Ghelardi Aꎬ Parazzini Fꎬ Martella Fꎬ et al.SPERANZA pro￣ ject: HPV vaccination after treatment for CIN2 [ J ].Gynecol Oncolꎬ 2018ꎬ 151: 229￣ 234.[63] Pieralli Aꎬ Bianchi Cꎬ Auzzi Nꎬ et al.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Indication of prophy￣ lactic vaccines as a tool for secondary prevention in HPV￣ linked disease [ J ].Arch Gynecol Obstetꎬ 2018ꎬ 298: 1205￣ 1210.[64] Swedish KAꎬ Factor SHꎬ Goldstone SE.Prevention of recur￣ rent high￣grade anal neoplasia with quadrivalent human pap￣ illomavirus vaccination of men who have sex with men: a nonconcurrent cohort study [J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Clin Infect Disꎬ 2012ꎬ 54: 891￣ 898.[65] Deshmukh AAꎬ Chhatwal Jꎬ Chiao EYꎬ et al.Long￣Term Outcomes of Adding HPV Vaccine to the Anal Intrae￣ pithelial Neoplasia Treatment Regimen in HIV￣Positive Men Who Have Sex With Men [ J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Clin Infect Disꎬ 2015ꎬ 61: 1527￣ 1535.[66] Markowitz LEꎬ Dunne EFꎬ Saraiya Mꎬ et al.Human Papil￣ lomavirus Vaccination: Recommendations of the Advisory Committee on Immunization Practices ( ACIP ) [ EB / OL].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "(2014￣08￣29)[2020￣11￣25].https:/ / www.cdc.gov / mmwr / preview / mmwrhtml / rr6305a1.htm.[67] Hemminki Kꎬ Dong Cꎬ Vaittinen P.Familial risks in cervical cancer: is there a hereditary component?[J].Int J Cancerꎬ 1999ꎬ 82: 775￣ 781.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "[68] Magnusson PKꎬ Lichtenstein Pꎬ Gyllensten UB.Heritability of cervical tumours [J].Int J Cancerꎬ 2000ꎬ 88: 698￣701.[69] Chen Dꎬ Juko￣Pecirep Iꎬ Hammer Jꎬ et al.Genome￣wide association study of susceptibility loci for cervical cancer [J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "J Natl Cancer Instꎬ 2013ꎬ 105: 624￣ 633.[70] Shi YYꎬ Li Lꎬ Hu ZBꎬ et al.A genome￣wide association study identifies two new cervical cancer susceptibility loci at 4q12 and 17q12 [J].Nat Genetꎬ 2013ꎬ 45: 918￣ 922.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "[71] Tovar JMꎬ Bazaldua OVꎬ Vargas Lꎬ et al.Human papillo￣ mavirusꎬ cervical cancerꎬ and the vaccines [ J].Postgrad Medꎬ 2008ꎬ 120: 79￣ 84.[72] Moscicki AB.Impact of HPV infection in adolescent popula￣ tions [J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "J Adolesc Healthꎬ 2005ꎬ 37: S3￣S9.[73] Zhao FHꎬ Forman MRꎬ Belinson Jꎬ et al.Risk factors for HPV infection and cervical cancer among unscreened women in a high￣risk rural area of China [J].Int J Cancerꎬ 2006ꎬ 118: 442￣ 448.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "[74] How CD4 Counts Help Treat HIV and AIDS [ EB / OL ].(2019￣ 06￣ 23) [ 2020￣ 11￣ 26].https:/ / www.webmd.com / hiv￣aids / cd4￣count￣what￣does￣it￣mean.[75] Denny Lꎬ Hendricks Bꎬ Gordon Cꎬ et al.Safety and immu￣ nogenicity of the HPV￣ 16 / 18 AS04￣adjuvanted vaccine in HIV￣positive women in South Africa: a partially￣blind ran￣ domised placebo￣controlled study [J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Vaccineꎬ 2013ꎬ 31: 5745￣ 5753.[76] Kojic EMꎬ Kang Mꎬ Cespedes MSꎬ et al.Immun￣ogenicity and safety of the quadrivalent human papillo￣mavirus vaccine in HIV￣ 1￣infected women [ J].Clin Infect Disꎬ 2014ꎬ 59: 127￣ 135.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "[77] McClymont Eꎬ Lee Mꎬ Raboud Jꎬ et al.The Efficacy of the Quadrivalent Human Papillomavirus Vaccine in Girls and Women Living With Human Immunodeficiency Virus [ J].Clin Infect Disꎬ 2019ꎬ 68: 788￣ 794.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "[78] Mok CCꎬ Ho LYꎬ Fong LSꎬ et al.Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case￣control study [J].Ann Rheum Disꎬ 2013ꎬ 72: 659￣ 664.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "[79] Nelson DRꎬ Neu AMꎬ Abraham Aꎬ et al.Immunogenicity of Human Papillomavirus Recombinant Vaccine in Children with CKD [ J ].Clin J Am Soc Nephrolꎬ 2016ꎬ 11: 776￣ 784.[80] Praditpornsilpa Kꎬ Kingwatanakul Pꎬ Deekajorndej Tꎬ et al.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Immunogenicity and safety of quadrivalent human papilloma￣ virus types 6 / 11 / 16 / 18 recombinant vaccine in chronic kidney disease stage IVꎬ V and VD [ J ].Nephrol Dial Transplantꎬ 2017ꎬ 32: 132￣ 136.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "[81] Reinholdt Kꎬ Thomsen LTꎬ Dehlendorff Cꎬ et al.Human papil￣ lomavirus￣related anogenitalpremalignancies and cancer in renal transplant recipients: A Danish nationwideꎬ registry￣based cohort study [J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Int J Cancerꎬ 2020ꎬ 146: 2413￣ 2422.[82] Kumar Dꎬ Unger ERꎬ Panicker Gꎬ et al.Immuno￣ genicity of quadrivalent human papillomavirus vaccine in organ trans￣plant recipients [ J ] .Am J Transplantꎬ 2013ꎬ 13: 2411￣ 2417.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "[83] CIOMS Working Groups.Guidelines for Preparing Core Clin￣ ical￣Safety Information on Drugs [ M / OL].[ 2020￣ 11￣ 26].https: / / cioms.ch / wp￣content / uploads / 2018 / 03 / Guidelines￣ for￣Preparing￣Core￣Clinical￣Safety￣Info￣Drugs￣Report￣of￣CI￣ OMS￣Working￣Group￣Ⅲ￣and￣Ⅴ.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "pdf.[84] Reiter PLꎬ Brewer NTꎬ Gottlieb SLꎬ et al.How much will it hurt?HPV vaccine side effects and influence on completion of the three￣dose regimen [ J ].Vaccineꎬ 2009ꎬ 27: 6840￣ 6844.[85] Einstein MHꎬ Baron Mꎬ Levin MJꎬ et al.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus ( HPV) cervical cancer vaccines in healthy women aged 18 － 45 years [ J].Hum Vaccinꎬ 2009ꎬ 5: 705￣ 719.[86] Einstein MHꎬ Baron Mꎬ Levin MJꎬ et al.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Comparative im￣ munogenicity and safety of human papillomavirus ( HPV)￣ 16 / 18 vaccine and HPV￣ 6 / 11 / 16 / 18 vaccine: follow￣up from months 12 － 24 in a Phase Ⅲ randomized study of healthy women aged 18－45 years [J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Hum Vaccinꎬ 2011ꎬ 7: 1343￣ 1358.[87] Zhu FCꎬ Hu SYꎬ Hong Yꎬ et al.Efficacyꎬ immunogenicityꎬ and safety of the HPV￣ 16 / 18 AS04￣adjuvanted vaccine in Chinese women aged 18 － 25 years: event￣triggered analysis of a randomized controlled trial [ J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Cancer Medꎬ 2017ꎬ 6: 12￣ 25.[88] Chen Wꎬ Zhao Yꎬ Xie Xꎬ et al.Safety of a quadrivalent hu￣ man papillomavirus vaccine in a Phase 3ꎬ randomizedꎬ double￣blindꎬ placebo￣controlled clinical trial among Chinese women during 90 months of follow￣up [ J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Vaccineꎬ 2019ꎬ 37: 889￣ 897.[89] Moreira ED Jrꎬ Block SLꎬ Ferris Dꎬ et al.Safety Profile of the 9￣Valent HPV Vaccine: A Combined Analysis of 7 Phase Ⅲ Clinical Trials [J].Pediatricsꎬ 2016ꎬ 138: e20154387.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "[90] Lu Bꎬ Kumar Aꎬ Castellsagué Xꎬ et al.Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review ＆ meta￣analysis [J].BMC Infect Disꎬ 2011ꎬ 11: 13.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "[91] Yih WKꎬ Greene SKꎬ Zichittella Lꎬ et al.Evaluation of the risk of venous thromboembolism after quadrivalent human papillomavirus vaccination among US females [J].Vaccineꎬ 2016ꎬ 34: 172￣ 178.[92] Centers for Disease Control and Prevertion.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "HPV Vaccine Safety and Effectiveness Data [ EB / OL].( 2019￣ 11￣ 15 ) [ 2020￣ 11￣ 26 ].https: / / www.cdc.gov / hpv / hcp / vaccine￣ safety￣data.html.(收稿: 2021￣ 01￣ 22 录用: 2021￣ 01￣ 22 在线: 2021￣ 02￣ 01)(本文编辑: 李玉乐)",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "# 美国国家综合癌症网络肿瘤学临床实践指南（NCCN Guidelines®） # 宫颈癌 中文版 2022.V1——2021.10.26 NCCN.org # NCCN Guidelines Version 1.2022 宫颈癌 \\*Nadeem R.Abu-Rustum, MD Ω/Chair Memorial Sloan Kettering Cancer Center \\*Catheryn M.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Yashar, MD §/Vice Chair UC San Diego Moores Cancer Center Kristin Bradley, MD $\\ S$ University of Wisconsin Carbone Cancer Center Rebecca Broks, MD Ω UC Davis Comprehensive Cancer Center Susana M.Campos, MD, MPH, MS † Dana-Farber/Brigham and Women’s Cancer Center Junzo Chino, MD $\\ S$ Duke Cancer Institute Hye Sook Chon, MD Ω Moffitt Cancer Center Christina Chu, MD Ω Fox Chase Cancer Center David Cohn, MD Ω The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute Marta Ann Crispens, MD Ω Vanderbilt-Ingram Cancer Center Shari Damast, MD $\\ S$ Yale Cancer Center/ Smilow Cancer Hospital Elisabeth Diver, MD Ω Stanford Cancer Institute Christine M.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Fisher, MD, MPH $\\ S$ University of Colorado Cancer Center Peter Frederick, MD Ω Roswell Park Cancer Institute David K.Gaffney, MD, PhD $\\ S$ Huntsman Cancer Institute at the University of Utah Robert Giuntoli II, MD Ω Abramson Cancer Center at the University of Pennsylvania Ernest Han, MD, PhD Ω City of Hope National Medical Center Brooke E.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Howitt, $M D \\neq$ Stanford Cancer Institute Warner K.Huh, MD Ω O'Neal Comprehensive Cancer Center at UAB Jayanthi Lea, MD Ω UT Southwestern Simmons Comprehensive Cancer Center Andrea Mariani, MD Ω Mayo Clinic Cancer Center David Mutch, MD Ω Siteman Cancer Center at Barnes- Jewish Hospital and Washington University School of Medicine Larissa Nekhlyudov, MD, MPH Þ Dana-Farber/Brigham and Women’s Cancer Center Mirna Podoll, MD ≠ Vanderbilt-Ingram Cancer Center Ω 妇科肿瘤学 Þ 内科学 † 医学肿瘤学 § 放射治疗/放射肿瘤学 ≠ 病理学 ¥ 患者宣教 讨论部分撰写委员会 Steven W.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Remmenga, MD Ω Fred & Pamela Buffett Cancer Center R.Kevin Reynolds, MD Ω University of Michigan Rogel Cancer Center Ritu Salani, MD, MBA Ω UCLA Jonsson Comprehensive Cancer Center Rachel Sisodia, MD Ω Massachusetts General Hospital Cancer Center Pamela Soliman, MD, MPH Ω The University of Texas MD Anderson Cancer Center Edward Tannder, MD Robert H.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Lurie Comprehensive Cancer Center of Northwestern University Stefanie Ueda, MD Ω UCSF Helen Diller Family Comprehensive Cancer Center Renata Urban, MD Ω Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance Stephanie L.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Wethington, MD MSc Ω The Sidney Kimmel Comprehensive Cancer Venter at Johns Hopkins Emily Wyse ¥ Patient Advocat Kristine Zanotti, MD Ω Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Insititute NCCN Nicole McMillian, MS Angela Motter, PhD # NCCN特别鸣谢美国国家综合癌症网络肿瘤学临床实践指南（NCCN Guidelines®）宫颈癌中文版专家组 <html><body><table><tr><td colspan=\"2\">主编：</td><td colspan=\"2\">副主编：</td><td rowspan=\"2\"></td></tr><tr><td>周琦</td><td>王丹波 辽宁省肿瘤医院</td><td>李力 广西医科大学附属肿瘤医院</td><td>盛修贵 中国医学科学院肿瘤医院深圳医院</td></tr><tr><td>重庆大学附属肿瘤医院</td><td></td><td></td><td></td><td></td></tr><tr><td>编委：</td><td></td><td></td><td></td><td></td></tr><tr><td>蔡红兵 武汉大学中南医院妇瘤科</td><td>陈锐</td><td>郭红燕 北京大学第三医院</td><td>古扎丽努尔·阿不力孜 新疆医科大学附属肿瘤医院</td><td></td></tr><tr><td></td><td>重庆大学附属肿瘤医院</td><td></td><td></td><td></td></tr><tr><td>黄鹤</td><td>黄曼妮</td><td>黄欣</td><td>黄奕 湖北省肿瘤医院</td><td></td></tr><tr><td>中山大学肿瘤防治中心</td><td>中国医学科学院肿瘤医院</td><td>中山大学肿瘤防治中心</td><td></td><td></td></tr><tr><td>柯桂好</td><td>康山</td><td>娄阁</td><td>李</td><td>复旦大学附属肿瘤医院</td></tr><tr><td>复旦大学附属肿瘤医院</td><td>河北医科大学第四医院</td><td>哈尔滨医科大学附属肿瘤医院</td><td></td><td></td></tr><tr><td>刘开江</td><td>刘乃富</td><td>刘淑娟</td><td>龙行涛</td><td>重庆大学附属肿瘤医院</td></tr><tr><td>上海交通大学医学院附属仁济医院 山东省肿瘤医院</td><td></td><td>空军军医大学西京医院</td><td></td><td></td></tr><tr><td>沈丹华</td><td>沈杨</td><td>佟锐</td><td>田小飞</td><td></td></tr><tr><td>北京大学人民医院</td><td>东南大学附属中大医院</td><td>辽宁省肿瘤医院</td><td></td><td>陕西省肿瘤医院</td></tr><tr><td>王莉</td><td>邹冬玲</td><td>张国楠</td><td>张新</td><td></td></tr><tr><td>河南省肿瘤医院</td><td>重庆大学附属肿瘤医院</td><td>四川省肿瘤医院/电子科技大学 医学院附属肿瘤医院</td><td>辽宁省肿瘤医院</td><td></td></tr></table></body></html> # 学术秘书（兼）： 龙行涛 佟 锐重庆大学附属肿瘤医院 辽宁省肿瘤医院 # NCCN宫颈癌委员会成员名单指南更新摘要 临床试验：NCCN认为对任何癌症患者的最佳治疗方法是参加临床试验。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "特别鼓励癌症患者参加临床试验。查找NCCN会员机构： http://www.nccn.org/home/member-institutions.临床分期（CERV-1） IA1期（无LVSI）、IA1期（伴LVSI）、IA2期、IB1期和选择性IB2期（保留生育能力）（CERV-2） IA1期（无LVSI）， IA1期（伴LVSI）和IA2期（不保留生育能力）（CERV-3） IB1期、IB2期和IIA1期（不保留生育能力）（CERV-4） IB3期、IIA2期（不保留生育能力）（CERV-4） IB3期、IIA2期、IIB期、III期和IVA期（CERV-6） 单纯子宫切除术后意外发现浸润性癌（CERV-9） 监测（CERV-10） 局部/区域复发（CERV-11） IVB期或远端转移（CERV-12） 宫颈小细胞神经内分泌癌（NECC）（CERV-13） NCCN证据和共识类别：除非另有说明，所有建议均为2A类。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "参见NCCN证据和共识类别。NCCN的倾向性类别：所有建议都被认为是适当的。参见NCCN倾向性类别。病理学原则（CERV-A） 影像学原则（CERV-B） 评估和手术分期原则（CERV-C） 放疗原则（CERV-D） 根治性子宫切除术后淋巴结阴性、切缘阴性、宫旁阴性病例盆腔外放射的Sedlis标准（CERV-E） 宫颈癌的全身性治疗（CERV-F） 妇科肿瘤患者生存原则（CERV-G） 分期 （ST-1） # 宫颈癌的NCCN指南包括宫颈鳞状细胞癌、腺鳞癌、腺癌和小细胞神经内分泌癌的管理。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "NCCN指南®包含证据声明和作者对目前公认的治疗方法的观点的共识。任何寻求应用或查询NCCN指南的临床医生都应根据个体临床情况使用独立的医疗判断来决定患者的护理或治疗措施。国家癌症综合网络®(NCCN®)对其内容、使用或应用不作任何形式的陈述或保证，并对其以任何方式使用或应用不承担任何责任。NCCN指南由国家综合癌症网络®版权所有，并保留所有权利。未经NCCN明确书面许可，不得以任何形式复制NCCN指南和其中的插图。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "$\\mathbb { O } 2 0 2 1$ 。权所有， 2022第一版，国家综合癌症网®（NCCN $\\circledast$ ） $\\circledcirc$ 2021 ， 10/26/2021发布。未经明确的书面许可，不得翻印任何形式的NCCN指南®及其解读。# NCCN Guidelines Version 1.2022 宫颈癌 NCCN宫颈癌指南2022.V1较2021.V1的更新包括:CERV-3 删除以下脚注（CERV-4的也删除） 基于常规外照射分割和低剂量率（40-70cGy/h）近距离放疗当量的总和，推荐大多数患者使用这些剂量。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "根据正常组织的耐受性、放疗分割方法和靶区大小调整方案。（见讨论）。A点总剂量一般为70-80Gy。# CERV-10  疾病持续或复发；在“检查”项下方增加两个新的条目：  考虑使用经验证的和/或FDA批准的检测方法进行全面的基因组分析（CGP）  如果转移灶组织活检不可行或无法获取组织，可考虑使用经验证的血浆ctDNA检测进行CGP # CERV-A 病理学原则 # 第1页/共3页 病理学评估  增加新的次条目：推荐对复发、进展或转移性疾病患者进行PD-L1检测  修订次级条目：推荐对复发、进展或转移性疾病患者进行MMR/MSI，PD-L1和（或）NTRK基因融合检测；和（或）对宫颈肉瘤患者进行NRTK基因融合检测 # 第2页/共3页 宫颈神经内分泌癌  组织学描述；修订第4个次级条目：与肺神经内分泌癌相似该肿瘤类型在形态学上与肺神经内分泌癌相似。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "免疫组织化学  小细胞NECC中嗜铬颗粒、CD56、突触素和PGP9.5呈不同程度阳性。# CERV-B 影像学原则 # 第1页/共4页 初始检查 Ⅰ期：该部分被大幅度修订。# CERV-B 影像学原则（续）  初始检查；II-IVA期  修订第1个次级条目：考虑行盆腔MRI增强扫描以评估局部病灶范围（首选）。 删除次级条目：考虑行盆腔MRI增强扫描以评估局部病灶范围。# 第3页/共4页 小细胞NECC：该部分被大幅度修订。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "# CERV-D 放疗原则 # 第3页/共6页  术中放疗：“……IORT通常使用电子线、近距离放疗或微型X射线源，可选择不同大小的施源器……” # 第4页/共6页 治疗信息-近距离放疗；修订第1个条目：“……近距离放疗前或近距离放疗期间行MRI检查，有助于勾画残留肿瘤形状……” # 第5页/共6页 剂量处方方案-近距离放疗 修订第1个条目：“……单个肿瘤与正常组织结构没有相关性。传统的A点剂量是基于经广泛验证的LDR近距离放疗的剂量分割所给出的。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "采用LDR的A点剂量为40-70cGy/h。传统LDR A点处方剂量为70-80Gy。通常，A点的处方剂量为早期病变5.5Gy×5次，肿瘤较大或退缩不佳时6Gy×5次。另一个合理选择是28Gy，分4次完成，该方案作为高危CTV的腔内照射剂量在欧洲的临床试验中被充分研究。” 新增条目：“对于联合EBRT的近距离放疗，外照射剂量为每日1.8-2.0Gy。如果采用高剂量率（HDR）近距离放疗，临床医生应当依据线性二次方程将标称HDR剂量转化成生物等效的LDR剂量（http://www.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "americanbrachytherapy.org/guidelines/）。HDR分割剂量（标称剂量6Gy×5次）的总标称剂量为30Gy，分5次完成，相当于采用LDR近距离放疗时A点的等效剂量为40Gy（肿瘤等效剂量）。” 更新 版权所有， 2022第一版，国家综合癌症网®（NCCN $\\circledast$ ） $\\circledcirc$ 2021 ， 10/26/2021发布。未经明确的书面许可，不得翻印任何形式的NCCN指南®及其解读。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "# NCCN Guidelines Version 1.2022 宫颈癌 # CERV-D 放疗原则（续） # 第5页/共6页 删除条目：“NCCN指南中A点剂量推荐是基于传统的并已经广泛证实的剂量分割及低剂量率(LDR)近距离放疗所给出的。在这些剂量推荐中，对EBRT而言，剂量分割为每日1.8-2.0Gy。对于近距离放疗，采用LDR的A点剂量为40-70cGy/h。如果采用高剂量率（HDR）近距离放疗，临床医生应当依据线性二次方程将标称HDR剂量转化成生物等效的LDR剂量（http://www.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "americanbrachytherapy.org/guidelines/）。当与EBRT联合时，近距离放疗有多种方案。但是，较为常用的其中一种HDR方法是5次置入放射源串联的宫腔管和阴道模具，每次6Gy。这个方案的标称HDR总剂量为30Gy，分5次完成，相当于采用LDR近距离放疗时A点的等效剂量为40Gy（肿瘤等效剂量）。另一个合理的选择是给予总剂量28Gy，分4次完成，该方案作为高危CTV的腔内照射剂量在欧洲的临床试验中被充分研究。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "# CERV-F 宫颈癌的系统治疗 # 第1页/共3页  鳞状细胞癌、腺癌或腺鳞癌 一线联合治疗；首选方案；新增以下方案： ◇帕博利珠单抗＋顺铂/紫杉醇±贝伐珠单抗（适用于PD-L1阳性肿瘤）（1类） ◇帕博利珠单抗+卡铂/紫杉醇±贝伐珠单抗（适用于PD-L1阳性肿瘤）（1类） 列标题修改为“二线或后续治疗”（CERV-F 第2页/共3页同时修 改）◇首选方案：增加纳武利尤单抗为PD-L1阳性肿瘤的2A类推荐。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "◇ 其他推荐方案：增加Tisotumab vedotin-tftv为2A类推荐。 修订脚注c：这些药物若先前未使用过，可根据临床适用情况作为二线或后续治疗。修订脚注e：推荐用于在化疗中或化疗后疾病进展的肿瘤表达PD-L1（CPS≥1，经FDA批准的检测方法确定）的患者。修订脚注f：二线治疗的更多参考文献见讨论章节。修订脚注h：“……（采用一种经验证的和/或FDA批准的方法检测）的肿瘤，既往治疗后疾病进展且没有其它合适的治疗选择的患者。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "” # 第2页/共3页 修订脚注k：“……（如果既往没有使用过）可用作小细胞神经内分泌癌的二线或后续治疗”。# 第3页/共3页 更新了参考文献 CERV-G 妇科肿瘤患者生存原则 修订社会心理影响：患癌后的社会心理变化可包括心理方面（例如抑郁、焦虑、对复发和身体形象改变的恐惧）、经济影响方面（例如重返工作、保险问题）和/或人际关系影响方面的（例如亲朋关系、性、亲密行为）。临床方法 第1个条目：“（……侧重慢性疾病管理，监测心血管疾病危险因素，建议接种疫苗……” 第2个条目：“……体检，并实施提供必要的影像学和/或实验室检查。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "对于所有女性患者（无论是否处于性活跃状态），均应询问关于泌尿生殖系统症状（包括外阴阴道干燥）的问题……” 新增条目：对于绝经前患者，应考虑激素替代治疗。![](images/54c69a11f2e28ca4a132544c0cc45281368eda9b5bd7cd9f9e0c4930fb5c88df.jpg) 指南中的所有分期均根据FIGO 2018版分期.（请见ST-1） d.考虑行HIV检查（特别是年轻患者）。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "携带HIV的宫颈癌患者应转诊给HIV专家，并按照指南治疗宫颈癌。不应仅因为HIV状态而调整肿瘤治疗方案。e.若怀疑膀胱/肠道受侵，需要行膀胱镜/直肠镜下活检。注：除非另有说明，所有建议均为2A类。临床试验： NCCN认为任何癌症患者最好的处理方式是参与临床研究。尤其鼓励癌症患者参加临床试验。f.IB期保留生育能力手术多数应用在肿瘤≤2cm的患者。小细胞神经内分泌癌（既往患有）和胃型腺癌被认为不适用此种手术。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "g.见评估和手术分期原则（CERV-C）。h.没有数据能够支持保留生育能力的手术可以用于小细胞神经内分泌肿瘤、胃型腺癌或恶性腺瘤。对于已生育的女性是否行全子宫切除术，患者和医生可权衡利弊斟酌决定，但强烈建议宫颈涂片结果持续异常或慢性持续性HPV感染的女性接受该手术。i.建议请生殖内分泌专家会诊 j.冷刀锥切术（CKC）是首选的诊断切除方法，环形电刀切除术（LEEP）只要可获得充分的切缘和适宜的定位也可选择。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "应根据临床需要加做宫颈搔刮术（ECC）。k.应保证切缘无浸润性病变或组织学高级别鳞状细胞上皮内病变（HSIL）。l.SLN显影在肿瘤＜2cm的患者中可以获得最佳的检测率和显影结果。注：除非另有说明，所有建议均为2A类。临床试验： NCCN认为对任何癌症患者最好的处理方法是参与临床研究。尤其鼓励癌症患者参加临床试验。c.见影像学原则（CERV-B）。g.见评估和手术分期原则（CERV-C）。j.冷刀锥切术（CKC）是首选的诊断切除方法，环形电刀切除术（LEEP）只要可获得充分的切缘和适宜的定位也可选择。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "应根据临床需要加做宫颈搔刮术（ECC）。m.医学原因无法手术或拒绝手术者可选择放疗。n.见放疗原则（CERV-D）。o.对于较高危的患者（例如IA2伴LVSI），可以考虑行EBRT联合同步含铂化疗（使用顺铂单药；如果顺铂不耐受，使用卡铂）。注：除非另有说明，所有建议均为2A类。临床试验： NCCN认为对任何癌症患者最好的处理方法是参与临床研究。尤其鼓励癌症患者参加临床试验。c.见影像学原则（CERV-B）。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "g.见评估和手术分期原则（CERV-C）。l.SLN显影在肿瘤＜2cm的患者中可以获得最佳的检测率和显影结果。m.医学上无法手术或拒绝手术者可选择放疗。n.见放疗原则（CERV-D）。p.EBRT联合同步含铂化疗使用顺铂单药，如果顺铂不耐受，使用卡铂。q.对于因肿瘤范围广、外照射 (EBRT) 有效，或子宫解剖结构使近距离放疗无法充分覆盖病灶的患者可以考虑这一治疗。注：除非另有说明，所有建议均为2A类。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "临床试验： NCCN认为对所有癌症患者最好的处理方法是参与临床研究。尤其鼓励癌症患者参加临床试验。r.危险因素不仅限于Sedlis标准。见Sedlis标准（CERV-E）。s.见宫颈癌的系统治疗（CERV-F）。注：除非另有说明，所有建议均为2A类。临床试验： NCCN认为对任何癌症患者最好的处理方法是参与临床研究。尤其鼓励癌症患者参加临床试验。c.见影像学原则（CERV-B）。g.见评估和手术分期原则（CERV-C）。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "n.见放疗原则（CERV-D）。p.EBRT联合同步含铂化疗使用顺铂单药，如果顺铂不耐受，使用卡铂。注：除非另有说明，所有建议均为2A类。临床试验： NCCN认为对所有癌症患者最好的处理方法是参与临床研究。尤其鼓励癌症患者参加临床试验。注：除非另有说明，所有建议均为2A类。临床试验： NCCN认为对所有癌症患者最好的处理方法是参与临床研究。尤其鼓励癌症患者参加临床试验。注：除非另有说明，所有建议均为2A类。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "临床试验： NCCN认为对所有癌症患者最好的处理方法是参与临床研究。尤其鼓励癌症患者参加临床试验。注：除非另有说明，所有建议均为2A类。临床试验： NCCN认为对所有癌症患者最好的处理方法是参与临床研究。尤其鼓励癌症患者参加临床试验。![](images/44253a150253035efc5b38a0284766658d21f3b9caeb561fc032d6fa7e9a70e5.jpg) ![](images/3f9b5003ae4e97e0f6e124ae6526283157fcaa69d67404262d86203f2f0e02a0.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "jpg) ![](images/3decf4ee33eafbc66382e998cec3e78cd644554791f16cc967f36b78632ad34d.jpg) ![](images/bc591b9a89b83f796cdc8cad0fe5139767b365a6513224cd88624d368fda0afe.jpg) ![](images/5a8d52474aeaf435adaf4872adacb55dbef85057f45d8c1c6c32f955892f8f57.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "jpg) ![](images/676fcbb88d4b683f4f8522c3573d486ff7244608ee89d43d2884101e456c79c0.jpg) ![](images/0202a19ddbfd376c44db4398b4016a25cb26b516578c309ae0291951497e8bde.jpg) ![](images/95d1c92119eb43d8939225bacc5704b658bdeb00a39deb7a3311ece040f29801.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "jpg) # 监测y ![](images/98824d5683b71cfb8833937d13809c81288833260b49649d6c1e23dea23edc0a.jpg) # c.见影像学原则（CERV-B） y.Salani R et al.Gynecol Oncol 2017;146:3-10.z.尽管常规细胞学检查在监测宫颈癌复发方面的价值有限，但是可以考虑用于检测下生殖道异型增生和用于免疫功能低下的患者。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "单用细胞学检查检出无症状复发的可能性很低。aa.对于接受过盆腔放疗的患者，细胞学检査结果的准确性可能会受到影响。bb.在制定治疗计划前，应通过活检确认肿瘤复发。cc.见妇科肿瘤患者生存原则（CERV-G）。注：除非另有说明，所有建议均为2A类。临床试验： NCCN认为对所有癌症患者最好的处理方法是参与临床研究。尤其鼓励癌症患者参加临床试验。注：除非另有说明，所有建议均为2A类。临床试验： NCCN认为对任何癌症患者最好的处理方法是参与临床研究。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "尤其鼓励癌症患者参加临床试验。n.见放射治疗原则（CERV-D）。s.见宫颈癌的系统治疗（CERV-F）。dd.由经过验证和/或FDA批准的方法确定，考虑采用肿瘤突变负荷（TMB）检验。ee.Perkins V, Gynecol Oncol 2020 Jan;156(1):100-106.![](images/5d91cf74fc304d82e81ac346d85c20c6eb50e8b30c86d101802ff7a26663821e.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "jpg) n.见放疗原则（CERV-D）p.EBRT联合同步含铂化疗使用顺铂单药，如果顺铂不耐受，使用卡铂。s.见宫颈癌的系统治疗（CERV-F）。![](images/f17a6fd5eec87ad44075442446283f227deb1b68e2d74067927a435e8709cf4a.jpg) 注：除非另有说明，否则所有建议均为2A类。临床试验： NCCN认为对任何癌症患者最好的处理方法是参与临床研究。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "尤其鼓励癌症患者参加临床试验 ![](images/238b28b594c275d3a4637daa391fabdb07fe310e34ccfd9ef4d665b17ab8ab28.jpg) 宫颈小细胞神经内分泌癌a a.见病理学原则（CERV-A）。c.见影像学原则（CERV-B）。g.见评估和手术分期原则（CERV-C）。n.见放疗原则（CERV-D）。s.见宫颈癌的系统治疗（CERV-F）。ff,外照射联合同步含铂方案化疗使用顺铂（如果顺铂不耐受，使用卡铂） $^ +$ 依托泊苷。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "注：除非另有说明，否则所有建议均为2A类。临床试验： NCCN认为对所有癌症患者最好的处理方法是参与临床研究。尤其鼓励癌症患者参加临床试验。c.见影像学原则（CERV-B）。g.见评估和手术分期原则（CERV-C）。n.见放射治疗原则（CERV-D）。s.见宫颈癌的系统治疗（CERV-F）。ff,外照射联合同步含铂化疗使用顺铂（如果顺铂不耐受，使用卡铂） $^ +$ 依托泊苷。注：除非另有说明，否则所有建议均为2A类。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "临床试验： NCCN认为对所有癌症患者最好的处理方法是参与临床研究。尤其鼓励癌症患者参加临床试验。![](images/a25de69c0c4ad859bc8dd6e66d757421d34767eaf7c40156e3f8fecc7c15ff2e.jpg) 宫颈小细胞神经内分泌癌 # 鳞状细胞癌、腺癌或腺鳞癌 # 病理学原则1 手术根治性子宫切除术病理学评估: 子宫$\\diamondsuit$ 子宫切除术类型（适用时）$\\diamondsuit$ 肿瘤部位$\\diamondsuit$ 肿瘤大小，包括最大径和其他两个径向$\\diamondsuit$ 组织学类型a$\\diamondsuit$ 组织学分级$\\diamondsuit$ 间质浸润(浸润深度[单位：mm]/宫颈壁厚度[单位：mm]) b$\\diamondsuit$ 肿瘤扩散宽度（单位：mm）$\\diamondsuit$ 手术切缘情况-如果切缘阴性，包括最近的切缘和距最近切缘的距离(单位-如果切缘阳性，包括阳性切缘的位置c $\\diamondsuit$ 脉管间隙是否受累（不会影响FIGO 2018版分期2）其他组织/器官受累(宫旁、阴道断端、输卵管、卵巢、腹膜、大网膜、其他)淋巴结(已切除标本) 应对前哨淋巴结（SLN）进行超分期以检测是否有微小转移非SLN不需要超分期，可按照常规程序进行处理包括肿瘤细胞分离、微转移和宏转移的淋巴结数目分离的肿瘤细胞分期记为pN0(i+) 对复发、进展或转移患者推荐行PD-L1检测对复发、进展或转移患者推荐行MMR/MSI检测；和/或对宫颈肉瘤患者进行NTRK基因融合检测3，4考虑采用经过验证和/或FDA批准的方法进行肿瘤突变负荷（TMB）检测5 a.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "根据2018年国际宫颈腺癌标准和分类(IECC) 6，形态学特征(管腔面可见核分裂象和凋亡)可以用于区分人类乳头瘤病毒(HPV)相关性宫颈管腺癌和非HPV相关性腺癌。可根据形态学特征对肿瘤进一步分型。b.评估宫颈管腺癌浸润的组织学模式是一个新近提出的概念7，8，9。目前已经描述了三种有临床意义的宫颈腺癌浸润的组织学模式。A型浸润的肿瘤(腺体边界清楚、圆形轮廓、无单个细胞、无促纤维增生性间质反应、无淋巴管血管侵袭)生存率高，无淋巴结转移或复发7。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "c.这些信息虽然不是必需提供，但了解这些信息有助于制定多学科治疗计划。d.超分期通常需要对SLN进行连续切片，并对多张经 HE 染色的切片进行复核，针对所有SLN组织块行细胞角蛋白免疫组化染色可有可无。目前尚缺乏淋巴结超分 期的标准流程。注：除非另有说明，所有建议均为2A类。临床试验： NCCN认为对所有癌症患者最好的处理方法是参与临床研究。尤其鼓励癌症患者参加临床试验。# 病理学原则10-13 # 宫颈神经内分泌癌（NECC） 组织学描述 尽管非常少见，仅占不到宫颈癌的5%，但在女性生殖道中，宫颈是高级别神经内分泌癌(如小细胞和大细胞神经内分泌癌)最常见的发生部位。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "临床上具有高侵袭性、转移快的特点，大多数预后不良。通常与HPV相关，16型和18型最为常见（18型比16型更常见）。该类肿瘤在形态学上与肺神经内分泌癌相似。小细胞NECC是一种形态学诊断，无论其免疫组化染色结果如何。主要呈弥漫性生长。其他的生长模式包括岛状(实性细胞巢/细胞岛，周围细胞呈栅栏状，伴有间质退缩改变)，也可围绕血管周围或呈宽的梁状波浪状生长。可伴有假腺管状和玫瑰形团样结构。细胞学特征包括形态一致的细胞，边界不清，细胞质稀少，细胞核深染，染色质呈细颗粒状。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "常见大量核分裂现象和凋亡碎片。其他特征包括细胞核成型及核仁不明显。常见坏死。可伴发宫颈腺性病变(癌前病变或明确恶性)。视情况而定，考虑将其诊断为腺癌伴神经内分泌癌。区分小细胞和大细胞NECC较为困难或不可能；在这些情况下宜使用“高级别NECC”一词。免疫组织化学  小细胞NECC中嗜铬粒蛋白、CD56和突触素呈不同程度阳性。◇CD56和突触素是最敏感的神经内分泌标志物，但CD56缺乏特异性。◇嗜铬粒蛋白是最特异的神经内分泌标志物，但缺乏敏感性，只有约50%-60%的小细胞NECC呈阳性。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "14-15◇神经元特异性烯醇化酶(NSE)和突触素是另外的神经内分泌肿瘤标志物，阳性率分别为80%和70%。14-15  如果肿瘤呈现小细胞NECC的典型形态学特征，则可在缺乏神经内分泌标志物免疫组化染色阳性的情况下作出诊断(不适用于大细胞NECC的诊断)。 小细胞NECC对于广谱细胞角蛋白可能仅局灶性阳性(常为点状胞浆染色)，甚至可能是阴性。 原发性高级别NECC中TTF1阳性的比例较高，部分呈弥漫性免疫反应性，该标志物在与肺转移性癌进行鉴别区分中没有价值。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": " 由于存在高危HPV，大多数高级别NECC呈p16弥漫阳性。然而，p16阳性不能用来确定肿瘤来源部位；其他部位的神经内分泌癌可强表达p16，但其是非HPV相关性机制所致。 已在一些高级别NECC中发现肽激素，包括促肾上腺皮质激素、血清素、生长抑素、降钙素、胰高血糖素和胃泌素等。注：除非另有说明，所有建议均为2A类。临床试验： NCCN认为对所有癌症患者最好的处理方法是参与临床研究。尤其鼓励癌症患者参加临床试验。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "# 病理学原则参考文献 1 Krishnamurti U, Movahedi-Lankarani S, Bell DA, et al.Protocol for the Examination of Specimens from Patients with Primary Carcinoma of the Uterine Cervix.College of American Pathologists 2018.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "2 Bhatla N, Berek JS, Fredes MC, et al.Revised FIGO Staging for carcinoma of the cervix uteri.Int J Gynecol Obstet 2019;145:129-135 and Corrigendum to \"Revised FIGO Staging for carcinoma of the cervix uteri” [Int J Gynecol Obstet 2019;145:129-135] Int J Gynecol Obstet 2019;147:279-280.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "3 Minion LE, Tewari KS.Cervical cancer - State of science: From angiogenesis blockade to checkpoint inhibition.Gynecol Oncol 2018; Mar;148(3):609-621.4 Chung HC, Schellens JH, Delord J-P, et al.Pembrolizumab treatment of advanced cervical cancer: Updated results from the phase 2 KEYNOTE-158 study.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "J Clin Oncol 2018:36; (suppl; abstr 5522).5 Merino DM, McShane LM, Fabrizio D, et al.Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "J Immunother Cancer 2020;8:e000147.doi:10.1136/jitc-2019-000147.6 Stolnicu S, Barsan I, Hoang L, et al.International Endocervical Adenocarcinoma Criteria and Classification (IECC): A New Pathogenetic Classification for Invasive Adenocarcinomas of the Endocervix.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Am J Surg Pathol 2018 Feb;42(2):214-226.7 Diaz De Vivar A, Roma AA, Park KJ, et al.Invasive endocervical adenocarcinoma: proposal for a new pattern-based classification system with significant clinical implications: a multi-institutional study.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Gynecol Pathol 2013 Nov;32(6):592-601.8 Roma AA, Mistretta TA, Diaz De Vivar A, et al.New pattern-based personalized risk stratification system for endocervical adenocarcinoma with important clinical implications and surgical outcome.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2016 Apr;141(1):36-42.9 Spaans VM, Scheunhage DA, Barzaghi B, et al.Independent validation of the prognostic significance of invasion patterns in endocervical adenocarcinoma: Pattern A predicts excellent survival.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2018;151:196-201.10 Rindi G, Klimstra DS, Abedi-Ardekani B, et al.A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Mod Pathol 2018;31(12):1770-1786.11 Howitt BE, Kelly P, McCluggage WG.Pathology of neuroendocrine tumours of the female genital tract.Curr Oncol Rep 2017 Sep;19(9):59.12 Ganesan R, Hirschowitz L, Dawson P, et al.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Neuroendocrine carcinoma of the cervix: Review of a series of cases and correlation with outcome.Int J Surg Pathol.2016;24(6):490-496.13 Perunovic B, Sunassee A.Small cell (neuroendocrine / undifferentiated) carcinoma.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "PathologyOutlines.com website (http://www.pathologyoutlines.com/topic/ cervixsmallcell.html).14 Wang HL, Lu DW.Detection of human papillomavirus DNA and expression of p16, Rb, and p53 proteins in small cell carcinomas of the uterine cervix.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Am J Surg Pathol 2004 Jul;28(7):901-908.15 Masumoto N, Fujii T, Ishikawa M, et al.P16 overexpression and human papillomavirus infection in small cell carcinoma of the uterine cervix.Hum Pathol 2003 Aug;34(8):778-783.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "# 影像学原则a，1-9 # 初始检查 I期 不保留生育功能 ◇考虑行盆腔MRI增强扫描以评估局部病灶范围（对于FIGO IB1-IB3期是首选推荐）。◇ 对于FIGO分期IB1-IB3期，行颈/胸/腹/盆腔/腹股沟PET/CT（首选）或胸/腹/盆腔CT或PET/MRI检查。◇全子宫切除术后意外发现的宫颈癌，考虑行颈/胸/腹/盆腔/腹股沟PET/CT或胸/腹/盆腔CT以评估转移情况，行盆腔MRI以评估盆腔残留病灶。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "◇对于有转移的疾病，应根据症状及临床体征，酌情行其他影像学检查b。保留生育功能 ◇行盆腔MRI检查（首选）以评估局部病灶范围以及肿瘤与宫颈内口的距离；不适合行MRI检查者行经阴道超声检查。◇对于FIGO分期IB1-IB3期患者，行颈/胸/腹/盆腔/腹股沟PET/CT（首选）或胸/腹/盆腔CT。考虑行胸部CT平扫和/或增强检查。对于有转移的疾病，应根据症状及临床体征，酌情行其他影像学检查b。II-IVA期  行盆腔MRI增强扫描以评估局部病灶范围（首选）。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": " 颈/胸/腹/盆腔/腹股沟PET/CT（首选）或胸/腹/盆腔CT检查以评估转移情况。 对于有转移的疾病，应根据症状及临床体征，酌情行其他初始的影像学检查c。 全子宫切除术后意外发现的宫颈癌，考虑行颈/胸/腹/盆腔/腹股沟PET/CT或胸/腹/盆腔CT以评估转移情况，行盆腔MRI增强以评估盆腔残留病灶。a.整个指南中提及的MRI和CT检查（实施时）均应使用造影剂增强，除非存在禁忌。胸部CT筛查不要求造影剂增强。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "b.这些因素可能包括异常体格检查结果或盆腔、腹部或肺部症状。c.这些因素可能包括异常体格检查结果、盆腔大肿块（＞4cm）、诊治延迟及盆腔、腹部或肺部症状。注：除非另有说明，所有建议均为2A类。临床试验： NCCN认为对所有癌症患者最好的处理方法是参与临床研究。尤其特别鼓励癌症患者参加临床试验。# 影像学原则a，1-9 # 随访/监测 I期 不保留生育功能 对于疾病复发/转移，应根据症状及临床体征，酌情行其它影像学检查b 。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "◇对于FIGO IB3期患者，或由于高危因素需要行术后行辅助放疗或放化疗的患者d，在完成治疗后3-6个月需行颈/胸/腹/盆腔/腹股沟PET/CT检查。保留生育功能 ◇考虑术后6个月行盆腔MRI增强扫描，此后2-3年每年复查。对于疾病复发/转移，应根据症状及临床体征，酌情行其它影像学检查b。II-IV期  在完成治疗后的3-6个月内行颈/胸/腹/盆腔/腹股沟PET/CT（首选）或胸/腹/盆腔CT增强扫描检查。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": " 在完成治疗后的3-6个月时考虑行盆腔MRI增强扫描。 对于疾病复发/转移，应根据症状及临床体征，酌情行其它影像学检查。e IVB期或复发  酌情行影像学检查（CT，MRI或PET/CT）以评估疗效或决定进一步治疗。# 怀疑复发或转移 $\\bullet$ 颈/胸/腹/盆腔/腹股沟PET/CT。考虑行盆腔MRI检查。a.整个指南中提及的MRI和CT检查（实施时）均应使用造影剂增强。胸部CT筛查不要求造影剂增强。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "b.这些因素可能包括异常体格检查结果或盆腔、腹部或肺部症状。d.危险因素可能包括淋巴结阳性、宫旁组织阳性、切缘阳性或宫颈局部因素（见Sedlis标准CERV-E）。e.这些因素可能包括异常体格检查结果，如可触及的肿块或肿大淋巴结，以及盆腔、腹部或肺部的新发症状 注：除非另有说明，所有建议均为2A类。临床试验： NCCN认为对所有癌症患者最好的处理方法是参与临床研究。尤其特别鼓励癌症患者参加临床试验。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "影像学原则a，1-9 # 小细胞NECC 附加检查  颈/胸/腹/盆腔/腹股沟PET/CT+脑MRI(首选) 或  胸/腹/盆腔CT+脑MRI  治疗效果评估 如果初级治疗是放化疗，行颈/胸/腹/盆腔/腹股沟PET/CT±脑MRI（首选）或胸/腹/盆腔CT±脑MRI 如果采用新辅助化疗，考虑在放化疗和近距离放疗前再次评估以排除转移性疾病 $\\bullet$ 监测  颈/胸/腹/盆腔/腹股沟PET/CT±脑MRI（首选） 或  胸/腹/盆腔CT±脑MRI a.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "整个指南中提及的MRI和CT检查（实施时）均应使用造影剂增强，除非存在禁忌。胸部CT筛查不要求造影剂增强。注：除非另有说明，所有建议均为2A类。临床试验： NCCN认为对所有癌症患者最好的处理方法是参与临床研究。尤其鼓励癌症患者参加临床试验。# 影像学原则参考文献 1 Salani R, Khanna N, Frimer M, et al.An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2017;146:3-10.2 Atri M, Zhang Z, Dehdashti F, et al.Utility of PET/CT to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer: Results of ACRIN6671/GOG0233 trial.Gynecol Oncol 2016;142:413-419.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "3 Rajendran JG, Greer BE.Expanding role of positron emission tomography in cancer of the uterine cervix.J Natl Compr Canc Netw 2006;4:463-469.4 Lakhman Y, Akin O, Park KJ, et al.Stage IB1 cervical cancer: role of preoperative MR imaging in selection of patients for fertility-sparing radical trachelectomy.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Radiology 2013;269:149-158.5 Elit L, Reade CJ.Recommendations for follow-up care for gynecologic cancer survivors.Obstet Gynecol 2015;126:1207-1214.6 Sala E, Rockall AG, Freeman SJ, et al.The added role of MR imaging in treatment stratification of patients with gynecologic malignancies: what the radiologist needs to know.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Radiology 2013;266:717-740.7 Balleyguier C, Sala E, Da Cunha T, et al.Staging of uterine cervical cancer with MRI: guidelines of the European Society of Urogenital Radiology.Eur Radiol 2011;21:1102-1110.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "8 Sala E, Micco M, Burger IA, et al.Complementary prognostic value of pelvic MRI and whole-body FDG PET/CT in the pretreatment assessment of patients with cervical cancer.Int J Gynecol Cancer 2015;25:1461-1467.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "9 Bhatla N, Berek JS, Fredes MC, et al.Revised FIGO Staging for carcinoma of the cervix uteri.Int J Gynecol Obstet 2019;145:129-135 and Corrigendum to \"Revised FIGO Staging for carcinoma of the cervix uteri” [Int J Gynecol Obstet 2019;145:129-135] Int J Gynecol Obstet 2019;147:279-280.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "# 注：除非另有说明，所有建议均为2A类。临床试验： NCCN认为对所有癌症患者最好的处理方法是参与临床研究。尤其鼓励癌症患者参加临床试验。权所有， 2022第一版，国家综合癌症网®（NCCN $\\circledast$ ） $\\circledcirc$ 2021 ， 10/26/2021发布。未经明确的书面许可，不得翻印任何形式的NCCN指南®及其解读。# 评估和手术分期原则a # 宫颈癌治疗的切除术类型和适宜性 • 微浸润癌被定义为FIGO IA1期无脉管间隙受累，其发生淋巴转移的几率小于1%，可行保守治疗：采用锥切活检，手术切缘阴性者可保留生育功能；对于保留生育力没有要求或不相关的患者也可行单纯子宫切除术。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "锥切活检的目的要求用手术刀完整切除宫颈及颈管。这样可为病理医生提供一个完整的、非碎片型的标本，无电切器械对手术切缘的影响，有利于评估切缘状态。如果选择环形电切术（LEEP）进行治疗，则应确保标本的完整性，并且小心操作，尽量减少电切器械对手术切缘的影响。锥切活检的形状和深度可以根据肿瘤病灶的大小、类型和位置进行调整。例如，位于宫颈管内可疑的浸润性腺癌或原位腺癌，锥切活检应设计成一个可深入宫颈内口的狭长锥形，以免遗漏宫颈管内可能存在的浸润性癌组织。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "冷刀锥切的长度最好至少达10mm，对于已经生育的患者，可以增加到18-20mm1。建议在锥顶上方进行宫颈管内取样以评估是否存在残留病灶。锥切活检适用于小肿瘤的分诊和治疗，肿瘤体积小则不太可能会径直切割到整个肿瘤。对于IA1期伴脉管间隙受累的患者，锥切术（切缘阴性）并盆腔SLN显影/淋巴结切除术是一个合理的策略。• 不要求保留生育功能时，根治性子宫切除术+双侧盆腔淋巴结切除术（无论是否行SLN显影）是FIGO IA2期、IB1期、IB2期和选择性IB3-IIA1 病变的首选治疗方法。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "与单纯子宫切除术相比，根治性子宫切除术切除的切缘范围更广，包括切除部分主韧带和宫骶韧带以及阴道上部1-2厘米; 此外，还要切除盆腔淋巴结，有时还包括切除主动脉旁淋巴结。Querleu和Morrow分类系统2是一种现代化的手术分类系统，它在三维平面上描述了切除范围和神经保护的情况3。最常用的子宫切除术的手术步骤详情如表1所示(见CERV-C 第5页[共7页])。• 根治性子宫切除术的标准和推荐方法是开腹入路(1类)。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "一项前瞻性随机试验4显示，与开腹根治性子宫切除术相比，微创根治性子宫切除术与无病生存率(DFS)和总生存率较低相关。此外，最近的两项流行病学研究也表明，在IA2-IB1期宫颈癌患者中，微创根治性子宫切除术的总生存期较开放性手术短5。更多细节请参阅讨论章节。a.按疾病分期提供的推荐方法是基于修订后的FIGO 2018分期（Bhatla N, Berek JS, Fredes MC, et al.Revised FIGO Staging for carcinoma ofthe cervix uteri.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Gynecol Obstet 2019;145:129-135，勘误为“Revised FIGO Staging for carcinoma of the cervix uteri” [Int JGynecol Obstet 2019;145:129-135] Int J Gynecol Obstet 2019;147:279-280）。然而，本节引用的研究数据使用的是2009年FIGO分级系统。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "注：除非另有说明，所有建议均为2A类。临床试验： NCCN认为对所有癌症患者最好的处理方法是参与临床研究。尤其鼓励癌症患者参加临床试验。# 评估和手术分期原则a # 宫颈癌手术治疗的类型和适应证（续） • 用于分期的主动脉旁淋巴结切除术通常在肠系膜下动脉（IMA）水平进行，向上清扫的范围可以根据临床和影像学检查结果调整。• 经阴道根治性宫颈切除术+腹腔镜下淋巴结切除术（±SLN显影）可实现保留生育功能，这种治疗方案适用于经严格选择的ⅠA2或ⅠB1期患者（病灶直径≤2cm）。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "与B型根治性子宫切除术一样，切除宫颈、阴道上段和支撑韧带，但保留宫体。在目前报告的300多例术后妊娠患者中，妊娠中期流产的可能性为10%，但72%的患者妊娠至37周或以上6。经腹根治性宫颈切除术是一种合理的保留生育功能的策略。与经阴道术式相比，这种术式宫旁可切除的范围更大7，适用于经过选择的ⅠB1-ⅠB2期患者，并且已经在病灶直径2-4cm的患者中实施。该手术类似于C型根治性子宫切除术b，2，3，7-10。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "• 如指南所述，FIGO ⅡB期及以上的晚期患者通常不采用子宫切除术治疗。在美国，大多数晚期患者采用根治性放化疗。在一些国家，部分经过选择的ⅡB期患者可先行根治性子宫切除术或新辅助化疗后行根治性子宫切除术。• 对放疗后盆腔中心中疾病复发或未控制的患者，实施盆腔廓清术可能有治愈的机会。廓清术的术前评估是旨在明确或排除远端转移。如果复发限于盆腔，可进行手术探查。如果术中切缘和淋巴结评估为阴性，则可行盆腔脏器切除。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "根据肿瘤的位置，可以采用前、后或全盆腔廓清术。若肿瘤部位可以保证足够的手术切缘，则盆底和肛门括约肌可保留作为上提肌廓清术。表2汇总了不同类型盆腔廓清术中通常会切除的组织（见CERV-C，第6页/共7页）。这些都是极复杂的术式，应当在具有较高廓清术水平的医疗中心进行。盆腔廓清术（之前未接受盆腔放疗）很少用于初始治疗，仅限于有盆腔放疗禁忌或既往接受过盆腔放疗治疗另外的适应症后发展为继发性、局部晚期宫颈癌并且不适合进一步放疗的少数病例。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "a.按疾病分期提供的推荐方法是基于修订后的FIGO 2018分期（Bhatla N, Berek JS, Fredes MC, et al.Revised FIGO Staging for carcinoma ofthe cervix uteri.Int J Gynecol Obstet 2019;145:129-135，勘误为“Revised FIGO Staging for carcinoma of the cervix uteri” [Int JGynecol Obstet 2019;145:129-135] Int J Gynecol Obstet 2019;147:279-280）。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "然而，本节引用的研究数据使用的是2009年FIGO分期系统。b.关于C型根治性子宫切除术的描述，见表1（CERV-C,第5页/共7页）。注：除非另有说明，所有建议均为2A类。临床试验： NCCN认为对所有癌症患者最好的处理方法是参与临床研究。尤其鼓励癌症患者参加临床试验。# 评估和手术分期原则a # 宫颈癌前哨淋巴结显影 • 前哨淋巴结显影作为经筛选的I期宫颈癌的手术治疗方案的一部分，在全球广泛用于妇科肿瘤医治实践中。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "虽然这项技术已被用于肿瘤直径达4cm的患者，但其在直径＜2cm 的前哨淋巴结显影已经被广泛用于经过选择的Ⅰ期宫颈癌患者的手术中。虽然这项技术已被用于治疗直径达4cm的肿瘤，但其在直径＜2cm 的肿瘤中检出率和显影效果最好11-15。此技术操作简单，直接在宫颈的2个点位或4个点位注射染料c或放射性胶体锝-99（99Tc），如下方图1所示。前哨淋巴结在手术中通过直接观察有色染料来识别，如果使用吲哚菁绿（ICG）16作为染料则采用荧光摄像头显影，如果使用99Tc则采用γ探测仪探测。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "宫颈注射显影剂后，前哨淋巴结通常在髂外血管内侧、髂内血管的子宫侧或闭孔窝的表面显影（图2）。前哨淋巴结通常由病理科医生进行超分期，以提高微转移的检出率，进而改变术后处理。4，a.按疾病分期提供的推荐方法是基于修订后的FIGO 2018分期（Bhatla N, Berek JS, F noma ofthe cervix uteri.Int J Gynecol Obstet 2019;145:129-135，勘误为“Revised FIGO Staging for carcinoma of the cervix uteri” [Int JGynecol Obstet 2019;145:129-135] Int J Gynecol Obstet 2019;147:279-280）。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "然而，本节引用的研究数据使用的是2009年FIGO分级系统。c.III期随机FILM研究显示，吲哚菁绿（ICG）非劣效于异硫蓝染料。(Frumovitz M, Plante M, Lee PS et al.Near-infrared fluorescence fordetection of sentinel lymph nodes in women with cervical and uterine cancers (FILM): a randomised, phase 3, multicentre, non-inferiority trial.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Lancet Oncol 2018;19:1394-1403) ![](images/92d353b703030702ce65974ad440bb6c050d907f8e1ddf4725efa0a5b402a6ab.jpg) 图1：前哨淋巴结宫颈注射部位的选择 ![](images/044649f80c2f7931ab7da02dd4c946713211fcef1ecbf2032b1de9ff784b1b8f.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "jpg) 图2：宫颈注射显影剂后，前哨淋巴结（蓝色，箭头所指）通常在髂外血管内侧、髂内血管的子宫侧或闭孔窝的表面显影d d.图1和图2经纪念斯隆-凯特琳癌症中心许可转载。$\\circledcirc$ 2013 Memorial Sloan Kettering Cancer Center.注：除非另有说明，所有建议均为2A类。临床试验：NCCN认为对所有癌症患者最好的处理方法是参与临床研究。尤其鼓励癌症患者参加临床试验。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "# 评估和手术分期原则（采用SLN显影时） 前哨淋巴结成功显影的关键在于遵守前哨淋巴结的检测流程，当一侧淋巴结显影失败时，切除该侧的淋巴结，以及切除任何可疑或增大的淋巴结，无论其是否显影（图3） ![](images/b0d660aeca26a12e576297d783905d2e5de5c944be7509cc1649c2d00897ba78.jpg) 图3：早期宫颈癌的手术/前哨淋巴结显影流程e H&E：苏木精-伊红染色法 LND：淋巴结切除术 SLN：前哨淋巴结 e.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "经许可转载自Cormier B，Diaz JP，Shih K，et al.Establishing a sentinel lymph node mapping algorithm for the treatment of early cervical cancer.Gynecol Oncol.2011 Aug;122:275-280.f.宫颈内注射染料、99Tc，或注射两者。g.目前尚缺乏超分期的标准流程。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "超分期通常包括对大体淋巴结进行连续切片，并进行H＆E染色读片（±细胞角蛋白免疫组化染色）。见病理学检查原则（CERV-A）。h.包括髂间/主动脉下淋巴结。i.特定患者做另外处理（见 CERV-C,1/7）。注：除非另有说明，所有建议均为2A类。临床试验： NCCN认为对所有癌症患者最好的处理方法是参与临床研究。尤其鼓励癌症患者参加临床试验。# NCCN Guidelines Version 1.2022 宫颈癌 # 评估和手术分期原则 表1：宫颈癌切除术作为初级治疗 <html><body><table><tr><td colspan=\"4\">子宫切除术类型比较</td><td colspan=\"2\">宫颈切除术类型比较（保留子宫）</td></tr><tr><td></td><td>筋膜外子宫切除术（A型）k</td><td>改良根治性子宫切除术</td><td>根治性子宫切除术（C1型）k</td><td>单纯宫颈切除</td><td>根治性宫颈切除!",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "</td></tr><tr><td>适应证</td><td>IA1期</td><td>IA1期伴LVSI和IA2期</td><td>激有照显转移的局部病灶，包括：</td><td>原位癌和IA1期</td><td>部分经过筛选的 1B2期</td></tr><tr><td>目的</td><td>微浸润根治</td><td>小病灶根治</td><td>大病灶根治</td><td>微浸润根治 保留生育功能</td><td>用一些选择性的 IA2-1B2 保留生育功能</td></tr><tr><td>子宫</td><td>切除</td><td>切除</td><td>切除</td><td>保留</td><td>保留</td></tr><tr><td>卵巢</td><td>选择性切除</td><td>选择性切除</td><td>选择性切除</td><td>保留</td><td>保留</td></tr><tr><td>宫颈</td><td>完全切除</td><td>完全切除</td><td>完全切除</td><td>大部分切除（官颈头侧</td><td>大部分切除（距窗信头侧</td></tr><tr><td>阴道切缘</td><td>极小切缘</td><td>1-2cm切缘</td><td>阴道上1/4至1/3</td><td>极小切缘</td><td>1-2cm切缘</td></tr><tr><td>游离输尿管</td><td>未涉及</td><td>将输尿管从宫颈分离</td><td>将输尿管从宫颈和宫旁侧方分离</td><td>未涉及</td><td>将输尿管从宫颈分离</td></tr><tr><td>切除宫颈旁/ 宫旁组织</td><td>不切除</td><td>在输尿管床水平切除 (水平切除1-2cm）</td><td>在骼内血管内侧方分离，深切缘是子宫深 静脉</td><td>在宫颈边缘处切除</td><td>在输尿管床水平切除（水平 切除1-2cm）</td></tr><tr><td>直富带）</td><td>宫颈边缘处分离</td><td>官辆侧1-2m（保留腹</td><td>1型保留神经，在宫颈背侧至少2cm处分</td><td>宫颈边缘处分离</td><td>富经貨侧1-2cm（保留腹下</td></tr><tr><td>膀胱</td><td>分离至宫颈外口</td><td>分离至阴道上部</td><td>分离至阴道中部</td><td>分离至腹膜反折</td><td>分离至阴道上部</td></tr><tr><td>直肠</td><td>未涉及</td><td>分离至宫颈下</td><td>分离至阴道中部下</td><td>分离至腹膜反折</td><td>分离至宫颈下方</td></tr><tr><td>手术途径</td><td>经阴道或开腹或微创</td><td>开腹</td><td>开腹</td><td>经阴道或开腹或微创\"</td><td>经阴是或开摧减微创（微创</td></tr></table></body></html> j.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Cibula D, Abu-Rustum NR, Benedetti-Panici P, et al.New classification system of radical hysterectomy $\\because$ Emphasis on a three-dimensional anatomic template foparametrial resection.Gynecol Oncol 2011;122:264-268.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "k.Querleu和Morrow手术分类系统在三位平面中描述了根治性子宫切除术的切除范围和神经保留的情况，并更新了过去使用的Piver-Rutledge分类法。（Querleu D, Morrow CP.Classification of radical hysterectomy.Lancet Oncol 2008;9:297-303.）l.保留生育功能的根治性宫颈切除术在直径≤2cm的病灶中得到最佳验证。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "目前不认为此术式适合小细胞神经内分泌组织和胃恶性腺瘤。m.目前尚缺乏关于微创根治性宫颈切除术的肿瘤学结局数据。注：除非另有说明，所有建议均为2A类。临床试验： NCCN认为对所有癌症患者最好的处理方法是参与临床研究。尤其鼓励癌症患者参加临床试验。# 评估和手术分期原则 表2：无远端转移的局部复发性宫颈癌切除j <html><body><table><tr><td colspan=\"4\">肛提肌下廓清术类型比较</td><td colspan=\"2\">肛提肌上廓清术类型比较</td></tr><tr><td></td><td>前盆腔</td><td>后盆腔</td><td>全盆腔</td><td>后盆腔</td><td>全盆腔</td></tr><tr><td>适应证</td><td colspan=\"5\">适用于经筛选的FICOIVA期患瞻的心复溶疗(当初始放疗不可行时)</td></tr><tr><td>目的</td><td colspan=\"5\">根治</td></tr><tr><td>子宫、输卵管、卵巢</td><td>如果仍然存在则切除</td><td>如果仍然存在则切除</td><td>如果仍然存在则切除</td><td>如果仍然存在则切除</td><td>如果仍然存在则切除</td></tr><tr><td>阴道</td><td>切除</td><td>切除</td><td>切除</td><td>切除</td><td></td></tr><tr><td>膀胱和尿道</td><td>切除</td><td>切除</td><td>切除</td><td>切除</td><td>切除</td></tr><tr><td>直肠</td><td>切除</td><td>切除</td><td>切除</td><td>切除</td><td>切除</td></tr><tr><td>肛门括约肌</td><td>切除</td><td>切除</td><td>切除</td><td>偶留，如果可以，与结</td><td>偶留，如果可以，与结</td></tr><tr><td>泌尿系统重建方案</td><td>回肠代膀胱术或可控性 尿流改道术</td><td>不适用</td><td>双管湿性结肠造口术\"、 原肠代术或可控性</td><td>不适用</td><td>双管湿性结肠造口术、 原肠代腾胱术或可控性</td></tr><tr><td>胃肠系统重建方案</td><td>不适用</td><td>末端结肠造口术</td><td>双管湿性结肠造口术或 末端结肠造口术</td><td>末端结肠造口术或吻合 术联合临时性回肠造口</td><td>双管湿性结肠造口术n、 末结肠口吻合</td></tr><tr><td>阴道重建方案</td><td colspan=\"5\">肌皮瓣（腹直肌、股薄肌等），或带大网膜J瓣中厚皮片移植</td></tr></table></body></html> 注：除非另有说明，所有建议均为2A类。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "临床试验： NCCN认为对所有癌症患者最好的处理方法是参与临床研究。尤其鼓励癌症患者参加临床试验。j.Cibula D, Abu-Rustum NR, Benedetti-Panici P, et al.New classification system of radical hysterectomy: Emphasis on a three-dimensional anatomic template for parametrial resection.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2011;122:264-268.n.Backes FJ, Tierney BJ, Eisenhauer EL t al.Complications after double-barreled wet colostomy compared to separate urinary and fecal diversion during pelvic exenteration: time to change back?",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2013 Jan;128:60-64.# 评估和手术分期原则 参考文献 1 Teoh D, Musa F, Salani R, et al.Diagnosis and management of adenocarcinoma in situ: A Society of Gynecologic Oncology Evidence-Based Review and Recommendations.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Obstet Gynecol 2020;135(4):869-878.2 Querleu D, Morrow CP.Classification of radical hysterectomy.Lancet Oncol 2008;9:297-303.3 Cibula D, Abu-Rustum NR, Benedetti-Panici P, et al.New classification system of radical hysterectomy: emphasis on a three-dimensional anatomic template for parametrial resection.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2011;122:264-268.4 Ramirez PT, Frumovitz M, Pareja R, et al.Minimally invasive versus abdominal radical hysterectomy for cervical cancer.N Engl J Med 2018;379:1895-1904.5 Melamed A, Margul DJ, Chen L, et al.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Survival after minimally invasive radical hysterectomy for early-stage cervical cancer.N Engl J Med 2018;379:1905-1914.6 Plante M, Gregoire J, Renaud MC, Roy M.The vaginal radical trachelectomy: an update of a series of 125 cases and 106 pregnancies.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2011;121:290-297.7 Einstein MH, Park KJ, Sonoda Y, et al.Radical vaginal versus abdominal trachelectomy for stage IB1 cervical cancer: a comparison of surgical and pathologic outcomes.Gynecol Oncol 2009;112:73-77.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "8 Piver MS, Rutledge F, Smith JP.Five classes of extended hysterectomy for women with cervical cancer.Obstet Gynecol 1974;44:265-272.9 Wethington SL, Sonoda Y, Park KJ, et al.Expanding the indications for radical trachelectomy: a report on 29 patients with stage IB1 tumors measuring 2 to 4 centimeters.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Gynecol Cancer 2013;23:1092-1098.10 Wethington SL, Cibula D, Duska LR, et al.An international series on abdominal radical trachelectomy: 101 patients and 28 pregnancies.Int J Gynecol Cancer 2012;22:1251-1257.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "11 Lintner B, Saso S, Tarnai L, et al.Use of abdominal radical trachelectomy to treat cervical cancer greater than 2 cm in diameter.Int J Gynecol Cancer 2013;23:1065-1070.12 Bats AS, Mathevet P, Buenerd A, et al.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "The sentinel node technique detects unexpected drainage pathways and allows nodal ultrastaging in early cervical cancer: insights from the multicenter prospective SENTICOL study.Ann Surg Oncol 2013;20:413-422.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "13 Eiriksson LR, Covens A.Sentinel lymph node mapping in cervical cancer: the future?BJOG 2012 Jan;119:129-133.14 Cormier B, Diaz JP, Shih K, et al.Establishing a 10/02/20 lymph node mapping algorithm for the treatment of early cervical cancer.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2011;122:275- 280.15 Altgassen C, Hertel H, Brandstädt A, et al.Multicenter validation study of the sentinel lymph node concept in cervical cancer: AGO Study Group.J Clin Oncol 2008;26:2943-2951.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "16 Frumovitz M, Plante M, Lee PS, et al.Near-infrared fluorescence for detection of sentinel lymph nodes in women with cervical and uterine cancers (FILM): a randomised, phase 3, multicentre, non-inferiority trial.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Lancet Oncol 2018;19:1394-1403.17 Cibula D, Abu-Rustum NR, Dusek L, et al.Prognostic significance of low volume sentinel lymph node disease in early-stage cervical cancer.Gynecol Oncol 2012;124:496-501.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "注：除非另有说明，所有建议均为2A类。临床试验： NCCN认为对所有癌症患者最好的处理方法是参与临床研究。尤其鼓励癌症患者参加临床试验。# 放疗原则 # 一般原则  以CT为基础的治疗计划和适形技术是外照射放疗（EBRT）的标准治疗。MRI是判断晚期肿瘤患者软组织和宫旁浸润的最佳影像学检查方法。对于没有手术分期的患者，PET成像有助于判断淋巴结转移范围，对于术后患者， PET有助于判断异常淋巴结是否已切除。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": " 放疗靶向于已知或可疑的肿瘤侵犯部位。EBRT靶区为盆腔±主动脉旁区域。 对于不适合手术的所有初治宫颈癌患者，近距离放疗是根治性治疗的关键部分，通过腔内和/或间质内的方式实施。 对于接受EBRT治疗宫颈癌的大多数患者，EBRT期间予同步含铂方案化疗。 8周内完成治疗者效果最佳。# 一般治疗信息 靶区：  肿瘤靶区（GTV）、临床靶区（CTV）、计划靶区（PTV） 、危及器官（OARs）、内部器官运动，以及剂量体积直方图（DVH）等概念已被明确定义用于适形放疗、特别是调强放疗（IMRT）中。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": " 需要特别注意细节和可重复性（包括考虑靶区和正常组织界定、患者和内部器官运动、软组织变形以及严格的剂量学和物理质量保证），这些对于正确地实施IMRT和相关的高度适形技术是必要的。常规的图像引导，如锥形束CT（CBCT），应该用于判断日常的内部软组织定位。 EBRT的范围应该包括大体肿瘤（如果存在）、宫旁、宫骶韧带以及距大体肿瘤足够的阴道范围（至少3cm）、骶前淋巴结以及其他危险的淋巴结区域。对于接受手术性及放射性成像的淋巴结阴性患者，照射范围应该包括髂内外、闭孔和骶前淋巴结区域。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "对于更高危的淋巴结转移的患者（如：大肿瘤；可疑或确定为限于低位真骨盆区域淋巴结转移），放射野需升高到包括髂总淋巴结区域。对于确定为髂总和/或主动脉旁区域淋巴结转移的患者，建议行包括盆腔+主动脉旁淋巴结区域的延伸野放射，直到肾血管水平，或者根据累及的淋巴结分布范围向头侧扩展。对于阴道下1/3有肿瘤侵袭的患者，照射范围需要包括双侧腹股沟区域。注：除非另有说明，所有建议均为2A类。临床试验： NCCN认为对所有癌症患者最好的处理方法是参与临床研究。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "尤其鼓励癌症患者参加临床试验。# 放疗原则 # 一般治疗信息（续） # 治疗信息-外照射  运用多个适形照射野或者容积调强技术实施 EBRT，例如 IMRT/适型调强/容积旋转调强/螺旋断层放疗。 在子宫切除术后放疗1以及有必要行主动脉旁淋巴结区域照射时，IMRT有助于减少肠道和其他关键部位结构所需的剂量。在需要高剂量治疗区域淋巴结中的大体病变时，这些技术也有用。但是，适形外照射疗法（如IMRT或者SBRT）不能作为近距离放疗的常规替代疗法，用于治疗宫颈完好的患者的中心病变。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": " 在完成初始的全盆腔照射后，对于有宫旁/盆壁大范围侵袭的筛选合适病例可考虑宫旁加量照射5-10Gy 。 调强放疗可计划给予大的淋巴结病变更高的剂量，同时给予较低的剂量来控制其他靶位的微小病变，称为同时补量照射（SIB）。IMRT 联合SIB使用可在更短时间内给予大的阳性淋巴结病变更高剂量，同时避开正常组织。总的来说，取决于靶区及OAR的体积，SIB靶区可以加量至约2.1～2.2Gy/次。外照射加量有时是必要的。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "淋巴结靶区剂量可以给到54-63Gy，在淋巴结加量时，应特别考虑近距离放疗所产生的作用，谨慎对待正常组织的剂量，同时注意邻近正常组织的剂量。 立体定向放疗（SBRT）是一种允许实施1-5次非常高剂量的聚焦式EBRT的放疗方式，可用于孤立的转移灶，也可以考虑用于局限性复发病灶的再程放疗2,3。# 剂量处方方案-外照射  覆盖微小淋巴结病变需要的外照射剂量为约40-45Gy（按传统分割每天1.8-2.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "0Gy，如果采用IMRT则可能需要 SIB），可给予未切除的淋巴结肿大的有限病变高度适形的额外加量10-20Gy，但需考虑近距离放疗贡献的剂量。对于大多数接受EBRT的宫颈癌患者，在EBRT期间给予同步含铂方案化疗。注：除非另有说明，所有建议均为2A类。临床试验： NCCN认为对所有癌症患者最好的处理方法是参与临床研究。尤其鼓励癌症患者参加临床试验。# 放疗原则 # 一般治疗信息（续） # 根治性放疗（有完整子宫）  对于未接受手术有完整子宫的患者，通常给予其原发肿瘤及有转移风险的区域淋巴结根治性外照射放疗（EBRT），剂量大约45Gy（40-50Gy）。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "外照射放疗的靶区范围取决于手术或影像学提示的淋巴结状态（如前所述）。然后使用近距离放疗对原发宫颈肿瘤进行推量照射，使用图像引导（首选）推量30-40Gy或者至A点（低剂量率[LDR]等效剂量），使宫颈小肿瘤的A点总剂量达到80Gy，或者大肿瘤的A点总剂量≥85Gy（根据指南中建议）。对于非常小的肿瘤（无法手术的IA1或IA2期），等效剂量（EQD2）D90的剂量可考虑为75-80Gy。对不可切除的淋巴结进行评估，可以通过高度适形的（或者减少照射区域的）EBRT给予额外推量10-15Gy。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "使用图像引导的EBRT时，必须注意避开高剂量区域中的正常组织或严格限制正常组织的受量(见讨论章节）。# 子宫切除术后的辅助放疗  子宫切除术后，病理学检查发现1个或多个危险因素时需行辅助放疗。放射野至少需要包括如下范围：阴道断端上3-4cm、宫旁组织、以及紧邻的淋巴结引流区（如髂内、外淋巴结区、闭孔和骶前）。如果有明确的淋巴结转移，放射野的上界还需要相应延伸（如前所述）。通常建议标准分割的IMRT剂量为45-50Gy4。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "对于未切除的大转移淋巴结，采用高度适形的外照射技术（并且缩野）推量10-20Gy。当使用更高剂量时，特别是EBRT时，高剂量区域必须注意避开正常组织或严格限制正常组织的照射剂量(见讨论章节）。# 术中放疗  术中放疗（IORT）是一项专门技术，在开腹手术中对有风险的瘤床或无法切除的孤立残留病灶给予单次高度集中的放射剂量5。尤其适合放疗后复发的病例。IORT时，可将高危区域内覆盖的的正常组织（例如肠道或其他内脏）移开。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "IORT通常使用电子线、近距离放疗或微型X射线源，可选择不同大小的施源器（与手术定义的高危区域匹配），这可进一步限制照射的面积和深度，避免周围正常组织受到照射。# 放疗原则 # 一般治疗信息（续） # 治疗信息-近距离放疗  近距离放疗是所有不适合手术的初治宫颈癌根治性放疗的关键部分。通常在腔内进行，采用串联放射源的宫腔管与阴道模具。根据患者及肿瘤解剖情况，有完整子宫颈的患者近距离放疗的阴道部分使用卵圆形、环状或者圆柱状施源器（结合宫腔内施源器）。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "对于更加晚期的患者或者肿瘤退缩不理想的患者，组织间插植可以提高靶区剂量并且最大限度减小正常组织受量。近距离放疗前或放疗中行MRI检查有助于勾画残留肿瘤形状。如果联合EBRT，近距离放疗通常安排在EBRT后，因为原发肿瘤退缩理想可以更好地放置近距离放疗施源器。对于经过仔细筛选的非常早期的患者（例如IA2期），单纯近距离放疗（不联合EBRT）也是一种选择。 对于少数由于解剖学或肿瘤形状不能实施腔内近距离放疗的患者，最好采用组织间插植的方式进行治疗；但是，组织间插植近距离放疗只能在有条件的医疗机构由有经验的专家来施行，否则，应尽早转诊、及时接受这种专业治疗，这至关重要。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": " 对于部分经过筛选的子宫切除术后患者（尤其是阴道黏膜切缘阳性或切缘靠近病灶者），EBRT后可使用阴道柱状施源器进行推量近距离放射治疗。通常在阴道粘膜表面或阴道粘膜表面下5mm位置施用处方。典型的分割方案是5.5Gy×2次（阴道粘膜下5mm）或者6Gy×3次（阴道表面）。 SBRT不适合作为近距离放疗的常规替代治疗。注：除非另有说明，所有建议均为2A类。临床试验： NCCN认为对所有癌症患者最好的处理方法是参与临床研究。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "尤其鼓励癌症患者参加临床试验。# 放疗原则 # 剂量处方方案-近距离放疗  A点，代表宫旁参考点，是迄今最为广泛使用的施用剂量参考点。但A点施用剂量没有考虑到肿瘤的三维形状及个体肿瘤与正常组织结构的关系，具有一定局限性。在传统层面上，A点剂量是基于已被广泛验证的LDR近距离放疗的剂量分割所给出的。假定采用LDR的A点剂量为40-70cGy/h。传统LDR A点处方剂量为70-80Gy。通常，A点的处方剂量为早期病变5.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "5Gy×5次，肿瘤较大或退缩不佳时6Gy×5次。另一个合理选择是28Gy，分4次完成，该方案作为高危CTV的腔内照射剂量在欧洲的临床试验中被广泛研究。 组织间近距离放疗是一种先进的技术，将多个针/导管植入到大体病灶/靶区中。对于不能进行腔内近距离放疗或解剖学层面上有利于组织间插植的病例，组织间近距离放疗可能是优选方案，可以使靶区照射剂量最大化并使OAR受量最小化。3D治疗计划可以在CT和/或MRI（含 DVH）上对靶区和OAR进行体积勾画。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "剂量和分割取决于既往放疗的剂量、靶区和OAR受量。 已有证据表明，图像引导的近距离放疗可以改善治疗结局并减少毒性。MRI是最佳的软组织成像方式，可提供残余肿瘤的图像，而最好是在设备就位的情况下行MRI检查，近距离治疗前行MRI检查有助于指导治疗。没有MRI设备时也可以使用CT，但CT在确定残余病灶方面不如 MRI而且勾画靶区也没有那么准确。治疗目标包括给予高危CTV（HR-CTV）的等效剂量为2Gy(EQD2),D90达80-85Gy；但是，对于肿瘤体积大或退缩不佳时，剂量目标为HR-CTV D90≥87Gy。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "根据已公布的指南，正常组织的限定剂量为：2-cc直肠≤65-75 Gy；2-cc乙状结肠≤70-75Gy；2-cc膀胱≤80-90 Gy。如果达不到这些参数要求，应该考虑使用组织间插植技术作为补充6-9。 对于联合EBRT的近距离放疗，外照射剂量为每日1.8-2.0Gy。如果采用高剂量率（HDR）近距离放疗，临床医生应当依据线性二次方程将标称HDR剂量转化成生物等效的LDR剂量来给予（http://www.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "americanbrachytherapy.org/guidelines/）。HDR分割剂量方案（标称剂量6Gy×5次）的总剂量为30Gy，分5次完成，相当于采用LDR近距离放疗时A点的等效剂量为40Gy（肿瘤等效剂量）。注：除非另有说明，所有建议均为2A类。临床试验： NCCN认为对所有癌症患者最好的处理方法是参与临床研究。尤其鼓励癌症患者参加临床试验。# 放疗原则 参考文献 1 Klopp, AH, Yeung AR, Deshmukh S, et al.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "A phase III randomized trial comparing patient-reported toxicity and quality of life (QOL) during pelvic intensity modulated radiation therapy as compared to conventional radiation therapy.Int J Radiat Oncol Biol Phys 2016;96:S3.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "2 Choi CW, Cho CK, Yoo SY, et al.Image-guided stereotactic body radiation therapy in patients with isolated para-aortic lymph node metastases from uterine cervical and corpus cancer.Int J Radiat Oncol Biol Phys 2009;74:147-153.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "3 Higginson DS, Morris DE, Jones EL, et al.Stereotactic body radiotherapy (SBRT): Technological innovation and application in gynecologic oncology.Gynecol Oncol 2011;120:404-412.4 Klopp AH, Yeung AR, Deshmukh SW et al.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Patient-reported toxicity during pelvic intensity-modulated radiation therapy: NRG Oncology-RTOG 1203.J Clin Oncol 2018;36(24):2538-2544.5 del Carmen MG, McIntyre JF, Goodman A.The role of radiation therapy (IORT) in the treatment of locally advanced gynecologic malignancies.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Oncologist 2000;5:18-25.6 Haie-Meder C, R Potter, E Van Limbergen E, et al.Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Radiother Oncol 2005;74:235-245.7 Pötter R, Georg P, Dimopoulos JC, et al.Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Radiother Oncol 2011;100:116-123.8 Pötter R, Haie-Meder C, Van Limbergen E, et al.Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D imagebased treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Radiother Oncol 2006;78:67-77.9 Viswanathan AN, Erickson BA.Three-dimensional imaging in gynecologic brachytherapy: a survey of the American Brachytherapy Society.Int J Radiat Oncol Biol Phys 2010;76:104-109.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "注：除非另有说明，所有建议均为2A类。临床试验： NCCN认为对所有癌症患者最好的处理方法是参与临床研究。尤其鼓励癌症患者参加临床试验。根治性子宫切除术后淋巴结阴性、切缘阴性和宫旁阴性病例行盆腔外放疗的Sedlis标准1-4 LVSI：淋巴脉管间隙浸润 <html><body><table><tr><td>LVSI</td><td>基质浸润</td><td>肿瘤大小(cm) （经临床触诊决定）</td></tr><tr><td>+</td><td>深1/3</td><td>任何</td></tr><tr><td>+</td><td>中1/3</td><td>22</td></tr><tr><td>+</td><td>浅1/3</td><td>25</td></tr><tr><td>-</td><td>中或深1/3</td><td>≥4</td></tr></table></body></html> 1.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "经许可改编自Sedlis A, Bundy BN, Rotman MZ, et al.A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a gynecologic oncology study group.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 1999;73:177-183.2.Delgado G, Bundy B, Zaino R, et al.Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a gynecologic oncology group study.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 1990;38:352-357.3.Rotman M, Sedlis A, Piedmont MR, et al.A phase III randomized trial of postoperative pelvic irradiation in stage IB cervical carcinoma with poor prognostic features:follow-up of a gynecologic oncology group study.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 2006;65:169-176.# 注：除非另有说明，所有建议均为2A类。临床试验： NCCN认为对所有癌症患者最好的处理方法是参与临床研究。尤其鼓励癌症患者参加临床试验 CERV-E 权所有， 2022第一版，国家综合癌症网®（NCCN $\\circledast$ ） $\\circledcirc$ 2021 ， 10/26/2021发布。未经明确的书面许可，不得翻印任何形式的NCCN指南®及其解读。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "# NCCN Guidelines Version 1.2022 宫颈癌 宫颈癌的系统治疗a <html><body><table><tr><td colspan=\"4\">鳞状细胞癌、腺癌或腺鳞癌</td></tr><tr><td>放化疗</td><td colspan=\"3\">复发或转移性疾病</td></tr><tr><td>首选方案</td><td>一线联合治疗b， 首选方案</td><td>可选的一线单药治疗c 首选方案</td><td>二线或后续治疗： 首选方案</td></tr><tr><td rowspan=\"4\">·顺铂 ·卡铂（如果不能 耐受顺铂)</td><td rowspan=\"4\">·帕博利珠单抗+顺铂/紫杉醇土贝伐珠单抗 （适用于PD-L1阳性肿瘤）（1类）d,e,f.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "1 ·帕博利珠单抗+卡铂/紫杉醇土贝伐珠单抗 （适用于PD-L1阳性肿瘤）（1类）d,e,f,1 ·顺铂/紫杉醇/贝伐珠单抗，2 (1类) ·卡铂/紫杉醇/贝伐珠单抗d</td><td>·顺铂4</td><td>帕博利珠单抗（适用于PD-L1阳性f或MSI-H/dMMR的肿瘤） e, f, 11 ·纳武利尤单抗(适用于PD-L1阳性肿瘤）é,f.12 其他推荐方案</td></tr><tr><td>其他推荐方案 卡铂 ·紫杉醇9，10</td><td>(除非另有说明，这里列出的所有药物均为2B类推荐) ·贝伐珠单抗d ·白蛋白结合型紫杉醇</td></tr><tr><td></td><td></td></tr><tr><td></td><td>多西他赛 氟尿嘧啶 吉西他滨 异环磷酰胺 伊立替康 ·丝裂霉素</td></tr><tr><td>其他推荐方案</td><td></td><td></td><td>·培美曲塞</td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>·拓扑替康 ·长春瑞滨</td></tr><tr><td></td><td>·顺铂/紫杉醇（1类）3，4</td><td></td><td></td></tr><tr><td></td><td>·卡铂/紫杉醇5，6（对于先前用过顺铂治疗的</td><td></td><td>·Tisotumab vedotin-tftv（2A类）13</td></tr><tr><td></td><td>患者是1类推荐)</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td></td><td>·拓扑替康/紫杉醇/贝伐珠单抗，2（1类) ·拓扑替康/紫杉醇2 ·顺铂/拓扑替康7</td><td></td><td>用于特定情况的方案 帕博利珠单抗（适用于TMB-H的肿瘤）é,h ·拉罗替尼或恩曲替尼（适用于NTRK基因融合的肿瘤）（2B类）</td></tr></table></body></html> a.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "顺铂、卡铂、多西他赛和紫杉醇可能引发药物反应（见NCCN卵巢癌指南——药物反应处理[OV-D]）。b.选择合适的治疗方案时应慎重考虑费用和毒性。c.这些药物若先前未使用过，可根据临床适用情况作为二线或后续治疗。d.FDA批准的生物类似药可以用于替代贝伐珠单抗。e.参见NCCN指南了解免疫治疗相关毒性管理。f.推荐用于肿瘤表达PD-L1（CPS≥1）的患者（经FDA批准的检测方法确定）。g.更多二线治疗的参考文献见讨论章节。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "h.适用于患有不可切除或转移性、高肿瘤突变负荷（TMB-H， ≥10mut/Mb）（采用经验证的和/或FDA批准的检测方法确定）的肿瘤，患者既往治疗后发生疾病进展且没有其它合适治疗选择。注：除非另有说明，所有建议均为2A类。临床试验： NCCN认为任何癌症患者最好的处理方式是参与临床研究。尤其鼓励癌症患者参加临床试验。# NCCN Guidelines Version 1.2022 宫颈癌 NCCN指导原则索引 宫颈癌的系统治疗 <html><body><table><tr><td colspan=\"3\">小细胞NECCj</td></tr><tr><td rowspan=\"2\">放化疗</td><td colspan=\"2\">新辅助治疗、辅助治疗、复发或转移性疾病的治疗</td></tr><tr><td>一线治疗</td><td>二线或以上治疗</td></tr><tr><td>首选方案 · 顺铂+依托泊苷j 其他推荐方案 卡铂+依托泊苷（如果不能耐受顺铂）」</td><td>首选方案 ·顺铂/依托泊苷 ·卡铂/依托泊苷</td><td>·见CERV-F第1页（共3页）的一线治疗或二线治疗</td></tr></table></body></html> i.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "顺铂、卡铂可能引发药物反应（见NCCN卵巢癌指南——药物反应处理[OV-D]）。j.给药剂量和计划，见NCCN指南中的小细胞肺癌——系统治疗原则（SCL-E）。k.CERV-F 第1页（共3页）推荐的一线或二线治疗方案（如果既往没有使用过）可用作小细胞神经内分泌癌的二线或后续治疗。注：除非另有说明，所有建议均为2A类。临床试验：NCCN认为对所有癌症患者最好的管理是在临床试验中。特别鼓励癌症患者参加临床试验。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "权所有， 2022第一版，国家综合癌症网®（NCCN $\\circledast$ ） $\\circledcirc$ 2021 ， 10/26/2021发布。未经明确的书面许可，不得翻印任何形式的NCCN指南®及其解读。# 宫颈癌的系统治疗参考文献 Colombo N, Dubot C, Lorusso D, et al.Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "N Engl J Med.2021.Tewari KS1, Sill MW, Long HJ 3rd, et al.Improved survival with bevacizumab in advanced cervical cancer.N Engl J Med 2014 Feb 20;370:734-743.3 Monk BJ, Sill MW, McMeekin DS, et al.Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "J Clin Oncol 2009;27:4649-4655.4 Moore DH, Blessing JA, McQuellon RP, et al.Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "J Clin Oncol 2004;22:3113-3119.5 Moore KN, Herzog TJ, Lewin S, et al.A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer.Gynecol Oncol 2007;105:299-303.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "6 Kitagawa R, Katsumata N, Shibata T, et al.Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505.J Clin Oncol 2015;33:2129-2135.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Long HJ 3rd, Bundy BN, Grendys EC Jr., et al.Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.J Clin Oncol 2005;23:4626-4633.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "8 Weiss GR, Green S, Hannigan EV, et al.A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: a Southwest Oncology Group study.Gynecol Oncol 1990;39:332-336.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "9 Tinker AV, Bhagat K, Swenerton KD, Hoskins PJ.Carboplatin and paclitaxel for advanced and recurrent cervical carcinoma: the British Columbia Cancer Agency experience.Gynecol Oncol 2005;98:54-58.10 McGuire WP, Blessing JA, Moore D, et al.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Paclitaxel has moderate activity in squamous cervix cancer.A Gynecologic Oncology Group study.J Clin Oncol 996;14:792-795.1 Marabelle A, Le DT, Ascierto PA, et al.Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: esults from the phase 2 KEYNOTE-158 study.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "J Clin Oncol 2020;38:1-10.2 Naumann RW, Hollebecque A, Meyer T, et al.Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "J Clin Oncol.2019;37:2825-2834.13 Coleman RL, Lorusso D, Gennigens C, et al.Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/ GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Lancet Oncol.2021;22:609-619.# 注：除非另有说明，所有建议均为2A类。临床试验： NCCN认为任何癌症患者最好的处理方式是参与临床研究。尤其鼓励癌症患者参加临床试验。# NCCN Guidelines Version 1.2022 宫颈癌 # 妇科肿瘤患者生存原则 # 躯体影响 • 妇科肿瘤的治疗通常包括手术、化疗、激素治疗、放疗和（或）免疫治疗。这些治疗会引起急性、短期和长期毒性。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "• 外科手术范围大、风险高，例如：形成粘连（可引起疼痛和小肠梗阻）、尿路或胃肠道并发症（如尿失禁、腹泻）、盆功能障碍（表现为排尿、排便和（或）性功能等多种影响）和淋巴水肿。• 化疗药物多种多样，常用的方案可能会引起神经毒性、心脏毒性、继发血液系统恶性肿瘤以及认知功能障碍等风险。• 长期缺乏雌激素可能会引起潮热、阴道干燥和骨质流失等症状。• 放疗可能会引起长期并发症（例如纤维化、外阴萎缩），还可能诱发临近放射野的皮下组织和/或下层器官的继发肿瘤。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "• 免疫治疗是新的治疗方法，迄今为止，免疫疗法的长期作用尚不清楚。# 社会心理影响 • 癌症对患者社会心理的影响表现为；心理方面（例如：抑郁、焦虑、对复发和身体形象改变的恐惧）、经济方面（例如返回工作、保险问题）和/或人际关系方面的（例如人际关系、性、亲密感）。# 临床方法 • 所有妇科肿瘤的生存者应定期接受全科医疗照护，侧重慢性疾病、监测心血管疾病危险因素、建议接种疫苗并鼓励采用健康的生活方式。• 为了评估妇科肿瘤的远期和长期影响，临床医生应全面记录患者的病史，进行全面的体检，并提供必要的影像学和（或）实验室检查。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "对于所有患者（无论是否处于性活跃状态），均应询问关于泌尿生殖系统症状（包括外阴阴道干燥）的问题。建议转诊至合适专业医护人士（例如，物理治疗、盆底治疗、性治疗、心理治疗）。由于大多数妇科肿瘤的治疗方法都会导致性功能障碍、早期停经和不孕，因此需要特别注意由此产生的医疗和社会心理影响。• 建议在放疗后使用阴道扩张器和润滑剂。• 对于绝经前患者，应考虑激素替代治疗。• 与参与肿瘤生存者治疗的所有临床医生（包括初级保健临床医生）的沟通和合作是至关重要的。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "建议向肿瘤生存者提供其治疗的总结，并提供随访建议。# 其它指南 NCCN心理痛苦管理指南NCCN戒烟指南NCCN癌症生存者指南 注：除非另有说明，所有建议均为2A类。临床试验： NCCN认为任何癌症患者最好的处理方式是参与临床研究。尤其鼓励癌症患者参加临床试验。表1：国际妇产科联盟（FIGO）子宫颈癌手术分期（2018） <html><body><table><tr><td>分期</td><td></td><td>描述</td></tr><tr><td>IA</td><td></td><td>癌变局限于宫颈（扩散至宫体应忽略）</td></tr><tr><td></td><td></td><td>仅在显微镜下诊断的浸润癌，最大浸润深度≤5mma</td></tr><tr><td></td><td>IA1</td><td>测得间质浸润深度≤3mm</td></tr><tr><td></td><td>1A2</td><td>测得间质浸润深度>3mm，且≤5mm</td></tr><tr><td></td><td></td><td>最大浸润深度>5mm的浸润癌（超过IA期）；病变局限于宫颈，病变大小为肿瘤最大径</td></tr><tr><td></td><td>IB1</td><td>间质浸润深度>5mm及最大径≤2cm的浸润癌</td></tr><tr><td></td><td>IB2</td><td>浸润癌最大径>2cm且≤4cm</td></tr><tr><td></td><td>IB3</td><td>浸润癌最大径>4cm</td></tr><tr><td></td><td></td><td>宫颈癌侵犯至子宫外，但未累及至阴道下1/3或盆壁</td></tr><tr><td>I1A</td><td></td><td>累及阴道上2/3，且无宫旁浸润</td></tr><tr><td></td><td>IIA1</td><td>最大径≤4cm的浸润癌</td></tr><tr><td></td><td>11A2</td><td>最大径>4cm的浸润癌</td></tr><tr><td></td><td></td><td>宫旁浸润，但未达盆壁</td></tr><tr><td></td><td>I11A</td><td>肿瘤累及阴道下1/3和（或）侵犯到盆壁和（或）导致肾孟积水或肾无功能和（或）累及盆腔和（或）主动脉旁淋巴结</td></tr><tr><td></td><td></td><td>肿瘤累及阴道下1/3，但未达盆壁</td></tr><tr><td></td><td>II1B</td><td>肿瘤侵犯到盆壁和（或）导致肾孟积水或肾无功能（排除其他原因所致）</td></tr><tr><td>IIIC</td><td></td><td>累及盆腔和（或）主动脉旁淋巴结（包括微转移），不论肿瘤大小与范围［标注r（影像学）或p（病理）］d</td></tr><tr><td></td><td>I1I1C1</td><td>仅盆腔淋巴结转移</td></tr><tr><td></td><td>111C2</td><td>主动脉旁淋巴结转移</td></tr><tr><td>IV</td><td></td><td>肿瘤扩散至真骨盆外，或已累及膀胱或直肠黏膜（活检证实）。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "泡状水肿不诊断为IV期。</td></tr><tr><td>IVA</td><td></td><td>扩散至邻近器官</td></tr><tr><td>IVB</td><td></td><td>转移至远端器官</td></tr></table></body></html> a.在所有疾病阶段中，均可利用影像学和病理学（如果可用）补充关于肿瘤大小和侵袭范围的临床结果。病理学结果优于影像学和临床结果。b.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "淋巴脉管间隙浸润不改变分期，不再考虑病变浸润宽度。c.孤立肿瘤细胞不改变分期，但应在记录中写清楚。d.添加“r（影像）”和“p（病理）”的标注，用于表明将患者诊断为IIIC期的依据。例如：影像学提示盆腔淋巴结转移时，则分期划分为IIIC1r期，如果经病理检查证实，则分期划分为IIIC1p期，所用的影像学检查方式或病理诊断技术均应记录在案。经国际妇产科联盟授权许可转载自：Bhatla N, Berek JS, Fredes MC, et al.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Revised FIGO Staging for carcinoma of the cervix uteri.Int J Gynecol Obstet 2019;145:129-135 及 Corrigendum to \"Revised FIGO Staging for carcinoma ofthe cervix uteri” [Int J Gynecol Obstet 2019;145:129-135] Int J Gynecol Obstet 2019;147:279-280.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Copyright 2019, 权所有， 2022第一版，国家综合癌症网®（NCCN $\\circledast$ ） $\\circledcirc$ 2021 ， 10/26/2021发布。未经明确的书面许可，不得翻印任何形式的NCCN指南®及其解读。<html><body><table><tr><td colspan=\"2\">NCCN证据及共识类别</td></tr><tr><td>1类</td><td>基于高级别证据，NCCN专家组一致认为干预措施是适当的。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "</td></tr><tr><td>2A类</td><td>基于较低级别证据，NCCN专家组一致认为干预措施是适当的。</td></tr><tr><td>2B类</td><td>基于较低级别证据，NCCN专家组认为干预措施是适当的。</td></tr><tr><td>3类</td><td>基于任何级别证据，NCCN专家组对于干预措施是否适当存在重大分歧。</td></tr></table></body></html> 所有建议均为2A类，除非另有说明。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "<html><body><table><tr><td colspan=\"2\">NCCN倾向性类别</td></tr><tr><td>推荐的干预措 施</td><td>基于更优的疗效、安全性和证据的干预措施；且在适用时，花费较低。</td></tr><tr><td>其他推荐的干 预措施</td><td>可能疗效较差、毒性较大或基于不太成熟数据的其他干预措施；或者疗效类似但花费 较高。</td></tr><tr><td>的干特猜情况</td><td>可用于经过筛选的患者群体的其他干预措施（由建议定义）。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "</td></tr></table></body></html> 所有建议都被认为是适当的。# 讨论 # 讨论部分与NCCN宫颈癌指南一致。最近一次（部分）更新于2019.03.29。# 目录 # 概述 …MS-2 文献检索标准及指南更新方法 …MS-2 诊断和检查… MS-3 分期和手术原则… …MS-3临床分期… …MS-3手术分期 …MS-4 初级治疗… MS-7支持治疗推荐的重要Ⅲ期临床试验 …MS-8早期疾病 …MS-8 辅助治疗 …MS-12 监测… …MS-13 复发的治疗 MS-14局部/区域治疗 …MS-14转移性疾病的治疗 MS-15 药物反应… …MS-17 最佳支持治疗 …MS-18 意外发现的宫颈癌 MS-18 # 放疗… …MS-18 放疗计划 MS-19保护正常组织的注意事项… …MS-20宫颈癌与妊娠… …MS-20总结… MS-21表1 MS-22参考文献 MS-23 # 概述 据估计，美国在2019年将诊断出13,170例新发宫颈癌，4250人将死于宫颈癌1。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "尽管美国妇女宫颈癌的发病率不断下降，但在西班牙/拉丁裔、黑人和亚洲妇女中，宫颈癌的发病率仍然很高2-5。然而，宫颈癌是全球女性面临的重要健康问题。2012年，全球大约有528,000例新发的宫颈癌病例，年死亡率为266,000例6。宫颈癌是全球女性第四大常见的癌症7，8，85％的病例发生于发展中国家——在这些国家宫颈癌是女性癌症死亡的主要原因6，9。持续的人乳头瘤病毒（HPV）感染是宫颈癌的最重要发病因素10，11。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "宫颈癌的发病率与人群中HPV感染情况有关。在宫颈癌发病率高的国家，慢性HPV的感染率为10％-20％，而发病率低的国家感染率为5%-10%7。针对HPV的免疫接种可以预防疫苗所针对的HPV型别的感染，有望预防女性患特定HPV癌症12-16。其他与宫颈癌相关的流行病学危险因素包括吸烟史、分娩、口服避孕药、性交过早、多个性伴侣、性传播疾病史、某些自身免疫性疾病和慢性免疫抑制17，18。建议吸烟者戒烟，已戒烟者应继续避免吸烟（见NCCN戒烟指南和 http://smokefree.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "gov/）。鳞状细胞癌约占所有宫颈癌的80％，腺癌约占20％。尽管存在种族、民族和地域差异，据推测，发达国家宫颈鳞状细胞癌发病率和死亡率大幅下降是得益于有效的筛查2，3，19，20。然而，在过去三十年中，宫颈腺癌有所增加，可能是因为宫颈细胞学筛查方法对腺癌不太有效21-24。利用HPV检测的筛选方法可以提高对腺癌的检出率，HPV疫苗接种也可以降低鳞状细胞癌和腺癌的发病率23，25。显然，NCCN指南不能包含所有可能的临床变化，并且并不旨在取代良好的临床判断或治疗的个体化。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "在制定这些指南的过程中，宫颈癌专家组成员也讨论了“许多规则之外的情况”。# 文献检索标准及指南更新方法 在此版本的 NCCN 宫颈癌指南®更新之前，使用以下检索词对 PubMed 数据库进行了电子搜索，以获取自上次指南更新以来发表的宫颈癌的关键文献：cervical cancer或cervicalcarcinoma或carcinoma of the cervix。选择 PubMed 数据库是因为它一直是最广泛应用的医学文献资源库，并且仅索引经同行评议的生物医学文献。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "通过选择以英文发表的人体研究来缩小搜索范围。结果仅限于以下文章类型：II 期临床试验；III期临床试验；IV 期临床试验； 指南； 随机对照试验; 荟萃分析； 系统评价；和验证研究。专家组在指南更新期间讨论的关键的PubMed 文章以及其他来源的被认为与指南相关的文章已被包含在此版本的讨论部分中。缺乏高级别证据的建议是基于专家组对低级别证据的审查和专家意见给出的。有关 NCCN 指南制定和更新的完整详细信息，请访问www.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "NCCN.org。# 诊断和检查 # 分期和手术原则 NCCN指南讨论了宫颈鳞状细胞癌、腺鳞癌、腺癌和小细胞神经内分泌癌。毛玻璃样细胞癌、肉瘤和其他组织学类型不在本指南的范围内。宫颈癌的早期阶段可能是无症状的，或有阴道排液、性交后出血或间歇性阴道流血的情况。这些早期症状通常不会被患者识别。由于宫颈的可及性，宫颈细胞学、巴氏涂片和宫颈活检通常可以明确诊断。如果宫颈活检不足以确定是否有浸润性疾病或需要准确的评估微浸润病灶，建议进行锥切活检（即锥形切除术）。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "然而，宫颈细胞学筛查对于诊断腺癌不太有效，因为原位腺癌侵犯的部位通常难以取样（如宫颈管内）5，24。美国病理学协会（CAP）发布的宫颈癌检测流程是较好的指南（https://cap.objects.frb.io/protocols/cp-femalereproductive-uterine-cervix-18protocol-4100.pdf）。该指南于2018年8月修订，并体现了AJCC分期的最新更新（即，第8版AJCC 癌症分期手册）。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "对于有可疑症状的患者，检查包括病史和体格检查，全血细胞计数（CBC，包括血小板）以及肝肾功能检查。推荐放射性影像学检查，包括：胸部X线，CT或结合PET/CT，有指征者行MRI检查（如排除位于宫颈内较高位置的病变） 26，27。关于按照分期和治疗计划进行的影像学检查建议，见NCCN宫颈癌指南——影像学原则。建议患者戒烟，接受戒烟咨询，进行HIV检测（尤其是年轻患者）。仅在怀疑膀胱或直肠侵犯时才建议进行膀胱镜检查和直肠镜检查（例如对于≥IB3期）。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "应考虑保留患者生育功能的方案。# 临床分期 根据修订后的2018版FIGO分期系统28，专家组对指南进行了更新。修订了I期病灶大小和微浸润的定义。IA期，病变浸润的宽度不再影响分期。IB期，目前分为了3个亚组：IB1期，间质浸润深度≥5mm且最大径＜2cm；IB2期，包含大小在2-4cm之间的肿瘤；IB3期，肿瘤大小≥4cm。对淋巴结转移的考虑也进行了修订；放射影像学（r）或病理学（p）结果可以用于评估腹膜后淋巴结受累情况，作为诊断 IIIC 期的依据。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "淋巴结受累目前被认定为IIIC 期，它被细分为仅有盆腔淋巴结转移的IIIC1期和主动脉旁淋巴结转移的 IIIC2期。重要的是，淋巴脉管间隙浸润 (LVSI)不会改变 FIGO分期。FIGO分期未包含LVSI因素，因为病理学家对于组织样本中是否存在LVSI的意见时常不一致。一些专家组成员认为，具有广泛LVSI的IA1期患者应根据IB1期指南进行治疗28 。尽管分期和根据分期给出的治疗建议已根据2018版FIGO修订，本部分（讨论部分）大量引用的数据仍采用的是之前的2009版FIGO分期系统29，30。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "# NCCN Guidelines Version 1.2022 宫颈癌 # 手术分期 # 病理评估 手术病理因素可用于指导手术分期和治疗决策。应仔细记录手术标本的病理评估结果。评估原发肿瘤的重要因素包括：肿瘤部位、原发肿瘤体积（多种肿瘤大小）、组织学类型和分级、间质浸润、手术切缘状态和淋巴脉管浸润情况。对于切除的淋巴结，应记录孤立肿瘤转移、微转移和宏转移的淋巴结数量。采用前哨淋巴结（SLN）显影时，SLN应进行超分期以检测微小转移，非SLN不需要超分期。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "其他重要因素包括组织/器官的肿瘤受累情况，例如宫旁、阴道断端、输卵管、卵巢、腹膜、网膜等。“Sedlis 标准”是用于指导辅助治疗决策的中等风险因素，包括：1) 大于1/3的间质浸润； 2) 毛细血管淋巴间隙受累；或 3) 宫颈肿瘤直径超过 4 厘米31。然而，潜在的重要复发风险因素可能不仅限于 Sedlis 标准。需要考虑的其他风险因素包括肿瘤组织学（例如，腺癌成分）32，33和手术切缘阳性或临近肿瘤34，35。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "最近研究结果表明，宫颈腺癌淋巴结转移的预后因素可能与鳞状细胞癌不同。回顾性研究的数据表明，宫颈腺癌间质浸润和毛细血管淋巴间隙受累，可以预测淋巴结转移的风险，而原发肿瘤的大小则不可以。已经针对腺癌提出了包含间质浸润模式的替代分类系统36，38。这些系统仍有待临床验证。# 保守/保留生育能力的方法 若经慎重选择的患者已经通过咨询充分了解疾病风险以及产前和围产期可能会出现的问题，则可以考虑保留生育能力的治疗方案39。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "推荐与生殖内分泌专家进行讨论。微浸润疾病（FIGO IA1期无LVSI）淋巴转移发生率极低40-43，对于没有LVSI证据的患者，推荐采用锥切保守治疗（2A类推荐）。明确有LVSI的IA1期患者，推荐锥切（切缘阴性）联合前哨淋巴结显影或盆腔淋巴结切除术。锥切需完整切除宫颈及颈管；锥体的形状取决于病变的大小、类型和位置（例如，疑似浸润性腺癌，应为窄长形锥体）。专家组建议将冷刀锥切作为锥切的首选方法。然而，当可以获得切缘充足、定位正确、且未受电外科影响的非破碎样本时，也可采用环形电切术（LEEP）44-49。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "应根据临床指征行宫颈管搔刮术。部分经过筛选的IA2期或IB1期宫颈癌患者，尤其是肿瘤直径小于2cm的患者，适合行保守性手术50，51。IA2期、IB1期和部分经过筛选的IB2期（病灶直径≤2cm）患者，推荐性保留生育能力的根治性宫颈切除术52-54。根治性宫颈切除术中，宫颈、阴道边缘和支撑韧带都被切除，留下完整的宫体和宫底55。腹腔镜下盆腔淋巴结切除术可以结合宫颈切除术进行，伴或不伴SLN显影均可（参见下述淋巴结显影和切除）。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "由于其侵袭性，小细胞神经内分泌癌被认为不适合根治性宫颈切除术56。鉴于诊断上的挑战和潜在的侵袭性，宫颈切除术也不适用于治疗胃型宫颈腺癌和恶性腺瘤（微偏腺癌）57。# NCCN Guidelines Version 1.2022 宫颈癌 经阴道根治性宫颈切除术（VRT）适用于经过仔细筛选的病变直径2cm或以下的患者58-60。经腹根治性宫颈切除术（ART）能够更加广泛地切除宫旁组织52，60，比阴式入路更常用于IB1期患者。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "多个病例系列研究评估了经阴道与经腹行根治性宫颈切除术的安全性和预后58，61-63，包括对VRT64和ART65的系统综述。少数专项研究研究了ART手术在肿瘤直径2-4厘米患者中的应用，并报告了安全的肿瘤结局；但是，正如预期的那样，这个亚组中的较多患者需要接受对生育功能有影响的辅助治疗66-68。各项研究中接受根治性宫颈切除术的妇女后续妊娠的成功率有所不同。一项包含125例接受VRT治疗的宫颈癌患者的病例系列研究显示：58例女性中有106个妊娠事件59。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "在一项包含413例接受ART治疗的女性患者的系统综述中，113例女性患者尝试怀孕，67例（59%）成功怀孕62。然而，在接受根治性宫颈切除术的妇女中，流产、早产的发生率较高59，69-71。# 不保留生育功能的方法 Querleu和Morrow外科分类系统72，73在三维平面上描述了根治性子宫切除术的切除范围和神经保留情况，并更新了先前使用的Piver-Rutledge分类74。子宫切除术的方法包括单纯/筋膜外子宫切除术（A型）、改良根治术（B型）和根治性子宫切除术（C型） 75，76。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "对于IA1期宫颈癌患者，可选择锥切术、单纯/筋膜外子宫切除术和改良根治性子宫切除术。根治性子宫切除术联合双侧盆腔淋巴结清扫切除术（±SLN显影）是FIGO IA2、IB1、IB2和IIA1期宫颈癌患者的首选治疗方法。根治性子宫切除术优于单纯子宫切除术，因为其宫颈旁切除的范围较广，包括主韧带和宫骶韧带，阴道上端，盆腔淋巴结，有时还包括主动脉旁淋巴结。在美国，对于部分经过筛选的FIGO IB3期患者和绝大多数FIGO IIA2期及以上的宫颈癌患者，根治性放化疗通常优于根治性手术。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "国际上，部分FIGO IB3-IIB期患者也有接受根治性子宫切除术或新辅助化疗后行根治性子宫切除术的情况。对于局限于盆腔中央的（即无远端转移的）复发性或持续性宫颈癌患者，盆腔廓清术可能是潜在的有效的手术选择77，78。Chi和同事讨论了多种盆腔廓清术的手术方式75，参见美国妇科肿瘤学组（GOG）外科手册76。# 淋巴结显影和切除 前哨淋巴结显影 最近的数据表明，SLN活检有助于减少早期宫颈癌患者对于盆腔淋巴结切除术的需要79，80。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "前瞻性研究普遍支持SLN显影在早期宫颈癌患者中的可行性，并且表明大部分早期病例可以通过SLN活检安全地避免盆腔淋巴结系统性切除79-90。# National Comprehensive NCCN Guidelines Version 1.2022 Cancer 宫颈癌 Network® SLN显影研究的荟萃分析表明，SLN的检出率为89-92％，灵敏度为89％-90％91-92。SLN检测的重要因素包括：腹腔镜检查、双蓝染料/放射性胶体示踪法，免疫组化的病理学检查。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "然而，最近的荟萃分析表明，吲哚菁绿（ICG）示踪剂与标准双蓝染料/99Tc的总体和双侧检出率类似93。III期随机FILM研究表明，ICG较蓝染可以检出更多的SLN（总体和双侧）94。研究数据还强调了SLN方法的灵敏度有限，术中评估（冷冻切片或印迹细胞学）可能漏诊SLN微转移和孤立肿瘤细胞82，86，88。在肿瘤直径≤2cm的患者中，这种方法的敏感性似乎更好79，81，83，95。已检出SLN的超分期可以更好地检测微转移84，85。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "SENTICOL长期研究表明，SLN显影的应用揭示了异常的淋巴引流模式83，96。它还强调了淋巴结造影和术中SLN显像的一致性有限96。此外，这项研究揭示了双侧SLN的检测和活检提供了更可靠的SLN转移评估，与单侧SLN活检相比假阴性更少见80。一般来说，在给定的一侧骨盆没有检出前哨淋巴结（如SLN显影流程所示），研究表明，，应切除该侧的盆腔淋巴结79，80，97。综合上述资料，专家组建议考虑采用SLN显影流程，并强调SLN显影最适于直径小于2cm的肿瘤。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "严格遵守SLN显影流程是非常重要的；当一侧淋巴结显影失败时，应切除该侧的淋巴结；应切除任何可疑或增大的淋巴结，无论其是否显影79。主动脉旁淋巴结检测 对IB-IIB期宫颈癌患者淋巴结转移的发生率和分布的研究表明，主动脉旁淋巴结受累与盆腔淋巴结转移、原发肿瘤较大（＞2cm）、髂总淋巴结转移高度相关98，99。对参与 GOG 试验（GOG 85、GOG 120 和 GOG 165）的 555例女性的结局分析显示，接受手术排除主动脉旁淋巴结转移的患者与通过影像判断的患者相比，预后更好100。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "一项研究评估了在主动脉旁淋巴结受累的患者中将放疗野延伸到主动脉旁淋巴结的疗效，结果显示出了治疗获益，尤其是淋巴结病灶体积小的患者101。一项比较手术和放射影像学用于判断主动脉旁淋巴结受累的分期和治疗的随机对照试验正在进行中102。专家组建议对IB1期及以上的患者进行主动脉旁淋巴结切除。# 微创手术 根治性子宫切除术的标准和传统方式是开腹手术。旧版指南表明根治性子宫切除术可以通过开腹手术或微创手术 (MIS) 腹腔镜（使用传统或机器人技术）的方式进行。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "既往的回顾性研究和前瞻性观察研究的数据表明，经过3-6年的随访，传统腹腔镜根治性子宫切除术的肿瘤结局与开腹手术相当103-106。同样，多中心回顾性研究和匹配的队列研究显示了，经过3-5年的随访，开腹和机器人根治性子宫切除术在疾病复发率和生存率方面结果相当106-109。此外，一项纳入26项研究的系统回顾和荟萃分析发现，腹腔镜和机器人根治性子宫切除术的术中和短期术后结果相当110 C # NCCN Guidelines Version 1.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "2022 宫颈癌 然而，一些关键的同期报告质疑了开腹手术与微创手术的假定的治疗等效性。最近发表的一项前瞻性随机试验表明，与开腹根治性子宫切除术相比，微创根治性子宫切除术的DFS和OS较差111。III期LACC试验(NCT00614211)旨在提供早期宫颈癌患者接受经腹根治性子宫切除术 (TARH) 与腹腔镜根治性子宫切除术/全机器人根治性子宫切除术比较的确切证据。研究终止时，319例患者接受了 MIS（84%腹腔镜，16%机器人），312例患者接受了TARH。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "两组均有92%的患者为IB1期。与开腹手术相比，MIS与较差的DFS相关（3年DFS率，91.2%vs.97.1%；HR 3.74；95% CI，1.63-8.58），OS也较差（3年OS率，93.8%vs.99.0%；HR 6.00；95% CI，1.77-20.30）111。与标准开腹手术相比，MIS没有达到预设的非劣效性标准 (P = 0.88)。最近另有两项流行病学研究表明，IA2-IB1期宫颈癌患者接受微创根治性子宫切除术较开腹手术与更短的OS相关112，113。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Melamed等人报告了一项基于SEER的队列研究，该研究比较了IA2或IB1期宫颈癌患者接受开腹手术(n = 1236)或MIS(n = 1225)的结局112。接受MIS的患者较开腹手术的患者4年死亡率更高（9.1%vs.5.3%，P = 0.002）。在采用MIS技术之前（2000-2006 年），宫颈癌患者的相对存活率是稳定的，但在采用MIS后的几年中出现了显著下降。Margul等人分析了2010-2013年的国家癌症数据库数据，以比较接受开腹与MIS方法进行根治性子宫切除术的IB1期宫颈癌患者的结局114。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "尽管MIS与降低手术并发症和成本有关，但肿瘤≥2cm的患者接受MIS较开放性根治性子宫切除术的5年生存率更低（81.3%vs.90.8%，P < .001）114。早期的系列参考文献表明MIS与开腹手术相比具有治疗等效性，以及 MIS 相关的潜在优势，即减少住院时间和更快的患者康复106，107，109，110，115-118。最新发现与早期研究相矛盾。鉴于最近发表的研究结果表明MIS较开腹手术的肿瘤结局和生存较差，应详尽告知患者不同手术方法的肿瘤风险和潜在的短期获益。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "# 初始治疗 注：根据分期给出的建议基于2018版FIGO分期（Bhatla etal.） 28。但是，本章节引用的研究数据主要采用的是2009版FIGO分期系统。早期宫颈癌的主要治疗方法是手术或放疗。手术通常用于早期病变，保留生育功能和小范围病变如IA、IB1、IB2及部分经过筛选的IIA1期119。专家组一致认为，基于5项随机临床研究的结果，同步放化疗通常是IB3至IVA期患者的初始治疗方案120，121。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "放化疗也可用于不适合子宫切除术的患者。尽管很少有研究探索针对腺癌的治疗方法，通常采用治疗鳞状细胞癌类似的治疗方案进行治疗122-124。# NCCN Guidelines Version 1.2022 宫颈癌 盆腔放疗或者放化疗将会导致绝经前患者卵巢功能衰竭125。为保留卵巢功能，对于部分45岁以下的鳞状细胞癌患者，可考虑在盆腔放疗前行卵巢移位。# 支撑治疗推荐的重要的III期临床研究 一项意大利的随机研究比较了单纯放疗与根治性子宫切除及淋巴结切除术在临床早期患者（IB-IIA 期）中的结局128。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "对宫旁浸润、宫颈间质受累3cm以上、切缘阳性或淋巴结阳性的患者进行辅助放疗。放疗与手术治疗（±术后放疗）的结局相同，但手术联合放疗的并发症发生率更高。根据随机临床试验的结果，同步含铂化疗（单药顺铂 [首选] 或顺铂/氟尿嘧啶）是IB3、II、III和IVA期患者的治疗选择129-134。这些试验已经表明，与单独放疗相比，同步放化疗死亡风险降低30%-50%。尽管与放疗一起应用的最佳同步化疗方案需要进一步研究，但临床试验明确确立了含顺铂化疗方案在同步放化疗中的地位。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "基于这些数据，NCI发出警告，指出对于浸润性宫颈癌，应强烈考虑使用放化疗而不是单纯放疗134。其中 3 项试验的长期随访证实，与放疗±羟基脲相比，同步含顺铂的放化疗可改善无进展生存期 (PFS) 和总生存期135-137。近期的一项荟萃分析称，放化疗可将 5 年生存率提高6%（HR 0.81；P < .001）138。加拿大的一项基于人群的大型分析 (n = 4069) 证实，与单独放疗相比，放化疗改善了治疗结局139。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "虽然放化疗是可以耐受的，但是目前已有急性和长期副作用的报道138，140，141。由于毒性较小，同步单药顺铂放化疗可能优于顺铂/氟尿嘧啶放化疗121，142。对于可能不能耐受含顺铂放化疗的患者，可以选择同步卡铂（如果顺铂不耐受则为首选）或非含铂放化疗方案138，143-148。卡铂已被添加到指南中，作为不耐受顺铂患者首选的放疗增敏剂。需要注意的是，当使用同步放化疗时，通常在盆腔EBRT时进行化疗121。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "专家组认为使用“全身巩固治疗”（即在放化疗后加用化疗）应仅在临床试验中使用（例如： OUTBACK[ANZGOG-0902/GOG 274, NCT01414608] 和 RTOG 724[NCT00980954]) 149。# 早期疾病 经过仔细的临床评估和分期，早期宫颈癌的初始治疗是手术或放疗。使用FIGO分期系统对治疗方案进行分层。对于IA、IB1和部分IB2期患者，可以采用保护生育功能的治疗方式。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "对于患有小细胞神经内分泌肿瘤、胃型腺癌、恶性腺瘤(微偏腺癌)的患者，因为存在高风险性且缺乏数据支持，通常不推荐保留生育功能的手术。# NCCN Guidelines Version 1.2022 宫颈癌 # IA1期 IA1期患者的推荐治疗方案取决于宫颈锥切术的结果，并考虑是否：1）患者想要保留生育能力；2）医学可以实现；3）有LVSI。淋巴结切除的范围取决于是否存在盆腔淋巴结转移和（或）LVSI以及肿瘤的大小。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "可以考虑SLN显影。保留生育功能 对于希望保留生育功能的患者，建议进行宫颈锥切术±盆腔淋巴结切除90，150，151。宫颈锥切术的目标是获取阴性切缘（浸润癌和高级别鳞状上皮内病变[HSIL]均为阴性）。对于宫颈锥切术后切缘为阴性且无LVSI的患者，如果具有强烈保留生育器官和功能的愿望，可以选择观察。对于宫颈锥切术后切缘阳性的患者，可选择重复宫颈锥切术以判断浸润深度（排除IA2/IB期病变）、或根治性宫颈切除术。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "关于宫颈锥切术后切缘阳性患者的研究表明，残留肿瘤的预测因素包括宫颈管诊刮阳性、宫颈管切缘联合宫颈管诊刮±宫颈内切缘阳性、以及肿瘤大小34，152，153。对于IA1期伴LVSI的患者，建议采用锥切术（切缘阴性）联合腹腔镜下盆腔SLN显影/淋巴结切除术。此外，也可采用根治性宫颈切除术联合SLN显影/盆腔淋巴结切除术63，154-157。完成生育后，建议有以下情况的接受过根治性宫颈切除术或锥切活检的早期患者采取子宫切除术治疗：1）慢性、持续性HPV感染，2）持续异常的宫颈涂片检测结果，3）患者希望进行该手术。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "对于选择保留卵巢（即仅行子宫切除术）的年轻（ $< 4 5$ 岁）绝经前早期鳞状细胞癌患者，其卵巢转移的发生率低158,159。不保留生育功能 对于在医学和技术上可手术的不需要保留生育功能的IA1期患者，推荐无LVSI且锥切活检切缘阴性或切缘见不典型增生的患者采取单纯筋膜外子宫切除术。对于切缘肿瘤阳性的患者，推荐采用改良根治性子宫切除术联合SLN显影/盆腔淋巴结切除（淋巴结清扫为2B类推荐）。可以考虑SLN显影。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "医师还可以考虑再次行宫颈锥切术以更好地评估浸润深度。如果存在LVSI，则推荐采用改良根治性子宫切除术联合SLN显影/盆腔淋巴结切除。对于宫颈锥切术切缘阴性的患者，如果在医学上不可手术或患者拒绝手术，建议观察。# IA2期 IA2期的推荐取决于患者是否希望保留生育功能以及在医学上是否可手术。保留生育功能 对于要求保留生育功能的患者，建议采用根治性宫颈切除术联合盆腔淋巴结切除。也可以考虑SLN显影。如果切缘阴性且盆腔淋巴结切除也为阴性，可以考虑锥切活检后继续观察。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "# 不保留生育功能 对于在医学上可手术的不要求保留生育功能的患者，推荐的治疗包括手术或放疗。推荐术式包括根治性子宫切除术和双侧盆腔淋巴结切除术。可以考虑SLN显影。对于已知或怀疑盆腔淋巴结转移的患者，应行主动脉旁淋巴结切除。对于IA2期患者，目前正在探索非根治性手术的创伤更小的治疗方案是否可行153，160。对于不可手术或拒绝手术的患者，可以选择盆腔EBRT联合近距离放疗（传统的A点总剂量为70-80Gy）161。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "推荐剂量是基于常规外照射分割和低剂量率（40-70cGy/h）近距离放疗等效的总剂量，适用于大多数患者。放疗计划应根据正常组织耐受性、剂量分割、靶区体积大小、使用高剂量率近距离放疗时重新计算的生物等效剂量进行调整。# IB1期：保留生育功能 对于希望保留生育功能的患者，推荐IB1期和经过筛选的IB2期患者行根治性宫颈切除术和盆腔淋巴结切除术±主动脉旁淋巴结切除术，NCCN宫颈癌指南仅推荐此方案用于直径≤2cm的肿瘤52，154-157，162。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "可以考虑SLN显影。对于肿瘤直径2-4cm的患者应谨慎采取保留生育功能的治疗方案，因为这些患者由于病理风险因素的存在（例如，Sedlis标准或阳性淋巴结）大多需要术后辅助治疗。然而，一些外科医生认为2cm可以作为采用经阴道宫颈切除术的截断值，4cm可以作为经腹宫颈切除术的截断值163。在一项研究中，4年随访表明IB1期宫颈癌患者接受根治性宫颈切除术和根治性子宫切除术的肿瘤学结局是相当的52。IB1或IB2期小细胞神经内分泌癌、胃型腺癌和恶性腺瘤不适合保留生育功能的手术。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "# IB期和IA期 根据分期和肿瘤大小，IB或IIA期患者可以通过手术、放疗或同步放化疗来治疗。保留生育功能的手术仅适用于IB1期和部分经过筛选的IB2期患者（见下一节）。在确定治疗方案前，可以联合PET/CT扫描以排除盆腔外转移。GOG认为晚期宫颈癌患者可以选择手术分期。推荐IB3期和IIA2期患者采用影像学分期（见NCN宫颈癌指南影像学原则）。# IB期和IIA期：不保留生育功能 对于IB1、IB2和IIA1期患者，初始手术包括根治性子宫切除术联合双侧盆腔淋巴结切除（1类）±主动脉旁淋巴结切除（主动脉旁淋巴结切除为2B类推荐）128，164。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "SLN显影也可考虑用于IB1、IB2和IIA1期患者。专家组认为，基于随机研究的结果，手术是IB1、IB2或IIA1期患者最合适的选择，而同步放化疗是IB3或IIA2期患者的最佳选择128-130，132，133。因此，初始手术治疗是IB1、IB2或IIA1期患者的1类推荐；然而，初始放化疗是IB3或IIA2期患者的1类推荐。对于肿瘤体积较大且疑似或已知盆腔淋巴结转移的患者，可进行主动脉旁淋巴结切除。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "一些专家组成员认为应首先进行盆腔淋巴结清扫，如果是阴性，则应行根治性子宫切除术；如果盆腔淋巴结阳性，则应放弃子宫切除术，行放化疗。# NCCN Guidelines Version 1.2022 宫颈癌 对于IB1、IB2或IIA期肿瘤患者（包括不适合子宫切除术的患者），也可推荐盆腔EBRT和近距离放疗±同步含铂化疗。首选的放疗增敏方案包括顺铂或卡铂（用于不能耐受顺铂的患者），备选同步化疗方案为顺铂/氟尿嘧啶。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "尽管已经证实同步放化疗在分期较晚的肿瘤患者中是有效的，但这种治疗方案尚未在IB1、IB2或IIA1期患者中进行专门的研究。如果将此方案应用于肿瘤较小的患者，应充分考虑其风险/获益比。对于接受根治性放疗的IB3或IIA2期患者，已证实同步含顺铂化疗可显着改善患者生存。专家组推荐根治性EBRT联合同步含铂化疗和近距离放疗（传统的A点总剂量为75-80Gy）。同样，应根据正常组织耐受性，剂量分割和靶区体积大小调整放疗方案。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "初始放化疗有1类推荐129，130。对于IB3或IIA2期肿瘤，专家组对于初始放化疗后推荐辅助子宫切除术（3类）（也称为全切除术）存在重大分歧129。放疗后辅助子宫切除术可以提高盆腔控制率，但不能改善总体生存，且可能增加患者的死亡率165。近期一项Cochrane回顾性研究探索了在标准非手术治疗基础上联合子宫切除术是否有益于局部晚期宫颈癌患者，目前尚缺乏证实手术有生存获益的证据166。行全切除术治疗的患者死亡率增加，但这可能可以通过腹腔镜技术改善167-170。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "虽然子宫切除术不是常规进行的，但是这种治疗方法适用于肿瘤范围较大或子宫在解剖上不适合采取近距离放疗的患者。# 晚期疾病 晚期宫颈癌传统上包括IIB-IVA期患者（即局部晚期肿瘤）。然而，目前许多肿瘤学家将IB3期和IIA2期也列为晚期宫颈癌。对于正在接受初始放化疗的分期较晚的肿瘤患者，放疗的靶区至关重要，应根据盆腔和主动脉旁淋巴结的累及情况而定。推荐对IB2期及以上患者进行影像学评估（包括PET/CT），重点评估有无淋巴结转移或盆腔外转移（参见NCN宫颈癌指南— 影像学原则）。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "MRI有助于描述局部肿瘤的范围并有助于制定放疗计划。然而，对于可疑的影像学结果，可以考虑对宫外异常病灶行活检。这些患者也可以选择手术分期（即腹膜外或腹腔镜淋巴结切除术）（2B类）171。手术分期也可以检测到影像学无法识别的淋巴结镜下转移172。对于通过手术分期判定无淋巴结转移或病灶局限于盆腔的患者，治疗方案包括盆腔EBRT联合同步含铂化疗和近距离放疗（1类）120，121，130，132-134，173。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "目前，可接受的同步含铂方案包括放疗期间顺铂周疗（首选）、卡铂（如果不能耐受顺铂）或每3-4周一次顺铂/氟尿嘧啶。一项国际III期随机试验显示，与标准方案（盆腔EBRT联合同步顺铂化疗）相比，EBRT联合同步顺铂/吉西他滨化疗后，再辅助2个疗程顺铂/吉西他滨化疗，可改善患者的PFS和OS174。但是，这项研究存在争议，因为其统计学设计发生了变更，且报道的优效方案EBRT联合同步顺铂/吉西他滨化疗出现了未解决的毒性反应174-177。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "# NCCN Guidelines Version 1.2022 宫颈癌 但是，对于影像学检查发现主动脉旁淋巴结和盆腔淋巴结阳性的患者，建议进一步针对肿瘤转移行影像学检查。推荐行延伸野EBRT、同步含铂化疗和近距离放疗。主动脉旁淋巴结阳性且存在远端转移的患者推荐行全身化疗±个体化EBRT178。随机试验（GOG 92）探索了淋巴结阴性的IB期宫颈癌患者在全子宮切除术和盆腔淋巴结切除术后行辅助盆腔放疗（对比无辅助治疗）的疗效31。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "参与此研究的患者被界定为“中风险”，入组患者需满足以下至少2个危险因素（通常称为“Sedlis标准”）：1）超过1/3的间质浸润；2）淋巴脉管受累；3）宫颈肿瘤直径超过4厘米。排除淋巴结阳性或手术切缘阳性的患者。随访2年时，辅助放疗的无复发率为88％，无辅助治疗组为79％。经过12年的长期随访，更新的结果证实辅助盆腔放疗可延长PFS；观察到OS的获益趋势（P=0.07）179。国际III期随机试验（GOG 263，NCT01101451）正在进行，旨在评估放疗联合同步顺铂化疗在中风险患者中的作用。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "# 远端转移 对于存在远端转移（即IVB期）的患者，初始治疗通常为含铂化疗（见讨论部分转移性疾病的治疗章节）。在这些情况下，可考虑采用个体化EBRT控制盆腔病灶和其他症状178。# 辅助治疗 根治性子宫切除术后，根据手术结果和肿瘤分期，决定是否需要行辅助治疗。对于IA2、IB或IIA1期患者，如果根治性子宫切除术后淋巴结阴性、切缘阴性、宫旁阴性且无宫颈癌危险因素（Sedlis标准），建议观察。然而，如果发现病理危险因素，应在根治性子宫切除术后行辅助治疗。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "对于IA2、IB或IIA1期患者，如果手术后淋巴结阴性，但原发肿瘤较大、间质浸润较深或伴LVSI，推荐行盆腔EBRT（1类推荐）±同步含铂化疗（化疗为2B类推荐）31，179-182。推荐的放疗增敏方案包括顺铂（首选）、卡铂（如果不能耐受顺铂）或顺铂/氟尿嘧啶。潜在的肿瘤复发的重要风险因素可能不限于“Sedlis标准”（即＞1/3间质浸润，LVSI，肿瘤大小）。还需要考虑的其他风险因素包括肿瘤组织学（例如，腺癌成分）32，33、手术切缘阳性或肿瘤临近切缘34，35。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "对于盆腔淋巴结阳性、手术切缘阳性和（或）宫旁组织阳性的患者（这些患者被界定为“高风险”），建议术后行盆腔EBRT联合同步含铂化疗（1类）131±阴道近距离放疗。阴道近距离放疗对阴道粘膜切缘阳性的患者可能是有用的补充治疗。对于接受根治性子宫切除术和盆腔淋巴结切除术的高风险早期患者（盆腔淋巴结阳性、宫旁浸润和（或）切缘阳性），辅助性同步放化疗可显著改善OS131。0107/GOG109研究表明，对于术中发现淋巴结阳性、切缘阳性和（或）宫颈镜下浸润的IA2，IB或IIA期患者，辅助盆腔放疗联合同步顺铂和氟尿嘧啶化疗获益显著131。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "近期一项研究重新评估了GOG 109的研究结果，利用国家癌症数据库在基于人群的队列（n=3053）中证实了辅助放化疗的生存获益，但提示这种获益可能在淋巴结阳性患者中最明显183。# NCCN Guidelines Version 1.2022 宫颈癌 根据初始手术的结果，可建议行影像学检查以确定是否存在远端转移。对于存在远端转移的患者，应根据指征行可疑病灶的活检。对于无远端转移的患者，推荐行延伸野的EBRT（包括盆腔和主动脉旁淋巴结）联合同步含铂化疗±阴道近距离放疗。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "推荐的放疗增敏方案包括顺铂（首选）、卡铂（如果不能耐受顺铂，则为首选）或顺铂/氟尿嘧啶。对于存在远端转移的患者，推荐行全身化疗±个体化EBRT178。在无法行放疗的地区，新辅助化疗后序贯手术的治疗方案已经得以应用，但是数据显示，对于早期184-186或局部晚期187，188宫颈癌患者，该方案与单纯手术相比未能改善患者生存。一项针对IB1-IIA期宫颈癌患者的荟萃分析表明，新辅助化疗可能通过减少肿瘤大小和转移来减少对辅助放疗的需求，但OS无获益188。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "然而，另一项荟萃分析表明新辅助化疗的疗效是PFS和OS的重要预后因素189，190。在临床试验之外，专家组不建议使用新辅助化疗。# 监测 专家组同意SGO关于治疗后监测的推荐意见191。所推荐的监测是基于患者的复发风险和个人偏好。建议前2年每3-6个月进行病史询问和体格检查，此后3-5年每6-12个月进行，随后每年进行。高风险患者随访的频率（例如，前2年每3个月）应该比低风险患者（例如，每6个月）更高。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "建议每年行宫颈/阴道细胞学检查，以确定下生殖道上皮的不典型增生（上皮内瘤变）（例如，保留生育功能的患者）。一些临床医生认为，严格的细胞学随访是不合理的，因为有研究表明，对于治疗后无症状的I期或II期宫颈癌患者，宫颈涂片检查没有检测出疾病复发191-193。应注意到这些患者与一般筛查人群之间存在固有差异，专家组不建议对监测期间发现的低级别鳞状上皮不典型增生进行检查，但建议患者至该领域专家处随访。强调良好的临床随访和保持高度怀疑是非常重要的，因为单纯使用宫颈和阴道细胞学检查，宫颈癌复发的检出率很低194。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "对于I期患者，应基于症状和对复发/转移的临床考虑进行影像学随访，例如异常的体格检查结果或新发的盆腔、腹部或肺部症状。如果接受了保留生育功能的治疗，应考虑在术后6个月行盆腔MRI检查，此后2-3年每年行盆腔MRI检查。如果怀疑转移，考虑行PET/CT检查195。对于II期或以上患者，完成治疗后的3-6个月内，应该行PET/CT（首选）或CT检查，也可选择盆腔MRI检查。其他影像学检查应基于复发/转移的症状及临床指征。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "影像学监测的特定适应证和推荐详见NCN宫颈癌指南— 影像学原则191，196-204。可基于临床指征选择其他检查，例如每半年一次全血细胞计数，血尿素氮和血清肌酐。疾病持续或复发的患者需根据临床指征行额外的影像学检查，或在经过筛选的患者中行手术探查，并进行复发后的治疗（见下一节）205。推荐对患者进行肿瘤复发症状的教育（例如，阴道分泌物；体重减轻；厌食症；盆腔、臀部、背部或腿部疼痛；持续咳嗽）。还应就健康的生活方式、肥胖、营养、运动、性健康、激素替代治疗以及潜在的长期和远期的治疗影响向患者提供咨询。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "应鼓励患者戒烟、脱瘾191。（见NCCN癌症生存者指南和NCCN戒烟指南，http://www.cancer.org/treatment/survivorship） 接受放疗的患者可能会出现阴道狭窄和干燥，应接受有关性健康和阴道健康的教育。应告知患者规律阴道性交和（或）阴道扩张器的使用以及阴道保湿剂/润滑剂（例如雌激素乳膏）的使用。有证据表明，阴道扩张器可用于防治阴道狭窄206。扩张器的使用可在放疗完成后2-4周开始，并可无限期进行。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "宫颈癌生存者有患第二肿瘤的风险。数据表明，接受盆腔放疗的患者有发生放疗诱发第二肿瘤的风险，特别是靠近宫颈的辐射部位(例如，结肠、直肠/肛门、膀胱)，因此，应对这些患者进行仔细的监测208，209。# 复发治疗 在复发的治疗前，应行活检明确是否复发。局部治疗 初始治疗后宫颈癌局部复发的患者可能适合行根治性治疗，方案包括：1）放疗和（或）化疗；2）手术120，210。在某些情况下，复发后治疗的长期DFS率约为40％ 211。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "对于经历过局部复发且既往未接受过放疗或在先前放疗野之外复发的患者，复发的治疗包括肿瘤EBRT±化疗和（或）近距离放疗；如果可行，可考虑手术切除。通常，复发肿瘤的放化疗使用单药顺铂或卡铂治疗，或顺铂联合氟尿嘧啶212，213。然而，对于完成初始放化疗后不久就复发的患者，可选用替代的化疗药物（例如卡铂、紫杉醇和吉西他滨）进行同步化疗。放疗后盆腔中心性复发的患者应行盆腔廓清术±术中放疗（IORT），尽管IORT为3类推荐214-221。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "手术死亡率一般为5％或更低，在经过仔细筛选的患者中生存率接近50％217。在实施这些根治性手术时，还应同时制定相应的其他措施，包括适当的康复计划（解决患者的社会心理和性心理问题）和重建手术216，222-224。# NCCN Guidelines Version 1.2022 宫颈癌 尽管廓清术是孤立的盆腔中心性复发患者的常见手术方式，但中央性小病灶（＜2cm）的患者也可选择根治性子宫切除术或近距离放疗。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "对于患有非中心性复发的患者，可以选择EBRT±化疗，手术切除±IORT（IORT为3类推荐），化疗（见NCCN姑息治疗指南）或参与临床试验。经过二线根治性治疗后出现复发的患者，无论手术或放疗，预后均不佳。这些患者可以接受系统治疗或最佳支持治疗，也可以参加临床试验。# 转移病灶的治疗 无论是初治还是复发时出现远端转移的患者，都很难治愈。对于经过高度选择的、具有可局部治疗的孤立性远端转移的患者，少数研究报道了采用以下方案治疗的长期存活率：1）手术切除±EBRT；2）局部消融治疗±EBRT；3）化疗±EBRT。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "可以考虑全身辅助化疗。例如，淋巴结、肺、肝或骨寡转移的患者可能受益于局部介入性治疗225，226。在局部治疗后，可以考虑辅助化疗。对于大多数远端转移的患者，可选择临床试验、化疗或最佳支持治疗（见NCCN姑息治疗指南）。对于不适合局部疼痛控制技术或手术切除的盆腔重点照射部位复发的患者，其姑息治疗十分困难。这些部位通常对化疗没有反应。充分缓解复发引起的疼痛和瘘管等并发症在临床上非常具有挑战性。（http://emedicine.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "medscape.com/article/270646-overview).然而，短程放疗可缓解骨转移、痛性主动脉旁淋巴结或锁骨上淋巴结转移的症状178,227,228。对于出现盆腔外复发或转移的患者，不适宜放疗或廓清术，通常推荐化疗。对化疗有反应的患者，其疼痛和其他症状可明显缓解。基于几项随机III期试验，如果之前治疗中使用过顺铂作为放疗增敏剂，在转移性疾病的治疗中，含铂的联合治疗方案优于单一药物化疗（见下节）229，230。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "但是，对化疗的反应通常持续时间短，生存很少得到改善。# 一线联合化疗 顺铂被认为是治疗转移性宫颈癌最有效的药物231。然而，大多数转移性宫颈癌患者同时接受顺铂和放疗作为初始治疗，对单药铂类治疗的敏感性可能有所降低229，230。含顺铂的联合化疗方案已在临床研究中得到广泛探索，例如顺铂/紫杉醇/贝伐珠单抗（首选方案，1类推荐）、顺铂/紫杉醇（首选方案，1类推荐）和顺铂/拓扑替康（2A类推荐） 229，230，232-235。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "随机III期研究（GOG 169）在264例患者中比较了顺铂联合紫杉醇和单药顺铂治疗转移性、复发性或持续性宫颈癌的效果。接受两药联合治疗的患者与接受单药顺铂的患者相比，尽管中位生存未见改善，但缓解率更高（36%vs.19%），PFS更长（4.8个月vs.2.8个月，P＞0.001 ）229。对顺铂/紫杉醇有反应的患者在生活质量方面有显著改善。# NCCN Guidelines Version 1.2022 宫颈癌 另一项随机III期研究（GOG 179）在294例患者中对比了顺铂联合拓扑替康和单药顺铂治疗复发性或持续性宫颈癌的结局。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "拓扑替康联合方案在总缓解率（27% vs.13%，P=0.004)、PFS（4.6个月 vs.2.9个月，P=0.014）、中位生存期（9.4个月 vs.6.5个月，P=0.017）方面优于单药顺铂230。FDA（美国食品和药物管理局）已经批准顺铂/拓扑替康方案用于晚期宫颈癌。然而，与顺铂/拓扑替康相比，顺铂/紫杉醇、卡铂/紫杉醇方案毒性更小、给药也更容易236。III期试验（GOG 204）在513例晚期转移性或复发性宫颈癌患者中比较了4种含顺铂的双药联合方案（顺铂／紫杉醇、顺铂／拓扑替康、顺铂／吉西他滨、顺铂／长春瑞滨）234。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "试验在无效性分析的基础上提前结束，因为顺铂/拓扑替康、顺铂/吉西他滨和顺铂/长春瑞滨方案并不优于对照组顺铂/紫杉醇。未观察到总体生存率的明显差异，但缓解率、PFS和OS（12.9个月vs.10个月）的趋势表明顺铂/紫杉醇优于其他方案。与其他方案相比，顺铂/紫杉醇引起的血小板减少和贫血较少（但恶心、呕吐、感染和脱发较多）。近期一项随机III期试验（GOG 240)在452例一线治疗的转移性、持续性或复发性宫颈癌患者中探索了在联合化疗的基础上加用贝伐珠单抗(顺铂/紫杉醇/贝伐珠单抗或拓扑替康/紫杉醇/贝伐珠单抗)的疗效。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "对两种化疗方案汇总数据的分析表明，接受贝伐珠单抗治疗的患者OS显著提高（16.8个月 vs.13.3个月，P=0.007）235。虽然拓扑替康/紫杉醇(2A类推荐)没有显示出优于顺铂/紫杉醇，但对于不适合用顺铂的患者来说，它是可以考虑的替代方案235。虽然贝伐珠单抗导致更高的毒性（如高血压、血栓栓塞事件和胃肠瘘），但与患者报告生活质量的统计学显著下降无相关性（P=0.27）237。一项2017年的系统综述和纳入19项探索复发性、持续性或转移性宫颈癌系统治疗的研究的荟萃分析显示，与所有其他不含贝伐珠单抗的化疗方案相比，在顺铂/紫杉醇或拓扑替康/紫杉醇的基础上加用贝伐珠单抗具有改善OS的趋势238。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "两个含贝伐珠单抗的方案均纳入为治疗持续性、复发性或转移性宫颈癌的首选1类推荐。近期公布的一项III期随机试验(JCOG0505）表明，在253例转移或复发的宫颈癌中，卡铂/紫杉醇不劣于顺铂/紫杉醇239。许多医生使用卡铂/紫杉醇，因为给药方便且耐受性好240。JCOG0505的结果显示卡铂/紫杉醇（TC）方案的中位OS不劣于顺铂/紫杉醇（TP） （TP 18.3个月vs.TC 17.5个月，HR0.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "994[90%CI 0.79-1.25]，P=0.032） ，且TC患者的非住院时间明显延长239。然而，在既往未接受过顺铂治疗的患者中，TC和TP的OS分别为13.0和23.2个月（HR 1.571，95%CI 1.06-2.32）239。基于这些数据，专家组推荐卡铂/紫杉醇作为既往接受过顺铂治疗的患者的首选1类推荐方案（对于其他适应证患者为2A类推荐）。近期一项针对顺铂/紫杉醇和卡铂/紫杉醇的系统综述表明，以卡铂为基础的方案毒性较低，可以作为含顺铂方案治疗复发性或转移性宫颈癌的等效的替代方案241。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "基于GOG 240和JGOG0505的共同发现，专家组将卡铂/紫杉醇/贝伐珠单抗纳入治疗复发性或转移性宫颈癌的其他推荐方案（2A类推荐）。基于以往的研究，顺铂/紫杉醇和卡铂/紫杉醇已成为转移性或复发性宫颈癌最为广泛应用的系统治疗方案。然而，对于不适合紫杉醇治疗的患者，顺铂/拓扑替康仍然是合理的替代方案230。2019年，专家组通过投票将顺铂/吉西他滨从一线联合治疗选择中移除。非含铂方案也正在研究中，可考虑用于不能耐受以铂类为基础的化疗的患者242。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "# 单药化疗 # 其它药物 顺铂是公认的最有效的药物，被推荐作为复发或转移性宫颈癌一线单药化疗的首选方案；据报道，顺铂的缓解率约为20％-30％，有时可出现完全缓解229，231，243，244。顺铂治疗的OS约为6-9个月。据报道，卡铂和紫杉醇都是可耐受且有效的药物，可以作为一线单药化疗的选择245-248。因此，单药（顺铂、卡铂或紫杉醇）姑息治疗对于不适宜手术或放疗的复发患者是合理的治疗方案。帕博利珠单抗已被列为PD-L1阳性或MSI-H/dMMR宫颈癌二线治疗的首选推荐（2A类推荐）249-251。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "其他有一定缓解率或可以延长PFS，可以用作二线治疗的可推荐药物（均为2B类推荐）包括：贝伐珠单抗252、白蛋白结合型紫杉醇253、多西他赛254、氟尿嘧啶255、吉西他滨256、异环磷酰胺257，258、伊利替康259、丝裂霉素260、培美曲塞261、拓扑替康262，263和长春瑞滨264。靶向治疗和生物制剂在部分经过筛选的宫颈癌患者中有一定的作用。帕博利珠单抗和贝伐珠单抗已经被纳入复发或转移性疾病的治疗指南。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "使用这些药物和其他靶向药物或生物制剂仍是研究的热点领域。# 药物反应 几乎所有药物在输注期间或输注后都可能引起不良反应265。在宫颈癌的治疗中，常引起不良反应的药物包括卡铂、顺铂、多西他赛、脂质体多柔比星和紫杉醇。大多数药物反应是轻微的输液反应（即皮肤反应，心血管反应，呼吸或喉咙发紧），但也有更为严重的过敏反应（即危及生命的过敏反应）发生266，267。此外，患者可能有严重的输液反应和轻微的过敏反应。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "输液反应更常见于紫杉醇268。过敏反应（即真正的药物过敏）更常见于铂类药物（如顺铂）268，269。NCCN卵巢癌指南讨论了药物反应的管理。重要的是，经历过严重的危及生命的药物反应的患者不应再次接受所涉及的药物，除非经过过敏症专家或药物脱敏专家的评估。如果先前发生过轻微过敏反应且适合再次使用该药物时，推荐采用脱敏方案，即使症状已经消退。多种不同的脱敏方案已经公布，应该严格遵循269-271。如果患者之前出现过药物反应，每次输液都必须进行脱敏治疗。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "几乎所有患者都可以脱敏265。为了最大限度地保证安全性，患者应该在重症监护病房进行脱敏治疗265。# NCCN Guidelines Version 1.2022 宫颈癌 # 最佳支持治疗 难治性全身性肿瘤患者需要根据个体情况，采取综合的治疗方法，包括临终关怀、疼痛咨询、情感和精神支持(见NCCN姑息护理指南)。# 意外发现的宫颈癌 浸润性宫颈癌有时会在筋膜外子宫切除术后意外发现。这些患者应该进行以下检查，包括病史询问和体格检查，全血细胞计数（包括血小板）和肝肾功能检查。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "推荐的放射性影像学检查包括胸部X线，CT或联合PET/CT检查；如有临床指征，可行MRI以排除大体残留肿瘤。然而，对于IB1期或更小的肿瘤患者，影像学检查是可选择的方案。尚无明确证据支持可用于指导这些患者进行适当的辅助治疗。对于IA1期无LVSI的患者，建议进行随访。对于IA1期伴LVSI、IA2或IB期、或切缘阳性/大体残留病灶的患者，专家组认为合理的治疗方案应基于手术切缘的状态。如果切缘阳性且影像学淋巴结阴性，推荐盆腔放疗联合同步含铂化疗±个体化近距离放疗。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "推荐的放疗增敏方案包括顺铂（首选）、卡铂（如果不能耐受顺铂，则为首选）或顺铂/氟尿嘧啶。对于IA2期或更大的肿瘤，如果切缘或影像学检查为阴性，可选方案包括：1) 盆腔放疗联合近距离放疗±同步含铂化疗；或2)如果子宫切除标本不符合Sedlis标准，考虑根治性宫旁组织切除术+阴道上段切除术+盆腔淋巴结清扫术±腹主动脉旁淋巴结取样（主动脉旁淋巴结取样为2B类推荐）。通常，对于淋巴结阴性且无残留病灶的患者，推荐进行观察。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "然而，对于后续发现淋巴结、手术切缘和（或）宫旁组织阳性的患者，建议行放化疗±阴道近距离放疗。对于子宫切除标本切缘阳性、存在大体残留病灶、影像学阳性或原发肿瘤特征符合Sedlis标准者，推荐盆腔 EBRT 联合同步含铂化疗（阴道切缘阳性者行个体化近距离放疗）31。# 放疗 放疗通常用于治疗以下宫颈癌患者：1）作为局部晚期患者或不适宜手术的患者的根治性治疗；2）作为根治性子宫切除术后具有一种或多种病理危险因素（例如，淋巴结阳性，宫旁浸润，手术切缘阳性，肿瘤直径大，深间质侵犯，LVSI）的患者的辅助治疗。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "该指南提供了放疗剂量的常规建议，但该建议不应被解释为一个单独的推荐方案，因为放疗技术和临床判断是制定合适的治疗方案的必要环节。对于IB2期、IIA2期或晚期肿瘤患者，建议对肿瘤进行最佳分期，包括腹盆腔放射学检查（CT、MRI或联合PET/CT扫描），以精确描述原发肿瘤体积和引流区淋巴结。影像学检查必须结合对临床发现进行仔细的评估，以明确肿瘤范围，尤其是阴道或宫旁的累及情况。# 放疗计划 成像技术、计算机治疗计划系统和直线加速器的技术进步，使盆腔放疗的剂量更加精确。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "然而，要想在物理学上准确地递送放疗剂量，必须清楚地了解肿瘤范围、潜在的扩散途径以及局部/区域复发的模式，以免遗漏放射野。以CT为基础的治疗计划辅以适形挡块和剂量测定是EBRT的标准。近距离放疗是不适合手术的宫颈癌患者（也就是说，这些患者有完整的宫颈）根治性治疗的关键部分；近距离放疗也可以用作辅助治疗。近距离放疗通常联合EBRT，作为一个综合的治疗计划。近距离放疗前立即行MRI成像可能有助于描绘残余肿瘤的几何形状。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "立体定向放疗（SBRT）可实现高剂量的聚焦式外照射，可应用于孤立的转移病灶272，273。常规图像引导，例如锥形束CT（CBCT），可能有助于确定常规的内部软组织的位置。GTV、CTV、PTV、OAR和DVH等概念已被明确定义用于适形放疗、尤其是IMRT中274-276。A点，代表宫旁参考点，是迄今最为广泛使用、最有效和可重复的剂量参考点。但是，A点没有考虑到肿瘤的三维形状及肿瘤与正常组织结构的关系，因而具有一定局限性。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "人们正在努力应用以成像（MR、CT或超声）为基础的容积近距离放疗并使其标准化。国际化的验证工作正在进行中(EMBRACE，NCT00920920) 277-280。对于局部晚期患者，通常需要对整个盆腔进行40-45Gy的初始放疗，以使肿瘤体积缩小，进而实现最理想的腔内放置。随着低剂量率腔内放射的应用，目前推荐对于小肿瘤，近距离放疗和EBRT至A点的放射总剂量至少80Gy，对于较大的肿瘤，建议剂量为85Gy或以上 （http://www.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "americanbrachytherapy.org/guidelines/cervical_cancer_taskgroup.pdf） 120。对于侵犯阴道下1/3的病变，必须照射腹股沟淋巴结。使用扩大野放疗治疗隐匿的或肉眼可见的主动脉旁淋巴结必须仔细计划，以确保在不超过肠道、脊髓或肾脏耐受性的情况下获得足够的剂量（对于微小病变，剂量为45Gy）281。关于放疗区域和剂量的一般建议见流程图。调强放疗（IMRT）的应用越来越广泛，然而，关于靶区定义，患者和靶区固定，组织变形，毒性和可重复性的问题仍有待验证282-289。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "来自RTOG418的初始II期血液学毒性数据表明，对于接受同步化疗的患者，限制骨髓照射体积（用IMRT进行治疗）是重要的考量因素290。近期报道的TIME-C试验（RTOG1203，NCT01672892）在子宫切除术后的患者中比较了辅助IMRT或标准四野放疗，以确定IMRT是否可以降低急性毒性。分析纳入了278例宫颈癌和子宫内膜癌患者，结果显示，与标准放疗相比，接受盆腔IMRT的患者胃肠道和泌尿系毒性评分显著较低291。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "# NCCN Guidelines Version 1.2022 宫颈癌 几项回顾性分析表明，延长放疗持续时间对结局有不利影响292-296。整体治疗时间延长至超过6-8周可导致盆腔控制率和疾病特异生存率降低，总体治疗时间每增加一天，盆腔控制率和疾病特异生存率减少约0.5％-1％。因此，虽然没有开展过前瞻性随机试验，但普遍认为整个放疗过程（包括EBRT和近距离放疗）应及时完成（8周内）；应尽可能避免放疗延误或中断。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "# 正常组织注意事项 宫颈癌的放疗计划必须考虑到对周围关键结构的潜在影响，例如直肠，膀胱，乙状结肠，小肠和骨。大多数接受放疗的患者会发生不同程度的急性反应（即腹泻，膀胱刺激，疲劳），同步化疗的患者通常反应更大。然而，急性反应通常可以通过药物和支持性治疗来控制，并且通常在完成放疗后很快得以解决。为了避免与治疗有关的绝经，对于经过筛选的年轻患者（＜45岁的早期患者），可以考虑在盆腔放疗前行卵巢移位术125-127。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "宫颈癌放疗后，远期副作用可能包括对膀胱、直肠、肠道和骨盆骨骼结构的潜在损伤297。主要并发症（如梗阻、纤维化/坏死和瘘管）的风险与靶区、总剂量、每次照射剂量和照射的正常组织特异的放射敏感性相关281，298，299。在保证覆盖肿瘤区域的同时，小心避开正常组织以减少正常组织暴露是获得最佳治疗结局的关键。此外，患者的相关疾病（炎症性肠病，胶原血管病，多次腹部/盆腔手术，盆腔炎性疾病史，糖尿病）影响放疗剂量和靶区的确定。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "对于大多数患者，通常认为整个盆腔可以耐受40-50Gy的EBRT剂量。宫旁大体病灶或未切除的淋巴结可以通过高度适形的EBRT推量至60-65Gy。实施腔内近距离推量照射时，需要注意将施源器放置在子宫内紧贴子宫颈和阴道顶端的适当位置，并适当的填充以最大程度地避开膀胱和直肠。SBRT不能常规替代近距离放疗。# 宫颈癌与妊娠 宫颈癌是妊娠期妇女最常被诊断出的妇科恶性肿瘤；不过，大多数为I期宫颈癌300-303。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "妊娠期间发现的浸润性宫颈癌造成了临床上的困境，需要多学科治疗300，304。患者必须做出艰难的决定，要么延迟治疗直至证实胎儿已成熟，要么根据疾病分期立即接受治疗301，304。延迟治疗直至胎儿成熟的患者应该通过剖宫产分娩303，305，306。保留妊娠的根治性宫颈切除术已在少数患早期宫颈癌的妊娠患者中得以成功实施53，307-309。早期宫颈癌患者可能选择采用根治性子宫切除术和淋巴结清扫术，而不是放疗，以避免放疗后纤维化以及保护卵巢。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "延迟治疗直至胎儿成熟的I期宫颈癌患者可以在剖宫产的同时接受根治性子宫切除术和盆腔淋巴结清扫术。对于选择放疗的患者，传统的放疗±化疗的方案（如前所述）可能需要调整303 C # 总结 由于筛查的广泛使用，美国的宫颈癌正在减少；然而，发展中国家的宫颈癌仍在增加（每年约275,000人死亡），因为许多妇女未能接受筛查。宫颈癌的有效治疗（包括手术和同步放化疗）可以使80％的早期（I-II期）患者和60％的III期患者得以治愈。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "希望针对HPV进行免疫接种（使用疫苗）可以预防疫苗所针对的HPV型别的持续性感染，从而预防女性患特定HPV相关的癌症15，16，310。表1：5项同步放化疗临床试验中死亡相对风险度的估计值 <html><body><table><tr><td>试验*</td><td>FIGO分期</td><td>对照组</td><td>对比组</td><td>树风死亡</td></tr><tr><td>Keys et al.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "t</td><td>IB2</td><td>放疗</td><td>放疗+顺铂周疗</td><td>0.54</td></tr><tr><td rowspan=\"2\">Rose, Bundy, Watkins et al.t</td><td rowspan=\"2\">IIB-IVA</td><td rowspan=\"2\">放疗+羟基脲</td><td>放疗+顺铂周疗</td><td>0.61</td></tr><tr><td>放疗+顺铂，氟尿嘧啶和羟基脲</td><td>0.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "58</td></tr><tr><td>Morris et al.t</td><td>IB2-IVA</td><td>扩大野放疗</td><td>放疗+顺铂和氟尿嘧啶</td><td>0.52</td></tr><tr><td>Whitney et al.</td><td>IIB-IVA</td><td>放疗+羟基脲</td><td>放疗+顺铂和氟尿嘧啶</td><td>0.72</td></tr><tr><td>Peters et al.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "</td><td>的患经过筛选</td><td>放疗</td><td>放疗+顺铂和氟尿嘧啶</td><td>0.50</td></tr></table></body></html> 经Thomas GM.许可后使用，Improved treatment for cervical cancer concurrent chemotherapy and radiotherapy.N Engl J Med 1999;340(15):1198-1200。",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Copyright© 1999 Massachusetts Medical Society.保留所有权利。# 参考文献 1.Siegel RL, Miller KD, Jemal A.Cancer statistics, 2019.CA Cancer J Clin 2019;69:7-34.Available at: https://www.ncbi.nlm.nih.gov/pubmed/30620402.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "2.Barnholtz-Sloan J, Patel N, Rollison D, et al.Incidence trends of invasive cervical cancer in the United States by combined race and ethnicity.Cancer Causes Control 2009;20:1129-1138.Available at: http://www.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "ncbi.nlm.nih.gov/pubmed/19253025.3.Wang SS, Carreon JD, Gomez SL, Devesa SS.Cervical cancer incidence among 6 asian ethnic groups in the United States, 1996 through 2004.Cancer 2010;116:949-956.Available at: http://www.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "ncbi.nlm.nih.gov/pubmed/20029972.4.Howe HL, Wu X, Ries LAG, et al.Annual report to the nation on the status of cancer, 1975-2003, featuring cancer among U.S.Hispanic/Latino populations.Cancer 2006;107:1711-1742.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Available at: http://www.ncbi.nlm.nih.gov/pubmed/16958083.5.Sherman ME, Wang SS, Carreon J, Devesa SS.Mortality trends for cervical squamous and adenocarcinoma in the United States.Relation to incidence and survival.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Cancer 2005;103:1258-1264.Available at: http://www.ncbi.nlm.nih.gov/pubmed/15693030.6.Cervical Cancer: Estimated Incidence, Mortality and Prevalence Worldwide in 2012.International Agency for Research on Cancer and World Health Organization; 2012.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Available at: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.Accessed January 26, 2015.7.Parkin DM, Bray F, Ferlay J, Pisani P.Global cancer statistics, 2002.CA Cancer J Clin 2005;55:74-7108.Available at: http://www.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "ncbi.nlm.nih.gov/pubmed/15761078.8.Kamangar F, Dores GM, Anderson WF.Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "J Clin Oncol 2006;24:2137-2150.Available at: http://www.ncbi.nlm.nih.gov/pubmed/16682732.9.Jemal A, Bray F, Center MM, et al.Global cancer statistics.CA Cancer J Clin 2011;61:69-90.Available at: http://www.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "ncbi.nlm.nih.gov/pubmed/21296855.10.Kjaer SK, Frederiksen K, Munk C, Iftner T.Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "J Natl Cancer Inst 2010;102:1478-1488.Available at: http://www.ncbi.nlm.nih.gov/pubmed/20841605.11.Rodriguez AC, Schiffman M, Herrero R, et al.Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "J Natl Cancer Inst 2010;102:315-324.Available at: http://www.ncbi.nlm.nih.gov/pubmed/20157096.12.Villa LL, Costa RL, Petta CA, et al.Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Lancet Oncol 2005;6:271-278.Available at: http://www.ncbi.nlm.nih.gov/pubmed/15863374.13.Ault KA.Effect of prophylactic human papillomavirus L1 virus-likeparticle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Lancet 2007;369:1861-1868.Available at: http://www.ncbi.nlm.nih.gov/pubmed/17544766.14.Quadrivalent vaccine against human papillomavirus to prevent highgrade cervical lesions.N Engl J Med 2007;356:1915-1927.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Available at: http://www.ncbi.nlm.nih.gov/pubmed/17494925.15.Arbyn M, Dillner J.Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "J Clin Virol 2007;38:189-197.Available at: http://www.ncbi.nlm.nih.gov/pubmed/17258503.16.Rambout L, Hopkins L, Hutton B, Fergusson D.Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "CMAJ 2007;177:469- 479.Available at: http://www.ncbi.nlm.nih.gov/pubmed/17671238.17.Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Cancer 2007;120:885-891.Available at: http://www.ncbi.nlm.nih.gov/pubmed/17131323.18.Dugue PA, Rebolj M, Garred P, Lynge E.Immunosuppression and risk of cervical cancer.Expert Rev Anticancer Ther 2013;13:29-42.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Available at: http://www.ncbi.nlm.nih.gov/pubmed/23259425.19.Bray F, Loos AH, McCarron P, et al.Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Cancer Epidemiol Biomarkers Prev 2005;14:677-686.Available at: http://www.ncbi.nlm.nih.gov/pubmed/15767349.20.Watson M, Saraiya M, Benard V, et al.Burden of cervical cancer in the United States, 1998-2003.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Cancer 2008;113:2855-2864.Available at: http://www.ncbi.nlm.nih.gov/pubmed/18980204.21.Bray F, Carstensen B, Moller H, et al.Incidence trends of adenocarcinoma of the cervix in 13 European countries.Cancer Epidemiol Biomarkers Prev 2005;14:2191-2199.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Available at: http://www.ncbi.nlm.nih.gov/pubmed/16172231.22.Wang SS, Sherman ME, Hildesheim A, et al.Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Cancer 2004;100:1035- 1044.Available at: http://www.ncbi.nlm.nih.gov/pubmed/14983500.23.Castellsague X, Diaz M, de Sanjose S, et al.Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "J Natl Cancer Inst 2006;98:303- 315.Available at: http://www.ncbi.nlm.nih.gov/pubmed/16507827.24.Sasieni P, Castanon A, Cuzick J.Screening and adenocarcinoma of the cervix.Int J Cancer 2009;125:525-529.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Available at: http://www.ncbi.nlm.nih.gov/pubmed/19449379.25.Dahlstrom LA, Ylitalo N, Sundstrom K, et al.Prospective study of human papillomavirus and risk of cervical adenocarcinoma.Int J Cancer 2010;127:1923-1930.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Available at: http://www.ncbi.nlm.nih.gov/pubmed/20473898.26.Siegel CL, Andreotti RF, Cardenes HR, et al.ACR Appropriateness Criteria(R) pretreatment planning of invasive cancer of the cervix.J Am Coll Radiol 2012;9:395-402.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Available at: http://www.ncbi.nlm.nih.gov/pubmed/22632665.27.Patel S, Liyanage SH, Sahdev A, et al.Imaging of endometrial and cervical cancer.Insights Imaging 2010;1:309-328.Available at: http://www.ncbi.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "nlm.nih.gov/pubmed/22347925.28.Bhatla N, Berek JS, Cuello Fredes M, et al.Revised FIGO staging for carcinoma of the cervix uteri.Int J Gynaecol Obstet 2019;145:129-135.Available at: https://www.ncbi.nlm.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "nih.gov/pubmed/30656645.29.Pecorelli S.Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium.Int J Gynaecol Obstet 2009;105:103-104.Available at: http://www.ncbi.nlm.nih.gov/pubmed/19367689.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "30.Pecorelli S, Zigliani L, Odicino F.Revised FIGO staging for carcinoma of the cervix.Int J Gynaecol Obstet 2009;105:107-108.Available at: http://www.ncbi.nlm.nih.gov/pubmed/19342051.31.Sedlis A, Bundy BN, Rotman MZ, et al.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 1999;73:177-183.Available at: http://www.ncbi.nlm.nih.gov/pubmed/10329031.32.Ryu SY, Kim MH, Nam BH, et al.Intermediate-risk grouping of cervical cancer patients treated with radical hysterectomy: a Korean Gynecologic # NCCN Guidelines Version 1.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "2022 宫颈癌 Oncology Group study.Br J Cancer 2014;110:278-285.Available at: http://www.ncbi.nlm.nih.gov/pubmed/24357798.33.Noh JM, Park W, Kim YS, et al.Comparison of clinical outcomes of adenocarcinoma and adenosquamous carcinoma in uterine cervical cancer patients receiving surgical resection followed by radiotherapy: a multicenter retrospective study (KROG 13-10).",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2014;132:618-623.Available at: http://www.ncbi.nlm.nih.gov/pubmed/24486605.34.Diaz ES, Aoyama C, Baquing MA, et al.Predictors of residual carcinoma or carcinoma-in-situ at hysterectomy following cervical conization with positive margins.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2014;132:76-80.Available at: http://www.ncbi.nlm.nih.gov/pubmed/24262876.35.Estape RE, Angioli R, Madrigal M, et al.Close vaginal margins as a prognostic factor after radical hysterectomy.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 1998;68:229- 232.Available at: http://www.ncbi.nlm.nih.gov/pubmed/9570971.36.Parra-Herran C, Taljaard M, Djordjevic B, et al.Pattern-based classification of invasive endocervical adenocarcinoma, depth of invasion measurement and distinction from adenocarcinoma in situ: interobserver variation among gynecologic pathologists.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Mod Pathol 2016;29:879-892.Available at: https://www.ncbi.nlm.nih.gov/pubmed/27174588.37.Roma AA, Mistretta TA, Diaz De Vivar A, et al.New pattern-based personalized risk stratification system for endocervical adenocarcinoma with important clinical implications and surgical outcome.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2016;141:36-42.Available at: https://www.ncbi.nlm.nih.gov/pubmed/27016227.38.Rutgers JK, Roma AA, Park KJ, et al.Pattern classification of endocervical adenocarcinoma: reproducibility and review of criteria.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Mod Pathol 2016;29:1083-1094.Available at: https://www.ncbi.nlm.nih.gov/pubmed/27255163.39.Bentivegna E, Gouy S, Maulard A, et al.Oncological outcomes after fertility-sparing surgery for cervical cancer: a systematic review.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Lancet Oncol 2016;17:e240-253.Available at: https://www.ncbi.nlm.nih.gov/pubmed/27299280.40.Ueki M, Okamoto Y, Misaki O, et al.Conservative therapy for microinvasive carcinoma of the uterine cervix.Gynecol Oncol 1994;53:109- 113.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Available at: http://www.ncbi.nlm.nih.gov/pubmed/8175008.41.Al-Kalbani M, McVeigh G, Nagar H, McCluggage WG.Do FIGO stage IA and small $( < / { = } 2$ cm) IB1 cervical adenocarcinomas have a good prognosis and warrant less radical surgery?",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Gynecol Cancer 2012;22:291-295.Available at: http://www.ncbi.nlm.nih.gov/pubmed/22080884.42.Webb JC, Key CR, Qualls CR, Smith HO.Population-based study of microinvasive adenocarcinoma of the uterine cervix.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Obstet Gynecol 2001;97:701-706.Available at: http://www.ncbi.nlm.nih.gov/pubmed/11339919.43.Sevin BU, Nadji M, Averette HE, et al.Microinvasive carcinoma of the cervix.Cancer 1992;70:2121-2128.Available at: http://www.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "ncbi.nlm.nih.gov/pubmed/1394041.44.Huang LW, Hwang JL.A comparison between loop electrosurgical excision procedure and cold knife conization for treatment of cervical dysplasia: residual disease in a subsequent hysterectomy specimen.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 1999;73:12-15.Available at: http://www.ncbi.nlm.nih.gov/pubmed/10094873.45.Miroshnichenko GG, Parva M, Holtz DO, et al.Interpretability of excisional biopsies of the cervix: cone biopsy and loop excision.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "J Low Genit Tract Dis 2009;13:10-12.Available at: http://www.ncbi.nlm.nih.gov/pubmed/19098600.46.Greenspan DL, Faubion M, Coonrod DV, et al.Compliance after loop electrosurgical excision procedure or cold knife cone biopsy.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Obstet Gynecol 2007;110:675-680.Available at: http://www.ncbi.nlm.nih.gov/pubmed/17766617.47.Fanning J, Padratzik J.Cold knife conization vs.LEEP.Are they the same procedure?J Reprod Med 2002;47:33-35.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Available at: http://www.ncbi.nlm.nih.gov/pubmed/11838307.48.Simmons JR, Anderson L, Hernandez E, Heller PB.Evaluating cervical neoplasia.LEEP as an alternative to cold knife conization.J Reprod Med 1998;43:1007-1013.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Available at: http://www.ncbi.nlm.nih.gov/pubmed/9883402.49.Kim MK, Kim MA, Kim JW, et al.Loop electrosurgical excision procedure findings for identification of patients with early-stage cervical cancer suitable for less radical surgery.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Gynecol Cancer 2012;22:1214- 1219.Available at: http://www.ncbi.nlm.nih.gov/pubmed/22801033.50.Bouchard-Fortier G, Reade CJ, Covens A.Non-radical surgery for small early-stage cervical cancer.Is it time?",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2014;132:624- 627.Available at: http://www.ncbi.nlm.nih.gov/pubmed/24480237.51.Kato T, Takashima A, Kasamatsu T, et al.Clinical tumor diameter and prognosis of patients with FIGO stage IB1 cervical cancer (JCOG0806-A).",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2015;137:34-39.Available at: http://www.ncbi.nlm.nih.gov/pubmed/25662625.52.Diaz JP, Sonoda Y, Leitao MM, et al.Oncologic outcome of fertilitysparing radical trachelectomy versus radical hysterectomy for stage IB1 cervical carcinoma.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2008;111:255-260.Available at: http://www.ncbi.nlm.nih.gov/pubmed/18755500.53.Abu-Rustum NR, Tal MN, DeLair D, et al.Radical abdominal trachelectomy for stage IB1 cervical cancer at 15-week gestation.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2010;116:151-152.Available at: http://www.ncbi.nlm.nih.gov/pubmed/19878979.54.Ramirez PT, Pareja R, Rendon GJ, et al.Management of low-risk early-stage cervical cancer: should conization, simple trachelectomy, or simple hysterectomy replace radical surgery as the new standard of care?",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2014;132:254-259.Available at: http://www.ncbi.nlm.nih.gov/pubmed/24041877.55.Dargent D, Martin X, Sacchetoni A, Mathevet P.Laparoscopic vaginal radical trachelectomy: a treatment to preserve the fertility of cervical carcinoma patients.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Cancer 2000;88:1877-1882.Available at: http://www.ncbi.nlm.nih.gov/pubmed/10760765.56.Viswanathan AN, Deavers MT, Jhingran A, et al.Small cell neuroendocrine carcinoma of the cervix: outcome and patterns of recurrence.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2004;93:27-33.Available at: http://www.ncbi.nlm.nih.gov/pubmed/15047210.57.Young RH, Clement PB.Endocervical adenocarcinoma and its variants: their morphology and differential diagnosis.Histopathology 2002;41:185-207.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Available at: http://www.ncbi.nlm.nih.gov/pubmed/12207781.58.Cao DY, Yang JX, Wu XH, et al.Comparisons of vaginal and abdominal radical trachelectomy for early-stage cervical cancer: preliminary results of a multi-center research in China.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Br J Cancer 2013;109:2778- 2782.Available at: http://www.ncbi.nlm.nih.gov/pubmed/24169350.59.Plante M, Gregoire J, Renaud MC, Roy M.The vaginal radical trachelectomy: an update of a series of 125 cases and 106 pregnancies.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2011;121:290-297.Available at: http://www.ncbi.nlm.nih.gov/pubmed/21255824.60.Abu-Rustum NR, Sonoda Y, Black D, et al.Fertility-sparing radical abdominal trachelectomy for cervical carcinoma: technique and review of the literature.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2006;103:807-813.Available at: http://www.ncbi.nlm.nih.gov/pubmed/16837027.61.Einstein MH, Park KJ, Sonoda Y, et al.Radical vaginal versus abdominal trachelectomy for stage IB1 cervical cancer: a comparison of surgical and pathologic outcomes.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2009;112:73-77.Available at: http://www.ncbi.nlm.nih.gov/pubmed/18973933.62.Wethington SL, Cibula D, Duska LR, et al.An international series on abdominal radical trachelectomy: 101 patients and 28 pregnancies.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Gynecol Cancer 2012;22:1251-1257.Available at: http://www.ncbi.nlm.nih.gov/pubmed/22914213.63.Abu-Rustum NR, Sonoda Y.Fertility-sparing surgery in early-stage cervical cancer: indications and applications.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "J Natl Compr Canc Netw 2010;8:1435-1438.Available at: http://www.ncbi.nlm.nih.gov/pubmed/21147906.64.Beiner ME, Covens A.Surgery insight: radical vaginal trachelectomy as a method of fertility preservation for cervical cancer.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Nat Clin Pract Oncol 2007;4:353-361.Available at: http://www.ncbi.nlm.nih.gov/pubmed/17534391.65.Pareja R, Rendon GJ, Sanz-Lomana CM, et al.Surgical, oncological, and obstetrical outcomes after abdominal radical trachelectomy - a systematic literature review.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2013;131:77-82.Available at: http://www.ncbi.nlm.nih.gov/pubmed/23769758.66.Lintner B, Saso S, Tarnai L, et al.Use of abdominal radical trachelectomy to treat cervical cancer greater than 2 cm in diameter.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Gynecol Cancer 2013;23:1065-1070.Available at: http://www.ncbi.nlm.nih.gov/pubmed/23722476.67.Wethington SL, Sonoda Y, Park KJ, et al.Expanding the indications for radical trachelectomy: a report on 29 patients with stage IB1 tumors measuring 2 to 4 centimeters.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Gynecol Cancer 2013;23:1092-1098.Available at: http://www.ncbi.nlm.nih.gov/pubmed/23714706.68.Lanowska M, Mangler M, Speiser D, et al.Radical vaginal trachelectomy after laparoscopic staging and neoadjuvant chemotherapy in women with early-stage cervical cancer over 2 cm: oncologic, fertility, and neonatal outcome in a series of 20 patients.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Gynecol Cancer 2014;24:586-593.Available at: http://www.ncbi.nlm.nih.gov/pubmed/24469326.69.Shepherd JH, Spencer C, Herod J, Ind TEJ.Radical vaginal trachelectomy as a fertility-sparing procedure in women with early-stage cervical cancer-cumulative pregnancy rate in a series of 123 women.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "BJOG 2006;113:719-724.Available at: http://www.ncbi.nlm.nih.gov/pubmed/16709216.70.Park JY, Kim DY, Suh DS, et al.Reproductive outcomes after laparoscopic radical trachelectomy for early-stage cervical cancer.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "J Gynecol Oncol 2014;25:9-13.Available at: http://www.ncbi.nlm.nih.gov/pubmed/24459575.71.Gizzo S, Ancona E, Saccardi C, et al.Radical trachelectomy: the first step of fertility preservation in young women with cervical cancer (Review).",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Oncol Rep 2013;30:2545-2554.Available at: http://www.ncbi.nlm.nih.gov/pubmed/24065029.72.Cibula D, Abu-Rustum NR, Benedetti-Panici P, et al.New classification system of radical hysterectomy: emphasis on a three dimensional anatomic template for parametrial resection.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2011;122:264-268.Available at: http://www.ncbi.nlm.nih.gov/pubmed/21592548.73.Querleu D, Morrow CP.Classification of radical hysterectomy.Lancet Oncol 2008;9:297-303.Available at: http://www.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "ncbi.nlm.nih.gov/pubmed/18308255.74.Piver MS, Rutledge F, Smith JP.Five classes of extended hysterectomy for women with cervical cancer.Obstet Gynecol 1974;44:265- 272.Available at: http://www.ncbi.nlm.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "nih.gov/pubmed/4417035.75.Chi DS, Abu-Rustum NR, Plante M, Roy M.Cancer of the cervix.In: Rock JA, Jones HW, eds, eds.TeLinde’s Operative Gynecology, 10th ed.Philadelphia: Lippincott Williams and Wilkins; 2008:1227.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "76.Whitney CW, Spirtos NM.Gynecologic Oncology Group Surgical Procedures Manual.Philadelphia: Gynecologic Oncology Group; 2009.Available at: https://gogmember.gog.org/manuals/pdf/surgman.pdf.Accessed April 18, 2014.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "77.Sardain H, Lavoue V, Redpath M, et al.Curative pelvic exenteration for recurrent cervical carcinoma in the era of concurrent chemotherapy and radiation therapy.A systematic review.Eur J Surg Oncol 2015;41:975- 985.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Available at: http://www.ncbi.nlm.nih.gov/pubmed/25922209.78.Chiantera V, Rossi M, De Iaco P, et al.Morbidity after pelvic exenteration for gynecological malignancies: a retrospective multicentric study of 230 patients.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Gynecol Cancer 2014;24:156-164.Available at: http://www.ncbi.nlm.nih.gov/pubmed/24362721.79.Cormier B, Diaz JP, Shih K, et al.Establishing a sentinel lymph node mapping algorithm for the treatment of early cervical cancer.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2011;122:275-280.Available at: http://www.ncbi.nlm.nih.gov/pubmed/21570713.80.Lecuru F, Mathevet P, Querleu D, et al.Bilateral negative sentinel nodes accurately predict absence of lymph node metastasis in early cervical cancer: results of the SENTICOL study.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "J Clin Oncol 2011;29:1686-1691.Available at: http://www.ncbi.nlm.nih.gov/pubmed/21444878.81.Altgassen C, Hertel H, Brandstadt A, et al.Multicenter validation study of the sentinel lymph node concept in cervical cancer: AGO Study Group.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "J Clin Oncol 2008;26:2943-2951.Available at: http://www.ncbi.nlm.nih.gov/pubmed/18565880.82.Bats AS, Buenerd A, Querleu D, et al.Diagnostic value of intraoperative examination of sentinel lymph node in early cervical cancer: a prospective, multicenter study.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2011;123:230-235.Available at: http://www.ncbi.nlm.nih.gov/pubmed/21893335.83.Bats AS, Mathevet P, Buenerd A, et al.The sentinel node technique detects unexpected drainage pathways and allows nodal ultrastaging in early cervical cancer: insights from the multicenter prospective SENTICOL study.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Ann Surg Oncol 2013;20:413-422.Available at: http://www.ncbi.nlm.nih.gov/pubmed/22911367.84.Cibula D, Abu-Rustum NR, Dusek L, et al.Bilateral ultrastaging of sentinel lymph node in cervical cancer: Lowering the false-negative rate and improving the detection of micrometastasis.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2012;127:462-466.Available at: http://www.ncbi.nlm.nih.gov/pubmed/22943880.85.Cibula D, Abu-Rustum NR, Dusek L, et al.Prognostic significance of low volume sentinel lymph node disease in early-stage cervical cancer.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2012;124:496-501.Available at: http://www.ncbi.nlm.nih.gov/pubmed/22120175.86.Fader AN, Edwards RP, Cost M, et al.Sentinel lymph node biopsy in early-stage cervical cancer: utility of intraoperative versus postoperative assessment.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2008;111:13-17.Available at: http://www.ncbi.nlm.nih.gov/pubmed/18684499.87.Lecuru F, Bats A, Mathevet P, et al.Impact of sentinel lymph node biopsy on staging of early cervical cancer: Results of a prospective, multicenter study [abstract].",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "J Clin Oncol 2009;27(Suppl 18):Abstract CRA5506.Available at: http://meeting.ascopubs.org/cgi/content/abstract/27/18S/CRA5506.88.Slama J, Dundr P, Dusek L, Cibula D.High false negative rate of frozen section examination of sentinel lymph nodes in patients with cervical cancer.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2013;129:384-388.Available at: http://www.ncbi.nlm.nih.gov/pubmed/23395889.89.van de Lande J, Torrenga B, Raijmakers PGHM, et al.Sentinel lymph node detection in early stage uterine cervix carcinoma: a systematic review.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2007;106:604-613.Available at: http://www.ncbi.nlm.nih.gov/pubmed/17628644.90.Andikyan V, Khoury-Collado F, Denesopolis J, et al.Cervical conization and sentinel lymph node mapping in the treatment of stage I cervical cancer: is less enough?",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Gynecol Cancer 2014;24:113-117.Available at: http://www.ncbi.nlm.nih.gov/pubmed/24335661.91.Wu Y, Li Z, Wu H, Yu J.Sentinel lymph node biopsy in cervical cancer: A meta-analysis.Mol Clin Oncol 2013;1:1025-1030.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Available at: http://www.ncbi.nlm.nih.gov/pubmed/24649288.92.Kadkhodayan S, Hasanzadeh M, Treglia G, et al.Sentinel node biopsy for lymph nodal staging of uterine cervix cancer: a systematic review and meta-analysis of the pertinent literature.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Eur J Surg Oncol 2015;41:1-20.Available at: http://www.ncbi.nlm.nih.gov/pubmed/25454828.93.Ruscito I, Gasparri ML, Braicu EI, et al.Sentinel Node Mapping in Cervical and Endometrial Cancer: Indocyanine Green Versus Other Conventional Dyes-A Meta-Analysis.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Ann Surg Oncol 2016;23:3749-3756.Available at: https://www.ncbi.nlm.nih.gov/pubmed/27160526.94.Frumovitz M, Plante M, Lee PS, et al.The FILM Trial: A randomized phase III multicenter study assessing near infrared fluorescence in the identification of sentinel lymph nodes (SLN) [Abstract].",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecologic Oncology 2018;149:7.Available at: https://doi.org/10.1016/j.ygyno.2018.04.023.95.Eiriksson LR, Covens A.Sentinel lymph node mapping in cervical cancer: the future?BJOG 2012;119:129-133.Available at: http://www.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "ncbi.nlm.nih.gov/pubmed/21917113.96.Bats AS, Frati A, Mathevet P, et al.Contribution of lymphoscintigraphy to intraoperative sentinel lymph node detection in early cervical cancer: Analysis of the prospective multicenter SENTICOL cohort.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2015;137:264-269.Available at: http://www.ncbi.nlm.nih.gov/pubmed/25727652.97.Darlin L, Persson J, Bossmar T, et al.The sentinel node concept in early cervical cancer performs well in tumors smaller than 2 cm.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2010;117:266-269.Available at: http://www.ncbi.nlm.nih.gov/pubmed/20167355.98.Sakuragi N, Satoh C, Takeda N, et al.Incidence and distribution pattern of pelvic and paraaortic lymph node metastasis in patients with Stages IB, IIA, and IIB cervical carcinoma treated with radical hysterectomy.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Cancer 1999;85:1547-1554.Available at: http://www.ncbi.nlm.nih.gov/pubmed/10193945.99.Huang H, Liu J, Li Y, et al.Metastasis to deep obturator and paraaortic lymph nodes in 649 patients with cervical carcinoma.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Eur J Surg Oncol 2011;37:978-983.Available at:http://www.ncbi.nlm.nih.gov/pubmed/21907530.100.Gold MA, Tian C, Whitney CW, et al.Surgical versus radiographic determination of para-aortic lymph node metastases before chemoradiation for locally advanced cervical carcinoma: a Gynecologic Oncology Group Study.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Cancer 2008;112:1954-1963.Available at: http://www.ncbi.nlm.nih.gov/pubmed/18338811.101.Gouy S, Morice P, Narducci F, et al.Prospective multicenter study evaluating the survival of patients with locally advanced cervical cancer undergoing laparoscopic para-aortic lymphadenectomy before chemoradiotherapy in the era of positron emission tomography imaging.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "J Clin Oncol 2013;31:3026-3033.Available at: http://www.ncbi.nlm.nih.gov/pubmed/23857967.102.Frumovitz M, Querleu D, Gil-Moreno A, et al.Lymphadenectomy in locally advanced cervical cancer study (LiLACS): Phase III clinical trial comparing surgical with radiologic staging in patients with stages IB2-IVA cervical cancer.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "J Minim Invasive Gynecol 2014;21:3-8.Available at: http://www.ncbi.nlm.nih.gov/pubmed/23911560.103.Chen Y, Xu H, Li Y, et al.The outcome of laparoscopic radical hysterectomy and lymphadenectomy for cervical cancer: a prospective analysis of 295 patients.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Ann Surg Oncol 2008;15:2847-2855.Available at: http://www.ncbi.nlm.nih.gov/pubmed/18649105.104.Puntambekar SP, Palep RJ, Puntambekar SS, et al.Laparoscopic total radical hysterectomy by the Pune technique: our experience of 248 cases.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "J Minim Invasive Gynecol 2007;14:682-689.Available at: http://www.ncbi.nlm.nih.gov/pubmed/17980327.105.Nam JH, Park JY, Kim DY, et al.Laparoscopic versus open radical hysterectomy in early-stage cervical cancer: long-term survival outcomes in a matched cohort study.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Ann Oncol 2012;23:903-911.Available at: http://www.ncbi.nlm.nih.gov/pubmed/21841155.106.Wang YZ, Deng L, Xu HC, et al.Laparoscopy versus laparotomy for the management of early stage cervical cancer.BMC Cancer 2015;15:928.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Available at: http://www.ncbi.nlm.nih.gov/pubmed/26596955.107.Sert BM, Boggess JF, Ahmad S, et al.Robot-assisted versus open radical hysterectomy: A multi-institutional experience for early-stage cervical cancer.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Eur J Surg Oncol 2016;42:513-522.Available at: http://www.ncbi.nlm.nih.gov/pubmed/26843445.108.Mendivil AA, Rettenmaier MA, Abaid LN, et al.Survival rate comparisons amongst cervical cancer patients treated with an open, roboticassisted or laparoscopic radical hysterectomy: A five year experience.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Surg Oncol 2016;25:66-71.Available at: http://www.ncbi.nlm.nih.gov/pubmed/26409687.109.Park DA, Yun JE, Kim SW, Lee SH.Surgical and clinical safety and effectiveness of robot-assisted laparoscopic hysterectomy compared to conventional laparoscopy and laparotomy for cervical cancer: A systematic review and meta-analysis.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Eur J Surg Oncol 2017;43:994- 1002.Available at: https://www.ncbi.nlm.nih.gov/pubmed/27546015.110.Shazly SA, Murad MH, Dowdy SC, et al.Robotic radical hysterectomy in early stage cervical cancer: A systematic review and meta-analysis.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2015;138:457-471.Available at: http://www.ncbi.nlm.nih.gov/pubmed/26056752.111.Ramirez PT, Frumovitz M, Pareja R, et al.Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "N Engl J Med 2018.Available at: https://www.ncbi.nlm.nih.gov/pubmed/30380365.112.Melamed A, Margul DJ, Chen L, et al.Survival after Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "N Engl J Med 2018.Available at: https://www.ncbi.nlm.nih.gov/pubmed/30379613.113.Margul DJ, Yang J, Seagle BL, et al.Outcomes and costs of open, robotic, and laparoscopic radical hysterectomy for stage IB1 cervical cancer.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Journal of Clinical Oncology 2018;36:5502-5502.Available at: http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.5502.114.Margul DJ, Yang J, Seagle BL, et al.Outcomes and costs of open, robotic, and laparoscopic radical hysterectomy for stage IB1 cervical cancer [Abstract].",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Journal of Clinical Oncology 2018;36:5502-5502.Available at: http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.5502.115.Nevis IF, Vali B, Higgins C, et al.Robot-assisted hysterectomy for endometrial and cervical cancers: a systematic review.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "J Robot Surg 2016.Available at: https://www.ncbi.nlm.nih.gov/pubmed/27424111.116.Lowe MP, Chamberlain DH, Kamelle SA, et al.A multi-institutional experience with robotic-assisted radical hysterectomy for early stage cervical cancer.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2009;113:191-194.Available at: http://www.ncbi.nlm.nih.gov/pubmed/19249082.117.Nezhat FR, Datta MS, Liu C, et al.Robotic radical hysterectomy versus total laparoscopic radical hysterectomy with pelvic lymphadenectomy for treatment of early cervical cancer.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "JSLS 2008;12:227-237.Available at: http://www.ncbi.nlm.nih.gov/pubmed/18765043.118.Cantrell LA, Mendivil A, Gehrig PA, Boggess JF.Survival outcomes for women undergoing type III robotic radical hysterectomy for cervical cancer: a 3-year experience.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2010;117:260-265.Available at: http://www.ncbi.nlm.nih.gov/pubmed/20153886.119.ACOG practice bulletin.Diagnosis and treatment of cervical carcinomas.Number 35, May 2002.American College of Obstetricians and Gynecologists.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Gynaecol Obstet 2002;78:79-91.Available at: http://www.ncbi.nlm.nih.gov/pubmed/12197489.120.Gaffney DK, Erickson-Wittmann BA, Jhingran A, et al.ACR Appropriateness Criteria(R) on Advanced Cervical Cancer Expert Panel on Radiation Oncology-Gynecology.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 2011;81:609- 614.Available at: http://www.ncbi.nlm.nih.gov/pubmed/21215531.121.Monk BJ, Tewari KS, Koh W-J.Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "J Clin Oncol 2007;25:2952-2965.Available at: http://www.ncbi.nlm.nih.gov/pubmed/17617527.122.Gien LT, Beauchemin MC, Thomas G.Adenocarcinoma: a unique cervical cancer.Gynecol Oncol 2010;116:140-146.Available at: http://www.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "ncbi.nlm.nih.gov/pubmed/19880165.123.Baalbergen A, Veenstra Y, Stalpers LL, Ansink AC.Primary surgery versus primary radiation therapy with or without chemotherapy for early adenocarcinoma of the uterine cervix.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Cochrane Database Syst Rev 2010:CD006248.Available at: http://www.ncbi.nlm.nih.gov/pubmed/20091590.124.Park JY, Kim DY, Kim JH, et al.Outcomes after radical hysterectomy in patients with early-stage adenocarcinoma of uterine cervix.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Br J Cancer 2010;102:1692-1698.Available at: http://www.ncbi.nlm.nih.gov/pubmed/20531414.125.Wo JY, Viswanathan AN.Impact of radiotherapy on fertility, pregnancy, and neonatal outcomes in female cancer patients.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 2009;73:1304-1312.Available at: http://www.ncbi.nlm.nih.gov/pubmed/19306747.126.Pahisa J, Martinez-Roman S, Martinez-Zamora MA, et al.Laparoscopic ovarian transposition in patients with early cervical cancer.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Gynecol Cancer 2008;18:584-589.Available at: http://www.ncbi.nlm.nih.gov/pubmed/18476952.127.Morice P, Juncker L, Rey A, et al.Ovarian transposition for patients with cervical carcinoma treated by radiosurgical combination.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Fertil Steril 2000;74:743-748.Available at: http://www.ncbi.nlm.nih.gov/pubmed/11020517.128.Landoni F, Maneo A, Colombo A, et al.Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Lancet 1997;350:535-540.Available at: http://www.ncbi.nlm.nih.gov/pubmed/9284774.129.Keys HM, Bundy BN, Stehman FB, et al.Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "N Engl J Med 1999;340:1154-1161.Available at: http://www.ncbi.nlm.nih.gov/pubmed/10202166.130.Morris M, Eifel PJ, Lu J, et al.Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "N Engl J Med 1999;340:1137-1143.Available at: http://www.ncbi.nlm.nih.gov/pubmed/10202164.131.Peters WA, Liu PY, Barrett RJ, et al.Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "J Clin Oncol 2000;18:1606-1613.Available at: http://www.ncbi.nlm.nih.gov/pubmed/10764420.132.Whitney CW, Sause W, Bundy BN, et al.Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "J Clin Oncol 1999;17:1339-1348.Available at: http://www.ncbi.nlm.nih.gov/pubmed/10334517.133.Rose PG, Bundy BN, Watkins EB, et al.Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "N Engl J Med 1999;340:1144-1153.Available at: http://www.ncbi.nlm.nih.gov/pubmed/10202165.134.Thomas GM.Improved treatment for cervical cancer--concurrent chemotherapy and radiotherapy.N Engl J Med 1999;340:1198-1200.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Available at: http://www.ncbi.nlm.nih.gov/pubmed/10202172.135.Rose PG, Ali S, Watkins E, et al.Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin- based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "J Clin Oncol 2007;25:2804-2810.Available at: http://www.ncbi.nlm.nih.gov/pubmed/17502627.136.Eifel PJ, Winter K, Morris M, et al.Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "J Clin Oncol 2004;22:872-880.Available at: http://www.ncbi.nlm.nih.gov/pubmed/14990643.137.Stehman FB, Ali S, Keys HM, et al.Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Am J Obstet Gynecol 2007;197:1-6.Available at: http://www.ncbi.nlm.nih.gov/pubmed/17980189.138.Chemoradiotherapy for Cervical Cancer Meta-Analysis C.Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "J Clin Oncol 2008;26:5802-5812.Available at: https://www.ncbi.nlm.nih.gov/pubmed/19001332.139.Pearcey R, Miao Q, Kong W, et al.Impact of adoption of chemoradiotherapy on the outcome of cervical cancer in Ontario: results of a population-based cohort study.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "J Clin Oncol 2007;25:2383-2388.Available at: http://www.ncbi.nlm.nih.gov/pubmed/17557951.140.King M, McConkey C, Latief TN, et al.Improved survival after concurrent weekly cisplatin and radiotherapy for cervical carcinoma with assessment of acute and late side-effects.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Clin Oncol (R Coll Radiol) 2006;18:38-45.Available at: http://www.ncbi.nlm.nih.gov/pubmed/16477918.141.Tan LT, Zahra M.Long-term survival and late toxicity after chemoradiotherapy for cervical cancer--the Addenbrooke's experience.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Clin Oncol (R Coll Radiol) 2008;20:358-364.Available at: http://www.ncbi.nlm.nih.gov/pubmed/18395427.142.Gaffney DK, Du Bois A, Narayan K, et al.Practice patterns of radiotherapy in cervical cancer among member groups of the Gynecologic Cancer Intergroup (GCIG).",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 2007;68:485-490.Available at: http://www.ncbi.nlm.nih.gov/pubmed/17336465.143.Cetina L, Garcia-Arias A, Uribe MdJ, et al.Concurrent chemoradiation with carboplatin for elderly, diabetic and hypertensive patients with locally advanced cervical cancer.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Eur J Gynaecol Oncol 2008;29:608-612.Available at: http://www.ncbi.nlm.nih.gov/pubmed/19115688.144.Dubay RA, Rose PG, O'Malley DM, et al.Evaluation of concurrent and adjuvant carboplatin with radiation therapy for locally advanced cervical cancer.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2004;94:121-124.Available at: http://www.ncbi.nlm.nih.gov/pubmed/15262129.145.Higgins RV, Naumann WR, Hall JB, Haake M.Concurrent carboplatin with pelvic radiation therapy in the primary treatment of cervix cancer.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2003;89:499-503.Available at: http://www.ncbi.nlm.nih.gov/pubmed/12798718.146.Lorvidhaya V, Chitapanarux I, Sangruchi S, et al.Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 2003;55:1226-1232.Available at: http://www.ncbi.nlm.nih.gov/pubmed/12654431.147.Wong LC, Ngan HY, Cheung AN, et al.Chemoradiation and adjuvant chemotherapy in cervical cancer.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "J Clin Oncol 1999;17:2055-2060.Available at: http://www.ncbi.nlm.nih.gov/pubmed/10561258.148.Tharavichitkul E, Lorvidhaya V, Kamnerdsupaphon P, et al.Combined chemoradiation of cisplatin versus carboplatin in cervical carcinoma: a single institution experience from Thailand.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "BMC Cancer 2016;16:501.Available at: https://www.ncbi.nlm.nih.gov/pubmed/27435245.149.Mileshkin LR, Narayan K, Moore KN, et al.A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: Outback (ANZGOG0902/GOG0274/RTOG1174) [abstract].",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Journal of Clinical Oncology 2014 32:abstract TPS5632.Available at: http://abstracts.asco.org/144/AbstView_144_132544.html.150.Koliopoulos G, Sotiriadis A, Kyrgiou M, et al.Conservative surgical methods for FIGO stage IA2 squamous cervical carcinoma and their role in preserving women's fertility.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2004;93:469-473.Available at: http://www.ncbi.nlm.nih.gov/pubmed/15099964.151.Wright JD, NathavithArana R, Lewin SN, et al.Fertility-conserving surgery for young women with stage IA1 cervical cancer: safety and access.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Obstet Gynecol 2010;115:585-590.Available at: http://www.ncbi.nlm.nih.gov/pubmed/20177290.152.Tierney KE, Lin PS, Amezcua C, et al.Cervical conization of adenocarcinoma in situ: a predicting model of residual disease.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Am J Obstet Gynecol 2014;210:366 e361-365.Available at: http://www.ncbi.nlm.nih.gov/pubmed/24370689.153.Yoneda JY, Braganca JF, Sarian LO, et al.Surgical treatment of microinvasive cervical cancer: analysis of pathologic features with implications on radicality.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Gynecol Cancer 2015;25:694-698.Available at: http://www.ncbi.nlm.nih.gov/pubmed/25742569.154.Bernardini M, Barrett J, Seaward G, Covens A.Pregnancy outcomes in patients after radical trachelectomy.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Am J Obstet Gynecol 2003;189:1378-1382.Available at: http://www.ncbi.nlm.nih.gov/pubmed/14634572.155.Boss EA, van Golde RJT, Beerendonk CCM, Massuger LFAG.Pregnancy after radical trachelectomy: a real option?",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2005;99:152-156.Available at: http://www.ncbi.nlm.nih.gov/pubmed/16140367.156.Plante M, Renaud M-C, Hoskins IA, Roy M.Vaginal radical trachelectomy: a valuable fertility-preserving option in the management of early-stage cervical cancer.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "A series of 50 pregnancies and review of the literature.Gynecol Oncol 2005;98:3-10.Available at: http://www.ncbi.nlm.nih.gov/pubmed/15936061.157.Marchiole P, Benchaib M, Buenerd A, et al.Oncological safety of laparoscopic-assisted vaginal radical trachelectomy (LARVT or Dargent's operation): a comparative study with laparoscopic-assisted vaginal radical hysterectomy (LARVH).",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2007;106:132-141.Available at: http://www.ncbi.nlm.nih.gov/pubmed/17493666.158.Landoni F, Zanagnolo V, Lovato-Diaz L, et al.Ovarian metastases in early-stage cervical cancer (IA2-IIA): a multicenter retrospective study of 1965 patients (a Cooperative Task Force study).",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Gynecol Cancer 2007;17:623-628.Available at: http://www.ncbi.nlm.nih.gov/pubmed/17309669.159.Shimada M, Kigawa J, Nishimura R, et al.Ovarian metastasis in carcinoma of the uterine cervix.Gynecol Oncol 2006;101:234-237.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Available at: http://www.ncbi.nlm.nih.gov/pubmed/16300819.160.Kokka F, Bryant A, Brockbank E, Jeyarajah A.Surgical treatment of stage IA2 cervical cancer.Cochrane Database Syst Rev 2014:CD010870.Available at: http://www.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "ncbi.nlm.nih.gov/pubmed/24874726.161.Small W, Jr., Strauss JB, Jhingran A, et al.ACR Appropriateness Criteria(R) definitive therapy for early-stage cervical cancer.Am J Clin Oncol 2012;35:399-405.Available at: http://www.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "ncbi.nlm.nih.gov/pubmed/22810416.162.Raju SK, Papadopoulos AJ, Montalto SA, et al.Fertility-sparing surgery for early cervical cancer-approach to less radical surgery.Int J Gynecol Cancer 2012;22:311-317.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Available at: http://www.ncbi.nlm.nih.gov/pubmed/22237381.163.Li J, Wu X, Li X, Ju X.Abdominal radical trachelectomy: Is it safe for IB1 cervical cancer with tumors $> / = 2$ cm?Gynecol Oncol 2013;131:87-92.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Available at: http://www.ncbi.nlm.nih.gov/pubmed/23872192.164.Landoni F, Maneo A, Cormio G, et al.Class II versus class III radical hysterectomy in stage IB-IIA cervical cancer: a prospective randomized study.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2001;80:3-12.Available at: http://www.ncbi.nlm.nih.gov/pubmed/11136561.165.Keys HM, Bundy BN, Stehman FB, et al.Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2003;89:343-353.Available at: http://www.ncbi.nlm.nih.gov/pubmed/12798694.166.Kokka F, Bryant A, Brockbank E, et al.Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Cochrane Database Syst Rev 2015;4:CD010260.Available at: http://www.ncbi.nlm.nih.gov/pubmed/25847525.167.Colombo PE, Bertrand MM, Gutowski M, et al.Total laparoscopic radical hysterectomy for locally advanced cervical carcinoma (stages IIB, IIA and bulky stages IB) after concurrent chemoradiation therapy: surgical morbidity and oncological results.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2009;114:404-409.Available at: http://www.ncbi.nlm.nih.gov/pubmed/19555996.168.Touboul C, Uzan C, Mauguen A, et al.Prognostic factors and morbidities after completion surgery in patients undergoing initial chemoradiation therapy for locally advanced cervical cancer.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Oncologist 2010;15:405-415.Available at: http://www.ncbi.nlm.nih.gov/pubmed/20332143.169.Huguet F, Cojocariu OM, Levy P, et al.Preoperative concurrent radiation therapy and chemotherapy for bulky stage IB2, IIA, and IIB carcinoma of the uterine cervix with proximal parametrial invasion.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 2008;72:1508-1515.Available at: http://www.ncbi.nlm.nih.gov/pubmed/18676093.170.Cetina L, Gonzalez-Enciso A, Cantu D, et al.Brachytherapy versus radical hysterectomy after external beam chemoradiation with gemcitabine plus cisplatin: a randomized, phase III study in IB2-IIB cervical cancer patients.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Ann Oncol 2013;24:2043-2047.Available at: http://www.ncbi.nlm.nih.gov/pubmed/23609186.171.Kohler C, Mustea A, Marnitz S, et al.Perioperative morbidity and rate of upstaging after laparoscopic staging for patients with locally advanced cervical cancer: results of a prospective randomized trial.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Am J Obstet Gynecol 2015;213:503 e501-507.Available at: http://www.ncbi.nlm.nih.gov/pubmed/25986030.172.Goff BA, Muntz HG, Paley PJ, et al.Impact of surgical staging in women with locally advanced cervical cancer.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 1999;74:436- 442.Available at: http://www.ncbi.nlm.nih.gov/pubmed/10479506.173.Rose PG.Combination therapy: New treatment paradigm for locally advanced cervical cancer?Nat Rev Clin Oncol 2011;8:388-390.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Available at: http://www.ncbi.nlm.nih.gov/pubmed/21629215.174.Duenas-Gonzalez A, Zarba JJ, Patel F, et al.Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "J Clin Oncol 2011;29:1678-1685.Available at: http://www.ncbi.nlm.nih.gov/pubmed/21444871.175.Thomas G.Are we making progress in curing advanced cervical cancer?J Clin Oncol 2011;29:1654-1656.Available at: http://www.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "ncbi.nlm.nih.gov/pubmed/21444860.176.Swisher EM, Swensen RE, Greer B, et al.Weekly gemcitabine and cisplatin in combination with pelvic radiation in the primary therapy of cervical cancer: a phase I trial of the Puget Sound Oncology Consortium.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2006;101:429-435.Available at: http://www.ncbi.nlm.nih.gov/pubmed/16337995.177.Rose PG, Degeest K, McMeekin S, Fusco N.A phase I study of gemcitabine followed by cisplatin concurrent with whole pelvic radiation therapy in locally advanced cervical cancer: a Gynecologic Oncology Group study.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2007;107:274-279.Available at: http://www.ncbi.nlm.nih.gov/pubmed/17688925.178.Lutz ST, Chow EL, Hartsell WF, Konski AA.A review of hypofractionated palliative radiotherapy.Cancer 2007;109:1462-1470.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Available at: http://www.ncbi.nlm.nih.gov/pubmed/17330854.179.Rotman M, Sedlis A, Piedmonte MR, et al.A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 2006;65:169-176.Available at: http://www.ncbi.nlm.nih.gov/pubmed/16427212.180.Monk BJ, Wang J, Im S, et al.Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2005;96:721-728.Available at: http://www.ncbi.nlm.nih.gov/pubmed/15721417.181.Chernofsky MR, Felix JC, Muderspach LI, et al.Influence of quantity of lymph vascular space invasion on time to recurrence in women with earlystage squamous cancer of the cervix.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2006;100:288-293.Available at: http://www.ncbi.nlm.nih.gov/pubmed/16182347.182.Marchiole P, Buenerd A, Benchaib M, et al.Clinical significance of lympho vascular space involvement and lymph node micrometastases in early-stage cervical cancer: a retrospective case-control surgicopathological study.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2005;97:727-732.Available at: http://www.ncbi.nlm.nih.gov/pubmed/15943983.183.Trifiletti DM, Swisher-McClure S, Showalter TN, et al.Postoperative Chemoradiation Therapy in High-Risk Cervical Cancer: Re-evaluating the Findings of Gynecologic Oncology Group Study 109 in a Large, PopulationBased Cohort.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 2015;93:1032- 1044.Available at: 184.Gong L, Lou JY, Wang P, et al.Clinical evaluation of neoadjuvant chemotherapy followed by radical surgery in the management of stage IB2- IIB cervical cancer.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Gynaecol Obstet 2012;117:23-26.Available at: http://www.ncbi.nlm.nih.gov/pubmed/22265255.185.Eddy GL, Bundy BN, Creasman WT, et al.Treatment of (\"bulky\") stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: a phase III trial of the gynecologic oncology group.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2007;106:362-369.Available at: http://www.ncbi.nlm.nih.gov/pubmed/17493669.186.Rydzewska L, Tierney J, Vale CL, Symonds PR.Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Cochrane Database Syst Rev 2010:CD007406.Available at: http://www.ncbi.nlm.nih.gov/pubmed/20091632.187.Katsumata N, Yoshikawa H, Kobayashi H, et al.Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102).",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Br J Cancer 2013;108:1957-1963.Available at: http://www.ncbi.nlm.nih.gov/pubmed/23640393.188.Kim HS, Sardi JE, Katsumata N, et al.Efficacy of neoadjuvant chemotherapy in patients with FIGO stage IB1 to IIA cervical cancer: an international collaborative meta-analysis.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Eur J Surg Oncol 2013;39:115-124.Available at: http://www.ncbi.nlm.nih.gov/pubmed/23084091.189.Landoni F, Sartori E, Maggino T, et al.Is there a role for postoperative treatment in patients with stage Ib2-IIb cervical cancer treated with neoadjuvant chemotherapy and radical surgery?",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "An Italian multicenter retrospective study.Gynecol Oncol 2014;132:611-617.Available at: http://www.ncbi.nlm.nih.gov/pubmed/24342439.190.Ye Q, Yuan HX, Chen HL.Responsiveness of neoadjuvant chemotherapy before surgery predicts favorable prognosis for cervical cancer patients: a meta-analysis.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "J Cancer Res Clin Oncol 2013;139:1887- 1898.Available at: http://www.ncbi.nlm.nih.gov/pubmed/24022086.191.Salani R, Khanna N, Frimer M, et al.An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2017;146:3-10.Available at: https://www.ncbi.nlm.nih.gov/pubmed/28372871.192.Bodurka-Bevers D, Morris M, Eifel PJ, et al.Posttherapy surveillance of women with cervical cancer: an outcomes analysis.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2000;78:187-193.Available at: http://www.ncbi.nlm.nih.gov/pubmed/10926801.193.Morice P, Deyrolle C, Rey A, et al.Value of routine follow-up procedures for patients with stage I/II cervical cancer treated with combined surgery-radiation therapy.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Ann Oncol 2004;15:218-223.Available at: http://www.ncbi.nlm.nih.gov/pubmed/14760112.194.Elit L, Fyles AW, Devries MC, et al.Follow-up for women after treatment for cervical cancer: a systematic review.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2009;114:528-535.Available at: http://www.ncbi.nlm.nih.gov/pubmed/19560188.195.Gee MS, Atri M, Bandos AI, et al.Identification of Distant Metastatic Disease in Uterine Cervical and Endometrial Cancers with FDG PET/CT: Analysis from the ACRIN 6671/GOG 0233 Multicenter Trial.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Radiology 2018;287:176-184.Available at: https://www.ncbi.nlm.nih.gov/pubmed/29185901.196.Sala E, Micco M, Burger IA, et al.Complementary Prognostic Value of Pelvic Magnetic Resonance Imaging and Whole-Body Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Pretreatment Assessment of Patients With Cervical Cancer.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Gynecol Cancer 2015;25:1461-1467.Available at: http://www.ncbi.nlm.nih.gov/pubmed/26397068.197.Balleyguier C, Sala E, Da Cunha T, et al.Staging of uterine cervical cancer with MRI: guidelines of the European Society of Urogenital Radiology.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Eur Radiol 2011;21:1102-1110.Available at: http://www.ncbi.nlm.nih.gov/pubmed/21063710.198.Sala E, Rockall AG, Freeman SJ, et al.The added role of MR imaging in treatment stratification of patients with gynecologic malignancies: what the radiologist needs to know.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Radiology 2013;266:717-740.Available at: http://www.ncbi.nlm.nih.gov/pubmed/23431227.199.Elit L, Reade CJ.Recommendations for Follow-up Care for Gynecologic Cancer Survivors.Obstet Gynecol 2015;126:1207-1214.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Available at: http://www.ncbi.nlm.nih.gov/pubmed/26551194.200.Rajendran JG, Greer BE.Expanding role of positron emission tomography in cancer of the uterine cervix.J Natl Compr Canc Netw 2006;4:463-469.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Available at: http://www.ncbi.nlm.nih.gov/pubmed/16687094.201.Atri M, Zhang Z, Dehdashti F, et al.Utility of PET/CT to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer: Results of ACRIN6671/GOG0233 trial.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2016;142:413-419.Available at: http://www.ncbi.nlm.nih.gov/pubmed/27178725.202.Brooks RA, Rader JS, Dehdashti F, et al.Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2009;112:104-109.Available at: http://www.ncbi.nlm.nih.gov/pubmed/18929403.203.Schwarz JK, Siegel BA, Dehdashti F, Grigsby PW.Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "JAMA 2007;298:2289-2295.Available at: http://www.ncbi.nlm.nih.gov/pubmed/18029833.204.Sironi S, Picchio M, Landoni C, et al.Post-therapy surveillance of patients with uterine cancers: value of integrated FDG PET/CT in the detection of recurrence.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Eur J Nucl Med Mol Imaging 2007;34:472-479.Available at: http://www.ncbi.nlm.nih.gov/pubmed/17106701.205.Chung HH, Jo H, Kang WJ, et al.Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2007;104:529-534.Available at: http://www.ncbi.nlm.nih.gov/pubmed/17049971.206.Wolfson AH, Varia MA, Moore D, et al.ACR Appropriateness Criteria(R) role of adjuvant therapy in the management of early stage cervical cancer.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2012;125:256-262.Available at: http://www.ncbi.nlm.nih.gov/pubmed/22155418.207.Chaturvedi AK, Kleinerman RA, Hildesheim A, et al.Second cancers after squamous cell carcinoma and adenocarcinoma of the cervix.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "J Clin Oncol 2009;27:967-973.Available at: http://www.ncbi.nlm.nih.gov/pubmed/19114696.208.Chaturvedi AK, Engels EA, Gilbert ES, et al.Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "J Natl Cancer Inst 2007;99:1634-1643.Available at: http://www.ncbi.nlm.nih.gov/pubmed/17971527.209.Kumar S, Shah JP, Bryant CS, et al.Radiation-associated endometrial cancer.Obstet Gynecol 2009;113:319-325.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Available at: http://www.ncbi.nlm.nih.gov/pubmed/19155901.210.Hong JH, Tsai CS, Lai CH, et al.Recurrent squamous cell carcinoma of cervix after definitive radiotherapy.Int J Radiat Oncol Biol Phys 2004;60:249-257.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Available at: http://www.ncbi.nlm.nih.gov/pubmed/15337563.211.Thomas GM, Dembo AJ, Myhr T, et al.Long-term results of concurrent radiation and chemotherapy for carcinoma of the cervix recurrent after surgery.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Gynecol Cancer 1993;3:193-198.Available at: http://www.ncbi.nlm.nih.gov/pubmed/11578344.212.Kim JS, Kim SY, Kim KH, Cho MJ.Hyperfractionated radiotherapy with concurrent chemotherapy for para-aortic lymph node recurrence in carcinoma of the cervix.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 2003;55:1247-1253.Available at: http://www.ncbi.nlm.nih.gov/pubmed/12654434.213.Chung YL, Jian JJ, Cheng SH, et al.Extended-field radiotherapy and high-dose-rate brachytherapy with concurrent and adjuvant cisplatin- based chemotherapy for locally advanced cervical cancer: a phase I/II study.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2005;97:126-135.Available at: http://www.ncbi.nlm.nih.gov/pubmed/15790448.214.Marnitz S, Dowdy S, Lanowska M, et al.Exenterations 60 years after first description: results of a survey among US and German Gynecologic Oncology Centers.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Gynecol Cancer 2009;19:974-977.Available at: http://www.ncbi.nlm.nih.gov/pubmed/19574795.215.Berek JS, Howe C, Lagasse LD, Hacker NF.Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidity analysis of the 45- year experience at UCLA.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2005;99:153-159.Available at: http://www.ncbi.nlm.nih.gov/pubmed/16054678.216.Goldberg GL, Sukumvanich P, Einstein MH, et al.Total pelvic exenteration: the Albert Einstein College of Medicine/Montefiore Medical Center Experience (1987 to 2003).",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2006;101:261-268.Available at: http://www.ncbi.nlm.nih.gov/pubmed/16426668.217.Morley GW, Hopkins MP, Lindenauer SM, Roberts JA.Pelvic exenteration, University of Michigan: 100 patients at 5 years.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Obstet Gynecol 1989;74:934-943.Available at: http://www.ncbi.nlm.nih.gov/pubmed/2586960.218.Fleisch MC, Pantke P, Beckmann MW, et al.Predictors for long-term survival after interdisciplinary salvage surgery for advanced or recurrent gynecologic cancers.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "J Surg Oncol 2007;95:476-484.Available at: http://www.ncbi.nlm.nih.gov/pubmed/17192947.219.Tran PT, Su Z, Hara W, et al.Long-term survivors using intraoperative radiotherapy for recurrent gynecologic malignancies.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 2007;69:504-511.Available at: http://www.ncbi.nlm.nih.gov/pubmed/17560736.220.Rutledge FN, Smith JP, Wharton JT, O'Quinn AG.Pelvic exenteration: analysis of 296 patients.Am J Obstet Gynecol 1977;129:881-892.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Available at: http://www.ncbi.nlm.nih.gov/pubmed/930972.221.Symmonds RE, Pratt JH, Webb MJ.Exenterative operations: experience with 198 patients.Am J Obstet Gynecol 1975;121:907-918.Available at: http://www.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "ncbi.nlm.nih.gov/pubmed/1115180.222.Soper JT, Secord AA, Havrilesky LJ, et al.Comparison of gracilis and rectus abdominis myocutaneous flap neovaginal reconstruction performed during radical pelvic surgery: flap-specific morbidity.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Gynecol Cancer 2007;17:298-303.Available at: http://www.ncbi.nlm.nih.gov/pubmed/17291272.223.Mirhashemi R, Averette HE, Lambrou N, et al.Vaginal reconstruction at the time of pelvic exenteration: a surgical and psychosexual analysis of techniques.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2002;87:39-45.Available at: http://www.ncbi.nlm.nih.gov/pubmed/12468340.224.Turns D.Psychosocial issues: pelvic exenterative surgery.J Surg Oncol 2001;76:224-236.Available at: http://www.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "ncbi.nlm.nih.gov/pubmed/11276026.225.Im JH, Yoon HI, Kim S, et al.Tailored radiotherapeutic strategies for disseminated uterine cervical cancer patients.Radiat Oncol 2015;10:77.Available at: https://www.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "ncbi.nlm.nih.gov/pubmed/25884833.226.Kim JY, Kim JY, Kim JH, et al.Curative chemoradiotherapy in patients with stage IVB cervical cancer presenting with paraortic and left supraclavicular lymph node metastases.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 2012;84:741-747.Available at: https://www.ncbi.nlm.nih.gov/pubmed/22898382.227.Smith SC, Koh WJ.Palliative radiation therapy for gynaecological malignancies.Best Pract Res Clin Obstet Gynaecol 2001;15:265-278.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Available at: http://www.ncbi.nlm.nih.gov/pubmed/11358401.228.Spanos WJ, Jr., Perez CA, Marcus S, et al.Effect of rest interval on tumor and normal tissue response--a report of phase III study of accelerated split course palliative radiation for advanced pelvic malignancies (RTOG8502).",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 1993;25:399-403.Available at: http://www.ncbi.nlm.nih.gov/pubmed/7679668.229.Moore DH, Blessing JA, McQuellon RP, et al.Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "J Clin Oncol 2004;22:3113-3119.Available at: http://www.ncbi.nlm.nih.gov/pubmed/15284262.230.Long HJ, 3rd, Bundy BN, Grendys EC, Jr., et al.Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "J Clin Oncol 2005;23:4626- 4633.Available at: http://www.ncbi.nlm.nih.gov/pubmed/15911865.231.Thigpen T, Shingleton H, Homesley H, et al.Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Cancer 1981;48:899-903.Available at: http://www.ncbi.nlm.nih.gov/pubmed/7196794.232.Moore DH.Chemotherapy for advanced, recurrent, and metastatic cervical cancer.J Natl Compr Canc Netw 2008;6:53-57.Available at: http://www.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "ncbi.nlm.nih.gov/pubmed/18267059.233.Tao X, Hu W, Ramirez PT, Kavanagh JJ.Chemotherapy for recurrent and metastatic cervical cancer.Gynecol Oncol 2008;110:67-71.Available at: http://www.ncbi.nlm.nih.gov/pubmed/18533239.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "234.Monk BJ, Sill MW, McMeekin DS, et al.Phase III trial of four cisplatincontaining doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.J Clin Oncol 2009;27:4649-4655.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Available at: http://www.ncbi.nlm.nih.gov/pubmed/19720909.235.Tewari KS, Sill MW, Penson RT, et al.Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Lancet 2017;390:1654-1663.Available at: https://www.ncbi.nlm.nih.gov/pubmed/28756902.236.Zighelboim I, Wright JD, Gao F, et al.Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2013;130:64-68.Available at: http://www.ncbi.nlm.nih.gov/pubmed/23591400.237.Penson RT, Huang HQ, Wenzel LB, et al.Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Lancet Oncol 2015;16:301-311.Available at: http://www.ncbi.nlm.nih.gov/pubmed/25638326.238.Rosen VM, Guerra I, McCormack M, et al.Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J # NCCN Guidelines Version 1.2022 宫颈癌 Gynecol Cancer 2017;27:1237-1246.Available at: https://www.ncbi.nlm.nih.gov/pubmed/28448304.239.Kitagawa R, Katsumata N, Shibata T, et al.Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "J Clin Oncol 2015;33:2129-2135.Available at: http://www.ncbi.nlm.nih.gov/pubmed/25732161.240.Moore KN, Herzog TJ, Lewin S, et al.A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2007;105:299-303.Available at: http://www.ncbi.nlm.nih.gov/pubmed/17303230.241.Lorusso D, Petrelli F, Coinu A, et al.A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2014;133:117-123.Available at: http://www.ncbi.nlm.nih.gov/pubmed/24486604.242.Leath CA, 3rd, Straughn JM, Jr.Chemotherapy for advanced and recurrent cervical carcinoma: results from cooperative group trials.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2013;129:251-257.Available at: http://www.ncbi.nlm.nih.gov/pubmed/23280089.243.Thigpen JT, Blessing JA, DiSaia PJ, et al.A randomized comparison of a rapid versus prolonged (24 hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 1989;32:198-202.Available at: http://www.ncbi.nlm.nih.gov/pubmed/2910782.244.Pectasides D, Kamposioras K, Papaxoinis G, Pectasides E.Chemotherapy for recurrent cervical cancer.Cancer Treat Rev 2008;34:603-613.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Available at: http://www.ncbi.nlm.nih.gov/pubmed/18657909.245.McGuire WP, Arseneau J, Blessing JA, et al.A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Clin Oncol 1989;7:1462-1468.Available at: http://www.ncbi.nlm.nih.gov/pubmed/2674333.246.Weiss GR, Green S, Hannigan EV, et al.A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: a Southwest Oncology Group study.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 1990;39:332-336.Available at: http://www.ncbi.nlm.nih.gov/pubmed/2258080.247.Kudelka AP, Winn R, Edwards CL, et al.An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Anticancer Drugs 1997;8:657-661.Available at: http://www.ncbi.nlm.nih.gov/pubmed/9311440.248.McGuire WP, Blessing JA, Moore D, et al.Paclitaxel has moderate activity in squamous cervix cancer.A Gynecologic Oncology Group study.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "J Clin Oncol 1996;14:792-795.Available at: http://www.ncbi.nlm.nih.gov/pubmed/8622025.249.Le DT, Durham JN, Smith KN, et al.Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Science 2017;357:409- 413.Available at: https://www.ncbi.nlm.nih.gov/pubmed/28596308.250.Frenel JS, Le Tourneau C, O'Neil B, et al.Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "J Clin Oncol 2017;35:4035-4041.Available at: https://www.ncbi.nlm.nih.gov/pubmed/29095678.251.Chung HC, Schellens JH, Delord J-P, et al.Pembrolizumab treatment of advanced cervical cancer: Updated results from the phase 2 KEYNOTE158 study [abstract].",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "J Clin Oncol 2018 36.Available at: https://meetinglibrary.asco.org/record/160523/abstract.252.Monk BJ, Sill MW, Burger RA, et al.Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "J Clin Oncol 2009;27:1069- 1074.Available at: http://www.ncbi.nlm.nih.gov/pubmed/19139430.253.Alberts DS, Blessing JA, Landrum LM, et al.Phase II trial of nabpaclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2012;127:451-455.Available at: http://www.ncbi.nlm.nih.gov/pubmed/22986144.254.Garcia AA, Blessing JA, Vaccarello L, Roman LD.Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Am J Clin Oncol 2007;30:428-431.Available at: http://www.ncbi.nlm.nih.gov/pubmed/17762444.255.Look KY, Blessing JA, Gallup DG, Lentz SS.A phase II trial of 5- fluorouracil and high-dose leucovorin in patients with recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Am J Clin Oncol 1996;19:439-441.Available at: http://www.ncbi.nlm.nih.gov/pubmed/8823469.256.Schilder RJ, Blessing J, Cohn DE.Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2005;96:103-107.Available at: http://www.ncbi.nlm.nih.gov/pubmed/15589587.257.Coleman RE, Harper PG, Gallagher C, et al.A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Cancer Chemother Pharmacol 1986;18:280-283.Available at: http://www.ncbi.nlm.nih.gov/pubmed/3802384.258.Sutton GP, Blessing JA, McGuire WP, et al.Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: a Gynecologic Oncology Group study.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Am J Obstet Gynecol 1993;168:805- 807.Available at: http://www.ncbi.nlm.nih.gov/pubmed/8456884.259.Verschraegen CF, Levy T, Kudelka AP, et al.Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "J Clin Oncol 1997;15:625-631.Available at: http://www.ncbi.nlm.nih.gov/pubmed/9053486.260.Wagenaar HC, Pecorelli S, Mangioni C, et al.Phase II study of mitomycin-C and cisplatin in disseminated, squamous cell carcinoma of the uterine cervix.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "A European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group study.Eur J Cancer 2001;37:1624-1628.Available at: http://www.ncbi.nlm.nih.gov/pubmed/11527687.261.Miller DS, Blessing JA, Bodurka DC, et al.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.Gynecol Oncol 2008;110:65-70.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Available at: http://www.ncbi.nlm.nih.gov/pubmed/18455781.262.Bookman MA, Blessing JA, Hanjani P, et al.Topotecan in squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2000;77:446-449.Available at: http://www.ncbi.nlm.nih.gov/pubmed/10831357.263.Muderspach LI, Blessing JA, Levenback C, Moore JL.A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2001;81:213-215.Available at: http://www.ncbi.nlm.nih.gov/pubmed/11354055.264.Muggia FM, Blessing JA, Method M, et al.Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2004;92:639-643.Available at: http://www.ncbi.nlm.nih.gov/pubmed/14766259.265.Castells MC, Tennant NM, Sloane DE, et al.Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "J Allergy Clin Immunol 2008;122:574-580.Available at: http://www.ncbi.nlm.nih.gov/pubmed/18502492.266.Sampson HA, Munoz-Furlong A, Campbell RL, et al.Second symposium on the definition and management of anaphylaxis: summary report--second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Ann Emerg Med 2006;47:373-380.Available at: http://www.ncbi.nlm.nih.gov/pubmed/16546624.267.Manivannan V, Decker WW, Stead LG, et al.Visual representation of National Institute of Allergy and Infectious Disease and Food Allergy and Anaphylaxis Network criteria for anaphylaxis.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Emerg Med 2009;2:3-5.Available at: http://www.ncbi.nlm.nih.gov/pubmed/19390910.268.Lenz HJ.Management and preparedness for infusion and hypersensitivity reactions.Oncologist 2007;12:601-609.Available at: http://www.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "ncbi.nlm.nih.gov/pubmed/17522249.269.Markman M, Zanotti K, Peterson G, et al.Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity.J Clin Oncol 2003;21:4611-4614.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Available at: http://www.ncbi.nlm.nih.gov/pubmed/14673050.270.Lee CW, Matulonis UA, Castells MC.Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2005;99:393-399.Available at: http://www.ncbi.nlm.nih.gov/pubmed/16054201.271.Lee CW, Matulonis UA, Castells MC.Carboplatin hypersensitivity: a 6- h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2004;95:370-376.Available at: http://www.ncbi.nlm.nih.gov/pubmed/15491759.272.Higginson DS, Morris DE, Jones EL, et al.Stereotactic body radiotherapy (SBRT): Technological innovation and application in gynecologic oncology.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Gynecol Oncol 2011;120:404-412.Available at: http://www.ncbi.nlm.nih.gov/pubmed/21194733.273.Choi CW, Cho CK, Yoo SY, et al.Image-guided stereotactic body radiation therapy in patients with isolated para-aortic lymph node metastases from uterine cervical and corpus cancer.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 2009;74:147-153.Available at: http://www.ncbi.nlm.nih.gov/pubmed/18990511.274.Jadon R, Pembroke CA, Hanna CL, et al.A systematic review of organ motion and image-guided strategies in external beam radiotherapy for cervical cancer.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Clin Oncol (R Coll Radiol) 2014;26:185-196.Available at: http://www.ncbi.nlm.nih.gov/pubmed/24566332.275.Eminowicz G, Hall-Craggs M, Diez P, McCormack M.Improving target volume delineation in intact cervical carcinoma: Literature review and stepby-step pictorial atlas to aid contouring.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Pract Radiat Oncol 2016;6:e203- 213.Available at: https://www.ncbi.nlm.nih.gov/pubmed/27032573.276.Klopp AH, Yeung AR, Deshmukh S, et al.A Phase III Randomized Trial Comparing Patient-Reported Toxicity and Quality of Life (QOL) During Pelvic Intensity Modulated Radiation Therapy as Compared to Conventional Radiation Therapy.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 2016;96:S3.Available at: https://www.ncbi.nlm.nih.gov/pubmed/27675895.277.Potter R, Georg P, Dimopoulos JC, et al.Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Radiother Oncol 2011;100:116-123.Available at: http://www.ncbi.nlm.nih.gov/pubmed/21821305.278.Haie-Meder C, Potter R, Van Limbergen E, et al.Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Radiother Oncol 2005;74:235-245.Available at: http://www.ncbi.nlm.nih.gov/pubmed/15763303.279.Yoshida K, Jastaniyah N, Sturdza A, et al.Assessment of Parametrial Response by Growth Pattern in Patients With International Federation of Gynecology and Obstetrics Stage IIB and IIIB Cervical Cancer: Analysis of Patients From a Prospective, Multicenter Trial (EMBRACE).",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 2015;93:788-796.Available at: http://www.ncbi.nlm.nih.gov/pubmed/26530747.280.Viswanathan AN, Erickson BA.Three-dimensional imaging in gynecologic brachytherapy: a survey of the American Brachytherapy Society.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 2010;76:104-109.Available at: http://www.ncbi.nlm.nih.gov/pubmed/19619956.281.Erickson-Whitmann B, Rownd J, Khater K.Biologic and physical aspects of radiation oncology.In: Barakat R, Markman M, Randall M, eds.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Principles and Practice of Gynecology Oncology, 5th ed.Philadelphia: Lippincott Williams & Wilkins; 2009:325-380.282.Lim K, Small W, Jr., Portelance L, et al.Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 2011;79:348-355.Available at: http://www.ncbi.nlm.nih.gov/pubmed/20472347.283.Loiselle C, Koh WJ.The emerging use of IMRT for treatment of cervical cancer.J Natl Compr Canc Netw 2010;8:1425-1434.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Available at: http://www.ncbi.nlm.nih.gov/pubmed/21147905.284.Beriwal S, Gan GN, Heron DE, et al.Early clinical outcome with concurrent chemotherapy and extended-field, intensity-modulated radiotherapy for cervical cancer.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 2007;68:166- 171.Available at: http://www.ncbi.nlm.nih.gov/pubmed/17321070.285.Chen M-F, Tseng C-J, Tseng C-C, et al.Clinical outcome in posthysterectomy cervical cancer patients treated with concurrent Cisplatin and intensity-modulated pelvic radiotherapy: comparison with conventional radiotherapy.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 2007;67:1438- 1444.Available at: http://www.ncbi.nlm.nih.gov/pubmed/17394944.286.Chen M-F, Tseng C-J, Tseng C-C, et al.Adjuvant concurrent chemoradiotherapy with intensity-modulated pelvic radiotherapy after surgery for high-risk, early stage cervical cancer patients.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Cancer J 2008;14:200-206.Available at: http://www.ncbi.nlm.nih.gov/pubmed/18536561.287.Salama JK, Mundt AJ, Roeske J, Mehta N.Preliminary outcome and toxicity report of extended-field, intensity-modulated radiation therapy for gynecologic malignancies.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 2006;65:1170- 1176.Available at: http://www.ncbi.nlm.nih.gov/pubmed/16730136.288.Small W, Mell LK, Anderson P, et al.Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 2008;71:428-434.Available at: http://www.ncbi.nlm.nih.gov/pubmed/18037584.289.Erpolat OP, Alco G, Caglar HB, et al.Comparison of hematologic toxicity between 3DCRT and IMRT planning in cervical cancer patients after concurrent chemoradiotherapy: a national multi-center study.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Eur J Gynaecol Oncol 2014;35:62-66.Available at: http://www.ncbi.nlm.nih.gov/pubmed/24654465.290.Klopp AH, Moughan J, Portelance L, et al.Hematologic toxicity in RTOG 0418: a phase 2 study of postoperative IMRT for gynecologic cancer.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 2013;86:83-90.Available at: http://www.ncbi.nlm.nih.gov/pubmed/23582248.291.Klopp AH, Yeung AR, Deshmukh S, et al.Patient-Reported Toxicity During Pelvic Intensity-Modulated Radiation Therapy: NRG OncologyRTOG 1203.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "J Clin Oncol 2018;36:2538-2544.Available at: https://www.ncbi.nlm.nih.gov/pubmed/29989857.292.Fyles A, Keane TJ, Barton M, Simm J.The effect of treatment duration in the local control of cervix cancer.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Radiother Oncol 1992;25:273-279.Available at: http://www.ncbi.nlm.nih.gov/pubmed/1480773.293.Girinsky T, Rey A, Roche B, et al.Overall treatment time in advanced cervical carcinomas: a critical parameter in treatment outcome.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 1993;27:1051-1056.Available at: http://www.ncbi.nlm.nih.gov/pubmed/8262826.294.Lanciano RM, Pajak TF, Martz K, Hanks GE.The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: a patterns-of-care study.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 1993;25:391-397.Available at: http://www.ncbi.nlm.nih.gov/pubmed/8436516.295.Perez CA, Grigsby PW, Castro-Vita H, Lockett MA.Carcinoma of the uterine cervix.I.Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 1995;32:1275-1288.Available at: http://www.ncbi.nlm.nih.gov/pubmed/7635767.296.Petereit DG, Sarkaria JN, Chappell R, et al.The adverse effect of treatment prolongation in cervical carcinoma.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 1995;32:1301-1307.Available at: http://www.ncbi.nlm.nih.gov/pubmed/7635769.297.Eifel PJ, Levenback C, Wharton JT, Oswald MJ.Time course and incidence of late complications in patients treated with radiation therapy for FIGO stage IB carcinoma of the uterine cervix.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 1995;32:1289-1300.Available at: http://www.ncbi.nlm.nih.gov/pubmed/7635768.298.Forrest JL, Ackerman I, Barbera L, et al.Patient outcome study of concurrent chemoradiation, external beam radiotherapy, and high-dose rate brachytherapy in locally advanced carcinoma of the cervix.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Gynecol Cancer 2010;20:1074-1078.Available at: http://www.ncbi.nlm.nih.gov/pubmed/20683420.299.Perez CA, Grigsby PW, Lockett MA, et al.Radiation therapy morbidity in carcinoma of the uterine cervix: dosimetric and clinical correlation.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys 1999;44:855-866.Available at: http://www.ncbi.nlm.nih.gov/pubmed/10386643.300.Van Calsteren K, Heyns L, De Smet F, et al.Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "J Clin Oncol 2010;28:683-689.Available at: http://www.ncbi.nlm.nih.gov/pubmed/19841323.301.Fukushima K, Ogawa S, Tsukimori K, et al.Can we diagnose invasive cervical cancer during pregnancy as precise as in nonpregnant women?",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": ": maternal and perinatal outcome in pregnancies complicated with cervical cancers.Int J Gynecol Cancer 2009;19:1439-1445.Available at: http://www.ncbi.nlm.nih.gov/pubmed/20009904.302.Smith LH, Danielsen B, Allen ME, Cress R.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Cancer associated with obstetric delivery: results of linkage with the California cancer registry.Am J Obstet Gynecol 2003;189:1128-1135.Available at: http://www.ncbi.nlm.nih.gov/pubmed/14586366.303.Swenson RE, Goff BA, Koh W-J, et al.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Cancer in the pregnant patient.In: Hoskins WJ, Perez CA, Young RC, eds.Principles and Practice of Gynecologic Oncology, 4th ed.Philadelphia: Lippincott Williams & Wilkins; 2004 1279-1311.304.Sadler L, Sykes P.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "How little is known about cervical cancer in pregnancy?Ann Oncol 2005;16:341-343.Available at: http://www.ncbi.nlm.nih.gov/pubmed/15722461.305.Morice P, Narducci F, Mathevet P, et al.French recommendations on the management of invasive cervical cancer during pregnancy.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Int J Gynecol Cancer 2009;19:1638-1641.Available at: http://www.ncbi.nlm.nih.gov/pubmed/19955951.306.Sood AK, Sorosky JI.Invasive cervical cancer complicating pregnancy.How to manage the dilemma.Obstet Gynecol Clin North Am 1998;25:343- 352.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Available at: http://www.ncbi.nlm.nih.gov/pubmed/9629575.307.van de Nieuwenhof HP, van Ham MAPC, Lotgering FK, Massuger LFAG.First case of vaginal radical trachelectomy in a pregnant patient.Int J Gynecol Cancer 2008;18:1381-1385.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Available at: http://www.ncbi.nlm.nih.gov/pubmed/18298565.308.Ben-Arie A, Levy R, Lavie O, et al.Conservative treatment of stage IA2 squamous cell carcinoma of the cervix during pregnancy.Obstet Gynecol 2004;104:1129-1131.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "Available at: http://www.ncbi.nlm.nih.gov/pubmed/15516424.309.Gurney EP, Blank SV.Postpartum radical trachelectomy for IB1 squamous cell carcinoma of the cervix diagnosed in pregnancy.Am J Obstet Gynecol 2009;201:e8-e10.Available at: http://www.ncbi.nlm.nih.gov/pubmed/19695559.",
    "source": "宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南/宫颈癌-美国国家综合癌症网络肿瘤学临床实践指南.md"
  },
  {
    "text": "# Contrast Analysis of CT Perfusion Imaging Staging and FIGO Staging and Pathological Staging of Cervical Carcinoma 论 著 # 宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析 CHEN Hui, HUANG Wen-qi, ZHU Ai-peng.Department of Radiology, Shangqiu First People's Hospital, Shangqiu 476100, Henan Province, China # 河南省商丘市第一人民医院放射科(河南 商丘 476100) 陈 辉 黄文起 褚爱鹏【摘要】目的 研究宫颈癌CT灌注成像分期与FIGO分期及病理分期的比较。",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "方法 采用GE Lightspeed UItra 16排多层螺旋CT扫描仪对我院148例宫颈癌患者进行增强扫描，图像传输至PACE系统并进行多平面重建(MPR)，得到冠状位、矢状位、斜冠状位图像，比较CT分期、FIGO分期及术后病理分期的差异。结果 148例宫颈癌患者CT分期诊断Ⅰa期27例、Ⅰb期41例、Ⅱa期28例、Ⅱb期18例、Ⅲa期6例，分期正确120例，占81.08%，其中7例CT、FIGO分期显示无病变，漏诊率4.",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "73%，后经术后脱落细胞学检出，CT诊断过低分期8例，占5.41%，过高分期20例，占13.51%，FIGO分期过低分期31例，过高分期28例，诊断准确率60.14%。结论 CT灌注成像分期准确率高于FIGO分期，并可提供更多的病理信息，可作为FIGO分期后的纠错检查措施，CT对术前分期、手术方案选择及预后有重要的指导意义。【关键词】宫颈癌；CT灌注成像；FIGO分期；病理分期 【中图分类号】R711.",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "74 【文献标识码】A D O I : 1 0 .3 9 6 9 / j .i s s n .1 6 7 2 - 5131.2017.04.035 通讯作者：陈 辉 [Abstract] Objective To compare CT perfusion imaging staging and FIGO staging and pathological staging of cervical carcinoma.",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "Methods 148 patients with cervical carcinoma were scanned with GE Lightspeed UItra 16 slice spiral CT scanner.The images were transmitted to the PACE system and were processed by multi planar reconstruction (MPR) to obtain coronal, sagittal and oblique coronal images.",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "The differences of CT staging, FIGO staging and postoperative pathological staging were compared.Results CT staging diagnosis of 148 patients with cervical carcinoma showed 27 cases of stageⅠa, 41 cases of stageⅠb, 28 cases of stageⅡa, 18 cases of stage $\\mathbb { I } \\mathrm { b }$ and 6 cases of stageⅢa.",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "Staging was correct in 120 cases, accounting for $8 1 .0 8 \\%$ , in which CT and FIGO staging showing no lesions in7 cases.The rate of missed diagnosis was $4 .7 3 \\%$ which was detected by postoperative exfoliative cytology.",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "CT diagnosed excessive low staging in 8 cases, accounting for $5 .4 1 \\%$ and excessive high staging in 20 cases, accounting for $1 3 .5 1 \\%$ .For FIGO staging, there was excessive low staging in 31 cases and excessive high staging in 28 cases.",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "The diagnostic accuracy was $60 .1 4 \\%$ .Conclusion The accurate rate of CT perfusion imaging staging is higher than that of FIGO staging and it can provide more information.It can be used as an error correction test after FIGO staging.",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "CT is of important guiding significance in preoperative staging, the selection of operation scheme and prognosis.[Key words] Cervical Carcinoma; CT Perfusion Imaging; FIGO Staging; Pathological Staging 宫颈癌在妇科恶性肿瘤中排名第三，在我国发病率仅次于乳腺癌，宫颈癌术前分期是治疗方案疗效保障的基本前提，国际妇产科联合会(FIGO)将宫颈癌分为四期，并认为Ⅱa期以下患者适用放疗及根治性手术治疗，而Ⅱb期或Ⅱ期以上患者则采取放疗[1]。",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "目前术前分期方式主要包括影像学分期及FIGO分期，但FIGO为单纯临床诊断，主要通过触诊、阴道镜、子宫镜或X线检查，准确率较低[2]，有研究调查发现，FIGO对Ⅰa期-Ⅱa期、Ⅱb期或更晚期的检出率分别为 $5 4 .7 \\%$ 、$2 1 \\%$ ，均处于较低水平[3]。而随着CT诊断技术的不断成熟，其用于宫颈癌术前诊断具有可能性，尤其是多层螺旋CT有较高的空间分辨率及强大的图像后处理技术，有利于提高分期准确性，但目前有关CT术前分期与FIGO分期、病理分期比较的研究较少，本次研究选取我院148例经病理证实为宫颈癌的患者为研究对象，观察CT灌注成像技术在宫颈癌术前分期中的应用价值，结果如下。",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "# 1 资料与方法 1.1 患者资料 选取我院2009年11月至2014年12月148例病理确诊为宫颈癌的患者为研究对象，均拟进行手术治疗，年龄 $2 6 \\sim 7 1$ 岁，平均( $( 4 3 .1 6 \\pm 4 .4 9 )$ )岁，入院时阴道分泌物增多73例，阴道出血或接触性出血55例，20例同时伴有阴道出血及分泌物增多。1.2 方法 收集所有患者FIGO分期结果，FIGO分期参照2009年19届国际妇产科联盟(International Federation of Gynecology and Obstetrics，FIGO)[1]制定的分期标准，并记录术后病理分期结果，以手术病理学检查为金标准。",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "行CT扫描，检测仪器为GE Lightspeed UItra 16排多层螺旋CT扫描仪，扫描时指导患者摒气，148例患者均进行增强扫描，电胍: $1 2 0 \\mathrm { k V }$ ，电流: $5 0 \\mathrm { m A }$ ，矩阵 $5 1 2 \\times 5 1 2$ ，高压注射器注入非离子造影剂碘海醇(国药准字H20084434，生产单位：江苏晨牌药业有限公司) $3 0 0 \\mathrm { { m g i / m l } }$ ，剂量视患者体重，约 $2 \\mathrm { m l / k g }$ ，3ml/s速率，延迟1min进行扫描，后进行薄层重建，阴道内放置阴道栓，1周后进行手术。",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "增强扫描图像传输至PACE系统并进行MPR重建，包括冠状位、矢状位、斜冠状位(长轴与宫体长轴、阴道长轴相同的平面)，阅片由我院2名高资历影像科医师共同阅片，阅片前不知FIGO分期结果，进行CT分期判断。1.3 统计学分析 比较CT分期与FIGO分期、术后病理分期结果，以术后分期为金标准，观察 表1 CT灌注成像分期与FIGO分期、术后病理分期结果对照 <html><body><table><tr><td>分期方式</td><td>0期</td><td>Ia期</td><td>Ib期</td><td>ⅡIa期</td><td>ⅡIb期</td><td>Ⅲla期</td><td>总数</td></tr><tr><td>CT分期</td><td>0</td><td>27</td><td>41</td><td>28</td><td>18</td><td>6</td><td>120</td></tr><tr><td>FIGO分期</td><td>0</td><td>22</td><td>35</td><td>16</td><td>13</td><td>3</td><td>89</td></tr><tr><td>术后分期</td><td>7</td><td>34</td><td>48</td><td>33</td><td>20</td><td>6</td><td>148</td></tr></table></body></html> CT、FIGO分期的准确性。",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "# 2 结 果 ![](images/6140e557b9a37bb8270cc9cbb041089c9db0f6cbe280b02e38bfe6a4d68f205a.jpg) 图1-3为同一患者的轴位、矢状位、冠状位图像，轴位可见子宫颈处有较大的软组织肿物，约7×4cm，且有不均匀坏死，子宫颈癌确诊。矢状位对病灶体积、边界的显像更清晰，可见不均匀坏死，冠状位同可观察处以上信息；图4可见子宫颈处有不均匀低密度影，且边界模糊，子宫颈癌；图5轴位可见子宫颈处不均匀低密度影，边界模糊，确诊为子宫颈癌；图6是非图5患者的轴位图像，同可见子宫颈处有低密度软组织肿物，且边界模糊。",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "2.1 CT灌注成像结果与术后病理分期结果对照 CT分期诊断Ⅰa期27例、Ⅰb期41例、Ⅱa期28例、Ⅱb期18例、Ⅲa期6例，分期正确120例，占 $8 1 .0 8 \\%$ ，其中 7 例 C T 、 F I G O 分 期 显 示 无 病变，漏诊率 $4 .7 3 \\%$ ，后经术后脱落细胞学检出，CT诊断过低分期8例，占 $5 .4 1 \\%$ ，过高分期20例，占 $1 3 .5 1 \\%$ ，FIGO分期过低分期31例，过高分期28例，诊断准确率$6 0 .",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "\\ 1 4 \\%$ ，各分期诊断准确率见表1。# 2.2 CT图像观察 见图1-6。# 3 讨 论 目前临床的宫颈癌患者大多采取化疗干预，尚未采取手术病理分期，因此需统一的分期标准，FIGO是术前分期的一种，最早应用1989年，需在一切治疗前完成判断，如治疗导致分期改变，则仍保留最初诊断结果，如无法做出分期判断，则以最早1级分期确定[4]，此种分期对医师技术、经验的要求较高，如操作不当则容易误判，众多研究均认为其判断分期的准确性较低[5]。",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "本次研究中FIGO准确率为 $6 0 .1 4 \\%$ ，明显低于CT分期，其原因是FIGO仅可分析病理表象，无法观察病灶大小、对周围组织的侵犯情况。本次研究显示CT对Ⅰa期、Ⅰb期的分期准确例数分别为27例、41例，尽管高于FIGO分期，但仍不够满意，考虑CT对早期子宫颈癌的显示不佳，主要因病灶多呈等密度，尽管可通多平面重建提高图像质量，但子宫颈增粗仍为主要征象，而对体积较大的肿瘤CT则检出率明显较高，因病灶呈低血供，且病变处可见溃疡、坏死，且病灶边界清晰，可通过上述征象完成确诊[6]。",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "同时CT可判断宫旁侵袭，这是FIGO无法做到的，且病变越晚，则检出率越高，如宫旁侵袭仅局限在宫旁组织、子宫韧带等处，CT则可能出现误诊。另外多排螺旋CT可实现阴道侵犯的观察，假阳性常见外生性子宫颈瘤，因此可作为FIGO的补充措施。宫颈癌有相对特殊C T 征象 ， 成 人 正 常 宫 颈 长 度 约$2 .3 { \\sim } 3 .0 \\mathrm { c m }$ ，而宫颈处于子宫下部[7]，CT通过扫描双侧股骨水平可完成宫颈的扫描，增强扫描后子宫体与宫颈的强化程度基本一致，且强化扫描后血管因强化可清晰显像。",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "CT主要通过肿瘤体积、宫旁侵袭、阴道侵犯实现分期判断[8]。CT对肿瘤体积的判断相对较差，主要因为与正常宫颈组织比较，肿瘤组织无较大的差异性，病灶多呈等密度变化，增强扫描后可见差异，本次研究中患者病灶大多为等、低密度，等密度时仅可依靠宫颈管增粗判断，对肿瘤大小判断较困难，而低密度时则提示病变坏死、血供减少等因素导致，但部分患者增强扫描后出现明显强化，病灶边缘清晰，对病灶的显像效果提高，对肿瘤体积的判断良好[9]。",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "宫旁侵袭程度的判断主要用于鉴别Ⅱa、Ⅱb期[10]，CT诊断后如见宫颈边缘毛躁、不规则，条纹不规则形影或周围脂肪间隙消失则需考虑为出现宫旁侵袭，而冠状位图像的表现更为明确，总的来说，CT通过宫旁侵袭进行分期判断的价值较高。阴道侵犯可区分Ⅲ、Ⅱ期，如侵犯至阴道下1/3处则为Ⅲ期，反之则为Ⅱ期，阴道侵袭的判断需在检查前放置阴道栓使阴道形态更加明确，从而提高阴道侵袭判断的准确性[11]。CT多平面重建可避免单纯横断面检测的局限性，本次研究后期进行冠状位、矢状位、斜冠状位的图像重建，可全面显示阴道和子宫颈的空间关系，显示肿瘤对阴道的侵袭程度，具有高度的准确性，肿瘤侵袭阴道的CT征象主要包括阴道上段可见软组织肿物，且肿物边缘和阴道壁贴合密切无分界限，阴道壁增厚且不规则[12]。",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "综上，通过与术后病理分期及FIGO分期的比较可知，CT分期准确性高于FIGO分期，可作为FIGO分期的补充措施完善治疗依据，可作为宫颈癌手术、放化疗前的常规检测方式进行推广。# 参考文献 [ 1 ] P e c o r e l l i S .R e v i s e d F I G Os t a g i n g f o r c a r c i n o m a o ft h e v u l v a , c e r v i x , a n dendometrium [J].",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "Int J GynaecolObstet,2009,105(2):103-104.[2]邱书珺,陆晓兰,蒋小平，等.MSCT和M R I 对浸润性宫颈癌术前分期 的 价 值 对 比 [ J ] .放 射 学 实践,2012,27(1):77-80.[3]郭强蕊.CT诊断在卵巢癌和宫颈癌放射治疗前后的临床运用价值[J].西部中医药,2015,19(1):125-128.[4]靳宏星,张建新,杜笑松，等.",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "MSCT与 多 平 面 重 组 诊 断 不 同 分 期宫 颈 癌 [ J ] .中 国 医 学 影 像 技术,2012,28(3):543-547.[5]张海燕,宋迪.多层螺旋CT与MRI对 宫 颈 癌 术 前 分 期 的 诊 断 价值 比 较 [ J ] .中 国 妇 幼 健 康 研究,2014,25(1):111-113.[6]姚铭,刘桂锋,王永亮,等.多排螺旋CT对宫颈癌影像诊断的价值[J].",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "中国老年学杂志,2012,32(10):2169-2170.[ 7 ] P a r k J M , C h a r n s a n g a v eC,Yoshimitsu K,et al.Pathwayo f n o d a l m e t a s t a s i sf r o m p e l v i c t u m o r s : C Td e m o n s t r a t i o n [ J ] .",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "R a d i o g -raphics,1994,16(14):1309-1321.[8]叶斌强,孙鹏飞.宫颈癌诊断及疗效评价的影像学研究进展[J].中国CT和MRI杂志,2014,14(2):109-112.[9]邱书珺,陆晓兰,蒋小平，等.16层 螺 旋 C T 在 宫 颈 癌 临 床 分 期中 的 价 值 [ J ] .实 用 放 射 学 杂志,2010,26(7):990-992.[10]孙瑞瑞,胡尔西旦·尼牙孜,赵化荣，等.",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "早期宫颈癌FIGO分期与手术病理分期的差异性及淋巴结转移危险因素的分析[J].临床肿瘤学杂志,2015,21(8):704-708.[11]孟建超,李宇光,刘玉虎,等.宫颈癌CT影像分析[J].中国美容医学,2012,21(z2):347.[12]钱跃龙.螺旋CT多期增强扫描及三维重建在宫颈癌诊断中的临床研究[J].河北医学,2012,18(9):1209-1211.(本文编辑: 刘龙平) # （上接第 105 页） [ 4 ] H a n s - J o r g W i t t s a c k , R i t z l A,Gereon Retal．MR Imaging in Acute Stroke: Diffusionw e i g h t e d a n d P e r f u s i o n I m a g i n g P a r a m e t e r s f o r Predicting Infarct Size1[J].",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "Radiology,2002,222(2):397-403.[5]靳瑞娟,马强华,杨晓萍,等.卵巢 良恶性病变的磁共振扩散加权成 像分析及应用[J].实用放射学杂 志,2009,25(6):825-828.[6]梁长松,陈忠,李伟峰.磁共振扩散加 权成像在卵巢囊腺癌与囊腺瘤鉴别 诊断中的价值[J].中国CT和MRI杂 志,2015(3):83-86 [ 7 ] S i e g e l m a n E S , O u t w a t e r E K.",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "Tissue characterization i n t h e f e m a l e p e l v i s b y m e a n s o f M R i m a g i n g [ J ] .Radiology,1999,212(1):5-18 [ 8 ] T h o m a s s i n - Naggara,IToussaint,NPerrot， et al.Characterization of complex adnexal masses:value o f a d d i n g p e r f u s i o n a n d diffusion-weighted MR imaging to conventional MR Imaging[J].",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "Radiology,2011,258(3):793-803.[9]Shu H Z，Jin W Q，Guo F Z， et al.Diffusion-weighted MR imaging for differentiating borderline from malignant e p i t h e l i a l t u m o u r s o f t h e o v a r y ： p a t h o l o g i c a l c o r r e l a t i o n [ J ] .",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "E u r o p e a n Radiology,2014,24(9):2292- 2299.[10]Thomassin-Naggara I,Bazot M E，Callard P，et al.Epithelial o v a r i a n t u m o r s : v a l u e o f dynamic contrast-enhanced MR imaging and correlation with tumor angiogenesis[J].",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "Radiology,2008,248(1):148-159.[11]Sohaib S A,Mills T D,Sahdev A，et al．The role of magnetic r e s o n a n c e i m a g i n g a n d ultrasound in patients with adnexal masses[J].Clinical Radiology,2005,60(3):340-348.(本文编辑: 刘龙平)",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "# ·述评· 【编者按】 国际癌症研究中心 GLOBOCAN 2020 数据库显示，宫颈癌无论是发病病例还是死亡病例，均居全球女性肿瘤第四位。宫颈癌年龄别发病率在 25 岁以后开始上升，在发达国家，发病率在 40 岁左右达到高峰，而在发展中国家，其发病率在55\\~69 岁达到高峰。故其早期疫苗接种、早期诊断和规范化治疗是减少该病发病和死亡例数的重要措施。本期就国内外最新指南中宫颈癌的分期和治疗、真实世界研究中存在的问题进行深入分析，以期为临床宫颈癌的诊治提供依据。",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "# 宫颈癌治疗的现状及问题：从临床指南到真实世界研究 张军 【摘要】 宫颈癌是严重威胁女性健康的恶性肿瘤之一，关于宫颈浸润癌的治疗，需要术前规范地分期和评估，早期宫颈癌以手术治疗为主，重视国内外指南更新，选择合适的手术范围和入路；晚期及复发性宫颈癌以放化疗为主，宫颈癌的治疗和临床研究中存在诸多挑战和争议。本文主要就宫颈癌的诊断及治疗的现状及问题进行探讨，以更好地应用临床指南指导真实世界的诊疗。【关键词】 妇科肿瘤；生殖器肿瘤，女（雌）性；宫颈肿瘤；诊断；治疗 【中图分类号】 R 737.",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "33 【文献标识码】 A DOI：10.12114/j.issn.1007-9572.2021.02.105张军.宫颈癌治疗的现状及问题：从临床指南到真实世界研究［J］.中国全科医学，2022，25（3）：259-263.［www.chinagp.net］ ZHANG J.Current status and challenges of cervical cancer treatment：from clinical guidelines to real-world study［J］.",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "Chinese General Practice，2022，25（3）：259-263.# Current Status and Challenges of Cervical Cancer Treatment：from Clinical Guidelines to Real-world Study ZHANG Jun Department of Obstetrics and Gynecology，Beijing Anzhen Hospital，Capital Medical University/Obstetrics and Gynecology Center for Severe Cardiovascular Diseases，Beijing 100029，China 【Abstract】 Cervical cancer is a type of malignancy that severely threatens women's health.",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "For invasive cervical cancer，standardized preoperative staging and assessment are essential before the start of treatment.With regard toearly cervical cancer，surgery is the major treatment，with considerations for the latest updates in relevant guidelines，and the determination of extent of resection as well as the selection of proper surgical approach.",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "For advanced or relapsed cervical cancer，radiotherapy and chemotherapy are the main treatments.However，there are many challenges and controversies regarding the treatment and clinical research of cervical cancer.",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "We mainly discussed the present status and challenges of cervical cancer diagnosis and treatment based on clinical guidelines and practices，aiming at bettering the real-world practice with the support of clinical guidelines.",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "【Key words】 Gynecologic neoplasms；Genital neoplasms，female；Uterine cervical neoplasms；Diagnosis；Therapy 宫颈癌是女性生殖系统三大恶性肿瘤之一，根据 2018 年全球癌症统计数据显示其发病率在所有癌症中居第 14 位，在女性癌症中居第 4 位［1-2］。根据世 界 卫 生 组 织（World Health Organization，WHO）2018 年发布的数据，每年全世界有超过32 万人因宫颈癌死亡，女性人群宫颈癌发病率为 $1 3 .",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "1 \\%$ 、死亡率为 $6 .9 \\%$ ，均居第 4 位；在发展中国家，宫颈癌发病 # 本文要点： 宫颈癌是严重威胁女性健康的生殖系统恶性肿瘤之一，临床医生应该重视对宫颈癌的规范化诊断和治疗。目前国内外指南对宫颈癌诊断和治疗的更新对临床有很好的指导作用。而在临床工作实践中，临床诊断仍不够精准，微创治疗亦存在诸多争议，此外还有诸多待改进的问题，需要广大医生重视。本文梳理了近年来发布的临床指南中关于宫颈癌的分期与手术治疗的进展及真实世界研究的一些问题。",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "率居女性肿瘤第 2 位［2］。宫颈癌死亡病例中 $8 5 \\%$ 在发展中国家［3-4］。宫颈癌的防治工作非常重要，主要包括预防与治疗。在宫颈癌预防方面，随着人乳头瘤病毒（HPV）疫苗的推广应用、宫颈癌筛查、宫颈上皮内瘤变的诊断和治疗等措施的开展，宫颈癌在全球很多地区尤其发达国家发病率已经开始下降，在美国，宫颈癌已经不再是发病率前十的恶性肿瘤［2］。2020 年根据WHO 癌症研究机构（IARC）发布的数据，中国宫颈癌新发病例达 11 万，死亡病例为 6 万，居人群恶性肿瘤第 10 位，而宫颈癌的发病率和死亡率居女性肿瘤的第6 位和第7 位。",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "关于宫颈浸润癌的治疗，涉及宫颈癌的分期诊断、手术及放化疗等方案选择和治疗过程中的诸多问题及关键点，一直是妇科肿瘤临床工作中的重点、难点。随着新的治疗方法、治疗效果及并发症等数据的积累，国内外指南不断更新，美国国立综合癌症网络（National ComprehensiveCencer Network，NCCN）、欧洲肿瘤医学会（EuropeanSociety for Medical Oncology，ESMO） 指 南、 国 际 妇产 科 联 盟（International Federation of Gynecology andObstetrics，FIGO）建议以及国内的指南和专家共识为临床工作提供了很好的指导。",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "但真实世界的临床及研究中所涉及和涵盖的宫颈癌治疗中诸多的异质性和不确定因素等问题非常普遍，临床的困惑和治疗的探索也会持续存在，本文梳理了近年来被临床医生广泛参考的临床指南中关于宫颈癌的分期与手术治疗的进展以及真实世界研究的一些问题，以期指导临床实践。# 1 宫颈癌诊断 宫颈癌的诊断包括分期和组织学分类。分期诊断直接决定治疗方案，在宫颈癌的临床诊治中至关重要。NCCN、ESMO、FIGO 和中国抗癌协会发布的宫颈癌的指南中关于宫颈癌的分期诊断标准一直是临床实践的主要参考。",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "2021 年 NCCN 和中国抗癌协会针对宫颈癌的分期诊断进行了更新，ESMO 和 NCCN及中国抗癌协会指南均采用的是FIGO 2018 年版分期标准。1.1 国内外指南关于宫颈癌的分期 对初次诊断的宫颈癌患者进行准确分期是选择治疗方案的主要依据。FIGO 2009 年版宫颈癌分期主要依靠临床检查结果，由 2 名高年资医生对患者进行体格检查，根据宫颈阴道、宫旁（包括主骶韧带及膀胱直肠的侵犯）及远处转移的情况进行分期，分期中不纳入淋巴结的转移情况，且术后不再根据病理结果进行分期的修正。",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "多年的临床实践结果表明FIGO 2009 年版宫颈癌分期带有很大的主观性，其准确性不能满足临床需求及对预后的判断。2018 年FIGO 对宫颈癌的分期进行了较大的修改［5］，并于2019 年对其中Ⅰ期和Ⅱ期中病灶浸润深度或肿瘤大小“ $\\mathbf { \\bar { \\rho } } = \\mathbf { \\bar { \\rho } }$ ”临界值时的分期进行了更正，由采用较高分期更正为较低分期，比如ⅠA期中原浸润深度为 $3 ~ \\mathrm { m m }$ ，2018 年将其划归为ⅠA2期，而 2019 年将其划归为ⅠA1 期，两者有着完全不同的治疗方案推荐，一个“=”的位置变化决定着宫颈癌患者的精准分期、治疗方案的选择及预后［6-7］。",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "2018 年发布（2019 年修订）的 FIGO 宫颈癌分期将影像学和病理学结果引入到分期系统中，术后根据病理结果可进行分期修正，对患者的诊断更加精准，能更好地指导此类患者的治疗、预后及随访。1.2 宫颈癌初治前的分期诊断 分期的判断是宫颈癌初次治疗前确定治疗方案的依据。对于 $\\mathbb { I } \\sim \\mathbb { I }$ A期宫颈癌需要通过术前评估分期来选择是否手术及手术范围。",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "FIGO 的分期标准中涉及了妇科检查所见及影像学、病理学结果，病理学结果需要术后确认。术前评估目前推荐依据体格检查和影像学进行综合判断。需要对Ⅰ A 期活检或锥切获得的宫颈组织标本进行肿瘤浸润深度的测量，需要对Ⅰ B\\~ Ⅱ A 期的患者肿瘤大小进行测量以进一步分期。国内外指南推荐手术治疗是Ⅰ B1、Ⅰ B2 期和Ⅱ A1 期患者的首选治疗方案，而对于Ⅰ B3 期和Ⅱ A2 期患者，首选治疗方式为同步放化疗，换言之，肿瘤直径是否 ${ > } 4 \\ \\mathrm { c m }$ 将决定治疗方案的选择。",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "在真实临床实践中，体格检查时主要依靠肉眼和手法的估测，显然不能实现准确测量，根据中国宫颈癌临床诊疗大数据库的资料，将患者按照肿瘤大小分为 $\\leqslant 4 ~ \\mathrm { c m }$ 和 ${ > } 4 \\ \\mathrm { c m }$ 两组，妇科检查肿瘤 $\\leqslant 4 ~ \\mathrm { c m }$ 但病理测量 ${ > } 4 \\ \\mathrm { c m }$ 者占 $2 1 .",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "7 \\%$ ，妇科检查肿瘤 ${ > } 4 \\ \\mathrm { c m }$ 而病理测量 $\\leqslant 4 ~ \\mathrm { c m }$ 者占 $1 7 .2 \\%$ ，妇科检查结果和术后病理符合率不足 $2 / 3 ^ { \\ [ 8 ] }$ 。诸多临床研究表明 MRI 的评估结果是现有手段中较为准确的，如能采用三维 MRI 评估肿瘤大小，则可进一步提高分期的准确性［8］。",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "对于宫颈癌的分期诊断，除了局部肿瘤的大小，宫旁是否受到侵犯、淋巴结及远处的转移也是分期的重要依据。是否存在宫旁浸润将决定患者的首选治疗方式为手术或同步放化疗。对于Ⅱ B 期及以上患者，对转移病灶的评估是制定同步放化疗方案的依据。术前评估中影像学的检查包括超声、CT、正电子发射计算机断层显像（PET-CT）和磁共振检查，除检查手段本身对宫颈病变的立体测量不够准确外，临床实践中发现影像学检查报告中并未完整报告肿瘤大小、浸润范围、淋巴结有无肿大等判断分期的关键信息的现象非常普遍，而不同级别和地区的医院诊断准确性也存在很大差距，无论是常规 CT、MRI检 查， 还 是 联 合 弥 散 加 权 成 像（diffusion weightedimaging，DWI），均未解决常规检查诊断淋巴结灵敏度低的问题。",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "PET-CT 诊断早期淋巴结转移的灵敏度为 $3 2 \\% { \\sim } 5 8 \\%$ ，但也有研究表明 PET-CT 评估淋巴结转移的总灵敏度可以达到86%［8-10］。总之，随着对宫颈癌诊断和治疗规范化要求的不断提升，临床医生应结合多种影像学方法进行宫颈癌治疗前分期的评估，以获得更准确、全面的信息。有研究提出影像组学的概念，以期提高宫颈癌患者治疗前分期诊断的准确性［11］。磁共振组学和 CT 组学计算机预测宫颈癌转移的模型研究已经显示有提高术前诊断准确性的可能，也有研究表明 T2 加权成像（T2WI）联合 T1 加权成像（T1WI） $^ +$ 序列影像组学模型对早期宫颈癌淋巴结转移有较好的预测能力［11-12］，相信医学影像和人工智能（AI）技术的结合将提高宫颈癌的诊断准确性。",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "1.3 宫颈癌的组织学诊断 术后所有患者需病理学的组织分型诊断，中国及 NCCN、ESMO 等指南均推荐组织类型按照 WHO-2014 年女性生殖器官肿瘤分类标准，组织学分级不纳入宫颈癌的分期诊断系统中［13］。总之，应用 FIGO 的新分期标准对宫颈癌患者进行评估，多种手段的应用使诊断更加精确，在临床工作中考虑到各种应用于术前诊断方法的局限性和可能产生的偏倚并予以纠正，是选择正确治疗方案的基础，术后结合组织学分类制定后续的管理和治疗方案。",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "# 2 宫颈癌的治疗 宫颈癌的治疗主要包括手术治疗和放疗，化疗可与手术、放疗配合或作为晚期及复发性宫颈癌的治疗方式。目前靶向治疗、免疫治疗等也用于复发或转移宫颈癌的治疗。中国抗癌协会妇科肿瘤专业委员会发布的《宫颈癌诊断与治疗指南（2021 年版）》［13］推荐手术治疗适合Ⅰ A 期、Ⅰ B1 期、Ⅰ B2 期、ⅡA1 期患者，对于ⅠB3 期及ⅡA2 期患者，首选同步放化疗，在放疗资源缺乏的地区可选择手术治疗。",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "对于尚未绝经的患者（特别是年龄 $< 4 0$ 岁者），放疗容易引起盆腔纤维化和阴道萎缩狭窄，故早于Ⅱ B期、无手术禁忌证者可选择手术治疗。手术入路推荐开腹手术或经阴道手术，对于Ⅰ A1 期无脉管侵犯的患者可选腔镜微创手术。目前以铂类药物为基础的单药或联合化疗广泛适用于宫颈癌治疗，化疗中可联合贝伐珠单抗治疗。靶向治疗或免疫治疗可作为二线治疗的选择。2.1 关于宫颈癌手术及治疗方案的建议 总结国内外指南关于宫颈癌的手术治疗方式均包括：保留生育功能手术、不保留生育功能手术、盆腔廓清术和腹主动脉 $\\pm$ 盆腔淋巴结切除分期手术。",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "保留生育功能手术包括子宫颈锥切术和经腹或经阴道根治性子宫颈切除术。2021 年版NCCN 指南［14］推荐Ⅰ A1 期无淋巴脉管侵犯（LVSI）及Ⅰ A1 期伴LVSI 或ⅠA2 期行锥切术时，推荐整块切除病灶、阴性切缘至少 $3 \\ \\mathrm { m m }$ 距离，Ⅰ A1 期伴 LVSI 或Ⅰ A2 期的首选根治性子宫颈切除 $^ +$ 盆腔淋巴结切除，次选锥切 $+$ 盆腔淋巴结切除。",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "不推荐小细胞神经内分泌癌、胃型腺癌保留生育功能。不保留生育功能手术采用 Querleu-Morrow（QM）分型。根治性子宫切除手术方式推荐开放性手术。对于治疗后复发，尤其是盆腔中心性复发可选择盆腔廓清术，包括前盆腔廓清术、后盆腔廓清术和全盆腔廓清术。关于盆腔淋巴结的处理，可选择盆腔淋巴结或前哨淋巴结切除。对于Ⅰ A2\\~ Ⅰ B2 期及部分Ⅰ B3\\~ Ⅱ A1 期的患者，NCCN 及 ESMO 均推荐根治性子宫切除术加双侧盆腔淋巴结切除术（或前哨淋巴结切除），必要时切除腹主动脉旁淋巴结，根治性子宫切除术的标准术式是开腹入路［13-15］。",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "Ⅱ B期及以上的晚期病例通常建议采用放、化疗。在部分国家和地区，有一部分Ⅱ B 期的病例可能会选择根治性子宫切除术或新辅助化疗后再手术。对于局部晚期或不能耐受手术者，放疗是最佳治疗方法，根治性子宫切除术后存在高危因素可以选择放疗作为辅助治疗。2020 年 ESMO 大会上公布了一项国际、多中心、回顾性队列研究（ENGOT-Cx3/CEEGOGCX2），该研究比较了早期宫颈癌中根治性子宫切除术和放化疗的疗效，不论肿瘤大小、类型或其他危险因素如何，根治性子宫切除术并不能改善淋巴结阳性宫颈癌患者的肿瘤结局。",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "建议如果术中发现淋巴结受累，应考虑放弃进一步的根治性手术，并建议患者进行放、化疗［16］。这也提示临床医生，应更加重视宫颈癌治疗前的分期和评估。2.2 关于宫颈癌根治手术入路的争议 对于 ⅠA2\\~ⅡA1期的早期宫颈癌，根治性子宫切除术（QM分型 B\\~D 型）已有 100 多年的历史，自 20 世纪 90年代初有医生开始报道腹腔镜下的宫颈癌手术，随着腔镜设备和技术的进展，腹腔镜宫颈癌手术在世界各地广泛开展，在2015—2018 年发布的NCCN 指南中，推荐宫颈癌的广泛子宫切除可以经腹腔镜或开腹实施［17］。",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "2018 年，一项涉及全球 33 个中心的前瞻性随机对照研究（LACC 研究）显示，微创组与开腹组3 年总生存率（OS）分别为 $9 3 .8 \\%$ 与 $9 9 .0 \\%$ ，宫颈癌死亡率分别为 $4 .4 \\%$ 与 $0 .6 \\%$ ，3 年无局部区域复发生存率分别为 $9 4 .3 \\%$ 与 $9 8 .3 \\%$ ，显示腹腔镜组比开腹组有更高的死亡率和复发率［18］。后续的一些临床研究同样提示了腹腔镜组有更高的死亡和复发风险［19］，因此 NCCN 系列指南建议应告知患者宫颈癌临床研究的结果，在患者知情同意的情况下选择手术入路，2020—2021 年 NCCN 发布的相关指南中明确推荐开腹入路是根治性子宫切除术的标准术式［17］。",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "宫颈癌微创手术与不良结局的关系引起了世界各地医生学者的重视，中国学者基于中国宫颈癌临床诊疗大数据库的真实世界研究资料，对诊断日期在 2009-01-01 至 2016-12-31 的 Ⅰ A1（LVSI+）\\~ Ⅱ A1 期宫颈癌腹腔镜和开腹手术患者结局进行对比分析，在真实世界研究条件下，经过多层次的分析，微创手术组患者的 5 年生存率和无瘤生存率均低于开腹手术组，微创手术是复发或死亡的独立危险因素［20］。",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "虽然前期的研究结果不尽一致，且目前尚没有大规模的中国微创手术后宫颈癌预后的数据，但在临床中偶有发现不同于以往特点的术后转移复发病例，结合 NCCN 指南的推荐，安全地实施宫颈癌根治微创手术已经得到了广泛重视。宫颈癌腹腔镜微创手术与开腹手术操作的不同点主要在于螺旋式举宫杯的应用可能造成对肿瘤局部的挤压以及二氧化碳气腹的潜在影响等，2019 年《宫颈癌微创手术的中国专家共识》［21］强调了选择手术方案需对患者进行充分地告知和知情选择，并要求加强对妇科肿瘤医师的培训及对病例的选择，尤其提到手术的“无瘤操作”原则。",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "建议改进举宫方法，推荐“提吊举宫法”，阴道离断前闭锁肿瘤下方的阴道，或经会阴离断阴道；淋巴结切除后立即放入标本袋；子宫标本取出后用注射用水冲洗盆腔、腹腔等措施。宫颈癌微创手术应用于临床已有 30 余年的时间，近年来随着对手术无瘤原则的重视和手术方法的改进，一直是临床关注的热点问题，2019 年开始的中国多中心宫颈癌微创与开腹手术的真实世界研究目前正在进行中，期待新的研究结果带给临床更多参考。总之，关于浸润性宫颈癌的分期演变和治疗目前还存在很多争议和探索，包括分期对预后的判断、宫颈癌治疗方案的选择、局部晚期宫颈癌手术或同期放化疗方案的制定、宫颈癌的手术入路等，临床工作中需在现有医疗条件下精确分期、兼顾生育要求和特殊病理类型等制定治疗方案、重视手术的无瘤原则。",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "临床研究中重视指南的推荐，随机对照试验与真实世界研究结合，将为宫颈癌的治疗方案的改进更新提供更多依据。本文无利益冲突。# 参考文献 ［1］FOWLER J R，MAANI E V，JACK B W.Cervical Cancer［M］.Treasure Island （FL）：StatPearls Publishing，2021.［2］BRAY F，FERLAY J，SOERJOMATARAM I，et al.",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "Global cancerstatistics 2018：GLOBOCAN estimates of incidence and mortalityworldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin，2018，68（6）：394-424.DOI：10.3322/caac.21492.［3］Comprehensive cervical cancer control：a guide to essentialpractice［M］.",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "2nd ed.Geneva：World Health Organization，2014.［4］HULL R，MBELE M，MAKHAFOLA T，et al.Cervical cancer inlow and middle-income countries［J］.Oncol Lett，2020，20（3）：2058-2074.DOI：10.3892/ol.2020.11754.［5］BHATLA N，DENNY L.",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "FIGO cancer report 2018［J］.Int JGynecol Obstet，2018，143：2-3.DOI：10.1002/ijgo.12608.［6］Corrigendum to “Revised FIGO staging for carcinoma of the cervixuteri” ［J］.Int J Gynaecol Obstet，2019，147（2）：279-280.",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "DOI：10.1002/ijgo.12969.［7］王登凤，张国楠.FIGO 2018年子宫颈癌分期的重要更正提示［J］.中国实用妇科与产科杂志，2020，36（9）：905-906.DOI：10.19538/j.fk2020090126.［8］刘萍，李朋飞 .子宫颈癌治疗前评估的规范化［J］.中国实用妇 科 与 产 科 杂 志，2021，37（1）：41-44.DOI：10.19538/j.fk2021010110.",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "LIU P，LI P F.Standardized evaluation of cervical cancer patientsbefore treatment［J］.Chin J Pract Gynecol Obstet，2021，37（1）：41-44.DOI：10.19538/j.fk2021010110.［9］KHIEWVAN B，TORIGIAN D A，EMAMZADEHFARD S，et al.",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "Update of the role of PET/CT and PET/MRI in the management ofpatients with cervical cancer［J］.Hell J Nucl Med，2016，19（3）：254-268.DOI：10.1967/s002449910409.［10］SONG J，HU Q，HUANG J，et al.Combining tumor size anddiffusion-weighted imaging to diagnose normal-sized metastaticpelvic lymph nodes in cervical cancers［J］.",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "Acta Radiol，2019，60（3）：388-395.DOI：10.1177/0284185118780903.［11］董诗洁，胡晓欣，王葳，等 .基于多序列 MRI 与多体系影像组学模型预测子宫颈癌淋巴结转移的研究［J］.中国癌症杂志，2021，31（6）：460-467.DOI：10.19401/j.cnki.1007-3639.2021.06.004.DONG S J，HU X X，WANG W，et al.",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "Prediction of lymph nodemetastasis of cervical cancer based on multi-sequence MRI andmulti-system imaging omics model［J］.China Oncol，2021，31（6）：460-467.DOI：10.19401/j.cnki.1007-3639.2021.06.004.［12］CHEN J，HE B，DONG D，et.",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "al.Noninvasive CT radiomic modelfor preoperative prediction of lymph node metastasis in early cervicalcarcinoma［J］.Br J Radiol，2020，93（1108）：20190558.DOI：10.1259/bjr.20190558.［13］中国抗癌协会妇科肿瘤专业委员会 .子宫颈癌诊断与治疗指南（2021 年版）［J］.",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "中国癌症杂志，2021，31（6）：474-489.DOI：10.19401/j.cnki.1007-3639.2021.06.06.［14］National Comprehensive Cancer Network.NCCN clinical practiceguidelines in oncology：cervical cancer（version I.2021）［EB/OL］.［2021-10-10］.",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "https://www.nccn.org/guidelines.［15］MARTH C，LANDONI F，MAHNER S，et al.Corrections to“Cervicalcancer：ESMO Clinical Practice Guidelines for diagnosis，treatmentand follow-up”［J］.$\\mathrm { A n n ~ O n c o l }$ ，2018，29（Suppl 4）：iv262.",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "DOI：10.1093/annonc/mdy160.［16］朱俊，吴小华.2020 年度妇科恶性肿瘤最新研究进展及展望［J］.中 国 癌 症 杂 志，2021，31（4）：250-256.DOI：10.19401/j.cnki.1007-3639.2021.04.002.ZHU J，WU X H.Leading research progress and prospect ofgynecological oncology in 2020［J］.",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "China Oncol，2021，31（4）：250-256.DOI：10.19401/j.cnki.1007-3639.2021.04.002.［17］National Comprehensive Cancer Network.NCCN clinical practice guidelines in oncology：cervical cancer（version I.2018）［EB/OL］.［2021-10-10］.",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "https://www.nccn.org/guidelines.［18］RAMIREZ P T，FRUMOVITZ M，PAREJA R，et al.Minimallyinvasive versus abdominal radical hysterectomy for cervicalcancer［J］.N Engl J Med，2018，379（20）：1895-1904.DOI：10.1056/nejmoa1806395.",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "［19］MELAMED A，MARGUL D J，CHEN L，et al.Survival afterminimally invasive radical hysterectomy for early-stage cervicalcancer［J］.N Engl J Med，2018，379（20）：1905-1914.DOI：10.1056/NEJMoa1804923.［20］马骏，陈晓林，王倩青，等 .",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "Ⅰ A1（ $\\mathrm { L V S I } +$ ）\\~ Ⅱ A1 期子宫颈癌腹腔镜与开腹手术长期肿瘤学结局的真实世界研究［J］.中国实用妇科与产科杂志，2020，36（5）：445-452.DOI：10.19538/j.fk2020050115.MA J，CHEN X L，WANG Q Q，et al.Long-term oncologicaloutcomes of laparoscopic vs.",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "abdominal approach to FIGOstage Ⅰ A1（ $\\mathrm { L V S I } +$ ）- Ⅱ A1 cervical cancer in real worldstudy［J］.Chin J Pract Gynecol Obstet，2020，36（5）：445-452.DOI：10.19538/j.fk2020050115.［21］中华医学会妇科肿瘤学分会 .",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "宫颈癌微创手术的中国专家共识［J］.现代妇产科进展，2019，28（11）：801-803.DOI：10.13283/j.cnki.xdfckjz.2019.11.001.Gynecological Oncology Branch of Chinese Medical Association.Consensus of Chinese experts on minimally invasive surgery forcervical cancer［J］.",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "Prog ObstetGynecol，2019，28（11）：801-803.DOI：10.13283/j.cnki.xdfckjz.2019.11.001.（收稿日期：2021-08-05；修回日期：2021-10-25）（本文编辑：赵跃翠） # ·信息速递· # 《中国全科医学》糖尿病系列专题研究简介与征稿 糖尿病防治工作一直是国家重点关注的健康问题，也是全科 / 基层医务人员的重要工作内容。“健康中国行动（2019—2030 年）”中首次将糖尿病防治列入专项行动并提出加强对糖尿病患者和高危人群的健康管理，促进基层糖尿病及并发症筛查标准化和诊疗规范化。",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "为此，《中国疗的糖全与化科综血医合红学管蛋》理白近”检“期测糖拟”尿围“病绕糖神糖尿经尿病高变及危并相人发关群症疾的”病健“的康如预管何防理正与”确诊等选治。择进降行糖系药列物专”题“报降道糖，药主物要与研心究血方管向获如益下”：“重糖视尿糖病尿的病药患物者治 限，述评/ 综述、现况调查、随机对照研究、队列研究、质性研究等均可；要求观点鲜明、内容详实、数据/ 证据充分，有一定的创新性和前沿性，能很好地反映临床难点和热点问题。投稿途径：请登录本刊官网 www.chinagp.net 进行在线投稿；投稿时文题前添加“糖尿病系列”专题研究字样，如“糖尿病系列”专题研究 $^ +$ 文题。（本刊编辑部整理）",
    "source": "宫颈癌治疗的现状及问题：从临床指南到真实世界研究",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌治疗的现状及问题：从临床指南到真实世界研究/宫颈癌治疗的现状及问题：从临床指南到真实世界研究.md"
  },
  {
    "text": "# 宫颈癌的临床病理研究进展 陈丽鹃1\\*，华媛媛2# 1重庆医科大学第二临床学院，重庆 2重庆医科大学附属第二医院妇科，重庆 收稿日期：2024年3月11日；录用日期：2024年4月4日；发布日期：2024年4月11日 # 摘 要 宫颈癌是全球各国中妇女发病率和死亡率最高的恶性肿瘤之一。近些年，宫颈癌的患病年龄呈现出年轻化的趋势。近期发现的Silva分型相比于目前的传统诊断依据，可更有效地预见宫颈腺癌的预后和指导临床处理。",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "许多免疫组织化学标志物对宫颈癌发病各个时期的作用目前仍不明确。本文就宫颈癌的组织病理学和免疫组化标志物相关问题进行综述。# 关键词 宫颈癌，组织病理学，Silva分型，免疫组化标志物 # Clinical and Pathological Research Progress in Cervical Cancer Lijuan Chen1\\*, Yuanyuan Hua2# 1The Second Clinical College of Chongqing Medical University, Chongqing 2Department of Gynecology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing Received: Mar.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "11th, 2024; accepted: Apr.$4 ^ { \\mathsf { t h } }$ , 2024; published: Apr.11th, 2024 # Abstract Cervical cancer is one of the most common malignant tumors with the highest incidence and mortality rates among women worldwide.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "In recent years, there has been an increasing trend of cervical cancer incidence among younger age groups.The recently discovered Silva classification is a more effective predictor of prognosis and guide for clinical management of cervical adenocarcinoma compared to traditional diagnostic criteria.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "The role of many immunohistochemical markers in the development of cervical cancer is still unclear.This article provides a comprehensive review of the issues related to the histopathology and immunohistochemical biomarkers of cervical cancer.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "# Keywords # Cervical Cancer, Histopathology, Silva Classification, Immunohistochemical Markers Copyright $\\circledcirc$ 2024 by author(s) and Hans Publishers Inc.This work is licensed under the Creative Commons Attribution International License (CC BY 4.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "0).http://creativecommons.org/licenses/by/4.0/ # 1.组织病理学特点 # 1.1.病理分级 上皮癌变常起源于化生。化生是指一种已分化组织转化为另一种相似性质的分化组织的过程。宫颈由两部分组成，包括宫颈管的柱状上皮和宫颈阴道部的鳞状上皮，鳞状上皮细胞和柱状上皮细胞之间的过渡区域称为鳞柱交界处，是宫颈的移行区，此区域是子宫颈鳞状上皮内病变及宫颈癌的好发部位[1]。",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "当宫颈长期处于 HPV 病毒感染、炎症等危险因素的长期刺激下，柱状上皮下未分化的储备细胞开始增生，并逐渐发生鳞状上皮化生，继之取代柱状上皮。未成熟的化生鳞状上皮细胞继续被 HPV 感染持续刺激后容易出现细胞异常分化，最后形成子宫颈鳞状上皮内病变(SIL) [2]。子宫颈鳞状上皮内病变(SIL)既往称为“子宫颈上皮内瘤变”(CIN)，CIN 根据瘤变程度分为3 级：CIN1，不成熟的异型细胞局限于上皮的下1/3；CIN2，不成熟非典型细胞局限于上皮的下1/3 至2/3；CIN3，增生的异型细胞超过上皮层的 2/3，包含原位癌。",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "CIN 逐级发展，突破上皮下基底膜，进而浸润间质，进一步发展为宫颈浸润癌。2014 年，世界卫生组织发表了宫颈癌前病变的新分类，即二分类法，分为低级别鳞状上皮内病变(LSIL)和高级别鳞状上皮内病变(HSIL)，LSIL 包括 CIN1 及相关的 HPV 感染，HSIL 包括 CIN3 和大部分 CIN2。# 1.2.组织学分类 宫颈癌的组织学分类主要包括鳞癌、腺癌、腺鳞癌和其他少见类型[3]。起源于宫颈外口的宫颈癌通常为鳞状细胞癌，约占宫颈癌的 $70 \\%$ [4]，是最常见的组织病理类型。",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "而起源于宫颈内口的通常为腺癌，近年来宫颈腺癌的发病率有上升趋势，从 $5 \\%$ 增加至 $20 \\% { \\sim } 2 5 \\%$ 。其他比较少见的组织学亚型包括宫颈浆液性乳头状癌、小细胞或神经内分泌癌、透明细胞癌等。对于宫颈鳞癌，2014 年 WHO 指南根据形态学进行分类，包括角化型、非角化型、乳头状鳞癌、基底样癌、湿疣性癌、疣状癌、鳞状–移行细胞癌、淋巴上皮样瘤样癌。而新版 2020 年 WHO 指南更注重发病机制及预后，分为 HPV 相关性、HPV 非相关性、非特指类型。",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "对于宫颈腺癌，2014 年 WHO 指南将其分为普通型、黏液性癌(包括非特殊型 NOS、肠型、胃型、印戒细胞型)、绒毛管状腺癌、子宫内膜样癌、透明细胞癌、浆液性癌、中肾管癌及混合性腺癌–神经内分泌癌。日益增多的研究结果证实宫颈腺癌是一组异质性肿瘤，在组织学、流行病学、预后因素和治疗结局等方面与宫颈鳞癌存在差异[5]。为此 2020 年 WHO 指南以 2018 年首次提出的国际宫颈腺癌标准和分类(IECC) [6]为基础，根据是否与 HPV 相关将宫颈腺癌分为 HPV 相关性与 HPV 非依赖性两大类。",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "总体来讲，HPV 相关性宫颈腺癌的特征为低倍镜下可见显著的顶端核分裂和凋亡小体；HPV非依赖性宫颈腺癌病灶广泛，组织学上看不到显著的凋亡小体及核分裂象，其发病年龄大，预后差，无 病生存期短。# 1.3.Silva 分型 # 1.3.1.Silva 分型的概述 美国妇产科病理学家 Silva 所带领的科研小组于 2013 年率先提出了一个针对宫颈腺癌风险分级的新系统模型，并于 2015 年证实了这种分型体系，遂将其定名为Silva 分型体系[7] [8] [9]。",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "此系统以浸润模式为基础对宫颈腺癌进行了分级，可较好预估淋巴结转移、复发的危险性和预后情况，其分级重复性较强、切实可行，有助于更好地进行临床医学工作。Silva 分型可分为Silva A、B、C 三种模式：Silva A 型肿瘤的特点表现为腺体边界清楚、轮廓完整，有时小叶结构保存较好，无破坏性间质浸润，无肿瘤硬化性间质，无脉管侵犯；Silva B 型肿瘤的特点是以A 型腺体特点为基础，间质中可见单个或小簇肿瘤细胞，有时可见脉管内瘤栓侵犯；Silva C 型肿瘤的特点主要表现为弥漫性的间质浸润破坏，出现广泛的硬化性肿瘤间质，常见脉管内瘤栓侵犯，腺体常呈棱角状或破碎状，呈融合性生长。",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "# 1.3.2.Silva 分型的临床应用 与传统的 2014 版 WHO 组织学分类、2020 版 WHO 病因学分类和 FIGO 临床病理分期相比，Silva分型通过肿瘤的生长方式来估计肿瘤的生物学行为，为临床工作提出新的治疗策略并指导手术方式。2016年 Roma 等人根据 Silva 分型对宫颈腺癌提出了新的分层治疗策略:Silva A 型患者预后较好，无瘤生存期较长，淋巴结转移和复发风险相对较低，在宫颈锥切标本切缘阴性时可以考虑保守治疗，不需切除子宫和淋巴结清扫。",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "Silva B 型患者需要冷刀锥切、LEEP 术或宫颈切除术，同时进行前哨淋巴结取样；在切缘阴性的前提下，若前哨淋巴结阳性或重新评估为 Pattern C 型，则选择根治性子宫切除术，并酌情进行淋巴清扫术和术后放、化疗。Silva C 型患者由于预后较差，发生复发和转移的风险极高，则行子宫广泛性切除术及淋巴结清扫术，必要时行放疗、化疗、免疫治疗等辅助治疗[9]。目前的NCCN 指南推荐大多数宫颈腺癌患者采用根治性手术和淋巴结清扫术。",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "然而，根治性手术和淋巴结清扫术的并发症显著，包括排尿困难、尿路感染、出血、戳孔血肿、疼痛、发热和神经损伤等早期并发症。晚期并发症包括淋巴水肿、淋巴囊肿、尿失禁和静脉血栓形成等；除此之外，年轻患者往往失去生育能力[10] [11]。2015 年 Roma 等对来自 12 个机构的 352 例宫颈腺癌病例分析显示 Silva 各型的比例分布：Silva A 型占比 $2 0 .7 \\%$ ，Silva B 型约占 $2 5 .",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "6 \\%$ ，Silva C 型占 $5 3 .7 \\%$ [7]。一项针对中国宫颈腺癌患者 Silva 分型的研究回顾性分析了3 个医疗中心 191 例宫颈腺癌病例的临床病理资料，其中 Silva A 型占 $2 4 .1 \\%$ ，Silva B 型占 $2 1 .5 \\%$ ，Silva C 型占 $5 4 .5 \\%$ [12]。Silva 分型在普通型宫颈腺癌中的占比大致相同。如果上述推荐分层治疗策略能够被广泛应用，会有将近半数的宫颈腺癌患者避免过度治疗，约 1/5 的宫颈腺癌女性甚至可以保留生育功能，从而减轻部分患者的术后并发症，提高生活质量。",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "# 1.3.3.Silva 分型的局限性 虽然 Silva 分型展示了良好的应用前景，并对WHO 分类、FIGO 分期和NCCN 指南进行了补充和提示，但其自身还存在很多问题，并有待于进一步验证、拓展和修订。目前 Silva 分型的样本组织类型仅针对宫颈腺癌普通型，尚未将其他特殊组织学亚型的浸润性子宫颈腺癌纳入研究范围，这在一定程度上限制了 Silva 分型的应用。另外，Silva 分型主要基于肿瘤生长的病理学特征进行分类，而没有考虑其他重要因素，如基因突变、免疫组化指标、HPV 感染亚型、患者年龄等，这可能导致分型结果无法全面反映患者的病情和预后，对于个体化治疗的指导有一定限制。",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "同时，Silva 分型在显微镜下的病理学诊断在不同的实验室和医生之间可能存在主观性和操作者依赖性的差异，这可能导致分型结果的不一致性，对于 临床的一致性和可靠性提出了一定的挑战。综上所述，Silva 分型在宫颈癌的诊断和治疗中具有一定的应用价值，但其尚处于新生阶段，目前还需要更多的研究和验证来进一步评估其准确性和可靠性，需经过严密的临床观察和检验，反复推敲打磨、补充完善才能在临床实践中大规模推广。# 2.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "免疫组化标志物 免疫组化全称为免疫组织化学，主要应用免疫学抗原和抗体特异性结合的基本原理，再通过化学反应使标记抗体的显色剂显色，从而对组织细胞内的抗原(主要为蛋白质)进行定性、定位及相对定量研究，有助于了解疾病的发病机理和鉴别诊断。宫颈肿瘤的发生、发展及预后，与许多抑癌基因有关，免疫组化最常见的标志物有以下一些类型。# 2.1.抑癌基因 # 2.1.1.p16 p16 参与细胞周期从G1 期到S 期的调控，是细胞周期蛋白依赖性激酶CDK4、CDK6 活性的抑制剂，可以阻断 CDK4 和 CDK6 介导的视网膜母细胞基因 Rb 磷酸化，通常 p16 其在细胞中的浓度极低[13]。",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "在大多数宫颈癌中，HPV E7 癌基因对视网膜母细胞基因 Rb 的功能失活导致 p16 的过度表达和 p16 蛋白在细胞内的积累。因此p16 是HPV E7 病毒癌基因介导的视网膜母细胞基因Rb 分解代谢的替代标志物[14]。p16 不仅是诊断宫颈鳞状细胞肿瘤和鳞状细胞癌的敏感而特异的标记物[15]，而且可用于鉴别宫颈腺上皮肿瘤的几种组织学类型[16]。免疫组化分析表明，p16 蛋白在宫颈鳞状上皮和腺上皮的癌前病变和恶性病变中广泛表达[17]。",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "# 2.1.2.p53 p53 在调节细胞增殖、DNA 修复、细胞凋亡、基因组稳定性、衰老和代谢稳态等方面发挥重要作用[18]。p53 蛋白在 DNA 损伤、缺氧、癌基因表达、核糖核苷酸耗竭等多种信号激活下，主要作为转录因子发挥作用。p53 功能缺失使细胞异常增殖，继之导致肿瘤的发生，在许多恶性肿瘤中都观察到 p53 的功能异常[19] [20]。在许多肿瘤细胞遗传不稳定的条件下，p53 基因发生突变，p53 蛋白的表达增加，这是肿瘤发生发展过程的标志。",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "p53 的失活与宫颈癌的发生有关，Notch1 是一种肿瘤抑制基因[21]，通过E6 和 E7 癌基因减少宫颈癌细胞系中的细胞增殖[22]。Yugawa 等人研究证明[23]，E6 通过失活 p53 抑制Notch1 的表达。此外，正常情况下编码跨膜受体蛋白的原癌基因 ErbB2 的表达被 p53 抑制，E6 通过灭活p53 使 ErbB2 积累，促进 HPV 感染的上皮形成细胞增殖[24]。# 2.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "1.3.p63 p63 是一个编码转录因子的基因，它属于 p53 家族，位于3q27\\~29 号染色体上[25]，p63 基因编码的蛋白质也被称为 p63，具有类似于p53 的结构域，但在功能上有所不同。p63 通常在表皮的基底细胞中强烈表达[26] [27] [28]，在复层鳞状上皮的发展和分化中起着至关重要的作用，具有肿瘤抑制和致癌性。p63的免疫组化染色可以帮助鉴别鳞状细胞癌和腺癌。Vosmik 等人分析了 70 名宫颈鳞状细胞癌患者，发现$9 4 .",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "2 9 \\%$ (66/70)的p63表达呈阳性[29]但是p63对宫颈鳞癌的诊断特异度和灵敏度并不十分理想，Kaufmann等人研究发现，p63 也可以在少量腺癌、基底细胞癌和移行上皮癌中表达[30]。# 2.1.4.p40 $\\mathsf { p } 4 0$ 是 p63 蛋白的一种亚型，表达于鳞状上皮细胞、尿路上皮细胞、乳腺的肌上皮细胞、汗腺和唾液腺以及前列腺的基底细胞，其在标记鳞状上皮时具有较高的特异性[31]，被认为是特异性和敏感性最高的鳞癌标志物。",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "近年来国内外大量文献报道 $\\mathsf { p } 4 0$ 在肺鳞状细胞癌病理诊断中具有指导意义[32] [33] [34]。Bishop 等人研究表明[35]，在 81 例肺鳞状细胞癌和 237 例肺腺癌中， $\\mathsf { p } 6 3$ 在肺鳞状细胞癌诊断中的敏感性和特异性分别为 $100 \\%$ 和 $60 \\%$ ， $\\mathsf { p } 4 0$ 的敏感性和特异性分别为 $100 \\%$ 和 $9 8 \\%$ 。",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "因此， $\\mathsf { p } 4 0$ 被认为是一种高度特异性和敏感性的鳞状上皮来源的肿瘤标志物。# 2.2.细胞角蛋白(CK) 细胞角蛋白(CK)主要分布于上皮细胞，是细胞骨架的中间丝蛋白家族中最大、最复杂的亚类，其主要功能是维持上皮组织的完整性及连续性，是上皮分化的标志物，已经有20 多种亚型的 CK 在不同类型的人类上皮细胞中被鉴定出来。CK5/6 是一种高分子量的基底细胞角蛋白，正常时主要表达于鳞状上皮细胞、导管上皮基底细胞、肌上皮细胞和间皮细胞中，而在腺上皮细胞中表达极少[36]。",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "一些研究结果表明 CK5/6 在鳞状细胞癌的诊断中具有很高的敏感性和特异性[36] [37]。Ma 等人研究发现在76 名肺鳞状细胞癌中，CK5/6 的敏感性和特异性分别为 $7 8 .9 \\%$ 和 $9 7 .7 \\%$ 。CK7 是鳞柱交界细胞标记物，主要分布于宫颈癌好发区域，即鳞柱交界处的基底与基底上层储备细胞胞浆内，在癌前病变及宫颈癌中均呈阳性表达。有学者指出，CK7 的表达与 HPV 感染有关[38]。",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "宫颈细胞感染 HPV 后，通常引起宫颈炎症，炎症作用下，残留胚胎鳞柱交界细胞迁移至相邻鳞状细胞中，此时 CK7 阳性细胞异常增生，随着病变级别增加，向下增殖扩张，最终诱发宫颈癌。CK8/18 存在于所有单层上皮，尤其是各种腺上皮，正常的角化/非角化的鳞状上皮不表达，是与上皮细胞增殖、分化密切相关的肿瘤标志物，在胃癌、乳腺癌中阳性表达明显增高[39] [40]。# 2.3.细胞增殖指数(Ki-67) Ki-67 是一种核抗原，与细胞增殖相关，是获得临床普遍认可的核增殖标志，Ki-67 存在于除 G0 期以外的所有细胞周期活跃阶段，包括G1、S、G2 和M 期，因此，Ki-67 用于确定细胞群的生长分数[41]。",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "在正常宫颈组织中，Ki-67 仅表达于复层鳞状上皮基底细胞层，而在子宫颈上皮内瘤变中Ki-67 表达于整个上皮层，表明细胞增殖[42]。多项研究表明，p16 和Ki-67 的共同表达提高了宫颈癌筛查的诊断准确性，并且 Ki-67 的表达与肿瘤分级呈线性增加[43] [44] [45]。# 3.展望 宫颈癌是全球性的健康问题，需要跨国界的合作来推动研究进展。未来的研究可以通过建立多中心合作网络和共享大规模数据集，这将有助于增加样本量、提高研究效力，并促进全球范围内的合作和知识交流。",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "组织病理学可以聚焦于宫颈癌不同亚型的分子特征和细胞特征，通过使用基因测序、单细胞测序和多组学分析等先进的研究方法，更全面地揭示宫颈癌的异质性和发展机制。另外，进一步探索新的免疫组化标志物，提高宫颈癌诊断的准确性和预测患者的生存率，目前已有一些免疫组化标志物被应用于临床实践，如 p16、Ki-67 等，但仍需要进一步验证和优化。希望通过这些研究，我们可以提高宫颈癌的早期诊断率和治疗效果，从而减少患者的发病率和死亡风险，并改善患者的生活质量。",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "# 参考文献 [1] Small Jr., W., Bacon, M.A., Bajaj, A., et al.(2017) Cervical Cancer: A Global Health Crisis.Cancer, 123, 2404-2412.https://doi.org/10.1002/cncr.30667 [2] Giroux, V.and Rustgi, A.K.(2017) Metaplasia: Tissue Injury Adaptation and a Precursor to the Dysplasia-Cancer Sequence.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "Nature Reviews Cancer, 17, 594-604.https://doi.org/10.1038/nrc.2017.68 [3] 方三高, 魏建国, 陈真伟.WHO (2020)女性生殖系统肿瘤分类[J].诊断病理学杂志, 2021, 28(2): 142-148.[4] Cohen, P.A., Jhingran, A., Oaknin, A., et al.(2019) Cervical Cancer.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "The Lancet (London, England), 393, 169-182.https://doi.org/10.1016/S0140-6736(18)32470-X [5] Xie, X., Song, K., Cui, B., et al.(2018) A Comparison of the Prognosis between Adenocarcinoma and Squamous Cell Carcinoma in Stage IB-IIA Cervical Cancer.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "International Journal of Clinical Oncology, 23, 522-531.https://doi.org/10.1007/s10147-017-1225-8 [6] Stolnicu, S., Barsan, I., Hoang, L., et al.(2018) International Endocervical Adenocarcinoma Criteria and Classification (IECC): A New Pathogenetic Classification for Invasive Adenocarcinomas of the Endocervix.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "The American Journal of Surgical Pathology, 42, 214-226.https://doi.org/10.1097/PAS.0000000000000986 [7] Roma, A.A., Diaz De Vivar, A., Park, K.J., et al.(2015) Invasive Endocervical Adenocarcinoma: A New Pattern-Based Classification System with Important Clinical Significance.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "The American Journal of Surgical Pathology, 39, 667-672.https://doi.org/10.1097/PAS.0000000000000986 [8] Rutgers, J.K.L., Roma, A.A., Park, K.J., et al.(2016) Pattern Classification of Endocervical Adenocarcinoma: Reproducibility and Review of Criteria.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "Modern Pathology, 29, 1083-1094.https://doi.org/10.1038/modpathol.2016.94 [9] Roma, A.A., Mistretta, T.A., Vivar, A.D.D., et al.(2016) New Pattern-Based Personalized Risk Stratification for Endocervical Adenocarcinoma with Important Clinical Implications and Surgical Outcome.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "Gynecologic Oncology, 141, 36-42.https://doi.org/10.1016/j.ygyno.2016.02.028 [10] Zikan, M., Fischerova, D., Pinkavova, I., et al.(2015) A Prospective Study Examining the Incidence of Asymptomatic and Symptomatic Lymphoceles Following Lymphadenectomy in Patients with Gynecological Cancer.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "Gynecologic Oncology, 137, 291-298.https://doi.org/10.1016/j.ygyno.2015.02.016 [11] Mehra, G., Weekes, A., Vantrappen, P., et al.(2010) Laparoscopic Assisted Radical Vaginal Hysterectomy for Cervical Carcinoma: Morbidity and Long-Term Follow-Up.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "European Journal of Surgical Oncology, 36, 304-308.https://doi.org/10.1016/j.ejso.2009.08.009 [12] Wang, W., Song, G., Lin, J., et al.(2019) Study of the Revisited, Revised, and Expanded Silva Pattern System for Chinese Endocervical Adenocarcinoma Patients.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "Human Pathology, 84, 35-43.https://doi.org/10.1016/j.humpath.2018.08.029 [13] Zhang, H.S., Postigo, A.A.and Dean, D.C.(1999) Active Transcriptional Repression by the Rb-E2F Complex Mediates G1 Arrest Triggered by $\\mathrm { P l } 6 ^ { \\mathrm { I N K 4 a } }$ , TGFβ, and Contact Inhibition.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "Cell, 97, 53-61.https://doi.org/10.1016/S0092-8674(00)80714-X [14] Klaes, R., Friedrich, T., Spitkovsky, D., et al.(2001) Overexpression of $\\mathrm { P l } 6 ^ { \\mathrm { I N K 4 a } }$ as a Specific Marker for Dysplastic and Neoplastic Epithelial Cells of the Cervix Uteri.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "International Journal of Cancer, 92, 276-284.https://doi.org/10.1002/ijc.1174 [15] Sarwath, H., Bansal, D., Husain, N.E., et al.(2017) Introduction of $\\mathrm { P l } 6 ^ { \\mathrm { I N K 4 a } }$ as a Surrogate Biomarker for HPV in Women with Invasive Cervical Cancer in Sudan.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "Infectious Agents and Cancer, 12, Article No.50.https://doi.org/10.1186/s13027-017-0159-0 [16] Lee, S., Sahasrabuddhe, V.V., Mendoza-Cervantes, D., et al.(2017) Tissue-Based Immunohistochemical Biomarker Expression in Malignant Glandular Lesions of the Uterine Cervix: A Systematic Review.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "International Journal of Gynecological Pathology: Official Journal of the International Society of Gynecological Pathologists, 36, 310-322.https://doi.org/10.1097/PGP.0000000000000345 [17] Tringler, B.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": ", Gup, C.J., Singh, M., et al.(2004) Evaluation of $\\mathrm { P l } 6 ^ { \\mathrm { I N K 4 a } }$ and pRb Expression in Cervical Squamous and Glandular Neoplasia.Human Pathology, 6, 689-696.https://doi.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "org/10.1016/j.humpath.2004.02.012 [18] Li, Y., Zhang, M.C., Xu, X.K., et al.(2019) Functional Diversity of p53 in Human and Wild Animals.Frontiers in Endocrinology, 10, Article No.152.https://doi.org/10.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "3389/fendo.2019.00152 [19] Olivier, M., Hollstein, M.and Hainaut, P.(2010) TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use.Cold Spring Harbor Perspectives in Biology, 2, A001008.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "https://doi.org/10.1101/cshperspect.a001008 [20] Petitjean, A., Mathe, E., Kato, S., et al.(2007) Impact of Mutant p53 Functional Properties on TP53 Mutation Patterns and Tumor Phenotype: Lessons from Recent Developments in the IARC TP53 Database.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "Human Mutation, 28, 622-629.https://doi.org/10.1002/humu.20495 [21] Nicolas, M., Wolfer, A., Raj, K., et al.(2003) Notch1 Functions as a Tumor Suppressor in Mouse Skin.Nature Genetics, 33, 416-421.https://doi.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "org/10.1038/ng1099 [22] Talora, C., Sgroi, D.C., Crum, C.P., et al.(2002) Specific Down-Modulation of Notch1 Signaling in Cervical Cancer Cells Is Required for Sustained HPV-E6/E7 Expression and Late Steps of Malignant Transformation.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "Genes & Development, 16, 2252-2263.https://doi.org/10.1101/gad.988902 [23] Yugawa, T., Handa, K., Narisawa-Saito, M., et al.(2007) Regulation of Notch1 Gene Expression by p53 in Epithelial Cells.Molecular and Cellular Biology, 27, 3732-3742.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "https://doi.org/10.1128/MCB.02119-06 [24] Narisawa-Saito, M., Handa, K., Yugawa, T., et al.(2007) HPV16 E6-Mediated Stabilization of ErbB2 in Neoplastic Transformation of Human Cervical Keratinocytes.Oncogene, 26, 2988-2996.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "https://doi.org/10.1038/sj.onc.1210118 [25] Yang, A., Kaghad, M., Wang, Y., et al.(1998) P63, a p53 Homolog at 3q27-29, Encodes Multiple Products with Transactivating, Death-Inducing, and Dominant-Negative Activities.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "Molecular Cell, 2, 305-316.https://doi.org/10.1016/S1097-2765(00)80275-0 [26] Pozzi, S., Zambelli, F., Merico, D., et al.(2009) Transcriptional Network of p63 in Human Keratinocytes.PLOS ONE, 4, e5008.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "https://doi.org/10.1371/journal.pone.0005008 [27] Senoo, M., Pinto, F., Crum, C.P., et al.(2007) P63 Is Essential for the Proliferative Potential of Stem Cells in Stratified Epithelia.Cell, 129, 523-536.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "https://doi.org/10.1016/j.cell.2007.02.045 [28] Barbieri, C.E.and Pietenpol, J.A.(2006) P63 and Epithelial Biology.Experimental Cell Research, 312, 695-706.https://doi.org/10.1016/j.yexcr.2005.11.028 [29] Vosmik, M.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": ", Laco, J., Sirak, I., et al.(2014) Prognostic Significance of Human Papillomavirus (HPV) Status and Expression of Selected Markers (HER2/Neu, EGFR, VEGF, CD34, p63, p53 and Ki67/MIB-1) on Outcome after (Chemo-) Radiotherapy in Patients with Squamous Cell Carcinoma of Uterine Cervix.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "Pathology & Oncology Research, 20, 131-137.https://doi.org/10.1007/s12253-013-9674-5 [30] Kaufmann, O., Fietze, E., Mengs, J., et al.(2001) Value of p63 and Cytokeratin 5/6 as Immunohistochemical Markers for the Differential Diagnosis of Poorly Differentiated and Undifferentiated Carcinomas.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "American Journal of Clinical Pathology, 116, 823-830.https://doi.org/10.1309/21TW-2NDG-JRK4-PFJX [31] 金雪梅, 韩龙哲.免疫组织化学方法检测P16 P13 P40 在颈部淋巴结转移性鳞状细胞癌鉴别诊断中的应用[J].实 用医技杂志, 2016, 23(8): 888-889.[32] 杜倩, 赵焕芬, 康林, 等.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "肺鳞状细胞癌组织中 p63、CK5/6 和 p40 的表达及其病理诊断价值[J].现代肿瘤医学, 2019, 27(11): 1907-1910.[33] Kriegsmann, K., Cremer, M., Zgorzelski, C., et al.(2019) Agreement of CK5/6, p40, and p63 Immunoreactivity in Non-Small Cell Lung Cancer.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "Pathology, 51, 240-245.https://doi.org/10.1016/j.pathol.2018.11.009 [34] Pelosi, G., Rossi, G., Cavazza, A., et al.(2013) ΔNp63 (P40) Distribution inside Lung Cancer: A Driver Biomarker Approach to Tumor Characterization.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "International Journal of Surgical Pathology, 21, 229-239.https://doi.org/10.1177/1066896913476750 [35] Bishop, J.A., Teruya-Feldstein, J., Westra, W.H., et al.(2012) P40 (ΔNp63) Is Superior to p63 for the Diagnosis of Pulmonary Squamous Cell Carcinoma.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "Modern Pathology, 25, 405-415.https://doi.org/10.1038/modpathol.2011.173 [36] Ma, Y., Fan, M., Dai, L., et al.(2015) Expression of p63 and CK5/6 in Early-Stage Lung Squamous Cell Carcinoma Is Not Only an Early Diagnostic Indicator but Also Correlates with a Good Prognosis.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "Thoracic Cancer, 6, 288-295.https://doi.org/10.1111/1759-7714.12181 [37] Downey, P., Cummins, R., Moran, M., et al.(2008) If It’s Not CK5/6 Positive, TTF-1 Negative It’s Not a Squamous Cell Carcinoma of Lung.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "APMIS: Acta Pathologica, Microbiologica, et Immunologica Scandinavica, 116, 526-529.https://doi.org/10.1111/j.1600-0463.2008.00932.x [38] Lee, H., Lee, H.and Cho, Y.K.(2017) Cytokeratin7 and Cytokeratin19 Expression in High Grade Cervical Intraepithelial Neoplasm and Squamous Cell Carcinoma and Their Possible Association in Cervical Carcinogenesis.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "Diagnostic Pathology, 12, Article No.18.https://doi.org/10.1186/s13000-017-0609-4 [39] 李亦明, 王贵明, 龙中华, 等.IHC 联合FISH 检测胃癌中HER2 与CK8/18、P53、CEA 的表达及其相关性研究[J].诊 断病理学杂志, 2019, 26(12): 812-816.[40] Raap, M., Gierendt, L.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": ", Werlein, C., et al.(2021) Co-Expression of Transcription Factor AP-2beta (TFAP2B) and GATA3 in Human Mammary Epithelial Cells with Intense, Apicobasal Immunoreactivity for CK8/18.Journal of Molecular Histology, 52, 1257-1264.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "https://doi.org/10.1007/s10735-021-09980-2 [41] Gerdes, J., Schwab, U., Lemke, H., et al.(1983) Production of a Mouse Monoclonal Antibody Reactive with a Human Nuclear Antigen Associated with Cell Proliferation.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "International Journal of Cancer, 31, 13-20.https://doi.org/10.1002/ijc.2910310104 [42] Konishi, I., Fujii, S., Nonogaki, H., et al.(1991) Immunohistochemical Analysis of Estrogen Receptors, Progesterone Receptors, Ki-67 Antigen, and Human Papillomavirus DNA in Normal and Neoplastic Epithelium of the Uterine Cervix.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "Cancer, 68, 1340-1350.https://doi.org/10.1002/1097-0142(19910915)68:6<1340::AID-CNCR2820680626>3.0.CO;2-Q [43] Tjalma, W.A.A.(2017) Diagnostic Performance of Dual-Staining Cytology for Cervical Cancer Screening: A Systematic Literature Review.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "European Journal of Obstetrics & Gynecology and Reproductive Biology, 210, 275-280.https://doi.org/10.1016/j.ejogrb.2017.01.009 [44] Silva, D.C., Gonçalves, A.K., Cobucci, R.N., et al.(2017) Immunohistochemical Expression of p16, Ki-67 and p53 in Cervical Lesions—A Systematic Review.Pathology, Research and Practice, 213, 723-729.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "DOI：10.19538/j.fk2018060111 【编者按】由中国抗癌协会妇科肿瘤专业委员会发布的常见妇科恶性肿瘤（宫颈癌、卵巢恶性肿瘤、子宫内膜癌、滋养细胞肿瘤、子宫肉瘤、外阴癌、阴道癌）诊治指南，将自本期开始连续刊登。1990年由原国家卫生部委托全国肿瘤防治办公室和中国抗癌协会编写了第一版妇科恶性肿瘤诊治指南，中国抗癌协会妇科肿瘤专业委员会又分别于1999年和2005年编写了第二版和第三版指南。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "本指南是由国内妇科肿瘤学家以循证医学为依据，结合目前国内诊治现状，并借鉴国外相关指南共同讨论制定的第四版，其意义在于规范妇科恶性肿瘤的诊断标准和治疗原则，指导临床实践，以提高我国妇科临床肿瘤医师的诊治水平。# 宫颈癌诊断与治疗指南（第四版） 中国抗癌协会妇科肿瘤专业委员会关键词：宫颈肿瘤；指南Keywords: cervical cancer；guideline中图分类号：R737.3 文献标志码：C 宫颈癌是女性恶性肿瘤发病率第2位的肿瘤，根据世界卫生组织（WHO）的数据，每年有新增病例53 万，约25 万女性因宫颈癌死亡，其中发展中国家占全球的 $80 \\%$ 。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "西方发达国家由于宫颈癌筛查的普及，宫颈癌发病率缓慢下降。在中国，每年新增宫颈癌病例约14万，死亡约3.7万。本指南适用于宫颈鳞癌、腺癌及腺鳞癌，其他特殊病理类型，如小细胞癌、透明细胞癌、肉瘤等发病率低，国际、国内尚未达成共识，本指南不包括这些少见病理类型，但可以参照本指南。在临床实践中，根据医院的设备和技术条件以及患者的病情，国际上推荐采用最适合的符合指南的方法诊治患者。对于病情复杂的宫颈癌，临床医师应灵活应用指南，不适用于本指南的情况下建议参加临床试验。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "# 1 分期 1.1 分期规则 宫颈癌分期采用国际上统一使用的FIGO 分期（见表1），其他分期作为参考。FI⁃GO 2009宫颈癌分期与原有分期相比，主要有以下两点不同：（1）取消了宫颈癌0 期，即原位癌，将宫颈原位癌归为CINⅢ（宫颈上皮内高度病变）。（2）将宫颈癌ⅡA 期根据宫颈病灶大小分为：直径≤$4 \\mathrm { c m }$ 为ⅡA1期，直径 $> 4 \\mathrm { c m }$ 为ⅡA2期。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "FIGO 2009 宫颈癌分期为临床分期，2009 年FIGO 临床分期委员会再次强调分期原则：（1）需2名以上高年资医师共同查体，明确分期，有条件时最好在麻醉状态下行盆腔检查。（2）分期有分歧时以分期较早的为准。（3）分期以治疗前盆腔检查为准，治疗后和术后病理结果不能改变分期。（4）微小浸润癌的诊断必须根据宫颈锥切标本由有经验的病理医师做出诊断。（5）输尿管梗阻和无功能肾（排除其他原因）应确定为ⅢB 期。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "（6）分期以临床分期为主，影像学检查可以辅助分期。表1 FIGO 2009宫颈癌分期 <html><body><table><tr><td>期别</td><td>肿瘤范围</td></tr><tr><td>I期</td><td>宫颈癌局限在宫颈(扩散至宫体将被忽略)</td></tr><tr><td>IA期</td><td>镜下浸润癌。所有肉眼可见的病灶，包括表浅浸</td></tr><tr><td></td><td>润，均为IB期</td></tr><tr><td></td><td>IA1期间质浸润深度≤3mm,水平扩散≤7mm</td></tr><tr><td></td><td>IA2期间质浸润深度>3mm～≤5mm,水平扩散≤7mm</td></tr><tr><td>IB期</td><td>肉眼可见癌灶局限于宫颈，或者镜下病灶>IA2期</td></tr><tr><td></td><td>IB1期肉眼可见癌灶最大径线≤4cm</td></tr><tr><td></td><td>IB2期肉眼可见癌灶最大径线>4cm</td></tr><tr><td>Ⅱ期</td><td>肿瘤超越子宫，但未达骨盆壁或未达阴道下1/3</td></tr><tr><td>ⅡA期</td><td>无宫旁浸润</td></tr><tr><td></td><td>ⅡA1期肉眼可见癌灶最大径线≤4cm</td></tr><tr><td></td><td>ⅡA2期肉眼可见癌灶最大径线>4cm</td></tr><tr><td>ⅡB期</td><td>有明显宫旁组织浸润</td></tr><tr><td>Ⅲ期</td><td>肿瘤扩展到骨盆壁和(或)累及阴道下1/3和(或)引</td></tr><tr><td>ⅢA期</td><td>起肾孟积水或肾无功能 肿瘤累及阴道下1/3，没有扩展到骨盆壁</td></tr><tr><td>ⅢB期</td><td>肿瘤扩展到骨盆壁和(或)引起肾孟积水或肾无功能</td></tr><tr><td>IV期</td><td>肿瘤浸润膀胱黏膜或直肠黏膜（活检证实 )和(或）</td></tr><tr><td></td><td>超出真骨盆</td></tr><tr><td>IVA期</td><td>肿瘤侵犯邻近器官</td></tr><tr><td>IVB期</td><td>肿瘤扩散到远处器官</td></tr></table></body></html> 1.",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "2 临床分期前检查 宫颈癌治疗前分期很重要，应全面检查及评估患者的病情及身体状态，避免遗漏转移病灶，以下检查应作为常规：（1）宫颈活检。镜下浸润必要时行宫颈锥切及宫颈管刮术以明确组织病理诊断及病变范围。（2）妇科检查仍然是临床分期的主要依据。（3）分期为ⅡB 期以上或有相关的临床症状或必要时，需行肾图、膀胱镜、肠镜检查。（4）血鳞状上皮细胞癌抗原（SCC，对于宫颈鳞癌）、CA125（对于宫颈腺癌）检查。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "（5）上下腹、盆腔超声和胸片、心电图、盆腔及上下腹（含腹主动脉旁）MRI 或CT，建议ⅠB1 期以上有条件者行PET-CT 检查。（6）宫颈HPV 定性或定量检测。（7）肿瘤相关基因检测可选择。1.3 手术分期 对于ⅠB2、ⅡA2\\~ⅣA期的患者可采用手术分期（2b 级证据），经腹膜外或腹腔内盆腔淋巴结切除 $+$ 腹主动脉旁淋巴结取样，根据淋巴结阳性情况决定放疗方案。# 2 治疗 2.1 治疗基本原则 宫颈癌治疗主要有手术治疗和放疗，化疗广泛应用于与手术、放疗配合的综合治疗和晚期复发性宫颈癌的治疗。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "宫颈癌综合治疗不是几种方法的盲目叠加，而是有计划的分步骤实施，治疗中根据手术结果和放疗后肿瘤消退情况予以调整，原则上早期宫颈癌以手术治疗为主，中晚期宫颈癌以放疗为主， 化疗为辅。放疗适用于各期宫颈癌，外照射可采用前后对穿野、盆腔四野、三维适形、调强放疗，适形放疗和调强放疗已应用于临床，由于宫颈癌后装腔内放疗的剂量学特点，具有不可替代性。手术治疗适用于分期早于ⅡB 期（不含ⅡB期）的患者。对于未绝经的患者，特别是年轻患者，放疗容易引起盆腔纤维化和阴道萎缩狭窄，早于ⅡB 期、无手术禁忌证者应选择手术治疗。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "手术入路可选择开腹、腹腔镜、机器人或经阴道联合腹腔镜等，应该根据手术者方法熟悉程度、手术资质和手术准入综合考虑予以选择。化疗目前广泛适用于宫颈癌治疗，采用以铂类（主要是顺铂）为基础的单药或联合化疗。治疗方式的选择应取决于本地区现有的设备、妇科肿瘤医师的技术水平以及患者的一般状况、年龄、肿瘤分期和患者愿望，治疗前应进行充分医患沟通。# 2.2 宫颈癌的手术治疗 2.2.1 手术分型 可采用 Querleu-Morrow（QM）分型（见表2）和Piver分型（见表3），腹腔镜手术已广泛应用于宫颈癌手术。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "其中C 型手术又可以分为保留膀胱神经型（C1）和不保留膀胱神经型（C2）。手术切除范围推荐水平切断膀胱宫颈韧带、距肿瘤或宫颈下缘 $1 5 \\mathrm { { \\sim } } 2 0 \\mathrm { { m m } }$ ，切除阴道及相应的阴道旁组织，输尿管完全游离。表 2 Querleu-Morrow 分型 <html><body><table><tr><td>QM分型 术式</td><td></td></tr><tr><td></td><td>A型亦称筋膜外子宫切除术，在输尿管和宫颈之间切断宫颈旁组织，宫韧带和膀胱宫颈韧带不切除，切除阴道<10mm,病灶< 20mm、盆腔淋巴结阴性、无脉管受浸者，为实施缩小手术的安全性评价的临床试验而设计;也适用于晚期癌放疗和（或）</td></tr><tr><td></td><td>化疗后患者 B型亦称改良式广泛性子宫切除术,在输尿管隧道处切断宫颈旁组织,不切除子宫深静脉后方的膀胱神经，切除阴道10mm或距 肿瘤10mm，也称B1型手术；B2型手术是B1+宫颈旁淋巴结切除</td></tr><tr><td>C型</td><td>是经典的广泛性子宫切除术，切除宫颈旁组织至与骼内血管系统交界处;直肠旁切断宫骶韧带、近膀胱切断宫颈膀胱韧带</td></tr><tr><td>D型</td><td>超广泛性子宫切除术,D1型近盆侧壁血管切除宫颈旁、下腹部血管及邻近的筋膜;D2型即盆腔器官廓清术(LEER术）</td></tr></table></body></html> 表 3 Piver 分型 <html><body><table><tr><td rowspan=\"2\">分型</td><td colspan=\"5\">手术范围</td><td rowspan=\"2\">适应证</td></tr><tr><td>子宫动脉</td><td>主韧带</td><td>宫骶韧带</td><td>阴道</td><td>淋巴结</td></tr><tr><td></td><td>I型宫颈筋膜外侧缘</td><td></td><td>宫颈筋膜外侧缘宫颈筋膜外侧缘宫颈外侧缘不切除</td><td></td><td></td><td>宫颈癌IA1期</td></tr><tr><td>Ⅱ型</td><td>与输卵管交汇处结扎</td><td>从中间切断</td><td>靠近子宫切断</td><td>切除上1/3</td><td>选择性切除增大的淋巴结宫颈癌IA2期</td><td></td></tr><tr><td></td><td>Ⅲ型骼内动脉起始处结扎</td><td>全部切除</td><td>近骶骨处切断</td><td>切除上1/2</td><td>常规行盆腔淋巴结切除术宫颈癌IB1期</td><td></td></tr><tr><td>IV型</td><td>必要时于盆壁结扎骼内动脉全部切除</td><td></td><td>近骶骨处切断</td><td>切除3/4</td><td>常规行盆腔淋巴结切除术宫颈癌中央型复发</td><td></td></tr><tr><td>V型结扎骼内动脉</td><td></td><td>全部切除</td><td>近骶骨处切断</td><td>切除3/4</td><td>常规行盆腔淋巴结切除术 宫颈癌中央型复发,累</td><td>及远端输尿管或膀胱</td></tr></table></body></html> 2.",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "2.2 前哨淋巴结切除术 前哨淋巴结（SLN）定位与切除（2a级证据）作为部分Ⅰ期宫颈癌患者手术时使用，肿瘤直径 $< 2 \\mathrm { c m }$ 的检出率和定位效果最好。采用宫颈局部注射染料或放射性胶体锝-99，如图1 所示。宫颈注射后，SLN 取样经病理诊断，识别微转移。SLN 注射染料采用直观观察有色染料来识别，放射性胶体锝-99采用γ探测器，使用吲哚菁绿（ICG）则采用荧光摄像，切除任何可疑或肿大的淋巴结以及将原发肿瘤和宫旁组织整块切除。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "宫颈癌手术治疗记录见表4。![](images/d0dcb1ea8c5f9117dcf2354c3283ffa89d13494989eca560b128556e449836a8.jpg) 图1 宫颈染料及标记注射点示意图 表4 宫颈癌手术治疗记录 <html><body><table><tr><td colspan=\"2\">姓名</td><td colspan=\"4\"></td><td colspan=\"4\">年龄</td></tr><tr><td colspan=\"2\">手术方案</td><td colspan=\"4\"></td><td colspan=\"2\">手术者</td><td colspan=\"2\"></td></tr><tr><td colspan=\"2\">手术方案</td><td colspan=\"4\"></td><td colspan=\"2\">抗生素类型、剂量、时间</td><td colspan=\"2\"></td></tr><tr><td rowspan=\"8\">术 中 所 见</td><td colspan=\"5\">上腹部：肝脾肾</td><td colspan=\"2\">腹主动脉淋巴结</td><td colspan=\"3\">盆腔</td></tr><tr><td colspan=\"5\">腹膜</td><td colspan=\"5\">大网膜</td></tr><tr><td colspan=\"5\">子宫</td><td colspan=\"5\">宫旁组织左 右</td></tr><tr><td colspan=\"5\">卵巢左 右</td><td colspan=\"5\">输卵管左 右</td></tr><tr><td colspan=\"5\">膀胱</td><td colspan=\"5\">输尿管左 右</td></tr><tr><td colspan=\"5\">主韧带左 cm右 cm 阴道旁组织 左 右</td><td colspan=\"5\">宫骶韧带左 右</td></tr><tr><td colspan=\"9\">淋巴结（增大、变硬、粘连，部位）</td></tr><tr><td colspan=\"9\"></td></tr><tr><td rowspan=\"6\">手 术 切 除 范</td><td>阴道前壁 cm</td><td colspan=\"2\">阴道后壁 cm</td><td></td><td>宫旁组织左cm右</td><td>cm</td><td colspan=\"2\"></td></tr><tr><td colspan=\"2\">主韧带左 cm右</td><td colspan=\"2\">cm</td><td>宫骶韧带左cm右</td><td colspan=\"2\">cm</td><td colspan=\"2\"></td></tr><tr><td colspan=\"2\">卵巢左去留 淋巴结：腹主</td><td colspan=\"2\"></td><td colspan=\"5\">卵巢右去留（标记情况</td></tr><tr><td colspan=\"5\">盆腔左 左卵巢：去 留（标记） 右卵巢：</td><td colspan=\"5\">右 去 留(标记）</td></tr><tr><td colspan=\"9\">围 其 阴道残端处理：1.",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "缝合无引流，2.开放无引流，3.开放引流</td></tr><tr><td colspan=\"2\">他 术中其他说明：</td><td colspan=\"5\"></td><td colspan=\"2\"></td></tr><tr><td rowspan=\"5\">术中并发症</td><td>损伤</td><td></td><td>发生时间/部位</td><td colspan=\"2\">原因</td><td></td><td>程度/持续时间 处理</td><td></td></tr><tr><td>出血</td><td colspan=\"2\"></td><td></td><td colspan=\"2\"></td><td></td><td></td></tr><tr><td>休克</td><td colspan=\"2\"></td><td></td><td colspan=\"2\"></td><td></td><td></td></tr><tr><td>死亡</td><td colspan=\"2\"></td><td></td><td colspan=\"2\"></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan=\"2\"></td><td></td><td></td><td></td></tr></table></body></html> 2.",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "3 宫颈癌放疗 各期宫颈癌都适合放疗，包括各种病理类型，特殊原因不能手术的CINⅢ也可以选择单纯腔内放疗。但对于年轻的早期宫颈癌患者，考虑对卵巢功能的保护，主要采用手术治疗或卵巢移位以后的盆腔放疗。2.3.1 宫颈癌放疗一般性原则 宫颈癌放疗包括远距离体外照射（体外照射）和近距离腔内照射（后装治疗），两者针对的靶区不同，外照射主要针对宫颈癌原发灶和盆腔蔓延及淋巴转移区域，后装治疗主要照射宫颈癌的原发病灶区域。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "应有足够的剂量以保证疗效，与此同时也需要最大限度地保护邻近正常组织，提高生存质量。需要根据患者一般状况、肿瘤范围以及治疗单位放疗设备条件、患者经济能力来选择。体外放疗可选择前后二野或四野照射的二维等中心照射，或精确放疗技术如三维适形放疗（3D-CRT）、调强放疗（IMRT）或螺旋断层放疗系统（TOMO）。腔内照射可选择二维或三维技术。宫颈癌的放疗剂量根据分期不同而有差别。A 点总剂量为盆腔体外照射联合后装治疗换算后的总的生物等效剂量，对于早期（Ⅰ、ⅡA 期）宫颈局部肿瘤小的患者，A 点总剂量75\\~80Gy，局部肿瘤大或晚期（Ⅲ期以上）患者A 点总剂量 $\\geqslant 8 5 \\mathrm { G y }$ 。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "治疗剂量应根据治疗过程中的患者症状、盆腔检查及影像学检查等获得的肿瘤变化及时调整，采用个体化放疗方案。2.3.2 体外照射 主要针对宫颈癌原发灶和盆腔蔓延及淋巴转移区域，要求在5\\~6 周内完成，尽量避免照射时间延长。强调不能以任何体外照射方式替代后装放疗。2.3.2.1 体外照射靶区设定 宫颈癌放疗靶区的设定应根据妇科检查情况和影像学检查（如CT、MRI、PET-CT）确认，应包括子宫、宫颈、宫旁和上1/3阴道（或距阴道受侵最低点下 $2 \\mathrm { c m }$ ，ⅢA期患者包括全部阴道）以及盆腔淋巴引流区如闭孔、髂内、髂外、髂总、骶前；如果腹股沟区淋巴结、腹主动脉旁淋巴结转移或可疑转移，应包括在照射野内。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "2.3.2.2 照射野设定 采用X 线模拟定位机或CT、MRI模拟定位机定位。（1）盆腔等中心照射：包括下腹及盆腔，设前后野等中心垂直照射。上界在 $\\mathrm { L } _ { 4 } { \\sim } \\mathrm { L } _ { 5 }$ 间隙，下界在闭孔下缘或肿瘤下界以下至少 $2 \\mathrm { c m }$ ，侧界在真骨盆最宽处向外 $1 .5 { \\sim } 2 \\mathrm { c m }$ 。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "同时，应用铅块或多叶光栅技术（MLC）遮挡正常器官。每次盆腔中平面处方剂量 $1 .8 { \\sim } 2 .0 \\mathrm { G y }$ ，每周 4\\~5次。盆腔等中心照射可分两阶段完成：第1 阶段：全盆腔等中心照射，DT 量： $2 0 { \\sim } 3 0 \\mathrm { G y } , 2 { \\sim } 3$ 周完成；第2 阶段：中间遮挡照射，全盆中间遮挡 $4 \\mathrm { { c m } \\times ( 8 \\sim }$ $1 2 ) \\mathrm { c m }$ ，以降低危及器官膀胱和直肠的受量，给后装治疗提供剂量空间，DT 量：20\\~25Gy，2\\~3 周完成。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "（2）四野箱式照射：即盆腔前后两野照射加两个侧野照射，主要适用于特别肥胖的患者拟增加宫旁或淋巴引流区的剂量。上界在 ${ \\mathrm { L } } _ { 4 } { \\sim } { \\mathrm { L } } _ { 5 }$ 间隙，下界在闭孔下缘或肿瘤下界以下至少 $2 \\mathrm { c m }$ ，侧界在真骨盆最宽处向外 $1 .5 { \\sim } 2 \\mathrm { c m }$ 。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "两侧野前缘达耻骨联合（包括髂外淋巴引流区），后缘在 ${ \\bf S } _ { 2 } { \\sim } { \\bf S } _ { 3 }$ 骶椎交界水平（包括骶前淋巴引流区），如宫颈原发灶大，宫骶韧带受侵，后缘可达 $\\mathrm { S } _ { 3 } { \\sim } \\mathrm { S } _ { 4 }$ 骶椎水平，应用铅块或MLC 技术遮挡正常器官。每日四野同时照射，一般给予B点DT量45\\~50Gy，4\\~5周完成。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "（3）腹主动脉旁野（延伸野）照射：髂总或主动脉旁淋巴结转移时需行延伸野照射，照射野的宽度一般 $6 { \\sim } 8 \\mathrm { c m }$ ，长度依据淋巴结转移的范围给予个体化设计。建议 DT 量 40\\~45Gy，4\\~5 周，每日 1 次 $1 .8 { \\sim } 2 .0 \\mathrm { G y }$ ，照射时要注意保护肾脏和脊髓。对腹主动脉旁淋巴引流区的照射，建议采用适形或调强精确放疗技术。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "2.3.2.3 射线选择 根据采用的放疗技术、照射野数以及医疗机构的设备、防护条件而定。射线能量越高，其穿透能力越强，需要的防护条件越高，前后二野照射选择10\\~15MV X 射线，多野照射可以选择6\\~10MV X射线。2.3.2.4 精确放疗 任何精确放疗技术的成功实施均基于靶区的精确定位，包括靶区准确定义、针对治疗中靶区变化和器官移动的应对、摆位及质量控制，其中合理的靶区勾画不仅是治疗成败的重要因素，也直接影响到放疗并发症的发生。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "建议应用MRI 或PET-CT 以保证照射靶区覆盖受侵宫旁及转移淋巴结组织，同时最大限度保护直肠、小肠、膀胱等危及器官。宫颈癌的靶区包括大体肿瘤区（GTV）、临床靶区（CTV）和计划靶区（PTV）。2.3.2.4.1 GTV 指临床可见的肿瘤灶，为一般的诊断手段（包括妇科检查和CT、MRI、PET-CT）能够确定的、具有一定形状和大小的病变范围，包括原发病灶、转移淋巴结和其他转移的病灶。理论上，宫颈癌行广泛性子宫切除术 $^ +$ 淋巴清扫术后没有GTV。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "未行手术切除者，GTV 包括宫颈和受累的阴道、宫体、宫旁、转移淋巴结及其他转移病灶。2.3.2.4.2 CTV 包括肿瘤临床灶、亚临床灶以及肿瘤可能侵犯的范围。宫颈癌临床靶区主要包括盆腔原发肿瘤区和淋巴引流区。盆腔原发肿瘤区指未行子宫切除者包括肿瘤、全子宫（宫颈 $^ +$ 宫体）、部分阴道、宫旁或阴道旁软组织；已行子宫切除者包括残存肿瘤、阴道残端、上段阴道（ $3 0 { \\sim } 4 0 \\mathrm { m m }$ ）、阴道旁或瘤床软组织。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "淋巴引流区包括闭孔、髂内、髂外、髂总 $\\pm$ 腹主动脉旁淋巴结引流区。对于宫颈影像学诊断宫颈间质受侵的患者，应包括骶前淋巴引流区；如果髂总淋巴结、腹主动脉旁淋巴结有转移则需行腹主动脉旁淋巴引流区照射，其靶区上界要求达肾血管水平；如果转移淋巴结超过肾血管水平，靶区应包括整个腹主动脉旁淋巴引流区；肿瘤侵及达阴道下1/3时，靶区需包括全阴道及双腹股沟淋巴引流区。特别指出，应建立考虑膀胱体积变化的内靶区（ITV），若在制订计划时发现直肠过度扩张，则应考虑再次行CT、MRI模拟定位。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "2.3.2.4.3 PTV 确定计划靶区的目的是确保临床靶区得到规定的治疗剂量。计划靶区应包括临床靶区、照射中患者器官运动和由于日常摆位、治疗中靶位置和靶体积变化等因素引起的扩大照射的范围。宫颈癌体外照射由CTV外放一定距离形成PTV，目前没有统一标准。2.3.3 后装治疗 主要照射宫颈癌的原发区域。以传统二维后装系统为主，探索图像引导的三维后装治疗。2.3.3.1 剂量率 根据后装治疗时放射源对A 点剂量的贡献速率分为低剂量率（LDR）、中剂量率和高剂量率（HDR）。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "目前，国内多使用高剂量率后装治疗机。A 点剂量是以传统剂量分割及LDR 近距离治疗为依据。对于近距离放疗，设定为一个4\\~7Gy/h的LDR。应用HDR近距离放疗应当依据线性二次型方程定义HDR 的A 点剂量，即转化成生物等效LDR的 A点剂量。如30Gy的HDR A点剂量被分割为5次照射，普遍认可为等同于采用LDR的A点的40Gy剂量（剂量率换算参考《肿瘤放射治疗学》）。2.3.3.2 腔内放疗剂量 应与体外照射剂量结合考虑，采用二维高剂量率后装治疗，A 点剂量 $4 0 \\sim$ 45Gy，每次5\\~6Gy，每周1次，腔内后装治疗当天不进行体外照射。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "体外照射联合腔内治疗A点的总剂量以期别而异，ⅠA2 期应达到75\\~80Gy，ⅠB1期和ⅡA1 期达 80\\~85Gy，ⅠB2、ⅡA2 和ⅡB\\~ⅣA期 $\\geqslant 8 5 \\mathrm { G y }$ ，采用不同剂量率后装机治疗时，应进行生物剂量转换（腔内剂量以体外常规分割等效生物剂量换算），同时注意对膀胱及直肠剂量的监测，避免膀胱及直肠的过高受量。2.3.3.3 后装治疗时机 通常在外照射开始后、宫颈口便于暴露时进行，在宫颈条件允许原则下应尽早进行，最好与体外照射同步进行，以缩短总放疗时间。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "最常用的传统二维后装治疗采用剂量参数系统包括A、B点及膀胱和直肠点的剂量。2.3.3.4 三维后装治疗 三维后装系统计划时间及治疗时间较长，应重视施源器的固定，避免移位。目前的三维影像技术引导下的后装治疗寻求对肿瘤的最佳剂量覆盖，可减少对邻近的膀胱、直肠和小肠的受量，但目前临床实践均基于 A 点剂量系统。由于可造成肿瘤受量不足，通过影像技术引导下的后装治疗来改进剂量设定需要谨慎。可采用欧洲妇科放射肿瘤协会（GEC-ESTRO）推荐的三维后装治疗的GTV、CTV 概念，应用MRI 图像勾画靶区，以 T2WI 序列所示的肿瘤范围为GTV。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "将CTV 按照肿瘤负荷和复发的危险程度分 3 类：高危CTV（HR-CTV）包括宫颈和肉眼可见的肿瘤侵犯的范围；中危CTV（IR-CTV）表示明显的显微镜下肿瘤区，推荐包括外照射开始前的肿瘤范围；低危CTV（LR-CTV）指可能的显微镜下播散区，一般用手术或外照射处理。根据肿瘤消退定义IR-CTV，如肿瘤完全消退或消退直径 $> 1 0 \\mathrm { m m }$ ，则IR-CTV 应包括HR-CTV 和最初诊断时肉眼可见肿瘤区，不增设安全边缘；若肿瘤消退直径 $\\angle { \\bf \\Phi } < \\mathbf { \\Phi }$ $1 0 \\mathrm { m m }$ ，则IR-CTV 应包括超过宫颈的残存病灶并向可能扩散的方向外放 $1 0 \\mathrm { m m }$ 的安全边界；如肿瘤无明显消退，则IR-CTV 应包括最初肿瘤范围加$1 0 \\mathrm { m m }$ 的安全边界。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "建议以 $\\mathrm { D } _ { 9 0 } \\setminus \\mathrm { D } _ { 1 0 0 }$ 评估GTV、HR-CTV 和 IR-CTV 的剂量，以 $\\mathrm { V } _ { 1 5 0 } , \\mathrm { V } _ { 2 0 0 }$ 评估高剂量体积；以 $\\mathrm { D } _ { \\mathrm { 1 c c } } \\setminus \\mathrm { D } _ { \\mathrm { 2 c c } }$ 评估危及器官（OaR）受量。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "对于传统剂量点是否可沿用，2009 年美国近距离放疗协会（abS）的调查显示，目前A点剂量常与剂量-体积直方图（DVH）参数一起报告，便于与传统的二维近距离放疗相比较；传统的膀胱剂量点并不能代表膀胱的最高受量，通常膀胱接受最高剂量的点位于参考点上方 $2 \\mathrm { c m }$ 左右；直肠参考点剂量尚能基本代表直肠的最高受量，可以沿用。2.3.3.5 特殊情况后装治疗 对于子宫切除术后患者（尤其是阴道切缘阳性或肿瘤近切缘者），可采用阴道施源器后装治疗作为体外放疗的补充。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "以阴道表面或距阴道容器内放射源 $5 { \\sim } 1 0 \\mathrm { m m }$ 处为参照点，高剂量率 $^ { 1 9 2 } \\mathrm { I r }$ 剂量为 $2 0 { \\sim } 2 4 \\mathrm { G y }$ 。对于宫颈外生型大肿瘤，特别是出血较多者，体外放疗前可先给予后装治疗消瘤止血，以源旁 $1 \\mathrm { c m }$ 为参考点，一般给予10\\~20Gy/1\\~2次，可不计入A点量。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "宫颈癌腔内治疗及三维后装计划总结记录单见表5。表5-1 宫颈癌腔内治疗记录单 <html><body><table><tr><td>姓名</td><td colspan=\"3\">年龄</td><td>科室病区</td><td>床号</td><td></td><td></td></tr><tr><td>诊断</td><td colspan=\"3\"></td><td colspan=\"3\">拟腔内治疗次数</td><td colspan=\"2\"></td></tr></table></body></html> 住院号 <html><body><table><tr><td>次数</td><td colspan=\"4\">日期</td><td colspan=\"2\">备注</td></tr><tr><td>医师</td><td colspan=\"2\">物理师</td><td colspan=\"2\"></td><td colspan=\"2\">技术员</td></tr><tr><td>A点</td><td colspan=\"2\">B点</td><td></td><td>黏膜下表面剂量</td><td colspan=\"2\">(球塞）</td><td>子宫位置、宫深</td></tr><tr><td colspan=\"2\"></td><td colspan=\"2\"></td><td colspan=\"2\"></td><td colspan=\"2\"></td></tr></table></body></html> <html><body><table><tr><td>次数</td><td></td><td>日期</td><td colspan=\"2\"></td><td>备注</td><td colspan=\"2\"></td></tr><tr><td colspan=\"2\">医师</td><td colspan=\"3\">物理师</td><td colspan=\"2\">技术员</td></tr><tr><td>A点</td><td colspan=\"2\">B点</td><td>黏膜下表面剂量</td><td colspan=\"3\">(球塞)</td><td>子宫位置、宫深</td></tr><tr><td></td><td colspan=\"2\"></td><td></td><td></td><td colspan=\"2\"></td><td></td></tr></table></body></html> 注：治疗记录单可依治疗次数而增加 表5-2 二维腔内治疗小结 <html><body><table><tr><td rowspan=\"2\">诊断</td><td rowspan=\"2\">累计A点剂量</td><td rowspan=\"2\">累计B点剂量</td><td rowspan=\"2\">累计阴道黏膜下0.",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "5cm</td><td rowspan=\"2\">累计阴道黏膜表面剂量</td><td rowspan=\"2\">备注（阴道壁有无挡铅）</td></tr><tr><td></td></tr><tr><td></td><td></td><td>月</td><td></td><td></td><td></td></tr><tr><td colspan=\"6\">治疗起止时间： 年 日一年月日</td></tr></table></body></html> 表5-3 三维后装计划记录单 <html><body><table><tr><td colspan=\"3\">次数</td><td colspan=\"4\">放射源Ir Ci</td><td colspan=\"2\">治疗时间</td><td colspan=\"2\">分 秒</td></tr><tr><td rowspan=\"2\">HRCTV</td><td colspan=\"2\">Vol(cc)</td><td colspan=\"2\">D90(cGv)</td><td colspan=\"3\">V200(%) V150(%)</td><td colspan=\"2\">EQD2(cGv)</td><td></td></tr><tr><td colspan=\"2\"></td><td colspan=\"3\"></td><td colspan=\"2\"></td><td colspan=\"2\"></td><td></td></tr><tr><td rowspan=\"2\">IRCTV</td><td colspan=\"2\">Vol(cc)</td><td colspan=\"2\">D90(cGv)</td><td colspan=\"2\">EQD2(cGv)</td><td colspan=\"2\">D98(cGv) EQD2(cGv)</td><td colspan=\"2\"></td></tr><tr><td colspan=\"2\"></td><td colspan=\"2\"></td><td colspan=\"2\"></td><td colspan=\"3\"></td><td></td></tr><tr><td>COIN</td><td colspan=\"9\">Vref(cc) Index</td></tr><tr><td colspan=\"2\">医生</td><td colspan=\"3\">物理师 技术号</td><td colspan=\"3\"></td><td colspan=\"2\">治疗日期</td></tr><tr><td>姓名</td><td colspan=\"2\"></td><td colspan=\"3\">年龄</td><td colspan=\"2\">科室病区</td><td>住院号</td><td></td></tr><tr><td>诊断</td><td colspan=\"4\"></td><td colspan=\"2\">腔疗方式</td><td colspan=\"3\"></td></tr></table></body></html> 表5-4 三维后装总结单 <html><body><table><tr><td>EBRT BT BT2 BT3 BT4 BTs</td></tr><tr><td>HRCTV D90(cGy)</td></tr><tr><td></td></tr><tr><td>IRCTV D90(cGy)</td></tr><tr><td>膀胱D2cc(cGy)</td></tr><tr><td>直肠 D2cc(cGy) 乙状结肠D2cc(cGy)</td></tr></table></body></html> 2.",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "3.4 危及器官的耐受剂量 宫颈癌放疗邻近器官的耐受剂量：宫颈癌放疗的危及器官包括膀胱、直肠、结肠、骨髓、皮肤、小肠、输尿管等，一般用$\\mathrm { T D } _ { 5 / 5 }$ 表示最小放射耐受量，表示在治疗后5 年内，也预计严重并发症发生率不超过 $5 \\%$ 。# 2.3.5 各期宫颈癌的放疗 2.3.5.1 ⅠA1期宫颈癌的放疗 主要以后装腔内治疗为主，如果宫颈锥切标本无淋巴脉管受侵，可单独行后装治疗，宫颈锥切标本有淋巴脉管受侵，后装治疗 $\\dot { \\bf \\Phi } _ { \\pm }$ 盆腔外照射，A点总剂量 $7 5 { \\sim } 8 0 \\mathrm { G y }$ 。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "2.3.5.2 ⅠA2、ⅠB1、ⅡA1期宫颈癌的放疗 采用盆腔外照射 $^ { \\cdot } + ,$ 后装治疗，盆腔外照射40\\~50Gy，后装治疗 $\\dot { } + \\dot { }$ 外照射给予A点剂量75\\~80Gy。2.3.5.3 ⅠB2、ⅡA2、ⅡB\\~ⅣA 期宫颈癌的放疗 放疗前必须进行盆腔淋巴结情况的评估，建议用影像评估或手术评估确定放射野，盆腔 $4 0 { \\sim } 5 0 \\mathrm { G y }$ 的体外放射剂量，局部病灶可以在图像引导下加量5\\~10Gy。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "如腹主动脉旁淋巴引流区需加量，应在影像引导下予以40\\~50Gy照射，局部病灶可缩野加量5\\~10Gy。对于宫颈局部病灶，后装治疗 $^ +$ 外照射给予A 点总剂量80Gy 以上。放疗中应该有2\\~3次临床和影像疗效评估，必要时重新定位，以确定个体化治疗剂量。2.3.5.4 ⅣB期宫颈癌的放疗 ⅣB期宫颈癌的放疗为姑息性治疗，剂量基本同ⅣA 期宫颈癌，但由于有直肠或膀胱侵犯，应尽量采用个体化原则进行治疗。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "2.3.6 术前放疗 通常采用：（1）后装治疗。剂量一般为全程腔内放疗剂量的1/3\\~1/2。（2）全程后装治疗和（或）体外照射剂量的1/2。术前后装治疗可以缩小局部病灶，提高手术切除率，但对盆腔淋巴转移无显著改善。2.3.7 术中放疗（IORT） 是指在开放性手术过程中，针对高危瘤床或孤立无法切除残余病灶给予单次、精确定位的放疗技术，尤其适用于在既往放疗体积内发生复发病灶的患者。在IORT 过程中，可以把所覆盖的正常组织（如肠或其他器官）人工移离风险区域。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "IORT 通常通过不同尺寸（匹配手术确定的风险区）的限光筒引入的电子束完成，以避开周围正常组织器官。2.3.8 术后放疗 主要针对有术后高危或中危因素的患者。但由于术后粘连，术后肠管的活动度变差，容易导致肠道局部剂量过大，建议术后放疗在图像引导下进行，给予适形或调强等立体放疗技术，放射野的确定可根据术后病理确定。无腹主动脉旁淋巴结转移，行盆腔照射；有腹主动脉旁淋巴结转移，则需进一步检查有无远处转移。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "照射野需包括腹主动脉旁淋巴结，如采用调强等立体照射技术，盆腔剂量可以给予50\\~55Gy，腹主动脉旁淋巴引流区也应在 $( 5 0 { \\pm } 5 ) \\mathrm { G y }$ 。2.4 宫颈癌的化疗 宫颈癌化疗以顺铂（DDP）为基础的联合化疗或单用DDP化疗为主。目前主要适用于：同步放化疗、姑息化疗和新辅助化疗。宫颈癌初治病例首选紫杉醇 $\\cdot + .$ 顺铂（TP 方案）或顺铂单药方案，也可选用氟尿嘧啶 $^ +$ 顺铂（FP 方案）、紫杉醇 $\\cdot +$ 卡铂（TC方案）、拓普替康 $^ +$ 顺铂、博莱霉素 $^ +$ 长春新碱 $^ + ,$ 顺铂（BVP方案）。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "复发性宫颈癌既往未化疗者首选TP 方案；曾使用过顺铂者首选TC或拓普替康 $^ + ,$ 顺铂方案。宫颈癌新辅助化疗主要用于ⅠB2或ⅡA2期，即肿瘤直径 $> 4 \\mathrm { c m }$ 的局部晚期宫颈癌术前化疗，一般2\\~3 个疗程。宫颈癌的新辅助化疗可以提高局部控制率和手术切净率，但不能改善宫颈癌的预后。宫颈癌的靶向治疗可采用联合贝伐单抗，用于初期同步放化疗患者及复发转移患者。体外化疗药物敏感实验和基因检测药物选用仅用于研究和临床试验。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "# 2.5 各期宫颈癌的治疗 2.5.1 ⅠA1 期宫颈癌治疗 ⅠA1 期宫颈癌治疗根据患者是否有生育要求选择治疗方法。有生育要求者可采用宫颈锥切，宫颈锥切标本无脉管浸润，切缘达 $3 \\mathrm { m m }$ 阴性距离为适应证；有脉管浸润时，采用广泛性宫颈切除术 $^ +$ 盆腔淋巴结切除术，手术先行盆腔淋巴结切除，送冰冻检查或快速石蜡切片。有转移者，改行改良广泛性子宫切除术（Ⅱ型子宫切除术） $\\pm$ 腹主动脉旁淋巴结取样；无转移者，行广泛性宫颈切除术。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "无生育要求者行筋膜外全子宫切除。如果患者伴有淋巴血管受侵，行改良广泛性子宫切除术（Ⅱ型子宫切除术） $^ +$ 盆腔淋巴结切除术。有手术禁忌者行后装腔内放疗，剂量参考点选择A点剂量 $7 5 { \\sim } 8 0 \\mathrm { G y }$ 。2.5.2 ⅠA2 期宫颈癌治疗 ⅠA2 期宫颈癌治疗仍可以按照是否有生育要求选择。有生育要求者行广泛性宫颈切除术 $^ +$ 盆腔淋巴结切除 $\\pm$ 腹主动脉旁淋巴结取样。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "手术先行盆腔淋巴结切除，送冰冻或快速石蜡切片检查，有转移者，改行广泛性子宫切除术（Ⅲ型） $\\pm$ 腹主动脉旁淋巴结取样（当髂总淋巴结阳性或疑有腹主动脉旁淋巴结转移者）；无转移者，再行广泛性宫颈切除术。无生育要求者行广泛性子宫切除术（Ⅲ型子宫切除术） $^ +$ 盆腔淋巴结切除术，年龄小于45 岁者可切除输卵管、保留双侧卵巢。有手术禁忌、无生育要求者可选择根治性放疗。腔内放疗±盆腔放疗A 点总剂量75\\~80GY，B点剂量40Gy，放疗前可根据需要行卵巢移位，并银夹标记。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "2.5.3 ⅠB1 期及ⅡA1 期宫颈癌 有生育要求者可行广泛性宫颈切除术，肿瘤直径小于 $2 \\mathrm { c m }$ 者可经阴道联合腹腔镜进行。肿瘤直径 $2 { \\sim } 4 \\mathrm { c m }$ 者，采用经腹或腹腔镜手术。术中先行盆腔淋巴结切除，送冰冻检查，如有转移，改行广泛性子宫切除术（Ⅲ型） $+$ 盆腔淋巴结切除术；如无转移，再行广泛性宫颈切除术 $^ +$ 盆腔淋巴结切除 $\\pm$ 腹主动脉旁淋巴结取样（当髂总淋巴结阳性或疑有腹主动脉旁淋巴结转移者）。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "无生育要求者行广泛性子宫切除术（Ⅲ型子宫切除术） $^ +$ 盆腔淋巴结切除术 $\\pm$ 主动脉旁淋巴结取样（当髂总淋巴结阳性或疑有腹主动脉旁淋巴结转移者）。有手术禁忌者采用根治性放疗，对于阴道明显侵犯者，加用阴道塞或阴道膜，给予黏膜下$0 .5 \\mathrm { c m }$ 处 $2 0 { \\sim } 3 0 \\mathrm { G y }$ 。2.5.4 ⅠB2 期及ⅡA2 期宫颈癌 （1）盆腔放疗 $^ +$ 铂类为主的同步化疗 $^ +$ 近距离放疗（A 点总剂量75\\~80Gy，B点剂量 $4 0 { \\sim } 5 0 \\mathrm { G y }$ ）。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "对于阴道侵犯明显的患者，必要时可予加用阴道塞进行后装腔内放疗，给予黏膜下 $0 .5 \\mathrm { c m }$ 处 $2 0 { \\sim } 3 0 \\mathrm { G y }$ ，需根据病情适当调整（首选）。（2）广泛性子宫切除术（Ⅲ型） $^ +$ 盆腔淋巴结切除 $+$ 腹主动脉旁淋巴结取样，术前可行铂类为基础的新辅助化疗，术后根据病理高危因素选择术后放疗或术后同步放化疗。（3）根治性放疗后宫颈病灶残存行辅助性全子宫切除术。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "2.5.5 $\\mathrm { { I I B } \\sim \\mathrm { { I V A } } }$ 期宫颈癌 采用铂类为基础同步放化疗，可选择周化疗或3 周化疗。常规放疗剂量：肿瘤直径 $\\geqslant 4 \\mathrm { c m }$ ，A 点剂量应达到 $8 5 \\mathrm { G y }$ ，ⅢB 期患者B 点剂量应达到 $4 5 { \\sim } 5 0 \\mathrm { G y }$ 。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "对于盆壁受侵明显的患者，必要时可高适形缩野局部盆腔加量 $5 \\sim$ $1 0 \\mathrm { G y }$ 。对于阴道侵犯明显的患者，必要时可加用阴道塞进行后装腔内放疗阴道补量，治疗剂量一般采用给予黏膜下 $0 .5 \\mathrm { c m }$ 处20\\~30Gy，需根据病情个体化调整。2.5.6 ⅣB期宫颈癌 盆腔局部放疗同时，应加强铂类为基础的联合化疗，并针对转移灶进行个体化治疗，加强对症治疗、营养治疗、止痛治疗，控制病情进展，改善生存质量。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "2.6 关于“手术分期” 对于ⅠB2、ⅡA2\\~ⅣA期的宫颈癌患者可以采用手术分期（2b 级证据），行腹膜外或腹腔镜的盆腔淋巴结切除 $^ +$ 腹主动脉旁淋巴结取样。根据淋巴结有无转移决定下一步治疗方案：（1）盆腔淋巴结及腹主动脉旁淋巴结阴性者行盆腔放疗 $^ { \\circ } +$ 同步化疗。（2）盆腔淋巴结阳性、腹主动脉旁淋巴结阴性者行盆腔同步放化疗。（3）腹主动脉旁淋巴结阳性者行影像学检查，无远处转移，或有远处转移但活检阴性者行盆腔同步放化疗 $^ +$ 腹主动脉旁淋巴结放疗。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "影像学检查有远处转移、活检阳性行全身治疗 $^ +$ 个体化放疗。2.7 关于宫颈癌术前影像学评估 对于ⅠB2、$\\mathbb { I } \\mathrm { A } 2 { \\sim } \\mathbb { N } \\mathrm { A }$ 期的宫颈癌患者，推荐采用影像学评估，根据影像学评估的淋巴结有否转移决定下一步治疗方案：（1）影像学评估无阳性淋巴结者行盆腔同步放化疗。（2）影像学评估有阳性盆腔淋巴结、腹主动脉旁淋巴结阴性者行盆腔同步放化疗 $\\pm$ 腹主动脉旁淋巴结放疗；或经腹膜外或经腹腔镜的淋巴结切除，如腹主动脉旁淋巴结阳性行盆腔同步放化疗 $^ +$ 腹主动脉旁淋巴结放疗。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "如腹主动脉旁淋巴结阴性行盆腔同步放化疗。（3）影像学评估盆腔淋巴结阳性、腹主动脉旁淋巴结阳性者考虑先行经腹膜外或腹腔镜的盆腔及腹主动脉旁淋巴结切除后再行盆腔同步放化疗 $^ +$ 腹主动脉旁引流区放疗。（4）影像学评估有远处转移且活检证实者行全身治疗 $^ { + }$ 个体化放疗。2.8 宫颈癌术后补充治疗 宫颈癌初始手术治疗的患者，应根据术后病理决定是否需要补充治疗。2.8.1 高危因素 存在以下任何一个高危因素术后均需补充放疗：盆腔淋巴结阳性、切缘阳性或宫旁组织阳性。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "术后补充盆腔放疗 $^ +$ 铂类同步化疗（1类证据） $\\pm$ 阴道近距离放疗。2.8.2 中危因素 推荐按照Sedlis 标准补充盆腔放疗 $\\dot { \\bf { \\underline { { \\mathbf { \\Pi } } } } } _ { \\bf { \\underline { { \\mathbf { \\Pi } } } } } \\mathbf { \\Psi } _ { \\pm }$ 铂类同步化疗。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "采用Sedlis标准的同时，还需考虑肿瘤的组织学类型（腺癌、腺鳞癌等）和病灶是否靠近切缘这两个因素。符合中危因素标准，术后辅助放疗体外放疗 $\\dot { \\bf \\Phi } _ { \\pm }$ 含铂类的同步化疗 $\\dot { \\bf { \\varepsilon } } _ { \\pm }$ 阴道腔内放疗。因国内病理连续切片数与NCCN 指南相关合作医院尚有差距，对于Sedlis标准需个体化考虑。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "2.8.3 腹主动脉旁淋巴结阳性 行PET-CT 检查明确有无其他转移。对于有远处转移的患者，只要有指征就应在可疑部位取活检以明确诊断，活检阴性者应接受针对腹主动脉旁淋巴结放疗 $^ +$ 以铂类为基础的同步化疗 $^ +$ 盆腔放疗 $\\dot { \\bf { \\underline { { \\mathbf { \\Pi } } } } } _ { \\bf { \\underline { { \\mathbf { \\Pi } } } } } ( { \\bf { \\underline { { \\mathbf { \\Pi } } } } } _ { \\bf { \\underline { { \\mathbf { \\Pi } } } } } )$ 近距离放疗，活检阳性者应接受全身化疗和个体化放疗。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "2.9 单纯子宫切除术意外发现浸润性宫颈癌 应对患者进行全面的评估，并进行临床分期，视分期决定处理方法：（1）ⅠA1期无淋巴血管腔隙浸润可随访。（2）ⅠA1 期有淋巴血管腔隙浸润或ⅠA2 期患者需要先进行全面评估： $\\textcircled{1}$ 切缘阴性且影像学检查未发现病灶，可选择盆腔放疗 $^ +$ 近距离放疗 $\\pm$ 铂类同期化疗或宫旁广泛切除 $^ +$ 阴道上段切除 $^ +$ 盆腔淋巴结切除 $\\pm$ 主动脉旁淋巴结取样，术后淋巴结阴性者，可随访；切缘阴性，淋巴结阴性，但原发肿瘤大和（或）发现深层间质浸润和（或）淋巴血管腔隙侵犯时，补充盆腔放疗 $\\dot { \\bf \\Phi } _ { \\pm }$ 阴道近距离放疗。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "$\\textcircled{2}$ 术后盆腔淋巴结阳性和（或）切缘受累和（或）宫旁阳性时，术后补充盆腔放疗（若主动脉旁淋巴结阳性，还需行主动脉旁放疗） $^ +$ 铂类同期化疗。$\\textcircled{3}$ 阴道切缘阳性，需行个体化经阴道近距离放疗。# 2.10 复发性宫颈癌的治疗 2.10.1 局部复发的治疗 既往无放疗史或复发灶位于既往放疗野外，可手术切除病灶，再行放疗 $\\mathrm { ^ { + } }$ 含铂方案化疗 $\\dot { \\bf \\Phi } _ { \\pm }$ 近距离放疗。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "治疗后再复发者，可化疗、支持治疗和参加临床试验。针对既往有放疗史或病灶位于既往放疗野内，中心性复发可选择：（1）盆腔器官切除术（前盆腔、后盆腔、全盆腔） $\\pm$ 放化疗。（2）病灶直径 $< 2 \\mathrm { c m }$ 并经仔细评估的病例，行广泛性子宫切除术或近距离放疗。治疗后再复发者可采用化疗、支持治疗和参加临床试验。非中心性复发可选择：（1）切除肿瘤并对切缘临近肿瘤或切缘阳性者给予术中放疗。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "（2）针对肿瘤局部的放疗 $\\pm$ 化疗。（3）化疗。（4）支持治疗。（5）参加临床试验。2.10.2 远处复发的治疗 复发灶为多病灶或无法切除者，选择化疗和支持治疗。病灶可切除者，选择：病灶切除，依术中情况进行放疗；化疗；参加临床试验。2.11 妊娠期宫颈癌的处理 其诊断方法同非妊娠期宫颈癌，重视结合组织类型、FIGO 分期、影像学检查（超声或 MRI）诊断有无淋巴结转移和肿瘤标志物（SCC），对宫颈癌恶性程度的评估和对胎儿的评估。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "治疗方案采取多学科管理模式，综合宫颈癌的恶性程度、孕周以及胎儿发育情况，严密监测患者病情发展及产科情况。患者及家属对妊娠的期望是非常重要的治疗方案选择因素，在决定治疗方案前，患者及家属有充分的知情权，应结合对肿瘤评估，选择是否保留胎儿和治疗方式，并取得知情同意。目前对各妊娠期的宫颈癌尚没有成熟的方案，国际妇科肿瘤协会（IGCS）和欧洲妇科肿瘤协会（ESGO）2014 年提出专家共识：不保留胎儿和生育功能，处理同非妊娠期宫颈癌。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "按照不同分期和孕期的治疗建议：（1）妊娠早期（20 周以内），除宫颈癌ⅠA1 期外，不建议患者继续妊娠。ⅠA1期患者应严密监测，每8周行1次阴道镜检查，必要时宫颈活检，直至妊娠结束开始治疗。（2）妊娠中期（20\\~28周）诊断宫颈癌、要求继续妊娠、ⅡB 期以内者，可继续妊娠。ⅡB 期以上者，不建议继续妊娠。对于妊娠中期的处理目前争议较大，应充分评估风险和尊重患者选择权。（3）妊娠晚期（28周以上）诊断宫颈癌，无论患者期别，患者要求继续妊娠者在孕34周、胎儿肺成熟后采用剖宫产结束妊娠为宜。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "然后根据分期制定相应治疗方案，小于ⅡB期者行剖宫产同时可行根治性手术，放疗可在切口愈合后进行。ⅡB期以上的宫颈癌，结束妊娠后按分期选择同期放化疗。# 2.12 随访 2.12.1 随访间隔 治疗结束6个月内，每2个月1次；第1\\~2 年，每3 个月1 次；第3\\~5 年，每6 个月1次；第5年以后，每年1次。2.12.2 随访内容 包括全身体格检查、妇科检查及鳞癌抗原、细胞角蛋白等肿瘤标志物检测和宫颈或阴道残端细胞学、人乳头瘤病毒检查，必要时行阴道镜检查和病理活检，胸片、胸部CT，盆腔MRI、超声，全身浅表淋巴结超声检查。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "执笔者：周琦（重庆市肿瘤医院/重庆大学附属肿瘤医院）、吴小华（复旦大学肿瘤医院）、刘继红（中山大学附属肿瘤医院）、李力（广西医科大学附属肿瘤医院）、朱笕青（浙江省肿瘤医院）、白萍（中国医学科学院肿瘤医院）、盛修贵（山东省肿瘤医院） 指南编写专家（排名不分先后）：蔡红兵（武汉大学中南医院）、高国兰（北京航空总医院）、高雨农（北京大学肿瘤医院）、郝敏（山西医科大学附属第二医院）、黄曼尼（中国医学科学院肿瘤医院）、柯桂好（复旦大学附属肿瘤医院）、孔为民（首都医科大学附属北京妇产医院）、李广太（北京煤炭总医院）、李隆玉（江西省妇幼保健院）、林仲秋（中山大学孙逸仙纪念医院）、娄阁（哈尔滨医科大学肿瘤医院）、曲芃芃（天津市中心妇产科医院）、王珂（天津市肿瘤医院）、王莉（河南省肿瘤医院）、王丹波（辽宁省肿瘤医院）、王建六（北京大学人民医院）、王淑珍（首都医科大学附属北京朝阳医院）、吴强（江苏省肿瘤医院）、吴令英（中国医学科学院肿瘤医院）、吴绪峰（湖北省妇幼保健院）、向阳（北京协和医院）、谢幸（浙江大学医学院附属妇产科医院）、杨宏英（云南省肿瘤医院）、张国楠（四川省肿瘤医院）、张师前（山东大学齐鲁医院） 秘书：邹冬玲（重庆市肿瘤医院/重庆大学附属肿瘤医院）、刘芳容（重庆市肿瘤医院/重庆大学附属肿瘤医院） # 主 要 参 考 文 献 ［1］ Torre LA，Bray F，Siegel RL，et al.",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "Global cancer statistics，2012［J］.CA Cancer J Clin，2015，65：87-108.［2］ 陈万青，郑荣寿，张思维，等.2012 年中国恶性肿瘤发病和死亡分析［J］.中国肿瘤，2016，5：1-8.［3］ 李琎，吴小华.宫颈癌保留生育功能的腹式根治性宫颈切除术— —一项潜在获益人群的研究［J］.中国癌症杂志，2012，22（6）：407-412.［4］ NCCN clinical practice guidelines in Oncology：cervical cancer（2017.",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "V1）.［5］ Jemal A，Bray F，Center MM，et al.Global cancer statistics［J］.CA Cancer J Clin，2011，61：69-90.［6］ Patel S，Liyanage SH，Sahdev A，et al.Imaging of endometrialand cervical cancer［J］.Insights Imaging，2010，1：309-328.",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "［7］ Pecorelli S，Zigliani L，Odicino F.Revised FIGO staging for car⁃cinoma of the cervix［J］.Int J Gynaecol Obstet，2009，105：107-108.［8］ Downey K，Jafar M，Attygalle AD，et al.Influencing surgicalmanagement in patients with carcinoma of the cervix using a T2-and ZOOM-diffusion-weighted endovaginal MRI technique［J］.",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "Br J Cancer，2013，109：615-622.［9］ Lakhman Y，Akin O，Park KJ，et al.StageⅠB1 cervical cancer：role of preoperative MR imaging in selection of patients for fertil⁃ity- sparing radical trachelectomy［J］.Radiology，2013，269：149-158.",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "［10］ Woo S，Kim HS，Chung HH，et al.Early stage cervical cancer：role of magnetic resonance imaging after conization in deter⁃mining residual tumor［J］.Acta Radiol，2016，57：1268-1276.［11］ Kato T，Takashima A，Kasamatsu T，et al.",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "Clinical tumor diame⁃ter and prognosis of patients with FIGO stage Ⅰ B1 cervicalcancer（JCOG0806-A）［J］.Gynecol Oncol，2015，137：34-39.［12］ Cormier B，Diaz JP，Shih K，et al.Establishing a sentinel lymphnode mapping algorithm for the treatment of early cervical can⁃cer［J］.",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "Gynecol Oncol，2011，122：275-280.［13］ Wu Y，Li Z，Wu H，et al.Sentinel lymph node biopsy in cervi⁃cal cancer：A meta- analysis［J］.Mol Clin Oncol，2013，1：1025-1030.［14］ Taylor A，Rockall AG，Reznek RH，et al.Mapping pelvic lymphnodes：guidelines for delineation in intensity-modulated radio⁃therapy［J］.",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys，2005，63（5）：1604-1612.［15］ Lim K，Small W Jr，Portelance L，et al.Consensus guidelinesfor delineation of clinical target volume for intensity-modulat⁃ed pelvic radiotherapy for the definitive treatment of cervix can⁃cer［J］.",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys，2011，79（2）：348-355.［16］ Haie-Meder C，Potter R，Van Limbergen E，et al.Recommenda⁃tions from Gynaecological（GYN） GEC- ESTRO WorkingGroup（I）：concepts and terms in 3D image based 3D treatmentplanning in cervix cancer brachytherapy with emphasis onMRI assessment of GTV and CTV［J］.",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "Radiother Oncol，2005，74（3）：235-245.［17］ 龙行涛，周琦.局部晚期宫颈癌治疗现状与进展［J］.中国实用妇科与产科杂志，2017，33（11）：1206-1209.［18］ Dimopoulos JC，Petrow P，Tanderup K，et al.Recommendationsfrom Gynaecological（GYN） GEC- ESTRO Working Group（Ⅳ）：Basic principles and parameters for MR imaging withinthe frame of image based adaptive cervix cancer brachythera⁃py［J］.",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "Radiother Oncol，2012，103（1）：113-122.［19］ Wo JY，Viswanathan AN.Impact of radiotherapy on fertility，pregnancy，and neonatal outcomes in female cancer pa⁃tients［J］.Int J Radiat Oncol Biol Phys，2009，73：1304-1312.",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "［20］ Kadkhodayan S，Hasanzadeh M，Treglia G，et al.Sentinel nodebiopsy for lymph nodal staging of uterine cervix cancer：a sys⁃tematic review and meta-analysis of the pertinent literature［J］.Eur J Surg Oncol，2015，41：1-20.",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "［21］ Mendivil AA，Rettenmaier MA，Abaid LN，et al.Survival ratecomparisons amongst cervical cancer patients treated with anopen，robotic-assisted or laparoscopic radical hysterectomy：Afive year experience［J］.",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "Surg Oncol，2016，25：66-71.［22］ Bats AS，Frati A，Mathevet P，et al.Contribution of lymphoscin⁃tigraphy to intraoperative sentinel lymph node detection in ear⁃ly cervical cancer：Analysis of the prospective multicenterSENTICOL cohort［J］.",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "Gynecol Oncol，2015，137：264-269.（2018-05-17收稿） 读者·作者·编者 # 如 何 撰 写 论 著 摘 要 为便于进行国际间学术交流，本刊论著所附的中、英文摘要采用国际通用的结构式摘要。摘要分“目的”、“方法”、“结果”和“结论”四部分，可以连续排列，但必须在前面分别写出这四个词。现将各部分的撰写要求叙述如下。目的(Objective)：简要说明研究的目的，说明提出问题的缘由，表明研究的范围和重要性。方法(Methods)：简要说明研究课题的基本设计，使用了什么材料和方法及数据和统计学处理方法等，须明确研究时间段、研究单位(不用第一人称)。结果(Results)：需要列出研究的主要结果和数据及其置信值、统计学显著性检验和确切值。结论(Conclusion)：简要说明经过验证、论证取得的正确观点及其理论价值或应用价值，是否可推荐或推广等。",
    "source": "宫颈癌诊断与治疗指南-第四版",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊断与治疗指南-第四版/宫颈癌诊断与治疗指南-第四版.md"
  },
  {
    "text": "# ·论著·宫颈癌专题研究· # 放射治疗在宫颈癌治疗中的应用及更新 林雨璇，孔为民 ，王元景，李凤霜 【摘要】 放射治疗作为宫颈癌三大治疗方法之一，在宫颈癌治疗中占有重要地位。近年来，三维体外照射及三维腔内照射等新技术开始广泛应用于宫颈癌治疗，这些新技术在提高肿瘤照射剂量的同时还减少了周围正常组织的受量。此外，对于以影像学指标指导个体化放射治疗、质子治疗的探索等研究也在不断进行中。本文对宫颈癌放射治疗的基本知识、放射治疗在宫颈癌治疗中的应用进展进行阐述，总结新技术的适用情况，并提出新技术使用中需注意的问题，以期指导临床应用。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "【关键词】 宫颈肿瘤；放射疗法；放射疗法，影像引导；分次剂量，放射疗法 【中图分类号】 R 737.33 【文献标识码】 DOI：10.12114/j.issn.1007-9572.2022.0058林雨璇，孔为民，王元景，等 .放射治疗在宫颈癌治疗中的应用及更新［J］.中国全科医学，2022，25（18）：2239-2243.［www.chinagp.net］LIN Y X，KONG W M，WANG Y J，et al.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "Application and update of radiotherapy in the treatment of cervical cancer［J］.Chinese General Practice，2022，25（18）：2239-2243.Application and Update of Radiotherapy in the Treatment of Cervical Cancer LIN Yuxuan，KONG Weimin\\*，WANG Yuanjing，LI Fengshuang Department of Gynecologic Oncology，Beijing Obstetrics and Gynecology Hospital，Capital Medical University，Beijing 10006， China \\*Corresponding author：KONG Weimin，Chief physician；E-mail：kwm1967@ccmu.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "edu.cn 【Abstract】 As one of the three major treatments for cervical cancer，radiotherapy plays an important role in treating cervical cancer.In recent years，new technologies such as three-dimensional external beam radiotherapy and image-based brachytherapy have been widely used in the treatment of cervical cancer，which can increase the dose of tumor radiation while reducing the dose radiating surrounding normal tissues.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "In addition，the researches on the use of individualized radiotherapy guided by imaging indicators and proton therapy are also in progress.This paper presents the basic knowledge of radiotherapy for cervical cancer and the application of radiotherapy in the treatment of cervical cancer，summarizes the application of new technologies，and proposes issues that need to be emphasized in the use of new technologies，in order to guide clinical application.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "【Key words】 Uterine cervical neoplasms；Radiotherapy；Radiotherapy，image-guided；Dose fractionation， radiation 放射治疗（以下简称放疗）作为宫颈癌的主要治疗方法之一，与 $70 \\% { \\sim } 8 0 \\%$ 的宫颈癌治疗相关［1］。近年来，以三维体外照射及三维腔内照射为主的放疗新技术广泛应用于宫颈癌治疗，并取得良好的效果。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "本文对宫颈癌放疗的基本知识，放疗（特别是放疗新技术）在宫颈癌治疗中的应用进行阐述，以提高广大妇科医师和全科医师对该方面知识的认识。# 1 各种放疗在宫颈癌治疗中的应用标准 1.1 单纯放疗 单纯放疗适用于以下情况：（1）Ⅱ B期及以上的宫颈癌：Ⅱ A 期以下首选手术治疗，Ⅱ B期以上则首选放疗，迄今为止，这个治疗格局尚无大的改变。（2）Ⅰ B3 期和Ⅱ A2 期宫颈癌：即狭义的局部晚期宫颈癌（locally advanced cervical cancer，LACC）；根 据 美 国 国 立 综 合 癌 症 网 络（National ComprehensiveCancer Network，NCCN）指南（2021 版）［2］，Ⅰ B3 期和Ⅱ A2 期首选根治性同步放化疗，即盆腔外照射 $^ +$ 含铂同期化疗 $^ +$ 阴道近距离放疗（证据等级1 级）。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "（3）Ⅱ a 期以前，有严重内科合并症，无法耐受手术的宫颈癌患者可推荐放疗或同步放化疗，预后与手术相当［3］。1.2 手术联合放疗 手术联合放疗包括术前放疗、术中放疗和术后放疗。术前放疗适用于：（1）狭义上的 LACC，如Ⅰ B3期和Ⅱ A2 期；（2）Ⅱ A 期，阴道侵犯较多；（3）不良病理类型，如透明细胞癌等。术前放疗作为手术的辅助方法，可缩小肿块、改善局部情况、降低手术难度、提高肿瘤切除率。目前，由于手术水平的提高及治疗方法的选择趋于单一，如上述（1）、（2）情况下临床倾向于直接选择放疗或同步放化疗，因此，术前放疗已经很少应用于宫颈癌的治疗［3］。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "术中放疗适用于宫颈癌局部复发或局部晚期患者。术中放疗是指在开腹手术过程中，对于肿瘤残留风险部位或无法切除的孤立瘤灶给予单次大剂量放疗。术中放疗需要手术时具备放疗的条件及较好的放射防护措施，因此其应用受到了限制，目前国内仅少数单位可进行术中放疗。术后放疗适用于术后发现病理存在高危或中危因素，其中，高危因素包括淋巴结阳性、宫旁浸润、切缘阳性。具备任何一项高危因素时，均推荐术后补充盆腔放疗 $^ +$ 顺铂同期化疗（证据等级 1 级）± 阴道近距离放疗；阴道切缘阳性者，阴道近距离放疗可以增加疗效。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "中危因素包括淋巴脉管间隙受侵（lymph-vascular space invasion，LVSI）、宫颈间质浸润深度（deepstromal invasion，DSI）、肿瘤大小（tumor size，TS）。术后出现中危因素时，若病理组织学类型为鳞癌时，采用 Sedlis 标准［4］（表 1）选择进行补充盆腔外照射 ±含铂同期化疗（证据等级 1 级），如若出现 LVSI，且${ \\mathrm { D S I } } { > } 2 / 3$ ，则无论肿瘤有多大，均需进行补充盆腔外照射 $\\pm$ 含铂同期化疗；若为腺癌或腺鳞癌，则参照“四因素模型”（腺癌或腺鳞癌合并下面三项之一：肿瘤最大直径 $\\geqslant 3 \\ \\mathrm { c m }$ 、LVSI、外 1/3 宫颈间质浸润），补充放疗可获益［4］。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "表 1 Sedlis 标准［4］Table 1 Sedlis eligibility criteria <html><body><table><tr><td>LVSI</td><td>DSI</td><td>TS</td></tr><tr><td>+</td><td>>2/3</td><td>任意大小</td></tr><tr><td>+</td><td>1/3~2/3</td><td>≥ 2 cm</td></tr><tr><td>+</td><td><1/3</td><td>≥ 5 cm</td></tr><tr><td></td><td>>1/3</td><td>≥ 4 cm</td></tr></table></body></html> 注：LVSI= 淋巴脉管间隙受侵， $\\mathrm { D S I } =$ 宫颈间质浸润深度， $\\mathrm { T S } =$ 肿瘤大小 1.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "3 化疗联合放疗 化疗联合放疗的具体方式包括序贯放化疗及同步放化疗。序贯放化疗包括先化疗后放疗、先放疗后化疗及化疗 $^ +$ 放疗 $^ +$ 化疗。由于序贯放化疗在宫颈癌治疗中尚缺乏充分的循证医学证据，因此目前在临床上尚未得到广泛应用。同步放化疗是指在放疗的同时穿插化疗（主要指在体外照射的同时，给予顺铂周疗或以顺铂为基础的双药化疗），多应用于Ⅱ B 期以后 LACC 或复发患者的治疗，并已成为目前中晚期宫颈癌的标准治疗方案。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "研究表明［5］同步放化疗相比单纯放疗，尽管增加了Ⅲ / Ⅳ级急性毒性反应，但是其对于 LACC 患者治疗效果有着显著优势（一般认为相校于单纯放疗，LACC 同步放化疗5 年生存率可提高 $6 \\% { \\sim } 1 0 \\%$ ）。# 2 传统放疗技术 传统放疗技术是三维体外照射及三维腔内照射技术的基础。目前，国内仍有少数医疗机构采用传统的二维体外照射及二维腔内照射技术。因此，本文对传统放疗技术进行简单地阐述。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "2.1 二维体外照射 二维体外照射主要包括全盆腔照射、盆腔四野照射、腹主动脉旁延伸野照射、腹股沟区照射、全腹照射等，其原理是基于二维平面设计剂量分布图，确定照射范围后输出射线，在穿透表面皮肤及其他组织后，最终到达肿瘤病灶进行治疗。然而，二维体外照射不能较好地防护病灶周围的正常组织。因此，放射性膀胱炎、放射性直肠炎等毒副作用的发生率较高，严重影响了患者放疗后的生活质量［6］。此外，传统体外照射受周围正常组织耐受剂量的限制，病灶区有时无法达到根治性放疗的剂量，从而影响治疗效果。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "2.2 近距离放疗 近距离放疗包括腔内放疗、管道内放疗及组织间放疗。宫颈癌放疗中最为常用的为腔内放疗，其原理为利用人体自然管道，将放射源放入阴道、子宫宫腔中进行放疗。百余年来，腔内放疗技术不断进步。为保护医疗工作人员免受射线照射，后装放疗技术开始用于腔内放疗。后装放疗是指先把不带放射源的治疗容器置于治疗部位，然后将患者送入治疗室，利用电机将放射源送入治疗容器进行治疗。在剂量率方面，高剂量率后装治疗逐渐得到青睐，缩短了患者治疗时间，也增加了每台机器的可治疗人数，经济而又高效。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "传统近距离放疗在治疗过程中虽然不断改进技术，但是由于其基于二维图像，因而不能很好地保护周围正常的器官。# 3 放疗新技术在宫颈癌治疗中的应用 近年来，随着计算机和影像技术的进步，诸多放疗新技术应运而生，主要包括三维适形放疗（3-dimensional conformal radiotherapy，3D-CRT）、 调强 放 疗（intensity-modulated radiotherapy，IMRT） 及 图像引导放疗等。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "3.1 体外照射新技术 目前，3D-CRT 和 IMRT 是体外放疗的主流技术。相比传统体外照射，三维放疗提高了放疗的精准性，在增加肿瘤靶区剂量的同时，可以更好地保护正常组织，进一步提高疗效。3.1.1 3D-CRT 一般意义上的 3D-CRT 是指射线束在射野方向和靶区形状一致的技术，其原理为利用计算机层析成像的集成，使得放疗剂量辐射以匹配或符合靶标的轮廓进行输出，这种辐射场的形成称为适形放疗。宋慧胜等［7］研究发现，与传统放疗相比，3D-CRT 能够明显降低直肠反应的发生率及严重性，改善患者的生存质量。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "郭智等［8］研究发现，3D-CRT 用于治疗复发宫颈癌时，其危及器官（organs at risk，OAR）的受照射体积明显小于常规放疗，从而减少 OAR 放疗毒副作用的发生率。因此，3D-CRT 与传统放疗技术相比，具有诸多优点：（1）具有定位准确、治疗剂量精确的优点，可减少对正常组织的损害，并提高疗效；（2）为宫颈癌术后或放疗后复发再治疗提供更有效、更能保护患者生活质量的治疗方法。3.1.2 IMRT IMRT 是新型 3D-CRT，采用了 3D-CRT的所有技术，而靶区的剂量分布与适形度较常规3D-CRT 明显改善，真正在三维空间上实现了剂量分布与肿瘤形状一致。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "适形 IMRT 在宫颈癌治疗中的应用最广泛，利用多叶光栅（multileaf collimators，MLC）技术实现对于辐射束强度和形状的调节，做到更精确地塑形。IMRT 的剂量分布对计划靶区（planning target volume，PTV）更加适形。与传统放疗相比，IMRT 在剂量学上更有优势，在宫颈癌术后和根治性放疗中可使膀胱、直肠、结肠和骨髓的受照射体积减小［9-10］，RTOG 1203（TIME-C）［11］报告显示，相比传统放疗，IMRT 可使患者胃肠道和泌尿系统放射性炎性反应发病率显著降低，生活质量显著提高。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "此外，与 3D-CRT 相比，IMRT也有明显优势：在盆腔/主动脉旁淋巴结行放疗时，使用 IMRT 可降低急性和慢性放射性炎性反应［12-13］，同时对淋巴结同步加量尤其是对于接受同步化疗的患者［14-15］；两项前瞻性随机对照试验和一项荟萃分析共同表明，IMRT 比 3D-CRT 更能降低患者急性和晚期胃肠道和泌尿系统放射性炎性反应发病率［10，13-14，16］；MARJANOVIC 等［17］研究发现，IMRT 组中 OAR 的保护效果比 3D-CRT 组更好，并在靶区覆盖方面表现出优势。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "然而，尚无数据表明 IMRT 比二维 / 三维适形技术能提高疾病特异性生存率或总生存率。IMRT 可 分 为 旋 转 调 强（volumetric modulated arctherapy，VMAT）、动态/ 静态调强、螺旋断层放疗（tomotherapy，TOMO）。VMAT 是指在旋转加速器机架的同时，也在调整加速器的剂量率和 MLC 射野形状，从而达到调强目的。VMAT 可调节的参数包括剂量率、MLC 位置、机架转速等。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "VMAT 最大的优势为在各个角度输出射线，在保证总剂量不变的情况下使正常组织平均受量减少，受到的放射损伤也相应减少。GUO 等［18］研究发现，与固定场IMRT（f-IMRT）相比，VMAT 显示出更好的靶区肿瘤剂量覆盖、更好的直肠和膀胱保护，并显著减少了治疗时间。WALI 等［19］研究发现，与高剂量率近距离放疗相比，VMAT 实现了直肠、膀胱和乙状结肠剂量的显著减少，以及更均匀地靶区覆盖。动态调强是指多叶准直器运动和照射同时进行的调强方法。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "静态调强是指多叶准直器运动和照射不同时进行的调强方法。TOMO 是一种基于螺旋断层放疗系统设备，在 CT的引导下，对瘤灶进行 $3 6 0 ^ { \\circ }$ 聚焦断层照射的放疗技术。TOMO 集调强适形放疗、影像引导放疗（image-guided radioherapy，IGRT）、剂量引导放疗（dose-guidedradiotherapy，DGRT）为一体。郭明芳等［20］研究认为TOMO 技术较IMRT 能获得更好的靶区适形度和均匀性，对于盆腔各正常器官（如卵巢）的保护更好，因此可以作为早期年轻宫颈癌患者保留卵巢根治术后放疗的一种选择。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "3.1.3 质子与调强质子治疗 由于质子治疗拥有独特的Bragg 型剂量分布，即质子在行进过程中转移给组织的能量与质子运动速度的平方呈反比，在质子接近其射程终点时能量损失最大，这一特性在肿瘤学放疗中备受瞩目。利用这一性质，将质子峰值能量对准瘤灶，而周围正常组织（包括瘤灶前与瘤灶后）所受到的剂量将极大减少，对于保护OAR 有重要的临床意义。有研究表明，质子治疗应用于宫颈癌放疗可显著降低 OAR 所受放射剂量以及小肠放射性炎［21］。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "这种治疗方式可成为宫颈癌放疗的一种选择。目前国内已有单位拥有质子放疗的设备。3.2 腔内照射新技术 腔内照射新技术主要为三维近距离照射技术（image-based brachytherapy，IBBT）的应用，其基于三维影像学，对照射野的剂量分布进行三维空间上的立体塑形，增加了腔内照射剂量分布的精准性。MAYADEV 等［22］回顾性分析了近年来相关研究，发现与传统 A 点剂量方案相比，IBBT 组报告了显著改善的盆腔控制率和无瘤生存期，同时泌尿生殖系统晚期毒性反应也得到改善。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "IBBT 可在CT、磁共振成像（magneticresonance imaging，MRI）的引导下进行，但 MRI 是目前 IBBT 的首选成像方式，因为 MRI 比 CT 具有更好的软组织对比度。在一项研究中，CT 对 TS 的估计明显偏大［23］，导致与 MRI 相比，肿瘤的 D90（照射 $9 0 \\%$ 肿瘤体积的剂量）和D100（照射 $100 \\%$ 肿瘤体积的剂量）显著降低。在另一项研究中，与 CT 相比，采用 MRI 引导腔内治疗，对原发肿瘤的覆盖范围得到了改善，而对于正常组织的剂量减少了，即提高了对靶区调控的精准性。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "MRI 的这些优势在肿瘤病灶较大或有宫旁侵犯的宫颈癌患者中最为显著［23］。3.3 影像学技术的应用 随着影像学技术发展，将CT、MRI、PET-CT、PET-MRI 等 技 术 引 入 宫 颈 癌 放疗中，使宫颈癌放疗告别了二维时代，迎来了三维时代。FIELDS 等［23］认为影像学的引导可以提高近距离放疗的精准性，可以显著改善针头定位的准确性。GYN GEC-ESTRO 工作组［24］强调了 MRI 有着卓越的软组织分辨率，可在近距离放疗中发挥关键作用。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "但无论是MRI 还是 CT 引导，两者在放射剂量学上无明显差异，但是 CT 目前仍是主要引导方式［25］。PET-CT 除了应用于宫颈癌初次分期、定位、检测淋巴结和远处转移、治疗效果评估等，目前还具有预测宫颈癌预后的重要价值［26］，其原理为通过成像结果、最大标准化摄取值、代谢肿瘤体积和总病变糖酵解等定量参数，进行预后及临床结果的预测。此外，使用其他放射性示踪剂检测和量化缺氧组织的 PET 成像可能也有助于识别侵袭性肿瘤并预测治疗结果，即使其目前还没有广泛用于临床。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "PET 通过预测宫颈癌预后，可以帮助医师及时调整放疗策略，使得放疗更趋于个体化，如对预后预测不佳的患者可以适当增加照射剂量、增大照射野等，以进一步改善患者预后［27］。# 4 放疗过程中如何提高靶区准确性 放疗过程中，由于治疗摆位误差、靶区移位或变形、靶区器官运动等因素的影响，治疗靶区的准确性受到极大挑战，更积极的应对策略是采用某些技术方式探测摆位误差和靶区运动，并采取相应措施。常用的图像引导放疗技术包括电子射线影像装置（electronic portalimaging device，EPID）、 锥 形 束 CT（cone beam-CT，CBCT）、呼吸门控技术和四维放疗技术。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "在每次治疗过程中，患者摆位完成后利用 EPID 技术采集患者位置图像，通过与模拟进行图像匹配，计算摆位误差，予以实时校正，然后实施放疗，可提高靶区准确性。CBCT即在直线加速器对侧导轨上安装一台 CT 机，在治疗开始前行 CT 扫描，根据 CT 断层图像和 3D 重建图像确定摆位误差。CBCT 技术图像具有以下优势：（1）提供 6个维度的摆位误差数据；（2）可追踪器官形态变化，采用变形匹配技术，提供更为精准的治疗误差数据；（3）可以将治疗计划整合到校位 3D 图像中，重新计算剂量分布，获得患者治疗时的实际受照射剂量分布，以便对后续分次治疗进行适当调整。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "目前三维新技术广泛应用于宫颈癌放疗，但是存在靶位准确性被忽视的问题，这可能导致放疗期间的脱靶，并影响最终的治疗效果。因此，减少靶器官形变及位移措施将成为宫颈癌放疗的一个关注重点。为减少靶区形变的影响，治疗过程中增加图像验证次数；对于靶区肿瘤缩小明显，可考虑再次定位，做二次计划再治疗，注意治疗过程不应被中断。宫颈癌放疗过程中靶区位移明显，以宫颈及子宫最著。受膀胱直肠充盈、肿瘤退缩等多个因素影响。针对靶区位移，有多种解决方法，其中以靶区外扩、图像引导及个体化治疗研究最多。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "靶区有均匀外扩及不均匀外扩两种方法，外扩边界大小尚存在争议。图像引导使靶区外扩边界缩小，放疗精确度提高。体外照射是放射物理学上的进步。三维体外照射技术的应用增加了肿瘤接受体外照射时的精准性，但是问题也随之而来，这种精准放疗（包括IMRT、3D-CRT）能否取代腔内照射呢？答案是否定的。一方面是由于腔内照射本身具有独特的物理学优势，即反平方定律，可以更好地保护周围正常器官；另一方面近年来放疗新技术包括IMRT、3D-CRT 等技术快速发展，在这个过程中，作为传统放疗方式之一的腔内照射的使用率有所降低。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "但有研究表明，腔内照射使用率降低可导致患者死亡率增加，对患者生存期产生负面影响［28］。因此，妇科肿瘤学会（Society of Gynecologic Oncology，SGO）、NCCN均认为外照射新技术不能完全取代腔内照射［28］。综上所述，放疗在宫颈癌治疗中占有重要地位。放疗技术的发展日新月异，对妇科肿瘤医生来说，掌握放疗，尤其是掌握放疗新技术进展较为重要。宫颈癌放疗技术主要包括体外照射和腔内治疗，但是两者联合才能保证单纯放疗的效果。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "三维技术（包括三维体外照射及三维腔内治疗等）的广泛应用，一方面可以提高肿瘤照射部位的剂量，另一方面可以减少周围正常组织的受量，进而提高肿瘤放疗的疗效。三维体外照射及三维腔内治疗应用于宫颈癌放疗已有近 20 年的时间，目前已积累了丰富的经验，大量临床数据表明可以广泛应用这些放疗新技术来治疗宫颈癌，但仍需强调以下几个方面的问题：（1）放疗新技术在基层医院应用时，仍需严格掌握应用的原则；（2）重视放疗经验的积累；（3）由于放疗新技术带来了治疗费用的大幅度上涨，部分患者因为经济承受能力差而影响了治疗，应引起社会及广大妇科肿瘤工作者的重视。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "作者贡献：林雨璇负责论文主要部分的撰写，完成相关文献资料的收集和分析及论文初稿的写作；孔为民负责论文的构思布局，指导论文写作、审查及编辑，进行最终版本的修订，并对论文负责；王元景、李凤霜负责文献资料的分析、整理。本文无利益冲突。# 参考文献 ［1］孙建衡，盛修贵，白萍.妇科肿瘤学［M］.2 版.北京：北京大学医学出版社，2019：236.［2］National Comprehensive Cancer Network.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "NCCN clinical practiceguidelines in oncology.Cervical cancer ［EB/OL］.［2021-02-19］.https://www.nccn.org/professionals/ physician_gls/pdf/cervical cancer.pdf.［3］LANDONI F，MANEO A，COLOMBO A，et al.Randomised studyof radical surgery versus radiotherapy for stage Ⅰ b- Ⅱ a cervicalcancer［J］.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "Lancet，1997，350（9077）：535-540.DOI：10.1016/S0140-6736（97）02250-2.［4］SEDLIS A，BUNDY B N，ROTMAN M Z，et al.A randomizedtrial of pelvic radiation therapy versus no further therapy in selectedpatients with stage Ⅰ B carcinoma of the cervix after radicalhysterectomy and pelvic lymphadenectomy：a Gynecologic OncologyGroup Study［J］.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "Gynecol Oncol，1999，73（2）：177-183.DOI：10.1006/gyno.1999.5387.［5］D A T T A N R ， S T U T Z E ， L I U M ， e t a l .C o n c u r r e n tchemoradiotherapy vs.radiotherapy alone in locally advancedcervix cancer：a systematic review and meta-analysis［J］Gynecol Oncol，2017，145（2）：374-385.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "DOI：10.1016/j.ygyno.2017.01.033.［6］CHINO J，ANNUNZIATA C M，BERIWAL S，et al.Radiationtherapy for cervical cancer：executive summary of an ASTROclinical practice guideline［J］.Pract Radiat Oncol，2020，10（4）：220-234.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "DOI：10.1016/j.prro.2020.04.002.［7］宋慧胜，陈龙华，冯正富，等 .宫颈癌三维适形放射治疗与常规放射治疗临床观察［J］.西部医学，2011，23（5）：838-841.DOI：10.3969/j.issn.1672-3511.2011.05.014.［8］郭智，臧志芳，麻富卯，等 .三维适形放疗治疗复发子宫颈癌的剂量学研究［J］.肿瘤研究与临床，2008，20（6）：387-389.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "DOI：10.3760/cma.j.issn.1006-9801.2008.06.010.［9］LUO H C，LIN G S，LIAO S G，et al.Cervical cancer treated withreduced-volume intensity-modulated radiation therapy base on Sedliscriteria（NCCN VS RTOG）［J］.Br J Radiol，2018，91（1081）：20170398.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "DOI：10.1259/bjr.20170398.［10］NAIK A，GURJAR O P，GUPTA K L，et al.Comparison ofdosimetric parameters and acute toxicity of intensity-modulated andthree-dimensional radiotherapy in patients with cervix carcinoma：a randomized prospective study［J］.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "Cancer Radiother，2016，20（5）：370-376.DOI：10.1016/j.canrad.2016.05.011.［11］KLOPP A H，YEUNG A R，DESHMUKH S，et al.Patient-reported toxicity during pelvic intensity-modulated radiationtherapy：NRG oncology-RTOG 1203［J］.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "J Clin Oncol，2018，36（24）：2538-2544.DOI：10.1200/JCO.2017.77.4273.［12］CHANG Y，YANG Z Y，LI G L，et al.Correlations betweenradiation dose in bone marrow and hematological toxicity in patientswith cervical cancer：a comparison of 3DCRT，IMRT，andRapidARC［J］.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "Int J Gynecol Cancer，2016，26（4）：770-776.DOI：10.1097/IGC.0000000000000660.［13］LIN A J，KIDD E，DEHDASHTI F，et al.Intensity modulatedradiation therapy and image-guided adapted brachytherapy forcervix cancer［J］.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys，2019，103（5）：1088-1097.DOI：10.1016/j.ijrobp.2018.11.012.［14］OSBORNE E M，KLOPP A H，JHINGRAN A，et al.Impactof treatment year on survival and adverse effects in patients withcervical cancer and paraortic lymph node metastases treatedwith definitive extended-field radiation therapy［J］.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "PractRadiat Oncol，2017，7（3）：e165-173.DOI：10.1016/j.prro.2016.09.003.［15］WAKATSUKI M，KATO S，OHNO T，et al.Multi-institutionalobservational study of prophylactic extended-field concurrentchemoradiation therapy using weekly cisplatin for patients withpelvic node-positive cervical cancer in east and SoutheastAsia［J］.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys，2019，105（1）：183-189.DOI：10.1016/j.ijrobp.2019.04.039.［16］YU C，ZHU W，JI Y，et al.A comparative study of intensity-modulated radiotherapy and standard radiation field with concurrentchemotherapy for local advanced cervical cancer［J］.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "Eur JGynaecol Oncol，2015，36（3）：278-282.［17］MARJANOVIC D，PLESINAC KARAPANDZIC V，STOJANOVICRUNDIC S，et al.Implementation of intensity-modulatedradiotherapy and comparison with three-dimensional conformalradiotherapy in the postoperative treatment of cervical cancer［J］.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "J BUON，2019，24（5）：2028-2034.［18］GUO M F，HUANG E L，LIU X F，et al.Volumetric modulatedarc therapy versus fixed-field intensity-modulated radiotherapy inradical irradiation for cervical cancer without lymphadenectasis：dosimetric and clinical results［J］.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "Oncol Res Treat，2018，41（3）：105-109.DOI：10.1159/000484608.［19］WALI L，HELAL A，DARWESH R，et al.A dosimetriccomparison of Volumetric Modulated Arc Therapy （VMAT）and High Dose Rate （HDR） brachytherapy in localized cervicalcancer radiotherapy［J］.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "J Xray Sci Technol，2019，27（3）：473-483.DOI：10.3233/XST-180468.［20］郭明芳，柳先锋，刘俐，等 .螺旋断层放疗在早期年轻宫颈癌患者保卵巢根治术后放疗中的剂量学研究［J］.重庆医科 大 学 学 报，2019，44（1）：39-42.DOI：10.13406/j.cnki.cyxb.001873.［21］DE BOER P，VAN DE SCHOOT A J A J，WESTERVELD H，et al.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "Target tailoring and proton beam therapy to reduce smallbowel dose in cervical cancer radiotherapy：a comparison ofbenefits［J］.Al，2018，194（3）：255-263.DOI：10.1007/s00066-017-1224-8.［22］MAYADEV J，VISWANATHAN A，LIU Y，et al.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "AmericanBrachytherapy Task Group Report：a pooled analysis ofclinical outcomes for high-dose-rate brachytherapy for cervicalcancer［J］.Brachytherapy，2017，16（1）：22-43.DOI：10.1016/j.brachy.2016.03.008.［23］FIELDS E C，HAZELL S，MORCOS M，et al.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "Image-guidedgynecologic brachytherapy for cervical cancer［J］.SeminRadiat Oncol，2020，30（1）：16-28.DOI：10.1016/j.semradonc.2019.08.010.［24］DIMOPOULOS J C A，PETROW P，TANDERUP K，et al.Recommendations from Gynaecological （GYN） GEC-ESTROWorking Group （IV）：basic principles and parameters for MRimaging within the frame of image based adaptive cervix cancerbrachytherapy［J］.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "Radiother Oncol，2012，103（1）：113-122.DOI：10.1016/j.radonc.2011.12.024.［25］BATUMALAI V，BURKE S，ROACH D，et al.Impact ofdosimetric differences between CT and MRI derived target volumesfor external beam cervical cancer radiotherapy［J］.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "Br J Radiol，2020，93（1114）：20190564.DOI：10.1259/bjr.20190564.［26］CARESIA-ARÓZTEGUI A P，DELGADO-BOLTON R C，ALVAREZ-RUIZ S，et al.18F-FDG PET/CT in locally advancedcervical cancer：a review［J］.Rev Esp Med Nucl ImagenMol （Engl Ed），2019，38（1）：59-68.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "DOI：10.1016/j.remn.2018.08.004.［27］KHIEWVAN B，TORIGIAN D A，EMAMZADEHFARD S，et al.Update of the role of PET/CT and PET/MRI in the management ofpatients with cervical cancer［J］.Hell J Nucl Med，2016，19（3）：254-268.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "DOI：10.1967/s002449910409.［28］HOLSCHNEIDER C H，PETEREIT D G，CHU C，et al.Brachytherapy：a critical component of primary radiation therapyfor cervical cancer：from the Society of Gynecologic Oncology（SGO） and the American Brachytherapy Society （ABS）［J］.Brachytherapy，2019，18（2）：123-132.DOI：10.1016/j.brachy.2018.11.009.（收稿日期：2021-12-12；修回日期：2022-03-30）（本文编辑：毛亚敏）",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "登录 <html><body><table><tr><td>用户名</td><td rowspan=\"3\"></td></tr><tr><td>密码</td></tr><tr><td></td></tr><tr><td>图形验证码</td><td>V </td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td>提交</td><td></td></tr><tr><td></td><td></td></tr></table></body></html> # 注册账号 | 忘记密码 社交账号登录 !",
    "source": "科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科.md"
  },
  {
    "text": "[](images/61a7860f73a8e815a2445f03fd63dff181570ab2ff79060863efc76cc6432a99.jpg) 首页 关于我们o 医院简介o 医院荣誉 新闻动态。医院动态行业资讯媒体报道 专家团队科室专家先进设备 治疗案例专家案例科研进展联系我们 请输入关键词首页 > 新闻动态 > 行业资讯 # 科普 | 宫颈癌的治疗与放疗选择 作者：小编 更新时间：2022-12-27 点击数：2693 近20年，我国宫颈癌的发病率呈持续上升趋势，且发病年轻化，大量的晚期患者，我们仍面临着较大的治疗压力。",
    "source": "科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科.md"
  },
  {
    "text": "由国家卫健委发布的《宫颈癌诊疗指南》(2022年版)指出，放射治疗适用于各期宫颈癌，包括体外照射和近距离放疗及二者的联合应用。放疗完成的期限是获得最佳疗效的必备因素。放疗时间超过 9 周比少于 7 周的患者有更高的盆腔控制失败率，推荐 56 天内完成所有的外照射和近距离放疗。宫颈癌的治疗选择依分期而定，宫颈癌分为四期，每期又分A、B两期。各期的治疗方案如下： 1）IA期以手术为首选，不能手术者可放疗。",
    "source": "科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科.md"
  },
  {
    "text": "2）IB、IIA期根治性手术或根治性放疗。3）IIB-IVA期首选放疗，增敏化疗可提高疗效 4）IVB期姑息治疗。![](images/fdf51e4cccad1abbf763e6959e86266c5ca930161d647e0b6c480aaaab9285ed.jpg) ▲图1/ 不同分期的宫颈癌治疗选择 其中，Ⅰ期和Ⅱ期的患者放射治愈率在 $7 0 \\sim 9 0 \\%$ ，Ⅲ期的患者放射治愈率在 $4 0 \\sim 6 0 \\%$ ，Ⅳ期患者放射治疗后5年生存率约 $20 \\%$ 。",
    "source": "科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科.md"
  },
  {
    "text": "因此，那种“放疗只是辅助，是不能手术者的无奈之举”的观点，对于宫颈癌的放射治疗是错误的。对于肿瘤直径大于4cm的早期宫颈癌，临床研究结果亦证明，放疗联合化疗效果优于手术联合放化疗。现代放射治疗技术下，宫颈癌放疗效果进一步提升、副反应继续下降。在精准治愈肿瘤的同时，完美保护了膀胱、直肠、阴道的正常功能，使患者获得了更高生活质量的生命延续。![](images/cdf06db4e9ed8727d8e9e66ea25b8d7d4af3b4ff0c514e0957e2a372b5fd44e8.",
    "source": "科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科.md"
  },
  {
    "text": "jpg) $\\blacktriangle$ 图2/ 宫颈癌的放射治疗选择 对于宫颈癌的放射治疗选择，程淑霞教授表示： 1）放射治疗是可以治愈宫颈癌的，特别对于中晚期宫颈癌，疗效优于手术； 2）正确规范的放疗才能保障好的治疗效果； 3）单纯化疗无法治愈宫颈癌，避免单用化疗，延误病情。与此同时，随着临床数据的积累，免疫药物（ICIs）在宫颈癌治疗中的推荐日渐增强。现有研究提示，免疫治疗宫颈癌的主要获益人群为 PD-L1 阳性患者。",
    "source": "科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科.md"
  },
  {
    "text": "Papadopoulos KP, et al 的研究显示，Cemiplimab 联合低分割放疗治疗晚期肿瘤，有助在免疫疗效基础上，进一步缩短反应时间，帮助较快降低肿瘤负荷。Yin Z, et al 的研究显示，初诊伴内脏转移的宫颈癌患者接受系统化疗时，同步行放疗，较单纯化疗 $\\pm$ 姑息性盆腔放疗，可带来生存裨益（OS：17.3 vs 10 月）。上述研究提示，在晚期转移性宫颈癌的治疗中，放疗 ± 免疫治疗有望提升反应率、降低初期进展风险，并带来生存获益。",
    "source": "科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科.md"
  },
  {
    "text": "<html><body><table><tr><td colspan=\"4\">宫颈癌系统治疗</td></tr><tr><td colspan=\"4\">鳞癌、腺癌、腺鳞癌</td></tr><tr><td rowspan=\"2\">放化疗</td><td colspan=\"3\">复发/转移性疾病</td></tr><tr><td>一线联合治疗</td><td>一线单药治疗</td><td>二纟</td></tr><tr><td>推荐方案：顺铂、 卡铂（顺铂不耐 受)</td><td>推荐方案: Pembrolizumab十顺铂/紫 杉醇±BEV（PD-L1+) （1类）、Pembrolizumab 十卡铂/紫杉醇土BEV （PD-L1+）（1类）、 顺铂/紫杉醇/BEV （1类）、 卡铂/紫杉醇/BEV</td><td>推荐方案：顺铂 其他推荐方案：卡 铂、紫杉醇</td><td>推荐方案：「 L1十或MSI-F Nivolumab ( 其他推荐方 杉醇，多西1 吉西他滨，!",
    "source": "科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科.md"
  },
  {
    "text": "替康，丝裂 拓扑替康，· 特定情况下j Pembrolizum Larotrectinib 融合阳性)</td></tr></table></body></html> 免疫治疗最初推荐二线/后线用于 MSI-H/dMMR，或 PD-L1 阳性宫颈癌患者，而在 2022.V1 NCCN 宫颈癌指南，PD-L1 表达阳性、复发/转移性宫颈癌患者，一线推荐 pembrolizumab 联合化疗治疗。加入收藏 上一篇：前列腺癌放射性粒子治疗 下一篇：什么是质子治疗、对哪些癌症疗效最好？",
    "source": "科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科.md"
  },
  {
    "text": "透视质子疗法 3 大优质 返回列表 # 随便看看 哪种肺癌需要通过放射治疗 老师傅突冒1.4公分肝癌 「精准放射治疗」消灭癌肿瘤 一文带你了解食管癌放疗，食管癌什么情况选择放疗？肺癌肿瘤分几期 结节大于几厘米需重视？肝癌肿瘤治疗新利器 成大引进新型微波消融治疗 乳腺癌放疗后，出现皮肤痒红肿，疲累想睡觉，怎么办？TOMO放疗：告别‘杀敌一千，自损八百’，精准治疗新篇章！放疗x化疗 有何优缺点？华式医学研究院隆重成立了（肿瘤患者的福音） 膀胱癌介绍：症状与放射、化疗、免疫治疗方式说明 # 产品推荐 # 【专家简介】 !",
    "source": "科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科.md"
  },
  {
    "text": "[](images/da7005d77a0413b9528248e6e4dad185f8c2fd9fe7f6334a5e93d79640534233.jpg) 武汉济和医院主任医师。从事肿瘤临床工作30多年，长期担任三甲医院科主任，对各种肿瘤的规范化诊疗，均有很深的研究。对内科常见病、多发病的诊断治疗有较丰富的经验。# 【专业擅长】 对临床肿瘤内科的实用技术熟练掌握，开展各种肿瘤的术前、术后的辅助放化疗及各种肿瘤的根治性放化疗、靶向、免疫及细胞免疫等治疗，放疗技术从普通外照射、适型、调强、放射治疗外科。",
    "source": "科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科.md"
  },
  {
    "text": "# 【坐诊时间：周一至周五】 # 肿瘤科专家 主任医师 马玉芳 ![](images/54202577a707b93cdd48b4c42ac17afe136eb4fe82e30f694b53c3c5b7a7872d.jpg) # 【专家简介】 湖北省肿瘤医院主任医师。从事肿瘤的基础和临床研究工作近20年，主要的研究方向包括肺癌脑转移转移生物标志物及信号传导、肿瘤放化疗、肿瘤抗血管生成治疗、正常组织的放射耐受及不良反应等。",
    "source": "科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科.md"
  },
  {
    "text": "# 【专业擅长】 擅长肺癌、食管癌、鼻咽癌、脑胶质瘤、头颈鳞癌和乳腺癌等各种常见恶性肿瘤的放化疗等综合治疗及靶向、免疫治疗。![](images/55ea3b12d17d46e874ad046f61b60a691b33ebbb25bd590166099c954d463c58.jpg) # 【专家简介】 湖北省人民医院副主任物理师。从事肿瘤放射物理技术工作20余年，在肿瘤医学放射物理技术领域有较深造谐，特别是现代的静态/动态/容积调强适形放疗、全身肿瘤放疗、立体定向放疗。",
    "source": "科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科.md"
  },
  {
    "text": "# 【专业擅长】 主要擅长临床数据采集、临床数据建模、辐射测量学、临床剂量学以及各种特殊放疗技术的剂量测量、各种放疗设备质控、各种肿瘤放射治疗计划的设计、各种放疗设备的验收评审。# 【坐诊时间：周四上午】 # 肿瘤科专家 副主任物理师 阮长利 ![](images/88503eedd0dcc0d9f7604f1211ee1e1b8af09bb9658cd3ee638bd4b147838b5f.jpg) # 【专家简介】 湖北省人民医院肿瘤中心主任医师，从事临床工作35年，兼任湖北省肺癌专业委员会委员，湖北省生物医学工程学会肿瘤靶向专业委员会常委，湖北省抗癌协会鼻咽癌专业委员会常委。",
    "source": "科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科.md"
  },
  {
    "text": "# 【专业擅长】 各种恶性肿瘤的早期诊断及综合治疗，擅长常见头颈部肿瘤、肺癌、乳腺癌、胃肠道肿瘤等恶性肿瘤放疗、化疗、生物靶向免疫综合治疗，尤其乳腺癌、鼻咽癌、肺癌、妇科肿瘤等恶性肿瘤的综合治疗。坐诊时间：周二下午） # 【专家简介】 ![](images/9acd87eaafa61c1c2913aecb02c5a239ffffda8e8e1216c8b4b5f8a109760b9d.jpg) 湖北省肿瘤医院主任医师。",
    "source": "科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科.md"
  },
  {
    "text": "从事肿瘤放化疗工作30余年，能熟练、正确地诊治放疗科常见复杂、疑难病症及危、急、重症病例，是胃肠道肿瘤MDT、肝癌MDT、泌尿系肿瘤MDT的核心成员。# 【专业擅长】 对胃肠道恶性肿瘤、泌尿系统肿瘤、肺癌、食管癌、肝胆胰恶性肿瘤、乳腺癌、淋巴瘤等恶性肿瘤有着丰富的临床经验，能熟练地进行上手肿瘤的精确放疗、化疗、靶向、免疫等综合治疗。# 【坐诊时间：周二上午】 # 肿瘤科专家 主任医师 陈卫东 # 关于我们 o 医院简介 o 医院荣誉 新闻动态 o 医院动态C 行业资讯o 媒体报道 专家团队 科室专家o 先进设备 治疗案例专家案例 武汉市蔡甸区蔡甸大街216号 18511195050 zhongliu@whjh120.com 关注我们 友情链接",
    "source": "科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科.md"
  },
  {
    "text": "# ·指南与共识· # 老年宫颈癌规范化诊疗中国专家共识(2024 年版) 中国老年医学学会妇科分会【关键词】 老年人;宫颈癌;手术;放疗;专家共识【中图分类号】 R592;R737.33【文献标志码】 A 【DOI】 10.11915 / j.issn.1671-5403.2025.01.001 宫颈癌( cervical cancer, CC) 是全球女性第四大常见癌症和癌症死亡的第四大原因[1]。",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "随着宫颈癌筛查技术及人乳头状瘤病毒(human papilloma-virus, HPV)疫苗的普及,许多发达国家宫颈癌的发病率正逐年下降[2]。然而研究表明,老年人群癌症发病率较其他人群增加了11 倍[3],而随着我国人口老龄化问题日趋严重,老年宫颈癌患者人数不降反增。2022 年我国新发宫颈癌达到 15.07 万,年死亡接近6 万例,其中老年女性(60 岁以上) 占比高达$2 9 .8 \\%$ [4],预计到 2040 年,中国宫颈癌死亡病例将达 7.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "5 万例[5]。世界卫生组织将老年定义为 65 岁以上,我国定义为 60 岁以上[6],老年患者由于就医意愿不强,恐惧妇科检查等原因,确诊宫颈癌时往往分期更晚,且因自身体质较差,内科合并症较多,通常预后更差[7]。本共识旨在规范老年宫颈癌患者的诊治,中国老年医学学会妇科分会组织国内专家根据现有国内外文献,参考美国国立综合癌症网络( National Comprehensive Cancer Network, NCCN )指南、中国临床肿瘤学会( Chinese society of clinicaloncology, CSCO)指南等,集体讨论并共同制定中国老年宫颈癌规范化治疗共识,为妇科肿瘤医师临床诊治老年宫颈癌提供参考。",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "本共识推荐级别及其代表意义见表1。表 1 本共识推荐级别及其代表意义 <html><body><table><tr><td>推荐级别</td><td>代表意义</td></tr><tr><td>1类</td><td>基于高级别临床研究证据，专家意见高度一致</td></tr><tr><td>2A类</td><td>基于高级别证据，专家意见基本一致；或基于低级别</td></tr><tr><td></td><td>临床研究证据，专家意见高度一致</td></tr><tr><td>2B类</td><td>基于低级别临床研究证据，专家意见基本一致</td></tr><tr><td>3类</td><td>不论基于何种级别临床证据，专家意见明显分歧</td></tr></table></body></html> 收稿日期: 2024-07-30; 接受日期: 2024-09-16基金项目:辽宁省重点研发项目(2024JH2 / 102500019);2022 年沈阳市科技计划(22-321-33-08);沈阳市科技局 2023 年助力中国医科大学高质量发展专项(23-506-3-01-10); 国家自然科学基金(82102711);北京市科技计划( Z221100007422087);北京市医院管理中心临床医学发展专项经费资助(ZLRK202529)通信作者: 张颐, E-mail: syzi $@$ 163.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "com; 吴玉梅, E-mail: $\\mathrm { w y m } 5 9 7 1 1 8 @ \\$ ccmu.edu.cn; 张师前, E-mail: r370112@ 126.com # 1 老年宫颈癌的诊断与评估 老年宫颈癌患者具有特殊性,需进行全面的诊断与评估,以制定适宜治疗方案。# 1.1 疾病诊断 宫颈癌的诊断主要包括临床诊断(病史及体格检查)及病理诊断。1.1.1 临床诊断 中国各地区宫颈癌筛查的应用并不平衡,即使在发达地区,罹患宫颈癌的老年妇女并不鲜见。",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "老年女性因其生殖道生理条件改变,性生活的频率低,多缺乏疾病早期的白带异常或接触性出血等典型症状,内生型宫颈癌多以白带恶臭或宫腔积液/ 积脓为首发症状。HPV 是宫颈癌主要致病因素,而老年女性属于高危型 HPV 易感人群(感染率为 $1 6 .7 \\%$ ),虽然感染率低于总体女性人群,但绝经后雌激素水平较低,无法维持阴道微生态平衡,机体免疫力下降,感染 HPV 的自然转阴率低,多为持续感染[8-10],进而导致宫颈上皮内瘤变(cervicalintraepithelial neoplasia,CIN) 并 进 展 至 宫 颈 浸 润 癌。",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "老年女性生殖道萎缩、粘连,妇科检查往往无法充分暴露子宫颈;宫颈鳞柱交界上移,甚至退缩至宫颈管内,即使发生病变,宫颈外观也可无异常。建议详细询问病史,并由2 名及以上高年资医师进行双合诊与三合诊检查,如患者配合度差,必要时联合麻醉进行妇检。同时参考“老年女性子宫颈病变筛查及异常管理的中国专家共识(2023 年版) [11] ”。1.1.2 病理诊断 病理学为宫颈癌诊断的金标准,主要通过宫颈活组织检查进行诊断,存在远处转移时(如腹股沟/ 颈部淋巴结),推荐进行活检或细针穿刺细胞学确诊。",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "当老年宫颈癌患者仅靠活检无法判断宫颈肿瘤浸润深度及微小浸润癌时,或宫颈液基细胞学检查( thinprep cytology test, TCT) 结果与阴道镜下活检病理不符时,推荐宫颈管搔刮和诊断性宫颈锥切。在老年宫颈癌患者中,鳞状细胞癌最为常见,约占 $7 5 \\%$ ;其次是腺癌,约占 $1 8 .4 \\% ^ { [ 1 2 ] }$ 。病理学诊断还可提供辅助诊断及治疗的生物标志物,常用的指标包括 P16、Ki67、CK7、CK20、CEA、ER、PR、MUC6、CD56 和 $\\mathrm { C g A }$ 等,对于复发、转移或持续性宫颈癌,可通过检测免疫检查点抑制剂相关指标包括细胞程序性 死 亡 配 体 - 1 ( programmed death ligand-1,PD-L1)、错配修复 / 微卫星不稳定( mismatch repair /microsatellite instability, MMR / MSI) 和 肿 瘤 突 变 负荷( tumor mutational burden, TMB ), 必 要 时 进 行NTRK 基因融合检测以指导全身治疗[13]。",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "C # 1.2 疾病评估 1.2.1 经阴道/ 直肠超声检查 经阴道/ 直肠超声(transvaginal / transrectal ultrasound, TVS / TRS) 检查具有简单、方便、价格低廉等特点,可作为老年宫颈癌患者的首选检查。宫颈肿瘤体积较大,TRS 是评估宫颈局部的首要选择,不仅能够减少肿瘤接触出血风险,还可清晰观察宫颈局部病灶及肿瘤血流情况,避免 TVS 因肿瘤出血、坏死和探头与肿瘤之间形成伪影的影响[14]。",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "不同病理类型宫颈癌的超声表现也有所不同,腺癌组织相较于周围基质通常表现为高回声或等回声, 鳞癌则通常表现为低回声[15,16] 。因不受肠道气体的干扰,TVS / TRS 能较好地评估盆腔淋巴结是否肿大。TVS / TRS 对宫颈癌肿瘤大小、间质浸润及宫旁浸润评估的灵敏性及准确性分别为 $78 \\% / 9 5 \\%$ 、 $8 8 \\% \\sim 9 1 \\% / 9 1 \\% \\sim 9 3 \\%$ 、$6 0 \\% \\sim 8 3 \\% / 8 7 \\% \\sim 9 9 \\% ^ { [ 1 7 - 2 0 ] }$ 。",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "鉴于超声检查受诊断医师的主观影响较大,本共识推荐由丰富经验的超声医师实施,以减少人为因素所致评估偏倚。1.2.2 盆腔核磁共振 盆腔核磁共振 ( magneticresonance imaging, MRI)具有较高的软组织分辨率,是评估宫颈癌局部病变的优选影像学检查手段。推荐盆腔 MRI 增强扫描,在 T2 加权图像上表现为典型的中等高信号,矢状面可以评估肿瘤是否已累及子宫体或阴道,轴向斜面更适合评估宫旁浸润情况。",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "动态增强 MRI( dynamic enhanced-MRI, DCE-MRI)能够精准显示宫颈肿瘤的界限,也可藉以鉴别病理无法区分的宫颈癌及子宫内膜癌,宫颈癌为特征性早期动脉期增强, 子宫内膜癌则表现为延迟增强[21]。MRI 对宫颈癌肿瘤大小、间质浸润及宫旁浸润的评估的灵敏度及准确度分别为 $8 1 \\% / 9 3 \\%$ 、$89 \\% / 8 8 \\%$ 、 $.4 0 \\% \\sim 7 4 \\% / 7 0 \\% \\sim 9 7 \\%$ ,对淋巴结转移评估的灵敏度为 $3 7 \\% \\sim 6 0 \\% ^ { [ 2 2 - 2 5 ] }$ O 1.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "2.3 计算机断层显像 局部晚期宫颈癌、盆腔MRI 或 TVS / TRS 有可疑淋巴结转移患者,或因无法取环行 MRI 检查时推荐进行胸腹盆计算机断层显像( computed tomography, CT) 检 查, 首 选 腹 盆增强 $\\mathrm { C T }$ 。但 CT 对于软组织分辨率低,评估宫颈局部不及 MRI,评估宫旁浸润的灵敏度及准确度为$1 4 \\% \\sim 5 5 \\% / 7 4 \\% \\sim 8 2 \\%$ ,盆腔淋巴结转移的灵敏度为 31% \\~ 58%[22-25] 。",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "O 1.2.4 正电子发射断层扫描计算机断层扫描 正电子发射断层扫描计算机断层扫描(positron emissiontomography-computed tomography, PET-CT)可同时显示肿瘤形态和组织代谢特征,诊断淋巴结转移的灵敏度为 $7 2 \\% \\sim 7 5 \\%$ ,仅次于前哨淋巴结活检,还可检出肿瘤有无远处转移,尤其适宜于晚期、复发或转移的高危患者[25-29] 。",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "。# 1.3 老年宫颈癌分期 目前宫颈癌分期仍采用 2018 年国际妇产科联合会( international federation of gynecology and obste-trics, FIGO)新分期(表 2),结合患者体格检查、影像学及病理学资料,对肿瘤大小、扩散程度进行综合评估,以诊断宫颈癌期别。# 【推荐意见】 老年宫颈癌患者应进行妇科检查、病理学诊断和影像学检查以全面评估肿瘤,指导制定适宜的治疗方案。",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "TVS / TRS 及盆腔 MRI 能够较精准评估局部肿瘤,为局部肿瘤首选检查手段。CT 更适用于评估有无淋巴结转移,高危患者可选择 PET-CT 以排除远处转移。(推荐级别:2A) # 2 患者整体机能评估 年龄本身不是宫颈癌手术治疗的绝对禁忌证,但对于老年患者来说,对整体机能评估是决策过程的关键一步。建议在制定治疗方案前应对老年患者进行个体化评估,评估内容包括:(1)根据肿瘤恶性程度和疾病进展情况评估患者预期寿命;(2) 评估患者的决策能力,即患者对自身病情的了解程度及能够合理选择治疗的能力;(3) 明确患者的治疗目标与其所能承受治疗的一致性[30]。",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "D # 2.1 衰弱评估 “衰弱”(frailty)是多系统生理功能退化为特征的一组老年疾病[31,32]。衰弱评估包括三个维度,即躯体、心理和社会。Fried 表型是最具代表性的衰弱评估量表,包括体质量减轻、手握力差、疲劳、行走迟缓 、体力活动受限五方面,评分 $\\geqslant 3$ 分为重度衰弱, 表 2 国际妇产科联盟宫颈癌临床分期标准(FIGO 2018) <html><body><table><tr><td>分期</td><td>描述</td></tr><tr><td>I</td><td>肿瘤严格局限于宫颈(扩展至宫体将被忽略)</td></tr><tr><td>IA</td><td>仅能在显微镜下诊断的浸润癌，所测量的最大浸润深度≤5.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "0mm</td></tr><tr><td>IA1</td><td>所测量间质浸润深度≤3.0mm</td></tr><tr><td>IA2</td><td>所测量间质浸润深度>3.0mm而≤5.0mm</td></tr><tr><td>IB</td><td>所测量的最大浸润深度>5.0mm的浸润癌（病变范围超过IA期）,病变局限于宫颈</td></tr><tr><td>IB1</td><td>间质浸润深度>5.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "0mm而最大径线≤2.0cm的浸润癌</td></tr><tr><td>IB2</td><td>最大径线>2.0cm而≤4.0cm的浸润癌</td></tr><tr><td>IB3</td><td>最大径线>4.0cm的浸润癌</td></tr><tr><td>Ⅱ</td><td>宫颈肿瘤侵犯超出子宫，但未达盆壁，且未达阴道下1/3</td></tr><tr><td>IIA</td><td>肿瘤侵犯限于阴道上2/3,无宫旁浸润</td></tr><tr><td>IIA1</td><td>最大径线≤4.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "0cm的浸润癌</td></tr><tr><td>IIA2</td><td>最大径线>4.0cm的浸润癌</td></tr><tr><td>IIB</td><td>有宫旁浸润，但未扩展至盆壁</td></tr><tr><td>ⅢI</td><td>肿瘤扩展到骨盆壁和(或)累及阴道下1/3和(或)导致肾孟积水或肾无功能者和(或)侵犯盆腔和(或)腹主动脉旁淋巴结</td></tr><tr><td>ⅢIA</td><td>肿瘤累及阴道下1/3，没有扩展到骨盆壁</td></tr><tr><td>ⅢIB ⅢIC</td><td>肿瘤扩展到骨盆壁和(或)引起肾盂积水或肾无功能</td></tr><tr><td>ⅢIC1</td><td>侵犯盆腔和(或)腹主动脉旁淋巴结（包括微转移）,无论肿瘤大小和范围;需标注r或p:r表示影像诊断,p表示病理诊断</td></tr><tr><td>ⅢIC2</td><td>仅有盆腔淋巴结转移 腹主动脉旁淋巴结转移</td></tr><tr><td>IV</td><td>肿瘤侵犯膀胱或直肠黏膜(病理证实)或肿瘤播散超出真骨盆。",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "泡状水肿不能分为IⅣ期</td></tr><tr><td>IVA</td><td>肿瘤侵犯膀胱或直肠黏膜</td></tr><tr><td>IVB</td><td></td></tr><tr><td></td><td>肿瘤播散至远处器官</td></tr></table></body></html> 1\\~2 分为中度衰弱,0 分为不衰弱[33]。临床衰弱性量表(clinical frailty scale, CFS) 是另一种常用的衰弱性筛查工具,多用于评估住院老年患者的衰弱状况,主要从移动能力、精力、体力活动和功能四个方面将脆弱程度分为9 个等级:从非常健康到终末期,研究表明 CFS 与死亡率密切相关[34]。",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "老年人群衰弱性增加意味着患者术后死亡率和并发症风险上升、住院时间延长[35-38],评估老年衰弱程度可协助规范治疗,降低治疗相关的不良事件发生率。# 2.2 心肺功能 老年患者心肺功能明显减退,罹患冠心病、高血压等心血管疾病及围手术期肺部并发症的风险增加[39] C 修订后的心脏风险指数(revised cardiac risk index,RCRI)广泛用于心脏评估,由六个独立的预测因子构成,包括高风险手术、缺血性心脏病史、充血性心力衰竭史、脑血管手术、需要胰岛素治疗的糖尿病、以及术前血清肌酐水平 ${ > } 2 .",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "0 \\ \\mathrm { m g / d l }$ 。并发症发生率随危险因素的增加而升高,存在 3 个以上危险因素时并发症发生率为 $9 \\% ^ { [ 4 0 ] }$ ,腹部四级手术患者围术期肺部并发症发生率为 $6 0 .8 \\% ^ { [ 4 1 ] }$ ,手术方式(尤其上腹部及胸部手术)、急诊手术、衰弱、术前呼吸道感染、美国麻醉医师协会( American society of anesh-esiologists, ASA) 分级高是术后呼吸衰竭的五大关键危险因素。",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "ARISCAT ( assess respiratory risk insurgical patients in Catalonia) 评分根据年龄、1 个月内的呼吸道感染、血氧饱和度、贫血、手术部位、手术时间、是否急诊七个因素, 将患者分为低危( $\\leqslant$ 26 分)、中危(27 \\~ 44 分)、高危( $\\geqslant 4 5$ 分) 三级。宫颈癌是风险高、难度大的四级手术,ARISCAT 评分能较为精准发现可能发生肺部并发症的患者,通过降风险因素( 如术前戒烟)、优化治疗慢性阻塞性疾病、呼吸训练或物理治疗,以期降低老年宫颈癌患者围术期肺部并发症的发生率[42] # 2.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "3 营养状态评估 营养不良通常与切口感染、肺炎、尿路感染和切口延迟愈合有关,甚至延长住院及重症监护时间,增加术后不良事件的发生率[43,44]。微营养评定简表(mini-nutritional assessment, MNA)是一种被广泛采用的营养状况评估工具,分数范围为 0 \\~ 14 分,其中12\\~14 分为正常营养状态,8 \\~ 11 分表示存在营养不良风险, $\\leqslant 7$ 分表示营养不良。",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "营养不良患者可能从严格的营养评估和康复中受益,可于术前$1 0 \\sim 1 4 \\mathrm { d }$ 开始口服蛋白质补充剂和富含碳水化合物的液体,改善机体营养状态[45] # 【推荐意见】 年龄不是老年宫颈癌患者手术治疗的危险因素,治疗决策前对患者进行整体机能评估,包括衰弱程度、心肺功能及营养状态等,给予针对性干预以减 少围术期不良事件的发生。(推荐级别:2A) # 2.4 多共病评估 “共病” 系指患者患一种疾病的同时存在另一种或多种疾病[46],多共病现象在老年患者中尤为突出,影响患者的预后,导致诊疗决策制订复杂化,增加治疗风险。",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "针对多共病的老年患者,需要进行全面评估,采用连续、综合、个体化的诊治。2.4.1 Charlson 共 病 指 数 Charlson 共 病 指 数(Charlson comorbidity index, CCI) 是目前使用最广泛的共病指数(表 3),通常被认为是临床研究中评估合并症的金标准[47],CCI 总分由权重分总和组成,分数越高表示患者合并症越严重,死亡风险越大[48]。此外,CCI 对患者再住院率及医疗费用具有一定的预测价值。",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "CCI 也演变出一些相关指数用于患者预后的预测,年龄-合并症指数(age-CCI) 在肿瘤学中最常使用,是死亡率的重要预测指标。表 3 Charlson 共病指数 <html><body><table><tr><td>事件</td><td>分配权重</td></tr><tr><td>心肌梗死</td><td>1</td></tr><tr><td>充血性心力衰竭</td><td>1</td></tr><tr><td>外周血管疾病</td><td>1</td></tr><tr><td>脑血管疾病</td><td>1</td></tr><tr><td>痴呆</td><td>1</td></tr><tr><td>肺慢性疾病</td><td>1</td></tr><tr><td>结缔组织病</td><td>1</td></tr><tr><td>溃疡</td><td>1</td></tr><tr><td>轻度肝病</td><td>1</td></tr><tr><td>糖尿病</td><td>1</td></tr><tr><td>偏瘫</td><td>2</td></tr><tr><td>中度或重度肾脏疾病</td><td></td></tr><tr><td>糖尿病引发的器官损害的终末期</td><td>2</td></tr><tr><td>无转移的任何肿瘤</td><td>2</td></tr><tr><td>白血病</td><td>2 2</td></tr><tr><td>淋巴瘤</td><td>2</td></tr><tr><td>中重度肝病</td><td>3</td></tr><tr><td>转移性实体瘤</td><td>6</td></tr><tr><td>艾滋病</td><td>6</td></tr></table></body></html> 2.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "4.2 疾病累积评分量表 疾病累积评分量表( cumulative illness rating scale, CIRS)是最早依据疾病系统分类的共病指数,根据器官和系统评估合并症的重要性进行评分, 总共纳入 13 个系统相关疾病。针对老年患者修订的 CIRS( CIRS-G),根据器官系统合并症的严重程度评为 0 \\~4 分,当同一系统同时出现1 种以上疾病时,只计算该系统最严重疾病, 统计总得分[49]。",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "美国临床肿瘤学会推荐CIRS-G 评估老年癌症患者的合并症[50],与 CCI 相比,CIRS 包含的疾病谱更广,灵敏性更高[46],但仍缺乏有关合并症类型、数量和某特定合并症的预后价值的数据。# 【推荐意见】 老年宫颈癌患者的多共病现象更加普遍,影响治疗策略制定和预后结局,推荐老年宫颈癌患者应用 CCI 及 CIRS-G 评估共病,以满足老年宫颈癌患者的个体化诊治。(推荐级别:2A) # 3 治疗原则 # 3.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "1 早期宫颈癌患者 手术是早期宫颈癌患者标准治疗方式。研究表明,手术能改善早期老年宫颈癌患者预后[51,52]。老年患者能否耐受根治性子宫切除术及盆腔淋巴结清扫术,需根据手术风险分层工具评估[53,54],重点考量患者合并症、体能状态对手术治疗的耐受性及术后相关并发症风险(图1)。3.1.1 可耐受手术者 对于早期可耐受手术的老年宫颈癌患者,推荐行手术治疗,此阶段患者治疗原则与年轻患者基本相同[55]。",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "O 经宫颈锥切确诊的ⅠA1 期淋巴脉管间隙浸润(lymphovascular space invasion, LVSI) 阴 性 的 老 年患者:(1)切缘阴性者,推荐筋膜外子宫切除术 $+$ 双侧输卵管卵巢切除术;(2) 切缘为高级别鳞状上皮内病 变 ( high-grade squamous intraepithelial lesion,HSIL)者,推荐再次锥切,如宫颈管萎缩、无法行二次锥切者,建议直接行筋膜外全子宫切除 $^ +$ 双侧输卵管卵巢切除术;(3)切缘为癌者,推荐改良根治性子宫切除术 $^ +$ 双侧输卵管卵巢切除术 $^ +$ 盆腔淋巴结切除术/ 前哨淋巴结活检。",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "LVSI 阳性的老年患者:推荐改良根治性子宫切除术 $+$ 双侧输卵管卵巢切除术 $^ +$ 盆腔淋巴结切除术/ 前哨淋巴结活检。经宫颈锥切确诊的 $\\mathrm { ~ I ~ A 2 \\sim ~ I ~ B 1 ~ }$ 期满足全部ConCerv 标准[LVSI 阴性,切缘阴性,鳞癌( 任何级别)或普通类型腺癌(G1 / G2),肿瘤直径 $\\leqslant 2 \\mathrm { c m }$ ,浸润深度 $\\leqslant 1 0 \\mathrm { m m }$ ,影像学检查无其他部位转移]的老年患者,推荐行筋膜外子宫切除 $^ +$ 双侧输卵管卵巢切除术 $^ +$ 盆腔淋巴结切除/ 前哨淋巴结活检,否则推荐行根治性子宫切除术 $+$ 双侧输卵管卵巢切除术 $+$ 盆腔淋巴结切除 $\\pm$ 主动脉旁淋巴结切除/ 前哨淋巴结活检。",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "经宫颈锥切诊断的ⅠB2、ⅡA1 期老年患者,推荐根治性子宫切除术 $^ +$ 双侧输卵管卵巢切除术 $+$ 盆腔淋巴结切除 $\\pm$ 主动脉旁淋巴结切除/ 前哨淋巴结活检[56] 。C ![](images/14ccd8b0cacc1b43ab5b2868bef44bddbd978a12c1996820dae66c80448f1ce6.jpg) 图 1 早期宫颈癌患者治疗原则 HSIL: 子宫颈高级别上皮内瘤变; LVSI: 淋巴血管间质浸润; SLN: 前哨淋巴结.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "文献报道,老年宫颈癌患者对根治性子宫切除及盆腔淋巴结切除术的耐受性良好,尽管术后住院时间及留置尿管时长有所延长,但术后并发症发生率未明显升高[57,58] 。也有观点认为,老年患者因盆底组织萎缩,子宫脱垂或移位,手术难度增大,出现副损伤及术后并发症率增加,可适当缩小手术范围,选择单纯筋膜外子宫切除术 $^ +$ 双侧输卵管卵巢切除术 $+$ 盆腔淋巴结切除术/ 前哨淋巴结活检[59] 。总之,老年患者如行手术治疗,需加强围手术全程管理,注意全身麻醉气管插管及肺部感染管控,加强营养支持治疗、降低和预防血栓栓塞性疾病的发生、规范静脉输液量,预防心脏并发症发生。",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "早期老年宫颈癌患者,术后需根据危险因素评估是否需补充治疗。切缘阳性、宫旁浸润及淋巴结转移是宫颈癌三大高危因素,存在 1 项及以上高危因素者,如术前全身评估不充分,必要时需进一步影像学检查以了解其他部位转移情况,后补充盆腔外照射 $+$ 含铂同期化疗 $\\pm$ 近距离放疗。中危因素包括但不限于肿瘤大小、间质浸润及 LVSI 阳性,鳞状细胞癌按照 Sedlis 标准进行评估(表 4),但中危因素不限于 Sedlis 标准。",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "研究表明,与鳞癌相比,腺癌患者的预后更差,术后补充放疗的获益更大[13];因此腺癌采用四因素模型:腺癌、LVSI 阳性、肿瘤 $> 3 \\ \\mathrm { c m }$ 和深间质浸润,若满足2 个及以上因素,术后均建议补充放疗。如老年宫颈癌患者在术前评估时既存在术后需补充放疗的危险因素,建议直接行根治性放疗[60],以减少非必要的联合治疗对预后的不良影响。表 4 Sedlis 标准 <html><body><table><tr><td>LVSI</td><td>间质浸润</td><td>肿瘤直径</td></tr><tr><td>+</td><td>外1/3</td><td>任何大小</td></tr><tr><td>+</td><td>中1/3</td><td>≥2 cm</td></tr><tr><td>+</td><td>内1/3</td><td>≥5 cm</td></tr><tr><td>二</td><td>中或外1/3</td><td>≥4 cm</td></tr></table></body></html> LVSI: 淋巴血管间质浸润.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "3.1.2 不可耐受手术/ 治疗意愿不强烈者 放疗作为宫颈癌另一主要治疗方式,疗效不亚于手术,老年患者也可良好耐受[61-64],对于不耐受手术/ 治疗意愿不强烈的早期老年宫颈癌患者,能够通过放疗获得良好预后,具体治疗方式需根据疾病阶段、身体状态综合决策。对于仅能耐受宫颈锥切的 $\\mathrm { ~ I ~ A ~ l ~ } \\sim \\mathrm { ~ I ~ A } 2$ 期老年宫颈癌患者,术后切缘阴性且无 LVSI 者,可随诊观察[65],余患者推荐盆腔外照射 $\\dot { \\bf \\Phi } _ { \\pm } ,$ 顺铂同期放化疗,不能耐受顺铂化疗者可更换为卡铂[66]。",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "ⅠB1、ⅠB2、ⅡA1 期老年患者推荐盆腔外照射 $^ +$ 近距离放疗 $\\pm$ 顺铂单药同期化疗(不能耐受顺铂者更换为卡铂) [56]。# 【推荐意见】 早期老年宫颈癌患者可能从手术治疗中获益(推荐级别:2B),年龄不是手术的禁忌证,可耐受手术者仍推荐行手术治疗,治疗原则基本同年轻患者,强调加强术后护理,减少术后并发症的发生(推荐级别:2A)。术后需根据中高危因素决定是否补充治疗,如术前评估存在相关危险因素及患者治疗意愿不强烈/ 无法耐受手术者推荐直接行根治性放疗。",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "(推荐级别:2A)。# 3.2 晚期宫颈癌患者 晚期宫颈癌生存结局差,放疗是局部晚期宫颈癌患者的主要治疗方式。研究证实,即使年龄 $\\geqslant$ 80 岁的宫颈癌患者行根治性放疗也能获得良好的治疗效果[67],年龄并不影响放射治疗效果及耐受性,即使仅行姑息性放射治疗也可达到控制局部出血、缩小肿瘤病灶、缓解压迫症状、减轻骨转移导致疼痛的目的[68]。C 确诊ⅠB3、ⅡA2 \\~ Ⅳa 期的局部晚期老年宫颈癌患者,推荐放疗联合以铂为基础的同步化疗为主要治疗方式,其中化疗方案推荐单药,优选顺铂;如存在顺铂禁忌证或不耐受,可更换为卡铂;如患者病理类型为鳞癌,尼妥珠单抗也作为可选方案[69]。",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "对于体弱无法耐受联合治疗的老年患者,可仅进行盆腔外照射 $^ +$ 近距离放疗。具体治疗方式如下。(1)影像学提示淋巴结阴性者:推荐盆腔外照射 $^ +$ 近距离放疗 $^ +$ 含铂同期化疗。(2) 影像学提示盆腔淋巴结阳性、主动脉旁淋巴结阴性:推荐行盆腔外照射 $^ +$ 近距离放疗 $^ +$ 含铂同期化疗 $\\pm$ 主动脉旁淋巴结放疗。(3)影像学提示盆腔及主动脉旁淋巴结均阳性者:推荐行延伸野放疗 $^ +$ 近距离放疗 $^ +$ 含铂同期化疗。",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "(4)影像学提示有远处转移并经活检证实转移者,推荐行全身治疗 $\\dot { \\bf { \\varepsilon } } \\pm \\mathbf { \\varepsilon }$ 个体化放疗。如远处转移的病灶部位仅局限于锁骨上淋巴结,可行根治性治疗;如果患者的原发灶已控制,其他部位存在 1 \\~ 5 个转移 灶,可考虑立体定向放疗。对于ⅣB 期出现远处转移的晚期老年宫颈癌患者,经评估适合局部治疗者,推荐行局部消融治疗±个体化放疗,或个体化放疗 $\\pm$ 全身系统治疗;不适合局部治疗者,推荐行全身系统性治疗,也可考虑通过放疗等姑息性治疗,改善患者生活质量[56]。",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "# 【推荐意见】 放疗是晚期老年宫颈癌患者的主要治疗方式,患者通常也可良好耐受,具体治疗方案需根据患者自身疾病特点及个体条件综合考量,以改善患者生活质量、适当延长生存期为主要目标。(推荐级别:2A) # 3.3 免疫及靶向治疗 免疫治疗、靶向治疗联合化疗可用于晚期、复发、转移宫颈癌患者。免疫检查点抑制剂帕博利珠单抗联合化疗可提高 PD-L1 阳性( $\\mathrm { C P S } \\geqslant 1$ ) 患者的生存期(无进展生存期及总生存期),对于ⅢA 期以上宫颈癌患者初治时使用同步放化疗联合帕博利珠单抗可显著提高患者生存;卡度尼利单抗是一种靶向程序性死亡受体 1(programmed death-1, PD-1)和细胞毒性 T 淋巴细胞抗原-4(cytotoxic T lymphocyteantigen 4, CTLA-4)的双特异性抗体,目前在我国被批准用于既往接受过含铂化疗治疗失败的患者,无论 PD-L1 状态如何,均能从中获益[70]。",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "贝伐珠单抗已被我国批准用于晚期、复发、转移宫颈癌患者的一线治疗,联合化疗发挥协同作用,能有效改善患者预后;其他免疫治疗药物如西米普利单抗( PD-1抑制剂)已被临床试验证实能够为宫颈癌患者带来生存获益;多靶点小分子酪氨酸激酶抑制剂如阿帕替尼/ 安罗替尼以及抗体偶联药物如替索单抗等,也正在临床试验探索中[71] ,因尚缺乏高质量循证证据在此不做推荐。老年宫颈癌患者应用免疫治疗时,应全面评估患者免疫基线水平,在符合指征情况下按疗程合理用药,治疗期间监测患者身体状态,积极管理免疫药物相关不良反应,避免严重并发症发生,在保证患者生活质量的同时改善患者预后。",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "# 【推荐意见】 免疫治疗、靶向治疗联合化疗能有效改善晚期、复发、转移宫颈癌患者预后,需全面评估老年患者机体状态,积极管理相关不良反应,以求更大获益。(推荐级别:2A) # 3.4 全身系统治疗 复发和转移性宫颈癌全身系统治疗标准方案为顺铂/ 卡铂 $^ +$ 紫杉醇 $+$ 贝伐珠单抗[72,73],目前对于老年患者没有针对性的化疗方案临床研究,有部分临床研究纳入了少量老年患者,但研究结论广泛应用于老年患者缺乏说服力。",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "对老年患者而言,单药化疗是一种选择,推荐药物包括顺铂、卡铂、紫杉醇;二线治疗可选药物包括白蛋白结合型紫杉醇、多西他赛、吉西他滨、培美曲塞、拓扑替康、异环磷酰胺、丝裂霉素、氟尿嘧啶、长春瑞滨、伊立替康等[74]。O # 4 总 结 老年宫颈癌患者的治疗,除全面评估肿瘤本身外,需结合整体机能、自身意愿评估患者对于治疗方式的耐受性,选择适宜的治疗方案。早期可耐受手术者仍应以手术治疗为主,围术期需加强管理,减少术后严重并发症的发生。",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "晚期及不可耐受手术者应进行个体化评估,首选放疗联合以铂为基础的同步化疗,也可按指征联合免疫及靶向治疗,但需积极管理不良反应,手术仅用于姑息性治疗,旨在控制局部肿瘤、缓解症状、延长生存时间、提高生活质量。本共识仅为临床诊疗提供指导性意见,但并非唯一的实践指南,不排除其他共识、意见与建议的合理性。# 利益冲突:无 共识制定与讨论专家(按姓氏拼音排序):艾浩(锦州医科大学附属第三医院);崔晓楠( 大连医科大学附属第一医院);窦磊(中国医科大学附属第一医院); 董延磊( 山东大学第二医院);范江涛(广西医科大学第一附属医院);范文生(中国人民解放军总医院妇产科医学部);李斌( 中国医学科学院肿瘤医院);李芳梅(中国医科大学附属第一医院);李静(中国医科大学附属第一医院);李圃(天津市中心妇产科医院);李昭(中国医科大学附属第一医院);刘禄斌(重庆市妇幼保健院);栾正刚(中国医科大学附属第一医院);牛菊敏(沈阳市妇婴医院);潘美竹(中国医科大学附属第一医院);郄明蓉(四川大学华西第二医院);申复进(武汉大学人民医院);宋玉丽(中国医科大学附属第一医院);孙蓬明(福建省妇幼保健院);谭姝( 哈尔滨医科大学附属肿瘤医院);谭文斐(中国医科大学附属第一医院);田文(中国医科大学附属第一医院);王建东(首都医科大学附属北京妇产医院);王玮(中国医科大学附属第一医院);王新波( 山东省妇幼保健院);王雅卓(河北省人民医院);吴绪峰(湖北省妇幼保健院);许天敏(吉林大学第二医院);杨萍(石河子大学医学院第一附属医院);严妍(中国医科大学附属第一医院);于云海( 山东大学第二医院);张广美(哈尔滨医科大学附属第一医院);张师前( 山东大学齐鲁医院);张颐(中国医科大学附属第一医院);赵辉(首都医科大学附属北京妇产医院);朱维培(苏州大学附属第二医院) 执笔作者:张颐(中国医科大学附属第一医院);严妍(中国医科大学附属第一医院); 何玥( 首都医科大学附属北京妇产医院);张师前(山东大学齐鲁医院);吴玉梅( 首都医科大学附属北京妇产医院) 【参考文献】 [ 1] Neumeyer S, Tanaka LF, Liang LA, et al.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "Epidemiology of cervical cancer in elderly women: analysis of incidence, treatment, and survival using German registry data[J].Cancer Med, 2023, 12(16): 17284-17295.DOI: 10.1002/ cam4.6318.[2] Bray F, Ferlay J, Soerjomataram I, et al.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[ J] .CA Cancer J Clin, 2018, 68: 394-424.DOI: 10.3322 / caac.21492.[3] Vitale SG, Capriglione S, Zito G, et al.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "Management of endometrial, ovarian and cervical cancer in the elderly: current approach to a challenging condition[J].Arch Gynecol Obstet, 2019, 299(2): 299-315.DOI: 10.1007/ s00404-018-5006-z.[4] 杨蜜, 张加勇, 张欣平, 等.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "免疫治疗联合热疗加放疗治疗老年 中晚期宫颈癌的疗效及安全性[J].现代肿瘤医学, 2024, 32(1): 125-129.DOI: $1 0 .3 9 6 9 / \\mathrm { j }$ .issn.1672-4992.2024.01.022.[5] 黄留叶, 赵雪莲, 赵方辉.宫颈癌的发病与死亡变化趋势及其 预防策略进展[J].肿瘤综合治疗电子杂志, 2021, 7(2): 21- 25.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "DOI: 10.12151 / JMCM.2021.02-03.[6] 陈小军, 陈小祥, 申震, 等.老年卵巢癌患者围手术期管理 专家共识(2024 年版)[J].中国实用妇科与产科杂志, 2024, 40(7): 729-736.DOI: 10.19538 / j.fk2024070113.[7] Sharma C, Deutsch I, Horowitz DP, et al.Patterns of care and treatment outcomes for elderly women with cervical cancer [ J] .",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "Cancer, 2012, 118(14): 3618-3626.DOI: 10.1002 / cncr.26589.[8] McKee KS, Carter KA, Bassis C, et al.The vaginal microbiota, high-risk human papillomavirus infection, and cervical cytology: results from a population-based study[ J] .",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "Gynecol Pelvic Med, 2020, 3: 18.DOI: 10.21037 / gpm-20-10.[9] 伊欣, 张蕾, 陈汶, 等.高危型人乳头瘤病毒与女性下生殖道 感染联合检测专家共识[ J].中国实用妇科与产科杂志, 2022, 38(5): 524-528.DOI: 10.19538 / j.fk20220501 11.[10] Wright TC Jr, Behrens CM, Ranger-Moore J, et al.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "Triaging HPV-positive women with p16 / Ki-67 dual-stained cytology: results from a sub-study nested into the ATHENA trial[J].Gynecol Oncol, 2017, 144(1): 51-56.DOI: 10.1016/ j.ygyno 2016.10.031.[11] 何玥, 吴玉梅, 王建东, 等.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "老年女性子宫颈病变筛查及异常 管理中国专家共识(2023 年版) [ J].中国实用妇科与产科杂 志, 2023, 39(5): 531-536.DOI: 10.19538 / j.fk 2023050112.[12] Birge Ö, Bakır MS, Karadag C, et al.Evaluation of elderly women with uterin cervical cancer[ J] .",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "Cancer Rep ( Hoboken) , 2022, 5(10): e1570.DOI: 10.1002 / cnr2.1570.[13] Ferrall L, Lin KY, Roden RBS, et al.Cervical cancer immunotherapy: facts and hopes[ J] .Clin Cancer Res, 2021, 27( 18) : 4953-4973.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "DOI: 10.1158 / 1078-0432.CCR-2 0-2833.[14] Haldorsen IS, Lura N, Blaakær J, et al.What is the role of imaging at primary diagnostic work-up in uterine cervical cancer?[J].Curr Oncol Rep, 2019, 21(9): 77.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "DOI: 10.1007/ s11912-019-0824-0.[15] Testa AC, Di LA, De Blasis I, et al.Imaging techniques for the evaluation of cervical cancer [ J ] .Best Pract Res Clin Obstet Gynaecol, 2014, 8( 5): 741 - 768.DOI: 10.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "1016 / j.bpobgyn.2014.04.009.[16] Epstein E, Di Legge A, Masback A, et al.Sonographic characteristics of squamous cell cancer and adenocarcinoma of the uterine cervix[J].Ultrasound Obstet Gynecol, 2010, 36(4): 512-516.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "DOI: 10.1002 / uog.7638.[17] Palsdottir K, Fischerova D, Franchi D, et al.Preoperative prediction of lymph node metastasis and deep stromal invasion in women with invasive cervical cancer: prospective multicenter study using 2D and 3D ultrasound[J].",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "Ultrasound Obstet Gynecol, 2015, 45(4): 470- 475.DOI: 10.1002/ uog.14643.[18] Fischerova D, Cibula D, Stenhova H, et al.Transrectal ultrasound and magnetic resonance imaging in staging of early cervical cancer[J].",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "Int J Gynecol Cancer, 2008,18(4): 766-772.DOI: 10.1111 / j.1525-1438.2007.01072.x.[19] Epstein E, Testa A, Gaurilcikas A, et al.Early-stage cervical cancer: tumor delineation by magnetic resonance imaging and ultrasound — a European multicenter trial [ J] .",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "Gynecol Oncol, 2013, 128 ( 3 ): 449 - 453.DOI: 10.1016 / j.ygyno.2012.09.025.[20] Innocenti P, Pulli F, Savino L, et al.Staging of cervical cancer: reliability of transrectal US[ J] .Radiology, 1992,185( 1) : 201- 205.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "DOI: 10.1148 / radiology.185.1.1523308.[21] He H, Bhosale P, Wei W, et al.MRI is highly specific in determining primary cervical versus endometrial cancer when biopsy results are inconclusive[J].Clin Radiol, 2013, 68(11): 1107- 1113.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "DOI: 10.1016 / j.crad.2013.05.095.[22] Lee SI, Catalano OA, Dehdashti F.Evaluation of gynecologic cancer with MR imaging, 18F-FDG PET / CT, and PET / MR imaging[J].J Nucl Med, 2015, 56( 3): 436 - 443.DOI: 10.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "2967 / jnumed.114.145011.[23] Bipat S, Glas AS, van der Velden J, et al.Computed tomography and magnetic resonance imaging in staging of uterine cervical carcinoma: a systematic review[J].Gynecol Oncol, 2003, 91(1): 59-66.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "DOI: 10.1016/ S0090-8258(03)00409-8.[ 24] Selman TJ, Mann C, Zamora J, et al.Diagnostic accuracy of tests for lymph node status in primary cervical cancer: a systematic review and meta-analysis[J].CMAJ, 2008, 178(7): 855-862.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "DOI: 10.1503 / cmaj.071124.[25] Hricak H, Gatsonis C, Coakley FV, et al.Early invasive cervical cancer: CT and MR imaging in preoperative evaluation-ACRIN / GOG comparative study of diagnostic performance and interobserver variability[J].",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "Radiology, 2007, 245(2): 491- 498.DOI: 10.1148 / radiol.2452061983.[26] Kang S, Kim SK, Chung DC, et al.Diagnostic value of ( 18) F-FDG PET for evaluation of paraaortic nodal metastasis in patients with cervical carcinoma: a metaanalysis[ J] .",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "J Nucl Med, 2010, 51(3): 360-367.DOI: 10.2967 / jnumed.109.066217.[27] Grant P, Sakellis C, Jacene HA.Gynecologic oncologic imaging with PET / CT[J].Semin Nucl Med, 2014, 44 ( 6): 461 - 478.DOI: 10.1053 / j.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "semnuclmed.2014.0 6.005.[28] Basu S, Li G, Alavi A.PET and PET-CT imaging of gynecological malignancies: present role and future promise [ J ].Expert Rev Anticancer Ther, 2009, 9(1): 75-96.DOI: 10.1586/ 14737140.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "9.1.75.[29] Papadia A, Gasparri ML, Genoud S, et al.The combination of preoperative PET / CT and sentinel lymph node biopsy in the surgical management of early-stage cervical cancer[ J].J Cancer Res Clin Oncol, 2017, 143(11): 2275-2281.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "DOI: 10.1007 / s00432-017- 2467-6.[30] 舒桐, 李斌.老年子宫颈癌的防控和诊疗策略[J].实用妇产科 杂志, 2019, 35 ( 8): 561 - 563.DOI: CNKI: SUN: SFCZ.0.2019-08-003.[31] Walston J.Frailty — the search for underlying causes [ J] .Sci Aging Knowledge Environ, 2004, 2004(4): pe4.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "DOI: 10.1126 / sageke.2004.4.pe4.[32] Ko FC.The clinical care of frail, older adults[ J] .Clin Geriatr Med, 2011, 27(1): 89-100.DOI: 10.1016 / j.cger.2010.08.007.[33] Bandeen-Roche K, Xue QL, Ferrucci L, et al.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "Phenotype of frailty: characterization in the women′ s health and aging studies [ J ] .J Gerontol A Biol Sci Med Sci, 2006, 61( 3): 262 - 266.DOI: 10.1093 / gerona / 61.3.262.[34] Aucoin SD, Hao M, Sohi R, et al.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "Accuracy and feasibility of clinically applied frailty instruments before surgery: a systematic review and meta-analysis [ J] .Anesthesiology, 2020, 133 ( 1) : 78-95.DOI: 10.1097 / ALN.0000000000003257.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "[ 35] Hogan DB, Maxwell CJ, Afilalo J, et al.A scoping review of frailty and acute care in middle-aged and older individuals with recommendations for future research[ J] .Can Geriatr J, 2017, 20(1) : 22-37.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "DOI: 10.5770 / cgj.20.240.[36] Shem Tov L, Matot I.Frailty and anesthesia [ J ] .Curr Opin Anaesthesiol, 2017, 30(3): 409-417.DOI: 10.1097 / ACO.000 0000000000456.[37] Trundle S, Gooneratne M, Rogerson A, et al.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "Perioperative comprehensive geriatric assessment: what do we need to know?[J].Br J Hosp Med ( Lond), 2019, 80 ( 5): 258 - 262.DOI: 10.12968 / hmed.2019.80.5.258.[38] Darvall JN, Gregorevic KJ, Story DA, et al.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "Frailty indexes in perioperative and critical care: a systematic review[J].Arch Gerontol Geriatr, 2018, 79: 88-96.DOI: 10.1016/ j.archger.2018.08.006.[39] Partridge JS, Harari D, Dhesi JK.Frailty in the older surgical patient: a review [ J] .",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "Age Ageing, 2012, 41 ( 2) : 142 - 147.DOI: 10.1093 / ageing / afr182.[40] Schipa C, Luca E, Ripa M, et al.Preoperative evaluation of the elderly patient[J].Saudi J Anaesth, 2023,17 ( 4): 482 - 490.DOI: 10.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "4103 / sja.sja_613_23.[41] 王小梅, 王思涵, 王可, 等.两种评分系统对腹部四级手术患 者术后肺部并发症预测效果的对比研究[ J].科学咨询, 2023, 2023( 5): 125 - 129.DOI: 10.3969 / j.issn.1671-4822.2023.5.kxzx202305039.[ 42] Perilli V, Aceto P, Sacco T, et al.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "Anaesthesiological strategies to improve outcome in liver transplantation recipients [ J] .Eur Rev Med Pharmacol Sci, 2016, 20: 3172-177.[43] Gupta R, Gan TJ.Preoperative nutrition and prehabilitation[ J] .",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "Anesthesiol Clin, 2016, 34(1): 143-153.DOI: 10.1016/ j.anclin.2015.10.012.[44] De Cosmo G, Congedo E, Clemente A, et al.Sedation in PACU: the role of propofol[ J] .Curr Drug Targets, 2005, 6( 7) : 741 - 744.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "DOI: 10.2174 / 138945005774574425.[45] Weimann A, Braga M, Carli F, et al.ESPEN guideline: clinical nutrition in surgery [ J].Clin Nutr, 2017, 36 ( 3): 623 - 650.DOI: 10.1016 / j.clnu.2017.02.013.[46] 陈阳希, 史兆荣, 朱小蔚, 等.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "共病状态评估工具的临床应用 及研究进展[ J].中华老年多器官疾病杂志, 2017, 16( 2): 147-151.DOI: 10.11915 / j.issn.1671-5403.2017.02.034.[47] Charlson ME, Pompei P, Ales KL, et al.A new method of classifying prognostic comorbidity in longitudinal studies: development and validation[J].",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "J Chronic Dis, 1987, 40(5): 373-383.DOI: 10.1016 / 0021-9681(87)90171-8.[48] Charlson ME, Carrozzino D, Guidi J, et al.Charlson comorbidity index: a critical review of clinimetric properties [ J] .Psychother Psychosom, 2022, 91(1): 8-35.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "DOI: 10.1159 / 000521288.[49] Benderra MA, Serrano AG, Paillaud E, et al.Prognostic value of comorbidities in older patients with cancer: the ELCAPA cohort study[J].ESMO Open, 2023, 8(5): 101831.DOI: 10.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "1016 / j.esmoop.2023.101831.[50] Mohile SG, Dale W, Somerfield MR, et al.Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology [ J ] .",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "J Clin Oncol, 2018, 36(22): 2326- 2347.DOI: 10.1200 / JCO.2018.78.8687.[51] Xie S, Pan S, Zou S, et al.Characteristics and treatments of patients aged 65 years or over with cervical cancer[ J] .Clin Interv Aging,2020,15:841-851.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "DOI: 10.2147 / CIA.S255305.[52] Gu Y, Cheng H, Cang $\\textrm { W } , e t$ al.Comparison of oncological outcomes in elderly early-stage cervical cancer patients treated with radical surgery or radiotherapy: a real-world retrospective study with propensity score matching [ J ] .",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "Front Oncol, 2023, 13: 1019254.DOI: 10.3389 / fonc.2023.1019254.[53] Mohanty S, Rosenthal RA, Russell MM, et al.Optimal perioperative management of the geriatric patient: a best practices guideline from the American College of Surgeons NSQIP and the American Geriatrics Society[J].",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "J Am Coll Surg, 2016, 222(5): 930- 947.DOI: 10.1016/ j.jamcollsurg.[ 54] George EM, Tergas AI, Ananth CV, et al.Safety and tolerance of radical hysterectomy for cervical cancer in the elderly[L].Gynecol Oncol, 2014, 134(1): 36-41.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "DOI: 10.1016/ j.ygyno.2014.04.010.[55] 刘朝燕.老年宫颈鳞状上皮内病变患者宫颈电环锥切术后 病灶残留的危险因素分析[ J].基层医学论坛, 2024, 28(4): 59-61,64.DOI: 10.19435 / j.1672-1721.2024.04.019.[56] 周晖, 刘昀昀, 罗铭, 等.《2023 NCCN 子宫颈癌临床实践指南 (第 1 版)》解读[J].",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "中国实用妇科与产科杂志, 2023, 39(2): 189-196.DOI: 10.19538 / j.fk2023020115.[ 57] Trimble EL, Harlan LC, Gius D, et al.Patterns of care for women with cervical cancer in the United States[J].Cancer, 2008, 113(4): 743-749.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "DOI: 10.1002/ cncr.23682.[58] Giannice R, Susini T, Ferrandina G, et al.Systematic pelvic and aortic lymphadenectomy in elderly gynecologic oncologic patients[J].Cancer, 2001, 92(10): 2562-2568.DOI: 10.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "1002 / 1097-0142 (20011115)92:10<2562:aid-cncr 1608>3.0.co;2-r.[59] 崔颖姝, 周红.老年宫颈癌特点与手术治疗新观念体会[J].中 国冶金工业医学杂志, 2017, 34( 4): 441.DOI: 10.13586 / j.cnki.yjyx1984.2017.04.058.[60] Folkert MR, Shih KK, Abu-Rustum NR, et al.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "Postoperative pelvic intensity-modulated radiotherapy and concurrent chemotherapy in intermediate- and high-risk cervical cancer [ J].Gynecol Oncol, 2013, 128(2): 288-293.DOI: 10.1016 / j.ygyno.2012.11.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "012.[61] Goodheart M, Jacobson G, Smith BJ, et al.Chemoradiation for invasive cervical cancer in elderly patients: outcomes and morbidity[J].Int J Gynecol Cancer, 2008, 18(1): 95-103.DOI: 10.1111 / j.1525-1438.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "2007.00967.x.[62] Ikushima H, Takegawa Y, Osaki K, et al.Radiation therapy for ·9· cervical cancer in the elderly[ J].Gynecol Oncol, 2007, 107(2): 339-343.DOI: 10.1016/ j.ygyno.2007.07.058.[63] Folkert MR, Shih KK, Abu-Rustum NR, et al.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "Postoperative pelvic intensity-modulated radiotherapy and concurrent chemotherapy in intermediate- and high-risk cervical cancer [ J].Gynecol Oncol, 2013, 128(2): 288-293.DOI: 10.1016 / j.ygyno.2012.11.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "012.[64] Landoni F, Maneo A, Colombo A, et al.Randomised study of radical surgery versus radiotherapy for stageⅠb-Ⅱa cervical cancer[J].Lancet, 1997, 350 ( 9077): 535 - 540.DOI: 10.1016 / S0140- 6736(97)02250-2.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "[65] Magné N, Mancy NC, Chajon E, et al.Patterns of care and outcome in elderly cervical cancer patients: a special focus on brachytherapy[J].Radiother Oncol, 2009, 91 (2) :197- 201.DOI: 10.1016 / j.radonc.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "2008.08.011.[66] Xiang M, Kidd EA.Benefit ofcisplatin with definitive radiotherapy in older women with cervical cancer [ J ] .J Natl Compr Canc Netw, 2019, 17(8): 969-975.DOI: 10.6004/ jnccn.2019.7289.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "[ 67] Hata M.Radiation therapy for elderly patients with uterine cervical cancer: feasibility of curative treatment[ J] .Int J Gynecol Cancer, 2019, 29(3): 622-629.DOI: 10.1136 / ijgc-2018-000077.[68] Lin MY, Kondalsamy-Chennakesavan S, Bernshaw D, et al.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "Carcinoma of the cervix in elderly patients treated with radiotherapy: patterns of care and treatment outcomes [ J].J Gynecol Oncol, 2016, 27(6): e59.DOI: 10.3802/ jgo.2016.27.e59.[69] Qu A, Wang JJ, Zhuo YH, et al.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "Nimotuzumab in combination with radiotherapy for elderly patients with locally advanced cervical squamous cell carcinoma: results from a prospective, multicenter, open-label, single-arm trial[J].J Clin Oncol, 2024, 42(16 suppl): 5527-5527.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "DOI: 10.1200/ JCO.2024.42.16_suppl.5527.[70] 中国抗癌协会宫颈癌专业委员会, 李晶, 林仲秋.子宫颈癌抗 血管生成药物临床应用指南(2023 年版) [ J].中国实用妇科 与产科 杂 志, 2023, 39 ( 12): 1201 - 1209.DOI: 10.19538 / j.fk2023120113.[71] Xing Y, Yasinjan F, Du Y, et al.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "Immunotherapy in cervical cancer: from the view of scientometric analysis and clinical trials[J].Front Immunol, 2023, 14: 1094437.DOI: 10.3389 / fimmu.2023.1094437.[72] Tewari KS, Sill MW, Penson RT, et al.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial ( Gynecologic Oncology Group 240)[J].Lancet, 2017, 390(10103): 1654-1663.",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "DOI: 10.1016/ S0140-6736(17)31607-0.[73] Kitagawa R, Katsumata N, Shibata T, et al.Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase Ⅲ trial JCOG0505[J].",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  },
  {
    "text": "J Clin Oncol, 2015, 33 ( 19): 2129 - 2135.DOI: 10.1200 / JCO.2014.58.4391.[74] Coleman RL, Lorusso D, Gennigens C, et al.Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer ( innovaTV 204 / GOG-3023 / ENGOT-cx6) : a multicentre, open-label, single-arm, phase 2 study [ J ] .Lancet Oncol, 2021, 22 ( 5): 609 - 619.DOI: 10.1016 / S1470-2045 (21)00056-5.(编辑: 王雪萍)",
    "source": "老年宫颈癌规范化诊疗中国专家共识(2024 年版)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/老年宫颈癌规范化诊疗中国专家共识(2024 年版)/老年宫颈癌规范化诊疗中国专家共识(2024 年版).md"
  }
]